ATT_SPAN_block_num=1
Filter_Strategy=True
Only_token_head=False
RANDOM_SEED=2023
accumulation_steps=1
bert_feature_dim=1024
block_num=1
dataset=Bio1
dataset_path=/mnt/SBN/datasets/CITwitterTripletData/
device=cpu
do_lower_case=True
drop_out=0.1
embedding_dim4width=200
epochs=5
init_model=dmis-lab/biobert-large-cased-v1.1-squad
init_vocab=dmis-lab/biobert-large-cased-v1.1-squad
kl_loss=True
kl_loss_mode=KLLoss
kl_loss_weight=0.5
learning_rate=1e-05
max_seq_length=100
max_span_length=8
mode=train
model_dir=./BioBERT/
model_para_test=False
muti_gpu=False
order_input=True
output_path=triples.json
random_shuffle=0
related_span_block_num=1
related_span_underline=False
span_generation=Max
task_learning_rate=0.0001
train_batch_size=16
warm_up=0.1
whether_warm_up=False
开始加载测试集
test_dataset:[[{'id': '0', 'tokens': ['I', 'charge', 'it', 'at', 'night', 'and', 'skip', 'taking', 'the', 'cord', 'with', 'me', 'because', 'of', 'the', 'good', 'battery', 'life', '.'], 'text_length': 19, 'triples': {'battery life|good': ([16, 17], [15, 15], 'positive')}, 'sentence': 'I charge it at night and skip taking the cord with me because of the good battery life .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(16, 17)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(15, 15)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['I', 'charge', 'it', 'at', 'night', 'and', 'skip', 'taking', 'the', 'cord', 'with', 'me', 'because', 'of', 'the', 'good', 'battery', 'life', '.', 'I charge', 'charge it', 'it at', 'at night', 'night and', 'and skip', 'skip taking', 'taking the', 'the cord', 'cord with', 'with me', 'me because', 'because of', 'of the', 'the good', 'good battery', 'battery life', 'life .', 'I charge it', 'charge it at', 'it at night', 'at night and', 'night and skip', 'and skip taking', 'skip taking the', 'taking the cord', 'the cord with', 'cord with me', 'with me because', 'me because of', 'because of the', 'of the good', 'the good battery', 'good battery life', 'battery life .', 'I charge it at', 'charge it at night', 'it at night and', 'at night and skip', 'night and skip taking', 'and skip taking the', 'skip taking the cord', 'taking the cord with', 'the cord with me', 'cord with me because', 'with me because of', 'me because of the', 'because of the good', 'of the good battery', 'the good battery life', 'good battery life .', 'I charge it at night', 'charge it at night and', 'it at night and skip', 'at night and skip taking', 'night and skip taking the', 'and skip taking the cord', 'skip taking the cord with', 'taking the cord with me', 'the cord with me because', 'cord with me because of', 'with me because of the', 'me because of the good', 'because of the good battery', 'of the good battery life', 'the good battery life .', 'I charge it at night and', 'charge it at night and skip', 'it at night and skip taking', 'at night and skip taking the', 'night and skip taking the cord', 'and skip taking the cord with', 'skip taking the cord with me', 'taking the cord with me because', 'the cord with me because of', 'cord with me because of the', 'with me because of the good', 'me because of the good battery', 'because of the good battery life', 'of the good battery life .', 'I charge it at night and skip', 'charge it at night and skip taking', 'it at night and skip taking the', 'at night and skip taking the cord', 'night and skip taking the cord with', 'and skip taking the cord with me', 'skip taking the cord with me because', 'taking the cord with me because of', 'the cord with me because of the', 'cord with me because of the good', 'with me because of the good battery', 'me because of the good battery life', 'because of the good battery life .', 'I charge it at night and skip taking', 'charge it at night and skip taking the', 'it at night and skip taking the cord', 'at night and skip taking the cord with', 'night and skip taking the cord with me', 'and skip taking the cord with me because', 'skip taking the cord with me because of', 'taking the cord with me because of the', 'the cord with me because of the good', 'cord with me because of the good battery', 'with me because of the good battery life', 'me because of the good battery life .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '1', 'tokens': ['superexciting', 'results', 'from', 'glofitamab', 'in', 'dlbcl,', 'presented', 'by', 'dr.', 'martin', 'hutchins', '#ash22', '(including', 'the', 'announcement', 'of', 'a', 'stillhotfromtheoven', 'nejm', 'publication).', ''], 'text_length': 21, 'triples': {'glofitamab|superexciting results': ([3, 3], [0, 1], 'positive')}, 'sentence': 'superexciting results from glofitamab in dlbcl, presented by dr. martin hutchins #ash22 (including the announcement of a stillhotfromtheoven nejm publication). ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['superexciting', 'results', 'from', 'glofitamab', 'in', 'dlbcl,', 'presented', 'by', 'dr.', 'martin', 'hutchins', '#ash22', '(including', 'the', 'announcement', 'of', 'a', 'stillhotfromtheoven', 'nejm', 'publication).', '', 'superexciting results', 'results from', 'from glofitamab', 'glofitamab in', 'in dlbcl,', 'dlbcl, presented', 'presented by', 'by dr.', 'dr. martin', 'martin hutchins', 'hutchins #ash22', '#ash22 (including', '(including the', 'the announcement', 'announcement of', 'of a', 'a stillhotfromtheoven', 'stillhotfromtheoven nejm', 'nejm publication).', 'publication). ', 'superexciting results from', 'results from glofitamab', 'from glofitamab in', 'glofitamab in dlbcl,', 'in dlbcl, presented', 'dlbcl, presented by', 'presented by dr.', 'by dr. martin', 'dr. martin hutchins', 'martin hutchins #ash22', 'hutchins #ash22 (including', '#ash22 (including the', '(including the announcement', 'the announcement of', 'announcement of a', 'of a stillhotfromtheoven', 'a stillhotfromtheoven nejm', 'stillhotfromtheoven nejm publication).', 'nejm publication). ', 'superexciting results from glofitamab', 'results from glofitamab in', 'from glofitamab in dlbcl,', 'glofitamab in dlbcl, presented', 'in dlbcl, presented by', 'dlbcl, presented by dr.', 'presented by dr. martin', 'by dr. martin hutchins', 'dr. martin hutchins #ash22', 'martin hutchins #ash22 (including', 'hutchins #ash22 (including the', '#ash22 (including the announcement', '(including the announcement of', 'the announcement of a', 'announcement of a stillhotfromtheoven', 'of a stillhotfromtheoven nejm', 'a stillhotfromtheoven nejm publication).', 'stillhotfromtheoven nejm publication). ', 'superexciting results from glofitamab in', 'results from glofitamab in dlbcl,', 'from glofitamab in dlbcl, presented', 'glofitamab in dlbcl, presented by', 'in dlbcl, presented by dr.', 'dlbcl, presented by dr. martin', 'presented by dr. martin hutchins', 'by dr. martin hutchins #ash22', 'dr. martin hutchins #ash22 (including', 'martin hutchins #ash22 (including the', 'hutchins #ash22 (including the announcement', '#ash22 (including the announcement of', '(including the announcement of a', 'the announcement of a stillhotfromtheoven', 'announcement of a stillhotfromtheoven nejm', 'of a stillhotfromtheoven nejm publication).', 'a stillhotfromtheoven nejm publication). ', 'superexciting results from glofitamab in dlbcl,', 'results from glofitamab in dlbcl, presented', 'from glofitamab in dlbcl, presented by', 'glofitamab in dlbcl, presented by dr.', 'in dlbcl, presented by dr. martin', 'dlbcl, presented by dr. martin hutchins', 'presented by dr. martin hutchins #ash22', 'by dr. martin hutchins #ash22 (including', 'dr. martin hutchins #ash22 (including the', 'martin hutchins #ash22 (including the announcement', 'hutchins #ash22 (including the announcement of', '#ash22 (including the announcement of a', '(including the announcement of a stillhotfromtheoven', 'the announcement of a stillhotfromtheoven nejm', 'announcement of a stillhotfromtheoven nejm publication).', 'of a stillhotfromtheoven nejm publication). ', 'superexciting results from glofitamab in dlbcl, presented', 'results from glofitamab in dlbcl, presented by', 'from glofitamab in dlbcl, presented by dr.', 'glofitamab in dlbcl, presented by dr. martin', 'in dlbcl, presented by dr. martin hutchins', 'dlbcl, presented by dr. martin hutchins #ash22', 'presented by dr. martin hutchins #ash22 (including', 'by dr. martin hutchins #ash22 (including the', 'dr. martin hutchins #ash22 (including the announcement', 'martin hutchins #ash22 (including the announcement of', 'hutchins #ash22 (including the announcement of a', '#ash22 (including the announcement of a stillhotfromtheoven', '(including the announcement of a stillhotfromtheoven nejm', 'the announcement of a stillhotfromtheoven nejm publication).', 'announcement of a stillhotfromtheoven nejm publication). ', 'superexciting results from glofitamab in dlbcl, presented by', 'results from glofitamab in dlbcl, presented by dr.', 'from glofitamab in dlbcl, presented by dr. martin', 'glofitamab in dlbcl, presented by dr. martin hutchins', 'in dlbcl, presented by dr. martin hutchins #ash22', 'dlbcl, presented by dr. martin hutchins #ash22 (including', 'presented by dr. martin hutchins #ash22 (including the', 'by dr. martin hutchins #ash22 (including the announcement', 'dr. martin hutchins #ash22 (including the announcement of', 'martin hutchins #ash22 (including the announcement of a', 'hutchins #ash22 (including the announcement of a stillhotfromtheoven', '#ash22 (including the announcement of a stillhotfromtheoven nejm', '(including the announcement of a stillhotfromtheoven nejm publication).', 'the announcement of a stillhotfromtheoven nejm publication). '], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '2', 'tokens': ['glofitamab', '(cd20/cd3)', 'in', 'r/r', 'lbcl,', 'focused', 'on', 'pts', 'who', 'achieve', 'cr', 'after', 'eot', 'by', 'durable', 'responses', 'after', '1st', 'cr.', 'more', 'follow-up', 'needed!', '#lymphoma', '#ash22.', ''], 'text_length': 25, 'triples': {'glofitamab|more follow-up needed!': ([0, 0], [19, 21], 'neutral')}, 'sentence': 'glofitamab (cd20/cd3) in r/r lbcl, focused on pts who achieve cr after eot by durable responses after 1st cr. more follow-up needed! #lymphoma #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(19, 21)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8)], 'span tokens': ['glofitamab', '(cd20/cd3)', 'in', 'r/r', 'lbcl,', 'focused', 'on', 'pts', 'who', 'achieve', 'cr', 'after', 'eot', 'by', 'durable', 'responses', 'after', '1st', 'cr.', 'more', 'follow-up', 'needed!', '#lymphoma', '#ash22.', '', 'glofitamab (cd20/cd3)', '(cd20/cd3) in', 'in r/r', 'r/r lbcl,', 'lbcl, focused', 'focused on', 'on pts', 'pts who', 'who achieve', 'achieve cr', 'cr after', 'after eot', 'eot by', 'by durable', 'durable responses', 'responses after', 'after 1st', '1st cr.', 'cr. more', 'more follow-up', 'follow-up needed!', 'needed! #lymphoma', '#lymphoma #ash22.', '#ash22. ', 'glofitamab (cd20/cd3) in', '(cd20/cd3) in r/r', 'in r/r lbcl,', 'r/r lbcl, focused', 'lbcl, focused on', 'focused on pts', 'on pts who', 'pts who achieve', 'who achieve cr', 'achieve cr after', 'cr after eot', 'after eot by', 'eot by durable', 'by durable responses', 'durable responses after', 'responses after 1st', 'after 1st cr.', '1st cr. more', 'cr. more follow-up', 'more follow-up needed!', 'follow-up needed! #lymphoma', 'needed! #lymphoma #ash22.', '#lymphoma #ash22. ', 'glofitamab (cd20/cd3) in r/r', '(cd20/cd3) in r/r lbcl,', 'in r/r lbcl, focused', 'r/r lbcl, focused on', 'lbcl, focused on pts', 'focused on pts who', 'on pts who achieve', 'pts who achieve cr', 'who achieve cr after', 'achieve cr after eot', 'cr after eot by', 'after eot by durable', 'eot by durable responses', 'by durable responses after', 'durable responses after 1st', 'responses after 1st cr.', 'after 1st cr. more', '1st cr. more follow-up', 'cr. more follow-up needed!', 'more follow-up needed! #lymphoma', 'follow-up needed! #lymphoma #ash22.', 'needed! #lymphoma #ash22. ', 'glofitamab (cd20/cd3) in r/r lbcl,', '(cd20/cd3) in r/r lbcl, focused', 'in r/r lbcl, focused on', 'r/r lbcl, focused on pts', 'lbcl, focused on pts who', 'focused on pts who achieve', 'on pts who achieve cr', 'pts who achieve cr after', 'who achieve cr after eot', 'achieve cr after eot by', 'cr after eot by durable', 'after eot by durable responses', 'eot by durable responses after', 'by durable responses after 1st', 'durable responses after 1st cr.', 'responses after 1st cr. more', 'after 1st cr. more follow-up', '1st cr. more follow-up needed!', 'cr. more follow-up needed! #lymphoma', 'more follow-up needed! #lymphoma #ash22.', 'follow-up needed! #lymphoma #ash22. ', 'glofitamab (cd20/cd3) in r/r lbcl, focused', '(cd20/cd3) in r/r lbcl, focused on', 'in r/r lbcl, focused on pts', 'r/r lbcl, focused on pts who', 'lbcl, focused on pts who achieve', 'focused on pts who achieve cr', 'on pts who achieve cr after', 'pts who achieve cr after eot', 'who achieve cr after eot by', 'achieve cr after eot by durable', 'cr after eot by durable responses', 'after eot by durable responses after', 'eot by durable responses after 1st', 'by durable responses after 1st cr.', 'durable responses after 1st cr. more', 'responses after 1st cr. more follow-up', 'after 1st cr. more follow-up needed!', '1st cr. more follow-up needed! #lymphoma', 'cr. more follow-up needed! #lymphoma #ash22.', 'more follow-up needed! #lymphoma #ash22. ', 'glofitamab (cd20/cd3) in r/r lbcl, focused on', '(cd20/cd3) in r/r lbcl, focused on pts', 'in r/r lbcl, focused on pts who', 'r/r lbcl, focused on pts who achieve', 'lbcl, focused on pts who achieve cr', 'focused on pts who achieve cr after', 'on pts who achieve cr after eot', 'pts who achieve cr after eot by', 'who achieve cr after eot by durable', 'achieve cr after eot by durable responses', 'cr after eot by durable responses after', 'after eot by durable responses after 1st', 'eot by durable responses after 1st cr.', 'by durable responses after 1st cr. more', 'durable responses after 1st cr. more follow-up', 'responses after 1st cr. more follow-up needed!', 'after 1st cr. more follow-up needed! #lymphoma', '1st cr. more follow-up needed! #lymphoma #ash22.', 'cr. more follow-up needed! #lymphoma #ash22. ', 'glofitamab (cd20/cd3) in r/r lbcl, focused on pts', '(cd20/cd3) in r/r lbcl, focused on pts who', 'in r/r lbcl, focused on pts who achieve', 'r/r lbcl, focused on pts who achieve cr', 'lbcl, focused on pts who achieve cr after', 'focused on pts who achieve cr after eot', 'on pts who achieve cr after eot by', 'pts who achieve cr after eot by durable', 'who achieve cr after eot by durable responses', 'achieve cr after eot by durable responses after', 'cr after eot by durable responses after 1st', 'after eot by durable responses after 1st cr.', 'eot by durable responses after 1st cr. more', 'by durable responses after 1st cr. more follow-up', 'durable responses after 1st cr. more follow-up needed!', 'responses after 1st cr. more follow-up needed! #lymphoma', 'after 1st cr. more follow-up needed! #lymphoma #ash22.', '1st cr. more follow-up needed! #lymphoma #ash22. '], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '3', 'tokens': ['#ash22', 'abstract', '441', '-', 'et', 'al.', 'off-treatment', 'progression', 'is', 'uncommon', 'in', 'highly', 'refractory', 'patients', 'with', 'lbcl', 'who', 'are', 'in', 'cr', 'at', 'the', 'end', 'of', 'fixed-course', 'glofitamab', 'treatment.', 'just', 'published', 'in.', ''], 'text_length': 31, 'triples': {'glofitamab|uncommon in highly refractory patients with lbcl who are in cr at the end of fixed-course glofitamab treatment. just published': ([25, 25], [9, 28], 'neutral')}, 'sentence': '#ash22 abstract 441 - et al. off-treatment progression is uncommon in highly refractory patients with lbcl who are in cr at the end of fixed-course glofitamab treatment. just published in. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(25, 25)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 28)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['#ash22', 'abstract', '441', '-', 'et', 'al.', 'off-treatment', 'progression', 'is', 'uncommon', 'in', 'highly', 'refractory', 'patients', 'with', 'lbcl', 'who', 'are', 'in', 'cr', 'at', 'the', 'end', 'of', 'fixed-course', 'glofitamab', 'treatment.', 'just', 'published', 'in.', '', '#ash22 abstract', 'abstract 441', '441 -', '- et', 'et al.', 'al. off-treatment', 'off-treatment progression', 'progression is', 'is uncommon', 'uncommon in', 'in highly', 'highly refractory', 'refractory patients', 'patients with', 'with lbcl', 'lbcl who', 'who are', 'are in', 'in cr', 'cr at', 'at the', 'the end', 'end of', 'of fixed-course', 'fixed-course glofitamab', 'glofitamab treatment.', 'treatment. just', 'just published', 'published in.', 'in. ', '#ash22 abstract 441', 'abstract 441 -', '441 - et', '- et al.', 'et al. off-treatment', 'al. off-treatment progression', 'off-treatment progression is', 'progression is uncommon', 'is uncommon in', 'uncommon in highly', 'in highly refractory', 'highly refractory patients', 'refractory patients with', 'patients with lbcl', 'with lbcl who', 'lbcl who are', 'who are in', 'are in cr', 'in cr at', 'cr at the', 'at the end', 'the end of', 'end of fixed-course', 'of fixed-course glofitamab', 'fixed-course glofitamab treatment.', 'glofitamab treatment. just', 'treatment. just published', 'just published in.', 'published in. ', '#ash22 abstract 441 -', 'abstract 441 - et', '441 - et al.', '- et al. off-treatment', 'et al. off-treatment progression', 'al. off-treatment progression is', 'off-treatment progression is uncommon', 'progression is uncommon in', 'is uncommon in highly', 'uncommon in highly refractory', 'in highly refractory patients', 'highly refractory patients with', 'refractory patients with lbcl', 'patients with lbcl who', 'with lbcl who are', 'lbcl who are in', 'who are in cr', 'are in cr at', 'in cr at the', 'cr at the end', 'at the end of', 'the end of fixed-course', 'end of fixed-course glofitamab', 'of fixed-course glofitamab treatment.', 'fixed-course glofitamab treatment. just', 'glofitamab treatment. just published', 'treatment. just published in.', 'just published in. ', '#ash22 abstract 441 - et', 'abstract 441 - et al.', '441 - et al. off-treatment', '- et al. off-treatment progression', 'et al. off-treatment progression is', 'al. off-treatment progression is uncommon', 'off-treatment progression is uncommon in', 'progression is uncommon in highly', 'is uncommon in highly refractory', 'uncommon in highly refractory patients', 'in highly refractory patients with', 'highly refractory patients with lbcl', 'refractory patients with lbcl who', 'patients with lbcl who are', 'with lbcl who are in', 'lbcl who are in cr', 'who are in cr at', 'are in cr at the', 'in cr at the end', 'cr at the end of', 'at the end of fixed-course', 'the end of fixed-course glofitamab', 'end of fixed-course glofitamab treatment.', 'of fixed-course glofitamab treatment. just', 'fixed-course glofitamab treatment. just published', 'glofitamab treatment. just published in.', 'treatment. just published in. ', '#ash22 abstract 441 - et al.', 'abstract 441 - et al. off-treatment', '441 - et al. off-treatment progression', '- et al. off-treatment progression is', 'et al. off-treatment progression is uncommon', 'al. off-treatment progression is uncommon in', 'off-treatment progression is uncommon in highly', 'progression is uncommon in highly refractory', 'is uncommon in highly refractory patients', 'uncommon in highly refractory patients with', 'in highly refractory patients with lbcl', 'highly refractory patients with lbcl who', 'refractory patients with lbcl who are', 'patients with lbcl who are in', 'with lbcl who are in cr', 'lbcl who are in cr at', 'who are in cr at the', 'are in cr at the end', 'in cr at the end of', 'cr at the end of fixed-course', 'at the end of fixed-course glofitamab', 'the end of fixed-course glofitamab treatment.', 'end of fixed-course glofitamab treatment. just', 'of fixed-course glofitamab treatment. just published', 'fixed-course glofitamab treatment. just published in.', 'glofitamab treatment. just published in. ', '#ash22 abstract 441 - et al. off-treatment', 'abstract 441 - et al. off-treatment progression', '441 - et al. off-treatment progression is', '- et al. off-treatment progression is uncommon', 'et al. off-treatment progression is uncommon in', 'al. off-treatment progression is uncommon in highly', 'off-treatment progression is uncommon in highly refractory', 'progression is uncommon in highly refractory patients', 'is uncommon in highly refractory patients with', 'uncommon in highly refractory patients with lbcl', 'in highly refractory patients with lbcl who', 'highly refractory patients with lbcl who are', 'refractory patients with lbcl who are in', 'patients with lbcl who are in cr', 'with lbcl who are in cr at', 'lbcl who are in cr at the', 'who are in cr at the end', 'are in cr at the end of', 'in cr at the end of fixed-course', 'cr at the end of fixed-course glofitamab', 'at the end of fixed-course glofitamab treatment.', 'the end of fixed-course glofitamab treatment. just', 'end of fixed-course glofitamab treatment. just published', 'of fixed-course glofitamab treatment. just published in.', 'fixed-course glofitamab treatment. just published in. ', '#ash22 abstract 441 - et al. off-treatment progression', 'abstract 441 - et al. off-treatment progression is', '441 - et al. off-treatment progression is uncommon', '- et al. off-treatment progression is uncommon in', 'et al. off-treatment progression is uncommon in highly', 'al. off-treatment progression is uncommon in highly refractory', 'off-treatment progression is uncommon in highly refractory patients', 'progression is uncommon in highly refractory patients with', 'is uncommon in highly refractory patients with lbcl', 'uncommon in highly refractory patients with lbcl who', 'in highly refractory patients with lbcl who are', 'highly refractory patients with lbcl who are in', 'refractory patients with lbcl who are in cr', 'patients with lbcl who are in cr at', 'with lbcl who are in cr at the', 'lbcl who are in cr at the end', 'who are in cr at the end of', 'are in cr at the end of fixed-course', 'in cr at the end of fixed-course glofitamab', 'cr at the end of fixed-course glofitamab treatment.', 'at the end of fixed-course glofitamab treatment. just', 'the end of fixed-course glofitamab treatment. just published', 'end of fixed-course glofitamab treatment. just published in.', 'of fixed-course glofitamab treatment. just published in. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '4', 'tokens': ['glofitamab', 'for', 'relapsed', 'or', 'refractory', 'diffuse', 'large', 'b-cell', 'lymphoma', '#ash22', '#lymsm.', ''], 'text_length': 12, 'triples': {'glofitamab|relapsed or refractory diffuse': ([0, 0], [2, 5], 'neutral')}, 'sentence': 'glofitamab for relapsed or refractory diffuse large b-cell lymphoma #ash22 #lymsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 5)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 0, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8)], 'span tokens': ['glofitamab', 'for', 'relapsed', 'or', 'refractory', 'diffuse', 'large', 'b-cell', 'lymphoma', '#ash22', '#lymsm.', '', 'glofitamab for', 'for relapsed', 'relapsed or', 'or refractory', 'refractory diffuse', 'diffuse large', 'large b-cell', 'b-cell lymphoma', 'lymphoma #ash22', '#ash22 #lymsm.', '#lymsm. ', 'glofitamab for relapsed', 'for relapsed or', 'relapsed or refractory', 'or refractory diffuse', 'refractory diffuse large', 'diffuse large b-cell', 'large b-cell lymphoma', 'b-cell lymphoma #ash22', 'lymphoma #ash22 #lymsm.', '#ash22 #lymsm. ', 'glofitamab for relapsed or', 'for relapsed or refractory', 'relapsed or refractory diffuse', 'or refractory diffuse large', 'refractory diffuse large b-cell', 'diffuse large b-cell lymphoma', 'large b-cell lymphoma #ash22', 'b-cell lymphoma #ash22 #lymsm.', 'lymphoma #ash22 #lymsm. ', 'glofitamab for relapsed or refractory', 'for relapsed or refractory diffuse', 'relapsed or refractory diffuse large', 'or refractory diffuse large b-cell', 'refractory diffuse large b-cell lymphoma', 'diffuse large b-cell lymphoma #ash22', 'large b-cell lymphoma #ash22 #lymsm.', 'b-cell lymphoma #ash22 #lymsm. ', 'glofitamab for relapsed or refractory diffuse', 'for relapsed or refractory diffuse large', 'relapsed or refractory diffuse large b-cell', 'or refractory diffuse large b-cell lymphoma', 'refractory diffuse large b-cell lymphoma #ash22', 'diffuse large b-cell lymphoma #ash22 #lymsm.', 'large b-cell lymphoma #ash22 #lymsm. ', 'glofitamab for relapsed or refractory diffuse large', 'for relapsed or refractory diffuse large b-cell', 'relapsed or refractory diffuse large b-cell lymphoma', 'or refractory diffuse large b-cell lymphoma #ash22', 'refractory diffuse large b-cell lymphoma #ash22 #lymsm.', 'diffuse large b-cell lymphoma #ash22 #lymsm. ', 'glofitamab for relapsed or refractory diffuse large b-cell', 'for relapsed or refractory diffuse large b-cell lymphoma', 'relapsed or refractory diffuse large b-cell lymphoma #ash22', 'or refractory diffuse large b-cell lymphoma #ash22 #lymsm.', 'refractory diffuse large b-cell lymphoma #ash22 #lymsm. '], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '5', 'tokens': ['day', '2', 'starting', 'off', 'with', 'exciting', 'updates', 'on', 'glofitamab', '-', 'excited', 'to', 'read', 'this', 'later', 'but', 'the', 'durable', 'responses', 'presented', 'today', 'in', 'the', 'r/r', 'setting', 'are', 'intriguing', 'although', 'need', 'to', 'get', 'a', 'better', 'sense', 'of', 'who', 'may', 'benefit', 'and', 'enter', 'the', 'initial', 'cr', 'group', '#ash22', '#lymsm.', ''], 'text_length': 47, 'triples': {'glofitamab|exciting updates on glofitamab - excited to read this later but the durable': ([8, 8], [5, 17], 'positive')}, 'sentence': 'day 2 starting off with exciting updates on glofitamab - excited to read this later but the durable responses presented today in the r/r setting are intriguing although need to get a better sense of who may benefit and enter the initial cr group #ash22 #lymsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 17)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8)], 'span tokens': ['day', '2', 'starting', 'off', 'with', 'exciting', 'updates', 'on', 'glofitamab', '-', 'excited', 'to', 'read', 'this', 'later', 'but', 'the', 'durable', 'responses', 'presented', 'today', 'in', 'the', 'r/r', 'setting', 'are', 'intriguing', 'although', 'need', 'to', 'get', 'a', 'better', 'sense', 'of', 'who', 'may', 'benefit', 'and', 'enter', 'the', 'initial', 'cr', 'group', '#ash22', '#lymsm.', '', 'day 2', '2 starting', 'starting off', 'off with', 'with exciting', 'exciting updates', 'updates on', 'on glofitamab', 'glofitamab -', '- excited', 'excited to', 'to read', 'read this', 'this later', 'later but', 'but the', 'the durable', 'durable responses', 'responses presented', 'presented today', 'today in', 'in the', 'the r/r', 'r/r setting', 'setting are', 'are intriguing', 'intriguing although', 'although need', 'need to', 'to get', 'get a', 'a better', 'better sense', 'sense of', 'of who', 'who may', 'may benefit', 'benefit and', 'and enter', 'enter the', 'the initial', 'initial cr', 'cr group', 'group #ash22', '#ash22 #lymsm.', '#lymsm. ', 'day 2 starting', '2 starting off', 'starting off with', 'off with exciting', 'with exciting updates', 'exciting updates on', 'updates on glofitamab', 'on glofitamab -', 'glofitamab - excited', '- excited to', 'excited to read', 'to read this', 'read this later', 'this later but', 'later but the', 'but the durable', 'the durable responses', 'durable responses presented', 'responses presented today', 'presented today in', 'today in the', 'in the r/r', 'the r/r setting', 'r/r setting are', 'setting are intriguing', 'are intriguing although', 'intriguing although need', 'although need to', 'need to get', 'to get a', 'get a better', 'a better sense', 'better sense of', 'sense of who', 'of who may', 'who may benefit', 'may benefit and', 'benefit and enter', 'and enter the', 'enter the initial', 'the initial cr', 'initial cr group', 'cr group #ash22', 'group #ash22 #lymsm.', '#ash22 #lymsm. ', 'day 2 starting off', '2 starting off with', 'starting off with exciting', 'off with exciting updates', 'with exciting updates on', 'exciting updates on glofitamab', 'updates on glofitamab -', 'on glofitamab - excited', 'glofitamab - excited to', '- excited to read', 'excited to read this', 'to read this later', 'read this later but', 'this later but the', 'later but the durable', 'but the durable responses', 'the durable responses presented', 'durable responses presented today', 'responses presented today in', 'presented today in the', 'today in the r/r', 'in the r/r setting', 'the r/r setting are', 'r/r setting are intriguing', 'setting are intriguing although', 'are intriguing although need', 'intriguing although need to', 'although need to get', 'need to get a', 'to get a better', 'get a better sense', 'a better sense of', 'better sense of who', 'sense of who may', 'of who may benefit', 'who may benefit and', 'may benefit and enter', 'benefit and enter the', 'and enter the initial', 'enter the initial cr', 'the initial cr group', 'initial cr group #ash22', 'cr group #ash22 #lymsm.', 'group #ash22 #lymsm. ', 'day 2 starting off with', '2 starting off with exciting', 'starting off with exciting updates', 'off with exciting updates on', 'with exciting updates on glofitamab', 'exciting updates on glofitamab -', 'updates on glofitamab - excited', 'on glofitamab - excited to', 'glofitamab - excited to read', '- excited to read this', 'excited to read this later', 'to read this later but', 'read this later but the', 'this later but the durable', 'later but the durable responses', 'but the durable responses presented', 'the durable responses presented today', 'durable responses presented today in', 'responses presented today in the', 'presented today in the r/r', 'today in the r/r setting', 'in the r/r setting are', 'the r/r setting are intriguing', 'r/r setting are intriguing although', 'setting are intriguing although need', 'are intriguing although need to', 'intriguing although need to get', 'although need to get a', 'need to get a better', 'to get a better sense', 'get a better sense of', 'a better sense of who', 'better sense of who may', 'sense of who may benefit', 'of who may benefit and', 'who may benefit and enter', 'may benefit and enter the', 'benefit and enter the initial', 'and enter the initial cr', 'enter the initial cr group', 'the initial cr group #ash22', 'initial cr group #ash22 #lymsm.', 'cr group #ash22 #lymsm. ', 'day 2 starting off with exciting', '2 starting off with exciting updates', 'starting off with exciting updates on', 'off with exciting updates on glofitamab', 'with exciting updates on glofitamab -', 'exciting updates on glofitamab - excited', 'updates on glofitamab - excited to', 'on glofitamab - excited to read', 'glofitamab - excited to read this', '- excited to read this later', 'excited to read this later but', 'to read this later but the', 'read this later but the durable', 'this later but the durable responses', 'later but the durable responses presented', 'but the durable responses presented today', 'the durable responses presented today in', 'durable responses presented today in the', 'responses presented today in the r/r', 'presented today in the r/r setting', 'today in the r/r setting are', 'in the r/r setting are intriguing', 'the r/r setting are intriguing although', 'r/r setting are intriguing although need', 'setting are intriguing although need to', 'are intriguing although need to get', 'intriguing although need to get a', 'although need to get a better', 'need to get a better sense', 'to get a better sense of', 'get a better sense of who', 'a better sense of who may', 'better sense of who may benefit', 'sense of who may benefit and', 'of who may benefit and enter', 'who may benefit and enter the', 'may benefit and enter the initial', 'benefit and enter the initial cr', 'and enter the initial cr group', 'enter the initial cr group #ash22', 'the initial cr group #ash22 #lymsm.', 'initial cr group #ash22 #lymsm. ', 'day 2 starting off with exciting updates', '2 starting off with exciting updates on', 'starting off with exciting updates on glofitamab', 'off with exciting updates on glofitamab -', 'with exciting updates on glofitamab - excited', 'exciting updates on glofitamab - excited to', 'updates on glofitamab - excited to read', 'on glofitamab - excited to read this', 'glofitamab - excited to read this later', '- excited to read this later but', 'excited to read this later but the', 'to read this later but the durable', 'read this later but the durable responses', 'this later but the durable responses presented', 'later but the durable responses presented today', 'but the durable responses presented today in', 'the durable responses presented today in the', 'durable responses presented today in the r/r', 'responses presented today in the r/r setting', 'presented today in the r/r setting are', 'today in the r/r setting are intriguing', 'in the r/r setting are intriguing although', 'the r/r setting are intriguing although need', 'r/r setting are intriguing although need to', 'setting are intriguing although need to get', 'are intriguing although need to get a', 'intriguing although need to get a better', 'although need to get a better sense', 'need to get a better sense of', 'to get a better sense of who', 'get a better sense of who may', 'a better sense of who may benefit', 'better sense of who may benefit and', 'sense of who may benefit and enter', 'of who may benefit and enter the', 'who may benefit and enter the initial', 'may benefit and enter the initial cr', 'benefit and enter the initial cr group', 'and enter the initial cr group #ash22', 'enter the initial cr group #ash22 #lymsm.', 'the initial cr group #ash22 #lymsm. ', 'day 2 starting off with exciting updates on', '2 starting off with exciting updates on glofitamab', 'starting off with exciting updates on glofitamab -', 'off with exciting updates on glofitamab - excited', 'with exciting updates on glofitamab - excited to', 'exciting updates on glofitamab - excited to read', 'updates on glofitamab - excited to read this', 'on glofitamab - excited to read this later', 'glofitamab - excited to read this later but', '- excited to read this later but the', 'excited to read this later but the durable', 'to read this later but the durable responses', 'read this later but the durable responses presented', 'this later but the durable responses presented today', 'later but the durable responses presented today in', 'but the durable responses presented today in the', 'the durable responses presented today in the r/r', 'durable responses presented today in the r/r setting', 'responses presented today in the r/r setting are', 'presented today in the r/r setting are intriguing', 'today in the r/r setting are intriguing although', 'in the r/r setting are intriguing although need', 'the r/r setting are intriguing although need to', 'r/r setting are intriguing although need to get', 'setting are intriguing although need to get a', 'are intriguing although need to get a better', 'intriguing although need to get a better sense', 'although need to get a better sense of', 'need to get a better sense of who', 'to get a better sense of who may', 'get a better sense of who may benefit', 'a better sense of who may benefit and', 'better sense of who may benefit and enter', 'sense of who may benefit and enter the', 'of who may benefit and enter the initial', 'who may benefit and enter the initial cr', 'may benefit and enter the initial cr group', 'benefit and enter the initial cr group #ash22', 'and enter the initial cr group #ash22 #lymsm.', 'enter the initial cr group #ash22 #lymsm. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '6', 'tokens': ['many', 'exciting', 'updates', 'from', 'presentation', 'today', 're', 'glofitamab', 'retreatment,', 'development', 'of', 'subcut', 'glofit,', 'durability', 'of', 'responses', '(', 'i', 'think', 'people', 'are', 'cured', 'but', 'i', 'don', 't', 'know', 'yet', ')', '#ash22', '.'], 'text_length': 31, 'triples': {'glofitamab|many exciting updates from presentation today re glofitamab retreatment, development of subcut glofit, durability of responses': ([7, 7], [0, 15], 'positive')}, 'sentence': 'many exciting updates from presentation today re glofitamab retreatment, development of subcut glofit, durability of responses ( i think people are cured but i don t know yet ) #ash22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 15)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['many', 'exciting', 'updates', 'from', 'presentation', 'today', 're', 'glofitamab', 'retreatment,', 'development', 'of', 'subcut', 'glofit,', 'durability', 'of', 'responses', '(', 'i', 'think', 'people', 'are', 'cured', 'but', 'i', 'don', 't', 'know', 'yet', ')', '#ash22', '.', 'many exciting', 'exciting updates', 'updates from', 'from presentation', 'presentation today', 'today re', 're glofitamab', 'glofitamab retreatment,', 'retreatment, development', 'development of', 'of subcut', 'subcut glofit,', 'glofit, durability', 'durability of', 'of responses', 'responses (', '( i', 'i think', 'think people', 'people are', 'are cured', 'cured but', 'but i', 'i don', 'don t', 't know', 'know yet', 'yet )', ') #ash22', '#ash22 .', 'many exciting updates', 'exciting updates from', 'updates from presentation', 'from presentation today', 'presentation today re', 'today re glofitamab', 're glofitamab retreatment,', 'glofitamab retreatment, development', 'retreatment, development of', 'development of subcut', 'of subcut glofit,', 'subcut glofit, durability', 'glofit, durability of', 'durability of responses', 'of responses (', 'responses ( i', '( i think', 'i think people', 'think people are', 'people are cured', 'are cured but', 'cured but i', 'but i don', 'i don t', 'don t know', 't know yet', 'know yet )', 'yet ) #ash22', ') #ash22 .', 'many exciting updates from', 'exciting updates from presentation', 'updates from presentation today', 'from presentation today re', 'presentation today re glofitamab', 'today re glofitamab retreatment,', 're glofitamab retreatment, development', 'glofitamab retreatment, development of', 'retreatment, development of subcut', 'development of subcut glofit,', 'of subcut glofit, durability', 'subcut glofit, durability of', 'glofit, durability of responses', 'durability of responses (', 'of responses ( i', 'responses ( i think', '( i think people', 'i think people are', 'think people are cured', 'people are cured but', 'are cured but i', 'cured but i don', 'but i don t', 'i don t know', 'don t know yet', 't know yet )', 'know yet ) #ash22', 'yet ) #ash22 .', 'many exciting updates from presentation', 'exciting updates from presentation today', 'updates from presentation today re', 'from presentation today re glofitamab', 'presentation today re glofitamab retreatment,', 'today re glofitamab retreatment, development', 're glofitamab retreatment, development of', 'glofitamab retreatment, development of subcut', 'retreatment, development of subcut glofit,', 'development of subcut glofit, durability', 'of subcut glofit, durability of', 'subcut glofit, durability of responses', 'glofit, durability of responses (', 'durability of responses ( i', 'of responses ( i think', 'responses ( i think people', '( i think people are', 'i think people are cured', 'think people are cured but', 'people are cured but i', 'are cured but i don', 'cured but i don t', 'but i don t know', 'i don t know yet', 'don t know yet )', 't know yet ) #ash22', 'know yet ) #ash22 .', 'many exciting updates from presentation today', 'exciting updates from presentation today re', 'updates from presentation today re glofitamab', 'from presentation today re glofitamab retreatment,', 'presentation today re glofitamab retreatment, development', 'today re glofitamab retreatment, development of', 're glofitamab retreatment, development of subcut', 'glofitamab retreatment, development of subcut glofit,', 'retreatment, development of subcut glofit, durability', 'development of subcut glofit, durability of', 'of subcut glofit, durability of responses', 'subcut glofit, durability of responses (', 'glofit, durability of responses ( i', 'durability of responses ( i think', 'of responses ( i think people', 'responses ( i think people are', '( i think people are cured', 'i think people are cured but', 'think people are cured but i', 'people are cured but i don', 'are cured but i don t', 'cured but i don t know', 'but i don t know yet', 'i don t know yet )', 'don t know yet ) #ash22', 't know yet ) #ash22 .', 'many exciting updates from presentation today re', 'exciting updates from presentation today re glofitamab', 'updates from presentation today re glofitamab retreatment,', 'from presentation today re glofitamab retreatment, development', 'presentation today re glofitamab retreatment, development of', 'today re glofitamab retreatment, development of subcut', 're glofitamab retreatment, development of subcut glofit,', 'glofitamab retreatment, development of subcut glofit, durability', 'retreatment, development of subcut glofit, durability of', 'development of subcut glofit, durability of responses', 'of subcut glofit, durability of responses (', 'subcut glofit, durability of responses ( i', 'glofit, durability of responses ( i think', 'durability of responses ( i think people', 'of responses ( i think people are', 'responses ( i think people are cured', '( i think people are cured but', 'i think people are cured but i', 'think people are cured but i don', 'people are cured but i don t', 'are cured but i don t know', 'cured but i don t know yet', 'but i don t know yet )', 'i don t know yet ) #ash22', 'don t know yet ) #ash22 .', 'many exciting updates from presentation today re glofitamab', 'exciting updates from presentation today re glofitamab retreatment,', 'updates from presentation today re glofitamab retreatment, development', 'from presentation today re glofitamab retreatment, development of', 'presentation today re glofitamab retreatment, development of subcut', 'today re glofitamab retreatment, development of subcut glofit,', 're glofitamab retreatment, development of subcut glofit, durability', 'glofitamab retreatment, development of subcut glofit, durability of', 'retreatment, development of subcut glofit, durability of responses', 'development of subcut glofit, durability of responses (', 'of subcut glofit, durability of responses ( i', 'subcut glofit, durability of responses ( i think', 'glofit, durability of responses ( i think people', 'durability of responses ( i think people are', 'of responses ( i think people are cured', 'responses ( i think people are cured but', '( i think people are cured but i', 'i think people are cured but i don', 'think people are cured but i don t', 'people are cured but i don t know', 'are cured but i don t know yet', 'cured but i don t know yet )', 'but i don t know yet ) #ash22', 'i don t know yet ) #ash22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '7', 'tokens': ['glofitamab', 'responses', 'quite', 'durable', 'for', 'responders,', 'but', 'cr', 'rate', 'is', '&lt;40%', 'overall.', 'another', 'tool', 'to', 'add', 'to', 'the', 'armamentarium?', '#ash22', '#lymsm', '.'], 'text_length': 22, 'triples': {'glofitamab|responses quite durable': ([0, 0], [1, 3], 'neutral')}, 'sentence': 'glofitamab responses quite durable for responders, but cr rate is &lt;40% overall. another tool to add to the armamentarium? #ash22 #lymsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['glofitamab', 'responses', 'quite', 'durable', 'for', 'responders,', 'but', 'cr', 'rate', 'is', '&lt;40%', 'overall.', 'another', 'tool', 'to', 'add', 'to', 'the', 'armamentarium?', '#ash22', '#lymsm', '.', 'glofitamab responses', 'responses quite', 'quite durable', 'durable for', 'for responders,', 'responders, but', 'but cr', 'cr rate', 'rate is', 'is &lt;40%', '&lt;40% overall.', 'overall. another', 'another tool', 'tool to', 'to add', 'add to', 'to the', 'the armamentarium?', 'armamentarium? #ash22', '#ash22 #lymsm', '#lymsm .', 'glofitamab responses quite', 'responses quite durable', 'quite durable for', 'durable for responders,', 'for responders, but', 'responders, but cr', 'but cr rate', 'cr rate is', 'rate is &lt;40%', 'is &lt;40% overall.', '&lt;40% overall. another', 'overall. another tool', 'another tool to', 'tool to add', 'to add to', 'add to the', 'to the armamentarium?', 'the armamentarium? #ash22', 'armamentarium? #ash22 #lymsm', '#ash22 #lymsm .', 'glofitamab responses quite durable', 'responses quite durable for', 'quite durable for responders,', 'durable for responders, but', 'for responders, but cr', 'responders, but cr rate', 'but cr rate is', 'cr rate is &lt;40%', 'rate is &lt;40% overall.', 'is &lt;40% overall. another', '&lt;40% overall. another tool', 'overall. another tool to', 'another tool to add', 'tool to add to', 'to add to the', 'add to the armamentarium?', 'to the armamentarium? #ash22', 'the armamentarium? #ash22 #lymsm', 'armamentarium? #ash22 #lymsm .', 'glofitamab responses quite durable for', 'responses quite durable for responders,', 'quite durable for responders, but', 'durable for responders, but cr', 'for responders, but cr rate', 'responders, but cr rate is', 'but cr rate is &lt;40%', 'cr rate is &lt;40% overall.', 'rate is &lt;40% overall. another', 'is &lt;40% overall. another tool', '&lt;40% overall. another tool to', 'overall. another tool to add', 'another tool to add to', 'tool to add to the', 'to add to the armamentarium?', 'add to the armamentarium? #ash22', 'to the armamentarium? #ash22 #lymsm', 'the armamentarium? #ash22 #lymsm .', 'glofitamab responses quite durable for responders,', 'responses quite durable for responders, but', 'quite durable for responders, but cr', 'durable for responders, but cr rate', 'for responders, but cr rate is', 'responders, but cr rate is &lt;40%', 'but cr rate is &lt;40% overall.', 'cr rate is &lt;40% overall. another', 'rate is &lt;40% overall. another tool', 'is &lt;40% overall. another tool to', '&lt;40% overall. another tool to add', 'overall. another tool to add to', 'another tool to add to the', 'tool to add to the armamentarium?', 'to add to the armamentarium? #ash22', 'add to the armamentarium? #ash22 #lymsm', 'to the armamentarium? #ash22 #lymsm .', 'glofitamab responses quite durable for responders, but', 'responses quite durable for responders, but cr', 'quite durable for responders, but cr rate', 'durable for responders, but cr rate is', 'for responders, but cr rate is &lt;40%', 'responders, but cr rate is &lt;40% overall.', 'but cr rate is &lt;40% overall. another', 'cr rate is &lt;40% overall. another tool', 'rate is &lt;40% overall. another tool to', 'is &lt;40% overall. another tool to add', '&lt;40% overall. another tool to add to', 'overall. another tool to add to the', 'another tool to add to the armamentarium?', 'tool to add to the armamentarium? #ash22', 'to add to the armamentarium? #ash22 #lymsm', 'add to the armamentarium? #ash22 #lymsm .', 'glofitamab responses quite durable for responders, but cr', 'responses quite durable for responders, but cr rate', 'quite durable for responders, but cr rate is', 'durable for responders, but cr rate is &lt;40%', 'for responders, but cr rate is &lt;40% overall.', 'responders, but cr rate is &lt;40% overall. another', 'but cr rate is &lt;40% overall. another tool', 'cr rate is &lt;40% overall. another tool to', 'rate is &lt;40% overall. another tool to add', 'is &lt;40% overall. another tool to add to', '&lt;40% overall. another tool to add to the', 'overall. another tool to add to the armamentarium?', 'another tool to add to the armamentarium? #ash22', 'tool to add to the armamentarium? #ash22 #lymsm', 'to add to the armamentarium? #ash22 #lymsm .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '8', 'tokens': ['durable', 'responses', 'with', 'fixed', 'duration', 'glofitamab.', '24m', 'docr', '79%.', 'curative', 'potential', 'of', 'this', 'strategy.', 'retreatment', 'of', 'relapsing', 'patients', 'after', 'achieving', 'cr', 'can', 'induce', 'a', 'new', 'cr.', 'can', 'we', 'switch', 'from', 'continuous', 'treatment', 'to', 'fix', 'duration', 'with', 'bispecific', 'antibodies?', '#ash22.', ''], 'text_length': 40, 'triples': {'glofitamab.|durable': ([5, 5], [0, 0], 'neutral')}, 'sentence': 'durable responses with fixed duration glofitamab. 24m docr 79%. curative potential of this strategy. retreatment of relapsing patients after achieving cr can induce a new cr. can we switch from continuous treatment to fix duration with bispecific antibodies? #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8)], 'span tokens': ['durable', 'responses', 'with', 'fixed', 'duration', 'glofitamab.', '24m', 'docr', '79%.', 'curative', 'potential', 'of', 'this', 'strategy.', 'retreatment', 'of', 'relapsing', 'patients', 'after', 'achieving', 'cr', 'can', 'induce', 'a', 'new', 'cr.', 'can', 'we', 'switch', 'from', 'continuous', 'treatment', 'to', 'fix', 'duration', 'with', 'bispecific', 'antibodies?', '#ash22.', '', 'durable responses', 'responses with', 'with fixed', 'fixed duration', 'duration glofitamab.', 'glofitamab. 24m', '24m docr', 'docr 79%.', '79%. curative', 'curative potential', 'potential of', 'of this', 'this strategy.', 'strategy. retreatment', 'retreatment of', 'of relapsing', 'relapsing patients', 'patients after', 'after achieving', 'achieving cr', 'cr can', 'can induce', 'induce a', 'a new', 'new cr.', 'cr. can', 'can we', 'we switch', 'switch from', 'from continuous', 'continuous treatment', 'treatment to', 'to fix', 'fix duration', 'duration with', 'with bispecific', 'bispecific antibodies?', 'antibodies? #ash22.', '#ash22. ', 'durable responses with', 'responses with fixed', 'with fixed duration', 'fixed duration glofitamab.', 'duration glofitamab. 24m', 'glofitamab. 24m docr', '24m docr 79%.', 'docr 79%. curative', '79%. curative potential', 'curative potential of', 'potential of this', 'of this strategy.', 'this strategy. retreatment', 'strategy. retreatment of', 'retreatment of relapsing', 'of relapsing patients', 'relapsing patients after', 'patients after achieving', 'after achieving cr', 'achieving cr can', 'cr can induce', 'can induce a', 'induce a new', 'a new cr.', 'new cr. can', 'cr. can we', 'can we switch', 'we switch from', 'switch from continuous', 'from continuous treatment', 'continuous treatment to', 'treatment to fix', 'to fix duration', 'fix duration with', 'duration with bispecific', 'with bispecific antibodies?', 'bispecific antibodies? #ash22.', 'antibodies? #ash22. ', 'durable responses with fixed', 'responses with fixed duration', 'with fixed duration glofitamab.', 'fixed duration glofitamab. 24m', 'duration glofitamab. 24m docr', 'glofitamab. 24m docr 79%.', '24m docr 79%. curative', 'docr 79%. curative potential', '79%. curative potential of', 'curative potential of this', 'potential of this strategy.', 'of this strategy. retreatment', 'this strategy. retreatment of', 'strategy. retreatment of relapsing', 'retreatment of relapsing patients', 'of relapsing patients after', 'relapsing patients after achieving', 'patients after achieving cr', 'after achieving cr can', 'achieving cr can induce', 'cr can induce a', 'can induce a new', 'induce a new cr.', 'a new cr. can', 'new cr. can we', 'cr. can we switch', 'can we switch from', 'we switch from continuous', 'switch from continuous treatment', 'from continuous treatment to', 'continuous treatment to fix', 'treatment to fix duration', 'to fix duration with', 'fix duration with bispecific', 'duration with bispecific antibodies?', 'with bispecific antibodies? #ash22.', 'bispecific antibodies? #ash22. ', 'durable responses with fixed duration', 'responses with fixed duration glofitamab.', 'with fixed duration glofitamab. 24m', 'fixed duration glofitamab. 24m docr', 'duration glofitamab. 24m docr 79%.', 'glofitamab. 24m docr 79%. curative', '24m docr 79%. curative potential', 'docr 79%. curative potential of', '79%. curative potential of this', 'curative potential of this strategy.', 'potential of this strategy. retreatment', 'of this strategy. retreatment of', 'this strategy. retreatment of relapsing', 'strategy. retreatment of relapsing patients', 'retreatment of relapsing patients after', 'of relapsing patients after achieving', 'relapsing patients after achieving cr', 'patients after achieving cr can', 'after achieving cr can induce', 'achieving cr can induce a', 'cr can induce a new', 'can induce a new cr.', 'induce a new cr. can', 'a new cr. can we', 'new cr. can we switch', 'cr. can we switch from', 'can we switch from continuous', 'we switch from continuous treatment', 'switch from continuous treatment to', 'from continuous treatment to fix', 'continuous treatment to fix duration', 'treatment to fix duration with', 'to fix duration with bispecific', 'fix duration with bispecific antibodies?', 'duration with bispecific antibodies? #ash22.', 'with bispecific antibodies? #ash22. ', 'durable responses with fixed duration glofitamab.', 'responses with fixed duration glofitamab. 24m', 'with fixed duration glofitamab. 24m docr', 'fixed duration glofitamab. 24m docr 79%.', 'duration glofitamab. 24m docr 79%. curative', 'glofitamab. 24m docr 79%. curative potential', '24m docr 79%. curative potential of', 'docr 79%. curative potential of this', '79%. curative potential of this strategy.', 'curative potential of this strategy. retreatment', 'potential of this strategy. retreatment of', 'of this strategy. retreatment of relapsing', 'this strategy. retreatment of relapsing patients', 'strategy. retreatment of relapsing patients after', 'retreatment of relapsing patients after achieving', 'of relapsing patients after achieving cr', 'relapsing patients after achieving cr can', 'patients after achieving cr can induce', 'after achieving cr can induce a', 'achieving cr can induce a new', 'cr can induce a new cr.', 'can induce a new cr. can', 'induce a new cr. can we', 'a new cr. can we switch', 'new cr. can we switch from', 'cr. can we switch from continuous', 'can we switch from continuous treatment', 'we switch from continuous treatment to', 'switch from continuous treatment to fix', 'from continuous treatment to fix duration', 'continuous treatment to fix duration with', 'treatment to fix duration with bispecific', 'to fix duration with bispecific antibodies?', 'fix duration with bispecific antibodies? #ash22.', 'duration with bispecific antibodies? #ash22. ', 'durable responses with fixed duration glofitamab. 24m', 'responses with fixed duration glofitamab. 24m docr', 'with fixed duration glofitamab. 24m docr 79%.', 'fixed duration glofitamab. 24m docr 79%. curative', 'duration glofitamab. 24m docr 79%. curative potential', 'glofitamab. 24m docr 79%. curative potential of', '24m docr 79%. curative potential of this', 'docr 79%. curative potential of this strategy.', '79%. curative potential of this strategy. retreatment', 'curative potential of this strategy. retreatment of', 'potential of this strategy. retreatment of relapsing', 'of this strategy. retreatment of relapsing patients', 'this strategy. retreatment of relapsing patients after', 'strategy. retreatment of relapsing patients after achieving', 'retreatment of relapsing patients after achieving cr', 'of relapsing patients after achieving cr can', 'relapsing patients after achieving cr can induce', 'patients after achieving cr can induce a', 'after achieving cr can induce a new', 'achieving cr can induce a new cr.', 'cr can induce a new cr. can', 'can induce a new cr. can we', 'induce a new cr. can we switch', 'a new cr. can we switch from', 'new cr. can we switch from continuous', 'cr. can we switch from continuous treatment', 'can we switch from continuous treatment to', 'we switch from continuous treatment to fix', 'switch from continuous treatment to fix duration', 'from continuous treatment to fix duration with', 'continuous treatment to fix duration with bispecific', 'treatment to fix duration with bispecific antibodies?', 'to fix duration with bispecific antibodies? #ash22.', 'fix duration with bispecific antibodies? #ash22. ', 'durable responses with fixed duration glofitamab. 24m docr', 'responses with fixed duration glofitamab. 24m docr 79%.', 'with fixed duration glofitamab. 24m docr 79%. curative', 'fixed duration glofitamab. 24m docr 79%. curative potential', 'duration glofitamab. 24m docr 79%. curative potential of', 'glofitamab. 24m docr 79%. curative potential of this', '24m docr 79%. curative potential of this strategy.', 'docr 79%. curative potential of this strategy. retreatment', '79%. curative potential of this strategy. retreatment of', 'curative potential of this strategy. retreatment of relapsing', 'potential of this strategy. retreatment of relapsing patients', 'of this strategy. retreatment of relapsing patients after', 'this strategy. retreatment of relapsing patients after achieving', 'strategy. retreatment of relapsing patients after achieving cr', 'retreatment of relapsing patients after achieving cr can', 'of relapsing patients after achieving cr can induce', 'relapsing patients after achieving cr can induce a', 'patients after achieving cr can induce a new', 'after achieving cr can induce a new cr.', 'achieving cr can induce a new cr. can', 'cr can induce a new cr. can we', 'can induce a new cr. can we switch', 'induce a new cr. can we switch from', 'a new cr. can we switch from continuous', 'new cr. can we switch from continuous treatment', 'cr. can we switch from continuous treatment to', 'can we switch from continuous treatment to fix', 'we switch from continuous treatment to fix duration', 'switch from continuous treatment to fix duration with', 'from continuous treatment to fix duration with bispecific', 'continuous treatment to fix duration with bispecific antibodies?', 'treatment to fix duration with bispecific antibodies? #ash22.', 'to fix duration with bispecific antibodies? #ash22. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '9', 'tokens': ['"', 'q:', 'is', 'glofitamab', 'a', 'curative', 'treatment?dr', 'hutchings', '-i', 'think', 'it', 'could', 'be', '.'], 'text_length': 14, 'triples': {'is|a curative': ([2, 2], [4, 5], 'neutral')}, 'sentence': '" q: is glofitamab a curative treatment?dr hutchings -i think it could be .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 5)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8)], 'span tokens': ['"', 'q:', 'is', 'glofitamab', 'a', 'curative', 'treatment?dr', 'hutchings', '-i', 'think', 'it', 'could', 'be', '.', '" q:', 'q: is', 'is glofitamab', 'glofitamab a', 'a curative', 'curative treatment?dr', 'treatment?dr hutchings', 'hutchings -i', '-i think', 'think it', 'it could', 'could be', 'be .', '" q: is', 'q: is glofitamab', 'is glofitamab a', 'glofitamab a curative', 'a curative treatment?dr', 'curative treatment?dr hutchings', 'treatment?dr hutchings -i', 'hutchings -i think', '-i think it', 'think it could', 'it could be', 'could be .', '" q: is glofitamab', 'q: is glofitamab a', 'is glofitamab a curative', 'glofitamab a curative treatment?dr', 'a curative treatment?dr hutchings', 'curative treatment?dr hutchings -i', 'treatment?dr hutchings -i think', 'hutchings -i think it', '-i think it could', 'think it could be', 'it could be .', '" q: is glofitamab a', 'q: is glofitamab a curative', 'is glofitamab a curative treatment?dr', 'glofitamab a curative treatment?dr hutchings', 'a curative treatment?dr hutchings -i', 'curative treatment?dr hutchings -i think', 'treatment?dr hutchings -i think it', 'hutchings -i think it could', '-i think it could be', 'think it could be .', '" q: is glofitamab a curative', 'q: is glofitamab a curative treatment?dr', 'is glofitamab a curative treatment?dr hutchings', 'glofitamab a curative treatment?dr hutchings -i', 'a curative treatment?dr hutchings -i think', 'curative treatment?dr hutchings -i think it', 'treatment?dr hutchings -i think it could', 'hutchings -i think it could be', '-i think it could be .', '" q: is glofitamab a curative treatment?dr', 'q: is glofitamab a curative treatment?dr hutchings', 'is glofitamab a curative treatment?dr hutchings -i', 'glofitamab a curative treatment?dr hutchings -i think', 'a curative treatment?dr hutchings -i think it', 'curative treatment?dr hutchings -i think it could', 'treatment?dr hutchings -i think it could be', 'hutchings -i think it could be .', '" q: is glofitamab a curative treatment?dr hutchings', 'q: is glofitamab a curative treatment?dr hutchings -i', 'is glofitamab a curative treatment?dr hutchings -i think', 'glofitamab a curative treatment?dr hutchings -i think it', 'a curative treatment?dr hutchings -i think it could', 'curative treatment?dr hutchings -i think it could be', 'treatment?dr hutchings -i think it could be .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '10', 'tokens': ['congrats', 'to', ',', 'on', 'the', 'impressive', 'pivotal', 'glofitamab', 'data', 'published', 'in', 'today:', '#ash22.', ''], 'text_length': 14, 'triples': {'pivotal|the': ([6, 6], [4, 4], 'positive')}, 'sentence': 'congrats to , on the impressive pivotal glofitamab data published in today: #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8)], 'span tokens': ['congrats', 'to', ',', 'on', 'the', 'impressive', 'pivotal', 'glofitamab', 'data', 'published', 'in', 'today:', '#ash22.', '', 'congrats to', 'to ,', ', on', 'on the', 'the impressive', 'impressive pivotal', 'pivotal glofitamab', 'glofitamab data', 'data published', 'published in', 'in today:', 'today: #ash22.', '#ash22. ', 'congrats to ,', 'to , on', ', on the', 'on the impressive', 'the impressive pivotal', 'impressive pivotal glofitamab', 'pivotal glofitamab data', 'glofitamab data published', 'data published in', 'published in today:', 'in today: #ash22.', 'today: #ash22. ', 'congrats to , on', 'to , on the', ', on the impressive', 'on the impressive pivotal', 'the impressive pivotal glofitamab', 'impressive pivotal glofitamab data', 'pivotal glofitamab data published', 'glofitamab data published in', 'data published in today:', 'published in today: #ash22.', 'in today: #ash22. ', 'congrats to , on the', 'to , on the impressive', ', on the impressive pivotal', 'on the impressive pivotal glofitamab', 'the impressive pivotal glofitamab data', 'impressive pivotal glofitamab data published', 'pivotal glofitamab data published in', 'glofitamab data published in today:', 'data published in today: #ash22.', 'published in today: #ash22. ', 'congrats to , on the impressive', 'to , on the impressive pivotal', ', on the impressive pivotal glofitamab', 'on the impressive pivotal glofitamab data', 'the impressive pivotal glofitamab data published', 'impressive pivotal glofitamab data published in', 'pivotal glofitamab data published in today:', 'glofitamab data published in today: #ash22.', 'data published in today: #ash22. ', 'congrats to , on the impressive pivotal', 'to , on the impressive pivotal glofitamab', ', on the impressive pivotal glofitamab data', 'on the impressive pivotal glofitamab data published', 'the impressive pivotal glofitamab data published in', 'impressive pivotal glofitamab data published in today:', 'pivotal glofitamab data published in today: #ash22.', 'glofitamab data published in today: #ash22. ', 'congrats to , on the impressive pivotal glofitamab', 'to , on the impressive pivotal glofitamab data', ', on the impressive pivotal glofitamab data published', 'on the impressive pivotal glofitamab data published in', 'the impressive pivotal glofitamab data published in today:', 'impressive pivotal glofitamab data published in today: #ash22.', 'pivotal glofitamab data published in today: #ash22. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '11', 'tokens': ['highly', 'pretreated', 'lbcl', 'patients', 'achieved', 'durable', 'responses', 'with', 'glofitamab', 'and', 'retreatment', 'could', 'be', 'an', 'option', 'in', 'those', 'patients', 'who', 'progressed', 'after', 'eot', '#ash22', '#immunotherapy', '#clinicaltrials', '#bites', 'glofitamab.', ''], 'text_length': 28, 'triples': {'glofitamab and retreatment could be an option in those patients who progressed after eot #ash22 #immunotherapy #clinicaltrials #bites glofitamab.|durable responses with glofitamab and retreatment': ([8, 26], [5, 10], 'neutral')}, 'sentence': 'highly pretreated lbcl patients achieved durable responses with glofitamab and retreatment could be an option in those patients who progressed after eot #ash22 #immunotherapy #clinicaltrials #bites glofitamab. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 26)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['highly', 'pretreated', 'lbcl', 'patients', 'achieved', 'durable', 'responses', 'with', 'glofitamab', 'and', 'retreatment', 'could', 'be', 'an', 'option', 'in', 'those', 'patients', 'who', 'progressed', 'after', 'eot', '#ash22', '#immunotherapy', '#clinicaltrials', '#bites', 'glofitamab.', '', 'highly pretreated', 'pretreated lbcl', 'lbcl patients', 'patients achieved', 'achieved durable', 'durable responses', 'responses with', 'with glofitamab', 'glofitamab and', 'and retreatment', 'retreatment could', 'could be', 'be an', 'an option', 'option in', 'in those', 'those patients', 'patients who', 'who progressed', 'progressed after', 'after eot', 'eot #ash22', '#ash22 #immunotherapy', '#immunotherapy #clinicaltrials', '#clinicaltrials #bites', '#bites glofitamab.', 'glofitamab. ', 'highly pretreated lbcl', 'pretreated lbcl patients', 'lbcl patients achieved', 'patients achieved durable', 'achieved durable responses', 'durable responses with', 'responses with glofitamab', 'with glofitamab and', 'glofitamab and retreatment', 'and retreatment could', 'retreatment could be', 'could be an', 'be an option', 'an option in', 'option in those', 'in those patients', 'those patients who', 'patients who progressed', 'who progressed after', 'progressed after eot', 'after eot #ash22', 'eot #ash22 #immunotherapy', '#ash22 #immunotherapy #clinicaltrials', '#immunotherapy #clinicaltrials #bites', '#clinicaltrials #bites glofitamab.', '#bites glofitamab. ', 'highly pretreated lbcl patients', 'pretreated lbcl patients achieved', 'lbcl patients achieved durable', 'patients achieved durable responses', 'achieved durable responses with', 'durable responses with glofitamab', 'responses with glofitamab and', 'with glofitamab and retreatment', 'glofitamab and retreatment could', 'and retreatment could be', 'retreatment could be an', 'could be an option', 'be an option in', 'an option in those', 'option in those patients', 'in those patients who', 'those patients who progressed', 'patients who progressed after', 'who progressed after eot', 'progressed after eot #ash22', 'after eot #ash22 #immunotherapy', 'eot #ash22 #immunotherapy #clinicaltrials', '#ash22 #immunotherapy #clinicaltrials #bites', '#immunotherapy #clinicaltrials #bites glofitamab.', '#clinicaltrials #bites glofitamab. ', 'highly pretreated lbcl patients achieved', 'pretreated lbcl patients achieved durable', 'lbcl patients achieved durable responses', 'patients achieved durable responses with', 'achieved durable responses with glofitamab', 'durable responses with glofitamab and', 'responses with glofitamab and retreatment', 'with glofitamab and retreatment could', 'glofitamab and retreatment could be', 'and retreatment could be an', 'retreatment could be an option', 'could be an option in', 'be an option in those', 'an option in those patients', 'option in those patients who', 'in those patients who progressed', 'those patients who progressed after', 'patients who progressed after eot', 'who progressed after eot #ash22', 'progressed after eot #ash22 #immunotherapy', 'after eot #ash22 #immunotherapy #clinicaltrials', 'eot #ash22 #immunotherapy #clinicaltrials #bites', '#ash22 #immunotherapy #clinicaltrials #bites glofitamab.', '#immunotherapy #clinicaltrials #bites glofitamab. ', 'highly pretreated lbcl patients achieved durable', 'pretreated lbcl patients achieved durable responses', 'lbcl patients achieved durable responses with', 'patients achieved durable responses with glofitamab', 'achieved durable responses with glofitamab and', 'durable responses with glofitamab and retreatment', 'responses with glofitamab and retreatment could', 'with glofitamab and retreatment could be', 'glofitamab and retreatment could be an', 'and retreatment could be an option', 'retreatment could be an option in', 'could be an option in those', 'be an option in those patients', 'an option in those patients who', 'option in those patients who progressed', 'in those patients who progressed after', 'those patients who progressed after eot', 'patients who progressed after eot #ash22', 'who progressed after eot #ash22 #immunotherapy', 'progressed after eot #ash22 #immunotherapy #clinicaltrials', 'after eot #ash22 #immunotherapy #clinicaltrials #bites', 'eot #ash22 #immunotherapy #clinicaltrials #bites glofitamab.', '#ash22 #immunotherapy #clinicaltrials #bites glofitamab. ', 'highly pretreated lbcl patients achieved durable responses', 'pretreated lbcl patients achieved durable responses with', 'lbcl patients achieved durable responses with glofitamab', 'patients achieved durable responses with glofitamab and', 'achieved durable responses with glofitamab and retreatment', 'durable responses with glofitamab and retreatment could', 'responses with glofitamab and retreatment could be', 'with glofitamab and retreatment could be an', 'glofitamab and retreatment could be an option', 'and retreatment could be an option in', 'retreatment could be an option in those', 'could be an option in those patients', 'be an option in those patients who', 'an option in those patients who progressed', 'option in those patients who progressed after', 'in those patients who progressed after eot', 'those patients who progressed after eot #ash22', 'patients who progressed after eot #ash22 #immunotherapy', 'who progressed after eot #ash22 #immunotherapy #clinicaltrials', 'progressed after eot #ash22 #immunotherapy #clinicaltrials #bites', 'after eot #ash22 #immunotherapy #clinicaltrials #bites glofitamab.', 'eot #ash22 #immunotherapy #clinicaltrials #bites glofitamab. ', 'highly pretreated lbcl patients achieved durable responses with', 'pretreated lbcl patients achieved durable responses with glofitamab', 'lbcl patients achieved durable responses with glofitamab and', 'patients achieved durable responses with glofitamab and retreatment', 'achieved durable responses with glofitamab and retreatment could', 'durable responses with glofitamab and retreatment could be', 'responses with glofitamab and retreatment could be an', 'with glofitamab and retreatment could be an option', 'glofitamab and retreatment could be an option in', 'and retreatment could be an option in those', 'retreatment could be an option in those patients', 'could be an option in those patients who', 'be an option in those patients who progressed', 'an option in those patients who progressed after', 'option in those patients who progressed after eot', 'in those patients who progressed after eot #ash22', 'those patients who progressed after eot #ash22 #immunotherapy', 'patients who progressed after eot #ash22 #immunotherapy #clinicaltrials', 'who progressed after eot #ash22 #immunotherapy #clinicaltrials #bites', 'progressed after eot #ash22 #immunotherapy #clinicaltrials #bites glofitamab.', 'after eot #ash22 #immunotherapy #clinicaltrials #bites glofitamab. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '12', 'tokens': ['presenting', 'glofitamab', 'follow', 'up', 'data', 'for', 'patients', 'achieving', 'cr', '(35%', 'of', 'treated).', 'not', 'yet', 'able', 'to', 'conclude', 'cure', 'when', 'considering', 'data', 'for', '#cart', 'median', 'follow', 'up', '11m.', 'will', 'wait', 'for', 'more', '#ash22', '#carvsbite.', ''], 'text_length': 34, 'triples': {'glofitamab|not yet able to conclude': ([1, 1], [12, 16], 'neutral')}, 'sentence': 'presenting glofitamab follow up data for patients achieving cr (35% of treated). not yet able to conclude cure when considering data for #cart median follow up 11m. will wait for more #ash22 #carvsbite. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(12, 16)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 0, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['presenting', 'glofitamab', 'follow', 'up', 'data', 'for', 'patients', 'achieving', 'cr', '(35%', 'of', 'treated).', 'not', 'yet', 'able', 'to', 'conclude', 'cure', 'when', 'considering', 'data', 'for', '#cart', 'median', 'follow', 'up', '11m.', 'will', 'wait', 'for', 'more', '#ash22', '#carvsbite.', '', 'presenting glofitamab', 'glofitamab follow', 'follow up', 'up data', 'data for', 'for patients', 'patients achieving', 'achieving cr', 'cr (35%', '(35% of', 'of treated).', 'treated). not', 'not yet', 'yet able', 'able to', 'to conclude', 'conclude cure', 'cure when', 'when considering', 'considering data', 'data for', 'for #cart', '#cart median', 'median follow', 'follow up', 'up 11m.', '11m. will', 'will wait', 'wait for', 'for more', 'more #ash22', '#ash22 #carvsbite.', '#carvsbite. ', 'presenting glofitamab follow', 'glofitamab follow up', 'follow up data', 'up data for', 'data for patients', 'for patients achieving', 'patients achieving cr', 'achieving cr (35%', 'cr (35% of', '(35% of treated).', 'of treated). not', 'treated). not yet', 'not yet able', 'yet able to', 'able to conclude', 'to conclude cure', 'conclude cure when', 'cure when considering', 'when considering data', 'considering data for', 'data for #cart', 'for #cart median', '#cart median follow', 'median follow up', 'follow up 11m.', 'up 11m. will', '11m. will wait', 'will wait for', 'wait for more', 'for more #ash22', 'more #ash22 #carvsbite.', '#ash22 #carvsbite. ', 'presenting glofitamab follow up', 'glofitamab follow up data', 'follow up data for', 'up data for patients', 'data for patients achieving', 'for patients achieving cr', 'patients achieving cr (35%', 'achieving cr (35% of', 'cr (35% of treated).', '(35% of treated). not', 'of treated). not yet', 'treated). not yet able', 'not yet able to', 'yet able to conclude', 'able to conclude cure', 'to conclude cure when', 'conclude cure when considering', 'cure when considering data', 'when considering data for', 'considering data for #cart', 'data for #cart median', 'for #cart median follow', '#cart median follow up', 'median follow up 11m.', 'follow up 11m. will', 'up 11m. will wait', '11m. will wait for', 'will wait for more', 'wait for more #ash22', 'for more #ash22 #carvsbite.', 'more #ash22 #carvsbite. ', 'presenting glofitamab follow up data', 'glofitamab follow up data for', 'follow up data for patients', 'up data for patients achieving', 'data for patients achieving cr', 'for patients achieving cr (35%', 'patients achieving cr (35% of', 'achieving cr (35% of treated).', 'cr (35% of treated). not', '(35% of treated). not yet', 'of treated). not yet able', 'treated). not yet able to', 'not yet able to conclude', 'yet able to conclude cure', 'able to conclude cure when', 'to conclude cure when considering', 'conclude cure when considering data', 'cure when considering data for', 'when considering data for #cart', 'considering data for #cart median', 'data for #cart median follow', 'for #cart median follow up', '#cart median follow up 11m.', 'median follow up 11m. will', 'follow up 11m. will wait', 'up 11m. will wait for', '11m. will wait for more', 'will wait for more #ash22', 'wait for more #ash22 #carvsbite.', 'for more #ash22 #carvsbite. ', 'presenting glofitamab follow up data for', 'glofitamab follow up data for patients', 'follow up data for patients achieving', 'up data for patients achieving cr', 'data for patients achieving cr (35%', 'for patients achieving cr (35% of', 'patients achieving cr (35% of treated).', 'achieving cr (35% of treated). not', 'cr (35% of treated). not yet', '(35% of treated). not yet able', 'of treated). not yet able to', 'treated). not yet able to conclude', 'not yet able to conclude cure', 'yet able to conclude cure when', 'able to conclude cure when considering', 'to conclude cure when considering data', 'conclude cure when considering data for', 'cure when considering data for #cart', 'when considering data for #cart median', 'considering data for #cart median follow', 'data for #cart median follow up', 'for #cart median follow up 11m.', '#cart median follow up 11m. will', 'median follow up 11m. will wait', 'follow up 11m. will wait for', 'up 11m. will wait for more', '11m. will wait for more #ash22', 'will wait for more #ash22 #carvsbite.', 'wait for more #ash22 #carvsbite. ', 'presenting glofitamab follow up data for patients', 'glofitamab follow up data for patients achieving', 'follow up data for patients achieving cr', 'up data for patients achieving cr (35%', 'data for patients achieving cr (35% of', 'for patients achieving cr (35% of treated).', 'patients achieving cr (35% of treated). not', 'achieving cr (35% of treated). not yet', 'cr (35% of treated). not yet able', '(35% of treated). not yet able to', 'of treated). not yet able to conclude', 'treated). not yet able to conclude cure', 'not yet able to conclude cure when', 'yet able to conclude cure when considering', 'able to conclude cure when considering data', 'to conclude cure when considering data for', 'conclude cure when considering data for #cart', 'cure when considering data for #cart median', 'when considering data for #cart median follow', 'considering data for #cart median follow up', 'data for #cart median follow up 11m.', 'for #cart median follow up 11m. will', '#cart median follow up 11m. will wait', 'median follow up 11m. will wait for', 'follow up 11m. will wait for more', 'up 11m. will wait for more #ash22', '11m. will wait for more #ash22 #carvsbite.', 'will wait for more #ash22 #carvsbite. ', 'presenting glofitamab follow up data for patients achieving', 'glofitamab follow up data for patients achieving cr', 'follow up data for patients achieving cr (35%', 'up data for patients achieving cr (35% of', 'data for patients achieving cr (35% of treated).', 'for patients achieving cr (35% of treated). not', 'patients achieving cr (35% of treated). not yet', 'achieving cr (35% of treated). not yet able', 'cr (35% of treated). not yet able to', '(35% of treated). not yet able to conclude', 'of treated). not yet able to conclude cure', 'treated). not yet able to conclude cure when', 'not yet able to conclude cure when considering', 'yet able to conclude cure when considering data', 'able to conclude cure when considering data for', 'to conclude cure when considering data for #cart', 'conclude cure when considering data for #cart median', 'cure when considering data for #cart median follow', 'when considering data for #cart median follow up', 'considering data for #cart median follow up 11m.', 'data for #cart median follow up 11m. will', 'for #cart median follow up 11m. will wait', '#cart median follow up 11m. will wait for', 'median follow up 11m. will wait for more', 'follow up 11m. will wait for more #ash22', 'up 11m. will wait for more #ash22 #carvsbite.', '11m. will wait for more #ash22 #carvsbite. '], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '13', 'tokens': ['longer', 'follow', 'up', 'needed', 'for', 'glofitamab', 'in', 'dlbcl', '#lymsm', ',', 'but', 'seems', 'patients', 'with', 'cr', 'maintain', 'the', 'remission', 'for', 'now', '#ash22.', ''], 'text_length': 22, 'triples': {'glofitamab|longer follow up needed': ([5, 5], [0, 3], 'neutral')}, 'sentence': 'longer follow up needed for glofitamab in dlbcl #lymsm , but seems patients with cr maintain the remission for now #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['longer', 'follow', 'up', 'needed', 'for', 'glofitamab', 'in', 'dlbcl', '#lymsm', ',', 'but', 'seems', 'patients', 'with', 'cr', 'maintain', 'the', 'remission', 'for', 'now', '#ash22.', '', 'longer follow', 'follow up', 'up needed', 'needed for', 'for glofitamab', 'glofitamab in', 'in dlbcl', 'dlbcl #lymsm', '#lymsm ,', ', but', 'but seems', 'seems patients', 'patients with', 'with cr', 'cr maintain', 'maintain the', 'the remission', 'remission for', 'for now', 'now #ash22.', '#ash22. ', 'longer follow up', 'follow up needed', 'up needed for', 'needed for glofitamab', 'for glofitamab in', 'glofitamab in dlbcl', 'in dlbcl #lymsm', 'dlbcl #lymsm ,', '#lymsm , but', ', but seems', 'but seems patients', 'seems patients with', 'patients with cr', 'with cr maintain', 'cr maintain the', 'maintain the remission', 'the remission for', 'remission for now', 'for now #ash22.', 'now #ash22. ', 'longer follow up needed', 'follow up needed for', 'up needed for glofitamab', 'needed for glofitamab in', 'for glofitamab in dlbcl', 'glofitamab in dlbcl #lymsm', 'in dlbcl #lymsm ,', 'dlbcl #lymsm , but', '#lymsm , but seems', ', but seems patients', 'but seems patients with', 'seems patients with cr', 'patients with cr maintain', 'with cr maintain the', 'cr maintain the remission', 'maintain the remission for', 'the remission for now', 'remission for now #ash22.', 'for now #ash22. ', 'longer follow up needed for', 'follow up needed for glofitamab', 'up needed for glofitamab in', 'needed for glofitamab in dlbcl', 'for glofitamab in dlbcl #lymsm', 'glofitamab in dlbcl #lymsm ,', 'in dlbcl #lymsm , but', 'dlbcl #lymsm , but seems', '#lymsm , but seems patients', ', but seems patients with', 'but seems patients with cr', 'seems patients with cr maintain', 'patients with cr maintain the', 'with cr maintain the remission', 'cr maintain the remission for', 'maintain the remission for now', 'the remission for now #ash22.', 'remission for now #ash22. ', 'longer follow up needed for glofitamab', 'follow up needed for glofitamab in', 'up needed for glofitamab in dlbcl', 'needed for glofitamab in dlbcl #lymsm', 'for glofitamab in dlbcl #lymsm ,', 'glofitamab in dlbcl #lymsm , but', 'in dlbcl #lymsm , but seems', 'dlbcl #lymsm , but seems patients', '#lymsm , but seems patients with', ', but seems patients with cr', 'but seems patients with cr maintain', 'seems patients with cr maintain the', 'patients with cr maintain the remission', 'with cr maintain the remission for', 'cr maintain the remission for now', 'maintain the remission for now #ash22.', 'the remission for now #ash22. ', 'longer follow up needed for glofitamab in', 'follow up needed for glofitamab in dlbcl', 'up needed for glofitamab in dlbcl #lymsm', 'needed for glofitamab in dlbcl #lymsm ,', 'for glofitamab in dlbcl #lymsm , but', 'glofitamab in dlbcl #lymsm , but seems', 'in dlbcl #lymsm , but seems patients', 'dlbcl #lymsm , but seems patients with', '#lymsm , but seems patients with cr', ', but seems patients with cr maintain', 'but seems patients with cr maintain the', 'seems patients with cr maintain the remission', 'patients with cr maintain the remission for', 'with cr maintain the remission for now', 'cr maintain the remission for now #ash22.', 'maintain the remission for now #ash22. ', 'longer follow up needed for glofitamab in dlbcl', 'follow up needed for glofitamab in dlbcl #lymsm', 'up needed for glofitamab in dlbcl #lymsm ,', 'needed for glofitamab in dlbcl #lymsm , but', 'for glofitamab in dlbcl #lymsm , but seems', 'glofitamab in dlbcl #lymsm , but seems patients', 'in dlbcl #lymsm , but seems patients with', 'dlbcl #lymsm , but seems patients with cr', '#lymsm , but seems patients with cr maintain', ', but seems patients with cr maintain the', 'but seems patients with cr maintain the remission', 'seems patients with cr maintain the remission for', 'patients with cr maintain the remission for now', 'with cr maintain the remission for now #ash22.', 'cr maintain the remission for now #ash22. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '14', 'tokens': ['landmark', 'analysis', 'of', 'bispecifics', 'glofitamab', 'by', 'for', 'cr', 'pts', 'at', 'one', 'year.', 'they', 'appear', 'durable', 'and', 'possibly', 'cure.', '#ash22', 'and', 'congrats', 'on', 'pub', '!!!.', ''], 'text_length': 25, 'triples': {'glofitamab|landmark analysis of bispecifics glofitamab by for cr pts at one year. they appear durable': ([4, 4], [0, 14], 'neutral')}, 'sentence': 'landmark analysis of bispecifics glofitamab by for cr pts at one year. they appear durable and possibly cure. #ash22 and congrats on pub !!!. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 14)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8)], 'span tokens': ['landmark', 'analysis', 'of', 'bispecifics', 'glofitamab', 'by', 'for', 'cr', 'pts', 'at', 'one', 'year.', 'they', 'appear', 'durable', 'and', 'possibly', 'cure.', '#ash22', 'and', 'congrats', 'on', 'pub', '!!!.', '', 'landmark analysis', 'analysis of', 'of bispecifics', 'bispecifics glofitamab', 'glofitamab by', 'by for', 'for cr', 'cr pts', 'pts at', 'at one', 'one year.', 'year. they', 'they appear', 'appear durable', 'durable and', 'and possibly', 'possibly cure.', 'cure. #ash22', '#ash22 and', 'and congrats', 'congrats on', 'on pub', 'pub !!!.', '!!!. ', 'landmark analysis of', 'analysis of bispecifics', 'of bispecifics glofitamab', 'bispecifics glofitamab by', 'glofitamab by for', 'by for cr', 'for cr pts', 'cr pts at', 'pts at one', 'at one year.', 'one year. they', 'year. they appear', 'they appear durable', 'appear durable and', 'durable and possibly', 'and possibly cure.', 'possibly cure. #ash22', 'cure. #ash22 and', '#ash22 and congrats', 'and congrats on', 'congrats on pub', 'on pub !!!.', 'pub !!!. ', 'landmark analysis of bispecifics', 'analysis of bispecifics glofitamab', 'of bispecifics glofitamab by', 'bispecifics glofitamab by for', 'glofitamab by for cr', 'by for cr pts', 'for cr pts at', 'cr pts at one', 'pts at one year.', 'at one year. they', 'one year. they appear', 'year. they appear durable', 'they appear durable and', 'appear durable and possibly', 'durable and possibly cure.', 'and possibly cure. #ash22', 'possibly cure. #ash22 and', 'cure. #ash22 and congrats', '#ash22 and congrats on', 'and congrats on pub', 'congrats on pub !!!.', 'on pub !!!. ', 'landmark analysis of bispecifics glofitamab', 'analysis of bispecifics glofitamab by', 'of bispecifics glofitamab by for', 'bispecifics glofitamab by for cr', 'glofitamab by for cr pts', 'by for cr pts at', 'for cr pts at one', 'cr pts at one year.', 'pts at one year. they', 'at one year. they appear', 'one year. they appear durable', 'year. they appear durable and', 'they appear durable and possibly', 'appear durable and possibly cure.', 'durable and possibly cure. #ash22', 'and possibly cure. #ash22 and', 'possibly cure. #ash22 and congrats', 'cure. #ash22 and congrats on', '#ash22 and congrats on pub', 'and congrats on pub !!!.', 'congrats on pub !!!. ', 'landmark analysis of bispecifics glofitamab by', 'analysis of bispecifics glofitamab by for', 'of bispecifics glofitamab by for cr', 'bispecifics glofitamab by for cr pts', 'glofitamab by for cr pts at', 'by for cr pts at one', 'for cr pts at one year.', 'cr pts at one year. they', 'pts at one year. they appear', 'at one year. they appear durable', 'one year. they appear durable and', 'year. they appear durable and possibly', 'they appear durable and possibly cure.', 'appear durable and possibly cure. #ash22', 'durable and possibly cure. #ash22 and', 'and possibly cure. #ash22 and congrats', 'possibly cure. #ash22 and congrats on', 'cure. #ash22 and congrats on pub', '#ash22 and congrats on pub !!!.', 'and congrats on pub !!!. ', 'landmark analysis of bispecifics glofitamab by for', 'analysis of bispecifics glofitamab by for cr', 'of bispecifics glofitamab by for cr pts', 'bispecifics glofitamab by for cr pts at', 'glofitamab by for cr pts at one', 'by for cr pts at one year.', 'for cr pts at one year. they', 'cr pts at one year. they appear', 'pts at one year. they appear durable', 'at one year. they appear durable and', 'one year. they appear durable and possibly', 'year. they appear durable and possibly cure.', 'they appear durable and possibly cure. #ash22', 'appear durable and possibly cure. #ash22 and', 'durable and possibly cure. #ash22 and congrats', 'and possibly cure. #ash22 and congrats on', 'possibly cure. #ash22 and congrats on pub', 'cure. #ash22 and congrats on pub !!!.', '#ash22 and congrats on pub !!!. ', 'landmark analysis of bispecifics glofitamab by for cr', 'analysis of bispecifics glofitamab by for cr pts', 'of bispecifics glofitamab by for cr pts at', 'bispecifics glofitamab by for cr pts at one', 'glofitamab by for cr pts at one year.', 'by for cr pts at one year. they', 'for cr pts at one year. they appear', 'cr pts at one year. they appear durable', 'pts at one year. they appear durable and', 'at one year. they appear durable and possibly', 'one year. they appear durable and possibly cure.', 'year. they appear durable and possibly cure. #ash22', 'they appear durable and possibly cure. #ash22 and', 'appear durable and possibly cure. #ash22 and congrats', 'durable and possibly cure. #ash22 and congrats on', 'and possibly cure. #ash22 and congrats on pub', 'possibly cure. #ash22 and congrats on pub !!!.', 'cure. #ash22 and congrats on pub !!!. '], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '15', 'tokens': ['#ash22', 'awesome', 'results', 'of', 'glofitamab', 'fix-duration', 'therapy', 'of', '13', 'cycles', 'in', 'r/r', 'dlbcl', 'in', 'patients', 'achieving', 'cr', '#lymsm.', ''], 'text_length': 19, 'triples': {'glofitamab|awesome': ([4, 4], [1, 1], 'positive')}, 'sentence': '#ash22 awesome results of glofitamab fix-duration therapy of 13 cycles in r/r dlbcl in patients achieving cr #lymsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['#ash22', 'awesome', 'results', 'of', 'glofitamab', 'fix-duration', 'therapy', 'of', '13', 'cycles', 'in', 'r/r', 'dlbcl', 'in', 'patients', 'achieving', 'cr', '#lymsm.', '', '#ash22 awesome', 'awesome results', 'results of', 'of glofitamab', 'glofitamab fix-duration', 'fix-duration therapy', 'therapy of', 'of 13', '13 cycles', 'cycles in', 'in r/r', 'r/r dlbcl', 'dlbcl in', 'in patients', 'patients achieving', 'achieving cr', 'cr #lymsm.', '#lymsm. ', '#ash22 awesome results', 'awesome results of', 'results of glofitamab', 'of glofitamab fix-duration', 'glofitamab fix-duration therapy', 'fix-duration therapy of', 'therapy of 13', 'of 13 cycles', '13 cycles in', 'cycles in r/r', 'in r/r dlbcl', 'r/r dlbcl in', 'dlbcl in patients', 'in patients achieving', 'patients achieving cr', 'achieving cr #lymsm.', 'cr #lymsm. ', '#ash22 awesome results of', 'awesome results of glofitamab', 'results of glofitamab fix-duration', 'of glofitamab fix-duration therapy', 'glofitamab fix-duration therapy of', 'fix-duration therapy of 13', 'therapy of 13 cycles', 'of 13 cycles in', '13 cycles in r/r', 'cycles in r/r dlbcl', 'in r/r dlbcl in', 'r/r dlbcl in patients', 'dlbcl in patients achieving', 'in patients achieving cr', 'patients achieving cr #lymsm.', 'achieving cr #lymsm. ', '#ash22 awesome results of glofitamab', 'awesome results of glofitamab fix-duration', 'results of glofitamab fix-duration therapy', 'of glofitamab fix-duration therapy of', 'glofitamab fix-duration therapy of 13', 'fix-duration therapy of 13 cycles', 'therapy of 13 cycles in', 'of 13 cycles in r/r', '13 cycles in r/r dlbcl', 'cycles in r/r dlbcl in', 'in r/r dlbcl in patients', 'r/r dlbcl in patients achieving', 'dlbcl in patients achieving cr', 'in patients achieving cr #lymsm.', 'patients achieving cr #lymsm. ', '#ash22 awesome results of glofitamab fix-duration', 'awesome results of glofitamab fix-duration therapy', 'results of glofitamab fix-duration therapy of', 'of glofitamab fix-duration therapy of 13', 'glofitamab fix-duration therapy of 13 cycles', 'fix-duration therapy of 13 cycles in', 'therapy of 13 cycles in r/r', 'of 13 cycles in r/r dlbcl', '13 cycles in r/r dlbcl in', 'cycles in r/r dlbcl in patients', 'in r/r dlbcl in patients achieving', 'r/r dlbcl in patients achieving cr', 'dlbcl in patients achieving cr #lymsm.', 'in patients achieving cr #lymsm. ', '#ash22 awesome results of glofitamab fix-duration therapy', 'awesome results of glofitamab fix-duration therapy of', 'results of glofitamab fix-duration therapy of 13', 'of glofitamab fix-duration therapy of 13 cycles', 'glofitamab fix-duration therapy of 13 cycles in', 'fix-duration therapy of 13 cycles in r/r', 'therapy of 13 cycles in r/r dlbcl', 'of 13 cycles in r/r dlbcl in', '13 cycles in r/r dlbcl in patients', 'cycles in r/r dlbcl in patients achieving', 'in r/r dlbcl in patients achieving cr', 'r/r dlbcl in patients achieving cr #lymsm.', 'dlbcl in patients achieving cr #lymsm. ', '#ash22 awesome results of glofitamab fix-duration therapy of', 'awesome results of glofitamab fix-duration therapy of 13', 'results of glofitamab fix-duration therapy of 13 cycles', 'of glofitamab fix-duration therapy of 13 cycles in', 'glofitamab fix-duration therapy of 13 cycles in r/r', 'fix-duration therapy of 13 cycles in r/r dlbcl', 'therapy of 13 cycles in r/r dlbcl in', 'of 13 cycles in r/r dlbcl in patients', '13 cycles in r/r dlbcl in patients achieving', 'cycles in r/r dlbcl in patients achieving cr', 'in r/r dlbcl in patients achieving cr #lymsm.', 'r/r dlbcl in patients achieving cr #lymsm. '], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '16', 'tokens': ['relapse', 'is', 'uncommon', 'in', 'patients', 'with', 'lbcl', 'who', 'are', 'in', 'cr', 'at', 'the', 'end', 'of', 'fixed-course', 'glofitamab.', '#ash22.', ''], 'text_length': 19, 'triples': {'glofitamab.|uncommon in patients with lbcl who are in cr at the end of fixed-course': ([16, 16], [2, 15], 'neutral')}, 'sentence': 'relapse is uncommon in patients with lbcl who are in cr at the end of fixed-course glofitamab. #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(16, 16)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 15)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['relapse', 'is', 'uncommon', 'in', 'patients', 'with', 'lbcl', 'who', 'are', 'in', 'cr', 'at', 'the', 'end', 'of', 'fixed-course', 'glofitamab.', '#ash22.', '', 'relapse is', 'is uncommon', 'uncommon in', 'in patients', 'patients with', 'with lbcl', 'lbcl who', 'who are', 'are in', 'in cr', 'cr at', 'at the', 'the end', 'end of', 'of fixed-course', 'fixed-course glofitamab.', 'glofitamab. #ash22.', '#ash22. ', 'relapse is uncommon', 'is uncommon in', 'uncommon in patients', 'in patients with', 'patients with lbcl', 'with lbcl who', 'lbcl who are', 'who are in', 'are in cr', 'in cr at', 'cr at the', 'at the end', 'the end of', 'end of fixed-course', 'of fixed-course glofitamab.', 'fixed-course glofitamab. #ash22.', 'glofitamab. #ash22. ', 'relapse is uncommon in', 'is uncommon in patients', 'uncommon in patients with', 'in patients with lbcl', 'patients with lbcl who', 'with lbcl who are', 'lbcl who are in', 'who are in cr', 'are in cr at', 'in cr at the', 'cr at the end', 'at the end of', 'the end of fixed-course', 'end of fixed-course glofitamab.', 'of fixed-course glofitamab. #ash22.', 'fixed-course glofitamab. #ash22. ', 'relapse is uncommon in patients', 'is uncommon in patients with', 'uncommon in patients with lbcl', 'in patients with lbcl who', 'patients with lbcl who are', 'with lbcl who are in', 'lbcl who are in cr', 'who are in cr at', 'are in cr at the', 'in cr at the end', 'cr at the end of', 'at the end of fixed-course', 'the end of fixed-course glofitamab.', 'end of fixed-course glofitamab. #ash22.', 'of fixed-course glofitamab. #ash22. ', 'relapse is uncommon in patients with', 'is uncommon in patients with lbcl', 'uncommon in patients with lbcl who', 'in patients with lbcl who are', 'patients with lbcl who are in', 'with lbcl who are in cr', 'lbcl who are in cr at', 'who are in cr at the', 'are in cr at the end', 'in cr at the end of', 'cr at the end of fixed-course', 'at the end of fixed-course glofitamab.', 'the end of fixed-course glofitamab. #ash22.', 'end of fixed-course glofitamab. #ash22. ', 'relapse is uncommon in patients with lbcl', 'is uncommon in patients with lbcl who', 'uncommon in patients with lbcl who are', 'in patients with lbcl who are in', 'patients with lbcl who are in cr', 'with lbcl who are in cr at', 'lbcl who are in cr at the', 'who are in cr at the end', 'are in cr at the end of', 'in cr at the end of fixed-course', 'cr at the end of fixed-course glofitamab.', 'at the end of fixed-course glofitamab. #ash22.', 'the end of fixed-course glofitamab. #ash22. ', 'relapse is uncommon in patients with lbcl who', 'is uncommon in patients with lbcl who are', 'uncommon in patients with lbcl who are in', 'in patients with lbcl who are in cr', 'patients with lbcl who are in cr at', 'with lbcl who are in cr at the', 'lbcl who are in cr at the end', 'who are in cr at the end of', 'are in cr at the end of fixed-course', 'in cr at the end of fixed-course glofitamab.', 'cr at the end of fixed-course glofitamab. #ash22.', 'at the end of fixed-course glofitamab. #ash22. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '17', 'tokens': ['glofitamab', 'data:', 'just', 'published', 'few', 'minutes', 'ago', 'in', 'outcomes', 'are', 'excellent', 'in', 'patients', 'achieving', 'cr.', '#ash22.', ''], 'text_length': 17, 'triples': {'glofitamab|excellent': ([0, 0], [10, 10], 'positive')}, 'sentence': 'glofitamab data: just published few minutes ago in outcomes are excellent in patients achieving cr. #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8)], 'span tokens': ['glofitamab', 'data:', 'just', 'published', 'few', 'minutes', 'ago', 'in', 'outcomes', 'are', 'excellent', 'in', 'patients', 'achieving', 'cr.', '#ash22.', '', 'glofitamab data:', 'data: just', 'just published', 'published few', 'few minutes', 'minutes ago', 'ago in', 'in outcomes', 'outcomes are', 'are excellent', 'excellent in', 'in patients', 'patients achieving', 'achieving cr.', 'cr. #ash22.', '#ash22. ', 'glofitamab data: just', 'data: just published', 'just published few', 'published few minutes', 'few minutes ago', 'minutes ago in', 'ago in outcomes', 'in outcomes are', 'outcomes are excellent', 'are excellent in', 'excellent in patients', 'in patients achieving', 'patients achieving cr.', 'achieving cr. #ash22.', 'cr. #ash22. ', 'glofitamab data: just published', 'data: just published few', 'just published few minutes', 'published few minutes ago', 'few minutes ago in', 'minutes ago in outcomes', 'ago in outcomes are', 'in outcomes are excellent', 'outcomes are excellent in', 'are excellent in patients', 'excellent in patients achieving', 'in patients achieving cr.', 'patients achieving cr. #ash22.', 'achieving cr. #ash22. ', 'glofitamab data: just published few', 'data: just published few minutes', 'just published few minutes ago', 'published few minutes ago in', 'few minutes ago in outcomes', 'minutes ago in outcomes are', 'ago in outcomes are excellent', 'in outcomes are excellent in', 'outcomes are excellent in patients', 'are excellent in patients achieving', 'excellent in patients achieving cr.', 'in patients achieving cr. #ash22.', 'patients achieving cr. #ash22. ', 'glofitamab data: just published few minutes', 'data: just published few minutes ago', 'just published few minutes ago in', 'published few minutes ago in outcomes', 'few minutes ago in outcomes are', 'minutes ago in outcomes are excellent', 'ago in outcomes are excellent in', 'in outcomes are excellent in patients', 'outcomes are excellent in patients achieving', 'are excellent in patients achieving cr.', 'excellent in patients achieving cr. #ash22.', 'in patients achieving cr. #ash22. ', 'glofitamab data: just published few minutes ago', 'data: just published few minutes ago in', 'just published few minutes ago in outcomes', 'published few minutes ago in outcomes are', 'few minutes ago in outcomes are excellent', 'minutes ago in outcomes are excellent in', 'ago in outcomes are excellent in patients', 'in outcomes are excellent in patients achieving', 'outcomes are excellent in patients achieving cr.', 'are excellent in patients achieving cr. #ash22.', 'excellent in patients achieving cr. #ash22. ', 'glofitamab data: just published few minutes ago in', 'data: just published few minutes ago in outcomes', 'just published few minutes ago in outcomes are', 'published few minutes ago in outcomes are excellent', 'few minutes ago in outcomes are excellent in', 'minutes ago in outcomes are excellent in patients', 'ago in outcomes are excellent in patients achieving', 'in outcomes are excellent in patients achieving cr.', 'outcomes are excellent in patients achieving cr. #ash22.', 'are excellent in patients achieving cr. #ash22. '], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '18', 'tokens': ['"#ash22', '#lymsm', '#dlbcl', 'hutchings', 'et', 'al', 'glofitamab', 'in', 'rr', 'dlbcl', 'fixed', 'duration', '12', 'cycles', '35.4%', 'cr', 'for', 'pts', 'in', 'cr:', '24', 'mo', 'cr', '79%', '12', 'mo', 'pfs', '92.6%', 'full', 'dataset', 'in', 'today.', ''], 'text_length': 33, 'triples': {'glofitamab|fixed duration 12 cycles 35.4% cr for pts in cr: 24 mo cr 79% 12 mo pfs 92.6% full dataset': ([6, 6], [10, 29], 'neutral')}, 'sentence': '"#ash22 #lymsm #dlbcl hutchings et al glofitamab in rr dlbcl fixed duration 12 cycles 35.4% cr for pts in cr: 24 mo cr 79% 12 mo pfs 92.6% full dataset in today. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['"#ash22', '#lymsm', '#dlbcl', 'hutchings', 'et', 'al', 'glofitamab', 'in', 'rr', 'dlbcl', 'fixed', 'duration', '12', 'cycles', '35.4%', 'cr', 'for', 'pts', 'in', 'cr:', '24', 'mo', 'cr', '79%', '12', 'mo', 'pfs', '92.6%', 'full', 'dataset', 'in', 'today.', '', '"#ash22 #lymsm', '#lymsm #dlbcl', '#dlbcl hutchings', 'hutchings et', 'et al', 'al glofitamab', 'glofitamab in', 'in rr', 'rr dlbcl', 'dlbcl fixed', 'fixed duration', 'duration 12', '12 cycles', 'cycles 35.4%', '35.4% cr', 'cr for', 'for pts', 'pts in', 'in cr:', 'cr: 24', '24 mo', 'mo cr', 'cr 79%', '79% 12', '12 mo', 'mo pfs', 'pfs 92.6%', '92.6% full', 'full dataset', 'dataset in', 'in today.', 'today. ', '"#ash22 #lymsm #dlbcl', '#lymsm #dlbcl hutchings', '#dlbcl hutchings et', 'hutchings et al', 'et al glofitamab', 'al glofitamab in', 'glofitamab in rr', 'in rr dlbcl', 'rr dlbcl fixed', 'dlbcl fixed duration', 'fixed duration 12', 'duration 12 cycles', '12 cycles 35.4%', 'cycles 35.4% cr', '35.4% cr for', 'cr for pts', 'for pts in', 'pts in cr:', 'in cr: 24', 'cr: 24 mo', '24 mo cr', 'mo cr 79%', 'cr 79% 12', '79% 12 mo', '12 mo pfs', 'mo pfs 92.6%', 'pfs 92.6% full', '92.6% full dataset', 'full dataset in', 'dataset in today.', 'in today. ', '"#ash22 #lymsm #dlbcl hutchings', '#lymsm #dlbcl hutchings et', '#dlbcl hutchings et al', 'hutchings et al glofitamab', 'et al glofitamab in', 'al glofitamab in rr', 'glofitamab in rr dlbcl', 'in rr dlbcl fixed', 'rr dlbcl fixed duration', 'dlbcl fixed duration 12', 'fixed duration 12 cycles', 'duration 12 cycles 35.4%', '12 cycles 35.4% cr', 'cycles 35.4% cr for', '35.4% cr for pts', 'cr for pts in', 'for pts in cr:', 'pts in cr: 24', 'in cr: 24 mo', 'cr: 24 mo cr', '24 mo cr 79%', 'mo cr 79% 12', 'cr 79% 12 mo', '79% 12 mo pfs', '12 mo pfs 92.6%', 'mo pfs 92.6% full', 'pfs 92.6% full dataset', '92.6% full dataset in', 'full dataset in today.', 'dataset in today. ', '"#ash22 #lymsm #dlbcl hutchings et', '#lymsm #dlbcl hutchings et al', '#dlbcl hutchings et al glofitamab', 'hutchings et al glofitamab in', 'et al glofitamab in rr', 'al glofitamab in rr dlbcl', 'glofitamab in rr dlbcl fixed', 'in rr dlbcl fixed duration', 'rr dlbcl fixed duration 12', 'dlbcl fixed duration 12 cycles', 'fixed duration 12 cycles 35.4%', 'duration 12 cycles 35.4% cr', '12 cycles 35.4% cr for', 'cycles 35.4% cr for pts', '35.4% cr for pts in', 'cr for pts in cr:', 'for pts in cr: 24', 'pts in cr: 24 mo', 'in cr: 24 mo cr', 'cr: 24 mo cr 79%', '24 mo cr 79% 12', 'mo cr 79% 12 mo', 'cr 79% 12 mo pfs', '79% 12 mo pfs 92.6%', '12 mo pfs 92.6% full', 'mo pfs 92.6% full dataset', 'pfs 92.6% full dataset in', '92.6% full dataset in today.', 'full dataset in today. ', '"#ash22 #lymsm #dlbcl hutchings et al', '#lymsm #dlbcl hutchings et al glofitamab', '#dlbcl hutchings et al glofitamab in', 'hutchings et al glofitamab in rr', 'et al glofitamab in rr dlbcl', 'al glofitamab in rr dlbcl fixed', 'glofitamab in rr dlbcl fixed duration', 'in rr dlbcl fixed duration 12', 'rr dlbcl fixed duration 12 cycles', 'dlbcl fixed duration 12 cycles 35.4%', 'fixed duration 12 cycles 35.4% cr', 'duration 12 cycles 35.4% cr for', '12 cycles 35.4% cr for pts', 'cycles 35.4% cr for pts in', '35.4% cr for pts in cr:', 'cr for pts in cr: 24', 'for pts in cr: 24 mo', 'pts in cr: 24 mo cr', 'in cr: 24 mo cr 79%', 'cr: 24 mo cr 79% 12', '24 mo cr 79% 12 mo', 'mo cr 79% 12 mo pfs', 'cr 79% 12 mo pfs 92.6%', '79% 12 mo pfs 92.6% full', '12 mo pfs 92.6% full dataset', 'mo pfs 92.6% full dataset in', 'pfs 92.6% full dataset in today.', '92.6% full dataset in today. ', '"#ash22 #lymsm #dlbcl hutchings et al glofitamab', '#lymsm #dlbcl hutchings et al glofitamab in', '#dlbcl hutchings et al glofitamab in rr', 'hutchings et al glofitamab in rr dlbcl', 'et al glofitamab in rr dlbcl fixed', 'al glofitamab in rr dlbcl fixed duration', 'glofitamab in rr dlbcl fixed duration 12', 'in rr dlbcl fixed duration 12 cycles', 'rr dlbcl fixed duration 12 cycles 35.4%', 'dlbcl fixed duration 12 cycles 35.4% cr', 'fixed duration 12 cycles 35.4% cr for', 'duration 12 cycles 35.4% cr for pts', '12 cycles 35.4% cr for pts in', 'cycles 35.4% cr for pts in cr:', '35.4% cr for pts in cr: 24', 'cr for pts in cr: 24 mo', 'for pts in cr: 24 mo cr', 'pts in cr: 24 mo cr 79%', 'in cr: 24 mo cr 79% 12', 'cr: 24 mo cr 79% 12 mo', '24 mo cr 79% 12 mo pfs', 'mo cr 79% 12 mo pfs 92.6%', 'cr 79% 12 mo pfs 92.6% full', '79% 12 mo pfs 92.6% full dataset', '12 mo pfs 92.6% full dataset in', 'mo pfs 92.6% full dataset in today.', 'pfs 92.6% full dataset in today. ', '"#ash22 #lymsm #dlbcl hutchings et al glofitamab in', '#lymsm #dlbcl hutchings et al glofitamab in rr', '#dlbcl hutchings et al glofitamab in rr dlbcl', 'hutchings et al glofitamab in rr dlbcl fixed', 'et al glofitamab in rr dlbcl fixed duration', 'al glofitamab in rr dlbcl fixed duration 12', 'glofitamab in rr dlbcl fixed duration 12 cycles', 'in rr dlbcl fixed duration 12 cycles 35.4%', 'rr dlbcl fixed duration 12 cycles 35.4% cr', 'dlbcl fixed duration 12 cycles 35.4% cr for', 'fixed duration 12 cycles 35.4% cr for pts', 'duration 12 cycles 35.4% cr for pts in', '12 cycles 35.4% cr for pts in cr:', 'cycles 35.4% cr for pts in cr: 24', '35.4% cr for pts in cr: 24 mo', 'cr for pts in cr: 24 mo cr', 'for pts in cr: 24 mo cr 79%', 'pts in cr: 24 mo cr 79% 12', 'in cr: 24 mo cr 79% 12 mo', 'cr: 24 mo cr 79% 12 mo pfs', '24 mo cr 79% 12 mo pfs 92.6%', 'mo cr 79% 12 mo pfs 92.6% full', 'cr 79% 12 mo pfs 92.6% full dataset', '79% 12 mo pfs 92.6% full dataset in', '12 mo pfs 92.6% full dataset in today.', 'mo pfs 92.6% full dataset in today. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '19', 'tokens': ['long', 'term', 'results', 'of', 'glofitamab', 'being', 'presented', 'today', '#ash22.', ''], 'text_length': 10, 'triples': {'glofitamab|long term results of glofitamab being presented': ([4, 4], [0, 6], 'neutral')}, 'sentence': 'long term results of glofitamab being presented today #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 6)], 'related_span_array': array([[1, 0, 0, ..., 1, 0, 0],
       [0, 1, 0, ..., 1, 1, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8)], 'span tokens': ['long', 'term', 'results', 'of', 'glofitamab', 'being', 'presented', 'today', '#ash22.', '', 'long term', 'term results', 'results of', 'of glofitamab', 'glofitamab being', 'being presented', 'presented today', 'today #ash22.', '#ash22. ', 'long term results', 'term results of', 'results of glofitamab', 'of glofitamab being', 'glofitamab being presented', 'being presented today', 'presented today #ash22.', 'today #ash22. ', 'long term results of', 'term results of glofitamab', 'results of glofitamab being', 'of glofitamab being presented', 'glofitamab being presented today', 'being presented today #ash22.', 'presented today #ash22. ', 'long term results of glofitamab', 'term results of glofitamab being', 'results of glofitamab being presented', 'of glofitamab being presented today', 'glofitamab being presented today #ash22.', 'being presented today #ash22. ', 'long term results of glofitamab being', 'term results of glofitamab being presented', 'results of glofitamab being presented today', 'of glofitamab being presented today #ash22.', 'glofitamab being presented today #ash22. ', 'long term results of glofitamab being presented', 'term results of glofitamab being presented today', 'results of glofitamab being presented today #ash22.', 'of glofitamab being presented today #ash22. ', 'long term results of glofitamab being presented today', 'term results of glofitamab being presented today #ash22.', 'results of glofitamab being presented today #ash22. '], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '20', 'tokens': ['"', 'shows', 'us', 'that', 'relapse', 'is', 'uncommon', 'in', 'patients', 'with', 'large', 'b-cell', 'lymphoma', 'who', 'are', 'in', 'complete', 'remission', 'at', 'the', 'end', 'of', 'fixed-course', 'glofitamab', 'treatment', '#ash22', '#lymsm.', ''], 'text_length': 28, 'triples': {'fixed-course|is uncommon in patients with large b-cell lymphoma who are in complete remission at the end of': ([22, 22], [5, 21], 'neutral')}, 'sentence': '" shows us that relapse is uncommon in patients with large b-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment #ash22 #lymsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(22, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 21)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['"', 'shows', 'us', 'that', 'relapse', 'is', 'uncommon', 'in', 'patients', 'with', 'large', 'b-cell', 'lymphoma', 'who', 'are', 'in', 'complete', 'remission', 'at', 'the', 'end', 'of', 'fixed-course', 'glofitamab', 'treatment', '#ash22', '#lymsm.', '', '" shows', 'shows us', 'us that', 'that relapse', 'relapse is', 'is uncommon', 'uncommon in', 'in patients', 'patients with', 'with large', 'large b-cell', 'b-cell lymphoma', 'lymphoma who', 'who are', 'are in', 'in complete', 'complete remission', 'remission at', 'at the', 'the end', 'end of', 'of fixed-course', 'fixed-course glofitamab', 'glofitamab treatment', 'treatment #ash22', '#ash22 #lymsm.', '#lymsm. ', '" shows us', 'shows us that', 'us that relapse', 'that relapse is', 'relapse is uncommon', 'is uncommon in', 'uncommon in patients', 'in patients with', 'patients with large', 'with large b-cell', 'large b-cell lymphoma', 'b-cell lymphoma who', 'lymphoma who are', 'who are in', 'are in complete', 'in complete remission', 'complete remission at', 'remission at the', 'at the end', 'the end of', 'end of fixed-course', 'of fixed-course glofitamab', 'fixed-course glofitamab treatment', 'glofitamab treatment #ash22', 'treatment #ash22 #lymsm.', '#ash22 #lymsm. ', '" shows us that', 'shows us that relapse', 'us that relapse is', 'that relapse is uncommon', 'relapse is uncommon in', 'is uncommon in patients', 'uncommon in patients with', 'in patients with large', 'patients with large b-cell', 'with large b-cell lymphoma', 'large b-cell lymphoma who', 'b-cell lymphoma who are', 'lymphoma who are in', 'who are in complete', 'are in complete remission', 'in complete remission at', 'complete remission at the', 'remission at the end', 'at the end of', 'the end of fixed-course', 'end of fixed-course glofitamab', 'of fixed-course glofitamab treatment', 'fixed-course glofitamab treatment #ash22', 'glofitamab treatment #ash22 #lymsm.', 'treatment #ash22 #lymsm. ', '" shows us that relapse', 'shows us that relapse is', 'us that relapse is uncommon', 'that relapse is uncommon in', 'relapse is uncommon in patients', 'is uncommon in patients with', 'uncommon in patients with large', 'in patients with large b-cell', 'patients with large b-cell lymphoma', 'with large b-cell lymphoma who', 'large b-cell lymphoma who are', 'b-cell lymphoma who are in', 'lymphoma who are in complete', 'who are in complete remission', 'are in complete remission at', 'in complete remission at the', 'complete remission at the end', 'remission at the end of', 'at the end of fixed-course', 'the end of fixed-course glofitamab', 'end of fixed-course glofitamab treatment', 'of fixed-course glofitamab treatment #ash22', 'fixed-course glofitamab treatment #ash22 #lymsm.', 'glofitamab treatment #ash22 #lymsm. ', '" shows us that relapse is', 'shows us that relapse is uncommon', 'us that relapse is uncommon in', 'that relapse is uncommon in patients', 'relapse is uncommon in patients with', 'is uncommon in patients with large', 'uncommon in patients with large b-cell', 'in patients with large b-cell lymphoma', 'patients with large b-cell lymphoma who', 'with large b-cell lymphoma who are', 'large b-cell lymphoma who are in', 'b-cell lymphoma who are in complete', 'lymphoma who are in complete remission', 'who are in complete remission at', 'are in complete remission at the', 'in complete remission at the end', 'complete remission at the end of', 'remission at the end of fixed-course', 'at the end of fixed-course glofitamab', 'the end of fixed-course glofitamab treatment', 'end of fixed-course glofitamab treatment #ash22', 'of fixed-course glofitamab treatment #ash22 #lymsm.', 'fixed-course glofitamab treatment #ash22 #lymsm. ', '" shows us that relapse is uncommon', 'shows us that relapse is uncommon in', 'us that relapse is uncommon in patients', 'that relapse is uncommon in patients with', 'relapse is uncommon in patients with large', 'is uncommon in patients with large b-cell', 'uncommon in patients with large b-cell lymphoma', 'in patients with large b-cell lymphoma who', 'patients with large b-cell lymphoma who are', 'with large b-cell lymphoma who are in', 'large b-cell lymphoma who are in complete', 'b-cell lymphoma who are in complete remission', 'lymphoma who are in complete remission at', 'who are in complete remission at the', 'are in complete remission at the end', 'in complete remission at the end of', 'complete remission at the end of fixed-course', 'remission at the end of fixed-course glofitamab', 'at the end of fixed-course glofitamab treatment', 'the end of fixed-course glofitamab treatment #ash22', 'end of fixed-course glofitamab treatment #ash22 #lymsm.', 'of fixed-course glofitamab treatment #ash22 #lymsm. ', '" shows us that relapse is uncommon in', 'shows us that relapse is uncommon in patients', 'us that relapse is uncommon in patients with', 'that relapse is uncommon in patients with large', 'relapse is uncommon in patients with large b-cell', 'is uncommon in patients with large b-cell lymphoma', 'uncommon in patients with large b-cell lymphoma who', 'in patients with large b-cell lymphoma who are', 'patients with large b-cell lymphoma who are in', 'with large b-cell lymphoma who are in complete', 'large b-cell lymphoma who are in complete remission', 'b-cell lymphoma who are in complete remission at', 'lymphoma who are in complete remission at the', 'who are in complete remission at the end', 'are in complete remission at the end of', 'in complete remission at the end of fixed-course', 'complete remission at the end of fixed-course glofitamab', 'remission at the end of fixed-course glofitamab treatment', 'at the end of fixed-course glofitamab treatment #ash22', 'the end of fixed-course glofitamab treatment #ash22 #lymsm.', 'end of fixed-course glofitamab treatment #ash22 #lymsm. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '21', 'tokens': ['"prof', 'larkin', 'discusses', 'adjuvant', 'io', 'in', 'rcc.', 'so', 'far,', 'kn564', 'is', 'positice', '(but', 'os', 'is', 'immature),', 'prosper', 'and', 'checkmate-914', 'are', 'negative.', 'is', 'adjuvant', 'treatment', 'necessary', 'or', 'more', 'toxic', 'than', 'anything', 'else?', 'same', 'io', 'effect', 'at', 'relapse?', 'the', 'right', 'trial', "hasn't", 'been', 'designed...', '#esmo2022.', ''], 'text_length': 44, 'triples': {'kn564|positice': ([9, 9], [11, 11], 'negative'), 'prosper|negative.': ([16, 16], [20, 20], 'negative'), 'checkmate-914|negative.': ([18, 18], [20, 20], 'negative')}, 'sentence': '"prof larkin discusses adjuvant io in rcc. so far, kn564 is positice (but os is immature), prosper and checkmate-914 are negative. is adjuvant treatment necessary or more toxic than anything else? same io effect at relapse? the right trial hasn\'t been designed... #esmo2022. ', 'aspect_num': 3, 'spans_aspect2opinion_label': [(9, 9), (16, 16), (18, 18)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(11, 11), (20, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8)], 'span tokens': ['"prof', 'larkin', 'discusses', 'adjuvant', 'io', 'in', 'rcc.', 'so', 'far,', 'kn564', 'is', 'positice', '(but', 'os', 'is', 'immature),', 'prosper', 'and', 'checkmate-914', 'are', 'negative.', 'is', 'adjuvant', 'treatment', 'necessary', 'or', 'more', 'toxic', 'than', 'anything', 'else?', 'same', 'io', 'effect', 'at', 'relapse?', 'the', 'right', 'trial', "hasn't", 'been', 'designed...', '#esmo2022.', '', '"prof larkin', 'larkin discusses', 'discusses adjuvant', 'adjuvant io', 'io in', 'in rcc.', 'rcc. so', 'so far,', 'far, kn564', 'kn564 is', 'is positice', 'positice (but', '(but os', 'os is', 'is immature),', 'immature), prosper', 'prosper and', 'and checkmate-914', 'checkmate-914 are', 'are negative.', 'negative. is', 'is adjuvant', 'adjuvant treatment', 'treatment necessary', 'necessary or', 'or more', 'more toxic', 'toxic than', 'than anything', 'anything else?', 'else? same', 'same io', 'io effect', 'effect at', 'at relapse?', 'relapse? the', 'the right', 'right trial', "trial hasn't", "hasn't been", 'been designed...', 'designed... #esmo2022.', '#esmo2022. ', '"prof larkin discusses', 'larkin discusses adjuvant', 'discusses adjuvant io', 'adjuvant io in', 'io in rcc.', 'in rcc. so', 'rcc. so far,', 'so far, kn564', 'far, kn564 is', 'kn564 is positice', 'is positice (but', 'positice (but os', '(but os is', 'os is immature),', 'is immature), prosper', 'immature), prosper and', 'prosper and checkmate-914', 'and checkmate-914 are', 'checkmate-914 are negative.', 'are negative. is', 'negative. is adjuvant', 'is adjuvant treatment', 'adjuvant treatment necessary', 'treatment necessary or', 'necessary or more', 'or more toxic', 'more toxic than', 'toxic than anything', 'than anything else?', 'anything else? same', 'else? same io', 'same io effect', 'io effect at', 'effect at relapse?', 'at relapse? the', 'relapse? the right', 'the right trial', "right trial hasn't", "trial hasn't been", "hasn't been designed...", 'been designed... #esmo2022.', 'designed... #esmo2022. ', '"prof larkin discusses adjuvant', 'larkin discusses adjuvant io', 'discusses adjuvant io in', 'adjuvant io in rcc.', 'io in rcc. so', 'in rcc. so far,', 'rcc. so far, kn564', 'so far, kn564 is', 'far, kn564 is positice', 'kn564 is positice (but', 'is positice (but os', 'positice (but os is', '(but os is immature),', 'os is immature), prosper', 'is immature), prosper and', 'immature), prosper and checkmate-914', 'prosper and checkmate-914 are', 'and checkmate-914 are negative.', 'checkmate-914 are negative. is', 'are negative. is adjuvant', 'negative. is adjuvant treatment', 'is adjuvant treatment necessary', 'adjuvant treatment necessary or', 'treatment necessary or more', 'necessary or more toxic', 'or more toxic than', 'more toxic than anything', 'toxic than anything else?', 'than anything else? same', 'anything else? same io', 'else? same io effect', 'same io effect at', 'io effect at relapse?', 'effect at relapse? the', 'at relapse? the right', 'relapse? the right trial', "the right trial hasn't", "right trial hasn't been", "trial hasn't been designed...", "hasn't been designed... #esmo2022.", 'been designed... #esmo2022. ', '"prof larkin discusses adjuvant io', 'larkin discusses adjuvant io in', 'discusses adjuvant io in rcc.', 'adjuvant io in rcc. so', 'io in rcc. so far,', 'in rcc. so far, kn564', 'rcc. so far, kn564 is', 'so far, kn564 is positice', 'far, kn564 is positice (but', 'kn564 is positice (but os', 'is positice (but os is', 'positice (but os is immature),', '(but os is immature), prosper', 'os is immature), prosper and', 'is immature), prosper and checkmate-914', 'immature), prosper and checkmate-914 are', 'prosper and checkmate-914 are negative.', 'and checkmate-914 are negative. is', 'checkmate-914 are negative. is adjuvant', 'are negative. is adjuvant treatment', 'negative. is adjuvant treatment necessary', 'is adjuvant treatment necessary or', 'adjuvant treatment necessary or more', 'treatment necessary or more toxic', 'necessary or more toxic than', 'or more toxic than anything', 'more toxic than anything else?', 'toxic than anything else? same', 'than anything else? same io', 'anything else? same io effect', 'else? same io effect at', 'same io effect at relapse?', 'io effect at relapse? the', 'effect at relapse? the right', 'at relapse? the right trial', "relapse? the right trial hasn't", "the right trial hasn't been", "right trial hasn't been designed...", "trial hasn't been designed... #esmo2022.", "hasn't been designed... #esmo2022. ", '"prof larkin discusses adjuvant io in', 'larkin discusses adjuvant io in rcc.', 'discusses adjuvant io in rcc. so', 'adjuvant io in rcc. so far,', 'io in rcc. so far, kn564', 'in rcc. so far, kn564 is', 'rcc. so far, kn564 is positice', 'so far, kn564 is positice (but', 'far, kn564 is positice (but os', 'kn564 is positice (but os is', 'is positice (but os is immature),', 'positice (but os is immature), prosper', '(but os is immature), prosper and', 'os is immature), prosper and checkmate-914', 'is immature), prosper and checkmate-914 are', 'immature), prosper and checkmate-914 are negative.', 'prosper and checkmate-914 are negative. is', 'and checkmate-914 are negative. is adjuvant', 'checkmate-914 are negative. is adjuvant treatment', 'are negative. is adjuvant treatment necessary', 'negative. is adjuvant treatment necessary or', 'is adjuvant treatment necessary or more', 'adjuvant treatment necessary or more toxic', 'treatment necessary or more toxic than', 'necessary or more toxic than anything', 'or more toxic than anything else?', 'more toxic than anything else? same', 'toxic than anything else? same io', 'than anything else? same io effect', 'anything else? same io effect at', 'else? same io effect at relapse?', 'same io effect at relapse? the', 'io effect at relapse? the right', 'effect at relapse? the right trial', "at relapse? the right trial hasn't", "relapse? the right trial hasn't been", "the right trial hasn't been designed...", "right trial hasn't been designed... #esmo2022.", "trial hasn't been designed... #esmo2022. ", '"prof larkin discusses adjuvant io in rcc.', 'larkin discusses adjuvant io in rcc. so', 'discusses adjuvant io in rcc. so far,', 'adjuvant io in rcc. so far, kn564', 'io in rcc. so far, kn564 is', 'in rcc. so far, kn564 is positice', 'rcc. so far, kn564 is positice (but', 'so far, kn564 is positice (but os', 'far, kn564 is positice (but os is', 'kn564 is positice (but os is immature),', 'is positice (but os is immature), prosper', 'positice (but os is immature), prosper and', '(but os is immature), prosper and checkmate-914', 'os is immature), prosper and checkmate-914 are', 'is immature), prosper and checkmate-914 are negative.', 'immature), prosper and checkmate-914 are negative. is', 'prosper and checkmate-914 are negative. is adjuvant', 'and checkmate-914 are negative. is adjuvant treatment', 'checkmate-914 are negative. is adjuvant treatment necessary', 'are negative. is adjuvant treatment necessary or', 'negative. is adjuvant treatment necessary or more', 'is adjuvant treatment necessary or more toxic', 'adjuvant treatment necessary or more toxic than', 'treatment necessary or more toxic than anything', 'necessary or more toxic than anything else?', 'or more toxic than anything else? same', 'more toxic than anything else? same io', 'toxic than anything else? same io effect', 'than anything else? same io effect at', 'anything else? same io effect at relapse?', 'else? same io effect at relapse? the', 'same io effect at relapse? the right', 'io effect at relapse? the right trial', "effect at relapse? the right trial hasn't", "at relapse? the right trial hasn't been", "relapse? the right trial hasn't been designed...", "the right trial hasn't been designed... #esmo2022.", "right trial hasn't been designed... #esmo2022. ", '"prof larkin discusses adjuvant io in rcc. so', 'larkin discusses adjuvant io in rcc. so far,', 'discusses adjuvant io in rcc. so far, kn564', 'adjuvant io in rcc. so far, kn564 is', 'io in rcc. so far, kn564 is positice', 'in rcc. so far, kn564 is positice (but', 'rcc. so far, kn564 is positice (but os', 'so far, kn564 is positice (but os is', 'far, kn564 is positice (but os is immature),', 'kn564 is positice (but os is immature), prosper', 'is positice (but os is immature), prosper and', 'positice (but os is immature), prosper and checkmate-914', '(but os is immature), prosper and checkmate-914 are', 'os is immature), prosper and checkmate-914 are negative.', 'is immature), prosper and checkmate-914 are negative. is', 'immature), prosper and checkmate-914 are negative. is adjuvant', 'prosper and checkmate-914 are negative. is adjuvant treatment', 'and checkmate-914 are negative. is adjuvant treatment necessary', 'checkmate-914 are negative. is adjuvant treatment necessary or', 'are negative. is adjuvant treatment necessary or more', 'negative. is adjuvant treatment necessary or more toxic', 'is adjuvant treatment necessary or more toxic than', 'adjuvant treatment necessary or more toxic than anything', 'treatment necessary or more toxic than anything else?', 'necessary or more toxic than anything else? same', 'or more toxic than anything else? same io', 'more toxic than anything else? same io effect', 'toxic than anything else? same io effect at', 'than anything else? same io effect at relapse?', 'anything else? same io effect at relapse? the', 'else? same io effect at relapse? the right', 'same io effect at relapse? the right trial', "io effect at relapse? the right trial hasn't", "effect at relapse? the right trial hasn't been", "at relapse? the right trial hasn't been designed...", "relapse? the right trial hasn't been designed... #esmo2022.", "the right trial hasn't been designed... #esmo2022. "], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '22', 'tokens': ['delighted', 'that', 'glofitamab', 'pivotal', 'data', 'for', 'dlbcl', 'is', 'now', 'online', '.', '39.4%', 'cr', 'in', 'patients', 'with', 'the', 'most', 'common', 'aggressive', '#lymphoma,', 'fixed', 'course,', 'durable', 'remissions,', 'good', 'safety', 'profile,', 'i', 'hope', 'this', 'data', 'changes', 'practice', 'for', 'patients', 'with', 'r/r', '#dlbcl', '#ash22', '#lymsm.', ''], 'text_length': 42, 'triples': {'glofitamab|delighted that glofitamab pivotal data for dlbcl is now online . 39.4% cr in patients with the most common aggressive #lymphoma, fixed course, durable remissions, good safety': ([2, 2], [0, 26], 'positive')}, 'sentence': 'delighted that glofitamab pivotal data for dlbcl is now online . 39.4% cr in patients with the most common aggressive #lymphoma, fixed course, durable remissions, good safety profile, i hope this data changes practice for patients with r/r #dlbcl #ash22 #lymsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8)], 'span tokens': ['delighted', 'that', 'glofitamab', 'pivotal', 'data', 'for', 'dlbcl', 'is', 'now', 'online', '.', '39.4%', 'cr', 'in', 'patients', 'with', 'the', 'most', 'common', 'aggressive', '#lymphoma,', 'fixed', 'course,', 'durable', 'remissions,', 'good', 'safety', 'profile,', 'i', 'hope', 'this', 'data', 'changes', 'practice', 'for', 'patients', 'with', 'r/r', '#dlbcl', '#ash22', '#lymsm.', '', 'delighted that', 'that glofitamab', 'glofitamab pivotal', 'pivotal data', 'data for', 'for dlbcl', 'dlbcl is', 'is now', 'now online', 'online .', '. 39.4%', '39.4% cr', 'cr in', 'in patients', 'patients with', 'with the', 'the most', 'most common', 'common aggressive', 'aggressive #lymphoma,', '#lymphoma, fixed', 'fixed course,', 'course, durable', 'durable remissions,', 'remissions, good', 'good safety', 'safety profile,', 'profile, i', 'i hope', 'hope this', 'this data', 'data changes', 'changes practice', 'practice for', 'for patients', 'patients with', 'with r/r', 'r/r #dlbcl', '#dlbcl #ash22', '#ash22 #lymsm.', '#lymsm. ', 'delighted that glofitamab', 'that glofitamab pivotal', 'glofitamab pivotal data', 'pivotal data for', 'data for dlbcl', 'for dlbcl is', 'dlbcl is now', 'is now online', 'now online .', 'online . 39.4%', '. 39.4% cr', '39.4% cr in', 'cr in patients', 'in patients with', 'patients with the', 'with the most', 'the most common', 'most common aggressive', 'common aggressive #lymphoma,', 'aggressive #lymphoma, fixed', '#lymphoma, fixed course,', 'fixed course, durable', 'course, durable remissions,', 'durable remissions, good', 'remissions, good safety', 'good safety profile,', 'safety profile, i', 'profile, i hope', 'i hope this', 'hope this data', 'this data changes', 'data changes practice', 'changes practice for', 'practice for patients', 'for patients with', 'patients with r/r', 'with r/r #dlbcl', 'r/r #dlbcl #ash22', '#dlbcl #ash22 #lymsm.', '#ash22 #lymsm. ', 'delighted that glofitamab pivotal', 'that glofitamab pivotal data', 'glofitamab pivotal data for', 'pivotal data for dlbcl', 'data for dlbcl is', 'for dlbcl is now', 'dlbcl is now online', 'is now online .', 'now online . 39.4%', 'online . 39.4% cr', '. 39.4% cr in', '39.4% cr in patients', 'cr in patients with', 'in patients with the', 'patients with the most', 'with the most common', 'the most common aggressive', 'most common aggressive #lymphoma,', 'common aggressive #lymphoma, fixed', 'aggressive #lymphoma, fixed course,', '#lymphoma, fixed course, durable', 'fixed course, durable remissions,', 'course, durable remissions, good', 'durable remissions, good safety', 'remissions, good safety profile,', 'good safety profile, i', 'safety profile, i hope', 'profile, i hope this', 'i hope this data', 'hope this data changes', 'this data changes practice', 'data changes practice for', 'changes practice for patients', 'practice for patients with', 'for patients with r/r', 'patients with r/r #dlbcl', 'with r/r #dlbcl #ash22', 'r/r #dlbcl #ash22 #lymsm.', '#dlbcl #ash22 #lymsm. ', 'delighted that glofitamab pivotal data', 'that glofitamab pivotal data for', 'glofitamab pivotal data for dlbcl', 'pivotal data for dlbcl is', 'data for dlbcl is now', 'for dlbcl is now online', 'dlbcl is now online .', 'is now online . 39.4%', 'now online . 39.4% cr', 'online . 39.4% cr in', '. 39.4% cr in patients', '39.4% cr in patients with', 'cr in patients with the', 'in patients with the most', 'patients with the most common', 'with the most common aggressive', 'the most common aggressive #lymphoma,', 'most common aggressive #lymphoma, fixed', 'common aggressive #lymphoma, fixed course,', 'aggressive #lymphoma, fixed course, durable', '#lymphoma, fixed course, durable remissions,', 'fixed course, durable remissions, good', 'course, durable remissions, good safety', 'durable remissions, good safety profile,', 'remissions, good safety profile, i', 'good safety profile, i hope', 'safety profile, i hope this', 'profile, i hope this data', 'i hope this data changes', 'hope this data changes practice', 'this data changes practice for', 'data changes practice for patients', 'changes practice for patients with', 'practice for patients with r/r', 'for patients with r/r #dlbcl', 'patients with r/r #dlbcl #ash22', 'with r/r #dlbcl #ash22 #lymsm.', 'r/r #dlbcl #ash22 #lymsm. ', 'delighted that glofitamab pivotal data for', 'that glofitamab pivotal data for dlbcl', 'glofitamab pivotal data for dlbcl is', 'pivotal data for dlbcl is now', 'data for dlbcl is now online', 'for dlbcl is now online .', 'dlbcl is now online . 39.4%', 'is now online . 39.4% cr', 'now online . 39.4% cr in', 'online . 39.4% cr in patients', '. 39.4% cr in patients with', '39.4% cr in patients with the', 'cr in patients with the most', 'in patients with the most common', 'patients with the most common aggressive', 'with the most common aggressive #lymphoma,', 'the most common aggressive #lymphoma, fixed', 'most common aggressive #lymphoma, fixed course,', 'common aggressive #lymphoma, fixed course, durable', 'aggressive #lymphoma, fixed course, durable remissions,', '#lymphoma, fixed course, durable remissions, good', 'fixed course, durable remissions, good safety', 'course, durable remissions, good safety profile,', 'durable remissions, good safety profile, i', 'remissions, good safety profile, i hope', 'good safety profile, i hope this', 'safety profile, i hope this data', 'profile, i hope this data changes', 'i hope this data changes practice', 'hope this data changes practice for', 'this data changes practice for patients', 'data changes practice for patients with', 'changes practice for patients with r/r', 'practice for patients with r/r #dlbcl', 'for patients with r/r #dlbcl #ash22', 'patients with r/r #dlbcl #ash22 #lymsm.', 'with r/r #dlbcl #ash22 #lymsm. ', 'delighted that glofitamab pivotal data for dlbcl', 'that glofitamab pivotal data for dlbcl is', 'glofitamab pivotal data for dlbcl is now', 'pivotal data for dlbcl is now online', 'data for dlbcl is now online .', 'for dlbcl is now online . 39.4%', 'dlbcl is now online . 39.4% cr', 'is now online . 39.4% cr in', 'now online . 39.4% cr in patients', 'online . 39.4% cr in patients with', '. 39.4% cr in patients with the', '39.4% cr in patients with the most', 'cr in patients with the most common', 'in patients with the most common aggressive', 'patients with the most common aggressive #lymphoma,', 'with the most common aggressive #lymphoma, fixed', 'the most common aggressive #lymphoma, fixed course,', 'most common aggressive #lymphoma, fixed course, durable', 'common aggressive #lymphoma, fixed course, durable remissions,', 'aggressive #lymphoma, fixed course, durable remissions, good', '#lymphoma, fixed course, durable remissions, good safety', 'fixed course, durable remissions, good safety profile,', 'course, durable remissions, good safety profile, i', 'durable remissions, good safety profile, i hope', 'remissions, good safety profile, i hope this', 'good safety profile, i hope this data', 'safety profile, i hope this data changes', 'profile, i hope this data changes practice', 'i hope this data changes practice for', 'hope this data changes practice for patients', 'this data changes practice for patients with', 'data changes practice for patients with r/r', 'changes practice for patients with r/r #dlbcl', 'practice for patients with r/r #dlbcl #ash22', 'for patients with r/r #dlbcl #ash22 #lymsm.', 'patients with r/r #dlbcl #ash22 #lymsm. ', 'delighted that glofitamab pivotal data for dlbcl is', 'that glofitamab pivotal data for dlbcl is now', 'glofitamab pivotal data for dlbcl is now online', 'pivotal data for dlbcl is now online .', 'data for dlbcl is now online . 39.4%', 'for dlbcl is now online . 39.4% cr', 'dlbcl is now online . 39.4% cr in', 'is now online . 39.4% cr in patients', 'now online . 39.4% cr in patients with', 'online . 39.4% cr in patients with the', '. 39.4% cr in patients with the most', '39.4% cr in patients with the most common', 'cr in patients with the most common aggressive', 'in patients with the most common aggressive #lymphoma,', 'patients with the most common aggressive #lymphoma, fixed', 'with the most common aggressive #lymphoma, fixed course,', 'the most common aggressive #lymphoma, fixed course, durable', 'most common aggressive #lymphoma, fixed course, durable remissions,', 'common aggressive #lymphoma, fixed course, durable remissions, good', 'aggressive #lymphoma, fixed course, durable remissions, good safety', '#lymphoma, fixed course, durable remissions, good safety profile,', 'fixed course, durable remissions, good safety profile, i', 'course, durable remissions, good safety profile, i hope', 'durable remissions, good safety profile, i hope this', 'remissions, good safety profile, i hope this data', 'good safety profile, i hope this data changes', 'safety profile, i hope this data changes practice', 'profile, i hope this data changes practice for', 'i hope this data changes practice for patients', 'hope this data changes practice for patients with', 'this data changes practice for patients with r/r', 'data changes practice for patients with r/r #dlbcl', 'changes practice for patients with r/r #dlbcl #ash22', 'practice for patients with r/r #dlbcl #ash22 #lymsm.', 'for patients with r/r #dlbcl #ash22 #lymsm. '], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '23', 'tokens': ['"impressive', 'mcl', 'studies', '#ash22', 'glofitamab', 'monotherapy', 'alr.', ''], 'text_length': 8, 'triples': {'glofitamab|"impressive': ([4, 4], [0, 0], 'positive')}, 'sentence': '"impressive mcl studies #ash22 glofitamab monotherapy alr. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 1, 0, 1],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1],
       [1, 1, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (0, 6, 7), (1, 7, 7), (0, 7, 8)], 'span tokens': ['"impressive', 'mcl', 'studies', '#ash22', 'glofitamab', 'monotherapy', 'alr.', '', '"impressive mcl', 'mcl studies', 'studies #ash22', '#ash22 glofitamab', 'glofitamab monotherapy', 'monotherapy alr.', 'alr. ', '"impressive mcl studies', 'mcl studies #ash22', 'studies #ash22 glofitamab', '#ash22 glofitamab monotherapy', 'glofitamab monotherapy alr.', 'monotherapy alr. ', '"impressive mcl studies #ash22', 'mcl studies #ash22 glofitamab', 'studies #ash22 glofitamab monotherapy', '#ash22 glofitamab monotherapy alr.', 'glofitamab monotherapy alr. ', '"impressive mcl studies #ash22 glofitamab', 'mcl studies #ash22 glofitamab monotherapy', 'studies #ash22 glofitamab monotherapy alr.', '#ash22 glofitamab monotherapy alr. ', '"impressive mcl studies #ash22 glofitamab monotherapy', 'mcl studies #ash22 glofitamab monotherapy alr.', 'studies #ash22 glofitamab monotherapy alr. ', '"impressive mcl studies #ash22 glofitamab monotherapy alr.', 'mcl studies #ash22 glofitamab monotherapy alr. ', '"impressive mcl studies #ash22 glofitamab monotherapy alr. '], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '24', 'tokens': ['"#ash22', 'abstract', '074', 'et', 'al.', 'glofitamab', 'monotherapy', 'in', 'patients', 'with', 'r/r', '#mcl.', 'high', 'and', 'durable', 'cr', 'rates', 'no', 'treatment', 'discontinuations', 'due', 'to', 'aes', 'manageable', 'low-grade', 'crs.', ''], 'text_length': 27, 'triples': {'glofitamab|high and durable cr rates no treatment discontinuations': ([5, 5], [12, 19], 'positive')}, 'sentence': '"#ash22 abstract 074 et al. glofitamab monotherapy in patients with r/r #mcl. high and durable cr rates no treatment discontinuations due to aes manageable low-grade crs. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(12, 19)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8)], 'span tokens': ['"#ash22', 'abstract', '074', 'et', 'al.', 'glofitamab', 'monotherapy', 'in', 'patients', 'with', 'r/r', '#mcl.', 'high', 'and', 'durable', 'cr', 'rates', 'no', 'treatment', 'discontinuations', 'due', 'to', 'aes', 'manageable', 'low-grade', 'crs.', '', '"#ash22 abstract', 'abstract 074', '074 et', 'et al.', 'al. glofitamab', 'glofitamab monotherapy', 'monotherapy in', 'in patients', 'patients with', 'with r/r', 'r/r #mcl.', '#mcl. high', 'high and', 'and durable', 'durable cr', 'cr rates', 'rates no', 'no treatment', 'treatment discontinuations', 'discontinuations due', 'due to', 'to aes', 'aes manageable', 'manageable low-grade', 'low-grade crs.', 'crs. ', '"#ash22 abstract 074', 'abstract 074 et', '074 et al.', 'et al. glofitamab', 'al. glofitamab monotherapy', 'glofitamab monotherapy in', 'monotherapy in patients', 'in patients with', 'patients with r/r', 'with r/r #mcl.', 'r/r #mcl. high', '#mcl. high and', 'high and durable', 'and durable cr', 'durable cr rates', 'cr rates no', 'rates no treatment', 'no treatment discontinuations', 'treatment discontinuations due', 'discontinuations due to', 'due to aes', 'to aes manageable', 'aes manageable low-grade', 'manageable low-grade crs.', 'low-grade crs. ', '"#ash22 abstract 074 et', 'abstract 074 et al.', '074 et al. glofitamab', 'et al. glofitamab monotherapy', 'al. glofitamab monotherapy in', 'glofitamab monotherapy in patients', 'monotherapy in patients with', 'in patients with r/r', 'patients with r/r #mcl.', 'with r/r #mcl. high', 'r/r #mcl. high and', '#mcl. high and durable', 'high and durable cr', 'and durable cr rates', 'durable cr rates no', 'cr rates no treatment', 'rates no treatment discontinuations', 'no treatment discontinuations due', 'treatment discontinuations due to', 'discontinuations due to aes', 'due to aes manageable', 'to aes manageable low-grade', 'aes manageable low-grade crs.', 'manageable low-grade crs. ', '"#ash22 abstract 074 et al.', 'abstract 074 et al. glofitamab', '074 et al. glofitamab monotherapy', 'et al. glofitamab monotherapy in', 'al. glofitamab monotherapy in patients', 'glofitamab monotherapy in patients with', 'monotherapy in patients with r/r', 'in patients with r/r #mcl.', 'patients with r/r #mcl. high', 'with r/r #mcl. high and', 'r/r #mcl. high and durable', '#mcl. high and durable cr', 'high and durable cr rates', 'and durable cr rates no', 'durable cr rates no treatment', 'cr rates no treatment discontinuations', 'rates no treatment discontinuations due', 'no treatment discontinuations due to', 'treatment discontinuations due to aes', 'discontinuations due to aes manageable', 'due to aes manageable low-grade', 'to aes manageable low-grade crs.', 'aes manageable low-grade crs. ', '"#ash22 abstract 074 et al. glofitamab', 'abstract 074 et al. glofitamab monotherapy', '074 et al. glofitamab monotherapy in', 'et al. glofitamab monotherapy in patients', 'al. glofitamab monotherapy in patients with', 'glofitamab monotherapy in patients with r/r', 'monotherapy in patients with r/r #mcl.', 'in patients with r/r #mcl. high', 'patients with r/r #mcl. high and', 'with r/r #mcl. high and durable', 'r/r #mcl. high and durable cr', '#mcl. high and durable cr rates', 'high and durable cr rates no', 'and durable cr rates no treatment', 'durable cr rates no treatment discontinuations', 'cr rates no treatment discontinuations due', 'rates no treatment discontinuations due to', 'no treatment discontinuations due to aes', 'treatment discontinuations due to aes manageable', 'discontinuations due to aes manageable low-grade', 'due to aes manageable low-grade crs.', 'to aes manageable low-grade crs. ', '"#ash22 abstract 074 et al. glofitamab monotherapy', 'abstract 074 et al. glofitamab monotherapy in', '074 et al. glofitamab monotherapy in patients', 'et al. glofitamab monotherapy in patients with', 'al. glofitamab monotherapy in patients with r/r', 'glofitamab monotherapy in patients with r/r #mcl.', 'monotherapy in patients with r/r #mcl. high', 'in patients with r/r #mcl. high and', 'patients with r/r #mcl. high and durable', 'with r/r #mcl. high and durable cr', 'r/r #mcl. high and durable cr rates', '#mcl. high and durable cr rates no', 'high and durable cr rates no treatment', 'and durable cr rates no treatment discontinuations', 'durable cr rates no treatment discontinuations due', 'cr rates no treatment discontinuations due to', 'rates no treatment discontinuations due to aes', 'no treatment discontinuations due to aes manageable', 'treatment discontinuations due to aes manageable low-grade', 'discontinuations due to aes manageable low-grade crs.', 'due to aes manageable low-grade crs. ', '"#ash22 abstract 074 et al. glofitamab monotherapy in', 'abstract 074 et al. glofitamab monotherapy in patients', '074 et al. glofitamab monotherapy in patients with', 'et al. glofitamab monotherapy in patients with r/r', 'al. glofitamab monotherapy in patients with r/r #mcl.', 'glofitamab monotherapy in patients with r/r #mcl. high', 'monotherapy in patients with r/r #mcl. high and', 'in patients with r/r #mcl. high and durable', 'patients with r/r #mcl. high and durable cr', 'with r/r #mcl. high and durable cr rates', 'r/r #mcl. high and durable cr rates no', '#mcl. high and durable cr rates no treatment', 'high and durable cr rates no treatment discontinuations', 'and durable cr rates no treatment discontinuations due', 'durable cr rates no treatment discontinuations due to', 'cr rates no treatment discontinuations due to aes', 'rates no treatment discontinuations due to aes manageable', 'no treatment discontinuations due to aes manageable low-grade', 'treatment discontinuations due to aes manageable low-grade crs.', 'discontinuations due to aes manageable low-grade crs. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '25', 'tokens': ['"latest', 'data', 're', 'glofitamab', 'for', 'rr', 'mcl', '#ash2022', 'n=37', 'med', '3', 'priot', 'lot,', '65%', 'btki', 'exposed', 'orr', '84%', 'crr', '73%', '74%', '(20/27)', 'of', 'pts', 'with', 'cr', 'remain', 'in', 'cr,', 'many', 'off', 'therapy', 'serious', 'infections', 'in', '1/3', 'key', 'toxicity', 'to', 'monitor', 'in', 'future', 'studies', 'very', 'potent', 'agent', 'in', 'mcl!.', ''], 'text_length': 49, 'triples': {'glofitamab|serious infections in 1/3 key toxicity to monitor in future': ([3, 3], [32, 41], 'negative')}, 'sentence': '"latest data re glofitamab for rr mcl #ash2022 n=37 med 3 priot lot, 65% btki exposed orr 84% crr 73% 74% (20/27) of pts with cr remain in cr, many off therapy serious infections in 1/3 key toxicity to monitor in future studies very potent agent in mcl!. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(32, 41)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8)], 'span tokens': ['"latest', 'data', 're', 'glofitamab', 'for', 'rr', 'mcl', '#ash2022', 'n=37', 'med', '3', 'priot', 'lot,', '65%', 'btki', 'exposed', 'orr', '84%', 'crr', '73%', '74%', '(20/27)', 'of', 'pts', 'with', 'cr', 'remain', 'in', 'cr,', 'many', 'off', 'therapy', 'serious', 'infections', 'in', '1/3', 'key', 'toxicity', 'to', 'monitor', 'in', 'future', 'studies', 'very', 'potent', 'agent', 'in', 'mcl!.', '', '"latest data', 'data re', 're glofitamab', 'glofitamab for', 'for rr', 'rr mcl', 'mcl #ash2022', '#ash2022 n=37', 'n=37 med', 'med 3', '3 priot', 'priot lot,', 'lot, 65%', '65% btki', 'btki exposed', 'exposed orr', 'orr 84%', '84% crr', 'crr 73%', '73% 74%', '74% (20/27)', '(20/27) of', 'of pts', 'pts with', 'with cr', 'cr remain', 'remain in', 'in cr,', 'cr, many', 'many off', 'off therapy', 'therapy serious', 'serious infections', 'infections in', 'in 1/3', '1/3 key', 'key toxicity', 'toxicity to', 'to monitor', 'monitor in', 'in future', 'future studies', 'studies very', 'very potent', 'potent agent', 'agent in', 'in mcl!.', 'mcl!. ', '"latest data re', 'data re glofitamab', 're glofitamab for', 'glofitamab for rr', 'for rr mcl', 'rr mcl #ash2022', 'mcl #ash2022 n=37', '#ash2022 n=37 med', 'n=37 med 3', 'med 3 priot', '3 priot lot,', 'priot lot, 65%', 'lot, 65% btki', '65% btki exposed', 'btki exposed orr', 'exposed orr 84%', 'orr 84% crr', '84% crr 73%', 'crr 73% 74%', '73% 74% (20/27)', '74% (20/27) of', '(20/27) of pts', 'of pts with', 'pts with cr', 'with cr remain', 'cr remain in', 'remain in cr,', 'in cr, many', 'cr, many off', 'many off therapy', 'off therapy serious', 'therapy serious infections', 'serious infections in', 'infections in 1/3', 'in 1/3 key', '1/3 key toxicity', 'key toxicity to', 'toxicity to monitor', 'to monitor in', 'monitor in future', 'in future studies', 'future studies very', 'studies very potent', 'very potent agent', 'potent agent in', 'agent in mcl!.', 'in mcl!. ', '"latest data re glofitamab', 'data re glofitamab for', 're glofitamab for rr', 'glofitamab for rr mcl', 'for rr mcl #ash2022', 'rr mcl #ash2022 n=37', 'mcl #ash2022 n=37 med', '#ash2022 n=37 med 3', 'n=37 med 3 priot', 'med 3 priot lot,', '3 priot lot, 65%', 'priot lot, 65% btki', 'lot, 65% btki exposed', '65% btki exposed orr', 'btki exposed orr 84%', 'exposed orr 84% crr', 'orr 84% crr 73%', '84% crr 73% 74%', 'crr 73% 74% (20/27)', '73% 74% (20/27) of', '74% (20/27) of pts', '(20/27) of pts with', 'of pts with cr', 'pts with cr remain', 'with cr remain in', 'cr remain in cr,', 'remain in cr, many', 'in cr, many off', 'cr, many off therapy', 'many off therapy serious', 'off therapy serious infections', 'therapy serious infections in', 'serious infections in 1/3', 'infections in 1/3 key', 'in 1/3 key toxicity', '1/3 key toxicity to', 'key toxicity to monitor', 'toxicity to monitor in', 'to monitor in future', 'monitor in future studies', 'in future studies very', 'future studies very potent', 'studies very potent agent', 'very potent agent in', 'potent agent in mcl!.', 'agent in mcl!. ', '"latest data re glofitamab for', 'data re glofitamab for rr', 're glofitamab for rr mcl', 'glofitamab for rr mcl #ash2022', 'for rr mcl #ash2022 n=37', 'rr mcl #ash2022 n=37 med', 'mcl #ash2022 n=37 med 3', '#ash2022 n=37 med 3 priot', 'n=37 med 3 priot lot,', 'med 3 priot lot, 65%', '3 priot lot, 65% btki', 'priot lot, 65% btki exposed', 'lot, 65% btki exposed orr', '65% btki exposed orr 84%', 'btki exposed orr 84% crr', 'exposed orr 84% crr 73%', 'orr 84% crr 73% 74%', '84% crr 73% 74% (20/27)', 'crr 73% 74% (20/27) of', '73% 74% (20/27) of pts', '74% (20/27) of pts with', '(20/27) of pts with cr', 'of pts with cr remain', 'pts with cr remain in', 'with cr remain in cr,', 'cr remain in cr, many', 'remain in cr, many off', 'in cr, many off therapy', 'cr, many off therapy serious', 'many off therapy serious infections', 'off therapy serious infections in', 'therapy serious infections in 1/3', 'serious infections in 1/3 key', 'infections in 1/3 key toxicity', 'in 1/3 key toxicity to', '1/3 key toxicity to monitor', 'key toxicity to monitor in', 'toxicity to monitor in future', 'to monitor in future studies', 'monitor in future studies very', 'in future studies very potent', 'future studies very potent agent', 'studies very potent agent in', 'very potent agent in mcl!.', 'potent agent in mcl!. ', '"latest data re glofitamab for rr', 'data re glofitamab for rr mcl', 're glofitamab for rr mcl #ash2022', 'glofitamab for rr mcl #ash2022 n=37', 'for rr mcl #ash2022 n=37 med', 'rr mcl #ash2022 n=37 med 3', 'mcl #ash2022 n=37 med 3 priot', '#ash2022 n=37 med 3 priot lot,', 'n=37 med 3 priot lot, 65%', 'med 3 priot lot, 65% btki', '3 priot lot, 65% btki exposed', 'priot lot, 65% btki exposed orr', 'lot, 65% btki exposed orr 84%', '65% btki exposed orr 84% crr', 'btki exposed orr 84% crr 73%', 'exposed orr 84% crr 73% 74%', 'orr 84% crr 73% 74% (20/27)', '84% crr 73% 74% (20/27) of', 'crr 73% 74% (20/27) of pts', '73% 74% (20/27) of pts with', '74% (20/27) of pts with cr', '(20/27) of pts with cr remain', 'of pts with cr remain in', 'pts with cr remain in cr,', 'with cr remain in cr, many', 'cr remain in cr, many off', 'remain in cr, many off therapy', 'in cr, many off therapy serious', 'cr, many off therapy serious infections', 'many off therapy serious infections in', 'off therapy serious infections in 1/3', 'therapy serious infections in 1/3 key', 'serious infections in 1/3 key toxicity', 'infections in 1/3 key toxicity to', 'in 1/3 key toxicity to monitor', '1/3 key toxicity to monitor in', 'key toxicity to monitor in future', 'toxicity to monitor in future studies', 'to monitor in future studies very', 'monitor in future studies very potent', 'in future studies very potent agent', 'future studies very potent agent in', 'studies very potent agent in mcl!.', 'very potent agent in mcl!. ', '"latest data re glofitamab for rr mcl', 'data re glofitamab for rr mcl #ash2022', 're glofitamab for rr mcl #ash2022 n=37', 'glofitamab for rr mcl #ash2022 n=37 med', 'for rr mcl #ash2022 n=37 med 3', 'rr mcl #ash2022 n=37 med 3 priot', 'mcl #ash2022 n=37 med 3 priot lot,', '#ash2022 n=37 med 3 priot lot, 65%', 'n=37 med 3 priot lot, 65% btki', 'med 3 priot lot, 65% btki exposed', '3 priot lot, 65% btki exposed orr', 'priot lot, 65% btki exposed orr 84%', 'lot, 65% btki exposed orr 84% crr', '65% btki exposed orr 84% crr 73%', 'btki exposed orr 84% crr 73% 74%', 'exposed orr 84% crr 73% 74% (20/27)', 'orr 84% crr 73% 74% (20/27) of', '84% crr 73% 74% (20/27) of pts', 'crr 73% 74% (20/27) of pts with', '73% 74% (20/27) of pts with cr', '74% (20/27) of pts with cr remain', '(20/27) of pts with cr remain in', 'of pts with cr remain in cr,', 'pts with cr remain in cr, many', 'with cr remain in cr, many off', 'cr remain in cr, many off therapy', 'remain in cr, many off therapy serious', 'in cr, many off therapy serious infections', 'cr, many off therapy serious infections in', 'many off therapy serious infections in 1/3', 'off therapy serious infections in 1/3 key', 'therapy serious infections in 1/3 key toxicity', 'serious infections in 1/3 key toxicity to', 'infections in 1/3 key toxicity to monitor', 'in 1/3 key toxicity to monitor in', '1/3 key toxicity to monitor in future', 'key toxicity to monitor in future studies', 'toxicity to monitor in future studies very', 'to monitor in future studies very potent', 'monitor in future studies very potent agent', 'in future studies very potent agent in', 'future studies very potent agent in mcl!.', 'studies very potent agent in mcl!. ', '"latest data re glofitamab for rr mcl #ash2022', 'data re glofitamab for rr mcl #ash2022 n=37', 're glofitamab for rr mcl #ash2022 n=37 med', 'glofitamab for rr mcl #ash2022 n=37 med 3', 'for rr mcl #ash2022 n=37 med 3 priot', 'rr mcl #ash2022 n=37 med 3 priot lot,', 'mcl #ash2022 n=37 med 3 priot lot, 65%', '#ash2022 n=37 med 3 priot lot, 65% btki', 'n=37 med 3 priot lot, 65% btki exposed', 'med 3 priot lot, 65% btki exposed orr', '3 priot lot, 65% btki exposed orr 84%', 'priot lot, 65% btki exposed orr 84% crr', 'lot, 65% btki exposed orr 84% crr 73%', '65% btki exposed orr 84% crr 73% 74%', 'btki exposed orr 84% crr 73% 74% (20/27)', 'exposed orr 84% crr 73% 74% (20/27) of', 'orr 84% crr 73% 74% (20/27) of pts', '84% crr 73% 74% (20/27) of pts with', 'crr 73% 74% (20/27) of pts with cr', '73% 74% (20/27) of pts with cr remain', '74% (20/27) of pts with cr remain in', '(20/27) of pts with cr remain in cr,', 'of pts with cr remain in cr, many', 'pts with cr remain in cr, many off', 'with cr remain in cr, many off therapy', 'cr remain in cr, many off therapy serious', 'remain in cr, many off therapy serious infections', 'in cr, many off therapy serious infections in', 'cr, many off therapy serious infections in 1/3', 'many off therapy serious infections in 1/3 key', 'off therapy serious infections in 1/3 key toxicity', 'therapy serious infections in 1/3 key toxicity to', 'serious infections in 1/3 key toxicity to monitor', 'infections in 1/3 key toxicity to monitor in', 'in 1/3 key toxicity to monitor in future', '1/3 key toxicity to monitor in future studies', 'key toxicity to monitor in future studies very', 'toxicity to monitor in future studies very potent', 'to monitor in future studies very potent agent', 'monitor in future studies very potent agent in', 'in future studies very potent agent in mcl!.', 'future studies very potent agent in mcl!. '], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '26', 'tokens': ['next', 'up:', '12', 'fixed', 'cycles', 'glofitamab', 'in', 'r/r', 'mantle', 'cell', 'lymphoma.', '37', 'pts,', 'most', 'with', 'refractory', 'dx', '&amp;', 'previous', 'btk', 'tx.', 'high', 'cr', 'rates', '&gt;70%,', 'with', '72%', 'of', 'cr', 'pts', 'with', 'ongoing', 'remissions.', 'more', 'tox', 'but', 'higher', 'cr', 'with', 'higher', 'dose', 'of', 'pretx', 'obinu.', 'most', 'common', 'ae', 'was', 'gr1-2', 'crs.', '#ash22', '#lymsm.', ''], 'text_length': 53, 'triples': {'glofitamab|next up: 12 fixed cycles glofitamab in r/r mantle cell lymphoma. 37 pts, most with refractory dx &amp; previous btk tx. high cr rates &gt;70%, with 72% of cr pts with ongoing remissions. more tox but higher cr with higher dose of pretx obinu. most common': ([5, 5], [0, 45], 'neutral')}, 'sentence': 'next up: 12 fixed cycles glofitamab in r/r mantle cell lymphoma. 37 pts, most with refractory dx &amp; previous btk tx. high cr rates &gt;70%, with 72% of cr pts with ongoing remissions. more tox but higher cr with higher dose of pretx obinu. most common ae was gr1-2 crs. #ash22 #lymsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 45)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (52, 52, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (51, 52, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (50, 52, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (49, 52, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (48, 52, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (47, 52, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (46, 52, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8), (45, 52, 8)], 'span tokens': ['next', 'up:', '12', 'fixed', 'cycles', 'glofitamab', 'in', 'r/r', 'mantle', 'cell', 'lymphoma.', '37', 'pts,', 'most', 'with', 'refractory', 'dx', '&amp;', 'previous', 'btk', 'tx.', 'high', 'cr', 'rates', '&gt;70%,', 'with', '72%', 'of', 'cr', 'pts', 'with', 'ongoing', 'remissions.', 'more', 'tox', 'but', 'higher', 'cr', 'with', 'higher', 'dose', 'of', 'pretx', 'obinu.', 'most', 'common', 'ae', 'was', 'gr1-2', 'crs.', '#ash22', '#lymsm.', '', 'next up:', 'up: 12', '12 fixed', 'fixed cycles', 'cycles glofitamab', 'glofitamab in', 'in r/r', 'r/r mantle', 'mantle cell', 'cell lymphoma.', 'lymphoma. 37', '37 pts,', 'pts, most', 'most with', 'with refractory', 'refractory dx', 'dx &amp;', '&amp; previous', 'previous btk', 'btk tx.', 'tx. high', 'high cr', 'cr rates', 'rates &gt;70%,', '&gt;70%, with', 'with 72%', '72% of', 'of cr', 'cr pts', 'pts with', 'with ongoing', 'ongoing remissions.', 'remissions. more', 'more tox', 'tox but', 'but higher', 'higher cr', 'cr with', 'with higher', 'higher dose', 'dose of', 'of pretx', 'pretx obinu.', 'obinu. most', 'most common', 'common ae', 'ae was', 'was gr1-2', 'gr1-2 crs.', 'crs. #ash22', '#ash22 #lymsm.', '#lymsm. ', 'next up: 12', 'up: 12 fixed', '12 fixed cycles', 'fixed cycles glofitamab', 'cycles glofitamab in', 'glofitamab in r/r', 'in r/r mantle', 'r/r mantle cell', 'mantle cell lymphoma.', 'cell lymphoma. 37', 'lymphoma. 37 pts,', '37 pts, most', 'pts, most with', 'most with refractory', 'with refractory dx', 'refractory dx &amp;', 'dx &amp; previous', '&amp; previous btk', 'previous btk tx.', 'btk tx. high', 'tx. high cr', 'high cr rates', 'cr rates &gt;70%,', 'rates &gt;70%, with', '&gt;70%, with 72%', 'with 72% of', '72% of cr', 'of cr pts', 'cr pts with', 'pts with ongoing', 'with ongoing remissions.', 'ongoing remissions. more', 'remissions. more tox', 'more tox but', 'tox but higher', 'but higher cr', 'higher cr with', 'cr with higher', 'with higher dose', 'higher dose of', 'dose of pretx', 'of pretx obinu.', 'pretx obinu. most', 'obinu. most common', 'most common ae', 'common ae was', 'ae was gr1-2', 'was gr1-2 crs.', 'gr1-2 crs. #ash22', 'crs. #ash22 #lymsm.', '#ash22 #lymsm. ', 'next up: 12 fixed', 'up: 12 fixed cycles', '12 fixed cycles glofitamab', 'fixed cycles glofitamab in', 'cycles glofitamab in r/r', 'glofitamab in r/r mantle', 'in r/r mantle cell', 'r/r mantle cell lymphoma.', 'mantle cell lymphoma. 37', 'cell lymphoma. 37 pts,', 'lymphoma. 37 pts, most', '37 pts, most with', 'pts, most with refractory', 'most with refractory dx', 'with refractory dx &amp;', 'refractory dx &amp; previous', 'dx &amp; previous btk', '&amp; previous btk tx.', 'previous btk tx. high', 'btk tx. high cr', 'tx. high cr rates', 'high cr rates &gt;70%,', 'cr rates &gt;70%, with', 'rates &gt;70%, with 72%', '&gt;70%, with 72% of', 'with 72% of cr', '72% of cr pts', 'of cr pts with', 'cr pts with ongoing', 'pts with ongoing remissions.', 'with ongoing remissions. more', 'ongoing remissions. more tox', 'remissions. more tox but', 'more tox but higher', 'tox but higher cr', 'but higher cr with', 'higher cr with higher', 'cr with higher dose', 'with higher dose of', 'higher dose of pretx', 'dose of pretx obinu.', 'of pretx obinu. most', 'pretx obinu. most common', 'obinu. most common ae', 'most common ae was', 'common ae was gr1-2', 'ae was gr1-2 crs.', 'was gr1-2 crs. #ash22', 'gr1-2 crs. #ash22 #lymsm.', 'crs. #ash22 #lymsm. ', 'next up: 12 fixed cycles', 'up: 12 fixed cycles glofitamab', '12 fixed cycles glofitamab in', 'fixed cycles glofitamab in r/r', 'cycles glofitamab in r/r mantle', 'glofitamab in r/r mantle cell', 'in r/r mantle cell lymphoma.', 'r/r mantle cell lymphoma. 37', 'mantle cell lymphoma. 37 pts,', 'cell lymphoma. 37 pts, most', 'lymphoma. 37 pts, most with', '37 pts, most with refractory', 'pts, most with refractory dx', 'most with refractory dx &amp;', 'with refractory dx &amp; previous', 'refractory dx &amp; previous btk', 'dx &amp; previous btk tx.', '&amp; previous btk tx. high', 'previous btk tx. high cr', 'btk tx. high cr rates', 'tx. high cr rates &gt;70%,', 'high cr rates &gt;70%, with', 'cr rates &gt;70%, with 72%', 'rates &gt;70%, with 72% of', '&gt;70%, with 72% of cr', 'with 72% of cr pts', '72% of cr pts with', 'of cr pts with ongoing', 'cr pts with ongoing remissions.', 'pts with ongoing remissions. more', 'with ongoing remissions. more tox', 'ongoing remissions. more tox but', 'remissions. more tox but higher', 'more tox but higher cr', 'tox but higher cr with', 'but higher cr with higher', 'higher cr with higher dose', 'cr with higher dose of', 'with higher dose of pretx', 'higher dose of pretx obinu.', 'dose of pretx obinu. most', 'of pretx obinu. most common', 'pretx obinu. most common ae', 'obinu. most common ae was', 'most common ae was gr1-2', 'common ae was gr1-2 crs.', 'ae was gr1-2 crs. #ash22', 'was gr1-2 crs. #ash22 #lymsm.', 'gr1-2 crs. #ash22 #lymsm. ', 'next up: 12 fixed cycles glofitamab', 'up: 12 fixed cycles glofitamab in', '12 fixed cycles glofitamab in r/r', 'fixed cycles glofitamab in r/r mantle', 'cycles glofitamab in r/r mantle cell', 'glofitamab in r/r mantle cell lymphoma.', 'in r/r mantle cell lymphoma. 37', 'r/r mantle cell lymphoma. 37 pts,', 'mantle cell lymphoma. 37 pts, most', 'cell lymphoma. 37 pts, most with', 'lymphoma. 37 pts, most with refractory', '37 pts, most with refractory dx', 'pts, most with refractory dx &amp;', 'most with refractory dx &amp; previous', 'with refractory dx &amp; previous btk', 'refractory dx &amp; previous btk tx.', 'dx &amp; previous btk tx. high', '&amp; previous btk tx. high cr', 'previous btk tx. high cr rates', 'btk tx. high cr rates &gt;70%,', 'tx. high cr rates &gt;70%, with', 'high cr rates &gt;70%, with 72%', 'cr rates &gt;70%, with 72% of', 'rates &gt;70%, with 72% of cr', '&gt;70%, with 72% of cr pts', 'with 72% of cr pts with', '72% of cr pts with ongoing', 'of cr pts with ongoing remissions.', 'cr pts with ongoing remissions. more', 'pts with ongoing remissions. more tox', 'with ongoing remissions. more tox but', 'ongoing remissions. more tox but higher', 'remissions. more tox but higher cr', 'more tox but higher cr with', 'tox but higher cr with higher', 'but higher cr with higher dose', 'higher cr with higher dose of', 'cr with higher dose of pretx', 'with higher dose of pretx obinu.', 'higher dose of pretx obinu. most', 'dose of pretx obinu. most common', 'of pretx obinu. most common ae', 'pretx obinu. most common ae was', 'obinu. most common ae was gr1-2', 'most common ae was gr1-2 crs.', 'common ae was gr1-2 crs. #ash22', 'ae was gr1-2 crs. #ash22 #lymsm.', 'was gr1-2 crs. #ash22 #lymsm. ', 'next up: 12 fixed cycles glofitamab in', 'up: 12 fixed cycles glofitamab in r/r', '12 fixed cycles glofitamab in r/r mantle', 'fixed cycles glofitamab in r/r mantle cell', 'cycles glofitamab in r/r mantle cell lymphoma.', 'glofitamab in r/r mantle cell lymphoma. 37', 'in r/r mantle cell lymphoma. 37 pts,', 'r/r mantle cell lymphoma. 37 pts, most', 'mantle cell lymphoma. 37 pts, most with', 'cell lymphoma. 37 pts, most with refractory', 'lymphoma. 37 pts, most with refractory dx', '37 pts, most with refractory dx &amp;', 'pts, most with refractory dx &amp; previous', 'most with refractory dx &amp; previous btk', 'with refractory dx &amp; previous btk tx.', 'refractory dx &amp; previous btk tx. high', 'dx &amp; previous btk tx. high cr', '&amp; previous btk tx. high cr rates', 'previous btk tx. high cr rates &gt;70%,', 'btk tx. high cr rates &gt;70%, with', 'tx. high cr rates &gt;70%, with 72%', 'high cr rates &gt;70%, with 72% of', 'cr rates &gt;70%, with 72% of cr', 'rates &gt;70%, with 72% of cr pts', '&gt;70%, with 72% of cr pts with', 'with 72% of cr pts with ongoing', '72% of cr pts with ongoing remissions.', 'of cr pts with ongoing remissions. more', 'cr pts with ongoing remissions. more tox', 'pts with ongoing remissions. more tox but', 'with ongoing remissions. more tox but higher', 'ongoing remissions. more tox but higher cr', 'remissions. more tox but higher cr with', 'more tox but higher cr with higher', 'tox but higher cr with higher dose', 'but higher cr with higher dose of', 'higher cr with higher dose of pretx', 'cr with higher dose of pretx obinu.', 'with higher dose of pretx obinu. most', 'higher dose of pretx obinu. most common', 'dose of pretx obinu. most common ae', 'of pretx obinu. most common ae was', 'pretx obinu. most common ae was gr1-2', 'obinu. most common ae was gr1-2 crs.', 'most common ae was gr1-2 crs. #ash22', 'common ae was gr1-2 crs. #ash22 #lymsm.', 'ae was gr1-2 crs. #ash22 #lymsm. ', 'next up: 12 fixed cycles glofitamab in r/r', 'up: 12 fixed cycles glofitamab in r/r mantle', '12 fixed cycles glofitamab in r/r mantle cell', 'fixed cycles glofitamab in r/r mantle cell lymphoma.', 'cycles glofitamab in r/r mantle cell lymphoma. 37', 'glofitamab in r/r mantle cell lymphoma. 37 pts,', 'in r/r mantle cell lymphoma. 37 pts, most', 'r/r mantle cell lymphoma. 37 pts, most with', 'mantle cell lymphoma. 37 pts, most with refractory', 'cell lymphoma. 37 pts, most with refractory dx', 'lymphoma. 37 pts, most with refractory dx &amp;', '37 pts, most with refractory dx &amp; previous', 'pts, most with refractory dx &amp; previous btk', 'most with refractory dx &amp; previous btk tx.', 'with refractory dx &amp; previous btk tx. high', 'refractory dx &amp; previous btk tx. high cr', 'dx &amp; previous btk tx. high cr rates', '&amp; previous btk tx. high cr rates &gt;70%,', 'previous btk tx. high cr rates &gt;70%, with', 'btk tx. high cr rates &gt;70%, with 72%', 'tx. high cr rates &gt;70%, with 72% of', 'high cr rates &gt;70%, with 72% of cr', 'cr rates &gt;70%, with 72% of cr pts', 'rates &gt;70%, with 72% of cr pts with', '&gt;70%, with 72% of cr pts with ongoing', 'with 72% of cr pts with ongoing remissions.', '72% of cr pts with ongoing remissions. more', 'of cr pts with ongoing remissions. more tox', 'cr pts with ongoing remissions. more tox but', 'pts with ongoing remissions. more tox but higher', 'with ongoing remissions. more tox but higher cr', 'ongoing remissions. more tox but higher cr with', 'remissions. more tox but higher cr with higher', 'more tox but higher cr with higher dose', 'tox but higher cr with higher dose of', 'but higher cr with higher dose of pretx', 'higher cr with higher dose of pretx obinu.', 'cr with higher dose of pretx obinu. most', 'with higher dose of pretx obinu. most common', 'higher dose of pretx obinu. most common ae', 'dose of pretx obinu. most common ae was', 'of pretx obinu. most common ae was gr1-2', 'pretx obinu. most common ae was gr1-2 crs.', 'obinu. most common ae was gr1-2 crs. #ash22', 'most common ae was gr1-2 crs. #ash22 #lymsm.', 'common ae was gr1-2 crs. #ash22 #lymsm. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '27', 'tokens': ['"glofitamab', 'monotherapy', 'r/r', 'mcl', 'phillips', 'et', 'al.', '-', '37', 'pts,', 'med', 'age', '72,', 'med', 'prio', '3', '-', 'orr', '84%', '/', 'cr', '73%', '-', 'durability', 'of', 'cr', 'seen', 'even', 'when', 'therapy', 'stopped', '-', '4', 'covid', 'deaths', '-', 'crs', 'seen,', 'less', 'with', '2g', 'obinutuz', 'prior', 'to', 'dosing', '-', 'ph3', 'trial', 'planned', 'very', 'impressive', 'data..', ''], 'text_length': 53, 'triples': {'"glofitamab|planned very': ([0, 0], [48, 49], 'positive')}, 'sentence': '"glofitamab monotherapy r/r mcl phillips et al. - 37 pts, med age 72, med prio 3 - orr 84% / cr 73% - durability of cr seen even when therapy stopped - 4 covid deaths - crs seen, less with 2g obinutuz prior to dosing - ph3 trial planned very impressive data.. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(48, 49)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (52, 52, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (51, 52, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (50, 52, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (49, 52, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (48, 52, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (47, 52, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (46, 52, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8), (45, 52, 8)], 'span tokens': ['"glofitamab', 'monotherapy', 'r/r', 'mcl', 'phillips', 'et', 'al.', '-', '37', 'pts,', 'med', 'age', '72,', 'med', 'prio', '3', '-', 'orr', '84%', '/', 'cr', '73%', '-', 'durability', 'of', 'cr', 'seen', 'even', 'when', 'therapy', 'stopped', '-', '4', 'covid', 'deaths', '-', 'crs', 'seen,', 'less', 'with', '2g', 'obinutuz', 'prior', 'to', 'dosing', '-', 'ph3', 'trial', 'planned', 'very', 'impressive', 'data..', '', '"glofitamab monotherapy', 'monotherapy r/r', 'r/r mcl', 'mcl phillips', 'phillips et', 'et al.', 'al. -', '- 37', '37 pts,', 'pts, med', 'med age', 'age 72,', '72, med', 'med prio', 'prio 3', '3 -', '- orr', 'orr 84%', '84% /', '/ cr', 'cr 73%', '73% -', '- durability', 'durability of', 'of cr', 'cr seen', 'seen even', 'even when', 'when therapy', 'therapy stopped', 'stopped -', '- 4', '4 covid', 'covid deaths', 'deaths -', '- crs', 'crs seen,', 'seen, less', 'less with', 'with 2g', '2g obinutuz', 'obinutuz prior', 'prior to', 'to dosing', 'dosing -', '- ph3', 'ph3 trial', 'trial planned', 'planned very', 'very impressive', 'impressive data..', 'data.. ', '"glofitamab monotherapy r/r', 'monotherapy r/r mcl', 'r/r mcl phillips', 'mcl phillips et', 'phillips et al.', 'et al. -', 'al. - 37', '- 37 pts,', '37 pts, med', 'pts, med age', 'med age 72,', 'age 72, med', '72, med prio', 'med prio 3', 'prio 3 -', '3 - orr', '- orr 84%', 'orr 84% /', '84% / cr', '/ cr 73%', 'cr 73% -', '73% - durability', '- durability of', 'durability of cr', 'of cr seen', 'cr seen even', 'seen even when', 'even when therapy', 'when therapy stopped', 'therapy stopped -', 'stopped - 4', '- 4 covid', '4 covid deaths', 'covid deaths -', 'deaths - crs', '- crs seen,', 'crs seen, less', 'seen, less with', 'less with 2g', 'with 2g obinutuz', '2g obinutuz prior', 'obinutuz prior to', 'prior to dosing', 'to dosing -', 'dosing - ph3', '- ph3 trial', 'ph3 trial planned', 'trial planned very', 'planned very impressive', 'very impressive data..', 'impressive data.. ', '"glofitamab monotherapy r/r mcl', 'monotherapy r/r mcl phillips', 'r/r mcl phillips et', 'mcl phillips et al.', 'phillips et al. -', 'et al. - 37', 'al. - 37 pts,', '- 37 pts, med', '37 pts, med age', 'pts, med age 72,', 'med age 72, med', 'age 72, med prio', '72, med prio 3', 'med prio 3 -', 'prio 3 - orr', '3 - orr 84%', '- orr 84% /', 'orr 84% / cr', '84% / cr 73%', '/ cr 73% -', 'cr 73% - durability', '73% - durability of', '- durability of cr', 'durability of cr seen', 'of cr seen even', 'cr seen even when', 'seen even when therapy', 'even when therapy stopped', 'when therapy stopped -', 'therapy stopped - 4', 'stopped - 4 covid', '- 4 covid deaths', '4 covid deaths -', 'covid deaths - crs', 'deaths - crs seen,', '- crs seen, less', 'crs seen, less with', 'seen, less with 2g', 'less with 2g obinutuz', 'with 2g obinutuz prior', '2g obinutuz prior to', 'obinutuz prior to dosing', 'prior to dosing -', 'to dosing - ph3', 'dosing - ph3 trial', '- ph3 trial planned', 'ph3 trial planned very', 'trial planned very impressive', 'planned very impressive data..', 'very impressive data.. ', '"glofitamab monotherapy r/r mcl phillips', 'monotherapy r/r mcl phillips et', 'r/r mcl phillips et al.', 'mcl phillips et al. -', 'phillips et al. - 37', 'et al. - 37 pts,', 'al. - 37 pts, med', '- 37 pts, med age', '37 pts, med age 72,', 'pts, med age 72, med', 'med age 72, med prio', 'age 72, med prio 3', '72, med prio 3 -', 'med prio 3 - orr', 'prio 3 - orr 84%', '3 - orr 84% /', '- orr 84% / cr', 'orr 84% / cr 73%', '84% / cr 73% -', '/ cr 73% - durability', 'cr 73% - durability of', '73% - durability of cr', '- durability of cr seen', 'durability of cr seen even', 'of cr seen even when', 'cr seen even when therapy', 'seen even when therapy stopped', 'even when therapy stopped -', 'when therapy stopped - 4', 'therapy stopped - 4 covid', 'stopped - 4 covid deaths', '- 4 covid deaths -', '4 covid deaths - crs', 'covid deaths - crs seen,', 'deaths - crs seen, less', '- crs seen, less with', 'crs seen, less with 2g', 'seen, less with 2g obinutuz', 'less with 2g obinutuz prior', 'with 2g obinutuz prior to', '2g obinutuz prior to dosing', 'obinutuz prior to dosing -', 'prior to dosing - ph3', 'to dosing - ph3 trial', 'dosing - ph3 trial planned', '- ph3 trial planned very', 'ph3 trial planned very impressive', 'trial planned very impressive data..', 'planned very impressive data.. ', '"glofitamab monotherapy r/r mcl phillips et', 'monotherapy r/r mcl phillips et al.', 'r/r mcl phillips et al. -', 'mcl phillips et al. - 37', 'phillips et al. - 37 pts,', 'et al. - 37 pts, med', 'al. - 37 pts, med age', '- 37 pts, med age 72,', '37 pts, med age 72, med', 'pts, med age 72, med prio', 'med age 72, med prio 3', 'age 72, med prio 3 -', '72, med prio 3 - orr', 'med prio 3 - orr 84%', 'prio 3 - orr 84% /', '3 - orr 84% / cr', '- orr 84% / cr 73%', 'orr 84% / cr 73% -', '84% / cr 73% - durability', '/ cr 73% - durability of', 'cr 73% - durability of cr', '73% - durability of cr seen', '- durability of cr seen even', 'durability of cr seen even when', 'of cr seen even when therapy', 'cr seen even when therapy stopped', 'seen even when therapy stopped -', 'even when therapy stopped - 4', 'when therapy stopped - 4 covid', 'therapy stopped - 4 covid deaths', 'stopped - 4 covid deaths -', '- 4 covid deaths - crs', '4 covid deaths - crs seen,', 'covid deaths - crs seen, less', 'deaths - crs seen, less with', '- crs seen, less with 2g', 'crs seen, less with 2g obinutuz', 'seen, less with 2g obinutuz prior', 'less with 2g obinutuz prior to', 'with 2g obinutuz prior to dosing', '2g obinutuz prior to dosing -', 'obinutuz prior to dosing - ph3', 'prior to dosing - ph3 trial', 'to dosing - ph3 trial planned', 'dosing - ph3 trial planned very', '- ph3 trial planned very impressive', 'ph3 trial planned very impressive data..', 'trial planned very impressive data.. ', '"glofitamab monotherapy r/r mcl phillips et al.', 'monotherapy r/r mcl phillips et al. -', 'r/r mcl phillips et al. - 37', 'mcl phillips et al. - 37 pts,', 'phillips et al. - 37 pts, med', 'et al. - 37 pts, med age', 'al. - 37 pts, med age 72,', '- 37 pts, med age 72, med', '37 pts, med age 72, med prio', 'pts, med age 72, med prio 3', 'med age 72, med prio 3 -', 'age 72, med prio 3 - orr', '72, med prio 3 - orr 84%', 'med prio 3 - orr 84% /', 'prio 3 - orr 84% / cr', '3 - orr 84% / cr 73%', '- orr 84% / cr 73% -', 'orr 84% / cr 73% - durability', '84% / cr 73% - durability of', '/ cr 73% - durability of cr', 'cr 73% - durability of cr seen', '73% - durability of cr seen even', '- durability of cr seen even when', 'durability of cr seen even when therapy', 'of cr seen even when therapy stopped', 'cr seen even when therapy stopped -', 'seen even when therapy stopped - 4', 'even when therapy stopped - 4 covid', 'when therapy stopped - 4 covid deaths', 'therapy stopped - 4 covid deaths -', 'stopped - 4 covid deaths - crs', '- 4 covid deaths - crs seen,', '4 covid deaths - crs seen, less', 'covid deaths - crs seen, less with', 'deaths - crs seen, less with 2g', '- crs seen, less with 2g obinutuz', 'crs seen, less with 2g obinutuz prior', 'seen, less with 2g obinutuz prior to', 'less with 2g obinutuz prior to dosing', 'with 2g obinutuz prior to dosing -', '2g obinutuz prior to dosing - ph3', 'obinutuz prior to dosing - ph3 trial', 'prior to dosing - ph3 trial planned', 'to dosing - ph3 trial planned very', 'dosing - ph3 trial planned very impressive', '- ph3 trial planned very impressive data..', 'ph3 trial planned very impressive data.. ', '"glofitamab monotherapy r/r mcl phillips et al. -', 'monotherapy r/r mcl phillips et al. - 37', 'r/r mcl phillips et al. - 37 pts,', 'mcl phillips et al. - 37 pts, med', 'phillips et al. - 37 pts, med age', 'et al. - 37 pts, med age 72,', 'al. - 37 pts, med age 72, med', '- 37 pts, med age 72, med prio', '37 pts, med age 72, med prio 3', 'pts, med age 72, med prio 3 -', 'med age 72, med prio 3 - orr', 'age 72, med prio 3 - orr 84%', '72, med prio 3 - orr 84% /', 'med prio 3 - orr 84% / cr', 'prio 3 - orr 84% / cr 73%', '3 - orr 84% / cr 73% -', '- orr 84% / cr 73% - durability', 'orr 84% / cr 73% - durability of', '84% / cr 73% - durability of cr', '/ cr 73% - durability of cr seen', 'cr 73% - durability of cr seen even', '73% - durability of cr seen even when', '- durability of cr seen even when therapy', 'durability of cr seen even when therapy stopped', 'of cr seen even when therapy stopped -', 'cr seen even when therapy stopped - 4', 'seen even when therapy stopped - 4 covid', 'even when therapy stopped - 4 covid deaths', 'when therapy stopped - 4 covid deaths -', 'therapy stopped - 4 covid deaths - crs', 'stopped - 4 covid deaths - crs seen,', '- 4 covid deaths - crs seen, less', '4 covid deaths - crs seen, less with', 'covid deaths - crs seen, less with 2g', 'deaths - crs seen, less with 2g obinutuz', '- crs seen, less with 2g obinutuz prior', 'crs seen, less with 2g obinutuz prior to', 'seen, less with 2g obinutuz prior to dosing', 'less with 2g obinutuz prior to dosing -', 'with 2g obinutuz prior to dosing - ph3', '2g obinutuz prior to dosing - ph3 trial', 'obinutuz prior to dosing - ph3 trial planned', 'prior to dosing - ph3 trial planned very', 'to dosing - ph3 trial planned very impressive', 'dosing - ph3 trial planned very impressive data..', '- ph3 trial planned very impressive data.. '], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '28', 'tokens': ['q:', '"how', 'would', 'you', 'sequence', 'brexu-cel', 'and', 'glofitamab', 'in', 'mcl', 'if', 'both', 'are', 'available?"', 'makes', 'the', 'points', 'that', 'although', 'bispecific', 'follow-up', 'data', 'is', 'only', 'early,', 'its', 'off-the-shelf', 'nature', 'is', 'promising', 'compared', 'to', 'logistical', 'challenges', 'of', 'car-t', '#tcellrx', '#ash22', '#lymsm', '.'], 'text_length': 40, 'triples': {'glofitamab|promising': ([7, 7], [29, 29], 'positive')}, 'sentence': 'q: "how would you sequence brexu-cel and glofitamab in mcl if both are available?" makes the points that although bispecific follow-up data is only early, its off-the-shelf nature is promising compared to logistical challenges of car-t #tcellrx #ash22 #lymsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(29, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8)], 'span tokens': ['q:', '"how', 'would', 'you', 'sequence', 'brexu-cel', 'and', 'glofitamab', 'in', 'mcl', 'if', 'both', 'are', 'available?"', 'makes', 'the', 'points', 'that', 'although', 'bispecific', 'follow-up', 'data', 'is', 'only', 'early,', 'its', 'off-the-shelf', 'nature', 'is', 'promising', 'compared', 'to', 'logistical', 'challenges', 'of', 'car-t', '#tcellrx', '#ash22', '#lymsm', '.', 'q: "how', '"how would', 'would you', 'you sequence', 'sequence brexu-cel', 'brexu-cel and', 'and glofitamab', 'glofitamab in', 'in mcl', 'mcl if', 'if both', 'both are', 'are available?"', 'available?" makes', 'makes the', 'the points', 'points that', 'that although', 'although bispecific', 'bispecific follow-up', 'follow-up data', 'data is', 'is only', 'only early,', 'early, its', 'its off-the-shelf', 'off-the-shelf nature', 'nature is', 'is promising', 'promising compared', 'compared to', 'to logistical', 'logistical challenges', 'challenges of', 'of car-t', 'car-t #tcellrx', '#tcellrx #ash22', '#ash22 #lymsm', '#lymsm .', 'q: "how would', '"how would you', 'would you sequence', 'you sequence brexu-cel', 'sequence brexu-cel and', 'brexu-cel and glofitamab', 'and glofitamab in', 'glofitamab in mcl', 'in mcl if', 'mcl if both', 'if both are', 'both are available?"', 'are available?" makes', 'available?" makes the', 'makes the points', 'the points that', 'points that although', 'that although bispecific', 'although bispecific follow-up', 'bispecific follow-up data', 'follow-up data is', 'data is only', 'is only early,', 'only early, its', 'early, its off-the-shelf', 'its off-the-shelf nature', 'off-the-shelf nature is', 'nature is promising', 'is promising compared', 'promising compared to', 'compared to logistical', 'to logistical challenges', 'logistical challenges of', 'challenges of car-t', 'of car-t #tcellrx', 'car-t #tcellrx #ash22', '#tcellrx #ash22 #lymsm', '#ash22 #lymsm .', 'q: "how would you', '"how would you sequence', 'would you sequence brexu-cel', 'you sequence brexu-cel and', 'sequence brexu-cel and glofitamab', 'brexu-cel and glofitamab in', 'and glofitamab in mcl', 'glofitamab in mcl if', 'in mcl if both', 'mcl if both are', 'if both are available?"', 'both are available?" makes', 'are available?" makes the', 'available?" makes the points', 'makes the points that', 'the points that although', 'points that although bispecific', 'that although bispecific follow-up', 'although bispecific follow-up data', 'bispecific follow-up data is', 'follow-up data is only', 'data is only early,', 'is only early, its', 'only early, its off-the-shelf', 'early, its off-the-shelf nature', 'its off-the-shelf nature is', 'off-the-shelf nature is promising', 'nature is promising compared', 'is promising compared to', 'promising compared to logistical', 'compared to logistical challenges', 'to logistical challenges of', 'logistical challenges of car-t', 'challenges of car-t #tcellrx', 'of car-t #tcellrx #ash22', 'car-t #tcellrx #ash22 #lymsm', '#tcellrx #ash22 #lymsm .', 'q: "how would you sequence', '"how would you sequence brexu-cel', 'would you sequence brexu-cel and', 'you sequence brexu-cel and glofitamab', 'sequence brexu-cel and glofitamab in', 'brexu-cel and glofitamab in mcl', 'and glofitamab in mcl if', 'glofitamab in mcl if both', 'in mcl if both are', 'mcl if both are available?"', 'if both are available?" makes', 'both are available?" makes the', 'are available?" makes the points', 'available?" makes the points that', 'makes the points that although', 'the points that although bispecific', 'points that although bispecific follow-up', 'that although bispecific follow-up data', 'although bispecific follow-up data is', 'bispecific follow-up data is only', 'follow-up data is only early,', 'data is only early, its', 'is only early, its off-the-shelf', 'only early, its off-the-shelf nature', 'early, its off-the-shelf nature is', 'its off-the-shelf nature is promising', 'off-the-shelf nature is promising compared', 'nature is promising compared to', 'is promising compared to logistical', 'promising compared to logistical challenges', 'compared to logistical challenges of', 'to logistical challenges of car-t', 'logistical challenges of car-t #tcellrx', 'challenges of car-t #tcellrx #ash22', 'of car-t #tcellrx #ash22 #lymsm', 'car-t #tcellrx #ash22 #lymsm .', 'q: "how would you sequence brexu-cel', '"how would you sequence brexu-cel and', 'would you sequence brexu-cel and glofitamab', 'you sequence brexu-cel and glofitamab in', 'sequence brexu-cel and glofitamab in mcl', 'brexu-cel and glofitamab in mcl if', 'and glofitamab in mcl if both', 'glofitamab in mcl if both are', 'in mcl if both are available?"', 'mcl if both are available?" makes', 'if both are available?" makes the', 'both are available?" makes the points', 'are available?" makes the points that', 'available?" makes the points that although', 'makes the points that although bispecific', 'the points that although bispecific follow-up', 'points that although bispecific follow-up data', 'that although bispecific follow-up data is', 'although bispecific follow-up data is only', 'bispecific follow-up data is only early,', 'follow-up data is only early, its', 'data is only early, its off-the-shelf', 'is only early, its off-the-shelf nature', 'only early, its off-the-shelf nature is', 'early, its off-the-shelf nature is promising', 'its off-the-shelf nature is promising compared', 'off-the-shelf nature is promising compared to', 'nature is promising compared to logistical', 'is promising compared to logistical challenges', 'promising compared to logistical challenges of', 'compared to logistical challenges of car-t', 'to logistical challenges of car-t #tcellrx', 'logistical challenges of car-t #tcellrx #ash22', 'challenges of car-t #tcellrx #ash22 #lymsm', 'of car-t #tcellrx #ash22 #lymsm .', 'q: "how would you sequence brexu-cel and', '"how would you sequence brexu-cel and glofitamab', 'would you sequence brexu-cel and glofitamab in', 'you sequence brexu-cel and glofitamab in mcl', 'sequence brexu-cel and glofitamab in mcl if', 'brexu-cel and glofitamab in mcl if both', 'and glofitamab in mcl if both are', 'glofitamab in mcl if both are available?"', 'in mcl if both are available?" makes', 'mcl if both are available?" makes the', 'if both are available?" makes the points', 'both are available?" makes the points that', 'are available?" makes the points that although', 'available?" makes the points that although bispecific', 'makes the points that although bispecific follow-up', 'the points that although bispecific follow-up data', 'points that although bispecific follow-up data is', 'that although bispecific follow-up data is only', 'although bispecific follow-up data is only early,', 'bispecific follow-up data is only early, its', 'follow-up data is only early, its off-the-shelf', 'data is only early, its off-the-shelf nature', 'is only early, its off-the-shelf nature is', 'only early, its off-the-shelf nature is promising', 'early, its off-the-shelf nature is promising compared', 'its off-the-shelf nature is promising compared to', 'off-the-shelf nature is promising compared to logistical', 'nature is promising compared to logistical challenges', 'is promising compared to logistical challenges of', 'promising compared to logistical challenges of car-t', 'compared to logistical challenges of car-t #tcellrx', 'to logistical challenges of car-t #tcellrx #ash22', 'logistical challenges of car-t #tcellrx #ash22 #lymsm', 'challenges of car-t #tcellrx #ash22 #lymsm .', 'q: "how would you sequence brexu-cel and glofitamab', '"how would you sequence brexu-cel and glofitamab in', 'would you sequence brexu-cel and glofitamab in mcl', 'you sequence brexu-cel and glofitamab in mcl if', 'sequence brexu-cel and glofitamab in mcl if both', 'brexu-cel and glofitamab in mcl if both are', 'and glofitamab in mcl if both are available?"', 'glofitamab in mcl if both are available?" makes', 'in mcl if both are available?" makes the', 'mcl if both are available?" makes the points', 'if both are available?" makes the points that', 'both are available?" makes the points that although', 'are available?" makes the points that although bispecific', 'available?" makes the points that although bispecific follow-up', 'makes the points that although bispecific follow-up data', 'the points that although bispecific follow-up data is', 'points that although bispecific follow-up data is only', 'that although bispecific follow-up data is only early,', 'although bispecific follow-up data is only early, its', 'bispecific follow-up data is only early, its off-the-shelf', 'follow-up data is only early, its off-the-shelf nature', 'data is only early, its off-the-shelf nature is', 'is only early, its off-the-shelf nature is promising', 'only early, its off-the-shelf nature is promising compared', 'early, its off-the-shelf nature is promising compared to', 'its off-the-shelf nature is promising compared to logistical', 'off-the-shelf nature is promising compared to logistical challenges', 'nature is promising compared to logistical challenges of', 'is promising compared to logistical challenges of car-t', 'promising compared to logistical challenges of car-t #tcellrx', 'compared to logistical challenges of car-t #tcellrx #ash22', 'to logistical challenges of car-t #tcellrx #ash22 #lymsm', 'logistical challenges of car-t #tcellrx #ash22 #lymsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '29', 'tokens': ["swimmer's", 'plot', 'and', 'km', 'curve', 'for', 'glofitamab', 'in', 'mantle-cell', 'lymphoma', 'promising', 'with', 'early', 'follow-up,', 'showing', 'durable', 'responses', 'so', 'far.', '#ash22', '#mcl', '#lymsm', '#glofitamab.', ''], 'text_length': 24, 'triples': {'glofitamab in mantle-cell lymphoma promising with early follow-up, showing durable responses so far. #ash22 #mcl #lymsm #glofitamab.|promising with early follow-up, showing durable responses': ([6, 22], [10, 16], 'positive')}, 'sentence': "swimmer's plot and km curve for glofitamab in mantle-cell lymphoma promising with early follow-up, showing durable responses so far. #ash22 #mcl #lymsm #glofitamab. ", 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 16)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8)], 'span tokens': ["swimmer's", 'plot', 'and', 'km', 'curve', 'for', 'glofitamab', 'in', 'mantle-cell', 'lymphoma', 'promising', 'with', 'early', 'follow-up,', 'showing', 'durable', 'responses', 'so', 'far.', '#ash22', '#mcl', '#lymsm', '#glofitamab.', '', "swimmer's plot", 'plot and', 'and km', 'km curve', 'curve for', 'for glofitamab', 'glofitamab in', 'in mantle-cell', 'mantle-cell lymphoma', 'lymphoma promising', 'promising with', 'with early', 'early follow-up,', 'follow-up, showing', 'showing durable', 'durable responses', 'responses so', 'so far.', 'far. #ash22', '#ash22 #mcl', '#mcl #lymsm', '#lymsm #glofitamab.', '#glofitamab. ', "swimmer's plot and", 'plot and km', 'and km curve', 'km curve for', 'curve for glofitamab', 'for glofitamab in', 'glofitamab in mantle-cell', 'in mantle-cell lymphoma', 'mantle-cell lymphoma promising', 'lymphoma promising with', 'promising with early', 'with early follow-up,', 'early follow-up, showing', 'follow-up, showing durable', 'showing durable responses', 'durable responses so', 'responses so far.', 'so far. #ash22', 'far. #ash22 #mcl', '#ash22 #mcl #lymsm', '#mcl #lymsm #glofitamab.', '#lymsm #glofitamab. ', "swimmer's plot and km", 'plot and km curve', 'and km curve for', 'km curve for glofitamab', 'curve for glofitamab in', 'for glofitamab in mantle-cell', 'glofitamab in mantle-cell lymphoma', 'in mantle-cell lymphoma promising', 'mantle-cell lymphoma promising with', 'lymphoma promising with early', 'promising with early follow-up,', 'with early follow-up, showing', 'early follow-up, showing durable', 'follow-up, showing durable responses', 'showing durable responses so', 'durable responses so far.', 'responses so far. #ash22', 'so far. #ash22 #mcl', 'far. #ash22 #mcl #lymsm', '#ash22 #mcl #lymsm #glofitamab.', '#mcl #lymsm #glofitamab. ', "swimmer's plot and km curve", 'plot and km curve for', 'and km curve for glofitamab', 'km curve for glofitamab in', 'curve for glofitamab in mantle-cell', 'for glofitamab in mantle-cell lymphoma', 'glofitamab in mantle-cell lymphoma promising', 'in mantle-cell lymphoma promising with', 'mantle-cell lymphoma promising with early', 'lymphoma promising with early follow-up,', 'promising with early follow-up, showing', 'with early follow-up, showing durable', 'early follow-up, showing durable responses', 'follow-up, showing durable responses so', 'showing durable responses so far.', 'durable responses so far. #ash22', 'responses so far. #ash22 #mcl', 'so far. #ash22 #mcl #lymsm', 'far. #ash22 #mcl #lymsm #glofitamab.', '#ash22 #mcl #lymsm #glofitamab. ', "swimmer's plot and km curve for", 'plot and km curve for glofitamab', 'and km curve for glofitamab in', 'km curve for glofitamab in mantle-cell', 'curve for glofitamab in mantle-cell lymphoma', 'for glofitamab in mantle-cell lymphoma promising', 'glofitamab in mantle-cell lymphoma promising with', 'in mantle-cell lymphoma promising with early', 'mantle-cell lymphoma promising with early follow-up,', 'lymphoma promising with early follow-up, showing', 'promising with early follow-up, showing durable', 'with early follow-up, showing durable responses', 'early follow-up, showing durable responses so', 'follow-up, showing durable responses so far.', 'showing durable responses so far. #ash22', 'durable responses so far. #ash22 #mcl', 'responses so far. #ash22 #mcl #lymsm', 'so far. #ash22 #mcl #lymsm #glofitamab.', 'far. #ash22 #mcl #lymsm #glofitamab. ', "swimmer's plot and km curve for glofitamab", 'plot and km curve for glofitamab in', 'and km curve for glofitamab in mantle-cell', 'km curve for glofitamab in mantle-cell lymphoma', 'curve for glofitamab in mantle-cell lymphoma promising', 'for glofitamab in mantle-cell lymphoma promising with', 'glofitamab in mantle-cell lymphoma promising with early', 'in mantle-cell lymphoma promising with early follow-up,', 'mantle-cell lymphoma promising with early follow-up, showing', 'lymphoma promising with early follow-up, showing durable', 'promising with early follow-up, showing durable responses', 'with early follow-up, showing durable responses so', 'early follow-up, showing durable responses so far.', 'follow-up, showing durable responses so far. #ash22', 'showing durable responses so far. #ash22 #mcl', 'durable responses so far. #ash22 #mcl #lymsm', 'responses so far. #ash22 #mcl #lymsm #glofitamab.', 'so far. #ash22 #mcl #lymsm #glofitamab. ', "swimmer's plot and km curve for glofitamab in", 'plot and km curve for glofitamab in mantle-cell', 'and km curve for glofitamab in mantle-cell lymphoma', 'km curve for glofitamab in mantle-cell lymphoma promising', 'curve for glofitamab in mantle-cell lymphoma promising with', 'for glofitamab in mantle-cell lymphoma promising with early', 'glofitamab in mantle-cell lymphoma promising with early follow-up,', 'in mantle-cell lymphoma promising with early follow-up, showing', 'mantle-cell lymphoma promising with early follow-up, showing durable', 'lymphoma promising with early follow-up, showing durable responses', 'promising with early follow-up, showing durable responses so', 'with early follow-up, showing durable responses so far.', 'early follow-up, showing durable responses so far. #ash22', 'follow-up, showing durable responses so far. #ash22 #mcl', 'showing durable responses so far. #ash22 #mcl #lymsm', 'durable responses so far. #ash22 #mcl #lymsm #glofitamab.', 'responses so far. #ash22 #mcl #lymsm #glofitamab. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '30', 'tokens': ['"#ash22', '#lymsm', '#mcl', 'glofitamab', '(+obin', 'priming)', 'in', 'rr', 'mcl', '12', 'cycles', 'n=37,', '72', 'y', 'orr', '83.8%', 'cr', '73%', 'high', 'ae', 'rate', 'crs', 'lower', 'with', '2g', 'obin.', ''], 'text_length': 27, 'triples': {'glofitamab|high ae rate crs lower': ([3, 3], [18, 22], 'neutral')}, 'sentence': '"#ash22 #lymsm #mcl glofitamab (+obin priming) in rr mcl 12 cycles n=37, 72 y orr 83.8% cr 73% high ae rate crs lower with 2g obin. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(18, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8)], 'span tokens': ['"#ash22', '#lymsm', '#mcl', 'glofitamab', '(+obin', 'priming)', 'in', 'rr', 'mcl', '12', 'cycles', 'n=37,', '72', 'y', 'orr', '83.8%', 'cr', '73%', 'high', 'ae', 'rate', 'crs', 'lower', 'with', '2g', 'obin.', '', '"#ash22 #lymsm', '#lymsm #mcl', '#mcl glofitamab', 'glofitamab (+obin', '(+obin priming)', 'priming) in', 'in rr', 'rr mcl', 'mcl 12', '12 cycles', 'cycles n=37,', 'n=37, 72', '72 y', 'y orr', 'orr 83.8%', '83.8% cr', 'cr 73%', '73% high', 'high ae', 'ae rate', 'rate crs', 'crs lower', 'lower with', 'with 2g', '2g obin.', 'obin. ', '"#ash22 #lymsm #mcl', '#lymsm #mcl glofitamab', '#mcl glofitamab (+obin', 'glofitamab (+obin priming)', '(+obin priming) in', 'priming) in rr', 'in rr mcl', 'rr mcl 12', 'mcl 12 cycles', '12 cycles n=37,', 'cycles n=37, 72', 'n=37, 72 y', '72 y orr', 'y orr 83.8%', 'orr 83.8% cr', '83.8% cr 73%', 'cr 73% high', '73% high ae', 'high ae rate', 'ae rate crs', 'rate crs lower', 'crs lower with', 'lower with 2g', 'with 2g obin.', '2g obin. ', '"#ash22 #lymsm #mcl glofitamab', '#lymsm #mcl glofitamab (+obin', '#mcl glofitamab (+obin priming)', 'glofitamab (+obin priming) in', '(+obin priming) in rr', 'priming) in rr mcl', 'in rr mcl 12', 'rr mcl 12 cycles', 'mcl 12 cycles n=37,', '12 cycles n=37, 72', 'cycles n=37, 72 y', 'n=37, 72 y orr', '72 y orr 83.8%', 'y orr 83.8% cr', 'orr 83.8% cr 73%', '83.8% cr 73% high', 'cr 73% high ae', '73% high ae rate', 'high ae rate crs', 'ae rate crs lower', 'rate crs lower with', 'crs lower with 2g', 'lower with 2g obin.', 'with 2g obin. ', '"#ash22 #lymsm #mcl glofitamab (+obin', '#lymsm #mcl glofitamab (+obin priming)', '#mcl glofitamab (+obin priming) in', 'glofitamab (+obin priming) in rr', '(+obin priming) in rr mcl', 'priming) in rr mcl 12', 'in rr mcl 12 cycles', 'rr mcl 12 cycles n=37,', 'mcl 12 cycles n=37, 72', '12 cycles n=37, 72 y', 'cycles n=37, 72 y orr', 'n=37, 72 y orr 83.8%', '72 y orr 83.8% cr', 'y orr 83.8% cr 73%', 'orr 83.8% cr 73% high', '83.8% cr 73% high ae', 'cr 73% high ae rate', '73% high ae rate crs', 'high ae rate crs lower', 'ae rate crs lower with', 'rate crs lower with 2g', 'crs lower with 2g obin.', 'lower with 2g obin. ', '"#ash22 #lymsm #mcl glofitamab (+obin priming)', '#lymsm #mcl glofitamab (+obin priming) in', '#mcl glofitamab (+obin priming) in rr', 'glofitamab (+obin priming) in rr mcl', '(+obin priming) in rr mcl 12', 'priming) in rr mcl 12 cycles', 'in rr mcl 12 cycles n=37,', 'rr mcl 12 cycles n=37, 72', 'mcl 12 cycles n=37, 72 y', '12 cycles n=37, 72 y orr', 'cycles n=37, 72 y orr 83.8%', 'n=37, 72 y orr 83.8% cr', '72 y orr 83.8% cr 73%', 'y orr 83.8% cr 73% high', 'orr 83.8% cr 73% high ae', '83.8% cr 73% high ae rate', 'cr 73% high ae rate crs', '73% high ae rate crs lower', 'high ae rate crs lower with', 'ae rate crs lower with 2g', 'rate crs lower with 2g obin.', 'crs lower with 2g obin. ', '"#ash22 #lymsm #mcl glofitamab (+obin priming) in', '#lymsm #mcl glofitamab (+obin priming) in rr', '#mcl glofitamab (+obin priming) in rr mcl', 'glofitamab (+obin priming) in rr mcl 12', '(+obin priming) in rr mcl 12 cycles', 'priming) in rr mcl 12 cycles n=37,', 'in rr mcl 12 cycles n=37, 72', 'rr mcl 12 cycles n=37, 72 y', 'mcl 12 cycles n=37, 72 y orr', '12 cycles n=37, 72 y orr 83.8%', 'cycles n=37, 72 y orr 83.8% cr', 'n=37, 72 y orr 83.8% cr 73%', '72 y orr 83.8% cr 73% high', 'y orr 83.8% cr 73% high ae', 'orr 83.8% cr 73% high ae rate', '83.8% cr 73% high ae rate crs', 'cr 73% high ae rate crs lower', '73% high ae rate crs lower with', 'high ae rate crs lower with 2g', 'ae rate crs lower with 2g obin.', 'rate crs lower with 2g obin. ', '"#ash22 #lymsm #mcl glofitamab (+obin priming) in rr', '#lymsm #mcl glofitamab (+obin priming) in rr mcl', '#mcl glofitamab (+obin priming) in rr mcl 12', 'glofitamab (+obin priming) in rr mcl 12 cycles', '(+obin priming) in rr mcl 12 cycles n=37,', 'priming) in rr mcl 12 cycles n=37, 72', 'in rr mcl 12 cycles n=37, 72 y', 'rr mcl 12 cycles n=37, 72 y orr', 'mcl 12 cycles n=37, 72 y orr 83.8%', '12 cycles n=37, 72 y orr 83.8% cr', 'cycles n=37, 72 y orr 83.8% cr 73%', 'n=37, 72 y orr 83.8% cr 73% high', '72 y orr 83.8% cr 73% high ae', 'y orr 83.8% cr 73% high ae rate', 'orr 83.8% cr 73% high ae rate crs', '83.8% cr 73% high ae rate crs lower', 'cr 73% high ae rate crs lower with', '73% high ae rate crs lower with 2g', 'high ae rate crs lower with 2g obin.', 'ae rate crs lower with 2g obin. '], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '31', 'tokens': ['first', 'up,', 'presents', 'promising', 'glofitamab', 'data', 'for', 'pts', 'w', 'mantle-cell', 'lymphoma;', 'two', 'thirds', 'of', 'pts', 'w', 'prior', 'btki', 'exposure,', 'with', 'impressive', 'responses', '#ash22', '#lymsm', '#bsab.', ''], 'text_length': 26, 'triples': {'glofitamab|impressive responses': ([4, 4], [20, 21], 'positive')}, 'sentence': 'first up, presents promising glofitamab data for pts w mantle-cell lymphoma; two thirds of pts w prior btki exposure, with impressive responses #ash22 #lymsm #bsab. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(20, 21)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['first', 'up,', 'presents', 'promising', 'glofitamab', 'data', 'for', 'pts', 'w', 'mantle-cell', 'lymphoma;', 'two', 'thirds', 'of', 'pts', 'w', 'prior', 'btki', 'exposure,', 'with', 'impressive', 'responses', '#ash22', '#lymsm', '#bsab.', '', 'first up,', 'up, presents', 'presents promising', 'promising glofitamab', 'glofitamab data', 'data for', 'for pts', 'pts w', 'w mantle-cell', 'mantle-cell lymphoma;', 'lymphoma; two', 'two thirds', 'thirds of', 'of pts', 'pts w', 'w prior', 'prior btki', 'btki exposure,', 'exposure, with', 'with impressive', 'impressive responses', 'responses #ash22', '#ash22 #lymsm', '#lymsm #bsab.', '#bsab. ', 'first up, presents', 'up, presents promising', 'presents promising glofitamab', 'promising glofitamab data', 'glofitamab data for', 'data for pts', 'for pts w', 'pts w mantle-cell', 'w mantle-cell lymphoma;', 'mantle-cell lymphoma; two', 'lymphoma; two thirds', 'two thirds of', 'thirds of pts', 'of pts w', 'pts w prior', 'w prior btki', 'prior btki exposure,', 'btki exposure, with', 'exposure, with impressive', 'with impressive responses', 'impressive responses #ash22', 'responses #ash22 #lymsm', '#ash22 #lymsm #bsab.', '#lymsm #bsab. ', 'first up, presents promising', 'up, presents promising glofitamab', 'presents promising glofitamab data', 'promising glofitamab data for', 'glofitamab data for pts', 'data for pts w', 'for pts w mantle-cell', 'pts w mantle-cell lymphoma;', 'w mantle-cell lymphoma; two', 'mantle-cell lymphoma; two thirds', 'lymphoma; two thirds of', 'two thirds of pts', 'thirds of pts w', 'of pts w prior', 'pts w prior btki', 'w prior btki exposure,', 'prior btki exposure, with', 'btki exposure, with impressive', 'exposure, with impressive responses', 'with impressive responses #ash22', 'impressive responses #ash22 #lymsm', 'responses #ash22 #lymsm #bsab.', '#ash22 #lymsm #bsab. ', 'first up, presents promising glofitamab', 'up, presents promising glofitamab data', 'presents promising glofitamab data for', 'promising glofitamab data for pts', 'glofitamab data for pts w', 'data for pts w mantle-cell', 'for pts w mantle-cell lymphoma;', 'pts w mantle-cell lymphoma; two', 'w mantle-cell lymphoma; two thirds', 'mantle-cell lymphoma; two thirds of', 'lymphoma; two thirds of pts', 'two thirds of pts w', 'thirds of pts w prior', 'of pts w prior btki', 'pts w prior btki exposure,', 'w prior btki exposure, with', 'prior btki exposure, with impressive', 'btki exposure, with impressive responses', 'exposure, with impressive responses #ash22', 'with impressive responses #ash22 #lymsm', 'impressive responses #ash22 #lymsm #bsab.', 'responses #ash22 #lymsm #bsab. ', 'first up, presents promising glofitamab data', 'up, presents promising glofitamab data for', 'presents promising glofitamab data for pts', 'promising glofitamab data for pts w', 'glofitamab data for pts w mantle-cell', 'data for pts w mantle-cell lymphoma;', 'for pts w mantle-cell lymphoma; two', 'pts w mantle-cell lymphoma; two thirds', 'w mantle-cell lymphoma; two thirds of', 'mantle-cell lymphoma; two thirds of pts', 'lymphoma; two thirds of pts w', 'two thirds of pts w prior', 'thirds of pts w prior btki', 'of pts w prior btki exposure,', 'pts w prior btki exposure, with', 'w prior btki exposure, with impressive', 'prior btki exposure, with impressive responses', 'btki exposure, with impressive responses #ash22', 'exposure, with impressive responses #ash22 #lymsm', 'with impressive responses #ash22 #lymsm #bsab.', 'impressive responses #ash22 #lymsm #bsab. ', 'first up, presents promising glofitamab data for', 'up, presents promising glofitamab data for pts', 'presents promising glofitamab data for pts w', 'promising glofitamab data for pts w mantle-cell', 'glofitamab data for pts w mantle-cell lymphoma;', 'data for pts w mantle-cell lymphoma; two', 'for pts w mantle-cell lymphoma; two thirds', 'pts w mantle-cell lymphoma; two thirds of', 'w mantle-cell lymphoma; two thirds of pts', 'mantle-cell lymphoma; two thirds of pts w', 'lymphoma; two thirds of pts w prior', 'two thirds of pts w prior btki', 'thirds of pts w prior btki exposure,', 'of pts w prior btki exposure, with', 'pts w prior btki exposure, with impressive', 'w prior btki exposure, with impressive responses', 'prior btki exposure, with impressive responses #ash22', 'btki exposure, with impressive responses #ash22 #lymsm', 'exposure, with impressive responses #ash22 #lymsm #bsab.', 'with impressive responses #ash22 #lymsm #bsab. ', 'first up, presents promising glofitamab data for pts', 'up, presents promising glofitamab data for pts w', 'presents promising glofitamab data for pts w mantle-cell', 'promising glofitamab data for pts w mantle-cell lymphoma;', 'glofitamab data for pts w mantle-cell lymphoma; two', 'data for pts w mantle-cell lymphoma; two thirds', 'for pts w mantle-cell lymphoma; two thirds of', 'pts w mantle-cell lymphoma; two thirds of pts', 'w mantle-cell lymphoma; two thirds of pts w', 'mantle-cell lymphoma; two thirds of pts w prior', 'lymphoma; two thirds of pts w prior btki', 'two thirds of pts w prior btki exposure,', 'thirds of pts w prior btki exposure, with', 'of pts w prior btki exposure, with impressive', 'pts w prior btki exposure, with impressive responses', 'w prior btki exposure, with impressive responses #ash22', 'prior btki exposure, with impressive responses #ash22 #lymsm', 'btki exposure, with impressive responses #ash22 #lymsm #bsab.', 'exposure, with impressive responses #ash22 #lymsm #bsab. '], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '32', 'tokens': ['early', 'data', 'continue', 'to', 'suggest', 'glofitamab', 'is', 'highly', 'effective', 'in', 'r/r', 'mcl-', 'exciting', 'presentation', 'by', 'tycel', 'philips', '-', 'roughly', '2/3', 'patients', 'with', 'prior', 'btki', 'achieve', 'cr.', '#lymsm', '#ash2022', '#ash22.', ''], 'text_length': 30, 'triples': {'glofitamab|highly effective in r/r mcl- exciting presentation': ([5, 5], [7, 13], 'positive')}, 'sentence': 'early data continue to suggest glofitamab is highly effective in r/r mcl- exciting presentation by tycel philips - roughly 2/3 patients with prior btki achieve cr. #lymsm #ash2022 #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8)], 'span tokens': ['early', 'data', 'continue', 'to', 'suggest', 'glofitamab', 'is', 'highly', 'effective', 'in', 'r/r', 'mcl-', 'exciting', 'presentation', 'by', 'tycel', 'philips', '-', 'roughly', '2/3', 'patients', 'with', 'prior', 'btki', 'achieve', 'cr.', '#lymsm', '#ash2022', '#ash22.', '', 'early data', 'data continue', 'continue to', 'to suggest', 'suggest glofitamab', 'glofitamab is', 'is highly', 'highly effective', 'effective in', 'in r/r', 'r/r mcl-', 'mcl- exciting', 'exciting presentation', 'presentation by', 'by tycel', 'tycel philips', 'philips -', '- roughly', 'roughly 2/3', '2/3 patients', 'patients with', 'with prior', 'prior btki', 'btki achieve', 'achieve cr.', 'cr. #lymsm', '#lymsm #ash2022', '#ash2022 #ash22.', '#ash22. ', 'early data continue', 'data continue to', 'continue to suggest', 'to suggest glofitamab', 'suggest glofitamab is', 'glofitamab is highly', 'is highly effective', 'highly effective in', 'effective in r/r', 'in r/r mcl-', 'r/r mcl- exciting', 'mcl- exciting presentation', 'exciting presentation by', 'presentation by tycel', 'by tycel philips', 'tycel philips -', 'philips - roughly', '- roughly 2/3', 'roughly 2/3 patients', '2/3 patients with', 'patients with prior', 'with prior btki', 'prior btki achieve', 'btki achieve cr.', 'achieve cr. #lymsm', 'cr. #lymsm #ash2022', '#lymsm #ash2022 #ash22.', '#ash2022 #ash22. ', 'early data continue to', 'data continue to suggest', 'continue to suggest glofitamab', 'to suggest glofitamab is', 'suggest glofitamab is highly', 'glofitamab is highly effective', 'is highly effective in', 'highly effective in r/r', 'effective in r/r mcl-', 'in r/r mcl- exciting', 'r/r mcl- exciting presentation', 'mcl- exciting presentation by', 'exciting presentation by tycel', 'presentation by tycel philips', 'by tycel philips -', 'tycel philips - roughly', 'philips - roughly 2/3', '- roughly 2/3 patients', 'roughly 2/3 patients with', '2/3 patients with prior', 'patients with prior btki', 'with prior btki achieve', 'prior btki achieve cr.', 'btki achieve cr. #lymsm', 'achieve cr. #lymsm #ash2022', 'cr. #lymsm #ash2022 #ash22.', '#lymsm #ash2022 #ash22. ', 'early data continue to suggest', 'data continue to suggest glofitamab', 'continue to suggest glofitamab is', 'to suggest glofitamab is highly', 'suggest glofitamab is highly effective', 'glofitamab is highly effective in', 'is highly effective in r/r', 'highly effective in r/r mcl-', 'effective in r/r mcl- exciting', 'in r/r mcl- exciting presentation', 'r/r mcl- exciting presentation by', 'mcl- exciting presentation by tycel', 'exciting presentation by tycel philips', 'presentation by tycel philips -', 'by tycel philips - roughly', 'tycel philips - roughly 2/3', 'philips - roughly 2/3 patients', '- roughly 2/3 patients with', 'roughly 2/3 patients with prior', '2/3 patients with prior btki', 'patients with prior btki achieve', 'with prior btki achieve cr.', 'prior btki achieve cr. #lymsm', 'btki achieve cr. #lymsm #ash2022', 'achieve cr. #lymsm #ash2022 #ash22.', 'cr. #lymsm #ash2022 #ash22. ', 'early data continue to suggest glofitamab', 'data continue to suggest glofitamab is', 'continue to suggest glofitamab is highly', 'to suggest glofitamab is highly effective', 'suggest glofitamab is highly effective in', 'glofitamab is highly effective in r/r', 'is highly effective in r/r mcl-', 'highly effective in r/r mcl- exciting', 'effective in r/r mcl- exciting presentation', 'in r/r mcl- exciting presentation by', 'r/r mcl- exciting presentation by tycel', 'mcl- exciting presentation by tycel philips', 'exciting presentation by tycel philips -', 'presentation by tycel philips - roughly', 'by tycel philips - roughly 2/3', 'tycel philips - roughly 2/3 patients', 'philips - roughly 2/3 patients with', '- roughly 2/3 patients with prior', 'roughly 2/3 patients with prior btki', '2/3 patients with prior btki achieve', 'patients with prior btki achieve cr.', 'with prior btki achieve cr. #lymsm', 'prior btki achieve cr. #lymsm #ash2022', 'btki achieve cr. #lymsm #ash2022 #ash22.', 'achieve cr. #lymsm #ash2022 #ash22. ', 'early data continue to suggest glofitamab is', 'data continue to suggest glofitamab is highly', 'continue to suggest glofitamab is highly effective', 'to suggest glofitamab is highly effective in', 'suggest glofitamab is highly effective in r/r', 'glofitamab is highly effective in r/r mcl-', 'is highly effective in r/r mcl- exciting', 'highly effective in r/r mcl- exciting presentation', 'effective in r/r mcl- exciting presentation by', 'in r/r mcl- exciting presentation by tycel', 'r/r mcl- exciting presentation by tycel philips', 'mcl- exciting presentation by tycel philips -', 'exciting presentation by tycel philips - roughly', 'presentation by tycel philips - roughly 2/3', 'by tycel philips - roughly 2/3 patients', 'tycel philips - roughly 2/3 patients with', 'philips - roughly 2/3 patients with prior', '- roughly 2/3 patients with prior btki', 'roughly 2/3 patients with prior btki achieve', '2/3 patients with prior btki achieve cr.', 'patients with prior btki achieve cr. #lymsm', 'with prior btki achieve cr. #lymsm #ash2022', 'prior btki achieve cr. #lymsm #ash2022 #ash22.', 'btki achieve cr. #lymsm #ash2022 #ash22. ', 'early data continue to suggest glofitamab is highly', 'data continue to suggest glofitamab is highly effective', 'continue to suggest glofitamab is highly effective in', 'to suggest glofitamab is highly effective in r/r', 'suggest glofitamab is highly effective in r/r mcl-', 'glofitamab is highly effective in r/r mcl- exciting', 'is highly effective in r/r mcl- exciting presentation', 'highly effective in r/r mcl- exciting presentation by', 'effective in r/r mcl- exciting presentation by tycel', 'in r/r mcl- exciting presentation by tycel philips', 'r/r mcl- exciting presentation by tycel philips -', 'mcl- exciting presentation by tycel philips - roughly', 'exciting presentation by tycel philips - roughly 2/3', 'presentation by tycel philips - roughly 2/3 patients', 'by tycel philips - roughly 2/3 patients with', 'tycel philips - roughly 2/3 patients with prior', 'philips - roughly 2/3 patients with prior btki', '- roughly 2/3 patients with prior btki achieve', 'roughly 2/3 patients with prior btki achieve cr.', '2/3 patients with prior btki achieve cr. #lymsm', 'patients with prior btki achieve cr. #lymsm #ash2022', 'with prior btki achieve cr. #lymsm #ash2022 #ash22.', 'prior btki achieve cr. #lymsm #ash2022 #ash22. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '33', 'tokens': ['"great', 'to', 'see', 'the', 'martins', '(dreyling', 'and', ')', 'at', '#ash22', 'both', 'have', 'practice', 'changing', 'presentations', 'at', 'this', 'meeting.', '-', 'triangle', 'study', 'in', '1l', 'transplant', 'eligible', 'mcl', '(presidential)', '-', 'glofitamab', 'durability', 'of', 'cr', 'in', 'r/r', 'dlbcl', 'do', 'check', 'them', 'out', '#lymsm.', ''], 'text_length': 41, 'triples': {'-|"great to see the martins (dreyling and ) at #ash22 both have practice changing presentations at this meeting. - triangle study in 1l transplant eligible mcl (presidential) - glofitamab': ([27, 27], [0, 28], 'positive')}, 'sentence': '"great to see the martins (dreyling and ) at #ash22 both have practice changing presentations at this meeting. - triangle study in 1l transplant eligible mcl (presidential) - glofitamab durability of cr in r/r dlbcl do check them out #lymsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(27, 27)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 28)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8)], 'span tokens': ['"great', 'to', 'see', 'the', 'martins', '(dreyling', 'and', ')', 'at', '#ash22', 'both', 'have', 'practice', 'changing', 'presentations', 'at', 'this', 'meeting.', '-', 'triangle', 'study', 'in', '1l', 'transplant', 'eligible', 'mcl', '(presidential)', '-', 'glofitamab', 'durability', 'of', 'cr', 'in', 'r/r', 'dlbcl', 'do', 'check', 'them', 'out', '#lymsm.', '', '"great to', 'to see', 'see the', 'the martins', 'martins (dreyling', '(dreyling and', 'and )', ') at', 'at #ash22', '#ash22 both', 'both have', 'have practice', 'practice changing', 'changing presentations', 'presentations at', 'at this', 'this meeting.', 'meeting. -', '- triangle', 'triangle study', 'study in', 'in 1l', '1l transplant', 'transplant eligible', 'eligible mcl', 'mcl (presidential)', '(presidential) -', '- glofitamab', 'glofitamab durability', 'durability of', 'of cr', 'cr in', 'in r/r', 'r/r dlbcl', 'dlbcl do', 'do check', 'check them', 'them out', 'out #lymsm.', '#lymsm. ', '"great to see', 'to see the', 'see the martins', 'the martins (dreyling', 'martins (dreyling and', '(dreyling and )', 'and ) at', ') at #ash22', 'at #ash22 both', '#ash22 both have', 'both have practice', 'have practice changing', 'practice changing presentations', 'changing presentations at', 'presentations at this', 'at this meeting.', 'this meeting. -', 'meeting. - triangle', '- triangle study', 'triangle study in', 'study in 1l', 'in 1l transplant', '1l transplant eligible', 'transplant eligible mcl', 'eligible mcl (presidential)', 'mcl (presidential) -', '(presidential) - glofitamab', '- glofitamab durability', 'glofitamab durability of', 'durability of cr', 'of cr in', 'cr in r/r', 'in r/r dlbcl', 'r/r dlbcl do', 'dlbcl do check', 'do check them', 'check them out', 'them out #lymsm.', 'out #lymsm. ', '"great to see the', 'to see the martins', 'see the martins (dreyling', 'the martins (dreyling and', 'martins (dreyling and )', '(dreyling and ) at', 'and ) at #ash22', ') at #ash22 both', 'at #ash22 both have', '#ash22 both have practice', 'both have practice changing', 'have practice changing presentations', 'practice changing presentations at', 'changing presentations at this', 'presentations at this meeting.', 'at this meeting. -', 'this meeting. - triangle', 'meeting. - triangle study', '- triangle study in', 'triangle study in 1l', 'study in 1l transplant', 'in 1l transplant eligible', '1l transplant eligible mcl', 'transplant eligible mcl (presidential)', 'eligible mcl (presidential) -', 'mcl (presidential) - glofitamab', '(presidential) - glofitamab durability', '- glofitamab durability of', 'glofitamab durability of cr', 'durability of cr in', 'of cr in r/r', 'cr in r/r dlbcl', 'in r/r dlbcl do', 'r/r dlbcl do check', 'dlbcl do check them', 'do check them out', 'check them out #lymsm.', 'them out #lymsm. ', '"great to see the martins', 'to see the martins (dreyling', 'see the martins (dreyling and', 'the martins (dreyling and )', 'martins (dreyling and ) at', '(dreyling and ) at #ash22', 'and ) at #ash22 both', ') at #ash22 both have', 'at #ash22 both have practice', '#ash22 both have practice changing', 'both have practice changing presentations', 'have practice changing presentations at', 'practice changing presentations at this', 'changing presentations at this meeting.', 'presentations at this meeting. -', 'at this meeting. - triangle', 'this meeting. - triangle study', 'meeting. - triangle study in', '- triangle study in 1l', 'triangle study in 1l transplant', 'study in 1l transplant eligible', 'in 1l transplant eligible mcl', '1l transplant eligible mcl (presidential)', 'transplant eligible mcl (presidential) -', 'eligible mcl (presidential) - glofitamab', 'mcl (presidential) - glofitamab durability', '(presidential) - glofitamab durability of', '- glofitamab durability of cr', 'glofitamab durability of cr in', 'durability of cr in r/r', 'of cr in r/r dlbcl', 'cr in r/r dlbcl do', 'in r/r dlbcl do check', 'r/r dlbcl do check them', 'dlbcl do check them out', 'do check them out #lymsm.', 'check them out #lymsm. ', '"great to see the martins (dreyling', 'to see the martins (dreyling and', 'see the martins (dreyling and )', 'the martins (dreyling and ) at', 'martins (dreyling and ) at #ash22', '(dreyling and ) at #ash22 both', 'and ) at #ash22 both have', ') at #ash22 both have practice', 'at #ash22 both have practice changing', '#ash22 both have practice changing presentations', 'both have practice changing presentations at', 'have practice changing presentations at this', 'practice changing presentations at this meeting.', 'changing presentations at this meeting. -', 'presentations at this meeting. - triangle', 'at this meeting. - triangle study', 'this meeting. - triangle study in', 'meeting. - triangle study in 1l', '- triangle study in 1l transplant', 'triangle study in 1l transplant eligible', 'study in 1l transplant eligible mcl', 'in 1l transplant eligible mcl (presidential)', '1l transplant eligible mcl (presidential) -', 'transplant eligible mcl (presidential) - glofitamab', 'eligible mcl (presidential) - glofitamab durability', 'mcl (presidential) - glofitamab durability of', '(presidential) - glofitamab durability of cr', '- glofitamab durability of cr in', 'glofitamab durability of cr in r/r', 'durability of cr in r/r dlbcl', 'of cr in r/r dlbcl do', 'cr in r/r dlbcl do check', 'in r/r dlbcl do check them', 'r/r dlbcl do check them out', 'dlbcl do check them out #lymsm.', 'do check them out #lymsm. ', '"great to see the martins (dreyling and', 'to see the martins (dreyling and )', 'see the martins (dreyling and ) at', 'the martins (dreyling and ) at #ash22', 'martins (dreyling and ) at #ash22 both', '(dreyling and ) at #ash22 both have', 'and ) at #ash22 both have practice', ') at #ash22 both have practice changing', 'at #ash22 both have practice changing presentations', '#ash22 both have practice changing presentations at', 'both have practice changing presentations at this', 'have practice changing presentations at this meeting.', 'practice changing presentations at this meeting. -', 'changing presentations at this meeting. - triangle', 'presentations at this meeting. - triangle study', 'at this meeting. - triangle study in', 'this meeting. - triangle study in 1l', 'meeting. - triangle study in 1l transplant', '- triangle study in 1l transplant eligible', 'triangle study in 1l transplant eligible mcl', 'study in 1l transplant eligible mcl (presidential)', 'in 1l transplant eligible mcl (presidential) -', '1l transplant eligible mcl (presidential) - glofitamab', 'transplant eligible mcl (presidential) - glofitamab durability', 'eligible mcl (presidential) - glofitamab durability of', 'mcl (presidential) - glofitamab durability of cr', '(presidential) - glofitamab durability of cr in', '- glofitamab durability of cr in r/r', 'glofitamab durability of cr in r/r dlbcl', 'durability of cr in r/r dlbcl do', 'of cr in r/r dlbcl do check', 'cr in r/r dlbcl do check them', 'in r/r dlbcl do check them out', 'r/r dlbcl do check them out #lymsm.', 'dlbcl do check them out #lymsm. ', '"great to see the martins (dreyling and )', 'to see the martins (dreyling and ) at', 'see the martins (dreyling and ) at #ash22', 'the martins (dreyling and ) at #ash22 both', 'martins (dreyling and ) at #ash22 both have', '(dreyling and ) at #ash22 both have practice', 'and ) at #ash22 both have practice changing', ') at #ash22 both have practice changing presentations', 'at #ash22 both have practice changing presentations at', '#ash22 both have practice changing presentations at this', 'both have practice changing presentations at this meeting.', 'have practice changing presentations at this meeting. -', 'practice changing presentations at this meeting. - triangle', 'changing presentations at this meeting. - triangle study', 'presentations at this meeting. - triangle study in', 'at this meeting. - triangle study in 1l', 'this meeting. - triangle study in 1l transplant', 'meeting. - triangle study in 1l transplant eligible', '- triangle study in 1l transplant eligible mcl', 'triangle study in 1l transplant eligible mcl (presidential)', 'study in 1l transplant eligible mcl (presidential) -', 'in 1l transplant eligible mcl (presidential) - glofitamab', '1l transplant eligible mcl (presidential) - glofitamab durability', 'transplant eligible mcl (presidential) - glofitamab durability of', 'eligible mcl (presidential) - glofitamab durability of cr', 'mcl (presidential) - glofitamab durability of cr in', '(presidential) - glofitamab durability of cr in r/r', '- glofitamab durability of cr in r/r dlbcl', 'glofitamab durability of cr in r/r dlbcl do', 'durability of cr in r/r dlbcl do check', 'of cr in r/r dlbcl do check them', 'cr in r/r dlbcl do check them out', 'in r/r dlbcl do check them out #lymsm.', 'r/r dlbcl do check them out #lymsm. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '34', 'tokens': ['the', 'phase', '2', 'study', 'showed', 'that', 'adding', 'the', 'cd73', 'inhibitor', 'oleclumab+durvalumab', 'plus', 'platinum-doublet', 'chemotherapy', 'does', 'not', 'improve', 'the', 'clinical', 'benefit', 'rate', 'among', 'women', 'with', 'treatment-na', 've', 'advanced', 'tnbc.', '#drugdevelopment', '#oncology', '#esmo2022', '.'], 'text_length': 32, 'triples': {'oleclumab+durvalumab|not improve the clinical benefit': ([10, 10], [15, 19], 'negative')}, 'sentence': 'the phase 2 study showed that adding the cd73 inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy does not improve the clinical benefit rate among women with treatment-na ve advanced tnbc. #drugdevelopment #oncology #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(15, 19)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['the', 'phase', '2', 'study', 'showed', 'that', 'adding', 'the', 'cd73', 'inhibitor', 'oleclumab+durvalumab', 'plus', 'platinum-doublet', 'chemotherapy', 'does', 'not', 'improve', 'the', 'clinical', 'benefit', 'rate', 'among', 'women', 'with', 'treatment-na', 've', 'advanced', 'tnbc.', '#drugdevelopment', '#oncology', '#esmo2022', '.', 'the phase', 'phase 2', '2 study', 'study showed', 'showed that', 'that adding', 'adding the', 'the cd73', 'cd73 inhibitor', 'inhibitor oleclumab+durvalumab', 'oleclumab+durvalumab plus', 'plus platinum-doublet', 'platinum-doublet chemotherapy', 'chemotherapy does', 'does not', 'not improve', 'improve the', 'the clinical', 'clinical benefit', 'benefit rate', 'rate among', 'among women', 'women with', 'with treatment-na', 'treatment-na ve', 've advanced', 'advanced tnbc.', 'tnbc. #drugdevelopment', '#drugdevelopment #oncology', '#oncology #esmo2022', '#esmo2022 .', 'the phase 2', 'phase 2 study', '2 study showed', 'study showed that', 'showed that adding', 'that adding the', 'adding the cd73', 'the cd73 inhibitor', 'cd73 inhibitor oleclumab+durvalumab', 'inhibitor oleclumab+durvalumab plus', 'oleclumab+durvalumab plus platinum-doublet', 'plus platinum-doublet chemotherapy', 'platinum-doublet chemotherapy does', 'chemotherapy does not', 'does not improve', 'not improve the', 'improve the clinical', 'the clinical benefit', 'clinical benefit rate', 'benefit rate among', 'rate among women', 'among women with', 'women with treatment-na', 'with treatment-na ve', 'treatment-na ve advanced', 've advanced tnbc.', 'advanced tnbc. #drugdevelopment', 'tnbc. #drugdevelopment #oncology', '#drugdevelopment #oncology #esmo2022', '#oncology #esmo2022 .', 'the phase 2 study', 'phase 2 study showed', '2 study showed that', 'study showed that adding', 'showed that adding the', 'that adding the cd73', 'adding the cd73 inhibitor', 'the cd73 inhibitor oleclumab+durvalumab', 'cd73 inhibitor oleclumab+durvalumab plus', 'inhibitor oleclumab+durvalumab plus platinum-doublet', 'oleclumab+durvalumab plus platinum-doublet chemotherapy', 'plus platinum-doublet chemotherapy does', 'platinum-doublet chemotherapy does not', 'chemotherapy does not improve', 'does not improve the', 'not improve the clinical', 'improve the clinical benefit', 'the clinical benefit rate', 'clinical benefit rate among', 'benefit rate among women', 'rate among women with', 'among women with treatment-na', 'women with treatment-na ve', 'with treatment-na ve advanced', 'treatment-na ve advanced tnbc.', 've advanced tnbc. #drugdevelopment', 'advanced tnbc. #drugdevelopment #oncology', 'tnbc. #drugdevelopment #oncology #esmo2022', '#drugdevelopment #oncology #esmo2022 .', 'the phase 2 study showed', 'phase 2 study showed that', '2 study showed that adding', 'study showed that adding the', 'showed that adding the cd73', 'that adding the cd73 inhibitor', 'adding the cd73 inhibitor oleclumab+durvalumab', 'the cd73 inhibitor oleclumab+durvalumab plus', 'cd73 inhibitor oleclumab+durvalumab plus platinum-doublet', 'inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy', 'oleclumab+durvalumab plus platinum-doublet chemotherapy does', 'plus platinum-doublet chemotherapy does not', 'platinum-doublet chemotherapy does not improve', 'chemotherapy does not improve the', 'does not improve the clinical', 'not improve the clinical benefit', 'improve the clinical benefit rate', 'the clinical benefit rate among', 'clinical benefit rate among women', 'benefit rate among women with', 'rate among women with treatment-na', 'among women with treatment-na ve', 'women with treatment-na ve advanced', 'with treatment-na ve advanced tnbc.', 'treatment-na ve advanced tnbc. #drugdevelopment', 've advanced tnbc. #drugdevelopment #oncology', 'advanced tnbc. #drugdevelopment #oncology #esmo2022', 'tnbc. #drugdevelopment #oncology #esmo2022 .', 'the phase 2 study showed that', 'phase 2 study showed that adding', '2 study showed that adding the', 'study showed that adding the cd73', 'showed that adding the cd73 inhibitor', 'that adding the cd73 inhibitor oleclumab+durvalumab', 'adding the cd73 inhibitor oleclumab+durvalumab plus', 'the cd73 inhibitor oleclumab+durvalumab plus platinum-doublet', 'cd73 inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy', 'inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy does', 'oleclumab+durvalumab plus platinum-doublet chemotherapy does not', 'plus platinum-doublet chemotherapy does not improve', 'platinum-doublet chemotherapy does not improve the', 'chemotherapy does not improve the clinical', 'does not improve the clinical benefit', 'not improve the clinical benefit rate', 'improve the clinical benefit rate among', 'the clinical benefit rate among women', 'clinical benefit rate among women with', 'benefit rate among women with treatment-na', 'rate among women with treatment-na ve', 'among women with treatment-na ve advanced', 'women with treatment-na ve advanced tnbc.', 'with treatment-na ve advanced tnbc. #drugdevelopment', 'treatment-na ve advanced tnbc. #drugdevelopment #oncology', 've advanced tnbc. #drugdevelopment #oncology #esmo2022', 'advanced tnbc. #drugdevelopment #oncology #esmo2022 .', 'the phase 2 study showed that adding', 'phase 2 study showed that adding the', '2 study showed that adding the cd73', 'study showed that adding the cd73 inhibitor', 'showed that adding the cd73 inhibitor oleclumab+durvalumab', 'that adding the cd73 inhibitor oleclumab+durvalumab plus', 'adding the cd73 inhibitor oleclumab+durvalumab plus platinum-doublet', 'the cd73 inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy', 'cd73 inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy does', 'inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy does not', 'oleclumab+durvalumab plus platinum-doublet chemotherapy does not improve', 'plus platinum-doublet chemotherapy does not improve the', 'platinum-doublet chemotherapy does not improve the clinical', 'chemotherapy does not improve the clinical benefit', 'does not improve the clinical benefit rate', 'not improve the clinical benefit rate among', 'improve the clinical benefit rate among women', 'the clinical benefit rate among women with', 'clinical benefit rate among women with treatment-na', 'benefit rate among women with treatment-na ve', 'rate among women with treatment-na ve advanced', 'among women with treatment-na ve advanced tnbc.', 'women with treatment-na ve advanced tnbc. #drugdevelopment', 'with treatment-na ve advanced tnbc. #drugdevelopment #oncology', 'treatment-na ve advanced tnbc. #drugdevelopment #oncology #esmo2022', 've advanced tnbc. #drugdevelopment #oncology #esmo2022 .', 'the phase 2 study showed that adding the', 'phase 2 study showed that adding the cd73', '2 study showed that adding the cd73 inhibitor', 'study showed that adding the cd73 inhibitor oleclumab+durvalumab', 'showed that adding the cd73 inhibitor oleclumab+durvalumab plus', 'that adding the cd73 inhibitor oleclumab+durvalumab plus platinum-doublet', 'adding the cd73 inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy', 'the cd73 inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy does', 'cd73 inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy does not', 'inhibitor oleclumab+durvalumab plus platinum-doublet chemotherapy does not improve', 'oleclumab+durvalumab plus platinum-doublet chemotherapy does not improve the', 'plus platinum-doublet chemotherapy does not improve the clinical', 'platinum-doublet chemotherapy does not improve the clinical benefit', 'chemotherapy does not improve the clinical benefit rate', 'does not improve the clinical benefit rate among', 'not improve the clinical benefit rate among women', 'improve the clinical benefit rate among women with', 'the clinical benefit rate among women with treatment-na', 'clinical benefit rate among women with treatment-na ve', 'benefit rate among women with treatment-na ve advanced', 'rate among women with treatment-na ve advanced tnbc.', 'among women with treatment-na ve advanced tnbc. #drugdevelopment', 'women with treatment-na ve advanced tnbc. #drugdevelopment #oncology', 'with treatment-na ve advanced tnbc. #drugdevelopment #oncology #esmo2022', 'treatment-na ve advanced tnbc. #drugdevelopment #oncology #esmo2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '35', 'tokens': ['"#esmo22', '#pivot09', 'bempeg+nivolumab', 'not', 'superior', 'to', 'tki', 'in', '1l', 'intermediate/poor', 'risk', 'mrcc', 'disappointing', 'results', 'presented', 'by', 'the', 'great', 'pr.', 'tannir', '.'], 'text_length': 21, 'triples': {'bempeg+nivolumab|not superior to tki in 1l intermediate/poor risk mrcc disappointing results': ([2, 2], [3, 13], 'negative')}, 'sentence': '"#esmo22 #pivot09 bempeg+nivolumab not superior to tki in 1l intermediate/poor risk mrcc disappointing results presented by the great pr. tannir .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['"#esmo22', '#pivot09', 'bempeg+nivolumab', 'not', 'superior', 'to', 'tki', 'in', '1l', 'intermediate/poor', 'risk', 'mrcc', 'disappointing', 'results', 'presented', 'by', 'the', 'great', 'pr.', 'tannir', '.', '"#esmo22 #pivot09', '#pivot09 bempeg+nivolumab', 'bempeg+nivolumab not', 'not superior', 'superior to', 'to tki', 'tki in', 'in 1l', '1l intermediate/poor', 'intermediate/poor risk', 'risk mrcc', 'mrcc disappointing', 'disappointing results', 'results presented', 'presented by', 'by the', 'the great', 'great pr.', 'pr. tannir', 'tannir .', '"#esmo22 #pivot09 bempeg+nivolumab', '#pivot09 bempeg+nivolumab not', 'bempeg+nivolumab not superior', 'not superior to', 'superior to tki', 'to tki in', 'tki in 1l', 'in 1l intermediate/poor', '1l intermediate/poor risk', 'intermediate/poor risk mrcc', 'risk mrcc disappointing', 'mrcc disappointing results', 'disappointing results presented', 'results presented by', 'presented by the', 'by the great', 'the great pr.', 'great pr. tannir', 'pr. tannir .', '"#esmo22 #pivot09 bempeg+nivolumab not', '#pivot09 bempeg+nivolumab not superior', 'bempeg+nivolumab not superior to', 'not superior to tki', 'superior to tki in', 'to tki in 1l', 'tki in 1l intermediate/poor', 'in 1l intermediate/poor risk', '1l intermediate/poor risk mrcc', 'intermediate/poor risk mrcc disappointing', 'risk mrcc disappointing results', 'mrcc disappointing results presented', 'disappointing results presented by', 'results presented by the', 'presented by the great', 'by the great pr.', 'the great pr. tannir', 'great pr. tannir .', '"#esmo22 #pivot09 bempeg+nivolumab not superior', '#pivot09 bempeg+nivolumab not superior to', 'bempeg+nivolumab not superior to tki', 'not superior to tki in', 'superior to tki in 1l', 'to tki in 1l intermediate/poor', 'tki in 1l intermediate/poor risk', 'in 1l intermediate/poor risk mrcc', '1l intermediate/poor risk mrcc disappointing', 'intermediate/poor risk mrcc disappointing results', 'risk mrcc disappointing results presented', 'mrcc disappointing results presented by', 'disappointing results presented by the', 'results presented by the great', 'presented by the great pr.', 'by the great pr. tannir', 'the great pr. tannir .', '"#esmo22 #pivot09 bempeg+nivolumab not superior to', '#pivot09 bempeg+nivolumab not superior to tki', 'bempeg+nivolumab not superior to tki in', 'not superior to tki in 1l', 'superior to tki in 1l intermediate/poor', 'to tki in 1l intermediate/poor risk', 'tki in 1l intermediate/poor risk mrcc', 'in 1l intermediate/poor risk mrcc disappointing', '1l intermediate/poor risk mrcc disappointing results', 'intermediate/poor risk mrcc disappointing results presented', 'risk mrcc disappointing results presented by', 'mrcc disappointing results presented by the', 'disappointing results presented by the great', 'results presented by the great pr.', 'presented by the great pr. tannir', 'by the great pr. tannir .', '"#esmo22 #pivot09 bempeg+nivolumab not superior to tki', '#pivot09 bempeg+nivolumab not superior to tki in', 'bempeg+nivolumab not superior to tki in 1l', 'not superior to tki in 1l intermediate/poor', 'superior to tki in 1l intermediate/poor risk', 'to tki in 1l intermediate/poor risk mrcc', 'tki in 1l intermediate/poor risk mrcc disappointing', 'in 1l intermediate/poor risk mrcc disappointing results', '1l intermediate/poor risk mrcc disappointing results presented', 'intermediate/poor risk mrcc disappointing results presented by', 'risk mrcc disappointing results presented by the', 'mrcc disappointing results presented by the great', 'disappointing results presented by the great pr.', 'results presented by the great pr. tannir', 'presented by the great pr. tannir .', '"#esmo22 #pivot09 bempeg+nivolumab not superior to tki in', '#pivot09 bempeg+nivolumab not superior to tki in 1l', 'bempeg+nivolumab not superior to tki in 1l intermediate/poor', 'not superior to tki in 1l intermediate/poor risk', 'superior to tki in 1l intermediate/poor risk mrcc', 'to tki in 1l intermediate/poor risk mrcc disappointing', 'tki in 1l intermediate/poor risk mrcc disappointing results', 'in 1l intermediate/poor risk mrcc disappointing results presented', '1l intermediate/poor risk mrcc disappointing results presented by', 'intermediate/poor risk mrcc disappointing results presented by the', 'risk mrcc disappointing results presented by the great', 'mrcc disappointing results presented by the great pr.', 'disappointing results presented by the great pr. tannir', 'results presented by the great pr. tannir .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '36', 'tokens': ['Additional', 'response', 'outcomes', 'from', 'RELATIVITY-047', 'show', 'numerically', 'lower', 'response', 'rates', 'for', 'patients', 'with', 'metastatic', 'or', 'unresectable', 'melanoma', 'treated', 'with', 'nivolumab', 'plus', 'relatlimab', 'compared', 'to', 'nivolumab', 'alone', '.'], 'text_length': 27, 'triples': {'RELATIVITY-047|response outcomes from RELATIVITY-047 show numerically lower response': ([4, 4], [1, 8], 'negative')}, 'sentence': 'Additional response outcomes from RELATIVITY-047 show numerically lower response rates for patients with metastatic or unresectable melanoma treated with nivolumab plus relatlimab compared to nivolumab alone .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8)], 'span tokens': ['Additional', 'response', 'outcomes', 'from', 'RELATIVITY-047', 'show', 'numerically', 'lower', 'response', 'rates', 'for', 'patients', 'with', 'metastatic', 'or', 'unresectable', 'melanoma', 'treated', 'with', 'nivolumab', 'plus', 'relatlimab', 'compared', 'to', 'nivolumab', 'alone', '.', 'Additional response', 'response outcomes', 'outcomes from', 'from RELATIVITY-047', 'RELATIVITY-047 show', 'show numerically', 'numerically lower', 'lower response', 'response rates', 'rates for', 'for patients', 'patients with', 'with metastatic', 'metastatic or', 'or unresectable', 'unresectable melanoma', 'melanoma treated', 'treated with', 'with nivolumab', 'nivolumab plus', 'plus relatlimab', 'relatlimab compared', 'compared to', 'to nivolumab', 'nivolumab alone', 'alone .', 'Additional response outcomes', 'response outcomes from', 'outcomes from RELATIVITY-047', 'from RELATIVITY-047 show', 'RELATIVITY-047 show numerically', 'show numerically lower', 'numerically lower response', 'lower response rates', 'response rates for', 'rates for patients', 'for patients with', 'patients with metastatic', 'with metastatic or', 'metastatic or unresectable', 'or unresectable melanoma', 'unresectable melanoma treated', 'melanoma treated with', 'treated with nivolumab', 'with nivolumab plus', 'nivolumab plus relatlimab', 'plus relatlimab compared', 'relatlimab compared to', 'compared to nivolumab', 'to nivolumab alone', 'nivolumab alone .', 'Additional response outcomes from', 'response outcomes from RELATIVITY-047', 'outcomes from RELATIVITY-047 show', 'from RELATIVITY-047 show numerically', 'RELATIVITY-047 show numerically lower', 'show numerically lower response', 'numerically lower response rates', 'lower response rates for', 'response rates for patients', 'rates for patients with', 'for patients with metastatic', 'patients with metastatic or', 'with metastatic or unresectable', 'metastatic or unresectable melanoma', 'or unresectable melanoma treated', 'unresectable melanoma treated with', 'melanoma treated with nivolumab', 'treated with nivolumab plus', 'with nivolumab plus relatlimab', 'nivolumab plus relatlimab compared', 'plus relatlimab compared to', 'relatlimab compared to nivolumab', 'compared to nivolumab alone', 'to nivolumab alone .', 'Additional response outcomes from RELATIVITY-047', 'response outcomes from RELATIVITY-047 show', 'outcomes from RELATIVITY-047 show numerically', 'from RELATIVITY-047 show numerically lower', 'RELATIVITY-047 show numerically lower response', 'show numerically lower response rates', 'numerically lower response rates for', 'lower response rates for patients', 'response rates for patients with', 'rates for patients with metastatic', 'for patients with metastatic or', 'patients with metastatic or unresectable', 'with metastatic or unresectable melanoma', 'metastatic or unresectable melanoma treated', 'or unresectable melanoma treated with', 'unresectable melanoma treated with nivolumab', 'melanoma treated with nivolumab plus', 'treated with nivolumab plus relatlimab', 'with nivolumab plus relatlimab compared', 'nivolumab plus relatlimab compared to', 'plus relatlimab compared to nivolumab', 'relatlimab compared to nivolumab alone', 'compared to nivolumab alone .', 'Additional response outcomes from RELATIVITY-047 show', 'response outcomes from RELATIVITY-047 show numerically', 'outcomes from RELATIVITY-047 show numerically lower', 'from RELATIVITY-047 show numerically lower response', 'RELATIVITY-047 show numerically lower response rates', 'show numerically lower response rates for', 'numerically lower response rates for patients', 'lower response rates for patients with', 'response rates for patients with metastatic', 'rates for patients with metastatic or', 'for patients with metastatic or unresectable', 'patients with metastatic or unresectable melanoma', 'with metastatic or unresectable melanoma treated', 'metastatic or unresectable melanoma treated with', 'or unresectable melanoma treated with nivolumab', 'unresectable melanoma treated with nivolumab plus', 'melanoma treated with nivolumab plus relatlimab', 'treated with nivolumab plus relatlimab compared', 'with nivolumab plus relatlimab compared to', 'nivolumab plus relatlimab compared to nivolumab', 'plus relatlimab compared to nivolumab alone', 'relatlimab compared to nivolumab alone .', 'Additional response outcomes from RELATIVITY-047 show numerically', 'response outcomes from RELATIVITY-047 show numerically lower', 'outcomes from RELATIVITY-047 show numerically lower response', 'from RELATIVITY-047 show numerically lower response rates', 'RELATIVITY-047 show numerically lower response rates for', 'show numerically lower response rates for patients', 'numerically lower response rates for patients with', 'lower response rates for patients with metastatic', 'response rates for patients with metastatic or', 'rates for patients with metastatic or unresectable', 'for patients with metastatic or unresectable melanoma', 'patients with metastatic or unresectable melanoma treated', 'with metastatic or unresectable melanoma treated with', 'metastatic or unresectable melanoma treated with nivolumab', 'or unresectable melanoma treated with nivolumab plus', 'unresectable melanoma treated with nivolumab plus relatlimab', 'melanoma treated with nivolumab plus relatlimab compared', 'treated with nivolumab plus relatlimab compared to', 'with nivolumab plus relatlimab compared to nivolumab', 'nivolumab plus relatlimab compared to nivolumab alone', 'plus relatlimab compared to nivolumab alone .', 'Additional response outcomes from RELATIVITY-047 show numerically lower', 'response outcomes from RELATIVITY-047 show numerically lower response', 'outcomes from RELATIVITY-047 show numerically lower response rates', 'from RELATIVITY-047 show numerically lower response rates for', 'RELATIVITY-047 show numerically lower response rates for patients', 'show numerically lower response rates for patients with', 'numerically lower response rates for patients with metastatic', 'lower response rates for patients with metastatic or', 'response rates for patients with metastatic or unresectable', 'rates for patients with metastatic or unresectable melanoma', 'for patients with metastatic or unresectable melanoma treated', 'patients with metastatic or unresectable melanoma treated with', 'with metastatic or unresectable melanoma treated with nivolumab', 'metastatic or unresectable melanoma treated with nivolumab plus', 'or unresectable melanoma treated with nivolumab plus relatlimab', 'unresectable melanoma treated with nivolumab plus relatlimab compared', 'melanoma treated with nivolumab plus relatlimab compared to', 'treated with nivolumab plus relatlimab compared to nivolumab', 'with nivolumab plus relatlimab compared to nivolumab alone', 'nivolumab plus relatlimab compared to nivolumab alone .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '37', 'tokens': ['New', 'trial', 'results', 'show', 'that', 'pembrolizumab', 'given', 'both', 'before', 'and', 'after', 'surgery', 'for', 'stage', '2B-3', '#melanoma', 'improved', 'event-free', 'survival', 'compared', 'with', 'adjuvant', 'therapy', 'alone.', '.'], 'text_length': 25, 'triples': {'pembrolizumab|improved event-free survival': ([5, 5], [16, 18], 'positive')}, 'sentence': 'New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 #melanoma improved event-free survival compared with adjuvant therapy alone. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(16, 18)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8)], 'span tokens': ['New', 'trial', 'results', 'show', 'that', 'pembrolizumab', 'given', 'both', 'before', 'and', 'after', 'surgery', 'for', 'stage', '2B-3', '#melanoma', 'improved', 'event-free', 'survival', 'compared', 'with', 'adjuvant', 'therapy', 'alone.', '.', 'New trial', 'trial results', 'results show', 'show that', 'that pembrolizumab', 'pembrolizumab given', 'given both', 'both before', 'before and', 'and after', 'after surgery', 'surgery for', 'for stage', 'stage 2B-3', '2B-3 #melanoma', '#melanoma improved', 'improved event-free', 'event-free survival', 'survival compared', 'compared with', 'with adjuvant', 'adjuvant therapy', 'therapy alone.', 'alone. .', 'New trial results', 'trial results show', 'results show that', 'show that pembrolizumab', 'that pembrolizumab given', 'pembrolizumab given both', 'given both before', 'both before and', 'before and after', 'and after surgery', 'after surgery for', 'surgery for stage', 'for stage 2B-3', 'stage 2B-3 #melanoma', '2B-3 #melanoma improved', '#melanoma improved event-free', 'improved event-free survival', 'event-free survival compared', 'survival compared with', 'compared with adjuvant', 'with adjuvant therapy', 'adjuvant therapy alone.', 'therapy alone. .', 'New trial results show', 'trial results show that', 'results show that pembrolizumab', 'show that pembrolizumab given', 'that pembrolizumab given both', 'pembrolizumab given both before', 'given both before and', 'both before and after', 'before and after surgery', 'and after surgery for', 'after surgery for stage', 'surgery for stage 2B-3', 'for stage 2B-3 #melanoma', 'stage 2B-3 #melanoma improved', '2B-3 #melanoma improved event-free', '#melanoma improved event-free survival', 'improved event-free survival compared', 'event-free survival compared with', 'survival compared with adjuvant', 'compared with adjuvant therapy', 'with adjuvant therapy alone.', 'adjuvant therapy alone. .', 'New trial results show that', 'trial results show that pembrolizumab', 'results show that pembrolizumab given', 'show that pembrolizumab given both', 'that pembrolizumab given both before', 'pembrolizumab given both before and', 'given both before and after', 'both before and after surgery', 'before and after surgery for', 'and after surgery for stage', 'after surgery for stage 2B-3', 'surgery for stage 2B-3 #melanoma', 'for stage 2B-3 #melanoma improved', 'stage 2B-3 #melanoma improved event-free', '2B-3 #melanoma improved event-free survival', '#melanoma improved event-free survival compared', 'improved event-free survival compared with', 'event-free survival compared with adjuvant', 'survival compared with adjuvant therapy', 'compared with adjuvant therapy alone.', 'with adjuvant therapy alone. .', 'New trial results show that pembrolizumab', 'trial results show that pembrolizumab given', 'results show that pembrolizumab given both', 'show that pembrolizumab given both before', 'that pembrolizumab given both before and', 'pembrolizumab given both before and after', 'given both before and after surgery', 'both before and after surgery for', 'before and after surgery for stage', 'and after surgery for stage 2B-3', 'after surgery for stage 2B-3 #melanoma', 'surgery for stage 2B-3 #melanoma improved', 'for stage 2B-3 #melanoma improved event-free', 'stage 2B-3 #melanoma improved event-free survival', '2B-3 #melanoma improved event-free survival compared', '#melanoma improved event-free survival compared with', 'improved event-free survival compared with adjuvant', 'event-free survival compared with adjuvant therapy', 'survival compared with adjuvant therapy alone.', 'compared with adjuvant therapy alone. .', 'New trial results show that pembrolizumab given', 'trial results show that pembrolizumab given both', 'results show that pembrolizumab given both before', 'show that pembrolizumab given both before and', 'that pembrolizumab given both before and after', 'pembrolizumab given both before and after surgery', 'given both before and after surgery for', 'both before and after surgery for stage', 'before and after surgery for stage 2B-3', 'and after surgery for stage 2B-3 #melanoma', 'after surgery for stage 2B-3 #melanoma improved', 'surgery for stage 2B-3 #melanoma improved event-free', 'for stage 2B-3 #melanoma improved event-free survival', 'stage 2B-3 #melanoma improved event-free survival compared', '2B-3 #melanoma improved event-free survival compared with', '#melanoma improved event-free survival compared with adjuvant', 'improved event-free survival compared with adjuvant therapy', 'event-free survival compared with adjuvant therapy alone.', 'survival compared with adjuvant therapy alone. .', 'New trial results show that pembrolizumab given both', 'trial results show that pembrolizumab given both before', 'results show that pembrolizumab given both before and', 'show that pembrolizumab given both before and after', 'that pembrolizumab given both before and after surgery', 'pembrolizumab given both before and after surgery for', 'given both before and after surgery for stage', 'both before and after surgery for stage 2B-3', 'before and after surgery for stage 2B-3 #melanoma', 'and after surgery for stage 2B-3 #melanoma improved', 'after surgery for stage 2B-3 #melanoma improved event-free', 'surgery for stage 2B-3 #melanoma improved event-free survival', 'for stage 2B-3 #melanoma improved event-free survival compared', 'stage 2B-3 #melanoma improved event-free survival compared with', '2B-3 #melanoma improved event-free survival compared with adjuvant', '#melanoma improved event-free survival compared with adjuvant therapy', 'improved event-free survival compared with adjuvant therapy alone.', 'event-free survival compared with adjuvant therapy alone. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '38', 'tokens': ['"Results', 'of', 'the', 'phase', '3', 'ARIEL4', 'trial', 'comparing', 'rucaparib', 'vs', 'chemotherapy', 'for', 'patients', 'with', 'relapsed', 'ovarian', 'cancer', 'and', 'deleterious', 'BRCA1/2', 'mutations', 'created', 'confusion', 'and', 'raised', 'various', 'questions', 'about', 'optimal', 'sequencing', 'of', 'PARP', 'inhibitors', 'in', 'this', 'setting.', '#gyncsm', '#ESMO22', '|', '@myESMO', 'https://t.co/uNbb4Uaf9v', '.'], 'text_length': 42, 'triples': {'ARIEL4|confusion and raised various questions': ([5, 5], [22, 26], 'negative'), 'rucaparib|confusion and raised various questions': ([8, 8], [22, 26], 'negative')}, 'sentence': '"Results of the phase 3 ARIEL4 trial comparing rucaparib vs chemotherapy for patients with relapsed ovarian cancer and deleterious BRCA1/2 mutations created confusion and raised various questions about optimal sequencing of PARP inhibitors in this setting. #gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 5), (8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(22, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8)], 'span tokens': ['"Results', 'of', 'the', 'phase', '3', 'ARIEL4', 'trial', 'comparing', 'rucaparib', 'vs', 'chemotherapy', 'for', 'patients', 'with', 'relapsed', 'ovarian', 'cancer', 'and', 'deleterious', 'BRCA1/2', 'mutations', 'created', 'confusion', 'and', 'raised', 'various', 'questions', 'about', 'optimal', 'sequencing', 'of', 'PARP', 'inhibitors', 'in', 'this', 'setting.', '#gyncsm', '#ESMO22', '|', '@myESMO', 'https://t.co/uNbb4Uaf9v', '.', '"Results of', 'of the', 'the phase', 'phase 3', '3 ARIEL4', 'ARIEL4 trial', 'trial comparing', 'comparing rucaparib', 'rucaparib vs', 'vs chemotherapy', 'chemotherapy for', 'for patients', 'patients with', 'with relapsed', 'relapsed ovarian', 'ovarian cancer', 'cancer and', 'and deleterious', 'deleterious BRCA1/2', 'BRCA1/2 mutations', 'mutations created', 'created confusion', 'confusion and', 'and raised', 'raised various', 'various questions', 'questions about', 'about optimal', 'optimal sequencing', 'sequencing of', 'of PARP', 'PARP inhibitors', 'inhibitors in', 'in this', 'this setting.', 'setting. #gyncsm', '#gyncsm #ESMO22', '#ESMO22 |', '| @myESMO', '@myESMO https://t.co/uNbb4Uaf9v', 'https://t.co/uNbb4Uaf9v .', '"Results of the', 'of the phase', 'the phase 3', 'phase 3 ARIEL4', '3 ARIEL4 trial', 'ARIEL4 trial comparing', 'trial comparing rucaparib', 'comparing rucaparib vs', 'rucaparib vs chemotherapy', 'vs chemotherapy for', 'chemotherapy for patients', 'for patients with', 'patients with relapsed', 'with relapsed ovarian', 'relapsed ovarian cancer', 'ovarian cancer and', 'cancer and deleterious', 'and deleterious BRCA1/2', 'deleterious BRCA1/2 mutations', 'BRCA1/2 mutations created', 'mutations created confusion', 'created confusion and', 'confusion and raised', 'and raised various', 'raised various questions', 'various questions about', 'questions about optimal', 'about optimal sequencing', 'optimal sequencing of', 'sequencing of PARP', 'of PARP inhibitors', 'PARP inhibitors in', 'inhibitors in this', 'in this setting.', 'this setting. #gyncsm', 'setting. #gyncsm #ESMO22', '#gyncsm #ESMO22 |', '#ESMO22 | @myESMO', '| @myESMO https://t.co/uNbb4Uaf9v', '@myESMO https://t.co/uNbb4Uaf9v .', '"Results of the phase', 'of the phase 3', 'the phase 3 ARIEL4', 'phase 3 ARIEL4 trial', '3 ARIEL4 trial comparing', 'ARIEL4 trial comparing rucaparib', 'trial comparing rucaparib vs', 'comparing rucaparib vs chemotherapy', 'rucaparib vs chemotherapy for', 'vs chemotherapy for patients', 'chemotherapy for patients with', 'for patients with relapsed', 'patients with relapsed ovarian', 'with relapsed ovarian cancer', 'relapsed ovarian cancer and', 'ovarian cancer and deleterious', 'cancer and deleterious BRCA1/2', 'and deleterious BRCA1/2 mutations', 'deleterious BRCA1/2 mutations created', 'BRCA1/2 mutations created confusion', 'mutations created confusion and', 'created confusion and raised', 'confusion and raised various', 'and raised various questions', 'raised various questions about', 'various questions about optimal', 'questions about optimal sequencing', 'about optimal sequencing of', 'optimal sequencing of PARP', 'sequencing of PARP inhibitors', 'of PARP inhibitors in', 'PARP inhibitors in this', 'inhibitors in this setting.', 'in this setting. #gyncsm', 'this setting. #gyncsm #ESMO22', 'setting. #gyncsm #ESMO22 |', '#gyncsm #ESMO22 | @myESMO', '#ESMO22 | @myESMO https://t.co/uNbb4Uaf9v', '| @myESMO https://t.co/uNbb4Uaf9v .', '"Results of the phase 3', 'of the phase 3 ARIEL4', 'the phase 3 ARIEL4 trial', 'phase 3 ARIEL4 trial comparing', '3 ARIEL4 trial comparing rucaparib', 'ARIEL4 trial comparing rucaparib vs', 'trial comparing rucaparib vs chemotherapy', 'comparing rucaparib vs chemotherapy for', 'rucaparib vs chemotherapy for patients', 'vs chemotherapy for patients with', 'chemotherapy for patients with relapsed', 'for patients with relapsed ovarian', 'patients with relapsed ovarian cancer', 'with relapsed ovarian cancer and', 'relapsed ovarian cancer and deleterious', 'ovarian cancer and deleterious BRCA1/2', 'cancer and deleterious BRCA1/2 mutations', 'and deleterious BRCA1/2 mutations created', 'deleterious BRCA1/2 mutations created confusion', 'BRCA1/2 mutations created confusion and', 'mutations created confusion and raised', 'created confusion and raised various', 'confusion and raised various questions', 'and raised various questions about', 'raised various questions about optimal', 'various questions about optimal sequencing', 'questions about optimal sequencing of', 'about optimal sequencing of PARP', 'optimal sequencing of PARP inhibitors', 'sequencing of PARP inhibitors in', 'of PARP inhibitors in this', 'PARP inhibitors in this setting.', 'inhibitors in this setting. #gyncsm', 'in this setting. #gyncsm #ESMO22', 'this setting. #gyncsm #ESMO22 |', 'setting. #gyncsm #ESMO22 | @myESMO', '#gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v', '#ESMO22 | @myESMO https://t.co/uNbb4Uaf9v .', '"Results of the phase 3 ARIEL4', 'of the phase 3 ARIEL4 trial', 'the phase 3 ARIEL4 trial comparing', 'phase 3 ARIEL4 trial comparing rucaparib', '3 ARIEL4 trial comparing rucaparib vs', 'ARIEL4 trial comparing rucaparib vs chemotherapy', 'trial comparing rucaparib vs chemotherapy for', 'comparing rucaparib vs chemotherapy for patients', 'rucaparib vs chemotherapy for patients with', 'vs chemotherapy for patients with relapsed', 'chemotherapy for patients with relapsed ovarian', 'for patients with relapsed ovarian cancer', 'patients with relapsed ovarian cancer and', 'with relapsed ovarian cancer and deleterious', 'relapsed ovarian cancer and deleterious BRCA1/2', 'ovarian cancer and deleterious BRCA1/2 mutations', 'cancer and deleterious BRCA1/2 mutations created', 'and deleterious BRCA1/2 mutations created confusion', 'deleterious BRCA1/2 mutations created confusion and', 'BRCA1/2 mutations created confusion and raised', 'mutations created confusion and raised various', 'created confusion and raised various questions', 'confusion and raised various questions about', 'and raised various questions about optimal', 'raised various questions about optimal sequencing', 'various questions about optimal sequencing of', 'questions about optimal sequencing of PARP', 'about optimal sequencing of PARP inhibitors', 'optimal sequencing of PARP inhibitors in', 'sequencing of PARP inhibitors in this', 'of PARP inhibitors in this setting.', 'PARP inhibitors in this setting. #gyncsm', 'inhibitors in this setting. #gyncsm #ESMO22', 'in this setting. #gyncsm #ESMO22 |', 'this setting. #gyncsm #ESMO22 | @myESMO', 'setting. #gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v', '#gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v .', '"Results of the phase 3 ARIEL4 trial', 'of the phase 3 ARIEL4 trial comparing', 'the phase 3 ARIEL4 trial comparing rucaparib', 'phase 3 ARIEL4 trial comparing rucaparib vs', '3 ARIEL4 trial comparing rucaparib vs chemotherapy', 'ARIEL4 trial comparing rucaparib vs chemotherapy for', 'trial comparing rucaparib vs chemotherapy for patients', 'comparing rucaparib vs chemotherapy for patients with', 'rucaparib vs chemotherapy for patients with relapsed', 'vs chemotherapy for patients with relapsed ovarian', 'chemotherapy for patients with relapsed ovarian cancer', 'for patients with relapsed ovarian cancer and', 'patients with relapsed ovarian cancer and deleterious', 'with relapsed ovarian cancer and deleterious BRCA1/2', 'relapsed ovarian cancer and deleterious BRCA1/2 mutations', 'ovarian cancer and deleterious BRCA1/2 mutations created', 'cancer and deleterious BRCA1/2 mutations created confusion', 'and deleterious BRCA1/2 mutations created confusion and', 'deleterious BRCA1/2 mutations created confusion and raised', 'BRCA1/2 mutations created confusion and raised various', 'mutations created confusion and raised various questions', 'created confusion and raised various questions about', 'confusion and raised various questions about optimal', 'and raised various questions about optimal sequencing', 'raised various questions about optimal sequencing of', 'various questions about optimal sequencing of PARP', 'questions about optimal sequencing of PARP inhibitors', 'about optimal sequencing of PARP inhibitors in', 'optimal sequencing of PARP inhibitors in this', 'sequencing of PARP inhibitors in this setting.', 'of PARP inhibitors in this setting. #gyncsm', 'PARP inhibitors in this setting. #gyncsm #ESMO22', 'inhibitors in this setting. #gyncsm #ESMO22 |', 'in this setting. #gyncsm #ESMO22 | @myESMO', 'this setting. #gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v', 'setting. #gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v .', '"Results of the phase 3 ARIEL4 trial comparing', 'of the phase 3 ARIEL4 trial comparing rucaparib', 'the phase 3 ARIEL4 trial comparing rucaparib vs', 'phase 3 ARIEL4 trial comparing rucaparib vs chemotherapy', '3 ARIEL4 trial comparing rucaparib vs chemotherapy for', 'ARIEL4 trial comparing rucaparib vs chemotherapy for patients', 'trial comparing rucaparib vs chemotherapy for patients with', 'comparing rucaparib vs chemotherapy for patients with relapsed', 'rucaparib vs chemotherapy for patients with relapsed ovarian', 'vs chemotherapy for patients with relapsed ovarian cancer', 'chemotherapy for patients with relapsed ovarian cancer and', 'for patients with relapsed ovarian cancer and deleterious', 'patients with relapsed ovarian cancer and deleterious BRCA1/2', 'with relapsed ovarian cancer and deleterious BRCA1/2 mutations', 'relapsed ovarian cancer and deleterious BRCA1/2 mutations created', 'ovarian cancer and deleterious BRCA1/2 mutations created confusion', 'cancer and deleterious BRCA1/2 mutations created confusion and', 'and deleterious BRCA1/2 mutations created confusion and raised', 'deleterious BRCA1/2 mutations created confusion and raised various', 'BRCA1/2 mutations created confusion and raised various questions', 'mutations created confusion and raised various questions about', 'created confusion and raised various questions about optimal', 'confusion and raised various questions about optimal sequencing', 'and raised various questions about optimal sequencing of', 'raised various questions about optimal sequencing of PARP', 'various questions about optimal sequencing of PARP inhibitors', 'questions about optimal sequencing of PARP inhibitors in', 'about optimal sequencing of PARP inhibitors in this', 'optimal sequencing of PARP inhibitors in this setting.', 'sequencing of PARP inhibitors in this setting. #gyncsm', 'of PARP inhibitors in this setting. #gyncsm #ESMO22', 'PARP inhibitors in this setting. #gyncsm #ESMO22 |', 'inhibitors in this setting. #gyncsm #ESMO22 | @myESMO', 'in this setting. #gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v', 'this setting. #gyncsm #ESMO22 | @myESMO https://t.co/uNbb4Uaf9v .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 2, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '39', 'tokens': ['excellent', 'session', 'on', 'bispecific', 'monoclonal', 'antibodies', 'chaired', 'by', 'my', 'mentor', '.', 'exciting', 'data', 'presented', 'on', 'talquetamab', '(monumental-1),', 'elranatamab', '(magnetismm),', 'forimtamig', '(rg6234),', 'alnuctamab', 'and', 'combination', 'of', 'teclistamab-daratumumab-lenalidomide', 'at', '#ash22.', ''], 'text_length': 29, 'triples': {'on|. exciting data': ([14, 14], [10, 12], 'positive'), 'talquetamab|. exciting data': ([15, 15], [10, 12], 'positive')}, 'sentence': 'excellent session on bispecific monoclonal antibodies chaired by my mentor . exciting data presented on talquetamab (monumental-1), elranatamab (magnetismm), forimtamig (rg6234), alnuctamab and combination of teclistamab-daratumumab-lenalidomide at #ash22. ', 'aspect_num': 2, 'spans_aspect2opinion_label': [(14, 14), (15, 15)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8)], 'span tokens': ['excellent', 'session', 'on', 'bispecific', 'monoclonal', 'antibodies', 'chaired', 'by', 'my', 'mentor', '.', 'exciting', 'data', 'presented', 'on', 'talquetamab', '(monumental-1),', 'elranatamab', '(magnetismm),', 'forimtamig', '(rg6234),', 'alnuctamab', 'and', 'combination', 'of', 'teclistamab-daratumumab-lenalidomide', 'at', '#ash22.', '', 'excellent session', 'session on', 'on bispecific', 'bispecific monoclonal', 'monoclonal antibodies', 'antibodies chaired', 'chaired by', 'by my', 'my mentor', 'mentor .', '. exciting', 'exciting data', 'data presented', 'presented on', 'on talquetamab', 'talquetamab (monumental-1),', '(monumental-1), elranatamab', 'elranatamab (magnetismm),', '(magnetismm), forimtamig', 'forimtamig (rg6234),', '(rg6234), alnuctamab', 'alnuctamab and', 'and combination', 'combination of', 'of teclistamab-daratumumab-lenalidomide', 'teclistamab-daratumumab-lenalidomide at', 'at #ash22.', '#ash22. ', 'excellent session on', 'session on bispecific', 'on bispecific monoclonal', 'bispecific monoclonal antibodies', 'monoclonal antibodies chaired', 'antibodies chaired by', 'chaired by my', 'by my mentor', 'my mentor .', 'mentor . exciting', '. exciting data', 'exciting data presented', 'data presented on', 'presented on talquetamab', 'on talquetamab (monumental-1),', 'talquetamab (monumental-1), elranatamab', '(monumental-1), elranatamab (magnetismm),', 'elranatamab (magnetismm), forimtamig', '(magnetismm), forimtamig (rg6234),', 'forimtamig (rg6234), alnuctamab', '(rg6234), alnuctamab and', 'alnuctamab and combination', 'and combination of', 'combination of teclistamab-daratumumab-lenalidomide', 'of teclistamab-daratumumab-lenalidomide at', 'teclistamab-daratumumab-lenalidomide at #ash22.', 'at #ash22. ', 'excellent session on bispecific', 'session on bispecific monoclonal', 'on bispecific monoclonal antibodies', 'bispecific monoclonal antibodies chaired', 'monoclonal antibodies chaired by', 'antibodies chaired by my', 'chaired by my mentor', 'by my mentor .', 'my mentor . exciting', 'mentor . exciting data', '. exciting data presented', 'exciting data presented on', 'data presented on talquetamab', 'presented on talquetamab (monumental-1),', 'on talquetamab (monumental-1), elranatamab', 'talquetamab (monumental-1), elranatamab (magnetismm),', '(monumental-1), elranatamab (magnetismm), forimtamig', 'elranatamab (magnetismm), forimtamig (rg6234),', '(magnetismm), forimtamig (rg6234), alnuctamab', 'forimtamig (rg6234), alnuctamab and', '(rg6234), alnuctamab and combination', 'alnuctamab and combination of', 'and combination of teclistamab-daratumumab-lenalidomide', 'combination of teclistamab-daratumumab-lenalidomide at', 'of teclistamab-daratumumab-lenalidomide at #ash22.', 'teclistamab-daratumumab-lenalidomide at #ash22. ', 'excellent session on bispecific monoclonal', 'session on bispecific monoclonal antibodies', 'on bispecific monoclonal antibodies chaired', 'bispecific monoclonal antibodies chaired by', 'monoclonal antibodies chaired by my', 'antibodies chaired by my mentor', 'chaired by my mentor .', 'by my mentor . exciting', 'my mentor . exciting data', 'mentor . exciting data presented', '. exciting data presented on', 'exciting data presented on talquetamab', 'data presented on talquetamab (monumental-1),', 'presented on talquetamab (monumental-1), elranatamab', 'on talquetamab (monumental-1), elranatamab (magnetismm),', 'talquetamab (monumental-1), elranatamab (magnetismm), forimtamig', '(monumental-1), elranatamab (magnetismm), forimtamig (rg6234),', 'elranatamab (magnetismm), forimtamig (rg6234), alnuctamab', '(magnetismm), forimtamig (rg6234), alnuctamab and', 'forimtamig (rg6234), alnuctamab and combination', '(rg6234), alnuctamab and combination of', 'alnuctamab and combination of teclistamab-daratumumab-lenalidomide', 'and combination of teclistamab-daratumumab-lenalidomide at', 'combination of teclistamab-daratumumab-lenalidomide at #ash22.', 'of teclistamab-daratumumab-lenalidomide at #ash22. ', 'excellent session on bispecific monoclonal antibodies', 'session on bispecific monoclonal antibodies chaired', 'on bispecific monoclonal antibodies chaired by', 'bispecific monoclonal antibodies chaired by my', 'monoclonal antibodies chaired by my mentor', 'antibodies chaired by my mentor .', 'chaired by my mentor . exciting', 'by my mentor . exciting data', 'my mentor . exciting data presented', 'mentor . exciting data presented on', '. exciting data presented on talquetamab', 'exciting data presented on talquetamab (monumental-1),', 'data presented on talquetamab (monumental-1), elranatamab', 'presented on talquetamab (monumental-1), elranatamab (magnetismm),', 'on talquetamab (monumental-1), elranatamab (magnetismm), forimtamig', 'talquetamab (monumental-1), elranatamab (magnetismm), forimtamig (rg6234),', '(monumental-1), elranatamab (magnetismm), forimtamig (rg6234), alnuctamab', 'elranatamab (magnetismm), forimtamig (rg6234), alnuctamab and', '(magnetismm), forimtamig (rg6234), alnuctamab and combination', 'forimtamig (rg6234), alnuctamab and combination of', '(rg6234), alnuctamab and combination of teclistamab-daratumumab-lenalidomide', 'alnuctamab and combination of teclistamab-daratumumab-lenalidomide at', 'and combination of teclistamab-daratumumab-lenalidomide at #ash22.', 'combination of teclistamab-daratumumab-lenalidomide at #ash22. ', 'excellent session on bispecific monoclonal antibodies chaired', 'session on bispecific monoclonal antibodies chaired by', 'on bispecific monoclonal antibodies chaired by my', 'bispecific monoclonal antibodies chaired by my mentor', 'monoclonal antibodies chaired by my mentor .', 'antibodies chaired by my mentor . exciting', 'chaired by my mentor . exciting data', 'by my mentor . exciting data presented', 'my mentor . exciting data presented on', 'mentor . exciting data presented on talquetamab', '. exciting data presented on talquetamab (monumental-1),', 'exciting data presented on talquetamab (monumental-1), elranatamab', 'data presented on talquetamab (monumental-1), elranatamab (magnetismm),', 'presented on talquetamab (monumental-1), elranatamab (magnetismm), forimtamig', 'on talquetamab (monumental-1), elranatamab (magnetismm), forimtamig (rg6234),', 'talquetamab (monumental-1), elranatamab (magnetismm), forimtamig (rg6234), alnuctamab', '(monumental-1), elranatamab (magnetismm), forimtamig (rg6234), alnuctamab and', 'elranatamab (magnetismm), forimtamig (rg6234), alnuctamab and combination', '(magnetismm), forimtamig (rg6234), alnuctamab and combination of', 'forimtamig (rg6234), alnuctamab and combination of teclistamab-daratumumab-lenalidomide', '(rg6234), alnuctamab and combination of teclistamab-daratumumab-lenalidomide at', 'alnuctamab and combination of teclistamab-daratumumab-lenalidomide at #ash22.', 'and combination of teclistamab-daratumumab-lenalidomide at #ash22. ', 'excellent session on bispecific monoclonal antibodies chaired by', 'session on bispecific monoclonal antibodies chaired by my', 'on bispecific monoclonal antibodies chaired by my mentor', 'bispecific monoclonal antibodies chaired by my mentor .', 'monoclonal antibodies chaired by my mentor . exciting', 'antibodies chaired by my mentor . exciting data', 'chaired by my mentor . exciting data presented', 'by my mentor . exciting data presented on', 'my mentor . exciting data presented on talquetamab', 'mentor . exciting data presented on talquetamab (monumental-1),', '. exciting data presented on talquetamab (monumental-1), elranatamab', 'exciting data presented on talquetamab (monumental-1), elranatamab (magnetismm),', 'data presented on talquetamab (monumental-1), elranatamab (magnetismm), forimtamig', 'presented on talquetamab (monumental-1), elranatamab (magnetismm), forimtamig (rg6234),', 'on talquetamab (monumental-1), elranatamab (magnetismm), forimtamig (rg6234), alnuctamab', 'talquetamab (monumental-1), elranatamab (magnetismm), forimtamig (rg6234), alnuctamab and', '(monumental-1), elranatamab (magnetismm), forimtamig (rg6234), alnuctamab and combination', 'elranatamab (magnetismm), forimtamig (rg6234), alnuctamab and combination of', '(magnetismm), forimtamig (rg6234), alnuctamab and combination of teclistamab-daratumumab-lenalidomide', 'forimtamig (rg6234), alnuctamab and combination of teclistamab-daratumumab-lenalidomide at', '(rg6234), alnuctamab and combination of teclistamab-daratumumab-lenalidomide at #ash22.', 'alnuctamab and combination of teclistamab-daratumumab-lenalidomide at #ash22. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '40', 'tokens': ['congratulations', 'to', 'the', 'authors', 'on', 'some', 'fantastic', 'data', 'and', 'grateful', 'to', 'see', 'more', 'therapy', 'with', 'a', 'meaningful', 'response', 'for', 'our', 'patients', 'with', 'relapsed', 'refractory', 'myeloma!', 'will', 'talquetamab', 'be', 'the', 'bi-specific', 'of', 'choice?', '#ash22', '.'], 'text_length': 34, 'triples': {'talquetamab|fantastic data and grateful to see more therapy with a meaningful response': ([26, 26], [6, 17], 'positive')}, 'sentence': 'congratulations to the authors on some fantastic data and grateful to see more therapy with a meaningful response for our patients with relapsed refractory myeloma! will talquetamab be the bi-specific of choice? #ash22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(26, 26)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 17)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['congratulations', 'to', 'the', 'authors', 'on', 'some', 'fantastic', 'data', 'and', 'grateful', 'to', 'see', 'more', 'therapy', 'with', 'a', 'meaningful', 'response', 'for', 'our', 'patients', 'with', 'relapsed', 'refractory', 'myeloma!', 'will', 'talquetamab', 'be', 'the', 'bi-specific', 'of', 'choice?', '#ash22', '.', 'congratulations to', 'to the', 'the authors', 'authors on', 'on some', 'some fantastic', 'fantastic data', 'data and', 'and grateful', 'grateful to', 'to see', 'see more', 'more therapy', 'therapy with', 'with a', 'a meaningful', 'meaningful response', 'response for', 'for our', 'our patients', 'patients with', 'with relapsed', 'relapsed refractory', 'refractory myeloma!', 'myeloma! will', 'will talquetamab', 'talquetamab be', 'be the', 'the bi-specific', 'bi-specific of', 'of choice?', 'choice? #ash22', '#ash22 .', 'congratulations to the', 'to the authors', 'the authors on', 'authors on some', 'on some fantastic', 'some fantastic data', 'fantastic data and', 'data and grateful', 'and grateful to', 'grateful to see', 'to see more', 'see more therapy', 'more therapy with', 'therapy with a', 'with a meaningful', 'a meaningful response', 'meaningful response for', 'response for our', 'for our patients', 'our patients with', 'patients with relapsed', 'with relapsed refractory', 'relapsed refractory myeloma!', 'refractory myeloma! will', 'myeloma! will talquetamab', 'will talquetamab be', 'talquetamab be the', 'be the bi-specific', 'the bi-specific of', 'bi-specific of choice?', 'of choice? #ash22', 'choice? #ash22 .', 'congratulations to the authors', 'to the authors on', 'the authors on some', 'authors on some fantastic', 'on some fantastic data', 'some fantastic data and', 'fantastic data and grateful', 'data and grateful to', 'and grateful to see', 'grateful to see more', 'to see more therapy', 'see more therapy with', 'more therapy with a', 'therapy with a meaningful', 'with a meaningful response', 'a meaningful response for', 'meaningful response for our', 'response for our patients', 'for our patients with', 'our patients with relapsed', 'patients with relapsed refractory', 'with relapsed refractory myeloma!', 'relapsed refractory myeloma! will', 'refractory myeloma! will talquetamab', 'myeloma! will talquetamab be', 'will talquetamab be the', 'talquetamab be the bi-specific', 'be the bi-specific of', 'the bi-specific of choice?', 'bi-specific of choice? #ash22', 'of choice? #ash22 .', 'congratulations to the authors on', 'to the authors on some', 'the authors on some fantastic', 'authors on some fantastic data', 'on some fantastic data and', 'some fantastic data and grateful', 'fantastic data and grateful to', 'data and grateful to see', 'and grateful to see more', 'grateful to see more therapy', 'to see more therapy with', 'see more therapy with a', 'more therapy with a meaningful', 'therapy with a meaningful response', 'with a meaningful response for', 'a meaningful response for our', 'meaningful response for our patients', 'response for our patients with', 'for our patients with relapsed', 'our patients with relapsed refractory', 'patients with relapsed refractory myeloma!', 'with relapsed refractory myeloma! will', 'relapsed refractory myeloma! will talquetamab', 'refractory myeloma! will talquetamab be', 'myeloma! will talquetamab be the', 'will talquetamab be the bi-specific', 'talquetamab be the bi-specific of', 'be the bi-specific of choice?', 'the bi-specific of choice? #ash22', 'bi-specific of choice? #ash22 .', 'congratulations to the authors on some', 'to the authors on some fantastic', 'the authors on some fantastic data', 'authors on some fantastic data and', 'on some fantastic data and grateful', 'some fantastic data and grateful to', 'fantastic data and grateful to see', 'data and grateful to see more', 'and grateful to see more therapy', 'grateful to see more therapy with', 'to see more therapy with a', 'see more therapy with a meaningful', 'more therapy with a meaningful response', 'therapy with a meaningful response for', 'with a meaningful response for our', 'a meaningful response for our patients', 'meaningful response for our patients with', 'response for our patients with relapsed', 'for our patients with relapsed refractory', 'our patients with relapsed refractory myeloma!', 'patients with relapsed refractory myeloma! will', 'with relapsed refractory myeloma! will talquetamab', 'relapsed refractory myeloma! will talquetamab be', 'refractory myeloma! will talquetamab be the', 'myeloma! will talquetamab be the bi-specific', 'will talquetamab be the bi-specific of', 'talquetamab be the bi-specific of choice?', 'be the bi-specific of choice? #ash22', 'the bi-specific of choice? #ash22 .', 'congratulations to the authors on some fantastic', 'to the authors on some fantastic data', 'the authors on some fantastic data and', 'authors on some fantastic data and grateful', 'on some fantastic data and grateful to', 'some fantastic data and grateful to see', 'fantastic data and grateful to see more', 'data and grateful to see more therapy', 'and grateful to see more therapy with', 'grateful to see more therapy with a', 'to see more therapy with a meaningful', 'see more therapy with a meaningful response', 'more therapy with a meaningful response for', 'therapy with a meaningful response for our', 'with a meaningful response for our patients', 'a meaningful response for our patients with', 'meaningful response for our patients with relapsed', 'response for our patients with relapsed refractory', 'for our patients with relapsed refractory myeloma!', 'our patients with relapsed refractory myeloma! will', 'patients with relapsed refractory myeloma! will talquetamab', 'with relapsed refractory myeloma! will talquetamab be', 'relapsed refractory myeloma! will talquetamab be the', 'refractory myeloma! will talquetamab be the bi-specific', 'myeloma! will talquetamab be the bi-specific of', 'will talquetamab be the bi-specific of choice?', 'talquetamab be the bi-specific of choice? #ash22', 'be the bi-specific of choice? #ash22 .', 'congratulations to the authors on some fantastic data', 'to the authors on some fantastic data and', 'the authors on some fantastic data and grateful', 'authors on some fantastic data and grateful to', 'on some fantastic data and grateful to see', 'some fantastic data and grateful to see more', 'fantastic data and grateful to see more therapy', 'data and grateful to see more therapy with', 'and grateful to see more therapy with a', 'grateful to see more therapy with a meaningful', 'to see more therapy with a meaningful response', 'see more therapy with a meaningful response for', 'more therapy with a meaningful response for our', 'therapy with a meaningful response for our patients', 'with a meaningful response for our patients with', 'a meaningful response for our patients with relapsed', 'meaningful response for our patients with relapsed refractory', 'response for our patients with relapsed refractory myeloma!', 'for our patients with relapsed refractory myeloma! will', 'our patients with relapsed refractory myeloma! will talquetamab', 'patients with relapsed refractory myeloma! will talquetamab be', 'with relapsed refractory myeloma! will talquetamab be the', 'relapsed refractory myeloma! will talquetamab be the bi-specific', 'refractory myeloma! will talquetamab be the bi-specific of', 'myeloma! will talquetamab be the bi-specific of choice?', 'will talquetamab be the bi-specific of choice? #ash22', 'talquetamab be the bi-specific of choice? #ash22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '41', 'tokens': ['adc', 'with', 'other', 'targets.', 'talquetamab', 'is', 'gprc5dxcd3', 'targeted.', 'also', 'showing', 'great', 'promise', 'with', 'toxicity', 'as', 'expected,', 'but', 'additional', 'off-target', 'ae', 'of', 'skin/hair/nail', 'and', 'dysgeusia.', 'management', 'will', 'be', 'key.', '#ash22', '#imfash22', '#mmsm.', ''], 'text_length': 32, 'triples': {'talquetamab|showing great promise': ([4, 4], [9, 11], 'positive')}, 'sentence': 'adc with other targets. talquetamab is gprc5dxcd3 targeted. also showing great promise with toxicity as expected, but additional off-target ae of skin/hair/nail and dysgeusia. management will be key. #ash22 #imfash22 #mmsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['adc', 'with', 'other', 'targets.', 'talquetamab', 'is', 'gprc5dxcd3', 'targeted.', 'also', 'showing', 'great', 'promise', 'with', 'toxicity', 'as', 'expected,', 'but', 'additional', 'off-target', 'ae', 'of', 'skin/hair/nail', 'and', 'dysgeusia.', 'management', 'will', 'be', 'key.', '#ash22', '#imfash22', '#mmsm.', '', 'adc with', 'with other', 'other targets.', 'targets. talquetamab', 'talquetamab is', 'is gprc5dxcd3', 'gprc5dxcd3 targeted.', 'targeted. also', 'also showing', 'showing great', 'great promise', 'promise with', 'with toxicity', 'toxicity as', 'as expected,', 'expected, but', 'but additional', 'additional off-target', 'off-target ae', 'ae of', 'of skin/hair/nail', 'skin/hair/nail and', 'and dysgeusia.', 'dysgeusia. management', 'management will', 'will be', 'be key.', 'key. #ash22', '#ash22 #imfash22', '#imfash22 #mmsm.', '#mmsm. ', 'adc with other', 'with other targets.', 'other targets. talquetamab', 'targets. talquetamab is', 'talquetamab is gprc5dxcd3', 'is gprc5dxcd3 targeted.', 'gprc5dxcd3 targeted. also', 'targeted. also showing', 'also showing great', 'showing great promise', 'great promise with', 'promise with toxicity', 'with toxicity as', 'toxicity as expected,', 'as expected, but', 'expected, but additional', 'but additional off-target', 'additional off-target ae', 'off-target ae of', 'ae of skin/hair/nail', 'of skin/hair/nail and', 'skin/hair/nail and dysgeusia.', 'and dysgeusia. management', 'dysgeusia. management will', 'management will be', 'will be key.', 'be key. #ash22', 'key. #ash22 #imfash22', '#ash22 #imfash22 #mmsm.', '#imfash22 #mmsm. ', 'adc with other targets.', 'with other targets. talquetamab', 'other targets. talquetamab is', 'targets. talquetamab is gprc5dxcd3', 'talquetamab is gprc5dxcd3 targeted.', 'is gprc5dxcd3 targeted. also', 'gprc5dxcd3 targeted. also showing', 'targeted. also showing great', 'also showing great promise', 'showing great promise with', 'great promise with toxicity', 'promise with toxicity as', 'with toxicity as expected,', 'toxicity as expected, but', 'as expected, but additional', 'expected, but additional off-target', 'but additional off-target ae', 'additional off-target ae of', 'off-target ae of skin/hair/nail', 'ae of skin/hair/nail and', 'of skin/hair/nail and dysgeusia.', 'skin/hair/nail and dysgeusia. management', 'and dysgeusia. management will', 'dysgeusia. management will be', 'management will be key.', 'will be key. #ash22', 'be key. #ash22 #imfash22', 'key. #ash22 #imfash22 #mmsm.', '#ash22 #imfash22 #mmsm. ', 'adc with other targets. talquetamab', 'with other targets. talquetamab is', 'other targets. talquetamab is gprc5dxcd3', 'targets. talquetamab is gprc5dxcd3 targeted.', 'talquetamab is gprc5dxcd3 targeted. also', 'is gprc5dxcd3 targeted. also showing', 'gprc5dxcd3 targeted. also showing great', 'targeted. also showing great promise', 'also showing great promise with', 'showing great promise with toxicity', 'great promise with toxicity as', 'promise with toxicity as expected,', 'with toxicity as expected, but', 'toxicity as expected, but additional', 'as expected, but additional off-target', 'expected, but additional off-target ae', 'but additional off-target ae of', 'additional off-target ae of skin/hair/nail', 'off-target ae of skin/hair/nail and', 'ae of skin/hair/nail and dysgeusia.', 'of skin/hair/nail and dysgeusia. management', 'skin/hair/nail and dysgeusia. management will', 'and dysgeusia. management will be', 'dysgeusia. management will be key.', 'management will be key. #ash22', 'will be key. #ash22 #imfash22', 'be key. #ash22 #imfash22 #mmsm.', 'key. #ash22 #imfash22 #mmsm. ', 'adc with other targets. talquetamab is', 'with other targets. talquetamab is gprc5dxcd3', 'other targets. talquetamab is gprc5dxcd3 targeted.', 'targets. talquetamab is gprc5dxcd3 targeted. also', 'talquetamab is gprc5dxcd3 targeted. also showing', 'is gprc5dxcd3 targeted. also showing great', 'gprc5dxcd3 targeted. also showing great promise', 'targeted. also showing great promise with', 'also showing great promise with toxicity', 'showing great promise with toxicity as', 'great promise with toxicity as expected,', 'promise with toxicity as expected, but', 'with toxicity as expected, but additional', 'toxicity as expected, but additional off-target', 'as expected, but additional off-target ae', 'expected, but additional off-target ae of', 'but additional off-target ae of skin/hair/nail', 'additional off-target ae of skin/hair/nail and', 'off-target ae of skin/hair/nail and dysgeusia.', 'ae of skin/hair/nail and dysgeusia. management', 'of skin/hair/nail and dysgeusia. management will', 'skin/hair/nail and dysgeusia. management will be', 'and dysgeusia. management will be key.', 'dysgeusia. management will be key. #ash22', 'management will be key. #ash22 #imfash22', 'will be key. #ash22 #imfash22 #mmsm.', 'be key. #ash22 #imfash22 #mmsm. ', 'adc with other targets. talquetamab is gprc5dxcd3', 'with other targets. talquetamab is gprc5dxcd3 targeted.', 'other targets. talquetamab is gprc5dxcd3 targeted. also', 'targets. talquetamab is gprc5dxcd3 targeted. also showing', 'talquetamab is gprc5dxcd3 targeted. also showing great', 'is gprc5dxcd3 targeted. also showing great promise', 'gprc5dxcd3 targeted. also showing great promise with', 'targeted. also showing great promise with toxicity', 'also showing great promise with toxicity as', 'showing great promise with toxicity as expected,', 'great promise with toxicity as expected, but', 'promise with toxicity as expected, but additional', 'with toxicity as expected, but additional off-target', 'toxicity as expected, but additional off-target ae', 'as expected, but additional off-target ae of', 'expected, but additional off-target ae of skin/hair/nail', 'but additional off-target ae of skin/hair/nail and', 'additional off-target ae of skin/hair/nail and dysgeusia.', 'off-target ae of skin/hair/nail and dysgeusia. management', 'ae of skin/hair/nail and dysgeusia. management will', 'of skin/hair/nail and dysgeusia. management will be', 'skin/hair/nail and dysgeusia. management will be key.', 'and dysgeusia. management will be key. #ash22', 'dysgeusia. management will be key. #ash22 #imfash22', 'management will be key. #ash22 #imfash22 #mmsm.', 'will be key. #ash22 #imfash22 #mmsm. ', 'adc with other targets. talquetamab is gprc5dxcd3 targeted.', 'with other targets. talquetamab is gprc5dxcd3 targeted. also', 'other targets. talquetamab is gprc5dxcd3 targeted. also showing', 'targets. talquetamab is gprc5dxcd3 targeted. also showing great', 'talquetamab is gprc5dxcd3 targeted. also showing great promise', 'is gprc5dxcd3 targeted. also showing great promise with', 'gprc5dxcd3 targeted. also showing great promise with toxicity', 'targeted. also showing great promise with toxicity as', 'also showing great promise with toxicity as expected,', 'showing great promise with toxicity as expected, but', 'great promise with toxicity as expected, but additional', 'promise with toxicity as expected, but additional off-target', 'with toxicity as expected, but additional off-target ae', 'toxicity as expected, but additional off-target ae of', 'as expected, but additional off-target ae of skin/hair/nail', 'expected, but additional off-target ae of skin/hair/nail and', 'but additional off-target ae of skin/hair/nail and dysgeusia.', 'additional off-target ae of skin/hair/nail and dysgeusia. management', 'off-target ae of skin/hair/nail and dysgeusia. management will', 'ae of skin/hair/nail and dysgeusia. management will be', 'of skin/hair/nail and dysgeusia. management will be key.', 'skin/hair/nail and dysgeusia. management will be key. #ash22', 'and dysgeusia. management will be key. #ash22 #imfash22', 'dysgeusia. management will be key. #ash22 #imfash22 #mmsm.', 'management will be key. #ash22 #imfash22 #mmsm. '], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '42', 'tokens': ['incredible!', 'just', 'published', 'nejm.', 'myeloma', 'patients', 'treated', 'w/', 'talquetamab', 'orr', '&gt;', '70%', 'in', 'phase', '1/2', 'monumental-1', 'study.', 'whopping', '70.6%', 'patients', 'prior', 'treated', 'w/', 'car', 't-cell,', '35.3%', 'received', 'prior', 'bispecific', 'antibody', '#ash22', 'click.', ''], 'text_length': 33, 'triples': {'talquetamab|incredible! just published': ([8, 8], [0, 2], 'positive'), 'monumental-1|incredible! just published': ([15, 15], [0, 2], 'positive')}, 'sentence': 'incredible! just published nejm. myeloma patients treated w/ talquetamab orr &gt; 70% in phase 1/2 monumental-1 study. whopping 70.6% patients prior treated w/ car t-cell, 35.3% received prior bispecific antibody #ash22 click. ', 'aspect_num': 2, 'spans_aspect2opinion_label': [(8, 8), (15, 15)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['incredible!', 'just', 'published', 'nejm.', 'myeloma', 'patients', 'treated', 'w/', 'talquetamab', 'orr', '&gt;', '70%', 'in', 'phase', '1/2', 'monumental-1', 'study.', 'whopping', '70.6%', 'patients', 'prior', 'treated', 'w/', 'car', 't-cell,', '35.3%', 'received', 'prior', 'bispecific', 'antibody', '#ash22', 'click.', '', 'incredible! just', 'just published', 'published nejm.', 'nejm. myeloma', 'myeloma patients', 'patients treated', 'treated w/', 'w/ talquetamab', 'talquetamab orr', 'orr &gt;', '&gt; 70%', '70% in', 'in phase', 'phase 1/2', '1/2 monumental-1', 'monumental-1 study.', 'study. whopping', 'whopping 70.6%', '70.6% patients', 'patients prior', 'prior treated', 'treated w/', 'w/ car', 'car t-cell,', 't-cell, 35.3%', '35.3% received', 'received prior', 'prior bispecific', 'bispecific antibody', 'antibody #ash22', '#ash22 click.', 'click. ', 'incredible! just published', 'just published nejm.', 'published nejm. myeloma', 'nejm. myeloma patients', 'myeloma patients treated', 'patients treated w/', 'treated w/ talquetamab', 'w/ talquetamab orr', 'talquetamab orr &gt;', 'orr &gt; 70%', '&gt; 70% in', '70% in phase', 'in phase 1/2', 'phase 1/2 monumental-1', '1/2 monumental-1 study.', 'monumental-1 study. whopping', 'study. whopping 70.6%', 'whopping 70.6% patients', '70.6% patients prior', 'patients prior treated', 'prior treated w/', 'treated w/ car', 'w/ car t-cell,', 'car t-cell, 35.3%', 't-cell, 35.3% received', '35.3% received prior', 'received prior bispecific', 'prior bispecific antibody', 'bispecific antibody #ash22', 'antibody #ash22 click.', '#ash22 click. ', 'incredible! just published nejm.', 'just published nejm. myeloma', 'published nejm. myeloma patients', 'nejm. myeloma patients treated', 'myeloma patients treated w/', 'patients treated w/ talquetamab', 'treated w/ talquetamab orr', 'w/ talquetamab orr &gt;', 'talquetamab orr &gt; 70%', 'orr &gt; 70% in', '&gt; 70% in phase', '70% in phase 1/2', 'in phase 1/2 monumental-1', 'phase 1/2 monumental-1 study.', '1/2 monumental-1 study. whopping', 'monumental-1 study. whopping 70.6%', 'study. whopping 70.6% patients', 'whopping 70.6% patients prior', '70.6% patients prior treated', 'patients prior treated w/', 'prior treated w/ car', 'treated w/ car t-cell,', 'w/ car t-cell, 35.3%', 'car t-cell, 35.3% received', 't-cell, 35.3% received prior', '35.3% received prior bispecific', 'received prior bispecific antibody', 'prior bispecific antibody #ash22', 'bispecific antibody #ash22 click.', 'antibody #ash22 click. ', 'incredible! just published nejm. myeloma', 'just published nejm. myeloma patients', 'published nejm. myeloma patients treated', 'nejm. myeloma patients treated w/', 'myeloma patients treated w/ talquetamab', 'patients treated w/ talquetamab orr', 'treated w/ talquetamab orr &gt;', 'w/ talquetamab orr &gt; 70%', 'talquetamab orr &gt; 70% in', 'orr &gt; 70% in phase', '&gt; 70% in phase 1/2', '70% in phase 1/2 monumental-1', 'in phase 1/2 monumental-1 study.', 'phase 1/2 monumental-1 study. whopping', '1/2 monumental-1 study. whopping 70.6%', 'monumental-1 study. whopping 70.6% patients', 'study. whopping 70.6% patients prior', 'whopping 70.6% patients prior treated', '70.6% patients prior treated w/', 'patients prior treated w/ car', 'prior treated w/ car t-cell,', 'treated w/ car t-cell, 35.3%', 'w/ car t-cell, 35.3% received', 'car t-cell, 35.3% received prior', 't-cell, 35.3% received prior bispecific', '35.3% received prior bispecific antibody', 'received prior bispecific antibody #ash22', 'prior bispecific antibody #ash22 click.', 'bispecific antibody #ash22 click. ', 'incredible! just published nejm. myeloma patients', 'just published nejm. myeloma patients treated', 'published nejm. myeloma patients treated w/', 'nejm. myeloma patients treated w/ talquetamab', 'myeloma patients treated w/ talquetamab orr', 'patients treated w/ talquetamab orr &gt;', 'treated w/ talquetamab orr &gt; 70%', 'w/ talquetamab orr &gt; 70% in', 'talquetamab orr &gt; 70% in phase', 'orr &gt; 70% in phase 1/2', '&gt; 70% in phase 1/2 monumental-1', '70% in phase 1/2 monumental-1 study.', 'in phase 1/2 monumental-1 study. whopping', 'phase 1/2 monumental-1 study. whopping 70.6%', '1/2 monumental-1 study. whopping 70.6% patients', 'monumental-1 study. whopping 70.6% patients prior', 'study. whopping 70.6% patients prior treated', 'whopping 70.6% patients prior treated w/', '70.6% patients prior treated w/ car', 'patients prior treated w/ car t-cell,', 'prior treated w/ car t-cell, 35.3%', 'treated w/ car t-cell, 35.3% received', 'w/ car t-cell, 35.3% received prior', 'car t-cell, 35.3% received prior bispecific', 't-cell, 35.3% received prior bispecific antibody', '35.3% received prior bispecific antibody #ash22', 'received prior bispecific antibody #ash22 click.', 'prior bispecific antibody #ash22 click. ', 'incredible! just published nejm. myeloma patients treated', 'just published nejm. myeloma patients treated w/', 'published nejm. myeloma patients treated w/ talquetamab', 'nejm. myeloma patients treated w/ talquetamab orr', 'myeloma patients treated w/ talquetamab orr &gt;', 'patients treated w/ talquetamab orr &gt; 70%', 'treated w/ talquetamab orr &gt; 70% in', 'w/ talquetamab orr &gt; 70% in phase', 'talquetamab orr &gt; 70% in phase 1/2', 'orr &gt; 70% in phase 1/2 monumental-1', '&gt; 70% in phase 1/2 monumental-1 study.', '70% in phase 1/2 monumental-1 study. whopping', 'in phase 1/2 monumental-1 study. whopping 70.6%', 'phase 1/2 monumental-1 study. whopping 70.6% patients', '1/2 monumental-1 study. whopping 70.6% patients prior', 'monumental-1 study. whopping 70.6% patients prior treated', 'study. whopping 70.6% patients prior treated w/', 'whopping 70.6% patients prior treated w/ car', '70.6% patients prior treated w/ car t-cell,', 'patients prior treated w/ car t-cell, 35.3%', 'prior treated w/ car t-cell, 35.3% received', 'treated w/ car t-cell, 35.3% received prior', 'w/ car t-cell, 35.3% received prior bispecific', 'car t-cell, 35.3% received prior bispecific antibody', 't-cell, 35.3% received prior bispecific antibody #ash22', '35.3% received prior bispecific antibody #ash22 click.', 'received prior bispecific antibody #ash22 click. ', 'incredible! just published nejm. myeloma patients treated w/', 'just published nejm. myeloma patients treated w/ talquetamab', 'published nejm. myeloma patients treated w/ talquetamab orr', 'nejm. myeloma patients treated w/ talquetamab orr &gt;', 'myeloma patients treated w/ talquetamab orr &gt; 70%', 'patients treated w/ talquetamab orr &gt; 70% in', 'treated w/ talquetamab orr &gt; 70% in phase', 'w/ talquetamab orr &gt; 70% in phase 1/2', 'talquetamab orr &gt; 70% in phase 1/2 monumental-1', 'orr &gt; 70% in phase 1/2 monumental-1 study.', '&gt; 70% in phase 1/2 monumental-1 study. whopping', '70% in phase 1/2 monumental-1 study. whopping 70.6%', 'in phase 1/2 monumental-1 study. whopping 70.6% patients', 'phase 1/2 monumental-1 study. whopping 70.6% patients prior', '1/2 monumental-1 study. whopping 70.6% patients prior treated', 'monumental-1 study. whopping 70.6% patients prior treated w/', 'study. whopping 70.6% patients prior treated w/ car', 'whopping 70.6% patients prior treated w/ car t-cell,', '70.6% patients prior treated w/ car t-cell, 35.3%', 'patients prior treated w/ car t-cell, 35.3% received', 'prior treated w/ car t-cell, 35.3% received prior', 'treated w/ car t-cell, 35.3% received prior bispecific', 'w/ car t-cell, 35.3% received prior bispecific antibody', 'car t-cell, 35.3% received prior bispecific antibody #ash22', 't-cell, 35.3% received prior bispecific antibody #ash22 click.', '35.3% received prior bispecific antibody #ash22 click. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '43', 'tokens': ['monumental-1.', 'gprc5d', 'bispecific', 't', 'cell', 'engager.', 'infection', 'risk', 'looking', 'better', 'than', 'bcma', 'bispecifics', 'but', 'with', 'skin,', 'nail,', 'oral', 'aes', 'that', 'we', 'need', 'to', 'learn', 'to', 'manage', 'better.', '#ash22', '#mmsm.', ''], 'text_length': 30, 'triples': {'monumental-1.|looking better than bcma bispecifics but with skin, nail, oral aes that we need to learn to manage better.': ([0, 0], [8, 26], 'positive')}, 'sentence': 'monumental-1. gprc5d bispecific t cell engager. infection risk looking better than bcma bispecifics but with skin, nail, oral aes that we need to learn to manage better. #ash22 #mmsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(8, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8)], 'span tokens': ['monumental-1.', 'gprc5d', 'bispecific', 't', 'cell', 'engager.', 'infection', 'risk', 'looking', 'better', 'than', 'bcma', 'bispecifics', 'but', 'with', 'skin,', 'nail,', 'oral', 'aes', 'that', 'we', 'need', 'to', 'learn', 'to', 'manage', 'better.', '#ash22', '#mmsm.', '', 'monumental-1. gprc5d', 'gprc5d bispecific', 'bispecific t', 't cell', 'cell engager.', 'engager. infection', 'infection risk', 'risk looking', 'looking better', 'better than', 'than bcma', 'bcma bispecifics', 'bispecifics but', 'but with', 'with skin,', 'skin, nail,', 'nail, oral', 'oral aes', 'aes that', 'that we', 'we need', 'need to', 'to learn', 'learn to', 'to manage', 'manage better.', 'better. #ash22', '#ash22 #mmsm.', '#mmsm. ', 'monumental-1. gprc5d bispecific', 'gprc5d bispecific t', 'bispecific t cell', 't cell engager.', 'cell engager. infection', 'engager. infection risk', 'infection risk looking', 'risk looking better', 'looking better than', 'better than bcma', 'than bcma bispecifics', 'bcma bispecifics but', 'bispecifics but with', 'but with skin,', 'with skin, nail,', 'skin, nail, oral', 'nail, oral aes', 'oral aes that', 'aes that we', 'that we need', 'we need to', 'need to learn', 'to learn to', 'learn to manage', 'to manage better.', 'manage better. #ash22', 'better. #ash22 #mmsm.', '#ash22 #mmsm. ', 'monumental-1. gprc5d bispecific t', 'gprc5d bispecific t cell', 'bispecific t cell engager.', 't cell engager. infection', 'cell engager. infection risk', 'engager. infection risk looking', 'infection risk looking better', 'risk looking better than', 'looking better than bcma', 'better than bcma bispecifics', 'than bcma bispecifics but', 'bcma bispecifics but with', 'bispecifics but with skin,', 'but with skin, nail,', 'with skin, nail, oral', 'skin, nail, oral aes', 'nail, oral aes that', 'oral aes that we', 'aes that we need', 'that we need to', 'we need to learn', 'need to learn to', 'to learn to manage', 'learn to manage better.', 'to manage better. #ash22', 'manage better. #ash22 #mmsm.', 'better. #ash22 #mmsm. ', 'monumental-1. gprc5d bispecific t cell', 'gprc5d bispecific t cell engager.', 'bispecific t cell engager. infection', 't cell engager. infection risk', 'cell engager. infection risk looking', 'engager. infection risk looking better', 'infection risk looking better than', 'risk looking better than bcma', 'looking better than bcma bispecifics', 'better than bcma bispecifics but', 'than bcma bispecifics but with', 'bcma bispecifics but with skin,', 'bispecifics but with skin, nail,', 'but with skin, nail, oral', 'with skin, nail, oral aes', 'skin, nail, oral aes that', 'nail, oral aes that we', 'oral aes that we need', 'aes that we need to', 'that we need to learn', 'we need to learn to', 'need to learn to manage', 'to learn to manage better.', 'learn to manage better. #ash22', 'to manage better. #ash22 #mmsm.', 'manage better. #ash22 #mmsm. ', 'monumental-1. gprc5d bispecific t cell engager.', 'gprc5d bispecific t cell engager. infection', 'bispecific t cell engager. infection risk', 't cell engager. infection risk looking', 'cell engager. infection risk looking better', 'engager. infection risk looking better than', 'infection risk looking better than bcma', 'risk looking better than bcma bispecifics', 'looking better than bcma bispecifics but', 'better than bcma bispecifics but with', 'than bcma bispecifics but with skin,', 'bcma bispecifics but with skin, nail,', 'bispecifics but with skin, nail, oral', 'but with skin, nail, oral aes', 'with skin, nail, oral aes that', 'skin, nail, oral aes that we', 'nail, oral aes that we need', 'oral aes that we need to', 'aes that we need to learn', 'that we need to learn to', 'we need to learn to manage', 'need to learn to manage better.', 'to learn to manage better. #ash22', 'learn to manage better. #ash22 #mmsm.', 'to manage better. #ash22 #mmsm. ', 'monumental-1. gprc5d bispecific t cell engager. infection', 'gprc5d bispecific t cell engager. infection risk', 'bispecific t cell engager. infection risk looking', 't cell engager. infection risk looking better', 'cell engager. infection risk looking better than', 'engager. infection risk looking better than bcma', 'infection risk looking better than bcma bispecifics', 'risk looking better than bcma bispecifics but', 'looking better than bcma bispecifics but with', 'better than bcma bispecifics but with skin,', 'than bcma bispecifics but with skin, nail,', 'bcma bispecifics but with skin, nail, oral', 'bispecifics but with skin, nail, oral aes', 'but with skin, nail, oral aes that', 'with skin, nail, oral aes that we', 'skin, nail, oral aes that we need', 'nail, oral aes that we need to', 'oral aes that we need to learn', 'aes that we need to learn to', 'that we need to learn to manage', 'we need to learn to manage better.', 'need to learn to manage better. #ash22', 'to learn to manage better. #ash22 #mmsm.', 'learn to manage better. #ash22 #mmsm. ', 'monumental-1. gprc5d bispecific t cell engager. infection risk', 'gprc5d bispecific t cell engager. infection risk looking', 'bispecific t cell engager. infection risk looking better', 't cell engager. infection risk looking better than', 'cell engager. infection risk looking better than bcma', 'engager. infection risk looking better than bcma bispecifics', 'infection risk looking better than bcma bispecifics but', 'risk looking better than bcma bispecifics but with', 'looking better than bcma bispecifics but with skin,', 'better than bcma bispecifics but with skin, nail,', 'than bcma bispecifics but with skin, nail, oral', 'bcma bispecifics but with skin, nail, oral aes', 'bispecifics but with skin, nail, oral aes that', 'but with skin, nail, oral aes that we', 'with skin, nail, oral aes that we need', 'skin, nail, oral aes that we need to', 'nail, oral aes that we need to learn', 'oral aes that we need to learn to', 'aes that we need to learn to manage', 'that we need to learn to manage better.', 'we need to learn to manage better. #ash22', 'need to learn to manage better. #ash22 #mmsm.', 'to learn to manage better. #ash22 #mmsm. '], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '44', 'tokens': ['master', 'presenter', 'ajai', 'chari', 'presenting', 'talquetamab', 'a', 'bispecific', 'antibody', 'targeting', 'gprc5d.', 'amazing', '74%', 'orr', 'and', 'even', 'more', 'remarkable', 'low', 'infection', 'rates', 'grade', '3/4', 'at', '17%', 'and', '12%.', 'this', 'is', 'remarkable', 'and', 'may', 'likely', 'be', 'the', 'next', 'bispecific', 'and', 'first', 'gprc5d', 'available', '#ash22', '#mediq22ash.', ''], 'text_length': 44, 'triples': {'talquetamab|amazing 74% orr and even more remarkable low infection rates grade 3/4 at 17% and 12%. this is remarkable': ([5, 5], [11, 29], 'positive')}, 'sentence': 'master presenter ajai chari presenting talquetamab a bispecific antibody targeting gprc5d. amazing 74% orr and even more remarkable low infection rates grade 3/4 at 17% and 12%. this is remarkable and may likely be the next bispecific and first gprc5d available #ash22 #mediq22ash. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(11, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8)], 'span tokens': ['master', 'presenter', 'ajai', 'chari', 'presenting', 'talquetamab', 'a', 'bispecific', 'antibody', 'targeting', 'gprc5d.', 'amazing', '74%', 'orr', 'and', 'even', 'more', 'remarkable', 'low', 'infection', 'rates', 'grade', '3/4', 'at', '17%', 'and', '12%.', 'this', 'is', 'remarkable', 'and', 'may', 'likely', 'be', 'the', 'next', 'bispecific', 'and', 'first', 'gprc5d', 'available', '#ash22', '#mediq22ash.', '', 'master presenter', 'presenter ajai', 'ajai chari', 'chari presenting', 'presenting talquetamab', 'talquetamab a', 'a bispecific', 'bispecific antibody', 'antibody targeting', 'targeting gprc5d.', 'gprc5d. amazing', 'amazing 74%', '74% orr', 'orr and', 'and even', 'even more', 'more remarkable', 'remarkable low', 'low infection', 'infection rates', 'rates grade', 'grade 3/4', '3/4 at', 'at 17%', '17% and', 'and 12%.', '12%. this', 'this is', 'is remarkable', 'remarkable and', 'and may', 'may likely', 'likely be', 'be the', 'the next', 'next bispecific', 'bispecific and', 'and first', 'first gprc5d', 'gprc5d available', 'available #ash22', '#ash22 #mediq22ash.', '#mediq22ash. ', 'master presenter ajai', 'presenter ajai chari', 'ajai chari presenting', 'chari presenting talquetamab', 'presenting talquetamab a', 'talquetamab a bispecific', 'a bispecific antibody', 'bispecific antibody targeting', 'antibody targeting gprc5d.', 'targeting gprc5d. amazing', 'gprc5d. amazing 74%', 'amazing 74% orr', '74% orr and', 'orr and even', 'and even more', 'even more remarkable', 'more remarkable low', 'remarkable low infection', 'low infection rates', 'infection rates grade', 'rates grade 3/4', 'grade 3/4 at', '3/4 at 17%', 'at 17% and', '17% and 12%.', 'and 12%. this', '12%. this is', 'this is remarkable', 'is remarkable and', 'remarkable and may', 'and may likely', 'may likely be', 'likely be the', 'be the next', 'the next bispecific', 'next bispecific and', 'bispecific and first', 'and first gprc5d', 'first gprc5d available', 'gprc5d available #ash22', 'available #ash22 #mediq22ash.', '#ash22 #mediq22ash. ', 'master presenter ajai chari', 'presenter ajai chari presenting', 'ajai chari presenting talquetamab', 'chari presenting talquetamab a', 'presenting talquetamab a bispecific', 'talquetamab a bispecific antibody', 'a bispecific antibody targeting', 'bispecific antibody targeting gprc5d.', 'antibody targeting gprc5d. amazing', 'targeting gprc5d. amazing 74%', 'gprc5d. amazing 74% orr', 'amazing 74% orr and', '74% orr and even', 'orr and even more', 'and even more remarkable', 'even more remarkable low', 'more remarkable low infection', 'remarkable low infection rates', 'low infection rates grade', 'infection rates grade 3/4', 'rates grade 3/4 at', 'grade 3/4 at 17%', '3/4 at 17% and', 'at 17% and 12%.', '17% and 12%. this', 'and 12%. this is', '12%. this is remarkable', 'this is remarkable and', 'is remarkable and may', 'remarkable and may likely', 'and may likely be', 'may likely be the', 'likely be the next', 'be the next bispecific', 'the next bispecific and', 'next bispecific and first', 'bispecific and first gprc5d', 'and first gprc5d available', 'first gprc5d available #ash22', 'gprc5d available #ash22 #mediq22ash.', 'available #ash22 #mediq22ash. ', 'master presenter ajai chari presenting', 'presenter ajai chari presenting talquetamab', 'ajai chari presenting talquetamab a', 'chari presenting talquetamab a bispecific', 'presenting talquetamab a bispecific antibody', 'talquetamab a bispecific antibody targeting', 'a bispecific antibody targeting gprc5d.', 'bispecific antibody targeting gprc5d. amazing', 'antibody targeting gprc5d. amazing 74%', 'targeting gprc5d. amazing 74% orr', 'gprc5d. amazing 74% orr and', 'amazing 74% orr and even', '74% orr and even more', 'orr and even more remarkable', 'and even more remarkable low', 'even more remarkable low infection', 'more remarkable low infection rates', 'remarkable low infection rates grade', 'low infection rates grade 3/4', 'infection rates grade 3/4 at', 'rates grade 3/4 at 17%', 'grade 3/4 at 17% and', '3/4 at 17% and 12%.', 'at 17% and 12%. this', '17% and 12%. this is', 'and 12%. this is remarkable', '12%. this is remarkable and', 'this is remarkable and may', 'is remarkable and may likely', 'remarkable and may likely be', 'and may likely be the', 'may likely be the next', 'likely be the next bispecific', 'be the next bispecific and', 'the next bispecific and first', 'next bispecific and first gprc5d', 'bispecific and first gprc5d available', 'and first gprc5d available #ash22', 'first gprc5d available #ash22 #mediq22ash.', 'gprc5d available #ash22 #mediq22ash. ', 'master presenter ajai chari presenting talquetamab', 'presenter ajai chari presenting talquetamab a', 'ajai chari presenting talquetamab a bispecific', 'chari presenting talquetamab a bispecific antibody', 'presenting talquetamab a bispecific antibody targeting', 'talquetamab a bispecific antibody targeting gprc5d.', 'a bispecific antibody targeting gprc5d. amazing', 'bispecific antibody targeting gprc5d. amazing 74%', 'antibody targeting gprc5d. amazing 74% orr', 'targeting gprc5d. amazing 74% orr and', 'gprc5d. amazing 74% orr and even', 'amazing 74% orr and even more', '74% orr and even more remarkable', 'orr and even more remarkable low', 'and even more remarkable low infection', 'even more remarkable low infection rates', 'more remarkable low infection rates grade', 'remarkable low infection rates grade 3/4', 'low infection rates grade 3/4 at', 'infection rates grade 3/4 at 17%', 'rates grade 3/4 at 17% and', 'grade 3/4 at 17% and 12%.', '3/4 at 17% and 12%. this', 'at 17% and 12%. this is', '17% and 12%. this is remarkable', 'and 12%. this is remarkable and', '12%. this is remarkable and may', 'this is remarkable and may likely', 'is remarkable and may likely be', 'remarkable and may likely be the', 'and may likely be the next', 'may likely be the next bispecific', 'likely be the next bispecific and', 'be the next bispecific and first', 'the next bispecific and first gprc5d', 'next bispecific and first gprc5d available', 'bispecific and first gprc5d available #ash22', 'and first gprc5d available #ash22 #mediq22ash.', 'first gprc5d available #ash22 #mediq22ash. ', 'master presenter ajai chari presenting talquetamab a', 'presenter ajai chari presenting talquetamab a bispecific', 'ajai chari presenting talquetamab a bispecific antibody', 'chari presenting talquetamab a bispecific antibody targeting', 'presenting talquetamab a bispecific antibody targeting gprc5d.', 'talquetamab a bispecific antibody targeting gprc5d. amazing', 'a bispecific antibody targeting gprc5d. amazing 74%', 'bispecific antibody targeting gprc5d. amazing 74% orr', 'antibody targeting gprc5d. amazing 74% orr and', 'targeting gprc5d. amazing 74% orr and even', 'gprc5d. amazing 74% orr and even more', 'amazing 74% orr and even more remarkable', '74% orr and even more remarkable low', 'orr and even more remarkable low infection', 'and even more remarkable low infection rates', 'even more remarkable low infection rates grade', 'more remarkable low infection rates grade 3/4', 'remarkable low infection rates grade 3/4 at', 'low infection rates grade 3/4 at 17%', 'infection rates grade 3/4 at 17% and', 'rates grade 3/4 at 17% and 12%.', 'grade 3/4 at 17% and 12%. this', '3/4 at 17% and 12%. this is', 'at 17% and 12%. this is remarkable', '17% and 12%. this is remarkable and', 'and 12%. this is remarkable and may', '12%. this is remarkable and may likely', 'this is remarkable and may likely be', 'is remarkable and may likely be the', 'remarkable and may likely be the next', 'and may likely be the next bispecific', 'may likely be the next bispecific and', 'likely be the next bispecific and first', 'be the next bispecific and first gprc5d', 'the next bispecific and first gprc5d available', 'next bispecific and first gprc5d available #ash22', 'bispecific and first gprc5d available #ash22 #mediq22ash.', 'and first gprc5d available #ash22 #mediq22ash. ', 'master presenter ajai chari presenting talquetamab a bispecific', 'presenter ajai chari presenting talquetamab a bispecific antibody', 'ajai chari presenting talquetamab a bispecific antibody targeting', 'chari presenting talquetamab a bispecific antibody targeting gprc5d.', 'presenting talquetamab a bispecific antibody targeting gprc5d. amazing', 'talquetamab a bispecific antibody targeting gprc5d. amazing 74%', 'a bispecific antibody targeting gprc5d. amazing 74% orr', 'bispecific antibody targeting gprc5d. amazing 74% orr and', 'antibody targeting gprc5d. amazing 74% orr and even', 'targeting gprc5d. amazing 74% orr and even more', 'gprc5d. amazing 74% orr and even more remarkable', 'amazing 74% orr and even more remarkable low', '74% orr and even more remarkable low infection', 'orr and even more remarkable low infection rates', 'and even more remarkable low infection rates grade', 'even more remarkable low infection rates grade 3/4', 'more remarkable low infection rates grade 3/4 at', 'remarkable low infection rates grade 3/4 at 17%', 'low infection rates grade 3/4 at 17% and', 'infection rates grade 3/4 at 17% and 12%.', 'rates grade 3/4 at 17% and 12%. this', 'grade 3/4 at 17% and 12%. this is', '3/4 at 17% and 12%. this is remarkable', 'at 17% and 12%. this is remarkable and', '17% and 12%. this is remarkable and may', 'and 12%. this is remarkable and may likely', '12%. this is remarkable and may likely be', 'this is remarkable and may likely be the', 'is remarkable and may likely be the next', 'remarkable and may likely be the next bispecific', 'and may likely be the next bispecific and', 'may likely be the next bispecific and first', 'likely be the next bispecific and first gprc5d', 'be the next bispecific and first gprc5d available', 'the next bispecific and first gprc5d available #ash22', 'next bispecific and first gprc5d available #ash22 #mediq22ash.', 'bispecific and first gprc5d available #ash22 #mediq22ash. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '45', 'tokens': ['discussing', 'elegantly', 'the', 'talquetamab', 'results!', 'an', 'amazing', 'new', 'option', 'including', 'for', 'those', 'patients', 'with', 'prior', 't-cell', 'redirection', 'therapy.', '#ash22.', ''], 'text_length': 20, 'triples': {'talquetamab|discussing elegantly the talquetamab results! an amazing new option': ([3, 3], [0, 8], 'positive')}, 'sentence': 'discussing elegantly the talquetamab results! an amazing new option including for those patients with prior t-cell redirection therapy. #ash22. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['discussing', 'elegantly', 'the', 'talquetamab', 'results!', 'an', 'amazing', 'new', 'option', 'including', 'for', 'those', 'patients', 'with', 'prior', 't-cell', 'redirection', 'therapy.', '#ash22.', '', 'discussing elegantly', 'elegantly the', 'the talquetamab', 'talquetamab results!', 'results! an', 'an amazing', 'amazing new', 'new option', 'option including', 'including for', 'for those', 'those patients', 'patients with', 'with prior', 'prior t-cell', 't-cell redirection', 'redirection therapy.', 'therapy. #ash22.', '#ash22. ', 'discussing elegantly the', 'elegantly the talquetamab', 'the talquetamab results!', 'talquetamab results! an', 'results! an amazing', 'an amazing new', 'amazing new option', 'new option including', 'option including for', 'including for those', 'for those patients', 'those patients with', 'patients with prior', 'with prior t-cell', 'prior t-cell redirection', 't-cell redirection therapy.', 'redirection therapy. #ash22.', 'therapy. #ash22. ', 'discussing elegantly the talquetamab', 'elegantly the talquetamab results!', 'the talquetamab results! an', 'talquetamab results! an amazing', 'results! an amazing new', 'an amazing new option', 'amazing new option including', 'new option including for', 'option including for those', 'including for those patients', 'for those patients with', 'those patients with prior', 'patients with prior t-cell', 'with prior t-cell redirection', 'prior t-cell redirection therapy.', 't-cell redirection therapy. #ash22.', 'redirection therapy. #ash22. ', 'discussing elegantly the talquetamab results!', 'elegantly the talquetamab results! an', 'the talquetamab results! an amazing', 'talquetamab results! an amazing new', 'results! an amazing new option', 'an amazing new option including', 'amazing new option including for', 'new option including for those', 'option including for those patients', 'including for those patients with', 'for those patients with prior', 'those patients with prior t-cell', 'patients with prior t-cell redirection', 'with prior t-cell redirection therapy.', 'prior t-cell redirection therapy. #ash22.', 't-cell redirection therapy. #ash22. ', 'discussing elegantly the talquetamab results! an', 'elegantly the talquetamab results! an amazing', 'the talquetamab results! an amazing new', 'talquetamab results! an amazing new option', 'results! an amazing new option including', 'an amazing new option including for', 'amazing new option including for those', 'new option including for those patients', 'option including for those patients with', 'including for those patients with prior', 'for those patients with prior t-cell', 'those patients with prior t-cell redirection', 'patients with prior t-cell redirection therapy.', 'with prior t-cell redirection therapy. #ash22.', 'prior t-cell redirection therapy. #ash22. ', 'discussing elegantly the talquetamab results! an amazing', 'elegantly the talquetamab results! an amazing new', 'the talquetamab results! an amazing new option', 'talquetamab results! an amazing new option including', 'results! an amazing new option including for', 'an amazing new option including for those', 'amazing new option including for those patients', 'new option including for those patients with', 'option including for those patients with prior', 'including for those patients with prior t-cell', 'for those patients with prior t-cell redirection', 'those patients with prior t-cell redirection therapy.', 'patients with prior t-cell redirection therapy. #ash22.', 'with prior t-cell redirection therapy. #ash22. ', 'discussing elegantly the talquetamab results! an amazing new', 'elegantly the talquetamab results! an amazing new option', 'the talquetamab results! an amazing new option including', 'talquetamab results! an amazing new option including for', 'results! an amazing new option including for those', 'an amazing new option including for those patients', 'amazing new option including for those patients with', 'new option including for those patients with prior', 'option including for those patients with prior t-cell', 'including for those patients with prior t-cell redirection', 'for those patients with prior t-cell redirection therapy.', 'those patients with prior t-cell redirection therapy. #ash22.', 'patients with prior t-cell redirection therapy. #ash22. '], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '46', 'tokens': ['the', 'talquatemab', 'data', 'looks', 'pretty', 'spectacular.', 'the', 'impact', 'of', 'dose', 'and', 'schedule', 'on', 'the', 'skin/nail/dysguesia', 'stuff', 'needs', 'to', 'be', 'examined', 'closely.', '#ash22', '#mmsm.', ''], 'text_length': 24, 'triples': {'talquatemab|looks pretty spectacular.': ([1, 1], [3, 5], 'positive')}, 'sentence': 'the talquatemab data looks pretty spectacular. the impact of dose and schedule on the skin/nail/dysguesia stuff needs to be examined closely. #ash22 #mmsm. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 5)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8)], 'span tokens': ['the', 'talquatemab', 'data', 'looks', 'pretty', 'spectacular.', 'the', 'impact', 'of', 'dose', 'and', 'schedule', 'on', 'the', 'skin/nail/dysguesia', 'stuff', 'needs', 'to', 'be', 'examined', 'closely.', '#ash22', '#mmsm.', '', 'the talquatemab', 'talquatemab data', 'data looks', 'looks pretty', 'pretty spectacular.', 'spectacular. the', 'the impact', 'impact of', 'of dose', 'dose and', 'and schedule', 'schedule on', 'on the', 'the skin/nail/dysguesia', 'skin/nail/dysguesia stuff', 'stuff needs', 'needs to', 'to be', 'be examined', 'examined closely.', 'closely. #ash22', '#ash22 #mmsm.', '#mmsm. ', 'the talquatemab data', 'talquatemab data looks', 'data looks pretty', 'looks pretty spectacular.', 'pretty spectacular. the', 'spectacular. the impact', 'the impact of', 'impact of dose', 'of dose and', 'dose and schedule', 'and schedule on', 'schedule on the', 'on the skin/nail/dysguesia', 'the skin/nail/dysguesia stuff', 'skin/nail/dysguesia stuff needs', 'stuff needs to', 'needs to be', 'to be examined', 'be examined closely.', 'examined closely. #ash22', 'closely. #ash22 #mmsm.', '#ash22 #mmsm. ', 'the talquatemab data looks', 'talquatemab data looks pretty', 'data looks pretty spectacular.', 'looks pretty spectacular. the', 'pretty spectacular. the impact', 'spectacular. the impact of', 'the impact of dose', 'impact of dose and', 'of dose and schedule', 'dose and schedule on', 'and schedule on the', 'schedule on the skin/nail/dysguesia', 'on the skin/nail/dysguesia stuff', 'the skin/nail/dysguesia stuff needs', 'skin/nail/dysguesia stuff needs to', 'stuff needs to be', 'needs to be examined', 'to be examined closely.', 'be examined closely. #ash22', 'examined closely. #ash22 #mmsm.', 'closely. #ash22 #mmsm. ', 'the talquatemab data looks pretty', 'talquatemab data looks pretty spectacular.', 'data looks pretty spectacular. the', 'looks pretty spectacular. the impact', 'pretty spectacular. the impact of', 'spectacular. the impact of dose', 'the impact of dose and', 'impact of dose and schedule', 'of dose and schedule on', 'dose and schedule on the', 'and schedule on the skin/nail/dysguesia', 'schedule on the skin/nail/dysguesia stuff', 'on the skin/nail/dysguesia stuff needs', 'the skin/nail/dysguesia stuff needs to', 'skin/nail/dysguesia stuff needs to be', 'stuff needs to be examined', 'needs to be examined closely.', 'to be examined closely. #ash22', 'be examined closely. #ash22 #mmsm.', 'examined closely. #ash22 #mmsm. ', 'the talquatemab data looks pretty spectacular.', 'talquatemab data looks pretty spectacular. the', 'data looks pretty spectacular. the impact', 'looks pretty spectacular. the impact of', 'pretty spectacular. the impact of dose', 'spectacular. the impact of dose and', 'the impact of dose and schedule', 'impact of dose and schedule on', 'of dose and schedule on the', 'dose and schedule on the skin/nail/dysguesia', 'and schedule on the skin/nail/dysguesia stuff', 'schedule on the skin/nail/dysguesia stuff needs', 'on the skin/nail/dysguesia stuff needs to', 'the skin/nail/dysguesia stuff needs to be', 'skin/nail/dysguesia stuff needs to be examined', 'stuff needs to be examined closely.', 'needs to be examined closely. #ash22', 'to be examined closely. #ash22 #mmsm.', 'be examined closely. #ash22 #mmsm. ', 'the talquatemab data looks pretty spectacular. the', 'talquatemab data looks pretty spectacular. the impact', 'data looks pretty spectacular. the impact of', 'looks pretty spectacular. the impact of dose', 'pretty spectacular. the impact of dose and', 'spectacular. the impact of dose and schedule', 'the impact of dose and schedule on', 'impact of dose and schedule on the', 'of dose and schedule on the skin/nail/dysguesia', 'dose and schedule on the skin/nail/dysguesia stuff', 'and schedule on the skin/nail/dysguesia stuff needs', 'schedule on the skin/nail/dysguesia stuff needs to', 'on the skin/nail/dysguesia stuff needs to be', 'the skin/nail/dysguesia stuff needs to be examined', 'skin/nail/dysguesia stuff needs to be examined closely.', 'stuff needs to be examined closely. #ash22', 'needs to be examined closely. #ash22 #mmsm.', 'to be examined closely. #ash22 #mmsm. ', 'the talquatemab data looks pretty spectacular. the impact', 'talquatemab data looks pretty spectacular. the impact of', 'data looks pretty spectacular. the impact of dose', 'looks pretty spectacular. the impact of dose and', 'pretty spectacular. the impact of dose and schedule', 'spectacular. the impact of dose and schedule on', 'the impact of dose and schedule on the', 'impact of dose and schedule on the skin/nail/dysguesia', 'of dose and schedule on the skin/nail/dysguesia stuff', 'dose and schedule on the skin/nail/dysguesia stuff needs', 'and schedule on the skin/nail/dysguesia stuff needs to', 'schedule on the skin/nail/dysguesia stuff needs to be', 'on the skin/nail/dysguesia stuff needs to be examined', 'the skin/nail/dysguesia stuff needs to be examined closely.', 'skin/nail/dysguesia stuff needs to be examined closely. #ash22', 'stuff needs to be examined closely. #ash22 #mmsm.', 'needs to be examined closely. #ash22 #mmsm. '], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '47', 'tokens': ['adjuvant', 'atezolizumab', 'does', 'not', 'improve', 'disease-free', 'survival', 'in', 'patients', 'with', 'rcc', '#esmo22', '#rcc', '#kcsm', '#kidneycancer', '#immunotherapy', '#oncology', '.'], 'text_length': 18, 'triples': {'atezolizumab|not improve disease-free': ([1, 1], [3, 5], 'negative')}, 'sentence': 'adjuvant atezolizumab does not improve disease-free survival in patients with rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy #oncology .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 5)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8)], 'span tokens': ['adjuvant', 'atezolizumab', 'does', 'not', 'improve', 'disease-free', 'survival', 'in', 'patients', 'with', 'rcc', '#esmo22', '#rcc', '#kcsm', '#kidneycancer', '#immunotherapy', '#oncology', '.', 'adjuvant atezolizumab', 'atezolizumab does', 'does not', 'not improve', 'improve disease-free', 'disease-free survival', 'survival in', 'in patients', 'patients with', 'with rcc', 'rcc #esmo22', '#esmo22 #rcc', '#rcc #kcsm', '#kcsm #kidneycancer', '#kidneycancer #immunotherapy', '#immunotherapy #oncology', '#oncology .', 'adjuvant atezolizumab does', 'atezolizumab does not', 'does not improve', 'not improve disease-free', 'improve disease-free survival', 'disease-free survival in', 'survival in patients', 'in patients with', 'patients with rcc', 'with rcc #esmo22', 'rcc #esmo22 #rcc', '#esmo22 #rcc #kcsm', '#rcc #kcsm #kidneycancer', '#kcsm #kidneycancer #immunotherapy', '#kidneycancer #immunotherapy #oncology', '#immunotherapy #oncology .', 'adjuvant atezolizumab does not', 'atezolizumab does not improve', 'does not improve disease-free', 'not improve disease-free survival', 'improve disease-free survival in', 'disease-free survival in patients', 'survival in patients with', 'in patients with rcc', 'patients with rcc #esmo22', 'with rcc #esmo22 #rcc', 'rcc #esmo22 #rcc #kcsm', '#esmo22 #rcc #kcsm #kidneycancer', '#rcc #kcsm #kidneycancer #immunotherapy', '#kcsm #kidneycancer #immunotherapy #oncology', '#kidneycancer #immunotherapy #oncology .', 'adjuvant atezolizumab does not improve', 'atezolizumab does not improve disease-free', 'does not improve disease-free survival', 'not improve disease-free survival in', 'improve disease-free survival in patients', 'disease-free survival in patients with', 'survival in patients with rcc', 'in patients with rcc #esmo22', 'patients with rcc #esmo22 #rcc', 'with rcc #esmo22 #rcc #kcsm', 'rcc #esmo22 #rcc #kcsm #kidneycancer', '#esmo22 #rcc #kcsm #kidneycancer #immunotherapy', '#rcc #kcsm #kidneycancer #immunotherapy #oncology', '#kcsm #kidneycancer #immunotherapy #oncology .', 'adjuvant atezolizumab does not improve disease-free', 'atezolizumab does not improve disease-free survival', 'does not improve disease-free survival in', 'not improve disease-free survival in patients', 'improve disease-free survival in patients with', 'disease-free survival in patients with rcc', 'survival in patients with rcc #esmo22', 'in patients with rcc #esmo22 #rcc', 'patients with rcc #esmo22 #rcc #kcsm', 'with rcc #esmo22 #rcc #kcsm #kidneycancer', 'rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy', '#esmo22 #rcc #kcsm #kidneycancer #immunotherapy #oncology', '#rcc #kcsm #kidneycancer #immunotherapy #oncology .', 'adjuvant atezolizumab does not improve disease-free survival', 'atezolizumab does not improve disease-free survival in', 'does not improve disease-free survival in patients', 'not improve disease-free survival in patients with', 'improve disease-free survival in patients with rcc', 'disease-free survival in patients with rcc #esmo22', 'survival in patients with rcc #esmo22 #rcc', 'in patients with rcc #esmo22 #rcc #kcsm', 'patients with rcc #esmo22 #rcc #kcsm #kidneycancer', 'with rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy', 'rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy #oncology', '#esmo22 #rcc #kcsm #kidneycancer #immunotherapy #oncology .', 'adjuvant atezolizumab does not improve disease-free survival in', 'atezolizumab does not improve disease-free survival in patients', 'does not improve disease-free survival in patients with', 'not improve disease-free survival in patients with rcc', 'improve disease-free survival in patients with rcc #esmo22', 'disease-free survival in patients with rcc #esmo22 #rcc', 'survival in patients with rcc #esmo22 #rcc #kcsm', 'in patients with rcc #esmo22 #rcc #kcsm #kidneycancer', 'patients with rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy', 'with rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy #oncology', 'rcc #esmo22 #rcc #kcsm #kidneycancer #immunotherapy #oncology .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '48', 'tokens': ['#gritstone', 'presents', 'negative', 'initial', 'phase', '2', 'slate', 'data', 'in', 'late-line', '#solidtumor', 'patients', 'treated', 'with', '#kras', 'directed', '#immunotherapy', 'at', '#esmo22', '$grts.', ''], 'text_length': 21, 'triples': {'slate|presents negative': ([6, 6], [1, 2], 'negative')}, 'sentence': '#gritstone presents negative initial phase 2 slate data in late-line #solidtumor patients treated with #kras directed #immunotherapy at #esmo22 $grts. ', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['#gritstone', 'presents', 'negative', 'initial', 'phase', '2', 'slate', 'data', 'in', 'late-line', '#solidtumor', 'patients', 'treated', 'with', '#kras', 'directed', '#immunotherapy', 'at', '#esmo22', '$grts.', '', '#gritstone presents', 'presents negative', 'negative initial', 'initial phase', 'phase 2', '2 slate', 'slate data', 'data in', 'in late-line', 'late-line #solidtumor', '#solidtumor patients', 'patients treated', 'treated with', 'with #kras', '#kras directed', 'directed #immunotherapy', '#immunotherapy at', 'at #esmo22', '#esmo22 $grts.', '$grts. ', '#gritstone presents negative', 'presents negative initial', 'negative initial phase', 'initial phase 2', 'phase 2 slate', '2 slate data', 'slate data in', 'data in late-line', 'in late-line #solidtumor', 'late-line #solidtumor patients', '#solidtumor patients treated', 'patients treated with', 'treated with #kras', 'with #kras directed', '#kras directed #immunotherapy', 'directed #immunotherapy at', '#immunotherapy at #esmo22', 'at #esmo22 $grts.', '#esmo22 $grts. ', '#gritstone presents negative initial', 'presents negative initial phase', 'negative initial phase 2', 'initial phase 2 slate', 'phase 2 slate data', '2 slate data in', 'slate data in late-line', 'data in late-line #solidtumor', 'in late-line #solidtumor patients', 'late-line #solidtumor patients treated', '#solidtumor patients treated with', 'patients treated with #kras', 'treated with #kras directed', 'with #kras directed #immunotherapy', '#kras directed #immunotherapy at', 'directed #immunotherapy at #esmo22', '#immunotherapy at #esmo22 $grts.', 'at #esmo22 $grts. ', '#gritstone presents negative initial phase', 'presents negative initial phase 2', 'negative initial phase 2 slate', 'initial phase 2 slate data', 'phase 2 slate data in', '2 slate data in late-line', 'slate data in late-line #solidtumor', 'data in late-line #solidtumor patients', 'in late-line #solidtumor patients treated', 'late-line #solidtumor patients treated with', '#solidtumor patients treated with #kras', 'patients treated with #kras directed', 'treated with #kras directed #immunotherapy', 'with #kras directed #immunotherapy at', '#kras directed #immunotherapy at #esmo22', 'directed #immunotherapy at #esmo22 $grts.', '#immunotherapy at #esmo22 $grts. ', '#gritstone presents negative initial phase 2', 'presents negative initial phase 2 slate', 'negative initial phase 2 slate data', 'initial phase 2 slate data in', 'phase 2 slate data in late-line', '2 slate data in late-line #solidtumor', 'slate data in late-line #solidtumor patients', 'data in late-line #solidtumor patients treated', 'in late-line #solidtumor patients treated with', 'late-line #solidtumor patients treated with #kras', '#solidtumor patients treated with #kras directed', 'patients treated with #kras directed #immunotherapy', 'treated with #kras directed #immunotherapy at', 'with #kras directed #immunotherapy at #esmo22', '#kras directed #immunotherapy at #esmo22 $grts.', 'directed #immunotherapy at #esmo22 $grts. ', '#gritstone presents negative initial phase 2 slate', 'presents negative initial phase 2 slate data', 'negative initial phase 2 slate data in', 'initial phase 2 slate data in late-line', 'phase 2 slate data in late-line #solidtumor', '2 slate data in late-line #solidtumor patients', 'slate data in late-line #solidtumor patients treated', 'data in late-line #solidtumor patients treated with', 'in late-line #solidtumor patients treated with #kras', 'late-line #solidtumor patients treated with #kras directed', '#solidtumor patients treated with #kras directed #immunotherapy', 'patients treated with #kras directed #immunotherapy at', 'treated with #kras directed #immunotherapy at #esmo22', 'with #kras directed #immunotherapy at #esmo22 $grts.', '#kras directed #immunotherapy at #esmo22 $grts. ', '#gritstone presents negative initial phase 2 slate data', 'presents negative initial phase 2 slate data in', 'negative initial phase 2 slate data in late-line', 'initial phase 2 slate data in late-line #solidtumor', 'phase 2 slate data in late-line #solidtumor patients', '2 slate data in late-line #solidtumor patients treated', 'slate data in late-line #solidtumor patients treated with', 'data in late-line #solidtumor patients treated with #kras', 'in late-line #solidtumor patients treated with #kras directed', 'late-line #solidtumor patients treated with #kras directed #immunotherapy', '#solidtumor patients treated with #kras directed #immunotherapy at', 'patients treated with #kras directed #immunotherapy at #esmo22', 'treated with #kras directed #immunotherapy at #esmo22 $grts.', 'with #kras directed #immunotherapy at #esmo22 $grts. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '49', 'tokens': ['not', 'sure', 'a', '3%', 'cr', 'will', 'drive', 'any', 'patient.', 'tox,', 'chance', 'at', 'deep', 'response,', 'chance', 'to', 'get', 'full', 'ipilimumab.', 'from', 'a', 'patients', 'view', 'point,', 'this', 'is', 'nothing', 'short', 'of', 'a', 'huge', 'disappointment.', '.'], 'text_length': 33, 'triples': {'ipilimumab.|huge disappointment.': ([18, 18], [30, 31], 'negative')}, 'sentence': 'not sure a 3% cr will drive any patient. tox, chance at deep response, chance to get full ipilimumab. from a patients view point, this is nothing short of a huge disappointment. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(30, 31)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['not', 'sure', 'a', '3%', 'cr', 'will', 'drive', 'any', 'patient.', 'tox,', 'chance', 'at', 'deep', 'response,', 'chance', 'to', 'get', 'full', 'ipilimumab.', 'from', 'a', 'patients', 'view', 'point,', 'this', 'is', 'nothing', 'short', 'of', 'a', 'huge', 'disappointment.', '.', 'not sure', 'sure a', 'a 3%', '3% cr', 'cr will', 'will drive', 'drive any', 'any patient.', 'patient. tox,', 'tox, chance', 'chance at', 'at deep', 'deep response,', 'response, chance', 'chance to', 'to get', 'get full', 'full ipilimumab.', 'ipilimumab. from', 'from a', 'a patients', 'patients view', 'view point,', 'point, this', 'this is', 'is nothing', 'nothing short', 'short of', 'of a', 'a huge', 'huge disappointment.', 'disappointment. .', 'not sure a', 'sure a 3%', 'a 3% cr', '3% cr will', 'cr will drive', 'will drive any', 'drive any patient.', 'any patient. tox,', 'patient. tox, chance', 'tox, chance at', 'chance at deep', 'at deep response,', 'deep response, chance', 'response, chance to', 'chance to get', 'to get full', 'get full ipilimumab.', 'full ipilimumab. from', 'ipilimumab. from a', 'from a patients', 'a patients view', 'patients view point,', 'view point, this', 'point, this is', 'this is nothing', 'is nothing short', 'nothing short of', 'short of a', 'of a huge', 'a huge disappointment.', 'huge disappointment. .', 'not sure a 3%', 'sure a 3% cr', 'a 3% cr will', '3% cr will drive', 'cr will drive any', 'will drive any patient.', 'drive any patient. tox,', 'any patient. tox, chance', 'patient. tox, chance at', 'tox, chance at deep', 'chance at deep response,', 'at deep response, chance', 'deep response, chance to', 'response, chance to get', 'chance to get full', 'to get full ipilimumab.', 'get full ipilimumab. from', 'full ipilimumab. from a', 'ipilimumab. from a patients', 'from a patients view', 'a patients view point,', 'patients view point, this', 'view point, this is', 'point, this is nothing', 'this is nothing short', 'is nothing short of', 'nothing short of a', 'short of a huge', 'of a huge disappointment.', 'a huge disappointment. .', 'not sure a 3% cr', 'sure a 3% cr will', 'a 3% cr will drive', '3% cr will drive any', 'cr will drive any patient.', 'will drive any patient. tox,', 'drive any patient. tox, chance', 'any patient. tox, chance at', 'patient. tox, chance at deep', 'tox, chance at deep response,', 'chance at deep response, chance', 'at deep response, chance to', 'deep response, chance to get', 'response, chance to get full', 'chance to get full ipilimumab.', 'to get full ipilimumab. from', 'get full ipilimumab. from a', 'full ipilimumab. from a patients', 'ipilimumab. from a patients view', 'from a patients view point,', 'a patients view point, this', 'patients view point, this is', 'view point, this is nothing', 'point, this is nothing short', 'this is nothing short of', 'is nothing short of a', 'nothing short of a huge', 'short of a huge disappointment.', 'of a huge disappointment. .', 'not sure a 3% cr will', 'sure a 3% cr will drive', 'a 3% cr will drive any', '3% cr will drive any patient.', 'cr will drive any patient. tox,', 'will drive any patient. tox, chance', 'drive any patient. tox, chance at', 'any patient. tox, chance at deep', 'patient. tox, chance at deep response,', 'tox, chance at deep response, chance', 'chance at deep response, chance to', 'at deep response, chance to get', 'deep response, chance to get full', 'response, chance to get full ipilimumab.', 'chance to get full ipilimumab. from', 'to get full ipilimumab. from a', 'get full ipilimumab. from a patients', 'full ipilimumab. from a patients view', 'ipilimumab. from a patients view point,', 'from a patients view point, this', 'a patients view point, this is', 'patients view point, this is nothing', 'view point, this is nothing short', 'point, this is nothing short of', 'this is nothing short of a', 'is nothing short of a huge', 'nothing short of a huge disappointment.', 'short of a huge disappointment. .', 'not sure a 3% cr will drive', 'sure a 3% cr will drive any', 'a 3% cr will drive any patient.', '3% cr will drive any patient. tox,', 'cr will drive any patient. tox, chance', 'will drive any patient. tox, chance at', 'drive any patient. tox, chance at deep', 'any patient. tox, chance at deep response,', 'patient. tox, chance at deep response, chance', 'tox, chance at deep response, chance to', 'chance at deep response, chance to get', 'at deep response, chance to get full', 'deep response, chance to get full ipilimumab.', 'response, chance to get full ipilimumab. from', 'chance to get full ipilimumab. from a', 'to get full ipilimumab. from a patients', 'get full ipilimumab. from a patients view', 'full ipilimumab. from a patients view point,', 'ipilimumab. from a patients view point, this', 'from a patients view point, this is', 'a patients view point, this is nothing', 'patients view point, this is nothing short', 'view point, this is nothing short of', 'point, this is nothing short of a', 'this is nothing short of a huge', 'is nothing short of a huge disappointment.', 'nothing short of a huge disappointment. .', 'not sure a 3% cr will drive any', 'sure a 3% cr will drive any patient.', 'a 3% cr will drive any patient. tox,', '3% cr will drive any patient. tox, chance', 'cr will drive any patient. tox, chance at', 'will drive any patient. tox, chance at deep', 'drive any patient. tox, chance at deep response,', 'any patient. tox, chance at deep response, chance', 'patient. tox, chance at deep response, chance to', 'tox, chance at deep response, chance to get', 'chance at deep response, chance to get full', 'at deep response, chance to get full ipilimumab.', 'deep response, chance to get full ipilimumab. from', 'response, chance to get full ipilimumab. from a', 'chance to get full ipilimumab. from a patients', 'to get full ipilimumab. from a patients view', 'get full ipilimumab. from a patients view point,', 'full ipilimumab. from a patients view point, this', 'ipilimumab. from a patients view point, this is', 'from a patients view point, this is nothing', 'a patients view point, this is nothing short', 'patients view point, this is nothing short of', 'view point, this is nothing short of a', 'point, this is nothing short of a huge', 'this is nothing short of a huge disappointment.', 'is nothing short of a huge disappointment. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '50', 'tokens': ['pazopanib+paclitaxel', 'did', 'not', 'improve', 'efficacy,', 'increased', 'toxicity,', 'and', 'compromised', 'chemo', 'delivery', 'in', 'recurrent', '#ovariancancer', 'progressing', 'during', 'maintenance', '#bevacizumab', '#tapaz', '.'], 'text_length': 20, 'triples': {'pazopanib+paclitaxel|not improve efficacy, increased toxicity, and compromised': ([0, 0], [2, 8], 'negative')}, 'sentence': 'pazopanib+paclitaxel did not improve efficacy, increased toxicity, and compromised chemo delivery in recurrent #ovariancancer progressing during maintenance #bevacizumab #tapaz .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['pazopanib+paclitaxel', 'did', 'not', 'improve', 'efficacy,', 'increased', 'toxicity,', 'and', 'compromised', 'chemo', 'delivery', 'in', 'recurrent', '#ovariancancer', 'progressing', 'during', 'maintenance', '#bevacizumab', '#tapaz', '.', 'pazopanib+paclitaxel did', 'did not', 'not improve', 'improve efficacy,', 'efficacy, increased', 'increased toxicity,', 'toxicity, and', 'and compromised', 'compromised chemo', 'chemo delivery', 'delivery in', 'in recurrent', 'recurrent #ovariancancer', '#ovariancancer progressing', 'progressing during', 'during maintenance', 'maintenance #bevacizumab', '#bevacizumab #tapaz', '#tapaz .', 'pazopanib+paclitaxel did not', 'did not improve', 'not improve efficacy,', 'improve efficacy, increased', 'efficacy, increased toxicity,', 'increased toxicity, and', 'toxicity, and compromised', 'and compromised chemo', 'compromised chemo delivery', 'chemo delivery in', 'delivery in recurrent', 'in recurrent #ovariancancer', 'recurrent #ovariancancer progressing', '#ovariancancer progressing during', 'progressing during maintenance', 'during maintenance #bevacizumab', 'maintenance #bevacizumab #tapaz', '#bevacizumab #tapaz .', 'pazopanib+paclitaxel did not improve', 'did not improve efficacy,', 'not improve efficacy, increased', 'improve efficacy, increased toxicity,', 'efficacy, increased toxicity, and', 'increased toxicity, and compromised', 'toxicity, and compromised chemo', 'and compromised chemo delivery', 'compromised chemo delivery in', 'chemo delivery in recurrent', 'delivery in recurrent #ovariancancer', 'in recurrent #ovariancancer progressing', 'recurrent #ovariancancer progressing during', '#ovariancancer progressing during maintenance', 'progressing during maintenance #bevacizumab', 'during maintenance #bevacizumab #tapaz', 'maintenance #bevacizumab #tapaz .', 'pazopanib+paclitaxel did not improve efficacy,', 'did not improve efficacy, increased', 'not improve efficacy, increased toxicity,', 'improve efficacy, increased toxicity, and', 'efficacy, increased toxicity, and compromised', 'increased toxicity, and compromised chemo', 'toxicity, and compromised chemo delivery', 'and compromised chemo delivery in', 'compromised chemo delivery in recurrent', 'chemo delivery in recurrent #ovariancancer', 'delivery in recurrent #ovariancancer progressing', 'in recurrent #ovariancancer progressing during', 'recurrent #ovariancancer progressing during maintenance', '#ovariancancer progressing during maintenance #bevacizumab', 'progressing during maintenance #bevacizumab #tapaz', 'during maintenance #bevacizumab #tapaz .', 'pazopanib+paclitaxel did not improve efficacy, increased', 'did not improve efficacy, increased toxicity,', 'not improve efficacy, increased toxicity, and', 'improve efficacy, increased toxicity, and compromised', 'efficacy, increased toxicity, and compromised chemo', 'increased toxicity, and compromised chemo delivery', 'toxicity, and compromised chemo delivery in', 'and compromised chemo delivery in recurrent', 'compromised chemo delivery in recurrent #ovariancancer', 'chemo delivery in recurrent #ovariancancer progressing', 'delivery in recurrent #ovariancancer progressing during', 'in recurrent #ovariancancer progressing during maintenance', 'recurrent #ovariancancer progressing during maintenance #bevacizumab', '#ovariancancer progressing during maintenance #bevacizumab #tapaz', 'progressing during maintenance #bevacizumab #tapaz .', 'pazopanib+paclitaxel did not improve efficacy, increased toxicity,', 'did not improve efficacy, increased toxicity, and', 'not improve efficacy, increased toxicity, and compromised', 'improve efficacy, increased toxicity, and compromised chemo', 'efficacy, increased toxicity, and compromised chemo delivery', 'increased toxicity, and compromised chemo delivery in', 'toxicity, and compromised chemo delivery in recurrent', 'and compromised chemo delivery in recurrent #ovariancancer', 'compromised chemo delivery in recurrent #ovariancancer progressing', 'chemo delivery in recurrent #ovariancancer progressing during', 'delivery in recurrent #ovariancancer progressing during maintenance', 'in recurrent #ovariancancer progressing during maintenance #bevacizumab', 'recurrent #ovariancancer progressing during maintenance #bevacizumab #tapaz', '#ovariancancer progressing during maintenance #bevacizumab #tapaz .', 'pazopanib+paclitaxel did not improve efficacy, increased toxicity, and', 'did not improve efficacy, increased toxicity, and compromised', 'not improve efficacy, increased toxicity, and compromised chemo', 'improve efficacy, increased toxicity, and compromised chemo delivery', 'efficacy, increased toxicity, and compromised chemo delivery in', 'increased toxicity, and compromised chemo delivery in recurrent', 'toxicity, and compromised chemo delivery in recurrent #ovariancancer', 'and compromised chemo delivery in recurrent #ovariancancer progressing', 'compromised chemo delivery in recurrent #ovariancancer progressing during', 'chemo delivery in recurrent #ovariancancer progressing during maintenance', 'delivery in recurrent #ovariancancer progressing during maintenance #bevacizumab', 'in recurrent #ovariancancer progressing during maintenance #bevacizumab #tapaz', 'recurrent #ovariancancer progressing during maintenance #bevacizumab #tapaz .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '51', 'tokens': ['patients', 'with', 'locally', 'advanced', 'head', 'and', 'neck', 'squamous', 'cell', 'carcinoma', 'did', 'not', 'show', 'statistically', 'significant', 'improvement', 'in', 'event-free', 'survival', 'with', 'pembrolizumab', '', 'vs', 'nivolumab.', '#hancsm', '#esmo2022', '|.', ''], 'text_length': 28, 'triples': {'pembrolizumab|not show statistically significant': ([20, 20], [11, 14], 'negative'), 'nivolumab.|not show statistically significant': ([22, 22], [11, 14], 'negative')}, 'sentence': 'patients with locally advanced head and neck squamous cell carcinoma did not show statistically significant improvement in event-free survival with pembrolizumab  vs nivolumab. #hancsm #esmo2022 |. ', 'aspect_num': 2, 'spans_aspect2opinion_label': [(20, 20), (22, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(11, 14)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 1, 1, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 1, 0, ..., 1, 1, 1],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['patients', 'with', 'locally', 'advanced', 'head', 'and', 'neck', 'squamous', 'cell', 'carcinoma', 'did', 'not', 'show', 'statistically', 'significant', 'improvement', 'in', 'event-free', 'survival', 'with', 'pembrolizumab', '', 'vs', 'nivolumab.', '#hancsm', '#esmo2022', '|.', '', 'patients with', 'with locally', 'locally advanced', 'advanced head', 'head and', 'and neck', 'neck squamous', 'squamous cell', 'cell carcinoma', 'carcinoma did', 'did not', 'not show', 'show statistically', 'statistically significant', 'significant improvement', 'improvement in', 'in event-free', 'event-free survival', 'survival with', 'with pembrolizumab', 'pembrolizumab ', ' vs', 'vs nivolumab.', 'nivolumab. #hancsm', '#hancsm #esmo2022', '#esmo2022 |.', '|. ', 'patients with locally', 'with locally advanced', 'locally advanced head', 'advanced head and', 'head and neck', 'and neck squamous', 'neck squamous cell', 'squamous cell carcinoma', 'cell carcinoma did', 'carcinoma did not', 'did not show', 'not show statistically', 'show statistically significant', 'statistically significant improvement', 'significant improvement in', 'improvement in event-free', 'in event-free survival', 'event-free survival with', 'survival with pembrolizumab', 'with pembrolizumab ', 'pembrolizumab  vs', ' vs nivolumab.', 'vs nivolumab. #hancsm', 'nivolumab. #hancsm #esmo2022', '#hancsm #esmo2022 |.', '#esmo2022 |. ', 'patients with locally advanced', 'with locally advanced head', 'locally advanced head and', 'advanced head and neck', 'head and neck squamous', 'and neck squamous cell', 'neck squamous cell carcinoma', 'squamous cell carcinoma did', 'cell carcinoma did not', 'carcinoma did not show', 'did not show statistically', 'not show statistically significant', 'show statistically significant improvement', 'statistically significant improvement in', 'significant improvement in event-free', 'improvement in event-free survival', 'in event-free survival with', 'event-free survival with pembrolizumab', 'survival with pembrolizumab ', 'with pembrolizumab  vs', 'pembrolizumab  vs nivolumab.', ' vs nivolumab. #hancsm', 'vs nivolumab. #hancsm #esmo2022', 'nivolumab. #hancsm #esmo2022 |.', '#hancsm #esmo2022 |. ', 'patients with locally advanced head', 'with locally advanced head and', 'locally advanced head and neck', 'advanced head and neck squamous', 'head and neck squamous cell', 'and neck squamous cell carcinoma', 'neck squamous cell carcinoma did', 'squamous cell carcinoma did not', 'cell carcinoma did not show', 'carcinoma did not show statistically', 'did not show statistically significant', 'not show statistically significant improvement', 'show statistically significant improvement in', 'statistically significant improvement in event-free', 'significant improvement in event-free survival', 'improvement in event-free survival with', 'in event-free survival with pembrolizumab', 'event-free survival with pembrolizumab ', 'survival with pembrolizumab  vs', 'with pembrolizumab  vs nivolumab.', 'pembrolizumab  vs nivolumab. #hancsm', ' vs nivolumab. #hancsm #esmo2022', 'vs nivolumab. #hancsm #esmo2022 |.', 'nivolumab. #hancsm #esmo2022 |. ', 'patients with locally advanced head and', 'with locally advanced head and neck', 'locally advanced head and neck squamous', 'advanced head and neck squamous cell', 'head and neck squamous cell carcinoma', 'and neck squamous cell carcinoma did', 'neck squamous cell carcinoma did not', 'squamous cell carcinoma did not show', 'cell carcinoma did not show statistically', 'carcinoma did not show statistically significant', 'did not show statistically significant improvement', 'not show statistically significant improvement in', 'show statistically significant improvement in event-free', 'statistically significant improvement in event-free survival', 'significant improvement in event-free survival with', 'improvement in event-free survival with pembrolizumab', 'in event-free survival with pembrolizumab ', 'event-free survival with pembrolizumab  vs', 'survival with pembrolizumab  vs nivolumab.', 'with pembrolizumab  vs nivolumab. #hancsm', 'pembrolizumab  vs nivolumab. #hancsm #esmo2022', ' vs nivolumab. #hancsm #esmo2022 |.', 'vs nivolumab. #hancsm #esmo2022 |. ', 'patients with locally advanced head and neck', 'with locally advanced head and neck squamous', 'locally advanced head and neck squamous cell', 'advanced head and neck squamous cell carcinoma', 'head and neck squamous cell carcinoma did', 'and neck squamous cell carcinoma did not', 'neck squamous cell carcinoma did not show', 'squamous cell carcinoma did not show statistically', 'cell carcinoma did not show statistically significant', 'carcinoma did not show statistically significant improvement', 'did not show statistically significant improvement in', 'not show statistically significant improvement in event-free', 'show statistically significant improvement in event-free survival', 'statistically significant improvement in event-free survival with', 'significant improvement in event-free survival with pembrolizumab', 'improvement in event-free survival with pembrolizumab ', 'in event-free survival with pembrolizumab  vs', 'event-free survival with pembrolizumab  vs nivolumab.', 'survival with pembrolizumab  vs nivolumab. #hancsm', 'with pembrolizumab  vs nivolumab. #hancsm #esmo2022', 'pembrolizumab  vs nivolumab. #hancsm #esmo2022 |.', ' vs nivolumab. #hancsm #esmo2022 |. ', 'patients with locally advanced head and neck squamous', 'with locally advanced head and neck squamous cell', 'locally advanced head and neck squamous cell carcinoma', 'advanced head and neck squamous cell carcinoma did', 'head and neck squamous cell carcinoma did not', 'and neck squamous cell carcinoma did not show', 'neck squamous cell carcinoma did not show statistically', 'squamous cell carcinoma did not show statistically significant', 'cell carcinoma did not show statistically significant improvement', 'carcinoma did not show statistically significant improvement in', 'did not show statistically significant improvement in event-free', 'not show statistically significant improvement in event-free survival', 'show statistically significant improvement in event-free survival with', 'statistically significant improvement in event-free survival with pembrolizumab', 'significant improvement in event-free survival with pembrolizumab ', 'improvement in event-free survival with pembrolizumab  vs', 'in event-free survival with pembrolizumab  vs nivolumab.', 'event-free survival with pembrolizumab  vs nivolumab. #hancsm', 'survival with pembrolizumab  vs nivolumab. #hancsm #esmo2022', 'with pembrolizumab  vs nivolumab. #hancsm #esmo2022 |.', 'pembrolizumab  vs nivolumab. #hancsm #esmo2022 |. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '52', 'tokens': ['#regeneron', 'reported', 'negative', '#neoadjuvant', '#libtayo', 'cemiplimab', '#monotherapy', 'data', 'in', 'resectable', '#cutaneous', '#squamouscellcarcinoma', 'presented', 'at', '#esmo22', 'and', 'published', 'in', '#nejm', '$regn', '.'], 'text_length': 21, 'triples': {'cemiplimab|reported negative': ([5, 5], [1, 2], 'negative')}, 'sentence': '#regeneron reported negative #neoadjuvant #libtayo cemiplimab #monotherapy data in resectable #cutaneous #squamouscellcarcinoma presented at #esmo22 and published in #nejm $regn .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['#regeneron', 'reported', 'negative', '#neoadjuvant', '#libtayo', 'cemiplimab', '#monotherapy', 'data', 'in', 'resectable', '#cutaneous', '#squamouscellcarcinoma', 'presented', 'at', '#esmo22', 'and', 'published', 'in', '#nejm', '$regn', '.', '#regeneron reported', 'reported negative', 'negative #neoadjuvant', '#neoadjuvant #libtayo', '#libtayo cemiplimab', 'cemiplimab #monotherapy', '#monotherapy data', 'data in', 'in resectable', 'resectable #cutaneous', '#cutaneous #squamouscellcarcinoma', '#squamouscellcarcinoma presented', 'presented at', 'at #esmo22', '#esmo22 and', 'and published', 'published in', 'in #nejm', '#nejm $regn', '$regn .', '#regeneron reported negative', 'reported negative #neoadjuvant', 'negative #neoadjuvant #libtayo', '#neoadjuvant #libtayo cemiplimab', '#libtayo cemiplimab #monotherapy', 'cemiplimab #monotherapy data', '#monotherapy data in', 'data in resectable', 'in resectable #cutaneous', 'resectable #cutaneous #squamouscellcarcinoma', '#cutaneous #squamouscellcarcinoma presented', '#squamouscellcarcinoma presented at', 'presented at #esmo22', 'at #esmo22 and', '#esmo22 and published', 'and published in', 'published in #nejm', 'in #nejm $regn', '#nejm $regn .', '#regeneron reported negative #neoadjuvant', 'reported negative #neoadjuvant #libtayo', 'negative #neoadjuvant #libtayo cemiplimab', '#neoadjuvant #libtayo cemiplimab #monotherapy', '#libtayo cemiplimab #monotherapy data', 'cemiplimab #monotherapy data in', '#monotherapy data in resectable', 'data in resectable #cutaneous', 'in resectable #cutaneous #squamouscellcarcinoma', 'resectable #cutaneous #squamouscellcarcinoma presented', '#cutaneous #squamouscellcarcinoma presented at', '#squamouscellcarcinoma presented at #esmo22', 'presented at #esmo22 and', 'at #esmo22 and published', '#esmo22 and published in', 'and published in #nejm', 'published in #nejm $regn', 'in #nejm $regn .', '#regeneron reported negative #neoadjuvant #libtayo', 'reported negative #neoadjuvant #libtayo cemiplimab', 'negative #neoadjuvant #libtayo cemiplimab #monotherapy', '#neoadjuvant #libtayo cemiplimab #monotherapy data', '#libtayo cemiplimab #monotherapy data in', 'cemiplimab #monotherapy data in resectable', '#monotherapy data in resectable #cutaneous', 'data in resectable #cutaneous #squamouscellcarcinoma', 'in resectable #cutaneous #squamouscellcarcinoma presented', 'resectable #cutaneous #squamouscellcarcinoma presented at', '#cutaneous #squamouscellcarcinoma presented at #esmo22', '#squamouscellcarcinoma presented at #esmo22 and', 'presented at #esmo22 and published', 'at #esmo22 and published in', '#esmo22 and published in #nejm', 'and published in #nejm $regn', 'published in #nejm $regn .', '#regeneron reported negative #neoadjuvant #libtayo cemiplimab', 'reported negative #neoadjuvant #libtayo cemiplimab #monotherapy', 'negative #neoadjuvant #libtayo cemiplimab #monotherapy data', '#neoadjuvant #libtayo cemiplimab #monotherapy data in', '#libtayo cemiplimab #monotherapy data in resectable', 'cemiplimab #monotherapy data in resectable #cutaneous', '#monotherapy data in resectable #cutaneous #squamouscellcarcinoma', 'data in resectable #cutaneous #squamouscellcarcinoma presented', 'in resectable #cutaneous #squamouscellcarcinoma presented at', 'resectable #cutaneous #squamouscellcarcinoma presented at #esmo22', '#cutaneous #squamouscellcarcinoma presented at #esmo22 and', '#squamouscellcarcinoma presented at #esmo22 and published', 'presented at #esmo22 and published in', 'at #esmo22 and published in #nejm', '#esmo22 and published in #nejm $regn', 'and published in #nejm $regn .', '#regeneron reported negative #neoadjuvant #libtayo cemiplimab #monotherapy', 'reported negative #neoadjuvant #libtayo cemiplimab #monotherapy data', 'negative #neoadjuvant #libtayo cemiplimab #monotherapy data in', '#neoadjuvant #libtayo cemiplimab #monotherapy data in resectable', '#libtayo cemiplimab #monotherapy data in resectable #cutaneous', 'cemiplimab #monotherapy data in resectable #cutaneous #squamouscellcarcinoma', '#monotherapy data in resectable #cutaneous #squamouscellcarcinoma presented', 'data in resectable #cutaneous #squamouscellcarcinoma presented at', 'in resectable #cutaneous #squamouscellcarcinoma presented at #esmo22', 'resectable #cutaneous #squamouscellcarcinoma presented at #esmo22 and', '#cutaneous #squamouscellcarcinoma presented at #esmo22 and published', '#squamouscellcarcinoma presented at #esmo22 and published in', 'presented at #esmo22 and published in #nejm', 'at #esmo22 and published in #nejm $regn', '#esmo22 and published in #nejm $regn .', '#regeneron reported negative #neoadjuvant #libtayo cemiplimab #monotherapy data', 'reported negative #neoadjuvant #libtayo cemiplimab #monotherapy data in', 'negative #neoadjuvant #libtayo cemiplimab #monotherapy data in resectable', '#neoadjuvant #libtayo cemiplimab #monotherapy data in resectable #cutaneous', '#libtayo cemiplimab #monotherapy data in resectable #cutaneous #squamouscellcarcinoma', 'cemiplimab #monotherapy data in resectable #cutaneous #squamouscellcarcinoma presented', '#monotherapy data in resectable #cutaneous #squamouscellcarcinoma presented at', 'data in resectable #cutaneous #squamouscellcarcinoma presented at #esmo22', 'in resectable #cutaneous #squamouscellcarcinoma presented at #esmo22 and', 'resectable #cutaneous #squamouscellcarcinoma presented at #esmo22 and published', '#cutaneous #squamouscellcarcinoma presented at #esmo22 and published in', '#squamouscellcarcinoma presented at #esmo22 and published in #nejm', 'presented at #esmo22 and published in #nejm $regn', 'at #esmo22 and published in #nejm $regn .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '53', 'tokens': ['in', 'a', 'late-stage', 'phase', 'iii', 'keynote-412', 'trial', 'for', 'unresected', 'locally', 'advanced', 'head', 'and', 'neck', 'squamous', 'cell', 'carcinoma,', "Merck's", 'pd-1', 'inhibitor', 'pembrolizumab', 'failed', 'to', 'meet', 'its', 'primary', 'endpoint.', 'get', 'more', 'detailed', 'insights:', '#esmo2022', '#esmo', '#esmo22', '.'], 'text_length': 35, 'triples': {'pembrolizumab|failed to meet its primary': ([20, 20], [21, 25], 'negative'), 'keynote-412|failed to meet its primary': ([5, 5], [21, 25], 'negative')}, 'sentence': "in a late-stage phase iii keynote-412 trial for unresected locally advanced head and neck squamous cell carcinoma, Merck's pd-1 inhibitor pembrolizumab failed to meet its primary endpoint. get more detailed insights: #esmo2022 #esmo #esmo22 .", 'aspect_num': 2, 'spans_aspect2opinion_label': [(20, 20), (5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(21, 25)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['in', 'a', 'late-stage', 'phase', 'iii', 'keynote-412', 'trial', 'for', 'unresected', 'locally', 'advanced', 'head', 'and', 'neck', 'squamous', 'cell', 'carcinoma,', "Merck's", 'pd-1', 'inhibitor', 'pembrolizumab', 'failed', 'to', 'meet', 'its', 'primary', 'endpoint.', 'get', 'more', 'detailed', 'insights:', '#esmo2022', '#esmo', '#esmo22', '.', 'in a', 'a late-stage', 'late-stage phase', 'phase iii', 'iii keynote-412', 'keynote-412 trial', 'trial for', 'for unresected', 'unresected locally', 'locally advanced', 'advanced head', 'head and', 'and neck', 'neck squamous', 'squamous cell', 'cell carcinoma,', "carcinoma, Merck's", "Merck's pd-1", 'pd-1 inhibitor', 'inhibitor pembrolizumab', 'pembrolizumab failed', 'failed to', 'to meet', 'meet its', 'its primary', 'primary endpoint.', 'endpoint. get', 'get more', 'more detailed', 'detailed insights:', 'insights: #esmo2022', '#esmo2022 #esmo', '#esmo #esmo22', '#esmo22 .', 'in a late-stage', 'a late-stage phase', 'late-stage phase iii', 'phase iii keynote-412', 'iii keynote-412 trial', 'keynote-412 trial for', 'trial for unresected', 'for unresected locally', 'unresected locally advanced', 'locally advanced head', 'advanced head and', 'head and neck', 'and neck squamous', 'neck squamous cell', 'squamous cell carcinoma,', "cell carcinoma, Merck's", "carcinoma, Merck's pd-1", "Merck's pd-1 inhibitor", 'pd-1 inhibitor pembrolizumab', 'inhibitor pembrolizumab failed', 'pembrolizumab failed to', 'failed to meet', 'to meet its', 'meet its primary', 'its primary endpoint.', 'primary endpoint. get', 'endpoint. get more', 'get more detailed', 'more detailed insights:', 'detailed insights: #esmo2022', 'insights: #esmo2022 #esmo', '#esmo2022 #esmo #esmo22', '#esmo #esmo22 .', 'in a late-stage phase', 'a late-stage phase iii', 'late-stage phase iii keynote-412', 'phase iii keynote-412 trial', 'iii keynote-412 trial for', 'keynote-412 trial for unresected', 'trial for unresected locally', 'for unresected locally advanced', 'unresected locally advanced head', 'locally advanced head and', 'advanced head and neck', 'head and neck squamous', 'and neck squamous cell', 'neck squamous cell carcinoma,', "squamous cell carcinoma, Merck's", "cell carcinoma, Merck's pd-1", "carcinoma, Merck's pd-1 inhibitor", "Merck's pd-1 inhibitor pembrolizumab", 'pd-1 inhibitor pembrolizumab failed', 'inhibitor pembrolizumab failed to', 'pembrolizumab failed to meet', 'failed to meet its', 'to meet its primary', 'meet its primary endpoint.', 'its primary endpoint. get', 'primary endpoint. get more', 'endpoint. get more detailed', 'get more detailed insights:', 'more detailed insights: #esmo2022', 'detailed insights: #esmo2022 #esmo', 'insights: #esmo2022 #esmo #esmo22', '#esmo2022 #esmo #esmo22 .', 'in a late-stage phase iii', 'a late-stage phase iii keynote-412', 'late-stage phase iii keynote-412 trial', 'phase iii keynote-412 trial for', 'iii keynote-412 trial for unresected', 'keynote-412 trial for unresected locally', 'trial for unresected locally advanced', 'for unresected locally advanced head', 'unresected locally advanced head and', 'locally advanced head and neck', 'advanced head and neck squamous', 'head and neck squamous cell', 'and neck squamous cell carcinoma,', "neck squamous cell carcinoma, Merck's", "squamous cell carcinoma, Merck's pd-1", "cell carcinoma, Merck's pd-1 inhibitor", "carcinoma, Merck's pd-1 inhibitor pembrolizumab", "Merck's pd-1 inhibitor pembrolizumab failed", 'pd-1 inhibitor pembrolizumab failed to', 'inhibitor pembrolizumab failed to meet', 'pembrolizumab failed to meet its', 'failed to meet its primary', 'to meet its primary endpoint.', 'meet its primary endpoint. get', 'its primary endpoint. get more', 'primary endpoint. get more detailed', 'endpoint. get more detailed insights:', 'get more detailed insights: #esmo2022', 'more detailed insights: #esmo2022 #esmo', 'detailed insights: #esmo2022 #esmo #esmo22', 'insights: #esmo2022 #esmo #esmo22 .', 'in a late-stage phase iii keynote-412', 'a late-stage phase iii keynote-412 trial', 'late-stage phase iii keynote-412 trial for', 'phase iii keynote-412 trial for unresected', 'iii keynote-412 trial for unresected locally', 'keynote-412 trial for unresected locally advanced', 'trial for unresected locally advanced head', 'for unresected locally advanced head and', 'unresected locally advanced head and neck', 'locally advanced head and neck squamous', 'advanced head and neck squamous cell', 'head and neck squamous cell carcinoma,', "and neck squamous cell carcinoma, Merck's", "neck squamous cell carcinoma, Merck's pd-1", "squamous cell carcinoma, Merck's pd-1 inhibitor", "cell carcinoma, Merck's pd-1 inhibitor pembrolizumab", "carcinoma, Merck's pd-1 inhibitor pembrolizumab failed", "Merck's pd-1 inhibitor pembrolizumab failed to", 'pd-1 inhibitor pembrolizumab failed to meet', 'inhibitor pembrolizumab failed to meet its', 'pembrolizumab failed to meet its primary', 'failed to meet its primary endpoint.', 'to meet its primary endpoint. get', 'meet its primary endpoint. get more', 'its primary endpoint. get more detailed', 'primary endpoint. get more detailed insights:', 'endpoint. get more detailed insights: #esmo2022', 'get more detailed insights: #esmo2022 #esmo', 'more detailed insights: #esmo2022 #esmo #esmo22', 'detailed insights: #esmo2022 #esmo #esmo22 .', 'in a late-stage phase iii keynote-412 trial', 'a late-stage phase iii keynote-412 trial for', 'late-stage phase iii keynote-412 trial for unresected', 'phase iii keynote-412 trial for unresected locally', 'iii keynote-412 trial for unresected locally advanced', 'keynote-412 trial for unresected locally advanced head', 'trial for unresected locally advanced head and', 'for unresected locally advanced head and neck', 'unresected locally advanced head and neck squamous', 'locally advanced head and neck squamous cell', 'advanced head and neck squamous cell carcinoma,', "head and neck squamous cell carcinoma, Merck's", "and neck squamous cell carcinoma, Merck's pd-1", "neck squamous cell carcinoma, Merck's pd-1 inhibitor", "squamous cell carcinoma, Merck's pd-1 inhibitor pembrolizumab", "cell carcinoma, Merck's pd-1 inhibitor pembrolizumab failed", "carcinoma, Merck's pd-1 inhibitor pembrolizumab failed to", "Merck's pd-1 inhibitor pembrolizumab failed to meet", 'pd-1 inhibitor pembrolizumab failed to meet its', 'inhibitor pembrolizumab failed to meet its primary', 'pembrolizumab failed to meet its primary endpoint.', 'failed to meet its primary endpoint. get', 'to meet its primary endpoint. get more', 'meet its primary endpoint. get more detailed', 'its primary endpoint. get more detailed insights:', 'primary endpoint. get more detailed insights: #esmo2022', 'endpoint. get more detailed insights: #esmo2022 #esmo', 'get more detailed insights: #esmo2022 #esmo #esmo22', 'more detailed insights: #esmo2022 #esmo #esmo22 .', 'in a late-stage phase iii keynote-412 trial for', 'a late-stage phase iii keynote-412 trial for unresected', 'late-stage phase iii keynote-412 trial for unresected locally', 'phase iii keynote-412 trial for unresected locally advanced', 'iii keynote-412 trial for unresected locally advanced head', 'keynote-412 trial for unresected locally advanced head and', 'trial for unresected locally advanced head and neck', 'for unresected locally advanced head and neck squamous', 'unresected locally advanced head and neck squamous cell', 'locally advanced head and neck squamous cell carcinoma,', "advanced head and neck squamous cell carcinoma, Merck's", "head and neck squamous cell carcinoma, Merck's pd-1", "and neck squamous cell carcinoma, Merck's pd-1 inhibitor", "neck squamous cell carcinoma, Merck's pd-1 inhibitor pembrolizumab", "squamous cell carcinoma, Merck's pd-1 inhibitor pembrolizumab failed", "cell carcinoma, Merck's pd-1 inhibitor pembrolizumab failed to", "carcinoma, Merck's pd-1 inhibitor pembrolizumab failed to meet", "Merck's pd-1 inhibitor pembrolizumab failed to meet its", 'pd-1 inhibitor pembrolizumab failed to meet its primary', 'inhibitor pembrolizumab failed to meet its primary endpoint.', 'pembrolizumab failed to meet its primary endpoint. get', 'failed to meet its primary endpoint. get more', 'to meet its primary endpoint. get more detailed', 'meet its primary endpoint. get more detailed insights:', 'its primary endpoint. get more detailed insights: #esmo2022', 'primary endpoint. get more detailed insights: #esmo2022 #esmo', 'endpoint. get more detailed insights: #esmo2022 #esmo #esmo22', 'get more detailed insights: #esmo2022 #esmo #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '54', 'tokens': ['disappointing', 'results', 'from', 'ARCHIVE', 'trial', 'of', 'adjuvant', 'immunotherapy', 'for', 'patients', 'with', 'rcc', 'who', 'underwent', 'nephrectomy', 'contrast', 'with', 'those', 'from', 'a', 'previous', 'trial', 'that', 'showed', 'benefit', 'with', 'another', 'agent.', '#esmo22', '.'], 'text_length': 30, 'triples': {'ARCHIVE|disappointing results from ARCHIVE trial of adjuvant immunotherapy for patients with rcc who underwent nephrectomy contrast with those from a previous trial that showed': ([3, 3], [0, 23], 'negative')}, 'sentence': 'disappointing results from ARCHIVE trial of adjuvant immunotherapy for patients with rcc who underwent nephrectomy contrast with those from a previous trial that showed benefit with another agent. #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 23)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8)], 'span tokens': ['disappointing', 'results', 'from', 'ARCHIVE', 'trial', 'of', 'adjuvant', 'immunotherapy', 'for', 'patients', 'with', 'rcc', 'who', 'underwent', 'nephrectomy', 'contrast', 'with', 'those', 'from', 'a', 'previous', 'trial', 'that', 'showed', 'benefit', 'with', 'another', 'agent.', '#esmo22', '.', 'disappointing results', 'results from', 'from ARCHIVE', 'ARCHIVE trial', 'trial of', 'of adjuvant', 'adjuvant immunotherapy', 'immunotherapy for', 'for patients', 'patients with', 'with rcc', 'rcc who', 'who underwent', 'underwent nephrectomy', 'nephrectomy contrast', 'contrast with', 'with those', 'those from', 'from a', 'a previous', 'previous trial', 'trial that', 'that showed', 'showed benefit', 'benefit with', 'with another', 'another agent.', 'agent. #esmo22', '#esmo22 .', 'disappointing results from', 'results from ARCHIVE', 'from ARCHIVE trial', 'ARCHIVE trial of', 'trial of adjuvant', 'of adjuvant immunotherapy', 'adjuvant immunotherapy for', 'immunotherapy for patients', 'for patients with', 'patients with rcc', 'with rcc who', 'rcc who underwent', 'who underwent nephrectomy', 'underwent nephrectomy contrast', 'nephrectomy contrast with', 'contrast with those', 'with those from', 'those from a', 'from a previous', 'a previous trial', 'previous trial that', 'trial that showed', 'that showed benefit', 'showed benefit with', 'benefit with another', 'with another agent.', 'another agent. #esmo22', 'agent. #esmo22 .', 'disappointing results from ARCHIVE', 'results from ARCHIVE trial', 'from ARCHIVE trial of', 'ARCHIVE trial of adjuvant', 'trial of adjuvant immunotherapy', 'of adjuvant immunotherapy for', 'adjuvant immunotherapy for patients', 'immunotherapy for patients with', 'for patients with rcc', 'patients with rcc who', 'with rcc who underwent', 'rcc who underwent nephrectomy', 'who underwent nephrectomy contrast', 'underwent nephrectomy contrast with', 'nephrectomy contrast with those', 'contrast with those from', 'with those from a', 'those from a previous', 'from a previous trial', 'a previous trial that', 'previous trial that showed', 'trial that showed benefit', 'that showed benefit with', 'showed benefit with another', 'benefit with another agent.', 'with another agent. #esmo22', 'another agent. #esmo22 .', 'disappointing results from ARCHIVE trial', 'results from ARCHIVE trial of', 'from ARCHIVE trial of adjuvant', 'ARCHIVE trial of adjuvant immunotherapy', 'trial of adjuvant immunotherapy for', 'of adjuvant immunotherapy for patients', 'adjuvant immunotherapy for patients with', 'immunotherapy for patients with rcc', 'for patients with rcc who', 'patients with rcc who underwent', 'with rcc who underwent nephrectomy', 'rcc who underwent nephrectomy contrast', 'who underwent nephrectomy contrast with', 'underwent nephrectomy contrast with those', 'nephrectomy contrast with those from', 'contrast with those from a', 'with those from a previous', 'those from a previous trial', 'from a previous trial that', 'a previous trial that showed', 'previous trial that showed benefit', 'trial that showed benefit with', 'that showed benefit with another', 'showed benefit with another agent.', 'benefit with another agent. #esmo22', 'with another agent. #esmo22 .', 'disappointing results from ARCHIVE trial of', 'results from ARCHIVE trial of adjuvant', 'from ARCHIVE trial of adjuvant immunotherapy', 'ARCHIVE trial of adjuvant immunotherapy for', 'trial of adjuvant immunotherapy for patients', 'of adjuvant immunotherapy for patients with', 'adjuvant immunotherapy for patients with rcc', 'immunotherapy for patients with rcc who', 'for patients with rcc who underwent', 'patients with rcc who underwent nephrectomy', 'with rcc who underwent nephrectomy contrast', 'rcc who underwent nephrectomy contrast with', 'who underwent nephrectomy contrast with those', 'underwent nephrectomy contrast with those from', 'nephrectomy contrast with those from a', 'contrast with those from a previous', 'with those from a previous trial', 'those from a previous trial that', 'from a previous trial that showed', 'a previous trial that showed benefit', 'previous trial that showed benefit with', 'trial that showed benefit with another', 'that showed benefit with another agent.', 'showed benefit with another agent. #esmo22', 'benefit with another agent. #esmo22 .', 'disappointing results from ARCHIVE trial of adjuvant', 'results from ARCHIVE trial of adjuvant immunotherapy', 'from ARCHIVE trial of adjuvant immunotherapy for', 'ARCHIVE trial of adjuvant immunotherapy for patients', 'trial of adjuvant immunotherapy for patients with', 'of adjuvant immunotherapy for patients with rcc', 'adjuvant immunotherapy for patients with rcc who', 'immunotherapy for patients with rcc who underwent', 'for patients with rcc who underwent nephrectomy', 'patients with rcc who underwent nephrectomy contrast', 'with rcc who underwent nephrectomy contrast with', 'rcc who underwent nephrectomy contrast with those', 'who underwent nephrectomy contrast with those from', 'underwent nephrectomy contrast with those from a', 'nephrectomy contrast with those from a previous', 'contrast with those from a previous trial', 'with those from a previous trial that', 'those from a previous trial that showed', 'from a previous trial that showed benefit', 'a previous trial that showed benefit with', 'previous trial that showed benefit with another', 'trial that showed benefit with another agent.', 'that showed benefit with another agent. #esmo22', 'showed benefit with another agent. #esmo22 .', 'disappointing results from ARCHIVE trial of adjuvant immunotherapy', 'results from ARCHIVE trial of adjuvant immunotherapy for', 'from ARCHIVE trial of adjuvant immunotherapy for patients', 'ARCHIVE trial of adjuvant immunotherapy for patients with', 'trial of adjuvant immunotherapy for patients with rcc', 'of adjuvant immunotherapy for patients with rcc who', 'adjuvant immunotherapy for patients with rcc who underwent', 'immunotherapy for patients with rcc who underwent nephrectomy', 'for patients with rcc who underwent nephrectomy contrast', 'patients with rcc who underwent nephrectomy contrast with', 'with rcc who underwent nephrectomy contrast with those', 'rcc who underwent nephrectomy contrast with those from', 'who underwent nephrectomy contrast with those from a', 'underwent nephrectomy contrast with those from a previous', 'nephrectomy contrast with those from a previous trial', 'contrast with those from a previous trial that', 'with those from a previous trial that showed', 'those from a previous trial that showed benefit', 'from a previous trial that showed benefit with', 'a previous trial that showed benefit with another', 'previous trial that showed benefit with another agent.', 'trial that showed benefit with another agent. #esmo22', 'that showed benefit with another agent. #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '55', 'tokens': ['dissapointing', 'preliminary', 'data', 'from', '1st-in-human', 'trial', 'of', 'zw49', '(anti-her2', 'bispecific', 'adc)', 'monotherapy,', 'show', 'antitumor', 'activity', '@', '2.5mg/kg', 'q3w', 'in', 'heavily', 'pretreated', 'pts', 'with', 'her2+', 'cancers', '(corr', '31%)', 'with', 'manageable', 'toxicity', '(no', 'interstitial', 'lung', 'disease).', '#esmo22', '.'], 'text_length': 36, 'triples': {'zw49|dissapointing': ([7, 7], [0, 0], 'negative')}, 'sentence': 'dissapointing preliminary data from 1st-in-human trial of zw49 (anti-her2 bispecific adc) monotherapy, show antitumor activity @ 2.5mg/kg q3w in heavily pretreated pts with her2+ cancers (corr 31%) with manageable toxicity (no interstitial lung disease). #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['dissapointing', 'preliminary', 'data', 'from', '1st-in-human', 'trial', 'of', 'zw49', '(anti-her2', 'bispecific', 'adc)', 'monotherapy,', 'show', 'antitumor', 'activity', '@', '2.5mg/kg', 'q3w', 'in', 'heavily', 'pretreated', 'pts', 'with', 'her2+', 'cancers', '(corr', '31%)', 'with', 'manageable', 'toxicity', '(no', 'interstitial', 'lung', 'disease).', '#esmo22', '.', 'dissapointing preliminary', 'preliminary data', 'data from', 'from 1st-in-human', '1st-in-human trial', 'trial of', 'of zw49', 'zw49 (anti-her2', '(anti-her2 bispecific', 'bispecific adc)', 'adc) monotherapy,', 'monotherapy, show', 'show antitumor', 'antitumor activity', 'activity @', '@ 2.5mg/kg', '2.5mg/kg q3w', 'q3w in', 'in heavily', 'heavily pretreated', 'pretreated pts', 'pts with', 'with her2+', 'her2+ cancers', 'cancers (corr', '(corr 31%)', '31%) with', 'with manageable', 'manageable toxicity', 'toxicity (no', '(no interstitial', 'interstitial lung', 'lung disease).', 'disease). #esmo22', '#esmo22 .', 'dissapointing preliminary data', 'preliminary data from', 'data from 1st-in-human', 'from 1st-in-human trial', '1st-in-human trial of', 'trial of zw49', 'of zw49 (anti-her2', 'zw49 (anti-her2 bispecific', '(anti-her2 bispecific adc)', 'bispecific adc) monotherapy,', 'adc) monotherapy, show', 'monotherapy, show antitumor', 'show antitumor activity', 'antitumor activity @', 'activity @ 2.5mg/kg', '@ 2.5mg/kg q3w', '2.5mg/kg q3w in', 'q3w in heavily', 'in heavily pretreated', 'heavily pretreated pts', 'pretreated pts with', 'pts with her2+', 'with her2+ cancers', 'her2+ cancers (corr', 'cancers (corr 31%)', '(corr 31%) with', '31%) with manageable', 'with manageable toxicity', 'manageable toxicity (no', 'toxicity (no interstitial', '(no interstitial lung', 'interstitial lung disease).', 'lung disease). #esmo22', 'disease). #esmo22 .', 'dissapointing preliminary data from', 'preliminary data from 1st-in-human', 'data from 1st-in-human trial', 'from 1st-in-human trial of', '1st-in-human trial of zw49', 'trial of zw49 (anti-her2', 'of zw49 (anti-her2 bispecific', 'zw49 (anti-her2 bispecific adc)', '(anti-her2 bispecific adc) monotherapy,', 'bispecific adc) monotherapy, show', 'adc) monotherapy, show antitumor', 'monotherapy, show antitumor activity', 'show antitumor activity @', 'antitumor activity @ 2.5mg/kg', 'activity @ 2.5mg/kg q3w', '@ 2.5mg/kg q3w in', '2.5mg/kg q3w in heavily', 'q3w in heavily pretreated', 'in heavily pretreated pts', 'heavily pretreated pts with', 'pretreated pts with her2+', 'pts with her2+ cancers', 'with her2+ cancers (corr', 'her2+ cancers (corr 31%)', 'cancers (corr 31%) with', '(corr 31%) with manageable', '31%) with manageable toxicity', 'with manageable toxicity (no', 'manageable toxicity (no interstitial', 'toxicity (no interstitial lung', '(no interstitial lung disease).', 'interstitial lung disease). #esmo22', 'lung disease). #esmo22 .', 'dissapointing preliminary data from 1st-in-human', 'preliminary data from 1st-in-human trial', 'data from 1st-in-human trial of', 'from 1st-in-human trial of zw49', '1st-in-human trial of zw49 (anti-her2', 'trial of zw49 (anti-her2 bispecific', 'of zw49 (anti-her2 bispecific adc)', 'zw49 (anti-her2 bispecific adc) monotherapy,', '(anti-her2 bispecific adc) monotherapy, show', 'bispecific adc) monotherapy, show antitumor', 'adc) monotherapy, show antitumor activity', 'monotherapy, show antitumor activity @', 'show antitumor activity @ 2.5mg/kg', 'antitumor activity @ 2.5mg/kg q3w', 'activity @ 2.5mg/kg q3w in', '@ 2.5mg/kg q3w in heavily', '2.5mg/kg q3w in heavily pretreated', 'q3w in heavily pretreated pts', 'in heavily pretreated pts with', 'heavily pretreated pts with her2+', 'pretreated pts with her2+ cancers', 'pts with her2+ cancers (corr', 'with her2+ cancers (corr 31%)', 'her2+ cancers (corr 31%) with', 'cancers (corr 31%) with manageable', '(corr 31%) with manageable toxicity', '31%) with manageable toxicity (no', 'with manageable toxicity (no interstitial', 'manageable toxicity (no interstitial lung', 'toxicity (no interstitial lung disease).', '(no interstitial lung disease). #esmo22', 'interstitial lung disease). #esmo22 .', 'dissapointing preliminary data from 1st-in-human trial', 'preliminary data from 1st-in-human trial of', 'data from 1st-in-human trial of zw49', 'from 1st-in-human trial of zw49 (anti-her2', '1st-in-human trial of zw49 (anti-her2 bispecific', 'trial of zw49 (anti-her2 bispecific adc)', 'of zw49 (anti-her2 bispecific adc) monotherapy,', 'zw49 (anti-her2 bispecific adc) monotherapy, show', '(anti-her2 bispecific adc) monotherapy, show antitumor', 'bispecific adc) monotherapy, show antitumor activity', 'adc) monotherapy, show antitumor activity @', 'monotherapy, show antitumor activity @ 2.5mg/kg', 'show antitumor activity @ 2.5mg/kg q3w', 'antitumor activity @ 2.5mg/kg q3w in', 'activity @ 2.5mg/kg q3w in heavily', '@ 2.5mg/kg q3w in heavily pretreated', '2.5mg/kg q3w in heavily pretreated pts', 'q3w in heavily pretreated pts with', 'in heavily pretreated pts with her2+', 'heavily pretreated pts with her2+ cancers', 'pretreated pts with her2+ cancers (corr', 'pts with her2+ cancers (corr 31%)', 'with her2+ cancers (corr 31%) with', 'her2+ cancers (corr 31%) with manageable', 'cancers (corr 31%) with manageable toxicity', '(corr 31%) with manageable toxicity (no', '31%) with manageable toxicity (no interstitial', 'with manageable toxicity (no interstitial lung', 'manageable toxicity (no interstitial lung disease).', 'toxicity (no interstitial lung disease). #esmo22', '(no interstitial lung disease). #esmo22 .', 'dissapointing preliminary data from 1st-in-human trial of', 'preliminary data from 1st-in-human trial of zw49', 'data from 1st-in-human trial of zw49 (anti-her2', 'from 1st-in-human trial of zw49 (anti-her2 bispecific', '1st-in-human trial of zw49 (anti-her2 bispecific adc)', 'trial of zw49 (anti-her2 bispecific adc) monotherapy,', 'of zw49 (anti-her2 bispecific adc) monotherapy, show', 'zw49 (anti-her2 bispecific adc) monotherapy, show antitumor', '(anti-her2 bispecific adc) monotherapy, show antitumor activity', 'bispecific adc) monotherapy, show antitumor activity @', 'adc) monotherapy, show antitumor activity @ 2.5mg/kg', 'monotherapy, show antitumor activity @ 2.5mg/kg q3w', 'show antitumor activity @ 2.5mg/kg q3w in', 'antitumor activity @ 2.5mg/kg q3w in heavily', 'activity @ 2.5mg/kg q3w in heavily pretreated', '@ 2.5mg/kg q3w in heavily pretreated pts', '2.5mg/kg q3w in heavily pretreated pts with', 'q3w in heavily pretreated pts with her2+', 'in heavily pretreated pts with her2+ cancers', 'heavily pretreated pts with her2+ cancers (corr', 'pretreated pts with her2+ cancers (corr 31%)', 'pts with her2+ cancers (corr 31%) with', 'with her2+ cancers (corr 31%) with manageable', 'her2+ cancers (corr 31%) with manageable toxicity', 'cancers (corr 31%) with manageable toxicity (no', '(corr 31%) with manageable toxicity (no interstitial', '31%) with manageable toxicity (no interstitial lung', 'with manageable toxicity (no interstitial lung disease).', 'manageable toxicity (no interstitial lung disease). #esmo22', 'toxicity (no interstitial lung disease). #esmo22 .', 'dissapointing preliminary data from 1st-in-human trial of zw49', 'preliminary data from 1st-in-human trial of zw49 (anti-her2', 'data from 1st-in-human trial of zw49 (anti-her2 bispecific', 'from 1st-in-human trial of zw49 (anti-her2 bispecific adc)', '1st-in-human trial of zw49 (anti-her2 bispecific adc) monotherapy,', 'trial of zw49 (anti-her2 bispecific adc) monotherapy, show', 'of zw49 (anti-her2 bispecific adc) monotherapy, show antitumor', 'zw49 (anti-her2 bispecific adc) monotherapy, show antitumor activity', '(anti-her2 bispecific adc) monotherapy, show antitumor activity @', 'bispecific adc) monotherapy, show antitumor activity @ 2.5mg/kg', 'adc) monotherapy, show antitumor activity @ 2.5mg/kg q3w', 'monotherapy, show antitumor activity @ 2.5mg/kg q3w in', 'show antitumor activity @ 2.5mg/kg q3w in heavily', 'antitumor activity @ 2.5mg/kg q3w in heavily pretreated', 'activity @ 2.5mg/kg q3w in heavily pretreated pts', '@ 2.5mg/kg q3w in heavily pretreated pts with', '2.5mg/kg q3w in heavily pretreated pts with her2+', 'q3w in heavily pretreated pts with her2+ cancers', 'in heavily pretreated pts with her2+ cancers (corr', 'heavily pretreated pts with her2+ cancers (corr 31%)', 'pretreated pts with her2+ cancers (corr 31%) with', 'pts with her2+ cancers (corr 31%) with manageable', 'with her2+ cancers (corr 31%) with manageable toxicity', 'her2+ cancers (corr 31%) with manageable toxicity (no', 'cancers (corr 31%) with manageable toxicity (no interstitial', '(corr 31%) with manageable toxicity (no interstitial lung', '31%) with manageable toxicity (no interstitial lung disease).', 'with manageable toxicity (no interstitial lung disease). #esmo22', 'manageable toxicity (no interstitial lung disease). #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '56', 'tokens': ['immotion010', 'phase', '3', 'trial', 'results', 'showed', 'that', 'adjuvant', 'treatment', 'with', 'atezolizumab', 'does', 'not', 'improve', 'the', 'outcomes', 'of', 'individuals', 'with', 'renal', 'cell', 'carcinoma', '(rcc)', 'at', 'increased', 'risk', 'for', 'recurrence', 'after', 'nephrectomy.', '#drugdevelopment', '#oncology', '#esmo2022.', ''], 'text_length': 34, 'triples': {'immotion010|not improve': ([0, 0], [12, 13], 'negative'), 'atezolizumab|not improve': ([10, 10], [12, 13], 'negative')}, 'sentence': 'immotion010 phase 3 trial results showed that adjuvant treatment with atezolizumab does not improve the outcomes of individuals with renal cell carcinoma (rcc) at increased risk for recurrence after nephrectomy. #drugdevelopment #oncology #esmo2022. ', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(12, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['immotion010', 'phase', '3', 'trial', 'results', 'showed', 'that', 'adjuvant', 'treatment', 'with', 'atezolizumab', 'does', 'not', 'improve', 'the', 'outcomes', 'of', 'individuals', 'with', 'renal', 'cell', 'carcinoma', '(rcc)', 'at', 'increased', 'risk', 'for', 'recurrence', 'after', 'nephrectomy.', '#drugdevelopment', '#oncology', '#esmo2022.', '', 'immotion010 phase', 'phase 3', '3 trial', 'trial results', 'results showed', 'showed that', 'that adjuvant', 'adjuvant treatment', 'treatment with', 'with atezolizumab', 'atezolizumab does', 'does not', 'not improve', 'improve the', 'the outcomes', 'outcomes of', 'of individuals', 'individuals with', 'with renal', 'renal cell', 'cell carcinoma', 'carcinoma (rcc)', '(rcc) at', 'at increased', 'increased risk', 'risk for', 'for recurrence', 'recurrence after', 'after nephrectomy.', 'nephrectomy. #drugdevelopment', '#drugdevelopment #oncology', '#oncology #esmo2022.', '#esmo2022. ', 'immotion010 phase 3', 'phase 3 trial', '3 trial results', 'trial results showed', 'results showed that', 'showed that adjuvant', 'that adjuvant treatment', 'adjuvant treatment with', 'treatment with atezolizumab', 'with atezolizumab does', 'atezolizumab does not', 'does not improve', 'not improve the', 'improve the outcomes', 'the outcomes of', 'outcomes of individuals', 'of individuals with', 'individuals with renal', 'with renal cell', 'renal cell carcinoma', 'cell carcinoma (rcc)', 'carcinoma (rcc) at', '(rcc) at increased', 'at increased risk', 'increased risk for', 'risk for recurrence', 'for recurrence after', 'recurrence after nephrectomy.', 'after nephrectomy. #drugdevelopment', 'nephrectomy. #drugdevelopment #oncology', '#drugdevelopment #oncology #esmo2022.', '#oncology #esmo2022. ', 'immotion010 phase 3 trial', 'phase 3 trial results', '3 trial results showed', 'trial results showed that', 'results showed that adjuvant', 'showed that adjuvant treatment', 'that adjuvant treatment with', 'adjuvant treatment with atezolizumab', 'treatment with atezolizumab does', 'with atezolizumab does not', 'atezolizumab does not improve', 'does not improve the', 'not improve the outcomes', 'improve the outcomes of', 'the outcomes of individuals', 'outcomes of individuals with', 'of individuals with renal', 'individuals with renal cell', 'with renal cell carcinoma', 'renal cell carcinoma (rcc)', 'cell carcinoma (rcc) at', 'carcinoma (rcc) at increased', '(rcc) at increased risk', 'at increased risk for', 'increased risk for recurrence', 'risk for recurrence after', 'for recurrence after nephrectomy.', 'recurrence after nephrectomy. #drugdevelopment', 'after nephrectomy. #drugdevelopment #oncology', 'nephrectomy. #drugdevelopment #oncology #esmo2022.', '#drugdevelopment #oncology #esmo2022. ', 'immotion010 phase 3 trial results', 'phase 3 trial results showed', '3 trial results showed that', 'trial results showed that adjuvant', 'results showed that adjuvant treatment', 'showed that adjuvant treatment with', 'that adjuvant treatment with atezolizumab', 'adjuvant treatment with atezolizumab does', 'treatment with atezolizumab does not', 'with atezolizumab does not improve', 'atezolizumab does not improve the', 'does not improve the outcomes', 'not improve the outcomes of', 'improve the outcomes of individuals', 'the outcomes of individuals with', 'outcomes of individuals with renal', 'of individuals with renal cell', 'individuals with renal cell carcinoma', 'with renal cell carcinoma (rcc)', 'renal cell carcinoma (rcc) at', 'cell carcinoma (rcc) at increased', 'carcinoma (rcc) at increased risk', '(rcc) at increased risk for', 'at increased risk for recurrence', 'increased risk for recurrence after', 'risk for recurrence after nephrectomy.', 'for recurrence after nephrectomy. #drugdevelopment', 'recurrence after nephrectomy. #drugdevelopment #oncology', 'after nephrectomy. #drugdevelopment #oncology #esmo2022.', 'nephrectomy. #drugdevelopment #oncology #esmo2022. ', 'immotion010 phase 3 trial results showed', 'phase 3 trial results showed that', '3 trial results showed that adjuvant', 'trial results showed that adjuvant treatment', 'results showed that adjuvant treatment with', 'showed that adjuvant treatment with atezolizumab', 'that adjuvant treatment with atezolizumab does', 'adjuvant treatment with atezolizumab does not', 'treatment with atezolizumab does not improve', 'with atezolizumab does not improve the', 'atezolizumab does not improve the outcomes', 'does not improve the outcomes of', 'not improve the outcomes of individuals', 'improve the outcomes of individuals with', 'the outcomes of individuals with renal', 'outcomes of individuals with renal cell', 'of individuals with renal cell carcinoma', 'individuals with renal cell carcinoma (rcc)', 'with renal cell carcinoma (rcc) at', 'renal cell carcinoma (rcc) at increased', 'cell carcinoma (rcc) at increased risk', 'carcinoma (rcc) at increased risk for', '(rcc) at increased risk for recurrence', 'at increased risk for recurrence after', 'increased risk for recurrence after nephrectomy.', 'risk for recurrence after nephrectomy. #drugdevelopment', 'for recurrence after nephrectomy. #drugdevelopment #oncology', 'recurrence after nephrectomy. #drugdevelopment #oncology #esmo2022.', 'after nephrectomy. #drugdevelopment #oncology #esmo2022. ', 'immotion010 phase 3 trial results showed that', 'phase 3 trial results showed that adjuvant', '3 trial results showed that adjuvant treatment', 'trial results showed that adjuvant treatment with', 'results showed that adjuvant treatment with atezolizumab', 'showed that adjuvant treatment with atezolizumab does', 'that adjuvant treatment with atezolizumab does not', 'adjuvant treatment with atezolizumab does not improve', 'treatment with atezolizumab does not improve the', 'with atezolizumab does not improve the outcomes', 'atezolizumab does not improve the outcomes of', 'does not improve the outcomes of individuals', 'not improve the outcomes of individuals with', 'improve the outcomes of individuals with renal', 'the outcomes of individuals with renal cell', 'outcomes of individuals with renal cell carcinoma', 'of individuals with renal cell carcinoma (rcc)', 'individuals with renal cell carcinoma (rcc) at', 'with renal cell carcinoma (rcc) at increased', 'renal cell carcinoma (rcc) at increased risk', 'cell carcinoma (rcc) at increased risk for', 'carcinoma (rcc) at increased risk for recurrence', '(rcc) at increased risk for recurrence after', 'at increased risk for recurrence after nephrectomy.', 'increased risk for recurrence after nephrectomy. #drugdevelopment', 'risk for recurrence after nephrectomy. #drugdevelopment #oncology', 'for recurrence after nephrectomy. #drugdevelopment #oncology #esmo2022.', 'recurrence after nephrectomy. #drugdevelopment #oncology #esmo2022. ', 'immotion010 phase 3 trial results showed that adjuvant', 'phase 3 trial results showed that adjuvant treatment', '3 trial results showed that adjuvant treatment with', 'trial results showed that adjuvant treatment with atezolizumab', 'results showed that adjuvant treatment with atezolizumab does', 'showed that adjuvant treatment with atezolizumab does not', 'that adjuvant treatment with atezolizumab does not improve', 'adjuvant treatment with atezolizumab does not improve the', 'treatment with atezolizumab does not improve the outcomes', 'with atezolizumab does not improve the outcomes of', 'atezolizumab does not improve the outcomes of individuals', 'does not improve the outcomes of individuals with', 'not improve the outcomes of individuals with renal', 'improve the outcomes of individuals with renal cell', 'the outcomes of individuals with renal cell carcinoma', 'outcomes of individuals with renal cell carcinoma (rcc)', 'of individuals with renal cell carcinoma (rcc) at', 'individuals with renal cell carcinoma (rcc) at increased', 'with renal cell carcinoma (rcc) at increased risk', 'renal cell carcinoma (rcc) at increased risk for', 'cell carcinoma (rcc) at increased risk for recurrence', 'carcinoma (rcc) at increased risk for recurrence after', '(rcc) at increased risk for recurrence after nephrectomy.', 'at increased risk for recurrence after nephrectomy. #drugdevelopment', 'increased risk for recurrence after nephrectomy. #drugdevelopment #oncology', 'risk for recurrence after nephrectomy. #drugdevelopment #oncology #esmo2022.', 'for recurrence after nephrectomy. #drugdevelopment #oncology #esmo2022. '], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '57', 'tokens': ['codebreak200:', 'ph3', 'study', 'comparing', 'sotorasib', 'vs.', 'docetaxel', 'in', 'second', 'line', 'nsclc', 'pfs', '5.6', 'vs', '4.5', 'mon', '(hr', '0.86)', 'although', 'no', 'difference', 'in', 'os', '(not', 'powered).', 'disappointing', 'but', 'not', 'the', 'end', 'of', 'the', 'kras', 'story!', '#esmo2022', '.'], 'text_length': 36, 'triples': {'codebreak200:|no difference in os (not powered). disappointing': ([0, 0], [19, 25], 'negative')}, 'sentence': 'codebreak200: ph3 study comparing sotorasib vs. docetaxel in second line nsclc pfs 5.6 vs 4.5 mon (hr 0.86) although no difference in os (not powered). disappointing but not the end of the kras story! #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(19, 25)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['codebreak200:', 'ph3', 'study', 'comparing', 'sotorasib', 'vs.', 'docetaxel', 'in', 'second', 'line', 'nsclc', 'pfs', '5.6', 'vs', '4.5', 'mon', '(hr', '0.86)', 'although', 'no', 'difference', 'in', 'os', '(not', 'powered).', 'disappointing', 'but', 'not', 'the', 'end', 'of', 'the', 'kras', 'story!', '#esmo2022', '.', 'codebreak200: ph3', 'ph3 study', 'study comparing', 'comparing sotorasib', 'sotorasib vs.', 'vs. docetaxel', 'docetaxel in', 'in second', 'second line', 'line nsclc', 'nsclc pfs', 'pfs 5.6', '5.6 vs', 'vs 4.5', '4.5 mon', 'mon (hr', '(hr 0.86)', '0.86) although', 'although no', 'no difference', 'difference in', 'in os', 'os (not', '(not powered).', 'powered). disappointing', 'disappointing but', 'but not', 'not the', 'the end', 'end of', 'of the', 'the kras', 'kras story!', 'story! #esmo2022', '#esmo2022 .', 'codebreak200: ph3 study', 'ph3 study comparing', 'study comparing sotorasib', 'comparing sotorasib vs.', 'sotorasib vs. docetaxel', 'vs. docetaxel in', 'docetaxel in second', 'in second line', 'second line nsclc', 'line nsclc pfs', 'nsclc pfs 5.6', 'pfs 5.6 vs', '5.6 vs 4.5', 'vs 4.5 mon', '4.5 mon (hr', 'mon (hr 0.86)', '(hr 0.86) although', '0.86) although no', 'although no difference', 'no difference in', 'difference in os', 'in os (not', 'os (not powered).', '(not powered). disappointing', 'powered). disappointing but', 'disappointing but not', 'but not the', 'not the end', 'the end of', 'end of the', 'of the kras', 'the kras story!', 'kras story! #esmo2022', 'story! #esmo2022 .', 'codebreak200: ph3 study comparing', 'ph3 study comparing sotorasib', 'study comparing sotorasib vs.', 'comparing sotorasib vs. docetaxel', 'sotorasib vs. docetaxel in', 'vs. docetaxel in second', 'docetaxel in second line', 'in second line nsclc', 'second line nsclc pfs', 'line nsclc pfs 5.6', 'nsclc pfs 5.6 vs', 'pfs 5.6 vs 4.5', '5.6 vs 4.5 mon', 'vs 4.5 mon (hr', '4.5 mon (hr 0.86)', 'mon (hr 0.86) although', '(hr 0.86) although no', '0.86) although no difference', 'although no difference in', 'no difference in os', 'difference in os (not', 'in os (not powered).', 'os (not powered). disappointing', '(not powered). disappointing but', 'powered). disappointing but not', 'disappointing but not the', 'but not the end', 'not the end of', 'the end of the', 'end of the kras', 'of the kras story!', 'the kras story! #esmo2022', 'kras story! #esmo2022 .', 'codebreak200: ph3 study comparing sotorasib', 'ph3 study comparing sotorasib vs.', 'study comparing sotorasib vs. docetaxel', 'comparing sotorasib vs. docetaxel in', 'sotorasib vs. docetaxel in second', 'vs. docetaxel in second line', 'docetaxel in second line nsclc', 'in second line nsclc pfs', 'second line nsclc pfs 5.6', 'line nsclc pfs 5.6 vs', 'nsclc pfs 5.6 vs 4.5', 'pfs 5.6 vs 4.5 mon', '5.6 vs 4.5 mon (hr', 'vs 4.5 mon (hr 0.86)', '4.5 mon (hr 0.86) although', 'mon (hr 0.86) although no', '(hr 0.86) although no difference', '0.86) although no difference in', 'although no difference in os', 'no difference in os (not', 'difference in os (not powered).', 'in os (not powered). disappointing', 'os (not powered). disappointing but', '(not powered). disappointing but not', 'powered). disappointing but not the', 'disappointing but not the end', 'but not the end of', 'not the end of the', 'the end of the kras', 'end of the kras story!', 'of the kras story! #esmo2022', 'the kras story! #esmo2022 .', 'codebreak200: ph3 study comparing sotorasib vs.', 'ph3 study comparing sotorasib vs. docetaxel', 'study comparing sotorasib vs. docetaxel in', 'comparing sotorasib vs. docetaxel in second', 'sotorasib vs. docetaxel in second line', 'vs. docetaxel in second line nsclc', 'docetaxel in second line nsclc pfs', 'in second line nsclc pfs 5.6', 'second line nsclc pfs 5.6 vs', 'line nsclc pfs 5.6 vs 4.5', 'nsclc pfs 5.6 vs 4.5 mon', 'pfs 5.6 vs 4.5 mon (hr', '5.6 vs 4.5 mon (hr 0.86)', 'vs 4.5 mon (hr 0.86) although', '4.5 mon (hr 0.86) although no', 'mon (hr 0.86) although no difference', '(hr 0.86) although no difference in', '0.86) although no difference in os', 'although no difference in os (not', 'no difference in os (not powered).', 'difference in os (not powered). disappointing', 'in os (not powered). disappointing but', 'os (not powered). disappointing but not', '(not powered). disappointing but not the', 'powered). disappointing but not the end', 'disappointing but not the end of', 'but not the end of the', 'not the end of the kras', 'the end of the kras story!', 'end of the kras story! #esmo2022', 'of the kras story! #esmo2022 .', 'codebreak200: ph3 study comparing sotorasib vs. docetaxel', 'ph3 study comparing sotorasib vs. docetaxel in', 'study comparing sotorasib vs. docetaxel in second', 'comparing sotorasib vs. docetaxel in second line', 'sotorasib vs. docetaxel in second line nsclc', 'vs. docetaxel in second line nsclc pfs', 'docetaxel in second line nsclc pfs 5.6', 'in second line nsclc pfs 5.6 vs', 'second line nsclc pfs 5.6 vs 4.5', 'line nsclc pfs 5.6 vs 4.5 mon', 'nsclc pfs 5.6 vs 4.5 mon (hr', 'pfs 5.6 vs 4.5 mon (hr 0.86)', '5.6 vs 4.5 mon (hr 0.86) although', 'vs 4.5 mon (hr 0.86) although no', '4.5 mon (hr 0.86) although no difference', 'mon (hr 0.86) although no difference in', '(hr 0.86) although no difference in os', '0.86) although no difference in os (not', 'although no difference in os (not powered).', 'no difference in os (not powered). disappointing', 'difference in os (not powered). disappointing but', 'in os (not powered). disappointing but not', 'os (not powered). disappointing but not the', '(not powered). disappointing but not the end', 'powered). disappointing but not the end of', 'disappointing but not the end of the', 'but not the end of the kras', 'not the end of the kras story!', 'the end of the kras story! #esmo2022', 'end of the kras story! #esmo2022 .', 'codebreak200: ph3 study comparing sotorasib vs. docetaxel in', 'ph3 study comparing sotorasib vs. docetaxel in second', 'study comparing sotorasib vs. docetaxel in second line', 'comparing sotorasib vs. docetaxel in second line nsclc', 'sotorasib vs. docetaxel in second line nsclc pfs', 'vs. docetaxel in second line nsclc pfs 5.6', 'docetaxel in second line nsclc pfs 5.6 vs', 'in second line nsclc pfs 5.6 vs 4.5', 'second line nsclc pfs 5.6 vs 4.5 mon', 'line nsclc pfs 5.6 vs 4.5 mon (hr', 'nsclc pfs 5.6 vs 4.5 mon (hr 0.86)', 'pfs 5.6 vs 4.5 mon (hr 0.86) although', '5.6 vs 4.5 mon (hr 0.86) although no', 'vs 4.5 mon (hr 0.86) although no difference', '4.5 mon (hr 0.86) although no difference in', 'mon (hr 0.86) although no difference in os', '(hr 0.86) although no difference in os (not', '0.86) although no difference in os (not powered).', 'although no difference in os (not powered). disappointing', 'no difference in os (not powered). disappointing but', 'difference in os (not powered). disappointing but not', 'in os (not powered). disappointing but not the', 'os (not powered). disappointing but not the end', '(not powered). disappointing but not the end of', 'powered). disappointing but not the end of the', 'disappointing but not the end of the kras', 'but not the end of the kras story!', 'not the end of the kras story! #esmo2022', 'the end of the kras story! #esmo2022 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '58', 'tokens': ['patients', 'with', 'localized', 'recall', 'cell', 'carcinoma', 'did', 'not', 'have', 'improved', 'disease-free', 'survival', 'when', 'given', 'adjuvant', 'nivolumab+ipilimumab', 'vs', 'sorafanib.', '#rccsm', '#esmo22', '|.', ''], 'text_length': 22, 'triples': {'nivolumab+ipilimumab|not have improved disease-free': ([15, 15], [7, 10], 'negative'), 'sorafanib.|improved': ([17, 17], [9, 9], 'positive')}, 'sentence': 'patients with localized recall cell carcinoma did not have improved disease-free survival when given adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22 |. ', 'aspect_num': 2, 'spans_aspect2opinion_label': [(15, 15), (17, 17)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(7, 10), (9, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['patients', 'with', 'localized', 'recall', 'cell', 'carcinoma', 'did', 'not', 'have', 'improved', 'disease-free', 'survival', 'when', 'given', 'adjuvant', 'nivolumab+ipilimumab', 'vs', 'sorafanib.', '#rccsm', '#esmo22', '|.', '', 'patients with', 'with localized', 'localized recall', 'recall cell', 'cell carcinoma', 'carcinoma did', 'did not', 'not have', 'have improved', 'improved disease-free', 'disease-free survival', 'survival when', 'when given', 'given adjuvant', 'adjuvant nivolumab+ipilimumab', 'nivolumab+ipilimumab vs', 'vs sorafanib.', 'sorafanib. #rccsm', '#rccsm #esmo22', '#esmo22 |.', '|. ', 'patients with localized', 'with localized recall', 'localized recall cell', 'recall cell carcinoma', 'cell carcinoma did', 'carcinoma did not', 'did not have', 'not have improved', 'have improved disease-free', 'improved disease-free survival', 'disease-free survival when', 'survival when given', 'when given adjuvant', 'given adjuvant nivolumab+ipilimumab', 'adjuvant nivolumab+ipilimumab vs', 'nivolumab+ipilimumab vs sorafanib.', 'vs sorafanib. #rccsm', 'sorafanib. #rccsm #esmo22', '#rccsm #esmo22 |.', '#esmo22 |. ', 'patients with localized recall', 'with localized recall cell', 'localized recall cell carcinoma', 'recall cell carcinoma did', 'cell carcinoma did not', 'carcinoma did not have', 'did not have improved', 'not have improved disease-free', 'have improved disease-free survival', 'improved disease-free survival when', 'disease-free survival when given', 'survival when given adjuvant', 'when given adjuvant nivolumab+ipilimumab', 'given adjuvant nivolumab+ipilimumab vs', 'adjuvant nivolumab+ipilimumab vs sorafanib.', 'nivolumab+ipilimumab vs sorafanib. #rccsm', 'vs sorafanib. #rccsm #esmo22', 'sorafanib. #rccsm #esmo22 |.', '#rccsm #esmo22 |. ', 'patients with localized recall cell', 'with localized recall cell carcinoma', 'localized recall cell carcinoma did', 'recall cell carcinoma did not', 'cell carcinoma did not have', 'carcinoma did not have improved', 'did not have improved disease-free', 'not have improved disease-free survival', 'have improved disease-free survival when', 'improved disease-free survival when given', 'disease-free survival when given adjuvant', 'survival when given adjuvant nivolumab+ipilimumab', 'when given adjuvant nivolumab+ipilimumab vs', 'given adjuvant nivolumab+ipilimumab vs sorafanib.', 'adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm', 'nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22', 'vs sorafanib. #rccsm #esmo22 |.', 'sorafanib. #rccsm #esmo22 |. ', 'patients with localized recall cell carcinoma', 'with localized recall cell carcinoma did', 'localized recall cell carcinoma did not', 'recall cell carcinoma did not have', 'cell carcinoma did not have improved', 'carcinoma did not have improved disease-free', 'did not have improved disease-free survival', 'not have improved disease-free survival when', 'have improved disease-free survival when given', 'improved disease-free survival when given adjuvant', 'disease-free survival when given adjuvant nivolumab+ipilimumab', 'survival when given adjuvant nivolumab+ipilimumab vs', 'when given adjuvant nivolumab+ipilimumab vs sorafanib.', 'given adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm', 'adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22', 'nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22 |.', 'vs sorafanib. #rccsm #esmo22 |. ', 'patients with localized recall cell carcinoma did', 'with localized recall cell carcinoma did not', 'localized recall cell carcinoma did not have', 'recall cell carcinoma did not have improved', 'cell carcinoma did not have improved disease-free', 'carcinoma did not have improved disease-free survival', 'did not have improved disease-free survival when', 'not have improved disease-free survival when given', 'have improved disease-free survival when given adjuvant', 'improved disease-free survival when given adjuvant nivolumab+ipilimumab', 'disease-free survival when given adjuvant nivolumab+ipilimumab vs', 'survival when given adjuvant nivolumab+ipilimumab vs sorafanib.', 'when given adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm', 'given adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22', 'adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22 |.', 'nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22 |. ', 'patients with localized recall cell carcinoma did not', 'with localized recall cell carcinoma did not have', 'localized recall cell carcinoma did not have improved', 'recall cell carcinoma did not have improved disease-free', 'cell carcinoma did not have improved disease-free survival', 'carcinoma did not have improved disease-free survival when', 'did not have improved disease-free survival when given', 'not have improved disease-free survival when given adjuvant', 'have improved disease-free survival when given adjuvant nivolumab+ipilimumab', 'improved disease-free survival when given adjuvant nivolumab+ipilimumab vs', 'disease-free survival when given adjuvant nivolumab+ipilimumab vs sorafanib.', 'survival when given adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm', 'when given adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22', 'given adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22 |.', 'adjuvant nivolumab+ipilimumab vs sorafanib. #rccsm #esmo22 |. '], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}]]
测试集加载完成
BertConfig {
  "_name_or_path": "dmis-lab/biobert-large-cased-v1.1-squad",
  "architectures": [
    "BertForQuestionAnswering"
  ],
  "attention_probs_dropout_prob": 0.1,
  "gradient_checkpointing": false,
  "hidden_act": "gelu",
  "hidden_dropout_prob": 0.1,
  "hidden_size": 1024,
  "initializer_range": 0.02,
  "intermediate_size": 4096,
  "layer_norm_eps": 1e-12,
  "max_position_embeddings": 512,
  "model_type": "bert",
  "num_attention_heads": 16,
  "num_hidden_layers": 24,
  "pad_token_id": 0,
  "position_embedding_type": "absolute",
  "transformers_version": "4.3.0",
  "type_vocab_size": 2,
  "use_cache": true,
  "vocab_size": 58996
}

开始加载训练与验证集
train_dataset:[[{'id': '0', 'tokens': ['#asco22', 'dr', 'chris', 'ryan', 'presenting', 'results', 'of', 'everest', 'ph3', 'results', 'for', '#rcc', '.'], 'text_length': 13, 'triples': {'everest|presenting': ([7, 7], [4, 4], 'neutral')}, 'sentence': '#asco22 dr chris ryan presenting results of everest ph3 results for #rcc .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8)], 'span tokens': ['#asco22', 'dr', 'chris', 'ryan', 'presenting', 'results', 'of', 'everest', 'ph3', 'results', 'for', '#rcc', '.', '#asco22 dr', 'dr chris', 'chris ryan', 'ryan presenting', 'presenting results', 'results of', 'of everest', 'everest ph3', 'ph3 results', 'results for', 'for #rcc', '#rcc .', '#asco22 dr chris', 'dr chris ryan', 'chris ryan presenting', 'ryan presenting results', 'presenting results of', 'results of everest', 'of everest ph3', 'everest ph3 results', 'ph3 results for', 'results for #rcc', 'for #rcc .', '#asco22 dr chris ryan', 'dr chris ryan presenting', 'chris ryan presenting results', 'ryan presenting results of', 'presenting results of everest', 'results of everest ph3', 'of everest ph3 results', 'everest ph3 results for', 'ph3 results for #rcc', 'results for #rcc .', '#asco22 dr chris ryan presenting', 'dr chris ryan presenting results', 'chris ryan presenting results of', 'ryan presenting results of everest', 'presenting results of everest ph3', 'results of everest ph3 results', 'of everest ph3 results for', 'everest ph3 results for #rcc', 'ph3 results for #rcc .', '#asco22 dr chris ryan presenting results', 'dr chris ryan presenting results of', 'chris ryan presenting results of everest', 'ryan presenting results of everest ph3', 'presenting results of everest ph3 results', 'results of everest ph3 results for', 'of everest ph3 results for #rcc', 'everest ph3 results for #rcc .', '#asco22 dr chris ryan presenting results of', 'dr chris ryan presenting results of everest', 'chris ryan presenting results of everest ph3', 'ryan presenting results of everest ph3 results', 'presenting results of everest ph3 results for', 'results of everest ph3 results for #rcc', 'of everest ph3 results for #rcc .', '#asco22 dr chris ryan presenting results of everest', 'dr chris ryan presenting results of everest ph3', 'chris ryan presenting results of everest ph3 results', 'ryan presenting results of everest ph3 results for', 'presenting results of everest ph3 results for #rcc', 'results of everest ph3 results for #rcc .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '1', 'tokens': ['enzamet', 'trial:', 'more', 'evidence', 'for', 'triplets', 'in', 'high', 'volume', 'mhspc.', 'benefit', 'for', 'adding', 'docetaxel+enzalutamide', 'in', 'this', 'setting.', '#asco22', '#prostatecancer', '.'], 'text_length': 20, 'triples': {'enzamet|more evidence for triplets in high': ([0, 0], [2, 7], 'neutral'), 'docetaxel+enzalutamide|benefit': ([13, 13], [10, 10], 'neutral')}, 'sentence': 'enzamet trial: more evidence for triplets in high volume mhspc. benefit for adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (13, 13)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(2, 7), (10, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['enzamet', 'trial:', 'more', 'evidence', 'for', 'triplets', 'in', 'high', 'volume', 'mhspc.', 'benefit', 'for', 'adding', 'docetaxel+enzalutamide', 'in', 'this', 'setting.', '#asco22', '#prostatecancer', '.', 'enzamet trial:', 'trial: more', 'more evidence', 'evidence for', 'for triplets', 'triplets in', 'in high', 'high volume', 'volume mhspc.', 'mhspc. benefit', 'benefit for', 'for adding', 'adding docetaxel+enzalutamide', 'docetaxel+enzalutamide in', 'in this', 'this setting.', 'setting. #asco22', '#asco22 #prostatecancer', '#prostatecancer .', 'enzamet trial: more', 'trial: more evidence', 'more evidence for', 'evidence for triplets', 'for triplets in', 'triplets in high', 'in high volume', 'high volume mhspc.', 'volume mhspc. benefit', 'mhspc. benefit for', 'benefit for adding', 'for adding docetaxel+enzalutamide', 'adding docetaxel+enzalutamide in', 'docetaxel+enzalutamide in this', 'in this setting.', 'this setting. #asco22', 'setting. #asco22 #prostatecancer', '#asco22 #prostatecancer .', 'enzamet trial: more evidence', 'trial: more evidence for', 'more evidence for triplets', 'evidence for triplets in', 'for triplets in high', 'triplets in high volume', 'in high volume mhspc.', 'high volume mhspc. benefit', 'volume mhspc. benefit for', 'mhspc. benefit for adding', 'benefit for adding docetaxel+enzalutamide', 'for adding docetaxel+enzalutamide in', 'adding docetaxel+enzalutamide in this', 'docetaxel+enzalutamide in this setting.', 'in this setting. #asco22', 'this setting. #asco22 #prostatecancer', 'setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for', 'trial: more evidence for triplets', 'more evidence for triplets in', 'evidence for triplets in high', 'for triplets in high volume', 'triplets in high volume mhspc.', 'in high volume mhspc. benefit', 'high volume mhspc. benefit for', 'volume mhspc. benefit for adding', 'mhspc. benefit for adding docetaxel+enzalutamide', 'benefit for adding docetaxel+enzalutamide in', 'for adding docetaxel+enzalutamide in this', 'adding docetaxel+enzalutamide in this setting.', 'docetaxel+enzalutamide in this setting. #asco22', 'in this setting. #asco22 #prostatecancer', 'this setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for triplets', 'trial: more evidence for triplets in', 'more evidence for triplets in high', 'evidence for triplets in high volume', 'for triplets in high volume mhspc.', 'triplets in high volume mhspc. benefit', 'in high volume mhspc. benefit for', 'high volume mhspc. benefit for adding', 'volume mhspc. benefit for adding docetaxel+enzalutamide', 'mhspc. benefit for adding docetaxel+enzalutamide in', 'benefit for adding docetaxel+enzalutamide in this', 'for adding docetaxel+enzalutamide in this setting.', 'adding docetaxel+enzalutamide in this setting. #asco22', 'docetaxel+enzalutamide in this setting. #asco22 #prostatecancer', 'in this setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for triplets in', 'trial: more evidence for triplets in high', 'more evidence for triplets in high volume', 'evidence for triplets in high volume mhspc.', 'for triplets in high volume mhspc. benefit', 'triplets in high volume mhspc. benefit for', 'in high volume mhspc. benefit for adding', 'high volume mhspc. benefit for adding docetaxel+enzalutamide', 'volume mhspc. benefit for adding docetaxel+enzalutamide in', 'mhspc. benefit for adding docetaxel+enzalutamide in this', 'benefit for adding docetaxel+enzalutamide in this setting.', 'for adding docetaxel+enzalutamide in this setting. #asco22', 'adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer', 'docetaxel+enzalutamide in this setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for triplets in high', 'trial: more evidence for triplets in high volume', 'more evidence for triplets in high volume mhspc.', 'evidence for triplets in high volume mhspc. benefit', 'for triplets in high volume mhspc. benefit for', 'triplets in high volume mhspc. benefit for adding', 'in high volume mhspc. benefit for adding docetaxel+enzalutamide', 'high volume mhspc. benefit for adding docetaxel+enzalutamide in', 'volume mhspc. benefit for adding docetaxel+enzalutamide in this', 'mhspc. benefit for adding docetaxel+enzalutamide in this setting.', 'benefit for adding docetaxel+enzalutamide in this setting. #asco22', 'for adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer', 'adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '2', 'tokens': ['excited,', 'nervous', '(have', 'you', 'seen', 'the', 'paris', 'hall?!)', 'but', 'most', 'of', 'all', 'proud', 'that', 'niche', 'was', 'selected', 'for', 'the', 'presidential', 'symposium', '!', '#esmo22', 'niche-2', 'is', 'a', 'great', 'example', 'of', 'multidisciplinary', 'effort', 'and', 'science.', 'see', 'you', 'there?!', '.'], 'text_length': 37, 'triples': {'#esmo22|a great': ([22, 22], [25, 26], 'positive')}, 'sentence': 'excited, nervous (have you seen the paris hall?!) but most of all proud that niche was selected for the presidential symposium ! #esmo22 niche-2 is a great example of multidisciplinary effort and science. see you there?! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(22, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(25, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8)], 'span tokens': ['excited,', 'nervous', '(have', 'you', 'seen', 'the', 'paris', 'hall?!)', 'but', 'most', 'of', 'all', 'proud', 'that', 'niche', 'was', 'selected', 'for', 'the', 'presidential', 'symposium', '!', '#esmo22', 'niche-2', 'is', 'a', 'great', 'example', 'of', 'multidisciplinary', 'effort', 'and', 'science.', 'see', 'you', 'there?!', '.', 'excited, nervous', 'nervous (have', '(have you', 'you seen', 'seen the', 'the paris', 'paris hall?!)', 'hall?!) but', 'but most', 'most of', 'of all', 'all proud', 'proud that', 'that niche', 'niche was', 'was selected', 'selected for', 'for the', 'the presidential', 'presidential symposium', 'symposium !', '! #esmo22', '#esmo22 niche-2', 'niche-2 is', 'is a', 'a great', 'great example', 'example of', 'of multidisciplinary', 'multidisciplinary effort', 'effort and', 'and science.', 'science. see', 'see you', 'you there?!', 'there?! .', 'excited, nervous (have', 'nervous (have you', '(have you seen', 'you seen the', 'seen the paris', 'the paris hall?!)', 'paris hall?!) but', 'hall?!) but most', 'but most of', 'most of all', 'of all proud', 'all proud that', 'proud that niche', 'that niche was', 'niche was selected', 'was selected for', 'selected for the', 'for the presidential', 'the presidential symposium', 'presidential symposium !', 'symposium ! #esmo22', '! #esmo22 niche-2', '#esmo22 niche-2 is', 'niche-2 is a', 'is a great', 'a great example', 'great example of', 'example of multidisciplinary', 'of multidisciplinary effort', 'multidisciplinary effort and', 'effort and science.', 'and science. see', 'science. see you', 'see you there?!', 'you there?! .', 'excited, nervous (have you', 'nervous (have you seen', '(have you seen the', 'you seen the paris', 'seen the paris hall?!)', 'the paris hall?!) but', 'paris hall?!) but most', 'hall?!) but most of', 'but most of all', 'most of all proud', 'of all proud that', 'all proud that niche', 'proud that niche was', 'that niche was selected', 'niche was selected for', 'was selected for the', 'selected for the presidential', 'for the presidential symposium', 'the presidential symposium !', 'presidential symposium ! #esmo22', 'symposium ! #esmo22 niche-2', '! #esmo22 niche-2 is', '#esmo22 niche-2 is a', 'niche-2 is a great', 'is a great example', 'a great example of', 'great example of multidisciplinary', 'example of multidisciplinary effort', 'of multidisciplinary effort and', 'multidisciplinary effort and science.', 'effort and science. see', 'and science. see you', 'science. see you there?!', 'see you there?! .', 'excited, nervous (have you seen', 'nervous (have you seen the', '(have you seen the paris', 'you seen the paris hall?!)', 'seen the paris hall?!) but', 'the paris hall?!) but most', 'paris hall?!) but most of', 'hall?!) but most of all', 'but most of all proud', 'most of all proud that', 'of all proud that niche', 'all proud that niche was', 'proud that niche was selected', 'that niche was selected for', 'niche was selected for the', 'was selected for the presidential', 'selected for the presidential symposium', 'for the presidential symposium !', 'the presidential symposium ! #esmo22', 'presidential symposium ! #esmo22 niche-2', 'symposium ! #esmo22 niche-2 is', '! #esmo22 niche-2 is a', '#esmo22 niche-2 is a great', 'niche-2 is a great example', 'is a great example of', 'a great example of multidisciplinary', 'great example of multidisciplinary effort', 'example of multidisciplinary effort and', 'of multidisciplinary effort and science.', 'multidisciplinary effort and science. see', 'effort and science. see you', 'and science. see you there?!', 'science. see you there?! .', 'excited, nervous (have you seen the', 'nervous (have you seen the paris', '(have you seen the paris hall?!)', 'you seen the paris hall?!) but', 'seen the paris hall?!) but most', 'the paris hall?!) but most of', 'paris hall?!) but most of all', 'hall?!) but most of all proud', 'but most of all proud that', 'most of all proud that niche', 'of all proud that niche was', 'all proud that niche was selected', 'proud that niche was selected for', 'that niche was selected for the', 'niche was selected for the presidential', 'was selected for the presidential symposium', 'selected for the presidential symposium !', 'for the presidential symposium ! #esmo22', 'the presidential symposium ! #esmo22 niche-2', 'presidential symposium ! #esmo22 niche-2 is', 'symposium ! #esmo22 niche-2 is a', '! #esmo22 niche-2 is a great', '#esmo22 niche-2 is a great example', 'niche-2 is a great example of', 'is a great example of multidisciplinary', 'a great example of multidisciplinary effort', 'great example of multidisciplinary effort and', 'example of multidisciplinary effort and science.', 'of multidisciplinary effort and science. see', 'multidisciplinary effort and science. see you', 'effort and science. see you there?!', 'and science. see you there?! .', 'excited, nervous (have you seen the paris', 'nervous (have you seen the paris hall?!)', '(have you seen the paris hall?!) but', 'you seen the paris hall?!) but most', 'seen the paris hall?!) but most of', 'the paris hall?!) but most of all', 'paris hall?!) but most of all proud', 'hall?!) but most of all proud that', 'but most of all proud that niche', 'most of all proud that niche was', 'of all proud that niche was selected', 'all proud that niche was selected for', 'proud that niche was selected for the', 'that niche was selected for the presidential', 'niche was selected for the presidential symposium', 'was selected for the presidential symposium !', 'selected for the presidential symposium ! #esmo22', 'for the presidential symposium ! #esmo22 niche-2', 'the presidential symposium ! #esmo22 niche-2 is', 'presidential symposium ! #esmo22 niche-2 is a', 'symposium ! #esmo22 niche-2 is a great', '! #esmo22 niche-2 is a great example', '#esmo22 niche-2 is a great example of', 'niche-2 is a great example of multidisciplinary', 'is a great example of multidisciplinary effort', 'a great example of multidisciplinary effort and', 'great example of multidisciplinary effort and science.', 'example of multidisciplinary effort and science. see', 'of multidisciplinary effort and science. see you', 'multidisciplinary effort and science. see you there?!', 'effort and science. see you there?! .', 'excited, nervous (have you seen the paris hall?!)', 'nervous (have you seen the paris hall?!) but', '(have you seen the paris hall?!) but most', 'you seen the paris hall?!) but most of', 'seen the paris hall?!) but most of all', 'the paris hall?!) but most of all proud', 'paris hall?!) but most of all proud that', 'hall?!) but most of all proud that niche', 'but most of all proud that niche was', 'most of all proud that niche was selected', 'of all proud that niche was selected for', 'all proud that niche was selected for the', 'proud that niche was selected for the presidential', 'that niche was selected for the presidential symposium', 'niche was selected for the presidential symposium !', 'was selected for the presidential symposium ! #esmo22', 'selected for the presidential symposium ! #esmo22 niche-2', 'for the presidential symposium ! #esmo22 niche-2 is', 'the presidential symposium ! #esmo22 niche-2 is a', 'presidential symposium ! #esmo22 niche-2 is a great', 'symposium ! #esmo22 niche-2 is a great example', '! #esmo22 niche-2 is a great example of', '#esmo22 niche-2 is a great example of multidisciplinary', 'niche-2 is a great example of multidisciplinary effort', 'is a great example of multidisciplinary effort and', 'a great example of multidisciplinary effort and science.', 'great example of multidisciplinary effort and science. see', 'example of multidisciplinary effort and science. see you', 'of multidisciplinary effort and science. see you there?!', 'multidisciplinary effort and science. see you there?! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '3', 'tokens': ['some', 'hints', 're', 'which', 'patients', 'should', 'receive', 'triplet', 'therapy', 'in', 'mhspc', 'from', 'enzamet', 'but', 'trial', 'can', 't', 'definitely', 'answer', 'the', 'question', 'as', 'docetaxel', 'use', 'not', 'randomised', 'so', 'outcomes', 'also', 'influenced', 'by', 'prognostic', 'factors', 'in', 'this', 'group', '#asco2022', '.'], 'text_length': 38, 'triples': {'enzamet|not randomised so outcomes also influenced': ([12, 12], [24, 29], 'neutral')}, 'sentence': 'some hints re which patients should receive triplet therapy in mhspc from enzamet but trial can t definitely answer the question as docetaxel use not randomised so outcomes also influenced by prognostic factors in this group #asco2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(24, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8)], 'span tokens': ['some', 'hints', 're', 'which', 'patients', 'should', 'receive', 'triplet', 'therapy', 'in', 'mhspc', 'from', 'enzamet', 'but', 'trial', 'can', 't', 'definitely', 'answer', 'the', 'question', 'as', 'docetaxel', 'use', 'not', 'randomised', 'so', 'outcomes', 'also', 'influenced', 'by', 'prognostic', 'factors', 'in', 'this', 'group', '#asco2022', '.', 'some hints', 'hints re', 're which', 'which patients', 'patients should', 'should receive', 'receive triplet', 'triplet therapy', 'therapy in', 'in mhspc', 'mhspc from', 'from enzamet', 'enzamet but', 'but trial', 'trial can', 'can t', 't definitely', 'definitely answer', 'answer the', 'the question', 'question as', 'as docetaxel', 'docetaxel use', 'use not', 'not randomised', 'randomised so', 'so outcomes', 'outcomes also', 'also influenced', 'influenced by', 'by prognostic', 'prognostic factors', 'factors in', 'in this', 'this group', 'group #asco2022', '#asco2022 .', 'some hints re', 'hints re which', 're which patients', 'which patients should', 'patients should receive', 'should receive triplet', 'receive triplet therapy', 'triplet therapy in', 'therapy in mhspc', 'in mhspc from', 'mhspc from enzamet', 'from enzamet but', 'enzamet but trial', 'but trial can', 'trial can t', 'can t definitely', 't definitely answer', 'definitely answer the', 'answer the question', 'the question as', 'question as docetaxel', 'as docetaxel use', 'docetaxel use not', 'use not randomised', 'not randomised so', 'randomised so outcomes', 'so outcomes also', 'outcomes also influenced', 'also influenced by', 'influenced by prognostic', 'by prognostic factors', 'prognostic factors in', 'factors in this', 'in this group', 'this group #asco2022', 'group #asco2022 .', 'some hints re which', 'hints re which patients', 're which patients should', 'which patients should receive', 'patients should receive triplet', 'should receive triplet therapy', 'receive triplet therapy in', 'triplet therapy in mhspc', 'therapy in mhspc from', 'in mhspc from enzamet', 'mhspc from enzamet but', 'from enzamet but trial', 'enzamet but trial can', 'but trial can t', 'trial can t definitely', 'can t definitely answer', 't definitely answer the', 'definitely answer the question', 'answer the question as', 'the question as docetaxel', 'question as docetaxel use', 'as docetaxel use not', 'docetaxel use not randomised', 'use not randomised so', 'not randomised so outcomes', 'randomised so outcomes also', 'so outcomes also influenced', 'outcomes also influenced by', 'also influenced by prognostic', 'influenced by prognostic factors', 'by prognostic factors in', 'prognostic factors in this', 'factors in this group', 'in this group #asco2022', 'this group #asco2022 .', 'some hints re which patients', 'hints re which patients should', 're which patients should receive', 'which patients should receive triplet', 'patients should receive triplet therapy', 'should receive triplet therapy in', 'receive triplet therapy in mhspc', 'triplet therapy in mhspc from', 'therapy in mhspc from enzamet', 'in mhspc from enzamet but', 'mhspc from enzamet but trial', 'from enzamet but trial can', 'enzamet but trial can t', 'but trial can t definitely', 'trial can t definitely answer', 'can t definitely answer the', 't definitely answer the question', 'definitely answer the question as', 'answer the question as docetaxel', 'the question as docetaxel use', 'question as docetaxel use not', 'as docetaxel use not randomised', 'docetaxel use not randomised so', 'use not randomised so outcomes', 'not randomised so outcomes also', 'randomised so outcomes also influenced', 'so outcomes also influenced by', 'outcomes also influenced by prognostic', 'also influenced by prognostic factors', 'influenced by prognostic factors in', 'by prognostic factors in this', 'prognostic factors in this group', 'factors in this group #asco2022', 'in this group #asco2022 .', 'some hints re which patients should', 'hints re which patients should receive', 're which patients should receive triplet', 'which patients should receive triplet therapy', 'patients should receive triplet therapy in', 'should receive triplet therapy in mhspc', 'receive triplet therapy in mhspc from', 'triplet therapy in mhspc from enzamet', 'therapy in mhspc from enzamet but', 'in mhspc from enzamet but trial', 'mhspc from enzamet but trial can', 'from enzamet but trial can t', 'enzamet but trial can t definitely', 'but trial can t definitely answer', 'trial can t definitely answer the', 'can t definitely answer the question', 't definitely answer the question as', 'definitely answer the question as docetaxel', 'answer the question as docetaxel use', 'the question as docetaxel use not', 'question as docetaxel use not randomised', 'as docetaxel use not randomised so', 'docetaxel use not randomised so outcomes', 'use not randomised so outcomes also', 'not randomised so outcomes also influenced', 'randomised so outcomes also influenced by', 'so outcomes also influenced by prognostic', 'outcomes also influenced by prognostic factors', 'also influenced by prognostic factors in', 'influenced by prognostic factors in this', 'by prognostic factors in this group', 'prognostic factors in this group #asco2022', 'factors in this group #asco2022 .', 'some hints re which patients should receive', 'hints re which patients should receive triplet', 're which patients should receive triplet therapy', 'which patients should receive triplet therapy in', 'patients should receive triplet therapy in mhspc', 'should receive triplet therapy in mhspc from', 'receive triplet therapy in mhspc from enzamet', 'triplet therapy in mhspc from enzamet but', 'therapy in mhspc from enzamet but trial', 'in mhspc from enzamet but trial can', 'mhspc from enzamet but trial can t', 'from enzamet but trial can t definitely', 'enzamet but trial can t definitely answer', 'but trial can t definitely answer the', 'trial can t definitely answer the question', 'can t definitely answer the question as', 't definitely answer the question as docetaxel', 'definitely answer the question as docetaxel use', 'answer the question as docetaxel use not', 'the question as docetaxel use not randomised', 'question as docetaxel use not randomised so', 'as docetaxel use not randomised so outcomes', 'docetaxel use not randomised so outcomes also', 'use not randomised so outcomes also influenced', 'not randomised so outcomes also influenced by', 'randomised so outcomes also influenced by prognostic', 'so outcomes also influenced by prognostic factors', 'outcomes also influenced by prognostic factors in', 'also influenced by prognostic factors in this', 'influenced by prognostic factors in this group', 'by prognostic factors in this group #asco2022', 'prognostic factors in this group #asco2022 .', 'some hints re which patients should receive triplet', 'hints re which patients should receive triplet therapy', 're which patients should receive triplet therapy in', 'which patients should receive triplet therapy in mhspc', 'patients should receive triplet therapy in mhspc from', 'should receive triplet therapy in mhspc from enzamet', 'receive triplet therapy in mhspc from enzamet but', 'triplet therapy in mhspc from enzamet but trial', 'therapy in mhspc from enzamet but trial can', 'in mhspc from enzamet but trial can t', 'mhspc from enzamet but trial can t definitely', 'from enzamet but trial can t definitely answer', 'enzamet but trial can t definitely answer the', 'but trial can t definitely answer the question', 'trial can t definitely answer the question as', 'can t definitely answer the question as docetaxel', 't definitely answer the question as docetaxel use', 'definitely answer the question as docetaxel use not', 'answer the question as docetaxel use not randomised', 'the question as docetaxel use not randomised so', 'question as docetaxel use not randomised so outcomes', 'as docetaxel use not randomised so outcomes also', 'docetaxel use not randomised so outcomes also influenced', 'use not randomised so outcomes also influenced by', 'not randomised so outcomes also influenced by prognostic', 'randomised so outcomes also influenced by prognostic factors', 'so outcomes also influenced by prognostic factors in', 'outcomes also influenced by prognostic factors in this', 'also influenced by prognostic factors in this group', 'influenced by prognostic factors in this group #asco2022', 'by prognostic factors in this group #asco2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '4', 'tokens': ['the', 'awaited', '#', 'propel', 'biomarker', 'analysis', 'by', 'esteemed', '#fredsaad', 'rpfs', 'of', 'abiraterone+olaparib', 'best', 'for', 'patients', 'w', 'brca1/2', 'alterations,', 'next', 'for', 'those', 'w', 'homologous', 'recombination', 'repair', 'defects,', 'finally', 'in', 'non-hrr', 'altered.', 'os', 'benefit', 'holds', 'in', 'intention', 'to', 'treat', 'group.', '#esmo22', '.'], 'text_length': 40, 'triples': {'#|abiraterone+olaparib best for patients w brca1/2 alterations, next for those w homologous recombination repair defects, finally in non-hrr altered. os benefit': ([2, 2], [11, 31], 'neutral'), 'of|abiraterone+olaparib best for patients w brca1/2 alterations, next for those w homologous recombination repair defects, finally in non-hrr altered. os benefit': ([10, 10], [11, 31], 'neutral')}, 'sentence': 'the awaited # propel biomarker analysis by esteemed #fredsaad rpfs of abiraterone+olaparib best for patients w brca1/2 alterations, next for those w homologous recombination repair defects, finally in non-hrr altered. os benefit holds in intention to treat group. #esmo22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(2, 2), (10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(11, 31)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8)], 'span tokens': ['the', 'awaited', '#', 'propel', 'biomarker', 'analysis', 'by', 'esteemed', '#fredsaad', 'rpfs', 'of', 'abiraterone+olaparib', 'best', 'for', 'patients', 'w', 'brca1/2', 'alterations,', 'next', 'for', 'those', 'w', 'homologous', 'recombination', 'repair', 'defects,', 'finally', 'in', 'non-hrr', 'altered.', 'os', 'benefit', 'holds', 'in', 'intention', 'to', 'treat', 'group.', '#esmo22', '.', 'the awaited', 'awaited #', '# propel', 'propel biomarker', 'biomarker analysis', 'analysis by', 'by esteemed', 'esteemed #fredsaad', '#fredsaad rpfs', 'rpfs of', 'of abiraterone+olaparib', 'abiraterone+olaparib best', 'best for', 'for patients', 'patients w', 'w brca1/2', 'brca1/2 alterations,', 'alterations, next', 'next for', 'for those', 'those w', 'w homologous', 'homologous recombination', 'recombination repair', 'repair defects,', 'defects, finally', 'finally in', 'in non-hrr', 'non-hrr altered.', 'altered. os', 'os benefit', 'benefit holds', 'holds in', 'in intention', 'intention to', 'to treat', 'treat group.', 'group. #esmo22', '#esmo22 .', 'the awaited #', 'awaited # propel', '# propel biomarker', 'propel biomarker analysis', 'biomarker analysis by', 'analysis by esteemed', 'by esteemed #fredsaad', 'esteemed #fredsaad rpfs', '#fredsaad rpfs of', 'rpfs of abiraterone+olaparib', 'of abiraterone+olaparib best', 'abiraterone+olaparib best for', 'best for patients', 'for patients w', 'patients w brca1/2', 'w brca1/2 alterations,', 'brca1/2 alterations, next', 'alterations, next for', 'next for those', 'for those w', 'those w homologous', 'w homologous recombination', 'homologous recombination repair', 'recombination repair defects,', 'repair defects, finally', 'defects, finally in', 'finally in non-hrr', 'in non-hrr altered.', 'non-hrr altered. os', 'altered. os benefit', 'os benefit holds', 'benefit holds in', 'holds in intention', 'in intention to', 'intention to treat', 'to treat group.', 'treat group. #esmo22', 'group. #esmo22 .', 'the awaited # propel', 'awaited # propel biomarker', '# propel biomarker analysis', 'propel biomarker analysis by', 'biomarker analysis by esteemed', 'analysis by esteemed #fredsaad', 'by esteemed #fredsaad rpfs', 'esteemed #fredsaad rpfs of', '#fredsaad rpfs of abiraterone+olaparib', 'rpfs of abiraterone+olaparib best', 'of abiraterone+olaparib best for', 'abiraterone+olaparib best for patients', 'best for patients w', 'for patients w brca1/2', 'patients w brca1/2 alterations,', 'w brca1/2 alterations, next', 'brca1/2 alterations, next for', 'alterations, next for those', 'next for those w', 'for those w homologous', 'those w homologous recombination', 'w homologous recombination repair', 'homologous recombination repair defects,', 'recombination repair defects, finally', 'repair defects, finally in', 'defects, finally in non-hrr', 'finally in non-hrr altered.', 'in non-hrr altered. os', 'non-hrr altered. os benefit', 'altered. os benefit holds', 'os benefit holds in', 'benefit holds in intention', 'holds in intention to', 'in intention to treat', 'intention to treat group.', 'to treat group. #esmo22', 'treat group. #esmo22 .', 'the awaited # propel biomarker', 'awaited # propel biomarker analysis', '# propel biomarker analysis by', 'propel biomarker analysis by esteemed', 'biomarker analysis by esteemed #fredsaad', 'analysis by esteemed #fredsaad rpfs', 'by esteemed #fredsaad rpfs of', 'esteemed #fredsaad rpfs of abiraterone+olaparib', '#fredsaad rpfs of abiraterone+olaparib best', 'rpfs of abiraterone+olaparib best for', 'of abiraterone+olaparib best for patients', 'abiraterone+olaparib best for patients w', 'best for patients w brca1/2', 'for patients w brca1/2 alterations,', 'patients w brca1/2 alterations, next', 'w brca1/2 alterations, next for', 'brca1/2 alterations, next for those', 'alterations, next for those w', 'next for those w homologous', 'for those w homologous recombination', 'those w homologous recombination repair', 'w homologous recombination repair defects,', 'homologous recombination repair defects, finally', 'recombination repair defects, finally in', 'repair defects, finally in non-hrr', 'defects, finally in non-hrr altered.', 'finally in non-hrr altered. os', 'in non-hrr altered. os benefit', 'non-hrr altered. os benefit holds', 'altered. os benefit holds in', 'os benefit holds in intention', 'benefit holds in intention to', 'holds in intention to treat', 'in intention to treat group.', 'intention to treat group. #esmo22', 'to treat group. #esmo22 .', 'the awaited # propel biomarker analysis', 'awaited # propel biomarker analysis by', '# propel biomarker analysis by esteemed', 'propel biomarker analysis by esteemed #fredsaad', 'biomarker analysis by esteemed #fredsaad rpfs', 'analysis by esteemed #fredsaad rpfs of', 'by esteemed #fredsaad rpfs of abiraterone+olaparib', 'esteemed #fredsaad rpfs of abiraterone+olaparib best', '#fredsaad rpfs of abiraterone+olaparib best for', 'rpfs of abiraterone+olaparib best for patients', 'of abiraterone+olaparib best for patients w', 'abiraterone+olaparib best for patients w brca1/2', 'best for patients w brca1/2 alterations,', 'for patients w brca1/2 alterations, next', 'patients w brca1/2 alterations, next for', 'w brca1/2 alterations, next for those', 'brca1/2 alterations, next for those w', 'alterations, next for those w homologous', 'next for those w homologous recombination', 'for those w homologous recombination repair', 'those w homologous recombination repair defects,', 'w homologous recombination repair defects, finally', 'homologous recombination repair defects, finally in', 'recombination repair defects, finally in non-hrr', 'repair defects, finally in non-hrr altered.', 'defects, finally in non-hrr altered. os', 'finally in non-hrr altered. os benefit', 'in non-hrr altered. os benefit holds', 'non-hrr altered. os benefit holds in', 'altered. os benefit holds in intention', 'os benefit holds in intention to', 'benefit holds in intention to treat', 'holds in intention to treat group.', 'in intention to treat group. #esmo22', 'intention to treat group. #esmo22 .', 'the awaited # propel biomarker analysis by', 'awaited # propel biomarker analysis by esteemed', '# propel biomarker analysis by esteemed #fredsaad', 'propel biomarker analysis by esteemed #fredsaad rpfs', 'biomarker analysis by esteemed #fredsaad rpfs of', 'analysis by esteemed #fredsaad rpfs of abiraterone+olaparib', 'by esteemed #fredsaad rpfs of abiraterone+olaparib best', 'esteemed #fredsaad rpfs of abiraterone+olaparib best for', '#fredsaad rpfs of abiraterone+olaparib best for patients', 'rpfs of abiraterone+olaparib best for patients w', 'of abiraterone+olaparib best for patients w brca1/2', 'abiraterone+olaparib best for patients w brca1/2 alterations,', 'best for patients w brca1/2 alterations, next', 'for patients w brca1/2 alterations, next for', 'patients w brca1/2 alterations, next for those', 'w brca1/2 alterations, next for those w', 'brca1/2 alterations, next for those w homologous', 'alterations, next for those w homologous recombination', 'next for those w homologous recombination repair', 'for those w homologous recombination repair defects,', 'those w homologous recombination repair defects, finally', 'w homologous recombination repair defects, finally in', 'homologous recombination repair defects, finally in non-hrr', 'recombination repair defects, finally in non-hrr altered.', 'repair defects, finally in non-hrr altered. os', 'defects, finally in non-hrr altered. os benefit', 'finally in non-hrr altered. os benefit holds', 'in non-hrr altered. os benefit holds in', 'non-hrr altered. os benefit holds in intention', 'altered. os benefit holds in intention to', 'os benefit holds in intention to treat', 'benefit holds in intention to treat group.', 'holds in intention to treat group. #esmo22', 'in intention to treat group. #esmo22 .', 'the awaited # propel biomarker analysis by esteemed', 'awaited # propel biomarker analysis by esteemed #fredsaad', '# propel biomarker analysis by esteemed #fredsaad rpfs', 'propel biomarker analysis by esteemed #fredsaad rpfs of', 'biomarker analysis by esteemed #fredsaad rpfs of abiraterone+olaparib', 'analysis by esteemed #fredsaad rpfs of abiraterone+olaparib best', 'by esteemed #fredsaad rpfs of abiraterone+olaparib best for', 'esteemed #fredsaad rpfs of abiraterone+olaparib best for patients', '#fredsaad rpfs of abiraterone+olaparib best for patients w', 'rpfs of abiraterone+olaparib best for patients w brca1/2', 'of abiraterone+olaparib best for patients w brca1/2 alterations,', 'abiraterone+olaparib best for patients w brca1/2 alterations, next', 'best for patients w brca1/2 alterations, next for', 'for patients w brca1/2 alterations, next for those', 'patients w brca1/2 alterations, next for those w', 'w brca1/2 alterations, next for those w homologous', 'brca1/2 alterations, next for those w homologous recombination', 'alterations, next for those w homologous recombination repair', 'next for those w homologous recombination repair defects,', 'for those w homologous recombination repair defects, finally', 'those w homologous recombination repair defects, finally in', 'w homologous recombination repair defects, finally in non-hrr', 'homologous recombination repair defects, finally in non-hrr altered.', 'recombination repair defects, finally in non-hrr altered. os', 'repair defects, finally in non-hrr altered. os benefit', 'defects, finally in non-hrr altered. os benefit holds', 'finally in non-hrr altered. os benefit holds in', 'in non-hrr altered. os benefit holds in intention', 'non-hrr altered. os benefit holds in intention to', 'altered. os benefit holds in intention to treat', 'os benefit holds in intention to treat group.', 'benefit holds in intention to treat group. #esmo22', 'holds in intention to treat group. #esmo22 .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '5', 'tokens': ['s1801', ':', 'neo-', 'vs.', 'adjuvant', 'pembrolizumab', 'for', 'stage', 'iii-iv', 'melanoma', 'by', '.', 'striking', 'efs', 'benefits', 'by', 'neoadjuvant!', 'simple', 'but', 'highly', 'important', 'clinical', 'question.', 'expect', 'that', 'it', 'is', 'not', 'limited', 'to', 'melanoma.', 'direct', 'comparison', 'is', 'needed', 'in', 'thoracic', 'oncology.', '#lcsm', '#esmo22', '.'], 'text_length': 41, 'triples': {'s1801|by': ([0, 0], [10, 10], 'positive')}, 'sentence': 's1801 : neo- vs. adjuvant pembrolizumab for stage iii-iv melanoma by . striking efs benefits by neoadjuvant! simple but highly important clinical question. expect that it is not limited to melanoma. direct comparison is needed in thoracic oncology. #lcsm #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8)], 'span tokens': ['s1801', ':', 'neo-', 'vs.', 'adjuvant', 'pembrolizumab', 'for', 'stage', 'iii-iv', 'melanoma', 'by', '.', 'striking', 'efs', 'benefits', 'by', 'neoadjuvant!', 'simple', 'but', 'highly', 'important', 'clinical', 'question.', 'expect', 'that', 'it', 'is', 'not', 'limited', 'to', 'melanoma.', 'direct', 'comparison', 'is', 'needed', 'in', 'thoracic', 'oncology.', '#lcsm', '#esmo22', '.', 's1801 :', ': neo-', 'neo- vs.', 'vs. adjuvant', 'adjuvant pembrolizumab', 'pembrolizumab for', 'for stage', 'stage iii-iv', 'iii-iv melanoma', 'melanoma by', 'by .', '. striking', 'striking efs', 'efs benefits', 'benefits by', 'by neoadjuvant!', 'neoadjuvant! simple', 'simple but', 'but highly', 'highly important', 'important clinical', 'clinical question.', 'question. expect', 'expect that', 'that it', 'it is', 'is not', 'not limited', 'limited to', 'to melanoma.', 'melanoma. direct', 'direct comparison', 'comparison is', 'is needed', 'needed in', 'in thoracic', 'thoracic oncology.', 'oncology. #lcsm', '#lcsm #esmo22', '#esmo22 .', 's1801 : neo-', ': neo- vs.', 'neo- vs. adjuvant', 'vs. adjuvant pembrolizumab', 'adjuvant pembrolizumab for', 'pembrolizumab for stage', 'for stage iii-iv', 'stage iii-iv melanoma', 'iii-iv melanoma by', 'melanoma by .', 'by . striking', '. striking efs', 'striking efs benefits', 'efs benefits by', 'benefits by neoadjuvant!', 'by neoadjuvant! simple', 'neoadjuvant! simple but', 'simple but highly', 'but highly important', 'highly important clinical', 'important clinical question.', 'clinical question. expect', 'question. expect that', 'expect that it', 'that it is', 'it is not', 'is not limited', 'not limited to', 'limited to melanoma.', 'to melanoma. direct', 'melanoma. direct comparison', 'direct comparison is', 'comparison is needed', 'is needed in', 'needed in thoracic', 'in thoracic oncology.', 'thoracic oncology. #lcsm', 'oncology. #lcsm #esmo22', '#lcsm #esmo22 .', 's1801 : neo- vs.', ': neo- vs. adjuvant', 'neo- vs. adjuvant pembrolizumab', 'vs. adjuvant pembrolizumab for', 'adjuvant pembrolizumab for stage', 'pembrolizumab for stage iii-iv', 'for stage iii-iv melanoma', 'stage iii-iv melanoma by', 'iii-iv melanoma by .', 'melanoma by . striking', 'by . striking efs', '. striking efs benefits', 'striking efs benefits by', 'efs benefits by neoadjuvant!', 'benefits by neoadjuvant! simple', 'by neoadjuvant! simple but', 'neoadjuvant! simple but highly', 'simple but highly important', 'but highly important clinical', 'highly important clinical question.', 'important clinical question. expect', 'clinical question. expect that', 'question. expect that it', 'expect that it is', 'that it is not', 'it is not limited', 'is not limited to', 'not limited to melanoma.', 'limited to melanoma. direct', 'to melanoma. direct comparison', 'melanoma. direct comparison is', 'direct comparison is needed', 'comparison is needed in', 'is needed in thoracic', 'needed in thoracic oncology.', 'in thoracic oncology. #lcsm', 'thoracic oncology. #lcsm #esmo22', 'oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant', ': neo- vs. adjuvant pembrolizumab', 'neo- vs. adjuvant pembrolizumab for', 'vs. adjuvant pembrolizumab for stage', 'adjuvant pembrolizumab for stage iii-iv', 'pembrolizumab for stage iii-iv melanoma', 'for stage iii-iv melanoma by', 'stage iii-iv melanoma by .', 'iii-iv melanoma by . striking', 'melanoma by . striking efs', 'by . striking efs benefits', '. striking efs benefits by', 'striking efs benefits by neoadjuvant!', 'efs benefits by neoadjuvant! simple', 'benefits by neoadjuvant! simple but', 'by neoadjuvant! simple but highly', 'neoadjuvant! simple but highly important', 'simple but highly important clinical', 'but highly important clinical question.', 'highly important clinical question. expect', 'important clinical question. expect that', 'clinical question. expect that it', 'question. expect that it is', 'expect that it is not', 'that it is not limited', 'it is not limited to', 'is not limited to melanoma.', 'not limited to melanoma. direct', 'limited to melanoma. direct comparison', 'to melanoma. direct comparison is', 'melanoma. direct comparison is needed', 'direct comparison is needed in', 'comparison is needed in thoracic', 'is needed in thoracic oncology.', 'needed in thoracic oncology. #lcsm', 'in thoracic oncology. #lcsm #esmo22', 'thoracic oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant pembrolizumab', ': neo- vs. adjuvant pembrolizumab for', 'neo- vs. adjuvant pembrolizumab for stage', 'vs. adjuvant pembrolizumab for stage iii-iv', 'adjuvant pembrolizumab for stage iii-iv melanoma', 'pembrolizumab for stage iii-iv melanoma by', 'for stage iii-iv melanoma by .', 'stage iii-iv melanoma by . striking', 'iii-iv melanoma by . striking efs', 'melanoma by . striking efs benefits', 'by . striking efs benefits by', '. striking efs benefits by neoadjuvant!', 'striking efs benefits by neoadjuvant! simple', 'efs benefits by neoadjuvant! simple but', 'benefits by neoadjuvant! simple but highly', 'by neoadjuvant! simple but highly important', 'neoadjuvant! simple but highly important clinical', 'simple but highly important clinical question.', 'but highly important clinical question. expect', 'highly important clinical question. expect that', 'important clinical question. expect that it', 'clinical question. expect that it is', 'question. expect that it is not', 'expect that it is not limited', 'that it is not limited to', 'it is not limited to melanoma.', 'is not limited to melanoma. direct', 'not limited to melanoma. direct comparison', 'limited to melanoma. direct comparison is', 'to melanoma. direct comparison is needed', 'melanoma. direct comparison is needed in', 'direct comparison is needed in thoracic', 'comparison is needed in thoracic oncology.', 'is needed in thoracic oncology. #lcsm', 'needed in thoracic oncology. #lcsm #esmo22', 'in thoracic oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant pembrolizumab for', ': neo- vs. adjuvant pembrolizumab for stage', 'neo- vs. adjuvant pembrolizumab for stage iii-iv', 'vs. adjuvant pembrolizumab for stage iii-iv melanoma', 'adjuvant pembrolizumab for stage iii-iv melanoma by', 'pembrolizumab for stage iii-iv melanoma by .', 'for stage iii-iv melanoma by . striking', 'stage iii-iv melanoma by . striking efs', 'iii-iv melanoma by . striking efs benefits', 'melanoma by . striking efs benefits by', 'by . striking efs benefits by neoadjuvant!', '. striking efs benefits by neoadjuvant! simple', 'striking efs benefits by neoadjuvant! simple but', 'efs benefits by neoadjuvant! simple but highly', 'benefits by neoadjuvant! simple but highly important', 'by neoadjuvant! simple but highly important clinical', 'neoadjuvant! simple but highly important clinical question.', 'simple but highly important clinical question. expect', 'but highly important clinical question. expect that', 'highly important clinical question. expect that it', 'important clinical question. expect that it is', 'clinical question. expect that it is not', 'question. expect that it is not limited', 'expect that it is not limited to', 'that it is not limited to melanoma.', 'it is not limited to melanoma. direct', 'is not limited to melanoma. direct comparison', 'not limited to melanoma. direct comparison is', 'limited to melanoma. direct comparison is needed', 'to melanoma. direct comparison is needed in', 'melanoma. direct comparison is needed in thoracic', 'direct comparison is needed in thoracic oncology.', 'comparison is needed in thoracic oncology. #lcsm', 'is needed in thoracic oncology. #lcsm #esmo22', 'needed in thoracic oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant pembrolizumab for stage', ': neo- vs. adjuvant pembrolizumab for stage iii-iv', 'neo- vs. adjuvant pembrolizumab for stage iii-iv melanoma', 'vs. adjuvant pembrolizumab for stage iii-iv melanoma by', 'adjuvant pembrolizumab for stage iii-iv melanoma by .', 'pembrolizumab for stage iii-iv melanoma by . striking', 'for stage iii-iv melanoma by . striking efs', 'stage iii-iv melanoma by . striking efs benefits', 'iii-iv melanoma by . striking efs benefits by', 'melanoma by . striking efs benefits by neoadjuvant!', 'by . striking efs benefits by neoadjuvant! simple', '. striking efs benefits by neoadjuvant! simple but', 'striking efs benefits by neoadjuvant! simple but highly', 'efs benefits by neoadjuvant! simple but highly important', 'benefits by neoadjuvant! simple but highly important clinical', 'by neoadjuvant! simple but highly important clinical question.', 'neoadjuvant! simple but highly important clinical question. expect', 'simple but highly important clinical question. expect that', 'but highly important clinical question. expect that it', 'highly important clinical question. expect that it is', 'important clinical question. expect that it is not', 'clinical question. expect that it is not limited', 'question. expect that it is not limited to', 'expect that it is not limited to melanoma.', 'that it is not limited to melanoma. direct', 'it is not limited to melanoma. direct comparison', 'is not limited to melanoma. direct comparison is', 'not limited to melanoma. direct comparison is needed', 'limited to melanoma. direct comparison is needed in', 'to melanoma. direct comparison is needed in thoracic', 'melanoma. direct comparison is needed in thoracic oncology.', 'direct comparison is needed in thoracic oncology. #lcsm', 'comparison is needed in thoracic oncology. #lcsm #esmo22', 'is needed in thoracic oncology. #lcsm #esmo22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '6', 'tokens': ['#esmo22', 'never', 'thought', 'that', 'i', 'would', 'see', 'near', '80%', 'event-free', 'survival', 'in', 'melanoma', 'during', 'my', 'professional', 'lifetime.', 'neoadjuvant', 'io', 'wins', 'indeed!!!', 's1801', '.'], 'text_length': 23, 'triples': {'s1801|see near 80% event-free survival in melanoma during my professional lifetime. neoadjuvant io wins indeed!!!': ([21, 21], [6, 20], 'positive')}, 'sentence': '#esmo22 never thought that i would see near 80% event-free survival in melanoma during my professional lifetime. neoadjuvant io wins indeed!!! s1801 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(21, 21)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8)], 'span tokens': ['#esmo22', 'never', 'thought', 'that', 'i', 'would', 'see', 'near', '80%', 'event-free', 'survival', 'in', 'melanoma', 'during', 'my', 'professional', 'lifetime.', 'neoadjuvant', 'io', 'wins', 'indeed!!!', 's1801', '.', '#esmo22 never', 'never thought', 'thought that', 'that i', 'i would', 'would see', 'see near', 'near 80%', '80% event-free', 'event-free survival', 'survival in', 'in melanoma', 'melanoma during', 'during my', 'my professional', 'professional lifetime.', 'lifetime. neoadjuvant', 'neoadjuvant io', 'io wins', 'wins indeed!!!', 'indeed!!! s1801', 's1801 .', '#esmo22 never thought', 'never thought that', 'thought that i', 'that i would', 'i would see', 'would see near', 'see near 80%', 'near 80% event-free', '80% event-free survival', 'event-free survival in', 'survival in melanoma', 'in melanoma during', 'melanoma during my', 'during my professional', 'my professional lifetime.', 'professional lifetime. neoadjuvant', 'lifetime. neoadjuvant io', 'neoadjuvant io wins', 'io wins indeed!!!', 'wins indeed!!! s1801', 'indeed!!! s1801 .', '#esmo22 never thought that', 'never thought that i', 'thought that i would', 'that i would see', 'i would see near', 'would see near 80%', 'see near 80% event-free', 'near 80% event-free survival', '80% event-free survival in', 'event-free survival in melanoma', 'survival in melanoma during', 'in melanoma during my', 'melanoma during my professional', 'during my professional lifetime.', 'my professional lifetime. neoadjuvant', 'professional lifetime. neoadjuvant io', 'lifetime. neoadjuvant io wins', 'neoadjuvant io wins indeed!!!', 'io wins indeed!!! s1801', 'wins indeed!!! s1801 .', '#esmo22 never thought that i', 'never thought that i would', 'thought that i would see', 'that i would see near', 'i would see near 80%', 'would see near 80% event-free', 'see near 80% event-free survival', 'near 80% event-free survival in', '80% event-free survival in melanoma', 'event-free survival in melanoma during', 'survival in melanoma during my', 'in melanoma during my professional', 'melanoma during my professional lifetime.', 'during my professional lifetime. neoadjuvant', 'my professional lifetime. neoadjuvant io', 'professional lifetime. neoadjuvant io wins', 'lifetime. neoadjuvant io wins indeed!!!', 'neoadjuvant io wins indeed!!! s1801', 'io wins indeed!!! s1801 .', '#esmo22 never thought that i would', 'never thought that i would see', 'thought that i would see near', 'that i would see near 80%', 'i would see near 80% event-free', 'would see near 80% event-free survival', 'see near 80% event-free survival in', 'near 80% event-free survival in melanoma', '80% event-free survival in melanoma during', 'event-free survival in melanoma during my', 'survival in melanoma during my professional', 'in melanoma during my professional lifetime.', 'melanoma during my professional lifetime. neoadjuvant', 'during my professional lifetime. neoadjuvant io', 'my professional lifetime. neoadjuvant io wins', 'professional lifetime. neoadjuvant io wins indeed!!!', 'lifetime. neoadjuvant io wins indeed!!! s1801', 'neoadjuvant io wins indeed!!! s1801 .', '#esmo22 never thought that i would see', 'never thought that i would see near', 'thought that i would see near 80%', 'that i would see near 80% event-free', 'i would see near 80% event-free survival', 'would see near 80% event-free survival in', 'see near 80% event-free survival in melanoma', 'near 80% event-free survival in melanoma during', '80% event-free survival in melanoma during my', 'event-free survival in melanoma during my professional', 'survival in melanoma during my professional lifetime.', 'in melanoma during my professional lifetime. neoadjuvant', 'melanoma during my professional lifetime. neoadjuvant io', 'during my professional lifetime. neoadjuvant io wins', 'my professional lifetime. neoadjuvant io wins indeed!!!', 'professional lifetime. neoadjuvant io wins indeed!!! s1801', 'lifetime. neoadjuvant io wins indeed!!! s1801 .', '#esmo22 never thought that i would see near', 'never thought that i would see near 80%', 'thought that i would see near 80% event-free', 'that i would see near 80% event-free survival', 'i would see near 80% event-free survival in', 'would see near 80% event-free survival in melanoma', 'see near 80% event-free survival in melanoma during', 'near 80% event-free survival in melanoma during my', '80% event-free survival in melanoma during my professional', 'event-free survival in melanoma during my professional lifetime.', 'survival in melanoma during my professional lifetime. neoadjuvant', 'in melanoma during my professional lifetime. neoadjuvant io', 'melanoma during my professional lifetime. neoadjuvant io wins', 'during my professional lifetime. neoadjuvant io wins indeed!!!', 'my professional lifetime. neoadjuvant io wins indeed!!! s1801', 'professional lifetime. neoadjuvant io wins indeed!!! s1801 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '7', 'tokens': ['And', 'the', 'battle', 'of', 'the', 'BTKi', 'giants', 'in', 'r/r', 'cll', 'goes', 'to...', 'zanubrutinib!', 'Pfs', 'benefit', 'also', 'in', 'del17p', 'or', 'tp53', 'aberrations.', 'zanubrutinib', '', '', '', '', 'had', 'a', 'more', 'favorable', 'cardiac', 'profile', 'in', 'addition.', '#ASH22', '@ASH_hematology', '.'], 'text_length': 37, 'triples': {'zanubrutinib! Pfs benefit also in del17p or tp53 aberrations. zanubrutinib|favorable': ([12, 21], [25, 25], 'neutral')}, 'sentence': 'And the battle of the BTKi giants in r/r cll goes to... zanubrutinib! Pfs benefit also in del17p or tp53 aberrations. zanubrutinib     had a more favorable cardiac profile in addition. #ASH22 @ASH_hematology .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 21)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(25, 25)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8)], 'span tokens': ['And', 'the', 'battle', 'of', 'the', 'BTKi', 'giants', 'in', 'r/r', 'cll', 'goes', 'to...', 'zanubrutinib!', 'Pfs', 'benefit', 'also', 'in', 'del17p', 'or', 'tp53', 'aberrations.', 'zanubrutinib', '', '', '', '', 'had', 'a', 'more', 'favorable', 'cardiac', 'profile', 'in', 'addition.', '#ASH22', '@ASH_hematology', '.', 'And the', 'the battle', 'battle of', 'of the', 'the BTKi', 'BTKi giants', 'giants in', 'in r/r', 'r/r cll', 'cll goes', 'goes to...', 'to... zanubrutinib!', 'zanubrutinib! Pfs', 'Pfs benefit', 'benefit also', 'also in', 'in del17p', 'del17p or', 'or tp53', 'tp53 aberrations.', 'aberrations. zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' had', 'had a', 'a more', 'more favorable', 'favorable cardiac', 'cardiac profile', 'profile in', 'in addition.', 'addition. #ASH22', '#ASH22 @ASH_hematology', '@ASH_hematology .', 'And the battle', 'the battle of', 'battle of the', 'of the BTKi', 'the BTKi giants', 'BTKi giants in', 'giants in r/r', 'in r/r cll', 'r/r cll goes', 'cll goes to...', 'goes to... zanubrutinib!', 'to... zanubrutinib! Pfs', 'zanubrutinib! Pfs benefit', 'Pfs benefit also', 'benefit also in', 'also in del17p', 'in del17p or', 'del17p or tp53', 'or tp53 aberrations.', 'tp53 aberrations. zanubrutinib', 'aberrations. zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  had', ' had a', 'had a more', 'a more favorable', 'more favorable cardiac', 'favorable cardiac profile', 'cardiac profile in', 'profile in addition.', 'in addition. #ASH22', 'addition. #ASH22 @ASH_hematology', '#ASH22 @ASH_hematology .', 'And the battle of', 'the battle of the', 'battle of the BTKi', 'of the BTKi giants', 'the BTKi giants in', 'BTKi giants in r/r', 'giants in r/r cll', 'in r/r cll goes', 'r/r cll goes to...', 'cll goes to... zanubrutinib!', 'goes to... zanubrutinib! Pfs', 'to... zanubrutinib! Pfs benefit', 'zanubrutinib! Pfs benefit also', 'Pfs benefit also in', 'benefit also in del17p', 'also in del17p or', 'in del17p or tp53', 'del17p or tp53 aberrations.', 'or tp53 aberrations. zanubrutinib', 'tp53 aberrations. zanubrutinib ', 'aberrations. zanubrutinib  ', 'zanubrutinib   ', '   ', '   had', '  had a', ' had a more', 'had a more favorable', 'a more favorable cardiac', 'more favorable cardiac profile', 'favorable cardiac profile in', 'cardiac profile in addition.', 'profile in addition. #ASH22', 'in addition. #ASH22 @ASH_hematology', 'addition. #ASH22 @ASH_hematology .', 'And the battle of the', 'the battle of the BTKi', 'battle of the BTKi giants', 'of the BTKi giants in', 'the BTKi giants in r/r', 'BTKi giants in r/r cll', 'giants in r/r cll goes', 'in r/r cll goes to...', 'r/r cll goes to... zanubrutinib!', 'cll goes to... zanubrutinib! Pfs', 'goes to... zanubrutinib! Pfs benefit', 'to... zanubrutinib! Pfs benefit also', 'zanubrutinib! Pfs benefit also in', 'Pfs benefit also in del17p', 'benefit also in del17p or', 'also in del17p or tp53', 'in del17p or tp53 aberrations.', 'del17p or tp53 aberrations. zanubrutinib', 'or tp53 aberrations. zanubrutinib ', 'tp53 aberrations. zanubrutinib  ', 'aberrations. zanubrutinib   ', 'zanubrutinib    ', '    had', '   had a', '  had a more', ' had a more favorable', 'had a more favorable cardiac', 'a more favorable cardiac profile', 'more favorable cardiac profile in', 'favorable cardiac profile in addition.', 'cardiac profile in addition. #ASH22', 'profile in addition. #ASH22 @ASH_hematology', 'in addition. #ASH22 @ASH_hematology .', 'And the battle of the BTKi', 'the battle of the BTKi giants', 'battle of the BTKi giants in', 'of the BTKi giants in r/r', 'the BTKi giants in r/r cll', 'BTKi giants in r/r cll goes', 'giants in r/r cll goes to...', 'in r/r cll goes to... zanubrutinib!', 'r/r cll goes to... zanubrutinib! Pfs', 'cll goes to... zanubrutinib! Pfs benefit', 'goes to... zanubrutinib! Pfs benefit also', 'to... zanubrutinib! Pfs benefit also in', 'zanubrutinib! Pfs benefit also in del17p', 'Pfs benefit also in del17p or', 'benefit also in del17p or tp53', 'also in del17p or tp53 aberrations.', 'in del17p or tp53 aberrations. zanubrutinib', 'del17p or tp53 aberrations. zanubrutinib ', 'or tp53 aberrations. zanubrutinib  ', 'tp53 aberrations. zanubrutinib   ', 'aberrations. zanubrutinib    ', 'zanubrutinib     had', '    had a', '   had a more', '  had a more favorable', ' had a more favorable cardiac', 'had a more favorable cardiac profile', 'a more favorable cardiac profile in', 'more favorable cardiac profile in addition.', 'favorable cardiac profile in addition. #ASH22', 'cardiac profile in addition. #ASH22 @ASH_hematology', 'profile in addition. #ASH22 @ASH_hematology .', 'And the battle of the BTKi giants', 'the battle of the BTKi giants in', 'battle of the BTKi giants in r/r', 'of the BTKi giants in r/r cll', 'the BTKi giants in r/r cll goes', 'BTKi giants in r/r cll goes to...', 'giants in r/r cll goes to... zanubrutinib!', 'in r/r cll goes to... zanubrutinib! Pfs', 'r/r cll goes to... zanubrutinib! Pfs benefit', 'cll goes to... zanubrutinib! Pfs benefit also', 'goes to... zanubrutinib! Pfs benefit also in', 'to... zanubrutinib! Pfs benefit also in del17p', 'zanubrutinib! Pfs benefit also in del17p or', 'Pfs benefit also in del17p or tp53', 'benefit also in del17p or tp53 aberrations.', 'also in del17p or tp53 aberrations. zanubrutinib', 'in del17p or tp53 aberrations. zanubrutinib ', 'del17p or tp53 aberrations. zanubrutinib  ', 'or tp53 aberrations. zanubrutinib   ', 'tp53 aberrations. zanubrutinib    ', 'aberrations. zanubrutinib     had', 'zanubrutinib     had a', '    had a more', '   had a more favorable', '  had a more favorable cardiac', ' had a more favorable cardiac profile', 'had a more favorable cardiac profile in', 'a more favorable cardiac profile in addition.', 'more favorable cardiac profile in addition. #ASH22', 'favorable cardiac profile in addition. #ASH22 @ASH_hematology', 'cardiac profile in addition. #ASH22 @ASH_hematology .', 'And the battle of the BTKi giants in', 'the battle of the BTKi giants in r/r', 'battle of the BTKi giants in r/r cll', 'of the BTKi giants in r/r cll goes', 'the BTKi giants in r/r cll goes to...', 'BTKi giants in r/r cll goes to... zanubrutinib!', 'giants in r/r cll goes to... zanubrutinib! Pfs', 'in r/r cll goes to... zanubrutinib! Pfs benefit', 'r/r cll goes to... zanubrutinib! Pfs benefit also', 'cll goes to... zanubrutinib! Pfs benefit also in', 'goes to... zanubrutinib! Pfs benefit also in del17p', 'to... zanubrutinib! Pfs benefit also in del17p or', 'zanubrutinib! Pfs benefit also in del17p or tp53', 'Pfs benefit also in del17p or tp53 aberrations.', 'benefit also in del17p or tp53 aberrations. zanubrutinib', 'also in del17p or tp53 aberrations. zanubrutinib ', 'in del17p or tp53 aberrations. zanubrutinib  ', 'del17p or tp53 aberrations. zanubrutinib   ', 'or tp53 aberrations. zanubrutinib    ', 'tp53 aberrations. zanubrutinib     had', 'aberrations. zanubrutinib     had a', 'zanubrutinib     had a more', '    had a more favorable', '   had a more favorable cardiac', '  had a more favorable cardiac profile', ' had a more favorable cardiac profile in', 'had a more favorable cardiac profile in addition.', 'a more favorable cardiac profile in addition. #ASH22', 'more favorable cardiac profile in addition. #ASH22 @ASH_hematology', 'favorable cardiac profile in addition. #ASH22 @ASH_hematology .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '8', 'tokens': ['it', 'would', 'be', 'interesting', 'to', 'see', 'the', 'data', 'from', 'stampede', 'based', 'on', 'gc', 'score', 'and', 'psa', 'response.', 'should', 'gc', 'low', 'with', 'a', 'psa', '&lt;', '0.2', 'a', 'good', 'population', 'to', 'stop', 'therapy?', '#esmo2022', '.'], 'text_length': 33, 'triples': {'stampede|interesting': ([9, 9], [3, 3], 'neutral')}, 'sentence': 'it would be interesting to see the data from stampede based on gc score and psa response. should gc low with a psa &lt; 0.2 a good population to stop therapy? #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(9, 9)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['it', 'would', 'be', 'interesting', 'to', 'see', 'the', 'data', 'from', 'stampede', 'based', 'on', 'gc', 'score', 'and', 'psa', 'response.', 'should', 'gc', 'low', 'with', 'a', 'psa', '&lt;', '0.2', 'a', 'good', 'population', 'to', 'stop', 'therapy?', '#esmo2022', '.', 'it would', 'would be', 'be interesting', 'interesting to', 'to see', 'see the', 'the data', 'data from', 'from stampede', 'stampede based', 'based on', 'on gc', 'gc score', 'score and', 'and psa', 'psa response.', 'response. should', 'should gc', 'gc low', 'low with', 'with a', 'a psa', 'psa &lt;', '&lt; 0.2', '0.2 a', 'a good', 'good population', 'population to', 'to stop', 'stop therapy?', 'therapy? #esmo2022', '#esmo2022 .', 'it would be', 'would be interesting', 'be interesting to', 'interesting to see', 'to see the', 'see the data', 'the data from', 'data from stampede', 'from stampede based', 'stampede based on', 'based on gc', 'on gc score', 'gc score and', 'score and psa', 'and psa response.', 'psa response. should', 'response. should gc', 'should gc low', 'gc low with', 'low with a', 'with a psa', 'a psa &lt;', 'psa &lt; 0.2', '&lt; 0.2 a', '0.2 a good', 'a good population', 'good population to', 'population to stop', 'to stop therapy?', 'stop therapy? #esmo2022', 'therapy? #esmo2022 .', 'it would be interesting', 'would be interesting to', 'be interesting to see', 'interesting to see the', 'to see the data', 'see the data from', 'the data from stampede', 'data from stampede based', 'from stampede based on', 'stampede based on gc', 'based on gc score', 'on gc score and', 'gc score and psa', 'score and psa response.', 'and psa response. should', 'psa response. should gc', 'response. should gc low', 'should gc low with', 'gc low with a', 'low with a psa', 'with a psa &lt;', 'a psa &lt; 0.2', 'psa &lt; 0.2 a', '&lt; 0.2 a good', '0.2 a good population', 'a good population to', 'good population to stop', 'population to stop therapy?', 'to stop therapy? #esmo2022', 'stop therapy? #esmo2022 .', 'it would be interesting to', 'would be interesting to see', 'be interesting to see the', 'interesting to see the data', 'to see the data from', 'see the data from stampede', 'the data from stampede based', 'data from stampede based on', 'from stampede based on gc', 'stampede based on gc score', 'based on gc score and', 'on gc score and psa', 'gc score and psa response.', 'score and psa response. should', 'and psa response. should gc', 'psa response. should gc low', 'response. should gc low with', 'should gc low with a', 'gc low with a psa', 'low with a psa &lt;', 'with a psa &lt; 0.2', 'a psa &lt; 0.2 a', 'psa &lt; 0.2 a good', '&lt; 0.2 a good population', '0.2 a good population to', 'a good population to stop', 'good population to stop therapy?', 'population to stop therapy? #esmo2022', 'to stop therapy? #esmo2022 .', 'it would be interesting to see', 'would be interesting to see the', 'be interesting to see the data', 'interesting to see the data from', 'to see the data from stampede', 'see the data from stampede based', 'the data from stampede based on', 'data from stampede based on gc', 'from stampede based on gc score', 'stampede based on gc score and', 'based on gc score and psa', 'on gc score and psa response.', 'gc score and psa response. should', 'score and psa response. should gc', 'and psa response. should gc low', 'psa response. should gc low with', 'response. should gc low with a', 'should gc low with a psa', 'gc low with a psa &lt;', 'low with a psa &lt; 0.2', 'with a psa &lt; 0.2 a', 'a psa &lt; 0.2 a good', 'psa &lt; 0.2 a good population', '&lt; 0.2 a good population to', '0.2 a good population to stop', 'a good population to stop therapy?', 'good population to stop therapy? #esmo2022', 'population to stop therapy? #esmo2022 .', 'it would be interesting to see the', 'would be interesting to see the data', 'be interesting to see the data from', 'interesting to see the data from stampede', 'to see the data from stampede based', 'see the data from stampede based on', 'the data from stampede based on gc', 'data from stampede based on gc score', 'from stampede based on gc score and', 'stampede based on gc score and psa', 'based on gc score and psa response.', 'on gc score and psa response. should', 'gc score and psa response. should gc', 'score and psa response. should gc low', 'and psa response. should gc low with', 'psa response. should gc low with a', 'response. should gc low with a psa', 'should gc low with a psa &lt;', 'gc low with a psa &lt; 0.2', 'low with a psa &lt; 0.2 a', 'with a psa &lt; 0.2 a good', 'a psa &lt; 0.2 a good population', 'psa &lt; 0.2 a good population to', '&lt; 0.2 a good population to stop', '0.2 a good population to stop therapy?', 'a good population to stop therapy? #esmo2022', 'good population to stop therapy? #esmo2022 .', 'it would be interesting to see the data', 'would be interesting to see the data from', 'be interesting to see the data from stampede', 'interesting to see the data from stampede based', 'to see the data from stampede based on', 'see the data from stampede based on gc', 'the data from stampede based on gc score', 'data from stampede based on gc score and', 'from stampede based on gc score and psa', 'stampede based on gc score and psa response.', 'based on gc score and psa response. should', 'on gc score and psa response. should gc', 'gc score and psa response. should gc low', 'score and psa response. should gc low with', 'and psa response. should gc low with a', 'psa response. should gc low with a psa', 'response. should gc low with a psa &lt;', 'should gc low with a psa &lt; 0.2', 'gc low with a psa &lt; 0.2 a', 'low with a psa &lt; 0.2 a good', 'with a psa &lt; 0.2 a good population', 'a psa &lt; 0.2 a good population to', 'psa &lt; 0.2 a good population to stop', '&lt; 0.2 a good population to stop therapy?', '0.2 a good population to stop therapy? #esmo2022', 'a good population to stop therapy? #esmo2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '9', 'tokens': ['vogel,', 'new', 'york', 'first', 'questions', 'fired', 'from', 'the', 'microphone', 'on', 'vision', '/therap', 'so', 'good', 'to', 'be', 'back', 'at', '#asco2022', '.'], 'text_length': 20, 'triples': {'vision|first questions fired from the microphone on vision /therap so good': ([10, 10], [3, 13], 'neutral')}, 'sentence': 'vogel, new york first questions fired from the microphone on vision /therap so good to be back at #asco2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['vogel,', 'new', 'york', 'first', 'questions', 'fired', 'from', 'the', 'microphone', 'on', 'vision', '/therap', 'so', 'good', 'to', 'be', 'back', 'at', '#asco2022', '.', 'vogel, new', 'new york', 'york first', 'first questions', 'questions fired', 'fired from', 'from the', 'the microphone', 'microphone on', 'on vision', 'vision /therap', '/therap so', 'so good', 'good to', 'to be', 'be back', 'back at', 'at #asco2022', '#asco2022 .', 'vogel, new york', 'new york first', 'york first questions', 'first questions fired', 'questions fired from', 'fired from the', 'from the microphone', 'the microphone on', 'microphone on vision', 'on vision /therap', 'vision /therap so', '/therap so good', 'so good to', 'good to be', 'to be back', 'be back at', 'back at #asco2022', 'at #asco2022 .', 'vogel, new york first', 'new york first questions', 'york first questions fired', 'first questions fired from', 'questions fired from the', 'fired from the microphone', 'from the microphone on', 'the microphone on vision', 'microphone on vision /therap', 'on vision /therap so', 'vision /therap so good', '/therap so good to', 'so good to be', 'good to be back', 'to be back at', 'be back at #asco2022', 'back at #asco2022 .', 'vogel, new york first questions', 'new york first questions fired', 'york first questions fired from', 'first questions fired from the', 'questions fired from the microphone', 'fired from the microphone on', 'from the microphone on vision', 'the microphone on vision /therap', 'microphone on vision /therap so', 'on vision /therap so good', 'vision /therap so good to', '/therap so good to be', 'so good to be back', 'good to be back at', 'to be back at #asco2022', 'be back at #asco2022 .', 'vogel, new york first questions fired', 'new york first questions fired from', 'york first questions fired from the', 'first questions fired from the microphone', 'questions fired from the microphone on', 'fired from the microphone on vision', 'from the microphone on vision /therap', 'the microphone on vision /therap so', 'microphone on vision /therap so good', 'on vision /therap so good to', 'vision /therap so good to be', '/therap so good to be back', 'so good to be back at', 'good to be back at #asco2022', 'to be back at #asco2022 .', 'vogel, new york first questions fired from', 'new york first questions fired from the', 'york first questions fired from the microphone', 'first questions fired from the microphone on', 'questions fired from the microphone on vision', 'fired from the microphone on vision /therap', 'from the microphone on vision /therap so', 'the microphone on vision /therap so good', 'microphone on vision /therap so good to', 'on vision /therap so good to be', 'vision /therap so good to be back', '/therap so good to be back at', 'so good to be back at #asco2022', 'good to be back at #asco2022 .', 'vogel, new york first questions fired from the', 'new york first questions fired from the microphone', 'york first questions fired from the microphone on', 'first questions fired from the microphone on vision', 'questions fired from the microphone on vision /therap', 'fired from the microphone on vision /therap so', 'from the microphone on vision /therap so good', 'the microphone on vision /therap so good to', 'microphone on vision /therap so good to be', 'on vision /therap so good to be back', 'vision /therap so good to be back at', '/therap so good to be back at #asco2022', 'so good to be back at #asco2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '10', 'tokens': ['#asco22', '#', 'nivolumab', 'cabozantinib', 'associated', 'with', 'greater', 'proportion', 'of', 'deep', 'objective', 'responses', 'for', 'advanced', '#renalcellcarcinoma', '.'], 'text_length': 16, 'triples': {'nivolumab|with greater proportion of deep': ([2, 2], [5, 9], 'neutral'), '#|with greater proportion of deep': ([1, 1], [5, 9], 'neutral')}, 'sentence': '#asco22 # nivolumab cabozantinib associated with greater proportion of deep objective responses for advanced #renalcellcarcinoma .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(2, 2), (1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8)], 'span tokens': ['#asco22', '#', 'nivolumab', 'cabozantinib', 'associated', 'with', 'greater', 'proportion', 'of', 'deep', 'objective', 'responses', 'for', 'advanced', '#renalcellcarcinoma', '.', '#asco22 #', '# nivolumab', 'nivolumab cabozantinib', 'cabozantinib associated', 'associated with', 'with greater', 'greater proportion', 'proportion of', 'of deep', 'deep objective', 'objective responses', 'responses for', 'for advanced', 'advanced #renalcellcarcinoma', '#renalcellcarcinoma .', '#asco22 # nivolumab', '# nivolumab cabozantinib', 'nivolumab cabozantinib associated', 'cabozantinib associated with', 'associated with greater', 'with greater proportion', 'greater proportion of', 'proportion of deep', 'of deep objective', 'deep objective responses', 'objective responses for', 'responses for advanced', 'for advanced #renalcellcarcinoma', 'advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib', '# nivolumab cabozantinib associated', 'nivolumab cabozantinib associated with', 'cabozantinib associated with greater', 'associated with greater proportion', 'with greater proportion of', 'greater proportion of deep', 'proportion of deep objective', 'of deep objective responses', 'deep objective responses for', 'objective responses for advanced', 'responses for advanced #renalcellcarcinoma', 'for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated', '# nivolumab cabozantinib associated with', 'nivolumab cabozantinib associated with greater', 'cabozantinib associated with greater proportion', 'associated with greater proportion of', 'with greater proportion of deep', 'greater proportion of deep objective', 'proportion of deep objective responses', 'of deep objective responses for', 'deep objective responses for advanced', 'objective responses for advanced #renalcellcarcinoma', 'responses for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated with', '# nivolumab cabozantinib associated with greater', 'nivolumab cabozantinib associated with greater proportion', 'cabozantinib associated with greater proportion of', 'associated with greater proportion of deep', 'with greater proportion of deep objective', 'greater proportion of deep objective responses', 'proportion of deep objective responses for', 'of deep objective responses for advanced', 'deep objective responses for advanced #renalcellcarcinoma', 'objective responses for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated with greater', '# nivolumab cabozantinib associated with greater proportion', 'nivolumab cabozantinib associated with greater proportion of', 'cabozantinib associated with greater proportion of deep', 'associated with greater proportion of deep objective', 'with greater proportion of deep objective responses', 'greater proportion of deep objective responses for', 'proportion of deep objective responses for advanced', 'of deep objective responses for advanced #renalcellcarcinoma', 'deep objective responses for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated with greater proportion', '# nivolumab cabozantinib associated with greater proportion of', 'nivolumab cabozantinib associated with greater proportion of deep', 'cabozantinib associated with greater proportion of deep objective', 'associated with greater proportion of deep objective responses', 'with greater proportion of deep objective responses for', 'greater proportion of deep objective responses for advanced', 'proportion of deep objective responses for advanced #renalcellcarcinoma', 'of deep objective responses for advanced #renalcellcarcinoma .'], 'spans_aspect_label': [0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '11', 'tokens': ['Zanubrutinib', 'superior', 'to', 'Ibrutinib', 'late', 'breaking', 'abstracts', '#ASH22', 'Congratulations', 'to', 'my', 'colleague', '.'], 'text_length': 13, 'triples': {'Ibrutinib|superior to Ibrutinib late breaking abstracts #ASH22 Congratulations to': ([3, 3], [1, 9], 'negative'), 'Zanubrutinib|superior': ([0, 0], [1, 1], 'positive')}, 'sentence': 'Zanubrutinib superior to Ibrutinib late breaking abstracts #ASH22 Congratulations to my colleague .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(3, 3), (0, 0)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(1, 9), (1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8)], 'span tokens': ['Zanubrutinib', 'superior', 'to', 'Ibrutinib', 'late', 'breaking', 'abstracts', '#ASH22', 'Congratulations', 'to', 'my', 'colleague', '.', 'Zanubrutinib superior', 'superior to', 'to Ibrutinib', 'Ibrutinib late', 'late breaking', 'breaking abstracts', 'abstracts #ASH22', '#ASH22 Congratulations', 'Congratulations to', 'to my', 'my colleague', 'colleague .', 'Zanubrutinib superior to', 'superior to Ibrutinib', 'to Ibrutinib late', 'Ibrutinib late breaking', 'late breaking abstracts', 'breaking abstracts #ASH22', 'abstracts #ASH22 Congratulations', '#ASH22 Congratulations to', 'Congratulations to my', 'to my colleague', 'my colleague .', 'Zanubrutinib superior to Ibrutinib', 'superior to Ibrutinib late', 'to Ibrutinib late breaking', 'Ibrutinib late breaking abstracts', 'late breaking abstracts #ASH22', 'breaking abstracts #ASH22 Congratulations', 'abstracts #ASH22 Congratulations to', '#ASH22 Congratulations to my', 'Congratulations to my colleague', 'to my colleague .', 'Zanubrutinib superior to Ibrutinib late', 'superior to Ibrutinib late breaking', 'to Ibrutinib late breaking abstracts', 'Ibrutinib late breaking abstracts #ASH22', 'late breaking abstracts #ASH22 Congratulations', 'breaking abstracts #ASH22 Congratulations to', 'abstracts #ASH22 Congratulations to my', '#ASH22 Congratulations to my colleague', 'Congratulations to my colleague .', 'Zanubrutinib superior to Ibrutinib late breaking', 'superior to Ibrutinib late breaking abstracts', 'to Ibrutinib late breaking abstracts #ASH22', 'Ibrutinib late breaking abstracts #ASH22 Congratulations', 'late breaking abstracts #ASH22 Congratulations to', 'breaking abstracts #ASH22 Congratulations to my', 'abstracts #ASH22 Congratulations to my colleague', '#ASH22 Congratulations to my colleague .', 'Zanubrutinib superior to Ibrutinib late breaking abstracts', 'superior to Ibrutinib late breaking abstracts #ASH22', 'to Ibrutinib late breaking abstracts #ASH22 Congratulations', 'Ibrutinib late breaking abstracts #ASH22 Congratulations to', 'late breaking abstracts #ASH22 Congratulations to my', 'breaking abstracts #ASH22 Congratulations to my colleague', 'abstracts #ASH22 Congratulations to my colleague .', 'Zanubrutinib superior to Ibrutinib late breaking abstracts #ASH22', 'superior to Ibrutinib late breaking abstracts #ASH22 Congratulations', 'to Ibrutinib late breaking abstracts #ASH22 Congratulations to', 'Ibrutinib late breaking abstracts #ASH22 Congratulations to my', 'late breaking abstracts #ASH22 Congratulations to my colleague', 'breaking abstracts #ASH22 Congratulations to my colleague .'], 'spans_aspect_label': [1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '12', 'tokens': ['updated', 'results', 'from', 'the', 'phase', '3', 'propel', 'trial', 'in', 'mcrpc', '#prostatecancer', 'showed', 'rpfs', 'benefit', 'of', 'using', 'abiraterone+olaparib', 'vs', 'abiraterone.', 'os', 'trending!', '#esmo22', 'pr.', 'fred', 'saad', '.'], 'text_length': 26, 'triples': {'propel|showed rpfs benefit': ([6, 6], [11, 13], 'positive'), 'abiraterone+olaparib|showed rpfs benefit': ([16, 16], [11, 13], 'positive')}, 'sentence': 'updated results from the phase 3 propel trial in mcrpc #prostatecancer showed rpfs benefit of using abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr. fred saad .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(6, 6), (16, 16)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(11, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['updated', 'results', 'from', 'the', 'phase', '3', 'propel', 'trial', 'in', 'mcrpc', '#prostatecancer', 'showed', 'rpfs', 'benefit', 'of', 'using', 'abiraterone+olaparib', 'vs', 'abiraterone.', 'os', 'trending!', '#esmo22', 'pr.', 'fred', 'saad', '.', 'updated results', 'results from', 'from the', 'the phase', 'phase 3', '3 propel', 'propel trial', 'trial in', 'in mcrpc', 'mcrpc #prostatecancer', '#prostatecancer showed', 'showed rpfs', 'rpfs benefit', 'benefit of', 'of using', 'using abiraterone+olaparib', 'abiraterone+olaparib vs', 'vs abiraterone.', 'abiraterone. os', 'os trending!', 'trending! #esmo22', '#esmo22 pr.', 'pr. fred', 'fred saad', 'saad .', 'updated results from', 'results from the', 'from the phase', 'the phase 3', 'phase 3 propel', '3 propel trial', 'propel trial in', 'trial in mcrpc', 'in mcrpc #prostatecancer', 'mcrpc #prostatecancer showed', '#prostatecancer showed rpfs', 'showed rpfs benefit', 'rpfs benefit of', 'benefit of using', 'of using abiraterone+olaparib', 'using abiraterone+olaparib vs', 'abiraterone+olaparib vs abiraterone.', 'vs abiraterone. os', 'abiraterone. os trending!', 'os trending! #esmo22', 'trending! #esmo22 pr.', '#esmo22 pr. fred', 'pr. fred saad', 'fred saad .', 'updated results from the', 'results from the phase', 'from the phase 3', 'the phase 3 propel', 'phase 3 propel trial', '3 propel trial in', 'propel trial in mcrpc', 'trial in mcrpc #prostatecancer', 'in mcrpc #prostatecancer showed', 'mcrpc #prostatecancer showed rpfs', '#prostatecancer showed rpfs benefit', 'showed rpfs benefit of', 'rpfs benefit of using', 'benefit of using abiraterone+olaparib', 'of using abiraterone+olaparib vs', 'using abiraterone+olaparib vs abiraterone.', 'abiraterone+olaparib vs abiraterone. os', 'vs abiraterone. os trending!', 'abiraterone. os trending! #esmo22', 'os trending! #esmo22 pr.', 'trending! #esmo22 pr. fred', '#esmo22 pr. fred saad', 'pr. fred saad .', 'updated results from the phase', 'results from the phase 3', 'from the phase 3 propel', 'the phase 3 propel trial', 'phase 3 propel trial in', '3 propel trial in mcrpc', 'propel trial in mcrpc #prostatecancer', 'trial in mcrpc #prostatecancer showed', 'in mcrpc #prostatecancer showed rpfs', 'mcrpc #prostatecancer showed rpfs benefit', '#prostatecancer showed rpfs benefit of', 'showed rpfs benefit of using', 'rpfs benefit of using abiraterone+olaparib', 'benefit of using abiraterone+olaparib vs', 'of using abiraterone+olaparib vs abiraterone.', 'using abiraterone+olaparib vs abiraterone. os', 'abiraterone+olaparib vs abiraterone. os trending!', 'vs abiraterone. os trending! #esmo22', 'abiraterone. os trending! #esmo22 pr.', 'os trending! #esmo22 pr. fred', 'trending! #esmo22 pr. fred saad', '#esmo22 pr. fred saad .', 'updated results from the phase 3', 'results from the phase 3 propel', 'from the phase 3 propel trial', 'the phase 3 propel trial in', 'phase 3 propel trial in mcrpc', '3 propel trial in mcrpc #prostatecancer', 'propel trial in mcrpc #prostatecancer showed', 'trial in mcrpc #prostatecancer showed rpfs', 'in mcrpc #prostatecancer showed rpfs benefit', 'mcrpc #prostatecancer showed rpfs benefit of', '#prostatecancer showed rpfs benefit of using', 'showed rpfs benefit of using abiraterone+olaparib', 'rpfs benefit of using abiraterone+olaparib vs', 'benefit of using abiraterone+olaparib vs abiraterone.', 'of using abiraterone+olaparib vs abiraterone. os', 'using abiraterone+olaparib vs abiraterone. os trending!', 'abiraterone+olaparib vs abiraterone. os trending! #esmo22', 'vs abiraterone. os trending! #esmo22 pr.', 'abiraterone. os trending! #esmo22 pr. fred', 'os trending! #esmo22 pr. fred saad', 'trending! #esmo22 pr. fred saad .', 'updated results from the phase 3 propel', 'results from the phase 3 propel trial', 'from the phase 3 propel trial in', 'the phase 3 propel trial in mcrpc', 'phase 3 propel trial in mcrpc #prostatecancer', '3 propel trial in mcrpc #prostatecancer showed', 'propel trial in mcrpc #prostatecancer showed rpfs', 'trial in mcrpc #prostatecancer showed rpfs benefit', 'in mcrpc #prostatecancer showed rpfs benefit of', 'mcrpc #prostatecancer showed rpfs benefit of using', '#prostatecancer showed rpfs benefit of using abiraterone+olaparib', 'showed rpfs benefit of using abiraterone+olaparib vs', 'rpfs benefit of using abiraterone+olaparib vs abiraterone.', 'benefit of using abiraterone+olaparib vs abiraterone. os', 'of using abiraterone+olaparib vs abiraterone. os trending!', 'using abiraterone+olaparib vs abiraterone. os trending! #esmo22', 'abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr.', 'vs abiraterone. os trending! #esmo22 pr. fred', 'abiraterone. os trending! #esmo22 pr. fred saad', 'os trending! #esmo22 pr. fred saad .', 'updated results from the phase 3 propel trial', 'results from the phase 3 propel trial in', 'from the phase 3 propel trial in mcrpc', 'the phase 3 propel trial in mcrpc #prostatecancer', 'phase 3 propel trial in mcrpc #prostatecancer showed', '3 propel trial in mcrpc #prostatecancer showed rpfs', 'propel trial in mcrpc #prostatecancer showed rpfs benefit', 'trial in mcrpc #prostatecancer showed rpfs benefit of', 'in mcrpc #prostatecancer showed rpfs benefit of using', 'mcrpc #prostatecancer showed rpfs benefit of using abiraterone+olaparib', '#prostatecancer showed rpfs benefit of using abiraterone+olaparib vs', 'showed rpfs benefit of using abiraterone+olaparib vs abiraterone.', 'rpfs benefit of using abiraterone+olaparib vs abiraterone. os', 'benefit of using abiraterone+olaparib vs abiraterone. os trending!', 'of using abiraterone+olaparib vs abiraterone. os trending! #esmo22', 'using abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr.', 'abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr. fred', 'vs abiraterone. os trending! #esmo22 pr. fred saad', 'abiraterone. os trending! #esmo22 pr. fred saad .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '13', 'tokens': ['with', 'a', 'great', 'presentation', 'on', 'concordance', 'of', 'ngs/ngf,', 'serological', 'response,', 'and', 'more', 'impressive', 'reapearance', 'of', 'normal', 'pc', 'as', 'poor', 'prognostic', 'factors', 'in', 'karmma', 'biomarker', 'for', 'loss', 'of', 'on-target,', 'off-tumor', 'effect?', '#ash22', '#mmsm', '.'], 'text_length': 33, 'triples': {'karmma|great presentation on concordance of ngs/ngf, serological response, and more impressive': ([22, 22], [2, 12], 'positive')}, 'sentence': 'with a great presentation on concordance of ngs/ngf, serological response, and more impressive reapearance of normal pc as poor prognostic factors in karmma biomarker for loss of on-target, off-tumor effect? #ash22 #mmsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(22, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['with', 'a', 'great', 'presentation', 'on', 'concordance', 'of', 'ngs/ngf,', 'serological', 'response,', 'and', 'more', 'impressive', 'reapearance', 'of', 'normal', 'pc', 'as', 'poor', 'prognostic', 'factors', 'in', 'karmma', 'biomarker', 'for', 'loss', 'of', 'on-target,', 'off-tumor', 'effect?', '#ash22', '#mmsm', '.', 'with a', 'a great', 'great presentation', 'presentation on', 'on concordance', 'concordance of', 'of ngs/ngf,', 'ngs/ngf, serological', 'serological response,', 'response, and', 'and more', 'more impressive', 'impressive reapearance', 'reapearance of', 'of normal', 'normal pc', 'pc as', 'as poor', 'poor prognostic', 'prognostic factors', 'factors in', 'in karmma', 'karmma biomarker', 'biomarker for', 'for loss', 'loss of', 'of on-target,', 'on-target, off-tumor', 'off-tumor effect?', 'effect? #ash22', '#ash22 #mmsm', '#mmsm .', 'with a great', 'a great presentation', 'great presentation on', 'presentation on concordance', 'on concordance of', 'concordance of ngs/ngf,', 'of ngs/ngf, serological', 'ngs/ngf, serological response,', 'serological response, and', 'response, and more', 'and more impressive', 'more impressive reapearance', 'impressive reapearance of', 'reapearance of normal', 'of normal pc', 'normal pc as', 'pc as poor', 'as poor prognostic', 'poor prognostic factors', 'prognostic factors in', 'factors in karmma', 'in karmma biomarker', 'karmma biomarker for', 'biomarker for loss', 'for loss of', 'loss of on-target,', 'of on-target, off-tumor', 'on-target, off-tumor effect?', 'off-tumor effect? #ash22', 'effect? #ash22 #mmsm', '#ash22 #mmsm .', 'with a great presentation', 'a great presentation on', 'great presentation on concordance', 'presentation on concordance of', 'on concordance of ngs/ngf,', 'concordance of ngs/ngf, serological', 'of ngs/ngf, serological response,', 'ngs/ngf, serological response, and', 'serological response, and more', 'response, and more impressive', 'and more impressive reapearance', 'more impressive reapearance of', 'impressive reapearance of normal', 'reapearance of normal pc', 'of normal pc as', 'normal pc as poor', 'pc as poor prognostic', 'as poor prognostic factors', 'poor prognostic factors in', 'prognostic factors in karmma', 'factors in karmma biomarker', 'in karmma biomarker for', 'karmma biomarker for loss', 'biomarker for loss of', 'for loss of on-target,', 'loss of on-target, off-tumor', 'of on-target, off-tumor effect?', 'on-target, off-tumor effect? #ash22', 'off-tumor effect? #ash22 #mmsm', 'effect? #ash22 #mmsm .', 'with a great presentation on', 'a great presentation on concordance', 'great presentation on concordance of', 'presentation on concordance of ngs/ngf,', 'on concordance of ngs/ngf, serological', 'concordance of ngs/ngf, serological response,', 'of ngs/ngf, serological response, and', 'ngs/ngf, serological response, and more', 'serological response, and more impressive', 'response, and more impressive reapearance', 'and more impressive reapearance of', 'more impressive reapearance of normal', 'impressive reapearance of normal pc', 'reapearance of normal pc as', 'of normal pc as poor', 'normal pc as poor prognostic', 'pc as poor prognostic factors', 'as poor prognostic factors in', 'poor prognostic factors in karmma', 'prognostic factors in karmma biomarker', 'factors in karmma biomarker for', 'in karmma biomarker for loss', 'karmma biomarker for loss of', 'biomarker for loss of on-target,', 'for loss of on-target, off-tumor', 'loss of on-target, off-tumor effect?', 'of on-target, off-tumor effect? #ash22', 'on-target, off-tumor effect? #ash22 #mmsm', 'off-tumor effect? #ash22 #mmsm .', 'with a great presentation on concordance', 'a great presentation on concordance of', 'great presentation on concordance of ngs/ngf,', 'presentation on concordance of ngs/ngf, serological', 'on concordance of ngs/ngf, serological response,', 'concordance of ngs/ngf, serological response, and', 'of ngs/ngf, serological response, and more', 'ngs/ngf, serological response, and more impressive', 'serological response, and more impressive reapearance', 'response, and more impressive reapearance of', 'and more impressive reapearance of normal', 'more impressive reapearance of normal pc', 'impressive reapearance of normal pc as', 'reapearance of normal pc as poor', 'of normal pc as poor prognostic', 'normal pc as poor prognostic factors', 'pc as poor prognostic factors in', 'as poor prognostic factors in karmma', 'poor prognostic factors in karmma biomarker', 'prognostic factors in karmma biomarker for', 'factors in karmma biomarker for loss', 'in karmma biomarker for loss of', 'karmma biomarker for loss of on-target,', 'biomarker for loss of on-target, off-tumor', 'for loss of on-target, off-tumor effect?', 'loss of on-target, off-tumor effect? #ash22', 'of on-target, off-tumor effect? #ash22 #mmsm', 'on-target, off-tumor effect? #ash22 #mmsm .', 'with a great presentation on concordance of', 'a great presentation on concordance of ngs/ngf,', 'great presentation on concordance of ngs/ngf, serological', 'presentation on concordance of ngs/ngf, serological response,', 'on concordance of ngs/ngf, serological response, and', 'concordance of ngs/ngf, serological response, and more', 'of ngs/ngf, serological response, and more impressive', 'ngs/ngf, serological response, and more impressive reapearance', 'serological response, and more impressive reapearance of', 'response, and more impressive reapearance of normal', 'and more impressive reapearance of normal pc', 'more impressive reapearance of normal pc as', 'impressive reapearance of normal pc as poor', 'reapearance of normal pc as poor prognostic', 'of normal pc as poor prognostic factors', 'normal pc as poor prognostic factors in', 'pc as poor prognostic factors in karmma', 'as poor prognostic factors in karmma biomarker', 'poor prognostic factors in karmma biomarker for', 'prognostic factors in karmma biomarker for loss', 'factors in karmma biomarker for loss of', 'in karmma biomarker for loss of on-target,', 'karmma biomarker for loss of on-target, off-tumor', 'biomarker for loss of on-target, off-tumor effect?', 'for loss of on-target, off-tumor effect? #ash22', 'loss of on-target, off-tumor effect? #ash22 #mmsm', 'of on-target, off-tumor effect? #ash22 #mmsm .', 'with a great presentation on concordance of ngs/ngf,', 'a great presentation on concordance of ngs/ngf, serological', 'great presentation on concordance of ngs/ngf, serological response,', 'presentation on concordance of ngs/ngf, serological response, and', 'on concordance of ngs/ngf, serological response, and more', 'concordance of ngs/ngf, serological response, and more impressive', 'of ngs/ngf, serological response, and more impressive reapearance', 'ngs/ngf, serological response, and more impressive reapearance of', 'serological response, and more impressive reapearance of normal', 'response, and more impressive reapearance of normal pc', 'and more impressive reapearance of normal pc as', 'more impressive reapearance of normal pc as poor', 'impressive reapearance of normal pc as poor prognostic', 'reapearance of normal pc as poor prognostic factors', 'of normal pc as poor prognostic factors in', 'normal pc as poor prognostic factors in karmma', 'pc as poor prognostic factors in karmma biomarker', 'as poor prognostic factors in karmma biomarker for', 'poor prognostic factors in karmma biomarker for loss', 'prognostic factors in karmma biomarker for loss of', 'factors in karmma biomarker for loss of on-target,', 'in karmma biomarker for loss of on-target, off-tumor', 'karmma biomarker for loss of on-target, off-tumor effect?', 'biomarker for loss of on-target, off-tumor effect? #ash22', 'for loss of on-target, off-tumor effect? #ash22 #mmsm', 'loss of on-target, off-tumor effect? #ash22 #mmsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '14', 'tokens': ['nodal', 'burden', 'and', 'nodal', 'metastases', 'response', 'in', 'mhspc', '(', 'stampede', ').', 'should', 'we', 'take', 'these', 'data', 'into', 'account', 'in', 'everyday', 'practice?', '#esmo22', '.'], 'text_length': 23, 'triples': {'(|stampede ). should': ([8, 8], [9, 11], 'neutral')}, 'sentence': 'nodal burden and nodal metastases response in mhspc ( stampede ). should we take these data into account in everyday practice? #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8)], 'span tokens': ['nodal', 'burden', 'and', 'nodal', 'metastases', 'response', 'in', 'mhspc', '(', 'stampede', ').', 'should', 'we', 'take', 'these', 'data', 'into', 'account', 'in', 'everyday', 'practice?', '#esmo22', '.', 'nodal burden', 'burden and', 'and nodal', 'nodal metastases', 'metastases response', 'response in', 'in mhspc', 'mhspc (', '( stampede', 'stampede ).', '). should', 'should we', 'we take', 'take these', 'these data', 'data into', 'into account', 'account in', 'in everyday', 'everyday practice?', 'practice? #esmo22', '#esmo22 .', 'nodal burden and', 'burden and nodal', 'and nodal metastases', 'nodal metastases response', 'metastases response in', 'response in mhspc', 'in mhspc (', 'mhspc ( stampede', '( stampede ).', 'stampede ). should', '). should we', 'should we take', 'we take these', 'take these data', 'these data into', 'data into account', 'into account in', 'account in everyday', 'in everyday practice?', 'everyday practice? #esmo22', 'practice? #esmo22 .', 'nodal burden and nodal', 'burden and nodal metastases', 'and nodal metastases response', 'nodal metastases response in', 'metastases response in mhspc', 'response in mhspc (', 'in mhspc ( stampede', 'mhspc ( stampede ).', '( stampede ). should', 'stampede ). should we', '). should we take', 'should we take these', 'we take these data', 'take these data into', 'these data into account', 'data into account in', 'into account in everyday', 'account in everyday practice?', 'in everyday practice? #esmo22', 'everyday practice? #esmo22 .', 'nodal burden and nodal metastases', 'burden and nodal metastases response', 'and nodal metastases response in', 'nodal metastases response in mhspc', 'metastases response in mhspc (', 'response in mhspc ( stampede', 'in mhspc ( stampede ).', 'mhspc ( stampede ). should', '( stampede ). should we', 'stampede ). should we take', '). should we take these', 'should we take these data', 'we take these data into', 'take these data into account', 'these data into account in', 'data into account in everyday', 'into account in everyday practice?', 'account in everyday practice? #esmo22', 'in everyday practice? #esmo22 .', 'nodal burden and nodal metastases response', 'burden and nodal metastases response in', 'and nodal metastases response in mhspc', 'nodal metastases response in mhspc (', 'metastases response in mhspc ( stampede', 'response in mhspc ( stampede ).', 'in mhspc ( stampede ). should', 'mhspc ( stampede ). should we', '( stampede ). should we take', 'stampede ). should we take these', '). should we take these data', 'should we take these data into', 'we take these data into account', 'take these data into account in', 'these data into account in everyday', 'data into account in everyday practice?', 'into account in everyday practice? #esmo22', 'account in everyday practice? #esmo22 .', 'nodal burden and nodal metastases response in', 'burden and nodal metastases response in mhspc', 'and nodal metastases response in mhspc (', 'nodal metastases response in mhspc ( stampede', 'metastases response in mhspc ( stampede ).', 'response in mhspc ( stampede ). should', 'in mhspc ( stampede ). should we', 'mhspc ( stampede ). should we take', '( stampede ). should we take these', 'stampede ). should we take these data', '). should we take these data into', 'should we take these data into account', 'we take these data into account in', 'take these data into account in everyday', 'these data into account in everyday practice?', 'data into account in everyday practice? #esmo22', 'into account in everyday practice? #esmo22 .', 'nodal burden and nodal metastases response in mhspc', 'burden and nodal metastases response in mhspc (', 'and nodal metastases response in mhspc ( stampede', 'nodal metastases response in mhspc ( stampede ).', 'metastases response in mhspc ( stampede ). should', 'response in mhspc ( stampede ). should we', 'in mhspc ( stampede ). should we take', 'mhspc ( stampede ). should we take these', '( stampede ). should we take these data', 'stampede ). should we take these data into', '). should we take these data into account', 'should we take these data into account in', 'we take these data into account in everyday', 'take these data into account in everyday practice?', 'these data into account in everyday practice? #esmo22', 'data into account in everyday practice? #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '15', 'tokens': ['3', 'excellent', '#mhspc', 'stampede', 'talks', 'at', '#esmo22', 'today:', 'lba62', 'os', 'results', 'of', 'm1', 'socvsadt+aap', '&amp;', 'socvsadt+aap+enza', '1358o', 'transcriptomic', 'signatures', 'in', 'adt', 'aap', '1359mo', 'nodal', 'mets', 'as', 'a', 'marker', 'of', 'prognosis', 'and', 'differential', 'rx', 'response', 'w/', 'aap', 'vs', 'doce', '.'], 'text_length': 39, 'triples': {'stampede|excellent': ([3, 3], [1, 1], 'neutral')}, 'sentence': '3 excellent #mhspc stampede talks at #esmo22 today: lba62 os results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt aap 1359mo nodal mets as a marker of prognosis and differential rx response w/ aap vs doce .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8)], 'span tokens': ['3', 'excellent', '#mhspc', 'stampede', 'talks', 'at', '#esmo22', 'today:', 'lba62', 'os', 'results', 'of', 'm1', 'socvsadt+aap', '&amp;', 'socvsadt+aap+enza', '1358o', 'transcriptomic', 'signatures', 'in', 'adt', 'aap', '1359mo', 'nodal', 'mets', 'as', 'a', 'marker', 'of', 'prognosis', 'and', 'differential', 'rx', 'response', 'w/', 'aap', 'vs', 'doce', '.', '3 excellent', 'excellent #mhspc', '#mhspc stampede', 'stampede talks', 'talks at', 'at #esmo22', '#esmo22 today:', 'today: lba62', 'lba62 os', 'os results', 'results of', 'of m1', 'm1 socvsadt+aap', 'socvsadt+aap &amp;', '&amp; socvsadt+aap+enza', 'socvsadt+aap+enza 1358o', '1358o transcriptomic', 'transcriptomic signatures', 'signatures in', 'in adt', 'adt aap', 'aap 1359mo', '1359mo nodal', 'nodal mets', 'mets as', 'as a', 'a marker', 'marker of', 'of prognosis', 'prognosis and', 'and differential', 'differential rx', 'rx response', 'response w/', 'w/ aap', 'aap vs', 'vs doce', 'doce .', '3 excellent #mhspc', 'excellent #mhspc stampede', '#mhspc stampede talks', 'stampede talks at', 'talks at #esmo22', 'at #esmo22 today:', '#esmo22 today: lba62', 'today: lba62 os', 'lba62 os results', 'os results of', 'results of m1', 'of m1 socvsadt+aap', 'm1 socvsadt+aap &amp;', 'socvsadt+aap &amp; socvsadt+aap+enza', '&amp; socvsadt+aap+enza 1358o', 'socvsadt+aap+enza 1358o transcriptomic', '1358o transcriptomic signatures', 'transcriptomic signatures in', 'signatures in adt', 'in adt aap', 'adt aap 1359mo', 'aap 1359mo nodal', '1359mo nodal mets', 'nodal mets as', 'mets as a', 'as a marker', 'a marker of', 'marker of prognosis', 'of prognosis and', 'prognosis and differential', 'and differential rx', 'differential rx response', 'rx response w/', 'response w/ aap', 'w/ aap vs', 'aap vs doce', 'vs doce .', '3 excellent #mhspc stampede', 'excellent #mhspc stampede talks', '#mhspc stampede talks at', 'stampede talks at #esmo22', 'talks at #esmo22 today:', 'at #esmo22 today: lba62', '#esmo22 today: lba62 os', 'today: lba62 os results', 'lba62 os results of', 'os results of m1', 'results of m1 socvsadt+aap', 'of m1 socvsadt+aap &amp;', 'm1 socvsadt+aap &amp; socvsadt+aap+enza', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o', '&amp; socvsadt+aap+enza 1358o transcriptomic', 'socvsadt+aap+enza 1358o transcriptomic signatures', '1358o transcriptomic signatures in', 'transcriptomic signatures in adt', 'signatures in adt aap', 'in adt aap 1359mo', 'adt aap 1359mo nodal', 'aap 1359mo nodal mets', '1359mo nodal mets as', 'nodal mets as a', 'mets as a marker', 'as a marker of', 'a marker of prognosis', 'marker of prognosis and', 'of prognosis and differential', 'prognosis and differential rx', 'and differential rx response', 'differential rx response w/', 'rx response w/ aap', 'response w/ aap vs', 'w/ aap vs doce', 'aap vs doce .', '3 excellent #mhspc stampede talks', 'excellent #mhspc stampede talks at', '#mhspc stampede talks at #esmo22', 'stampede talks at #esmo22 today:', 'talks at #esmo22 today: lba62', 'at #esmo22 today: lba62 os', '#esmo22 today: lba62 os results', 'today: lba62 os results of', 'lba62 os results of m1', 'os results of m1 socvsadt+aap', 'results of m1 socvsadt+aap &amp;', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures', 'socvsadt+aap+enza 1358o transcriptomic signatures in', '1358o transcriptomic signatures in adt', 'transcriptomic signatures in adt aap', 'signatures in adt aap 1359mo', 'in adt aap 1359mo nodal', 'adt aap 1359mo nodal mets', 'aap 1359mo nodal mets as', '1359mo nodal mets as a', 'nodal mets as a marker', 'mets as a marker of', 'as a marker of prognosis', 'a marker of prognosis and', 'marker of prognosis and differential', 'of prognosis and differential rx', 'prognosis and differential rx response', 'and differential rx response w/', 'differential rx response w/ aap', 'rx response w/ aap vs', 'response w/ aap vs doce', 'w/ aap vs doce .', '3 excellent #mhspc stampede talks at', 'excellent #mhspc stampede talks at #esmo22', '#mhspc stampede talks at #esmo22 today:', 'stampede talks at #esmo22 today: lba62', 'talks at #esmo22 today: lba62 os', 'at #esmo22 today: lba62 os results', '#esmo22 today: lba62 os results of', 'today: lba62 os results of m1', 'lba62 os results of m1 socvsadt+aap', 'os results of m1 socvsadt+aap &amp;', 'results of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures in', 'socvsadt+aap+enza 1358o transcriptomic signatures in adt', '1358o transcriptomic signatures in adt aap', 'transcriptomic signatures in adt aap 1359mo', 'signatures in adt aap 1359mo nodal', 'in adt aap 1359mo nodal mets', 'adt aap 1359mo nodal mets as', 'aap 1359mo nodal mets as a', '1359mo nodal mets as a marker', 'nodal mets as a marker of', 'mets as a marker of prognosis', 'as a marker of prognosis and', 'a marker of prognosis and differential', 'marker of prognosis and differential rx', 'of prognosis and differential rx response', 'prognosis and differential rx response w/', 'and differential rx response w/ aap', 'differential rx response w/ aap vs', 'rx response w/ aap vs doce', 'response w/ aap vs doce .', '3 excellent #mhspc stampede talks at #esmo22', 'excellent #mhspc stampede talks at #esmo22 today:', '#mhspc stampede talks at #esmo22 today: lba62', 'stampede talks at #esmo22 today: lba62 os', 'talks at #esmo22 today: lba62 os results', 'at #esmo22 today: lba62 os results of', '#esmo22 today: lba62 os results of m1', 'today: lba62 os results of m1 socvsadt+aap', 'lba62 os results of m1 socvsadt+aap &amp;', 'os results of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt', 'socvsadt+aap+enza 1358o transcriptomic signatures in adt aap', '1358o transcriptomic signatures in adt aap 1359mo', 'transcriptomic signatures in adt aap 1359mo nodal', 'signatures in adt aap 1359mo nodal mets', 'in adt aap 1359mo nodal mets as', 'adt aap 1359mo nodal mets as a', 'aap 1359mo nodal mets as a marker', '1359mo nodal mets as a marker of', 'nodal mets as a marker of prognosis', 'mets as a marker of prognosis and', 'as a marker of prognosis and differential', 'a marker of prognosis and differential rx', 'marker of prognosis and differential rx response', 'of prognosis and differential rx response w/', 'prognosis and differential rx response w/ aap', 'and differential rx response w/ aap vs', 'differential rx response w/ aap vs doce', 'rx response w/ aap vs doce .', '3 excellent #mhspc stampede talks at #esmo22 today:', 'excellent #mhspc stampede talks at #esmo22 today: lba62', '#mhspc stampede talks at #esmo22 today: lba62 os', 'stampede talks at #esmo22 today: lba62 os results', 'talks at #esmo22 today: lba62 os results of', 'at #esmo22 today: lba62 os results of m1', '#esmo22 today: lba62 os results of m1 socvsadt+aap', 'today: lba62 os results of m1 socvsadt+aap &amp;', 'lba62 os results of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'os results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt aap', 'socvsadt+aap+enza 1358o transcriptomic signatures in adt aap 1359mo', '1358o transcriptomic signatures in adt aap 1359mo nodal', 'transcriptomic signatures in adt aap 1359mo nodal mets', 'signatures in adt aap 1359mo nodal mets as', 'in adt aap 1359mo nodal mets as a', 'adt aap 1359mo nodal mets as a marker', 'aap 1359mo nodal mets as a marker of', '1359mo nodal mets as a marker of prognosis', 'nodal mets as a marker of prognosis and', 'mets as a marker of prognosis and differential', 'as a marker of prognosis and differential rx', 'a marker of prognosis and differential rx response', 'marker of prognosis and differential rx response w/', 'of prognosis and differential rx response w/ aap', 'prognosis and differential rx response w/ aap vs', 'and differential rx response w/ aap vs doce', 'differential rx response w/ aap vs doce .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '16', 'tokens': ['disappointing', 'results', 'of', 'kn412', 'on', 'the', 'heals', 'of', 'negative', 'javelin', 'trial;', 'despite', 'trend', 'favoring', 'high', 'cps', 'score', 'it', 'is', 'clear', 'that', 'high', 'q3', 'weeks', 'cis', '+', 'xrt', '+', 'io', 'is', 'not', 'the', 'right', 'strategy,', '.'], 'text_length': 35, 'triples': {'kn412|disappointing results': ([3, 3], [0, 1], 'negative')}, 'sentence': 'disappointing results of kn412 on the heals of negative javelin trial; despite trend favoring high cps score it is clear that high q3 weeks cis + xrt + io is not the right strategy, .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['disappointing', 'results', 'of', 'kn412', 'on', 'the', 'heals', 'of', 'negative', 'javelin', 'trial;', 'despite', 'trend', 'favoring', 'high', 'cps', 'score', 'it', 'is', 'clear', 'that', 'high', 'q3', 'weeks', 'cis', '+', 'xrt', '+', 'io', 'is', 'not', 'the', 'right', 'strategy,', '.', 'disappointing results', 'results of', 'of kn412', 'kn412 on', 'on the', 'the heals', 'heals of', 'of negative', 'negative javelin', 'javelin trial;', 'trial; despite', 'despite trend', 'trend favoring', 'favoring high', 'high cps', 'cps score', 'score it', 'it is', 'is clear', 'clear that', 'that high', 'high q3', 'q3 weeks', 'weeks cis', 'cis +', '+ xrt', 'xrt +', '+ io', 'io is', 'is not', 'not the', 'the right', 'right strategy,', 'strategy, .', 'disappointing results of', 'results of kn412', 'of kn412 on', 'kn412 on the', 'on the heals', 'the heals of', 'heals of negative', 'of negative javelin', 'negative javelin trial;', 'javelin trial; despite', 'trial; despite trend', 'despite trend favoring', 'trend favoring high', 'favoring high cps', 'high cps score', 'cps score it', 'score it is', 'it is clear', 'is clear that', 'clear that high', 'that high q3', 'high q3 weeks', 'q3 weeks cis', 'weeks cis +', 'cis + xrt', '+ xrt +', 'xrt + io', '+ io is', 'io is not', 'is not the', 'not the right', 'the right strategy,', 'right strategy, .', 'disappointing results of kn412', 'results of kn412 on', 'of kn412 on the', 'kn412 on the heals', 'on the heals of', 'the heals of negative', 'heals of negative javelin', 'of negative javelin trial;', 'negative javelin trial; despite', 'javelin trial; despite trend', 'trial; despite trend favoring', 'despite trend favoring high', 'trend favoring high cps', 'favoring high cps score', 'high cps score it', 'cps score it is', 'score it is clear', 'it is clear that', 'is clear that high', 'clear that high q3', 'that high q3 weeks', 'high q3 weeks cis', 'q3 weeks cis +', 'weeks cis + xrt', 'cis + xrt +', '+ xrt + io', 'xrt + io is', '+ io is not', 'io is not the', 'is not the right', 'not the right strategy,', 'the right strategy, .', 'disappointing results of kn412 on', 'results of kn412 on the', 'of kn412 on the heals', 'kn412 on the heals of', 'on the heals of negative', 'the heals of negative javelin', 'heals of negative javelin trial;', 'of negative javelin trial; despite', 'negative javelin trial; despite trend', 'javelin trial; despite trend favoring', 'trial; despite trend favoring high', 'despite trend favoring high cps', 'trend favoring high cps score', 'favoring high cps score it', 'high cps score it is', 'cps score it is clear', 'score it is clear that', 'it is clear that high', 'is clear that high q3', 'clear that high q3 weeks', 'that high q3 weeks cis', 'high q3 weeks cis +', 'q3 weeks cis + xrt', 'weeks cis + xrt +', 'cis + xrt + io', '+ xrt + io is', 'xrt + io is not', '+ io is not the', 'io is not the right', 'is not the right strategy,', 'not the right strategy, .', 'disappointing results of kn412 on the', 'results of kn412 on the heals', 'of kn412 on the heals of', 'kn412 on the heals of negative', 'on the heals of negative javelin', 'the heals of negative javelin trial;', 'heals of negative javelin trial; despite', 'of negative javelin trial; despite trend', 'negative javelin trial; despite trend favoring', 'javelin trial; despite trend favoring high', 'trial; despite trend favoring high cps', 'despite trend favoring high cps score', 'trend favoring high cps score it', 'favoring high cps score it is', 'high cps score it is clear', 'cps score it is clear that', 'score it is clear that high', 'it is clear that high q3', 'is clear that high q3 weeks', 'clear that high q3 weeks cis', 'that high q3 weeks cis +', 'high q3 weeks cis + xrt', 'q3 weeks cis + xrt +', 'weeks cis + xrt + io', 'cis + xrt + io is', '+ xrt + io is not', 'xrt + io is not the', '+ io is not the right', 'io is not the right strategy,', 'is not the right strategy, .', 'disappointing results of kn412 on the heals', 'results of kn412 on the heals of', 'of kn412 on the heals of negative', 'kn412 on the heals of negative javelin', 'on the heals of negative javelin trial;', 'the heals of negative javelin trial; despite', 'heals of negative javelin trial; despite trend', 'of negative javelin trial; despite trend favoring', 'negative javelin trial; despite trend favoring high', 'javelin trial; despite trend favoring high cps', 'trial; despite trend favoring high cps score', 'despite trend favoring high cps score it', 'trend favoring high cps score it is', 'favoring high cps score it is clear', 'high cps score it is clear that', 'cps score it is clear that high', 'score it is clear that high q3', 'it is clear that high q3 weeks', 'is clear that high q3 weeks cis', 'clear that high q3 weeks cis +', 'that high q3 weeks cis + xrt', 'high q3 weeks cis + xrt +', 'q3 weeks cis + xrt + io', 'weeks cis + xrt + io is', 'cis + xrt + io is not', '+ xrt + io is not the', 'xrt + io is not the right', '+ io is not the right strategy,', 'io is not the right strategy, .', 'disappointing results of kn412 on the heals of', 'results of kn412 on the heals of negative', 'of kn412 on the heals of negative javelin', 'kn412 on the heals of negative javelin trial;', 'on the heals of negative javelin trial; despite', 'the heals of negative javelin trial; despite trend', 'heals of negative javelin trial; despite trend favoring', 'of negative javelin trial; despite trend favoring high', 'negative javelin trial; despite trend favoring high cps', 'javelin trial; despite trend favoring high cps score', 'trial; despite trend favoring high cps score it', 'despite trend favoring high cps score it is', 'trend favoring high cps score it is clear', 'favoring high cps score it is clear that', 'high cps score it is clear that high', 'cps score it is clear that high q3', 'score it is clear that high q3 weeks', 'it is clear that high q3 weeks cis', 'is clear that high q3 weeks cis +', 'clear that high q3 weeks cis + xrt', 'that high q3 weeks cis + xrt +', 'high q3 weeks cis + xrt + io', 'q3 weeks cis + xrt + io is', 'weeks cis + xrt + io is not', 'cis + xrt + io is not the', '+ xrt + io is not the right', 'xrt + io is not the right strategy,', '+ io is not the right strategy, .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '17', 'tokens': ['#asco22', 'oral', 'presentation', 'on', 'phase', '3', 'everest', 'trial', 's', 'primary', 'results', 'of', 'adjuvant', 'rx', 'with', 'everolimus', 'in', '#kidneycancer', 'rcc', 'post', 'surgery', 'barely', 'missed', 'the', 'primary', 'endpoint', 'in', 'all', 'patients', ',', 'benefit', 'only', 'high', 'risk', 'patients', '.'], 'text_length': 36, 'triples': {'everest|primary results of adjuvant rx with everolimus in #kidneycancer rcc post surgery barely missed the primary endpoint in all patients , benefit only high': ([6, 6], [9, 32], 'positive'), 'everolimus|primary results of adjuvant rx with everolimus in #kidneycancer rcc post surgery barely missed the primary endpoint in all patients , benefit only high': ([15, 15], [9, 32], 'positive')}, 'sentence': '#asco22 oral presentation on phase 3 everest trial s primary results of adjuvant rx with everolimus in #kidneycancer rcc post surgery barely missed the primary endpoint in all patients , benefit only high risk patients .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(6, 6), (15, 15)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 32)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['#asco22', 'oral', 'presentation', 'on', 'phase', '3', 'everest', 'trial', 's', 'primary', 'results', 'of', 'adjuvant', 'rx', 'with', 'everolimus', 'in', '#kidneycancer', 'rcc', 'post', 'surgery', 'barely', 'missed', 'the', 'primary', 'endpoint', 'in', 'all', 'patients', ',', 'benefit', 'only', 'high', 'risk', 'patients', '.', '#asco22 oral', 'oral presentation', 'presentation on', 'on phase', 'phase 3', '3 everest', 'everest trial', 'trial s', 's primary', 'primary results', 'results of', 'of adjuvant', 'adjuvant rx', 'rx with', 'with everolimus', 'everolimus in', 'in #kidneycancer', '#kidneycancer rcc', 'rcc post', 'post surgery', 'surgery barely', 'barely missed', 'missed the', 'the primary', 'primary endpoint', 'endpoint in', 'in all', 'all patients', 'patients ,', ', benefit', 'benefit only', 'only high', 'high risk', 'risk patients', 'patients .', '#asco22 oral presentation', 'oral presentation on', 'presentation on phase', 'on phase 3', 'phase 3 everest', '3 everest trial', 'everest trial s', 'trial s primary', 's primary results', 'primary results of', 'results of adjuvant', 'of adjuvant rx', 'adjuvant rx with', 'rx with everolimus', 'with everolimus in', 'everolimus in #kidneycancer', 'in #kidneycancer rcc', '#kidneycancer rcc post', 'rcc post surgery', 'post surgery barely', 'surgery barely missed', 'barely missed the', 'missed the primary', 'the primary endpoint', 'primary endpoint in', 'endpoint in all', 'in all patients', 'all patients ,', 'patients , benefit', ', benefit only', 'benefit only high', 'only high risk', 'high risk patients', 'risk patients .', '#asco22 oral presentation on', 'oral presentation on phase', 'presentation on phase 3', 'on phase 3 everest', 'phase 3 everest trial', '3 everest trial s', 'everest trial s primary', 'trial s primary results', 's primary results of', 'primary results of adjuvant', 'results of adjuvant rx', 'of adjuvant rx with', 'adjuvant rx with everolimus', 'rx with everolimus in', 'with everolimus in #kidneycancer', 'everolimus in #kidneycancer rcc', 'in #kidneycancer rcc post', '#kidneycancer rcc post surgery', 'rcc post surgery barely', 'post surgery barely missed', 'surgery barely missed the', 'barely missed the primary', 'missed the primary endpoint', 'the primary endpoint in', 'primary endpoint in all', 'endpoint in all patients', 'in all patients ,', 'all patients , benefit', 'patients , benefit only', ', benefit only high', 'benefit only high risk', 'only high risk patients', 'high risk patients .', '#asco22 oral presentation on phase', 'oral presentation on phase 3', 'presentation on phase 3 everest', 'on phase 3 everest trial', 'phase 3 everest trial s', '3 everest trial s primary', 'everest trial s primary results', 'trial s primary results of', 's primary results of adjuvant', 'primary results of adjuvant rx', 'results of adjuvant rx with', 'of adjuvant rx with everolimus', 'adjuvant rx with everolimus in', 'rx with everolimus in #kidneycancer', 'with everolimus in #kidneycancer rcc', 'everolimus in #kidneycancer rcc post', 'in #kidneycancer rcc post surgery', '#kidneycancer rcc post surgery barely', 'rcc post surgery barely missed', 'post surgery barely missed the', 'surgery barely missed the primary', 'barely missed the primary endpoint', 'missed the primary endpoint in', 'the primary endpoint in all', 'primary endpoint in all patients', 'endpoint in all patients ,', 'in all patients , benefit', 'all patients , benefit only', 'patients , benefit only high', ', benefit only high risk', 'benefit only high risk patients', 'only high risk patients .', '#asco22 oral presentation on phase 3', 'oral presentation on phase 3 everest', 'presentation on phase 3 everest trial', 'on phase 3 everest trial s', 'phase 3 everest trial s primary', '3 everest trial s primary results', 'everest trial s primary results of', 'trial s primary results of adjuvant', 's primary results of adjuvant rx', 'primary results of adjuvant rx with', 'results of adjuvant rx with everolimus', 'of adjuvant rx with everolimus in', 'adjuvant rx with everolimus in #kidneycancer', 'rx with everolimus in #kidneycancer rcc', 'with everolimus in #kidneycancer rcc post', 'everolimus in #kidneycancer rcc post surgery', 'in #kidneycancer rcc post surgery barely', '#kidneycancer rcc post surgery barely missed', 'rcc post surgery barely missed the', 'post surgery barely missed the primary', 'surgery barely missed the primary endpoint', 'barely missed the primary endpoint in', 'missed the primary endpoint in all', 'the primary endpoint in all patients', 'primary endpoint in all patients ,', 'endpoint in all patients , benefit', 'in all patients , benefit only', 'all patients , benefit only high', 'patients , benefit only high risk', ', benefit only high risk patients', 'benefit only high risk patients .', '#asco22 oral presentation on phase 3 everest', 'oral presentation on phase 3 everest trial', 'presentation on phase 3 everest trial s', 'on phase 3 everest trial s primary', 'phase 3 everest trial s primary results', '3 everest trial s primary results of', 'everest trial s primary results of adjuvant', 'trial s primary results of adjuvant rx', 's primary results of adjuvant rx with', 'primary results of adjuvant rx with everolimus', 'results of adjuvant rx with everolimus in', 'of adjuvant rx with everolimus in #kidneycancer', 'adjuvant rx with everolimus in #kidneycancer rcc', 'rx with everolimus in #kidneycancer rcc post', 'with everolimus in #kidneycancer rcc post surgery', 'everolimus in #kidneycancer rcc post surgery barely', 'in #kidneycancer rcc post surgery barely missed', '#kidneycancer rcc post surgery barely missed the', 'rcc post surgery barely missed the primary', 'post surgery barely missed the primary endpoint', 'surgery barely missed the primary endpoint in', 'barely missed the primary endpoint in all', 'missed the primary endpoint in all patients', 'the primary endpoint in all patients ,', 'primary endpoint in all patients , benefit', 'endpoint in all patients , benefit only', 'in all patients , benefit only high', 'all patients , benefit only high risk', 'patients , benefit only high risk patients', ', benefit only high risk patients .', '#asco22 oral presentation on phase 3 everest trial', 'oral presentation on phase 3 everest trial s', 'presentation on phase 3 everest trial s primary', 'on phase 3 everest trial s primary results', 'phase 3 everest trial s primary results of', '3 everest trial s primary results of adjuvant', 'everest trial s primary results of adjuvant rx', 'trial s primary results of adjuvant rx with', 's primary results of adjuvant rx with everolimus', 'primary results of adjuvant rx with everolimus in', 'results of adjuvant rx with everolimus in #kidneycancer', 'of adjuvant rx with everolimus in #kidneycancer rcc', 'adjuvant rx with everolimus in #kidneycancer rcc post', 'rx with everolimus in #kidneycancer rcc post surgery', 'with everolimus in #kidneycancer rcc post surgery barely', 'everolimus in #kidneycancer rcc post surgery barely missed', 'in #kidneycancer rcc post surgery barely missed the', '#kidneycancer rcc post surgery barely missed the primary', 'rcc post surgery barely missed the primary endpoint', 'post surgery barely missed the primary endpoint in', 'surgery barely missed the primary endpoint in all', 'barely missed the primary endpoint in all patients', 'missed the primary endpoint in all patients ,', 'the primary endpoint in all patients , benefit', 'primary endpoint in all patients , benefit only', 'endpoint in all patients , benefit only high', 'in all patients , benefit only high risk', 'all patients , benefit only high risk patients', 'patients , benefit only high risk patients .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '18', 'tokens': ['"another', 'negative', 'adjuvant', 'io', 'trial', 'in', 'rcc', '-', 'no', 'benefit', 'to', 'atezolizumab', 'immotion010', '#esmo22', '.'], 'text_length': 15, 'triples': {'immotion010|negative adjuvant io trial in rcc - no benefit': ([12, 12], [1, 9], 'negative'), 'atezolizumab|negative adjuvant io trial in rcc - no benefit': ([11, 11], [1, 9], 'negative')}, 'sentence': '"another negative adjuvant io trial in rcc - no benefit to atezolizumab immotion010 #esmo22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(12, 12), (11, 11)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8)], 'span tokens': ['"another', 'negative', 'adjuvant', 'io', 'trial', 'in', 'rcc', '-', 'no', 'benefit', 'to', 'atezolizumab', 'immotion010', '#esmo22', '.', '"another negative', 'negative adjuvant', 'adjuvant io', 'io trial', 'trial in', 'in rcc', 'rcc -', '- no', 'no benefit', 'benefit to', 'to atezolizumab', 'atezolizumab immotion010', 'immotion010 #esmo22', '#esmo22 .', '"another negative adjuvant', 'negative adjuvant io', 'adjuvant io trial', 'io trial in', 'trial in rcc', 'in rcc -', 'rcc - no', '- no benefit', 'no benefit to', 'benefit to atezolizumab', 'to atezolizumab immotion010', 'atezolizumab immotion010 #esmo22', 'immotion010 #esmo22 .', '"another negative adjuvant io', 'negative adjuvant io trial', 'adjuvant io trial in', 'io trial in rcc', 'trial in rcc -', 'in rcc - no', 'rcc - no benefit', '- no benefit to', 'no benefit to atezolizumab', 'benefit to atezolizumab immotion010', 'to atezolizumab immotion010 #esmo22', 'atezolizumab immotion010 #esmo22 .', '"another negative adjuvant io trial', 'negative adjuvant io trial in', 'adjuvant io trial in rcc', 'io trial in rcc -', 'trial in rcc - no', 'in rcc - no benefit', 'rcc - no benefit to', '- no benefit to atezolizumab', 'no benefit to atezolizumab immotion010', 'benefit to atezolizumab immotion010 #esmo22', 'to atezolizumab immotion010 #esmo22 .', '"another negative adjuvant io trial in', 'negative adjuvant io trial in rcc', 'adjuvant io trial in rcc -', 'io trial in rcc - no', 'trial in rcc - no benefit', 'in rcc - no benefit to', 'rcc - no benefit to atezolizumab', '- no benefit to atezolizumab immotion010', 'no benefit to atezolizumab immotion010 #esmo22', 'benefit to atezolizumab immotion010 #esmo22 .', '"another negative adjuvant io trial in rcc', 'negative adjuvant io trial in rcc -', 'adjuvant io trial in rcc - no', 'io trial in rcc - no benefit', 'trial in rcc - no benefit to', 'in rcc - no benefit to atezolizumab', 'rcc - no benefit to atezolizumab immotion010', '- no benefit to atezolizumab immotion010 #esmo22', 'no benefit to atezolizumab immotion010 #esmo22 .', '"another negative adjuvant io trial in rcc -', 'negative adjuvant io trial in rcc - no', 'adjuvant io trial in rcc - no benefit', 'io trial in rcc - no benefit to', 'trial in rcc - no benefit to atezolizumab', 'in rcc - no benefit to atezolizumab immotion010', 'rcc - no benefit to atezolizumab immotion010 #esmo22', '- no benefit to atezolizumab immotion010 #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '19', 'tokens': ['with', 'stampede', 'data', 'time', 'to', 'look', 'at', 'demographic', 'transcriptome', 'variations.', 'our', 'work', 'with', 'the', 'decipher-veracyte', 'team', 'at', '#esmo2022', 'asian', 'vs', 'na', 'lower', 'pten', 'loss', 'tumours', 'lower', 'ar', 'activity', 'more', 'immune', 'suppressive', '.'], 'text_length': 32, 'triples': {'stampede|more immune': ([1, 1], [28, 29], 'positive')}, 'sentence': 'with stampede data time to look at demographic transcriptome variations. our work with the decipher-veracyte team at #esmo2022 asian vs na lower pten loss tumours lower ar activity more immune suppressive .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(28, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['with', 'stampede', 'data', 'time', 'to', 'look', 'at', 'demographic', 'transcriptome', 'variations.', 'our', 'work', 'with', 'the', 'decipher-veracyte', 'team', 'at', '#esmo2022', 'asian', 'vs', 'na', 'lower', 'pten', 'loss', 'tumours', 'lower', 'ar', 'activity', 'more', 'immune', 'suppressive', '.', 'with stampede', 'stampede data', 'data time', 'time to', 'to look', 'look at', 'at demographic', 'demographic transcriptome', 'transcriptome variations.', 'variations. our', 'our work', 'work with', 'with the', 'the decipher-veracyte', 'decipher-veracyte team', 'team at', 'at #esmo2022', '#esmo2022 asian', 'asian vs', 'vs na', 'na lower', 'lower pten', 'pten loss', 'loss tumours', 'tumours lower', 'lower ar', 'ar activity', 'activity more', 'more immune', 'immune suppressive', 'suppressive .', 'with stampede data', 'stampede data time', 'data time to', 'time to look', 'to look at', 'look at demographic', 'at demographic transcriptome', 'demographic transcriptome variations.', 'transcriptome variations. our', 'variations. our work', 'our work with', 'work with the', 'with the decipher-veracyte', 'the decipher-veracyte team', 'decipher-veracyte team at', 'team at #esmo2022', 'at #esmo2022 asian', '#esmo2022 asian vs', 'asian vs na', 'vs na lower', 'na lower pten', 'lower pten loss', 'pten loss tumours', 'loss tumours lower', 'tumours lower ar', 'lower ar activity', 'ar activity more', 'activity more immune', 'more immune suppressive', 'immune suppressive .', 'with stampede data time', 'stampede data time to', 'data time to look', 'time to look at', 'to look at demographic', 'look at demographic transcriptome', 'at demographic transcriptome variations.', 'demographic transcriptome variations. our', 'transcriptome variations. our work', 'variations. our work with', 'our work with the', 'work with the decipher-veracyte', 'with the decipher-veracyte team', 'the decipher-veracyte team at', 'decipher-veracyte team at #esmo2022', 'team at #esmo2022 asian', 'at #esmo2022 asian vs', '#esmo2022 asian vs na', 'asian vs na lower', 'vs na lower pten', 'na lower pten loss', 'lower pten loss tumours', 'pten loss tumours lower', 'loss tumours lower ar', 'tumours lower ar activity', 'lower ar activity more', 'ar activity more immune', 'activity more immune suppressive', 'more immune suppressive .', 'with stampede data time to', 'stampede data time to look', 'data time to look at', 'time to look at demographic', 'to look at demographic transcriptome', 'look at demographic transcriptome variations.', 'at demographic transcriptome variations. our', 'demographic transcriptome variations. our work', 'transcriptome variations. our work with', 'variations. our work with the', 'our work with the decipher-veracyte', 'work with the decipher-veracyte team', 'with the decipher-veracyte team at', 'the decipher-veracyte team at #esmo2022', 'decipher-veracyte team at #esmo2022 asian', 'team at #esmo2022 asian vs', 'at #esmo2022 asian vs na', '#esmo2022 asian vs na lower', 'asian vs na lower pten', 'vs na lower pten loss', 'na lower pten loss tumours', 'lower pten loss tumours lower', 'pten loss tumours lower ar', 'loss tumours lower ar activity', 'tumours lower ar activity more', 'lower ar activity more immune', 'ar activity more immune suppressive', 'activity more immune suppressive .', 'with stampede data time to look', 'stampede data time to look at', 'data time to look at demographic', 'time to look at demographic transcriptome', 'to look at demographic transcriptome variations.', 'look at demographic transcriptome variations. our', 'at demographic transcriptome variations. our work', 'demographic transcriptome variations. our work with', 'transcriptome variations. our work with the', 'variations. our work with the decipher-veracyte', 'our work with the decipher-veracyte team', 'work with the decipher-veracyte team at', 'with the decipher-veracyte team at #esmo2022', 'the decipher-veracyte team at #esmo2022 asian', 'decipher-veracyte team at #esmo2022 asian vs', 'team at #esmo2022 asian vs na', 'at #esmo2022 asian vs na lower', '#esmo2022 asian vs na lower pten', 'asian vs na lower pten loss', 'vs na lower pten loss tumours', 'na lower pten loss tumours lower', 'lower pten loss tumours lower ar', 'pten loss tumours lower ar activity', 'loss tumours lower ar activity more', 'tumours lower ar activity more immune', 'lower ar activity more immune suppressive', 'ar activity more immune suppressive .', 'with stampede data time to look at', 'stampede data time to look at demographic', 'data time to look at demographic transcriptome', 'time to look at demographic transcriptome variations.', 'to look at demographic transcriptome variations. our', 'look at demographic transcriptome variations. our work', 'at demographic transcriptome variations. our work with', 'demographic transcriptome variations. our work with the', 'transcriptome variations. our work with the decipher-veracyte', 'variations. our work with the decipher-veracyte team', 'our work with the decipher-veracyte team at', 'work with the decipher-veracyte team at #esmo2022', 'with the decipher-veracyte team at #esmo2022 asian', 'the decipher-veracyte team at #esmo2022 asian vs', 'decipher-veracyte team at #esmo2022 asian vs na', 'team at #esmo2022 asian vs na lower', 'at #esmo2022 asian vs na lower pten', '#esmo2022 asian vs na lower pten loss', 'asian vs na lower pten loss tumours', 'vs na lower pten loss tumours lower', 'na lower pten loss tumours lower ar', 'lower pten loss tumours lower ar activity', 'pten loss tumours lower ar activity more', 'loss tumours lower ar activity more immune', 'tumours lower ar activity more immune suppressive', 'lower ar activity more immune suppressive .', 'with stampede data time to look at demographic', 'stampede data time to look at demographic transcriptome', 'data time to look at demographic transcriptome variations.', 'time to look at demographic transcriptome variations. our', 'to look at demographic transcriptome variations. our work', 'look at demographic transcriptome variations. our work with', 'at demographic transcriptome variations. our work with the', 'demographic transcriptome variations. our work with the decipher-veracyte', 'transcriptome variations. our work with the decipher-veracyte team', 'variations. our work with the decipher-veracyte team at', 'our work with the decipher-veracyte team at #esmo2022', 'work with the decipher-veracyte team at #esmo2022 asian', 'with the decipher-veracyte team at #esmo2022 asian vs', 'the decipher-veracyte team at #esmo2022 asian vs na', 'decipher-veracyte team at #esmo2022 asian vs na lower', 'team at #esmo2022 asian vs na lower pten', 'at #esmo2022 asian vs na lower pten loss', '#esmo2022 asian vs na lower pten loss tumours', 'asian vs na lower pten loss tumours lower', 'vs na lower pten loss tumours lower ar', 'na lower pten loss tumours lower ar activity', 'lower pten loss tumours lower ar activity more', 'pten loss tumours lower ar activity more immune', 'loss tumours lower ar activity more immune suppressive', 'tumours lower ar activity more immune suppressive .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '20', 'tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'Zanubrutinib', '(greater', 'BTK', 'specificity', 'and', 'more', 'sustained', 'BTK', 'inhibition)', 'superior', 'to', 'ibrutinib', 'in', 'RR', 'CLL/SLL.', 'N=652', 'rand', '1:1,', 'primary', 'endpt', 'ORR.', '.'], 'text_length': 26, 'triples': {'ibrutinib|superior to': ([15, 15], [13, 14], 'negative'), 'Zanubrutinib|more sustained BTK inhibition) superior': ([4, 4], [9, 13], 'positive')}, 'sentence': '#ASH22 #leusm #lymsm Brown: Zanubrutinib (greater BTK specificity and more sustained BTK inhibition) superior to ibrutinib in RR CLL/SLL. N=652 rand 1:1, primary endpt ORR. .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(15, 15), (4, 4)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(13, 14), (9, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'Zanubrutinib', '(greater', 'BTK', 'specificity', 'and', 'more', 'sustained', 'BTK', 'inhibition)', 'superior', 'to', 'ibrutinib', 'in', 'RR', 'CLL/SLL.', 'N=652', 'rand', '1:1,', 'primary', 'endpt', 'ORR.', '.', '#ASH22 #leusm', '#leusm #lymsm', '#lymsm Brown:', 'Brown: Zanubrutinib', 'Zanubrutinib (greater', '(greater BTK', 'BTK specificity', 'specificity and', 'and more', 'more sustained', 'sustained BTK', 'BTK inhibition)', 'inhibition) superior', 'superior to', 'to ibrutinib', 'ibrutinib in', 'in RR', 'RR CLL/SLL.', 'CLL/SLL. N=652', 'N=652 rand', 'rand 1:1,', '1:1, primary', 'primary endpt', 'endpt ORR.', 'ORR. .', '#ASH22 #leusm #lymsm', '#leusm #lymsm Brown:', '#lymsm Brown: Zanubrutinib', 'Brown: Zanubrutinib (greater', 'Zanubrutinib (greater BTK', '(greater BTK specificity', 'BTK specificity and', 'specificity and more', 'and more sustained', 'more sustained BTK', 'sustained BTK inhibition)', 'BTK inhibition) superior', 'inhibition) superior to', 'superior to ibrutinib', 'to ibrutinib in', 'ibrutinib in RR', 'in RR CLL/SLL.', 'RR CLL/SLL. N=652', 'CLL/SLL. N=652 rand', 'N=652 rand 1:1,', 'rand 1:1, primary', '1:1, primary endpt', 'primary endpt ORR.', 'endpt ORR. .', '#ASH22 #leusm #lymsm Brown:', '#leusm #lymsm Brown: Zanubrutinib', '#lymsm Brown: Zanubrutinib (greater', 'Brown: Zanubrutinib (greater BTK', 'Zanubrutinib (greater BTK specificity', '(greater BTK specificity and', 'BTK specificity and more', 'specificity and more sustained', 'and more sustained BTK', 'more sustained BTK inhibition)', 'sustained BTK inhibition) superior', 'BTK inhibition) superior to', 'inhibition) superior to ibrutinib', 'superior to ibrutinib in', 'to ibrutinib in RR', 'ibrutinib in RR CLL/SLL.', 'in RR CLL/SLL. N=652', 'RR CLL/SLL. N=652 rand', 'CLL/SLL. N=652 rand 1:1,', 'N=652 rand 1:1, primary', 'rand 1:1, primary endpt', '1:1, primary endpt ORR.', 'primary endpt ORR. .', '#ASH22 #leusm #lymsm Brown: Zanubrutinib', '#leusm #lymsm Brown: Zanubrutinib (greater', '#lymsm Brown: Zanubrutinib (greater BTK', 'Brown: Zanubrutinib (greater BTK specificity', 'Zanubrutinib (greater BTK specificity and', '(greater BTK specificity and more', 'BTK specificity and more sustained', 'specificity and more sustained BTK', 'and more sustained BTK inhibition)', 'more sustained BTK inhibition) superior', 'sustained BTK inhibition) superior to', 'BTK inhibition) superior to ibrutinib', 'inhibition) superior to ibrutinib in', 'superior to ibrutinib in RR', 'to ibrutinib in RR CLL/SLL.', 'ibrutinib in RR CLL/SLL. N=652', 'in RR CLL/SLL. N=652 rand', 'RR CLL/SLL. N=652 rand 1:1,', 'CLL/SLL. N=652 rand 1:1, primary', 'N=652 rand 1:1, primary endpt', 'rand 1:1, primary endpt ORR.', '1:1, primary endpt ORR. .', '#ASH22 #leusm #lymsm Brown: Zanubrutinib (greater', '#leusm #lymsm Brown: Zanubrutinib (greater BTK', '#lymsm Brown: Zanubrutinib (greater BTK specificity', 'Brown: Zanubrutinib (greater BTK specificity and', 'Zanubrutinib (greater BTK specificity and more', '(greater BTK specificity and more sustained', 'BTK specificity and more sustained BTK', 'specificity and more sustained BTK inhibition)', 'and more sustained BTK inhibition) superior', 'more sustained BTK inhibition) superior to', 'sustained BTK inhibition) superior to ibrutinib', 'BTK inhibition) superior to ibrutinib in', 'inhibition) superior to ibrutinib in RR', 'superior to ibrutinib in RR CLL/SLL.', 'to ibrutinib in RR CLL/SLL. N=652', 'ibrutinib in RR CLL/SLL. N=652 rand', 'in RR CLL/SLL. N=652 rand 1:1,', 'RR CLL/SLL. N=652 rand 1:1, primary', 'CLL/SLL. N=652 rand 1:1, primary endpt', 'N=652 rand 1:1, primary endpt ORR.', 'rand 1:1, primary endpt ORR. .', '#ASH22 #leusm #lymsm Brown: Zanubrutinib (greater BTK', '#leusm #lymsm Brown: Zanubrutinib (greater BTK specificity', '#lymsm Brown: Zanubrutinib (greater BTK specificity and', 'Brown: Zanubrutinib (greater BTK specificity and more', 'Zanubrutinib (greater BTK specificity and more sustained', '(greater BTK specificity and more sustained BTK', 'BTK specificity and more sustained BTK inhibition)', 'specificity and more sustained BTK inhibition) superior', 'and more sustained BTK inhibition) superior to', 'more sustained BTK inhibition) superior to ibrutinib', 'sustained BTK inhibition) superior to ibrutinib in', 'BTK inhibition) superior to ibrutinib in RR', 'inhibition) superior to ibrutinib in RR CLL/SLL.', 'superior to ibrutinib in RR CLL/SLL. N=652', 'to ibrutinib in RR CLL/SLL. N=652 rand', 'ibrutinib in RR CLL/SLL. N=652 rand 1:1,', 'in RR CLL/SLL. N=652 rand 1:1, primary', 'RR CLL/SLL. N=652 rand 1:1, primary endpt', 'CLL/SLL. N=652 rand 1:1, primary endpt ORR.', 'N=652 rand 1:1, primary endpt ORR. .', '#ASH22 #leusm #lymsm Brown: Zanubrutinib (greater BTK specificity', '#leusm #lymsm Brown: Zanubrutinib (greater BTK specificity and', '#lymsm Brown: Zanubrutinib (greater BTK specificity and more', 'Brown: Zanubrutinib (greater BTK specificity and more sustained', 'Zanubrutinib (greater BTK specificity and more sustained BTK', '(greater BTK specificity and more sustained BTK inhibition)', 'BTK specificity and more sustained BTK inhibition) superior', 'specificity and more sustained BTK inhibition) superior to', 'and more sustained BTK inhibition) superior to ibrutinib', 'more sustained BTK inhibition) superior to ibrutinib in', 'sustained BTK inhibition) superior to ibrutinib in RR', 'BTK inhibition) superior to ibrutinib in RR CLL/SLL.', 'inhibition) superior to ibrutinib in RR CLL/SLL. N=652', 'superior to ibrutinib in RR CLL/SLL. N=652 rand', 'to ibrutinib in RR CLL/SLL. N=652 rand 1:1,', 'ibrutinib in RR CLL/SLL. N=652 rand 1:1, primary', 'in RR CLL/SLL. N=652 rand 1:1, primary endpt', 'RR CLL/SLL. N=652 rand 1:1, primary endpt ORR.', 'CLL/SLL. N=652 rand 1:1, primary endpt ORR. .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '21', 'tokens': ['#ash22', 'exposure', 'to', 'anti', 'bcma', 'therapies', '(76%', 'blenrep)', 'prior', 'to', 'ide-cel', 'showed', 'orr', 'of', '74%', 'vs', '88%', 'in', 'those', 'who', 'did', 'not', 'have', 'prior', 'bcma', 'directed', 'therapy...mva', 'showed', 'this', 'factor', 'lowered', 'likelyhood', 'of', 'getting', 'to', 'a', 'cr....', 'much', 'more', 'needs', 'to', 'be', 'learnt', 'about', 'sequencing', 'these', 'therapies!', '.'], 'text_length': 48, 'triples': {'ide-cel|to anti bcma therapies (76% blenrep) prior to ide-cel showed orr of 74% vs 88% in those who did not have prior bcma directed therapy...mva showed this factor lowered likelyhood of getting to a cr.... much more needs to be learnt': ([10, 10], [2, 42], 'neutral')}, 'sentence': '#ash22 exposure to anti bcma therapies (76% blenrep) prior to ide-cel showed orr of 74% vs 88% in those who did not have prior bcma directed therapy...mva showed this factor lowered likelyhood of getting to a cr.... much more needs to be learnt about sequencing these therapies! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 42)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8)], 'span tokens': ['#ash22', 'exposure', 'to', 'anti', 'bcma', 'therapies', '(76%', 'blenrep)', 'prior', 'to', 'ide-cel', 'showed', 'orr', 'of', '74%', 'vs', '88%', 'in', 'those', 'who', 'did', 'not', 'have', 'prior', 'bcma', 'directed', 'therapy...mva', 'showed', 'this', 'factor', 'lowered', 'likelyhood', 'of', 'getting', 'to', 'a', 'cr....', 'much', 'more', 'needs', 'to', 'be', 'learnt', 'about', 'sequencing', 'these', 'therapies!', '.', '#ash22 exposure', 'exposure to', 'to anti', 'anti bcma', 'bcma therapies', 'therapies (76%', '(76% blenrep)', 'blenrep) prior', 'prior to', 'to ide-cel', 'ide-cel showed', 'showed orr', 'orr of', 'of 74%', '74% vs', 'vs 88%', '88% in', 'in those', 'those who', 'who did', 'did not', 'not have', 'have prior', 'prior bcma', 'bcma directed', 'directed therapy...mva', 'therapy...mva showed', 'showed this', 'this factor', 'factor lowered', 'lowered likelyhood', 'likelyhood of', 'of getting', 'getting to', 'to a', 'a cr....', 'cr.... much', 'much more', 'more needs', 'needs to', 'to be', 'be learnt', 'learnt about', 'about sequencing', 'sequencing these', 'these therapies!', 'therapies! .', '#ash22 exposure to', 'exposure to anti', 'to anti bcma', 'anti bcma therapies', 'bcma therapies (76%', 'therapies (76% blenrep)', '(76% blenrep) prior', 'blenrep) prior to', 'prior to ide-cel', 'to ide-cel showed', 'ide-cel showed orr', 'showed orr of', 'orr of 74%', 'of 74% vs', '74% vs 88%', 'vs 88% in', '88% in those', 'in those who', 'those who did', 'who did not', 'did not have', 'not have prior', 'have prior bcma', 'prior bcma directed', 'bcma directed therapy...mva', 'directed therapy...mva showed', 'therapy...mva showed this', 'showed this factor', 'this factor lowered', 'factor lowered likelyhood', 'lowered likelyhood of', 'likelyhood of getting', 'of getting to', 'getting to a', 'to a cr....', 'a cr.... much', 'cr.... much more', 'much more needs', 'more needs to', 'needs to be', 'to be learnt', 'be learnt about', 'learnt about sequencing', 'about sequencing these', 'sequencing these therapies!', 'these therapies! .', '#ash22 exposure to anti', 'exposure to anti bcma', 'to anti bcma therapies', 'anti bcma therapies (76%', 'bcma therapies (76% blenrep)', 'therapies (76% blenrep) prior', '(76% blenrep) prior to', 'blenrep) prior to ide-cel', 'prior to ide-cel showed', 'to ide-cel showed orr', 'ide-cel showed orr of', 'showed orr of 74%', 'orr of 74% vs', 'of 74% vs 88%', '74% vs 88% in', 'vs 88% in those', '88% in those who', 'in those who did', 'those who did not', 'who did not have', 'did not have prior', 'not have prior bcma', 'have prior bcma directed', 'prior bcma directed therapy...mva', 'bcma directed therapy...mva showed', 'directed therapy...mva showed this', 'therapy...mva showed this factor', 'showed this factor lowered', 'this factor lowered likelyhood', 'factor lowered likelyhood of', 'lowered likelyhood of getting', 'likelyhood of getting to', 'of getting to a', 'getting to a cr....', 'to a cr.... much', 'a cr.... much more', 'cr.... much more needs', 'much more needs to', 'more needs to be', 'needs to be learnt', 'to be learnt about', 'be learnt about sequencing', 'learnt about sequencing these', 'about sequencing these therapies!', 'sequencing these therapies! .', '#ash22 exposure to anti bcma', 'exposure to anti bcma therapies', 'to anti bcma therapies (76%', 'anti bcma therapies (76% blenrep)', 'bcma therapies (76% blenrep) prior', 'therapies (76% blenrep) prior to', '(76% blenrep) prior to ide-cel', 'blenrep) prior to ide-cel showed', 'prior to ide-cel showed orr', 'to ide-cel showed orr of', 'ide-cel showed orr of 74%', 'showed orr of 74% vs', 'orr of 74% vs 88%', 'of 74% vs 88% in', '74% vs 88% in those', 'vs 88% in those who', '88% in those who did', 'in those who did not', 'those who did not have', 'who did not have prior', 'did not have prior bcma', 'not have prior bcma directed', 'have prior bcma directed therapy...mva', 'prior bcma directed therapy...mva showed', 'bcma directed therapy...mva showed this', 'directed therapy...mva showed this factor', 'therapy...mva showed this factor lowered', 'showed this factor lowered likelyhood', 'this factor lowered likelyhood of', 'factor lowered likelyhood of getting', 'lowered likelyhood of getting to', 'likelyhood of getting to a', 'of getting to a cr....', 'getting to a cr.... much', 'to a cr.... much more', 'a cr.... much more needs', 'cr.... much more needs to', 'much more needs to be', 'more needs to be learnt', 'needs to be learnt about', 'to be learnt about sequencing', 'be learnt about sequencing these', 'learnt about sequencing these therapies!', 'about sequencing these therapies! .', '#ash22 exposure to anti bcma therapies', 'exposure to anti bcma therapies (76%', 'to anti bcma therapies (76% blenrep)', 'anti bcma therapies (76% blenrep) prior', 'bcma therapies (76% blenrep) prior to', 'therapies (76% blenrep) prior to ide-cel', '(76% blenrep) prior to ide-cel showed', 'blenrep) prior to ide-cel showed orr', 'prior to ide-cel showed orr of', 'to ide-cel showed orr of 74%', 'ide-cel showed orr of 74% vs', 'showed orr of 74% vs 88%', 'orr of 74% vs 88% in', 'of 74% vs 88% in those', '74% vs 88% in those who', 'vs 88% in those who did', '88% in those who did not', 'in those who did not have', 'those who did not have prior', 'who did not have prior bcma', 'did not have prior bcma directed', 'not have prior bcma directed therapy...mva', 'have prior bcma directed therapy...mva showed', 'prior bcma directed therapy...mva showed this', 'bcma directed therapy...mva showed this factor', 'directed therapy...mva showed this factor lowered', 'therapy...mva showed this factor lowered likelyhood', 'showed this factor lowered likelyhood of', 'this factor lowered likelyhood of getting', 'factor lowered likelyhood of getting to', 'lowered likelyhood of getting to a', 'likelyhood of getting to a cr....', 'of getting to a cr.... much', 'getting to a cr.... much more', 'to a cr.... much more needs', 'a cr.... much more needs to', 'cr.... much more needs to be', 'much more needs to be learnt', 'more needs to be learnt about', 'needs to be learnt about sequencing', 'to be learnt about sequencing these', 'be learnt about sequencing these therapies!', 'learnt about sequencing these therapies! .', '#ash22 exposure to anti bcma therapies (76%', 'exposure to anti bcma therapies (76% blenrep)', 'to anti bcma therapies (76% blenrep) prior', 'anti bcma therapies (76% blenrep) prior to', 'bcma therapies (76% blenrep) prior to ide-cel', 'therapies (76% blenrep) prior to ide-cel showed', '(76% blenrep) prior to ide-cel showed orr', 'blenrep) prior to ide-cel showed orr of', 'prior to ide-cel showed orr of 74%', 'to ide-cel showed orr of 74% vs', 'ide-cel showed orr of 74% vs 88%', 'showed orr of 74% vs 88% in', 'orr of 74% vs 88% in those', 'of 74% vs 88% in those who', '74% vs 88% in those who did', 'vs 88% in those who did not', '88% in those who did not have', 'in those who did not have prior', 'those who did not have prior bcma', 'who did not have prior bcma directed', 'did not have prior bcma directed therapy...mva', 'not have prior bcma directed therapy...mva showed', 'have prior bcma directed therapy...mva showed this', 'prior bcma directed therapy...mva showed this factor', 'bcma directed therapy...mva showed this factor lowered', 'directed therapy...mva showed this factor lowered likelyhood', 'therapy...mva showed this factor lowered likelyhood of', 'showed this factor lowered likelyhood of getting', 'this factor lowered likelyhood of getting to', 'factor lowered likelyhood of getting to a', 'lowered likelyhood of getting to a cr....', 'likelyhood of getting to a cr.... much', 'of getting to a cr.... much more', 'getting to a cr.... much more needs', 'to a cr.... much more needs to', 'a cr.... much more needs to be', 'cr.... much more needs to be learnt', 'much more needs to be learnt about', 'more needs to be learnt about sequencing', 'needs to be learnt about sequencing these', 'to be learnt about sequencing these therapies!', 'be learnt about sequencing these therapies! .', '#ash22 exposure to anti bcma therapies (76% blenrep)', 'exposure to anti bcma therapies (76% blenrep) prior', 'to anti bcma therapies (76% blenrep) prior to', 'anti bcma therapies (76% blenrep) prior to ide-cel', 'bcma therapies (76% blenrep) prior to ide-cel showed', 'therapies (76% blenrep) prior to ide-cel showed orr', '(76% blenrep) prior to ide-cel showed orr of', 'blenrep) prior to ide-cel showed orr of 74%', 'prior to ide-cel showed orr of 74% vs', 'to ide-cel showed orr of 74% vs 88%', 'ide-cel showed orr of 74% vs 88% in', 'showed orr of 74% vs 88% in those', 'orr of 74% vs 88% in those who', 'of 74% vs 88% in those who did', '74% vs 88% in those who did not', 'vs 88% in those who did not have', '88% in those who did not have prior', 'in those who did not have prior bcma', 'those who did not have prior bcma directed', 'who did not have prior bcma directed therapy...mva', 'did not have prior bcma directed therapy...mva showed', 'not have prior bcma directed therapy...mva showed this', 'have prior bcma directed therapy...mva showed this factor', 'prior bcma directed therapy...mva showed this factor lowered', 'bcma directed therapy...mva showed this factor lowered likelyhood', 'directed therapy...mva showed this factor lowered likelyhood of', 'therapy...mva showed this factor lowered likelyhood of getting', 'showed this factor lowered likelyhood of getting to', 'this factor lowered likelyhood of getting to a', 'factor lowered likelyhood of getting to a cr....', 'lowered likelyhood of getting to a cr.... much', 'likelyhood of getting to a cr.... much more', 'of getting to a cr.... much more needs', 'getting to a cr.... much more needs to', 'to a cr.... much more needs to be', 'a cr.... much more needs to be learnt', 'cr.... much more needs to be learnt about', 'much more needs to be learnt about sequencing', 'more needs to be learnt about sequencing these', 'needs to be learnt about sequencing these therapies!', 'to be learnt about sequencing these therapies! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '22', 'tokens': ['now', 'seen', 'in', 'both', 'therap', 'anzup', '1603', 'and', 'vision', 'phiii', '#mcrpc', 'trials', 'of', '177lu-psma-617', 'of', 'psma', 'imaging', 'parameters,', 'psmamean', '&gt;10', 'highly', 'predictive', 'of', 'psa', 'orr,', 'rpfs,', 'and', 'os', 'nearly', '6x', 'better', 'than', 'psmamean', '&lt;10', 'w/psa', 'orr', 'subset', '#asco22', '.'], 'text_length': 39, 'triples': {'vision|nearly 6x better': ([8, 8], [28, 30], 'neutral'), '177lu-psma-617|nearly 6x better': ([13, 13], [28, 30], 'neutral')}, 'sentence': 'now seen in both therap anzup 1603 and vision phiii #mcrpc trials of 177lu-psma-617 of psma imaging parameters, psmamean &gt;10 highly predictive of psa orr, rpfs, and os nearly 6x better than psmamean &lt;10 w/psa orr subset #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(8, 8), (13, 13)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(28, 30)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8)], 'span tokens': ['now', 'seen', 'in', 'both', 'therap', 'anzup', '1603', 'and', 'vision', 'phiii', '#mcrpc', 'trials', 'of', '177lu-psma-617', 'of', 'psma', 'imaging', 'parameters,', 'psmamean', '&gt;10', 'highly', 'predictive', 'of', 'psa', 'orr,', 'rpfs,', 'and', 'os', 'nearly', '6x', 'better', 'than', 'psmamean', '&lt;10', 'w/psa', 'orr', 'subset', '#asco22', '.', 'now seen', 'seen in', 'in both', 'both therap', 'therap anzup', 'anzup 1603', '1603 and', 'and vision', 'vision phiii', 'phiii #mcrpc', '#mcrpc trials', 'trials of', 'of 177lu-psma-617', '177lu-psma-617 of', 'of psma', 'psma imaging', 'imaging parameters,', 'parameters, psmamean', 'psmamean &gt;10', '&gt;10 highly', 'highly predictive', 'predictive of', 'of psa', 'psa orr,', 'orr, rpfs,', 'rpfs, and', 'and os', 'os nearly', 'nearly 6x', '6x better', 'better than', 'than psmamean', 'psmamean &lt;10', '&lt;10 w/psa', 'w/psa orr', 'orr subset', 'subset #asco22', '#asco22 .', 'now seen in', 'seen in both', 'in both therap', 'both therap anzup', 'therap anzup 1603', 'anzup 1603 and', '1603 and vision', 'and vision phiii', 'vision phiii #mcrpc', 'phiii #mcrpc trials', '#mcrpc trials of', 'trials of 177lu-psma-617', 'of 177lu-psma-617 of', '177lu-psma-617 of psma', 'of psma imaging', 'psma imaging parameters,', 'imaging parameters, psmamean', 'parameters, psmamean &gt;10', 'psmamean &gt;10 highly', '&gt;10 highly predictive', 'highly predictive of', 'predictive of psa', 'of psa orr,', 'psa orr, rpfs,', 'orr, rpfs, and', 'rpfs, and os', 'and os nearly', 'os nearly 6x', 'nearly 6x better', '6x better than', 'better than psmamean', 'than psmamean &lt;10', 'psmamean &lt;10 w/psa', '&lt;10 w/psa orr', 'w/psa orr subset', 'orr subset #asco22', 'subset #asco22 .', 'now seen in both', 'seen in both therap', 'in both therap anzup', 'both therap anzup 1603', 'therap anzup 1603 and', 'anzup 1603 and vision', '1603 and vision phiii', 'and vision phiii #mcrpc', 'vision phiii #mcrpc trials', 'phiii #mcrpc trials of', '#mcrpc trials of 177lu-psma-617', 'trials of 177lu-psma-617 of', 'of 177lu-psma-617 of psma', '177lu-psma-617 of psma imaging', 'of psma imaging parameters,', 'psma imaging parameters, psmamean', 'imaging parameters, psmamean &gt;10', 'parameters, psmamean &gt;10 highly', 'psmamean &gt;10 highly predictive', '&gt;10 highly predictive of', 'highly predictive of psa', 'predictive of psa orr,', 'of psa orr, rpfs,', 'psa orr, rpfs, and', 'orr, rpfs, and os', 'rpfs, and os nearly', 'and os nearly 6x', 'os nearly 6x better', 'nearly 6x better than', '6x better than psmamean', 'better than psmamean &lt;10', 'than psmamean &lt;10 w/psa', 'psmamean &lt;10 w/psa orr', '&lt;10 w/psa orr subset', 'w/psa orr subset #asco22', 'orr subset #asco22 .', 'now seen in both therap', 'seen in both therap anzup', 'in both therap anzup 1603', 'both therap anzup 1603 and', 'therap anzup 1603 and vision', 'anzup 1603 and vision phiii', '1603 and vision phiii #mcrpc', 'and vision phiii #mcrpc trials', 'vision phiii #mcrpc trials of', 'phiii #mcrpc trials of 177lu-psma-617', '#mcrpc trials of 177lu-psma-617 of', 'trials of 177lu-psma-617 of psma', 'of 177lu-psma-617 of psma imaging', '177lu-psma-617 of psma imaging parameters,', 'of psma imaging parameters, psmamean', 'psma imaging parameters, psmamean &gt;10', 'imaging parameters, psmamean &gt;10 highly', 'parameters, psmamean &gt;10 highly predictive', 'psmamean &gt;10 highly predictive of', '&gt;10 highly predictive of psa', 'highly predictive of psa orr,', 'predictive of psa orr, rpfs,', 'of psa orr, rpfs, and', 'psa orr, rpfs, and os', 'orr, rpfs, and os nearly', 'rpfs, and os nearly 6x', 'and os nearly 6x better', 'os nearly 6x better than', 'nearly 6x better than psmamean', '6x better than psmamean &lt;10', 'better than psmamean &lt;10 w/psa', 'than psmamean &lt;10 w/psa orr', 'psmamean &lt;10 w/psa orr subset', '&lt;10 w/psa orr subset #asco22', 'w/psa orr subset #asco22 .', 'now seen in both therap anzup', 'seen in both therap anzup 1603', 'in both therap anzup 1603 and', 'both therap anzup 1603 and vision', 'therap anzup 1603 and vision phiii', 'anzup 1603 and vision phiii #mcrpc', '1603 and vision phiii #mcrpc trials', 'and vision phiii #mcrpc trials of', 'vision phiii #mcrpc trials of 177lu-psma-617', 'phiii #mcrpc trials of 177lu-psma-617 of', '#mcrpc trials of 177lu-psma-617 of psma', 'trials of 177lu-psma-617 of psma imaging', 'of 177lu-psma-617 of psma imaging parameters,', '177lu-psma-617 of psma imaging parameters, psmamean', 'of psma imaging parameters, psmamean &gt;10', 'psma imaging parameters, psmamean &gt;10 highly', 'imaging parameters, psmamean &gt;10 highly predictive', 'parameters, psmamean &gt;10 highly predictive of', 'psmamean &gt;10 highly predictive of psa', '&gt;10 highly predictive of psa orr,', 'highly predictive of psa orr, rpfs,', 'predictive of psa orr, rpfs, and', 'of psa orr, rpfs, and os', 'psa orr, rpfs, and os nearly', 'orr, rpfs, and os nearly 6x', 'rpfs, and os nearly 6x better', 'and os nearly 6x better than', 'os nearly 6x better than psmamean', 'nearly 6x better than psmamean &lt;10', '6x better than psmamean &lt;10 w/psa', 'better than psmamean &lt;10 w/psa orr', 'than psmamean &lt;10 w/psa orr subset', 'psmamean &lt;10 w/psa orr subset #asco22', '&lt;10 w/psa orr subset #asco22 .', 'now seen in both therap anzup 1603', 'seen in both therap anzup 1603 and', 'in both therap anzup 1603 and vision', 'both therap anzup 1603 and vision phiii', 'therap anzup 1603 and vision phiii #mcrpc', 'anzup 1603 and vision phiii #mcrpc trials', '1603 and vision phiii #mcrpc trials of', 'and vision phiii #mcrpc trials of 177lu-psma-617', 'vision phiii #mcrpc trials of 177lu-psma-617 of', 'phiii #mcrpc trials of 177lu-psma-617 of psma', '#mcrpc trials of 177lu-psma-617 of psma imaging', 'trials of 177lu-psma-617 of psma imaging parameters,', 'of 177lu-psma-617 of psma imaging parameters, psmamean', '177lu-psma-617 of psma imaging parameters, psmamean &gt;10', 'of psma imaging parameters, psmamean &gt;10 highly', 'psma imaging parameters, psmamean &gt;10 highly predictive', 'imaging parameters, psmamean &gt;10 highly predictive of', 'parameters, psmamean &gt;10 highly predictive of psa', 'psmamean &gt;10 highly predictive of psa orr,', '&gt;10 highly predictive of psa orr, rpfs,', 'highly predictive of psa orr, rpfs, and', 'predictive of psa orr, rpfs, and os', 'of psa orr, rpfs, and os nearly', 'psa orr, rpfs, and os nearly 6x', 'orr, rpfs, and os nearly 6x better', 'rpfs, and os nearly 6x better than', 'and os nearly 6x better than psmamean', 'os nearly 6x better than psmamean &lt;10', 'nearly 6x better than psmamean &lt;10 w/psa', '6x better than psmamean &lt;10 w/psa orr', 'better than psmamean &lt;10 w/psa orr subset', 'than psmamean &lt;10 w/psa orr subset #asco22', 'psmamean &lt;10 w/psa orr subset #asco22 .', 'now seen in both therap anzup 1603 and', 'seen in both therap anzup 1603 and vision', 'in both therap anzup 1603 and vision phiii', 'both therap anzup 1603 and vision phiii #mcrpc', 'therap anzup 1603 and vision phiii #mcrpc trials', 'anzup 1603 and vision phiii #mcrpc trials of', '1603 and vision phiii #mcrpc trials of 177lu-psma-617', 'and vision phiii #mcrpc trials of 177lu-psma-617 of', 'vision phiii #mcrpc trials of 177lu-psma-617 of psma', 'phiii #mcrpc trials of 177lu-psma-617 of psma imaging', '#mcrpc trials of 177lu-psma-617 of psma imaging parameters,', 'trials of 177lu-psma-617 of psma imaging parameters, psmamean', 'of 177lu-psma-617 of psma imaging parameters, psmamean &gt;10', '177lu-psma-617 of psma imaging parameters, psmamean &gt;10 highly', 'of psma imaging parameters, psmamean &gt;10 highly predictive', 'psma imaging parameters, psmamean &gt;10 highly predictive of', 'imaging parameters, psmamean &gt;10 highly predictive of psa', 'parameters, psmamean &gt;10 highly predictive of psa orr,', 'psmamean &gt;10 highly predictive of psa orr, rpfs,', '&gt;10 highly predictive of psa orr, rpfs, and', 'highly predictive of psa orr, rpfs, and os', 'predictive of psa orr, rpfs, and os nearly', 'of psa orr, rpfs, and os nearly 6x', 'psa orr, rpfs, and os nearly 6x better', 'orr, rpfs, and os nearly 6x better than', 'rpfs, and os nearly 6x better than psmamean', 'and os nearly 6x better than psmamean &lt;10', 'os nearly 6x better than psmamean &lt;10 w/psa', 'nearly 6x better than psmamean &lt;10 w/psa orr', '6x better than psmamean &lt;10 w/psa orr subset', 'better than psmamean &lt;10 w/psa orr subset #asco22', 'than psmamean &lt;10 w/psa orr subset #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '23', 'tokens': ['"codebreak-200', 'study', 'for', 'pts', 'with', '#krasg12c-mut', 'platinum/io', 'pretreated', '#nsclc', 'sotorasib', '(oral', 'krasg12c', 'inhibitor)', 'showed', 'superiority', 'over', 'docetaxel!', '1y-pfs:', '24.8', 'vs', '10.1%', '(hr=0.66;', 'p=0.002)', 'orr:', '28.1', 'vs', '13.2%', 'grade', '3', 'traes', 'congrats', '&amp;', 'team!', '#esmo22', '.'], 'text_length': 35, 'triples': {'"codebreak-200|showed superiority': ([0, 0], [13, 14], 'positive')}, 'sentence': '"codebreak-200 study for pts with #krasg12c-mut platinum/io pretreated #nsclc sotorasib (oral krasg12c inhibitor) showed superiority over docetaxel! 1y-pfs: 24.8 vs 10.1% (hr=0.66; p=0.002) orr: 28.1 vs 13.2% grade 3 traes congrats &amp; team! #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(13, 14)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['"codebreak-200', 'study', 'for', 'pts', 'with', '#krasg12c-mut', 'platinum/io', 'pretreated', '#nsclc', 'sotorasib', '(oral', 'krasg12c', 'inhibitor)', 'showed', 'superiority', 'over', 'docetaxel!', '1y-pfs:', '24.8', 'vs', '10.1%', '(hr=0.66;', 'p=0.002)', 'orr:', '28.1', 'vs', '13.2%', 'grade', '3', 'traes', 'congrats', '&amp;', 'team!', '#esmo22', '.', '"codebreak-200 study', 'study for', 'for pts', 'pts with', 'with #krasg12c-mut', '#krasg12c-mut platinum/io', 'platinum/io pretreated', 'pretreated #nsclc', '#nsclc sotorasib', 'sotorasib (oral', '(oral krasg12c', 'krasg12c inhibitor)', 'inhibitor) showed', 'showed superiority', 'superiority over', 'over docetaxel!', 'docetaxel! 1y-pfs:', '1y-pfs: 24.8', '24.8 vs', 'vs 10.1%', '10.1% (hr=0.66;', '(hr=0.66; p=0.002)', 'p=0.002) orr:', 'orr: 28.1', '28.1 vs', 'vs 13.2%', '13.2% grade', 'grade 3', '3 traes', 'traes congrats', 'congrats &amp;', '&amp; team!', 'team! #esmo22', '#esmo22 .', '"codebreak-200 study for', 'study for pts', 'for pts with', 'pts with #krasg12c-mut', 'with #krasg12c-mut platinum/io', '#krasg12c-mut platinum/io pretreated', 'platinum/io pretreated #nsclc', 'pretreated #nsclc sotorasib', '#nsclc sotorasib (oral', 'sotorasib (oral krasg12c', '(oral krasg12c inhibitor)', 'krasg12c inhibitor) showed', 'inhibitor) showed superiority', 'showed superiority over', 'superiority over docetaxel!', 'over docetaxel! 1y-pfs:', 'docetaxel! 1y-pfs: 24.8', '1y-pfs: 24.8 vs', '24.8 vs 10.1%', 'vs 10.1% (hr=0.66;', '10.1% (hr=0.66; p=0.002)', '(hr=0.66; p=0.002) orr:', 'p=0.002) orr: 28.1', 'orr: 28.1 vs', '28.1 vs 13.2%', 'vs 13.2% grade', '13.2% grade 3', 'grade 3 traes', '3 traes congrats', 'traes congrats &amp;', 'congrats &amp; team!', '&amp; team! #esmo22', 'team! #esmo22 .', '"codebreak-200 study for pts', 'study for pts with', 'for pts with #krasg12c-mut', 'pts with #krasg12c-mut platinum/io', 'with #krasg12c-mut platinum/io pretreated', '#krasg12c-mut platinum/io pretreated #nsclc', 'platinum/io pretreated #nsclc sotorasib', 'pretreated #nsclc sotorasib (oral', '#nsclc sotorasib (oral krasg12c', 'sotorasib (oral krasg12c inhibitor)', '(oral krasg12c inhibitor) showed', 'krasg12c inhibitor) showed superiority', 'inhibitor) showed superiority over', 'showed superiority over docetaxel!', 'superiority over docetaxel! 1y-pfs:', 'over docetaxel! 1y-pfs: 24.8', 'docetaxel! 1y-pfs: 24.8 vs', '1y-pfs: 24.8 vs 10.1%', '24.8 vs 10.1% (hr=0.66;', 'vs 10.1% (hr=0.66; p=0.002)', '10.1% (hr=0.66; p=0.002) orr:', '(hr=0.66; p=0.002) orr: 28.1', 'p=0.002) orr: 28.1 vs', 'orr: 28.1 vs 13.2%', '28.1 vs 13.2% grade', 'vs 13.2% grade 3', '13.2% grade 3 traes', 'grade 3 traes congrats', '3 traes congrats &amp;', 'traes congrats &amp; team!', 'congrats &amp; team! #esmo22', '&amp; team! #esmo22 .', '"codebreak-200 study for pts with', 'study for pts with #krasg12c-mut', 'for pts with #krasg12c-mut platinum/io', 'pts with #krasg12c-mut platinum/io pretreated', 'with #krasg12c-mut platinum/io pretreated #nsclc', '#krasg12c-mut platinum/io pretreated #nsclc sotorasib', 'platinum/io pretreated #nsclc sotorasib (oral', 'pretreated #nsclc sotorasib (oral krasg12c', '#nsclc sotorasib (oral krasg12c inhibitor)', 'sotorasib (oral krasg12c inhibitor) showed', '(oral krasg12c inhibitor) showed superiority', 'krasg12c inhibitor) showed superiority over', 'inhibitor) showed superiority over docetaxel!', 'showed superiority over docetaxel! 1y-pfs:', 'superiority over docetaxel! 1y-pfs: 24.8', 'over docetaxel! 1y-pfs: 24.8 vs', 'docetaxel! 1y-pfs: 24.8 vs 10.1%', '1y-pfs: 24.8 vs 10.1% (hr=0.66;', '24.8 vs 10.1% (hr=0.66; p=0.002)', 'vs 10.1% (hr=0.66; p=0.002) orr:', '10.1% (hr=0.66; p=0.002) orr: 28.1', '(hr=0.66; p=0.002) orr: 28.1 vs', 'p=0.002) orr: 28.1 vs 13.2%', 'orr: 28.1 vs 13.2% grade', '28.1 vs 13.2% grade 3', 'vs 13.2% grade 3 traes', '13.2% grade 3 traes congrats', 'grade 3 traes congrats &amp;', '3 traes congrats &amp; team!', 'traes congrats &amp; team! #esmo22', 'congrats &amp; team! #esmo22 .', '"codebreak-200 study for pts with #krasg12c-mut', 'study for pts with #krasg12c-mut platinum/io', 'for pts with #krasg12c-mut platinum/io pretreated', 'pts with #krasg12c-mut platinum/io pretreated #nsclc', 'with #krasg12c-mut platinum/io pretreated #nsclc sotorasib', '#krasg12c-mut platinum/io pretreated #nsclc sotorasib (oral', 'platinum/io pretreated #nsclc sotorasib (oral krasg12c', 'pretreated #nsclc sotorasib (oral krasg12c inhibitor)', '#nsclc sotorasib (oral krasg12c inhibitor) showed', 'sotorasib (oral krasg12c inhibitor) showed superiority', '(oral krasg12c inhibitor) showed superiority over', 'krasg12c inhibitor) showed superiority over docetaxel!', 'inhibitor) showed superiority over docetaxel! 1y-pfs:', 'showed superiority over docetaxel! 1y-pfs: 24.8', 'superiority over docetaxel! 1y-pfs: 24.8 vs', 'over docetaxel! 1y-pfs: 24.8 vs 10.1%', 'docetaxel! 1y-pfs: 24.8 vs 10.1% (hr=0.66;', '1y-pfs: 24.8 vs 10.1% (hr=0.66; p=0.002)', '24.8 vs 10.1% (hr=0.66; p=0.002) orr:', 'vs 10.1% (hr=0.66; p=0.002) orr: 28.1', '10.1% (hr=0.66; p=0.002) orr: 28.1 vs', '(hr=0.66; p=0.002) orr: 28.1 vs 13.2%', 'p=0.002) orr: 28.1 vs 13.2% grade', 'orr: 28.1 vs 13.2% grade 3', '28.1 vs 13.2% grade 3 traes', 'vs 13.2% grade 3 traes congrats', '13.2% grade 3 traes congrats &amp;', 'grade 3 traes congrats &amp; team!', '3 traes congrats &amp; team! #esmo22', 'traes congrats &amp; team! #esmo22 .', '"codebreak-200 study for pts with #krasg12c-mut platinum/io', 'study for pts with #krasg12c-mut platinum/io pretreated', 'for pts with #krasg12c-mut platinum/io pretreated #nsclc', 'pts with #krasg12c-mut platinum/io pretreated #nsclc sotorasib', 'with #krasg12c-mut platinum/io pretreated #nsclc sotorasib (oral', '#krasg12c-mut platinum/io pretreated #nsclc sotorasib (oral krasg12c', 'platinum/io pretreated #nsclc sotorasib (oral krasg12c inhibitor)', 'pretreated #nsclc sotorasib (oral krasg12c inhibitor) showed', '#nsclc sotorasib (oral krasg12c inhibitor) showed superiority', 'sotorasib (oral krasg12c inhibitor) showed superiority over', '(oral krasg12c inhibitor) showed superiority over docetaxel!', 'krasg12c inhibitor) showed superiority over docetaxel! 1y-pfs:', 'inhibitor) showed superiority over docetaxel! 1y-pfs: 24.8', 'showed superiority over docetaxel! 1y-pfs: 24.8 vs', 'superiority over docetaxel! 1y-pfs: 24.8 vs 10.1%', 'over docetaxel! 1y-pfs: 24.8 vs 10.1% (hr=0.66;', 'docetaxel! 1y-pfs: 24.8 vs 10.1% (hr=0.66; p=0.002)', '1y-pfs: 24.8 vs 10.1% (hr=0.66; p=0.002) orr:', '24.8 vs 10.1% (hr=0.66; p=0.002) orr: 28.1', 'vs 10.1% (hr=0.66; p=0.002) orr: 28.1 vs', '10.1% (hr=0.66; p=0.002) orr: 28.1 vs 13.2%', '(hr=0.66; p=0.002) orr: 28.1 vs 13.2% grade', 'p=0.002) orr: 28.1 vs 13.2% grade 3', 'orr: 28.1 vs 13.2% grade 3 traes', '28.1 vs 13.2% grade 3 traes congrats', 'vs 13.2% grade 3 traes congrats &amp;', '13.2% grade 3 traes congrats &amp; team!', 'grade 3 traes congrats &amp; team! #esmo22', '3 traes congrats &amp; team! #esmo22 .', '"codebreak-200 study for pts with #krasg12c-mut platinum/io pretreated', 'study for pts with #krasg12c-mut platinum/io pretreated #nsclc', 'for pts with #krasg12c-mut platinum/io pretreated #nsclc sotorasib', 'pts with #krasg12c-mut platinum/io pretreated #nsclc sotorasib (oral', 'with #krasg12c-mut platinum/io pretreated #nsclc sotorasib (oral krasg12c', '#krasg12c-mut platinum/io pretreated #nsclc sotorasib (oral krasg12c inhibitor)', 'platinum/io pretreated #nsclc sotorasib (oral krasg12c inhibitor) showed', 'pretreated #nsclc sotorasib (oral krasg12c inhibitor) showed superiority', '#nsclc sotorasib (oral krasg12c inhibitor) showed superiority over', 'sotorasib (oral krasg12c inhibitor) showed superiority over docetaxel!', '(oral krasg12c inhibitor) showed superiority over docetaxel! 1y-pfs:', 'krasg12c inhibitor) showed superiority over docetaxel! 1y-pfs: 24.8', 'inhibitor) showed superiority over docetaxel! 1y-pfs: 24.8 vs', 'showed superiority over docetaxel! 1y-pfs: 24.8 vs 10.1%', 'superiority over docetaxel! 1y-pfs: 24.8 vs 10.1% (hr=0.66;', 'over docetaxel! 1y-pfs: 24.8 vs 10.1% (hr=0.66; p=0.002)', 'docetaxel! 1y-pfs: 24.8 vs 10.1% (hr=0.66; p=0.002) orr:', '1y-pfs: 24.8 vs 10.1% (hr=0.66; p=0.002) orr: 28.1', '24.8 vs 10.1% (hr=0.66; p=0.002) orr: 28.1 vs', 'vs 10.1% (hr=0.66; p=0.002) orr: 28.1 vs 13.2%', '10.1% (hr=0.66; p=0.002) orr: 28.1 vs 13.2% grade', '(hr=0.66; p=0.002) orr: 28.1 vs 13.2% grade 3', 'p=0.002) orr: 28.1 vs 13.2% grade 3 traes', 'orr: 28.1 vs 13.2% grade 3 traes congrats', '28.1 vs 13.2% grade 3 traes congrats &amp;', 'vs 13.2% grade 3 traes congrats &amp; team!', '13.2% grade 3 traes congrats &amp; team! #esmo22', 'grade 3 traes congrats &amp; team! #esmo22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '24', 'tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial', 'in', 'men', 'with', 'mhspc', '#prostatecancer,', 'addition', 'of', 'aap', 'to', 'adt', 'continues', 'to', 'os.', 'no', 'benefit', 'of', 'adding', 'enza', 'to', 'abi', '.'], 'text_length': 28, 'triples': {'stampede|continues to os. no benefit': ([5, 5], [17, 21], 'neutral')}, 'sentence': '#esmo22 abs# lba62: in the stampede trial in men with mhspc #prostatecancer, addition of aap to adt continues to os. no benefit of adding enza to abi .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 21)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial', 'in', 'men', 'with', 'mhspc', '#prostatecancer,', 'addition', 'of', 'aap', 'to', 'adt', 'continues', 'to', 'os.', 'no', 'benefit', 'of', 'adding', 'enza', 'to', 'abi', '.', '#esmo22 abs#', 'abs# lba62:', 'lba62: in', 'in the', 'the stampede', 'stampede trial', 'trial in', 'in men', 'men with', 'with mhspc', 'mhspc #prostatecancer,', '#prostatecancer, addition', 'addition of', 'of aap', 'aap to', 'to adt', 'adt continues', 'continues to', 'to os.', 'os. no', 'no benefit', 'benefit of', 'of adding', 'adding enza', 'enza to', 'to abi', 'abi .', '#esmo22 abs# lba62:', 'abs# lba62: in', 'lba62: in the', 'in the stampede', 'the stampede trial', 'stampede trial in', 'trial in men', 'in men with', 'men with mhspc', 'with mhspc #prostatecancer,', 'mhspc #prostatecancer, addition', '#prostatecancer, addition of', 'addition of aap', 'of aap to', 'aap to adt', 'to adt continues', 'adt continues to', 'continues to os.', 'to os. no', 'os. no benefit', 'no benefit of', 'benefit of adding', 'of adding enza', 'adding enza to', 'enza to abi', 'to abi .', '#esmo22 abs# lba62: in', 'abs# lba62: in the', 'lba62: in the stampede', 'in the stampede trial', 'the stampede trial in', 'stampede trial in men', 'trial in men with', 'in men with mhspc', 'men with mhspc #prostatecancer,', 'with mhspc #prostatecancer, addition', 'mhspc #prostatecancer, addition of', '#prostatecancer, addition of aap', 'addition of aap to', 'of aap to adt', 'aap to adt continues', 'to adt continues to', 'adt continues to os.', 'continues to os. no', 'to os. no benefit', 'os. no benefit of', 'no benefit of adding', 'benefit of adding enza', 'of adding enza to', 'adding enza to abi', 'enza to abi .', '#esmo22 abs# lba62: in the', 'abs# lba62: in the stampede', 'lba62: in the stampede trial', 'in the stampede trial in', 'the stampede trial in men', 'stampede trial in men with', 'trial in men with mhspc', 'in men with mhspc #prostatecancer,', 'men with mhspc #prostatecancer, addition', 'with mhspc #prostatecancer, addition of', 'mhspc #prostatecancer, addition of aap', '#prostatecancer, addition of aap to', 'addition of aap to adt', 'of aap to adt continues', 'aap to adt continues to', 'to adt continues to os.', 'adt continues to os. no', 'continues to os. no benefit', 'to os. no benefit of', 'os. no benefit of adding', 'no benefit of adding enza', 'benefit of adding enza to', 'of adding enza to abi', 'adding enza to abi .', '#esmo22 abs# lba62: in the stampede', 'abs# lba62: in the stampede trial', 'lba62: in the stampede trial in', 'in the stampede trial in men', 'the stampede trial in men with', 'stampede trial in men with mhspc', 'trial in men with mhspc #prostatecancer,', 'in men with mhspc #prostatecancer, addition', 'men with mhspc #prostatecancer, addition of', 'with mhspc #prostatecancer, addition of aap', 'mhspc #prostatecancer, addition of aap to', '#prostatecancer, addition of aap to adt', 'addition of aap to adt continues', 'of aap to adt continues to', 'aap to adt continues to os.', 'to adt continues to os. no', 'adt continues to os. no benefit', 'continues to os. no benefit of', 'to os. no benefit of adding', 'os. no benefit of adding enza', 'no benefit of adding enza to', 'benefit of adding enza to abi', 'of adding enza to abi .', '#esmo22 abs# lba62: in the stampede trial', 'abs# lba62: in the stampede trial in', 'lba62: in the stampede trial in men', 'in the stampede trial in men with', 'the stampede trial in men with mhspc', 'stampede trial in men with mhspc #prostatecancer,', 'trial in men with mhspc #prostatecancer, addition', 'in men with mhspc #prostatecancer, addition of', 'men with mhspc #prostatecancer, addition of aap', 'with mhspc #prostatecancer, addition of aap to', 'mhspc #prostatecancer, addition of aap to adt', '#prostatecancer, addition of aap to adt continues', 'addition of aap to adt continues to', 'of aap to adt continues to os.', 'aap to adt continues to os. no', 'to adt continues to os. no benefit', 'adt continues to os. no benefit of', 'continues to os. no benefit of adding', 'to os. no benefit of adding enza', 'os. no benefit of adding enza to', 'no benefit of adding enza to abi', 'benefit of adding enza to abi .', '#esmo22 abs# lba62: in the stampede trial in', 'abs# lba62: in the stampede trial in men', 'lba62: in the stampede trial in men with', 'in the stampede trial in men with mhspc', 'the stampede trial in men with mhspc #prostatecancer,', 'stampede trial in men with mhspc #prostatecancer, addition', 'trial in men with mhspc #prostatecancer, addition of', 'in men with mhspc #prostatecancer, addition of aap', 'men with mhspc #prostatecancer, addition of aap to', 'with mhspc #prostatecancer, addition of aap to adt', 'mhspc #prostatecancer, addition of aap to adt continues', '#prostatecancer, addition of aap to adt continues to', 'addition of aap to adt continues to os.', 'of aap to adt continues to os. no', 'aap to adt continues to os. no benefit', 'to adt continues to os. no benefit of', 'adt continues to os. no benefit of adding', 'continues to os. no benefit of adding enza', 'to os. no benefit of adding enza to', 'os. no benefit of adding enza to abi', 'no benefit of adding enza to abi .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '25', 'tokens': ['with', 'a', 'wonderful', 'presentation', 'of', 'the', 'karmma', 'cohort', '2', 'data', '-&gt;', 'orr', '83%', 'in', 'high', 'risk', 'mm.', 'meaningful', 'results', 'and', 'mrd', 'negativity', 'in', '70%!', '#ash22', '#mmsm', '.'], 'text_length': 27, 'triples': {'karmma|wonderful presentation of the karmma cohort 2 data -&gt; orr 83% in high risk mm. meaningful': ([6, 6], [2, 17], 'positive')}, 'sentence': 'with a wonderful presentation of the karmma cohort 2 data -&gt; orr 83% in high risk mm. meaningful results and mrd negativity in 70%! #ash22 #mmsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 17)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8)], 'span tokens': ['with', 'a', 'wonderful', 'presentation', 'of', 'the', 'karmma', 'cohort', '2', 'data', '-&gt;', 'orr', '83%', 'in', 'high', 'risk', 'mm.', 'meaningful', 'results', 'and', 'mrd', 'negativity', 'in', '70%!', '#ash22', '#mmsm', '.', 'with a', 'a wonderful', 'wonderful presentation', 'presentation of', 'of the', 'the karmma', 'karmma cohort', 'cohort 2', '2 data', 'data -&gt;', '-&gt; orr', 'orr 83%', '83% in', 'in high', 'high risk', 'risk mm.', 'mm. meaningful', 'meaningful results', 'results and', 'and mrd', 'mrd negativity', 'negativity in', 'in 70%!', '70%! #ash22', '#ash22 #mmsm', '#mmsm .', 'with a wonderful', 'a wonderful presentation', 'wonderful presentation of', 'presentation of the', 'of the karmma', 'the karmma cohort', 'karmma cohort 2', 'cohort 2 data', '2 data -&gt;', 'data -&gt; orr', '-&gt; orr 83%', 'orr 83% in', '83% in high', 'in high risk', 'high risk mm.', 'risk mm. meaningful', 'mm. meaningful results', 'meaningful results and', 'results and mrd', 'and mrd negativity', 'mrd negativity in', 'negativity in 70%!', 'in 70%! #ash22', '70%! #ash22 #mmsm', '#ash22 #mmsm .', 'with a wonderful presentation', 'a wonderful presentation of', 'wonderful presentation of the', 'presentation of the karmma', 'of the karmma cohort', 'the karmma cohort 2', 'karmma cohort 2 data', 'cohort 2 data -&gt;', '2 data -&gt; orr', 'data -&gt; orr 83%', '-&gt; orr 83% in', 'orr 83% in high', '83% in high risk', 'in high risk mm.', 'high risk mm. meaningful', 'risk mm. meaningful results', 'mm. meaningful results and', 'meaningful results and mrd', 'results and mrd negativity', 'and mrd negativity in', 'mrd negativity in 70%!', 'negativity in 70%! #ash22', 'in 70%! #ash22 #mmsm', '70%! #ash22 #mmsm .', 'with a wonderful presentation of', 'a wonderful presentation of the', 'wonderful presentation of the karmma', 'presentation of the karmma cohort', 'of the karmma cohort 2', 'the karmma cohort 2 data', 'karmma cohort 2 data -&gt;', 'cohort 2 data -&gt; orr', '2 data -&gt; orr 83%', 'data -&gt; orr 83% in', '-&gt; orr 83% in high', 'orr 83% in high risk', '83% in high risk mm.', 'in high risk mm. meaningful', 'high risk mm. meaningful results', 'risk mm. meaningful results and', 'mm. meaningful results and mrd', 'meaningful results and mrd negativity', 'results and mrd negativity in', 'and mrd negativity in 70%!', 'mrd negativity in 70%! #ash22', 'negativity in 70%! #ash22 #mmsm', 'in 70%! #ash22 #mmsm .', 'with a wonderful presentation of the', 'a wonderful presentation of the karmma', 'wonderful presentation of the karmma cohort', 'presentation of the karmma cohort 2', 'of the karmma cohort 2 data', 'the karmma cohort 2 data -&gt;', 'karmma cohort 2 data -&gt; orr', 'cohort 2 data -&gt; orr 83%', '2 data -&gt; orr 83% in', 'data -&gt; orr 83% in high', '-&gt; orr 83% in high risk', 'orr 83% in high risk mm.', '83% in high risk mm. meaningful', 'in high risk mm. meaningful results', 'high risk mm. meaningful results and', 'risk mm. meaningful results and mrd', 'mm. meaningful results and mrd negativity', 'meaningful results and mrd negativity in', 'results and mrd negativity in 70%!', 'and mrd negativity in 70%! #ash22', 'mrd negativity in 70%! #ash22 #mmsm', 'negativity in 70%! #ash22 #mmsm .', 'with a wonderful presentation of the karmma', 'a wonderful presentation of the karmma cohort', 'wonderful presentation of the karmma cohort 2', 'presentation of the karmma cohort 2 data', 'of the karmma cohort 2 data -&gt;', 'the karmma cohort 2 data -&gt; orr', 'karmma cohort 2 data -&gt; orr 83%', 'cohort 2 data -&gt; orr 83% in', '2 data -&gt; orr 83% in high', 'data -&gt; orr 83% in high risk', '-&gt; orr 83% in high risk mm.', 'orr 83% in high risk mm. meaningful', '83% in high risk mm. meaningful results', 'in high risk mm. meaningful results and', 'high risk mm. meaningful results and mrd', 'risk mm. meaningful results and mrd negativity', 'mm. meaningful results and mrd negativity in', 'meaningful results and mrd negativity in 70%!', 'results and mrd negativity in 70%! #ash22', 'and mrd negativity in 70%! #ash22 #mmsm', 'mrd negativity in 70%! #ash22 #mmsm .', 'with a wonderful presentation of the karmma cohort', 'a wonderful presentation of the karmma cohort 2', 'wonderful presentation of the karmma cohort 2 data', 'presentation of the karmma cohort 2 data -&gt;', 'of the karmma cohort 2 data -&gt; orr', 'the karmma cohort 2 data -&gt; orr 83%', 'karmma cohort 2 data -&gt; orr 83% in', 'cohort 2 data -&gt; orr 83% in high', '2 data -&gt; orr 83% in high risk', 'data -&gt; orr 83% in high risk mm.', '-&gt; orr 83% in high risk mm. meaningful', 'orr 83% in high risk mm. meaningful results', '83% in high risk mm. meaningful results and', 'in high risk mm. meaningful results and mrd', 'high risk mm. meaningful results and mrd negativity', 'risk mm. meaningful results and mrd negativity in', 'mm. meaningful results and mrd negativity in 70%!', 'meaningful results and mrd negativity in 70%! #ash22', 'results and mrd negativity in 70%! #ash22 #mmsm', 'and mrd negativity in 70%! #ash22 #mmsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '26', 'tokens': ['#esmo22', 'abs#', '1357o:', 'updated', 'results', 'from', 'the', 'propel', 'trial', 'showed', 'rpfs', 'benefit', 'of', 'using', 'aap+olaparib', 'for', 'all', 'subgroups', '(non-hrrm,', 'hrrm,brcam', 'status).', 'improved', 'os', 'with', 'aap+olaparib', 'vs', 'aap+placebo', 'is', 'reported', '(hr', '0.83).', '.'], 'text_length': 32, 'triples': {'propel|showed rpfs benefit': ([7, 7], [9, 11], 'positive'), 'aap+olaparib for all subgroups (non-hrrm, hrrm,brcam status). improved os with aap+olaparib vs|os with': ([14, 25], [22, 23], 'positive')}, 'sentence': '#esmo22 abs# 1357o: updated results from the propel trial showed rpfs benefit of using aap+olaparib for all subgroups (non-hrrm, hrrm,brcam status). improved os with aap+olaparib vs aap+placebo is reported (hr 0.83). .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(7, 7), (14, 25)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(9, 11), (22, 23)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['#esmo22', 'abs#', '1357o:', 'updated', 'results', 'from', 'the', 'propel', 'trial', 'showed', 'rpfs', 'benefit', 'of', 'using', 'aap+olaparib', 'for', 'all', 'subgroups', '(non-hrrm,', 'hrrm,brcam', 'status).', 'improved', 'os', 'with', 'aap+olaparib', 'vs', 'aap+placebo', 'is', 'reported', '(hr', '0.83).', '.', '#esmo22 abs#', 'abs# 1357o:', '1357o: updated', 'updated results', 'results from', 'from the', 'the propel', 'propel trial', 'trial showed', 'showed rpfs', 'rpfs benefit', 'benefit of', 'of using', 'using aap+olaparib', 'aap+olaparib for', 'for all', 'all subgroups', 'subgroups (non-hrrm,', '(non-hrrm, hrrm,brcam', 'hrrm,brcam status).', 'status). improved', 'improved os', 'os with', 'with aap+olaparib', 'aap+olaparib vs', 'vs aap+placebo', 'aap+placebo is', 'is reported', 'reported (hr', '(hr 0.83).', '0.83). .', '#esmo22 abs# 1357o:', 'abs# 1357o: updated', '1357o: updated results', 'updated results from', 'results from the', 'from the propel', 'the propel trial', 'propel trial showed', 'trial showed rpfs', 'showed rpfs benefit', 'rpfs benefit of', 'benefit of using', 'of using aap+olaparib', 'using aap+olaparib for', 'aap+olaparib for all', 'for all subgroups', 'all subgroups (non-hrrm,', 'subgroups (non-hrrm, hrrm,brcam', '(non-hrrm, hrrm,brcam status).', 'hrrm,brcam status). improved', 'status). improved os', 'improved os with', 'os with aap+olaparib', 'with aap+olaparib vs', 'aap+olaparib vs aap+placebo', 'vs aap+placebo is', 'aap+placebo is reported', 'is reported (hr', 'reported (hr 0.83).', '(hr 0.83). .', '#esmo22 abs# 1357o: updated', 'abs# 1357o: updated results', '1357o: updated results from', 'updated results from the', 'results from the propel', 'from the propel trial', 'the propel trial showed', 'propel trial showed rpfs', 'trial showed rpfs benefit', 'showed rpfs benefit of', 'rpfs benefit of using', 'benefit of using aap+olaparib', 'of using aap+olaparib for', 'using aap+olaparib for all', 'aap+olaparib for all subgroups', 'for all subgroups (non-hrrm,', 'all subgroups (non-hrrm, hrrm,brcam', 'subgroups (non-hrrm, hrrm,brcam status).', '(non-hrrm, hrrm,brcam status). improved', 'hrrm,brcam status). improved os', 'status). improved os with', 'improved os with aap+olaparib', 'os with aap+olaparib vs', 'with aap+olaparib vs aap+placebo', 'aap+olaparib vs aap+placebo is', 'vs aap+placebo is reported', 'aap+placebo is reported (hr', 'is reported (hr 0.83).', 'reported (hr 0.83). .', '#esmo22 abs# 1357o: updated results', 'abs# 1357o: updated results from', '1357o: updated results from the', 'updated results from the propel', 'results from the propel trial', 'from the propel trial showed', 'the propel trial showed rpfs', 'propel trial showed rpfs benefit', 'trial showed rpfs benefit of', 'showed rpfs benefit of using', 'rpfs benefit of using aap+olaparib', 'benefit of using aap+olaparib for', 'of using aap+olaparib for all', 'using aap+olaparib for all subgroups', 'aap+olaparib for all subgroups (non-hrrm,', 'for all subgroups (non-hrrm, hrrm,brcam', 'all subgroups (non-hrrm, hrrm,brcam status).', 'subgroups (non-hrrm, hrrm,brcam status). improved', '(non-hrrm, hrrm,brcam status). improved os', 'hrrm,brcam status). improved os with', 'status). improved os with aap+olaparib', 'improved os with aap+olaparib vs', 'os with aap+olaparib vs aap+placebo', 'with aap+olaparib vs aap+placebo is', 'aap+olaparib vs aap+placebo is reported', 'vs aap+placebo is reported (hr', 'aap+placebo is reported (hr 0.83).', 'is reported (hr 0.83). .', '#esmo22 abs# 1357o: updated results from', 'abs# 1357o: updated results from the', '1357o: updated results from the propel', 'updated results from the propel trial', 'results from the propel trial showed', 'from the propel trial showed rpfs', 'the propel trial showed rpfs benefit', 'propel trial showed rpfs benefit of', 'trial showed rpfs benefit of using', 'showed rpfs benefit of using aap+olaparib', 'rpfs benefit of using aap+olaparib for', 'benefit of using aap+olaparib for all', 'of using aap+olaparib for all subgroups', 'using aap+olaparib for all subgroups (non-hrrm,', 'aap+olaparib for all subgroups (non-hrrm, hrrm,brcam', 'for all subgroups (non-hrrm, hrrm,brcam status).', 'all subgroups (non-hrrm, hrrm,brcam status). improved', 'subgroups (non-hrrm, hrrm,brcam status). improved os', '(non-hrrm, hrrm,brcam status). improved os with', 'hrrm,brcam status). improved os with aap+olaparib', 'status). improved os with aap+olaparib vs', 'improved os with aap+olaparib vs aap+placebo', 'os with aap+olaparib vs aap+placebo is', 'with aap+olaparib vs aap+placebo is reported', 'aap+olaparib vs aap+placebo is reported (hr', 'vs aap+placebo is reported (hr 0.83).', 'aap+placebo is reported (hr 0.83). .', '#esmo22 abs# 1357o: updated results from the', 'abs# 1357o: updated results from the propel', '1357o: updated results from the propel trial', 'updated results from the propel trial showed', 'results from the propel trial showed rpfs', 'from the propel trial showed rpfs benefit', 'the propel trial showed rpfs benefit of', 'propel trial showed rpfs benefit of using', 'trial showed rpfs benefit of using aap+olaparib', 'showed rpfs benefit of using aap+olaparib for', 'rpfs benefit of using aap+olaparib for all', 'benefit of using aap+olaparib for all subgroups', 'of using aap+olaparib for all subgroups (non-hrrm,', 'using aap+olaparib for all subgroups (non-hrrm, hrrm,brcam', 'aap+olaparib for all subgroups (non-hrrm, hrrm,brcam status).', 'for all subgroups (non-hrrm, hrrm,brcam status). improved', 'all subgroups (non-hrrm, hrrm,brcam status). improved os', 'subgroups (non-hrrm, hrrm,brcam status). improved os with', '(non-hrrm, hrrm,brcam status). improved os with aap+olaparib', 'hrrm,brcam status). improved os with aap+olaparib vs', 'status). improved os with aap+olaparib vs aap+placebo', 'improved os with aap+olaparib vs aap+placebo is', 'os with aap+olaparib vs aap+placebo is reported', 'with aap+olaparib vs aap+placebo is reported (hr', 'aap+olaparib vs aap+placebo is reported (hr 0.83).', 'vs aap+placebo is reported (hr 0.83). .', '#esmo22 abs# 1357o: updated results from the propel', 'abs# 1357o: updated results from the propel trial', '1357o: updated results from the propel trial showed', 'updated results from the propel trial showed rpfs', 'results from the propel trial showed rpfs benefit', 'from the propel trial showed rpfs benefit of', 'the propel trial showed rpfs benefit of using', 'propel trial showed rpfs benefit of using aap+olaparib', 'trial showed rpfs benefit of using aap+olaparib for', 'showed rpfs benefit of using aap+olaparib for all', 'rpfs benefit of using aap+olaparib for all subgroups', 'benefit of using aap+olaparib for all subgroups (non-hrrm,', 'of using aap+olaparib for all subgroups (non-hrrm, hrrm,brcam', 'using aap+olaparib for all subgroups (non-hrrm, hrrm,brcam status).', 'aap+olaparib for all subgroups (non-hrrm, hrrm,brcam status). improved', 'for all subgroups (non-hrrm, hrrm,brcam status). improved os', 'all subgroups (non-hrrm, hrrm,brcam status). improved os with', 'subgroups (non-hrrm, hrrm,brcam status). improved os with aap+olaparib', '(non-hrrm, hrrm,brcam status). improved os with aap+olaparib vs', 'hrrm,brcam status). improved os with aap+olaparib vs aap+placebo', 'status). improved os with aap+olaparib vs aap+placebo is', 'improved os with aap+olaparib vs aap+placebo is reported', 'os with aap+olaparib vs aap+placebo is reported (hr', 'with aap+olaparib vs aap+placebo is reported (hr 0.83).', 'aap+olaparib vs aap+placebo is reported (hr 0.83). .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '27', 'tokens': ['fully', 'agree', 'with', 'on', 'astonishing', 'niche-2', 'results', 'and', 'future', 'perspectives', 'of', 'neoadjuvant', 'treatment', '.'], 'text_length': 14, 'triples': {'niche-2|astonishing': ([5, 5], [4, 4], 'positive')}, 'sentence': 'fully agree with on astonishing niche-2 results and future perspectives of neoadjuvant treatment .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8)], 'span tokens': ['fully', 'agree', 'with', 'on', 'astonishing', 'niche-2', 'results', 'and', 'future', 'perspectives', 'of', 'neoadjuvant', 'treatment', '.', 'fully agree', 'agree with', 'with on', 'on astonishing', 'astonishing niche-2', 'niche-2 results', 'results and', 'and future', 'future perspectives', 'perspectives of', 'of neoadjuvant', 'neoadjuvant treatment', 'treatment .', 'fully agree with', 'agree with on', 'with on astonishing', 'on astonishing niche-2', 'astonishing niche-2 results', 'niche-2 results and', 'results and future', 'and future perspectives', 'future perspectives of', 'perspectives of neoadjuvant', 'of neoadjuvant treatment', 'neoadjuvant treatment .', 'fully agree with on', 'agree with on astonishing', 'with on astonishing niche-2', 'on astonishing niche-2 results', 'astonishing niche-2 results and', 'niche-2 results and future', 'results and future perspectives', 'and future perspectives of', 'future perspectives of neoadjuvant', 'perspectives of neoadjuvant treatment', 'of neoadjuvant treatment .', 'fully agree with on astonishing', 'agree with on astonishing niche-2', 'with on astonishing niche-2 results', 'on astonishing niche-2 results and', 'astonishing niche-2 results and future', 'niche-2 results and future perspectives', 'results and future perspectives of', 'and future perspectives of neoadjuvant', 'future perspectives of neoadjuvant treatment', 'perspectives of neoadjuvant treatment .', 'fully agree with on astonishing niche-2', 'agree with on astonishing niche-2 results', 'with on astonishing niche-2 results and', 'on astonishing niche-2 results and future', 'astonishing niche-2 results and future perspectives', 'niche-2 results and future perspectives of', 'results and future perspectives of neoadjuvant', 'and future perspectives of neoadjuvant treatment', 'future perspectives of neoadjuvant treatment .', 'fully agree with on astonishing niche-2 results', 'agree with on astonishing niche-2 results and', 'with on astonishing niche-2 results and future', 'on astonishing niche-2 results and future perspectives', 'astonishing niche-2 results and future perspectives of', 'niche-2 results and future perspectives of neoadjuvant', 'results and future perspectives of neoadjuvant treatment', 'and future perspectives of neoadjuvant treatment .', 'fully agree with on astonishing niche-2 results and', 'agree with on astonishing niche-2 results and future', 'with on astonishing niche-2 results and future perspectives', 'on astonishing niche-2 results and future perspectives of', 'astonishing niche-2 results and future perspectives of neoadjuvant', 'niche-2 results and future perspectives of neoadjuvant treatment', 'results and future perspectives of neoadjuvant treatment .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '28', 'tokens': ['(1)', 'both', 'cr', 'and', 'mrd-', 'at', '3', 'months', '(only', 'mrd-', 'at', '1', 'month)', 'of', 'ide-cel', 'infusion', 'were', 'required', 'to', 'identify', 'pts', 'with', 'longer', 'pfs.', '(2)', 'reappearence', 'of', 'normal', 'pc', 'as', 'a', 'surrogate', 'of', 'relapse.', 'thank', 'you,', '!', '#ash2022', '.'], 'text_length': 39, 'triples': {'ide-cel|required to identify pts with longer pfs. (2) reappearence of normal pc as a surrogate of relapse. thank you,': ([14, 14], [17, 35], 'neutral')}, 'sentence': '(1) both cr and mrd- at 3 months (only mrd- at 1 month) of ide-cel infusion were required to identify pts with longer pfs. (2) reappearence of normal pc as a surrogate of relapse. thank you, ! #ash2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(14, 14)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 35)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8)], 'span tokens': ['(1)', 'both', 'cr', 'and', 'mrd-', 'at', '3', 'months', '(only', 'mrd-', 'at', '1', 'month)', 'of', 'ide-cel', 'infusion', 'were', 'required', 'to', 'identify', 'pts', 'with', 'longer', 'pfs.', '(2)', 'reappearence', 'of', 'normal', 'pc', 'as', 'a', 'surrogate', 'of', 'relapse.', 'thank', 'you,', '!', '#ash2022', '.', '(1) both', 'both cr', 'cr and', 'and mrd-', 'mrd- at', 'at 3', '3 months', 'months (only', '(only mrd-', 'mrd- at', 'at 1', '1 month)', 'month) of', 'of ide-cel', 'ide-cel infusion', 'infusion were', 'were required', 'required to', 'to identify', 'identify pts', 'pts with', 'with longer', 'longer pfs.', 'pfs. (2)', '(2) reappearence', 'reappearence of', 'of normal', 'normal pc', 'pc as', 'as a', 'a surrogate', 'surrogate of', 'of relapse.', 'relapse. thank', 'thank you,', 'you, !', '! #ash2022', '#ash2022 .', '(1) both cr', 'both cr and', 'cr and mrd-', 'and mrd- at', 'mrd- at 3', 'at 3 months', '3 months (only', 'months (only mrd-', '(only mrd- at', 'mrd- at 1', 'at 1 month)', '1 month) of', 'month) of ide-cel', 'of ide-cel infusion', 'ide-cel infusion were', 'infusion were required', 'were required to', 'required to identify', 'to identify pts', 'identify pts with', 'pts with longer', 'with longer pfs.', 'longer pfs. (2)', 'pfs. (2) reappearence', '(2) reappearence of', 'reappearence of normal', 'of normal pc', 'normal pc as', 'pc as a', 'as a surrogate', 'a surrogate of', 'surrogate of relapse.', 'of relapse. thank', 'relapse. thank you,', 'thank you, !', 'you, ! #ash2022', '! #ash2022 .', '(1) both cr and', 'both cr and mrd-', 'cr and mrd- at', 'and mrd- at 3', 'mrd- at 3 months', 'at 3 months (only', '3 months (only mrd-', 'months (only mrd- at', '(only mrd- at 1', 'mrd- at 1 month)', 'at 1 month) of', '1 month) of ide-cel', 'month) of ide-cel infusion', 'of ide-cel infusion were', 'ide-cel infusion were required', 'infusion were required to', 'were required to identify', 'required to identify pts', 'to identify pts with', 'identify pts with longer', 'pts with longer pfs.', 'with longer pfs. (2)', 'longer pfs. (2) reappearence', 'pfs. (2) reappearence of', '(2) reappearence of normal', 'reappearence of normal pc', 'of normal pc as', 'normal pc as a', 'pc as a surrogate', 'as a surrogate of', 'a surrogate of relapse.', 'surrogate of relapse. thank', 'of relapse. thank you,', 'relapse. thank you, !', 'thank you, ! #ash2022', 'you, ! #ash2022 .', '(1) both cr and mrd-', 'both cr and mrd- at', 'cr and mrd- at 3', 'and mrd- at 3 months', 'mrd- at 3 months (only', 'at 3 months (only mrd-', '3 months (only mrd- at', 'months (only mrd- at 1', '(only mrd- at 1 month)', 'mrd- at 1 month) of', 'at 1 month) of ide-cel', '1 month) of ide-cel infusion', 'month) of ide-cel infusion were', 'of ide-cel infusion were required', 'ide-cel infusion were required to', 'infusion were required to identify', 'were required to identify pts', 'required to identify pts with', 'to identify pts with longer', 'identify pts with longer pfs.', 'pts with longer pfs. (2)', 'with longer pfs. (2) reappearence', 'longer pfs. (2) reappearence of', 'pfs. (2) reappearence of normal', '(2) reappearence of normal pc', 'reappearence of normal pc as', 'of normal pc as a', 'normal pc as a surrogate', 'pc as a surrogate of', 'as a surrogate of relapse.', 'a surrogate of relapse. thank', 'surrogate of relapse. thank you,', 'of relapse. thank you, !', 'relapse. thank you, ! #ash2022', 'thank you, ! #ash2022 .', '(1) both cr and mrd- at', 'both cr and mrd- at 3', 'cr and mrd- at 3 months', 'and mrd- at 3 months (only', 'mrd- at 3 months (only mrd-', 'at 3 months (only mrd- at', '3 months (only mrd- at 1', 'months (only mrd- at 1 month)', '(only mrd- at 1 month) of', 'mrd- at 1 month) of ide-cel', 'at 1 month) of ide-cel infusion', '1 month) of ide-cel infusion were', 'month) of ide-cel infusion were required', 'of ide-cel infusion were required to', 'ide-cel infusion were required to identify', 'infusion were required to identify pts', 'were required to identify pts with', 'required to identify pts with longer', 'to identify pts with longer pfs.', 'identify pts with longer pfs. (2)', 'pts with longer pfs. (2) reappearence', 'with longer pfs. (2) reappearence of', 'longer pfs. (2) reappearence of normal', 'pfs. (2) reappearence of normal pc', '(2) reappearence of normal pc as', 'reappearence of normal pc as a', 'of normal pc as a surrogate', 'normal pc as a surrogate of', 'pc as a surrogate of relapse.', 'as a surrogate of relapse. thank', 'a surrogate of relapse. thank you,', 'surrogate of relapse. thank you, !', 'of relapse. thank you, ! #ash2022', 'relapse. thank you, ! #ash2022 .', '(1) both cr and mrd- at 3', 'both cr and mrd- at 3 months', 'cr and mrd- at 3 months (only', 'and mrd- at 3 months (only mrd-', 'mrd- at 3 months (only mrd- at', 'at 3 months (only mrd- at 1', '3 months (only mrd- at 1 month)', 'months (only mrd- at 1 month) of', '(only mrd- at 1 month) of ide-cel', 'mrd- at 1 month) of ide-cel infusion', 'at 1 month) of ide-cel infusion were', '1 month) of ide-cel infusion were required', 'month) of ide-cel infusion were required to', 'of ide-cel infusion were required to identify', 'ide-cel infusion were required to identify pts', 'infusion were required to identify pts with', 'were required to identify pts with longer', 'required to identify pts with longer pfs.', 'to identify pts with longer pfs. (2)', 'identify pts with longer pfs. (2) reappearence', 'pts with longer pfs. (2) reappearence of', 'with longer pfs. (2) reappearence of normal', 'longer pfs. (2) reappearence of normal pc', 'pfs. (2) reappearence of normal pc as', '(2) reappearence of normal pc as a', 'reappearence of normal pc as a surrogate', 'of normal pc as a surrogate of', 'normal pc as a surrogate of relapse.', 'pc as a surrogate of relapse. thank', 'as a surrogate of relapse. thank you,', 'a surrogate of relapse. thank you, !', 'surrogate of relapse. thank you, ! #ash2022', 'of relapse. thank you, ! #ash2022 .', '(1) both cr and mrd- at 3 months', 'both cr and mrd- at 3 months (only', 'cr and mrd- at 3 months (only mrd-', 'and mrd- at 3 months (only mrd- at', 'mrd- at 3 months (only mrd- at 1', 'at 3 months (only mrd- at 1 month)', '3 months (only mrd- at 1 month) of', 'months (only mrd- at 1 month) of ide-cel', '(only mrd- at 1 month) of ide-cel infusion', 'mrd- at 1 month) of ide-cel infusion were', 'at 1 month) of ide-cel infusion were required', '1 month) of ide-cel infusion were required to', 'month) of ide-cel infusion were required to identify', 'of ide-cel infusion were required to identify pts', 'ide-cel infusion were required to identify pts with', 'infusion were required to identify pts with longer', 'were required to identify pts with longer pfs.', 'required to identify pts with longer pfs. (2)', 'to identify pts with longer pfs. (2) reappearence', 'identify pts with longer pfs. (2) reappearence of', 'pts with longer pfs. (2) reappearence of normal', 'with longer pfs. (2) reappearence of normal pc', 'longer pfs. (2) reappearence of normal pc as', 'pfs. (2) reappearence of normal pc as a', '(2) reappearence of normal pc as a surrogate', 'reappearence of normal pc as a surrogate of', 'of normal pc as a surrogate of relapse.', 'normal pc as a surrogate of relapse. thank', 'pc as a surrogate of relapse. thank you,', 'as a surrogate of relapse. thank you, !', 'a surrogate of relapse. thank you, ! #ash2022', 'surrogate of relapse. thank you, ! #ash2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '29', 'tokens': ['Jennifer', 'Brown', 'from', '', 'shows', 'that', 'zanubrutinib', 'is', 'superior', 'to', 'ibrutinib', 'for', 'relapsed/refractory', 'CLL/SLL', 'for', 'everything', 'except', 'for', 'overall', 'survival.', '#LBA', '#ASH22.', 'Published', 'today', 'in.', '.'], 'text_length': 26, 'triples': {'ibrutinib|superior to': ([9, 9], [7, 8], 'negative'), 'zanubrutinib|superior': ([5, 5], [7, 7], 'positive')}, 'sentence': 'Jennifer Brown from  shows that zanubrutinib is superior to ibrutinib for relapsed/refractory CLL/SLL for everything except for overall survival. #LBA #ASH22. Published today in. .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(9, 9), (5, 5)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(7, 8), (7, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['Jennifer', 'Brown', 'from', '', 'shows', 'that', 'zanubrutinib', 'is', 'superior', 'to', 'ibrutinib', 'for', 'relapsed/refractory', 'CLL/SLL', 'for', 'everything', 'except', 'for', 'overall', 'survival.', '#LBA', '#ASH22.', 'Published', 'today', 'in.', '.', 'Jennifer Brown', 'Brown from', 'from ', ' shows', 'shows that', 'that zanubrutinib', 'zanubrutinib is', 'is superior', 'superior to', 'to ibrutinib', 'ibrutinib for', 'for relapsed/refractory', 'relapsed/refractory CLL/SLL', 'CLL/SLL for', 'for everything', 'everything except', 'except for', 'for overall', 'overall survival.', 'survival. #LBA', '#LBA #ASH22.', '#ASH22. Published', 'Published today', 'today in.', 'in. .', 'Jennifer Brown from', 'Brown from ', 'from  shows', ' shows that', 'shows that zanubrutinib', 'that zanubrutinib is', 'zanubrutinib is superior', 'is superior to', 'superior to ibrutinib', 'to ibrutinib for', 'ibrutinib for relapsed/refractory', 'for relapsed/refractory CLL/SLL', 'relapsed/refractory CLL/SLL for', 'CLL/SLL for everything', 'for everything except', 'everything except for', 'except for overall', 'for overall survival.', 'overall survival. #LBA', 'survival. #LBA #ASH22.', '#LBA #ASH22. Published', '#ASH22. Published today', 'Published today in.', 'today in. .', 'Jennifer Brown from ', 'Brown from  shows', 'from  shows that', ' shows that zanubrutinib', 'shows that zanubrutinib is', 'that zanubrutinib is superior', 'zanubrutinib is superior to', 'is superior to ibrutinib', 'superior to ibrutinib for', 'to ibrutinib for relapsed/refractory', 'ibrutinib for relapsed/refractory CLL/SLL', 'for relapsed/refractory CLL/SLL for', 'relapsed/refractory CLL/SLL for everything', 'CLL/SLL for everything except', 'for everything except for', 'everything except for overall', 'except for overall survival.', 'for overall survival. #LBA', 'overall survival. #LBA #ASH22.', 'survival. #LBA #ASH22. Published', '#LBA #ASH22. Published today', '#ASH22. Published today in.', 'Published today in. .', 'Jennifer Brown from  shows', 'Brown from  shows that', 'from  shows that zanubrutinib', ' shows that zanubrutinib is', 'shows that zanubrutinib is superior', 'that zanubrutinib is superior to', 'zanubrutinib is superior to ibrutinib', 'is superior to ibrutinib for', 'superior to ibrutinib for relapsed/refractory', 'to ibrutinib for relapsed/refractory CLL/SLL', 'ibrutinib for relapsed/refractory CLL/SLL for', 'for relapsed/refractory CLL/SLL for everything', 'relapsed/refractory CLL/SLL for everything except', 'CLL/SLL for everything except for', 'for everything except for overall', 'everything except for overall survival.', 'except for overall survival. #LBA', 'for overall survival. #LBA #ASH22.', 'overall survival. #LBA #ASH22. Published', 'survival. #LBA #ASH22. Published today', '#LBA #ASH22. Published today in.', '#ASH22. Published today in. .', 'Jennifer Brown from  shows that', 'Brown from  shows that zanubrutinib', 'from  shows that zanubrutinib is', ' shows that zanubrutinib is superior', 'shows that zanubrutinib is superior to', 'that zanubrutinib is superior to ibrutinib', 'zanubrutinib is superior to ibrutinib for', 'is superior to ibrutinib for relapsed/refractory', 'superior to ibrutinib for relapsed/refractory CLL/SLL', 'to ibrutinib for relapsed/refractory CLL/SLL for', 'ibrutinib for relapsed/refractory CLL/SLL for everything', 'for relapsed/refractory CLL/SLL for everything except', 'relapsed/refractory CLL/SLL for everything except for', 'CLL/SLL for everything except for overall', 'for everything except for overall survival.', 'everything except for overall survival. #LBA', 'except for overall survival. #LBA #ASH22.', 'for overall survival. #LBA #ASH22. Published', 'overall survival. #LBA #ASH22. Published today', 'survival. #LBA #ASH22. Published today in.', '#LBA #ASH22. Published today in. .', 'Jennifer Brown from  shows that zanubrutinib', 'Brown from  shows that zanubrutinib is', 'from  shows that zanubrutinib is superior', ' shows that zanubrutinib is superior to', 'shows that zanubrutinib is superior to ibrutinib', 'that zanubrutinib is superior to ibrutinib for', 'zanubrutinib is superior to ibrutinib for relapsed/refractory', 'is superior to ibrutinib for relapsed/refractory CLL/SLL', 'superior to ibrutinib for relapsed/refractory CLL/SLL for', 'to ibrutinib for relapsed/refractory CLL/SLL for everything', 'ibrutinib for relapsed/refractory CLL/SLL for everything except', 'for relapsed/refractory CLL/SLL for everything except for', 'relapsed/refractory CLL/SLL for everything except for overall', 'CLL/SLL for everything except for overall survival.', 'for everything except for overall survival. #LBA', 'everything except for overall survival. #LBA #ASH22.', 'except for overall survival. #LBA #ASH22. Published', 'for overall survival. #LBA #ASH22. Published today', 'overall survival. #LBA #ASH22. Published today in.', 'survival. #LBA #ASH22. Published today in. .', 'Jennifer Brown from  shows that zanubrutinib is', 'Brown from  shows that zanubrutinib is superior', 'from  shows that zanubrutinib is superior to', ' shows that zanubrutinib is superior to ibrutinib', 'shows that zanubrutinib is superior to ibrutinib for', 'that zanubrutinib is superior to ibrutinib for relapsed/refractory', 'zanubrutinib is superior to ibrutinib for relapsed/refractory CLL/SLL', 'is superior to ibrutinib for relapsed/refractory CLL/SLL for', 'superior to ibrutinib for relapsed/refractory CLL/SLL for everything', 'to ibrutinib for relapsed/refractory CLL/SLL for everything except', 'ibrutinib for relapsed/refractory CLL/SLL for everything except for', 'for relapsed/refractory CLL/SLL for everything except for overall', 'relapsed/refractory CLL/SLL for everything except for overall survival.', 'CLL/SLL for everything except for overall survival. #LBA', 'for everything except for overall survival. #LBA #ASH22.', 'everything except for overall survival. #LBA #ASH22. Published', 'except for overall survival. #LBA #ASH22. Published today', 'for overall survival. #LBA #ASH22. Published today in.', 'overall survival. #LBA #ASH22. Published today in. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '30', 'tokens': ['"#ASH22', '#LBA', '👉', 'Zanubrutinib', 'in', 'relapsed', 'CLL', '.'], 'text_length': 8, 'triples': {'👉|in': ([2, 2], [4, 4], 'negative')}, 'sentence': '"#ASH22 #LBA 👉 Zanubrutinib in relapsed CLL .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 4)], 'related_span_array': array([[1, 0, 0, ..., 1, 0, 1],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1],
       [1, 1, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (0, 6, 7), (1, 7, 7), (0, 7, 8)], 'span tokens': ['"#ASH22', '#LBA', '👉', 'Zanubrutinib', 'in', 'relapsed', 'CLL', '.', '"#ASH22 #LBA', '#LBA 👉', '👉 Zanubrutinib', 'Zanubrutinib in', 'in relapsed', 'relapsed CLL', 'CLL .', '"#ASH22 #LBA 👉', '#LBA 👉 Zanubrutinib', '👉 Zanubrutinib in', 'Zanubrutinib in relapsed', 'in relapsed CLL', 'relapsed CLL .', '"#ASH22 #LBA 👉 Zanubrutinib', '#LBA 👉 Zanubrutinib in', '👉 Zanubrutinib in relapsed', 'Zanubrutinib in relapsed CLL', 'in relapsed CLL .', '"#ASH22 #LBA 👉 Zanubrutinib in', '#LBA 👉 Zanubrutinib in relapsed', '👉 Zanubrutinib in relapsed CLL', 'Zanubrutinib in relapsed CLL .', '"#ASH22 #LBA 👉 Zanubrutinib in relapsed', '#LBA 👉 Zanubrutinib in relapsed CLL', '👉 Zanubrutinib in relapsed CLL .', '"#ASH22 #LBA 👉 Zanubrutinib in relapsed CLL', '#LBA 👉 Zanubrutinib in relapsed CLL .', '"#ASH22 #LBA 👉 Zanubrutinib in relapsed CLL .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '31', 'tokens': ['to', 'have', 'the', 'renowned', 'reference', 's1801', 'study', 'in', 'this', 'way', 'as', 'one', 'of', 'the', 'most', 'impactful', 'at', '#esmo22', 'is', 'an', 'honor!!', 'he', 'is', 'humbly', 'omitting', 'his', 'triplet', 'regimen', 'in', 'cosmic-313', 'which', 'had', 'a', 'strong', 'signal', 'in', 'intermediate-risk', 'rcc', '#neoadjuvant', '#melsm', '.'], 'text_length': 41, 'triples': {'s1801|renowned reference s1801 study in this way as one of the most impactful': ([5, 5], [3, 15], 'positive'), 'cosmic-313|strong': ([29, 29], [33, 33], 'positive')}, 'sentence': 'to have the renowned reference s1801 study in this way as one of the most impactful at #esmo22 is an honor!! he is humbly omitting his triplet regimen in cosmic-313 which had a strong signal in intermediate-risk rcc #neoadjuvant #melsm .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 5), (29, 29)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(3, 15), (33, 33)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8)], 'span tokens': ['to', 'have', 'the', 'renowned', 'reference', 's1801', 'study', 'in', 'this', 'way', 'as', 'one', 'of', 'the', 'most', 'impactful', 'at', '#esmo22', 'is', 'an', 'honor!!', 'he', 'is', 'humbly', 'omitting', 'his', 'triplet', 'regimen', 'in', 'cosmic-313', 'which', 'had', 'a', 'strong', 'signal', 'in', 'intermediate-risk', 'rcc', '#neoadjuvant', '#melsm', '.', 'to have', 'have the', 'the renowned', 'renowned reference', 'reference s1801', 's1801 study', 'study in', 'in this', 'this way', 'way as', 'as one', 'one of', 'of the', 'the most', 'most impactful', 'impactful at', 'at #esmo22', '#esmo22 is', 'is an', 'an honor!!', 'honor!! he', 'he is', 'is humbly', 'humbly omitting', 'omitting his', 'his triplet', 'triplet regimen', 'regimen in', 'in cosmic-313', 'cosmic-313 which', 'which had', 'had a', 'a strong', 'strong signal', 'signal in', 'in intermediate-risk', 'intermediate-risk rcc', 'rcc #neoadjuvant', '#neoadjuvant #melsm', '#melsm .', 'to have the', 'have the renowned', 'the renowned reference', 'renowned reference s1801', 'reference s1801 study', 's1801 study in', 'study in this', 'in this way', 'this way as', 'way as one', 'as one of', 'one of the', 'of the most', 'the most impactful', 'most impactful at', 'impactful at #esmo22', 'at #esmo22 is', '#esmo22 is an', 'is an honor!!', 'an honor!! he', 'honor!! he is', 'he is humbly', 'is humbly omitting', 'humbly omitting his', 'omitting his triplet', 'his triplet regimen', 'triplet regimen in', 'regimen in cosmic-313', 'in cosmic-313 which', 'cosmic-313 which had', 'which had a', 'had a strong', 'a strong signal', 'strong signal in', 'signal in intermediate-risk', 'in intermediate-risk rcc', 'intermediate-risk rcc #neoadjuvant', 'rcc #neoadjuvant #melsm', '#neoadjuvant #melsm .', 'to have the renowned', 'have the renowned reference', 'the renowned reference s1801', 'renowned reference s1801 study', 'reference s1801 study in', 's1801 study in this', 'study in this way', 'in this way as', 'this way as one', 'way as one of', 'as one of the', 'one of the most', 'of the most impactful', 'the most impactful at', 'most impactful at #esmo22', 'impactful at #esmo22 is', 'at #esmo22 is an', '#esmo22 is an honor!!', 'is an honor!! he', 'an honor!! he is', 'honor!! he is humbly', 'he is humbly omitting', 'is humbly omitting his', 'humbly omitting his triplet', 'omitting his triplet regimen', 'his triplet regimen in', 'triplet regimen in cosmic-313', 'regimen in cosmic-313 which', 'in cosmic-313 which had', 'cosmic-313 which had a', 'which had a strong', 'had a strong signal', 'a strong signal in', 'strong signal in intermediate-risk', 'signal in intermediate-risk rcc', 'in intermediate-risk rcc #neoadjuvant', 'intermediate-risk rcc #neoadjuvant #melsm', 'rcc #neoadjuvant #melsm .', 'to have the renowned reference', 'have the renowned reference s1801', 'the renowned reference s1801 study', 'renowned reference s1801 study in', 'reference s1801 study in this', 's1801 study in this way', 'study in this way as', 'in this way as one', 'this way as one of', 'way as one of the', 'as one of the most', 'one of the most impactful', 'of the most impactful at', 'the most impactful at #esmo22', 'most impactful at #esmo22 is', 'impactful at #esmo22 is an', 'at #esmo22 is an honor!!', '#esmo22 is an honor!! he', 'is an honor!! he is', 'an honor!! he is humbly', 'honor!! he is humbly omitting', 'he is humbly omitting his', 'is humbly omitting his triplet', 'humbly omitting his triplet regimen', 'omitting his triplet regimen in', 'his triplet regimen in cosmic-313', 'triplet regimen in cosmic-313 which', 'regimen in cosmic-313 which had', 'in cosmic-313 which had a', 'cosmic-313 which had a strong', 'which had a strong signal', 'had a strong signal in', 'a strong signal in intermediate-risk', 'strong signal in intermediate-risk rcc', 'signal in intermediate-risk rcc #neoadjuvant', 'in intermediate-risk rcc #neoadjuvant #melsm', 'intermediate-risk rcc #neoadjuvant #melsm .', 'to have the renowned reference s1801', 'have the renowned reference s1801 study', 'the renowned reference s1801 study in', 'renowned reference s1801 study in this', 'reference s1801 study in this way', 's1801 study in this way as', 'study in this way as one', 'in this way as one of', 'this way as one of the', 'way as one of the most', 'as one of the most impactful', 'one of the most impactful at', 'of the most impactful at #esmo22', 'the most impactful at #esmo22 is', 'most impactful at #esmo22 is an', 'impactful at #esmo22 is an honor!!', 'at #esmo22 is an honor!! he', '#esmo22 is an honor!! he is', 'is an honor!! he is humbly', 'an honor!! he is humbly omitting', 'honor!! he is humbly omitting his', 'he is humbly omitting his triplet', 'is humbly omitting his triplet regimen', 'humbly omitting his triplet regimen in', 'omitting his triplet regimen in cosmic-313', 'his triplet regimen in cosmic-313 which', 'triplet regimen in cosmic-313 which had', 'regimen in cosmic-313 which had a', 'in cosmic-313 which had a strong', 'cosmic-313 which had a strong signal', 'which had a strong signal in', 'had a strong signal in intermediate-risk', 'a strong signal in intermediate-risk rcc', 'strong signal in intermediate-risk rcc #neoadjuvant', 'signal in intermediate-risk rcc #neoadjuvant #melsm', 'in intermediate-risk rcc #neoadjuvant #melsm .', 'to have the renowned reference s1801 study', 'have the renowned reference s1801 study in', 'the renowned reference s1801 study in this', 'renowned reference s1801 study in this way', 'reference s1801 study in this way as', 's1801 study in this way as one', 'study in this way as one of', 'in this way as one of the', 'this way as one of the most', 'way as one of the most impactful', 'as one of the most impactful at', 'one of the most impactful at #esmo22', 'of the most impactful at #esmo22 is', 'the most impactful at #esmo22 is an', 'most impactful at #esmo22 is an honor!!', 'impactful at #esmo22 is an honor!! he', 'at #esmo22 is an honor!! he is', '#esmo22 is an honor!! he is humbly', 'is an honor!! he is humbly omitting', 'an honor!! he is humbly omitting his', 'honor!! he is humbly omitting his triplet', 'he is humbly omitting his triplet regimen', 'is humbly omitting his triplet regimen in', 'humbly omitting his triplet regimen in cosmic-313', 'omitting his triplet regimen in cosmic-313 which', 'his triplet regimen in cosmic-313 which had', 'triplet regimen in cosmic-313 which had a', 'regimen in cosmic-313 which had a strong', 'in cosmic-313 which had a strong signal', 'cosmic-313 which had a strong signal in', 'which had a strong signal in intermediate-risk', 'had a strong signal in intermediate-risk rcc', 'a strong signal in intermediate-risk rcc #neoadjuvant', 'strong signal in intermediate-risk rcc #neoadjuvant #melsm', 'signal in intermediate-risk rcc #neoadjuvant #melsm .', 'to have the renowned reference s1801 study in', 'have the renowned reference s1801 study in this', 'the renowned reference s1801 study in this way', 'renowned reference s1801 study in this way as', 'reference s1801 study in this way as one', 's1801 study in this way as one of', 'study in this way as one of the', 'in this way as one of the most', 'this way as one of the most impactful', 'way as one of the most impactful at', 'as one of the most impactful at #esmo22', 'one of the most impactful at #esmo22 is', 'of the most impactful at #esmo22 is an', 'the most impactful at #esmo22 is an honor!!', 'most impactful at #esmo22 is an honor!! he', 'impactful at #esmo22 is an honor!! he is', 'at #esmo22 is an honor!! he is humbly', '#esmo22 is an honor!! he is humbly omitting', 'is an honor!! he is humbly omitting his', 'an honor!! he is humbly omitting his triplet', 'honor!! he is humbly omitting his triplet regimen', 'he is humbly omitting his triplet regimen in', 'is humbly omitting his triplet regimen in cosmic-313', 'humbly omitting his triplet regimen in cosmic-313 which', 'omitting his triplet regimen in cosmic-313 which had', 'his triplet regimen in cosmic-313 which had a', 'triplet regimen in cosmic-313 which had a strong', 'regimen in cosmic-313 which had a strong signal', 'in cosmic-313 which had a strong signal in', 'cosmic-313 which had a strong signal in intermediate-risk', 'which had a strong signal in intermediate-risk rcc', 'had a strong signal in intermediate-risk rcc #neoadjuvant', 'a strong signal in intermediate-risk rcc #neoadjuvant #melsm', 'strong signal in intermediate-risk rcc #neoadjuvant #melsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '32', 'tokens': ['lots', 'more', 'to', 'come', 'yet', 'from', '#', 'enzamet', ':', 'comprehensive', 'suite', 'of', 'translational', 'work,', 'health', 'economics,', 'pooled', '/', 'ipd', 'meta-analyses', 'with', 'other', 'major', 'trials,', 'and', 'of', 'course', 'longer', 'followup', 'to', 'see', 'what', 'happens', 'to', 'all', 'those', 'people', 'whose', '#prostatecancer', 'has', 'still', 'not', 'yet', 'progressed.', '#asco22', '.'], 'text_length': 46, 'triples': {'#|yet from # enzamet : comprehensive suite of translational work, health economics, pooled / ipd meta-analyses with other major trials, and of course longer followup to see what happens to all those people whose #prostatecancer has still': ([6, 6], [4, 40], 'neutral')}, 'sentence': 'lots more to come yet from # enzamet : comprehensive suite of translational work, health economics, pooled / ipd meta-analyses with other major trials, and of course longer followup to see what happens to all those people whose #prostatecancer has still not yet progressed. #asco22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 40)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8)], 'span tokens': ['lots', 'more', 'to', 'come', 'yet', 'from', '#', 'enzamet', ':', 'comprehensive', 'suite', 'of', 'translational', 'work,', 'health', 'economics,', 'pooled', '/', 'ipd', 'meta-analyses', 'with', 'other', 'major', 'trials,', 'and', 'of', 'course', 'longer', 'followup', 'to', 'see', 'what', 'happens', 'to', 'all', 'those', 'people', 'whose', '#prostatecancer', 'has', 'still', 'not', 'yet', 'progressed.', '#asco22', '.', 'lots more', 'more to', 'to come', 'come yet', 'yet from', 'from #', '# enzamet', 'enzamet :', ': comprehensive', 'comprehensive suite', 'suite of', 'of translational', 'translational work,', 'work, health', 'health economics,', 'economics, pooled', 'pooled /', '/ ipd', 'ipd meta-analyses', 'meta-analyses with', 'with other', 'other major', 'major trials,', 'trials, and', 'and of', 'of course', 'course longer', 'longer followup', 'followup to', 'to see', 'see what', 'what happens', 'happens to', 'to all', 'all those', 'those people', 'people whose', 'whose #prostatecancer', '#prostatecancer has', 'has still', 'still not', 'not yet', 'yet progressed.', 'progressed. #asco22', '#asco22 .', 'lots more to', 'more to come', 'to come yet', 'come yet from', 'yet from #', 'from # enzamet', '# enzamet :', 'enzamet : comprehensive', ': comprehensive suite', 'comprehensive suite of', 'suite of translational', 'of translational work,', 'translational work, health', 'work, health economics,', 'health economics, pooled', 'economics, pooled /', 'pooled / ipd', '/ ipd meta-analyses', 'ipd meta-analyses with', 'meta-analyses with other', 'with other major', 'other major trials,', 'major trials, and', 'trials, and of', 'and of course', 'of course longer', 'course longer followup', 'longer followup to', 'followup to see', 'to see what', 'see what happens', 'what happens to', 'happens to all', 'to all those', 'all those people', 'those people whose', 'people whose #prostatecancer', 'whose #prostatecancer has', '#prostatecancer has still', 'has still not', 'still not yet', 'not yet progressed.', 'yet progressed. #asco22', 'progressed. #asco22 .', 'lots more to come', 'more to come yet', 'to come yet from', 'come yet from #', 'yet from # enzamet', 'from # enzamet :', '# enzamet : comprehensive', 'enzamet : comprehensive suite', ': comprehensive suite of', 'comprehensive suite of translational', 'suite of translational work,', 'of translational work, health', 'translational work, health economics,', 'work, health economics, pooled', 'health economics, pooled /', 'economics, pooled / ipd', 'pooled / ipd meta-analyses', '/ ipd meta-analyses with', 'ipd meta-analyses with other', 'meta-analyses with other major', 'with other major trials,', 'other major trials, and', 'major trials, and of', 'trials, and of course', 'and of course longer', 'of course longer followup', 'course longer followup to', 'longer followup to see', 'followup to see what', 'to see what happens', 'see what happens to', 'what happens to all', 'happens to all those', 'to all those people', 'all those people whose', 'those people whose #prostatecancer', 'people whose #prostatecancer has', 'whose #prostatecancer has still', '#prostatecancer has still not', 'has still not yet', 'still not yet progressed.', 'not yet progressed. #asco22', 'yet progressed. #asco22 .', 'lots more to come yet', 'more to come yet from', 'to come yet from #', 'come yet from # enzamet', 'yet from # enzamet :', 'from # enzamet : comprehensive', '# enzamet : comprehensive suite', 'enzamet : comprehensive suite of', ': comprehensive suite of translational', 'comprehensive suite of translational work,', 'suite of translational work, health', 'of translational work, health economics,', 'translational work, health economics, pooled', 'work, health economics, pooled /', 'health economics, pooled / ipd', 'economics, pooled / ipd meta-analyses', 'pooled / ipd meta-analyses with', '/ ipd meta-analyses with other', 'ipd meta-analyses with other major', 'meta-analyses with other major trials,', 'with other major trials, and', 'other major trials, and of', 'major trials, and of course', 'trials, and of course longer', 'and of course longer followup', 'of course longer followup to', 'course longer followup to see', 'longer followup to see what', 'followup to see what happens', 'to see what happens to', 'see what happens to all', 'what happens to all those', 'happens to all those people', 'to all those people whose', 'all those people whose #prostatecancer', 'those people whose #prostatecancer has', 'people whose #prostatecancer has still', 'whose #prostatecancer has still not', '#prostatecancer has still not yet', 'has still not yet progressed.', 'still not yet progressed. #asco22', 'not yet progressed. #asco22 .', 'lots more to come yet from', 'more to come yet from #', 'to come yet from # enzamet', 'come yet from # enzamet :', 'yet from # enzamet : comprehensive', 'from # enzamet : comprehensive suite', '# enzamet : comprehensive suite of', 'enzamet : comprehensive suite of translational', ': comprehensive suite of translational work,', 'comprehensive suite of translational work, health', 'suite of translational work, health economics,', 'of translational work, health economics, pooled', 'translational work, health economics, pooled /', 'work, health economics, pooled / ipd', 'health economics, pooled / ipd meta-analyses', 'economics, pooled / ipd meta-analyses with', 'pooled / ipd meta-analyses with other', '/ ipd meta-analyses with other major', 'ipd meta-analyses with other major trials,', 'meta-analyses with other major trials, and', 'with other major trials, and of', 'other major trials, and of course', 'major trials, and of course longer', 'trials, and of course longer followup', 'and of course longer followup to', 'of course longer followup to see', 'course longer followup to see what', 'longer followup to see what happens', 'followup to see what happens to', 'to see what happens to all', 'see what happens to all those', 'what happens to all those people', 'happens to all those people whose', 'to all those people whose #prostatecancer', 'all those people whose #prostatecancer has', 'those people whose #prostatecancer has still', 'people whose #prostatecancer has still not', 'whose #prostatecancer has still not yet', '#prostatecancer has still not yet progressed.', 'has still not yet progressed. #asco22', 'still not yet progressed. #asco22 .', 'lots more to come yet from #', 'more to come yet from # enzamet', 'to come yet from # enzamet :', 'come yet from # enzamet : comprehensive', 'yet from # enzamet : comprehensive suite', 'from # enzamet : comprehensive suite of', '# enzamet : comprehensive suite of translational', 'enzamet : comprehensive suite of translational work,', ': comprehensive suite of translational work, health', 'comprehensive suite of translational work, health economics,', 'suite of translational work, health economics, pooled', 'of translational work, health economics, pooled /', 'translational work, health economics, pooled / ipd', 'work, health economics, pooled / ipd meta-analyses', 'health economics, pooled / ipd meta-analyses with', 'economics, pooled / ipd meta-analyses with other', 'pooled / ipd meta-analyses with other major', '/ ipd meta-analyses with other major trials,', 'ipd meta-analyses with other major trials, and', 'meta-analyses with other major trials, and of', 'with other major trials, and of course', 'other major trials, and of course longer', 'major trials, and of course longer followup', 'trials, and of course longer followup to', 'and of course longer followup to see', 'of course longer followup to see what', 'course longer followup to see what happens', 'longer followup to see what happens to', 'followup to see what happens to all', 'to see what happens to all those', 'see what happens to all those people', 'what happens to all those people whose', 'happens to all those people whose #prostatecancer', 'to all those people whose #prostatecancer has', 'all those people whose #prostatecancer has still', 'those people whose #prostatecancer has still not', 'people whose #prostatecancer has still not yet', 'whose #prostatecancer has still not yet progressed.', '#prostatecancer has still not yet progressed. #asco22', 'has still not yet progressed. #asco22 .', 'lots more to come yet from # enzamet', 'more to come yet from # enzamet :', 'to come yet from # enzamet : comprehensive', 'come yet from # enzamet : comprehensive suite', 'yet from # enzamet : comprehensive suite of', 'from # enzamet : comprehensive suite of translational', '# enzamet : comprehensive suite of translational work,', 'enzamet : comprehensive suite of translational work, health', ': comprehensive suite of translational work, health economics,', 'comprehensive suite of translational work, health economics, pooled', 'suite of translational work, health economics, pooled /', 'of translational work, health economics, pooled / ipd', 'translational work, health economics, pooled / ipd meta-analyses', 'work, health economics, pooled / ipd meta-analyses with', 'health economics, pooled / ipd meta-analyses with other', 'economics, pooled / ipd meta-analyses with other major', 'pooled / ipd meta-analyses with other major trials,', '/ ipd meta-analyses with other major trials, and', 'ipd meta-analyses with other major trials, and of', 'meta-analyses with other major trials, and of course', 'with other major trials, and of course longer', 'other major trials, and of course longer followup', 'major trials, and of course longer followup to', 'trials, and of course longer followup to see', 'and of course longer followup to see what', 'of course longer followup to see what happens', 'course longer followup to see what happens to', 'longer followup to see what happens to all', 'followup to see what happens to all those', 'to see what happens to all those people', 'see what happens to all those people whose', 'what happens to all those people whose #prostatecancer', 'happens to all those people whose #prostatecancer has', 'to all those people whose #prostatecancer has still', 'all those people whose #prostatecancer has still not', 'those people whose #prostatecancer has still not yet', 'people whose #prostatecancer has still not yet progressed.', 'whose #prostatecancer has still not yet progressed. #asco22', '#prostatecancer has still not yet progressed. #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '33', 'tokens': ['importantly,', 'niche-2', 'will', 'be', 'considered', 'a', 'success', 'from', 'the', 'safety', 'and', 'feasibility', 'endpoint', '(but', 'we', 'all', 'want', 'to', 'see', 'the', '3-year', 'survival', 'too', 'coming', 'at', 'a', 'future', ')', '#esmo22', '.'], 'text_length': 30, 'triples': {'niche-2|success from the safety and feasibility': ([1, 1], [6, 11], 'positive')}, 'sentence': 'importantly, niche-2 will be considered a success from the safety and feasibility endpoint (but we all want to see the 3-year survival too coming at a future ) #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8)], 'span tokens': ['importantly,', 'niche-2', 'will', 'be', 'considered', 'a', 'success', 'from', 'the', 'safety', 'and', 'feasibility', 'endpoint', '(but', 'we', 'all', 'want', 'to', 'see', 'the', '3-year', 'survival', 'too', 'coming', 'at', 'a', 'future', ')', '#esmo22', '.', 'importantly, niche-2', 'niche-2 will', 'will be', 'be considered', 'considered a', 'a success', 'success from', 'from the', 'the safety', 'safety and', 'and feasibility', 'feasibility endpoint', 'endpoint (but', '(but we', 'we all', 'all want', 'want to', 'to see', 'see the', 'the 3-year', '3-year survival', 'survival too', 'too coming', 'coming at', 'at a', 'a future', 'future )', ') #esmo22', '#esmo22 .', 'importantly, niche-2 will', 'niche-2 will be', 'will be considered', 'be considered a', 'considered a success', 'a success from', 'success from the', 'from the safety', 'the safety and', 'safety and feasibility', 'and feasibility endpoint', 'feasibility endpoint (but', 'endpoint (but we', '(but we all', 'we all want', 'all want to', 'want to see', 'to see the', 'see the 3-year', 'the 3-year survival', '3-year survival too', 'survival too coming', 'too coming at', 'coming at a', 'at a future', 'a future )', 'future ) #esmo22', ') #esmo22 .', 'importantly, niche-2 will be', 'niche-2 will be considered', 'will be considered a', 'be considered a success', 'considered a success from', 'a success from the', 'success from the safety', 'from the safety and', 'the safety and feasibility', 'safety and feasibility endpoint', 'and feasibility endpoint (but', 'feasibility endpoint (but we', 'endpoint (but we all', '(but we all want', 'we all want to', 'all want to see', 'want to see the', 'to see the 3-year', 'see the 3-year survival', 'the 3-year survival too', '3-year survival too coming', 'survival too coming at', 'too coming at a', 'coming at a future', 'at a future )', 'a future ) #esmo22', 'future ) #esmo22 .', 'importantly, niche-2 will be considered', 'niche-2 will be considered a', 'will be considered a success', 'be considered a success from', 'considered a success from the', 'a success from the safety', 'success from the safety and', 'from the safety and feasibility', 'the safety and feasibility endpoint', 'safety and feasibility endpoint (but', 'and feasibility endpoint (but we', 'feasibility endpoint (but we all', 'endpoint (but we all want', '(but we all want to', 'we all want to see', 'all want to see the', 'want to see the 3-year', 'to see the 3-year survival', 'see the 3-year survival too', 'the 3-year survival too coming', '3-year survival too coming at', 'survival too coming at a', 'too coming at a future', 'coming at a future )', 'at a future ) #esmo22', 'a future ) #esmo22 .', 'importantly, niche-2 will be considered a', 'niche-2 will be considered a success', 'will be considered a success from', 'be considered a success from the', 'considered a success from the safety', 'a success from the safety and', 'success from the safety and feasibility', 'from the safety and feasibility endpoint', 'the safety and feasibility endpoint (but', 'safety and feasibility endpoint (but we', 'and feasibility endpoint (but we all', 'feasibility endpoint (but we all want', 'endpoint (but we all want to', '(but we all want to see', 'we all want to see the', 'all want to see the 3-year', 'want to see the 3-year survival', 'to see the 3-year survival too', 'see the 3-year survival too coming', 'the 3-year survival too coming at', '3-year survival too coming at a', 'survival too coming at a future', 'too coming at a future )', 'coming at a future ) #esmo22', 'at a future ) #esmo22 .', 'importantly, niche-2 will be considered a success', 'niche-2 will be considered a success from', 'will be considered a success from the', 'be considered a success from the safety', 'considered a success from the safety and', 'a success from the safety and feasibility', 'success from the safety and feasibility endpoint', 'from the safety and feasibility endpoint (but', 'the safety and feasibility endpoint (but we', 'safety and feasibility endpoint (but we all', 'and feasibility endpoint (but we all want', 'feasibility endpoint (but we all want to', 'endpoint (but we all want to see', '(but we all want to see the', 'we all want to see the 3-year', 'all want to see the 3-year survival', 'want to see the 3-year survival too', 'to see the 3-year survival too coming', 'see the 3-year survival too coming at', 'the 3-year survival too coming at a', '3-year survival too coming at a future', 'survival too coming at a future )', 'too coming at a future ) #esmo22', 'coming at a future ) #esmo22 .', 'importantly, niche-2 will be considered a success from', 'niche-2 will be considered a success from the', 'will be considered a success from the safety', 'be considered a success from the safety and', 'considered a success from the safety and feasibility', 'a success from the safety and feasibility endpoint', 'success from the safety and feasibility endpoint (but', 'from the safety and feasibility endpoint (but we', 'the safety and feasibility endpoint (but we all', 'safety and feasibility endpoint (but we all want', 'and feasibility endpoint (but we all want to', 'feasibility endpoint (but we all want to see', 'endpoint (but we all want to see the', '(but we all want to see the 3-year', 'we all want to see the 3-year survival', 'all want to see the 3-year survival too', 'want to see the 3-year survival too coming', 'to see the 3-year survival too coming at', 'see the 3-year survival too coming at a', 'the 3-year survival too coming at a future', '3-year survival too coming at a future )', 'survival too coming at a future ) #esmo22', 'too coming at a future ) #esmo22 .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '34', 'tokens': ['#esmo22', 'research', 'seems', 'great,', 'real', 'life', '-', 'not', 'so.', 'during', 'presidential', 'session', 'ii,', 'prof.', 'alex', 'eggermont', 'urged', 'education', 'in', 'the', 'larger', 'medical', 'community', 'to', 'consider', 'neoadjuvant', 'therapy', 'before', 'performing', 'useless', 'surgery', 'in', 'metastatic', 'patients:', 's1801', 'and', 'niche2!', '.'], 'text_length': 38, 'triples': {'s1801|great, real life - not so. during presidential session ii, prof. alex eggermont urged education in the larger': ([34, 34], [3, 20], 'positive')}, 'sentence': '#esmo22 research seems great, real life - not so. during presidential session ii, prof. alex eggermont urged education in the larger medical community to consider neoadjuvant therapy before performing useless surgery in metastatic patients: s1801 and niche2! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(34, 34)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8)], 'span tokens': ['#esmo22', 'research', 'seems', 'great,', 'real', 'life', '-', 'not', 'so.', 'during', 'presidential', 'session', 'ii,', 'prof.', 'alex', 'eggermont', 'urged', 'education', 'in', 'the', 'larger', 'medical', 'community', 'to', 'consider', 'neoadjuvant', 'therapy', 'before', 'performing', 'useless', 'surgery', 'in', 'metastatic', 'patients:', 's1801', 'and', 'niche2!', '.', '#esmo22 research', 'research seems', 'seems great,', 'great, real', 'real life', 'life -', '- not', 'not so.', 'so. during', 'during presidential', 'presidential session', 'session ii,', 'ii, prof.', 'prof. alex', 'alex eggermont', 'eggermont urged', 'urged education', 'education in', 'in the', 'the larger', 'larger medical', 'medical community', 'community to', 'to consider', 'consider neoadjuvant', 'neoadjuvant therapy', 'therapy before', 'before performing', 'performing useless', 'useless surgery', 'surgery in', 'in metastatic', 'metastatic patients:', 'patients: s1801', 's1801 and', 'and niche2!', 'niche2! .', '#esmo22 research seems', 'research seems great,', 'seems great, real', 'great, real life', 'real life -', 'life - not', '- not so.', 'not so. during', 'so. during presidential', 'during presidential session', 'presidential session ii,', 'session ii, prof.', 'ii, prof. alex', 'prof. alex eggermont', 'alex eggermont urged', 'eggermont urged education', 'urged education in', 'education in the', 'in the larger', 'the larger medical', 'larger medical community', 'medical community to', 'community to consider', 'to consider neoadjuvant', 'consider neoadjuvant therapy', 'neoadjuvant therapy before', 'therapy before performing', 'before performing useless', 'performing useless surgery', 'useless surgery in', 'surgery in metastatic', 'in metastatic patients:', 'metastatic patients: s1801', 'patients: s1801 and', 's1801 and niche2!', 'and niche2! .', '#esmo22 research seems great,', 'research seems great, real', 'seems great, real life', 'great, real life -', 'real life - not', 'life - not so.', '- not so. during', 'not so. during presidential', 'so. during presidential session', 'during presidential session ii,', 'presidential session ii, prof.', 'session ii, prof. alex', 'ii, prof. alex eggermont', 'prof. alex eggermont urged', 'alex eggermont urged education', 'eggermont urged education in', 'urged education in the', 'education in the larger', 'in the larger medical', 'the larger medical community', 'larger medical community to', 'medical community to consider', 'community to consider neoadjuvant', 'to consider neoadjuvant therapy', 'consider neoadjuvant therapy before', 'neoadjuvant therapy before performing', 'therapy before performing useless', 'before performing useless surgery', 'performing useless surgery in', 'useless surgery in metastatic', 'surgery in metastatic patients:', 'in metastatic patients: s1801', 'metastatic patients: s1801 and', 'patients: s1801 and niche2!', 's1801 and niche2! .', '#esmo22 research seems great, real', 'research seems great, real life', 'seems great, real life -', 'great, real life - not', 'real life - not so.', 'life - not so. during', '- not so. during presidential', 'not so. during presidential session', 'so. during presidential session ii,', 'during presidential session ii, prof.', 'presidential session ii, prof. alex', 'session ii, prof. alex eggermont', 'ii, prof. alex eggermont urged', 'prof. alex eggermont urged education', 'alex eggermont urged education in', 'eggermont urged education in the', 'urged education in the larger', 'education in the larger medical', 'in the larger medical community', 'the larger medical community to', 'larger medical community to consider', 'medical community to consider neoadjuvant', 'community to consider neoadjuvant therapy', 'to consider neoadjuvant therapy before', 'consider neoadjuvant therapy before performing', 'neoadjuvant therapy before performing useless', 'therapy before performing useless surgery', 'before performing useless surgery in', 'performing useless surgery in metastatic', 'useless surgery in metastatic patients:', 'surgery in metastatic patients: s1801', 'in metastatic patients: s1801 and', 'metastatic patients: s1801 and niche2!', 'patients: s1801 and niche2! .', '#esmo22 research seems great, real life', 'research seems great, real life -', 'seems great, real life - not', 'great, real life - not so.', 'real life - not so. during', 'life - not so. during presidential', '- not so. during presidential session', 'not so. during presidential session ii,', 'so. during presidential session ii, prof.', 'during presidential session ii, prof. alex', 'presidential session ii, prof. alex eggermont', 'session ii, prof. alex eggermont urged', 'ii, prof. alex eggermont urged education', 'prof. alex eggermont urged education in', 'alex eggermont urged education in the', 'eggermont urged education in the larger', 'urged education in the larger medical', 'education in the larger medical community', 'in the larger medical community to', 'the larger medical community to consider', 'larger medical community to consider neoadjuvant', 'medical community to consider neoadjuvant therapy', 'community to consider neoadjuvant therapy before', 'to consider neoadjuvant therapy before performing', 'consider neoadjuvant therapy before performing useless', 'neoadjuvant therapy before performing useless surgery', 'therapy before performing useless surgery in', 'before performing useless surgery in metastatic', 'performing useless surgery in metastatic patients:', 'useless surgery in metastatic patients: s1801', 'surgery in metastatic patients: s1801 and', 'in metastatic patients: s1801 and niche2!', 'metastatic patients: s1801 and niche2! .', '#esmo22 research seems great, real life -', 'research seems great, real life - not', 'seems great, real life - not so.', 'great, real life - not so. during', 'real life - not so. during presidential', 'life - not so. during presidential session', '- not so. during presidential session ii,', 'not so. during presidential session ii, prof.', 'so. during presidential session ii, prof. alex', 'during presidential session ii, prof. alex eggermont', 'presidential session ii, prof. alex eggermont urged', 'session ii, prof. alex eggermont urged education', 'ii, prof. alex eggermont urged education in', 'prof. alex eggermont urged education in the', 'alex eggermont urged education in the larger', 'eggermont urged education in the larger medical', 'urged education in the larger medical community', 'education in the larger medical community to', 'in the larger medical community to consider', 'the larger medical community to consider neoadjuvant', 'larger medical community to consider neoadjuvant therapy', 'medical community to consider neoadjuvant therapy before', 'community to consider neoadjuvant therapy before performing', 'to consider neoadjuvant therapy before performing useless', 'consider neoadjuvant therapy before performing useless surgery', 'neoadjuvant therapy before performing useless surgery in', 'therapy before performing useless surgery in metastatic', 'before performing useless surgery in metastatic patients:', 'performing useless surgery in metastatic patients: s1801', 'useless surgery in metastatic patients: s1801 and', 'surgery in metastatic patients: s1801 and niche2!', 'in metastatic patients: s1801 and niche2! .', '#esmo22 research seems great, real life - not', 'research seems great, real life - not so.', 'seems great, real life - not so. during', 'great, real life - not so. during presidential', 'real life - not so. during presidential session', 'life - not so. during presidential session ii,', '- not so. during presidential session ii, prof.', 'not so. during presidential session ii, prof. alex', 'so. during presidential session ii, prof. alex eggermont', 'during presidential session ii, prof. alex eggermont urged', 'presidential session ii, prof. alex eggermont urged education', 'session ii, prof. alex eggermont urged education in', 'ii, prof. alex eggermont urged education in the', 'prof. alex eggermont urged education in the larger', 'alex eggermont urged education in the larger medical', 'eggermont urged education in the larger medical community', 'urged education in the larger medical community to', 'education in the larger medical community to consider', 'in the larger medical community to consider neoadjuvant', 'the larger medical community to consider neoadjuvant therapy', 'larger medical community to consider neoadjuvant therapy before', 'medical community to consider neoadjuvant therapy before performing', 'community to consider neoadjuvant therapy before performing useless', 'to consider neoadjuvant therapy before performing useless surgery', 'consider neoadjuvant therapy before performing useless surgery in', 'neoadjuvant therapy before performing useless surgery in metastatic', 'therapy before performing useless surgery in metastatic patients:', 'before performing useless surgery in metastatic patients: s1801', 'performing useless surgery in metastatic patients: s1801 and', 'useless surgery in metastatic patients: s1801 and niche2!', 'surgery in metastatic patients: s1801 and niche2! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '35', 'tokens': ['ALPINE', 'is', 'out', 'finally', '#lymsm', '#leusm', '#ASH22', '.'], 'text_length': 8, 'triples': {'ALPINE|out finally': ([0, 0], [2, 3], 'neutral')}, 'sentence': 'ALPINE is out finally #lymsm #leusm #ASH22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 3)], 'related_span_array': array([[1, 0, 0, ..., 1, 0, 1],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1],
       [1, 1, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (0, 6, 7), (1, 7, 7), (0, 7, 8)], 'span tokens': ['ALPINE', 'is', 'out', 'finally', '#lymsm', '#leusm', '#ASH22', '.', 'ALPINE is', 'is out', 'out finally', 'finally #lymsm', '#lymsm #leusm', '#leusm #ASH22', '#ASH22 .', 'ALPINE is out', 'is out finally', 'out finally #lymsm', 'finally #lymsm #leusm', '#lymsm #leusm #ASH22', '#leusm #ASH22 .', 'ALPINE is out finally', 'is out finally #lymsm', 'out finally #lymsm #leusm', 'finally #lymsm #leusm #ASH22', '#lymsm #leusm #ASH22 .', 'ALPINE is out finally #lymsm', 'is out finally #lymsm #leusm', 'out finally #lymsm #leusm #ASH22', 'finally #lymsm #leusm #ASH22 .', 'ALPINE is out finally #lymsm #leusm', 'is out finally #lymsm #leusm #ASH22', 'out finally #lymsm #leusm #ASH22 .', 'ALPINE is out finally #lymsm #leusm #ASH22', 'is out finally #lymsm #leusm #ASH22 .', 'ALPINE is out finally #lymsm #leusm #ASH22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '36', 'tokens': ['my', 'dear', 'friend', 'and', 'former', 'colleague', 'saved', 'the', 'day', 'after', 'disappointing', 'results', 'presented', 'earlier', 'in', 'the', 'session.', 'exciting', 'data', 'from', 's1801', 'in', 'operable', '(neoadjuvant', 'vs.', 'adjuvant', 'pembro)', '#melanoma', 'at', '#esmo22', '.'], 'text_length': 31, 'triples': {'s1801|exciting': ([20, 20], [17, 17], 'positive')}, 'sentence': 'my dear friend and former colleague saved the day after disappointing results presented earlier in the session. exciting data from s1801 in operable (neoadjuvant vs. adjuvant pembro) #melanoma at #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(20, 20)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 17)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['my', 'dear', 'friend', 'and', 'former', 'colleague', 'saved', 'the', 'day', 'after', 'disappointing', 'results', 'presented', 'earlier', 'in', 'the', 'session.', 'exciting', 'data', 'from', 's1801', 'in', 'operable', '(neoadjuvant', 'vs.', 'adjuvant', 'pembro)', '#melanoma', 'at', '#esmo22', '.', 'my dear', 'dear friend', 'friend and', 'and former', 'former colleague', 'colleague saved', 'saved the', 'the day', 'day after', 'after disappointing', 'disappointing results', 'results presented', 'presented earlier', 'earlier in', 'in the', 'the session.', 'session. exciting', 'exciting data', 'data from', 'from s1801', 's1801 in', 'in operable', 'operable (neoadjuvant', '(neoadjuvant vs.', 'vs. adjuvant', 'adjuvant pembro)', 'pembro) #melanoma', '#melanoma at', 'at #esmo22', '#esmo22 .', 'my dear friend', 'dear friend and', 'friend and former', 'and former colleague', 'former colleague saved', 'colleague saved the', 'saved the day', 'the day after', 'day after disappointing', 'after disappointing results', 'disappointing results presented', 'results presented earlier', 'presented earlier in', 'earlier in the', 'in the session.', 'the session. exciting', 'session. exciting data', 'exciting data from', 'data from s1801', 'from s1801 in', 's1801 in operable', 'in operable (neoadjuvant', 'operable (neoadjuvant vs.', '(neoadjuvant vs. adjuvant', 'vs. adjuvant pembro)', 'adjuvant pembro) #melanoma', 'pembro) #melanoma at', '#melanoma at #esmo22', 'at #esmo22 .', 'my dear friend and', 'dear friend and former', 'friend and former colleague', 'and former colleague saved', 'former colleague saved the', 'colleague saved the day', 'saved the day after', 'the day after disappointing', 'day after disappointing results', 'after disappointing results presented', 'disappointing results presented earlier', 'results presented earlier in', 'presented earlier in the', 'earlier in the session.', 'in the session. exciting', 'the session. exciting data', 'session. exciting data from', 'exciting data from s1801', 'data from s1801 in', 'from s1801 in operable', 's1801 in operable (neoadjuvant', 'in operable (neoadjuvant vs.', 'operable (neoadjuvant vs. adjuvant', '(neoadjuvant vs. adjuvant pembro)', 'vs. adjuvant pembro) #melanoma', 'adjuvant pembro) #melanoma at', 'pembro) #melanoma at #esmo22', '#melanoma at #esmo22 .', 'my dear friend and former', 'dear friend and former colleague', 'friend and former colleague saved', 'and former colleague saved the', 'former colleague saved the day', 'colleague saved the day after', 'saved the day after disappointing', 'the day after disappointing results', 'day after disappointing results presented', 'after disappointing results presented earlier', 'disappointing results presented earlier in', 'results presented earlier in the', 'presented earlier in the session.', 'earlier in the session. exciting', 'in the session. exciting data', 'the session. exciting data from', 'session. exciting data from s1801', 'exciting data from s1801 in', 'data from s1801 in operable', 'from s1801 in operable (neoadjuvant', 's1801 in operable (neoadjuvant vs.', 'in operable (neoadjuvant vs. adjuvant', 'operable (neoadjuvant vs. adjuvant pembro)', '(neoadjuvant vs. adjuvant pembro) #melanoma', 'vs. adjuvant pembro) #melanoma at', 'adjuvant pembro) #melanoma at #esmo22', 'pembro) #melanoma at #esmo22 .', 'my dear friend and former colleague', 'dear friend and former colleague saved', 'friend and former colleague saved the', 'and former colleague saved the day', 'former colleague saved the day after', 'colleague saved the day after disappointing', 'saved the day after disappointing results', 'the day after disappointing results presented', 'day after disappointing results presented earlier', 'after disappointing results presented earlier in', 'disappointing results presented earlier in the', 'results presented earlier in the session.', 'presented earlier in the session. exciting', 'earlier in the session. exciting data', 'in the session. exciting data from', 'the session. exciting data from s1801', 'session. exciting data from s1801 in', 'exciting data from s1801 in operable', 'data from s1801 in operable (neoadjuvant', 'from s1801 in operable (neoadjuvant vs.', 's1801 in operable (neoadjuvant vs. adjuvant', 'in operable (neoadjuvant vs. adjuvant pembro)', 'operable (neoadjuvant vs. adjuvant pembro) #melanoma', '(neoadjuvant vs. adjuvant pembro) #melanoma at', 'vs. adjuvant pembro) #melanoma at #esmo22', 'adjuvant pembro) #melanoma at #esmo22 .', 'my dear friend and former colleague saved', 'dear friend and former colleague saved the', 'friend and former colleague saved the day', 'and former colleague saved the day after', 'former colleague saved the day after disappointing', 'colleague saved the day after disappointing results', 'saved the day after disappointing results presented', 'the day after disappointing results presented earlier', 'day after disappointing results presented earlier in', 'after disappointing results presented earlier in the', 'disappointing results presented earlier in the session.', 'results presented earlier in the session. exciting', 'presented earlier in the session. exciting data', 'earlier in the session. exciting data from', 'in the session. exciting data from s1801', 'the session. exciting data from s1801 in', 'session. exciting data from s1801 in operable', 'exciting data from s1801 in operable (neoadjuvant', 'data from s1801 in operable (neoadjuvant vs.', 'from s1801 in operable (neoadjuvant vs. adjuvant', 's1801 in operable (neoadjuvant vs. adjuvant pembro)', 'in operable (neoadjuvant vs. adjuvant pembro) #melanoma', 'operable (neoadjuvant vs. adjuvant pembro) #melanoma at', '(neoadjuvant vs. adjuvant pembro) #melanoma at #esmo22', 'vs. adjuvant pembro) #melanoma at #esmo22 .', 'my dear friend and former colleague saved the', 'dear friend and former colleague saved the day', 'friend and former colleague saved the day after', 'and former colleague saved the day after disappointing', 'former colleague saved the day after disappointing results', 'colleague saved the day after disappointing results presented', 'saved the day after disappointing results presented earlier', 'the day after disappointing results presented earlier in', 'day after disappointing results presented earlier in the', 'after disappointing results presented earlier in the session.', 'disappointing results presented earlier in the session. exciting', 'results presented earlier in the session. exciting data', 'presented earlier in the session. exciting data from', 'earlier in the session. exciting data from s1801', 'in the session. exciting data from s1801 in', 'the session. exciting data from s1801 in operable', 'session. exciting data from s1801 in operable (neoadjuvant', 'exciting data from s1801 in operable (neoadjuvant vs.', 'data from s1801 in operable (neoadjuvant vs. adjuvant', 'from s1801 in operable (neoadjuvant vs. adjuvant pembro)', 's1801 in operable (neoadjuvant vs. adjuvant pembro) #melanoma', 'in operable (neoadjuvant vs. adjuvant pembro) #melanoma at', 'operable (neoadjuvant vs. adjuvant pembro) #melanoma at #esmo22', '(neoadjuvant vs. adjuvant pembro) #melanoma at #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '37', 'tokens': ['"stampede', ':', 'the', 'transcriptomic', 'landscape', 'at', 'diagnosis', 'can', 'predict', 'benefit', 'and', 'identify', 'patients', 'with', 'better', 'prognoses', 'in', '#prostatecancer', 'decipher', 'signature', 'is', 'strongly', 'prognostic', 'across', 'disease', 'states', '#esmo22', '.'], 'text_length': 28, 'triples': {'"stampede|can predict benefit and': ([0, 0], [7, 10], 'neutral')}, 'sentence': '"stampede : the transcriptomic landscape at diagnosis can predict benefit and identify patients with better prognoses in #prostatecancer decipher signature is strongly prognostic across disease states #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['"stampede', ':', 'the', 'transcriptomic', 'landscape', 'at', 'diagnosis', 'can', 'predict', 'benefit', 'and', 'identify', 'patients', 'with', 'better', 'prognoses', 'in', '#prostatecancer', 'decipher', 'signature', 'is', 'strongly', 'prognostic', 'across', 'disease', 'states', '#esmo22', '.', '"stampede :', ': the', 'the transcriptomic', 'transcriptomic landscape', 'landscape at', 'at diagnosis', 'diagnosis can', 'can predict', 'predict benefit', 'benefit and', 'and identify', 'identify patients', 'patients with', 'with better', 'better prognoses', 'prognoses in', 'in #prostatecancer', '#prostatecancer decipher', 'decipher signature', 'signature is', 'is strongly', 'strongly prognostic', 'prognostic across', 'across disease', 'disease states', 'states #esmo22', '#esmo22 .', '"stampede : the', ': the transcriptomic', 'the transcriptomic landscape', 'transcriptomic landscape at', 'landscape at diagnosis', 'at diagnosis can', 'diagnosis can predict', 'can predict benefit', 'predict benefit and', 'benefit and identify', 'and identify patients', 'identify patients with', 'patients with better', 'with better prognoses', 'better prognoses in', 'prognoses in #prostatecancer', 'in #prostatecancer decipher', '#prostatecancer decipher signature', 'decipher signature is', 'signature is strongly', 'is strongly prognostic', 'strongly prognostic across', 'prognostic across disease', 'across disease states', 'disease states #esmo22', 'states #esmo22 .', '"stampede : the transcriptomic', ': the transcriptomic landscape', 'the transcriptomic landscape at', 'transcriptomic landscape at diagnosis', 'landscape at diagnosis can', 'at diagnosis can predict', 'diagnosis can predict benefit', 'can predict benefit and', 'predict benefit and identify', 'benefit and identify patients', 'and identify patients with', 'identify patients with better', 'patients with better prognoses', 'with better prognoses in', 'better prognoses in #prostatecancer', 'prognoses in #prostatecancer decipher', 'in #prostatecancer decipher signature', '#prostatecancer decipher signature is', 'decipher signature is strongly', 'signature is strongly prognostic', 'is strongly prognostic across', 'strongly prognostic across disease', 'prognostic across disease states', 'across disease states #esmo22', 'disease states #esmo22 .', '"stampede : the transcriptomic landscape', ': the transcriptomic landscape at', 'the transcriptomic landscape at diagnosis', 'transcriptomic landscape at diagnosis can', 'landscape at diagnosis can predict', 'at diagnosis can predict benefit', 'diagnosis can predict benefit and', 'can predict benefit and identify', 'predict benefit and identify patients', 'benefit and identify patients with', 'and identify patients with better', 'identify patients with better prognoses', 'patients with better prognoses in', 'with better prognoses in #prostatecancer', 'better prognoses in #prostatecancer decipher', 'prognoses in #prostatecancer decipher signature', 'in #prostatecancer decipher signature is', '#prostatecancer decipher signature is strongly', 'decipher signature is strongly prognostic', 'signature is strongly prognostic across', 'is strongly prognostic across disease', 'strongly prognostic across disease states', 'prognostic across disease states #esmo22', 'across disease states #esmo22 .', '"stampede : the transcriptomic landscape at', ': the transcriptomic landscape at diagnosis', 'the transcriptomic landscape at diagnosis can', 'transcriptomic landscape at diagnosis can predict', 'landscape at diagnosis can predict benefit', 'at diagnosis can predict benefit and', 'diagnosis can predict benefit and identify', 'can predict benefit and identify patients', 'predict benefit and identify patients with', 'benefit and identify patients with better', 'and identify patients with better prognoses', 'identify patients with better prognoses in', 'patients with better prognoses in #prostatecancer', 'with better prognoses in #prostatecancer decipher', 'better prognoses in #prostatecancer decipher signature', 'prognoses in #prostatecancer decipher signature is', 'in #prostatecancer decipher signature is strongly', '#prostatecancer decipher signature is strongly prognostic', 'decipher signature is strongly prognostic across', 'signature is strongly prognostic across disease', 'is strongly prognostic across disease states', 'strongly prognostic across disease states #esmo22', 'prognostic across disease states #esmo22 .', '"stampede : the transcriptomic landscape at diagnosis', ': the transcriptomic landscape at diagnosis can', 'the transcriptomic landscape at diagnosis can predict', 'transcriptomic landscape at diagnosis can predict benefit', 'landscape at diagnosis can predict benefit and', 'at diagnosis can predict benefit and identify', 'diagnosis can predict benefit and identify patients', 'can predict benefit and identify patients with', 'predict benefit and identify patients with better', 'benefit and identify patients with better prognoses', 'and identify patients with better prognoses in', 'identify patients with better prognoses in #prostatecancer', 'patients with better prognoses in #prostatecancer decipher', 'with better prognoses in #prostatecancer decipher signature', 'better prognoses in #prostatecancer decipher signature is', 'prognoses in #prostatecancer decipher signature is strongly', 'in #prostatecancer decipher signature is strongly prognostic', '#prostatecancer decipher signature is strongly prognostic across', 'decipher signature is strongly prognostic across disease', 'signature is strongly prognostic across disease states', 'is strongly prognostic across disease states #esmo22', 'strongly prognostic across disease states #esmo22 .', '"stampede : the transcriptomic landscape at diagnosis can', ': the transcriptomic landscape at diagnosis can predict', 'the transcriptomic landscape at diagnosis can predict benefit', 'transcriptomic landscape at diagnosis can predict benefit and', 'landscape at diagnosis can predict benefit and identify', 'at diagnosis can predict benefit and identify patients', 'diagnosis can predict benefit and identify patients with', 'can predict benefit and identify patients with better', 'predict benefit and identify patients with better prognoses', 'benefit and identify patients with better prognoses in', 'and identify patients with better prognoses in #prostatecancer', 'identify patients with better prognoses in #prostatecancer decipher', 'patients with better prognoses in #prostatecancer decipher signature', 'with better prognoses in #prostatecancer decipher signature is', 'better prognoses in #prostatecancer decipher signature is strongly', 'prognoses in #prostatecancer decipher signature is strongly prognostic', 'in #prostatecancer decipher signature is strongly prognostic across', '#prostatecancer decipher signature is strongly prognostic across disease', 'decipher signature is strongly prognostic across disease states', 'signature is strongly prognostic across disease states #esmo22', 'is strongly prognostic across disease states #esmo22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '38', 'tokens': ['Congratulations', 'Dr', '@MyriamChalabi', 'NICHE-2', 'great', 'study!', 'Immunotherapy', 'for', 'deficient', 'MisMatch', 'Repair', 'colon', 'cancer', 'patients:', 'Major', 'path', 'Response', 'in', '95%,', '&amp;', 'pCR', 'in', '67%', 'patients.', 'Superb', 'applaud', '&amp;', 'nice', 'discussions', 'by', '@LoiSher', '(👍', '#breast', 'oncologist', '😄)', '&amp;', 'James', 'Larkin', '#ESMO22', '@OncoAlert', 'https://t.co/KByQvvGRWO', '.'], 'text_length': 42, 'triples': {'NICHE-2|great study! Immunotherapy for deficient MisMatch Repair colon cancer patients: Major path Response in 95%, &amp; pCR in 67% patients. Superb': ([3, 3], [4, 24], 'positive')}, 'sentence': 'Congratulations Dr @MyriamChalabi NICHE-2 great study! Immunotherapy for deficient MisMatch Repair colon cancer patients: Major path Response in 95%, &amp; pCR in 67% patients. Superb applaud &amp; nice discussions by @LoiSher (👍 #breast oncologist 😄) &amp; James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 24)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8)], 'span tokens': ['Congratulations', 'Dr', '@MyriamChalabi', 'NICHE-2', 'great', 'study!', 'Immunotherapy', 'for', 'deficient', 'MisMatch', 'Repair', 'colon', 'cancer', 'patients:', 'Major', 'path', 'Response', 'in', '95%,', '&amp;', 'pCR', 'in', '67%', 'patients.', 'Superb', 'applaud', '&amp;', 'nice', 'discussions', 'by', '@LoiSher', '(👍', '#breast', 'oncologist', '😄)', '&amp;', 'James', 'Larkin', '#ESMO22', '@OncoAlert', 'https://t.co/KByQvvGRWO', '.', 'Congratulations Dr', 'Dr @MyriamChalabi', '@MyriamChalabi NICHE-2', 'NICHE-2 great', 'great study!', 'study! Immunotherapy', 'Immunotherapy for', 'for deficient', 'deficient MisMatch', 'MisMatch Repair', 'Repair colon', 'colon cancer', 'cancer patients:', 'patients: Major', 'Major path', 'path Response', 'Response in', 'in 95%,', '95%, &amp;', '&amp; pCR', 'pCR in', 'in 67%', '67% patients.', 'patients. Superb', 'Superb applaud', 'applaud &amp;', '&amp; nice', 'nice discussions', 'discussions by', 'by @LoiSher', '@LoiSher (👍', '(👍 #breast', '#breast oncologist', 'oncologist 😄)', '😄) &amp;', '&amp; James', 'James Larkin', 'Larkin #ESMO22', '#ESMO22 @OncoAlert', '@OncoAlert https://t.co/KByQvvGRWO', 'https://t.co/KByQvvGRWO .', 'Congratulations Dr @MyriamChalabi', 'Dr @MyriamChalabi NICHE-2', '@MyriamChalabi NICHE-2 great', 'NICHE-2 great study!', 'great study! Immunotherapy', 'study! Immunotherapy for', 'Immunotherapy for deficient', 'for deficient MisMatch', 'deficient MisMatch Repair', 'MisMatch Repair colon', 'Repair colon cancer', 'colon cancer patients:', 'cancer patients: Major', 'patients: Major path', 'Major path Response', 'path Response in', 'Response in 95%,', 'in 95%, &amp;', '95%, &amp; pCR', '&amp; pCR in', 'pCR in 67%', 'in 67% patients.', '67% patients. Superb', 'patients. Superb applaud', 'Superb applaud &amp;', 'applaud &amp; nice', '&amp; nice discussions', 'nice discussions by', 'discussions by @LoiSher', 'by @LoiSher (👍', '@LoiSher (👍 #breast', '(👍 #breast oncologist', '#breast oncologist 😄)', 'oncologist 😄) &amp;', '😄) &amp; James', '&amp; James Larkin', 'James Larkin #ESMO22', 'Larkin #ESMO22 @OncoAlert', '#ESMO22 @OncoAlert https://t.co/KByQvvGRWO', '@OncoAlert https://t.co/KByQvvGRWO .', 'Congratulations Dr @MyriamChalabi NICHE-2', 'Dr @MyriamChalabi NICHE-2 great', '@MyriamChalabi NICHE-2 great study!', 'NICHE-2 great study! Immunotherapy', 'great study! Immunotherapy for', 'study! Immunotherapy for deficient', 'Immunotherapy for deficient MisMatch', 'for deficient MisMatch Repair', 'deficient MisMatch Repair colon', 'MisMatch Repair colon cancer', 'Repair colon cancer patients:', 'colon cancer patients: Major', 'cancer patients: Major path', 'patients: Major path Response', 'Major path Response in', 'path Response in 95%,', 'Response in 95%, &amp;', 'in 95%, &amp; pCR', '95%, &amp; pCR in', '&amp; pCR in 67%', 'pCR in 67% patients.', 'in 67% patients. Superb', '67% patients. Superb applaud', 'patients. Superb applaud &amp;', 'Superb applaud &amp; nice', 'applaud &amp; nice discussions', '&amp; nice discussions by', 'nice discussions by @LoiSher', 'discussions by @LoiSher (👍', 'by @LoiSher (👍 #breast', '@LoiSher (👍 #breast oncologist', '(👍 #breast oncologist 😄)', '#breast oncologist 😄) &amp;', 'oncologist 😄) &amp; James', '😄) &amp; James Larkin', '&amp; James Larkin #ESMO22', 'James Larkin #ESMO22 @OncoAlert', 'Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO', '#ESMO22 @OncoAlert https://t.co/KByQvvGRWO .', 'Congratulations Dr @MyriamChalabi NICHE-2 great', 'Dr @MyriamChalabi NICHE-2 great study!', '@MyriamChalabi NICHE-2 great study! Immunotherapy', 'NICHE-2 great study! Immunotherapy for', 'great study! Immunotherapy for deficient', 'study! Immunotherapy for deficient MisMatch', 'Immunotherapy for deficient MisMatch Repair', 'for deficient MisMatch Repair colon', 'deficient MisMatch Repair colon cancer', 'MisMatch Repair colon cancer patients:', 'Repair colon cancer patients: Major', 'colon cancer patients: Major path', 'cancer patients: Major path Response', 'patients: Major path Response in', 'Major path Response in 95%,', 'path Response in 95%, &amp;', 'Response in 95%, &amp; pCR', 'in 95%, &amp; pCR in', '95%, &amp; pCR in 67%', '&amp; pCR in 67% patients.', 'pCR in 67% patients. Superb', 'in 67% patients. Superb applaud', '67% patients. Superb applaud &amp;', 'patients. Superb applaud &amp; nice', 'Superb applaud &amp; nice discussions', 'applaud &amp; nice discussions by', '&amp; nice discussions by @LoiSher', 'nice discussions by @LoiSher (👍', 'discussions by @LoiSher (👍 #breast', 'by @LoiSher (👍 #breast oncologist', '@LoiSher (👍 #breast oncologist 😄)', '(👍 #breast oncologist 😄) &amp;', '#breast oncologist 😄) &amp; James', 'oncologist 😄) &amp; James Larkin', '😄) &amp; James Larkin #ESMO22', '&amp; James Larkin #ESMO22 @OncoAlert', 'James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO', 'Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO .', 'Congratulations Dr @MyriamChalabi NICHE-2 great study!', 'Dr @MyriamChalabi NICHE-2 great study! Immunotherapy', '@MyriamChalabi NICHE-2 great study! Immunotherapy for', 'NICHE-2 great study! Immunotherapy for deficient', 'great study! Immunotherapy for deficient MisMatch', 'study! Immunotherapy for deficient MisMatch Repair', 'Immunotherapy for deficient MisMatch Repair colon', 'for deficient MisMatch Repair colon cancer', 'deficient MisMatch Repair colon cancer patients:', 'MisMatch Repair colon cancer patients: Major', 'Repair colon cancer patients: Major path', 'colon cancer patients: Major path Response', 'cancer patients: Major path Response in', 'patients: Major path Response in 95%,', 'Major path Response in 95%, &amp;', 'path Response in 95%, &amp; pCR', 'Response in 95%, &amp; pCR in', 'in 95%, &amp; pCR in 67%', '95%, &amp; pCR in 67% patients.', '&amp; pCR in 67% patients. Superb', 'pCR in 67% patients. Superb applaud', 'in 67% patients. Superb applaud &amp;', '67% patients. Superb applaud &amp; nice', 'patients. Superb applaud &amp; nice discussions', 'Superb applaud &amp; nice discussions by', 'applaud &amp; nice discussions by @LoiSher', '&amp; nice discussions by @LoiSher (👍', 'nice discussions by @LoiSher (👍 #breast', 'discussions by @LoiSher (👍 #breast oncologist', 'by @LoiSher (👍 #breast oncologist 😄)', '@LoiSher (👍 #breast oncologist 😄) &amp;', '(👍 #breast oncologist 😄) &amp; James', '#breast oncologist 😄) &amp; James Larkin', 'oncologist 😄) &amp; James Larkin #ESMO22', '😄) &amp; James Larkin #ESMO22 @OncoAlert', '&amp; James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO', 'James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO .', 'Congratulations Dr @MyriamChalabi NICHE-2 great study! Immunotherapy', 'Dr @MyriamChalabi NICHE-2 great study! Immunotherapy for', '@MyriamChalabi NICHE-2 great study! Immunotherapy for deficient', 'NICHE-2 great study! Immunotherapy for deficient MisMatch', 'great study! Immunotherapy for deficient MisMatch Repair', 'study! Immunotherapy for deficient MisMatch Repair colon', 'Immunotherapy for deficient MisMatch Repair colon cancer', 'for deficient MisMatch Repair colon cancer patients:', 'deficient MisMatch Repair colon cancer patients: Major', 'MisMatch Repair colon cancer patients: Major path', 'Repair colon cancer patients: Major path Response', 'colon cancer patients: Major path Response in', 'cancer patients: Major path Response in 95%,', 'patients: Major path Response in 95%, &amp;', 'Major path Response in 95%, &amp; pCR', 'path Response in 95%, &amp; pCR in', 'Response in 95%, &amp; pCR in 67%', 'in 95%, &amp; pCR in 67% patients.', '95%, &amp; pCR in 67% patients. Superb', '&amp; pCR in 67% patients. Superb applaud', 'pCR in 67% patients. Superb applaud &amp;', 'in 67% patients. Superb applaud &amp; nice', '67% patients. Superb applaud &amp; nice discussions', 'patients. Superb applaud &amp; nice discussions by', 'Superb applaud &amp; nice discussions by @LoiSher', 'applaud &amp; nice discussions by @LoiSher (👍', '&amp; nice discussions by @LoiSher (👍 #breast', 'nice discussions by @LoiSher (👍 #breast oncologist', 'discussions by @LoiSher (👍 #breast oncologist 😄)', 'by @LoiSher (👍 #breast oncologist 😄) &amp;', '@LoiSher (👍 #breast oncologist 😄) &amp; James', '(👍 #breast oncologist 😄) &amp; James Larkin', '#breast oncologist 😄) &amp; James Larkin #ESMO22', 'oncologist 😄) &amp; James Larkin #ESMO22 @OncoAlert', '😄) &amp; James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO', '&amp; James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO .', 'Congratulations Dr @MyriamChalabi NICHE-2 great study! Immunotherapy for', 'Dr @MyriamChalabi NICHE-2 great study! Immunotherapy for deficient', '@MyriamChalabi NICHE-2 great study! Immunotherapy for deficient MisMatch', 'NICHE-2 great study! Immunotherapy for deficient MisMatch Repair', 'great study! Immunotherapy for deficient MisMatch Repair colon', 'study! Immunotherapy for deficient MisMatch Repair colon cancer', 'Immunotherapy for deficient MisMatch Repair colon cancer patients:', 'for deficient MisMatch Repair colon cancer patients: Major', 'deficient MisMatch Repair colon cancer patients: Major path', 'MisMatch Repair colon cancer patients: Major path Response', 'Repair colon cancer patients: Major path Response in', 'colon cancer patients: Major path Response in 95%,', 'cancer patients: Major path Response in 95%, &amp;', 'patients: Major path Response in 95%, &amp; pCR', 'Major path Response in 95%, &amp; pCR in', 'path Response in 95%, &amp; pCR in 67%', 'Response in 95%, &amp; pCR in 67% patients.', 'in 95%, &amp; pCR in 67% patients. Superb', '95%, &amp; pCR in 67% patients. Superb applaud', '&amp; pCR in 67% patients. Superb applaud &amp;', 'pCR in 67% patients. Superb applaud &amp; nice', 'in 67% patients. Superb applaud &amp; nice discussions', '67% patients. Superb applaud &amp; nice discussions by', 'patients. Superb applaud &amp; nice discussions by @LoiSher', 'Superb applaud &amp; nice discussions by @LoiSher (👍', 'applaud &amp; nice discussions by @LoiSher (👍 #breast', '&amp; nice discussions by @LoiSher (👍 #breast oncologist', 'nice discussions by @LoiSher (👍 #breast oncologist 😄)', 'discussions by @LoiSher (👍 #breast oncologist 😄) &amp;', 'by @LoiSher (👍 #breast oncologist 😄) &amp; James', '@LoiSher (👍 #breast oncologist 😄) &amp; James Larkin', '(👍 #breast oncologist 😄) &amp; James Larkin #ESMO22', '#breast oncologist 😄) &amp; James Larkin #ESMO22 @OncoAlert', 'oncologist 😄) &amp; James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO', '😄) &amp; James Larkin #ESMO22 @OncoAlert https://t.co/KByQvvGRWO .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '39', 'tokens': ['updated', 'os', 'data', 'from', 'enzamet', '.', 'in', 'my', 'opinion,', 'the', 'question', 'remains', 'the', 'same.', 'who', 'needs', 'triplet', 'therapy?', 'who', 'is', 'fine', 'just', 'with', 'nht?', 'is', 'it', 'all', 'about', 'patient', 'fitness', 'for', 'chemotherapy?', '#asco22', '.'], 'text_length': 34, 'triples': {'enzamet|question remains the': ([4, 4], [10, 12], 'neutral')}, 'sentence': 'updated os data from enzamet . in my opinion, the question remains the same. who needs triplet therapy? who is fine just with nht? is it all about patient fitness for chemotherapy? #asco22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['updated', 'os', 'data', 'from', 'enzamet', '.', 'in', 'my', 'opinion,', 'the', 'question', 'remains', 'the', 'same.', 'who', 'needs', 'triplet', 'therapy?', 'who', 'is', 'fine', 'just', 'with', 'nht?', 'is', 'it', 'all', 'about', 'patient', 'fitness', 'for', 'chemotherapy?', '#asco22', '.', 'updated os', 'os data', 'data from', 'from enzamet', 'enzamet .', '. in', 'in my', 'my opinion,', 'opinion, the', 'the question', 'question remains', 'remains the', 'the same.', 'same. who', 'who needs', 'needs triplet', 'triplet therapy?', 'therapy? who', 'who is', 'is fine', 'fine just', 'just with', 'with nht?', 'nht? is', 'is it', 'it all', 'all about', 'about patient', 'patient fitness', 'fitness for', 'for chemotherapy?', 'chemotherapy? #asco22', '#asco22 .', 'updated os data', 'os data from', 'data from enzamet', 'from enzamet .', 'enzamet . in', '. in my', 'in my opinion,', 'my opinion, the', 'opinion, the question', 'the question remains', 'question remains the', 'remains the same.', 'the same. who', 'same. who needs', 'who needs triplet', 'needs triplet therapy?', 'triplet therapy? who', 'therapy? who is', 'who is fine', 'is fine just', 'fine just with', 'just with nht?', 'with nht? is', 'nht? is it', 'is it all', 'it all about', 'all about patient', 'about patient fitness', 'patient fitness for', 'fitness for chemotherapy?', 'for chemotherapy? #asco22', 'chemotherapy? #asco22 .', 'updated os data from', 'os data from enzamet', 'data from enzamet .', 'from enzamet . in', 'enzamet . in my', '. in my opinion,', 'in my opinion, the', 'my opinion, the question', 'opinion, the question remains', 'the question remains the', 'question remains the same.', 'remains the same. who', 'the same. who needs', 'same. who needs triplet', 'who needs triplet therapy?', 'needs triplet therapy? who', 'triplet therapy? who is', 'therapy? who is fine', 'who is fine just', 'is fine just with', 'fine just with nht?', 'just with nht? is', 'with nht? is it', 'nht? is it all', 'is it all about', 'it all about patient', 'all about patient fitness', 'about patient fitness for', 'patient fitness for chemotherapy?', 'fitness for chemotherapy? #asco22', 'for chemotherapy? #asco22 .', 'updated os data from enzamet', 'os data from enzamet .', 'data from enzamet . in', 'from enzamet . in my', 'enzamet . in my opinion,', '. in my opinion, the', 'in my opinion, the question', 'my opinion, the question remains', 'opinion, the question remains the', 'the question remains the same.', 'question remains the same. who', 'remains the same. who needs', 'the same. who needs triplet', 'same. who needs triplet therapy?', 'who needs triplet therapy? who', 'needs triplet therapy? who is', 'triplet therapy? who is fine', 'therapy? who is fine just', 'who is fine just with', 'is fine just with nht?', 'fine just with nht? is', 'just with nht? is it', 'with nht? is it all', 'nht? is it all about', 'is it all about patient', 'it all about patient fitness', 'all about patient fitness for', 'about patient fitness for chemotherapy?', 'patient fitness for chemotherapy? #asco22', 'fitness for chemotherapy? #asco22 .', 'updated os data from enzamet .', 'os data from enzamet . in', 'data from enzamet . in my', 'from enzamet . in my opinion,', 'enzamet . in my opinion, the', '. in my opinion, the question', 'in my opinion, the question remains', 'my opinion, the question remains the', 'opinion, the question remains the same.', 'the question remains the same. who', 'question remains the same. who needs', 'remains the same. who needs triplet', 'the same. who needs triplet therapy?', 'same. who needs triplet therapy? who', 'who needs triplet therapy? who is', 'needs triplet therapy? who is fine', 'triplet therapy? who is fine just', 'therapy? who is fine just with', 'who is fine just with nht?', 'is fine just with nht? is', 'fine just with nht? is it', 'just with nht? is it all', 'with nht? is it all about', 'nht? is it all about patient', 'is it all about patient fitness', 'it all about patient fitness for', 'all about patient fitness for chemotherapy?', 'about patient fitness for chemotherapy? #asco22', 'patient fitness for chemotherapy? #asco22 .', 'updated os data from enzamet . in', 'os data from enzamet . in my', 'data from enzamet . in my opinion,', 'from enzamet . in my opinion, the', 'enzamet . in my opinion, the question', '. in my opinion, the question remains', 'in my opinion, the question remains the', 'my opinion, the question remains the same.', 'opinion, the question remains the same. who', 'the question remains the same. who needs', 'question remains the same. who needs triplet', 'remains the same. who needs triplet therapy?', 'the same. who needs triplet therapy? who', 'same. who needs triplet therapy? who is', 'who needs triplet therapy? who is fine', 'needs triplet therapy? who is fine just', 'triplet therapy? who is fine just with', 'therapy? who is fine just with nht?', 'who is fine just with nht? is', 'is fine just with nht? is it', 'fine just with nht? is it all', 'just with nht? is it all about', 'with nht? is it all about patient', 'nht? is it all about patient fitness', 'is it all about patient fitness for', 'it all about patient fitness for chemotherapy?', 'all about patient fitness for chemotherapy? #asco22', 'about patient fitness for chemotherapy? #asco22 .', 'updated os data from enzamet . in my', 'os data from enzamet . in my opinion,', 'data from enzamet . in my opinion, the', 'from enzamet . in my opinion, the question', 'enzamet . in my opinion, the question remains', '. in my opinion, the question remains the', 'in my opinion, the question remains the same.', 'my opinion, the question remains the same. who', 'opinion, the question remains the same. who needs', 'the question remains the same. who needs triplet', 'question remains the same. who needs triplet therapy?', 'remains the same. who needs triplet therapy? who', 'the same. who needs triplet therapy? who is', 'same. who needs triplet therapy? who is fine', 'who needs triplet therapy? who is fine just', 'needs triplet therapy? who is fine just with', 'triplet therapy? who is fine just with nht?', 'therapy? who is fine just with nht? is', 'who is fine just with nht? is it', 'is fine just with nht? is it all', 'fine just with nht? is it all about', 'just with nht? is it all about patient', 'with nht? is it all about patient fitness', 'nht? is it all about patient fitness for', 'is it all about patient fitness for chemotherapy?', 'it all about patient fitness for chemotherapy? #asco22', 'all about patient fitness for chemotherapy? #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '40', 'tokens': ['genomic', 'bio', 'markers', 'in', 'javelin-bladder-100', 'by', 'pou2f2', 'expression', 'in', 'tumor', 'is', 'associated', 'with', 'maintenance', 'avelumab', 'survival', 'benefit!', '#esmo22', '.'], 'text_length': 19, 'triples': {'javelin-bladder-100|survival benefit!': ([4, 4], [15, 16], 'positive')}, 'sentence': 'genomic bio markers in javelin-bladder-100 by pou2f2 expression in tumor is associated with maintenance avelumab survival benefit! #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(15, 16)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['genomic', 'bio', 'markers', 'in', 'javelin-bladder-100', 'by', 'pou2f2', 'expression', 'in', 'tumor', 'is', 'associated', 'with', 'maintenance', 'avelumab', 'survival', 'benefit!', '#esmo22', '.', 'genomic bio', 'bio markers', 'markers in', 'in javelin-bladder-100', 'javelin-bladder-100 by', 'by pou2f2', 'pou2f2 expression', 'expression in', 'in tumor', 'tumor is', 'is associated', 'associated with', 'with maintenance', 'maintenance avelumab', 'avelumab survival', 'survival benefit!', 'benefit! #esmo22', '#esmo22 .', 'genomic bio markers', 'bio markers in', 'markers in javelin-bladder-100', 'in javelin-bladder-100 by', 'javelin-bladder-100 by pou2f2', 'by pou2f2 expression', 'pou2f2 expression in', 'expression in tumor', 'in tumor is', 'tumor is associated', 'is associated with', 'associated with maintenance', 'with maintenance avelumab', 'maintenance avelumab survival', 'avelumab survival benefit!', 'survival benefit! #esmo22', 'benefit! #esmo22 .', 'genomic bio markers in', 'bio markers in javelin-bladder-100', 'markers in javelin-bladder-100 by', 'in javelin-bladder-100 by pou2f2', 'javelin-bladder-100 by pou2f2 expression', 'by pou2f2 expression in', 'pou2f2 expression in tumor', 'expression in tumor is', 'in tumor is associated', 'tumor is associated with', 'is associated with maintenance', 'associated with maintenance avelumab', 'with maintenance avelumab survival', 'maintenance avelumab survival benefit!', 'avelumab survival benefit! #esmo22', 'survival benefit! #esmo22 .', 'genomic bio markers in javelin-bladder-100', 'bio markers in javelin-bladder-100 by', 'markers in javelin-bladder-100 by pou2f2', 'in javelin-bladder-100 by pou2f2 expression', 'javelin-bladder-100 by pou2f2 expression in', 'by pou2f2 expression in tumor', 'pou2f2 expression in tumor is', 'expression in tumor is associated', 'in tumor is associated with', 'tumor is associated with maintenance', 'is associated with maintenance avelumab', 'associated with maintenance avelumab survival', 'with maintenance avelumab survival benefit!', 'maintenance avelumab survival benefit! #esmo22', 'avelumab survival benefit! #esmo22 .', 'genomic bio markers in javelin-bladder-100 by', 'bio markers in javelin-bladder-100 by pou2f2', 'markers in javelin-bladder-100 by pou2f2 expression', 'in javelin-bladder-100 by pou2f2 expression in', 'javelin-bladder-100 by pou2f2 expression in tumor', 'by pou2f2 expression in tumor is', 'pou2f2 expression in tumor is associated', 'expression in tumor is associated with', 'in tumor is associated with maintenance', 'tumor is associated with maintenance avelumab', 'is associated with maintenance avelumab survival', 'associated with maintenance avelumab survival benefit!', 'with maintenance avelumab survival benefit! #esmo22', 'maintenance avelumab survival benefit! #esmo22 .', 'genomic bio markers in javelin-bladder-100 by pou2f2', 'bio markers in javelin-bladder-100 by pou2f2 expression', 'markers in javelin-bladder-100 by pou2f2 expression in', 'in javelin-bladder-100 by pou2f2 expression in tumor', 'javelin-bladder-100 by pou2f2 expression in tumor is', 'by pou2f2 expression in tumor is associated', 'pou2f2 expression in tumor is associated with', 'expression in tumor is associated with maintenance', 'in tumor is associated with maintenance avelumab', 'tumor is associated with maintenance avelumab survival', 'is associated with maintenance avelumab survival benefit!', 'associated with maintenance avelumab survival benefit! #esmo22', 'with maintenance avelumab survival benefit! #esmo22 .', 'genomic bio markers in javelin-bladder-100 by pou2f2 expression', 'bio markers in javelin-bladder-100 by pou2f2 expression in', 'markers in javelin-bladder-100 by pou2f2 expression in tumor', 'in javelin-bladder-100 by pou2f2 expression in tumor is', 'javelin-bladder-100 by pou2f2 expression in tumor is associated', 'by pou2f2 expression in tumor is associated with', 'pou2f2 expression in tumor is associated with maintenance', 'expression in tumor is associated with maintenance avelumab', 'in tumor is associated with maintenance avelumab survival', 'tumor is associated with maintenance avelumab survival benefit!', 'is associated with maintenance avelumab survival benefit! #esmo22', 'associated with maintenance avelumab survival benefit! #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '41', 'tokens': ['prior', 'bcma', 'impacts', 'response', 'rates', 'to', 'ide-cel,', 'but', 'timing', 'matters!', '#ash22', '#mmsm', '#cartsm', 'congratulations', 'to', 'and', 'us', 'mm', 'consortium!', '.'], 'text_length': 20, 'triples': {'ide-cel,|impacts response rates to ide-cel, but timing matters!': ([6, 6], [2, 9], 'neutral')}, 'sentence': 'prior bcma impacts response rates to ide-cel, but timing matters! #ash22 #mmsm #cartsm congratulations to and us mm consortium! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['prior', 'bcma', 'impacts', 'response', 'rates', 'to', 'ide-cel,', 'but', 'timing', 'matters!', '#ash22', '#mmsm', '#cartsm', 'congratulations', 'to', 'and', 'us', 'mm', 'consortium!', '.', 'prior bcma', 'bcma impacts', 'impacts response', 'response rates', 'rates to', 'to ide-cel,', 'ide-cel, but', 'but timing', 'timing matters!', 'matters! #ash22', '#ash22 #mmsm', '#mmsm #cartsm', '#cartsm congratulations', 'congratulations to', 'to and', 'and us', 'us mm', 'mm consortium!', 'consortium! .', 'prior bcma impacts', 'bcma impacts response', 'impacts response rates', 'response rates to', 'rates to ide-cel,', 'to ide-cel, but', 'ide-cel, but timing', 'but timing matters!', 'timing matters! #ash22', 'matters! #ash22 #mmsm', '#ash22 #mmsm #cartsm', '#mmsm #cartsm congratulations', '#cartsm congratulations to', 'congratulations to and', 'to and us', 'and us mm', 'us mm consortium!', 'mm consortium! .', 'prior bcma impacts response', 'bcma impacts response rates', 'impacts response rates to', 'response rates to ide-cel,', 'rates to ide-cel, but', 'to ide-cel, but timing', 'ide-cel, but timing matters!', 'but timing matters! #ash22', 'timing matters! #ash22 #mmsm', 'matters! #ash22 #mmsm #cartsm', '#ash22 #mmsm #cartsm congratulations', '#mmsm #cartsm congratulations to', '#cartsm congratulations to and', 'congratulations to and us', 'to and us mm', 'and us mm consortium!', 'us mm consortium! .', 'prior bcma impacts response rates', 'bcma impacts response rates to', 'impacts response rates to ide-cel,', 'response rates to ide-cel, but', 'rates to ide-cel, but timing', 'to ide-cel, but timing matters!', 'ide-cel, but timing matters! #ash22', 'but timing matters! #ash22 #mmsm', 'timing matters! #ash22 #mmsm #cartsm', 'matters! #ash22 #mmsm #cartsm congratulations', '#ash22 #mmsm #cartsm congratulations to', '#mmsm #cartsm congratulations to and', '#cartsm congratulations to and us', 'congratulations to and us mm', 'to and us mm consortium!', 'and us mm consortium! .', 'prior bcma impacts response rates to', 'bcma impacts response rates to ide-cel,', 'impacts response rates to ide-cel, but', 'response rates to ide-cel, but timing', 'rates to ide-cel, but timing matters!', 'to ide-cel, but timing matters! #ash22', 'ide-cel, but timing matters! #ash22 #mmsm', 'but timing matters! #ash22 #mmsm #cartsm', 'timing matters! #ash22 #mmsm #cartsm congratulations', 'matters! #ash22 #mmsm #cartsm congratulations to', '#ash22 #mmsm #cartsm congratulations to and', '#mmsm #cartsm congratulations to and us', '#cartsm congratulations to and us mm', 'congratulations to and us mm consortium!', 'to and us mm consortium! .', 'prior bcma impacts response rates to ide-cel,', 'bcma impacts response rates to ide-cel, but', 'impacts response rates to ide-cel, but timing', 'response rates to ide-cel, but timing matters!', 'rates to ide-cel, but timing matters! #ash22', 'to ide-cel, but timing matters! #ash22 #mmsm', 'ide-cel, but timing matters! #ash22 #mmsm #cartsm', 'but timing matters! #ash22 #mmsm #cartsm congratulations', 'timing matters! #ash22 #mmsm #cartsm congratulations to', 'matters! #ash22 #mmsm #cartsm congratulations to and', '#ash22 #mmsm #cartsm congratulations to and us', '#mmsm #cartsm congratulations to and us mm', '#cartsm congratulations to and us mm consortium!', 'congratulations to and us mm consortium! .', 'prior bcma impacts response rates to ide-cel, but', 'bcma impacts response rates to ide-cel, but timing', 'impacts response rates to ide-cel, but timing matters!', 'response rates to ide-cel, but timing matters! #ash22', 'rates to ide-cel, but timing matters! #ash22 #mmsm', 'to ide-cel, but timing matters! #ash22 #mmsm #cartsm', 'ide-cel, but timing matters! #ash22 #mmsm #cartsm congratulations', 'but timing matters! #ash22 #mmsm #cartsm congratulations to', 'timing matters! #ash22 #mmsm #cartsm congratulations to and', 'matters! #ash22 #mmsm #cartsm congratulations to and us', '#ash22 #mmsm #cartsm congratulations to and us mm', '#mmsm #cartsm congratulations to and us mm consortium!', '#cartsm congratulations to and us mm consortium! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '42', 'tokens': ['177lu-psma-617', 'in', 'psma-positive', 'metastatic', 'castration-resistant', 'prostate', 'cancer:', 'prior', 'and', 'concomitant', 'treatment', 'subgroup', 'analyses', 'of', 'the', 'vision', 'trial', '#asco22', '.'], 'text_length': 19, 'triples': {'vision|treatment subgroup analyses': ([15, 15], [10, 12], 'neutral'), '177lu-psma-617|treatment subgroup analyses': ([0, 0], [10, 12], 'neutral')}, 'sentence': '177lu-psma-617 in psma-positive metastatic castration-resistant prostate cancer: prior and concomitant treatment subgroup analyses of the vision trial #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(15, 15), (0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['177lu-psma-617', 'in', 'psma-positive', 'metastatic', 'castration-resistant', 'prostate', 'cancer:', 'prior', 'and', 'concomitant', 'treatment', 'subgroup', 'analyses', 'of', 'the', 'vision', 'trial', '#asco22', '.', '177lu-psma-617 in', 'in psma-positive', 'psma-positive metastatic', 'metastatic castration-resistant', 'castration-resistant prostate', 'prostate cancer:', 'cancer: prior', 'prior and', 'and concomitant', 'concomitant treatment', 'treatment subgroup', 'subgroup analyses', 'analyses of', 'of the', 'the vision', 'vision trial', 'trial #asco22', '#asco22 .', '177lu-psma-617 in psma-positive', 'in psma-positive metastatic', 'psma-positive metastatic castration-resistant', 'metastatic castration-resistant prostate', 'castration-resistant prostate cancer:', 'prostate cancer: prior', 'cancer: prior and', 'prior and concomitant', 'and concomitant treatment', 'concomitant treatment subgroup', 'treatment subgroup analyses', 'subgroup analyses of', 'analyses of the', 'of the vision', 'the vision trial', 'vision trial #asco22', 'trial #asco22 .', '177lu-psma-617 in psma-positive metastatic', 'in psma-positive metastatic castration-resistant', 'psma-positive metastatic castration-resistant prostate', 'metastatic castration-resistant prostate cancer:', 'castration-resistant prostate cancer: prior', 'prostate cancer: prior and', 'cancer: prior and concomitant', 'prior and concomitant treatment', 'and concomitant treatment subgroup', 'concomitant treatment subgroup analyses', 'treatment subgroup analyses of', 'subgroup analyses of the', 'analyses of the vision', 'of the vision trial', 'the vision trial #asco22', 'vision trial #asco22 .', '177lu-psma-617 in psma-positive metastatic castration-resistant', 'in psma-positive metastatic castration-resistant prostate', 'psma-positive metastatic castration-resistant prostate cancer:', 'metastatic castration-resistant prostate cancer: prior', 'castration-resistant prostate cancer: prior and', 'prostate cancer: prior and concomitant', 'cancer: prior and concomitant treatment', 'prior and concomitant treatment subgroup', 'and concomitant treatment subgroup analyses', 'concomitant treatment subgroup analyses of', 'treatment subgroup analyses of the', 'subgroup analyses of the vision', 'analyses of the vision trial', 'of the vision trial #asco22', 'the vision trial #asco22 .', '177lu-psma-617 in psma-positive metastatic castration-resistant prostate', 'in psma-positive metastatic castration-resistant prostate cancer:', 'psma-positive metastatic castration-resistant prostate cancer: prior', 'metastatic castration-resistant prostate cancer: prior and', 'castration-resistant prostate cancer: prior and concomitant', 'prostate cancer: prior and concomitant treatment', 'cancer: prior and concomitant treatment subgroup', 'prior and concomitant treatment subgroup analyses', 'and concomitant treatment subgroup analyses of', 'concomitant treatment subgroup analyses of the', 'treatment subgroup analyses of the vision', 'subgroup analyses of the vision trial', 'analyses of the vision trial #asco22', 'of the vision trial #asco22 .', '177lu-psma-617 in psma-positive metastatic castration-resistant prostate cancer:', 'in psma-positive metastatic castration-resistant prostate cancer: prior', 'psma-positive metastatic castration-resistant prostate cancer: prior and', 'metastatic castration-resistant prostate cancer: prior and concomitant', 'castration-resistant prostate cancer: prior and concomitant treatment', 'prostate cancer: prior and concomitant treatment subgroup', 'cancer: prior and concomitant treatment subgroup analyses', 'prior and concomitant treatment subgroup analyses of', 'and concomitant treatment subgroup analyses of the', 'concomitant treatment subgroup analyses of the vision', 'treatment subgroup analyses of the vision trial', 'subgroup analyses of the vision trial #asco22', 'analyses of the vision trial #asco22 .', '177lu-psma-617 in psma-positive metastatic castration-resistant prostate cancer: prior', 'in psma-positive metastatic castration-resistant prostate cancer: prior and', 'psma-positive metastatic castration-resistant prostate cancer: prior and concomitant', 'metastatic castration-resistant prostate cancer: prior and concomitant treatment', 'castration-resistant prostate cancer: prior and concomitant treatment subgroup', 'prostate cancer: prior and concomitant treatment subgroup analyses', 'cancer: prior and concomitant treatment subgroup analyses of', 'prior and concomitant treatment subgroup analyses of the', 'and concomitant treatment subgroup analyses of the vision', 'concomitant treatment subgroup analyses of the vision trial', 'treatment subgroup analyses of the vision trial #asco22', 'subgroup analyses of the vision trial #asco22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '43', 'tokens': ['everolimus', 'did', 'not', 'show', 'a', 'significant', 'dfs', 'or', 'os', 'advantage', 'in', 'adjuvant', 'rcc.', 'this', 'study', 'probably', 'draws', 'a', 'line', 'under', 'the', 'investigation', 'of', 'mtor', '(torc1/2)', 'in', 'rcc', 'and', 'draws', 'a', 'line', 'under', 'adjuvant', 'targeted', 'therapies', 'in', 'rcc.', 'everolimus', 'role', 'is', 'relatively', 'limited.', '#asco22', '.'], 'text_length': 44, 'triples': {'everolimus did not show a significant dfs or os advantage in adjuvant rcc. this study probably draws a line under the investigation of mtor (torc1/2) in rcc and draws a line under adjuvant targeted therapies in rcc. everolimus|not show a significant dfs or os advantage in adjuvant rcc. this study probably draws a line under the investigation of mtor (torc1/2) in rcc and draws a line under adjuvant targeted therapies in rcc. everolimus role is relatively limited.': ([0, 37], [2, 41], 'negative')}, 'sentence': 'everolimus did not show a significant dfs or os advantage in adjuvant rcc. this study probably draws a line under the investigation of mtor (torc1/2) in rcc and draws a line under adjuvant targeted therapies in rcc. everolimus role is relatively limited. #asco22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 37)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 41)], 'related_span_array': array([[1, 0, 0, ..., 1, 1, 1],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [1, 0, 0, ..., 1, 1, 1],
       [1, 0, 0, ..., 1, 1, 1],
       [1, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8)], 'span tokens': ['everolimus', 'did', 'not', 'show', 'a', 'significant', 'dfs', 'or', 'os', 'advantage', 'in', 'adjuvant', 'rcc.', 'this', 'study', 'probably', 'draws', 'a', 'line', 'under', 'the', 'investigation', 'of', 'mtor', '(torc1/2)', 'in', 'rcc', 'and', 'draws', 'a', 'line', 'under', 'adjuvant', 'targeted', 'therapies', 'in', 'rcc.', 'everolimus', 'role', 'is', 'relatively', 'limited.', '#asco22', '.', 'everolimus did', 'did not', 'not show', 'show a', 'a significant', 'significant dfs', 'dfs or', 'or os', 'os advantage', 'advantage in', 'in adjuvant', 'adjuvant rcc.', 'rcc. this', 'this study', 'study probably', 'probably draws', 'draws a', 'a line', 'line under', 'under the', 'the investigation', 'investigation of', 'of mtor', 'mtor (torc1/2)', '(torc1/2) in', 'in rcc', 'rcc and', 'and draws', 'draws a', 'a line', 'line under', 'under adjuvant', 'adjuvant targeted', 'targeted therapies', 'therapies in', 'in rcc.', 'rcc. everolimus', 'everolimus role', 'role is', 'is relatively', 'relatively limited.', 'limited. #asco22', '#asco22 .', 'everolimus did not', 'did not show', 'not show a', 'show a significant', 'a significant dfs', 'significant dfs or', 'dfs or os', 'or os advantage', 'os advantage in', 'advantage in adjuvant', 'in adjuvant rcc.', 'adjuvant rcc. this', 'rcc. this study', 'this study probably', 'study probably draws', 'probably draws a', 'draws a line', 'a line under', 'line under the', 'under the investigation', 'the investigation of', 'investigation of mtor', 'of mtor (torc1/2)', 'mtor (torc1/2) in', '(torc1/2) in rcc', 'in rcc and', 'rcc and draws', 'and draws a', 'draws a line', 'a line under', 'line under adjuvant', 'under adjuvant targeted', 'adjuvant targeted therapies', 'targeted therapies in', 'therapies in rcc.', 'in rcc. everolimus', 'rcc. everolimus role', 'everolimus role is', 'role is relatively', 'is relatively limited.', 'relatively limited. #asco22', 'limited. #asco22 .', 'everolimus did not show', 'did not show a', 'not show a significant', 'show a significant dfs', 'a significant dfs or', 'significant dfs or os', 'dfs or os advantage', 'or os advantage in', 'os advantage in adjuvant', 'advantage in adjuvant rcc.', 'in adjuvant rcc. this', 'adjuvant rcc. this study', 'rcc. this study probably', 'this study probably draws', 'study probably draws a', 'probably draws a line', 'draws a line under', 'a line under the', 'line under the investigation', 'under the investigation of', 'the investigation of mtor', 'investigation of mtor (torc1/2)', 'of mtor (torc1/2) in', 'mtor (torc1/2) in rcc', '(torc1/2) in rcc and', 'in rcc and draws', 'rcc and draws a', 'and draws a line', 'draws a line under', 'a line under adjuvant', 'line under adjuvant targeted', 'under adjuvant targeted therapies', 'adjuvant targeted therapies in', 'targeted therapies in rcc.', 'therapies in rcc. everolimus', 'in rcc. everolimus role', 'rcc. everolimus role is', 'everolimus role is relatively', 'role is relatively limited.', 'is relatively limited. #asco22', 'relatively limited. #asco22 .', 'everolimus did not show a', 'did not show a significant', 'not show a significant dfs', 'show a significant dfs or', 'a significant dfs or os', 'significant dfs or os advantage', 'dfs or os advantage in', 'or os advantage in adjuvant', 'os advantage in adjuvant rcc.', 'advantage in adjuvant rcc. this', 'in adjuvant rcc. this study', 'adjuvant rcc. this study probably', 'rcc. this study probably draws', 'this study probably draws a', 'study probably draws a line', 'probably draws a line under', 'draws a line under the', 'a line under the investigation', 'line under the investigation of', 'under the investigation of mtor', 'the investigation of mtor (torc1/2)', 'investigation of mtor (torc1/2) in', 'of mtor (torc1/2) in rcc', 'mtor (torc1/2) in rcc and', '(torc1/2) in rcc and draws', 'in rcc and draws a', 'rcc and draws a line', 'and draws a line under', 'draws a line under adjuvant', 'a line under adjuvant targeted', 'line under adjuvant targeted therapies', 'under adjuvant targeted therapies in', 'adjuvant targeted therapies in rcc.', 'targeted therapies in rcc. everolimus', 'therapies in rcc. everolimus role', 'in rcc. everolimus role is', 'rcc. everolimus role is relatively', 'everolimus role is relatively limited.', 'role is relatively limited. #asco22', 'is relatively limited. #asco22 .', 'everolimus did not show a significant', 'did not show a significant dfs', 'not show a significant dfs or', 'show a significant dfs or os', 'a significant dfs or os advantage', 'significant dfs or os advantage in', 'dfs or os advantage in adjuvant', 'or os advantage in adjuvant rcc.', 'os advantage in adjuvant rcc. this', 'advantage in adjuvant rcc. this study', 'in adjuvant rcc. this study probably', 'adjuvant rcc. this study probably draws', 'rcc. this study probably draws a', 'this study probably draws a line', 'study probably draws a line under', 'probably draws a line under the', 'draws a line under the investigation', 'a line under the investigation of', 'line under the investigation of mtor', 'under the investigation of mtor (torc1/2)', 'the investigation of mtor (torc1/2) in', 'investigation of mtor (torc1/2) in rcc', 'of mtor (torc1/2) in rcc and', 'mtor (torc1/2) in rcc and draws', '(torc1/2) in rcc and draws a', 'in rcc and draws a line', 'rcc and draws a line under', 'and draws a line under adjuvant', 'draws a line under adjuvant targeted', 'a line under adjuvant targeted therapies', 'line under adjuvant targeted therapies in', 'under adjuvant targeted therapies in rcc.', 'adjuvant targeted therapies in rcc. everolimus', 'targeted therapies in rcc. everolimus role', 'therapies in rcc. everolimus role is', 'in rcc. everolimus role is relatively', 'rcc. everolimus role is relatively limited.', 'everolimus role is relatively limited. #asco22', 'role is relatively limited. #asco22 .', 'everolimus did not show a significant dfs', 'did not show a significant dfs or', 'not show a significant dfs or os', 'show a significant dfs or os advantage', 'a significant dfs or os advantage in', 'significant dfs or os advantage in adjuvant', 'dfs or os advantage in adjuvant rcc.', 'or os advantage in adjuvant rcc. this', 'os advantage in adjuvant rcc. this study', 'advantage in adjuvant rcc. this study probably', 'in adjuvant rcc. this study probably draws', 'adjuvant rcc. this study probably draws a', 'rcc. this study probably draws a line', 'this study probably draws a line under', 'study probably draws a line under the', 'probably draws a line under the investigation', 'draws a line under the investigation of', 'a line under the investigation of mtor', 'line under the investigation of mtor (torc1/2)', 'under the investigation of mtor (torc1/2) in', 'the investigation of mtor (torc1/2) in rcc', 'investigation of mtor (torc1/2) in rcc and', 'of mtor (torc1/2) in rcc and draws', 'mtor (torc1/2) in rcc and draws a', '(torc1/2) in rcc and draws a line', 'in rcc and draws a line under', 'rcc and draws a line under adjuvant', 'and draws a line under adjuvant targeted', 'draws a line under adjuvant targeted therapies', 'a line under adjuvant targeted therapies in', 'line under adjuvant targeted therapies in rcc.', 'under adjuvant targeted therapies in rcc. everolimus', 'adjuvant targeted therapies in rcc. everolimus role', 'targeted therapies in rcc. everolimus role is', 'therapies in rcc. everolimus role is relatively', 'in rcc. everolimus role is relatively limited.', 'rcc. everolimus role is relatively limited. #asco22', 'everolimus role is relatively limited. #asco22 .', 'everolimus did not show a significant dfs or', 'did not show a significant dfs or os', 'not show a significant dfs or os advantage', 'show a significant dfs or os advantage in', 'a significant dfs or os advantage in adjuvant', 'significant dfs or os advantage in adjuvant rcc.', 'dfs or os advantage in adjuvant rcc. this', 'or os advantage in adjuvant rcc. this study', 'os advantage in adjuvant rcc. this study probably', 'advantage in adjuvant rcc. this study probably draws', 'in adjuvant rcc. this study probably draws a', 'adjuvant rcc. this study probably draws a line', 'rcc. this study probably draws a line under', 'this study probably draws a line under the', 'study probably draws a line under the investigation', 'probably draws a line under the investigation of', 'draws a line under the investigation of mtor', 'a line under the investigation of mtor (torc1/2)', 'line under the investigation of mtor (torc1/2) in', 'under the investigation of mtor (torc1/2) in rcc', 'the investigation of mtor (torc1/2) in rcc and', 'investigation of mtor (torc1/2) in rcc and draws', 'of mtor (torc1/2) in rcc and draws a', 'mtor (torc1/2) in rcc and draws a line', '(torc1/2) in rcc and draws a line under', 'in rcc and draws a line under adjuvant', 'rcc and draws a line under adjuvant targeted', 'and draws a line under adjuvant targeted therapies', 'draws a line under adjuvant targeted therapies in', 'a line under adjuvant targeted therapies in rcc.', 'line under adjuvant targeted therapies in rcc. everolimus', 'under adjuvant targeted therapies in rcc. everolimus role', 'adjuvant targeted therapies in rcc. everolimus role is', 'targeted therapies in rcc. everolimus role is relatively', 'therapies in rcc. everolimus role is relatively limited.', 'in rcc. everolimus role is relatively limited. #asco22', 'rcc. everolimus role is relatively limited. #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '44', 'tokens': ['"great', 'question', 'and', 'suggestion', 'by', 'dr.', 'appleman', 'for', 'possible', 'everest', '2', '-', 'isolate', 'to', 'high-risk', 'patients', 'with', 'pld1', 'negative/mtor', 'positive.', 'would', 'think', "that's", 'a', 'low', 'number', 'though', 'and', 'hard', 'to', 'accrue.', '#asco22', '#kidneycancer', '.'], 'text_length': 34, 'triples': {'everest|"great question and suggestion by dr. appleman for possible everest 2 - isolate to high-risk patients with pld1 negative/mtor positive. would think that\'s a low number though and hard': ([9, 9], [0, 28], 'neutral')}, 'sentence': '"great question and suggestion by dr. appleman for possible everest 2 - isolate to high-risk patients with pld1 negative/mtor positive. would think that\'s a low number though and hard to accrue. #asco22 #kidneycancer .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(9, 9)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 28)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['"great', 'question', 'and', 'suggestion', 'by', 'dr.', 'appleman', 'for', 'possible', 'everest', '2', '-', 'isolate', 'to', 'high-risk', 'patients', 'with', 'pld1', 'negative/mtor', 'positive.', 'would', 'think', "that's", 'a', 'low', 'number', 'though', 'and', 'hard', 'to', 'accrue.', '#asco22', '#kidneycancer', '.', '"great question', 'question and', 'and suggestion', 'suggestion by', 'by dr.', 'dr. appleman', 'appleman for', 'for possible', 'possible everest', 'everest 2', '2 -', '- isolate', 'isolate to', 'to high-risk', 'high-risk patients', 'patients with', 'with pld1', 'pld1 negative/mtor', 'negative/mtor positive.', 'positive. would', 'would think', "think that's", "that's a", 'a low', 'low number', 'number though', 'though and', 'and hard', 'hard to', 'to accrue.', 'accrue. #asco22', '#asco22 #kidneycancer', '#kidneycancer .', '"great question and', 'question and suggestion', 'and suggestion by', 'suggestion by dr.', 'by dr. appleman', 'dr. appleman for', 'appleman for possible', 'for possible everest', 'possible everest 2', 'everest 2 -', '2 - isolate', '- isolate to', 'isolate to high-risk', 'to high-risk patients', 'high-risk patients with', 'patients with pld1', 'with pld1 negative/mtor', 'pld1 negative/mtor positive.', 'negative/mtor positive. would', 'positive. would think', "would think that's", "think that's a", "that's a low", 'a low number', 'low number though', 'number though and', 'though and hard', 'and hard to', 'hard to accrue.', 'to accrue. #asco22', 'accrue. #asco22 #kidneycancer', '#asco22 #kidneycancer .', '"great question and suggestion', 'question and suggestion by', 'and suggestion by dr.', 'suggestion by dr. appleman', 'by dr. appleman for', 'dr. appleman for possible', 'appleman for possible everest', 'for possible everest 2', 'possible everest 2 -', 'everest 2 - isolate', '2 - isolate to', '- isolate to high-risk', 'isolate to high-risk patients', 'to high-risk patients with', 'high-risk patients with pld1', 'patients with pld1 negative/mtor', 'with pld1 negative/mtor positive.', 'pld1 negative/mtor positive. would', 'negative/mtor positive. would think', "positive. would think that's", "would think that's a", "think that's a low", "that's a low number", 'a low number though', 'low number though and', 'number though and hard', 'though and hard to', 'and hard to accrue.', 'hard to accrue. #asco22', 'to accrue. #asco22 #kidneycancer', 'accrue. #asco22 #kidneycancer .', '"great question and suggestion by', 'question and suggestion by dr.', 'and suggestion by dr. appleman', 'suggestion by dr. appleman for', 'by dr. appleman for possible', 'dr. appleman for possible everest', 'appleman for possible everest 2', 'for possible everest 2 -', 'possible everest 2 - isolate', 'everest 2 - isolate to', '2 - isolate to high-risk', '- isolate to high-risk patients', 'isolate to high-risk patients with', 'to high-risk patients with pld1', 'high-risk patients with pld1 negative/mtor', 'patients with pld1 negative/mtor positive.', 'with pld1 negative/mtor positive. would', 'pld1 negative/mtor positive. would think', "negative/mtor positive. would think that's", "positive. would think that's a", "would think that's a low", "think that's a low number", "that's a low number though", 'a low number though and', 'low number though and hard', 'number though and hard to', 'though and hard to accrue.', 'and hard to accrue. #asco22', 'hard to accrue. #asco22 #kidneycancer', 'to accrue. #asco22 #kidneycancer .', '"great question and suggestion by dr.', 'question and suggestion by dr. appleman', 'and suggestion by dr. appleman for', 'suggestion by dr. appleman for possible', 'by dr. appleman for possible everest', 'dr. appleman for possible everest 2', 'appleman for possible everest 2 -', 'for possible everest 2 - isolate', 'possible everest 2 - isolate to', 'everest 2 - isolate to high-risk', '2 - isolate to high-risk patients', '- isolate to high-risk patients with', 'isolate to high-risk patients with pld1', 'to high-risk patients with pld1 negative/mtor', 'high-risk patients with pld1 negative/mtor positive.', 'patients with pld1 negative/mtor positive. would', 'with pld1 negative/mtor positive. would think', "pld1 negative/mtor positive. would think that's", "negative/mtor positive. would think that's a", "positive. would think that's a low", "would think that's a low number", "think that's a low number though", "that's a low number though and", 'a low number though and hard', 'low number though and hard to', 'number though and hard to accrue.', 'though and hard to accrue. #asco22', 'and hard to accrue. #asco22 #kidneycancer', 'hard to accrue. #asco22 #kidneycancer .', '"great question and suggestion by dr. appleman', 'question and suggestion by dr. appleman for', 'and suggestion by dr. appleman for possible', 'suggestion by dr. appleman for possible everest', 'by dr. appleman for possible everest 2', 'dr. appleman for possible everest 2 -', 'appleman for possible everest 2 - isolate', 'for possible everest 2 - isolate to', 'possible everest 2 - isolate to high-risk', 'everest 2 - isolate to high-risk patients', '2 - isolate to high-risk patients with', '- isolate to high-risk patients with pld1', 'isolate to high-risk patients with pld1 negative/mtor', 'to high-risk patients with pld1 negative/mtor positive.', 'high-risk patients with pld1 negative/mtor positive. would', 'patients with pld1 negative/mtor positive. would think', "with pld1 negative/mtor positive. would think that's", "pld1 negative/mtor positive. would think that's a", "negative/mtor positive. would think that's a low", "positive. would think that's a low number", "would think that's a low number though", "think that's a low number though and", "that's a low number though and hard", 'a low number though and hard to', 'low number though and hard to accrue.', 'number though and hard to accrue. #asco22', 'though and hard to accrue. #asco22 #kidneycancer', 'and hard to accrue. #asco22 #kidneycancer .', '"great question and suggestion by dr. appleman for', 'question and suggestion by dr. appleman for possible', 'and suggestion by dr. appleman for possible everest', 'suggestion by dr. appleman for possible everest 2', 'by dr. appleman for possible everest 2 -', 'dr. appleman for possible everest 2 - isolate', 'appleman for possible everest 2 - isolate to', 'for possible everest 2 - isolate to high-risk', 'possible everest 2 - isolate to high-risk patients', 'everest 2 - isolate to high-risk patients with', '2 - isolate to high-risk patients with pld1', '- isolate to high-risk patients with pld1 negative/mtor', 'isolate to high-risk patients with pld1 negative/mtor positive.', 'to high-risk patients with pld1 negative/mtor positive. would', 'high-risk patients with pld1 negative/mtor positive. would think', "patients with pld1 negative/mtor positive. would think that's", "with pld1 negative/mtor positive. would think that's a", "pld1 negative/mtor positive. would think that's a low", "negative/mtor positive. would think that's a low number", "positive. would think that's a low number though", "would think that's a low number though and", "think that's a low number though and hard", "that's a low number though and hard to", 'a low number though and hard to accrue.', 'low number though and hard to accrue. #asco22', 'number though and hard to accrue. #asco22 #kidneycancer', 'though and hard to accrue. #asco22 #kidneycancer .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '45', 'tokens': ['adt', 'plus', 'abiraterone', 'improve', 'os', 'in', 'mhspc,', 'no', 'additional', 'benefit', 'of', 'combining', 'abiraterone', 'and', 'enzalutamide', 'for', 'mhspc.', '#esmo22', '#', 'stampede', '.'], 'text_length': 21, 'triples': {'#|improve os in mhspc, no additional benefit': ([18, 18], [3, 9], 'neutral'), 'enzalutamide|no additional benefit': ([14, 14], [7, 9], 'neutral')}, 'sentence': 'adt plus abiraterone improve os in mhspc, no additional benefit of combining abiraterone and enzalutamide for mhspc. #esmo22 # stampede .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(18, 18), (14, 14)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(3, 9), (7, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['adt', 'plus', 'abiraterone', 'improve', 'os', 'in', 'mhspc,', 'no', 'additional', 'benefit', 'of', 'combining', 'abiraterone', 'and', 'enzalutamide', 'for', 'mhspc.', '#esmo22', '#', 'stampede', '.', 'adt plus', 'plus abiraterone', 'abiraterone improve', 'improve os', 'os in', 'in mhspc,', 'mhspc, no', 'no additional', 'additional benefit', 'benefit of', 'of combining', 'combining abiraterone', 'abiraterone and', 'and enzalutamide', 'enzalutamide for', 'for mhspc.', 'mhspc. #esmo22', '#esmo22 #', '# stampede', 'stampede .', 'adt plus abiraterone', 'plus abiraterone improve', 'abiraterone improve os', 'improve os in', 'os in mhspc,', 'in mhspc, no', 'mhspc, no additional', 'no additional benefit', 'additional benefit of', 'benefit of combining', 'of combining abiraterone', 'combining abiraterone and', 'abiraterone and enzalutamide', 'and enzalutamide for', 'enzalutamide for mhspc.', 'for mhspc. #esmo22', 'mhspc. #esmo22 #', '#esmo22 # stampede', '# stampede .', 'adt plus abiraterone improve', 'plus abiraterone improve os', 'abiraterone improve os in', 'improve os in mhspc,', 'os in mhspc, no', 'in mhspc, no additional', 'mhspc, no additional benefit', 'no additional benefit of', 'additional benefit of combining', 'benefit of combining abiraterone', 'of combining abiraterone and', 'combining abiraterone and enzalutamide', 'abiraterone and enzalutamide for', 'and enzalutamide for mhspc.', 'enzalutamide for mhspc. #esmo22', 'for mhspc. #esmo22 #', 'mhspc. #esmo22 # stampede', '#esmo22 # stampede .', 'adt plus abiraterone improve os', 'plus abiraterone improve os in', 'abiraterone improve os in mhspc,', 'improve os in mhspc, no', 'os in mhspc, no additional', 'in mhspc, no additional benefit', 'mhspc, no additional benefit of', 'no additional benefit of combining', 'additional benefit of combining abiraterone', 'benefit of combining abiraterone and', 'of combining abiraterone and enzalutamide', 'combining abiraterone and enzalutamide for', 'abiraterone and enzalutamide for mhspc.', 'and enzalutamide for mhspc. #esmo22', 'enzalutamide for mhspc. #esmo22 #', 'for mhspc. #esmo22 # stampede', 'mhspc. #esmo22 # stampede .', 'adt plus abiraterone improve os in', 'plus abiraterone improve os in mhspc,', 'abiraterone improve os in mhspc, no', 'improve os in mhspc, no additional', 'os in mhspc, no additional benefit', 'in mhspc, no additional benefit of', 'mhspc, no additional benefit of combining', 'no additional benefit of combining abiraterone', 'additional benefit of combining abiraterone and', 'benefit of combining abiraterone and enzalutamide', 'of combining abiraterone and enzalutamide for', 'combining abiraterone and enzalutamide for mhspc.', 'abiraterone and enzalutamide for mhspc. #esmo22', 'and enzalutamide for mhspc. #esmo22 #', 'enzalutamide for mhspc. #esmo22 # stampede', 'for mhspc. #esmo22 # stampede .', 'adt plus abiraterone improve os in mhspc,', 'plus abiraterone improve os in mhspc, no', 'abiraterone improve os in mhspc, no additional', 'improve os in mhspc, no additional benefit', 'os in mhspc, no additional benefit of', 'in mhspc, no additional benefit of combining', 'mhspc, no additional benefit of combining abiraterone', 'no additional benefit of combining abiraterone and', 'additional benefit of combining abiraterone and enzalutamide', 'benefit of combining abiraterone and enzalutamide for', 'of combining abiraterone and enzalutamide for mhspc.', 'combining abiraterone and enzalutamide for mhspc. #esmo22', 'abiraterone and enzalutamide for mhspc. #esmo22 #', 'and enzalutamide for mhspc. #esmo22 # stampede', 'enzalutamide for mhspc. #esmo22 # stampede .', 'adt plus abiraterone improve os in mhspc, no', 'plus abiraterone improve os in mhspc, no additional', 'abiraterone improve os in mhspc, no additional benefit', 'improve os in mhspc, no additional benefit of', 'os in mhspc, no additional benefit of combining', 'in mhspc, no additional benefit of combining abiraterone', 'mhspc, no additional benefit of combining abiraterone and', 'no additional benefit of combining abiraterone and enzalutamide', 'additional benefit of combining abiraterone and enzalutamide for', 'benefit of combining abiraterone and enzalutamide for mhspc.', 'of combining abiraterone and enzalutamide for mhspc. #esmo22', 'combining abiraterone and enzalutamide for mhspc. #esmo22 #', 'abiraterone and enzalutamide for mhspc. #esmo22 # stampede', 'and enzalutamide for mhspc. #esmo22 # stampede .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '46', 'tokens': ['s0931', 'presented', 'at', '#asco22', 'by', 'dr.', 'ryan', ':', 'everolimus', 'vs', 'placebo', 'for', 'adjuvant', 'rcc.', '1400', 'pts,', '~400', 'sites;', 'tremendous', 'scale.', 'everolimus', 'used', 'less', 'frequently', 'in', 'mrcc', 'care', 'now', '(sometimes', 'paired', 'with', 'lenva', 'in', '3+l', 'setting).', 'pts', 'elig', 'w', 'variety', 'of', 't', 'stage/grade', '.'], 'text_length': 43, 'triples': {': everolimus vs placebo for adjuvant rcc. 1400 pts, ~400 sites; tremendous scale.|used less': ([7, 19], [21, 22], 'neutral')}, 'sentence': 's0931 presented at #asco22 by dr. ryan : everolimus vs placebo for adjuvant rcc. 1400 pts, ~400 sites; tremendous scale. everolimus used less frequently in mrcc care now (sometimes paired with lenva in 3+l setting). pts elig w variety of t stage/grade .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 19)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(21, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8)], 'span tokens': ['s0931', 'presented', 'at', '#asco22', 'by', 'dr.', 'ryan', ':', 'everolimus', 'vs', 'placebo', 'for', 'adjuvant', 'rcc.', '1400', 'pts,', '~400', 'sites;', 'tremendous', 'scale.', 'everolimus', 'used', 'less', 'frequently', 'in', 'mrcc', 'care', 'now', '(sometimes', 'paired', 'with', 'lenva', 'in', '3+l', 'setting).', 'pts', 'elig', 'w', 'variety', 'of', 't', 'stage/grade', '.', 's0931 presented', 'presented at', 'at #asco22', '#asco22 by', 'by dr.', 'dr. ryan', 'ryan :', ': everolimus', 'everolimus vs', 'vs placebo', 'placebo for', 'for adjuvant', 'adjuvant rcc.', 'rcc. 1400', '1400 pts,', 'pts, ~400', '~400 sites;', 'sites; tremendous', 'tremendous scale.', 'scale. everolimus', 'everolimus used', 'used less', 'less frequently', 'frequently in', 'in mrcc', 'mrcc care', 'care now', 'now (sometimes', '(sometimes paired', 'paired with', 'with lenva', 'lenva in', 'in 3+l', '3+l setting).', 'setting). pts', 'pts elig', 'elig w', 'w variety', 'variety of', 'of t', 't stage/grade', 'stage/grade .', 's0931 presented at', 'presented at #asco22', 'at #asco22 by', '#asco22 by dr.', 'by dr. ryan', 'dr. ryan :', 'ryan : everolimus', ': everolimus vs', 'everolimus vs placebo', 'vs placebo for', 'placebo for adjuvant', 'for adjuvant rcc.', 'adjuvant rcc. 1400', 'rcc. 1400 pts,', '1400 pts, ~400', 'pts, ~400 sites;', '~400 sites; tremendous', 'sites; tremendous scale.', 'tremendous scale. everolimus', 'scale. everolimus used', 'everolimus used less', 'used less frequently', 'less frequently in', 'frequently in mrcc', 'in mrcc care', 'mrcc care now', 'care now (sometimes', 'now (sometimes paired', '(sometimes paired with', 'paired with lenva', 'with lenva in', 'lenva in 3+l', 'in 3+l setting).', '3+l setting). pts', 'setting). pts elig', 'pts elig w', 'elig w variety', 'w variety of', 'variety of t', 'of t stage/grade', 't stage/grade .', 's0931 presented at #asco22', 'presented at #asco22 by', 'at #asco22 by dr.', '#asco22 by dr. ryan', 'by dr. ryan :', 'dr. ryan : everolimus', 'ryan : everolimus vs', ': everolimus vs placebo', 'everolimus vs placebo for', 'vs placebo for adjuvant', 'placebo for adjuvant rcc.', 'for adjuvant rcc. 1400', 'adjuvant rcc. 1400 pts,', 'rcc. 1400 pts, ~400', '1400 pts, ~400 sites;', 'pts, ~400 sites; tremendous', '~400 sites; tremendous scale.', 'sites; tremendous scale. everolimus', 'tremendous scale. everolimus used', 'scale. everolimus used less', 'everolimus used less frequently', 'used less frequently in', 'less frequently in mrcc', 'frequently in mrcc care', 'in mrcc care now', 'mrcc care now (sometimes', 'care now (sometimes paired', 'now (sometimes paired with', '(sometimes paired with lenva', 'paired with lenva in', 'with lenva in 3+l', 'lenva in 3+l setting).', 'in 3+l setting). pts', '3+l setting). pts elig', 'setting). pts elig w', 'pts elig w variety', 'elig w variety of', 'w variety of t', 'variety of t stage/grade', 'of t stage/grade .', 's0931 presented at #asco22 by', 'presented at #asco22 by dr.', 'at #asco22 by dr. ryan', '#asco22 by dr. ryan :', 'by dr. ryan : everolimus', 'dr. ryan : everolimus vs', 'ryan : everolimus vs placebo', ': everolimus vs placebo for', 'everolimus vs placebo for adjuvant', 'vs placebo for adjuvant rcc.', 'placebo for adjuvant rcc. 1400', 'for adjuvant rcc. 1400 pts,', 'adjuvant rcc. 1400 pts, ~400', 'rcc. 1400 pts, ~400 sites;', '1400 pts, ~400 sites; tremendous', 'pts, ~400 sites; tremendous scale.', '~400 sites; tremendous scale. everolimus', 'sites; tremendous scale. everolimus used', 'tremendous scale. everolimus used less', 'scale. everolimus used less frequently', 'everolimus used less frequently in', 'used less frequently in mrcc', 'less frequently in mrcc care', 'frequently in mrcc care now', 'in mrcc care now (sometimes', 'mrcc care now (sometimes paired', 'care now (sometimes paired with', 'now (sometimes paired with lenva', '(sometimes paired with lenva in', 'paired with lenva in 3+l', 'with lenva in 3+l setting).', 'lenva in 3+l setting). pts', 'in 3+l setting). pts elig', '3+l setting). pts elig w', 'setting). pts elig w variety', 'pts elig w variety of', 'elig w variety of t', 'w variety of t stage/grade', 'variety of t stage/grade .', 's0931 presented at #asco22 by dr.', 'presented at #asco22 by dr. ryan', 'at #asco22 by dr. ryan :', '#asco22 by dr. ryan : everolimus', 'by dr. ryan : everolimus vs', 'dr. ryan : everolimus vs placebo', 'ryan : everolimus vs placebo for', ': everolimus vs placebo for adjuvant', 'everolimus vs placebo for adjuvant rcc.', 'vs placebo for adjuvant rcc. 1400', 'placebo for adjuvant rcc. 1400 pts,', 'for adjuvant rcc. 1400 pts, ~400', 'adjuvant rcc. 1400 pts, ~400 sites;', 'rcc. 1400 pts, ~400 sites; tremendous', '1400 pts, ~400 sites; tremendous scale.', 'pts, ~400 sites; tremendous scale. everolimus', '~400 sites; tremendous scale. everolimus used', 'sites; tremendous scale. everolimus used less', 'tremendous scale. everolimus used less frequently', 'scale. everolimus used less frequently in', 'everolimus used less frequently in mrcc', 'used less frequently in mrcc care', 'less frequently in mrcc care now', 'frequently in mrcc care now (sometimes', 'in mrcc care now (sometimes paired', 'mrcc care now (sometimes paired with', 'care now (sometimes paired with lenva', 'now (sometimes paired with lenva in', '(sometimes paired with lenva in 3+l', 'paired with lenva in 3+l setting).', 'with lenva in 3+l setting). pts', 'lenva in 3+l setting). pts elig', 'in 3+l setting). pts elig w', '3+l setting). pts elig w variety', 'setting). pts elig w variety of', 'pts elig w variety of t', 'elig w variety of t stage/grade', 'w variety of t stage/grade .', 's0931 presented at #asco22 by dr. ryan', 'presented at #asco22 by dr. ryan :', 'at #asco22 by dr. ryan : everolimus', '#asco22 by dr. ryan : everolimus vs', 'by dr. ryan : everolimus vs placebo', 'dr. ryan : everolimus vs placebo for', 'ryan : everolimus vs placebo for adjuvant', ': everolimus vs placebo for adjuvant rcc.', 'everolimus vs placebo for adjuvant rcc. 1400', 'vs placebo for adjuvant rcc. 1400 pts,', 'placebo for adjuvant rcc. 1400 pts, ~400', 'for adjuvant rcc. 1400 pts, ~400 sites;', 'adjuvant rcc. 1400 pts, ~400 sites; tremendous', 'rcc. 1400 pts, ~400 sites; tremendous scale.', '1400 pts, ~400 sites; tremendous scale. everolimus', 'pts, ~400 sites; tremendous scale. everolimus used', '~400 sites; tremendous scale. everolimus used less', 'sites; tremendous scale. everolimus used less frequently', 'tremendous scale. everolimus used less frequently in', 'scale. everolimus used less frequently in mrcc', 'everolimus used less frequently in mrcc care', 'used less frequently in mrcc care now', 'less frequently in mrcc care now (sometimes', 'frequently in mrcc care now (sometimes paired', 'in mrcc care now (sometimes paired with', 'mrcc care now (sometimes paired with lenva', 'care now (sometimes paired with lenva in', 'now (sometimes paired with lenva in 3+l', '(sometimes paired with lenva in 3+l setting).', 'paired with lenva in 3+l setting). pts', 'with lenva in 3+l setting). pts elig', 'lenva in 3+l setting). pts elig w', 'in 3+l setting). pts elig w variety', '3+l setting). pts elig w variety of', 'setting). pts elig w variety of t', 'pts elig w variety of t stage/grade', 'elig w variety of t stage/grade .', 's0931 presented at #asco22 by dr. ryan :', 'presented at #asco22 by dr. ryan : everolimus', 'at #asco22 by dr. ryan : everolimus vs', '#asco22 by dr. ryan : everolimus vs placebo', 'by dr. ryan : everolimus vs placebo for', 'dr. ryan : everolimus vs placebo for adjuvant', 'ryan : everolimus vs placebo for adjuvant rcc.', ': everolimus vs placebo for adjuvant rcc. 1400', 'everolimus vs placebo for adjuvant rcc. 1400 pts,', 'vs placebo for adjuvant rcc. 1400 pts, ~400', 'placebo for adjuvant rcc. 1400 pts, ~400 sites;', 'for adjuvant rcc. 1400 pts, ~400 sites; tremendous', 'adjuvant rcc. 1400 pts, ~400 sites; tremendous scale.', 'rcc. 1400 pts, ~400 sites; tremendous scale. everolimus', '1400 pts, ~400 sites; tremendous scale. everolimus used', 'pts, ~400 sites; tremendous scale. everolimus used less', '~400 sites; tremendous scale. everolimus used less frequently', 'sites; tremendous scale. everolimus used less frequently in', 'tremendous scale. everolimus used less frequently in mrcc', 'scale. everolimus used less frequently in mrcc care', 'everolimus used less frequently in mrcc care now', 'used less frequently in mrcc care now (sometimes', 'less frequently in mrcc care now (sometimes paired', 'frequently in mrcc care now (sometimes paired with', 'in mrcc care now (sometimes paired with lenva', 'mrcc care now (sometimes paired with lenva in', 'care now (sometimes paired with lenva in 3+l', 'now (sometimes paired with lenva in 3+l setting).', '(sometimes paired with lenva in 3+l setting). pts', 'paired with lenva in 3+l setting). pts elig', 'with lenva in 3+l setting). pts elig w', 'lenva in 3+l setting). pts elig w variety', 'in 3+l setting). pts elig w variety of', '3+l setting). pts elig w variety of t', 'setting). pts elig w variety of t stage/grade', 'pts elig w variety of t stage/grade .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '47', 'tokens': ['*suvmean&gt;10', '.', 'similar', 'finding', 'presented', 'form', 'vision', 'trial', 'today', '#asco2022', '-&gt;', 'should', 'use', 'psma', 'suvmean', 'to', 'select', 'patients', 'for', '177lu-psma-617', '.', 'note', 'from', 'vision', '-', 'liver', 'mets', 'unsurprisingly', 'associated', 'with', 'worse', 'outcomes', '.'], 'text_length': 33, 'triples': {'form vision trial today #asco2022 -&gt; should use psma suvmean to select patients for 177lu-psma-617 . note|finding presented form vision trial': ([5, 21], [3, 7], 'negative'), 'for|finding presented form vision trial': ([18, 18], [3, 7], 'negative')}, 'sentence': '*suvmean&gt;10 . similar finding presented form vision trial today #asco2022 -&gt; should use psma suvmean to select patients for 177lu-psma-617 . note from vision - liver mets unsurprisingly associated with worse outcomes .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 21), (18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 1],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 1, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['*suvmean&gt;10', '.', 'similar', 'finding', 'presented', 'form', 'vision', 'trial', 'today', '#asco2022', '-&gt;', 'should', 'use', 'psma', 'suvmean', 'to', 'select', 'patients', 'for', '177lu-psma-617', '.', 'note', 'from', 'vision', '-', 'liver', 'mets', 'unsurprisingly', 'associated', 'with', 'worse', 'outcomes', '.', '*suvmean&gt;10 .', '. similar', 'similar finding', 'finding presented', 'presented form', 'form vision', 'vision trial', 'trial today', 'today #asco2022', '#asco2022 -&gt;', '-&gt; should', 'should use', 'use psma', 'psma suvmean', 'suvmean to', 'to select', 'select patients', 'patients for', 'for 177lu-psma-617', '177lu-psma-617 .', '. note', 'note from', 'from vision', 'vision -', '- liver', 'liver mets', 'mets unsurprisingly', 'unsurprisingly associated', 'associated with', 'with worse', 'worse outcomes', 'outcomes .', '*suvmean&gt;10 . similar', '. similar finding', 'similar finding presented', 'finding presented form', 'presented form vision', 'form vision trial', 'vision trial today', 'trial today #asco2022', 'today #asco2022 -&gt;', '#asco2022 -&gt; should', '-&gt; should use', 'should use psma', 'use psma suvmean', 'psma suvmean to', 'suvmean to select', 'to select patients', 'select patients for', 'patients for 177lu-psma-617', 'for 177lu-psma-617 .', '177lu-psma-617 . note', '. note from', 'note from vision', 'from vision -', 'vision - liver', '- liver mets', 'liver mets unsurprisingly', 'mets unsurprisingly associated', 'unsurprisingly associated with', 'associated with worse', 'with worse outcomes', 'worse outcomes .', '*suvmean&gt;10 . similar finding', '. similar finding presented', 'similar finding presented form', 'finding presented form vision', 'presented form vision trial', 'form vision trial today', 'vision trial today #asco2022', 'trial today #asco2022 -&gt;', 'today #asco2022 -&gt; should', '#asco2022 -&gt; should use', '-&gt; should use psma', 'should use psma suvmean', 'use psma suvmean to', 'psma suvmean to select', 'suvmean to select patients', 'to select patients for', 'select patients for 177lu-psma-617', 'patients for 177lu-psma-617 .', 'for 177lu-psma-617 . note', '177lu-psma-617 . note from', '. note from vision', 'note from vision -', 'from vision - liver', 'vision - liver mets', '- liver mets unsurprisingly', 'liver mets unsurprisingly associated', 'mets unsurprisingly associated with', 'unsurprisingly associated with worse', 'associated with worse outcomes', 'with worse outcomes .', '*suvmean&gt;10 . similar finding presented', '. similar finding presented form', 'similar finding presented form vision', 'finding presented form vision trial', 'presented form vision trial today', 'form vision trial today #asco2022', 'vision trial today #asco2022 -&gt;', 'trial today #asco2022 -&gt; should', 'today #asco2022 -&gt; should use', '#asco2022 -&gt; should use psma', '-&gt; should use psma suvmean', 'should use psma suvmean to', 'use psma suvmean to select', 'psma suvmean to select patients', 'suvmean to select patients for', 'to select patients for 177lu-psma-617', 'select patients for 177lu-psma-617 .', 'patients for 177lu-psma-617 . note', 'for 177lu-psma-617 . note from', '177lu-psma-617 . note from vision', '. note from vision -', 'note from vision - liver', 'from vision - liver mets', 'vision - liver mets unsurprisingly', '- liver mets unsurprisingly associated', 'liver mets unsurprisingly associated with', 'mets unsurprisingly associated with worse', 'unsurprisingly associated with worse outcomes', 'associated with worse outcomes .', '*suvmean&gt;10 . similar finding presented form', '. similar finding presented form vision', 'similar finding presented form vision trial', 'finding presented form vision trial today', 'presented form vision trial today #asco2022', 'form vision trial today #asco2022 -&gt;', 'vision trial today #asco2022 -&gt; should', 'trial today #asco2022 -&gt; should use', 'today #asco2022 -&gt; should use psma', '#asco2022 -&gt; should use psma suvmean', '-&gt; should use psma suvmean to', 'should use psma suvmean to select', 'use psma suvmean to select patients', 'psma suvmean to select patients for', 'suvmean to select patients for 177lu-psma-617', 'to select patients for 177lu-psma-617 .', 'select patients for 177lu-psma-617 . note', 'patients for 177lu-psma-617 . note from', 'for 177lu-psma-617 . note from vision', '177lu-psma-617 . note from vision -', '. note from vision - liver', 'note from vision - liver mets', 'from vision - liver mets unsurprisingly', 'vision - liver mets unsurprisingly associated', '- liver mets unsurprisingly associated with', 'liver mets unsurprisingly associated with worse', 'mets unsurprisingly associated with worse outcomes', 'unsurprisingly associated with worse outcomes .', '*suvmean&gt;10 . similar finding presented form vision', '. similar finding presented form vision trial', 'similar finding presented form vision trial today', 'finding presented form vision trial today #asco2022', 'presented form vision trial today #asco2022 -&gt;', 'form vision trial today #asco2022 -&gt; should', 'vision trial today #asco2022 -&gt; should use', 'trial today #asco2022 -&gt; should use psma', 'today #asco2022 -&gt; should use psma suvmean', '#asco2022 -&gt; should use psma suvmean to', '-&gt; should use psma suvmean to select', 'should use psma suvmean to select patients', 'use psma suvmean to select patients for', 'psma suvmean to select patients for 177lu-psma-617', 'suvmean to select patients for 177lu-psma-617 .', 'to select patients for 177lu-psma-617 . note', 'select patients for 177lu-psma-617 . note from', 'patients for 177lu-psma-617 . note from vision', 'for 177lu-psma-617 . note from vision -', '177lu-psma-617 . note from vision - liver', '. note from vision - liver mets', 'note from vision - liver mets unsurprisingly', 'from vision - liver mets unsurprisingly associated', 'vision - liver mets unsurprisingly associated with', '- liver mets unsurprisingly associated with worse', 'liver mets unsurprisingly associated with worse outcomes', 'mets unsurprisingly associated with worse outcomes .', '*suvmean&gt;10 . similar finding presented form vision trial', '. similar finding presented form vision trial today', 'similar finding presented form vision trial today #asco2022', 'finding presented form vision trial today #asco2022 -&gt;', 'presented form vision trial today #asco2022 -&gt; should', 'form vision trial today #asco2022 -&gt; should use', 'vision trial today #asco2022 -&gt; should use psma', 'trial today #asco2022 -&gt; should use psma suvmean', 'today #asco2022 -&gt; should use psma suvmean to', '#asco2022 -&gt; should use psma suvmean to select', '-&gt; should use psma suvmean to select patients', 'should use psma suvmean to select patients for', 'use psma suvmean to select patients for 177lu-psma-617', 'psma suvmean to select patients for 177lu-psma-617 .', 'suvmean to select patients for 177lu-psma-617 . note', 'to select patients for 177lu-psma-617 . note from', 'select patients for 177lu-psma-617 . note from vision', 'patients for 177lu-psma-617 . note from vision -', 'for 177lu-psma-617 . note from vision - liver', '177lu-psma-617 . note from vision - liver mets', '. note from vision - liver mets unsurprisingly', 'note from vision - liver mets unsurprisingly associated', 'from vision - liver mets unsurprisingly associated with', 'vision - liver mets unsurprisingly associated with worse', '- liver mets unsurprisingly associated with worse outcomes', 'liver mets unsurprisingly associated with worse outcomes .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '48', 'tokens': ['incredible', 'data', 'presented', 'by', 'from', 's1801', 'in', 'operable', 'melanoma', 'with', 'neoadjuvant', 'vs.', 'adjuvant', 'pembrolizumab', 'at', '#esmo22', '.'], 'text_length': 17, 'triples': {'s1801|incredible': ([5, 5], [0, 0], 'positive'), 'pembrolizumab|incredible': ([13, 13], [0, 0], 'positive')}, 'sentence': 'incredible data presented by from s1801 in operable melanoma with neoadjuvant vs. adjuvant pembrolizumab at #esmo22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 5), (13, 13)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8)], 'span tokens': ['incredible', 'data', 'presented', 'by', 'from', 's1801', 'in', 'operable', 'melanoma', 'with', 'neoadjuvant', 'vs.', 'adjuvant', 'pembrolizumab', 'at', '#esmo22', '.', 'incredible data', 'data presented', 'presented by', 'by from', 'from s1801', 's1801 in', 'in operable', 'operable melanoma', 'melanoma with', 'with neoadjuvant', 'neoadjuvant vs.', 'vs. adjuvant', 'adjuvant pembrolizumab', 'pembrolizumab at', 'at #esmo22', '#esmo22 .', 'incredible data presented', 'data presented by', 'presented by from', 'by from s1801', 'from s1801 in', 's1801 in operable', 'in operable melanoma', 'operable melanoma with', 'melanoma with neoadjuvant', 'with neoadjuvant vs.', 'neoadjuvant vs. adjuvant', 'vs. adjuvant pembrolizumab', 'adjuvant pembrolizumab at', 'pembrolizumab at #esmo22', 'at #esmo22 .', 'incredible data presented by', 'data presented by from', 'presented by from s1801', 'by from s1801 in', 'from s1801 in operable', 's1801 in operable melanoma', 'in operable melanoma with', 'operable melanoma with neoadjuvant', 'melanoma with neoadjuvant vs.', 'with neoadjuvant vs. adjuvant', 'neoadjuvant vs. adjuvant pembrolizumab', 'vs. adjuvant pembrolizumab at', 'adjuvant pembrolizumab at #esmo22', 'pembrolizumab at #esmo22 .', 'incredible data presented by from', 'data presented by from s1801', 'presented by from s1801 in', 'by from s1801 in operable', 'from s1801 in operable melanoma', 's1801 in operable melanoma with', 'in operable melanoma with neoadjuvant', 'operable melanoma with neoadjuvant vs.', 'melanoma with neoadjuvant vs. adjuvant', 'with neoadjuvant vs. adjuvant pembrolizumab', 'neoadjuvant vs. adjuvant pembrolizumab at', 'vs. adjuvant pembrolizumab at #esmo22', 'adjuvant pembrolizumab at #esmo22 .', 'incredible data presented by from s1801', 'data presented by from s1801 in', 'presented by from s1801 in operable', 'by from s1801 in operable melanoma', 'from s1801 in operable melanoma with', 's1801 in operable melanoma with neoadjuvant', 'in operable melanoma with neoadjuvant vs.', 'operable melanoma with neoadjuvant vs. adjuvant', 'melanoma with neoadjuvant vs. adjuvant pembrolizumab', 'with neoadjuvant vs. adjuvant pembrolizumab at', 'neoadjuvant vs. adjuvant pembrolizumab at #esmo22', 'vs. adjuvant pembrolizumab at #esmo22 .', 'incredible data presented by from s1801 in', 'data presented by from s1801 in operable', 'presented by from s1801 in operable melanoma', 'by from s1801 in operable melanoma with', 'from s1801 in operable melanoma with neoadjuvant', 's1801 in operable melanoma with neoadjuvant vs.', 'in operable melanoma with neoadjuvant vs. adjuvant', 'operable melanoma with neoadjuvant vs. adjuvant pembrolizumab', 'melanoma with neoadjuvant vs. adjuvant pembrolizumab at', 'with neoadjuvant vs. adjuvant pembrolizumab at #esmo22', 'neoadjuvant vs. adjuvant pembrolizumab at #esmo22 .', 'incredible data presented by from s1801 in operable', 'data presented by from s1801 in operable melanoma', 'presented by from s1801 in operable melanoma with', 'by from s1801 in operable melanoma with neoadjuvant', 'from s1801 in operable melanoma with neoadjuvant vs.', 's1801 in operable melanoma with neoadjuvant vs. adjuvant', 'in operable melanoma with neoadjuvant vs. adjuvant pembrolizumab', 'operable melanoma with neoadjuvant vs. adjuvant pembrolizumab at', 'melanoma with neoadjuvant vs. adjuvant pembrolizumab at #esmo22', 'with neoadjuvant vs. adjuvant pembrolizumab at #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '49', 'tokens': ['pivotal', 'ide-cel', 'trial.', 'cilta-cell', 'trial.', 'cart', 'providing', 'strong', 'pfs', 'and', 'orr,', 'improved', 'os.', '#ash22', '#mmsm', '#myeloma', '.'], 'text_length': 17, 'triples': {'ide-cel|strong pfs and orr, improved': ([1, 1], [7, 11], 'positive'), 'cilta-cell|strong pfs and orr, improved': ([3, 3], [7, 11], 'positive')}, 'sentence': 'pivotal ide-cel trial. cilta-cell trial. cart providing strong pfs and orr, improved os. #ash22 #mmsm #myeloma .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(1, 1), (3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8)], 'span tokens': ['pivotal', 'ide-cel', 'trial.', 'cilta-cell', 'trial.', 'cart', 'providing', 'strong', 'pfs', 'and', 'orr,', 'improved', 'os.', '#ash22', '#mmsm', '#myeloma', '.', 'pivotal ide-cel', 'ide-cel trial.', 'trial. cilta-cell', 'cilta-cell trial.', 'trial. cart', 'cart providing', 'providing strong', 'strong pfs', 'pfs and', 'and orr,', 'orr, improved', 'improved os.', 'os. #ash22', '#ash22 #mmsm', '#mmsm #myeloma', '#myeloma .', 'pivotal ide-cel trial.', 'ide-cel trial. cilta-cell', 'trial. cilta-cell trial.', 'cilta-cell trial. cart', 'trial. cart providing', 'cart providing strong', 'providing strong pfs', 'strong pfs and', 'pfs and orr,', 'and orr, improved', 'orr, improved os.', 'improved os. #ash22', 'os. #ash22 #mmsm', '#ash22 #mmsm #myeloma', '#mmsm #myeloma .', 'pivotal ide-cel trial. cilta-cell', 'ide-cel trial. cilta-cell trial.', 'trial. cilta-cell trial. cart', 'cilta-cell trial. cart providing', 'trial. cart providing strong', 'cart providing strong pfs', 'providing strong pfs and', 'strong pfs and orr,', 'pfs and orr, improved', 'and orr, improved os.', 'orr, improved os. #ash22', 'improved os. #ash22 #mmsm', 'os. #ash22 #mmsm #myeloma', '#ash22 #mmsm #myeloma .', 'pivotal ide-cel trial. cilta-cell trial.', 'ide-cel trial. cilta-cell trial. cart', 'trial. cilta-cell trial. cart providing', 'cilta-cell trial. cart providing strong', 'trial. cart providing strong pfs', 'cart providing strong pfs and', 'providing strong pfs and orr,', 'strong pfs and orr, improved', 'pfs and orr, improved os.', 'and orr, improved os. #ash22', 'orr, improved os. #ash22 #mmsm', 'improved os. #ash22 #mmsm #myeloma', 'os. #ash22 #mmsm #myeloma .', 'pivotal ide-cel trial. cilta-cell trial. cart', 'ide-cel trial. cilta-cell trial. cart providing', 'trial. cilta-cell trial. cart providing strong', 'cilta-cell trial. cart providing strong pfs', 'trial. cart providing strong pfs and', 'cart providing strong pfs and orr,', 'providing strong pfs and orr, improved', 'strong pfs and orr, improved os.', 'pfs and orr, improved os. #ash22', 'and orr, improved os. #ash22 #mmsm', 'orr, improved os. #ash22 #mmsm #myeloma', 'improved os. #ash22 #mmsm #myeloma .', 'pivotal ide-cel trial. cilta-cell trial. cart providing', 'ide-cel trial. cilta-cell trial. cart providing strong', 'trial. cilta-cell trial. cart providing strong pfs', 'cilta-cell trial. cart providing strong pfs and', 'trial. cart providing strong pfs and orr,', 'cart providing strong pfs and orr, improved', 'providing strong pfs and orr, improved os.', 'strong pfs and orr, improved os. #ash22', 'pfs and orr, improved os. #ash22 #mmsm', 'and orr, improved os. #ash22 #mmsm #myeloma', 'orr, improved os. #ash22 #mmsm #myeloma .', 'pivotal ide-cel trial. cilta-cell trial. cart providing strong', 'ide-cel trial. cilta-cell trial. cart providing strong pfs', 'trial. cilta-cell trial. cart providing strong pfs and', 'cilta-cell trial. cart providing strong pfs and orr,', 'trial. cart providing strong pfs and orr, improved', 'cart providing strong pfs and orr, improved os.', 'providing strong pfs and orr, improved os. #ash22', 'strong pfs and orr, improved os. #ash22 #mmsm', 'pfs and orr, improved os. #ash22 #mmsm #myeloma', 'and orr, improved os. #ash22 #mmsm #myeloma .'], 'spans_aspect_label': [0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '50', 'tokens': ['nice', 'data', 'from', 'stampede', 'at', '#esmo22', 'showing', 'benefits', 'of', 'docetaxel', 'only', 'in', 'bone', 'metastatic', 'hspc', 'not', 'node', 'only', 'mets,', 'but', 'benefit', 'of', 'abiraterone', 'in', 'both', 'groups.', 'clinically', 'relevant!', '.'], 'text_length': 29, 'triples': {'stampede|nice data from stampede at #esmo22 showing benefits': ([3, 3], [0, 7], 'positive')}, 'sentence': 'nice data from stampede at #esmo22 showing benefits of docetaxel only in bone metastatic hspc not node only mets, but benefit of abiraterone in both groups. clinically relevant! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8)], 'span tokens': ['nice', 'data', 'from', 'stampede', 'at', '#esmo22', 'showing', 'benefits', 'of', 'docetaxel', 'only', 'in', 'bone', 'metastatic', 'hspc', 'not', 'node', 'only', 'mets,', 'but', 'benefit', 'of', 'abiraterone', 'in', 'both', 'groups.', 'clinically', 'relevant!', '.', 'nice data', 'data from', 'from stampede', 'stampede at', 'at #esmo22', '#esmo22 showing', 'showing benefits', 'benefits of', 'of docetaxel', 'docetaxel only', 'only in', 'in bone', 'bone metastatic', 'metastatic hspc', 'hspc not', 'not node', 'node only', 'only mets,', 'mets, but', 'but benefit', 'benefit of', 'of abiraterone', 'abiraterone in', 'in both', 'both groups.', 'groups. clinically', 'clinically relevant!', 'relevant! .', 'nice data from', 'data from stampede', 'from stampede at', 'stampede at #esmo22', 'at #esmo22 showing', '#esmo22 showing benefits', 'showing benefits of', 'benefits of docetaxel', 'of docetaxel only', 'docetaxel only in', 'only in bone', 'in bone metastatic', 'bone metastatic hspc', 'metastatic hspc not', 'hspc not node', 'not node only', 'node only mets,', 'only mets, but', 'mets, but benefit', 'but benefit of', 'benefit of abiraterone', 'of abiraterone in', 'abiraterone in both', 'in both groups.', 'both groups. clinically', 'groups. clinically relevant!', 'clinically relevant! .', 'nice data from stampede', 'data from stampede at', 'from stampede at #esmo22', 'stampede at #esmo22 showing', 'at #esmo22 showing benefits', '#esmo22 showing benefits of', 'showing benefits of docetaxel', 'benefits of docetaxel only', 'of docetaxel only in', 'docetaxel only in bone', 'only in bone metastatic', 'in bone metastatic hspc', 'bone metastatic hspc not', 'metastatic hspc not node', 'hspc not node only', 'not node only mets,', 'node only mets, but', 'only mets, but benefit', 'mets, but benefit of', 'but benefit of abiraterone', 'benefit of abiraterone in', 'of abiraterone in both', 'abiraterone in both groups.', 'in both groups. clinically', 'both groups. clinically relevant!', 'groups. clinically relevant! .', 'nice data from stampede at', 'data from stampede at #esmo22', 'from stampede at #esmo22 showing', 'stampede at #esmo22 showing benefits', 'at #esmo22 showing benefits of', '#esmo22 showing benefits of docetaxel', 'showing benefits of docetaxel only', 'benefits of docetaxel only in', 'of docetaxel only in bone', 'docetaxel only in bone metastatic', 'only in bone metastatic hspc', 'in bone metastatic hspc not', 'bone metastatic hspc not node', 'metastatic hspc not node only', 'hspc not node only mets,', 'not node only mets, but', 'node only mets, but benefit', 'only mets, but benefit of', 'mets, but benefit of abiraterone', 'but benefit of abiraterone in', 'benefit of abiraterone in both', 'of abiraterone in both groups.', 'abiraterone in both groups. clinically', 'in both groups. clinically relevant!', 'both groups. clinically relevant! .', 'nice data from stampede at #esmo22', 'data from stampede at #esmo22 showing', 'from stampede at #esmo22 showing benefits', 'stampede at #esmo22 showing benefits of', 'at #esmo22 showing benefits of docetaxel', '#esmo22 showing benefits of docetaxel only', 'showing benefits of docetaxel only in', 'benefits of docetaxel only in bone', 'of docetaxel only in bone metastatic', 'docetaxel only in bone metastatic hspc', 'only in bone metastatic hspc not', 'in bone metastatic hspc not node', 'bone metastatic hspc not node only', 'metastatic hspc not node only mets,', 'hspc not node only mets, but', 'not node only mets, but benefit', 'node only mets, but benefit of', 'only mets, but benefit of abiraterone', 'mets, but benefit of abiraterone in', 'but benefit of abiraterone in both', 'benefit of abiraterone in both groups.', 'of abiraterone in both groups. clinically', 'abiraterone in both groups. clinically relevant!', 'in both groups. clinically relevant! .', 'nice data from stampede at #esmo22 showing', 'data from stampede at #esmo22 showing benefits', 'from stampede at #esmo22 showing benefits of', 'stampede at #esmo22 showing benefits of docetaxel', 'at #esmo22 showing benefits of docetaxel only', '#esmo22 showing benefits of docetaxel only in', 'showing benefits of docetaxel only in bone', 'benefits of docetaxel only in bone metastatic', 'of docetaxel only in bone metastatic hspc', 'docetaxel only in bone metastatic hspc not', 'only in bone metastatic hspc not node', 'in bone metastatic hspc not node only', 'bone metastatic hspc not node only mets,', 'metastatic hspc not node only mets, but', 'hspc not node only mets, but benefit', 'not node only mets, but benefit of', 'node only mets, but benefit of abiraterone', 'only mets, but benefit of abiraterone in', 'mets, but benefit of abiraterone in both', 'but benefit of abiraterone in both groups.', 'benefit of abiraterone in both groups. clinically', 'of abiraterone in both groups. clinically relevant!', 'abiraterone in both groups. clinically relevant! .', 'nice data from stampede at #esmo22 showing benefits', 'data from stampede at #esmo22 showing benefits of', 'from stampede at #esmo22 showing benefits of docetaxel', 'stampede at #esmo22 showing benefits of docetaxel only', 'at #esmo22 showing benefits of docetaxel only in', '#esmo22 showing benefits of docetaxel only in bone', 'showing benefits of docetaxel only in bone metastatic', 'benefits of docetaxel only in bone metastatic hspc', 'of docetaxel only in bone metastatic hspc not', 'docetaxel only in bone metastatic hspc not node', 'only in bone metastatic hspc not node only', 'in bone metastatic hspc not node only mets,', 'bone metastatic hspc not node only mets, but', 'metastatic hspc not node only mets, but benefit', 'hspc not node only mets, but benefit of', 'not node only mets, but benefit of abiraterone', 'node only mets, but benefit of abiraterone in', 'only mets, but benefit of abiraterone in both', 'mets, but benefit of abiraterone in both groups.', 'but benefit of abiraterone in both groups. clinically', 'benefit of abiraterone in both groups. clinically relevant!', 'of abiraterone in both groups. clinically relevant! .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '51', 'tokens': ['i', 'found', 'this', 'result', 'a', 'little', 'perplexing-', 'in', 'context', 'of', 'absence', 'of', '177lu-psma-617', '+', 'in', 'bone', 'portending', 'improved', 'os', 'in', 'prostate', 'cancer', '.', '.'], 'text_length': 24, 'triples': {'177lu-psma-617|improved os': ([12, 12], [17, 18], 'positive')}, 'sentence': 'i found this result a little perplexing- in context of absence of 177lu-psma-617 + in bone portending improved os in prostate cancer . .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 18)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8)], 'span tokens': ['i', 'found', 'this', 'result', 'a', 'little', 'perplexing-', 'in', 'context', 'of', 'absence', 'of', '177lu-psma-617', '+', 'in', 'bone', 'portending', 'improved', 'os', 'in', 'prostate', 'cancer', '.', '.', 'i found', 'found this', 'this result', 'result a', 'a little', 'little perplexing-', 'perplexing- in', 'in context', 'context of', 'of absence', 'absence of', 'of 177lu-psma-617', '177lu-psma-617 +', '+ in', 'in bone', 'bone portending', 'portending improved', 'improved os', 'os in', 'in prostate', 'prostate cancer', 'cancer .', '. .', 'i found this', 'found this result', 'this result a', 'result a little', 'a little perplexing-', 'little perplexing- in', 'perplexing- in context', 'in context of', 'context of absence', 'of absence of', 'absence of 177lu-psma-617', 'of 177lu-psma-617 +', '177lu-psma-617 + in', '+ in bone', 'in bone portending', 'bone portending improved', 'portending improved os', 'improved os in', 'os in prostate', 'in prostate cancer', 'prostate cancer .', 'cancer . .', 'i found this result', 'found this result a', 'this result a little', 'result a little perplexing-', 'a little perplexing- in', 'little perplexing- in context', 'perplexing- in context of', 'in context of absence', 'context of absence of', 'of absence of 177lu-psma-617', 'absence of 177lu-psma-617 +', 'of 177lu-psma-617 + in', '177lu-psma-617 + in bone', '+ in bone portending', 'in bone portending improved', 'bone portending improved os', 'portending improved os in', 'improved os in prostate', 'os in prostate cancer', 'in prostate cancer .', 'prostate cancer . .', 'i found this result a', 'found this result a little', 'this result a little perplexing-', 'result a little perplexing- in', 'a little perplexing- in context', 'little perplexing- in context of', 'perplexing- in context of absence', 'in context of absence of', 'context of absence of 177lu-psma-617', 'of absence of 177lu-psma-617 +', 'absence of 177lu-psma-617 + in', 'of 177lu-psma-617 + in bone', '177lu-psma-617 + in bone portending', '+ in bone portending improved', 'in bone portending improved os', 'bone portending improved os in', 'portending improved os in prostate', 'improved os in prostate cancer', 'os in prostate cancer .', 'in prostate cancer . .', 'i found this result a little', 'found this result a little perplexing-', 'this result a little perplexing- in', 'result a little perplexing- in context', 'a little perplexing- in context of', 'little perplexing- in context of absence', 'perplexing- in context of absence of', 'in context of absence of 177lu-psma-617', 'context of absence of 177lu-psma-617 +', 'of absence of 177lu-psma-617 + in', 'absence of 177lu-psma-617 + in bone', 'of 177lu-psma-617 + in bone portending', '177lu-psma-617 + in bone portending improved', '+ in bone portending improved os', 'in bone portending improved os in', 'bone portending improved os in prostate', 'portending improved os in prostate cancer', 'improved os in prostate cancer .', 'os in prostate cancer . .', 'i found this result a little perplexing-', 'found this result a little perplexing- in', 'this result a little perplexing- in context', 'result a little perplexing- in context of', 'a little perplexing- in context of absence', 'little perplexing- in context of absence of', 'perplexing- in context of absence of 177lu-psma-617', 'in context of absence of 177lu-psma-617 +', 'context of absence of 177lu-psma-617 + in', 'of absence of 177lu-psma-617 + in bone', 'absence of 177lu-psma-617 + in bone portending', 'of 177lu-psma-617 + in bone portending improved', '177lu-psma-617 + in bone portending improved os', '+ in bone portending improved os in', 'in bone portending improved os in prostate', 'bone portending improved os in prostate cancer', 'portending improved os in prostate cancer .', 'improved os in prostate cancer . .', 'i found this result a little perplexing- in', 'found this result a little perplexing- in context', 'this result a little perplexing- in context of', 'result a little perplexing- in context of absence', 'a little perplexing- in context of absence of', 'little perplexing- in context of absence of 177lu-psma-617', 'perplexing- in context of absence of 177lu-psma-617 +', 'in context of absence of 177lu-psma-617 + in', 'context of absence of 177lu-psma-617 + in bone', 'of absence of 177lu-psma-617 + in bone portending', 'absence of 177lu-psma-617 + in bone portending improved', 'of 177lu-psma-617 + in bone portending improved os', '177lu-psma-617 + in bone portending improved os in', '+ in bone portending improved os in prostate', 'in bone portending improved os in prostate cancer', 'bone portending improved os in prostate cancer .', 'portending improved os in prostate cancer . .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '52', 'tokens': ['stampede', ':', 'comparison', 'of', 'aap', 'vs', 'aap', '+', 'enza', 'for', 'mhspc', 'os:', 'aap', '+', 'enza', 'trial', '(hr', '0.65,', '95%', 'ci', '0.55', '0.77);', 'aap', 'trial', '(hr', '0.62,', '95%', 'ci', '0.53-0.73)', '7', 'yrs', 'f/u', 'aap', 'trial', '-', 'rmst:', '50.4', 'mos', 'adt', 'vs', '60.6', 'mos', 'adt+aap', '(p&lt;0.001)', 'enza+aap:', 'should', 'not', 'be', 'combined', 'for', 'mhspc', '#esmo22', '.'], 'text_length': 53, 'triples': {'stampede|should not be': ([0, 0], [45, 47], 'neutral')}, 'sentence': 'stampede : comparison of aap vs aap + enza for mhspc os: aap + enza trial (hr 0.65, 95% ci 0.55 0.77); aap trial (hr 0.62, 95% ci 0.53-0.73) 7 yrs f/u aap trial - rmst: 50.4 mos adt vs 60.6 mos adt+aap (p&lt;0.001) enza+aap: should not be combined for mhspc #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(45, 47)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (52, 52, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (51, 52, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (50, 52, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (49, 52, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (48, 52, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (47, 52, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (46, 52, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8), (45, 52, 8)], 'span tokens': ['stampede', ':', 'comparison', 'of', 'aap', 'vs', 'aap', '+', 'enza', 'for', 'mhspc', 'os:', 'aap', '+', 'enza', 'trial', '(hr', '0.65,', '95%', 'ci', '0.55', '0.77);', 'aap', 'trial', '(hr', '0.62,', '95%', 'ci', '0.53-0.73)', '7', 'yrs', 'f/u', 'aap', 'trial', '-', 'rmst:', '50.4', 'mos', 'adt', 'vs', '60.6', 'mos', 'adt+aap', '(p&lt;0.001)', 'enza+aap:', 'should', 'not', 'be', 'combined', 'for', 'mhspc', '#esmo22', '.', 'stampede :', ': comparison', 'comparison of', 'of aap', 'aap vs', 'vs aap', 'aap +', '+ enza', 'enza for', 'for mhspc', 'mhspc os:', 'os: aap', 'aap +', '+ enza', 'enza trial', 'trial (hr', '(hr 0.65,', '0.65, 95%', '95% ci', 'ci 0.55', '0.55 0.77);', '0.77); aap', 'aap trial', 'trial (hr', '(hr 0.62,', '0.62, 95%', '95% ci', 'ci 0.53-0.73)', '0.53-0.73) 7', '7 yrs', 'yrs f/u', 'f/u aap', 'aap trial', 'trial -', '- rmst:', 'rmst: 50.4', '50.4 mos', 'mos adt', 'adt vs', 'vs 60.6', '60.6 mos', 'mos adt+aap', 'adt+aap (p&lt;0.001)', '(p&lt;0.001) enza+aap:', 'enza+aap: should', 'should not', 'not be', 'be combined', 'combined for', 'for mhspc', 'mhspc #esmo22', '#esmo22 .', 'stampede : comparison', ': comparison of', 'comparison of aap', 'of aap vs', 'aap vs aap', 'vs aap +', 'aap + enza', '+ enza for', 'enza for mhspc', 'for mhspc os:', 'mhspc os: aap', 'os: aap +', 'aap + enza', '+ enza trial', 'enza trial (hr', 'trial (hr 0.65,', '(hr 0.65, 95%', '0.65, 95% ci', '95% ci 0.55', 'ci 0.55 0.77);', '0.55 0.77); aap', '0.77); aap trial', 'aap trial (hr', 'trial (hr 0.62,', '(hr 0.62, 95%', '0.62, 95% ci', '95% ci 0.53-0.73)', 'ci 0.53-0.73) 7', '0.53-0.73) 7 yrs', '7 yrs f/u', 'yrs f/u aap', 'f/u aap trial', 'aap trial -', 'trial - rmst:', '- rmst: 50.4', 'rmst: 50.4 mos', '50.4 mos adt', 'mos adt vs', 'adt vs 60.6', 'vs 60.6 mos', '60.6 mos adt+aap', 'mos adt+aap (p&lt;0.001)', 'adt+aap (p&lt;0.001) enza+aap:', '(p&lt;0.001) enza+aap: should', 'enza+aap: should not', 'should not be', 'not be combined', 'be combined for', 'combined for mhspc', 'for mhspc #esmo22', 'mhspc #esmo22 .', 'stampede : comparison of', ': comparison of aap', 'comparison of aap vs', 'of aap vs aap', 'aap vs aap +', 'vs aap + enza', 'aap + enza for', '+ enza for mhspc', 'enza for mhspc os:', 'for mhspc os: aap', 'mhspc os: aap +', 'os: aap + enza', 'aap + enza trial', '+ enza trial (hr', 'enza trial (hr 0.65,', 'trial (hr 0.65, 95%', '(hr 0.65, 95% ci', '0.65, 95% ci 0.55', '95% ci 0.55 0.77);', 'ci 0.55 0.77); aap', '0.55 0.77); aap trial', '0.77); aap trial (hr', 'aap trial (hr 0.62,', 'trial (hr 0.62, 95%', '(hr 0.62, 95% ci', '0.62, 95% ci 0.53-0.73)', '95% ci 0.53-0.73) 7', 'ci 0.53-0.73) 7 yrs', '0.53-0.73) 7 yrs f/u', '7 yrs f/u aap', 'yrs f/u aap trial', 'f/u aap trial -', 'aap trial - rmst:', 'trial - rmst: 50.4', '- rmst: 50.4 mos', 'rmst: 50.4 mos adt', '50.4 mos adt vs', 'mos adt vs 60.6', 'adt vs 60.6 mos', 'vs 60.6 mos adt+aap', '60.6 mos adt+aap (p&lt;0.001)', 'mos adt+aap (p&lt;0.001) enza+aap:', 'adt+aap (p&lt;0.001) enza+aap: should', '(p&lt;0.001) enza+aap: should not', 'enza+aap: should not be', 'should not be combined', 'not be combined for', 'be combined for mhspc', 'combined for mhspc #esmo22', 'for mhspc #esmo22 .', 'stampede : comparison of aap', ': comparison of aap vs', 'comparison of aap vs aap', 'of aap vs aap +', 'aap vs aap + enza', 'vs aap + enza for', 'aap + enza for mhspc', '+ enza for mhspc os:', 'enza for mhspc os: aap', 'for mhspc os: aap +', 'mhspc os: aap + enza', 'os: aap + enza trial', 'aap + enza trial (hr', '+ enza trial (hr 0.65,', 'enza trial (hr 0.65, 95%', 'trial (hr 0.65, 95% ci', '(hr 0.65, 95% ci 0.55', '0.65, 95% ci 0.55 0.77);', '95% ci 0.55 0.77); aap', 'ci 0.55 0.77); aap trial', '0.55 0.77); aap trial (hr', '0.77); aap trial (hr 0.62,', 'aap trial (hr 0.62, 95%', 'trial (hr 0.62, 95% ci', '(hr 0.62, 95% ci 0.53-0.73)', '0.62, 95% ci 0.53-0.73) 7', '95% ci 0.53-0.73) 7 yrs', 'ci 0.53-0.73) 7 yrs f/u', '0.53-0.73) 7 yrs f/u aap', '7 yrs f/u aap trial', 'yrs f/u aap trial -', 'f/u aap trial - rmst:', 'aap trial - rmst: 50.4', 'trial - rmst: 50.4 mos', '- rmst: 50.4 mos adt', 'rmst: 50.4 mos adt vs', '50.4 mos adt vs 60.6', 'mos adt vs 60.6 mos', 'adt vs 60.6 mos adt+aap', 'vs 60.6 mos adt+aap (p&lt;0.001)', '60.6 mos adt+aap (p&lt;0.001) enza+aap:', 'mos adt+aap (p&lt;0.001) enza+aap: should', 'adt+aap (p&lt;0.001) enza+aap: should not', '(p&lt;0.001) enza+aap: should not be', 'enza+aap: should not be combined', 'should not be combined for', 'not be combined for mhspc', 'be combined for mhspc #esmo22', 'combined for mhspc #esmo22 .', 'stampede : comparison of aap vs', ': comparison of aap vs aap', 'comparison of aap vs aap +', 'of aap vs aap + enza', 'aap vs aap + enza for', 'vs aap + enza for mhspc', 'aap + enza for mhspc os:', '+ enza for mhspc os: aap', 'enza for mhspc os: aap +', 'for mhspc os: aap + enza', 'mhspc os: aap + enza trial', 'os: aap + enza trial (hr', 'aap + enza trial (hr 0.65,', '+ enza trial (hr 0.65, 95%', 'enza trial (hr 0.65, 95% ci', 'trial (hr 0.65, 95% ci 0.55', '(hr 0.65, 95% ci 0.55 0.77);', '0.65, 95% ci 0.55 0.77); aap', '95% ci 0.55 0.77); aap trial', 'ci 0.55 0.77); aap trial (hr', '0.55 0.77); aap trial (hr 0.62,', '0.77); aap trial (hr 0.62, 95%', 'aap trial (hr 0.62, 95% ci', 'trial (hr 0.62, 95% ci 0.53-0.73)', '(hr 0.62, 95% ci 0.53-0.73) 7', '0.62, 95% ci 0.53-0.73) 7 yrs', '95% ci 0.53-0.73) 7 yrs f/u', 'ci 0.53-0.73) 7 yrs f/u aap', '0.53-0.73) 7 yrs f/u aap trial', '7 yrs f/u aap trial -', 'yrs f/u aap trial - rmst:', 'f/u aap trial - rmst: 50.4', 'aap trial - rmst: 50.4 mos', 'trial - rmst: 50.4 mos adt', '- rmst: 50.4 mos adt vs', 'rmst: 50.4 mos adt vs 60.6', '50.4 mos adt vs 60.6 mos', 'mos adt vs 60.6 mos adt+aap', 'adt vs 60.6 mos adt+aap (p&lt;0.001)', 'vs 60.6 mos adt+aap (p&lt;0.001) enza+aap:', '60.6 mos adt+aap (p&lt;0.001) enza+aap: should', 'mos adt+aap (p&lt;0.001) enza+aap: should not', 'adt+aap (p&lt;0.001) enza+aap: should not be', '(p&lt;0.001) enza+aap: should not be combined', 'enza+aap: should not be combined for', 'should not be combined for mhspc', 'not be combined for mhspc #esmo22', 'be combined for mhspc #esmo22 .', 'stampede : comparison of aap vs aap', ': comparison of aap vs aap +', 'comparison of aap vs aap + enza', 'of aap vs aap + enza for', 'aap vs aap + enza for mhspc', 'vs aap + enza for mhspc os:', 'aap + enza for mhspc os: aap', '+ enza for mhspc os: aap +', 'enza for mhspc os: aap + enza', 'for mhspc os: aap + enza trial', 'mhspc os: aap + enza trial (hr', 'os: aap + enza trial (hr 0.65,', 'aap + enza trial (hr 0.65, 95%', '+ enza trial (hr 0.65, 95% ci', 'enza trial (hr 0.65, 95% ci 0.55', 'trial (hr 0.65, 95% ci 0.55 0.77);', '(hr 0.65, 95% ci 0.55 0.77); aap', '0.65, 95% ci 0.55 0.77); aap trial', '95% ci 0.55 0.77); aap trial (hr', 'ci 0.55 0.77); aap trial (hr 0.62,', '0.55 0.77); aap trial (hr 0.62, 95%', '0.77); aap trial (hr 0.62, 95% ci', 'aap trial (hr 0.62, 95% ci 0.53-0.73)', 'trial (hr 0.62, 95% ci 0.53-0.73) 7', '(hr 0.62, 95% ci 0.53-0.73) 7 yrs', '0.62, 95% ci 0.53-0.73) 7 yrs f/u', '95% ci 0.53-0.73) 7 yrs f/u aap', 'ci 0.53-0.73) 7 yrs f/u aap trial', '0.53-0.73) 7 yrs f/u aap trial -', '7 yrs f/u aap trial - rmst:', 'yrs f/u aap trial - rmst: 50.4', 'f/u aap trial - rmst: 50.4 mos', 'aap trial - rmst: 50.4 mos adt', 'trial - rmst: 50.4 mos adt vs', '- rmst: 50.4 mos adt vs 60.6', 'rmst: 50.4 mos adt vs 60.6 mos', '50.4 mos adt vs 60.6 mos adt+aap', 'mos adt vs 60.6 mos adt+aap (p&lt;0.001)', 'adt vs 60.6 mos adt+aap (p&lt;0.001) enza+aap:', 'vs 60.6 mos adt+aap (p&lt;0.001) enza+aap: should', '60.6 mos adt+aap (p&lt;0.001) enza+aap: should not', 'mos adt+aap (p&lt;0.001) enza+aap: should not be', 'adt+aap (p&lt;0.001) enza+aap: should not be combined', '(p&lt;0.001) enza+aap: should not be combined for', 'enza+aap: should not be combined for mhspc', 'should not be combined for mhspc #esmo22', 'not be combined for mhspc #esmo22 .', 'stampede : comparison of aap vs aap +', ': comparison of aap vs aap + enza', 'comparison of aap vs aap + enza for', 'of aap vs aap + enza for mhspc', 'aap vs aap + enza for mhspc os:', 'vs aap + enza for mhspc os: aap', 'aap + enza for mhspc os: aap +', '+ enza for mhspc os: aap + enza', 'enza for mhspc os: aap + enza trial', 'for mhspc os: aap + enza trial (hr', 'mhspc os: aap + enza trial (hr 0.65,', 'os: aap + enza trial (hr 0.65, 95%', 'aap + enza trial (hr 0.65, 95% ci', '+ enza trial (hr 0.65, 95% ci 0.55', 'enza trial (hr 0.65, 95% ci 0.55 0.77);', 'trial (hr 0.65, 95% ci 0.55 0.77); aap', '(hr 0.65, 95% ci 0.55 0.77); aap trial', '0.65, 95% ci 0.55 0.77); aap trial (hr', '95% ci 0.55 0.77); aap trial (hr 0.62,', 'ci 0.55 0.77); aap trial (hr 0.62, 95%', '0.55 0.77); aap trial (hr 0.62, 95% ci', '0.77); aap trial (hr 0.62, 95% ci 0.53-0.73)', 'aap trial (hr 0.62, 95% ci 0.53-0.73) 7', 'trial (hr 0.62, 95% ci 0.53-0.73) 7 yrs', '(hr 0.62, 95% ci 0.53-0.73) 7 yrs f/u', '0.62, 95% ci 0.53-0.73) 7 yrs f/u aap', '95% ci 0.53-0.73) 7 yrs f/u aap trial', 'ci 0.53-0.73) 7 yrs f/u aap trial -', '0.53-0.73) 7 yrs f/u aap trial - rmst:', '7 yrs f/u aap trial - rmst: 50.4', 'yrs f/u aap trial - rmst: 50.4 mos', 'f/u aap trial - rmst: 50.4 mos adt', 'aap trial - rmst: 50.4 mos adt vs', 'trial - rmst: 50.4 mos adt vs 60.6', '- rmst: 50.4 mos adt vs 60.6 mos', 'rmst: 50.4 mos adt vs 60.6 mos adt+aap', '50.4 mos adt vs 60.6 mos adt+aap (p&lt;0.001)', 'mos adt vs 60.6 mos adt+aap (p&lt;0.001) enza+aap:', 'adt vs 60.6 mos adt+aap (p&lt;0.001) enza+aap: should', 'vs 60.6 mos adt+aap (p&lt;0.001) enza+aap: should not', '60.6 mos adt+aap (p&lt;0.001) enza+aap: should not be', 'mos adt+aap (p&lt;0.001) enza+aap: should not be combined', 'adt+aap (p&lt;0.001) enza+aap: should not be combined for', '(p&lt;0.001) enza+aap: should not be combined for mhspc', 'enza+aap: should not be combined for mhspc #esmo22', 'should not be combined for mhspc #esmo22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '53', 'tokens': ['#asco22', 'better', 'than', 'expected', 'outcome', 'for', 'everolimus', 'in', 'the', 'adjuvant', 'setting', 'of', 'all', 'histologies', 'rcc', 'pts.', 'congrats', 'to', 'the', 'authors', 'would', 'love', 'to', 'see', 'translational', 'data', 'related', 'to', 'pi3k', 'pathway', 'and', 'outcomes', '.'], 'text_length': 33, 'triples': {'everolimus|better than expected': ([6, 6], [1, 3], 'positive')}, 'sentence': '#asco22 better than expected outcome for everolimus in the adjuvant setting of all histologies rcc pts. congrats to the authors would love to see translational data related to pi3k pathway and outcomes .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['#asco22', 'better', 'than', 'expected', 'outcome', 'for', 'everolimus', 'in', 'the', 'adjuvant', 'setting', 'of', 'all', 'histologies', 'rcc', 'pts.', 'congrats', 'to', 'the', 'authors', 'would', 'love', 'to', 'see', 'translational', 'data', 'related', 'to', 'pi3k', 'pathway', 'and', 'outcomes', '.', '#asco22 better', 'better than', 'than expected', 'expected outcome', 'outcome for', 'for everolimus', 'everolimus in', 'in the', 'the adjuvant', 'adjuvant setting', 'setting of', 'of all', 'all histologies', 'histologies rcc', 'rcc pts.', 'pts. congrats', 'congrats to', 'to the', 'the authors', 'authors would', 'would love', 'love to', 'to see', 'see translational', 'translational data', 'data related', 'related to', 'to pi3k', 'pi3k pathway', 'pathway and', 'and outcomes', 'outcomes .', '#asco22 better than', 'better than expected', 'than expected outcome', 'expected outcome for', 'outcome for everolimus', 'for everolimus in', 'everolimus in the', 'in the adjuvant', 'the adjuvant setting', 'adjuvant setting of', 'setting of all', 'of all histologies', 'all histologies rcc', 'histologies rcc pts.', 'rcc pts. congrats', 'pts. congrats to', 'congrats to the', 'to the authors', 'the authors would', 'authors would love', 'would love to', 'love to see', 'to see translational', 'see translational data', 'translational data related', 'data related to', 'related to pi3k', 'to pi3k pathway', 'pi3k pathway and', 'pathway and outcomes', 'and outcomes .', '#asco22 better than expected', 'better than expected outcome', 'than expected outcome for', 'expected outcome for everolimus', 'outcome for everolimus in', 'for everolimus in the', 'everolimus in the adjuvant', 'in the adjuvant setting', 'the adjuvant setting of', 'adjuvant setting of all', 'setting of all histologies', 'of all histologies rcc', 'all histologies rcc pts.', 'histologies rcc pts. congrats', 'rcc pts. congrats to', 'pts. congrats to the', 'congrats to the authors', 'to the authors would', 'the authors would love', 'authors would love to', 'would love to see', 'love to see translational', 'to see translational data', 'see translational data related', 'translational data related to', 'data related to pi3k', 'related to pi3k pathway', 'to pi3k pathway and', 'pi3k pathway and outcomes', 'pathway and outcomes .', '#asco22 better than expected outcome', 'better than expected outcome for', 'than expected outcome for everolimus', 'expected outcome for everolimus in', 'outcome for everolimus in the', 'for everolimus in the adjuvant', 'everolimus in the adjuvant setting', 'in the adjuvant setting of', 'the adjuvant setting of all', 'adjuvant setting of all histologies', 'setting of all histologies rcc', 'of all histologies rcc pts.', 'all histologies rcc pts. congrats', 'histologies rcc pts. congrats to', 'rcc pts. congrats to the', 'pts. congrats to the authors', 'congrats to the authors would', 'to the authors would love', 'the authors would love to', 'authors would love to see', 'would love to see translational', 'love to see translational data', 'to see translational data related', 'see translational data related to', 'translational data related to pi3k', 'data related to pi3k pathway', 'related to pi3k pathway and', 'to pi3k pathway and outcomes', 'pi3k pathway and outcomes .', '#asco22 better than expected outcome for', 'better than expected outcome for everolimus', 'than expected outcome for everolimus in', 'expected outcome for everolimus in the', 'outcome for everolimus in the adjuvant', 'for everolimus in the adjuvant setting', 'everolimus in the adjuvant setting of', 'in the adjuvant setting of all', 'the adjuvant setting of all histologies', 'adjuvant setting of all histologies rcc', 'setting of all histologies rcc pts.', 'of all histologies rcc pts. congrats', 'all histologies rcc pts. congrats to', 'histologies rcc pts. congrats to the', 'rcc pts. congrats to the authors', 'pts. congrats to the authors would', 'congrats to the authors would love', 'to the authors would love to', 'the authors would love to see', 'authors would love to see translational', 'would love to see translational data', 'love to see translational data related', 'to see translational data related to', 'see translational data related to pi3k', 'translational data related to pi3k pathway', 'data related to pi3k pathway and', 'related to pi3k pathway and outcomes', 'to pi3k pathway and outcomes .', '#asco22 better than expected outcome for everolimus', 'better than expected outcome for everolimus in', 'than expected outcome for everolimus in the', 'expected outcome for everolimus in the adjuvant', 'outcome for everolimus in the adjuvant setting', 'for everolimus in the adjuvant setting of', 'everolimus in the adjuvant setting of all', 'in the adjuvant setting of all histologies', 'the adjuvant setting of all histologies rcc', 'adjuvant setting of all histologies rcc pts.', 'setting of all histologies rcc pts. congrats', 'of all histologies rcc pts. congrats to', 'all histologies rcc pts. congrats to the', 'histologies rcc pts. congrats to the authors', 'rcc pts. congrats to the authors would', 'pts. congrats to the authors would love', 'congrats to the authors would love to', 'to the authors would love to see', 'the authors would love to see translational', 'authors would love to see translational data', 'would love to see translational data related', 'love to see translational data related to', 'to see translational data related to pi3k', 'see translational data related to pi3k pathway', 'translational data related to pi3k pathway and', 'data related to pi3k pathway and outcomes', 'related to pi3k pathway and outcomes .', '#asco22 better than expected outcome for everolimus in', 'better than expected outcome for everolimus in the', 'than expected outcome for everolimus in the adjuvant', 'expected outcome for everolimus in the adjuvant setting', 'outcome for everolimus in the adjuvant setting of', 'for everolimus in the adjuvant setting of all', 'everolimus in the adjuvant setting of all histologies', 'in the adjuvant setting of all histologies rcc', 'the adjuvant setting of all histologies rcc pts.', 'adjuvant setting of all histologies rcc pts. congrats', 'setting of all histologies rcc pts. congrats to', 'of all histologies rcc pts. congrats to the', 'all histologies rcc pts. congrats to the authors', 'histologies rcc pts. congrats to the authors would', 'rcc pts. congrats to the authors would love', 'pts. congrats to the authors would love to', 'congrats to the authors would love to see', 'to the authors would love to see translational', 'the authors would love to see translational data', 'authors would love to see translational data related', 'would love to see translational data related to', 'love to see translational data related to pi3k', 'to see translational data related to pi3k pathway', 'see translational data related to pi3k pathway and', 'translational data related to pi3k pathway and outcomes', 'data related to pi3k pathway and outcomes .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '54', 'tokens': ['all', 'subgroups', 'based', 'on', 'prior', 'or', 'concurrent', 'treatment', 'appear', 'to', 'derive', 'similar', 'benefit', 'from', 'lutetium', 'psma', '#asco2022', '#pcsm', 'in', 'vision', 'trial', '.'], 'text_length': 22, 'triples': {'vision|appear to derive similar benefit': ([19, 19], [8, 12], 'neutral')}, 'sentence': 'all subgroups based on prior or concurrent treatment appear to derive similar benefit from lutetium psma #asco2022 #pcsm in vision trial .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(19, 19)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(8, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['all', 'subgroups', 'based', 'on', 'prior', 'or', 'concurrent', 'treatment', 'appear', 'to', 'derive', 'similar', 'benefit', 'from', 'lutetium', 'psma', '#asco2022', '#pcsm', 'in', 'vision', 'trial', '.', 'all subgroups', 'subgroups based', 'based on', 'on prior', 'prior or', 'or concurrent', 'concurrent treatment', 'treatment appear', 'appear to', 'to derive', 'derive similar', 'similar benefit', 'benefit from', 'from lutetium', 'lutetium psma', 'psma #asco2022', '#asco2022 #pcsm', '#pcsm in', 'in vision', 'vision trial', 'trial .', 'all subgroups based', 'subgroups based on', 'based on prior', 'on prior or', 'prior or concurrent', 'or concurrent treatment', 'concurrent treatment appear', 'treatment appear to', 'appear to derive', 'to derive similar', 'derive similar benefit', 'similar benefit from', 'benefit from lutetium', 'from lutetium psma', 'lutetium psma #asco2022', 'psma #asco2022 #pcsm', '#asco2022 #pcsm in', '#pcsm in vision', 'in vision trial', 'vision trial .', 'all subgroups based on', 'subgroups based on prior', 'based on prior or', 'on prior or concurrent', 'prior or concurrent treatment', 'or concurrent treatment appear', 'concurrent treatment appear to', 'treatment appear to derive', 'appear to derive similar', 'to derive similar benefit', 'derive similar benefit from', 'similar benefit from lutetium', 'benefit from lutetium psma', 'from lutetium psma #asco2022', 'lutetium psma #asco2022 #pcsm', 'psma #asco2022 #pcsm in', '#asco2022 #pcsm in vision', '#pcsm in vision trial', 'in vision trial .', 'all subgroups based on prior', 'subgroups based on prior or', 'based on prior or concurrent', 'on prior or concurrent treatment', 'prior or concurrent treatment appear', 'or concurrent treatment appear to', 'concurrent treatment appear to derive', 'treatment appear to derive similar', 'appear to derive similar benefit', 'to derive similar benefit from', 'derive similar benefit from lutetium', 'similar benefit from lutetium psma', 'benefit from lutetium psma #asco2022', 'from lutetium psma #asco2022 #pcsm', 'lutetium psma #asco2022 #pcsm in', 'psma #asco2022 #pcsm in vision', '#asco2022 #pcsm in vision trial', '#pcsm in vision trial .', 'all subgroups based on prior or', 'subgroups based on prior or concurrent', 'based on prior or concurrent treatment', 'on prior or concurrent treatment appear', 'prior or concurrent treatment appear to', 'or concurrent treatment appear to derive', 'concurrent treatment appear to derive similar', 'treatment appear to derive similar benefit', 'appear to derive similar benefit from', 'to derive similar benefit from lutetium', 'derive similar benefit from lutetium psma', 'similar benefit from lutetium psma #asco2022', 'benefit from lutetium psma #asco2022 #pcsm', 'from lutetium psma #asco2022 #pcsm in', 'lutetium psma #asco2022 #pcsm in vision', 'psma #asco2022 #pcsm in vision trial', '#asco2022 #pcsm in vision trial .', 'all subgroups based on prior or concurrent', 'subgroups based on prior or concurrent treatment', 'based on prior or concurrent treatment appear', 'on prior or concurrent treatment appear to', 'prior or concurrent treatment appear to derive', 'or concurrent treatment appear to derive similar', 'concurrent treatment appear to derive similar benefit', 'treatment appear to derive similar benefit from', 'appear to derive similar benefit from lutetium', 'to derive similar benefit from lutetium psma', 'derive similar benefit from lutetium psma #asco2022', 'similar benefit from lutetium psma #asco2022 #pcsm', 'benefit from lutetium psma #asco2022 #pcsm in', 'from lutetium psma #asco2022 #pcsm in vision', 'lutetium psma #asco2022 #pcsm in vision trial', 'psma #asco2022 #pcsm in vision trial .', 'all subgroups based on prior or concurrent treatment', 'subgroups based on prior or concurrent treatment appear', 'based on prior or concurrent treatment appear to', 'on prior or concurrent treatment appear to derive', 'prior or concurrent treatment appear to derive similar', 'or concurrent treatment appear to derive similar benefit', 'concurrent treatment appear to derive similar benefit from', 'treatment appear to derive similar benefit from lutetium', 'appear to derive similar benefit from lutetium psma', 'to derive similar benefit from lutetium psma #asco2022', 'derive similar benefit from lutetium psma #asco2022 #pcsm', 'similar benefit from lutetium psma #asco2022 #pcsm in', 'benefit from lutetium psma #asco2022 #pcsm in vision', 'from lutetium psma #asco2022 #pcsm in vision trial', 'lutetium psma #asco2022 #pcsm in vision trial .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '55', 'tokens': ['"vision:', 'among', 'men', 'with', 'psma-positive', 'mcrpc', 'on', 'pet/ct', 'treated', 'with', '177lu-psma-617', ',', 'a', 'higher', 'suvmean', 'was', 'associated', 'with', 'improved', 'long-term', 'clinical', 'outcomes', '#asco22', '.'], 'text_length': 24, 'triples': {'"vision:|with improved long-term clinical': ([0, 0], [17, 20], 'positive'), '177lu-psma-617|with improved long-term clinical': ([10, 10], [17, 20], 'positive')}, 'sentence': '"vision: among men with psma-positive mcrpc on pet/ct treated with 177lu-psma-617 , a higher suvmean was associated with improved long-term clinical outcomes #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8)], 'span tokens': ['"vision:', 'among', 'men', 'with', 'psma-positive', 'mcrpc', 'on', 'pet/ct', 'treated', 'with', '177lu-psma-617', ',', 'a', 'higher', 'suvmean', 'was', 'associated', 'with', 'improved', 'long-term', 'clinical', 'outcomes', '#asco22', '.', '"vision: among', 'among men', 'men with', 'with psma-positive', 'psma-positive mcrpc', 'mcrpc on', 'on pet/ct', 'pet/ct treated', 'treated with', 'with 177lu-psma-617', '177lu-psma-617 ,', ', a', 'a higher', 'higher suvmean', 'suvmean was', 'was associated', 'associated with', 'with improved', 'improved long-term', 'long-term clinical', 'clinical outcomes', 'outcomes #asco22', '#asco22 .', '"vision: among men', 'among men with', 'men with psma-positive', 'with psma-positive mcrpc', 'psma-positive mcrpc on', 'mcrpc on pet/ct', 'on pet/ct treated', 'pet/ct treated with', 'treated with 177lu-psma-617', 'with 177lu-psma-617 ,', '177lu-psma-617 , a', ', a higher', 'a higher suvmean', 'higher suvmean was', 'suvmean was associated', 'was associated with', 'associated with improved', 'with improved long-term', 'improved long-term clinical', 'long-term clinical outcomes', 'clinical outcomes #asco22', 'outcomes #asco22 .', '"vision: among men with', 'among men with psma-positive', 'men with psma-positive mcrpc', 'with psma-positive mcrpc on', 'psma-positive mcrpc on pet/ct', 'mcrpc on pet/ct treated', 'on pet/ct treated with', 'pet/ct treated with 177lu-psma-617', 'treated with 177lu-psma-617 ,', 'with 177lu-psma-617 , a', '177lu-psma-617 , a higher', ', a higher suvmean', 'a higher suvmean was', 'higher suvmean was associated', 'suvmean was associated with', 'was associated with improved', 'associated with improved long-term', 'with improved long-term clinical', 'improved long-term clinical outcomes', 'long-term clinical outcomes #asco22', 'clinical outcomes #asco22 .', '"vision: among men with psma-positive', 'among men with psma-positive mcrpc', 'men with psma-positive mcrpc on', 'with psma-positive mcrpc on pet/ct', 'psma-positive mcrpc on pet/ct treated', 'mcrpc on pet/ct treated with', 'on pet/ct treated with 177lu-psma-617', 'pet/ct treated with 177lu-psma-617 ,', 'treated with 177lu-psma-617 , a', 'with 177lu-psma-617 , a higher', '177lu-psma-617 , a higher suvmean', ', a higher suvmean was', 'a higher suvmean was associated', 'higher suvmean was associated with', 'suvmean was associated with improved', 'was associated with improved long-term', 'associated with improved long-term clinical', 'with improved long-term clinical outcomes', 'improved long-term clinical outcomes #asco22', 'long-term clinical outcomes #asco22 .', '"vision: among men with psma-positive mcrpc', 'among men with psma-positive mcrpc on', 'men with psma-positive mcrpc on pet/ct', 'with psma-positive mcrpc on pet/ct treated', 'psma-positive mcrpc on pet/ct treated with', 'mcrpc on pet/ct treated with 177lu-psma-617', 'on pet/ct treated with 177lu-psma-617 ,', 'pet/ct treated with 177lu-psma-617 , a', 'treated with 177lu-psma-617 , a higher', 'with 177lu-psma-617 , a higher suvmean', '177lu-psma-617 , a higher suvmean was', ', a higher suvmean was associated', 'a higher suvmean was associated with', 'higher suvmean was associated with improved', 'suvmean was associated with improved long-term', 'was associated with improved long-term clinical', 'associated with improved long-term clinical outcomes', 'with improved long-term clinical outcomes #asco22', 'improved long-term clinical outcomes #asco22 .', '"vision: among men with psma-positive mcrpc on', 'among men with psma-positive mcrpc on pet/ct', 'men with psma-positive mcrpc on pet/ct treated', 'with psma-positive mcrpc on pet/ct treated with', 'psma-positive mcrpc on pet/ct treated with 177lu-psma-617', 'mcrpc on pet/ct treated with 177lu-psma-617 ,', 'on pet/ct treated with 177lu-psma-617 , a', 'pet/ct treated with 177lu-psma-617 , a higher', 'treated with 177lu-psma-617 , a higher suvmean', 'with 177lu-psma-617 , a higher suvmean was', '177lu-psma-617 , a higher suvmean was associated', ', a higher suvmean was associated with', 'a higher suvmean was associated with improved', 'higher suvmean was associated with improved long-term', 'suvmean was associated with improved long-term clinical', 'was associated with improved long-term clinical outcomes', 'associated with improved long-term clinical outcomes #asco22', 'with improved long-term clinical outcomes #asco22 .', '"vision: among men with psma-positive mcrpc on pet/ct', 'among men with psma-positive mcrpc on pet/ct treated', 'men with psma-positive mcrpc on pet/ct treated with', 'with psma-positive mcrpc on pet/ct treated with 177lu-psma-617', 'psma-positive mcrpc on pet/ct treated with 177lu-psma-617 ,', 'mcrpc on pet/ct treated with 177lu-psma-617 , a', 'on pet/ct treated with 177lu-psma-617 , a higher', 'pet/ct treated with 177lu-psma-617 , a higher suvmean', 'treated with 177lu-psma-617 , a higher suvmean was', 'with 177lu-psma-617 , a higher suvmean was associated', '177lu-psma-617 , a higher suvmean was associated with', ', a higher suvmean was associated with improved', 'a higher suvmean was associated with improved long-term', 'higher suvmean was associated with improved long-term clinical', 'suvmean was associated with improved long-term clinical outcomes', 'was associated with improved long-term clinical outcomes #asco22', 'associated with improved long-term clinical outcomes #asco22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '56', 'tokens': ['delivering', 'an', 'outstanding', 'presentation', 'in', 'the', 'presidential', 'symposium', 'at', '#esmo22!', 'thanks', 'to', 'all', 'of', 'the', 'patients', 'and', 'the', 'codebreak-200', 'team', 'of', 'investigators', '-', 'ph', 'iii', 'proving', 'sotorasib', 'pfs', 'efficacy', 'over', 'docetaxel', '(hr', '0.66)', 'in', 'patients', 'with', 'refractory', 'g12c', 'nsclc.', '.'], 'text_length': 40, 'triples': {'codebreak-200|outstanding': ([18, 18], [2, 2], 'positive')}, 'sentence': 'delivering an outstanding presentation in the presidential symposium at #esmo22! thanks to all of the patients and the codebreak-200 team of investigators - ph iii proving sotorasib pfs efficacy over docetaxel (hr 0.66) in patients with refractory g12c nsclc. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8)], 'span tokens': ['delivering', 'an', 'outstanding', 'presentation', 'in', 'the', 'presidential', 'symposium', 'at', '#esmo22!', 'thanks', 'to', 'all', 'of', 'the', 'patients', 'and', 'the', 'codebreak-200', 'team', 'of', 'investigators', '-', 'ph', 'iii', 'proving', 'sotorasib', 'pfs', 'efficacy', 'over', 'docetaxel', '(hr', '0.66)', 'in', 'patients', 'with', 'refractory', 'g12c', 'nsclc.', '.', 'delivering an', 'an outstanding', 'outstanding presentation', 'presentation in', 'in the', 'the presidential', 'presidential symposium', 'symposium at', 'at #esmo22!', '#esmo22! thanks', 'thanks to', 'to all', 'all of', 'of the', 'the patients', 'patients and', 'and the', 'the codebreak-200', 'codebreak-200 team', 'team of', 'of investigators', 'investigators -', '- ph', 'ph iii', 'iii proving', 'proving sotorasib', 'sotorasib pfs', 'pfs efficacy', 'efficacy over', 'over docetaxel', 'docetaxel (hr', '(hr 0.66)', '0.66) in', 'in patients', 'patients with', 'with refractory', 'refractory g12c', 'g12c nsclc.', 'nsclc. .', 'delivering an outstanding', 'an outstanding presentation', 'outstanding presentation in', 'presentation in the', 'in the presidential', 'the presidential symposium', 'presidential symposium at', 'symposium at #esmo22!', 'at #esmo22! thanks', '#esmo22! thanks to', 'thanks to all', 'to all of', 'all of the', 'of the patients', 'the patients and', 'patients and the', 'and the codebreak-200', 'the codebreak-200 team', 'codebreak-200 team of', 'team of investigators', 'of investigators -', 'investigators - ph', '- ph iii', 'ph iii proving', 'iii proving sotorasib', 'proving sotorasib pfs', 'sotorasib pfs efficacy', 'pfs efficacy over', 'efficacy over docetaxel', 'over docetaxel (hr', 'docetaxel (hr 0.66)', '(hr 0.66) in', '0.66) in patients', 'in patients with', 'patients with refractory', 'with refractory g12c', 'refractory g12c nsclc.', 'g12c nsclc. .', 'delivering an outstanding presentation', 'an outstanding presentation in', 'outstanding presentation in the', 'presentation in the presidential', 'in the presidential symposium', 'the presidential symposium at', 'presidential symposium at #esmo22!', 'symposium at #esmo22! thanks', 'at #esmo22! thanks to', '#esmo22! thanks to all', 'thanks to all of', 'to all of the', 'all of the patients', 'of the patients and', 'the patients and the', 'patients and the codebreak-200', 'and the codebreak-200 team', 'the codebreak-200 team of', 'codebreak-200 team of investigators', 'team of investigators -', 'of investigators - ph', 'investigators - ph iii', '- ph iii proving', 'ph iii proving sotorasib', 'iii proving sotorasib pfs', 'proving sotorasib pfs efficacy', 'sotorasib pfs efficacy over', 'pfs efficacy over docetaxel', 'efficacy over docetaxel (hr', 'over docetaxel (hr 0.66)', 'docetaxel (hr 0.66) in', '(hr 0.66) in patients', '0.66) in patients with', 'in patients with refractory', 'patients with refractory g12c', 'with refractory g12c nsclc.', 'refractory g12c nsclc. .', 'delivering an outstanding presentation in', 'an outstanding presentation in the', 'outstanding presentation in the presidential', 'presentation in the presidential symposium', 'in the presidential symposium at', 'the presidential symposium at #esmo22!', 'presidential symposium at #esmo22! thanks', 'symposium at #esmo22! thanks to', 'at #esmo22! thanks to all', '#esmo22! thanks to all of', 'thanks to all of the', 'to all of the patients', 'all of the patients and', 'of the patients and the', 'the patients and the codebreak-200', 'patients and the codebreak-200 team', 'and the codebreak-200 team of', 'the codebreak-200 team of investigators', 'codebreak-200 team of investigators -', 'team of investigators - ph', 'of investigators - ph iii', 'investigators - ph iii proving', '- ph iii proving sotorasib', 'ph iii proving sotorasib pfs', 'iii proving sotorasib pfs efficacy', 'proving sotorasib pfs efficacy over', 'sotorasib pfs efficacy over docetaxel', 'pfs efficacy over docetaxel (hr', 'efficacy over docetaxel (hr 0.66)', 'over docetaxel (hr 0.66) in', 'docetaxel (hr 0.66) in patients', '(hr 0.66) in patients with', '0.66) in patients with refractory', 'in patients with refractory g12c', 'patients with refractory g12c nsclc.', 'with refractory g12c nsclc. .', 'delivering an outstanding presentation in the', 'an outstanding presentation in the presidential', 'outstanding presentation in the presidential symposium', 'presentation in the presidential symposium at', 'in the presidential symposium at #esmo22!', 'the presidential symposium at #esmo22! thanks', 'presidential symposium at #esmo22! thanks to', 'symposium at #esmo22! thanks to all', 'at #esmo22! thanks to all of', '#esmo22! thanks to all of the', 'thanks to all of the patients', 'to all of the patients and', 'all of the patients and the', 'of the patients and the codebreak-200', 'the patients and the codebreak-200 team', 'patients and the codebreak-200 team of', 'and the codebreak-200 team of investigators', 'the codebreak-200 team of investigators -', 'codebreak-200 team of investigators - ph', 'team of investigators - ph iii', 'of investigators - ph iii proving', 'investigators - ph iii proving sotorasib', '- ph iii proving sotorasib pfs', 'ph iii proving sotorasib pfs efficacy', 'iii proving sotorasib pfs efficacy over', 'proving sotorasib pfs efficacy over docetaxel', 'sotorasib pfs efficacy over docetaxel (hr', 'pfs efficacy over docetaxel (hr 0.66)', 'efficacy over docetaxel (hr 0.66) in', 'over docetaxel (hr 0.66) in patients', 'docetaxel (hr 0.66) in patients with', '(hr 0.66) in patients with refractory', '0.66) in patients with refractory g12c', 'in patients with refractory g12c nsclc.', 'patients with refractory g12c nsclc. .', 'delivering an outstanding presentation in the presidential', 'an outstanding presentation in the presidential symposium', 'outstanding presentation in the presidential symposium at', 'presentation in the presidential symposium at #esmo22!', 'in the presidential symposium at #esmo22! thanks', 'the presidential symposium at #esmo22! thanks to', 'presidential symposium at #esmo22! thanks to all', 'symposium at #esmo22! thanks to all of', 'at #esmo22! thanks to all of the', '#esmo22! thanks to all of the patients', 'thanks to all of the patients and', 'to all of the patients and the', 'all of the patients and the codebreak-200', 'of the patients and the codebreak-200 team', 'the patients and the codebreak-200 team of', 'patients and the codebreak-200 team of investigators', 'and the codebreak-200 team of investigators -', 'the codebreak-200 team of investigators - ph', 'codebreak-200 team of investigators - ph iii', 'team of investigators - ph iii proving', 'of investigators - ph iii proving sotorasib', 'investigators - ph iii proving sotorasib pfs', '- ph iii proving sotorasib pfs efficacy', 'ph iii proving sotorasib pfs efficacy over', 'iii proving sotorasib pfs efficacy over docetaxel', 'proving sotorasib pfs efficacy over docetaxel (hr', 'sotorasib pfs efficacy over docetaxel (hr 0.66)', 'pfs efficacy over docetaxel (hr 0.66) in', 'efficacy over docetaxel (hr 0.66) in patients', 'over docetaxel (hr 0.66) in patients with', 'docetaxel (hr 0.66) in patients with refractory', '(hr 0.66) in patients with refractory g12c', '0.66) in patients with refractory g12c nsclc.', 'in patients with refractory g12c nsclc. .', 'delivering an outstanding presentation in the presidential symposium', 'an outstanding presentation in the presidential symposium at', 'outstanding presentation in the presidential symposium at #esmo22!', 'presentation in the presidential symposium at #esmo22! thanks', 'in the presidential symposium at #esmo22! thanks to', 'the presidential symposium at #esmo22! thanks to all', 'presidential symposium at #esmo22! thanks to all of', 'symposium at #esmo22! thanks to all of the', 'at #esmo22! thanks to all of the patients', '#esmo22! thanks to all of the patients and', 'thanks to all of the patients and the', 'to all of the patients and the codebreak-200', 'all of the patients and the codebreak-200 team', 'of the patients and the codebreak-200 team of', 'the patients and the codebreak-200 team of investigators', 'patients and the codebreak-200 team of investigators -', 'and the codebreak-200 team of investigators - ph', 'the codebreak-200 team of investigators - ph iii', 'codebreak-200 team of investigators - ph iii proving', 'team of investigators - ph iii proving sotorasib', 'of investigators - ph iii proving sotorasib pfs', 'investigators - ph iii proving sotorasib pfs efficacy', '- ph iii proving sotorasib pfs efficacy over', 'ph iii proving sotorasib pfs efficacy over docetaxel', 'iii proving sotorasib pfs efficacy over docetaxel (hr', 'proving sotorasib pfs efficacy over docetaxel (hr 0.66)', 'sotorasib pfs efficacy over docetaxel (hr 0.66) in', 'pfs efficacy over docetaxel (hr 0.66) in patients', 'efficacy over docetaxel (hr 0.66) in patients with', 'over docetaxel (hr 0.66) in patients with refractory', 'docetaxel (hr 0.66) in patients with refractory g12c', '(hr 0.66) in patients with refractory g12c nsclc.', '0.66) in patients with refractory g12c nsclc. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '57', 'tokens': ['mind', 'blown', 'by', 's1801', '.', 'congrats', 'et', 'al!', 'thinking', '~', 'this', 'all', 'day', '&amp;', 'really', 'wondering', 'if', 'should', 'give', '1', 'dose', 'pd1+low', 'dose', 'ipi', 'to', 'all', "pt's", 'w', 't3b/t4', '#melanoma', 'or', 'clin', '+', 'node', 'bf', 'resect.', 'we', 'need', 'a', 'trial', 'pd1+ipi', 'neoadj', 'then', 'stop', 'vs', 'neo', '+', 'adj', 'pd1', 'asap!', '#esmo22', '.'], 'text_length': 52, 'triples': {'s1801|mind blown': ([3, 3], [0, 1], 'positive')}, 'sentence': "mind blown by s1801 . congrats et al! thinking ~ this all day &amp; really wondering if should give 1 dose pd1+low dose ipi to all pt's w t3b/t4 #melanoma or clin + node bf resect. we need a trial pd1+ipi neoadj then stop vs neo + adj pd1 asap! #esmo22 .", 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8)], 'span tokens': ['mind', 'blown', 'by', 's1801', '.', 'congrats', 'et', 'al!', 'thinking', '~', 'this', 'all', 'day', '&amp;', 'really', 'wondering', 'if', 'should', 'give', '1', 'dose', 'pd1+low', 'dose', 'ipi', 'to', 'all', "pt's", 'w', 't3b/t4', '#melanoma', 'or', 'clin', '+', 'node', 'bf', 'resect.', 'we', 'need', 'a', 'trial', 'pd1+ipi', 'neoadj', 'then', 'stop', 'vs', 'neo', '+', 'adj', 'pd1', 'asap!', '#esmo22', '.', 'mind blown', 'blown by', 'by s1801', 's1801 .', '. congrats', 'congrats et', 'et al!', 'al! thinking', 'thinking ~', '~ this', 'this all', 'all day', 'day &amp;', '&amp; really', 'really wondering', 'wondering if', 'if should', 'should give', 'give 1', '1 dose', 'dose pd1+low', 'pd1+low dose', 'dose ipi', 'ipi to', 'to all', "all pt's", "pt's w", 'w t3b/t4', 't3b/t4 #melanoma', '#melanoma or', 'or clin', 'clin +', '+ node', 'node bf', 'bf resect.', 'resect. we', 'we need', 'need a', 'a trial', 'trial pd1+ipi', 'pd1+ipi neoadj', 'neoadj then', 'then stop', 'stop vs', 'vs neo', 'neo +', '+ adj', 'adj pd1', 'pd1 asap!', 'asap! #esmo22', '#esmo22 .', 'mind blown by', 'blown by s1801', 'by s1801 .', 's1801 . congrats', '. congrats et', 'congrats et al!', 'et al! thinking', 'al! thinking ~', 'thinking ~ this', '~ this all', 'this all day', 'all day &amp;', 'day &amp; really', '&amp; really wondering', 'really wondering if', 'wondering if should', 'if should give', 'should give 1', 'give 1 dose', '1 dose pd1+low', 'dose pd1+low dose', 'pd1+low dose ipi', 'dose ipi to', 'ipi to all', "to all pt's", "all pt's w", "pt's w t3b/t4", 'w t3b/t4 #melanoma', 't3b/t4 #melanoma or', '#melanoma or clin', 'or clin +', 'clin + node', '+ node bf', 'node bf resect.', 'bf resect. we', 'resect. we need', 'we need a', 'need a trial', 'a trial pd1+ipi', 'trial pd1+ipi neoadj', 'pd1+ipi neoadj then', 'neoadj then stop', 'then stop vs', 'stop vs neo', 'vs neo +', 'neo + adj', '+ adj pd1', 'adj pd1 asap!', 'pd1 asap! #esmo22', 'asap! #esmo22 .', 'mind blown by s1801', 'blown by s1801 .', 'by s1801 . congrats', 's1801 . congrats et', '. congrats et al!', 'congrats et al! thinking', 'et al! thinking ~', 'al! thinking ~ this', 'thinking ~ this all', '~ this all day', 'this all day &amp;', 'all day &amp; really', 'day &amp; really wondering', '&amp; really wondering if', 'really wondering if should', 'wondering if should give', 'if should give 1', 'should give 1 dose', 'give 1 dose pd1+low', '1 dose pd1+low dose', 'dose pd1+low dose ipi', 'pd1+low dose ipi to', 'dose ipi to all', "ipi to all pt's", "to all pt's w", "all pt's w t3b/t4", "pt's w t3b/t4 #melanoma", 'w t3b/t4 #melanoma or', 't3b/t4 #melanoma or clin', '#melanoma or clin +', 'or clin + node', 'clin + node bf', '+ node bf resect.', 'node bf resect. we', 'bf resect. we need', 'resect. we need a', 'we need a trial', 'need a trial pd1+ipi', 'a trial pd1+ipi neoadj', 'trial pd1+ipi neoadj then', 'pd1+ipi neoadj then stop', 'neoadj then stop vs', 'then stop vs neo', 'stop vs neo +', 'vs neo + adj', 'neo + adj pd1', '+ adj pd1 asap!', 'adj pd1 asap! #esmo22', 'pd1 asap! #esmo22 .', 'mind blown by s1801 .', 'blown by s1801 . congrats', 'by s1801 . congrats et', 's1801 . congrats et al!', '. congrats et al! thinking', 'congrats et al! thinking ~', 'et al! thinking ~ this', 'al! thinking ~ this all', 'thinking ~ this all day', '~ this all day &amp;', 'this all day &amp; really', 'all day &amp; really wondering', 'day &amp; really wondering if', '&amp; really wondering if should', 'really wondering if should give', 'wondering if should give 1', 'if should give 1 dose', 'should give 1 dose pd1+low', 'give 1 dose pd1+low dose', '1 dose pd1+low dose ipi', 'dose pd1+low dose ipi to', 'pd1+low dose ipi to all', "dose ipi to all pt's", "ipi to all pt's w", "to all pt's w t3b/t4", "all pt's w t3b/t4 #melanoma", "pt's w t3b/t4 #melanoma or", 'w t3b/t4 #melanoma or clin', 't3b/t4 #melanoma or clin +', '#melanoma or clin + node', 'or clin + node bf', 'clin + node bf resect.', '+ node bf resect. we', 'node bf resect. we need', 'bf resect. we need a', 'resect. we need a trial', 'we need a trial pd1+ipi', 'need a trial pd1+ipi neoadj', 'a trial pd1+ipi neoadj then', 'trial pd1+ipi neoadj then stop', 'pd1+ipi neoadj then stop vs', 'neoadj then stop vs neo', 'then stop vs neo +', 'stop vs neo + adj', 'vs neo + adj pd1', 'neo + adj pd1 asap!', '+ adj pd1 asap! #esmo22', 'adj pd1 asap! #esmo22 .', 'mind blown by s1801 . congrats', 'blown by s1801 . congrats et', 'by s1801 . congrats et al!', 's1801 . congrats et al! thinking', '. congrats et al! thinking ~', 'congrats et al! thinking ~ this', 'et al! thinking ~ this all', 'al! thinking ~ this all day', 'thinking ~ this all day &amp;', '~ this all day &amp; really', 'this all day &amp; really wondering', 'all day &amp; really wondering if', 'day &amp; really wondering if should', '&amp; really wondering if should give', 'really wondering if should give 1', 'wondering if should give 1 dose', 'if should give 1 dose pd1+low', 'should give 1 dose pd1+low dose', 'give 1 dose pd1+low dose ipi', '1 dose pd1+low dose ipi to', 'dose pd1+low dose ipi to all', "pd1+low dose ipi to all pt's", "dose ipi to all pt's w", "ipi to all pt's w t3b/t4", "to all pt's w t3b/t4 #melanoma", "all pt's w t3b/t4 #melanoma or", "pt's w t3b/t4 #melanoma or clin", 'w t3b/t4 #melanoma or clin +', 't3b/t4 #melanoma or clin + node', '#melanoma or clin + node bf', 'or clin + node bf resect.', 'clin + node bf resect. we', '+ node bf resect. we need', 'node bf resect. we need a', 'bf resect. we need a trial', 'resect. we need a trial pd1+ipi', 'we need a trial pd1+ipi neoadj', 'need a trial pd1+ipi neoadj then', 'a trial pd1+ipi neoadj then stop', 'trial pd1+ipi neoadj then stop vs', 'pd1+ipi neoadj then stop vs neo', 'neoadj then stop vs neo +', 'then stop vs neo + adj', 'stop vs neo + adj pd1', 'vs neo + adj pd1 asap!', 'neo + adj pd1 asap! #esmo22', '+ adj pd1 asap! #esmo22 .', 'mind blown by s1801 . congrats et', 'blown by s1801 . congrats et al!', 'by s1801 . congrats et al! thinking', 's1801 . congrats et al! thinking ~', '. congrats et al! thinking ~ this', 'congrats et al! thinking ~ this all', 'et al! thinking ~ this all day', 'al! thinking ~ this all day &amp;', 'thinking ~ this all day &amp; really', '~ this all day &amp; really wondering', 'this all day &amp; really wondering if', 'all day &amp; really wondering if should', 'day &amp; really wondering if should give', '&amp; really wondering if should give 1', 'really wondering if should give 1 dose', 'wondering if should give 1 dose pd1+low', 'if should give 1 dose pd1+low dose', 'should give 1 dose pd1+low dose ipi', 'give 1 dose pd1+low dose ipi to', '1 dose pd1+low dose ipi to all', "dose pd1+low dose ipi to all pt's", "pd1+low dose ipi to all pt's w", "dose ipi to all pt's w t3b/t4", "ipi to all pt's w t3b/t4 #melanoma", "to all pt's w t3b/t4 #melanoma or", "all pt's w t3b/t4 #melanoma or clin", "pt's w t3b/t4 #melanoma or clin +", 'w t3b/t4 #melanoma or clin + node', 't3b/t4 #melanoma or clin + node bf', '#melanoma or clin + node bf resect.', 'or clin + node bf resect. we', 'clin + node bf resect. we need', '+ node bf resect. we need a', 'node bf resect. we need a trial', 'bf resect. we need a trial pd1+ipi', 'resect. we need a trial pd1+ipi neoadj', 'we need a trial pd1+ipi neoadj then', 'need a trial pd1+ipi neoadj then stop', 'a trial pd1+ipi neoadj then stop vs', 'trial pd1+ipi neoadj then stop vs neo', 'pd1+ipi neoadj then stop vs neo +', 'neoadj then stop vs neo + adj', 'then stop vs neo + adj pd1', 'stop vs neo + adj pd1 asap!', 'vs neo + adj pd1 asap! #esmo22', 'neo + adj pd1 asap! #esmo22 .', 'mind blown by s1801 . congrats et al!', 'blown by s1801 . congrats et al! thinking', 'by s1801 . congrats et al! thinking ~', 's1801 . congrats et al! thinking ~ this', '. congrats et al! thinking ~ this all', 'congrats et al! thinking ~ this all day', 'et al! thinking ~ this all day &amp;', 'al! thinking ~ this all day &amp; really', 'thinking ~ this all day &amp; really wondering', '~ this all day &amp; really wondering if', 'this all day &amp; really wondering if should', 'all day &amp; really wondering if should give', 'day &amp; really wondering if should give 1', '&amp; really wondering if should give 1 dose', 'really wondering if should give 1 dose pd1+low', 'wondering if should give 1 dose pd1+low dose', 'if should give 1 dose pd1+low dose ipi', 'should give 1 dose pd1+low dose ipi to', 'give 1 dose pd1+low dose ipi to all', "1 dose pd1+low dose ipi to all pt's", "dose pd1+low dose ipi to all pt's w", "pd1+low dose ipi to all pt's w t3b/t4", "dose ipi to all pt's w t3b/t4 #melanoma", "ipi to all pt's w t3b/t4 #melanoma or", "to all pt's w t3b/t4 #melanoma or clin", "all pt's w t3b/t4 #melanoma or clin +", "pt's w t3b/t4 #melanoma or clin + node", 'w t3b/t4 #melanoma or clin + node bf', 't3b/t4 #melanoma or clin + node bf resect.', '#melanoma or clin + node bf resect. we', 'or clin + node bf resect. we need', 'clin + node bf resect. we need a', '+ node bf resect. we need a trial', 'node bf resect. we need a trial pd1+ipi', 'bf resect. we need a trial pd1+ipi neoadj', 'resect. we need a trial pd1+ipi neoadj then', 'we need a trial pd1+ipi neoadj then stop', 'need a trial pd1+ipi neoadj then stop vs', 'a trial pd1+ipi neoadj then stop vs neo', 'trial pd1+ipi neoadj then stop vs neo +', 'pd1+ipi neoadj then stop vs neo + adj', 'neoadj then stop vs neo + adj pd1', 'then stop vs neo + adj pd1 asap!', 'stop vs neo + adj pd1 asap! #esmo22', 'vs neo + adj pd1 asap! #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '58', 'tokens': ['"Late', 'breaking', 'abstracts', '#ASH22', 'Final', 'analysis', 'of', 'ALPINE', 'Randomized', 'Phase', '3', 'Study:', 'Zanubrutinib', 'Demonstrates', 'Superior', 'PFS', 'and', 'ORR', 'Compared', 'with', 'Ibrutinib', 'for', 'Treatment', 'of', 'Relapsed/Refractory', 'Chronic', 'Lymphocytic', 'Leukemia', 'and', 'SLL.', '.'], 'text_length': 31, 'triples': {'ALPINE|Superior': ([7, 7], [14, 14], 'positive'), 'Ibrutinib|Compared with': ([20, 20], [18, 19], 'negative'), 'Zanubrutinib|Superior': ([12, 12], [14, 14], 'positive')}, 'sentence': '"Late breaking abstracts #ASH22 Final analysis of ALPINE Randomized Phase 3 Study: Zanubrutinib Demonstrates Superior PFS and ORR Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and SLL. .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(7, 7), (20, 20), (12, 12)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(14, 14), (18, 19)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['"Late', 'breaking', 'abstracts', '#ASH22', 'Final', 'analysis', 'of', 'ALPINE', 'Randomized', 'Phase', '3', 'Study:', 'Zanubrutinib', 'Demonstrates', 'Superior', 'PFS', 'and', 'ORR', 'Compared', 'with', 'Ibrutinib', 'for', 'Treatment', 'of', 'Relapsed/Refractory', 'Chronic', 'Lymphocytic', 'Leukemia', 'and', 'SLL.', '.', '"Late breaking', 'breaking abstracts', 'abstracts #ASH22', '#ASH22 Final', 'Final analysis', 'analysis of', 'of ALPINE', 'ALPINE Randomized', 'Randomized Phase', 'Phase 3', '3 Study:', 'Study: Zanubrutinib', 'Zanubrutinib Demonstrates', 'Demonstrates Superior', 'Superior PFS', 'PFS and', 'and ORR', 'ORR Compared', 'Compared with', 'with Ibrutinib', 'Ibrutinib for', 'for Treatment', 'Treatment of', 'of Relapsed/Refractory', 'Relapsed/Refractory Chronic', 'Chronic Lymphocytic', 'Lymphocytic Leukemia', 'Leukemia and', 'and SLL.', 'SLL. .', '"Late breaking abstracts', 'breaking abstracts #ASH22', 'abstracts #ASH22 Final', '#ASH22 Final analysis', 'Final analysis of', 'analysis of ALPINE', 'of ALPINE Randomized', 'ALPINE Randomized Phase', 'Randomized Phase 3', 'Phase 3 Study:', '3 Study: Zanubrutinib', 'Study: Zanubrutinib Demonstrates', 'Zanubrutinib Demonstrates Superior', 'Demonstrates Superior PFS', 'Superior PFS and', 'PFS and ORR', 'and ORR Compared', 'ORR Compared with', 'Compared with Ibrutinib', 'with Ibrutinib for', 'Ibrutinib for Treatment', 'for Treatment of', 'Treatment of Relapsed/Refractory', 'of Relapsed/Refractory Chronic', 'Relapsed/Refractory Chronic Lymphocytic', 'Chronic Lymphocytic Leukemia', 'Lymphocytic Leukemia and', 'Leukemia and SLL.', 'and SLL. .', '"Late breaking abstracts #ASH22', 'breaking abstracts #ASH22 Final', 'abstracts #ASH22 Final analysis', '#ASH22 Final analysis of', 'Final analysis of ALPINE', 'analysis of ALPINE Randomized', 'of ALPINE Randomized Phase', 'ALPINE Randomized Phase 3', 'Randomized Phase 3 Study:', 'Phase 3 Study: Zanubrutinib', '3 Study: Zanubrutinib Demonstrates', 'Study: Zanubrutinib Demonstrates Superior', 'Zanubrutinib Demonstrates Superior PFS', 'Demonstrates Superior PFS and', 'Superior PFS and ORR', 'PFS and ORR Compared', 'and ORR Compared with', 'ORR Compared with Ibrutinib', 'Compared with Ibrutinib for', 'with Ibrutinib for Treatment', 'Ibrutinib for Treatment of', 'for Treatment of Relapsed/Refractory', 'Treatment of Relapsed/Refractory Chronic', 'of Relapsed/Refractory Chronic Lymphocytic', 'Relapsed/Refractory Chronic Lymphocytic Leukemia', 'Chronic Lymphocytic Leukemia and', 'Lymphocytic Leukemia and SLL.', 'Leukemia and SLL. .', '"Late breaking abstracts #ASH22 Final', 'breaking abstracts #ASH22 Final analysis', 'abstracts #ASH22 Final analysis of', '#ASH22 Final analysis of ALPINE', 'Final analysis of ALPINE Randomized', 'analysis of ALPINE Randomized Phase', 'of ALPINE Randomized Phase 3', 'ALPINE Randomized Phase 3 Study:', 'Randomized Phase 3 Study: Zanubrutinib', 'Phase 3 Study: Zanubrutinib Demonstrates', '3 Study: Zanubrutinib Demonstrates Superior', 'Study: Zanubrutinib Demonstrates Superior PFS', 'Zanubrutinib Demonstrates Superior PFS and', 'Demonstrates Superior PFS and ORR', 'Superior PFS and ORR Compared', 'PFS and ORR Compared with', 'and ORR Compared with Ibrutinib', 'ORR Compared with Ibrutinib for', 'Compared with Ibrutinib for Treatment', 'with Ibrutinib for Treatment of', 'Ibrutinib for Treatment of Relapsed/Refractory', 'for Treatment of Relapsed/Refractory Chronic', 'Treatment of Relapsed/Refractory Chronic Lymphocytic', 'of Relapsed/Refractory Chronic Lymphocytic Leukemia', 'Relapsed/Refractory Chronic Lymphocytic Leukemia and', 'Chronic Lymphocytic Leukemia and SLL.', 'Lymphocytic Leukemia and SLL. .', '"Late breaking abstracts #ASH22 Final analysis', 'breaking abstracts #ASH22 Final analysis of', 'abstracts #ASH22 Final analysis of ALPINE', '#ASH22 Final analysis of ALPINE Randomized', 'Final analysis of ALPINE Randomized Phase', 'analysis of ALPINE Randomized Phase 3', 'of ALPINE Randomized Phase 3 Study:', 'ALPINE Randomized Phase 3 Study: Zanubrutinib', 'Randomized Phase 3 Study: Zanubrutinib Demonstrates', 'Phase 3 Study: Zanubrutinib Demonstrates Superior', '3 Study: Zanubrutinib Demonstrates Superior PFS', 'Study: Zanubrutinib Demonstrates Superior PFS and', 'Zanubrutinib Demonstrates Superior PFS and ORR', 'Demonstrates Superior PFS and ORR Compared', 'Superior PFS and ORR Compared with', 'PFS and ORR Compared with Ibrutinib', 'and ORR Compared with Ibrutinib for', 'ORR Compared with Ibrutinib for Treatment', 'Compared with Ibrutinib for Treatment of', 'with Ibrutinib for Treatment of Relapsed/Refractory', 'Ibrutinib for Treatment of Relapsed/Refractory Chronic', 'for Treatment of Relapsed/Refractory Chronic Lymphocytic', 'Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia', 'of Relapsed/Refractory Chronic Lymphocytic Leukemia and', 'Relapsed/Refractory Chronic Lymphocytic Leukemia and SLL.', 'Chronic Lymphocytic Leukemia and SLL. .', '"Late breaking abstracts #ASH22 Final analysis of', 'breaking abstracts #ASH22 Final analysis of ALPINE', 'abstracts #ASH22 Final analysis of ALPINE Randomized', '#ASH22 Final analysis of ALPINE Randomized Phase', 'Final analysis of ALPINE Randomized Phase 3', 'analysis of ALPINE Randomized Phase 3 Study:', 'of ALPINE Randomized Phase 3 Study: Zanubrutinib', 'ALPINE Randomized Phase 3 Study: Zanubrutinib Demonstrates', 'Randomized Phase 3 Study: Zanubrutinib Demonstrates Superior', 'Phase 3 Study: Zanubrutinib Demonstrates Superior PFS', '3 Study: Zanubrutinib Demonstrates Superior PFS and', 'Study: Zanubrutinib Demonstrates Superior PFS and ORR', 'Zanubrutinib Demonstrates Superior PFS and ORR Compared', 'Demonstrates Superior PFS and ORR Compared with', 'Superior PFS and ORR Compared with Ibrutinib', 'PFS and ORR Compared with Ibrutinib for', 'and ORR Compared with Ibrutinib for Treatment', 'ORR Compared with Ibrutinib for Treatment of', 'Compared with Ibrutinib for Treatment of Relapsed/Refractory', 'with Ibrutinib for Treatment of Relapsed/Refractory Chronic', 'Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic', 'for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia', 'Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and', 'of Relapsed/Refractory Chronic Lymphocytic Leukemia and SLL.', 'Relapsed/Refractory Chronic Lymphocytic Leukemia and SLL. .', '"Late breaking abstracts #ASH22 Final analysis of ALPINE', 'breaking abstracts #ASH22 Final analysis of ALPINE Randomized', 'abstracts #ASH22 Final analysis of ALPINE Randomized Phase', '#ASH22 Final analysis of ALPINE Randomized Phase 3', 'Final analysis of ALPINE Randomized Phase 3 Study:', 'analysis of ALPINE Randomized Phase 3 Study: Zanubrutinib', 'of ALPINE Randomized Phase 3 Study: Zanubrutinib Demonstrates', 'ALPINE Randomized Phase 3 Study: Zanubrutinib Demonstrates Superior', 'Randomized Phase 3 Study: Zanubrutinib Demonstrates Superior PFS', 'Phase 3 Study: Zanubrutinib Demonstrates Superior PFS and', '3 Study: Zanubrutinib Demonstrates Superior PFS and ORR', 'Study: Zanubrutinib Demonstrates Superior PFS and ORR Compared', 'Zanubrutinib Demonstrates Superior PFS and ORR Compared with', 'Demonstrates Superior PFS and ORR Compared with Ibrutinib', 'Superior PFS and ORR Compared with Ibrutinib for', 'PFS and ORR Compared with Ibrutinib for Treatment', 'and ORR Compared with Ibrutinib for Treatment of', 'ORR Compared with Ibrutinib for Treatment of Relapsed/Refractory', 'Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic', 'with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic', 'Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia', 'for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and', 'Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and SLL.', 'of Relapsed/Refractory Chronic Lymphocytic Leukemia and SLL. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '59', 'tokens': ['vision', 'post-hoc', 'study', 'suv', 'mean', 'prognostic', 'of', 'rpfs,', 'os,', 'orr,', 'psa', 'outcomes', 'w/', '177lu-psma-617', '(suv', 'mean', 'of', '10', 'appears', 'to', 'be', 'psma', 'high', 'cutoff', 'for', 'sig', 'increased', 'rpfs,', 'os),', 'absence', 'of', 'liver/bone', 'but', '+ln', 'mets', 'do', 'best', 'w/', '177lu-psma-617', '#mcrpc', '#asco22', '#pcsm', '.'], 'text_length': 43, 'triples': {'vision|appears to be psma high': ([0, 0], [18, 22], 'neutral'), '177lu-psma-617 (suv mean of 10 appears to be psma high cutoff for sig increased rpfs, os), absence of liver/bone but +ln mets do best w/ 177lu-psma-617|appears to be psma high': ([13, 38], [18, 22], 'neutral')}, 'sentence': 'vision post-hoc study suv mean prognostic of rpfs, os, orr, psa outcomes w/ 177lu-psma-617 (suv mean of 10 appears to be psma high cutoff for sig increased rpfs, os), absence of liver/bone but +ln mets do best w/ 177lu-psma-617 #mcrpc #asco22 #pcsm .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (13, 38)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(18, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8)], 'span tokens': ['vision', 'post-hoc', 'study', 'suv', 'mean', 'prognostic', 'of', 'rpfs,', 'os,', 'orr,', 'psa', 'outcomes', 'w/', '177lu-psma-617', '(suv', 'mean', 'of', '10', 'appears', 'to', 'be', 'psma', 'high', 'cutoff', 'for', 'sig', 'increased', 'rpfs,', 'os),', 'absence', 'of', 'liver/bone', 'but', '+ln', 'mets', 'do', 'best', 'w/', '177lu-psma-617', '#mcrpc', '#asco22', '#pcsm', '.', 'vision post-hoc', 'post-hoc study', 'study suv', 'suv mean', 'mean prognostic', 'prognostic of', 'of rpfs,', 'rpfs, os,', 'os, orr,', 'orr, psa', 'psa outcomes', 'outcomes w/', 'w/ 177lu-psma-617', '177lu-psma-617 (suv', '(suv mean', 'mean of', 'of 10', '10 appears', 'appears to', 'to be', 'be psma', 'psma high', 'high cutoff', 'cutoff for', 'for sig', 'sig increased', 'increased rpfs,', 'rpfs, os),', 'os), absence', 'absence of', 'of liver/bone', 'liver/bone but', 'but +ln', '+ln mets', 'mets do', 'do best', 'best w/', 'w/ 177lu-psma-617', '177lu-psma-617 #mcrpc', '#mcrpc #asco22', '#asco22 #pcsm', '#pcsm .', 'vision post-hoc study', 'post-hoc study suv', 'study suv mean', 'suv mean prognostic', 'mean prognostic of', 'prognostic of rpfs,', 'of rpfs, os,', 'rpfs, os, orr,', 'os, orr, psa', 'orr, psa outcomes', 'psa outcomes w/', 'outcomes w/ 177lu-psma-617', 'w/ 177lu-psma-617 (suv', '177lu-psma-617 (suv mean', '(suv mean of', 'mean of 10', 'of 10 appears', '10 appears to', 'appears to be', 'to be psma', 'be psma high', 'psma high cutoff', 'high cutoff for', 'cutoff for sig', 'for sig increased', 'sig increased rpfs,', 'increased rpfs, os),', 'rpfs, os), absence', 'os), absence of', 'absence of liver/bone', 'of liver/bone but', 'liver/bone but +ln', 'but +ln mets', '+ln mets do', 'mets do best', 'do best w/', 'best w/ 177lu-psma-617', 'w/ 177lu-psma-617 #mcrpc', '177lu-psma-617 #mcrpc #asco22', '#mcrpc #asco22 #pcsm', '#asco22 #pcsm .', 'vision post-hoc study suv', 'post-hoc study suv mean', 'study suv mean prognostic', 'suv mean prognostic of', 'mean prognostic of rpfs,', 'prognostic of rpfs, os,', 'of rpfs, os, orr,', 'rpfs, os, orr, psa', 'os, orr, psa outcomes', 'orr, psa outcomes w/', 'psa outcomes w/ 177lu-psma-617', 'outcomes w/ 177lu-psma-617 (suv', 'w/ 177lu-psma-617 (suv mean', '177lu-psma-617 (suv mean of', '(suv mean of 10', 'mean of 10 appears', 'of 10 appears to', '10 appears to be', 'appears to be psma', 'to be psma high', 'be psma high cutoff', 'psma high cutoff for', 'high cutoff for sig', 'cutoff for sig increased', 'for sig increased rpfs,', 'sig increased rpfs, os),', 'increased rpfs, os), absence', 'rpfs, os), absence of', 'os), absence of liver/bone', 'absence of liver/bone but', 'of liver/bone but +ln', 'liver/bone but +ln mets', 'but +ln mets do', '+ln mets do best', 'mets do best w/', 'do best w/ 177lu-psma-617', 'best w/ 177lu-psma-617 #mcrpc', 'w/ 177lu-psma-617 #mcrpc #asco22', '177lu-psma-617 #mcrpc #asco22 #pcsm', '#mcrpc #asco22 #pcsm .', 'vision post-hoc study suv mean', 'post-hoc study suv mean prognostic', 'study suv mean prognostic of', 'suv mean prognostic of rpfs,', 'mean prognostic of rpfs, os,', 'prognostic of rpfs, os, orr,', 'of rpfs, os, orr, psa', 'rpfs, os, orr, psa outcomes', 'os, orr, psa outcomes w/', 'orr, psa outcomes w/ 177lu-psma-617', 'psa outcomes w/ 177lu-psma-617 (suv', 'outcomes w/ 177lu-psma-617 (suv mean', 'w/ 177lu-psma-617 (suv mean of', '177lu-psma-617 (suv mean of 10', '(suv mean of 10 appears', 'mean of 10 appears to', 'of 10 appears to be', '10 appears to be psma', 'appears to be psma high', 'to be psma high cutoff', 'be psma high cutoff for', 'psma high cutoff for sig', 'high cutoff for sig increased', 'cutoff for sig increased rpfs,', 'for sig increased rpfs, os),', 'sig increased rpfs, os), absence', 'increased rpfs, os), absence of', 'rpfs, os), absence of liver/bone', 'os), absence of liver/bone but', 'absence of liver/bone but +ln', 'of liver/bone but +ln mets', 'liver/bone but +ln mets do', 'but +ln mets do best', '+ln mets do best w/', 'mets do best w/ 177lu-psma-617', 'do best w/ 177lu-psma-617 #mcrpc', 'best w/ 177lu-psma-617 #mcrpc #asco22', 'w/ 177lu-psma-617 #mcrpc #asco22 #pcsm', '177lu-psma-617 #mcrpc #asco22 #pcsm .', 'vision post-hoc study suv mean prognostic', 'post-hoc study suv mean prognostic of', 'study suv mean prognostic of rpfs,', 'suv mean prognostic of rpfs, os,', 'mean prognostic of rpfs, os, orr,', 'prognostic of rpfs, os, orr, psa', 'of rpfs, os, orr, psa outcomes', 'rpfs, os, orr, psa outcomes w/', 'os, orr, psa outcomes w/ 177lu-psma-617', 'orr, psa outcomes w/ 177lu-psma-617 (suv', 'psa outcomes w/ 177lu-psma-617 (suv mean', 'outcomes w/ 177lu-psma-617 (suv mean of', 'w/ 177lu-psma-617 (suv mean of 10', '177lu-psma-617 (suv mean of 10 appears', '(suv mean of 10 appears to', 'mean of 10 appears to be', 'of 10 appears to be psma', '10 appears to be psma high', 'appears to be psma high cutoff', 'to be psma high cutoff for', 'be psma high cutoff for sig', 'psma high cutoff for sig increased', 'high cutoff for sig increased rpfs,', 'cutoff for sig increased rpfs, os),', 'for sig increased rpfs, os), absence', 'sig increased rpfs, os), absence of', 'increased rpfs, os), absence of liver/bone', 'rpfs, os), absence of liver/bone but', 'os), absence of liver/bone but +ln', 'absence of liver/bone but +ln mets', 'of liver/bone but +ln mets do', 'liver/bone but +ln mets do best', 'but +ln mets do best w/', '+ln mets do best w/ 177lu-psma-617', 'mets do best w/ 177lu-psma-617 #mcrpc', 'do best w/ 177lu-psma-617 #mcrpc #asco22', 'best w/ 177lu-psma-617 #mcrpc #asco22 #pcsm', 'w/ 177lu-psma-617 #mcrpc #asco22 #pcsm .', 'vision post-hoc study suv mean prognostic of', 'post-hoc study suv mean prognostic of rpfs,', 'study suv mean prognostic of rpfs, os,', 'suv mean prognostic of rpfs, os, orr,', 'mean prognostic of rpfs, os, orr, psa', 'prognostic of rpfs, os, orr, psa outcomes', 'of rpfs, os, orr, psa outcomes w/', 'rpfs, os, orr, psa outcomes w/ 177lu-psma-617', 'os, orr, psa outcomes w/ 177lu-psma-617 (suv', 'orr, psa outcomes w/ 177lu-psma-617 (suv mean', 'psa outcomes w/ 177lu-psma-617 (suv mean of', 'outcomes w/ 177lu-psma-617 (suv mean of 10', 'w/ 177lu-psma-617 (suv mean of 10 appears', '177lu-psma-617 (suv mean of 10 appears to', '(suv mean of 10 appears to be', 'mean of 10 appears to be psma', 'of 10 appears to be psma high', '10 appears to be psma high cutoff', 'appears to be psma high cutoff for', 'to be psma high cutoff for sig', 'be psma high cutoff for sig increased', 'psma high cutoff for sig increased rpfs,', 'high cutoff for sig increased rpfs, os),', 'cutoff for sig increased rpfs, os), absence', 'for sig increased rpfs, os), absence of', 'sig increased rpfs, os), absence of liver/bone', 'increased rpfs, os), absence of liver/bone but', 'rpfs, os), absence of liver/bone but +ln', 'os), absence of liver/bone but +ln mets', 'absence of liver/bone but +ln mets do', 'of liver/bone but +ln mets do best', 'liver/bone but +ln mets do best w/', 'but +ln mets do best w/ 177lu-psma-617', '+ln mets do best w/ 177lu-psma-617 #mcrpc', 'mets do best w/ 177lu-psma-617 #mcrpc #asco22', 'do best w/ 177lu-psma-617 #mcrpc #asco22 #pcsm', 'best w/ 177lu-psma-617 #mcrpc #asco22 #pcsm .', 'vision post-hoc study suv mean prognostic of rpfs,', 'post-hoc study suv mean prognostic of rpfs, os,', 'study suv mean prognostic of rpfs, os, orr,', 'suv mean prognostic of rpfs, os, orr, psa', 'mean prognostic of rpfs, os, orr, psa outcomes', 'prognostic of rpfs, os, orr, psa outcomes w/', 'of rpfs, os, orr, psa outcomes w/ 177lu-psma-617', 'rpfs, os, orr, psa outcomes w/ 177lu-psma-617 (suv', 'os, orr, psa outcomes w/ 177lu-psma-617 (suv mean', 'orr, psa outcomes w/ 177lu-psma-617 (suv mean of', 'psa outcomes w/ 177lu-psma-617 (suv mean of 10', 'outcomes w/ 177lu-psma-617 (suv mean of 10 appears', 'w/ 177lu-psma-617 (suv mean of 10 appears to', '177lu-psma-617 (suv mean of 10 appears to be', '(suv mean of 10 appears to be psma', 'mean of 10 appears to be psma high', 'of 10 appears to be psma high cutoff', '10 appears to be psma high cutoff for', 'appears to be psma high cutoff for sig', 'to be psma high cutoff for sig increased', 'be psma high cutoff for sig increased rpfs,', 'psma high cutoff for sig increased rpfs, os),', 'high cutoff for sig increased rpfs, os), absence', 'cutoff for sig increased rpfs, os), absence of', 'for sig increased rpfs, os), absence of liver/bone', 'sig increased rpfs, os), absence of liver/bone but', 'increased rpfs, os), absence of liver/bone but +ln', 'rpfs, os), absence of liver/bone but +ln mets', 'os), absence of liver/bone but +ln mets do', 'absence of liver/bone but +ln mets do best', 'of liver/bone but +ln mets do best w/', 'liver/bone but +ln mets do best w/ 177lu-psma-617', 'but +ln mets do best w/ 177lu-psma-617 #mcrpc', '+ln mets do best w/ 177lu-psma-617 #mcrpc #asco22', 'mets do best w/ 177lu-psma-617 #mcrpc #asco22 #pcsm', 'do best w/ 177lu-psma-617 #mcrpc #asco22 #pcsm .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '60', 'tokens': ['congrats', 'to', 'christopher', 'ryan', 'and', 'all', 'involved', 'in', 'everest', 'trial', '#asco22', '-', 'represents', 'tremendous', 'dedication', 'from', 'all', 'patients', 'and', 'researchers', 'involved.', 'slightly...missed', 'stats', 'mark', 'but', 'provides', 'very', 'valuable', 'data', 'to', 'understand', 'mtor', 'in', 'rcc.', 'congrats!', '.'], 'text_length': 36, 'triples': {'everest|tremendous dedication from all patients and researchers involved. slightly...missed stats mark but provides very valuable': ([8, 8], [13, 27], 'positive')}, 'sentence': 'congrats to christopher ryan and all involved in everest trial #asco22 - represents tremendous dedication from all patients and researchers involved. slightly...missed stats mark but provides very valuable data to understand mtor in rcc. congrats! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(13, 27)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 1, 0, ..., 1, 1, 1],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 1, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['congrats', 'to', 'christopher', 'ryan', 'and', 'all', 'involved', 'in', 'everest', 'trial', '#asco22', '-', 'represents', 'tremendous', 'dedication', 'from', 'all', 'patients', 'and', 'researchers', 'involved.', 'slightly...missed', 'stats', 'mark', 'but', 'provides', 'very', 'valuable', 'data', 'to', 'understand', 'mtor', 'in', 'rcc.', 'congrats!', '.', 'congrats to', 'to christopher', 'christopher ryan', 'ryan and', 'and all', 'all involved', 'involved in', 'in everest', 'everest trial', 'trial #asco22', '#asco22 -', '- represents', 'represents tremendous', 'tremendous dedication', 'dedication from', 'from all', 'all patients', 'patients and', 'and researchers', 'researchers involved.', 'involved. slightly...missed', 'slightly...missed stats', 'stats mark', 'mark but', 'but provides', 'provides very', 'very valuable', 'valuable data', 'data to', 'to understand', 'understand mtor', 'mtor in', 'in rcc.', 'rcc. congrats!', 'congrats! .', 'congrats to christopher', 'to christopher ryan', 'christopher ryan and', 'ryan and all', 'and all involved', 'all involved in', 'involved in everest', 'in everest trial', 'everest trial #asco22', 'trial #asco22 -', '#asco22 - represents', '- represents tremendous', 'represents tremendous dedication', 'tremendous dedication from', 'dedication from all', 'from all patients', 'all patients and', 'patients and researchers', 'and researchers involved.', 'researchers involved. slightly...missed', 'involved. slightly...missed stats', 'slightly...missed stats mark', 'stats mark but', 'mark but provides', 'but provides very', 'provides very valuable', 'very valuable data', 'valuable data to', 'data to understand', 'to understand mtor', 'understand mtor in', 'mtor in rcc.', 'in rcc. congrats!', 'rcc. congrats! .', 'congrats to christopher ryan', 'to christopher ryan and', 'christopher ryan and all', 'ryan and all involved', 'and all involved in', 'all involved in everest', 'involved in everest trial', 'in everest trial #asco22', 'everest trial #asco22 -', 'trial #asco22 - represents', '#asco22 - represents tremendous', '- represents tremendous dedication', 'represents tremendous dedication from', 'tremendous dedication from all', 'dedication from all patients', 'from all patients and', 'all patients and researchers', 'patients and researchers involved.', 'and researchers involved. slightly...missed', 'researchers involved. slightly...missed stats', 'involved. slightly...missed stats mark', 'slightly...missed stats mark but', 'stats mark but provides', 'mark but provides very', 'but provides very valuable', 'provides very valuable data', 'very valuable data to', 'valuable data to understand', 'data to understand mtor', 'to understand mtor in', 'understand mtor in rcc.', 'mtor in rcc. congrats!', 'in rcc. congrats! .', 'congrats to christopher ryan and', 'to christopher ryan and all', 'christopher ryan and all involved', 'ryan and all involved in', 'and all involved in everest', 'all involved in everest trial', 'involved in everest trial #asco22', 'in everest trial #asco22 -', 'everest trial #asco22 - represents', 'trial #asco22 - represents tremendous', '#asco22 - represents tremendous dedication', '- represents tremendous dedication from', 'represents tremendous dedication from all', 'tremendous dedication from all patients', 'dedication from all patients and', 'from all patients and researchers', 'all patients and researchers involved.', 'patients and researchers involved. slightly...missed', 'and researchers involved. slightly...missed stats', 'researchers involved. slightly...missed stats mark', 'involved. slightly...missed stats mark but', 'slightly...missed stats mark but provides', 'stats mark but provides very', 'mark but provides very valuable', 'but provides very valuable data', 'provides very valuable data to', 'very valuable data to understand', 'valuable data to understand mtor', 'data to understand mtor in', 'to understand mtor in rcc.', 'understand mtor in rcc. congrats!', 'mtor in rcc. congrats! .', 'congrats to christopher ryan and all', 'to christopher ryan and all involved', 'christopher ryan and all involved in', 'ryan and all involved in everest', 'and all involved in everest trial', 'all involved in everest trial #asco22', 'involved in everest trial #asco22 -', 'in everest trial #asco22 - represents', 'everest trial #asco22 - represents tremendous', 'trial #asco22 - represents tremendous dedication', '#asco22 - represents tremendous dedication from', '- represents tremendous dedication from all', 'represents tremendous dedication from all patients', 'tremendous dedication from all patients and', 'dedication from all patients and researchers', 'from all patients and researchers involved.', 'all patients and researchers involved. slightly...missed', 'patients and researchers involved. slightly...missed stats', 'and researchers involved. slightly...missed stats mark', 'researchers involved. slightly...missed stats mark but', 'involved. slightly...missed stats mark but provides', 'slightly...missed stats mark but provides very', 'stats mark but provides very valuable', 'mark but provides very valuable data', 'but provides very valuable data to', 'provides very valuable data to understand', 'very valuable data to understand mtor', 'valuable data to understand mtor in', 'data to understand mtor in rcc.', 'to understand mtor in rcc. congrats!', 'understand mtor in rcc. congrats! .', 'congrats to christopher ryan and all involved', 'to christopher ryan and all involved in', 'christopher ryan and all involved in everest', 'ryan and all involved in everest trial', 'and all involved in everest trial #asco22', 'all involved in everest trial #asco22 -', 'involved in everest trial #asco22 - represents', 'in everest trial #asco22 - represents tremendous', 'everest trial #asco22 - represents tremendous dedication', 'trial #asco22 - represents tremendous dedication from', '#asco22 - represents tremendous dedication from all', '- represents tremendous dedication from all patients', 'represents tremendous dedication from all patients and', 'tremendous dedication from all patients and researchers', 'dedication from all patients and researchers involved.', 'from all patients and researchers involved. slightly...missed', 'all patients and researchers involved. slightly...missed stats', 'patients and researchers involved. slightly...missed stats mark', 'and researchers involved. slightly...missed stats mark but', 'researchers involved. slightly...missed stats mark but provides', 'involved. slightly...missed stats mark but provides very', 'slightly...missed stats mark but provides very valuable', 'stats mark but provides very valuable data', 'mark but provides very valuable data to', 'but provides very valuable data to understand', 'provides very valuable data to understand mtor', 'very valuable data to understand mtor in', 'valuable data to understand mtor in rcc.', 'data to understand mtor in rcc. congrats!', 'to understand mtor in rcc. congrats! .', 'congrats to christopher ryan and all involved in', 'to christopher ryan and all involved in everest', 'christopher ryan and all involved in everest trial', 'ryan and all involved in everest trial #asco22', 'and all involved in everest trial #asco22 -', 'all involved in everest trial #asco22 - represents', 'involved in everest trial #asco22 - represents tremendous', 'in everest trial #asco22 - represents tremendous dedication', 'everest trial #asco22 - represents tremendous dedication from', 'trial #asco22 - represents tremendous dedication from all', '#asco22 - represents tremendous dedication from all patients', '- represents tremendous dedication from all patients and', 'represents tremendous dedication from all patients and researchers', 'tremendous dedication from all patients and researchers involved.', 'dedication from all patients and researchers involved. slightly...missed', 'from all patients and researchers involved. slightly...missed stats', 'all patients and researchers involved. slightly...missed stats mark', 'patients and researchers involved. slightly...missed stats mark but', 'and researchers involved. slightly...missed stats mark but provides', 'researchers involved. slightly...missed stats mark but provides very', 'involved. slightly...missed stats mark but provides very valuable', 'slightly...missed stats mark but provides very valuable data', 'stats mark but provides very valuable data to', 'mark but provides very valuable data to understand', 'but provides very valuable data to understand mtor', 'provides very valuable data to understand mtor in', 'very valuable data to understand mtor in rcc.', 'valuable data to understand mtor in rcc. congrats!', 'data to understand mtor in rcc. congrats! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '61', 'tokens': ['no', 'benefit', 'of', 'adding', 'enzalutamide', 'to', 'abiraterone+adt', 'in', 'metastatic', 'hormone', 'sensitive', '#prostatecancer', 'congrats', 'to', 'and', 'the', 'whole', 'stampede', 'team', '#esmo2022', '.'], 'text_length': 21, 'triples': {'stampede|congrats': ([17, 17], [12, 12], 'positive')}, 'sentence': 'no benefit of adding enzalutamide to abiraterone+adt in metastatic hormone sensitive #prostatecancer congrats to and the whole stampede team #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(17, 17)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(12, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['no', 'benefit', 'of', 'adding', 'enzalutamide', 'to', 'abiraterone+adt', 'in', 'metastatic', 'hormone', 'sensitive', '#prostatecancer', 'congrats', 'to', 'and', 'the', 'whole', 'stampede', 'team', '#esmo2022', '.', 'no benefit', 'benefit of', 'of adding', 'adding enzalutamide', 'enzalutamide to', 'to abiraterone+adt', 'abiraterone+adt in', 'in metastatic', 'metastatic hormone', 'hormone sensitive', 'sensitive #prostatecancer', '#prostatecancer congrats', 'congrats to', 'to and', 'and the', 'the whole', 'whole stampede', 'stampede team', 'team #esmo2022', '#esmo2022 .', 'no benefit of', 'benefit of adding', 'of adding enzalutamide', 'adding enzalutamide to', 'enzalutamide to abiraterone+adt', 'to abiraterone+adt in', 'abiraterone+adt in metastatic', 'in metastatic hormone', 'metastatic hormone sensitive', 'hormone sensitive #prostatecancer', 'sensitive #prostatecancer congrats', '#prostatecancer congrats to', 'congrats to and', 'to and the', 'and the whole', 'the whole stampede', 'whole stampede team', 'stampede team #esmo2022', 'team #esmo2022 .', 'no benefit of adding', 'benefit of adding enzalutamide', 'of adding enzalutamide to', 'adding enzalutamide to abiraterone+adt', 'enzalutamide to abiraterone+adt in', 'to abiraterone+adt in metastatic', 'abiraterone+adt in metastatic hormone', 'in metastatic hormone sensitive', 'metastatic hormone sensitive #prostatecancer', 'hormone sensitive #prostatecancer congrats', 'sensitive #prostatecancer congrats to', '#prostatecancer congrats to and', 'congrats to and the', 'to and the whole', 'and the whole stampede', 'the whole stampede team', 'whole stampede team #esmo2022', 'stampede team #esmo2022 .', 'no benefit of adding enzalutamide', 'benefit of adding enzalutamide to', 'of adding enzalutamide to abiraterone+adt', 'adding enzalutamide to abiraterone+adt in', 'enzalutamide to abiraterone+adt in metastatic', 'to abiraterone+adt in metastatic hormone', 'abiraterone+adt in metastatic hormone sensitive', 'in metastatic hormone sensitive #prostatecancer', 'metastatic hormone sensitive #prostatecancer congrats', 'hormone sensitive #prostatecancer congrats to', 'sensitive #prostatecancer congrats to and', '#prostatecancer congrats to and the', 'congrats to and the whole', 'to and the whole stampede', 'and the whole stampede team', 'the whole stampede team #esmo2022', 'whole stampede team #esmo2022 .', 'no benefit of adding enzalutamide to', 'benefit of adding enzalutamide to abiraterone+adt', 'of adding enzalutamide to abiraterone+adt in', 'adding enzalutamide to abiraterone+adt in metastatic', 'enzalutamide to abiraterone+adt in metastatic hormone', 'to abiraterone+adt in metastatic hormone sensitive', 'abiraterone+adt in metastatic hormone sensitive #prostatecancer', 'in metastatic hormone sensitive #prostatecancer congrats', 'metastatic hormone sensitive #prostatecancer congrats to', 'hormone sensitive #prostatecancer congrats to and', 'sensitive #prostatecancer congrats to and the', '#prostatecancer congrats to and the whole', 'congrats to and the whole stampede', 'to and the whole stampede team', 'and the whole stampede team #esmo2022', 'the whole stampede team #esmo2022 .', 'no benefit of adding enzalutamide to abiraterone+adt', 'benefit of adding enzalutamide to abiraterone+adt in', 'of adding enzalutamide to abiraterone+adt in metastatic', 'adding enzalutamide to abiraterone+adt in metastatic hormone', 'enzalutamide to abiraterone+adt in metastatic hormone sensitive', 'to abiraterone+adt in metastatic hormone sensitive #prostatecancer', 'abiraterone+adt in metastatic hormone sensitive #prostatecancer congrats', 'in metastatic hormone sensitive #prostatecancer congrats to', 'metastatic hormone sensitive #prostatecancer congrats to and', 'hormone sensitive #prostatecancer congrats to and the', 'sensitive #prostatecancer congrats to and the whole', '#prostatecancer congrats to and the whole stampede', 'congrats to and the whole stampede team', 'to and the whole stampede team #esmo2022', 'and the whole stampede team #esmo2022 .', 'no benefit of adding enzalutamide to abiraterone+adt in', 'benefit of adding enzalutamide to abiraterone+adt in metastatic', 'of adding enzalutamide to abiraterone+adt in metastatic hormone', 'adding enzalutamide to abiraterone+adt in metastatic hormone sensitive', 'enzalutamide to abiraterone+adt in metastatic hormone sensitive #prostatecancer', 'to abiraterone+adt in metastatic hormone sensitive #prostatecancer congrats', 'abiraterone+adt in metastatic hormone sensitive #prostatecancer congrats to', 'in metastatic hormone sensitive #prostatecancer congrats to and', 'metastatic hormone sensitive #prostatecancer congrats to and the', 'hormone sensitive #prostatecancer congrats to and the whole', 'sensitive #prostatecancer congrats to and the whole stampede', '#prostatecancer congrats to and the whole stampede team', 'congrats to and the whole stampede team #esmo2022', 'to and the whole stampede team #esmo2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '62', 'tokens': ['adjuvant', 'atezolizumab', 'does', 'not', 'show', 'benefit', 'over', 'placebo', 'in', 'high', 'risk', 'renal', 'cancer', 'for', 'dfs/os.', 'no', 'benefit', 'even', 'in', 'm1', 'subgroup?', 'this', 'contrasts', 'the', 'pembro.', 'immotion150', 'showed', 'atezo', 'had', 'a', 'rr', '~25%', 'in', 'advanced', 'disease.', 'pd-l1', 'therapy', 'maybe', 'less', 'good', 'than', 'pd1', 'therapy', 'here.', '#esmo22', '.'], 'text_length': 46, 'triples': {'atezolizumab|not show': ([1, 1], [3, 4], 'negative')}, 'sentence': 'adjuvant atezolizumab does not show benefit over placebo in high risk renal cancer for dfs/os. no benefit even in m1 subgroup? this contrasts the pembro. immotion150 showed atezo had a rr ~25% in advanced disease. pd-l1 therapy maybe less good than pd1 therapy here. #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8)], 'span tokens': ['adjuvant', 'atezolizumab', 'does', 'not', 'show', 'benefit', 'over', 'placebo', 'in', 'high', 'risk', 'renal', 'cancer', 'for', 'dfs/os.', 'no', 'benefit', 'even', 'in', 'm1', 'subgroup?', 'this', 'contrasts', 'the', 'pembro.', 'immotion150', 'showed', 'atezo', 'had', 'a', 'rr', '~25%', 'in', 'advanced', 'disease.', 'pd-l1', 'therapy', 'maybe', 'less', 'good', 'than', 'pd1', 'therapy', 'here.', '#esmo22', '.', 'adjuvant atezolizumab', 'atezolizumab does', 'does not', 'not show', 'show benefit', 'benefit over', 'over placebo', 'placebo in', 'in high', 'high risk', 'risk renal', 'renal cancer', 'cancer for', 'for dfs/os.', 'dfs/os. no', 'no benefit', 'benefit even', 'even in', 'in m1', 'm1 subgroup?', 'subgroup? this', 'this contrasts', 'contrasts the', 'the pembro.', 'pembro. immotion150', 'immotion150 showed', 'showed atezo', 'atezo had', 'had a', 'a rr', 'rr ~25%', '~25% in', 'in advanced', 'advanced disease.', 'disease. pd-l1', 'pd-l1 therapy', 'therapy maybe', 'maybe less', 'less good', 'good than', 'than pd1', 'pd1 therapy', 'therapy here.', 'here. #esmo22', '#esmo22 .', 'adjuvant atezolizumab does', 'atezolizumab does not', 'does not show', 'not show benefit', 'show benefit over', 'benefit over placebo', 'over placebo in', 'placebo in high', 'in high risk', 'high risk renal', 'risk renal cancer', 'renal cancer for', 'cancer for dfs/os.', 'for dfs/os. no', 'dfs/os. no benefit', 'no benefit even', 'benefit even in', 'even in m1', 'in m1 subgroup?', 'm1 subgroup? this', 'subgroup? this contrasts', 'this contrasts the', 'contrasts the pembro.', 'the pembro. immotion150', 'pembro. immotion150 showed', 'immotion150 showed atezo', 'showed atezo had', 'atezo had a', 'had a rr', 'a rr ~25%', 'rr ~25% in', '~25% in advanced', 'in advanced disease.', 'advanced disease. pd-l1', 'disease. pd-l1 therapy', 'pd-l1 therapy maybe', 'therapy maybe less', 'maybe less good', 'less good than', 'good than pd1', 'than pd1 therapy', 'pd1 therapy here.', 'therapy here. #esmo22', 'here. #esmo22 .', 'adjuvant atezolizumab does not', 'atezolizumab does not show', 'does not show benefit', 'not show benefit over', 'show benefit over placebo', 'benefit over placebo in', 'over placebo in high', 'placebo in high risk', 'in high risk renal', 'high risk renal cancer', 'risk renal cancer for', 'renal cancer for dfs/os.', 'cancer for dfs/os. no', 'for dfs/os. no benefit', 'dfs/os. no benefit even', 'no benefit even in', 'benefit even in m1', 'even in m1 subgroup?', 'in m1 subgroup? this', 'm1 subgroup? this contrasts', 'subgroup? this contrasts the', 'this contrasts the pembro.', 'contrasts the pembro. immotion150', 'the pembro. immotion150 showed', 'pembro. immotion150 showed atezo', 'immotion150 showed atezo had', 'showed atezo had a', 'atezo had a rr', 'had a rr ~25%', 'a rr ~25% in', 'rr ~25% in advanced', '~25% in advanced disease.', 'in advanced disease. pd-l1', 'advanced disease. pd-l1 therapy', 'disease. pd-l1 therapy maybe', 'pd-l1 therapy maybe less', 'therapy maybe less good', 'maybe less good than', 'less good than pd1', 'good than pd1 therapy', 'than pd1 therapy here.', 'pd1 therapy here. #esmo22', 'therapy here. #esmo22 .', 'adjuvant atezolizumab does not show', 'atezolizumab does not show benefit', 'does not show benefit over', 'not show benefit over placebo', 'show benefit over placebo in', 'benefit over placebo in high', 'over placebo in high risk', 'placebo in high risk renal', 'in high risk renal cancer', 'high risk renal cancer for', 'risk renal cancer for dfs/os.', 'renal cancer for dfs/os. no', 'cancer for dfs/os. no benefit', 'for dfs/os. no benefit even', 'dfs/os. no benefit even in', 'no benefit even in m1', 'benefit even in m1 subgroup?', 'even in m1 subgroup? this', 'in m1 subgroup? this contrasts', 'm1 subgroup? this contrasts the', 'subgroup? this contrasts the pembro.', 'this contrasts the pembro. immotion150', 'contrasts the pembro. immotion150 showed', 'the pembro. immotion150 showed atezo', 'pembro. immotion150 showed atezo had', 'immotion150 showed atezo had a', 'showed atezo had a rr', 'atezo had a rr ~25%', 'had a rr ~25% in', 'a rr ~25% in advanced', 'rr ~25% in advanced disease.', '~25% in advanced disease. pd-l1', 'in advanced disease. pd-l1 therapy', 'advanced disease. pd-l1 therapy maybe', 'disease. pd-l1 therapy maybe less', 'pd-l1 therapy maybe less good', 'therapy maybe less good than', 'maybe less good than pd1', 'less good than pd1 therapy', 'good than pd1 therapy here.', 'than pd1 therapy here. #esmo22', 'pd1 therapy here. #esmo22 .', 'adjuvant atezolizumab does not show benefit', 'atezolizumab does not show benefit over', 'does not show benefit over placebo', 'not show benefit over placebo in', 'show benefit over placebo in high', 'benefit over placebo in high risk', 'over placebo in high risk renal', 'placebo in high risk renal cancer', 'in high risk renal cancer for', 'high risk renal cancer for dfs/os.', 'risk renal cancer for dfs/os. no', 'renal cancer for dfs/os. no benefit', 'cancer for dfs/os. no benefit even', 'for dfs/os. no benefit even in', 'dfs/os. no benefit even in m1', 'no benefit even in m1 subgroup?', 'benefit even in m1 subgroup? this', 'even in m1 subgroup? this contrasts', 'in m1 subgroup? this contrasts the', 'm1 subgroup? this contrasts the pembro.', 'subgroup? this contrasts the pembro. immotion150', 'this contrasts the pembro. immotion150 showed', 'contrasts the pembro. immotion150 showed atezo', 'the pembro. immotion150 showed atezo had', 'pembro. immotion150 showed atezo had a', 'immotion150 showed atezo had a rr', 'showed atezo had a rr ~25%', 'atezo had a rr ~25% in', 'had a rr ~25% in advanced', 'a rr ~25% in advanced disease.', 'rr ~25% in advanced disease. pd-l1', '~25% in advanced disease. pd-l1 therapy', 'in advanced disease. pd-l1 therapy maybe', 'advanced disease. pd-l1 therapy maybe less', 'disease. pd-l1 therapy maybe less good', 'pd-l1 therapy maybe less good than', 'therapy maybe less good than pd1', 'maybe less good than pd1 therapy', 'less good than pd1 therapy here.', 'good than pd1 therapy here. #esmo22', 'than pd1 therapy here. #esmo22 .', 'adjuvant atezolizumab does not show benefit over', 'atezolizumab does not show benefit over placebo', 'does not show benefit over placebo in', 'not show benefit over placebo in high', 'show benefit over placebo in high risk', 'benefit over placebo in high risk renal', 'over placebo in high risk renal cancer', 'placebo in high risk renal cancer for', 'in high risk renal cancer for dfs/os.', 'high risk renal cancer for dfs/os. no', 'risk renal cancer for dfs/os. no benefit', 'renal cancer for dfs/os. no benefit even', 'cancer for dfs/os. no benefit even in', 'for dfs/os. no benefit even in m1', 'dfs/os. no benefit even in m1 subgroup?', 'no benefit even in m1 subgroup? this', 'benefit even in m1 subgroup? this contrasts', 'even in m1 subgroup? this contrasts the', 'in m1 subgroup? this contrasts the pembro.', 'm1 subgroup? this contrasts the pembro. immotion150', 'subgroup? this contrasts the pembro. immotion150 showed', 'this contrasts the pembro. immotion150 showed atezo', 'contrasts the pembro. immotion150 showed atezo had', 'the pembro. immotion150 showed atezo had a', 'pembro. immotion150 showed atezo had a rr', 'immotion150 showed atezo had a rr ~25%', 'showed atezo had a rr ~25% in', 'atezo had a rr ~25% in advanced', 'had a rr ~25% in advanced disease.', 'a rr ~25% in advanced disease. pd-l1', 'rr ~25% in advanced disease. pd-l1 therapy', '~25% in advanced disease. pd-l1 therapy maybe', 'in advanced disease. pd-l1 therapy maybe less', 'advanced disease. pd-l1 therapy maybe less good', 'disease. pd-l1 therapy maybe less good than', 'pd-l1 therapy maybe less good than pd1', 'therapy maybe less good than pd1 therapy', 'maybe less good than pd1 therapy here.', 'less good than pd1 therapy here. #esmo22', 'good than pd1 therapy here. #esmo22 .', 'adjuvant atezolizumab does not show benefit over placebo', 'atezolizumab does not show benefit over placebo in', 'does not show benefit over placebo in high', 'not show benefit over placebo in high risk', 'show benefit over placebo in high risk renal', 'benefit over placebo in high risk renal cancer', 'over placebo in high risk renal cancer for', 'placebo in high risk renal cancer for dfs/os.', 'in high risk renal cancer for dfs/os. no', 'high risk renal cancer for dfs/os. no benefit', 'risk renal cancer for dfs/os. no benefit even', 'renal cancer for dfs/os. no benefit even in', 'cancer for dfs/os. no benefit even in m1', 'for dfs/os. no benefit even in m1 subgroup?', 'dfs/os. no benefit even in m1 subgroup? this', 'no benefit even in m1 subgroup? this contrasts', 'benefit even in m1 subgroup? this contrasts the', 'even in m1 subgroup? this contrasts the pembro.', 'in m1 subgroup? this contrasts the pembro. immotion150', 'm1 subgroup? this contrasts the pembro. immotion150 showed', 'subgroup? this contrasts the pembro. immotion150 showed atezo', 'this contrasts the pembro. immotion150 showed atezo had', 'contrasts the pembro. immotion150 showed atezo had a', 'the pembro. immotion150 showed atezo had a rr', 'pembro. immotion150 showed atezo had a rr ~25%', 'immotion150 showed atezo had a rr ~25% in', 'showed atezo had a rr ~25% in advanced', 'atezo had a rr ~25% in advanced disease.', 'had a rr ~25% in advanced disease. pd-l1', 'a rr ~25% in advanced disease. pd-l1 therapy', 'rr ~25% in advanced disease. pd-l1 therapy maybe', '~25% in advanced disease. pd-l1 therapy maybe less', 'in advanced disease. pd-l1 therapy maybe less good', 'advanced disease. pd-l1 therapy maybe less good than', 'disease. pd-l1 therapy maybe less good than pd1', 'pd-l1 therapy maybe less good than pd1 therapy', 'therapy maybe less good than pd1 therapy here.', 'maybe less good than pd1 therapy here. #esmo22', 'less good than pd1 therapy here. #esmo22 .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '63', 'tokens': ['"#esmo22', 'update', 'on', '#prostatecancer', '#', 'stampede', 'no', 'benefit', 'to', 'add', 'aa-p', 'to', '#enz', '#propel', 'olaparib', 'and', 'aa-p', 'shows', 'benefit', 'in', 'pfs', 'but', 'not', 'in', 'os', 'in', 'itt', 'increment', 'in', 'hrd+', 'and', 'brca', '#presto', 'does', 'aa-p', 'added', 'to', 'apa', 'add', 'benefit', 'in', 'm0', 'mcrpc?', '1a', 'end', 'point:', 'psa', 'pd', 'free-survival', '.'], 'text_length': 50, 'triples': {'#|aa-p': ([4, 4], [16, 16], 'positive')}, 'sentence': '"#esmo22 update on #prostatecancer # stampede no benefit to add aa-p to #enz #propel olaparib and aa-p shows benefit in pfs but not in os in itt increment in hrd+ and brca #presto does aa-p added to apa add benefit in m0 mcrpc? 1a end point: psa pd free-survival .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(16, 16)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8)], 'span tokens': ['"#esmo22', 'update', 'on', '#prostatecancer', '#', 'stampede', 'no', 'benefit', 'to', 'add', 'aa-p', 'to', '#enz', '#propel', 'olaparib', 'and', 'aa-p', 'shows', 'benefit', 'in', 'pfs', 'but', 'not', 'in', 'os', 'in', 'itt', 'increment', 'in', 'hrd+', 'and', 'brca', '#presto', 'does', 'aa-p', 'added', 'to', 'apa', 'add', 'benefit', 'in', 'm0', 'mcrpc?', '1a', 'end', 'point:', 'psa', 'pd', 'free-survival', '.', '"#esmo22 update', 'update on', 'on #prostatecancer', '#prostatecancer #', '# stampede', 'stampede no', 'no benefit', 'benefit to', 'to add', 'add aa-p', 'aa-p to', 'to #enz', '#enz #propel', '#propel olaparib', 'olaparib and', 'and aa-p', 'aa-p shows', 'shows benefit', 'benefit in', 'in pfs', 'pfs but', 'but not', 'not in', 'in os', 'os in', 'in itt', 'itt increment', 'increment in', 'in hrd+', 'hrd+ and', 'and brca', 'brca #presto', '#presto does', 'does aa-p', 'aa-p added', 'added to', 'to apa', 'apa add', 'add benefit', 'benefit in', 'in m0', 'm0 mcrpc?', 'mcrpc? 1a', '1a end', 'end point:', 'point: psa', 'psa pd', 'pd free-survival', 'free-survival .', '"#esmo22 update on', 'update on #prostatecancer', 'on #prostatecancer #', '#prostatecancer # stampede', '# stampede no', 'stampede no benefit', 'no benefit to', 'benefit to add', 'to add aa-p', 'add aa-p to', 'aa-p to #enz', 'to #enz #propel', '#enz #propel olaparib', '#propel olaparib and', 'olaparib and aa-p', 'and aa-p shows', 'aa-p shows benefit', 'shows benefit in', 'benefit in pfs', 'in pfs but', 'pfs but not', 'but not in', 'not in os', 'in os in', 'os in itt', 'in itt increment', 'itt increment in', 'increment in hrd+', 'in hrd+ and', 'hrd+ and brca', 'and brca #presto', 'brca #presto does', '#presto does aa-p', 'does aa-p added', 'aa-p added to', 'added to apa', 'to apa add', 'apa add benefit', 'add benefit in', 'benefit in m0', 'in m0 mcrpc?', 'm0 mcrpc? 1a', 'mcrpc? 1a end', '1a end point:', 'end point: psa', 'point: psa pd', 'psa pd free-survival', 'pd free-survival .', '"#esmo22 update on #prostatecancer', 'update on #prostatecancer #', 'on #prostatecancer # stampede', '#prostatecancer # stampede no', '# stampede no benefit', 'stampede no benefit to', 'no benefit to add', 'benefit to add aa-p', 'to add aa-p to', 'add aa-p to #enz', 'aa-p to #enz #propel', 'to #enz #propel olaparib', '#enz #propel olaparib and', '#propel olaparib and aa-p', 'olaparib and aa-p shows', 'and aa-p shows benefit', 'aa-p shows benefit in', 'shows benefit in pfs', 'benefit in pfs but', 'in pfs but not', 'pfs but not in', 'but not in os', 'not in os in', 'in os in itt', 'os in itt increment', 'in itt increment in', 'itt increment in hrd+', 'increment in hrd+ and', 'in hrd+ and brca', 'hrd+ and brca #presto', 'and brca #presto does', 'brca #presto does aa-p', '#presto does aa-p added', 'does aa-p added to', 'aa-p added to apa', 'added to apa add', 'to apa add benefit', 'apa add benefit in', 'add benefit in m0', 'benefit in m0 mcrpc?', 'in m0 mcrpc? 1a', 'm0 mcrpc? 1a end', 'mcrpc? 1a end point:', '1a end point: psa', 'end point: psa pd', 'point: psa pd free-survival', 'psa pd free-survival .', '"#esmo22 update on #prostatecancer #', 'update on #prostatecancer # stampede', 'on #prostatecancer # stampede no', '#prostatecancer # stampede no benefit', '# stampede no benefit to', 'stampede no benefit to add', 'no benefit to add aa-p', 'benefit to add aa-p to', 'to add aa-p to #enz', 'add aa-p to #enz #propel', 'aa-p to #enz #propel olaparib', 'to #enz #propel olaparib and', '#enz #propel olaparib and aa-p', '#propel olaparib and aa-p shows', 'olaparib and aa-p shows benefit', 'and aa-p shows benefit in', 'aa-p shows benefit in pfs', 'shows benefit in pfs but', 'benefit in pfs but not', 'in pfs but not in', 'pfs but not in os', 'but not in os in', 'not in os in itt', 'in os in itt increment', 'os in itt increment in', 'in itt increment in hrd+', 'itt increment in hrd+ and', 'increment in hrd+ and brca', 'in hrd+ and brca #presto', 'hrd+ and brca #presto does', 'and brca #presto does aa-p', 'brca #presto does aa-p added', '#presto does aa-p added to', 'does aa-p added to apa', 'aa-p added to apa add', 'added to apa add benefit', 'to apa add benefit in', 'apa add benefit in m0', 'add benefit in m0 mcrpc?', 'benefit in m0 mcrpc? 1a', 'in m0 mcrpc? 1a end', 'm0 mcrpc? 1a end point:', 'mcrpc? 1a end point: psa', '1a end point: psa pd', 'end point: psa pd free-survival', 'point: psa pd free-survival .', '"#esmo22 update on #prostatecancer # stampede', 'update on #prostatecancer # stampede no', 'on #prostatecancer # stampede no benefit', '#prostatecancer # stampede no benefit to', '# stampede no benefit to add', 'stampede no benefit to add aa-p', 'no benefit to add aa-p to', 'benefit to add aa-p to #enz', 'to add aa-p to #enz #propel', 'add aa-p to #enz #propel olaparib', 'aa-p to #enz #propel olaparib and', 'to #enz #propel olaparib and aa-p', '#enz #propel olaparib and aa-p shows', '#propel olaparib and aa-p shows benefit', 'olaparib and aa-p shows benefit in', 'and aa-p shows benefit in pfs', 'aa-p shows benefit in pfs but', 'shows benefit in pfs but not', 'benefit in pfs but not in', 'in pfs but not in os', 'pfs but not in os in', 'but not in os in itt', 'not in os in itt increment', 'in os in itt increment in', 'os in itt increment in hrd+', 'in itt increment in hrd+ and', 'itt increment in hrd+ and brca', 'increment in hrd+ and brca #presto', 'in hrd+ and brca #presto does', 'hrd+ and brca #presto does aa-p', 'and brca #presto does aa-p added', 'brca #presto does aa-p added to', '#presto does aa-p added to apa', 'does aa-p added to apa add', 'aa-p added to apa add benefit', 'added to apa add benefit in', 'to apa add benefit in m0', 'apa add benefit in m0 mcrpc?', 'add benefit in m0 mcrpc? 1a', 'benefit in m0 mcrpc? 1a end', 'in m0 mcrpc? 1a end point:', 'm0 mcrpc? 1a end point: psa', 'mcrpc? 1a end point: psa pd', '1a end point: psa pd free-survival', 'end point: psa pd free-survival .', '"#esmo22 update on #prostatecancer # stampede no', 'update on #prostatecancer # stampede no benefit', 'on #prostatecancer # stampede no benefit to', '#prostatecancer # stampede no benefit to add', '# stampede no benefit to add aa-p', 'stampede no benefit to add aa-p to', 'no benefit to add aa-p to #enz', 'benefit to add aa-p to #enz #propel', 'to add aa-p to #enz #propel olaparib', 'add aa-p to #enz #propel olaparib and', 'aa-p to #enz #propel olaparib and aa-p', 'to #enz #propel olaparib and aa-p shows', '#enz #propel olaparib and aa-p shows benefit', '#propel olaparib and aa-p shows benefit in', 'olaparib and aa-p shows benefit in pfs', 'and aa-p shows benefit in pfs but', 'aa-p shows benefit in pfs but not', 'shows benefit in pfs but not in', 'benefit in pfs but not in os', 'in pfs but not in os in', 'pfs but not in os in itt', 'but not in os in itt increment', 'not in os in itt increment in', 'in os in itt increment in hrd+', 'os in itt increment in hrd+ and', 'in itt increment in hrd+ and brca', 'itt increment in hrd+ and brca #presto', 'increment in hrd+ and brca #presto does', 'in hrd+ and brca #presto does aa-p', 'hrd+ and brca #presto does aa-p added', 'and brca #presto does aa-p added to', 'brca #presto does aa-p added to apa', '#presto does aa-p added to apa add', 'does aa-p added to apa add benefit', 'aa-p added to apa add benefit in', 'added to apa add benefit in m0', 'to apa add benefit in m0 mcrpc?', 'apa add benefit in m0 mcrpc? 1a', 'add benefit in m0 mcrpc? 1a end', 'benefit in m0 mcrpc? 1a end point:', 'in m0 mcrpc? 1a end point: psa', 'm0 mcrpc? 1a end point: psa pd', 'mcrpc? 1a end point: psa pd free-survival', '1a end point: psa pd free-survival .', '"#esmo22 update on #prostatecancer # stampede no benefit', 'update on #prostatecancer # stampede no benefit to', 'on #prostatecancer # stampede no benefit to add', '#prostatecancer # stampede no benefit to add aa-p', '# stampede no benefit to add aa-p to', 'stampede no benefit to add aa-p to #enz', 'no benefit to add aa-p to #enz #propel', 'benefit to add aa-p to #enz #propel olaparib', 'to add aa-p to #enz #propel olaparib and', 'add aa-p to #enz #propel olaparib and aa-p', 'aa-p to #enz #propel olaparib and aa-p shows', 'to #enz #propel olaparib and aa-p shows benefit', '#enz #propel olaparib and aa-p shows benefit in', '#propel olaparib and aa-p shows benefit in pfs', 'olaparib and aa-p shows benefit in pfs but', 'and aa-p shows benefit in pfs but not', 'aa-p shows benefit in pfs but not in', 'shows benefit in pfs but not in os', 'benefit in pfs but not in os in', 'in pfs but not in os in itt', 'pfs but not in os in itt increment', 'but not in os in itt increment in', 'not in os in itt increment in hrd+', 'in os in itt increment in hrd+ and', 'os in itt increment in hrd+ and brca', 'in itt increment in hrd+ and brca #presto', 'itt increment in hrd+ and brca #presto does', 'increment in hrd+ and brca #presto does aa-p', 'in hrd+ and brca #presto does aa-p added', 'hrd+ and brca #presto does aa-p added to', 'and brca #presto does aa-p added to apa', 'brca #presto does aa-p added to apa add', '#presto does aa-p added to apa add benefit', 'does aa-p added to apa add benefit in', 'aa-p added to apa add benefit in m0', 'added to apa add benefit in m0 mcrpc?', 'to apa add benefit in m0 mcrpc? 1a', 'apa add benefit in m0 mcrpc? 1a end', 'add benefit in m0 mcrpc? 1a end point:', 'benefit in m0 mcrpc? 1a end point: psa', 'in m0 mcrpc? 1a end point: psa pd', 'm0 mcrpc? 1a end point: psa pd free-survival', 'mcrpc? 1a end point: psa pd free-survival .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '64', 'tokens': ['dr.', 'nilton', 'vaishampayan', 'updated', 'the', 'results', 'of', 'ph3', 'vision', 'trial', '(', '177lu-psma-617', 'vs', 'soc)', 'with', 'subgroup', 'analysis.', 'overall', '177lu-psma-617', 'benefited', 'all', 'subgroups.', '#asco22', '.'], 'text_length': 24, 'triples': {'vision|updated': ([8, 8], [3, 3], 'neutral'), '( 177lu-psma-617 vs soc) with subgroup analysis. overall|177lu-psma-617': ([10, 17], [18, 18], 'positive')}, 'sentence': 'dr. nilton vaishampayan updated the results of ph3 vision trial ( 177lu-psma-617 vs soc) with subgroup analysis. overall 177lu-psma-617 benefited all subgroups. #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(8, 8), (10, 17)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(3, 3), (18, 18)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8)], 'span tokens': ['dr.', 'nilton', 'vaishampayan', 'updated', 'the', 'results', 'of', 'ph3', 'vision', 'trial', '(', '177lu-psma-617', 'vs', 'soc)', 'with', 'subgroup', 'analysis.', 'overall', '177lu-psma-617', 'benefited', 'all', 'subgroups.', '#asco22', '.', 'dr. nilton', 'nilton vaishampayan', 'vaishampayan updated', 'updated the', 'the results', 'results of', 'of ph3', 'ph3 vision', 'vision trial', 'trial (', '( 177lu-psma-617', '177lu-psma-617 vs', 'vs soc)', 'soc) with', 'with subgroup', 'subgroup analysis.', 'analysis. overall', 'overall 177lu-psma-617', '177lu-psma-617 benefited', 'benefited all', 'all subgroups.', 'subgroups. #asco22', '#asco22 .', 'dr. nilton vaishampayan', 'nilton vaishampayan updated', 'vaishampayan updated the', 'updated the results', 'the results of', 'results of ph3', 'of ph3 vision', 'ph3 vision trial', 'vision trial (', 'trial ( 177lu-psma-617', '( 177lu-psma-617 vs', '177lu-psma-617 vs soc)', 'vs soc) with', 'soc) with subgroup', 'with subgroup analysis.', 'subgroup analysis. overall', 'analysis. overall 177lu-psma-617', 'overall 177lu-psma-617 benefited', '177lu-psma-617 benefited all', 'benefited all subgroups.', 'all subgroups. #asco22', 'subgroups. #asco22 .', 'dr. nilton vaishampayan updated', 'nilton vaishampayan updated the', 'vaishampayan updated the results', 'updated the results of', 'the results of ph3', 'results of ph3 vision', 'of ph3 vision trial', 'ph3 vision trial (', 'vision trial ( 177lu-psma-617', 'trial ( 177lu-psma-617 vs', '( 177lu-psma-617 vs soc)', '177lu-psma-617 vs soc) with', 'vs soc) with subgroup', 'soc) with subgroup analysis.', 'with subgroup analysis. overall', 'subgroup analysis. overall 177lu-psma-617', 'analysis. overall 177lu-psma-617 benefited', 'overall 177lu-psma-617 benefited all', '177lu-psma-617 benefited all subgroups.', 'benefited all subgroups. #asco22', 'all subgroups. #asco22 .', 'dr. nilton vaishampayan updated the', 'nilton vaishampayan updated the results', 'vaishampayan updated the results of', 'updated the results of ph3', 'the results of ph3 vision', 'results of ph3 vision trial', 'of ph3 vision trial (', 'ph3 vision trial ( 177lu-psma-617', 'vision trial ( 177lu-psma-617 vs', 'trial ( 177lu-psma-617 vs soc)', '( 177lu-psma-617 vs soc) with', '177lu-psma-617 vs soc) with subgroup', 'vs soc) with subgroup analysis.', 'soc) with subgroup analysis. overall', 'with subgroup analysis. overall 177lu-psma-617', 'subgroup analysis. overall 177lu-psma-617 benefited', 'analysis. overall 177lu-psma-617 benefited all', 'overall 177lu-psma-617 benefited all subgroups.', '177lu-psma-617 benefited all subgroups. #asco22', 'benefited all subgroups. #asco22 .', 'dr. nilton vaishampayan updated the results', 'nilton vaishampayan updated the results of', 'vaishampayan updated the results of ph3', 'updated the results of ph3 vision', 'the results of ph3 vision trial', 'results of ph3 vision trial (', 'of ph3 vision trial ( 177lu-psma-617', 'ph3 vision trial ( 177lu-psma-617 vs', 'vision trial ( 177lu-psma-617 vs soc)', 'trial ( 177lu-psma-617 vs soc) with', '( 177lu-psma-617 vs soc) with subgroup', '177lu-psma-617 vs soc) with subgroup analysis.', 'vs soc) with subgroup analysis. overall', 'soc) with subgroup analysis. overall 177lu-psma-617', 'with subgroup analysis. overall 177lu-psma-617 benefited', 'subgroup analysis. overall 177lu-psma-617 benefited all', 'analysis. overall 177lu-psma-617 benefited all subgroups.', 'overall 177lu-psma-617 benefited all subgroups. #asco22', '177lu-psma-617 benefited all subgroups. #asco22 .', 'dr. nilton vaishampayan updated the results of', 'nilton vaishampayan updated the results of ph3', 'vaishampayan updated the results of ph3 vision', 'updated the results of ph3 vision trial', 'the results of ph3 vision trial (', 'results of ph3 vision trial ( 177lu-psma-617', 'of ph3 vision trial ( 177lu-psma-617 vs', 'ph3 vision trial ( 177lu-psma-617 vs soc)', 'vision trial ( 177lu-psma-617 vs soc) with', 'trial ( 177lu-psma-617 vs soc) with subgroup', '( 177lu-psma-617 vs soc) with subgroup analysis.', '177lu-psma-617 vs soc) with subgroup analysis. overall', 'vs soc) with subgroup analysis. overall 177lu-psma-617', 'soc) with subgroup analysis. overall 177lu-psma-617 benefited', 'with subgroup analysis. overall 177lu-psma-617 benefited all', 'subgroup analysis. overall 177lu-psma-617 benefited all subgroups.', 'analysis. overall 177lu-psma-617 benefited all subgroups. #asco22', 'overall 177lu-psma-617 benefited all subgroups. #asco22 .', 'dr. nilton vaishampayan updated the results of ph3', 'nilton vaishampayan updated the results of ph3 vision', 'vaishampayan updated the results of ph3 vision trial', 'updated the results of ph3 vision trial (', 'the results of ph3 vision trial ( 177lu-psma-617', 'results of ph3 vision trial ( 177lu-psma-617 vs', 'of ph3 vision trial ( 177lu-psma-617 vs soc)', 'ph3 vision trial ( 177lu-psma-617 vs soc) with', 'vision trial ( 177lu-psma-617 vs soc) with subgroup', 'trial ( 177lu-psma-617 vs soc) with subgroup analysis.', '( 177lu-psma-617 vs soc) with subgroup analysis. overall', '177lu-psma-617 vs soc) with subgroup analysis. overall 177lu-psma-617', 'vs soc) with subgroup analysis. overall 177lu-psma-617 benefited', 'soc) with subgroup analysis. overall 177lu-psma-617 benefited all', 'with subgroup analysis. overall 177lu-psma-617 benefited all subgroups.', 'subgroup analysis. overall 177lu-psma-617 benefited all subgroups. #asco22', 'analysis. overall 177lu-psma-617 benefited all subgroups. #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]]}, {'id': '65', 'tokens': ['no', 'esmo', 'meeting', 'seems', 'complete', 'without', 'one', 'important', 'presentation', 'from', 'the', '#', 'stampede', 'group!', '.'], 'text_length': 15, 'triples': {'#|without one important presentation': ([11, 11], [5, 8], 'neutral')}, 'sentence': 'no esmo meeting seems complete without one important presentation from the # stampede group! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(11, 11)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8)], 'span tokens': ['no', 'esmo', 'meeting', 'seems', 'complete', 'without', 'one', 'important', 'presentation', 'from', 'the', '#', 'stampede', 'group!', '.', 'no esmo', 'esmo meeting', 'meeting seems', 'seems complete', 'complete without', 'without one', 'one important', 'important presentation', 'presentation from', 'from the', 'the #', '# stampede', 'stampede group!', 'group! .', 'no esmo meeting', 'esmo meeting seems', 'meeting seems complete', 'seems complete without', 'complete without one', 'without one important', 'one important presentation', 'important presentation from', 'presentation from the', 'from the #', 'the # stampede', '# stampede group!', 'stampede group! .', 'no esmo meeting seems', 'esmo meeting seems complete', 'meeting seems complete without', 'seems complete without one', 'complete without one important', 'without one important presentation', 'one important presentation from', 'important presentation from the', 'presentation from the #', 'from the # stampede', 'the # stampede group!', '# stampede group! .', 'no esmo meeting seems complete', 'esmo meeting seems complete without', 'meeting seems complete without one', 'seems complete without one important', 'complete without one important presentation', 'without one important presentation from', 'one important presentation from the', 'important presentation from the #', 'presentation from the # stampede', 'from the # stampede group!', 'the # stampede group! .', 'no esmo meeting seems complete without', 'esmo meeting seems complete without one', 'meeting seems complete without one important', 'seems complete without one important presentation', 'complete without one important presentation from', 'without one important presentation from the', 'one important presentation from the #', 'important presentation from the # stampede', 'presentation from the # stampede group!', 'from the # stampede group! .', 'no esmo meeting seems complete without one', 'esmo meeting seems complete without one important', 'meeting seems complete without one important presentation', 'seems complete without one important presentation from', 'complete without one important presentation from the', 'without one important presentation from the #', 'one important presentation from the # stampede', 'important presentation from the # stampede group!', 'presentation from the # stampede group! .', 'no esmo meeting seems complete without one important', 'esmo meeting seems complete without one important presentation', 'meeting seems complete without one important presentation from', 'seems complete without one important presentation from the', 'complete without one important presentation from the #', 'without one important presentation from the # stampede', 'one important presentation from the # stampede group!', 'important presentation from the # stampede group! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '66', 'tokens': ['"everest', 'study', 'of', '12', 'months', 'adjuvant', 'everolimus', 'in', 'rcc.', 'several', 'updates', 'on', 'study', 'design,', 'final', 'analysis', 'without', 'all', 'prespecified', 'events.', 'almost', 'half', 'of', 'patients', 'in', 'everolimus', 'arm', 'discontinued', 'treatment', '#asco22', '#gucsm', '.'], 'text_length': 32, 'triples': {'"everest|several updates': ([0, 0], [9, 10], 'neutral'), 'everolimus in rcc. several updates on study design, final analysis without all prespecified events. almost half of patients in everolimus|discontinued': ([6, 25], [27, 27], 'negative')}, 'sentence': '"everest study of 12 months adjuvant everolimus in rcc. several updates on study design, final analysis without all prespecified events. almost half of patients in everolimus arm discontinued treatment #asco22 #gucsm .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (6, 25)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(9, 10), (27, 27)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 0, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['"everest', 'study', 'of', '12', 'months', 'adjuvant', 'everolimus', 'in', 'rcc.', 'several', 'updates', 'on', 'study', 'design,', 'final', 'analysis', 'without', 'all', 'prespecified', 'events.', 'almost', 'half', 'of', 'patients', 'in', 'everolimus', 'arm', 'discontinued', 'treatment', '#asco22', '#gucsm', '.', '"everest study', 'study of', 'of 12', '12 months', 'months adjuvant', 'adjuvant everolimus', 'everolimus in', 'in rcc.', 'rcc. several', 'several updates', 'updates on', 'on study', 'study design,', 'design, final', 'final analysis', 'analysis without', 'without all', 'all prespecified', 'prespecified events.', 'events. almost', 'almost half', 'half of', 'of patients', 'patients in', 'in everolimus', 'everolimus arm', 'arm discontinued', 'discontinued treatment', 'treatment #asco22', '#asco22 #gucsm', '#gucsm .', '"everest study of', 'study of 12', 'of 12 months', '12 months adjuvant', 'months adjuvant everolimus', 'adjuvant everolimus in', 'everolimus in rcc.', 'in rcc. several', 'rcc. several updates', 'several updates on', 'updates on study', 'on study design,', 'study design, final', 'design, final analysis', 'final analysis without', 'analysis without all', 'without all prespecified', 'all prespecified events.', 'prespecified events. almost', 'events. almost half', 'almost half of', 'half of patients', 'of patients in', 'patients in everolimus', 'in everolimus arm', 'everolimus arm discontinued', 'arm discontinued treatment', 'discontinued treatment #asco22', 'treatment #asco22 #gucsm', '#asco22 #gucsm .', '"everest study of 12', 'study of 12 months', 'of 12 months adjuvant', '12 months adjuvant everolimus', 'months adjuvant everolimus in', 'adjuvant everolimus in rcc.', 'everolimus in rcc. several', 'in rcc. several updates', 'rcc. several updates on', 'several updates on study', 'updates on study design,', 'on study design, final', 'study design, final analysis', 'design, final analysis without', 'final analysis without all', 'analysis without all prespecified', 'without all prespecified events.', 'all prespecified events. almost', 'prespecified events. almost half', 'events. almost half of', 'almost half of patients', 'half of patients in', 'of patients in everolimus', 'patients in everolimus arm', 'in everolimus arm discontinued', 'everolimus arm discontinued treatment', 'arm discontinued treatment #asco22', 'discontinued treatment #asco22 #gucsm', 'treatment #asco22 #gucsm .', '"everest study of 12 months', 'study of 12 months adjuvant', 'of 12 months adjuvant everolimus', '12 months adjuvant everolimus in', 'months adjuvant everolimus in rcc.', 'adjuvant everolimus in rcc. several', 'everolimus in rcc. several updates', 'in rcc. several updates on', 'rcc. several updates on study', 'several updates on study design,', 'updates on study design, final', 'on study design, final analysis', 'study design, final analysis without', 'design, final analysis without all', 'final analysis without all prespecified', 'analysis without all prespecified events.', 'without all prespecified events. almost', 'all prespecified events. almost half', 'prespecified events. almost half of', 'events. almost half of patients', 'almost half of patients in', 'half of patients in everolimus', 'of patients in everolimus arm', 'patients in everolimus arm discontinued', 'in everolimus arm discontinued treatment', 'everolimus arm discontinued treatment #asco22', 'arm discontinued treatment #asco22 #gucsm', 'discontinued treatment #asco22 #gucsm .', '"everest study of 12 months adjuvant', 'study of 12 months adjuvant everolimus', 'of 12 months adjuvant everolimus in', '12 months adjuvant everolimus in rcc.', 'months adjuvant everolimus in rcc. several', 'adjuvant everolimus in rcc. several updates', 'everolimus in rcc. several updates on', 'in rcc. several updates on study', 'rcc. several updates on study design,', 'several updates on study design, final', 'updates on study design, final analysis', 'on study design, final analysis without', 'study design, final analysis without all', 'design, final analysis without all prespecified', 'final analysis without all prespecified events.', 'analysis without all prespecified events. almost', 'without all prespecified events. almost half', 'all prespecified events. almost half of', 'prespecified events. almost half of patients', 'events. almost half of patients in', 'almost half of patients in everolimus', 'half of patients in everolimus arm', 'of patients in everolimus arm discontinued', 'patients in everolimus arm discontinued treatment', 'in everolimus arm discontinued treatment #asco22', 'everolimus arm discontinued treatment #asco22 #gucsm', 'arm discontinued treatment #asco22 #gucsm .', '"everest study of 12 months adjuvant everolimus', 'study of 12 months adjuvant everolimus in', 'of 12 months adjuvant everolimus in rcc.', '12 months adjuvant everolimus in rcc. several', 'months adjuvant everolimus in rcc. several updates', 'adjuvant everolimus in rcc. several updates on', 'everolimus in rcc. several updates on study', 'in rcc. several updates on study design,', 'rcc. several updates on study design, final', 'several updates on study design, final analysis', 'updates on study design, final analysis without', 'on study design, final analysis without all', 'study design, final analysis without all prespecified', 'design, final analysis without all prespecified events.', 'final analysis without all prespecified events. almost', 'analysis without all prespecified events. almost half', 'without all prespecified events. almost half of', 'all prespecified events. almost half of patients', 'prespecified events. almost half of patients in', 'events. almost half of patients in everolimus', 'almost half of patients in everolimus arm', 'half of patients in everolimus arm discontinued', 'of patients in everolimus arm discontinued treatment', 'patients in everolimus arm discontinued treatment #asco22', 'in everolimus arm discontinued treatment #asco22 #gucsm', 'everolimus arm discontinued treatment #asco22 #gucsm .', '"everest study of 12 months adjuvant everolimus in', 'study of 12 months adjuvant everolimus in rcc.', 'of 12 months adjuvant everolimus in rcc. several', '12 months adjuvant everolimus in rcc. several updates', 'months adjuvant everolimus in rcc. several updates on', 'adjuvant everolimus in rcc. several updates on study', 'everolimus in rcc. several updates on study design,', 'in rcc. several updates on study design, final', 'rcc. several updates on study design, final analysis', 'several updates on study design, final analysis without', 'updates on study design, final analysis without all', 'on study design, final analysis without all prespecified', 'study design, final analysis without all prespecified events.', 'design, final analysis without all prespecified events. almost', 'final analysis without all prespecified events. almost half', 'analysis without all prespecified events. almost half of', 'without all prespecified events. almost half of patients', 'all prespecified events. almost half of patients in', 'prespecified events. almost half of patients in everolimus', 'events. almost half of patients in everolimus arm', 'almost half of patients in everolimus arm discontinued', 'half of patients in everolimus arm discontinued treatment', 'of patients in everolimus arm discontinued treatment #asco22', 'patients in everolimus arm discontinued treatment #asco22 #gucsm', 'in everolimus arm discontinued treatment #asco22 #gucsm .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '67', 'tokens': ['late-breaking', 'abstract', 'for', 'codebreak-200', ':', 'the', 'first-ever', 'positive', 'clinical', 'trial', 'of', 'a', 'kras', 'inhibitor', 'in', '#lungcancer.', '#lcsm', '#esmo22', 'press', 'release', 'data', 'presentation', '.'], 'text_length': 23, 'triples': {'codebreak-200|the first-ever positive clinical': ([3, 3], [5, 8], 'positive')}, 'sentence': 'late-breaking abstract for codebreak-200 : the first-ever positive clinical trial of a kras inhibitor in #lungcancer. #lcsm #esmo22 press release data presentation .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8)], 'span tokens': ['late-breaking', 'abstract', 'for', 'codebreak-200', ':', 'the', 'first-ever', 'positive', 'clinical', 'trial', 'of', 'a', 'kras', 'inhibitor', 'in', '#lungcancer.', '#lcsm', '#esmo22', 'press', 'release', 'data', 'presentation', '.', 'late-breaking abstract', 'abstract for', 'for codebreak-200', 'codebreak-200 :', ': the', 'the first-ever', 'first-ever positive', 'positive clinical', 'clinical trial', 'trial of', 'of a', 'a kras', 'kras inhibitor', 'inhibitor in', 'in #lungcancer.', '#lungcancer. #lcsm', '#lcsm #esmo22', '#esmo22 press', 'press release', 'release data', 'data presentation', 'presentation .', 'late-breaking abstract for', 'abstract for codebreak-200', 'for codebreak-200 :', 'codebreak-200 : the', ': the first-ever', 'the first-ever positive', 'first-ever positive clinical', 'positive clinical trial', 'clinical trial of', 'trial of a', 'of a kras', 'a kras inhibitor', 'kras inhibitor in', 'inhibitor in #lungcancer.', 'in #lungcancer. #lcsm', '#lungcancer. #lcsm #esmo22', '#lcsm #esmo22 press', '#esmo22 press release', 'press release data', 'release data presentation', 'data presentation .', 'late-breaking abstract for codebreak-200', 'abstract for codebreak-200 :', 'for codebreak-200 : the', 'codebreak-200 : the first-ever', ': the first-ever positive', 'the first-ever positive clinical', 'first-ever positive clinical trial', 'positive clinical trial of', 'clinical trial of a', 'trial of a kras', 'of a kras inhibitor', 'a kras inhibitor in', 'kras inhibitor in #lungcancer.', 'inhibitor in #lungcancer. #lcsm', 'in #lungcancer. #lcsm #esmo22', '#lungcancer. #lcsm #esmo22 press', '#lcsm #esmo22 press release', '#esmo22 press release data', 'press release data presentation', 'release data presentation .', 'late-breaking abstract for codebreak-200 :', 'abstract for codebreak-200 : the', 'for codebreak-200 : the first-ever', 'codebreak-200 : the first-ever positive', ': the first-ever positive clinical', 'the first-ever positive clinical trial', 'first-ever positive clinical trial of', 'positive clinical trial of a', 'clinical trial of a kras', 'trial of a kras inhibitor', 'of a kras inhibitor in', 'a kras inhibitor in #lungcancer.', 'kras inhibitor in #lungcancer. #lcsm', 'inhibitor in #lungcancer. #lcsm #esmo22', 'in #lungcancer. #lcsm #esmo22 press', '#lungcancer. #lcsm #esmo22 press release', '#lcsm #esmo22 press release data', '#esmo22 press release data presentation', 'press release data presentation .', 'late-breaking abstract for codebreak-200 : the', 'abstract for codebreak-200 : the first-ever', 'for codebreak-200 : the first-ever positive', 'codebreak-200 : the first-ever positive clinical', ': the first-ever positive clinical trial', 'the first-ever positive clinical trial of', 'first-ever positive clinical trial of a', 'positive clinical trial of a kras', 'clinical trial of a kras inhibitor', 'trial of a kras inhibitor in', 'of a kras inhibitor in #lungcancer.', 'a kras inhibitor in #lungcancer. #lcsm', 'kras inhibitor in #lungcancer. #lcsm #esmo22', 'inhibitor in #lungcancer. #lcsm #esmo22 press', 'in #lungcancer. #lcsm #esmo22 press release', '#lungcancer. #lcsm #esmo22 press release data', '#lcsm #esmo22 press release data presentation', '#esmo22 press release data presentation .', 'late-breaking abstract for codebreak-200 : the first-ever', 'abstract for codebreak-200 : the first-ever positive', 'for codebreak-200 : the first-ever positive clinical', 'codebreak-200 : the first-ever positive clinical trial', ': the first-ever positive clinical trial of', 'the first-ever positive clinical trial of a', 'first-ever positive clinical trial of a kras', 'positive clinical trial of a kras inhibitor', 'clinical trial of a kras inhibitor in', 'trial of a kras inhibitor in #lungcancer.', 'of a kras inhibitor in #lungcancer. #lcsm', 'a kras inhibitor in #lungcancer. #lcsm #esmo22', 'kras inhibitor in #lungcancer. #lcsm #esmo22 press', 'inhibitor in #lungcancer. #lcsm #esmo22 press release', 'in #lungcancer. #lcsm #esmo22 press release data', '#lungcancer. #lcsm #esmo22 press release data presentation', '#lcsm #esmo22 press release data presentation .', 'late-breaking abstract for codebreak-200 : the first-ever positive', 'abstract for codebreak-200 : the first-ever positive clinical', 'for codebreak-200 : the first-ever positive clinical trial', 'codebreak-200 : the first-ever positive clinical trial of', ': the first-ever positive clinical trial of a', 'the first-ever positive clinical trial of a kras', 'first-ever positive clinical trial of a kras inhibitor', 'positive clinical trial of a kras inhibitor in', 'clinical trial of a kras inhibitor in #lungcancer.', 'trial of a kras inhibitor in #lungcancer. #lcsm', 'of a kras inhibitor in #lungcancer. #lcsm #esmo22', 'a kras inhibitor in #lungcancer. #lcsm #esmo22 press', 'kras inhibitor in #lungcancer. #lcsm #esmo22 press release', 'inhibitor in #lungcancer. #lcsm #esmo22 press release data', 'in #lungcancer. #lcsm #esmo22 press release data presentation', '#lungcancer. #lcsm #esmo22 press release data presentation .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '68', 'tokens': ['#asco22', 'presents', 'updated', 'os', 'in', '#', 'enzamet', 'with', 'interesting', 'subgroup', 'analysis.', '.'], 'text_length': 12, 'triples': {'#|presents updated os in # enzamet with': ([5, 5], [1, 7], 'positive')}, 'sentence': '#asco22 presents updated os in # enzamet with interesting subgroup analysis. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 0, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8)], 'span tokens': ['#asco22', 'presents', 'updated', 'os', 'in', '#', 'enzamet', 'with', 'interesting', 'subgroup', 'analysis.', '.', '#asco22 presents', 'presents updated', 'updated os', 'os in', 'in #', '# enzamet', 'enzamet with', 'with interesting', 'interesting subgroup', 'subgroup analysis.', 'analysis. .', '#asco22 presents updated', 'presents updated os', 'updated os in', 'os in #', 'in # enzamet', '# enzamet with', 'enzamet with interesting', 'with interesting subgroup', 'interesting subgroup analysis.', 'subgroup analysis. .', '#asco22 presents updated os', 'presents updated os in', 'updated os in #', 'os in # enzamet', 'in # enzamet with', '# enzamet with interesting', 'enzamet with interesting subgroup', 'with interesting subgroup analysis.', 'interesting subgroup analysis. .', '#asco22 presents updated os in', 'presents updated os in #', 'updated os in # enzamet', 'os in # enzamet with', 'in # enzamet with interesting', '# enzamet with interesting subgroup', 'enzamet with interesting subgroup analysis.', 'with interesting subgroup analysis. .', '#asco22 presents updated os in #', 'presents updated os in # enzamet', 'updated os in # enzamet with', 'os in # enzamet with interesting', 'in # enzamet with interesting subgroup', '# enzamet with interesting subgroup analysis.', 'enzamet with interesting subgroup analysis. .', '#asco22 presents updated os in # enzamet', 'presents updated os in # enzamet with', 'updated os in # enzamet with interesting', 'os in # enzamet with interesting subgroup', 'in # enzamet with interesting subgroup analysis.', '# enzamet with interesting subgroup analysis. .', '#asco22 presents updated os in # enzamet with', 'presents updated os in # enzamet with interesting', 'updated os in # enzamet with interesting subgroup', 'os in # enzamet with interesting subgroup analysis.', 'in # enzamet with interesting subgroup analysis. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '69', 'tokens': ['#asco22', 'ironically,', 'enzamet', 'provides', 'the', 'best', 'evidence', 'yet', 'that', 'docetaxel', 'layered', 'on', 'ar', 'targeted', 'therapy', 'is', 'still', 'valuable', 'for', 'patients', 'with', 'the', 'poorest', 'prognosis', '(ie', 'high', 'volume,', 'synchronous', 'prostate', 'cancer).', 'os', 'benefit', 'seen', 'in', 'the', 'first', '2-3', 'years', 'only', '.'], 'text_length': 40, 'triples': {'enzamet|provides the best evidence yet that docetaxel layered on ar targeted therapy is still valuable for patients with the poorest prognosis (ie high volume, synchronous prostate cancer). os benefit': ([2, 2], [3, 31], 'positive')}, 'sentence': '#asco22 ironically, enzamet provides the best evidence yet that docetaxel layered on ar targeted therapy is still valuable for patients with the poorest prognosis (ie high volume, synchronous prostate cancer). os benefit seen in the first 2-3 years only .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 31)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8)], 'span tokens': ['#asco22', 'ironically,', 'enzamet', 'provides', 'the', 'best', 'evidence', 'yet', 'that', 'docetaxel', 'layered', 'on', 'ar', 'targeted', 'therapy', 'is', 'still', 'valuable', 'for', 'patients', 'with', 'the', 'poorest', 'prognosis', '(ie', 'high', 'volume,', 'synchronous', 'prostate', 'cancer).', 'os', 'benefit', 'seen', 'in', 'the', 'first', '2-3', 'years', 'only', '.', '#asco22 ironically,', 'ironically, enzamet', 'enzamet provides', 'provides the', 'the best', 'best evidence', 'evidence yet', 'yet that', 'that docetaxel', 'docetaxel layered', 'layered on', 'on ar', 'ar targeted', 'targeted therapy', 'therapy is', 'is still', 'still valuable', 'valuable for', 'for patients', 'patients with', 'with the', 'the poorest', 'poorest prognosis', 'prognosis (ie', '(ie high', 'high volume,', 'volume, synchronous', 'synchronous prostate', 'prostate cancer).', 'cancer). os', 'os benefit', 'benefit seen', 'seen in', 'in the', 'the first', 'first 2-3', '2-3 years', 'years only', 'only .', '#asco22 ironically, enzamet', 'ironically, enzamet provides', 'enzamet provides the', 'provides the best', 'the best evidence', 'best evidence yet', 'evidence yet that', 'yet that docetaxel', 'that docetaxel layered', 'docetaxel layered on', 'layered on ar', 'on ar targeted', 'ar targeted therapy', 'targeted therapy is', 'therapy is still', 'is still valuable', 'still valuable for', 'valuable for patients', 'for patients with', 'patients with the', 'with the poorest', 'the poorest prognosis', 'poorest prognosis (ie', 'prognosis (ie high', '(ie high volume,', 'high volume, synchronous', 'volume, synchronous prostate', 'synchronous prostate cancer).', 'prostate cancer). os', 'cancer). os benefit', 'os benefit seen', 'benefit seen in', 'seen in the', 'in the first', 'the first 2-3', 'first 2-3 years', '2-3 years only', 'years only .', '#asco22 ironically, enzamet provides', 'ironically, enzamet provides the', 'enzamet provides the best', 'provides the best evidence', 'the best evidence yet', 'best evidence yet that', 'evidence yet that docetaxel', 'yet that docetaxel layered', 'that docetaxel layered on', 'docetaxel layered on ar', 'layered on ar targeted', 'on ar targeted therapy', 'ar targeted therapy is', 'targeted therapy is still', 'therapy is still valuable', 'is still valuable for', 'still valuable for patients', 'valuable for patients with', 'for patients with the', 'patients with the poorest', 'with the poorest prognosis', 'the poorest prognosis (ie', 'poorest prognosis (ie high', 'prognosis (ie high volume,', '(ie high volume, synchronous', 'high volume, synchronous prostate', 'volume, synchronous prostate cancer).', 'synchronous prostate cancer). os', 'prostate cancer). os benefit', 'cancer). os benefit seen', 'os benefit seen in', 'benefit seen in the', 'seen in the first', 'in the first 2-3', 'the first 2-3 years', 'first 2-3 years only', '2-3 years only .', '#asco22 ironically, enzamet provides the', 'ironically, enzamet provides the best', 'enzamet provides the best evidence', 'provides the best evidence yet', 'the best evidence yet that', 'best evidence yet that docetaxel', 'evidence yet that docetaxel layered', 'yet that docetaxel layered on', 'that docetaxel layered on ar', 'docetaxel layered on ar targeted', 'layered on ar targeted therapy', 'on ar targeted therapy is', 'ar targeted therapy is still', 'targeted therapy is still valuable', 'therapy is still valuable for', 'is still valuable for patients', 'still valuable for patients with', 'valuable for patients with the', 'for patients with the poorest', 'patients with the poorest prognosis', 'with the poorest prognosis (ie', 'the poorest prognosis (ie high', 'poorest prognosis (ie high volume,', 'prognosis (ie high volume, synchronous', '(ie high volume, synchronous prostate', 'high volume, synchronous prostate cancer).', 'volume, synchronous prostate cancer). os', 'synchronous prostate cancer). os benefit', 'prostate cancer). os benefit seen', 'cancer). os benefit seen in', 'os benefit seen in the', 'benefit seen in the first', 'seen in the first 2-3', 'in the first 2-3 years', 'the first 2-3 years only', 'first 2-3 years only .', '#asco22 ironically, enzamet provides the best', 'ironically, enzamet provides the best evidence', 'enzamet provides the best evidence yet', 'provides the best evidence yet that', 'the best evidence yet that docetaxel', 'best evidence yet that docetaxel layered', 'evidence yet that docetaxel layered on', 'yet that docetaxel layered on ar', 'that docetaxel layered on ar targeted', 'docetaxel layered on ar targeted therapy', 'layered on ar targeted therapy is', 'on ar targeted therapy is still', 'ar targeted therapy is still valuable', 'targeted therapy is still valuable for', 'therapy is still valuable for patients', 'is still valuable for patients with', 'still valuable for patients with the', 'valuable for patients with the poorest', 'for patients with the poorest prognosis', 'patients with the poorest prognosis (ie', 'with the poorest prognosis (ie high', 'the poorest prognosis (ie high volume,', 'poorest prognosis (ie high volume, synchronous', 'prognosis (ie high volume, synchronous prostate', '(ie high volume, synchronous prostate cancer).', 'high volume, synchronous prostate cancer). os', 'volume, synchronous prostate cancer). os benefit', 'synchronous prostate cancer). os benefit seen', 'prostate cancer). os benefit seen in', 'cancer). os benefit seen in the', 'os benefit seen in the first', 'benefit seen in the first 2-3', 'seen in the first 2-3 years', 'in the first 2-3 years only', 'the first 2-3 years only .', '#asco22 ironically, enzamet provides the best evidence', 'ironically, enzamet provides the best evidence yet', 'enzamet provides the best evidence yet that', 'provides the best evidence yet that docetaxel', 'the best evidence yet that docetaxel layered', 'best evidence yet that docetaxel layered on', 'evidence yet that docetaxel layered on ar', 'yet that docetaxel layered on ar targeted', 'that docetaxel layered on ar targeted therapy', 'docetaxel layered on ar targeted therapy is', 'layered on ar targeted therapy is still', 'on ar targeted therapy is still valuable', 'ar targeted therapy is still valuable for', 'targeted therapy is still valuable for patients', 'therapy is still valuable for patients with', 'is still valuable for patients with the', 'still valuable for patients with the poorest', 'valuable for patients with the poorest prognosis', 'for patients with the poorest prognosis (ie', 'patients with the poorest prognosis (ie high', 'with the poorest prognosis (ie high volume,', 'the poorest prognosis (ie high volume, synchronous', 'poorest prognosis (ie high volume, synchronous prostate', 'prognosis (ie high volume, synchronous prostate cancer).', '(ie high volume, synchronous prostate cancer). os', 'high volume, synchronous prostate cancer). os benefit', 'volume, synchronous prostate cancer). os benefit seen', 'synchronous prostate cancer). os benefit seen in', 'prostate cancer). os benefit seen in the', 'cancer). os benefit seen in the first', 'os benefit seen in the first 2-3', 'benefit seen in the first 2-3 years', 'seen in the first 2-3 years only', 'in the first 2-3 years only .', '#asco22 ironically, enzamet provides the best evidence yet', 'ironically, enzamet provides the best evidence yet that', 'enzamet provides the best evidence yet that docetaxel', 'provides the best evidence yet that docetaxel layered', 'the best evidence yet that docetaxel layered on', 'best evidence yet that docetaxel layered on ar', 'evidence yet that docetaxel layered on ar targeted', 'yet that docetaxel layered on ar targeted therapy', 'that docetaxel layered on ar targeted therapy is', 'docetaxel layered on ar targeted therapy is still', 'layered on ar targeted therapy is still valuable', 'on ar targeted therapy is still valuable for', 'ar targeted therapy is still valuable for patients', 'targeted therapy is still valuable for patients with', 'therapy is still valuable for patients with the', 'is still valuable for patients with the poorest', 'still valuable for patients with the poorest prognosis', 'valuable for patients with the poorest prognosis (ie', 'for patients with the poorest prognosis (ie high', 'patients with the poorest prognosis (ie high volume,', 'with the poorest prognosis (ie high volume, synchronous', 'the poorest prognosis (ie high volume, synchronous prostate', 'poorest prognosis (ie high volume, synchronous prostate cancer).', 'prognosis (ie high volume, synchronous prostate cancer). os', '(ie high volume, synchronous prostate cancer). os benefit', 'high volume, synchronous prostate cancer). os benefit seen', 'volume, synchronous prostate cancer). os benefit seen in', 'synchronous prostate cancer). os benefit seen in the', 'prostate cancer). os benefit seen in the first', 'cancer). os benefit seen in the first 2-3', 'os benefit seen in the first 2-3 years', 'benefit seen in the first 2-3 years only', 'seen in the first 2-3 years only .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '70', 'tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial', 'in', 'men', 'with', 'mhspc', '#prostatecancer,', 'addition', 'of', 'abiraterone', 'to', 'adt', 'continues', 'to', 'os.', 'no', 'benefit', 'of', 'adding', 'enza', 'to', 'abi.', 'congrats', '.'], 'text_length': 29, 'triples': {'stampede|continues to os. no benefit': ([5, 5], [17, 21], 'neutral')}, 'sentence': '#esmo22 abs# lba62: in the stampede trial in men with mhspc #prostatecancer, addition of abiraterone to adt continues to os. no benefit of adding enza to abi. congrats .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 21)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8)], 'span tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial', 'in', 'men', 'with', 'mhspc', '#prostatecancer,', 'addition', 'of', 'abiraterone', 'to', 'adt', 'continues', 'to', 'os.', 'no', 'benefit', 'of', 'adding', 'enza', 'to', 'abi.', 'congrats', '.', '#esmo22 abs#', 'abs# lba62:', 'lba62: in', 'in the', 'the stampede', 'stampede trial', 'trial in', 'in men', 'men with', 'with mhspc', 'mhspc #prostatecancer,', '#prostatecancer, addition', 'addition of', 'of abiraterone', 'abiraterone to', 'to adt', 'adt continues', 'continues to', 'to os.', 'os. no', 'no benefit', 'benefit of', 'of adding', 'adding enza', 'enza to', 'to abi.', 'abi. congrats', 'congrats .', '#esmo22 abs# lba62:', 'abs# lba62: in', 'lba62: in the', 'in the stampede', 'the stampede trial', 'stampede trial in', 'trial in men', 'in men with', 'men with mhspc', 'with mhspc #prostatecancer,', 'mhspc #prostatecancer, addition', '#prostatecancer, addition of', 'addition of abiraterone', 'of abiraterone to', 'abiraterone to adt', 'to adt continues', 'adt continues to', 'continues to os.', 'to os. no', 'os. no benefit', 'no benefit of', 'benefit of adding', 'of adding enza', 'adding enza to', 'enza to abi.', 'to abi. congrats', 'abi. congrats .', '#esmo22 abs# lba62: in', 'abs# lba62: in the', 'lba62: in the stampede', 'in the stampede trial', 'the stampede trial in', 'stampede trial in men', 'trial in men with', 'in men with mhspc', 'men with mhspc #prostatecancer,', 'with mhspc #prostatecancer, addition', 'mhspc #prostatecancer, addition of', '#prostatecancer, addition of abiraterone', 'addition of abiraterone to', 'of abiraterone to adt', 'abiraterone to adt continues', 'to adt continues to', 'adt continues to os.', 'continues to os. no', 'to os. no benefit', 'os. no benefit of', 'no benefit of adding', 'benefit of adding enza', 'of adding enza to', 'adding enza to abi.', 'enza to abi. congrats', 'to abi. congrats .', '#esmo22 abs# lba62: in the', 'abs# lba62: in the stampede', 'lba62: in the stampede trial', 'in the stampede trial in', 'the stampede trial in men', 'stampede trial in men with', 'trial in men with mhspc', 'in men with mhspc #prostatecancer,', 'men with mhspc #prostatecancer, addition', 'with mhspc #prostatecancer, addition of', 'mhspc #prostatecancer, addition of abiraterone', '#prostatecancer, addition of abiraterone to', 'addition of abiraterone to adt', 'of abiraterone to adt continues', 'abiraterone to adt continues to', 'to adt continues to os.', 'adt continues to os. no', 'continues to os. no benefit', 'to os. no benefit of', 'os. no benefit of adding', 'no benefit of adding enza', 'benefit of adding enza to', 'of adding enza to abi.', 'adding enza to abi. congrats', 'enza to abi. congrats .', '#esmo22 abs# lba62: in the stampede', 'abs# lba62: in the stampede trial', 'lba62: in the stampede trial in', 'in the stampede trial in men', 'the stampede trial in men with', 'stampede trial in men with mhspc', 'trial in men with mhspc #prostatecancer,', 'in men with mhspc #prostatecancer, addition', 'men with mhspc #prostatecancer, addition of', 'with mhspc #prostatecancer, addition of abiraterone', 'mhspc #prostatecancer, addition of abiraterone to', '#prostatecancer, addition of abiraterone to adt', 'addition of abiraterone to adt continues', 'of abiraterone to adt continues to', 'abiraterone to adt continues to os.', 'to adt continues to os. no', 'adt continues to os. no benefit', 'continues to os. no benefit of', 'to os. no benefit of adding', 'os. no benefit of adding enza', 'no benefit of adding enza to', 'benefit of adding enza to abi.', 'of adding enza to abi. congrats', 'adding enza to abi. congrats .', '#esmo22 abs# lba62: in the stampede trial', 'abs# lba62: in the stampede trial in', 'lba62: in the stampede trial in men', 'in the stampede trial in men with', 'the stampede trial in men with mhspc', 'stampede trial in men with mhspc #prostatecancer,', 'trial in men with mhspc #prostatecancer, addition', 'in men with mhspc #prostatecancer, addition of', 'men with mhspc #prostatecancer, addition of abiraterone', 'with mhspc #prostatecancer, addition of abiraterone to', 'mhspc #prostatecancer, addition of abiraterone to adt', '#prostatecancer, addition of abiraterone to adt continues', 'addition of abiraterone to adt continues to', 'of abiraterone to adt continues to os.', 'abiraterone to adt continues to os. no', 'to adt continues to os. no benefit', 'adt continues to os. no benefit of', 'continues to os. no benefit of adding', 'to os. no benefit of adding enza', 'os. no benefit of adding enza to', 'no benefit of adding enza to abi.', 'benefit of adding enza to abi. congrats', 'of adding enza to abi. congrats .', '#esmo22 abs# lba62: in the stampede trial in', 'abs# lba62: in the stampede trial in men', 'lba62: in the stampede trial in men with', 'in the stampede trial in men with mhspc', 'the stampede trial in men with mhspc #prostatecancer,', 'stampede trial in men with mhspc #prostatecancer, addition', 'trial in men with mhspc #prostatecancer, addition of', 'in men with mhspc #prostatecancer, addition of abiraterone', 'men with mhspc #prostatecancer, addition of abiraterone to', 'with mhspc #prostatecancer, addition of abiraterone to adt', 'mhspc #prostatecancer, addition of abiraterone to adt continues', '#prostatecancer, addition of abiraterone to adt continues to', 'addition of abiraterone to adt continues to os.', 'of abiraterone to adt continues to os. no', 'abiraterone to adt continues to os. no benefit', 'to adt continues to os. no benefit of', 'adt continues to os. no benefit of adding', 'continues to os. no benefit of adding enza', 'to os. no benefit of adding enza to', 'os. no benefit of adding enza to abi.', 'no benefit of adding enza to abi. congrats', 'benefit of adding enza to abi. congrats .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '71', 'tokens': ['"#ASH22', 'LBA', '-', 'Jennifer', 'Brown', 'et', 'al.', 'Zanubrutinib', 'demonstrated', 'superior', 'PFS', 'and', 'favorable', 'safety', 'profile', 'over', 'ibrutinib', 'in', 'patients', 'with', 'relapsed/refractory', 'CLL/SLL.', 'Just', 'published', 'in', '@NEJM', '👉', 'https://t.co/6BBlf9HOH8', 'https://t.co/aeJjIXDdEe', '.'], 'text_length': 30, 'triples': {'Zanubrutinib|demonstrated superior PFS and favorable safety': ([7, 7], [8, 13], 'positive'), 'ibrutinib|demonstrated superior PFS and favorable safety profile over': ([16, 16], [8, 15], 'negative')}, 'sentence': '"#ASH22 LBA - Jennifer Brown et al. Zanubrutinib demonstrated superior PFS and favorable safety profile over ibrutinib in patients with relapsed/refractory CLL/SLL. Just published in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(7, 7), (16, 16)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(8, 13), (8, 15)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8)], 'span tokens': ['"#ASH22', 'LBA', '-', 'Jennifer', 'Brown', 'et', 'al.', 'Zanubrutinib', 'demonstrated', 'superior', 'PFS', 'and', 'favorable', 'safety', 'profile', 'over', 'ibrutinib', 'in', 'patients', 'with', 'relapsed/refractory', 'CLL/SLL.', 'Just', 'published', 'in', '@NEJM', '👉', 'https://t.co/6BBlf9HOH8', 'https://t.co/aeJjIXDdEe', '.', '"#ASH22 LBA', 'LBA -', '- Jennifer', 'Jennifer Brown', 'Brown et', 'et al.', 'al. Zanubrutinib', 'Zanubrutinib demonstrated', 'demonstrated superior', 'superior PFS', 'PFS and', 'and favorable', 'favorable safety', 'safety profile', 'profile over', 'over ibrutinib', 'ibrutinib in', 'in patients', 'patients with', 'with relapsed/refractory', 'relapsed/refractory CLL/SLL.', 'CLL/SLL. Just', 'Just published', 'published in', 'in @NEJM', '@NEJM 👉', '👉 https://t.co/6BBlf9HOH8', 'https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe', 'https://t.co/aeJjIXDdEe .', '"#ASH22 LBA -', 'LBA - Jennifer', '- Jennifer Brown', 'Jennifer Brown et', 'Brown et al.', 'et al. Zanubrutinib', 'al. Zanubrutinib demonstrated', 'Zanubrutinib demonstrated superior', 'demonstrated superior PFS', 'superior PFS and', 'PFS and favorable', 'and favorable safety', 'favorable safety profile', 'safety profile over', 'profile over ibrutinib', 'over ibrutinib in', 'ibrutinib in patients', 'in patients with', 'patients with relapsed/refractory', 'with relapsed/refractory CLL/SLL.', 'relapsed/refractory CLL/SLL. Just', 'CLL/SLL. Just published', 'Just published in', 'published in @NEJM', 'in @NEJM 👉', '@NEJM 👉 https://t.co/6BBlf9HOH8', '👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe', 'https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe .', '"#ASH22 LBA - Jennifer', 'LBA - Jennifer Brown', '- Jennifer Brown et', 'Jennifer Brown et al.', 'Brown et al. Zanubrutinib', 'et al. Zanubrutinib demonstrated', 'al. Zanubrutinib demonstrated superior', 'Zanubrutinib demonstrated superior PFS', 'demonstrated superior PFS and', 'superior PFS and favorable', 'PFS and favorable safety', 'and favorable safety profile', 'favorable safety profile over', 'safety profile over ibrutinib', 'profile over ibrutinib in', 'over ibrutinib in patients', 'ibrutinib in patients with', 'in patients with relapsed/refractory', 'patients with relapsed/refractory CLL/SLL.', 'with relapsed/refractory CLL/SLL. Just', 'relapsed/refractory CLL/SLL. Just published', 'CLL/SLL. Just published in', 'Just published in @NEJM', 'published in @NEJM 👉', 'in @NEJM 👉 https://t.co/6BBlf9HOH8', '@NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe', '👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe .', '"#ASH22 LBA - Jennifer Brown', 'LBA - Jennifer Brown et', '- Jennifer Brown et al.', 'Jennifer Brown et al. Zanubrutinib', 'Brown et al. Zanubrutinib demonstrated', 'et al. Zanubrutinib demonstrated superior', 'al. Zanubrutinib demonstrated superior PFS', 'Zanubrutinib demonstrated superior PFS and', 'demonstrated superior PFS and favorable', 'superior PFS and favorable safety', 'PFS and favorable safety profile', 'and favorable safety profile over', 'favorable safety profile over ibrutinib', 'safety profile over ibrutinib in', 'profile over ibrutinib in patients', 'over ibrutinib in patients with', 'ibrutinib in patients with relapsed/refractory', 'in patients with relapsed/refractory CLL/SLL.', 'patients with relapsed/refractory CLL/SLL. Just', 'with relapsed/refractory CLL/SLL. Just published', 'relapsed/refractory CLL/SLL. Just published in', 'CLL/SLL. Just published in @NEJM', 'Just published in @NEJM 👉', 'published in @NEJM 👉 https://t.co/6BBlf9HOH8', 'in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe', '@NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe .', '"#ASH22 LBA - Jennifer Brown et', 'LBA - Jennifer Brown et al.', '- Jennifer Brown et al. Zanubrutinib', 'Jennifer Brown et al. Zanubrutinib demonstrated', 'Brown et al. Zanubrutinib demonstrated superior', 'et al. Zanubrutinib demonstrated superior PFS', 'al. Zanubrutinib demonstrated superior PFS and', 'Zanubrutinib demonstrated superior PFS and favorable', 'demonstrated superior PFS and favorable safety', 'superior PFS and favorable safety profile', 'PFS and favorable safety profile over', 'and favorable safety profile over ibrutinib', 'favorable safety profile over ibrutinib in', 'safety profile over ibrutinib in patients', 'profile over ibrutinib in patients with', 'over ibrutinib in patients with relapsed/refractory', 'ibrutinib in patients with relapsed/refractory CLL/SLL.', 'in patients with relapsed/refractory CLL/SLL. Just', 'patients with relapsed/refractory CLL/SLL. Just published', 'with relapsed/refractory CLL/SLL. Just published in', 'relapsed/refractory CLL/SLL. Just published in @NEJM', 'CLL/SLL. Just published in @NEJM 👉', 'Just published in @NEJM 👉 https://t.co/6BBlf9HOH8', 'published in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe', 'in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe .', '"#ASH22 LBA - Jennifer Brown et al.', 'LBA - Jennifer Brown et al. Zanubrutinib', '- Jennifer Brown et al. Zanubrutinib demonstrated', 'Jennifer Brown et al. Zanubrutinib demonstrated superior', 'Brown et al. Zanubrutinib demonstrated superior PFS', 'et al. Zanubrutinib demonstrated superior PFS and', 'al. Zanubrutinib demonstrated superior PFS and favorable', 'Zanubrutinib demonstrated superior PFS and favorable safety', 'demonstrated superior PFS and favorable safety profile', 'superior PFS and favorable safety profile over', 'PFS and favorable safety profile over ibrutinib', 'and favorable safety profile over ibrutinib in', 'favorable safety profile over ibrutinib in patients', 'safety profile over ibrutinib in patients with', 'profile over ibrutinib in patients with relapsed/refractory', 'over ibrutinib in patients with relapsed/refractory CLL/SLL.', 'ibrutinib in patients with relapsed/refractory CLL/SLL. Just', 'in patients with relapsed/refractory CLL/SLL. Just published', 'patients with relapsed/refractory CLL/SLL. Just published in', 'with relapsed/refractory CLL/SLL. Just published in @NEJM', 'relapsed/refractory CLL/SLL. Just published in @NEJM 👉', 'CLL/SLL. Just published in @NEJM 👉 https://t.co/6BBlf9HOH8', 'Just published in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe', 'published in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe .', '"#ASH22 LBA - Jennifer Brown et al. Zanubrutinib', 'LBA - Jennifer Brown et al. Zanubrutinib demonstrated', '- Jennifer Brown et al. Zanubrutinib demonstrated superior', 'Jennifer Brown et al. Zanubrutinib demonstrated superior PFS', 'Brown et al. Zanubrutinib demonstrated superior PFS and', 'et al. Zanubrutinib demonstrated superior PFS and favorable', 'al. Zanubrutinib demonstrated superior PFS and favorable safety', 'Zanubrutinib demonstrated superior PFS and favorable safety profile', 'demonstrated superior PFS and favorable safety profile over', 'superior PFS and favorable safety profile over ibrutinib', 'PFS and favorable safety profile over ibrutinib in', 'and favorable safety profile over ibrutinib in patients', 'favorable safety profile over ibrutinib in patients with', 'safety profile over ibrutinib in patients with relapsed/refractory', 'profile over ibrutinib in patients with relapsed/refractory CLL/SLL.', 'over ibrutinib in patients with relapsed/refractory CLL/SLL. Just', 'ibrutinib in patients with relapsed/refractory CLL/SLL. Just published', 'in patients with relapsed/refractory CLL/SLL. Just published in', 'patients with relapsed/refractory CLL/SLL. Just published in @NEJM', 'with relapsed/refractory CLL/SLL. Just published in @NEJM 👉', 'relapsed/refractory CLL/SLL. Just published in @NEJM 👉 https://t.co/6BBlf9HOH8', 'CLL/SLL. Just published in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe', 'Just published in @NEJM 👉 https://t.co/6BBlf9HOH8 https://t.co/aeJjIXDdEe .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '72', 'tokens': ['in', 'propel,', 'parpi+abi', 'is', 'effective', 'as', 'the', '1st', 'line', 'treatment', 'for', 'mcrpc', 'regardless', 'of', 'hrr', 'status.', 'os', 'is', 'maturing.', 'simple', 'is', 'the', 'best!', '#esmo22', '#prostatecancer', '.'], 'text_length': 26, 'triples': {'propel,|effective as the 1st line treatment for mcrpc regardless of hrr status. os is maturing. simple is the best!': ([1, 1], [4, 22], 'positive'), 'parpi+abi|effective as the 1st line treatment for mcrpc regardless of hrr status. os is maturing. simple is the best!': ([2, 2], [4, 22], 'positive')}, 'sentence': 'in propel, parpi+abi is effective as the 1st line treatment for mcrpc regardless of hrr status. os is maturing. simple is the best! #esmo22 #prostatecancer .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(1, 1), (2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['in', 'propel,', 'parpi+abi', 'is', 'effective', 'as', 'the', '1st', 'line', 'treatment', 'for', 'mcrpc', 'regardless', 'of', 'hrr', 'status.', 'os', 'is', 'maturing.', 'simple', 'is', 'the', 'best!', '#esmo22', '#prostatecancer', '.', 'in propel,', 'propel, parpi+abi', 'parpi+abi is', 'is effective', 'effective as', 'as the', 'the 1st', '1st line', 'line treatment', 'treatment for', 'for mcrpc', 'mcrpc regardless', 'regardless of', 'of hrr', 'hrr status.', 'status. os', 'os is', 'is maturing.', 'maturing. simple', 'simple is', 'is the', 'the best!', 'best! #esmo22', '#esmo22 #prostatecancer', '#prostatecancer .', 'in propel, parpi+abi', 'propel, parpi+abi is', 'parpi+abi is effective', 'is effective as', 'effective as the', 'as the 1st', 'the 1st line', '1st line treatment', 'line treatment for', 'treatment for mcrpc', 'for mcrpc regardless', 'mcrpc regardless of', 'regardless of hrr', 'of hrr status.', 'hrr status. os', 'status. os is', 'os is maturing.', 'is maturing. simple', 'maturing. simple is', 'simple is the', 'is the best!', 'the best! #esmo22', 'best! #esmo22 #prostatecancer', '#esmo22 #prostatecancer .', 'in propel, parpi+abi is', 'propel, parpi+abi is effective', 'parpi+abi is effective as', 'is effective as the', 'effective as the 1st', 'as the 1st line', 'the 1st line treatment', '1st line treatment for', 'line treatment for mcrpc', 'treatment for mcrpc regardless', 'for mcrpc regardless of', 'mcrpc regardless of hrr', 'regardless of hrr status.', 'of hrr status. os', 'hrr status. os is', 'status. os is maturing.', 'os is maturing. simple', 'is maturing. simple is', 'maturing. simple is the', 'simple is the best!', 'is the best! #esmo22', 'the best! #esmo22 #prostatecancer', 'best! #esmo22 #prostatecancer .', 'in propel, parpi+abi is effective', 'propel, parpi+abi is effective as', 'parpi+abi is effective as the', 'is effective as the 1st', 'effective as the 1st line', 'as the 1st line treatment', 'the 1st line treatment for', '1st line treatment for mcrpc', 'line treatment for mcrpc regardless', 'treatment for mcrpc regardless of', 'for mcrpc regardless of hrr', 'mcrpc regardless of hrr status.', 'regardless of hrr status. os', 'of hrr status. os is', 'hrr status. os is maturing.', 'status. os is maturing. simple', 'os is maturing. simple is', 'is maturing. simple is the', 'maturing. simple is the best!', 'simple is the best! #esmo22', 'is the best! #esmo22 #prostatecancer', 'the best! #esmo22 #prostatecancer .', 'in propel, parpi+abi is effective as', 'propel, parpi+abi is effective as the', 'parpi+abi is effective as the 1st', 'is effective as the 1st line', 'effective as the 1st line treatment', 'as the 1st line treatment for', 'the 1st line treatment for mcrpc', '1st line treatment for mcrpc regardless', 'line treatment for mcrpc regardless of', 'treatment for mcrpc regardless of hrr', 'for mcrpc regardless of hrr status.', 'mcrpc regardless of hrr status. os', 'regardless of hrr status. os is', 'of hrr status. os is maturing.', 'hrr status. os is maturing. simple', 'status. os is maturing. simple is', 'os is maturing. simple is the', 'is maturing. simple is the best!', 'maturing. simple is the best! #esmo22', 'simple is the best! #esmo22 #prostatecancer', 'is the best! #esmo22 #prostatecancer .', 'in propel, parpi+abi is effective as the', 'propel, parpi+abi is effective as the 1st', 'parpi+abi is effective as the 1st line', 'is effective as the 1st line treatment', 'effective as the 1st line treatment for', 'as the 1st line treatment for mcrpc', 'the 1st line treatment for mcrpc regardless', '1st line treatment for mcrpc regardless of', 'line treatment for mcrpc regardless of hrr', 'treatment for mcrpc regardless of hrr status.', 'for mcrpc regardless of hrr status. os', 'mcrpc regardless of hrr status. os is', 'regardless of hrr status. os is maturing.', 'of hrr status. os is maturing. simple', 'hrr status. os is maturing. simple is', 'status. os is maturing. simple is the', 'os is maturing. simple is the best!', 'is maturing. simple is the best! #esmo22', 'maturing. simple is the best! #esmo22 #prostatecancer', 'simple is the best! #esmo22 #prostatecancer .', 'in propel, parpi+abi is effective as the 1st', 'propel, parpi+abi is effective as the 1st line', 'parpi+abi is effective as the 1st line treatment', 'is effective as the 1st line treatment for', 'effective as the 1st line treatment for mcrpc', 'as the 1st line treatment for mcrpc regardless', 'the 1st line treatment for mcrpc regardless of', '1st line treatment for mcrpc regardless of hrr', 'line treatment for mcrpc regardless of hrr status.', 'treatment for mcrpc regardless of hrr status. os', 'for mcrpc regardless of hrr status. os is', 'mcrpc regardless of hrr status. os is maturing.', 'regardless of hrr status. os is maturing. simple', 'of hrr status. os is maturing. simple is', 'hrr status. os is maturing. simple is the', 'status. os is maturing. simple is the best!', 'os is maturing. simple is the best! #esmo22', 'is maturing. simple is the best! #esmo22 #prostatecancer', 'maturing. simple is the best! #esmo22 #prostatecancer .'], 'spans_aspect_label': [0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '73', 'tokens': ['excellent', 'presentation', 'by', 'on', 'updated', 'data', 'from', 'enzamet', 'trial', 'on', 'effect', 'of', 'volume,', 'm1', 'timing,', 'and', 'docetaxel', 'use.', 'benefit', 'of', 'enzalutamide', 'independent', 'of', 'docetaxel', 'use.', '.'], 'text_length': 26, 'triples': {'enzamet|excellent': ([7, 7], [0, 0], 'positive'), 'enzalutamide|benefit of enzalutamide independent': ([20, 20], [18, 21], 'positive')}, 'sentence': 'excellent presentation by on updated data from enzamet trial on effect of volume, m1 timing, and docetaxel use. benefit of enzalutamide independent of docetaxel use. .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(7, 7), (20, 20)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(0, 0), (18, 21)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['excellent', 'presentation', 'by', 'on', 'updated', 'data', 'from', 'enzamet', 'trial', 'on', 'effect', 'of', 'volume,', 'm1', 'timing,', 'and', 'docetaxel', 'use.', 'benefit', 'of', 'enzalutamide', 'independent', 'of', 'docetaxel', 'use.', '.', 'excellent presentation', 'presentation by', 'by on', 'on updated', 'updated data', 'data from', 'from enzamet', 'enzamet trial', 'trial on', 'on effect', 'effect of', 'of volume,', 'volume, m1', 'm1 timing,', 'timing, and', 'and docetaxel', 'docetaxel use.', 'use. benefit', 'benefit of', 'of enzalutamide', 'enzalutamide independent', 'independent of', 'of docetaxel', 'docetaxel use.', 'use. .', 'excellent presentation by', 'presentation by on', 'by on updated', 'on updated data', 'updated data from', 'data from enzamet', 'from enzamet trial', 'enzamet trial on', 'trial on effect', 'on effect of', 'effect of volume,', 'of volume, m1', 'volume, m1 timing,', 'm1 timing, and', 'timing, and docetaxel', 'and docetaxel use.', 'docetaxel use. benefit', 'use. benefit of', 'benefit of enzalutamide', 'of enzalutamide independent', 'enzalutamide independent of', 'independent of docetaxel', 'of docetaxel use.', 'docetaxel use. .', 'excellent presentation by on', 'presentation by on updated', 'by on updated data', 'on updated data from', 'updated data from enzamet', 'data from enzamet trial', 'from enzamet trial on', 'enzamet trial on effect', 'trial on effect of', 'on effect of volume,', 'effect of volume, m1', 'of volume, m1 timing,', 'volume, m1 timing, and', 'm1 timing, and docetaxel', 'timing, and docetaxel use.', 'and docetaxel use. benefit', 'docetaxel use. benefit of', 'use. benefit of enzalutamide', 'benefit of enzalutamide independent', 'of enzalutamide independent of', 'enzalutamide independent of docetaxel', 'independent of docetaxel use.', 'of docetaxel use. .', 'excellent presentation by on updated', 'presentation by on updated data', 'by on updated data from', 'on updated data from enzamet', 'updated data from enzamet trial', 'data from enzamet trial on', 'from enzamet trial on effect', 'enzamet trial on effect of', 'trial on effect of volume,', 'on effect of volume, m1', 'effect of volume, m1 timing,', 'of volume, m1 timing, and', 'volume, m1 timing, and docetaxel', 'm1 timing, and docetaxel use.', 'timing, and docetaxel use. benefit', 'and docetaxel use. benefit of', 'docetaxel use. benefit of enzalutamide', 'use. benefit of enzalutamide independent', 'benefit of enzalutamide independent of', 'of enzalutamide independent of docetaxel', 'enzalutamide independent of docetaxel use.', 'independent of docetaxel use. .', 'excellent presentation by on updated data', 'presentation by on updated data from', 'by on updated data from enzamet', 'on updated data from enzamet trial', 'updated data from enzamet trial on', 'data from enzamet trial on effect', 'from enzamet trial on effect of', 'enzamet trial on effect of volume,', 'trial on effect of volume, m1', 'on effect of volume, m1 timing,', 'effect of volume, m1 timing, and', 'of volume, m1 timing, and docetaxel', 'volume, m1 timing, and docetaxel use.', 'm1 timing, and docetaxel use. benefit', 'timing, and docetaxel use. benefit of', 'and docetaxel use. benefit of enzalutamide', 'docetaxel use. benefit of enzalutamide independent', 'use. benefit of enzalutamide independent of', 'benefit of enzalutamide independent of docetaxel', 'of enzalutamide independent of docetaxel use.', 'enzalutamide independent of docetaxel use. .', 'excellent presentation by on updated data from', 'presentation by on updated data from enzamet', 'by on updated data from enzamet trial', 'on updated data from enzamet trial on', 'updated data from enzamet trial on effect', 'data from enzamet trial on effect of', 'from enzamet trial on effect of volume,', 'enzamet trial on effect of volume, m1', 'trial on effect of volume, m1 timing,', 'on effect of volume, m1 timing, and', 'effect of volume, m1 timing, and docetaxel', 'of volume, m1 timing, and docetaxel use.', 'volume, m1 timing, and docetaxel use. benefit', 'm1 timing, and docetaxel use. benefit of', 'timing, and docetaxel use. benefit of enzalutamide', 'and docetaxel use. benefit of enzalutamide independent', 'docetaxel use. benefit of enzalutamide independent of', 'use. benefit of enzalutamide independent of docetaxel', 'benefit of enzalutamide independent of docetaxel use.', 'of enzalutamide independent of docetaxel use. .', 'excellent presentation by on updated data from enzamet', 'presentation by on updated data from enzamet trial', 'by on updated data from enzamet trial on', 'on updated data from enzamet trial on effect', 'updated data from enzamet trial on effect of', 'data from enzamet trial on effect of volume,', 'from enzamet trial on effect of volume, m1', 'enzamet trial on effect of volume, m1 timing,', 'trial on effect of volume, m1 timing, and', 'on effect of volume, m1 timing, and docetaxel', 'effect of volume, m1 timing, and docetaxel use.', 'of volume, m1 timing, and docetaxel use. benefit', 'volume, m1 timing, and docetaxel use. benefit of', 'm1 timing, and docetaxel use. benefit of enzalutamide', 'timing, and docetaxel use. benefit of enzalutamide independent', 'and docetaxel use. benefit of enzalutamide independent of', 'docetaxel use. benefit of enzalutamide independent of docetaxel', 'use. benefit of enzalutamide independent of docetaxel use.', 'benefit of enzalutamide independent of docetaxel use. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '74', 'tokens': ['"beautiful', 'presentation-', 'stampede', '781', 'pts', 'transcriptome', 'treated', 'ar', 'targeted', 'predefined', 'stats', 'prognostic', 'effects', 'of', '54', 'signatures', 'transcriptomic', 'signatures', 'show', 'promise', 'in', 'stratifying', 'hspc', 'pts', 'and', 'can', 'help', 'uncover', 'biological', 'basis', 'of', 'disease', '#esmo22', '.'], 'text_length': 34, 'triples': {'stampede|"beautiful presentation- stampede 781 pts transcriptome treated ar targeted predefined stats prognostic effects of 54 signatures transcriptomic signatures show promise': ([2, 2], [0, 19], 'positive')}, 'sentence': '"beautiful presentation- stampede 781 pts transcriptome treated ar targeted predefined stats prognostic effects of 54 signatures transcriptomic signatures show promise in stratifying hspc pts and can help uncover biological basis of disease #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 19)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['"beautiful', 'presentation-', 'stampede', '781', 'pts', 'transcriptome', 'treated', 'ar', 'targeted', 'predefined', 'stats', 'prognostic', 'effects', 'of', '54', 'signatures', 'transcriptomic', 'signatures', 'show', 'promise', 'in', 'stratifying', 'hspc', 'pts', 'and', 'can', 'help', 'uncover', 'biological', 'basis', 'of', 'disease', '#esmo22', '.', '"beautiful presentation-', 'presentation- stampede', 'stampede 781', '781 pts', 'pts transcriptome', 'transcriptome treated', 'treated ar', 'ar targeted', 'targeted predefined', 'predefined stats', 'stats prognostic', 'prognostic effects', 'effects of', 'of 54', '54 signatures', 'signatures transcriptomic', 'transcriptomic signatures', 'signatures show', 'show promise', 'promise in', 'in stratifying', 'stratifying hspc', 'hspc pts', 'pts and', 'and can', 'can help', 'help uncover', 'uncover biological', 'biological basis', 'basis of', 'of disease', 'disease #esmo22', '#esmo22 .', '"beautiful presentation- stampede', 'presentation- stampede 781', 'stampede 781 pts', '781 pts transcriptome', 'pts transcriptome treated', 'transcriptome treated ar', 'treated ar targeted', 'ar targeted predefined', 'targeted predefined stats', 'predefined stats prognostic', 'stats prognostic effects', 'prognostic effects of', 'effects of 54', 'of 54 signatures', '54 signatures transcriptomic', 'signatures transcriptomic signatures', 'transcriptomic signatures show', 'signatures show promise', 'show promise in', 'promise in stratifying', 'in stratifying hspc', 'stratifying hspc pts', 'hspc pts and', 'pts and can', 'and can help', 'can help uncover', 'help uncover biological', 'uncover biological basis', 'biological basis of', 'basis of disease', 'of disease #esmo22', 'disease #esmo22 .', '"beautiful presentation- stampede 781', 'presentation- stampede 781 pts', 'stampede 781 pts transcriptome', '781 pts transcriptome treated', 'pts transcriptome treated ar', 'transcriptome treated ar targeted', 'treated ar targeted predefined', 'ar targeted predefined stats', 'targeted predefined stats prognostic', 'predefined stats prognostic effects', 'stats prognostic effects of', 'prognostic effects of 54', 'effects of 54 signatures', 'of 54 signatures transcriptomic', '54 signatures transcriptomic signatures', 'signatures transcriptomic signatures show', 'transcriptomic signatures show promise', 'signatures show promise in', 'show promise in stratifying', 'promise in stratifying hspc', 'in stratifying hspc pts', 'stratifying hspc pts and', 'hspc pts and can', 'pts and can help', 'and can help uncover', 'can help uncover biological', 'help uncover biological basis', 'uncover biological basis of', 'biological basis of disease', 'basis of disease #esmo22', 'of disease #esmo22 .', '"beautiful presentation- stampede 781 pts', 'presentation- stampede 781 pts transcriptome', 'stampede 781 pts transcriptome treated', '781 pts transcriptome treated ar', 'pts transcriptome treated ar targeted', 'transcriptome treated ar targeted predefined', 'treated ar targeted predefined stats', 'ar targeted predefined stats prognostic', 'targeted predefined stats prognostic effects', 'predefined stats prognostic effects of', 'stats prognostic effects of 54', 'prognostic effects of 54 signatures', 'effects of 54 signatures transcriptomic', 'of 54 signatures transcriptomic signatures', '54 signatures transcriptomic signatures show', 'signatures transcriptomic signatures show promise', 'transcriptomic signatures show promise in', 'signatures show promise in stratifying', 'show promise in stratifying hspc', 'promise in stratifying hspc pts', 'in stratifying hspc pts and', 'stratifying hspc pts and can', 'hspc pts and can help', 'pts and can help uncover', 'and can help uncover biological', 'can help uncover biological basis', 'help uncover biological basis of', 'uncover biological basis of disease', 'biological basis of disease #esmo22', 'basis of disease #esmo22 .', '"beautiful presentation- stampede 781 pts transcriptome', 'presentation- stampede 781 pts transcriptome treated', 'stampede 781 pts transcriptome treated ar', '781 pts transcriptome treated ar targeted', 'pts transcriptome treated ar targeted predefined', 'transcriptome treated ar targeted predefined stats', 'treated ar targeted predefined stats prognostic', 'ar targeted predefined stats prognostic effects', 'targeted predefined stats prognostic effects of', 'predefined stats prognostic effects of 54', 'stats prognostic effects of 54 signatures', 'prognostic effects of 54 signatures transcriptomic', 'effects of 54 signatures transcriptomic signatures', 'of 54 signatures transcriptomic signatures show', '54 signatures transcriptomic signatures show promise', 'signatures transcriptomic signatures show promise in', 'transcriptomic signatures show promise in stratifying', 'signatures show promise in stratifying hspc', 'show promise in stratifying hspc pts', 'promise in stratifying hspc pts and', 'in stratifying hspc pts and can', 'stratifying hspc pts and can help', 'hspc pts and can help uncover', 'pts and can help uncover biological', 'and can help uncover biological basis', 'can help uncover biological basis of', 'help uncover biological basis of disease', 'uncover biological basis of disease #esmo22', 'biological basis of disease #esmo22 .', '"beautiful presentation- stampede 781 pts transcriptome treated', 'presentation- stampede 781 pts transcriptome treated ar', 'stampede 781 pts transcriptome treated ar targeted', '781 pts transcriptome treated ar targeted predefined', 'pts transcriptome treated ar targeted predefined stats', 'transcriptome treated ar targeted predefined stats prognostic', 'treated ar targeted predefined stats prognostic effects', 'ar targeted predefined stats prognostic effects of', 'targeted predefined stats prognostic effects of 54', 'predefined stats prognostic effects of 54 signatures', 'stats prognostic effects of 54 signatures transcriptomic', 'prognostic effects of 54 signatures transcriptomic signatures', 'effects of 54 signatures transcriptomic signatures show', 'of 54 signatures transcriptomic signatures show promise', '54 signatures transcriptomic signatures show promise in', 'signatures transcriptomic signatures show promise in stratifying', 'transcriptomic signatures show promise in stratifying hspc', 'signatures show promise in stratifying hspc pts', 'show promise in stratifying hspc pts and', 'promise in stratifying hspc pts and can', 'in stratifying hspc pts and can help', 'stratifying hspc pts and can help uncover', 'hspc pts and can help uncover biological', 'pts and can help uncover biological basis', 'and can help uncover biological basis of', 'can help uncover biological basis of disease', 'help uncover biological basis of disease #esmo22', 'uncover biological basis of disease #esmo22 .', '"beautiful presentation- stampede 781 pts transcriptome treated ar', 'presentation- stampede 781 pts transcriptome treated ar targeted', 'stampede 781 pts transcriptome treated ar targeted predefined', '781 pts transcriptome treated ar targeted predefined stats', 'pts transcriptome treated ar targeted predefined stats prognostic', 'transcriptome treated ar targeted predefined stats prognostic effects', 'treated ar targeted predefined stats prognostic effects of', 'ar targeted predefined stats prognostic effects of 54', 'targeted predefined stats prognostic effects of 54 signatures', 'predefined stats prognostic effects of 54 signatures transcriptomic', 'stats prognostic effects of 54 signatures transcriptomic signatures', 'prognostic effects of 54 signatures transcriptomic signatures show', 'effects of 54 signatures transcriptomic signatures show promise', 'of 54 signatures transcriptomic signatures show promise in', '54 signatures transcriptomic signatures show promise in stratifying', 'signatures transcriptomic signatures show promise in stratifying hspc', 'transcriptomic signatures show promise in stratifying hspc pts', 'signatures show promise in stratifying hspc pts and', 'show promise in stratifying hspc pts and can', 'promise in stratifying hspc pts and can help', 'in stratifying hspc pts and can help uncover', 'stratifying hspc pts and can help uncover biological', 'hspc pts and can help uncover biological basis', 'pts and can help uncover biological basis of', 'and can help uncover biological basis of disease', 'can help uncover biological basis of disease #esmo22', 'help uncover biological basis of disease #esmo22 .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '75', 'tokens': ['nivolumab', '/', 'cabozantinib', 'associated', 'with', 'greater', 'proportion', 'of', 'deep', 'objective', 'responses', 'for', 'advanced', 'renal', 'cell', 'carcinoma', '#asco22', '.'], 'text_length': 18, 'triples': {'/|of deep objective': ([1, 1], [7, 9], 'neutral'), 'nivolumab|of deep objective': ([0, 0], [7, 9], 'neutral')}, 'sentence': 'nivolumab / cabozantinib associated with greater proportion of deep objective responses for advanced renal cell carcinoma #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(1, 1), (0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8)], 'span tokens': ['nivolumab', '/', 'cabozantinib', 'associated', 'with', 'greater', 'proportion', 'of', 'deep', 'objective', 'responses', 'for', 'advanced', 'renal', 'cell', 'carcinoma', '#asco22', '.', 'nivolumab /', '/ cabozantinib', 'cabozantinib associated', 'associated with', 'with greater', 'greater proportion', 'proportion of', 'of deep', 'deep objective', 'objective responses', 'responses for', 'for advanced', 'advanced renal', 'renal cell', 'cell carcinoma', 'carcinoma #asco22', '#asco22 .', 'nivolumab / cabozantinib', '/ cabozantinib associated', 'cabozantinib associated with', 'associated with greater', 'with greater proportion', 'greater proportion of', 'proportion of deep', 'of deep objective', 'deep objective responses', 'objective responses for', 'responses for advanced', 'for advanced renal', 'advanced renal cell', 'renal cell carcinoma', 'cell carcinoma #asco22', 'carcinoma #asco22 .', 'nivolumab / cabozantinib associated', '/ cabozantinib associated with', 'cabozantinib associated with greater', 'associated with greater proportion', 'with greater proportion of', 'greater proportion of deep', 'proportion of deep objective', 'of deep objective responses', 'deep objective responses for', 'objective responses for advanced', 'responses for advanced renal', 'for advanced renal cell', 'advanced renal cell carcinoma', 'renal cell carcinoma #asco22', 'cell carcinoma #asco22 .', 'nivolumab / cabozantinib associated with', '/ cabozantinib associated with greater', 'cabozantinib associated with greater proportion', 'associated with greater proportion of', 'with greater proportion of deep', 'greater proportion of deep objective', 'proportion of deep objective responses', 'of deep objective responses for', 'deep objective responses for advanced', 'objective responses for advanced renal', 'responses for advanced renal cell', 'for advanced renal cell carcinoma', 'advanced renal cell carcinoma #asco22', 'renal cell carcinoma #asco22 .', 'nivolumab / cabozantinib associated with greater', '/ cabozantinib associated with greater proportion', 'cabozantinib associated with greater proportion of', 'associated with greater proportion of deep', 'with greater proportion of deep objective', 'greater proportion of deep objective responses', 'proportion of deep objective responses for', 'of deep objective responses for advanced', 'deep objective responses for advanced renal', 'objective responses for advanced renal cell', 'responses for advanced renal cell carcinoma', 'for advanced renal cell carcinoma #asco22', 'advanced renal cell carcinoma #asco22 .', 'nivolumab / cabozantinib associated with greater proportion', '/ cabozantinib associated with greater proportion of', 'cabozantinib associated with greater proportion of deep', 'associated with greater proportion of deep objective', 'with greater proportion of deep objective responses', 'greater proportion of deep objective responses for', 'proportion of deep objective responses for advanced', 'of deep objective responses for advanced renal', 'deep objective responses for advanced renal cell', 'objective responses for advanced renal cell carcinoma', 'responses for advanced renal cell carcinoma #asco22', 'for advanced renal cell carcinoma #asco22 .', 'nivolumab / cabozantinib associated with greater proportion of', '/ cabozantinib associated with greater proportion of deep', 'cabozantinib associated with greater proportion of deep objective', 'associated with greater proportion of deep objective responses', 'with greater proportion of deep objective responses for', 'greater proportion of deep objective responses for advanced', 'proportion of deep objective responses for advanced renal', 'of deep objective responses for advanced renal cell', 'deep objective responses for advanced renal cell carcinoma', 'objective responses for advanced renal cell carcinoma #asco22', 'responses for advanced renal cell carcinoma #asco22 .'], 'spans_aspect_label': [1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '76', 'tokens': ['One', 'last', 'great', 'late-breaking', '#ASH22', 'abstract:', 'zanubrutinib', 'vs', 'ibrutinib', 'PhIII', 'ALPINE', 'study', 'showing', 'superiority', 'of', 'zanubrutinib', 'in', 'PFS', 'and', 'OS', 'for', 'R/R', 'CLL/SLL.', 'Lower', 'cardiac', 'tox,', 'less', 'treatment', 'discontinuation,', 'and', 'improved', 'PFS', 'for', 'those', 'with', 'TP53', 'mutations', '#lymsm', '#leusm', '.'], 'text_length': 40, 'triples': {'ALPINE|great late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib PhIII ALPINE study showing superiority of zanubrutinib in PFS and OS for R/R CLL/SLL. Lower cardiac tox, less treatment discontinuation, and improved': ([10, 10], [2, 30], 'positive'), 'zanubrutinib vs ibrutinib PhIII ALPINE study showing superiority of zanubrutinib|superiority': ([6, 15], [13, 13], 'positive'), 'ibrutinib|discontinuation,': ([8, 8], [28, 28], 'negative')}, 'sentence': 'One last great late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib PhIII ALPINE study showing superiority of zanubrutinib in PFS and OS for R/R CLL/SLL. Lower cardiac tox, less treatment discontinuation, and improved PFS for those with TP53 mutations #lymsm #leusm .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(10, 10), (6, 15), (8, 8)], 'reverse_opinion_num': 3, 'reverse_opinion2aspect_label': [(2, 30), (13, 13), (28, 28)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8)], 'span tokens': ['One', 'last', 'great', 'late-breaking', '#ASH22', 'abstract:', 'zanubrutinib', 'vs', 'ibrutinib', 'PhIII', 'ALPINE', 'study', 'showing', 'superiority', 'of', 'zanubrutinib', 'in', 'PFS', 'and', 'OS', 'for', 'R/R', 'CLL/SLL.', 'Lower', 'cardiac', 'tox,', 'less', 'treatment', 'discontinuation,', 'and', 'improved', 'PFS', 'for', 'those', 'with', 'TP53', 'mutations', '#lymsm', '#leusm', '.', 'One last', 'last great', 'great late-breaking', 'late-breaking #ASH22', '#ASH22 abstract:', 'abstract: zanubrutinib', 'zanubrutinib vs', 'vs ibrutinib', 'ibrutinib PhIII', 'PhIII ALPINE', 'ALPINE study', 'study showing', 'showing superiority', 'superiority of', 'of zanubrutinib', 'zanubrutinib in', 'in PFS', 'PFS and', 'and OS', 'OS for', 'for R/R', 'R/R CLL/SLL.', 'CLL/SLL. Lower', 'Lower cardiac', 'cardiac tox,', 'tox, less', 'less treatment', 'treatment discontinuation,', 'discontinuation, and', 'and improved', 'improved PFS', 'PFS for', 'for those', 'those with', 'with TP53', 'TP53 mutations', 'mutations #lymsm', '#lymsm #leusm', '#leusm .', 'One last great', 'last great late-breaking', 'great late-breaking #ASH22', 'late-breaking #ASH22 abstract:', '#ASH22 abstract: zanubrutinib', 'abstract: zanubrutinib vs', 'zanubrutinib vs ibrutinib', 'vs ibrutinib PhIII', 'ibrutinib PhIII ALPINE', 'PhIII ALPINE study', 'ALPINE study showing', 'study showing superiority', 'showing superiority of', 'superiority of zanubrutinib', 'of zanubrutinib in', 'zanubrutinib in PFS', 'in PFS and', 'PFS and OS', 'and OS for', 'OS for R/R', 'for R/R CLL/SLL.', 'R/R CLL/SLL. Lower', 'CLL/SLL. Lower cardiac', 'Lower cardiac tox,', 'cardiac tox, less', 'tox, less treatment', 'less treatment discontinuation,', 'treatment discontinuation, and', 'discontinuation, and improved', 'and improved PFS', 'improved PFS for', 'PFS for those', 'for those with', 'those with TP53', 'with TP53 mutations', 'TP53 mutations #lymsm', 'mutations #lymsm #leusm', '#lymsm #leusm .', 'One last great late-breaking', 'last great late-breaking #ASH22', 'great late-breaking #ASH22 abstract:', 'late-breaking #ASH22 abstract: zanubrutinib', '#ASH22 abstract: zanubrutinib vs', 'abstract: zanubrutinib vs ibrutinib', 'zanubrutinib vs ibrutinib PhIII', 'vs ibrutinib PhIII ALPINE', 'ibrutinib PhIII ALPINE study', 'PhIII ALPINE study showing', 'ALPINE study showing superiority', 'study showing superiority of', 'showing superiority of zanubrutinib', 'superiority of zanubrutinib in', 'of zanubrutinib in PFS', 'zanubrutinib in PFS and', 'in PFS and OS', 'PFS and OS for', 'and OS for R/R', 'OS for R/R CLL/SLL.', 'for R/R CLL/SLL. Lower', 'R/R CLL/SLL. Lower cardiac', 'CLL/SLL. Lower cardiac tox,', 'Lower cardiac tox, less', 'cardiac tox, less treatment', 'tox, less treatment discontinuation,', 'less treatment discontinuation, and', 'treatment discontinuation, and improved', 'discontinuation, and improved PFS', 'and improved PFS for', 'improved PFS for those', 'PFS for those with', 'for those with TP53', 'those with TP53 mutations', 'with TP53 mutations #lymsm', 'TP53 mutations #lymsm #leusm', 'mutations #lymsm #leusm .', 'One last great late-breaking #ASH22', 'last great late-breaking #ASH22 abstract:', 'great late-breaking #ASH22 abstract: zanubrutinib', 'late-breaking #ASH22 abstract: zanubrutinib vs', '#ASH22 abstract: zanubrutinib vs ibrutinib', 'abstract: zanubrutinib vs ibrutinib PhIII', 'zanubrutinib vs ibrutinib PhIII ALPINE', 'vs ibrutinib PhIII ALPINE study', 'ibrutinib PhIII ALPINE study showing', 'PhIII ALPINE study showing superiority', 'ALPINE study showing superiority of', 'study showing superiority of zanubrutinib', 'showing superiority of zanubrutinib in', 'superiority of zanubrutinib in PFS', 'of zanubrutinib in PFS and', 'zanubrutinib in PFS and OS', 'in PFS and OS for', 'PFS and OS for R/R', 'and OS for R/R CLL/SLL.', 'OS for R/R CLL/SLL. Lower', 'for R/R CLL/SLL. Lower cardiac', 'R/R CLL/SLL. Lower cardiac tox,', 'CLL/SLL. Lower cardiac tox, less', 'Lower cardiac tox, less treatment', 'cardiac tox, less treatment discontinuation,', 'tox, less treatment discontinuation, and', 'less treatment discontinuation, and improved', 'treatment discontinuation, and improved PFS', 'discontinuation, and improved PFS for', 'and improved PFS for those', 'improved PFS for those with', 'PFS for those with TP53', 'for those with TP53 mutations', 'those with TP53 mutations #lymsm', 'with TP53 mutations #lymsm #leusm', 'TP53 mutations #lymsm #leusm .', 'One last great late-breaking #ASH22 abstract:', 'last great late-breaking #ASH22 abstract: zanubrutinib', 'great late-breaking #ASH22 abstract: zanubrutinib vs', 'late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib', '#ASH22 abstract: zanubrutinib vs ibrutinib PhIII', 'abstract: zanubrutinib vs ibrutinib PhIII ALPINE', 'zanubrutinib vs ibrutinib PhIII ALPINE study', 'vs ibrutinib PhIII ALPINE study showing', 'ibrutinib PhIII ALPINE study showing superiority', 'PhIII ALPINE study showing superiority of', 'ALPINE study showing superiority of zanubrutinib', 'study showing superiority of zanubrutinib in', 'showing superiority of zanubrutinib in PFS', 'superiority of zanubrutinib in PFS and', 'of zanubrutinib in PFS and OS', 'zanubrutinib in PFS and OS for', 'in PFS and OS for R/R', 'PFS and OS for R/R CLL/SLL.', 'and OS for R/R CLL/SLL. Lower', 'OS for R/R CLL/SLL. Lower cardiac', 'for R/R CLL/SLL. Lower cardiac tox,', 'R/R CLL/SLL. Lower cardiac tox, less', 'CLL/SLL. Lower cardiac tox, less treatment', 'Lower cardiac tox, less treatment discontinuation,', 'cardiac tox, less treatment discontinuation, and', 'tox, less treatment discontinuation, and improved', 'less treatment discontinuation, and improved PFS', 'treatment discontinuation, and improved PFS for', 'discontinuation, and improved PFS for those', 'and improved PFS for those with', 'improved PFS for those with TP53', 'PFS for those with TP53 mutations', 'for those with TP53 mutations #lymsm', 'those with TP53 mutations #lymsm #leusm', 'with TP53 mutations #lymsm #leusm .', 'One last great late-breaking #ASH22 abstract: zanubrutinib', 'last great late-breaking #ASH22 abstract: zanubrutinib vs', 'great late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib', 'late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib PhIII', '#ASH22 abstract: zanubrutinib vs ibrutinib PhIII ALPINE', 'abstract: zanubrutinib vs ibrutinib PhIII ALPINE study', 'zanubrutinib vs ibrutinib PhIII ALPINE study showing', 'vs ibrutinib PhIII ALPINE study showing superiority', 'ibrutinib PhIII ALPINE study showing superiority of', 'PhIII ALPINE study showing superiority of zanubrutinib', 'ALPINE study showing superiority of zanubrutinib in', 'study showing superiority of zanubrutinib in PFS', 'showing superiority of zanubrutinib in PFS and', 'superiority of zanubrutinib in PFS and OS', 'of zanubrutinib in PFS and OS for', 'zanubrutinib in PFS and OS for R/R', 'in PFS and OS for R/R CLL/SLL.', 'PFS and OS for R/R CLL/SLL. Lower', 'and OS for R/R CLL/SLL. Lower cardiac', 'OS for R/R CLL/SLL. Lower cardiac tox,', 'for R/R CLL/SLL. Lower cardiac tox, less', 'R/R CLL/SLL. Lower cardiac tox, less treatment', 'CLL/SLL. Lower cardiac tox, less treatment discontinuation,', 'Lower cardiac tox, less treatment discontinuation, and', 'cardiac tox, less treatment discontinuation, and improved', 'tox, less treatment discontinuation, and improved PFS', 'less treatment discontinuation, and improved PFS for', 'treatment discontinuation, and improved PFS for those', 'discontinuation, and improved PFS for those with', 'and improved PFS for those with TP53', 'improved PFS for those with TP53 mutations', 'PFS for those with TP53 mutations #lymsm', 'for those with TP53 mutations #lymsm #leusm', 'those with TP53 mutations #lymsm #leusm .', 'One last great late-breaking #ASH22 abstract: zanubrutinib vs', 'last great late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib', 'great late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib PhIII', 'late-breaking #ASH22 abstract: zanubrutinib vs ibrutinib PhIII ALPINE', '#ASH22 abstract: zanubrutinib vs ibrutinib PhIII ALPINE study', 'abstract: zanubrutinib vs ibrutinib PhIII ALPINE study showing', 'zanubrutinib vs ibrutinib PhIII ALPINE study showing superiority', 'vs ibrutinib PhIII ALPINE study showing superiority of', 'ibrutinib PhIII ALPINE study showing superiority of zanubrutinib', 'PhIII ALPINE study showing superiority of zanubrutinib in', 'ALPINE study showing superiority of zanubrutinib in PFS', 'study showing superiority of zanubrutinib in PFS and', 'showing superiority of zanubrutinib in PFS and OS', 'superiority of zanubrutinib in PFS and OS for', 'of zanubrutinib in PFS and OS for R/R', 'zanubrutinib in PFS and OS for R/R CLL/SLL.', 'in PFS and OS for R/R CLL/SLL. Lower', 'PFS and OS for R/R CLL/SLL. Lower cardiac', 'and OS for R/R CLL/SLL. Lower cardiac tox,', 'OS for R/R CLL/SLL. Lower cardiac tox, less', 'for R/R CLL/SLL. Lower cardiac tox, less treatment', 'R/R CLL/SLL. Lower cardiac tox, less treatment discontinuation,', 'CLL/SLL. Lower cardiac tox, less treatment discontinuation, and', 'Lower cardiac tox, less treatment discontinuation, and improved', 'cardiac tox, less treatment discontinuation, and improved PFS', 'tox, less treatment discontinuation, and improved PFS for', 'less treatment discontinuation, and improved PFS for those', 'treatment discontinuation, and improved PFS for those with', 'discontinuation, and improved PFS for those with TP53', 'and improved PFS for those with TP53 mutations', 'improved PFS for those with TP53 mutations #lymsm', 'PFS for those with TP53 mutations #lymsm #leusm', 'for those with TP53 mutations #lymsm #leusm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '77', 'tokens': ['another', 'confirmation', 'of', 'the', 'effectiveness', 'of', 'this', 'combination.#asco22', '#cm-9er', '#kidneycancer', '.'], 'text_length': 11, 'triples': {'#cm-9er|confirmation of the effectiveness': ([8, 8], [1, 4], 'neutral')}, 'sentence': 'another confirmation of the effectiveness of this combination.#asco22 #cm-9er #kidneycancer .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 1, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 1, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8)], 'span tokens': ['another', 'confirmation', 'of', 'the', 'effectiveness', 'of', 'this', 'combination.#asco22', '#cm-9er', '#kidneycancer', '.', 'another confirmation', 'confirmation of', 'of the', 'the effectiveness', 'effectiveness of', 'of this', 'this combination.#asco22', 'combination.#asco22 #cm-9er', '#cm-9er #kidneycancer', '#kidneycancer .', 'another confirmation of', 'confirmation of the', 'of the effectiveness', 'the effectiveness of', 'effectiveness of this', 'of this combination.#asco22', 'this combination.#asco22 #cm-9er', 'combination.#asco22 #cm-9er #kidneycancer', '#cm-9er #kidneycancer .', 'another confirmation of the', 'confirmation of the effectiveness', 'of the effectiveness of', 'the effectiveness of this', 'effectiveness of this combination.#asco22', 'of this combination.#asco22 #cm-9er', 'this combination.#asco22 #cm-9er #kidneycancer', 'combination.#asco22 #cm-9er #kidneycancer .', 'another confirmation of the effectiveness', 'confirmation of the effectiveness of', 'of the effectiveness of this', 'the effectiveness of this combination.#asco22', 'effectiveness of this combination.#asco22 #cm-9er', 'of this combination.#asco22 #cm-9er #kidneycancer', 'this combination.#asco22 #cm-9er #kidneycancer .', 'another confirmation of the effectiveness of', 'confirmation of the effectiveness of this', 'of the effectiveness of this combination.#asco22', 'the effectiveness of this combination.#asco22 #cm-9er', 'effectiveness of this combination.#asco22 #cm-9er #kidneycancer', 'of this combination.#asco22 #cm-9er #kidneycancer .', 'another confirmation of the effectiveness of this', 'confirmation of the effectiveness of this combination.#asco22', 'of the effectiveness of this combination.#asco22 #cm-9er', 'the effectiveness of this combination.#asco22 #cm-9er #kidneycancer', 'effectiveness of this combination.#asco22 #cm-9er #kidneycancer .', 'another confirmation of the effectiveness of this combination.#asco22', 'confirmation of the effectiveness of this combination.#asco22 #cm-9er', 'of the effectiveness of this combination.#asco22 #cm-9er #kidneycancer', 'the effectiveness of this combination.#asco22 #cm-9er #kidneycancer .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '78', 'tokens': ['watching', 'moderate', 'dr.', 'ryan', 'during', 'everest', 'discussion', 'from', 'afar!', 'great', 'virtual', 'platform', '#asco22', '.'], 'text_length': 14, 'triples': {'everest|watching': ([5, 5], [0, 0], 'neutral')}, 'sentence': 'watching moderate dr. ryan during everest discussion from afar! great virtual platform #asco22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8)], 'span tokens': ['watching', 'moderate', 'dr.', 'ryan', 'during', 'everest', 'discussion', 'from', 'afar!', 'great', 'virtual', 'platform', '#asco22', '.', 'watching moderate', 'moderate dr.', 'dr. ryan', 'ryan during', 'during everest', 'everest discussion', 'discussion from', 'from afar!', 'afar! great', 'great virtual', 'virtual platform', 'platform #asco22', '#asco22 .', 'watching moderate dr.', 'moderate dr. ryan', 'dr. ryan during', 'ryan during everest', 'during everest discussion', 'everest discussion from', 'discussion from afar!', 'from afar! great', 'afar! great virtual', 'great virtual platform', 'virtual platform #asco22', 'platform #asco22 .', 'watching moderate dr. ryan', 'moderate dr. ryan during', 'dr. ryan during everest', 'ryan during everest discussion', 'during everest discussion from', 'everest discussion from afar!', 'discussion from afar! great', 'from afar! great virtual', 'afar! great virtual platform', 'great virtual platform #asco22', 'virtual platform #asco22 .', 'watching moderate dr. ryan during', 'moderate dr. ryan during everest', 'dr. ryan during everest discussion', 'ryan during everest discussion from', 'during everest discussion from afar!', 'everest discussion from afar! great', 'discussion from afar! great virtual', 'from afar! great virtual platform', 'afar! great virtual platform #asco22', 'great virtual platform #asco22 .', 'watching moderate dr. ryan during everest', 'moderate dr. ryan during everest discussion', 'dr. ryan during everest discussion from', 'ryan during everest discussion from afar!', 'during everest discussion from afar! great', 'everest discussion from afar! great virtual', 'discussion from afar! great virtual platform', 'from afar! great virtual platform #asco22', 'afar! great virtual platform #asco22 .', 'watching moderate dr. ryan during everest discussion', 'moderate dr. ryan during everest discussion from', 'dr. ryan during everest discussion from afar!', 'ryan during everest discussion from afar! great', 'during everest discussion from afar! great virtual', 'everest discussion from afar! great virtual platform', 'discussion from afar! great virtual platform #asco22', 'from afar! great virtual platform #asco22 .', 'watching moderate dr. ryan during everest discussion from', 'moderate dr. ryan during everest discussion from afar!', 'dr. ryan during everest discussion from afar! great', 'ryan during everest discussion from afar! great virtual', 'during everest discussion from afar! great virtual platform', 'everest discussion from afar! great virtual platform #asco22', 'discussion from afar! great virtual platform #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '79', 'tokens': ['#icymi', 'results', 'presented', 'at', '#esmo22', 'this', 'weekend', 'from', 'the', '#crukfunded', '#', 'stampede', 'trial', 'and', 'ancillary', 'studies', 'of', '#stampede', '#prostatecancer', '#pcsm', '.'], 'text_length': 21, 'triples': {'# stampede trial and ancillary studies of|presented': ([10, 16], [2, 2], 'neutral')}, 'sentence': '#icymi results presented at #esmo22 this weekend from the #crukfunded # stampede trial and ancillary studies of #stampede #prostatecancer #pcsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(10, 16)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['#icymi', 'results', 'presented', 'at', '#esmo22', 'this', 'weekend', 'from', 'the', '#crukfunded', '#', 'stampede', 'trial', 'and', 'ancillary', 'studies', 'of', '#stampede', '#prostatecancer', '#pcsm', '.', '#icymi results', 'results presented', 'presented at', 'at #esmo22', '#esmo22 this', 'this weekend', 'weekend from', 'from the', 'the #crukfunded', '#crukfunded #', '# stampede', 'stampede trial', 'trial and', 'and ancillary', 'ancillary studies', 'studies of', 'of #stampede', '#stampede #prostatecancer', '#prostatecancer #pcsm', '#pcsm .', '#icymi results presented', 'results presented at', 'presented at #esmo22', 'at #esmo22 this', '#esmo22 this weekend', 'this weekend from', 'weekend from the', 'from the #crukfunded', 'the #crukfunded #', '#crukfunded # stampede', '# stampede trial', 'stampede trial and', 'trial and ancillary', 'and ancillary studies', 'ancillary studies of', 'studies of #stampede', 'of #stampede #prostatecancer', '#stampede #prostatecancer #pcsm', '#prostatecancer #pcsm .', '#icymi results presented at', 'results presented at #esmo22', 'presented at #esmo22 this', 'at #esmo22 this weekend', '#esmo22 this weekend from', 'this weekend from the', 'weekend from the #crukfunded', 'from the #crukfunded #', 'the #crukfunded # stampede', '#crukfunded # stampede trial', '# stampede trial and', 'stampede trial and ancillary', 'trial and ancillary studies', 'and ancillary studies of', 'ancillary studies of #stampede', 'studies of #stampede #prostatecancer', 'of #stampede #prostatecancer #pcsm', '#stampede #prostatecancer #pcsm .', '#icymi results presented at #esmo22', 'results presented at #esmo22 this', 'presented at #esmo22 this weekend', 'at #esmo22 this weekend from', '#esmo22 this weekend from the', 'this weekend from the #crukfunded', 'weekend from the #crukfunded #', 'from the #crukfunded # stampede', 'the #crukfunded # stampede trial', '#crukfunded # stampede trial and', '# stampede trial and ancillary', 'stampede trial and ancillary studies', 'trial and ancillary studies of', 'and ancillary studies of #stampede', 'ancillary studies of #stampede #prostatecancer', 'studies of #stampede #prostatecancer #pcsm', 'of #stampede #prostatecancer #pcsm .', '#icymi results presented at #esmo22 this', 'results presented at #esmo22 this weekend', 'presented at #esmo22 this weekend from', 'at #esmo22 this weekend from the', '#esmo22 this weekend from the #crukfunded', 'this weekend from the #crukfunded #', 'weekend from the #crukfunded # stampede', 'from the #crukfunded # stampede trial', 'the #crukfunded # stampede trial and', '#crukfunded # stampede trial and ancillary', '# stampede trial and ancillary studies', 'stampede trial and ancillary studies of', 'trial and ancillary studies of #stampede', 'and ancillary studies of #stampede #prostatecancer', 'ancillary studies of #stampede #prostatecancer #pcsm', 'studies of #stampede #prostatecancer #pcsm .', '#icymi results presented at #esmo22 this weekend', 'results presented at #esmo22 this weekend from', 'presented at #esmo22 this weekend from the', 'at #esmo22 this weekend from the #crukfunded', '#esmo22 this weekend from the #crukfunded #', 'this weekend from the #crukfunded # stampede', 'weekend from the #crukfunded # stampede trial', 'from the #crukfunded # stampede trial and', 'the #crukfunded # stampede trial and ancillary', '#crukfunded # stampede trial and ancillary studies', '# stampede trial and ancillary studies of', 'stampede trial and ancillary studies of #stampede', 'trial and ancillary studies of #stampede #prostatecancer', 'and ancillary studies of #stampede #prostatecancer #pcsm', 'ancillary studies of #stampede #prostatecancer #pcsm .', '#icymi results presented at #esmo22 this weekend from', 'results presented at #esmo22 this weekend from the', 'presented at #esmo22 this weekend from the #crukfunded', 'at #esmo22 this weekend from the #crukfunded #', '#esmo22 this weekend from the #crukfunded # stampede', 'this weekend from the #crukfunded # stampede trial', 'weekend from the #crukfunded # stampede trial and', 'from the #crukfunded # stampede trial and ancillary', 'the #crukfunded # stampede trial and ancillary studies', '#crukfunded # stampede trial and ancillary studies of', '# stampede trial and ancillary studies of #stampede', 'stampede trial and ancillary studies of #stampede #prostatecancer', 'trial and ancillary studies of #stampede #prostatecancer #pcsm', 'and ancillary studies of #stampede #prostatecancer #pcsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '80', 'tokens': ['#ash22', 'awesome', 'presentation', 'by', 're:', 'karmma', '(ide-cel', 'car-t', 'for', 'functional', 'high-risk,', 'i.e.', 'early', '#mmsm', 'relapse).', 'median', 'dor', '16', 'mo.', 'better', 'than', 'karmma-1', '(4+', 'lines,', 'mpfs', '8.8mo)', 'even', 'given', 'clear', 'higher', 'risk,', 'likely', 'since', 'given', 'earlier.', 'bad', 'news:', 'still', 'no', 'plateau', '.'], 'text_length': 41, 'triples': {'karmma (ide-cel car-t for functional high-risk, i.e. early #mmsm relapse). median dor 16 mo. better than karmma-1|awesome': ([5, 21], [1, 1], 'positive'), 'karmma-1|better than': ([21, 21], [19, 20], 'negative'), '(ide-cel|awesome presentation': ([6, 6], [1, 2], 'positive')}, 'sentence': '#ash22 awesome presentation by re: karmma (ide-cel car-t for functional high-risk, i.e. early #mmsm relapse). median dor 16 mo. better than karmma-1 (4+ lines, mpfs 8.8mo) even given clear higher risk, likely since given earlier. bad news: still no plateau .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(5, 21), (21, 21), (6, 6)], 'reverse_opinion_num': 3, 'reverse_opinion2aspect_label': [(1, 1), (19, 20), (1, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8)], 'span tokens': ['#ash22', 'awesome', 'presentation', 'by', 're:', 'karmma', '(ide-cel', 'car-t', 'for', 'functional', 'high-risk,', 'i.e.', 'early', '#mmsm', 'relapse).', 'median', 'dor', '16', 'mo.', 'better', 'than', 'karmma-1', '(4+', 'lines,', 'mpfs', '8.8mo)', 'even', 'given', 'clear', 'higher', 'risk,', 'likely', 'since', 'given', 'earlier.', 'bad', 'news:', 'still', 'no', 'plateau', '.', '#ash22 awesome', 'awesome presentation', 'presentation by', 'by re:', 're: karmma', 'karmma (ide-cel', '(ide-cel car-t', 'car-t for', 'for functional', 'functional high-risk,', 'high-risk, i.e.', 'i.e. early', 'early #mmsm', '#mmsm relapse).', 'relapse). median', 'median dor', 'dor 16', '16 mo.', 'mo. better', 'better than', 'than karmma-1', 'karmma-1 (4+', '(4+ lines,', 'lines, mpfs', 'mpfs 8.8mo)', '8.8mo) even', 'even given', 'given clear', 'clear higher', 'higher risk,', 'risk, likely', 'likely since', 'since given', 'given earlier.', 'earlier. bad', 'bad news:', 'news: still', 'still no', 'no plateau', 'plateau .', '#ash22 awesome presentation', 'awesome presentation by', 'presentation by re:', 'by re: karmma', 're: karmma (ide-cel', 'karmma (ide-cel car-t', '(ide-cel car-t for', 'car-t for functional', 'for functional high-risk,', 'functional high-risk, i.e.', 'high-risk, i.e. early', 'i.e. early #mmsm', 'early #mmsm relapse).', '#mmsm relapse). median', 'relapse). median dor', 'median dor 16', 'dor 16 mo.', '16 mo. better', 'mo. better than', 'better than karmma-1', 'than karmma-1 (4+', 'karmma-1 (4+ lines,', '(4+ lines, mpfs', 'lines, mpfs 8.8mo)', 'mpfs 8.8mo) even', '8.8mo) even given', 'even given clear', 'given clear higher', 'clear higher risk,', 'higher risk, likely', 'risk, likely since', 'likely since given', 'since given earlier.', 'given earlier. bad', 'earlier. bad news:', 'bad news: still', 'news: still no', 'still no plateau', 'no plateau .', '#ash22 awesome presentation by', 'awesome presentation by re:', 'presentation by re: karmma', 'by re: karmma (ide-cel', 're: karmma (ide-cel car-t', 'karmma (ide-cel car-t for', '(ide-cel car-t for functional', 'car-t for functional high-risk,', 'for functional high-risk, i.e.', 'functional high-risk, i.e. early', 'high-risk, i.e. early #mmsm', 'i.e. early #mmsm relapse).', 'early #mmsm relapse). median', '#mmsm relapse). median dor', 'relapse). median dor 16', 'median dor 16 mo.', 'dor 16 mo. better', '16 mo. better than', 'mo. better than karmma-1', 'better than karmma-1 (4+', 'than karmma-1 (4+ lines,', 'karmma-1 (4+ lines, mpfs', '(4+ lines, mpfs 8.8mo)', 'lines, mpfs 8.8mo) even', 'mpfs 8.8mo) even given', '8.8mo) even given clear', 'even given clear higher', 'given clear higher risk,', 'clear higher risk, likely', 'higher risk, likely since', 'risk, likely since given', 'likely since given earlier.', 'since given earlier. bad', 'given earlier. bad news:', 'earlier. bad news: still', 'bad news: still no', 'news: still no plateau', 'still no plateau .', '#ash22 awesome presentation by re:', 'awesome presentation by re: karmma', 'presentation by re: karmma (ide-cel', 'by re: karmma (ide-cel car-t', 're: karmma (ide-cel car-t for', 'karmma (ide-cel car-t for functional', '(ide-cel car-t for functional high-risk,', 'car-t for functional high-risk, i.e.', 'for functional high-risk, i.e. early', 'functional high-risk, i.e. early #mmsm', 'high-risk, i.e. early #mmsm relapse).', 'i.e. early #mmsm relapse). median', 'early #mmsm relapse). median dor', '#mmsm relapse). median dor 16', 'relapse). median dor 16 mo.', 'median dor 16 mo. better', 'dor 16 mo. better than', '16 mo. better than karmma-1', 'mo. better than karmma-1 (4+', 'better than karmma-1 (4+ lines,', 'than karmma-1 (4+ lines, mpfs', 'karmma-1 (4+ lines, mpfs 8.8mo)', '(4+ lines, mpfs 8.8mo) even', 'lines, mpfs 8.8mo) even given', 'mpfs 8.8mo) even given clear', '8.8mo) even given clear higher', 'even given clear higher risk,', 'given clear higher risk, likely', 'clear higher risk, likely since', 'higher risk, likely since given', 'risk, likely since given earlier.', 'likely since given earlier. bad', 'since given earlier. bad news:', 'given earlier. bad news: still', 'earlier. bad news: still no', 'bad news: still no plateau', 'news: still no plateau .', '#ash22 awesome presentation by re: karmma', 'awesome presentation by re: karmma (ide-cel', 'presentation by re: karmma (ide-cel car-t', 'by re: karmma (ide-cel car-t for', 're: karmma (ide-cel car-t for functional', 'karmma (ide-cel car-t for functional high-risk,', '(ide-cel car-t for functional high-risk, i.e.', 'car-t for functional high-risk, i.e. early', 'for functional high-risk, i.e. early #mmsm', 'functional high-risk, i.e. early #mmsm relapse).', 'high-risk, i.e. early #mmsm relapse). median', 'i.e. early #mmsm relapse). median dor', 'early #mmsm relapse). median dor 16', '#mmsm relapse). median dor 16 mo.', 'relapse). median dor 16 mo. better', 'median dor 16 mo. better than', 'dor 16 mo. better than karmma-1', '16 mo. better than karmma-1 (4+', 'mo. better than karmma-1 (4+ lines,', 'better than karmma-1 (4+ lines, mpfs', 'than karmma-1 (4+ lines, mpfs 8.8mo)', 'karmma-1 (4+ lines, mpfs 8.8mo) even', '(4+ lines, mpfs 8.8mo) even given', 'lines, mpfs 8.8mo) even given clear', 'mpfs 8.8mo) even given clear higher', '8.8mo) even given clear higher risk,', 'even given clear higher risk, likely', 'given clear higher risk, likely since', 'clear higher risk, likely since given', 'higher risk, likely since given earlier.', 'risk, likely since given earlier. bad', 'likely since given earlier. bad news:', 'since given earlier. bad news: still', 'given earlier. bad news: still no', 'earlier. bad news: still no plateau', 'bad news: still no plateau .', '#ash22 awesome presentation by re: karmma (ide-cel', 'awesome presentation by re: karmma (ide-cel car-t', 'presentation by re: karmma (ide-cel car-t for', 'by re: karmma (ide-cel car-t for functional', 're: karmma (ide-cel car-t for functional high-risk,', 'karmma (ide-cel car-t for functional high-risk, i.e.', '(ide-cel car-t for functional high-risk, i.e. early', 'car-t for functional high-risk, i.e. early #mmsm', 'for functional high-risk, i.e. early #mmsm relapse).', 'functional high-risk, i.e. early #mmsm relapse). median', 'high-risk, i.e. early #mmsm relapse). median dor', 'i.e. early #mmsm relapse). median dor 16', 'early #mmsm relapse). median dor 16 mo.', '#mmsm relapse). median dor 16 mo. better', 'relapse). median dor 16 mo. better than', 'median dor 16 mo. better than karmma-1', 'dor 16 mo. better than karmma-1 (4+', '16 mo. better than karmma-1 (4+ lines,', 'mo. better than karmma-1 (4+ lines, mpfs', 'better than karmma-1 (4+ lines, mpfs 8.8mo)', 'than karmma-1 (4+ lines, mpfs 8.8mo) even', 'karmma-1 (4+ lines, mpfs 8.8mo) even given', '(4+ lines, mpfs 8.8mo) even given clear', 'lines, mpfs 8.8mo) even given clear higher', 'mpfs 8.8mo) even given clear higher risk,', '8.8mo) even given clear higher risk, likely', 'even given clear higher risk, likely since', 'given clear higher risk, likely since given', 'clear higher risk, likely since given earlier.', 'higher risk, likely since given earlier. bad', 'risk, likely since given earlier. bad news:', 'likely since given earlier. bad news: still', 'since given earlier. bad news: still no', 'given earlier. bad news: still no plateau', 'earlier. bad news: still no plateau .', '#ash22 awesome presentation by re: karmma (ide-cel car-t', 'awesome presentation by re: karmma (ide-cel car-t for', 'presentation by re: karmma (ide-cel car-t for functional', 'by re: karmma (ide-cel car-t for functional high-risk,', 're: karmma (ide-cel car-t for functional high-risk, i.e.', 'karmma (ide-cel car-t for functional high-risk, i.e. early', '(ide-cel car-t for functional high-risk, i.e. early #mmsm', 'car-t for functional high-risk, i.e. early #mmsm relapse).', 'for functional high-risk, i.e. early #mmsm relapse). median', 'functional high-risk, i.e. early #mmsm relapse). median dor', 'high-risk, i.e. early #mmsm relapse). median dor 16', 'i.e. early #mmsm relapse). median dor 16 mo.', 'early #mmsm relapse). median dor 16 mo. better', '#mmsm relapse). median dor 16 mo. better than', 'relapse). median dor 16 mo. better than karmma-1', 'median dor 16 mo. better than karmma-1 (4+', 'dor 16 mo. better than karmma-1 (4+ lines,', '16 mo. better than karmma-1 (4+ lines, mpfs', 'mo. better than karmma-1 (4+ lines, mpfs 8.8mo)', 'better than karmma-1 (4+ lines, mpfs 8.8mo) even', 'than karmma-1 (4+ lines, mpfs 8.8mo) even given', 'karmma-1 (4+ lines, mpfs 8.8mo) even given clear', '(4+ lines, mpfs 8.8mo) even given clear higher', 'lines, mpfs 8.8mo) even given clear higher risk,', 'mpfs 8.8mo) even given clear higher risk, likely', '8.8mo) even given clear higher risk, likely since', 'even given clear higher risk, likely since given', 'given clear higher risk, likely since given earlier.', 'clear higher risk, likely since given earlier. bad', 'higher risk, likely since given earlier. bad news:', 'risk, likely since given earlier. bad news: still', 'likely since given earlier. bad news: still no', 'since given earlier. bad news: still no plateau', 'given earlier. bad news: still no plateau .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '81', 'tokens': ['bm', 'mrd', 'in', 'karmma', '&amp;', 'cartitude-1', 'are', 'presented', '#ash22.', 'monday', 'morning,', 'will', 'present', 'analysis', 'of', 'bm', '&amp;', 'pet', 'mrd', 'prognostic', 'value', 'in', '#cart', '#mmsm', '.'], 'text_length': 25, 'triples': {'karmma|presented': ([3, 3], [7, 7], 'neutral')}, 'sentence': 'bm mrd in karmma &amp; cartitude-1 are presented #ash22. monday morning, will present analysis of bm &amp; pet mrd prognostic value in #cart #mmsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 7)], 'related_span_array': array([[1, 0, 0, ..., 1, 0, 0],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8)], 'span tokens': ['bm', 'mrd', 'in', 'karmma', '&amp;', 'cartitude-1', 'are', 'presented', '#ash22.', 'monday', 'morning,', 'will', 'present', 'analysis', 'of', 'bm', '&amp;', 'pet', 'mrd', 'prognostic', 'value', 'in', '#cart', '#mmsm', '.', 'bm mrd', 'mrd in', 'in karmma', 'karmma &amp;', '&amp; cartitude-1', 'cartitude-1 are', 'are presented', 'presented #ash22.', '#ash22. monday', 'monday morning,', 'morning, will', 'will present', 'present analysis', 'analysis of', 'of bm', 'bm &amp;', '&amp; pet', 'pet mrd', 'mrd prognostic', 'prognostic value', 'value in', 'in #cart', '#cart #mmsm', '#mmsm .', 'bm mrd in', 'mrd in karmma', 'in karmma &amp;', 'karmma &amp; cartitude-1', '&amp; cartitude-1 are', 'cartitude-1 are presented', 'are presented #ash22.', 'presented #ash22. monday', '#ash22. monday morning,', 'monday morning, will', 'morning, will present', 'will present analysis', 'present analysis of', 'analysis of bm', 'of bm &amp;', 'bm &amp; pet', '&amp; pet mrd', 'pet mrd prognostic', 'mrd prognostic value', 'prognostic value in', 'value in #cart', 'in #cart #mmsm', '#cart #mmsm .', 'bm mrd in karmma', 'mrd in karmma &amp;', 'in karmma &amp; cartitude-1', 'karmma &amp; cartitude-1 are', '&amp; cartitude-1 are presented', 'cartitude-1 are presented #ash22.', 'are presented #ash22. monday', 'presented #ash22. monday morning,', '#ash22. monday morning, will', 'monday morning, will present', 'morning, will present analysis', 'will present analysis of', 'present analysis of bm', 'analysis of bm &amp;', 'of bm &amp; pet', 'bm &amp; pet mrd', '&amp; pet mrd prognostic', 'pet mrd prognostic value', 'mrd prognostic value in', 'prognostic value in #cart', 'value in #cart #mmsm', 'in #cart #mmsm .', 'bm mrd in karmma &amp;', 'mrd in karmma &amp; cartitude-1', 'in karmma &amp; cartitude-1 are', 'karmma &amp; cartitude-1 are presented', '&amp; cartitude-1 are presented #ash22.', 'cartitude-1 are presented #ash22. monday', 'are presented #ash22. monday morning,', 'presented #ash22. monday morning, will', '#ash22. monday morning, will present', 'monday morning, will present analysis', 'morning, will present analysis of', 'will present analysis of bm', 'present analysis of bm &amp;', 'analysis of bm &amp; pet', 'of bm &amp; pet mrd', 'bm &amp; pet mrd prognostic', '&amp; pet mrd prognostic value', 'pet mrd prognostic value in', 'mrd prognostic value in #cart', 'prognostic value in #cart #mmsm', 'value in #cart #mmsm .', 'bm mrd in karmma &amp; cartitude-1', 'mrd in karmma &amp; cartitude-1 are', 'in karmma &amp; cartitude-1 are presented', 'karmma &amp; cartitude-1 are presented #ash22.', '&amp; cartitude-1 are presented #ash22. monday', 'cartitude-1 are presented #ash22. monday morning,', 'are presented #ash22. monday morning, will', 'presented #ash22. monday morning, will present', '#ash22. monday morning, will present analysis', 'monday morning, will present analysis of', 'morning, will present analysis of bm', 'will present analysis of bm &amp;', 'present analysis of bm &amp; pet', 'analysis of bm &amp; pet mrd', 'of bm &amp; pet mrd prognostic', 'bm &amp; pet mrd prognostic value', '&amp; pet mrd prognostic value in', 'pet mrd prognostic value in #cart', 'mrd prognostic value in #cart #mmsm', 'prognostic value in #cart #mmsm .', 'bm mrd in karmma &amp; cartitude-1 are', 'mrd in karmma &amp; cartitude-1 are presented', 'in karmma &amp; cartitude-1 are presented #ash22.', 'karmma &amp; cartitude-1 are presented #ash22. monday', '&amp; cartitude-1 are presented #ash22. monday morning,', 'cartitude-1 are presented #ash22. monday morning, will', 'are presented #ash22. monday morning, will present', 'presented #ash22. monday morning, will present analysis', '#ash22. monday morning, will present analysis of', 'monday morning, will present analysis of bm', 'morning, will present analysis of bm &amp;', 'will present analysis of bm &amp; pet', 'present analysis of bm &amp; pet mrd', 'analysis of bm &amp; pet mrd prognostic', 'of bm &amp; pet mrd prognostic value', 'bm &amp; pet mrd prognostic value in', '&amp; pet mrd prognostic value in #cart', 'pet mrd prognostic value in #cart #mmsm', 'mrd prognostic value in #cart #mmsm .', 'bm mrd in karmma &amp; cartitude-1 are presented', 'mrd in karmma &amp; cartitude-1 are presented #ash22.', 'in karmma &amp; cartitude-1 are presented #ash22. monday', 'karmma &amp; cartitude-1 are presented #ash22. monday morning,', '&amp; cartitude-1 are presented #ash22. monday morning, will', 'cartitude-1 are presented #ash22. monday morning, will present', 'are presented #ash22. monday morning, will present analysis', 'presented #ash22. monday morning, will present analysis of', '#ash22. monday morning, will present analysis of bm', 'monday morning, will present analysis of bm &amp;', 'morning, will present analysis of bm &amp; pet', 'will present analysis of bm &amp; pet mrd', 'present analysis of bm &amp; pet mrd prognostic', 'analysis of bm &amp; pet mrd prognostic value', 'of bm &amp; pet mrd prognostic value in', 'bm &amp; pet mrd prognostic value in #cart', '&amp; pet mrd prognostic value in #cart #mmsm', 'pet mrd prognostic value in #cart #mmsm .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '82', 'tokens': ['[68ga]ga-psma-11', 'pet', 'baseline', 'imaging', 'as', 'a', 'prognostic', 'tool', 'for', 'clinical', 'outcomes', 'to', '[177lu]lu-psma-617', 'in', 'patients', 'with', 'mcrpc:', 'a', 'vision', 'substudy', '#asco22', '.'], 'text_length': 22, 'triples': {'vision|prognostic tool for clinical outcomes': ([18, 18], [6, 10], 'neutral')}, 'sentence': '[68ga]ga-psma-11 pet baseline imaging as a prognostic tool for clinical outcomes to [177lu]lu-psma-617 in patients with mcrpc: a vision substudy #asco22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['[68ga]ga-psma-11', 'pet', 'baseline', 'imaging', 'as', 'a', 'prognostic', 'tool', 'for', 'clinical', 'outcomes', 'to', '[177lu]lu-psma-617', 'in', 'patients', 'with', 'mcrpc:', 'a', 'vision', 'substudy', '#asco22', '.', '[68ga]ga-psma-11 pet', 'pet baseline', 'baseline imaging', 'imaging as', 'as a', 'a prognostic', 'prognostic tool', 'tool for', 'for clinical', 'clinical outcomes', 'outcomes to', 'to [177lu]lu-psma-617', '[177lu]lu-psma-617 in', 'in patients', 'patients with', 'with mcrpc:', 'mcrpc: a', 'a vision', 'vision substudy', 'substudy #asco22', '#asco22 .', '[68ga]ga-psma-11 pet baseline', 'pet baseline imaging', 'baseline imaging as', 'imaging as a', 'as a prognostic', 'a prognostic tool', 'prognostic tool for', 'tool for clinical', 'for clinical outcomes', 'clinical outcomes to', 'outcomes to [177lu]lu-psma-617', 'to [177lu]lu-psma-617 in', '[177lu]lu-psma-617 in patients', 'in patients with', 'patients with mcrpc:', 'with mcrpc: a', 'mcrpc: a vision', 'a vision substudy', 'vision substudy #asco22', 'substudy #asco22 .', '[68ga]ga-psma-11 pet baseline imaging', 'pet baseline imaging as', 'baseline imaging as a', 'imaging as a prognostic', 'as a prognostic tool', 'a prognostic tool for', 'prognostic tool for clinical', 'tool for clinical outcomes', 'for clinical outcomes to', 'clinical outcomes to [177lu]lu-psma-617', 'outcomes to [177lu]lu-psma-617 in', 'to [177lu]lu-psma-617 in patients', '[177lu]lu-psma-617 in patients with', 'in patients with mcrpc:', 'patients with mcrpc: a', 'with mcrpc: a vision', 'mcrpc: a vision substudy', 'a vision substudy #asco22', 'vision substudy #asco22 .', '[68ga]ga-psma-11 pet baseline imaging as', 'pet baseline imaging as a', 'baseline imaging as a prognostic', 'imaging as a prognostic tool', 'as a prognostic tool for', 'a prognostic tool for clinical', 'prognostic tool for clinical outcomes', 'tool for clinical outcomes to', 'for clinical outcomes to [177lu]lu-psma-617', 'clinical outcomes to [177lu]lu-psma-617 in', 'outcomes to [177lu]lu-psma-617 in patients', 'to [177lu]lu-psma-617 in patients with', '[177lu]lu-psma-617 in patients with mcrpc:', 'in patients with mcrpc: a', 'patients with mcrpc: a vision', 'with mcrpc: a vision substudy', 'mcrpc: a vision substudy #asco22', 'a vision substudy #asco22 .', '[68ga]ga-psma-11 pet baseline imaging as a', 'pet baseline imaging as a prognostic', 'baseline imaging as a prognostic tool', 'imaging as a prognostic tool for', 'as a prognostic tool for clinical', 'a prognostic tool for clinical outcomes', 'prognostic tool for clinical outcomes to', 'tool for clinical outcomes to [177lu]lu-psma-617', 'for clinical outcomes to [177lu]lu-psma-617 in', 'clinical outcomes to [177lu]lu-psma-617 in patients', 'outcomes to [177lu]lu-psma-617 in patients with', 'to [177lu]lu-psma-617 in patients with mcrpc:', '[177lu]lu-psma-617 in patients with mcrpc: a', 'in patients with mcrpc: a vision', 'patients with mcrpc: a vision substudy', 'with mcrpc: a vision substudy #asco22', 'mcrpc: a vision substudy #asco22 .', '[68ga]ga-psma-11 pet baseline imaging as a prognostic', 'pet baseline imaging as a prognostic tool', 'baseline imaging as a prognostic tool for', 'imaging as a prognostic tool for clinical', 'as a prognostic tool for clinical outcomes', 'a prognostic tool for clinical outcomes to', 'prognostic tool for clinical outcomes to [177lu]lu-psma-617', 'tool for clinical outcomes to [177lu]lu-psma-617 in', 'for clinical outcomes to [177lu]lu-psma-617 in patients', 'clinical outcomes to [177lu]lu-psma-617 in patients with', 'outcomes to [177lu]lu-psma-617 in patients with mcrpc:', 'to [177lu]lu-psma-617 in patients with mcrpc: a', '[177lu]lu-psma-617 in patients with mcrpc: a vision', 'in patients with mcrpc: a vision substudy', 'patients with mcrpc: a vision substudy #asco22', 'with mcrpc: a vision substudy #asco22 .', '[68ga]ga-psma-11 pet baseline imaging as a prognostic tool', 'pet baseline imaging as a prognostic tool for', 'baseline imaging as a prognostic tool for clinical', 'imaging as a prognostic tool for clinical outcomes', 'as a prognostic tool for clinical outcomes to', 'a prognostic tool for clinical outcomes to [177lu]lu-psma-617', 'prognostic tool for clinical outcomes to [177lu]lu-psma-617 in', 'tool for clinical outcomes to [177lu]lu-psma-617 in patients', 'for clinical outcomes to [177lu]lu-psma-617 in patients with', 'clinical outcomes to [177lu]lu-psma-617 in patients with mcrpc:', 'outcomes to [177lu]lu-psma-617 in patients with mcrpc: a', 'to [177lu]lu-psma-617 in patients with mcrpc: a vision', '[177lu]lu-psma-617 in patients with mcrpc: a vision substudy', 'in patients with mcrpc: a vision substudy #asco22', 'patients with mcrpc: a vision substudy #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '83', 'tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'zanubrutinib', 'more', 'effective', 'in', 'del17p/TP53m', '(2yr', 'PFS', '77.6%', 'v', '55.7%).', 'ORR', '86.2%', 'v', '75.7%.', 'Overall', 'tolerability', 'similar', 'but', 'importantly', 'significantly', 'less', 'Afib', 'w', 'ZAN', '(5.2%', 'v', '13.3%).', 'Serious', 'cards', 'AEs', '1.9%', '(ZAN)', 'v', '7.7%', '.'], 'text_length': 39, 'triples': {'zanubrutinib|more effective': ([4, 4], [5, 6], 'positive')}, 'sentence': '#ASH22 #leusm #lymsm Brown: zanubrutinib more effective in del17p/TP53m (2yr PFS 77.6% v 55.7%). ORR 86.2% v 75.7%. Overall tolerability similar but importantly significantly less Afib w ZAN (5.2% v 13.3%). Serious cards AEs 1.9% (ZAN) v 7.7% .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 6)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8)], 'span tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'zanubrutinib', 'more', 'effective', 'in', 'del17p/TP53m', '(2yr', 'PFS', '77.6%', 'v', '55.7%).', 'ORR', '86.2%', 'v', '75.7%.', 'Overall', 'tolerability', 'similar', 'but', 'importantly', 'significantly', 'less', 'Afib', 'w', 'ZAN', '(5.2%', 'v', '13.3%).', 'Serious', 'cards', 'AEs', '1.9%', '(ZAN)', 'v', '7.7%', '.', '#ASH22 #leusm', '#leusm #lymsm', '#lymsm Brown:', 'Brown: zanubrutinib', 'zanubrutinib more', 'more effective', 'effective in', 'in del17p/TP53m', 'del17p/TP53m (2yr', '(2yr PFS', 'PFS 77.6%', '77.6% v', 'v 55.7%).', '55.7%). ORR', 'ORR 86.2%', '86.2% v', 'v 75.7%.', '75.7%. Overall', 'Overall tolerability', 'tolerability similar', 'similar but', 'but importantly', 'importantly significantly', 'significantly less', 'less Afib', 'Afib w', 'w ZAN', 'ZAN (5.2%', '(5.2% v', 'v 13.3%).', '13.3%). Serious', 'Serious cards', 'cards AEs', 'AEs 1.9%', '1.9% (ZAN)', '(ZAN) v', 'v 7.7%', '7.7% .', '#ASH22 #leusm #lymsm', '#leusm #lymsm Brown:', '#lymsm Brown: zanubrutinib', 'Brown: zanubrutinib more', 'zanubrutinib more effective', 'more effective in', 'effective in del17p/TP53m', 'in del17p/TP53m (2yr', 'del17p/TP53m (2yr PFS', '(2yr PFS 77.6%', 'PFS 77.6% v', '77.6% v 55.7%).', 'v 55.7%). ORR', '55.7%). ORR 86.2%', 'ORR 86.2% v', '86.2% v 75.7%.', 'v 75.7%. Overall', '75.7%. Overall tolerability', 'Overall tolerability similar', 'tolerability similar but', 'similar but importantly', 'but importantly significantly', 'importantly significantly less', 'significantly less Afib', 'less Afib w', 'Afib w ZAN', 'w ZAN (5.2%', 'ZAN (5.2% v', '(5.2% v 13.3%).', 'v 13.3%). Serious', '13.3%). Serious cards', 'Serious cards AEs', 'cards AEs 1.9%', 'AEs 1.9% (ZAN)', '1.9% (ZAN) v', '(ZAN) v 7.7%', 'v 7.7% .', '#ASH22 #leusm #lymsm Brown:', '#leusm #lymsm Brown: zanubrutinib', '#lymsm Brown: zanubrutinib more', 'Brown: zanubrutinib more effective', 'zanubrutinib more effective in', 'more effective in del17p/TP53m', 'effective in del17p/TP53m (2yr', 'in del17p/TP53m (2yr PFS', 'del17p/TP53m (2yr PFS 77.6%', '(2yr PFS 77.6% v', 'PFS 77.6% v 55.7%).', '77.6% v 55.7%). ORR', 'v 55.7%). ORR 86.2%', '55.7%). ORR 86.2% v', 'ORR 86.2% v 75.7%.', '86.2% v 75.7%. Overall', 'v 75.7%. Overall tolerability', '75.7%. Overall tolerability similar', 'Overall tolerability similar but', 'tolerability similar but importantly', 'similar but importantly significantly', 'but importantly significantly less', 'importantly significantly less Afib', 'significantly less Afib w', 'less Afib w ZAN', 'Afib w ZAN (5.2%', 'w ZAN (5.2% v', 'ZAN (5.2% v 13.3%).', '(5.2% v 13.3%). Serious', 'v 13.3%). Serious cards', '13.3%). Serious cards AEs', 'Serious cards AEs 1.9%', 'cards AEs 1.9% (ZAN)', 'AEs 1.9% (ZAN) v', '1.9% (ZAN) v 7.7%', '(ZAN) v 7.7% .', '#ASH22 #leusm #lymsm Brown: zanubrutinib', '#leusm #lymsm Brown: zanubrutinib more', '#lymsm Brown: zanubrutinib more effective', 'Brown: zanubrutinib more effective in', 'zanubrutinib more effective in del17p/TP53m', 'more effective in del17p/TP53m (2yr', 'effective in del17p/TP53m (2yr PFS', 'in del17p/TP53m (2yr PFS 77.6%', 'del17p/TP53m (2yr PFS 77.6% v', '(2yr PFS 77.6% v 55.7%).', 'PFS 77.6% v 55.7%). ORR', '77.6% v 55.7%). ORR 86.2%', 'v 55.7%). ORR 86.2% v', '55.7%). ORR 86.2% v 75.7%.', 'ORR 86.2% v 75.7%. Overall', '86.2% v 75.7%. Overall tolerability', 'v 75.7%. Overall tolerability similar', '75.7%. Overall tolerability similar but', 'Overall tolerability similar but importantly', 'tolerability similar but importantly significantly', 'similar but importantly significantly less', 'but importantly significantly less Afib', 'importantly significantly less Afib w', 'significantly less Afib w ZAN', 'less Afib w ZAN (5.2%', 'Afib w ZAN (5.2% v', 'w ZAN (5.2% v 13.3%).', 'ZAN (5.2% v 13.3%). Serious', '(5.2% v 13.3%). Serious cards', 'v 13.3%). Serious cards AEs', '13.3%). Serious cards AEs 1.9%', 'Serious cards AEs 1.9% (ZAN)', 'cards AEs 1.9% (ZAN) v', 'AEs 1.9% (ZAN) v 7.7%', '1.9% (ZAN) v 7.7% .', '#ASH22 #leusm #lymsm Brown: zanubrutinib more', '#leusm #lymsm Brown: zanubrutinib more effective', '#lymsm Brown: zanubrutinib more effective in', 'Brown: zanubrutinib more effective in del17p/TP53m', 'zanubrutinib more effective in del17p/TP53m (2yr', 'more effective in del17p/TP53m (2yr PFS', 'effective in del17p/TP53m (2yr PFS 77.6%', 'in del17p/TP53m (2yr PFS 77.6% v', 'del17p/TP53m (2yr PFS 77.6% v 55.7%).', '(2yr PFS 77.6% v 55.7%). ORR', 'PFS 77.6% v 55.7%). ORR 86.2%', '77.6% v 55.7%). ORR 86.2% v', 'v 55.7%). ORR 86.2% v 75.7%.', '55.7%). ORR 86.2% v 75.7%. Overall', 'ORR 86.2% v 75.7%. Overall tolerability', '86.2% v 75.7%. Overall tolerability similar', 'v 75.7%. Overall tolerability similar but', '75.7%. Overall tolerability similar but importantly', 'Overall tolerability similar but importantly significantly', 'tolerability similar but importantly significantly less', 'similar but importantly significantly less Afib', 'but importantly significantly less Afib w', 'importantly significantly less Afib w ZAN', 'significantly less Afib w ZAN (5.2%', 'less Afib w ZAN (5.2% v', 'Afib w ZAN (5.2% v 13.3%).', 'w ZAN (5.2% v 13.3%). Serious', 'ZAN (5.2% v 13.3%). Serious cards', '(5.2% v 13.3%). Serious cards AEs', 'v 13.3%). Serious cards AEs 1.9%', '13.3%). Serious cards AEs 1.9% (ZAN)', 'Serious cards AEs 1.9% (ZAN) v', 'cards AEs 1.9% (ZAN) v 7.7%', 'AEs 1.9% (ZAN) v 7.7% .', '#ASH22 #leusm #lymsm Brown: zanubrutinib more effective', '#leusm #lymsm Brown: zanubrutinib more effective in', '#lymsm Brown: zanubrutinib more effective in del17p/TP53m', 'Brown: zanubrutinib more effective in del17p/TP53m (2yr', 'zanubrutinib more effective in del17p/TP53m (2yr PFS', 'more effective in del17p/TP53m (2yr PFS 77.6%', 'effective in del17p/TP53m (2yr PFS 77.6% v', 'in del17p/TP53m (2yr PFS 77.6% v 55.7%).', 'del17p/TP53m (2yr PFS 77.6% v 55.7%). ORR', '(2yr PFS 77.6% v 55.7%). ORR 86.2%', 'PFS 77.6% v 55.7%). ORR 86.2% v', '77.6% v 55.7%). ORR 86.2% v 75.7%.', 'v 55.7%). ORR 86.2% v 75.7%. Overall', '55.7%). ORR 86.2% v 75.7%. Overall tolerability', 'ORR 86.2% v 75.7%. Overall tolerability similar', '86.2% v 75.7%. Overall tolerability similar but', 'v 75.7%. Overall tolerability similar but importantly', '75.7%. Overall tolerability similar but importantly significantly', 'Overall tolerability similar but importantly significantly less', 'tolerability similar but importantly significantly less Afib', 'similar but importantly significantly less Afib w', 'but importantly significantly less Afib w ZAN', 'importantly significantly less Afib w ZAN (5.2%', 'significantly less Afib w ZAN (5.2% v', 'less Afib w ZAN (5.2% v 13.3%).', 'Afib w ZAN (5.2% v 13.3%). Serious', 'w ZAN (5.2% v 13.3%). Serious cards', 'ZAN (5.2% v 13.3%). Serious cards AEs', '(5.2% v 13.3%). Serious cards AEs 1.9%', 'v 13.3%). Serious cards AEs 1.9% (ZAN)', '13.3%). Serious cards AEs 1.9% (ZAN) v', 'Serious cards AEs 1.9% (ZAN) v 7.7%', 'cards AEs 1.9% (ZAN) v 7.7% .', '#ASH22 #leusm #lymsm Brown: zanubrutinib more effective in', '#leusm #lymsm Brown: zanubrutinib more effective in del17p/TP53m', '#lymsm Brown: zanubrutinib more effective in del17p/TP53m (2yr', 'Brown: zanubrutinib more effective in del17p/TP53m (2yr PFS', 'zanubrutinib more effective in del17p/TP53m (2yr PFS 77.6%', 'more effective in del17p/TP53m (2yr PFS 77.6% v', 'effective in del17p/TP53m (2yr PFS 77.6% v 55.7%).', 'in del17p/TP53m (2yr PFS 77.6% v 55.7%). ORR', 'del17p/TP53m (2yr PFS 77.6% v 55.7%). ORR 86.2%', '(2yr PFS 77.6% v 55.7%). ORR 86.2% v', 'PFS 77.6% v 55.7%). ORR 86.2% v 75.7%.', '77.6% v 55.7%). ORR 86.2% v 75.7%. Overall', 'v 55.7%). ORR 86.2% v 75.7%. Overall tolerability', '55.7%). ORR 86.2% v 75.7%. Overall tolerability similar', 'ORR 86.2% v 75.7%. Overall tolerability similar but', '86.2% v 75.7%. Overall tolerability similar but importantly', 'v 75.7%. Overall tolerability similar but importantly significantly', '75.7%. Overall tolerability similar but importantly significantly less', 'Overall tolerability similar but importantly significantly less Afib', 'tolerability similar but importantly significantly less Afib w', 'similar but importantly significantly less Afib w ZAN', 'but importantly significantly less Afib w ZAN (5.2%', 'importantly significantly less Afib w ZAN (5.2% v', 'significantly less Afib w ZAN (5.2% v 13.3%).', 'less Afib w ZAN (5.2% v 13.3%). Serious', 'Afib w ZAN (5.2% v 13.3%). Serious cards', 'w ZAN (5.2% v 13.3%). Serious cards AEs', 'ZAN (5.2% v 13.3%). Serious cards AEs 1.9%', '(5.2% v 13.3%). Serious cards AEs 1.9% (ZAN)', 'v 13.3%). Serious cards AEs 1.9% (ZAN) v', '13.3%). Serious cards AEs 1.9% (ZAN) v 7.7%', 'Serious cards AEs 1.9% (ZAN) v 7.7% .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '84', 'tokens': ['phiii', 'enzamet', 'updated', 'survival', 'in', '#mhspc', 'median', 'f/u', '68', 'mos', 'sustained', 'os', 'benefit', 'w/', 'enzalutamide+nsaa', 'vs', 'nsaa', 'even', 'w/76%', 'receiving', 'nht', 'at', 'pd', 'in', 'control,', '45%', 'w/enza', '+', 'early', 'docetaxel', 'planned', 'w/potential', 'signal', 'of', 'benefit', 'in', 'explor', 'analyses', '(synchronous,', 'high-volume)', '#asco22', '.'], 'text_length': 42, 'triples': {'enzamet|updated survival': ([1, 1], [2, 3], 'neutral'), 'enzalutamide+nsaa|sustained os benefit w/ enzalutamide+nsaa vs nsaa even w/76% receiving nht at pd in control, 45% w/enza + early docetaxel planned w/potential signal of benefit in explor analyses': ([14, 14], [10, 37], 'positive')}, 'sentence': 'phiii enzamet updated survival in #mhspc median f/u 68 mos sustained os benefit w/ enzalutamide+nsaa vs nsaa even w/76% receiving nht at pd in control, 45% w/enza + early docetaxel planned w/potential signal of benefit in explor analyses (synchronous, high-volume) #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(1, 1), (14, 14)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(2, 3), (10, 37)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8)], 'span tokens': ['phiii', 'enzamet', 'updated', 'survival', 'in', '#mhspc', 'median', 'f/u', '68', 'mos', 'sustained', 'os', 'benefit', 'w/', 'enzalutamide+nsaa', 'vs', 'nsaa', 'even', 'w/76%', 'receiving', 'nht', 'at', 'pd', 'in', 'control,', '45%', 'w/enza', '+', 'early', 'docetaxel', 'planned', 'w/potential', 'signal', 'of', 'benefit', 'in', 'explor', 'analyses', '(synchronous,', 'high-volume)', '#asco22', '.', 'phiii enzamet', 'enzamet updated', 'updated survival', 'survival in', 'in #mhspc', '#mhspc median', 'median f/u', 'f/u 68', '68 mos', 'mos sustained', 'sustained os', 'os benefit', 'benefit w/', 'w/ enzalutamide+nsaa', 'enzalutamide+nsaa vs', 'vs nsaa', 'nsaa even', 'even w/76%', 'w/76% receiving', 'receiving nht', 'nht at', 'at pd', 'pd in', 'in control,', 'control, 45%', '45% w/enza', 'w/enza +', '+ early', 'early docetaxel', 'docetaxel planned', 'planned w/potential', 'w/potential signal', 'signal of', 'of benefit', 'benefit in', 'in explor', 'explor analyses', 'analyses (synchronous,', '(synchronous, high-volume)', 'high-volume) #asco22', '#asco22 .', 'phiii enzamet updated', 'enzamet updated survival', 'updated survival in', 'survival in #mhspc', 'in #mhspc median', '#mhspc median f/u', 'median f/u 68', 'f/u 68 mos', '68 mos sustained', 'mos sustained os', 'sustained os benefit', 'os benefit w/', 'benefit w/ enzalutamide+nsaa', 'w/ enzalutamide+nsaa vs', 'enzalutamide+nsaa vs nsaa', 'vs nsaa even', 'nsaa even w/76%', 'even w/76% receiving', 'w/76% receiving nht', 'receiving nht at', 'nht at pd', 'at pd in', 'pd in control,', 'in control, 45%', 'control, 45% w/enza', '45% w/enza +', 'w/enza + early', '+ early docetaxel', 'early docetaxel planned', 'docetaxel planned w/potential', 'planned w/potential signal', 'w/potential signal of', 'signal of benefit', 'of benefit in', 'benefit in explor', 'in explor analyses', 'explor analyses (synchronous,', 'analyses (synchronous, high-volume)', '(synchronous, high-volume) #asco22', 'high-volume) #asco22 .', 'phiii enzamet updated survival', 'enzamet updated survival in', 'updated survival in #mhspc', 'survival in #mhspc median', 'in #mhspc median f/u', '#mhspc median f/u 68', 'median f/u 68 mos', 'f/u 68 mos sustained', '68 mos sustained os', 'mos sustained os benefit', 'sustained os benefit w/', 'os benefit w/ enzalutamide+nsaa', 'benefit w/ enzalutamide+nsaa vs', 'w/ enzalutamide+nsaa vs nsaa', 'enzalutamide+nsaa vs nsaa even', 'vs nsaa even w/76%', 'nsaa even w/76% receiving', 'even w/76% receiving nht', 'w/76% receiving nht at', 'receiving nht at pd', 'nht at pd in', 'at pd in control,', 'pd in control, 45%', 'in control, 45% w/enza', 'control, 45% w/enza +', '45% w/enza + early', 'w/enza + early docetaxel', '+ early docetaxel planned', 'early docetaxel planned w/potential', 'docetaxel planned w/potential signal', 'planned w/potential signal of', 'w/potential signal of benefit', 'signal of benefit in', 'of benefit in explor', 'benefit in explor analyses', 'in explor analyses (synchronous,', 'explor analyses (synchronous, high-volume)', 'analyses (synchronous, high-volume) #asco22', '(synchronous, high-volume) #asco22 .', 'phiii enzamet updated survival in', 'enzamet updated survival in #mhspc', 'updated survival in #mhspc median', 'survival in #mhspc median f/u', 'in #mhspc median f/u 68', '#mhspc median f/u 68 mos', 'median f/u 68 mos sustained', 'f/u 68 mos sustained os', '68 mos sustained os benefit', 'mos sustained os benefit w/', 'sustained os benefit w/ enzalutamide+nsaa', 'os benefit w/ enzalutamide+nsaa vs', 'benefit w/ enzalutamide+nsaa vs nsaa', 'w/ enzalutamide+nsaa vs nsaa even', 'enzalutamide+nsaa vs nsaa even w/76%', 'vs nsaa even w/76% receiving', 'nsaa even w/76% receiving nht', 'even w/76% receiving nht at', 'w/76% receiving nht at pd', 'receiving nht at pd in', 'nht at pd in control,', 'at pd in control, 45%', 'pd in control, 45% w/enza', 'in control, 45% w/enza +', 'control, 45% w/enza + early', '45% w/enza + early docetaxel', 'w/enza + early docetaxel planned', '+ early docetaxel planned w/potential', 'early docetaxel planned w/potential signal', 'docetaxel planned w/potential signal of', 'planned w/potential signal of benefit', 'w/potential signal of benefit in', 'signal of benefit in explor', 'of benefit in explor analyses', 'benefit in explor analyses (synchronous,', 'in explor analyses (synchronous, high-volume)', 'explor analyses (synchronous, high-volume) #asco22', 'analyses (synchronous, high-volume) #asco22 .', 'phiii enzamet updated survival in #mhspc', 'enzamet updated survival in #mhspc median', 'updated survival in #mhspc median f/u', 'survival in #mhspc median f/u 68', 'in #mhspc median f/u 68 mos', '#mhspc median f/u 68 mos sustained', 'median f/u 68 mos sustained os', 'f/u 68 mos sustained os benefit', '68 mos sustained os benefit w/', 'mos sustained os benefit w/ enzalutamide+nsaa', 'sustained os benefit w/ enzalutamide+nsaa vs', 'os benefit w/ enzalutamide+nsaa vs nsaa', 'benefit w/ enzalutamide+nsaa vs nsaa even', 'w/ enzalutamide+nsaa vs nsaa even w/76%', 'enzalutamide+nsaa vs nsaa even w/76% receiving', 'vs nsaa even w/76% receiving nht', 'nsaa even w/76% receiving nht at', 'even w/76% receiving nht at pd', 'w/76% receiving nht at pd in', 'receiving nht at pd in control,', 'nht at pd in control, 45%', 'at pd in control, 45% w/enza', 'pd in control, 45% w/enza +', 'in control, 45% w/enza + early', 'control, 45% w/enza + early docetaxel', '45% w/enza + early docetaxel planned', 'w/enza + early docetaxel planned w/potential', '+ early docetaxel planned w/potential signal', 'early docetaxel planned w/potential signal of', 'docetaxel planned w/potential signal of benefit', 'planned w/potential signal of benefit in', 'w/potential signal of benefit in explor', 'signal of benefit in explor analyses', 'of benefit in explor analyses (synchronous,', 'benefit in explor analyses (synchronous, high-volume)', 'in explor analyses (synchronous, high-volume) #asco22', 'explor analyses (synchronous, high-volume) #asco22 .', 'phiii enzamet updated survival in #mhspc median', 'enzamet updated survival in #mhspc median f/u', 'updated survival in #mhspc median f/u 68', 'survival in #mhspc median f/u 68 mos', 'in #mhspc median f/u 68 mos sustained', '#mhspc median f/u 68 mos sustained os', 'median f/u 68 mos sustained os benefit', 'f/u 68 mos sustained os benefit w/', '68 mos sustained os benefit w/ enzalutamide+nsaa', 'mos sustained os benefit w/ enzalutamide+nsaa vs', 'sustained os benefit w/ enzalutamide+nsaa vs nsaa', 'os benefit w/ enzalutamide+nsaa vs nsaa even', 'benefit w/ enzalutamide+nsaa vs nsaa even w/76%', 'w/ enzalutamide+nsaa vs nsaa even w/76% receiving', 'enzalutamide+nsaa vs nsaa even w/76% receiving nht', 'vs nsaa even w/76% receiving nht at', 'nsaa even w/76% receiving nht at pd', 'even w/76% receiving nht at pd in', 'w/76% receiving nht at pd in control,', 'receiving nht at pd in control, 45%', 'nht at pd in control, 45% w/enza', 'at pd in control, 45% w/enza +', 'pd in control, 45% w/enza + early', 'in control, 45% w/enza + early docetaxel', 'control, 45% w/enza + early docetaxel planned', '45% w/enza + early docetaxel planned w/potential', 'w/enza + early docetaxel planned w/potential signal', '+ early docetaxel planned w/potential signal of', 'early docetaxel planned w/potential signal of benefit', 'docetaxel planned w/potential signal of benefit in', 'planned w/potential signal of benefit in explor', 'w/potential signal of benefit in explor analyses', 'signal of benefit in explor analyses (synchronous,', 'of benefit in explor analyses (synchronous, high-volume)', 'benefit in explor analyses (synchronous, high-volume) #asco22', 'in explor analyses (synchronous, high-volume) #asco22 .', 'phiii enzamet updated survival in #mhspc median f/u', 'enzamet updated survival in #mhspc median f/u 68', 'updated survival in #mhspc median f/u 68 mos', 'survival in #mhspc median f/u 68 mos sustained', 'in #mhspc median f/u 68 mos sustained os', '#mhspc median f/u 68 mos sustained os benefit', 'median f/u 68 mos sustained os benefit w/', 'f/u 68 mos sustained os benefit w/ enzalutamide+nsaa', '68 mos sustained os benefit w/ enzalutamide+nsaa vs', 'mos sustained os benefit w/ enzalutamide+nsaa vs nsaa', 'sustained os benefit w/ enzalutamide+nsaa vs nsaa even', 'os benefit w/ enzalutamide+nsaa vs nsaa even w/76%', 'benefit w/ enzalutamide+nsaa vs nsaa even w/76% receiving', 'w/ enzalutamide+nsaa vs nsaa even w/76% receiving nht', 'enzalutamide+nsaa vs nsaa even w/76% receiving nht at', 'vs nsaa even w/76% receiving nht at pd', 'nsaa even w/76% receiving nht at pd in', 'even w/76% receiving nht at pd in control,', 'w/76% receiving nht at pd in control, 45%', 'receiving nht at pd in control, 45% w/enza', 'nht at pd in control, 45% w/enza +', 'at pd in control, 45% w/enza + early', 'pd in control, 45% w/enza + early docetaxel', 'in control, 45% w/enza + early docetaxel planned', 'control, 45% w/enza + early docetaxel planned w/potential', '45% w/enza + early docetaxel planned w/potential signal', 'w/enza + early docetaxel planned w/potential signal of', '+ early docetaxel planned w/potential signal of benefit', 'early docetaxel planned w/potential signal of benefit in', 'docetaxel planned w/potential signal of benefit in explor', 'planned w/potential signal of benefit in explor analyses', 'w/potential signal of benefit in explor analyses (synchronous,', 'signal of benefit in explor analyses (synchronous, high-volume)', 'of benefit in explor analyses (synchronous, high-volume) #asco22', 'benefit in explor analyses (synchronous, high-volume) #asco22 .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '85', 'tokens': ['"the', 'codebreak-200', 'trial', 'shows', 'that', 'among', 'pts', 'with', '#nsclc', 'with', 'kras', 'g12c+', 'after', 'ct-io:', 'better', 'pfs', 'with', 'sotorasib', 'vs', 'docetaxel', 'no', 'diff', 'in', 'os', '(but', 'underpowered)', 'better', 'orr', 'with', 'sotorasib', 'better', 'tolerance', '&amp;', 'qol', 'clearly', 'a', 'new', 'soc', 'in', 'this', 'setting!', '#esmo22', '#lcsm', '.'], 'text_length': 44, 'triples': {'codebreak-200|better pfs with sotorasib vs docetaxel no diff in os (but underpowered) better orr with sotorasib better': ([1, 1], [14, 30], 'positive')}, 'sentence': '"the codebreak-200 trial shows that among pts with #nsclc with kras g12c+ after ct-io: better pfs with sotorasib vs docetaxel no diff in os (but underpowered) better orr with sotorasib better tolerance &amp; qol clearly a new soc in this setting! #esmo22 #lcsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(14, 30)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8)], 'span tokens': ['"the', 'codebreak-200', 'trial', 'shows', 'that', 'among', 'pts', 'with', '#nsclc', 'with', 'kras', 'g12c+', 'after', 'ct-io:', 'better', 'pfs', 'with', 'sotorasib', 'vs', 'docetaxel', 'no', 'diff', 'in', 'os', '(but', 'underpowered)', 'better', 'orr', 'with', 'sotorasib', 'better', 'tolerance', '&amp;', 'qol', 'clearly', 'a', 'new', 'soc', 'in', 'this', 'setting!', '#esmo22', '#lcsm', '.', '"the codebreak-200', 'codebreak-200 trial', 'trial shows', 'shows that', 'that among', 'among pts', 'pts with', 'with #nsclc', '#nsclc with', 'with kras', 'kras g12c+', 'g12c+ after', 'after ct-io:', 'ct-io: better', 'better pfs', 'pfs with', 'with sotorasib', 'sotorasib vs', 'vs docetaxel', 'docetaxel no', 'no diff', 'diff in', 'in os', 'os (but', '(but underpowered)', 'underpowered) better', 'better orr', 'orr with', 'with sotorasib', 'sotorasib better', 'better tolerance', 'tolerance &amp;', '&amp; qol', 'qol clearly', 'clearly a', 'a new', 'new soc', 'soc in', 'in this', 'this setting!', 'setting! #esmo22', '#esmo22 #lcsm', '#lcsm .', '"the codebreak-200 trial', 'codebreak-200 trial shows', 'trial shows that', 'shows that among', 'that among pts', 'among pts with', 'pts with #nsclc', 'with #nsclc with', '#nsclc with kras', 'with kras g12c+', 'kras g12c+ after', 'g12c+ after ct-io:', 'after ct-io: better', 'ct-io: better pfs', 'better pfs with', 'pfs with sotorasib', 'with sotorasib vs', 'sotorasib vs docetaxel', 'vs docetaxel no', 'docetaxel no diff', 'no diff in', 'diff in os', 'in os (but', 'os (but underpowered)', '(but underpowered) better', 'underpowered) better orr', 'better orr with', 'orr with sotorasib', 'with sotorasib better', 'sotorasib better tolerance', 'better tolerance &amp;', 'tolerance &amp; qol', '&amp; qol clearly', 'qol clearly a', 'clearly a new', 'a new soc', 'new soc in', 'soc in this', 'in this setting!', 'this setting! #esmo22', 'setting! #esmo22 #lcsm', '#esmo22 #lcsm .', '"the codebreak-200 trial shows', 'codebreak-200 trial shows that', 'trial shows that among', 'shows that among pts', 'that among pts with', 'among pts with #nsclc', 'pts with #nsclc with', 'with #nsclc with kras', '#nsclc with kras g12c+', 'with kras g12c+ after', 'kras g12c+ after ct-io:', 'g12c+ after ct-io: better', 'after ct-io: better pfs', 'ct-io: better pfs with', 'better pfs with sotorasib', 'pfs with sotorasib vs', 'with sotorasib vs docetaxel', 'sotorasib vs docetaxel no', 'vs docetaxel no diff', 'docetaxel no diff in', 'no diff in os', 'diff in os (but', 'in os (but underpowered)', 'os (but underpowered) better', '(but underpowered) better orr', 'underpowered) better orr with', 'better orr with sotorasib', 'orr with sotorasib better', 'with sotorasib better tolerance', 'sotorasib better tolerance &amp;', 'better tolerance &amp; qol', 'tolerance &amp; qol clearly', '&amp; qol clearly a', 'qol clearly a new', 'clearly a new soc', 'a new soc in', 'new soc in this', 'soc in this setting!', 'in this setting! #esmo22', 'this setting! #esmo22 #lcsm', 'setting! #esmo22 #lcsm .', '"the codebreak-200 trial shows that', 'codebreak-200 trial shows that among', 'trial shows that among pts', 'shows that among pts with', 'that among pts with #nsclc', 'among pts with #nsclc with', 'pts with #nsclc with kras', 'with #nsclc with kras g12c+', '#nsclc with kras g12c+ after', 'with kras g12c+ after ct-io:', 'kras g12c+ after ct-io: better', 'g12c+ after ct-io: better pfs', 'after ct-io: better pfs with', 'ct-io: better pfs with sotorasib', 'better pfs with sotorasib vs', 'pfs with sotorasib vs docetaxel', 'with sotorasib vs docetaxel no', 'sotorasib vs docetaxel no diff', 'vs docetaxel no diff in', 'docetaxel no diff in os', 'no diff in os (but', 'diff in os (but underpowered)', 'in os (but underpowered) better', 'os (but underpowered) better orr', '(but underpowered) better orr with', 'underpowered) better orr with sotorasib', 'better orr with sotorasib better', 'orr with sotorasib better tolerance', 'with sotorasib better tolerance &amp;', 'sotorasib better tolerance &amp; qol', 'better tolerance &amp; qol clearly', 'tolerance &amp; qol clearly a', '&amp; qol clearly a new', 'qol clearly a new soc', 'clearly a new soc in', 'a new soc in this', 'new soc in this setting!', 'soc in this setting! #esmo22', 'in this setting! #esmo22 #lcsm', 'this setting! #esmo22 #lcsm .', '"the codebreak-200 trial shows that among', 'codebreak-200 trial shows that among pts', 'trial shows that among pts with', 'shows that among pts with #nsclc', 'that among pts with #nsclc with', 'among pts with #nsclc with kras', 'pts with #nsclc with kras g12c+', 'with #nsclc with kras g12c+ after', '#nsclc with kras g12c+ after ct-io:', 'with kras g12c+ after ct-io: better', 'kras g12c+ after ct-io: better pfs', 'g12c+ after ct-io: better pfs with', 'after ct-io: better pfs with sotorasib', 'ct-io: better pfs with sotorasib vs', 'better pfs with sotorasib vs docetaxel', 'pfs with sotorasib vs docetaxel no', 'with sotorasib vs docetaxel no diff', 'sotorasib vs docetaxel no diff in', 'vs docetaxel no diff in os', 'docetaxel no diff in os (but', 'no diff in os (but underpowered)', 'diff in os (but underpowered) better', 'in os (but underpowered) better orr', 'os (but underpowered) better orr with', '(but underpowered) better orr with sotorasib', 'underpowered) better orr with sotorasib better', 'better orr with sotorasib better tolerance', 'orr with sotorasib better tolerance &amp;', 'with sotorasib better tolerance &amp; qol', 'sotorasib better tolerance &amp; qol clearly', 'better tolerance &amp; qol clearly a', 'tolerance &amp; qol clearly a new', '&amp; qol clearly a new soc', 'qol clearly a new soc in', 'clearly a new soc in this', 'a new soc in this setting!', 'new soc in this setting! #esmo22', 'soc in this setting! #esmo22 #lcsm', 'in this setting! #esmo22 #lcsm .', '"the codebreak-200 trial shows that among pts', 'codebreak-200 trial shows that among pts with', 'trial shows that among pts with #nsclc', 'shows that among pts with #nsclc with', 'that among pts with #nsclc with kras', 'among pts with #nsclc with kras g12c+', 'pts with #nsclc with kras g12c+ after', 'with #nsclc with kras g12c+ after ct-io:', '#nsclc with kras g12c+ after ct-io: better', 'with kras g12c+ after ct-io: better pfs', 'kras g12c+ after ct-io: better pfs with', 'g12c+ after ct-io: better pfs with sotorasib', 'after ct-io: better pfs with sotorasib vs', 'ct-io: better pfs with sotorasib vs docetaxel', 'better pfs with sotorasib vs docetaxel no', 'pfs with sotorasib vs docetaxel no diff', 'with sotorasib vs docetaxel no diff in', 'sotorasib vs docetaxel no diff in os', 'vs docetaxel no diff in os (but', 'docetaxel no diff in os (but underpowered)', 'no diff in os (but underpowered) better', 'diff in os (but underpowered) better orr', 'in os (but underpowered) better orr with', 'os (but underpowered) better orr with sotorasib', '(but underpowered) better orr with sotorasib better', 'underpowered) better orr with sotorasib better tolerance', 'better orr with sotorasib better tolerance &amp;', 'orr with sotorasib better tolerance &amp; qol', 'with sotorasib better tolerance &amp; qol clearly', 'sotorasib better tolerance &amp; qol clearly a', 'better tolerance &amp; qol clearly a new', 'tolerance &amp; qol clearly a new soc', '&amp; qol clearly a new soc in', 'qol clearly a new soc in this', 'clearly a new soc in this setting!', 'a new soc in this setting! #esmo22', 'new soc in this setting! #esmo22 #lcsm', 'soc in this setting! #esmo22 #lcsm .', '"the codebreak-200 trial shows that among pts with', 'codebreak-200 trial shows that among pts with #nsclc', 'trial shows that among pts with #nsclc with', 'shows that among pts with #nsclc with kras', 'that among pts with #nsclc with kras g12c+', 'among pts with #nsclc with kras g12c+ after', 'pts with #nsclc with kras g12c+ after ct-io:', 'with #nsclc with kras g12c+ after ct-io: better', '#nsclc with kras g12c+ after ct-io: better pfs', 'with kras g12c+ after ct-io: better pfs with', 'kras g12c+ after ct-io: better pfs with sotorasib', 'g12c+ after ct-io: better pfs with sotorasib vs', 'after ct-io: better pfs with sotorasib vs docetaxel', 'ct-io: better pfs with sotorasib vs docetaxel no', 'better pfs with sotorasib vs docetaxel no diff', 'pfs with sotorasib vs docetaxel no diff in', 'with sotorasib vs docetaxel no diff in os', 'sotorasib vs docetaxel no diff in os (but', 'vs docetaxel no diff in os (but underpowered)', 'docetaxel no diff in os (but underpowered) better', 'no diff in os (but underpowered) better orr', 'diff in os (but underpowered) better orr with', 'in os (but underpowered) better orr with sotorasib', 'os (but underpowered) better orr with sotorasib better', '(but underpowered) better orr with sotorasib better tolerance', 'underpowered) better orr with sotorasib better tolerance &amp;', 'better orr with sotorasib better tolerance &amp; qol', 'orr with sotorasib better tolerance &amp; qol clearly', 'with sotorasib better tolerance &amp; qol clearly a', 'sotorasib better tolerance &amp; qol clearly a new', 'better tolerance &amp; qol clearly a new soc', 'tolerance &amp; qol clearly a new soc in', '&amp; qol clearly a new soc in this', 'qol clearly a new soc in this setting!', 'clearly a new soc in this setting! #esmo22', 'a new soc in this setting! #esmo22 #lcsm', 'new soc in this setting! #esmo22 #lcsm .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '86', 'tokens': ['everolimus', '(mtor', 'inh)', 'like', 'most', 'tkis,', 'fail', 'to', 'significantly', 'improve', 'rfs/dfs', 'in', 'rcc', 'adjuvant', 'setting.', 'hope', 'icis', 'will', 'show', 'os', 'improvement', 'in', 'the', 'near', 'future.', '#asco22', '#kcsm', '.'], 'text_length': 28, 'triples': {'everolimus|fail to significantly improve': ([0, 0], [6, 9], 'negative')}, 'sentence': 'everolimus (mtor inh) like most tkis, fail to significantly improve rfs/dfs in rcc adjuvant setting. hope icis will show os improvement in the near future. #asco22 #kcsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['everolimus', '(mtor', 'inh)', 'like', 'most', 'tkis,', 'fail', 'to', 'significantly', 'improve', 'rfs/dfs', 'in', 'rcc', 'adjuvant', 'setting.', 'hope', 'icis', 'will', 'show', 'os', 'improvement', 'in', 'the', 'near', 'future.', '#asco22', '#kcsm', '.', 'everolimus (mtor', '(mtor inh)', 'inh) like', 'like most', 'most tkis,', 'tkis, fail', 'fail to', 'to significantly', 'significantly improve', 'improve rfs/dfs', 'rfs/dfs in', 'in rcc', 'rcc adjuvant', 'adjuvant setting.', 'setting. hope', 'hope icis', 'icis will', 'will show', 'show os', 'os improvement', 'improvement in', 'in the', 'the near', 'near future.', 'future. #asco22', '#asco22 #kcsm', '#kcsm .', 'everolimus (mtor inh)', '(mtor inh) like', 'inh) like most', 'like most tkis,', 'most tkis, fail', 'tkis, fail to', 'fail to significantly', 'to significantly improve', 'significantly improve rfs/dfs', 'improve rfs/dfs in', 'rfs/dfs in rcc', 'in rcc adjuvant', 'rcc adjuvant setting.', 'adjuvant setting. hope', 'setting. hope icis', 'hope icis will', 'icis will show', 'will show os', 'show os improvement', 'os improvement in', 'improvement in the', 'in the near', 'the near future.', 'near future. #asco22', 'future. #asco22 #kcsm', '#asco22 #kcsm .', 'everolimus (mtor inh) like', '(mtor inh) like most', 'inh) like most tkis,', 'like most tkis, fail', 'most tkis, fail to', 'tkis, fail to significantly', 'fail to significantly improve', 'to significantly improve rfs/dfs', 'significantly improve rfs/dfs in', 'improve rfs/dfs in rcc', 'rfs/dfs in rcc adjuvant', 'in rcc adjuvant setting.', 'rcc adjuvant setting. hope', 'adjuvant setting. hope icis', 'setting. hope icis will', 'hope icis will show', 'icis will show os', 'will show os improvement', 'show os improvement in', 'os improvement in the', 'improvement in the near', 'in the near future.', 'the near future. #asco22', 'near future. #asco22 #kcsm', 'future. #asco22 #kcsm .', 'everolimus (mtor inh) like most', '(mtor inh) like most tkis,', 'inh) like most tkis, fail', 'like most tkis, fail to', 'most tkis, fail to significantly', 'tkis, fail to significantly improve', 'fail to significantly improve rfs/dfs', 'to significantly improve rfs/dfs in', 'significantly improve rfs/dfs in rcc', 'improve rfs/dfs in rcc adjuvant', 'rfs/dfs in rcc adjuvant setting.', 'in rcc adjuvant setting. hope', 'rcc adjuvant setting. hope icis', 'adjuvant setting. hope icis will', 'setting. hope icis will show', 'hope icis will show os', 'icis will show os improvement', 'will show os improvement in', 'show os improvement in the', 'os improvement in the near', 'improvement in the near future.', 'in the near future. #asco22', 'the near future. #asco22 #kcsm', 'near future. #asco22 #kcsm .', 'everolimus (mtor inh) like most tkis,', '(mtor inh) like most tkis, fail', 'inh) like most tkis, fail to', 'like most tkis, fail to significantly', 'most tkis, fail to significantly improve', 'tkis, fail to significantly improve rfs/dfs', 'fail to significantly improve rfs/dfs in', 'to significantly improve rfs/dfs in rcc', 'significantly improve rfs/dfs in rcc adjuvant', 'improve rfs/dfs in rcc adjuvant setting.', 'rfs/dfs in rcc adjuvant setting. hope', 'in rcc adjuvant setting. hope icis', 'rcc adjuvant setting. hope icis will', 'adjuvant setting. hope icis will show', 'setting. hope icis will show os', 'hope icis will show os improvement', 'icis will show os improvement in', 'will show os improvement in the', 'show os improvement in the near', 'os improvement in the near future.', 'improvement in the near future. #asco22', 'in the near future. #asco22 #kcsm', 'the near future. #asco22 #kcsm .', 'everolimus (mtor inh) like most tkis, fail', '(mtor inh) like most tkis, fail to', 'inh) like most tkis, fail to significantly', 'like most tkis, fail to significantly improve', 'most tkis, fail to significantly improve rfs/dfs', 'tkis, fail to significantly improve rfs/dfs in', 'fail to significantly improve rfs/dfs in rcc', 'to significantly improve rfs/dfs in rcc adjuvant', 'significantly improve rfs/dfs in rcc adjuvant setting.', 'improve rfs/dfs in rcc adjuvant setting. hope', 'rfs/dfs in rcc adjuvant setting. hope icis', 'in rcc adjuvant setting. hope icis will', 'rcc adjuvant setting. hope icis will show', 'adjuvant setting. hope icis will show os', 'setting. hope icis will show os improvement', 'hope icis will show os improvement in', 'icis will show os improvement in the', 'will show os improvement in the near', 'show os improvement in the near future.', 'os improvement in the near future. #asco22', 'improvement in the near future. #asco22 #kcsm', 'in the near future. #asco22 #kcsm .', 'everolimus (mtor inh) like most tkis, fail to', '(mtor inh) like most tkis, fail to significantly', 'inh) like most tkis, fail to significantly improve', 'like most tkis, fail to significantly improve rfs/dfs', 'most tkis, fail to significantly improve rfs/dfs in', 'tkis, fail to significantly improve rfs/dfs in rcc', 'fail to significantly improve rfs/dfs in rcc adjuvant', 'to significantly improve rfs/dfs in rcc adjuvant setting.', 'significantly improve rfs/dfs in rcc adjuvant setting. hope', 'improve rfs/dfs in rcc adjuvant setting. hope icis', 'rfs/dfs in rcc adjuvant setting. hope icis will', 'in rcc adjuvant setting. hope icis will show', 'rcc adjuvant setting. hope icis will show os', 'adjuvant setting. hope icis will show os improvement', 'setting. hope icis will show os improvement in', 'hope icis will show os improvement in the', 'icis will show os improvement in the near', 'will show os improvement in the near future.', 'show os improvement in the near future. #asco22', 'os improvement in the near future. #asco22 #kcsm', 'improvement in the near future. #asco22 #kcsm .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '87', 'tokens': ['"#asco22', 'key', 'takeaways', 'from', 'vision', 'and', 'anzup', '1603:', '1.', '177lu-psma-617', 'more', 'active', 'than', 'cabazitaxel,', 'sequencing', 'may', 'not', 'matter', 'given', 'os', 'results', '2.', 'psma', 'pet', 'suv', 'is', 'an', 'emerging', 'biomarker,', 'cutoff', '&gt;10', 'most', 'likely', 'to', 'benefit.', 'should', 'prioritize', 'these', 'patients', 'until', 'drug', 'shortages', 'resolve', '.'], 'text_length': 44, 'triples': {'177lu-psma-617|more active than': ([9, 9], [10, 12], 'positive')}, 'sentence': '"#asco22 key takeaways from vision and anzup 1603: 1. 177lu-psma-617 more active than cabazitaxel, sequencing may not matter given os results 2. psma pet suv is an emerging biomarker, cutoff &gt;10 most likely to benefit. should prioritize these patients until drug shortages resolve .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(9, 9)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8)], 'span tokens': ['"#asco22', 'key', 'takeaways', 'from', 'vision', 'and', 'anzup', '1603:', '1.', '177lu-psma-617', 'more', 'active', 'than', 'cabazitaxel,', 'sequencing', 'may', 'not', 'matter', 'given', 'os', 'results', '2.', 'psma', 'pet', 'suv', 'is', 'an', 'emerging', 'biomarker,', 'cutoff', '&gt;10', 'most', 'likely', 'to', 'benefit.', 'should', 'prioritize', 'these', 'patients', 'until', 'drug', 'shortages', 'resolve', '.', '"#asco22 key', 'key takeaways', 'takeaways from', 'from vision', 'vision and', 'and anzup', 'anzup 1603:', '1603: 1.', '1. 177lu-psma-617', '177lu-psma-617 more', 'more active', 'active than', 'than cabazitaxel,', 'cabazitaxel, sequencing', 'sequencing may', 'may not', 'not matter', 'matter given', 'given os', 'os results', 'results 2.', '2. psma', 'psma pet', 'pet suv', 'suv is', 'is an', 'an emerging', 'emerging biomarker,', 'biomarker, cutoff', 'cutoff &gt;10', '&gt;10 most', 'most likely', 'likely to', 'to benefit.', 'benefit. should', 'should prioritize', 'prioritize these', 'these patients', 'patients until', 'until drug', 'drug shortages', 'shortages resolve', 'resolve .', '"#asco22 key takeaways', 'key takeaways from', 'takeaways from vision', 'from vision and', 'vision and anzup', 'and anzup 1603:', 'anzup 1603: 1.', '1603: 1. 177lu-psma-617', '1. 177lu-psma-617 more', '177lu-psma-617 more active', 'more active than', 'active than cabazitaxel,', 'than cabazitaxel, sequencing', 'cabazitaxel, sequencing may', 'sequencing may not', 'may not matter', 'not matter given', 'matter given os', 'given os results', 'os results 2.', 'results 2. psma', '2. psma pet', 'psma pet suv', 'pet suv is', 'suv is an', 'is an emerging', 'an emerging biomarker,', 'emerging biomarker, cutoff', 'biomarker, cutoff &gt;10', 'cutoff &gt;10 most', '&gt;10 most likely', 'most likely to', 'likely to benefit.', 'to benefit. should', 'benefit. should prioritize', 'should prioritize these', 'prioritize these patients', 'these patients until', 'patients until drug', 'until drug shortages', 'drug shortages resolve', 'shortages resolve .', '"#asco22 key takeaways from', 'key takeaways from vision', 'takeaways from vision and', 'from vision and anzup', 'vision and anzup 1603:', 'and anzup 1603: 1.', 'anzup 1603: 1. 177lu-psma-617', '1603: 1. 177lu-psma-617 more', '1. 177lu-psma-617 more active', '177lu-psma-617 more active than', 'more active than cabazitaxel,', 'active than cabazitaxel, sequencing', 'than cabazitaxel, sequencing may', 'cabazitaxel, sequencing may not', 'sequencing may not matter', 'may not matter given', 'not matter given os', 'matter given os results', 'given os results 2.', 'os results 2. psma', 'results 2. psma pet', '2. psma pet suv', 'psma pet suv is', 'pet suv is an', 'suv is an emerging', 'is an emerging biomarker,', 'an emerging biomarker, cutoff', 'emerging biomarker, cutoff &gt;10', 'biomarker, cutoff &gt;10 most', 'cutoff &gt;10 most likely', '&gt;10 most likely to', 'most likely to benefit.', 'likely to benefit. should', 'to benefit. should prioritize', 'benefit. should prioritize these', 'should prioritize these patients', 'prioritize these patients until', 'these patients until drug', 'patients until drug shortages', 'until drug shortages resolve', 'drug shortages resolve .', '"#asco22 key takeaways from vision', 'key takeaways from vision and', 'takeaways from vision and anzup', 'from vision and anzup 1603:', 'vision and anzup 1603: 1.', 'and anzup 1603: 1. 177lu-psma-617', 'anzup 1603: 1. 177lu-psma-617 more', '1603: 1. 177lu-psma-617 more active', '1. 177lu-psma-617 more active than', '177lu-psma-617 more active than cabazitaxel,', 'more active than cabazitaxel, sequencing', 'active than cabazitaxel, sequencing may', 'than cabazitaxel, sequencing may not', 'cabazitaxel, sequencing may not matter', 'sequencing may not matter given', 'may not matter given os', 'not matter given os results', 'matter given os results 2.', 'given os results 2. psma', 'os results 2. psma pet', 'results 2. psma pet suv', '2. psma pet suv is', 'psma pet suv is an', 'pet suv is an emerging', 'suv is an emerging biomarker,', 'is an emerging biomarker, cutoff', 'an emerging biomarker, cutoff &gt;10', 'emerging biomarker, cutoff &gt;10 most', 'biomarker, cutoff &gt;10 most likely', 'cutoff &gt;10 most likely to', '&gt;10 most likely to benefit.', 'most likely to benefit. should', 'likely to benefit. should prioritize', 'to benefit. should prioritize these', 'benefit. should prioritize these patients', 'should prioritize these patients until', 'prioritize these patients until drug', 'these patients until drug shortages', 'patients until drug shortages resolve', 'until drug shortages resolve .', '"#asco22 key takeaways from vision and', 'key takeaways from vision and anzup', 'takeaways from vision and anzup 1603:', 'from vision and anzup 1603: 1.', 'vision and anzup 1603: 1. 177lu-psma-617', 'and anzup 1603: 1. 177lu-psma-617 more', 'anzup 1603: 1. 177lu-psma-617 more active', '1603: 1. 177lu-psma-617 more active than', '1. 177lu-psma-617 more active than cabazitaxel,', '177lu-psma-617 more active than cabazitaxel, sequencing', 'more active than cabazitaxel, sequencing may', 'active than cabazitaxel, sequencing may not', 'than cabazitaxel, sequencing may not matter', 'cabazitaxel, sequencing may not matter given', 'sequencing may not matter given os', 'may not matter given os results', 'not matter given os results 2.', 'matter given os results 2. psma', 'given os results 2. psma pet', 'os results 2. psma pet suv', 'results 2. psma pet suv is', '2. psma pet suv is an', 'psma pet suv is an emerging', 'pet suv is an emerging biomarker,', 'suv is an emerging biomarker, cutoff', 'is an emerging biomarker, cutoff &gt;10', 'an emerging biomarker, cutoff &gt;10 most', 'emerging biomarker, cutoff &gt;10 most likely', 'biomarker, cutoff &gt;10 most likely to', 'cutoff &gt;10 most likely to benefit.', '&gt;10 most likely to benefit. should', 'most likely to benefit. should prioritize', 'likely to benefit. should prioritize these', 'to benefit. should prioritize these patients', 'benefit. should prioritize these patients until', 'should prioritize these patients until drug', 'prioritize these patients until drug shortages', 'these patients until drug shortages resolve', 'patients until drug shortages resolve .', '"#asco22 key takeaways from vision and anzup', 'key takeaways from vision and anzup 1603:', 'takeaways from vision and anzup 1603: 1.', 'from vision and anzup 1603: 1. 177lu-psma-617', 'vision and anzup 1603: 1. 177lu-psma-617 more', 'and anzup 1603: 1. 177lu-psma-617 more active', 'anzup 1603: 1. 177lu-psma-617 more active than', '1603: 1. 177lu-psma-617 more active than cabazitaxel,', '1. 177lu-psma-617 more active than cabazitaxel, sequencing', '177lu-psma-617 more active than cabazitaxel, sequencing may', 'more active than cabazitaxel, sequencing may not', 'active than cabazitaxel, sequencing may not matter', 'than cabazitaxel, sequencing may not matter given', 'cabazitaxel, sequencing may not matter given os', 'sequencing may not matter given os results', 'may not matter given os results 2.', 'not matter given os results 2. psma', 'matter given os results 2. psma pet', 'given os results 2. psma pet suv', 'os results 2. psma pet suv is', 'results 2. psma pet suv is an', '2. psma pet suv is an emerging', 'psma pet suv is an emerging biomarker,', 'pet suv is an emerging biomarker, cutoff', 'suv is an emerging biomarker, cutoff &gt;10', 'is an emerging biomarker, cutoff &gt;10 most', 'an emerging biomarker, cutoff &gt;10 most likely', 'emerging biomarker, cutoff &gt;10 most likely to', 'biomarker, cutoff &gt;10 most likely to benefit.', 'cutoff &gt;10 most likely to benefit. should', '&gt;10 most likely to benefit. should prioritize', 'most likely to benefit. should prioritize these', 'likely to benefit. should prioritize these patients', 'to benefit. should prioritize these patients until', 'benefit. should prioritize these patients until drug', 'should prioritize these patients until drug shortages', 'prioritize these patients until drug shortages resolve', 'these patients until drug shortages resolve .', '"#asco22 key takeaways from vision and anzup 1603:', 'key takeaways from vision and anzup 1603: 1.', 'takeaways from vision and anzup 1603: 1. 177lu-psma-617', 'from vision and anzup 1603: 1. 177lu-psma-617 more', 'vision and anzup 1603: 1. 177lu-psma-617 more active', 'and anzup 1603: 1. 177lu-psma-617 more active than', 'anzup 1603: 1. 177lu-psma-617 more active than cabazitaxel,', '1603: 1. 177lu-psma-617 more active than cabazitaxel, sequencing', '1. 177lu-psma-617 more active than cabazitaxel, sequencing may', '177lu-psma-617 more active than cabazitaxel, sequencing may not', 'more active than cabazitaxel, sequencing may not matter', 'active than cabazitaxel, sequencing may not matter given', 'than cabazitaxel, sequencing may not matter given os', 'cabazitaxel, sequencing may not matter given os results', 'sequencing may not matter given os results 2.', 'may not matter given os results 2. psma', 'not matter given os results 2. psma pet', 'matter given os results 2. psma pet suv', 'given os results 2. psma pet suv is', 'os results 2. psma pet suv is an', 'results 2. psma pet suv is an emerging', '2. psma pet suv is an emerging biomarker,', 'psma pet suv is an emerging biomarker, cutoff', 'pet suv is an emerging biomarker, cutoff &gt;10', 'suv is an emerging biomarker, cutoff &gt;10 most', 'is an emerging biomarker, cutoff &gt;10 most likely', 'an emerging biomarker, cutoff &gt;10 most likely to', 'emerging biomarker, cutoff &gt;10 most likely to benefit.', 'biomarker, cutoff &gt;10 most likely to benefit. should', 'cutoff &gt;10 most likely to benefit. should prioritize', '&gt;10 most likely to benefit. should prioritize these', 'most likely to benefit. should prioritize these patients', 'likely to benefit. should prioritize these patients until', 'to benefit. should prioritize these patients until drug', 'benefit. should prioritize these patients until drug shortages', 'should prioritize these patients until drug shortages resolve', 'prioritize these patients until drug shortages resolve .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '88', 'tokens': ['ALPINE', 'RCT', 'of', 'zanubrutinib', '', '', '', '', 'vs', 'ibrutinib', 'in', 'R/R', 'CLL.', 'More', 'discontinuation', 'in', 'ibr', 'arm', '(mostly', 'due', 'to', 'AEs).', 'Most', 'IGHV', 'unmut,', '22%', 'TP53mut,', '45%', 'bulky.', 'Superior', 'PFS', '(including', 'in', 'TP53mut;', 'look', 'at', 'that', 'curve!).', 'No', 'OS', 'difference.', 'Fewer', 'all-grade', '&amp;', 'fatal', 'cardiac', 'events', 'with', 'zanubrutinib.', 'New', 'SOC!', '#ASH22', '#lymsm', '.'], 'text_length': 54, 'triples': {'ALPINE|Superior': ([0, 0], [25, 25], 'positive'), 'zanubrutinib vs ibrutinib in R/R CLL. More discontinuation in ibr arm (mostly due to AEs). Most IGHV unmut, 22% TP53mut, 45% bulky. Superior PFS (including in TP53mut; look at that curve!). No OS difference. Fewer all-grade &amp; fatal cardiac events with zanubrutinib.|Superior': ([3, 44], [25, 25], 'positive'), 'ibrutinib|More discontinuation': ([5, 5], [9, 10], 'neutral')}, 'sentence': 'ALPINE RCT of zanubrutinib     vs ibrutinib in R/R CLL. More discontinuation in ibr arm (mostly due to AEs). Most IGHV unmut, 22% TP53mut, 45% bulky. Superior PFS (including in TP53mut; look at that curve!). No OS difference. Fewer all-grade &amp; fatal cardiac events with zanubrutinib. New SOC! #ASH22 #lymsm .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(0, 0), (3, 44), (5, 5)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(25, 25), (9, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (52, 52, 1), (53, 53, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (51, 52, 2), (52, 53, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (50, 52, 3), (51, 53, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (49, 52, 4), (50, 53, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (48, 52, 5), (49, 53, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (47, 52, 6), (48, 53, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (46, 52, 7), (47, 53, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8), (45, 52, 8), (46, 53, 8)], 'span tokens': ['ALPINE', 'RCT', 'of', 'zanubrutinib', '', '', '', '', 'vs', 'ibrutinib', 'in', 'R/R', 'CLL.', 'More', 'discontinuation', 'in', 'ibr', 'arm', '(mostly', 'due', 'to', 'AEs).', 'Most', 'IGHV', 'unmut,', '22%', 'TP53mut,', '45%', 'bulky.', 'Superior', 'PFS', '(including', 'in', 'TP53mut;', 'look', 'at', 'that', 'curve!).', 'No', 'OS', 'difference.', 'Fewer', 'all-grade', '&amp;', 'fatal', 'cardiac', 'events', 'with', 'zanubrutinib.', 'New', 'SOC!', '#ASH22', '#lymsm', '.', 'ALPINE RCT', 'RCT of', 'of zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' vs', 'vs ibrutinib', 'ibrutinib in', 'in R/R', 'R/R CLL.', 'CLL. More', 'More discontinuation', 'discontinuation in', 'in ibr', 'ibr arm', 'arm (mostly', '(mostly due', 'due to', 'to AEs).', 'AEs). Most', 'Most IGHV', 'IGHV unmut,', 'unmut, 22%', '22% TP53mut,', 'TP53mut, 45%', '45% bulky.', 'bulky. Superior', 'Superior PFS', 'PFS (including', '(including in', 'in TP53mut;', 'TP53mut; look', 'look at', 'at that', 'that curve!).', 'curve!). No', 'No OS', 'OS difference.', 'difference. Fewer', 'Fewer all-grade', 'all-grade &amp;', '&amp; fatal', 'fatal cardiac', 'cardiac events', 'events with', 'with zanubrutinib.', 'zanubrutinib. New', 'New SOC!', 'SOC! #ASH22', '#ASH22 #lymsm', '#lymsm .', 'ALPINE RCT of', 'RCT of zanubrutinib', 'of zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  vs', ' vs ibrutinib', 'vs ibrutinib in', 'ibrutinib in R/R', 'in R/R CLL.', 'R/R CLL. More', 'CLL. More discontinuation', 'More discontinuation in', 'discontinuation in ibr', 'in ibr arm', 'ibr arm (mostly', 'arm (mostly due', '(mostly due to', 'due to AEs).', 'to AEs). Most', 'AEs). Most IGHV', 'Most IGHV unmut,', 'IGHV unmut, 22%', 'unmut, 22% TP53mut,', '22% TP53mut, 45%', 'TP53mut, 45% bulky.', '45% bulky. Superior', 'bulky. Superior PFS', 'Superior PFS (including', 'PFS (including in', '(including in TP53mut;', 'in TP53mut; look', 'TP53mut; look at', 'look at that', 'at that curve!).', 'that curve!). No', 'curve!). No OS', 'No OS difference.', 'OS difference. Fewer', 'difference. Fewer all-grade', 'Fewer all-grade &amp;', 'all-grade &amp; fatal', '&amp; fatal cardiac', 'fatal cardiac events', 'cardiac events with', 'events with zanubrutinib.', 'with zanubrutinib. New', 'zanubrutinib. New SOC!', 'New SOC! #ASH22', 'SOC! #ASH22 #lymsm', '#ASH22 #lymsm .', 'ALPINE RCT of zanubrutinib', 'RCT of zanubrutinib ', 'of zanubrutinib  ', 'zanubrutinib   ', '   ', '   vs', '  vs ibrutinib', ' vs ibrutinib in', 'vs ibrutinib in R/R', 'ibrutinib in R/R CLL.', 'in R/R CLL. More', 'R/R CLL. More discontinuation', 'CLL. More discontinuation in', 'More discontinuation in ibr', 'discontinuation in ibr arm', 'in ibr arm (mostly', 'ibr arm (mostly due', 'arm (mostly due to', '(mostly due to AEs).', 'due to AEs). Most', 'to AEs). Most IGHV', 'AEs). Most IGHV unmut,', 'Most IGHV unmut, 22%', 'IGHV unmut, 22% TP53mut,', 'unmut, 22% TP53mut, 45%', '22% TP53mut, 45% bulky.', 'TP53mut, 45% bulky. Superior', '45% bulky. Superior PFS', 'bulky. Superior PFS (including', 'Superior PFS (including in', 'PFS (including in TP53mut;', '(including in TP53mut; look', 'in TP53mut; look at', 'TP53mut; look at that', 'look at that curve!).', 'at that curve!). No', 'that curve!). No OS', 'curve!). No OS difference.', 'No OS difference. Fewer', 'OS difference. Fewer all-grade', 'difference. Fewer all-grade &amp;', 'Fewer all-grade &amp; fatal', 'all-grade &amp; fatal cardiac', '&amp; fatal cardiac events', 'fatal cardiac events with', 'cardiac events with zanubrutinib.', 'events with zanubrutinib. New', 'with zanubrutinib. New SOC!', 'zanubrutinib. New SOC! #ASH22', 'New SOC! #ASH22 #lymsm', 'SOC! #ASH22 #lymsm .', 'ALPINE RCT of zanubrutinib ', 'RCT of zanubrutinib  ', 'of zanubrutinib   ', 'zanubrutinib    ', '    vs', '   vs ibrutinib', '  vs ibrutinib in', ' vs ibrutinib in R/R', 'vs ibrutinib in R/R CLL.', 'ibrutinib in R/R CLL. More', 'in R/R CLL. More discontinuation', 'R/R CLL. More discontinuation in', 'CLL. More discontinuation in ibr', 'More discontinuation in ibr arm', 'discontinuation in ibr arm (mostly', 'in ibr arm (mostly due', 'ibr arm (mostly due to', 'arm (mostly due to AEs).', '(mostly due to AEs). Most', 'due to AEs). Most IGHV', 'to AEs). Most IGHV unmut,', 'AEs). Most IGHV unmut, 22%', 'Most IGHV unmut, 22% TP53mut,', 'IGHV unmut, 22% TP53mut, 45%', 'unmut, 22% TP53mut, 45% bulky.', '22% TP53mut, 45% bulky. Superior', 'TP53mut, 45% bulky. Superior PFS', '45% bulky. Superior PFS (including', 'bulky. Superior PFS (including in', 'Superior PFS (including in TP53mut;', 'PFS (including in TP53mut; look', '(including in TP53mut; look at', 'in TP53mut; look at that', 'TP53mut; look at that curve!).', 'look at that curve!). No', 'at that curve!). No OS', 'that curve!). No OS difference.', 'curve!). No OS difference. Fewer', 'No OS difference. Fewer all-grade', 'OS difference. Fewer all-grade &amp;', 'difference. Fewer all-grade &amp; fatal', 'Fewer all-grade &amp; fatal cardiac', 'all-grade &amp; fatal cardiac events', '&amp; fatal cardiac events with', 'fatal cardiac events with zanubrutinib.', 'cardiac events with zanubrutinib. New', 'events with zanubrutinib. New SOC!', 'with zanubrutinib. New SOC! #ASH22', 'zanubrutinib. New SOC! #ASH22 #lymsm', 'New SOC! #ASH22 #lymsm .', 'ALPINE RCT of zanubrutinib  ', 'RCT of zanubrutinib   ', 'of zanubrutinib    ', 'zanubrutinib     vs', '    vs ibrutinib', '   vs ibrutinib in', '  vs ibrutinib in R/R', ' vs ibrutinib in R/R CLL.', 'vs ibrutinib in R/R CLL. More', 'ibrutinib in R/R CLL. More discontinuation', 'in R/R CLL. More discontinuation in', 'R/R CLL. More discontinuation in ibr', 'CLL. More discontinuation in ibr arm', 'More discontinuation in ibr arm (mostly', 'discontinuation in ibr arm (mostly due', 'in ibr arm (mostly due to', 'ibr arm (mostly due to AEs).', 'arm (mostly due to AEs). Most', '(mostly due to AEs). Most IGHV', 'due to AEs). Most IGHV unmut,', 'to AEs). Most IGHV unmut, 22%', 'AEs). Most IGHV unmut, 22% TP53mut,', 'Most IGHV unmut, 22% TP53mut, 45%', 'IGHV unmut, 22% TP53mut, 45% bulky.', 'unmut, 22% TP53mut, 45% bulky. Superior', '22% TP53mut, 45% bulky. Superior PFS', 'TP53mut, 45% bulky. Superior PFS (including', '45% bulky. Superior PFS (including in', 'bulky. Superior PFS (including in TP53mut;', 'Superior PFS (including in TP53mut; look', 'PFS (including in TP53mut; look at', '(including in TP53mut; look at that', 'in TP53mut; look at that curve!).', 'TP53mut; look at that curve!). No', 'look at that curve!). No OS', 'at that curve!). No OS difference.', 'that curve!). No OS difference. Fewer', 'curve!). No OS difference. Fewer all-grade', 'No OS difference. Fewer all-grade &amp;', 'OS difference. Fewer all-grade &amp; fatal', 'difference. Fewer all-grade &amp; fatal cardiac', 'Fewer all-grade &amp; fatal cardiac events', 'all-grade &amp; fatal cardiac events with', '&amp; fatal cardiac events with zanubrutinib.', 'fatal cardiac events with zanubrutinib. New', 'cardiac events with zanubrutinib. New SOC!', 'events with zanubrutinib. New SOC! #ASH22', 'with zanubrutinib. New SOC! #ASH22 #lymsm', 'zanubrutinib. New SOC! #ASH22 #lymsm .', 'ALPINE RCT of zanubrutinib   ', 'RCT of zanubrutinib    ', 'of zanubrutinib     vs', 'zanubrutinib     vs ibrutinib', '    vs ibrutinib in', '   vs ibrutinib in R/R', '  vs ibrutinib in R/R CLL.', ' vs ibrutinib in R/R CLL. More', 'vs ibrutinib in R/R CLL. More discontinuation', 'ibrutinib in R/R CLL. More discontinuation in', 'in R/R CLL. More discontinuation in ibr', 'R/R CLL. More discontinuation in ibr arm', 'CLL. More discontinuation in ibr arm (mostly', 'More discontinuation in ibr arm (mostly due', 'discontinuation in ibr arm (mostly due to', 'in ibr arm (mostly due to AEs).', 'ibr arm (mostly due to AEs). Most', 'arm (mostly due to AEs). Most IGHV', '(mostly due to AEs). Most IGHV unmut,', 'due to AEs). Most IGHV unmut, 22%', 'to AEs). Most IGHV unmut, 22% TP53mut,', 'AEs). Most IGHV unmut, 22% TP53mut, 45%', 'Most IGHV unmut, 22% TP53mut, 45% bulky.', 'IGHV unmut, 22% TP53mut, 45% bulky. Superior', 'unmut, 22% TP53mut, 45% bulky. Superior PFS', '22% TP53mut, 45% bulky. Superior PFS (including', 'TP53mut, 45% bulky. Superior PFS (including in', '45% bulky. Superior PFS (including in TP53mut;', 'bulky. Superior PFS (including in TP53mut; look', 'Superior PFS (including in TP53mut; look at', 'PFS (including in TP53mut; look at that', '(including in TP53mut; look at that curve!).', 'in TP53mut; look at that curve!). No', 'TP53mut; look at that curve!). No OS', 'look at that curve!). No OS difference.', 'at that curve!). No OS difference. Fewer', 'that curve!). No OS difference. Fewer all-grade', 'curve!). No OS difference. Fewer all-grade &amp;', 'No OS difference. Fewer all-grade &amp; fatal', 'OS difference. Fewer all-grade &amp; fatal cardiac', 'difference. Fewer all-grade &amp; fatal cardiac events', 'Fewer all-grade &amp; fatal cardiac events with', 'all-grade &amp; fatal cardiac events with zanubrutinib.', '&amp; fatal cardiac events with zanubrutinib. New', 'fatal cardiac events with zanubrutinib. New SOC!', 'cardiac events with zanubrutinib. New SOC! #ASH22', 'events with zanubrutinib. New SOC! #ASH22 #lymsm', 'with zanubrutinib. New SOC! #ASH22 #lymsm .', 'ALPINE RCT of zanubrutinib    ', 'RCT of zanubrutinib     vs', 'of zanubrutinib     vs ibrutinib', 'zanubrutinib     vs ibrutinib in', '    vs ibrutinib in R/R', '   vs ibrutinib in R/R CLL.', '  vs ibrutinib in R/R CLL. More', ' vs ibrutinib in R/R CLL. More discontinuation', 'vs ibrutinib in R/R CLL. More discontinuation in', 'ibrutinib in R/R CLL. More discontinuation in ibr', 'in R/R CLL. More discontinuation in ibr arm', 'R/R CLL. More discontinuation in ibr arm (mostly', 'CLL. More discontinuation in ibr arm (mostly due', 'More discontinuation in ibr arm (mostly due to', 'discontinuation in ibr arm (mostly due to AEs).', 'in ibr arm (mostly due to AEs). Most', 'ibr arm (mostly due to AEs). Most IGHV', 'arm (mostly due to AEs). Most IGHV unmut,', '(mostly due to AEs). Most IGHV unmut, 22%', 'due to AEs). Most IGHV unmut, 22% TP53mut,', 'to AEs). Most IGHV unmut, 22% TP53mut, 45%', 'AEs). Most IGHV unmut, 22% TP53mut, 45% bulky.', 'Most IGHV unmut, 22% TP53mut, 45% bulky. Superior', 'IGHV unmut, 22% TP53mut, 45% bulky. Superior PFS', 'unmut, 22% TP53mut, 45% bulky. Superior PFS (including', '22% TP53mut, 45% bulky. Superior PFS (including in', 'TP53mut, 45% bulky. Superior PFS (including in TP53mut;', '45% bulky. Superior PFS (including in TP53mut; look', 'bulky. Superior PFS (including in TP53mut; look at', 'Superior PFS (including in TP53mut; look at that', 'PFS (including in TP53mut; look at that curve!).', '(including in TP53mut; look at that curve!). No', 'in TP53mut; look at that curve!). No OS', 'TP53mut; look at that curve!). No OS difference.', 'look at that curve!). No OS difference. Fewer', 'at that curve!). No OS difference. Fewer all-grade', 'that curve!). No OS difference. Fewer all-grade &amp;', 'curve!). No OS difference. Fewer all-grade &amp; fatal', 'No OS difference. Fewer all-grade &amp; fatal cardiac', 'OS difference. Fewer all-grade &amp; fatal cardiac events', 'difference. Fewer all-grade &amp; fatal cardiac events with', 'Fewer all-grade &amp; fatal cardiac events with zanubrutinib.', 'all-grade &amp; fatal cardiac events with zanubrutinib. New', '&amp; fatal cardiac events with zanubrutinib. New SOC!', 'fatal cardiac events with zanubrutinib. New SOC! #ASH22', 'cardiac events with zanubrutinib. New SOC! #ASH22 #lymsm', 'events with zanubrutinib. New SOC! #ASH22 #lymsm .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '89', 'tokens': ['"#esmo22', '#', 'pivot09', 'bempeg', '+', 'nivo', 'not', 'superior', 'to', 'tki', 'in', '1l', 'intermediate/poor', 'risk', 'mrcc', 'disappointing', 'results', 'presented', 'by', 'the', 'great', 'pr.', 'tannir', '.'], 'text_length': 24, 'triples': {'#|nivo not superior to tki in 1l intermediate/poor risk mrcc disappointing': ([1, 1], [5, 15], 'negative')}, 'sentence': '"#esmo22 # pivot09 bempeg + nivo not superior to tki in 1l intermediate/poor risk mrcc disappointing results presented by the great pr. tannir .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 15)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8)], 'span tokens': ['"#esmo22', '#', 'pivot09', 'bempeg', '+', 'nivo', 'not', 'superior', 'to', 'tki', 'in', '1l', 'intermediate/poor', 'risk', 'mrcc', 'disappointing', 'results', 'presented', 'by', 'the', 'great', 'pr.', 'tannir', '.', '"#esmo22 #', '# pivot09', 'pivot09 bempeg', 'bempeg +', '+ nivo', 'nivo not', 'not superior', 'superior to', 'to tki', 'tki in', 'in 1l', '1l intermediate/poor', 'intermediate/poor risk', 'risk mrcc', 'mrcc disappointing', 'disappointing results', 'results presented', 'presented by', 'by the', 'the great', 'great pr.', 'pr. tannir', 'tannir .', '"#esmo22 # pivot09', '# pivot09 bempeg', 'pivot09 bempeg +', 'bempeg + nivo', '+ nivo not', 'nivo not superior', 'not superior to', 'superior to tki', 'to tki in', 'tki in 1l', 'in 1l intermediate/poor', '1l intermediate/poor risk', 'intermediate/poor risk mrcc', 'risk mrcc disappointing', 'mrcc disappointing results', 'disappointing results presented', 'results presented by', 'presented by the', 'by the great', 'the great pr.', 'great pr. tannir', 'pr. tannir .', '"#esmo22 # pivot09 bempeg', '# pivot09 bempeg +', 'pivot09 bempeg + nivo', 'bempeg + nivo not', '+ nivo not superior', 'nivo not superior to', 'not superior to tki', 'superior to tki in', 'to tki in 1l', 'tki in 1l intermediate/poor', 'in 1l intermediate/poor risk', '1l intermediate/poor risk mrcc', 'intermediate/poor risk mrcc disappointing', 'risk mrcc disappointing results', 'mrcc disappointing results presented', 'disappointing results presented by', 'results presented by the', 'presented by the great', 'by the great pr.', 'the great pr. tannir', 'great pr. tannir .', '"#esmo22 # pivot09 bempeg +', '# pivot09 bempeg + nivo', 'pivot09 bempeg + nivo not', 'bempeg + nivo not superior', '+ nivo not superior to', 'nivo not superior to tki', 'not superior to tki in', 'superior to tki in 1l', 'to tki in 1l intermediate/poor', 'tki in 1l intermediate/poor risk', 'in 1l intermediate/poor risk mrcc', '1l intermediate/poor risk mrcc disappointing', 'intermediate/poor risk mrcc disappointing results', 'risk mrcc disappointing results presented', 'mrcc disappointing results presented by', 'disappointing results presented by the', 'results presented by the great', 'presented by the great pr.', 'by the great pr. tannir', 'the great pr. tannir .', '"#esmo22 # pivot09 bempeg + nivo', '# pivot09 bempeg + nivo not', 'pivot09 bempeg + nivo not superior', 'bempeg + nivo not superior to', '+ nivo not superior to tki', 'nivo not superior to tki in', 'not superior to tki in 1l', 'superior to tki in 1l intermediate/poor', 'to tki in 1l intermediate/poor risk', 'tki in 1l intermediate/poor risk mrcc', 'in 1l intermediate/poor risk mrcc disappointing', '1l intermediate/poor risk mrcc disappointing results', 'intermediate/poor risk mrcc disappointing results presented', 'risk mrcc disappointing results presented by', 'mrcc disappointing results presented by the', 'disappointing results presented by the great', 'results presented by the great pr.', 'presented by the great pr. tannir', 'by the great pr. tannir .', '"#esmo22 # pivot09 bempeg + nivo not', '# pivot09 bempeg + nivo not superior', 'pivot09 bempeg + nivo not superior to', 'bempeg + nivo not superior to tki', '+ nivo not superior to tki in', 'nivo not superior to tki in 1l', 'not superior to tki in 1l intermediate/poor', 'superior to tki in 1l intermediate/poor risk', 'to tki in 1l intermediate/poor risk mrcc', 'tki in 1l intermediate/poor risk mrcc disappointing', 'in 1l intermediate/poor risk mrcc disappointing results', '1l intermediate/poor risk mrcc disappointing results presented', 'intermediate/poor risk mrcc disappointing results presented by', 'risk mrcc disappointing results presented by the', 'mrcc disappointing results presented by the great', 'disappointing results presented by the great pr.', 'results presented by the great pr. tannir', 'presented by the great pr. tannir .', '"#esmo22 # pivot09 bempeg + nivo not superior', '# pivot09 bempeg + nivo not superior to', 'pivot09 bempeg + nivo not superior to tki', 'bempeg + nivo not superior to tki in', '+ nivo not superior to tki in 1l', 'nivo not superior to tki in 1l intermediate/poor', 'not superior to tki in 1l intermediate/poor risk', 'superior to tki in 1l intermediate/poor risk mrcc', 'to tki in 1l intermediate/poor risk mrcc disappointing', 'tki in 1l intermediate/poor risk mrcc disappointing results', 'in 1l intermediate/poor risk mrcc disappointing results presented', '1l intermediate/poor risk mrcc disappointing results presented by', 'intermediate/poor risk mrcc disappointing results presented by the', 'risk mrcc disappointing results presented by the great', 'mrcc disappointing results presented by the great pr.', 'disappointing results presented by the great pr. tannir', 'results presented by the great pr. tannir .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '90', 'tokens': ['"In', 'RR', 'CLL', 'zanibrutinib', 'was', 'superior', 'to', 'ibrutinib', 'in', 'terms', 'of', 'ORR', 'and', 'PFS.', 'Zanibrutinib', 'was', 'associated', 'with', 'better', 'toxicity', 'profile', 'with', 'less', 'atrial', 'fibrillation.', '#ASH22', '.'], 'text_length': 27, 'triples': {'was|to ibrutinib': ([4, 4], [6, 7], 'negative'), 'was|toxicity profile': ([15, 15], [19, 20], 'positive')}, 'sentence': '"In RR CLL zanibrutinib was superior to ibrutinib in terms of ORR and PFS. Zanibrutinib was associated with better toxicity profile with less atrial fibrillation. #ASH22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(4, 4), (15, 15)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(6, 7), (19, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8)], 'span tokens': ['"In', 'RR', 'CLL', 'zanibrutinib', 'was', 'superior', 'to', 'ibrutinib', 'in', 'terms', 'of', 'ORR', 'and', 'PFS.', 'Zanibrutinib', 'was', 'associated', 'with', 'better', 'toxicity', 'profile', 'with', 'less', 'atrial', 'fibrillation.', '#ASH22', '.', '"In RR', 'RR CLL', 'CLL zanibrutinib', 'zanibrutinib was', 'was superior', 'superior to', 'to ibrutinib', 'ibrutinib in', 'in terms', 'terms of', 'of ORR', 'ORR and', 'and PFS.', 'PFS. Zanibrutinib', 'Zanibrutinib was', 'was associated', 'associated with', 'with better', 'better toxicity', 'toxicity profile', 'profile with', 'with less', 'less atrial', 'atrial fibrillation.', 'fibrillation. #ASH22', '#ASH22 .', '"In RR CLL', 'RR CLL zanibrutinib', 'CLL zanibrutinib was', 'zanibrutinib was superior', 'was superior to', 'superior to ibrutinib', 'to ibrutinib in', 'ibrutinib in terms', 'in terms of', 'terms of ORR', 'of ORR and', 'ORR and PFS.', 'and PFS. Zanibrutinib', 'PFS. Zanibrutinib was', 'Zanibrutinib was associated', 'was associated with', 'associated with better', 'with better toxicity', 'better toxicity profile', 'toxicity profile with', 'profile with less', 'with less atrial', 'less atrial fibrillation.', 'atrial fibrillation. #ASH22', 'fibrillation. #ASH22 .', '"In RR CLL zanibrutinib', 'RR CLL zanibrutinib was', 'CLL zanibrutinib was superior', 'zanibrutinib was superior to', 'was superior to ibrutinib', 'superior to ibrutinib in', 'to ibrutinib in terms', 'ibrutinib in terms of', 'in terms of ORR', 'terms of ORR and', 'of ORR and PFS.', 'ORR and PFS. Zanibrutinib', 'and PFS. Zanibrutinib was', 'PFS. Zanibrutinib was associated', 'Zanibrutinib was associated with', 'was associated with better', 'associated with better toxicity', 'with better toxicity profile', 'better toxicity profile with', 'toxicity profile with less', 'profile with less atrial', 'with less atrial fibrillation.', 'less atrial fibrillation. #ASH22', 'atrial fibrillation. #ASH22 .', '"In RR CLL zanibrutinib was', 'RR CLL zanibrutinib was superior', 'CLL zanibrutinib was superior to', 'zanibrutinib was superior to ibrutinib', 'was superior to ibrutinib in', 'superior to ibrutinib in terms', 'to ibrutinib in terms of', 'ibrutinib in terms of ORR', 'in terms of ORR and', 'terms of ORR and PFS.', 'of ORR and PFS. Zanibrutinib', 'ORR and PFS. Zanibrutinib was', 'and PFS. Zanibrutinib was associated', 'PFS. Zanibrutinib was associated with', 'Zanibrutinib was associated with better', 'was associated with better toxicity', 'associated with better toxicity profile', 'with better toxicity profile with', 'better toxicity profile with less', 'toxicity profile with less atrial', 'profile with less atrial fibrillation.', 'with less atrial fibrillation. #ASH22', 'less atrial fibrillation. #ASH22 .', '"In RR CLL zanibrutinib was superior', 'RR CLL zanibrutinib was superior to', 'CLL zanibrutinib was superior to ibrutinib', 'zanibrutinib was superior to ibrutinib in', 'was superior to ibrutinib in terms', 'superior to ibrutinib in terms of', 'to ibrutinib in terms of ORR', 'ibrutinib in terms of ORR and', 'in terms of ORR and PFS.', 'terms of ORR and PFS. Zanibrutinib', 'of ORR and PFS. Zanibrutinib was', 'ORR and PFS. Zanibrutinib was associated', 'and PFS. Zanibrutinib was associated with', 'PFS. Zanibrutinib was associated with better', 'Zanibrutinib was associated with better toxicity', 'was associated with better toxicity profile', 'associated with better toxicity profile with', 'with better toxicity profile with less', 'better toxicity profile with less atrial', 'toxicity profile with less atrial fibrillation.', 'profile with less atrial fibrillation. #ASH22', 'with less atrial fibrillation. #ASH22 .', '"In RR CLL zanibrutinib was superior to', 'RR CLL zanibrutinib was superior to ibrutinib', 'CLL zanibrutinib was superior to ibrutinib in', 'zanibrutinib was superior to ibrutinib in terms', 'was superior to ibrutinib in terms of', 'superior to ibrutinib in terms of ORR', 'to ibrutinib in terms of ORR and', 'ibrutinib in terms of ORR and PFS.', 'in terms of ORR and PFS. Zanibrutinib', 'terms of ORR and PFS. Zanibrutinib was', 'of ORR and PFS. Zanibrutinib was associated', 'ORR and PFS. Zanibrutinib was associated with', 'and PFS. Zanibrutinib was associated with better', 'PFS. Zanibrutinib was associated with better toxicity', 'Zanibrutinib was associated with better toxicity profile', 'was associated with better toxicity profile with', 'associated with better toxicity profile with less', 'with better toxicity profile with less atrial', 'better toxicity profile with less atrial fibrillation.', 'toxicity profile with less atrial fibrillation. #ASH22', 'profile with less atrial fibrillation. #ASH22 .', '"In RR CLL zanibrutinib was superior to ibrutinib', 'RR CLL zanibrutinib was superior to ibrutinib in', 'CLL zanibrutinib was superior to ibrutinib in terms', 'zanibrutinib was superior to ibrutinib in terms of', 'was superior to ibrutinib in terms of ORR', 'superior to ibrutinib in terms of ORR and', 'to ibrutinib in terms of ORR and PFS.', 'ibrutinib in terms of ORR and PFS. Zanibrutinib', 'in terms of ORR and PFS. Zanibrutinib was', 'terms of ORR and PFS. Zanibrutinib was associated', 'of ORR and PFS. Zanibrutinib was associated with', 'ORR and PFS. Zanibrutinib was associated with better', 'and PFS. Zanibrutinib was associated with better toxicity', 'PFS. Zanibrutinib was associated with better toxicity profile', 'Zanibrutinib was associated with better toxicity profile with', 'was associated with better toxicity profile with less', 'associated with better toxicity profile with less atrial', 'with better toxicity profile with less atrial fibrillation.', 'better toxicity profile with less atrial fibrillation. #ASH22', 'toxicity profile with less atrial fibrillation. #ASH22 .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '91', 'tokens': ['#asco22', '#kidneycancer', 'oral', 'abstract', 'breakdown', 'part', '2.', 'depth', 'of', 'response', 'analysis', 'from', 'cm-9er', 'study', 'nivolumab,cabozantinib,sunitinib', '', 'by', 'dr.', 'cristina', 'suarez.', 'goal', 'was', 'to', 'see', 'if', 'depth', 'of', 'response', '(%', 'reduction', 'of', 'baseline', 'target', 'lesions)', 'is', 'a', 'good', 'surrogate', 'for', 'long', 'term', 'benefit/outcomes.', '.'], 'text_length': 43, 'triples': {'by|oral': ([15, 15], [2, 2], 'neutral'), 'cm-9er|depth': ([12, 12], [24, 24], 'neutral'), 'nivolumab,cabozantinib,sunitinib|surrogate for long term': ([14, 14], [36, 39], 'neutral')}, 'sentence': '#asco22 #kidneycancer oral abstract breakdown part 2. depth of response analysis from cm-9er study nivolumab,cabozantinib,sunitinib  by dr. cristina suarez. goal was to see if depth of response (% reduction of baseline target lesions) is a good surrogate for long term benefit/outcomes. .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(15, 15), (12, 12), (14, 14)], 'reverse_opinion_num': 3, 'reverse_opinion2aspect_label': [(2, 2), (24, 24), (36, 39)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8)], 'span tokens': ['#asco22', '#kidneycancer', 'oral', 'abstract', 'breakdown', 'part', '2.', 'depth', 'of', 'response', 'analysis', 'from', 'cm-9er', 'study', 'nivolumab,cabozantinib,sunitinib', '', 'by', 'dr.', 'cristina', 'suarez.', 'goal', 'was', 'to', 'see', 'if', 'depth', 'of', 'response', '(%', 'reduction', 'of', 'baseline', 'target', 'lesions)', 'is', 'a', 'good', 'surrogate', 'for', 'long', 'term', 'benefit/outcomes.', '.', '#asco22 #kidneycancer', '#kidneycancer oral', 'oral abstract', 'abstract breakdown', 'breakdown part', 'part 2.', '2. depth', 'depth of', 'of response', 'response analysis', 'analysis from', 'from cm-9er', 'cm-9er study', 'study nivolumab,cabozantinib,sunitinib', 'nivolumab,cabozantinib,sunitinib ', ' by', 'by dr.', 'dr. cristina', 'cristina suarez.', 'suarez. goal', 'goal was', 'was to', 'to see', 'see if', 'if depth', 'depth of', 'of response', 'response (%', '(% reduction', 'reduction of', 'of baseline', 'baseline target', 'target lesions)', 'lesions) is', 'is a', 'a good', 'good surrogate', 'surrogate for', 'for long', 'long term', 'term benefit/outcomes.', 'benefit/outcomes. .', '#asco22 #kidneycancer oral', '#kidneycancer oral abstract', 'oral abstract breakdown', 'abstract breakdown part', 'breakdown part 2.', 'part 2. depth', '2. depth of', 'depth of response', 'of response analysis', 'response analysis from', 'analysis from cm-9er', 'from cm-9er study', 'cm-9er study nivolumab,cabozantinib,sunitinib', 'study nivolumab,cabozantinib,sunitinib ', 'nivolumab,cabozantinib,sunitinib  by', ' by dr.', 'by dr. cristina', 'dr. cristina suarez.', 'cristina suarez. goal', 'suarez. goal was', 'goal was to', 'was to see', 'to see if', 'see if depth', 'if depth of', 'depth of response', 'of response (%', 'response (% reduction', '(% reduction of', 'reduction of baseline', 'of baseline target', 'baseline target lesions)', 'target lesions) is', 'lesions) is a', 'is a good', 'a good surrogate', 'good surrogate for', 'surrogate for long', 'for long term', 'long term benefit/outcomes.', 'term benefit/outcomes. .', '#asco22 #kidneycancer oral abstract', '#kidneycancer oral abstract breakdown', 'oral abstract breakdown part', 'abstract breakdown part 2.', 'breakdown part 2. depth', 'part 2. depth of', '2. depth of response', 'depth of response analysis', 'of response analysis from', 'response analysis from cm-9er', 'analysis from cm-9er study', 'from cm-9er study nivolumab,cabozantinib,sunitinib', 'cm-9er study nivolumab,cabozantinib,sunitinib ', 'study nivolumab,cabozantinib,sunitinib  by', 'nivolumab,cabozantinib,sunitinib  by dr.', ' by dr. cristina', 'by dr. cristina suarez.', 'dr. cristina suarez. goal', 'cristina suarez. goal was', 'suarez. goal was to', 'goal was to see', 'was to see if', 'to see if depth', 'see if depth of', 'if depth of response', 'depth of response (%', 'of response (% reduction', 'response (% reduction of', '(% reduction of baseline', 'reduction of baseline target', 'of baseline target lesions)', 'baseline target lesions) is', 'target lesions) is a', 'lesions) is a good', 'is a good surrogate', 'a good surrogate for', 'good surrogate for long', 'surrogate for long term', 'for long term benefit/outcomes.', 'long term benefit/outcomes. .', '#asco22 #kidneycancer oral abstract breakdown', '#kidneycancer oral abstract breakdown part', 'oral abstract breakdown part 2.', 'abstract breakdown part 2. depth', 'breakdown part 2. depth of', 'part 2. depth of response', '2. depth of response analysis', 'depth of response analysis from', 'of response analysis from cm-9er', 'response analysis from cm-9er study', 'analysis from cm-9er study nivolumab,cabozantinib,sunitinib', 'from cm-9er study nivolumab,cabozantinib,sunitinib ', 'cm-9er study nivolumab,cabozantinib,sunitinib  by', 'study nivolumab,cabozantinib,sunitinib  by dr.', 'nivolumab,cabozantinib,sunitinib  by dr. cristina', ' by dr. cristina suarez.', 'by dr. cristina suarez. goal', 'dr. cristina suarez. goal was', 'cristina suarez. goal was to', 'suarez. goal was to see', 'goal was to see if', 'was to see if depth', 'to see if depth of', 'see if depth of response', 'if depth of response (%', 'depth of response (% reduction', 'of response (% reduction of', 'response (% reduction of baseline', '(% reduction of baseline target', 'reduction of baseline target lesions)', 'of baseline target lesions) is', 'baseline target lesions) is a', 'target lesions) is a good', 'lesions) is a good surrogate', 'is a good surrogate for', 'a good surrogate for long', 'good surrogate for long term', 'surrogate for long term benefit/outcomes.', 'for long term benefit/outcomes. .', '#asco22 #kidneycancer oral abstract breakdown part', '#kidneycancer oral abstract breakdown part 2.', 'oral abstract breakdown part 2. depth', 'abstract breakdown part 2. depth of', 'breakdown part 2. depth of response', 'part 2. depth of response analysis', '2. depth of response analysis from', 'depth of response analysis from cm-9er', 'of response analysis from cm-9er study', 'response analysis from cm-9er study nivolumab,cabozantinib,sunitinib', 'analysis from cm-9er study nivolumab,cabozantinib,sunitinib ', 'from cm-9er study nivolumab,cabozantinib,sunitinib  by', 'cm-9er study nivolumab,cabozantinib,sunitinib  by dr.', 'study nivolumab,cabozantinib,sunitinib  by dr. cristina', 'nivolumab,cabozantinib,sunitinib  by dr. cristina suarez.', ' by dr. cristina suarez. goal', 'by dr. cristina suarez. goal was', 'dr. cristina suarez. goal was to', 'cristina suarez. goal was to see', 'suarez. goal was to see if', 'goal was to see if depth', 'was to see if depth of', 'to see if depth of response', 'see if depth of response (%', 'if depth of response (% reduction', 'depth of response (% reduction of', 'of response (% reduction of baseline', 'response (% reduction of baseline target', '(% reduction of baseline target lesions)', 'reduction of baseline target lesions) is', 'of baseline target lesions) is a', 'baseline target lesions) is a good', 'target lesions) is a good surrogate', 'lesions) is a good surrogate for', 'is a good surrogate for long', 'a good surrogate for long term', 'good surrogate for long term benefit/outcomes.', 'surrogate for long term benefit/outcomes. .', '#asco22 #kidneycancer oral abstract breakdown part 2.', '#kidneycancer oral abstract breakdown part 2. depth', 'oral abstract breakdown part 2. depth of', 'abstract breakdown part 2. depth of response', 'breakdown part 2. depth of response analysis', 'part 2. depth of response analysis from', '2. depth of response analysis from cm-9er', 'depth of response analysis from cm-9er study', 'of response analysis from cm-9er study nivolumab,cabozantinib,sunitinib', 'response analysis from cm-9er study nivolumab,cabozantinib,sunitinib ', 'analysis from cm-9er study nivolumab,cabozantinib,sunitinib  by', 'from cm-9er study nivolumab,cabozantinib,sunitinib  by dr.', 'cm-9er study nivolumab,cabozantinib,sunitinib  by dr. cristina', 'study nivolumab,cabozantinib,sunitinib  by dr. cristina suarez.', 'nivolumab,cabozantinib,sunitinib  by dr. cristina suarez. goal', ' by dr. cristina suarez. goal was', 'by dr. cristina suarez. goal was to', 'dr. cristina suarez. goal was to see', 'cristina suarez. goal was to see if', 'suarez. goal was to see if depth', 'goal was to see if depth of', 'was to see if depth of response', 'to see if depth of response (%', 'see if depth of response (% reduction', 'if depth of response (% reduction of', 'depth of response (% reduction of baseline', 'of response (% reduction of baseline target', 'response (% reduction of baseline target lesions)', '(% reduction of baseline target lesions) is', 'reduction of baseline target lesions) is a', 'of baseline target lesions) is a good', 'baseline target lesions) is a good surrogate', 'target lesions) is a good surrogate for', 'lesions) is a good surrogate for long', 'is a good surrogate for long term', 'a good surrogate for long term benefit/outcomes.', 'good surrogate for long term benefit/outcomes. .', '#asco22 #kidneycancer oral abstract breakdown part 2. depth', '#kidneycancer oral abstract breakdown part 2. depth of', 'oral abstract breakdown part 2. depth of response', 'abstract breakdown part 2. depth of response analysis', 'breakdown part 2. depth of response analysis from', 'part 2. depth of response analysis from cm-9er', '2. depth of response analysis from cm-9er study', 'depth of response analysis from cm-9er study nivolumab,cabozantinib,sunitinib', 'of response analysis from cm-9er study nivolumab,cabozantinib,sunitinib ', 'response analysis from cm-9er study nivolumab,cabozantinib,sunitinib  by', 'analysis from cm-9er study nivolumab,cabozantinib,sunitinib  by dr.', 'from cm-9er study nivolumab,cabozantinib,sunitinib  by dr. cristina', 'cm-9er study nivolumab,cabozantinib,sunitinib  by dr. cristina suarez.', 'study nivolumab,cabozantinib,sunitinib  by dr. cristina suarez. goal', 'nivolumab,cabozantinib,sunitinib  by dr. cristina suarez. goal was', ' by dr. cristina suarez. goal was to', 'by dr. cristina suarez. goal was to see', 'dr. cristina suarez. goal was to see if', 'cristina suarez. goal was to see if depth', 'suarez. goal was to see if depth of', 'goal was to see if depth of response', 'was to see if depth of response (%', 'to see if depth of response (% reduction', 'see if depth of response (% reduction of', 'if depth of response (% reduction of baseline', 'depth of response (% reduction of baseline target', 'of response (% reduction of baseline target lesions)', 'response (% reduction of baseline target lesions) is', '(% reduction of baseline target lesions) is a', 'reduction of baseline target lesions) is a good', 'of baseline target lesions) is a good surrogate', 'baseline target lesions) is a good surrogate for', 'target lesions) is a good surrogate for long', 'lesions) is a good surrogate for long term', 'is a good surrogate for long term benefit/outcomes.', 'a good surrogate for long term benefit/outcomes. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '92', 'tokens': ['everest', ':', 'everolimus', 'for', 'renal', 'cancer', 'ensuing', 'surgical', 'therapy', 'a', 'phase', 'iii', 'study', '(swog', 's0931,', 'nct01120249)', '#asco22', '#christopherryan', '.'], 'text_length': 19, 'triples': {'everest|cancer': ([0, 0], [5, 5], 'neutral'), ':|cancer': ([1, 1], [5, 5], 'neutral')}, 'sentence': 'everest : everolimus for renal cancer ensuing surgical therapy a phase iii study (swog s0931, nct01120249) #asco22 #christopherryan .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 5)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['everest', ':', 'everolimus', 'for', 'renal', 'cancer', 'ensuing', 'surgical', 'therapy', 'a', 'phase', 'iii', 'study', '(swog', 's0931,', 'nct01120249)', '#asco22', '#christopherryan', '.', 'everest :', ': everolimus', 'everolimus for', 'for renal', 'renal cancer', 'cancer ensuing', 'ensuing surgical', 'surgical therapy', 'therapy a', 'a phase', 'phase iii', 'iii study', 'study (swog', '(swog s0931,', 's0931, nct01120249)', 'nct01120249) #asco22', '#asco22 #christopherryan', '#christopherryan .', 'everest : everolimus', ': everolimus for', 'everolimus for renal', 'for renal cancer', 'renal cancer ensuing', 'cancer ensuing surgical', 'ensuing surgical therapy', 'surgical therapy a', 'therapy a phase', 'a phase iii', 'phase iii study', 'iii study (swog', 'study (swog s0931,', '(swog s0931, nct01120249)', 's0931, nct01120249) #asco22', 'nct01120249) #asco22 #christopherryan', '#asco22 #christopherryan .', 'everest : everolimus for', ': everolimus for renal', 'everolimus for renal cancer', 'for renal cancer ensuing', 'renal cancer ensuing surgical', 'cancer ensuing surgical therapy', 'ensuing surgical therapy a', 'surgical therapy a phase', 'therapy a phase iii', 'a phase iii study', 'phase iii study (swog', 'iii study (swog s0931,', 'study (swog s0931, nct01120249)', '(swog s0931, nct01120249) #asco22', 's0931, nct01120249) #asco22 #christopherryan', 'nct01120249) #asco22 #christopherryan .', 'everest : everolimus for renal', ': everolimus for renal cancer', 'everolimus for renal cancer ensuing', 'for renal cancer ensuing surgical', 'renal cancer ensuing surgical therapy', 'cancer ensuing surgical therapy a', 'ensuing surgical therapy a phase', 'surgical therapy a phase iii', 'therapy a phase iii study', 'a phase iii study (swog', 'phase iii study (swog s0931,', 'iii study (swog s0931, nct01120249)', 'study (swog s0931, nct01120249) #asco22', '(swog s0931, nct01120249) #asco22 #christopherryan', 's0931, nct01120249) #asco22 #christopherryan .', 'everest : everolimus for renal cancer', ': everolimus for renal cancer ensuing', 'everolimus for renal cancer ensuing surgical', 'for renal cancer ensuing surgical therapy', 'renal cancer ensuing surgical therapy a', 'cancer ensuing surgical therapy a phase', 'ensuing surgical therapy a phase iii', 'surgical therapy a phase iii study', 'therapy a phase iii study (swog', 'a phase iii study (swog s0931,', 'phase iii study (swog s0931, nct01120249)', 'iii study (swog s0931, nct01120249) #asco22', 'study (swog s0931, nct01120249) #asco22 #christopherryan', '(swog s0931, nct01120249) #asco22 #christopherryan .', 'everest : everolimus for renal cancer ensuing', ': everolimus for renal cancer ensuing surgical', 'everolimus for renal cancer ensuing surgical therapy', 'for renal cancer ensuing surgical therapy a', 'renal cancer ensuing surgical therapy a phase', 'cancer ensuing surgical therapy a phase iii', 'ensuing surgical therapy a phase iii study', 'surgical therapy a phase iii study (swog', 'therapy a phase iii study (swog s0931,', 'a phase iii study (swog s0931, nct01120249)', 'phase iii study (swog s0931, nct01120249) #asco22', 'iii study (swog s0931, nct01120249) #asco22 #christopherryan', 'study (swog s0931, nct01120249) #asco22 #christopherryan .', 'everest : everolimus for renal cancer ensuing surgical', ': everolimus for renal cancer ensuing surgical therapy', 'everolimus for renal cancer ensuing surgical therapy a', 'for renal cancer ensuing surgical therapy a phase', 'renal cancer ensuing surgical therapy a phase iii', 'cancer ensuing surgical therapy a phase iii study', 'ensuing surgical therapy a phase iii study (swog', 'surgical therapy a phase iii study (swog s0931,', 'therapy a phase iii study (swog s0931, nct01120249)', 'a phase iii study (swog s0931, nct01120249) #asco22', 'phase iii study (swog s0931, nct01120249) #asco22 #christopherryan', 'iii study (swog s0931, nct01120249) #asco22 #christopherryan .'], 'spans_aspect_label': [1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '93', 'tokens': ['enzalutamide', 'added', 'to', 'testosterone', 'suppression', 'for', 'mhspc', 'provided', 'clinically', 'meaningful', 'improvements', 'in', 'os', 'for', 'the', 'combined', 'study', 'cohort;', 'most', 'apparent', 'for', 'low', 'volume', 'mhspc', 'in', 'those', 'for', 'whom', 'docetaxel', 'was', 'not', 'deemed', 'necessary', '#asco22', '.'], 'text_length': 35, 'triples': {'enzalutamide|provided clinically meaningful improvements': ([0, 0], [7, 10], 'positive')}, 'sentence': 'enzalutamide added to testosterone suppression for mhspc provided clinically meaningful improvements in os for the combined study cohort; most apparent for low volume mhspc in those for whom docetaxel was not deemed necessary #asco22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['enzalutamide', 'added', 'to', 'testosterone', 'suppression', 'for', 'mhspc', 'provided', 'clinically', 'meaningful', 'improvements', 'in', 'os', 'for', 'the', 'combined', 'study', 'cohort;', 'most', 'apparent', 'for', 'low', 'volume', 'mhspc', 'in', 'those', 'for', 'whom', 'docetaxel', 'was', 'not', 'deemed', 'necessary', '#asco22', '.', 'enzalutamide added', 'added to', 'to testosterone', 'testosterone suppression', 'suppression for', 'for mhspc', 'mhspc provided', 'provided clinically', 'clinically meaningful', 'meaningful improvements', 'improvements in', 'in os', 'os for', 'for the', 'the combined', 'combined study', 'study cohort;', 'cohort; most', 'most apparent', 'apparent for', 'for low', 'low volume', 'volume mhspc', 'mhspc in', 'in those', 'those for', 'for whom', 'whom docetaxel', 'docetaxel was', 'was not', 'not deemed', 'deemed necessary', 'necessary #asco22', '#asco22 .', 'enzalutamide added to', 'added to testosterone', 'to testosterone suppression', 'testosterone suppression for', 'suppression for mhspc', 'for mhspc provided', 'mhspc provided clinically', 'provided clinically meaningful', 'clinically meaningful improvements', 'meaningful improvements in', 'improvements in os', 'in os for', 'os for the', 'for the combined', 'the combined study', 'combined study cohort;', 'study cohort; most', 'cohort; most apparent', 'most apparent for', 'apparent for low', 'for low volume', 'low volume mhspc', 'volume mhspc in', 'mhspc in those', 'in those for', 'those for whom', 'for whom docetaxel', 'whom docetaxel was', 'docetaxel was not', 'was not deemed', 'not deemed necessary', 'deemed necessary #asco22', 'necessary #asco22 .', 'enzalutamide added to testosterone', 'added to testosterone suppression', 'to testosterone suppression for', 'testosterone suppression for mhspc', 'suppression for mhspc provided', 'for mhspc provided clinically', 'mhspc provided clinically meaningful', 'provided clinically meaningful improvements', 'clinically meaningful improvements in', 'meaningful improvements in os', 'improvements in os for', 'in os for the', 'os for the combined', 'for the combined study', 'the combined study cohort;', 'combined study cohort; most', 'study cohort; most apparent', 'cohort; most apparent for', 'most apparent for low', 'apparent for low volume', 'for low volume mhspc', 'low volume mhspc in', 'volume mhspc in those', 'mhspc in those for', 'in those for whom', 'those for whom docetaxel', 'for whom docetaxel was', 'whom docetaxel was not', 'docetaxel was not deemed', 'was not deemed necessary', 'not deemed necessary #asco22', 'deemed necessary #asco22 .', 'enzalutamide added to testosterone suppression', 'added to testosterone suppression for', 'to testosterone suppression for mhspc', 'testosterone suppression for mhspc provided', 'suppression for mhspc provided clinically', 'for mhspc provided clinically meaningful', 'mhspc provided clinically meaningful improvements', 'provided clinically meaningful improvements in', 'clinically meaningful improvements in os', 'meaningful improvements in os for', 'improvements in os for the', 'in os for the combined', 'os for the combined study', 'for the combined study cohort;', 'the combined study cohort; most', 'combined study cohort; most apparent', 'study cohort; most apparent for', 'cohort; most apparent for low', 'most apparent for low volume', 'apparent for low volume mhspc', 'for low volume mhspc in', 'low volume mhspc in those', 'volume mhspc in those for', 'mhspc in those for whom', 'in those for whom docetaxel', 'those for whom docetaxel was', 'for whom docetaxel was not', 'whom docetaxel was not deemed', 'docetaxel was not deemed necessary', 'was not deemed necessary #asco22', 'not deemed necessary #asco22 .', 'enzalutamide added to testosterone suppression for', 'added to testosterone suppression for mhspc', 'to testosterone suppression for mhspc provided', 'testosterone suppression for mhspc provided clinically', 'suppression for mhspc provided clinically meaningful', 'for mhspc provided clinically meaningful improvements', 'mhspc provided clinically meaningful improvements in', 'provided clinically meaningful improvements in os', 'clinically meaningful improvements in os for', 'meaningful improvements in os for the', 'improvements in os for the combined', 'in os for the combined study', 'os for the combined study cohort;', 'for the combined study cohort; most', 'the combined study cohort; most apparent', 'combined study cohort; most apparent for', 'study cohort; most apparent for low', 'cohort; most apparent for low volume', 'most apparent for low volume mhspc', 'apparent for low volume mhspc in', 'for low volume mhspc in those', 'low volume mhspc in those for', 'volume mhspc in those for whom', 'mhspc in those for whom docetaxel', 'in those for whom docetaxel was', 'those for whom docetaxel was not', 'for whom docetaxel was not deemed', 'whom docetaxel was not deemed necessary', 'docetaxel was not deemed necessary #asco22', 'was not deemed necessary #asco22 .', 'enzalutamide added to testosterone suppression for mhspc', 'added to testosterone suppression for mhspc provided', 'to testosterone suppression for mhspc provided clinically', 'testosterone suppression for mhspc provided clinically meaningful', 'suppression for mhspc provided clinically meaningful improvements', 'for mhspc provided clinically meaningful improvements in', 'mhspc provided clinically meaningful improvements in os', 'provided clinically meaningful improvements in os for', 'clinically meaningful improvements in os for the', 'meaningful improvements in os for the combined', 'improvements in os for the combined study', 'in os for the combined study cohort;', 'os for the combined study cohort; most', 'for the combined study cohort; most apparent', 'the combined study cohort; most apparent for', 'combined study cohort; most apparent for low', 'study cohort; most apparent for low volume', 'cohort; most apparent for low volume mhspc', 'most apparent for low volume mhspc in', 'apparent for low volume mhspc in those', 'for low volume mhspc in those for', 'low volume mhspc in those for whom', 'volume mhspc in those for whom docetaxel', 'mhspc in those for whom docetaxel was', 'in those for whom docetaxel was not', 'those for whom docetaxel was not deemed', 'for whom docetaxel was not deemed necessary', 'whom docetaxel was not deemed necessary #asco22', 'docetaxel was not deemed necessary #asco22 .', 'enzalutamide added to testosterone suppression for mhspc provided', 'added to testosterone suppression for mhspc provided clinically', 'to testosterone suppression for mhspc provided clinically meaningful', 'testosterone suppression for mhspc provided clinically meaningful improvements', 'suppression for mhspc provided clinically meaningful improvements in', 'for mhspc provided clinically meaningful improvements in os', 'mhspc provided clinically meaningful improvements in os for', 'provided clinically meaningful improvements in os for the', 'clinically meaningful improvements in os for the combined', 'meaningful improvements in os for the combined study', 'improvements in os for the combined study cohort;', 'in os for the combined study cohort; most', 'os for the combined study cohort; most apparent', 'for the combined study cohort; most apparent for', 'the combined study cohort; most apparent for low', 'combined study cohort; most apparent for low volume', 'study cohort; most apparent for low volume mhspc', 'cohort; most apparent for low volume mhspc in', 'most apparent for low volume mhspc in those', 'apparent for low volume mhspc in those for', 'for low volume mhspc in those for whom', 'low volume mhspc in those for whom docetaxel', 'volume mhspc in those for whom docetaxel was', 'mhspc in those for whom docetaxel was not', 'in those for whom docetaxel was not deemed', 'those for whom docetaxel was not deemed necessary', 'for whom docetaxel was not deemed necessary #asco22', 'whom docetaxel was not deemed necessary #asco22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '94', 'tokens': ['Here', 'for', 'the', '', '#ASH22', 'late-breaking', 'abstracts!', 'Looking', 'forward', 'to', 'the', 'zanubrutinib', '', '', '', '', 'results.', '#lymsm', '.'], 'text_length': 19, 'triples': {'zanubrutinib|Looking forward': ([10, 10], [6, 7], 'neutral')}, 'sentence': 'Here for the  #ASH22 late-breaking abstracts! Looking forward to the zanubrutinib     results. #lymsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['Here', 'for', 'the', '', '#ASH22', 'late-breaking', 'abstracts!', 'Looking', 'forward', 'to', 'the', 'zanubrutinib', '', '', '', '', 'results.', '#lymsm', '.', 'Here for', 'for the', 'the ', ' #ASH22', '#ASH22 late-breaking', 'late-breaking abstracts!', 'abstracts! Looking', 'Looking forward', 'forward to', 'to the', 'the zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' results.', 'results. #lymsm', '#lymsm .', 'Here for the', 'for the ', 'the  #ASH22', ' #ASH22 late-breaking', '#ASH22 late-breaking abstracts!', 'late-breaking abstracts! Looking', 'abstracts! Looking forward', 'Looking forward to', 'forward to the', 'to the zanubrutinib', 'the zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  results.', ' results. #lymsm', 'results. #lymsm .', 'Here for the ', 'for the  #ASH22', 'the  #ASH22 late-breaking', ' #ASH22 late-breaking abstracts!', '#ASH22 late-breaking abstracts! Looking', 'late-breaking abstracts! Looking forward', 'abstracts! Looking forward to', 'Looking forward to the', 'forward to the zanubrutinib', 'to the zanubrutinib ', 'the zanubrutinib  ', 'zanubrutinib   ', '   ', '   results.', '  results. #lymsm', ' results. #lymsm .', 'Here for the  #ASH22', 'for the  #ASH22 late-breaking', 'the  #ASH22 late-breaking abstracts!', ' #ASH22 late-breaking abstracts! Looking', '#ASH22 late-breaking abstracts! Looking forward', 'late-breaking abstracts! Looking forward to', 'abstracts! Looking forward to the', 'Looking forward to the zanubrutinib', 'forward to the zanubrutinib ', 'to the zanubrutinib  ', 'the zanubrutinib   ', 'zanubrutinib    ', '    results.', '   results. #lymsm', '  results. #lymsm .', 'Here for the  #ASH22 late-breaking', 'for the  #ASH22 late-breaking abstracts!', 'the  #ASH22 late-breaking abstracts! Looking', ' #ASH22 late-breaking abstracts! Looking forward', '#ASH22 late-breaking abstracts! Looking forward to', 'late-breaking abstracts! Looking forward to the', 'abstracts! Looking forward to the zanubrutinib', 'Looking forward to the zanubrutinib ', 'forward to the zanubrutinib  ', 'to the zanubrutinib   ', 'the zanubrutinib    ', 'zanubrutinib     results.', '    results. #lymsm', '   results. #lymsm .', 'Here for the  #ASH22 late-breaking abstracts!', 'for the  #ASH22 late-breaking abstracts! Looking', 'the  #ASH22 late-breaking abstracts! Looking forward', ' #ASH22 late-breaking abstracts! Looking forward to', '#ASH22 late-breaking abstracts! Looking forward to the', 'late-breaking abstracts! Looking forward to the zanubrutinib', 'abstracts! Looking forward to the zanubrutinib ', 'Looking forward to the zanubrutinib  ', 'forward to the zanubrutinib   ', 'to the zanubrutinib    ', 'the zanubrutinib     results.', 'zanubrutinib     results. #lymsm', '    results. #lymsm .', 'Here for the  #ASH22 late-breaking abstracts! Looking', 'for the  #ASH22 late-breaking abstracts! Looking forward', 'the  #ASH22 late-breaking abstracts! Looking forward to', ' #ASH22 late-breaking abstracts! Looking forward to the', '#ASH22 late-breaking abstracts! Looking forward to the zanubrutinib', 'late-breaking abstracts! Looking forward to the zanubrutinib ', 'abstracts! Looking forward to the zanubrutinib  ', 'Looking forward to the zanubrutinib   ', 'forward to the zanubrutinib    ', 'to the zanubrutinib     results.', 'the zanubrutinib     results. #lymsm', 'zanubrutinib     results. #lymsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '95', 'tokens': ['fantastic', 'presentation', 'updating', 'us', 'on', 'outcomes', 'with', 'enzamet', '.', 'os', 'benefit', 'of', 'enzalutamide', 'is', 'sustained', 'and', 'pts', 'with', 'synchronous', 'hv', 'disease', 'may', 'benefit', 'from', 'addition', 'of', 'docetaxel.', '#asco22', '.'], 'text_length': 29, 'triples': {'enzamet|fantastic': ([7, 7], [0, 0], 'positive'), 'of|. os benefit of enzalutamide is sustained and pts with synchronous hv disease may': ([11, 11], [8, 21], 'positive')}, 'sentence': 'fantastic presentation updating us on outcomes with enzamet . os benefit of enzalutamide is sustained and pts with synchronous hv disease may benefit from addition of docetaxel. #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(7, 7), (11, 11)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(0, 0), (8, 21)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8)], 'span tokens': ['fantastic', 'presentation', 'updating', 'us', 'on', 'outcomes', 'with', 'enzamet', '.', 'os', 'benefit', 'of', 'enzalutamide', 'is', 'sustained', 'and', 'pts', 'with', 'synchronous', 'hv', 'disease', 'may', 'benefit', 'from', 'addition', 'of', 'docetaxel.', '#asco22', '.', 'fantastic presentation', 'presentation updating', 'updating us', 'us on', 'on outcomes', 'outcomes with', 'with enzamet', 'enzamet .', '. os', 'os benefit', 'benefit of', 'of enzalutamide', 'enzalutamide is', 'is sustained', 'sustained and', 'and pts', 'pts with', 'with synchronous', 'synchronous hv', 'hv disease', 'disease may', 'may benefit', 'benefit from', 'from addition', 'addition of', 'of docetaxel.', 'docetaxel. #asco22', '#asco22 .', 'fantastic presentation updating', 'presentation updating us', 'updating us on', 'us on outcomes', 'on outcomes with', 'outcomes with enzamet', 'with enzamet .', 'enzamet . os', '. os benefit', 'os benefit of', 'benefit of enzalutamide', 'of enzalutamide is', 'enzalutamide is sustained', 'is sustained and', 'sustained and pts', 'and pts with', 'pts with synchronous', 'with synchronous hv', 'synchronous hv disease', 'hv disease may', 'disease may benefit', 'may benefit from', 'benefit from addition', 'from addition of', 'addition of docetaxel.', 'of docetaxel. #asco22', 'docetaxel. #asco22 .', 'fantastic presentation updating us', 'presentation updating us on', 'updating us on outcomes', 'us on outcomes with', 'on outcomes with enzamet', 'outcomes with enzamet .', 'with enzamet . os', 'enzamet . os benefit', '. os benefit of', 'os benefit of enzalutamide', 'benefit of enzalutamide is', 'of enzalutamide is sustained', 'enzalutamide is sustained and', 'is sustained and pts', 'sustained and pts with', 'and pts with synchronous', 'pts with synchronous hv', 'with synchronous hv disease', 'synchronous hv disease may', 'hv disease may benefit', 'disease may benefit from', 'may benefit from addition', 'benefit from addition of', 'from addition of docetaxel.', 'addition of docetaxel. #asco22', 'of docetaxel. #asco22 .', 'fantastic presentation updating us on', 'presentation updating us on outcomes', 'updating us on outcomes with', 'us on outcomes with enzamet', 'on outcomes with enzamet .', 'outcomes with enzamet . os', 'with enzamet . os benefit', 'enzamet . os benefit of', '. os benefit of enzalutamide', 'os benefit of enzalutamide is', 'benefit of enzalutamide is sustained', 'of enzalutamide is sustained and', 'enzalutamide is sustained and pts', 'is sustained and pts with', 'sustained and pts with synchronous', 'and pts with synchronous hv', 'pts with synchronous hv disease', 'with synchronous hv disease may', 'synchronous hv disease may benefit', 'hv disease may benefit from', 'disease may benefit from addition', 'may benefit from addition of', 'benefit from addition of docetaxel.', 'from addition of docetaxel. #asco22', 'addition of docetaxel. #asco22 .', 'fantastic presentation updating us on outcomes', 'presentation updating us on outcomes with', 'updating us on outcomes with enzamet', 'us on outcomes with enzamet .', 'on outcomes with enzamet . os', 'outcomes with enzamet . os benefit', 'with enzamet . os benefit of', 'enzamet . os benefit of enzalutamide', '. os benefit of enzalutamide is', 'os benefit of enzalutamide is sustained', 'benefit of enzalutamide is sustained and', 'of enzalutamide is sustained and pts', 'enzalutamide is sustained and pts with', 'is sustained and pts with synchronous', 'sustained and pts with synchronous hv', 'and pts with synchronous hv disease', 'pts with synchronous hv disease may', 'with synchronous hv disease may benefit', 'synchronous hv disease may benefit from', 'hv disease may benefit from addition', 'disease may benefit from addition of', 'may benefit from addition of docetaxel.', 'benefit from addition of docetaxel. #asco22', 'from addition of docetaxel. #asco22 .', 'fantastic presentation updating us on outcomes with', 'presentation updating us on outcomes with enzamet', 'updating us on outcomes with enzamet .', 'us on outcomes with enzamet . os', 'on outcomes with enzamet . os benefit', 'outcomes with enzamet . os benefit of', 'with enzamet . os benefit of enzalutamide', 'enzamet . os benefit of enzalutamide is', '. os benefit of enzalutamide is sustained', 'os benefit of enzalutamide is sustained and', 'benefit of enzalutamide is sustained and pts', 'of enzalutamide is sustained and pts with', 'enzalutamide is sustained and pts with synchronous', 'is sustained and pts with synchronous hv', 'sustained and pts with synchronous hv disease', 'and pts with synchronous hv disease may', 'pts with synchronous hv disease may benefit', 'with synchronous hv disease may benefit from', 'synchronous hv disease may benefit from addition', 'hv disease may benefit from addition of', 'disease may benefit from addition of docetaxel.', 'may benefit from addition of docetaxel. #asco22', 'benefit from addition of docetaxel. #asco22 .', 'fantastic presentation updating us on outcomes with enzamet', 'presentation updating us on outcomes with enzamet .', 'updating us on outcomes with enzamet . os', 'us on outcomes with enzamet . os benefit', 'on outcomes with enzamet . os benefit of', 'outcomes with enzamet . os benefit of enzalutamide', 'with enzamet . os benefit of enzalutamide is', 'enzamet . os benefit of enzalutamide is sustained', '. os benefit of enzalutamide is sustained and', 'os benefit of enzalutamide is sustained and pts', 'benefit of enzalutamide is sustained and pts with', 'of enzalutamide is sustained and pts with synchronous', 'enzalutamide is sustained and pts with synchronous hv', 'is sustained and pts with synchronous hv disease', 'sustained and pts with synchronous hv disease may', 'and pts with synchronous hv disease may benefit', 'pts with synchronous hv disease may benefit from', 'with synchronous hv disease may benefit from addition', 'synchronous hv disease may benefit from addition of', 'hv disease may benefit from addition of docetaxel.', 'disease may benefit from addition of docetaxel. #asco22', 'may benefit from addition of docetaxel. #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '96', 'tokens': ['impressive', 'results', 'from', 'niche-2', 'trial', 'may', 'open', 'a', 'way', 'to', 'a', 'watch', 'and', 'wait', 'approach', 'for', 'patients', 'with', 'stage', 'iii', 'dmmr', '#crc:', '95%', 'major', 'pathologic', 'responses', '(67%', 'pcr)', 'with', 'neoadjuvant', 'immunotherapy', '(io)', 'ipilimumab+nivolumab', '#esmo22', '#crcsm', '.'], 'text_length': 36, 'triples': {'niche-2|impressive results': ([3, 3], [0, 1], 'positive'), 'ipilimumab+nivolumab|impressive results': ([32, 32], [0, 1], 'positive')}, 'sentence': 'impressive results from niche-2 trial may open a way to a watch and wait approach for patients with stage iii dmmr #crc: 95% major pathologic responses (67% pcr) with neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(3, 3), (32, 32)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['impressive', 'results', 'from', 'niche-2', 'trial', 'may', 'open', 'a', 'way', 'to', 'a', 'watch', 'and', 'wait', 'approach', 'for', 'patients', 'with', 'stage', 'iii', 'dmmr', '#crc:', '95%', 'major', 'pathologic', 'responses', '(67%', 'pcr)', 'with', 'neoadjuvant', 'immunotherapy', '(io)', 'ipilimumab+nivolumab', '#esmo22', '#crcsm', '.', 'impressive results', 'results from', 'from niche-2', 'niche-2 trial', 'trial may', 'may open', 'open a', 'a way', 'way to', 'to a', 'a watch', 'watch and', 'and wait', 'wait approach', 'approach for', 'for patients', 'patients with', 'with stage', 'stage iii', 'iii dmmr', 'dmmr #crc:', '#crc: 95%', '95% major', 'major pathologic', 'pathologic responses', 'responses (67%', '(67% pcr)', 'pcr) with', 'with neoadjuvant', 'neoadjuvant immunotherapy', 'immunotherapy (io)', '(io) ipilimumab+nivolumab', 'ipilimumab+nivolumab #esmo22', '#esmo22 #crcsm', '#crcsm .', 'impressive results from', 'results from niche-2', 'from niche-2 trial', 'niche-2 trial may', 'trial may open', 'may open a', 'open a way', 'a way to', 'way to a', 'to a watch', 'a watch and', 'watch and wait', 'and wait approach', 'wait approach for', 'approach for patients', 'for patients with', 'patients with stage', 'with stage iii', 'stage iii dmmr', 'iii dmmr #crc:', 'dmmr #crc: 95%', '#crc: 95% major', '95% major pathologic', 'major pathologic responses', 'pathologic responses (67%', 'responses (67% pcr)', '(67% pcr) with', 'pcr) with neoadjuvant', 'with neoadjuvant immunotherapy', 'neoadjuvant immunotherapy (io)', 'immunotherapy (io) ipilimumab+nivolumab', '(io) ipilimumab+nivolumab #esmo22', 'ipilimumab+nivolumab #esmo22 #crcsm', '#esmo22 #crcsm .', 'impressive results from niche-2', 'results from niche-2 trial', 'from niche-2 trial may', 'niche-2 trial may open', 'trial may open a', 'may open a way', 'open a way to', 'a way to a', 'way to a watch', 'to a watch and', 'a watch and wait', 'watch and wait approach', 'and wait approach for', 'wait approach for patients', 'approach for patients with', 'for patients with stage', 'patients with stage iii', 'with stage iii dmmr', 'stage iii dmmr #crc:', 'iii dmmr #crc: 95%', 'dmmr #crc: 95% major', '#crc: 95% major pathologic', '95% major pathologic responses', 'major pathologic responses (67%', 'pathologic responses (67% pcr)', 'responses (67% pcr) with', '(67% pcr) with neoadjuvant', 'pcr) with neoadjuvant immunotherapy', 'with neoadjuvant immunotherapy (io)', 'neoadjuvant immunotherapy (io) ipilimumab+nivolumab', 'immunotherapy (io) ipilimumab+nivolumab #esmo22', '(io) ipilimumab+nivolumab #esmo22 #crcsm', 'ipilimumab+nivolumab #esmo22 #crcsm .', 'impressive results from niche-2 trial', 'results from niche-2 trial may', 'from niche-2 trial may open', 'niche-2 trial may open a', 'trial may open a way', 'may open a way to', 'open a way to a', 'a way to a watch', 'way to a watch and', 'to a watch and wait', 'a watch and wait approach', 'watch and wait approach for', 'and wait approach for patients', 'wait approach for patients with', 'approach for patients with stage', 'for patients with stage iii', 'patients with stage iii dmmr', 'with stage iii dmmr #crc:', 'stage iii dmmr #crc: 95%', 'iii dmmr #crc: 95% major', 'dmmr #crc: 95% major pathologic', '#crc: 95% major pathologic responses', '95% major pathologic responses (67%', 'major pathologic responses (67% pcr)', 'pathologic responses (67% pcr) with', 'responses (67% pcr) with neoadjuvant', '(67% pcr) with neoadjuvant immunotherapy', 'pcr) with neoadjuvant immunotherapy (io)', 'with neoadjuvant immunotherapy (io) ipilimumab+nivolumab', 'neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22', 'immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm', '(io) ipilimumab+nivolumab #esmo22 #crcsm .', 'impressive results from niche-2 trial may', 'results from niche-2 trial may open', 'from niche-2 trial may open a', 'niche-2 trial may open a way', 'trial may open a way to', 'may open a way to a', 'open a way to a watch', 'a way to a watch and', 'way to a watch and wait', 'to a watch and wait approach', 'a watch and wait approach for', 'watch and wait approach for patients', 'and wait approach for patients with', 'wait approach for patients with stage', 'approach for patients with stage iii', 'for patients with stage iii dmmr', 'patients with stage iii dmmr #crc:', 'with stage iii dmmr #crc: 95%', 'stage iii dmmr #crc: 95% major', 'iii dmmr #crc: 95% major pathologic', 'dmmr #crc: 95% major pathologic responses', '#crc: 95% major pathologic responses (67%', '95% major pathologic responses (67% pcr)', 'major pathologic responses (67% pcr) with', 'pathologic responses (67% pcr) with neoadjuvant', 'responses (67% pcr) with neoadjuvant immunotherapy', '(67% pcr) with neoadjuvant immunotherapy (io)', 'pcr) with neoadjuvant immunotherapy (io) ipilimumab+nivolumab', 'with neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22', 'neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm', 'immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm .', 'impressive results from niche-2 trial may open', 'results from niche-2 trial may open a', 'from niche-2 trial may open a way', 'niche-2 trial may open a way to', 'trial may open a way to a', 'may open a way to a watch', 'open a way to a watch and', 'a way to a watch and wait', 'way to a watch and wait approach', 'to a watch and wait approach for', 'a watch and wait approach for patients', 'watch and wait approach for patients with', 'and wait approach for patients with stage', 'wait approach for patients with stage iii', 'approach for patients with stage iii dmmr', 'for patients with stage iii dmmr #crc:', 'patients with stage iii dmmr #crc: 95%', 'with stage iii dmmr #crc: 95% major', 'stage iii dmmr #crc: 95% major pathologic', 'iii dmmr #crc: 95% major pathologic responses', 'dmmr #crc: 95% major pathologic responses (67%', '#crc: 95% major pathologic responses (67% pcr)', '95% major pathologic responses (67% pcr) with', 'major pathologic responses (67% pcr) with neoadjuvant', 'pathologic responses (67% pcr) with neoadjuvant immunotherapy', 'responses (67% pcr) with neoadjuvant immunotherapy (io)', '(67% pcr) with neoadjuvant immunotherapy (io) ipilimumab+nivolumab', 'pcr) with neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22', 'with neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm', 'neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm .', 'impressive results from niche-2 trial may open a', 'results from niche-2 trial may open a way', 'from niche-2 trial may open a way to', 'niche-2 trial may open a way to a', 'trial may open a way to a watch', 'may open a way to a watch and', 'open a way to a watch and wait', 'a way to a watch and wait approach', 'way to a watch and wait approach for', 'to a watch and wait approach for patients', 'a watch and wait approach for patients with', 'watch and wait approach for patients with stage', 'and wait approach for patients with stage iii', 'wait approach for patients with stage iii dmmr', 'approach for patients with stage iii dmmr #crc:', 'for patients with stage iii dmmr #crc: 95%', 'patients with stage iii dmmr #crc: 95% major', 'with stage iii dmmr #crc: 95% major pathologic', 'stage iii dmmr #crc: 95% major pathologic responses', 'iii dmmr #crc: 95% major pathologic responses (67%', 'dmmr #crc: 95% major pathologic responses (67% pcr)', '#crc: 95% major pathologic responses (67% pcr) with', '95% major pathologic responses (67% pcr) with neoadjuvant', 'major pathologic responses (67% pcr) with neoadjuvant immunotherapy', 'pathologic responses (67% pcr) with neoadjuvant immunotherapy (io)', 'responses (67% pcr) with neoadjuvant immunotherapy (io) ipilimumab+nivolumab', '(67% pcr) with neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22', 'pcr) with neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm', 'with neoadjuvant immunotherapy (io) ipilimumab+nivolumab #esmo22 #crcsm .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '97', 'tokens': ['interesting', 'genomic', 'data', 'from', 'stampede', 'particularly', 'm0', 'patients.', 'can', 'we', 'avoid', 'abiraterone', 'safely', 'in', 'low', 'genomic', 'but', 'high', 'clinical', 'risk', 'm0', 'hspc', 'patients?', '#esmo2022', 'interactions', 'not', 'significant', 'but', 'absolute', 'benefits', 'lower.', '.'], 'text_length': 32, 'triples': {'stampede|interesting genomic data from stampede particularly m0 patients. can we avoid abiraterone safely in low genomic': ([4, 4], [0, 15], 'positive')}, 'sentence': 'interesting genomic data from stampede particularly m0 patients. can we avoid abiraterone safely in low genomic but high clinical risk m0 hspc patients? #esmo2022 interactions not significant but absolute benefits lower. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 15)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['interesting', 'genomic', 'data', 'from', 'stampede', 'particularly', 'm0', 'patients.', 'can', 'we', 'avoid', 'abiraterone', 'safely', 'in', 'low', 'genomic', 'but', 'high', 'clinical', 'risk', 'm0', 'hspc', 'patients?', '#esmo2022', 'interactions', 'not', 'significant', 'but', 'absolute', 'benefits', 'lower.', '.', 'interesting genomic', 'genomic data', 'data from', 'from stampede', 'stampede particularly', 'particularly m0', 'm0 patients.', 'patients. can', 'can we', 'we avoid', 'avoid abiraterone', 'abiraterone safely', 'safely in', 'in low', 'low genomic', 'genomic but', 'but high', 'high clinical', 'clinical risk', 'risk m0', 'm0 hspc', 'hspc patients?', 'patients? #esmo2022', '#esmo2022 interactions', 'interactions not', 'not significant', 'significant but', 'but absolute', 'absolute benefits', 'benefits lower.', 'lower. .', 'interesting genomic data', 'genomic data from', 'data from stampede', 'from stampede particularly', 'stampede particularly m0', 'particularly m0 patients.', 'm0 patients. can', 'patients. can we', 'can we avoid', 'we avoid abiraterone', 'avoid abiraterone safely', 'abiraterone safely in', 'safely in low', 'in low genomic', 'low genomic but', 'genomic but high', 'but high clinical', 'high clinical risk', 'clinical risk m0', 'risk m0 hspc', 'm0 hspc patients?', 'hspc patients? #esmo2022', 'patients? #esmo2022 interactions', '#esmo2022 interactions not', 'interactions not significant', 'not significant but', 'significant but absolute', 'but absolute benefits', 'absolute benefits lower.', 'benefits lower. .', 'interesting genomic data from', 'genomic data from stampede', 'data from stampede particularly', 'from stampede particularly m0', 'stampede particularly m0 patients.', 'particularly m0 patients. can', 'm0 patients. can we', 'patients. can we avoid', 'can we avoid abiraterone', 'we avoid abiraterone safely', 'avoid abiraterone safely in', 'abiraterone safely in low', 'safely in low genomic', 'in low genomic but', 'low genomic but high', 'genomic but high clinical', 'but high clinical risk', 'high clinical risk m0', 'clinical risk m0 hspc', 'risk m0 hspc patients?', 'm0 hspc patients? #esmo2022', 'hspc patients? #esmo2022 interactions', 'patients? #esmo2022 interactions not', '#esmo2022 interactions not significant', 'interactions not significant but', 'not significant but absolute', 'significant but absolute benefits', 'but absolute benefits lower.', 'absolute benefits lower. .', 'interesting genomic data from stampede', 'genomic data from stampede particularly', 'data from stampede particularly m0', 'from stampede particularly m0 patients.', 'stampede particularly m0 patients. can', 'particularly m0 patients. can we', 'm0 patients. can we avoid', 'patients. can we avoid abiraterone', 'can we avoid abiraterone safely', 'we avoid abiraterone safely in', 'avoid abiraterone safely in low', 'abiraterone safely in low genomic', 'safely in low genomic but', 'in low genomic but high', 'low genomic but high clinical', 'genomic but high clinical risk', 'but high clinical risk m0', 'high clinical risk m0 hspc', 'clinical risk m0 hspc patients?', 'risk m0 hspc patients? #esmo2022', 'm0 hspc patients? #esmo2022 interactions', 'hspc patients? #esmo2022 interactions not', 'patients? #esmo2022 interactions not significant', '#esmo2022 interactions not significant but', 'interactions not significant but absolute', 'not significant but absolute benefits', 'significant but absolute benefits lower.', 'but absolute benefits lower. .', 'interesting genomic data from stampede particularly', 'genomic data from stampede particularly m0', 'data from stampede particularly m0 patients.', 'from stampede particularly m0 patients. can', 'stampede particularly m0 patients. can we', 'particularly m0 patients. can we avoid', 'm0 patients. can we avoid abiraterone', 'patients. can we avoid abiraterone safely', 'can we avoid abiraterone safely in', 'we avoid abiraterone safely in low', 'avoid abiraterone safely in low genomic', 'abiraterone safely in low genomic but', 'safely in low genomic but high', 'in low genomic but high clinical', 'low genomic but high clinical risk', 'genomic but high clinical risk m0', 'but high clinical risk m0 hspc', 'high clinical risk m0 hspc patients?', 'clinical risk m0 hspc patients? #esmo2022', 'risk m0 hspc patients? #esmo2022 interactions', 'm0 hspc patients? #esmo2022 interactions not', 'hspc patients? #esmo2022 interactions not significant', 'patients? #esmo2022 interactions not significant but', '#esmo2022 interactions not significant but absolute', 'interactions not significant but absolute benefits', 'not significant but absolute benefits lower.', 'significant but absolute benefits lower. .', 'interesting genomic data from stampede particularly m0', 'genomic data from stampede particularly m0 patients.', 'data from stampede particularly m0 patients. can', 'from stampede particularly m0 patients. can we', 'stampede particularly m0 patients. can we avoid', 'particularly m0 patients. can we avoid abiraterone', 'm0 patients. can we avoid abiraterone safely', 'patients. can we avoid abiraterone safely in', 'can we avoid abiraterone safely in low', 'we avoid abiraterone safely in low genomic', 'avoid abiraterone safely in low genomic but', 'abiraterone safely in low genomic but high', 'safely in low genomic but high clinical', 'in low genomic but high clinical risk', 'low genomic but high clinical risk m0', 'genomic but high clinical risk m0 hspc', 'but high clinical risk m0 hspc patients?', 'high clinical risk m0 hspc patients? #esmo2022', 'clinical risk m0 hspc patients? #esmo2022 interactions', 'risk m0 hspc patients? #esmo2022 interactions not', 'm0 hspc patients? #esmo2022 interactions not significant', 'hspc patients? #esmo2022 interactions not significant but', 'patients? #esmo2022 interactions not significant but absolute', '#esmo2022 interactions not significant but absolute benefits', 'interactions not significant but absolute benefits lower.', 'not significant but absolute benefits lower. .', 'interesting genomic data from stampede particularly m0 patients.', 'genomic data from stampede particularly m0 patients. can', 'data from stampede particularly m0 patients. can we', 'from stampede particularly m0 patients. can we avoid', 'stampede particularly m0 patients. can we avoid abiraterone', 'particularly m0 patients. can we avoid abiraterone safely', 'm0 patients. can we avoid abiraterone safely in', 'patients. can we avoid abiraterone safely in low', 'can we avoid abiraterone safely in low genomic', 'we avoid abiraterone safely in low genomic but', 'avoid abiraterone safely in low genomic but high', 'abiraterone safely in low genomic but high clinical', 'safely in low genomic but high clinical risk', 'in low genomic but high clinical risk m0', 'low genomic but high clinical risk m0 hspc', 'genomic but high clinical risk m0 hspc patients?', 'but high clinical risk m0 hspc patients? #esmo2022', 'high clinical risk m0 hspc patients? #esmo2022 interactions', 'clinical risk m0 hspc patients? #esmo2022 interactions not', 'risk m0 hspc patients? #esmo2022 interactions not significant', 'm0 hspc patients? #esmo2022 interactions not significant but', 'hspc patients? #esmo2022 interactions not significant but absolute', 'patients? #esmo2022 interactions not significant but absolute benefits', '#esmo2022 interactions not significant but absolute benefits lower.', 'interactions not significant but absolute benefits lower. .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '98', 'tokens': ['excellent', 'coverage', 'as', 'always', 'from', '#asco22', '#', 'enzamet', '.'], 'text_length': 9, 'triples': {'#|excellent': ([6, 6], [0, 0], 'positive')}, 'sentence': 'excellent coverage as always from #asco22 # enzamet .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 0, 1, 0],
       [0, 1, 0, ..., 0, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (0, 7, 8), (1, 8, 8)], 'span tokens': ['excellent', 'coverage', 'as', 'always', 'from', '#asco22', '#', 'enzamet', '.', 'excellent coverage', 'coverage as', 'as always', 'always from', 'from #asco22', '#asco22 #', '# enzamet', 'enzamet .', 'excellent coverage as', 'coverage as always', 'as always from', 'always from #asco22', 'from #asco22 #', '#asco22 # enzamet', '# enzamet .', 'excellent coverage as always', 'coverage as always from', 'as always from #asco22', 'always from #asco22 #', 'from #asco22 # enzamet', '#asco22 # enzamet .', 'excellent coverage as always from', 'coverage as always from #asco22', 'as always from #asco22 #', 'always from #asco22 # enzamet', 'from #asco22 # enzamet .', 'excellent coverage as always from #asco22', 'coverage as always from #asco22 #', 'as always from #asco22 # enzamet', 'always from #asco22 # enzamet .', 'excellent coverage as always from #asco22 #', 'coverage as always from #asco22 # enzamet', 'as always from #asco22 # enzamet .', 'excellent coverage as always from #asco22 # enzamet', 'coverage as always from #asco22 # enzamet .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '99', 'tokens': ['impressive', 'pathological', 'responses', 'to', 'neoadjuvant', 'preop', 'immunotherapy', 'in', 'colon', 'cancer', 'with', 'msi.', 'Niche-2', 'trial', 'presented', 'at', '#esmo22.', '.'], 'text_length': 18, 'triples': {'Niche-2|impressive': ([12, 12], [0, 0], 'positive')}, 'sentence': 'impressive pathological responses to neoadjuvant preop immunotherapy in colon cancer with msi. Niche-2 trial presented at #esmo22. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8)], 'span tokens': ['impressive', 'pathological', 'responses', 'to', 'neoadjuvant', 'preop', 'immunotherapy', 'in', 'colon', 'cancer', 'with', 'msi.', 'Niche-2', 'trial', 'presented', 'at', '#esmo22.', '.', 'impressive pathological', 'pathological responses', 'responses to', 'to neoadjuvant', 'neoadjuvant preop', 'preop immunotherapy', 'immunotherapy in', 'in colon', 'colon cancer', 'cancer with', 'with msi.', 'msi. Niche-2', 'Niche-2 trial', 'trial presented', 'presented at', 'at #esmo22.', '#esmo22. .', 'impressive pathological responses', 'pathological responses to', 'responses to neoadjuvant', 'to neoadjuvant preop', 'neoadjuvant preop immunotherapy', 'preop immunotherapy in', 'immunotherapy in colon', 'in colon cancer', 'colon cancer with', 'cancer with msi.', 'with msi. Niche-2', 'msi. Niche-2 trial', 'Niche-2 trial presented', 'trial presented at', 'presented at #esmo22.', 'at #esmo22. .', 'impressive pathological responses to', 'pathological responses to neoadjuvant', 'responses to neoadjuvant preop', 'to neoadjuvant preop immunotherapy', 'neoadjuvant preop immunotherapy in', 'preop immunotherapy in colon', 'immunotherapy in colon cancer', 'in colon cancer with', 'colon cancer with msi.', 'cancer with msi. Niche-2', 'with msi. Niche-2 trial', 'msi. Niche-2 trial presented', 'Niche-2 trial presented at', 'trial presented at #esmo22.', 'presented at #esmo22. .', 'impressive pathological responses to neoadjuvant', 'pathological responses to neoadjuvant preop', 'responses to neoadjuvant preop immunotherapy', 'to neoadjuvant preop immunotherapy in', 'neoadjuvant preop immunotherapy in colon', 'preop immunotherapy in colon cancer', 'immunotherapy in colon cancer with', 'in colon cancer with msi.', 'colon cancer with msi. Niche-2', 'cancer with msi. Niche-2 trial', 'with msi. Niche-2 trial presented', 'msi. Niche-2 trial presented at', 'Niche-2 trial presented at #esmo22.', 'trial presented at #esmo22. .', 'impressive pathological responses to neoadjuvant preop', 'pathological responses to neoadjuvant preop immunotherapy', 'responses to neoadjuvant preop immunotherapy in', 'to neoadjuvant preop immunotherapy in colon', 'neoadjuvant preop immunotherapy in colon cancer', 'preop immunotherapy in colon cancer with', 'immunotherapy in colon cancer with msi.', 'in colon cancer with msi. Niche-2', 'colon cancer with msi. Niche-2 trial', 'cancer with msi. Niche-2 trial presented', 'with msi. Niche-2 trial presented at', 'msi. Niche-2 trial presented at #esmo22.', 'Niche-2 trial presented at #esmo22. .', 'impressive pathological responses to neoadjuvant preop immunotherapy', 'pathological responses to neoadjuvant preop immunotherapy in', 'responses to neoadjuvant preop immunotherapy in colon', 'to neoadjuvant preop immunotherapy in colon cancer', 'neoadjuvant preop immunotherapy in colon cancer with', 'preop immunotherapy in colon cancer with msi.', 'immunotherapy in colon cancer with msi. Niche-2', 'in colon cancer with msi. Niche-2 trial', 'colon cancer with msi. Niche-2 trial presented', 'cancer with msi. Niche-2 trial presented at', 'with msi. Niche-2 trial presented at #esmo22.', 'msi. Niche-2 trial presented at #esmo22. .', 'impressive pathological responses to neoadjuvant preop immunotherapy in', 'pathological responses to neoadjuvant preop immunotherapy in colon', 'responses to neoadjuvant preop immunotherapy in colon cancer', 'to neoadjuvant preop immunotherapy in colon cancer with', 'neoadjuvant preop immunotherapy in colon cancer with msi.', 'preop immunotherapy in colon cancer with msi. Niche-2', 'immunotherapy in colon cancer with msi. Niche-2 trial', 'in colon cancer with msi. Niche-2 trial presented', 'colon cancer with msi. Niche-2 trial presented at', 'cancer with msi. Niche-2 trial presented at #esmo22.', 'with msi. Niche-2 trial presented at #esmo22. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '100', 'tokens': ['codebreak-200', ',', 'randomized', 'trial', 'of', 'sotorasib', 'vs', 'docetaxel', 'in', 'pts', 'w/', 'kras', 'g12c', 'mutant', 'nsclc', 'pre', 'treated', 'with', 'chemo', '&amp;', 'io', '#esmo22:', 'pfs', '5.6', 'vs', '4.5', 'mo', '(hr', '0.66)', 'orr', '28.1', '%', 'vs.', '13.2%', 'dcr', '82.5%', 'vs', '60.3%', 'improved', 'safety', 'profile', '&amp;', 'pros', 'as', 'expected', 'with', 'sotorasib', '.'], 'text_length': 48, 'triples': {'codebreak-200|vs 60.3%': ([0, 0], [36, 37], 'positive')}, 'sentence': 'codebreak-200 , randomized trial of sotorasib vs docetaxel in pts w/ kras g12c mutant nsclc pre treated with chemo &amp; io #esmo22: pfs 5.6 vs 4.5 mo (hr 0.66) orr 28.1 % vs. 13.2% dcr 82.5% vs 60.3% improved safety profile &amp; pros as expected with sotorasib .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(36, 37)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8)], 'span tokens': ['codebreak-200', ',', 'randomized', 'trial', 'of', 'sotorasib', 'vs', 'docetaxel', 'in', 'pts', 'w/', 'kras', 'g12c', 'mutant', 'nsclc', 'pre', 'treated', 'with', 'chemo', '&amp;', 'io', '#esmo22:', 'pfs', '5.6', 'vs', '4.5', 'mo', '(hr', '0.66)', 'orr', '28.1', '%', 'vs.', '13.2%', 'dcr', '82.5%', 'vs', '60.3%', 'improved', 'safety', 'profile', '&amp;', 'pros', 'as', 'expected', 'with', 'sotorasib', '.', 'codebreak-200 ,', ', randomized', 'randomized trial', 'trial of', 'of sotorasib', 'sotorasib vs', 'vs docetaxel', 'docetaxel in', 'in pts', 'pts w/', 'w/ kras', 'kras g12c', 'g12c mutant', 'mutant nsclc', 'nsclc pre', 'pre treated', 'treated with', 'with chemo', 'chemo &amp;', '&amp; io', 'io #esmo22:', '#esmo22: pfs', 'pfs 5.6', '5.6 vs', 'vs 4.5', '4.5 mo', 'mo (hr', '(hr 0.66)', '0.66) orr', 'orr 28.1', '28.1 %', '% vs.', 'vs. 13.2%', '13.2% dcr', 'dcr 82.5%', '82.5% vs', 'vs 60.3%', '60.3% improved', 'improved safety', 'safety profile', 'profile &amp;', '&amp; pros', 'pros as', 'as expected', 'expected with', 'with sotorasib', 'sotorasib .', 'codebreak-200 , randomized', ', randomized trial', 'randomized trial of', 'trial of sotorasib', 'of sotorasib vs', 'sotorasib vs docetaxel', 'vs docetaxel in', 'docetaxel in pts', 'in pts w/', 'pts w/ kras', 'w/ kras g12c', 'kras g12c mutant', 'g12c mutant nsclc', 'mutant nsclc pre', 'nsclc pre treated', 'pre treated with', 'treated with chemo', 'with chemo &amp;', 'chemo &amp; io', '&amp; io #esmo22:', 'io #esmo22: pfs', '#esmo22: pfs 5.6', 'pfs 5.6 vs', '5.6 vs 4.5', 'vs 4.5 mo', '4.5 mo (hr', 'mo (hr 0.66)', '(hr 0.66) orr', '0.66) orr 28.1', 'orr 28.1 %', '28.1 % vs.', '% vs. 13.2%', 'vs. 13.2% dcr', '13.2% dcr 82.5%', 'dcr 82.5% vs', '82.5% vs 60.3%', 'vs 60.3% improved', '60.3% improved safety', 'improved safety profile', 'safety profile &amp;', 'profile &amp; pros', '&amp; pros as', 'pros as expected', 'as expected with', 'expected with sotorasib', 'with sotorasib .', 'codebreak-200 , randomized trial', ', randomized trial of', 'randomized trial of sotorasib', 'trial of sotorasib vs', 'of sotorasib vs docetaxel', 'sotorasib vs docetaxel in', 'vs docetaxel in pts', 'docetaxel in pts w/', 'in pts w/ kras', 'pts w/ kras g12c', 'w/ kras g12c mutant', 'kras g12c mutant nsclc', 'g12c mutant nsclc pre', 'mutant nsclc pre treated', 'nsclc pre treated with', 'pre treated with chemo', 'treated with chemo &amp;', 'with chemo &amp; io', 'chemo &amp; io #esmo22:', '&amp; io #esmo22: pfs', 'io #esmo22: pfs 5.6', '#esmo22: pfs 5.6 vs', 'pfs 5.6 vs 4.5', '5.6 vs 4.5 mo', 'vs 4.5 mo (hr', '4.5 mo (hr 0.66)', 'mo (hr 0.66) orr', '(hr 0.66) orr 28.1', '0.66) orr 28.1 %', 'orr 28.1 % vs.', '28.1 % vs. 13.2%', '% vs. 13.2% dcr', 'vs. 13.2% dcr 82.5%', '13.2% dcr 82.5% vs', 'dcr 82.5% vs 60.3%', '82.5% vs 60.3% improved', 'vs 60.3% improved safety', '60.3% improved safety profile', 'improved safety profile &amp;', 'safety profile &amp; pros', 'profile &amp; pros as', '&amp; pros as expected', 'pros as expected with', 'as expected with sotorasib', 'expected with sotorasib .', 'codebreak-200 , randomized trial of', ', randomized trial of sotorasib', 'randomized trial of sotorasib vs', 'trial of sotorasib vs docetaxel', 'of sotorasib vs docetaxel in', 'sotorasib vs docetaxel in pts', 'vs docetaxel in pts w/', 'docetaxel in pts w/ kras', 'in pts w/ kras g12c', 'pts w/ kras g12c mutant', 'w/ kras g12c mutant nsclc', 'kras g12c mutant nsclc pre', 'g12c mutant nsclc pre treated', 'mutant nsclc pre treated with', 'nsclc pre treated with chemo', 'pre treated with chemo &amp;', 'treated with chemo &amp; io', 'with chemo &amp; io #esmo22:', 'chemo &amp; io #esmo22: pfs', '&amp; io #esmo22: pfs 5.6', 'io #esmo22: pfs 5.6 vs', '#esmo22: pfs 5.6 vs 4.5', 'pfs 5.6 vs 4.5 mo', '5.6 vs 4.5 mo (hr', 'vs 4.5 mo (hr 0.66)', '4.5 mo (hr 0.66) orr', 'mo (hr 0.66) orr 28.1', '(hr 0.66) orr 28.1 %', '0.66) orr 28.1 % vs.', 'orr 28.1 % vs. 13.2%', '28.1 % vs. 13.2% dcr', '% vs. 13.2% dcr 82.5%', 'vs. 13.2% dcr 82.5% vs', '13.2% dcr 82.5% vs 60.3%', 'dcr 82.5% vs 60.3% improved', '82.5% vs 60.3% improved safety', 'vs 60.3% improved safety profile', '60.3% improved safety profile &amp;', 'improved safety profile &amp; pros', 'safety profile &amp; pros as', 'profile &amp; pros as expected', '&amp; pros as expected with', 'pros as expected with sotorasib', 'as expected with sotorasib .', 'codebreak-200 , randomized trial of sotorasib', ', randomized trial of sotorasib vs', 'randomized trial of sotorasib vs docetaxel', 'trial of sotorasib vs docetaxel in', 'of sotorasib vs docetaxel in pts', 'sotorasib vs docetaxel in pts w/', 'vs docetaxel in pts w/ kras', 'docetaxel in pts w/ kras g12c', 'in pts w/ kras g12c mutant', 'pts w/ kras g12c mutant nsclc', 'w/ kras g12c mutant nsclc pre', 'kras g12c mutant nsclc pre treated', 'g12c mutant nsclc pre treated with', 'mutant nsclc pre treated with chemo', 'nsclc pre treated with chemo &amp;', 'pre treated with chemo &amp; io', 'treated with chemo &amp; io #esmo22:', 'with chemo &amp; io #esmo22: pfs', 'chemo &amp; io #esmo22: pfs 5.6', '&amp; io #esmo22: pfs 5.6 vs', 'io #esmo22: pfs 5.6 vs 4.5', '#esmo22: pfs 5.6 vs 4.5 mo', 'pfs 5.6 vs 4.5 mo (hr', '5.6 vs 4.5 mo (hr 0.66)', 'vs 4.5 mo (hr 0.66) orr', '4.5 mo (hr 0.66) orr 28.1', 'mo (hr 0.66) orr 28.1 %', '(hr 0.66) orr 28.1 % vs.', '0.66) orr 28.1 % vs. 13.2%', 'orr 28.1 % vs. 13.2% dcr', '28.1 % vs. 13.2% dcr 82.5%', '% vs. 13.2% dcr 82.5% vs', 'vs. 13.2% dcr 82.5% vs 60.3%', '13.2% dcr 82.5% vs 60.3% improved', 'dcr 82.5% vs 60.3% improved safety', '82.5% vs 60.3% improved safety profile', 'vs 60.3% improved safety profile &amp;', '60.3% improved safety profile &amp; pros', 'improved safety profile &amp; pros as', 'safety profile &amp; pros as expected', 'profile &amp; pros as expected with', '&amp; pros as expected with sotorasib', 'pros as expected with sotorasib .', 'codebreak-200 , randomized trial of sotorasib vs', ', randomized trial of sotorasib vs docetaxel', 'randomized trial of sotorasib vs docetaxel in', 'trial of sotorasib vs docetaxel in pts', 'of sotorasib vs docetaxel in pts w/', 'sotorasib vs docetaxel in pts w/ kras', 'vs docetaxel in pts w/ kras g12c', 'docetaxel in pts w/ kras g12c mutant', 'in pts w/ kras g12c mutant nsclc', 'pts w/ kras g12c mutant nsclc pre', 'w/ kras g12c mutant nsclc pre treated', 'kras g12c mutant nsclc pre treated with', 'g12c mutant nsclc pre treated with chemo', 'mutant nsclc pre treated with chemo &amp;', 'nsclc pre treated with chemo &amp; io', 'pre treated with chemo &amp; io #esmo22:', 'treated with chemo &amp; io #esmo22: pfs', 'with chemo &amp; io #esmo22: pfs 5.6', 'chemo &amp; io #esmo22: pfs 5.6 vs', '&amp; io #esmo22: pfs 5.6 vs 4.5', 'io #esmo22: pfs 5.6 vs 4.5 mo', '#esmo22: pfs 5.6 vs 4.5 mo (hr', 'pfs 5.6 vs 4.5 mo (hr 0.66)', '5.6 vs 4.5 mo (hr 0.66) orr', 'vs 4.5 mo (hr 0.66) orr 28.1', '4.5 mo (hr 0.66) orr 28.1 %', 'mo (hr 0.66) orr 28.1 % vs.', '(hr 0.66) orr 28.1 % vs. 13.2%', '0.66) orr 28.1 % vs. 13.2% dcr', 'orr 28.1 % vs. 13.2% dcr 82.5%', '28.1 % vs. 13.2% dcr 82.5% vs', '% vs. 13.2% dcr 82.5% vs 60.3%', 'vs. 13.2% dcr 82.5% vs 60.3% improved', '13.2% dcr 82.5% vs 60.3% improved safety', 'dcr 82.5% vs 60.3% improved safety profile', '82.5% vs 60.3% improved safety profile &amp;', 'vs 60.3% improved safety profile &amp; pros', '60.3% improved safety profile &amp; pros as', 'improved safety profile &amp; pros as expected', 'safety profile &amp; pros as expected with', 'profile &amp; pros as expected with sotorasib', '&amp; pros as expected with sotorasib .', 'codebreak-200 , randomized trial of sotorasib vs docetaxel', ', randomized trial of sotorasib vs docetaxel in', 'randomized trial of sotorasib vs docetaxel in pts', 'trial of sotorasib vs docetaxel in pts w/', 'of sotorasib vs docetaxel in pts w/ kras', 'sotorasib vs docetaxel in pts w/ kras g12c', 'vs docetaxel in pts w/ kras g12c mutant', 'docetaxel in pts w/ kras g12c mutant nsclc', 'in pts w/ kras g12c mutant nsclc pre', 'pts w/ kras g12c mutant nsclc pre treated', 'w/ kras g12c mutant nsclc pre treated with', 'kras g12c mutant nsclc pre treated with chemo', 'g12c mutant nsclc pre treated with chemo &amp;', 'mutant nsclc pre treated with chemo &amp; io', 'nsclc pre treated with chemo &amp; io #esmo22:', 'pre treated with chemo &amp; io #esmo22: pfs', 'treated with chemo &amp; io #esmo22: pfs 5.6', 'with chemo &amp; io #esmo22: pfs 5.6 vs', 'chemo &amp; io #esmo22: pfs 5.6 vs 4.5', '&amp; io #esmo22: pfs 5.6 vs 4.5 mo', 'io #esmo22: pfs 5.6 vs 4.5 mo (hr', '#esmo22: pfs 5.6 vs 4.5 mo (hr 0.66)', 'pfs 5.6 vs 4.5 mo (hr 0.66) orr', '5.6 vs 4.5 mo (hr 0.66) orr 28.1', 'vs 4.5 mo (hr 0.66) orr 28.1 %', '4.5 mo (hr 0.66) orr 28.1 % vs.', 'mo (hr 0.66) orr 28.1 % vs. 13.2%', '(hr 0.66) orr 28.1 % vs. 13.2% dcr', '0.66) orr 28.1 % vs. 13.2% dcr 82.5%', 'orr 28.1 % vs. 13.2% dcr 82.5% vs', '28.1 % vs. 13.2% dcr 82.5% vs 60.3%', '% vs. 13.2% dcr 82.5% vs 60.3% improved', 'vs. 13.2% dcr 82.5% vs 60.3% improved safety', '13.2% dcr 82.5% vs 60.3% improved safety profile', 'dcr 82.5% vs 60.3% improved safety profile &amp;', '82.5% vs 60.3% improved safety profile &amp; pros', 'vs 60.3% improved safety profile &amp; pros as', '60.3% improved safety profile &amp; pros as expected', 'improved safety profile &amp; pros as expected with', 'safety profile &amp; pros as expected with sotorasib', 'profile &amp; pros as expected with sotorasib .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '101', 'tokens': ['in', "'s", 'discussion', '-', 'are', 'there', 'patients', 'who', 'might', 'not', 'benefit', 'from', 'adjuvant', 'pembro', 'who', 'would', 'benefit', 'from', 'everolimus', '?', 'are', 'there', 'biomarkers', 'that', 'can', 'predict', 'that', 'benefit?', 'next', 'adjuvant', 'trial', 'design?', '#asco22', '.'], 'text_length': 34, 'triples': {'everolimus|might not benefit from adjuvant pembro who would benefit from everolimus ? are there biomarkers that can predict that': ([18, 18], [8, 26], 'neutral')}, 'sentence': "in 's discussion - are there patients who might not benefit from adjuvant pembro who would benefit from everolimus ? are there biomarkers that can predict that benefit? next adjuvant trial design? #asco22 .", 'aspect_num': 1, 'spans_aspect2opinion_label': [(18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(8, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['in', "'s", 'discussion', '-', 'are', 'there', 'patients', 'who', 'might', 'not', 'benefit', 'from', 'adjuvant', 'pembro', 'who', 'would', 'benefit', 'from', 'everolimus', '?', 'are', 'there', 'biomarkers', 'that', 'can', 'predict', 'that', 'benefit?', 'next', 'adjuvant', 'trial', 'design?', '#asco22', '.', "in 's", "'s discussion", 'discussion -', '- are', 'are there', 'there patients', 'patients who', 'who might', 'might not', 'not benefit', 'benefit from', 'from adjuvant', 'adjuvant pembro', 'pembro who', 'who would', 'would benefit', 'benefit from', 'from everolimus', 'everolimus ?', '? are', 'are there', 'there biomarkers', 'biomarkers that', 'that can', 'can predict', 'predict that', 'that benefit?', 'benefit? next', 'next adjuvant', 'adjuvant trial', 'trial design?', 'design? #asco22', '#asco22 .', "in 's discussion", "'s discussion -", 'discussion - are', '- are there', 'are there patients', 'there patients who', 'patients who might', 'who might not', 'might not benefit', 'not benefit from', 'benefit from adjuvant', 'from adjuvant pembro', 'adjuvant pembro who', 'pembro who would', 'who would benefit', 'would benefit from', 'benefit from everolimus', 'from everolimus ?', 'everolimus ? are', '? are there', 'are there biomarkers', 'there biomarkers that', 'biomarkers that can', 'that can predict', 'can predict that', 'predict that benefit?', 'that benefit? next', 'benefit? next adjuvant', 'next adjuvant trial', 'adjuvant trial design?', 'trial design? #asco22', 'design? #asco22 .', "in 's discussion -", "'s discussion - are", 'discussion - are there', '- are there patients', 'are there patients who', 'there patients who might', 'patients who might not', 'who might not benefit', 'might not benefit from', 'not benefit from adjuvant', 'benefit from adjuvant pembro', 'from adjuvant pembro who', 'adjuvant pembro who would', 'pembro who would benefit', 'who would benefit from', 'would benefit from everolimus', 'benefit from everolimus ?', 'from everolimus ? are', 'everolimus ? are there', '? are there biomarkers', 'are there biomarkers that', 'there biomarkers that can', 'biomarkers that can predict', 'that can predict that', 'can predict that benefit?', 'predict that benefit? next', 'that benefit? next adjuvant', 'benefit? next adjuvant trial', 'next adjuvant trial design?', 'adjuvant trial design? #asco22', 'trial design? #asco22 .', "in 's discussion - are", "'s discussion - are there", 'discussion - are there patients', '- are there patients who', 'are there patients who might', 'there patients who might not', 'patients who might not benefit', 'who might not benefit from', 'might not benefit from adjuvant', 'not benefit from adjuvant pembro', 'benefit from adjuvant pembro who', 'from adjuvant pembro who would', 'adjuvant pembro who would benefit', 'pembro who would benefit from', 'who would benefit from everolimus', 'would benefit from everolimus ?', 'benefit from everolimus ? are', 'from everolimus ? are there', 'everolimus ? are there biomarkers', '? are there biomarkers that', 'are there biomarkers that can', 'there biomarkers that can predict', 'biomarkers that can predict that', 'that can predict that benefit?', 'can predict that benefit? next', 'predict that benefit? next adjuvant', 'that benefit? next adjuvant trial', 'benefit? next adjuvant trial design?', 'next adjuvant trial design? #asco22', 'adjuvant trial design? #asco22 .', "in 's discussion - are there", "'s discussion - are there patients", 'discussion - are there patients who', '- are there patients who might', 'are there patients who might not', 'there patients who might not benefit', 'patients who might not benefit from', 'who might not benefit from adjuvant', 'might not benefit from adjuvant pembro', 'not benefit from adjuvant pembro who', 'benefit from adjuvant pembro who would', 'from adjuvant pembro who would benefit', 'adjuvant pembro who would benefit from', 'pembro who would benefit from everolimus', 'who would benefit from everolimus ?', 'would benefit from everolimus ? are', 'benefit from everolimus ? are there', 'from everolimus ? are there biomarkers', 'everolimus ? are there biomarkers that', '? are there biomarkers that can', 'are there biomarkers that can predict', 'there biomarkers that can predict that', 'biomarkers that can predict that benefit?', 'that can predict that benefit? next', 'can predict that benefit? next adjuvant', 'predict that benefit? next adjuvant trial', 'that benefit? next adjuvant trial design?', 'benefit? next adjuvant trial design? #asco22', 'next adjuvant trial design? #asco22 .', "in 's discussion - are there patients", "'s discussion - are there patients who", 'discussion - are there patients who might', '- are there patients who might not', 'are there patients who might not benefit', 'there patients who might not benefit from', 'patients who might not benefit from adjuvant', 'who might not benefit from adjuvant pembro', 'might not benefit from adjuvant pembro who', 'not benefit from adjuvant pembro who would', 'benefit from adjuvant pembro who would benefit', 'from adjuvant pembro who would benefit from', 'adjuvant pembro who would benefit from everolimus', 'pembro who would benefit from everolimus ?', 'who would benefit from everolimus ? are', 'would benefit from everolimus ? are there', 'benefit from everolimus ? are there biomarkers', 'from everolimus ? are there biomarkers that', 'everolimus ? are there biomarkers that can', '? are there biomarkers that can predict', 'are there biomarkers that can predict that', 'there biomarkers that can predict that benefit?', 'biomarkers that can predict that benefit? next', 'that can predict that benefit? next adjuvant', 'can predict that benefit? next adjuvant trial', 'predict that benefit? next adjuvant trial design?', 'that benefit? next adjuvant trial design? #asco22', 'benefit? next adjuvant trial design? #asco22 .', "in 's discussion - are there patients who", "'s discussion - are there patients who might", 'discussion - are there patients who might not', '- are there patients who might not benefit', 'are there patients who might not benefit from', 'there patients who might not benefit from adjuvant', 'patients who might not benefit from adjuvant pembro', 'who might not benefit from adjuvant pembro who', 'might not benefit from adjuvant pembro who would', 'not benefit from adjuvant pembro who would benefit', 'benefit from adjuvant pembro who would benefit from', 'from adjuvant pembro who would benefit from everolimus', 'adjuvant pembro who would benefit from everolimus ?', 'pembro who would benefit from everolimus ? are', 'who would benefit from everolimus ? are there', 'would benefit from everolimus ? are there biomarkers', 'benefit from everolimus ? are there biomarkers that', 'from everolimus ? are there biomarkers that can', 'everolimus ? are there biomarkers that can predict', '? are there biomarkers that can predict that', 'are there biomarkers that can predict that benefit?', 'there biomarkers that can predict that benefit? next', 'biomarkers that can predict that benefit? next adjuvant', 'that can predict that benefit? next adjuvant trial', 'can predict that benefit? next adjuvant trial design?', 'predict that benefit? next adjuvant trial design? #asco22', 'that benefit? next adjuvant trial design? #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '102', 'tokens': ['excellent', 'presentation', 'by', 'rockstar', 'co-fellow', 'and', 'myeloma', 'phenom', 'on', 'real', 'world', 'experience', 'with', 'ide-cel', 'car-t', 'in', 'rrmm.', 'great', 'insights', 'on', 'irl', 'efficacy.', 'kudos.', '#ash2022', '.'], 'text_length': 25, 'triples': {'ide-cel|excellent presentation by rockstar co-fellow and myeloma phenom on real world experience with ide-cel car-t in rrmm. great insights': ([13, 13], [0, 18], 'positive')}, 'sentence': 'excellent presentation by rockstar co-fellow and myeloma phenom on real world experience with ide-cel car-t in rrmm. great insights on irl efficacy. kudos. #ash2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(13, 13)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 18)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8)], 'span tokens': ['excellent', 'presentation', 'by', 'rockstar', 'co-fellow', 'and', 'myeloma', 'phenom', 'on', 'real', 'world', 'experience', 'with', 'ide-cel', 'car-t', 'in', 'rrmm.', 'great', 'insights', 'on', 'irl', 'efficacy.', 'kudos.', '#ash2022', '.', 'excellent presentation', 'presentation by', 'by rockstar', 'rockstar co-fellow', 'co-fellow and', 'and myeloma', 'myeloma phenom', 'phenom on', 'on real', 'real world', 'world experience', 'experience with', 'with ide-cel', 'ide-cel car-t', 'car-t in', 'in rrmm.', 'rrmm. great', 'great insights', 'insights on', 'on irl', 'irl efficacy.', 'efficacy. kudos.', 'kudos. #ash2022', '#ash2022 .', 'excellent presentation by', 'presentation by rockstar', 'by rockstar co-fellow', 'rockstar co-fellow and', 'co-fellow and myeloma', 'and myeloma phenom', 'myeloma phenom on', 'phenom on real', 'on real world', 'real world experience', 'world experience with', 'experience with ide-cel', 'with ide-cel car-t', 'ide-cel car-t in', 'car-t in rrmm.', 'in rrmm. great', 'rrmm. great insights', 'great insights on', 'insights on irl', 'on irl efficacy.', 'irl efficacy. kudos.', 'efficacy. kudos. #ash2022', 'kudos. #ash2022 .', 'excellent presentation by rockstar', 'presentation by rockstar co-fellow', 'by rockstar co-fellow and', 'rockstar co-fellow and myeloma', 'co-fellow and myeloma phenom', 'and myeloma phenom on', 'myeloma phenom on real', 'phenom on real world', 'on real world experience', 'real world experience with', 'world experience with ide-cel', 'experience with ide-cel car-t', 'with ide-cel car-t in', 'ide-cel car-t in rrmm.', 'car-t in rrmm. great', 'in rrmm. great insights', 'rrmm. great insights on', 'great insights on irl', 'insights on irl efficacy.', 'on irl efficacy. kudos.', 'irl efficacy. kudos. #ash2022', 'efficacy. kudos. #ash2022 .', 'excellent presentation by rockstar co-fellow', 'presentation by rockstar co-fellow and', 'by rockstar co-fellow and myeloma', 'rockstar co-fellow and myeloma phenom', 'co-fellow and myeloma phenom on', 'and myeloma phenom on real', 'myeloma phenom on real world', 'phenom on real world experience', 'on real world experience with', 'real world experience with ide-cel', 'world experience with ide-cel car-t', 'experience with ide-cel car-t in', 'with ide-cel car-t in rrmm.', 'ide-cel car-t in rrmm. great', 'car-t in rrmm. great insights', 'in rrmm. great insights on', 'rrmm. great insights on irl', 'great insights on irl efficacy.', 'insights on irl efficacy. kudos.', 'on irl efficacy. kudos. #ash2022', 'irl efficacy. kudos. #ash2022 .', 'excellent presentation by rockstar co-fellow and', 'presentation by rockstar co-fellow and myeloma', 'by rockstar co-fellow and myeloma phenom', 'rockstar co-fellow and myeloma phenom on', 'co-fellow and myeloma phenom on real', 'and myeloma phenom on real world', 'myeloma phenom on real world experience', 'phenom on real world experience with', 'on real world experience with ide-cel', 'real world experience with ide-cel car-t', 'world experience with ide-cel car-t in', 'experience with ide-cel car-t in rrmm.', 'with ide-cel car-t in rrmm. great', 'ide-cel car-t in rrmm. great insights', 'car-t in rrmm. great insights on', 'in rrmm. great insights on irl', 'rrmm. great insights on irl efficacy.', 'great insights on irl efficacy. kudos.', 'insights on irl efficacy. kudos. #ash2022', 'on irl efficacy. kudos. #ash2022 .', 'excellent presentation by rockstar co-fellow and myeloma', 'presentation by rockstar co-fellow and myeloma phenom', 'by rockstar co-fellow and myeloma phenom on', 'rockstar co-fellow and myeloma phenom on real', 'co-fellow and myeloma phenom on real world', 'and myeloma phenom on real world experience', 'myeloma phenom on real world experience with', 'phenom on real world experience with ide-cel', 'on real world experience with ide-cel car-t', 'real world experience with ide-cel car-t in', 'world experience with ide-cel car-t in rrmm.', 'experience with ide-cel car-t in rrmm. great', 'with ide-cel car-t in rrmm. great insights', 'ide-cel car-t in rrmm. great insights on', 'car-t in rrmm. great insights on irl', 'in rrmm. great insights on irl efficacy.', 'rrmm. great insights on irl efficacy. kudos.', 'great insights on irl efficacy. kudos. #ash2022', 'insights on irl efficacy. kudos. #ash2022 .', 'excellent presentation by rockstar co-fellow and myeloma phenom', 'presentation by rockstar co-fellow and myeloma phenom on', 'by rockstar co-fellow and myeloma phenom on real', 'rockstar co-fellow and myeloma phenom on real world', 'co-fellow and myeloma phenom on real world experience', 'and myeloma phenom on real world experience with', 'myeloma phenom on real world experience with ide-cel', 'phenom on real world experience with ide-cel car-t', 'on real world experience with ide-cel car-t in', 'real world experience with ide-cel car-t in rrmm.', 'world experience with ide-cel car-t in rrmm. great', 'experience with ide-cel car-t in rrmm. great insights', 'with ide-cel car-t in rrmm. great insights on', 'ide-cel car-t in rrmm. great insights on irl', 'car-t in rrmm. great insights on irl efficacy.', 'in rrmm. great insights on irl efficacy. kudos.', 'rrmm. great insights on irl efficacy. kudos. #ash2022', 'great insights on irl efficacy. kudos. #ash2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '103', 'tokens': ['Time-limited', 'ibrutinib+venetoclax', 'for', '2', 'years', 'in', 'frontline', "Waldenstrom's.", 'Time', 'to', 'response', '1.9', 'months.', 'PFS', 'was', '92%', 'and', 'OS', '95%', 'with', '~1', 'year', 'of', 'follow-up.', '2', 'Grade', '5', 'AEs', 'due', 'to', 'ventricular', 'arrhythmias', '(known', 'problem', 'with', 'ibrutinib).', 'Based', 'on', 'ALPINE,', 'zanubrutinib', '', '', '', '', 'instead?', '#ASH22', '#lymsm', '.'], 'text_length': 48, 'triples': {'ALPINE,|Based on ALPINE, zanubrutinib instead?': ([38, 38], [36, 40], 'neutral'), "ibrutinib+venetoclax for 2 years in frontline Waldenstrom's. Time to response 1.9 months. PFS was 92% and OS 95% with ~1 year of follow-up. 2 Grade 5 AEs due to ventricular arrhythmias (known problem with ibrutinib).|with ~1 year of follow-up. 2 Grade 5 AEs due to ventricular arrhythmias (known problem with": ([1, 35], [19, 34], 'negative'), 'zanubrutinib|Based on ALPINE, zanubrutinib instead?': ([39, 39], [36, 40], 'neutral')}, 'sentence': "Time-limited ibrutinib+venetoclax for 2 years in frontline Waldenstrom's. Time to response 1.9 months. PFS was 92% and OS 95% with ~1 year of follow-up. 2 Grade 5 AEs due to ventricular arrhythmias (known problem with ibrutinib). Based on ALPINE, zanubrutinib     instead? #ASH22 #lymsm .", 'aspect_num': 3, 'spans_aspect2opinion_label': [(38, 38), (1, 35), (39, 39)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(36, 40), (19, 34)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8)], 'span tokens': ['Time-limited', 'ibrutinib+venetoclax', 'for', '2', 'years', 'in', 'frontline', "Waldenstrom's.", 'Time', 'to', 'response', '1.9', 'months.', 'PFS', 'was', '92%', 'and', 'OS', '95%', 'with', '~1', 'year', 'of', 'follow-up.', '2', 'Grade', '5', 'AEs', 'due', 'to', 'ventricular', 'arrhythmias', '(known', 'problem', 'with', 'ibrutinib).', 'Based', 'on', 'ALPINE,', 'zanubrutinib', '', '', '', '', 'instead?', '#ASH22', '#lymsm', '.', 'Time-limited ibrutinib+venetoclax', 'ibrutinib+venetoclax for', 'for 2', '2 years', 'years in', 'in frontline', "frontline Waldenstrom's.", "Waldenstrom's. Time", 'Time to', 'to response', 'response 1.9', '1.9 months.', 'months. PFS', 'PFS was', 'was 92%', '92% and', 'and OS', 'OS 95%', '95% with', 'with ~1', '~1 year', 'year of', 'of follow-up.', 'follow-up. 2', '2 Grade', 'Grade 5', '5 AEs', 'AEs due', 'due to', 'to ventricular', 'ventricular arrhythmias', 'arrhythmias (known', '(known problem', 'problem with', 'with ibrutinib).', 'ibrutinib). Based', 'Based on', 'on ALPINE,', 'ALPINE, zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' instead?', 'instead? #ASH22', '#ASH22 #lymsm', '#lymsm .', 'Time-limited ibrutinib+venetoclax for', 'ibrutinib+venetoclax for 2', 'for 2 years', '2 years in', 'years in frontline', "in frontline Waldenstrom's.", "frontline Waldenstrom's. Time", "Waldenstrom's. Time to", 'Time to response', 'to response 1.9', 'response 1.9 months.', '1.9 months. PFS', 'months. PFS was', 'PFS was 92%', 'was 92% and', '92% and OS', 'and OS 95%', 'OS 95% with', '95% with ~1', 'with ~1 year', '~1 year of', 'year of follow-up.', 'of follow-up. 2', 'follow-up. 2 Grade', '2 Grade 5', 'Grade 5 AEs', '5 AEs due', 'AEs due to', 'due to ventricular', 'to ventricular arrhythmias', 'ventricular arrhythmias (known', 'arrhythmias (known problem', '(known problem with', 'problem with ibrutinib).', 'with ibrutinib). Based', 'ibrutinib). Based on', 'Based on ALPINE,', 'on ALPINE, zanubrutinib', 'ALPINE, zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  instead?', ' instead? #ASH22', 'instead? #ASH22 #lymsm', '#ASH22 #lymsm .', 'Time-limited ibrutinib+venetoclax for 2', 'ibrutinib+venetoclax for 2 years', 'for 2 years in', '2 years in frontline', "years in frontline Waldenstrom's.", "in frontline Waldenstrom's. Time", "frontline Waldenstrom's. Time to", "Waldenstrom's. Time to response", 'Time to response 1.9', 'to response 1.9 months.', 'response 1.9 months. PFS', '1.9 months. PFS was', 'months. PFS was 92%', 'PFS was 92% and', 'was 92% and OS', '92% and OS 95%', 'and OS 95% with', 'OS 95% with ~1', '95% with ~1 year', 'with ~1 year of', '~1 year of follow-up.', 'year of follow-up. 2', 'of follow-up. 2 Grade', 'follow-up. 2 Grade 5', '2 Grade 5 AEs', 'Grade 5 AEs due', '5 AEs due to', 'AEs due to ventricular', 'due to ventricular arrhythmias', 'to ventricular arrhythmias (known', 'ventricular arrhythmias (known problem', 'arrhythmias (known problem with', '(known problem with ibrutinib).', 'problem with ibrutinib). Based', 'with ibrutinib). Based on', 'ibrutinib). Based on ALPINE,', 'Based on ALPINE, zanubrutinib', 'on ALPINE, zanubrutinib ', 'ALPINE, zanubrutinib  ', 'zanubrutinib   ', '   ', '   instead?', '  instead? #ASH22', ' instead? #ASH22 #lymsm', 'instead? #ASH22 #lymsm .', 'Time-limited ibrutinib+venetoclax for 2 years', 'ibrutinib+venetoclax for 2 years in', 'for 2 years in frontline', "2 years in frontline Waldenstrom's.", "years in frontline Waldenstrom's. Time", "in frontline Waldenstrom's. Time to", "frontline Waldenstrom's. Time to response", "Waldenstrom's. Time to response 1.9", 'Time to response 1.9 months.', 'to response 1.9 months. PFS', 'response 1.9 months. PFS was', '1.9 months. PFS was 92%', 'months. PFS was 92% and', 'PFS was 92% and OS', 'was 92% and OS 95%', '92% and OS 95% with', 'and OS 95% with ~1', 'OS 95% with ~1 year', '95% with ~1 year of', 'with ~1 year of follow-up.', '~1 year of follow-up. 2', 'year of follow-up. 2 Grade', 'of follow-up. 2 Grade 5', 'follow-up. 2 Grade 5 AEs', '2 Grade 5 AEs due', 'Grade 5 AEs due to', '5 AEs due to ventricular', 'AEs due to ventricular arrhythmias', 'due to ventricular arrhythmias (known', 'to ventricular arrhythmias (known problem', 'ventricular arrhythmias (known problem with', 'arrhythmias (known problem with ibrutinib).', '(known problem with ibrutinib). Based', 'problem with ibrutinib). Based on', 'with ibrutinib). Based on ALPINE,', 'ibrutinib). Based on ALPINE, zanubrutinib', 'Based on ALPINE, zanubrutinib ', 'on ALPINE, zanubrutinib  ', 'ALPINE, zanubrutinib   ', 'zanubrutinib    ', '    instead?', '   instead? #ASH22', '  instead? #ASH22 #lymsm', ' instead? #ASH22 #lymsm .', 'Time-limited ibrutinib+venetoclax for 2 years in', 'ibrutinib+venetoclax for 2 years in frontline', "for 2 years in frontline Waldenstrom's.", "2 years in frontline Waldenstrom's. Time", "years in frontline Waldenstrom's. Time to", "in frontline Waldenstrom's. Time to response", "frontline Waldenstrom's. Time to response 1.9", "Waldenstrom's. Time to response 1.9 months.", 'Time to response 1.9 months. PFS', 'to response 1.9 months. PFS was', 'response 1.9 months. PFS was 92%', '1.9 months. PFS was 92% and', 'months. PFS was 92% and OS', 'PFS was 92% and OS 95%', 'was 92% and OS 95% with', '92% and OS 95% with ~1', 'and OS 95% with ~1 year', 'OS 95% with ~1 year of', '95% with ~1 year of follow-up.', 'with ~1 year of follow-up. 2', '~1 year of follow-up. 2 Grade', 'year of follow-up. 2 Grade 5', 'of follow-up. 2 Grade 5 AEs', 'follow-up. 2 Grade 5 AEs due', '2 Grade 5 AEs due to', 'Grade 5 AEs due to ventricular', '5 AEs due to ventricular arrhythmias', 'AEs due to ventricular arrhythmias (known', 'due to ventricular arrhythmias (known problem', 'to ventricular arrhythmias (known problem with', 'ventricular arrhythmias (known problem with ibrutinib).', 'arrhythmias (known problem with ibrutinib). Based', '(known problem with ibrutinib). Based on', 'problem with ibrutinib). Based on ALPINE,', 'with ibrutinib). Based on ALPINE, zanubrutinib', 'ibrutinib). Based on ALPINE, zanubrutinib ', 'Based on ALPINE, zanubrutinib  ', 'on ALPINE, zanubrutinib   ', 'ALPINE, zanubrutinib    ', 'zanubrutinib     instead?', '    instead? #ASH22', '   instead? #ASH22 #lymsm', '  instead? #ASH22 #lymsm .', 'Time-limited ibrutinib+venetoclax for 2 years in frontline', "ibrutinib+venetoclax for 2 years in frontline Waldenstrom's.", "for 2 years in frontline Waldenstrom's. Time", "2 years in frontline Waldenstrom's. Time to", "years in frontline Waldenstrom's. Time to response", "in frontline Waldenstrom's. Time to response 1.9", "frontline Waldenstrom's. Time to response 1.9 months.", "Waldenstrom's. Time to response 1.9 months. PFS", 'Time to response 1.9 months. PFS was', 'to response 1.9 months. PFS was 92%', 'response 1.9 months. PFS was 92% and', '1.9 months. PFS was 92% and OS', 'months. PFS was 92% and OS 95%', 'PFS was 92% and OS 95% with', 'was 92% and OS 95% with ~1', '92% and OS 95% with ~1 year', 'and OS 95% with ~1 year of', 'OS 95% with ~1 year of follow-up.', '95% with ~1 year of follow-up. 2', 'with ~1 year of follow-up. 2 Grade', '~1 year of follow-up. 2 Grade 5', 'year of follow-up. 2 Grade 5 AEs', 'of follow-up. 2 Grade 5 AEs due', 'follow-up. 2 Grade 5 AEs due to', '2 Grade 5 AEs due to ventricular', 'Grade 5 AEs due to ventricular arrhythmias', '5 AEs due to ventricular arrhythmias (known', 'AEs due to ventricular arrhythmias (known problem', 'due to ventricular arrhythmias (known problem with', 'to ventricular arrhythmias (known problem with ibrutinib).', 'ventricular arrhythmias (known problem with ibrutinib). Based', 'arrhythmias (known problem with ibrutinib). Based on', '(known problem with ibrutinib). Based on ALPINE,', 'problem with ibrutinib). Based on ALPINE, zanubrutinib', 'with ibrutinib). Based on ALPINE, zanubrutinib ', 'ibrutinib). Based on ALPINE, zanubrutinib  ', 'Based on ALPINE, zanubrutinib   ', 'on ALPINE, zanubrutinib    ', 'ALPINE, zanubrutinib     instead?', 'zanubrutinib     instead? #ASH22', '    instead? #ASH22 #lymsm', '   instead? #ASH22 #lymsm .', "Time-limited ibrutinib+venetoclax for 2 years in frontline Waldenstrom's.", "ibrutinib+venetoclax for 2 years in frontline Waldenstrom's. Time", "for 2 years in frontline Waldenstrom's. Time to", "2 years in frontline Waldenstrom's. Time to response", "years in frontline Waldenstrom's. Time to response 1.9", "in frontline Waldenstrom's. Time to response 1.9 months.", "frontline Waldenstrom's. Time to response 1.9 months. PFS", "Waldenstrom's. Time to response 1.9 months. PFS was", 'Time to response 1.9 months. PFS was 92%', 'to response 1.9 months. PFS was 92% and', 'response 1.9 months. PFS was 92% and OS', '1.9 months. PFS was 92% and OS 95%', 'months. PFS was 92% and OS 95% with', 'PFS was 92% and OS 95% with ~1', 'was 92% and OS 95% with ~1 year', '92% and OS 95% with ~1 year of', 'and OS 95% with ~1 year of follow-up.', 'OS 95% with ~1 year of follow-up. 2', '95% with ~1 year of follow-up. 2 Grade', 'with ~1 year of follow-up. 2 Grade 5', '~1 year of follow-up. 2 Grade 5 AEs', 'year of follow-up. 2 Grade 5 AEs due', 'of follow-up. 2 Grade 5 AEs due to', 'follow-up. 2 Grade 5 AEs due to ventricular', '2 Grade 5 AEs due to ventricular arrhythmias', 'Grade 5 AEs due to ventricular arrhythmias (known', '5 AEs due to ventricular arrhythmias (known problem', 'AEs due to ventricular arrhythmias (known problem with', 'due to ventricular arrhythmias (known problem with ibrutinib).', 'to ventricular arrhythmias (known problem with ibrutinib). Based', 'ventricular arrhythmias (known problem with ibrutinib). Based on', 'arrhythmias (known problem with ibrutinib). Based on ALPINE,', '(known problem with ibrutinib). Based on ALPINE, zanubrutinib', 'problem with ibrutinib). Based on ALPINE, zanubrutinib ', 'with ibrutinib). Based on ALPINE, zanubrutinib  ', 'ibrutinib). Based on ALPINE, zanubrutinib   ', 'Based on ALPINE, zanubrutinib    ', 'on ALPINE, zanubrutinib     instead?', 'ALPINE, zanubrutinib     instead? #ASH22', 'zanubrutinib     instead? #ASH22 #lymsm', '    instead? #ASH22 #lymsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '104', 'tokens': ['Particularly', 'impressive', 'results', 'for', 'zilovertamab+ibrutinib', 'in', 'chronic', 'lymphocytic', 'leukaemia', '(CLL),', 'especially', 'in', 'patients', 'with', 'TP53', 'mutations,', 'who', 'had', 'a', 'PFS', 'of', '100%', 'at', 'median', 'follow', 'up', 'of', '42', 'months', '', '#lymsm', '#ASH22', '.'], 'text_length': 33, 'triples': {'zilovertamab+ibrutinib|impressive results': ([4, 4], [1, 2], 'positive')}, 'sentence': 'Particularly impressive results for zilovertamab+ibrutinib in chronic lymphocytic leukaemia (CLL), especially in patients with TP53 mutations, who had a PFS of 100% at median follow up of 42 months  #lymsm #ASH22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['Particularly', 'impressive', 'results', 'for', 'zilovertamab+ibrutinib', 'in', 'chronic', 'lymphocytic', 'leukaemia', '(CLL),', 'especially', 'in', 'patients', 'with', 'TP53', 'mutations,', 'who', 'had', 'a', 'PFS', 'of', '100%', 'at', 'median', 'follow', 'up', 'of', '42', 'months', '', '#lymsm', '#ASH22', '.', 'Particularly impressive', 'impressive results', 'results for', 'for zilovertamab+ibrutinib', 'zilovertamab+ibrutinib in', 'in chronic', 'chronic lymphocytic', 'lymphocytic leukaemia', 'leukaemia (CLL),', '(CLL), especially', 'especially in', 'in patients', 'patients with', 'with TP53', 'TP53 mutations,', 'mutations, who', 'who had', 'had a', 'a PFS', 'PFS of', 'of 100%', '100% at', 'at median', 'median follow', 'follow up', 'up of', 'of 42', '42 months', 'months ', ' #lymsm', '#lymsm #ASH22', '#ASH22 .', 'Particularly impressive results', 'impressive results for', 'results for zilovertamab+ibrutinib', 'for zilovertamab+ibrutinib in', 'zilovertamab+ibrutinib in chronic', 'in chronic lymphocytic', 'chronic lymphocytic leukaemia', 'lymphocytic leukaemia (CLL),', 'leukaemia (CLL), especially', '(CLL), especially in', 'especially in patients', 'in patients with', 'patients with TP53', 'with TP53 mutations,', 'TP53 mutations, who', 'mutations, who had', 'who had a', 'had a PFS', 'a PFS of', 'PFS of 100%', 'of 100% at', '100% at median', 'at median follow', 'median follow up', 'follow up of', 'up of 42', 'of 42 months', '42 months ', 'months  #lymsm', ' #lymsm #ASH22', '#lymsm #ASH22 .', 'Particularly impressive results for', 'impressive results for zilovertamab+ibrutinib', 'results for zilovertamab+ibrutinib in', 'for zilovertamab+ibrutinib in chronic', 'zilovertamab+ibrutinib in chronic lymphocytic', 'in chronic lymphocytic leukaemia', 'chronic lymphocytic leukaemia (CLL),', 'lymphocytic leukaemia (CLL), especially', 'leukaemia (CLL), especially in', '(CLL), especially in patients', 'especially in patients with', 'in patients with TP53', 'patients with TP53 mutations,', 'with TP53 mutations, who', 'TP53 mutations, who had', 'mutations, who had a', 'who had a PFS', 'had a PFS of', 'a PFS of 100%', 'PFS of 100% at', 'of 100% at median', '100% at median follow', 'at median follow up', 'median follow up of', 'follow up of 42', 'up of 42 months', 'of 42 months ', '42 months  #lymsm', 'months  #lymsm #ASH22', ' #lymsm #ASH22 .', 'Particularly impressive results for zilovertamab+ibrutinib', 'impressive results for zilovertamab+ibrutinib in', 'results for zilovertamab+ibrutinib in chronic', 'for zilovertamab+ibrutinib in chronic lymphocytic', 'zilovertamab+ibrutinib in chronic lymphocytic leukaemia', 'in chronic lymphocytic leukaemia (CLL),', 'chronic lymphocytic leukaemia (CLL), especially', 'lymphocytic leukaemia (CLL), especially in', 'leukaemia (CLL), especially in patients', '(CLL), especially in patients with', 'especially in patients with TP53', 'in patients with TP53 mutations,', 'patients with TP53 mutations, who', 'with TP53 mutations, who had', 'TP53 mutations, who had a', 'mutations, who had a PFS', 'who had a PFS of', 'had a PFS of 100%', 'a PFS of 100% at', 'PFS of 100% at median', 'of 100% at median follow', '100% at median follow up', 'at median follow up of', 'median follow up of 42', 'follow up of 42 months', 'up of 42 months ', 'of 42 months  #lymsm', '42 months  #lymsm #ASH22', 'months  #lymsm #ASH22 .', 'Particularly impressive results for zilovertamab+ibrutinib in', 'impressive results for zilovertamab+ibrutinib in chronic', 'results for zilovertamab+ibrutinib in chronic lymphocytic', 'for zilovertamab+ibrutinib in chronic lymphocytic leukaemia', 'zilovertamab+ibrutinib in chronic lymphocytic leukaemia (CLL),', 'in chronic lymphocytic leukaemia (CLL), especially', 'chronic lymphocytic leukaemia (CLL), especially in', 'lymphocytic leukaemia (CLL), especially in patients', 'leukaemia (CLL), especially in patients with', '(CLL), especially in patients with TP53', 'especially in patients with TP53 mutations,', 'in patients with TP53 mutations, who', 'patients with TP53 mutations, who had', 'with TP53 mutations, who had a', 'TP53 mutations, who had a PFS', 'mutations, who had a PFS of', 'who had a PFS of 100%', 'had a PFS of 100% at', 'a PFS of 100% at median', 'PFS of 100% at median follow', 'of 100% at median follow up', '100% at median follow up of', 'at median follow up of 42', 'median follow up of 42 months', 'follow up of 42 months ', 'up of 42 months  #lymsm', 'of 42 months  #lymsm #ASH22', '42 months  #lymsm #ASH22 .', 'Particularly impressive results for zilovertamab+ibrutinib in chronic', 'impressive results for zilovertamab+ibrutinib in chronic lymphocytic', 'results for zilovertamab+ibrutinib in chronic lymphocytic leukaemia', 'for zilovertamab+ibrutinib in chronic lymphocytic leukaemia (CLL),', 'zilovertamab+ibrutinib in chronic lymphocytic leukaemia (CLL), especially', 'in chronic lymphocytic leukaemia (CLL), especially in', 'chronic lymphocytic leukaemia (CLL), especially in patients', 'lymphocytic leukaemia (CLL), especially in patients with', 'leukaemia (CLL), especially in patients with TP53', '(CLL), especially in patients with TP53 mutations,', 'especially in patients with TP53 mutations, who', 'in patients with TP53 mutations, who had', 'patients with TP53 mutations, who had a', 'with TP53 mutations, who had a PFS', 'TP53 mutations, who had a PFS of', 'mutations, who had a PFS of 100%', 'who had a PFS of 100% at', 'had a PFS of 100% at median', 'a PFS of 100% at median follow', 'PFS of 100% at median follow up', 'of 100% at median follow up of', '100% at median follow up of 42', 'at median follow up of 42 months', 'median follow up of 42 months ', 'follow up of 42 months  #lymsm', 'up of 42 months  #lymsm #ASH22', 'of 42 months  #lymsm #ASH22 .', 'Particularly impressive results for zilovertamab+ibrutinib in chronic lymphocytic', 'impressive results for zilovertamab+ibrutinib in chronic lymphocytic leukaemia', 'results for zilovertamab+ibrutinib in chronic lymphocytic leukaemia (CLL),', 'for zilovertamab+ibrutinib in chronic lymphocytic leukaemia (CLL), especially', 'zilovertamab+ibrutinib in chronic lymphocytic leukaemia (CLL), especially in', 'in chronic lymphocytic leukaemia (CLL), especially in patients', 'chronic lymphocytic leukaemia (CLL), especially in patients with', 'lymphocytic leukaemia (CLL), especially in patients with TP53', 'leukaemia (CLL), especially in patients with TP53 mutations,', '(CLL), especially in patients with TP53 mutations, who', 'especially in patients with TP53 mutations, who had', 'in patients with TP53 mutations, who had a', 'patients with TP53 mutations, who had a PFS', 'with TP53 mutations, who had a PFS of', 'TP53 mutations, who had a PFS of 100%', 'mutations, who had a PFS of 100% at', 'who had a PFS of 100% at median', 'had a PFS of 100% at median follow', 'a PFS of 100% at median follow up', 'PFS of 100% at median follow up of', 'of 100% at median follow up of 42', '100% at median follow up of 42 months', 'at median follow up of 42 months ', 'median follow up of 42 months  #lymsm', 'follow up of 42 months  #lymsm #ASH22', 'up of 42 months  #lymsm #ASH22 .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '105', 'tokens': ['exciting', 'esmo', 'data,', 's1801', ':', 'improved', 'event', 'free', 'survival', 'for', 'stage', 'iii', 'melanoma', 'patients', 'receiving', 'pembro', 'prior', 'to/after', 'surgery', 'compared', 'to', 'adjuvant', 'alone.', 'is', 'proud', 'to', 'have', 'enrolled', 'patients/supported', 'this', 'practice', 'changing', 'trial!', '.'], 'text_length': 34, 'triples': {'s1801|exciting esmo data, s1801 : improved event free survival for stage iii melanoma patients receiving pembro prior to/after surgery compared to adjuvant alone. is proud to have enrolled patients/supported this practice': ([3, 3], [0, 30], 'positive')}, 'sentence': 'exciting esmo data, s1801 : improved event free survival for stage iii melanoma patients receiving pembro prior to/after surgery compared to adjuvant alone. is proud to have enrolled patients/supported this practice changing trial! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 30)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['exciting', 'esmo', 'data,', 's1801', ':', 'improved', 'event', 'free', 'survival', 'for', 'stage', 'iii', 'melanoma', 'patients', 'receiving', 'pembro', 'prior', 'to/after', 'surgery', 'compared', 'to', 'adjuvant', 'alone.', 'is', 'proud', 'to', 'have', 'enrolled', 'patients/supported', 'this', 'practice', 'changing', 'trial!', '.', 'exciting esmo', 'esmo data,', 'data, s1801', 's1801 :', ': improved', 'improved event', 'event free', 'free survival', 'survival for', 'for stage', 'stage iii', 'iii melanoma', 'melanoma patients', 'patients receiving', 'receiving pembro', 'pembro prior', 'prior to/after', 'to/after surgery', 'surgery compared', 'compared to', 'to adjuvant', 'adjuvant alone.', 'alone. is', 'is proud', 'proud to', 'to have', 'have enrolled', 'enrolled patients/supported', 'patients/supported this', 'this practice', 'practice changing', 'changing trial!', 'trial! .', 'exciting esmo data,', 'esmo data, s1801', 'data, s1801 :', 's1801 : improved', ': improved event', 'improved event free', 'event free survival', 'free survival for', 'survival for stage', 'for stage iii', 'stage iii melanoma', 'iii melanoma patients', 'melanoma patients receiving', 'patients receiving pembro', 'receiving pembro prior', 'pembro prior to/after', 'prior to/after surgery', 'to/after surgery compared', 'surgery compared to', 'compared to adjuvant', 'to adjuvant alone.', 'adjuvant alone. is', 'alone. is proud', 'is proud to', 'proud to have', 'to have enrolled', 'have enrolled patients/supported', 'enrolled patients/supported this', 'patients/supported this practice', 'this practice changing', 'practice changing trial!', 'changing trial! .', 'exciting esmo data, s1801', 'esmo data, s1801 :', 'data, s1801 : improved', 's1801 : improved event', ': improved event free', 'improved event free survival', 'event free survival for', 'free survival for stage', 'survival for stage iii', 'for stage iii melanoma', 'stage iii melanoma patients', 'iii melanoma patients receiving', 'melanoma patients receiving pembro', 'patients receiving pembro prior', 'receiving pembro prior to/after', 'pembro prior to/after surgery', 'prior to/after surgery compared', 'to/after surgery compared to', 'surgery compared to adjuvant', 'compared to adjuvant alone.', 'to adjuvant alone. is', 'adjuvant alone. is proud', 'alone. is proud to', 'is proud to have', 'proud to have enrolled', 'to have enrolled patients/supported', 'have enrolled patients/supported this', 'enrolled patients/supported this practice', 'patients/supported this practice changing', 'this practice changing trial!', 'practice changing trial! .', 'exciting esmo data, s1801 :', 'esmo data, s1801 : improved', 'data, s1801 : improved event', 's1801 : improved event free', ': improved event free survival', 'improved event free survival for', 'event free survival for stage', 'free survival for stage iii', 'survival for stage iii melanoma', 'for stage iii melanoma patients', 'stage iii melanoma patients receiving', 'iii melanoma patients receiving pembro', 'melanoma patients receiving pembro prior', 'patients receiving pembro prior to/after', 'receiving pembro prior to/after surgery', 'pembro prior to/after surgery compared', 'prior to/after surgery compared to', 'to/after surgery compared to adjuvant', 'surgery compared to adjuvant alone.', 'compared to adjuvant alone. is', 'to adjuvant alone. is proud', 'adjuvant alone. is proud to', 'alone. is proud to have', 'is proud to have enrolled', 'proud to have enrolled patients/supported', 'to have enrolled patients/supported this', 'have enrolled patients/supported this practice', 'enrolled patients/supported this practice changing', 'patients/supported this practice changing trial!', 'this practice changing trial! .', 'exciting esmo data, s1801 : improved', 'esmo data, s1801 : improved event', 'data, s1801 : improved event free', 's1801 : improved event free survival', ': improved event free survival for', 'improved event free survival for stage', 'event free survival for stage iii', 'free survival for stage iii melanoma', 'survival for stage iii melanoma patients', 'for stage iii melanoma patients receiving', 'stage iii melanoma patients receiving pembro', 'iii melanoma patients receiving pembro prior', 'melanoma patients receiving pembro prior to/after', 'patients receiving pembro prior to/after surgery', 'receiving pembro prior to/after surgery compared', 'pembro prior to/after surgery compared to', 'prior to/after surgery compared to adjuvant', 'to/after surgery compared to adjuvant alone.', 'surgery compared to adjuvant alone. is', 'compared to adjuvant alone. is proud', 'to adjuvant alone. is proud to', 'adjuvant alone. is proud to have', 'alone. is proud to have enrolled', 'is proud to have enrolled patients/supported', 'proud to have enrolled patients/supported this', 'to have enrolled patients/supported this practice', 'have enrolled patients/supported this practice changing', 'enrolled patients/supported this practice changing trial!', 'patients/supported this practice changing trial! .', 'exciting esmo data, s1801 : improved event', 'esmo data, s1801 : improved event free', 'data, s1801 : improved event free survival', 's1801 : improved event free survival for', ': improved event free survival for stage', 'improved event free survival for stage iii', 'event free survival for stage iii melanoma', 'free survival for stage iii melanoma patients', 'survival for stage iii melanoma patients receiving', 'for stage iii melanoma patients receiving pembro', 'stage iii melanoma patients receiving pembro prior', 'iii melanoma patients receiving pembro prior to/after', 'melanoma patients receiving pembro prior to/after surgery', 'patients receiving pembro prior to/after surgery compared', 'receiving pembro prior to/after surgery compared to', 'pembro prior to/after surgery compared to adjuvant', 'prior to/after surgery compared to adjuvant alone.', 'to/after surgery compared to adjuvant alone. is', 'surgery compared to adjuvant alone. is proud', 'compared to adjuvant alone. is proud to', 'to adjuvant alone. is proud to have', 'adjuvant alone. is proud to have enrolled', 'alone. is proud to have enrolled patients/supported', 'is proud to have enrolled patients/supported this', 'proud to have enrolled patients/supported this practice', 'to have enrolled patients/supported this practice changing', 'have enrolled patients/supported this practice changing trial!', 'enrolled patients/supported this practice changing trial! .', 'exciting esmo data, s1801 : improved event free', 'esmo data, s1801 : improved event free survival', 'data, s1801 : improved event free survival for', 's1801 : improved event free survival for stage', ': improved event free survival for stage iii', 'improved event free survival for stage iii melanoma', 'event free survival for stage iii melanoma patients', 'free survival for stage iii melanoma patients receiving', 'survival for stage iii melanoma patients receiving pembro', 'for stage iii melanoma patients receiving pembro prior', 'stage iii melanoma patients receiving pembro prior to/after', 'iii melanoma patients receiving pembro prior to/after surgery', 'melanoma patients receiving pembro prior to/after surgery compared', 'patients receiving pembro prior to/after surgery compared to', 'receiving pembro prior to/after surgery compared to adjuvant', 'pembro prior to/after surgery compared to adjuvant alone.', 'prior to/after surgery compared to adjuvant alone. is', 'to/after surgery compared to adjuvant alone. is proud', 'surgery compared to adjuvant alone. is proud to', 'compared to adjuvant alone. is proud to have', 'to adjuvant alone. is proud to have enrolled', 'adjuvant alone. is proud to have enrolled patients/supported', 'alone. is proud to have enrolled patients/supported this', 'is proud to have enrolled patients/supported this practice', 'proud to have enrolled patients/supported this practice changing', 'to have enrolled patients/supported this practice changing trial!', 'have enrolled patients/supported this practice changing trial! .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '106', 'tokens': ['do', 'we', 'need', 'fdg', 'pet!', 'note', 'that', '51/291', 'pts', '(17%)', 'excluded', 'from', 'therap', 'based', 'on', 'fdg/psma', 'discordant', 'disease,', 'supports', 'use', 'of', 'both', 'imaging', 'modalities.', 'this', 'is', 'soc', 'in', 'to', 'choose', 'pts.', 'vision', 'did', 'not', 'require', 'fdg', 'pet', 'so', 'seems', 'less', 'likely', 'in', 'to', 'be', 'used', '#asco2022', '.'], 'text_length': 47, 'triples': {'vision|not require': ([31, 31], [33, 34], 'neutral')}, 'sentence': 'do we need fdg pet! note that 51/291 pts (17%) excluded from therap based on fdg/psma discordant disease, supports use of both imaging modalities. this is soc in to choose pts. vision did not require fdg pet so seems less likely in to be used #asco2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(31, 31)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(33, 34)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8)], 'span tokens': ['do', 'we', 'need', 'fdg', 'pet!', 'note', 'that', '51/291', 'pts', '(17%)', 'excluded', 'from', 'therap', 'based', 'on', 'fdg/psma', 'discordant', 'disease,', 'supports', 'use', 'of', 'both', 'imaging', 'modalities.', 'this', 'is', 'soc', 'in', 'to', 'choose', 'pts.', 'vision', 'did', 'not', 'require', 'fdg', 'pet', 'so', 'seems', 'less', 'likely', 'in', 'to', 'be', 'used', '#asco2022', '.', 'do we', 'we need', 'need fdg', 'fdg pet!', 'pet! note', 'note that', 'that 51/291', '51/291 pts', 'pts (17%)', '(17%) excluded', 'excluded from', 'from therap', 'therap based', 'based on', 'on fdg/psma', 'fdg/psma discordant', 'discordant disease,', 'disease, supports', 'supports use', 'use of', 'of both', 'both imaging', 'imaging modalities.', 'modalities. this', 'this is', 'is soc', 'soc in', 'in to', 'to choose', 'choose pts.', 'pts. vision', 'vision did', 'did not', 'not require', 'require fdg', 'fdg pet', 'pet so', 'so seems', 'seems less', 'less likely', 'likely in', 'in to', 'to be', 'be used', 'used #asco2022', '#asco2022 .', 'do we need', 'we need fdg', 'need fdg pet!', 'fdg pet! note', 'pet! note that', 'note that 51/291', 'that 51/291 pts', '51/291 pts (17%)', 'pts (17%) excluded', '(17%) excluded from', 'excluded from therap', 'from therap based', 'therap based on', 'based on fdg/psma', 'on fdg/psma discordant', 'fdg/psma discordant disease,', 'discordant disease, supports', 'disease, supports use', 'supports use of', 'use of both', 'of both imaging', 'both imaging modalities.', 'imaging modalities. this', 'modalities. this is', 'this is soc', 'is soc in', 'soc in to', 'in to choose', 'to choose pts.', 'choose pts. vision', 'pts. vision did', 'vision did not', 'did not require', 'not require fdg', 'require fdg pet', 'fdg pet so', 'pet so seems', 'so seems less', 'seems less likely', 'less likely in', 'likely in to', 'in to be', 'to be used', 'be used #asco2022', 'used #asco2022 .', 'do we need fdg', 'we need fdg pet!', 'need fdg pet! note', 'fdg pet! note that', 'pet! note that 51/291', 'note that 51/291 pts', 'that 51/291 pts (17%)', '51/291 pts (17%) excluded', 'pts (17%) excluded from', '(17%) excluded from therap', 'excluded from therap based', 'from therap based on', 'therap based on fdg/psma', 'based on fdg/psma discordant', 'on fdg/psma discordant disease,', 'fdg/psma discordant disease, supports', 'discordant disease, supports use', 'disease, supports use of', 'supports use of both', 'use of both imaging', 'of both imaging modalities.', 'both imaging modalities. this', 'imaging modalities. this is', 'modalities. this is soc', 'this is soc in', 'is soc in to', 'soc in to choose', 'in to choose pts.', 'to choose pts. vision', 'choose pts. vision did', 'pts. vision did not', 'vision did not require', 'did not require fdg', 'not require fdg pet', 'require fdg pet so', 'fdg pet so seems', 'pet so seems less', 'so seems less likely', 'seems less likely in', 'less likely in to', 'likely in to be', 'in to be used', 'to be used #asco2022', 'be used #asco2022 .', 'do we need fdg pet!', 'we need fdg pet! note', 'need fdg pet! note that', 'fdg pet! note that 51/291', 'pet! note that 51/291 pts', 'note that 51/291 pts (17%)', 'that 51/291 pts (17%) excluded', '51/291 pts (17%) excluded from', 'pts (17%) excluded from therap', '(17%) excluded from therap based', 'excluded from therap based on', 'from therap based on fdg/psma', 'therap based on fdg/psma discordant', 'based on fdg/psma discordant disease,', 'on fdg/psma discordant disease, supports', 'fdg/psma discordant disease, supports use', 'discordant disease, supports use of', 'disease, supports use of both', 'supports use of both imaging', 'use of both imaging modalities.', 'of both imaging modalities. this', 'both imaging modalities. this is', 'imaging modalities. this is soc', 'modalities. this is soc in', 'this is soc in to', 'is soc in to choose', 'soc in to choose pts.', 'in to choose pts. vision', 'to choose pts. vision did', 'choose pts. vision did not', 'pts. vision did not require', 'vision did not require fdg', 'did not require fdg pet', 'not require fdg pet so', 'require fdg pet so seems', 'fdg pet so seems less', 'pet so seems less likely', 'so seems less likely in', 'seems less likely in to', 'less likely in to be', 'likely in to be used', 'in to be used #asco2022', 'to be used #asco2022 .', 'do we need fdg pet! note', 'we need fdg pet! note that', 'need fdg pet! note that 51/291', 'fdg pet! note that 51/291 pts', 'pet! note that 51/291 pts (17%)', 'note that 51/291 pts (17%) excluded', 'that 51/291 pts (17%) excluded from', '51/291 pts (17%) excluded from therap', 'pts (17%) excluded from therap based', '(17%) excluded from therap based on', 'excluded from therap based on fdg/psma', 'from therap based on fdg/psma discordant', 'therap based on fdg/psma discordant disease,', 'based on fdg/psma discordant disease, supports', 'on fdg/psma discordant disease, supports use', 'fdg/psma discordant disease, supports use of', 'discordant disease, supports use of both', 'disease, supports use of both imaging', 'supports use of both imaging modalities.', 'use of both imaging modalities. this', 'of both imaging modalities. this is', 'both imaging modalities. this is soc', 'imaging modalities. this is soc in', 'modalities. this is soc in to', 'this is soc in to choose', 'is soc in to choose pts.', 'soc in to choose pts. vision', 'in to choose pts. vision did', 'to choose pts. vision did not', 'choose pts. vision did not require', 'pts. vision did not require fdg', 'vision did not require fdg pet', 'did not require fdg pet so', 'not require fdg pet so seems', 'require fdg pet so seems less', 'fdg pet so seems less likely', 'pet so seems less likely in', 'so seems less likely in to', 'seems less likely in to be', 'less likely in to be used', 'likely in to be used #asco2022', 'in to be used #asco2022 .', 'do we need fdg pet! note that', 'we need fdg pet! note that 51/291', 'need fdg pet! note that 51/291 pts', 'fdg pet! note that 51/291 pts (17%)', 'pet! note that 51/291 pts (17%) excluded', 'note that 51/291 pts (17%) excluded from', 'that 51/291 pts (17%) excluded from therap', '51/291 pts (17%) excluded from therap based', 'pts (17%) excluded from therap based on', '(17%) excluded from therap based on fdg/psma', 'excluded from therap based on fdg/psma discordant', 'from therap based on fdg/psma discordant disease,', 'therap based on fdg/psma discordant disease, supports', 'based on fdg/psma discordant disease, supports use', 'on fdg/psma discordant disease, supports use of', 'fdg/psma discordant disease, supports use of both', 'discordant disease, supports use of both imaging', 'disease, supports use of both imaging modalities.', 'supports use of both imaging modalities. this', 'use of both imaging modalities. this is', 'of both imaging modalities. this is soc', 'both imaging modalities. this is soc in', 'imaging modalities. this is soc in to', 'modalities. this is soc in to choose', 'this is soc in to choose pts.', 'is soc in to choose pts. vision', 'soc in to choose pts. vision did', 'in to choose pts. vision did not', 'to choose pts. vision did not require', 'choose pts. vision did not require fdg', 'pts. vision did not require fdg pet', 'vision did not require fdg pet so', 'did not require fdg pet so seems', 'not require fdg pet so seems less', 'require fdg pet so seems less likely', 'fdg pet so seems less likely in', 'pet so seems less likely in to', 'so seems less likely in to be', 'seems less likely in to be used', 'less likely in to be used #asco2022', 'likely in to be used #asco2022 .', 'do we need fdg pet! note that 51/291', 'we need fdg pet! note that 51/291 pts', 'need fdg pet! note that 51/291 pts (17%)', 'fdg pet! note that 51/291 pts (17%) excluded', 'pet! note that 51/291 pts (17%) excluded from', 'note that 51/291 pts (17%) excluded from therap', 'that 51/291 pts (17%) excluded from therap based', '51/291 pts (17%) excluded from therap based on', 'pts (17%) excluded from therap based on fdg/psma', '(17%) excluded from therap based on fdg/psma discordant', 'excluded from therap based on fdg/psma discordant disease,', 'from therap based on fdg/psma discordant disease, supports', 'therap based on fdg/psma discordant disease, supports use', 'based on fdg/psma discordant disease, supports use of', 'on fdg/psma discordant disease, supports use of both', 'fdg/psma discordant disease, supports use of both imaging', 'discordant disease, supports use of both imaging modalities.', 'disease, supports use of both imaging modalities. this', 'supports use of both imaging modalities. this is', 'use of both imaging modalities. this is soc', 'of both imaging modalities. this is soc in', 'both imaging modalities. this is soc in to', 'imaging modalities. this is soc in to choose', 'modalities. this is soc in to choose pts.', 'this is soc in to choose pts. vision', 'is soc in to choose pts. vision did', 'soc in to choose pts. vision did not', 'in to choose pts. vision did not require', 'to choose pts. vision did not require fdg', 'choose pts. vision did not require fdg pet', 'pts. vision did not require fdg pet so', 'vision did not require fdg pet so seems', 'did not require fdg pet so seems less', 'not require fdg pet so seems less likely', 'require fdg pet so seems less likely in', 'fdg pet so seems less likely in to', 'pet so seems less likely in to be', 'so seems less likely in to be used', 'seems less likely in to be used #asco2022', 'less likely in to be used #asco2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '108', 'tokens': ['5', 'presentation', 'including', '2', 'orals', 'at', '#ash22', 'on', 'ide-cel', '#mmsm', '#cartsm', '.'], 'text_length': 12, 'triples': {'ide-cel|presentation': ([8, 8], [1, 1], 'neutral')}, 'sentence': '5 presentation including 2 orals at #ash22 on ide-cel #mmsm #cartsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 0, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8)], 'span tokens': ['5', 'presentation', 'including', '2', 'orals', 'at', '#ash22', 'on', 'ide-cel', '#mmsm', '#cartsm', '.', '5 presentation', 'presentation including', 'including 2', '2 orals', 'orals at', 'at #ash22', '#ash22 on', 'on ide-cel', 'ide-cel #mmsm', '#mmsm #cartsm', '#cartsm .', '5 presentation including', 'presentation including 2', 'including 2 orals', '2 orals at', 'orals at #ash22', 'at #ash22 on', '#ash22 on ide-cel', 'on ide-cel #mmsm', 'ide-cel #mmsm #cartsm', '#mmsm #cartsm .', '5 presentation including 2', 'presentation including 2 orals', 'including 2 orals at', '2 orals at #ash22', 'orals at #ash22 on', 'at #ash22 on ide-cel', '#ash22 on ide-cel #mmsm', 'on ide-cel #mmsm #cartsm', 'ide-cel #mmsm #cartsm .', '5 presentation including 2 orals', 'presentation including 2 orals at', 'including 2 orals at #ash22', '2 orals at #ash22 on', 'orals at #ash22 on ide-cel', 'at #ash22 on ide-cel #mmsm', '#ash22 on ide-cel #mmsm #cartsm', 'on ide-cel #mmsm #cartsm .', '5 presentation including 2 orals at', 'presentation including 2 orals at #ash22', 'including 2 orals at #ash22 on', '2 orals at #ash22 on ide-cel', 'orals at #ash22 on ide-cel #mmsm', 'at #ash22 on ide-cel #mmsm #cartsm', '#ash22 on ide-cel #mmsm #cartsm .', '5 presentation including 2 orals at #ash22', 'presentation including 2 orals at #ash22 on', 'including 2 orals at #ash22 on ide-cel', '2 orals at #ash22 on ide-cel #mmsm', 'orals at #ash22 on ide-cel #mmsm #cartsm', 'at #ash22 on ide-cel #mmsm #cartsm .', '5 presentation including 2 orals at #ash22 on', 'presentation including 2 orals at #ash22 on ide-cel', 'including 2 orals at #ash22 on ide-cel #mmsm', '2 orals at #ash22 on ide-cel #mmsm #cartsm', 'orals at #ash22 on ide-cel #mmsm #cartsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '109', 'tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial,', 'authors', 'noted', 'no', 'os', 'benefit', 'in', 'adt+/-', 'aap', '+', 'enz', 'arm', '(hr', '0.65)', 'compared', 'to', 'in', 'adt+/-', 'aap', 'arm', '(hr', '0.62)', 'in', 'patients', 'with', 'metastatic', 'hormone-sensitive', '#prostate', 'cancer.', '.'], 'text_length': 36, 'triples': {'stampede|no os benefit': ([5, 5], [9, 11], 'negative')}, 'sentence': '#esmo22 abs# lba62: in the stampede trial, authors noted no os benefit in adt+/- aap + enz arm (hr 0.65) compared to in adt+/- aap arm (hr 0.62) in patients with metastatic hormone-sensitive #prostate cancer. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial,', 'authors', 'noted', 'no', 'os', 'benefit', 'in', 'adt+/-', 'aap', '+', 'enz', 'arm', '(hr', '0.65)', 'compared', 'to', 'in', 'adt+/-', 'aap', 'arm', '(hr', '0.62)', 'in', 'patients', 'with', 'metastatic', 'hormone-sensitive', '#prostate', 'cancer.', '.', '#esmo22 abs#', 'abs# lba62:', 'lba62: in', 'in the', 'the stampede', 'stampede trial,', 'trial, authors', 'authors noted', 'noted no', 'no os', 'os benefit', 'benefit in', 'in adt+/-', 'adt+/- aap', 'aap +', '+ enz', 'enz arm', 'arm (hr', '(hr 0.65)', '0.65) compared', 'compared to', 'to in', 'in adt+/-', 'adt+/- aap', 'aap arm', 'arm (hr', '(hr 0.62)', '0.62) in', 'in patients', 'patients with', 'with metastatic', 'metastatic hormone-sensitive', 'hormone-sensitive #prostate', '#prostate cancer.', 'cancer. .', '#esmo22 abs# lba62:', 'abs# lba62: in', 'lba62: in the', 'in the stampede', 'the stampede trial,', 'stampede trial, authors', 'trial, authors noted', 'authors noted no', 'noted no os', 'no os benefit', 'os benefit in', 'benefit in adt+/-', 'in adt+/- aap', 'adt+/- aap +', 'aap + enz', '+ enz arm', 'enz arm (hr', 'arm (hr 0.65)', '(hr 0.65) compared', '0.65) compared to', 'compared to in', 'to in adt+/-', 'in adt+/- aap', 'adt+/- aap arm', 'aap arm (hr', 'arm (hr 0.62)', '(hr 0.62) in', '0.62) in patients', 'in patients with', 'patients with metastatic', 'with metastatic hormone-sensitive', 'metastatic hormone-sensitive #prostate', 'hormone-sensitive #prostate cancer.', '#prostate cancer. .', '#esmo22 abs# lba62: in', 'abs# lba62: in the', 'lba62: in the stampede', 'in the stampede trial,', 'the stampede trial, authors', 'stampede trial, authors noted', 'trial, authors noted no', 'authors noted no os', 'noted no os benefit', 'no os benefit in', 'os benefit in adt+/-', 'benefit in adt+/- aap', 'in adt+/- aap +', 'adt+/- aap + enz', 'aap + enz arm', '+ enz arm (hr', 'enz arm (hr 0.65)', 'arm (hr 0.65) compared', '(hr 0.65) compared to', '0.65) compared to in', 'compared to in adt+/-', 'to in adt+/- aap', 'in adt+/- aap arm', 'adt+/- aap arm (hr', 'aap arm (hr 0.62)', 'arm (hr 0.62) in', '(hr 0.62) in patients', '0.62) in patients with', 'in patients with metastatic', 'patients with metastatic hormone-sensitive', 'with metastatic hormone-sensitive #prostate', 'metastatic hormone-sensitive #prostate cancer.', 'hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the', 'abs# lba62: in the stampede', 'lba62: in the stampede trial,', 'in the stampede trial, authors', 'the stampede trial, authors noted', 'stampede trial, authors noted no', 'trial, authors noted no os', 'authors noted no os benefit', 'noted no os benefit in', 'no os benefit in adt+/-', 'os benefit in adt+/- aap', 'benefit in adt+/- aap +', 'in adt+/- aap + enz', 'adt+/- aap + enz arm', 'aap + enz arm (hr', '+ enz arm (hr 0.65)', 'enz arm (hr 0.65) compared', 'arm (hr 0.65) compared to', '(hr 0.65) compared to in', '0.65) compared to in adt+/-', 'compared to in adt+/- aap', 'to in adt+/- aap arm', 'in adt+/- aap arm (hr', 'adt+/- aap arm (hr 0.62)', 'aap arm (hr 0.62) in', 'arm (hr 0.62) in patients', '(hr 0.62) in patients with', '0.62) in patients with metastatic', 'in patients with metastatic hormone-sensitive', 'patients with metastatic hormone-sensitive #prostate', 'with metastatic hormone-sensitive #prostate cancer.', 'metastatic hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the stampede', 'abs# lba62: in the stampede trial,', 'lba62: in the stampede trial, authors', 'in the stampede trial, authors noted', 'the stampede trial, authors noted no', 'stampede trial, authors noted no os', 'trial, authors noted no os benefit', 'authors noted no os benefit in', 'noted no os benefit in adt+/-', 'no os benefit in adt+/- aap', 'os benefit in adt+/- aap +', 'benefit in adt+/- aap + enz', 'in adt+/- aap + enz arm', 'adt+/- aap + enz arm (hr', 'aap + enz arm (hr 0.65)', '+ enz arm (hr 0.65) compared', 'enz arm (hr 0.65) compared to', 'arm (hr 0.65) compared to in', '(hr 0.65) compared to in adt+/-', '0.65) compared to in adt+/- aap', 'compared to in adt+/- aap arm', 'to in adt+/- aap arm (hr', 'in adt+/- aap arm (hr 0.62)', 'adt+/- aap arm (hr 0.62) in', 'aap arm (hr 0.62) in patients', 'arm (hr 0.62) in patients with', '(hr 0.62) in patients with metastatic', '0.62) in patients with metastatic hormone-sensitive', 'in patients with metastatic hormone-sensitive #prostate', 'patients with metastatic hormone-sensitive #prostate cancer.', 'with metastatic hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the stampede trial,', 'abs# lba62: in the stampede trial, authors', 'lba62: in the stampede trial, authors noted', 'in the stampede trial, authors noted no', 'the stampede trial, authors noted no os', 'stampede trial, authors noted no os benefit', 'trial, authors noted no os benefit in', 'authors noted no os benefit in adt+/-', 'noted no os benefit in adt+/- aap', 'no os benefit in adt+/- aap +', 'os benefit in adt+/- aap + enz', 'benefit in adt+/- aap + enz arm', 'in adt+/- aap + enz arm (hr', 'adt+/- aap + enz arm (hr 0.65)', 'aap + enz arm (hr 0.65) compared', '+ enz arm (hr 0.65) compared to', 'enz arm (hr 0.65) compared to in', 'arm (hr 0.65) compared to in adt+/-', '(hr 0.65) compared to in adt+/- aap', '0.65) compared to in adt+/- aap arm', 'compared to in adt+/- aap arm (hr', 'to in adt+/- aap arm (hr 0.62)', 'in adt+/- aap arm (hr 0.62) in', 'adt+/- aap arm (hr 0.62) in patients', 'aap arm (hr 0.62) in patients with', 'arm (hr 0.62) in patients with metastatic', '(hr 0.62) in patients with metastatic hormone-sensitive', '0.62) in patients with metastatic hormone-sensitive #prostate', 'in patients with metastatic hormone-sensitive #prostate cancer.', 'patients with metastatic hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the stampede trial, authors', 'abs# lba62: in the stampede trial, authors noted', 'lba62: in the stampede trial, authors noted no', 'in the stampede trial, authors noted no os', 'the stampede trial, authors noted no os benefit', 'stampede trial, authors noted no os benefit in', 'trial, authors noted no os benefit in adt+/-', 'authors noted no os benefit in adt+/- aap', 'noted no os benefit in adt+/- aap +', 'no os benefit in adt+/- aap + enz', 'os benefit in adt+/- aap + enz arm', 'benefit in adt+/- aap + enz arm (hr', 'in adt+/- aap + enz arm (hr 0.65)', 'adt+/- aap + enz arm (hr 0.65) compared', 'aap + enz arm (hr 0.65) compared to', '+ enz arm (hr 0.65) compared to in', 'enz arm (hr 0.65) compared to in adt+/-', 'arm (hr 0.65) compared to in adt+/- aap', '(hr 0.65) compared to in adt+/- aap arm', '0.65) compared to in adt+/- aap arm (hr', 'compared to in adt+/- aap arm (hr 0.62)', 'to in adt+/- aap arm (hr 0.62) in', 'in adt+/- aap arm (hr 0.62) in patients', 'adt+/- aap arm (hr 0.62) in patients with', 'aap arm (hr 0.62) in patients with metastatic', 'arm (hr 0.62) in patients with metastatic hormone-sensitive', '(hr 0.62) in patients with metastatic hormone-sensitive #prostate', '0.62) in patients with metastatic hormone-sensitive #prostate cancer.', 'in patients with metastatic hormone-sensitive #prostate cancer. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '110', 'tokens': ['"""it\'s', 'not', 'just', 'what', 'you', 'give,', "it's", 'when', 'you', 'give', 'it""', '--', 'quotable', 'wisdom', 'from', 'on', 's1801', 'results', 'she', 'presented', 'at', '#esmo22,', 'here', 'covered', 'by', '.', '#melsm', 'not', 'just', 'what,', 'but', 'when:', 'neoadjuvant', 'pembrolizumab', 'in', 'melanoma', '.'], 'text_length': 37, 'triples': {'s1801|presented': ([16, 16], [19, 19], 'neutral'), 'neoadjuvant|presented': ([32, 32], [19, 19], 'neutral')}, 'sentence': '"""it\'s not just what you give, it\'s when you give it"" -- quotable wisdom from on s1801 results she presented at #esmo22, here covered by . #melsm not just what, but when: neoadjuvant pembrolizumab in melanoma .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(16, 16), (32, 32)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(19, 19)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 1, 0, 0],
       [0, 0, 1, ..., 1, 1, 0],
       ...,
       [0, 1, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8)], 'span tokens': ['"""it\'s', 'not', 'just', 'what', 'you', 'give,', "it's", 'when', 'you', 'give', 'it""', '--', 'quotable', 'wisdom', 'from', 'on', 's1801', 'results', 'she', 'presented', 'at', '#esmo22,', 'here', 'covered', 'by', '.', '#melsm', 'not', 'just', 'what,', 'but', 'when:', 'neoadjuvant', 'pembrolizumab', 'in', 'melanoma', '.', '"""it\'s not', 'not just', 'just what', 'what you', 'you give,', "give, it's", "it's when", 'when you', 'you give', 'give it""', 'it"" --', '-- quotable', 'quotable wisdom', 'wisdom from', 'from on', 'on s1801', 's1801 results', 'results she', 'she presented', 'presented at', 'at #esmo22,', '#esmo22, here', 'here covered', 'covered by', 'by .', '. #melsm', '#melsm not', 'not just', 'just what,', 'what, but', 'but when:', 'when: neoadjuvant', 'neoadjuvant pembrolizumab', 'pembrolizumab in', 'in melanoma', 'melanoma .', '"""it\'s not just', 'not just what', 'just what you', 'what you give,', "you give, it's", "give, it's when", "it's when you", 'when you give', 'you give it""', 'give it"" --', 'it"" -- quotable', '-- quotable wisdom', 'quotable wisdom from', 'wisdom from on', 'from on s1801', 'on s1801 results', 's1801 results she', 'results she presented', 'she presented at', 'presented at #esmo22,', 'at #esmo22, here', '#esmo22, here covered', 'here covered by', 'covered by .', 'by . #melsm', '. #melsm not', '#melsm not just', 'not just what,', 'just what, but', 'what, but when:', 'but when: neoadjuvant', 'when: neoadjuvant pembrolizumab', 'neoadjuvant pembrolizumab in', 'pembrolizumab in melanoma', 'in melanoma .', '"""it\'s not just what', 'not just what you', 'just what you give,', "what you give, it's", "you give, it's when", "give, it's when you", "it's when you give", 'when you give it""', 'you give it"" --', 'give it"" -- quotable', 'it"" -- quotable wisdom', '-- quotable wisdom from', 'quotable wisdom from on', 'wisdom from on s1801', 'from on s1801 results', 'on s1801 results she', 's1801 results she presented', 'results she presented at', 'she presented at #esmo22,', 'presented at #esmo22, here', 'at #esmo22, here covered', '#esmo22, here covered by', 'here covered by .', 'covered by . #melsm', 'by . #melsm not', '. #melsm not just', '#melsm not just what,', 'not just what, but', 'just what, but when:', 'what, but when: neoadjuvant', 'but when: neoadjuvant pembrolizumab', 'when: neoadjuvant pembrolizumab in', 'neoadjuvant pembrolizumab in melanoma', 'pembrolizumab in melanoma .', '"""it\'s not just what you', 'not just what you give,', "just what you give, it's", "what you give, it's when", "you give, it's when you", "give, it's when you give", 'it\'s when you give it""', 'when you give it"" --', 'you give it"" -- quotable', 'give it"" -- quotable wisdom', 'it"" -- quotable wisdom from', '-- quotable wisdom from on', 'quotable wisdom from on s1801', 'wisdom from on s1801 results', 'from on s1801 results she', 'on s1801 results she presented', 's1801 results she presented at', 'results she presented at #esmo22,', 'she presented at #esmo22, here', 'presented at #esmo22, here covered', 'at #esmo22, here covered by', '#esmo22, here covered by .', 'here covered by . #melsm', 'covered by . #melsm not', 'by . #melsm not just', '. #melsm not just what,', '#melsm not just what, but', 'not just what, but when:', 'just what, but when: neoadjuvant', 'what, but when: neoadjuvant pembrolizumab', 'but when: neoadjuvant pembrolizumab in', 'when: neoadjuvant pembrolizumab in melanoma', 'neoadjuvant pembrolizumab in melanoma .', '"""it\'s not just what you give,', "not just what you give, it's", "just what you give, it's when", "what you give, it's when you", "you give, it's when you give", 'give, it\'s when you give it""', 'it\'s when you give it"" --', 'when you give it"" -- quotable', 'you give it"" -- quotable wisdom', 'give it"" -- quotable wisdom from', 'it"" -- quotable wisdom from on', '-- quotable wisdom from on s1801', 'quotable wisdom from on s1801 results', 'wisdom from on s1801 results she', 'from on s1801 results she presented', 'on s1801 results she presented at', 's1801 results she presented at #esmo22,', 'results she presented at #esmo22, here', 'she presented at #esmo22, here covered', 'presented at #esmo22, here covered by', 'at #esmo22, here covered by .', '#esmo22, here covered by . #melsm', 'here covered by . #melsm not', 'covered by . #melsm not just', 'by . #melsm not just what,', '. #melsm not just what, but', '#melsm not just what, but when:', 'not just what, but when: neoadjuvant', 'just what, but when: neoadjuvant pembrolizumab', 'what, but when: neoadjuvant pembrolizumab in', 'but when: neoadjuvant pembrolizumab in melanoma', 'when: neoadjuvant pembrolizumab in melanoma .', '"""it\'s not just what you give, it\'s', "not just what you give, it's when", "just what you give, it's when you", "what you give, it's when you give", 'you give, it\'s when you give it""', 'give, it\'s when you give it"" --', 'it\'s when you give it"" -- quotable', 'when you give it"" -- quotable wisdom', 'you give it"" -- quotable wisdom from', 'give it"" -- quotable wisdom from on', 'it"" -- quotable wisdom from on s1801', '-- quotable wisdom from on s1801 results', 'quotable wisdom from on s1801 results she', 'wisdom from on s1801 results she presented', 'from on s1801 results she presented at', 'on s1801 results she presented at #esmo22,', 's1801 results she presented at #esmo22, here', 'results she presented at #esmo22, here covered', 'she presented at #esmo22, here covered by', 'presented at #esmo22, here covered by .', 'at #esmo22, here covered by . #melsm', '#esmo22, here covered by . #melsm not', 'here covered by . #melsm not just', 'covered by . #melsm not just what,', 'by . #melsm not just what, but', '. #melsm not just what, but when:', '#melsm not just what, but when: neoadjuvant', 'not just what, but when: neoadjuvant pembrolizumab', 'just what, but when: neoadjuvant pembrolizumab in', 'what, but when: neoadjuvant pembrolizumab in melanoma', 'but when: neoadjuvant pembrolizumab in melanoma .', '"""it\'s not just what you give, it\'s when', "not just what you give, it's when you", "just what you give, it's when you give", 'what you give, it\'s when you give it""', 'you give, it\'s when you give it"" --', 'give, it\'s when you give it"" -- quotable', 'it\'s when you give it"" -- quotable wisdom', 'when you give it"" -- quotable wisdom from', 'you give it"" -- quotable wisdom from on', 'give it"" -- quotable wisdom from on s1801', 'it"" -- quotable wisdom from on s1801 results', '-- quotable wisdom from on s1801 results she', 'quotable wisdom from on s1801 results she presented', 'wisdom from on s1801 results she presented at', 'from on s1801 results she presented at #esmo22,', 'on s1801 results she presented at #esmo22, here', 's1801 results she presented at #esmo22, here covered', 'results she presented at #esmo22, here covered by', 'she presented at #esmo22, here covered by .', 'presented at #esmo22, here covered by . #melsm', 'at #esmo22, here covered by . #melsm not', '#esmo22, here covered by . #melsm not just', 'here covered by . #melsm not just what,', 'covered by . #melsm not just what, but', 'by . #melsm not just what, but when:', '. #melsm not just what, but when: neoadjuvant', '#melsm not just what, but when: neoadjuvant pembrolizumab', 'not just what, but when: neoadjuvant pembrolizumab in', 'just what, but when: neoadjuvant pembrolizumab in melanoma', 'what, but when: neoadjuvant pembrolizumab in melanoma .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '111', 'tokens': ['Here', 'for', 'the', '', '#ASH22', 'late-breaking', 'abstracts!', 'Looking', 'forward', 'to', 'the', 'zanubrutinib', '', '', '', '', 'results.', '#lymsm', '.'], 'text_length': 19, 'triples': {'zanubrutinib|Looking forward': ([10, 10], [6, 7], 'neutral')}, 'sentence': 'Here for the  #ASH22 late-breaking abstracts! Looking forward to the zanubrutinib     results. #lymsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['Here', 'for', 'the', '', '#ASH22', 'late-breaking', 'abstracts!', 'Looking', 'forward', 'to', 'the', 'zanubrutinib', '', '', '', '', 'results.', '#lymsm', '.', 'Here for', 'for the', 'the ', ' #ASH22', '#ASH22 late-breaking', 'late-breaking abstracts!', 'abstracts! Looking', 'Looking forward', 'forward to', 'to the', 'the zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' results.', 'results. #lymsm', '#lymsm .', 'Here for the', 'for the ', 'the  #ASH22', ' #ASH22 late-breaking', '#ASH22 late-breaking abstracts!', 'late-breaking abstracts! Looking', 'abstracts! Looking forward', 'Looking forward to', 'forward to the', 'to the zanubrutinib', 'the zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  results.', ' results. #lymsm', 'results. #lymsm .', 'Here for the ', 'for the  #ASH22', 'the  #ASH22 late-breaking', ' #ASH22 late-breaking abstracts!', '#ASH22 late-breaking abstracts! Looking', 'late-breaking abstracts! Looking forward', 'abstracts! Looking forward to', 'Looking forward to the', 'forward to the zanubrutinib', 'to the zanubrutinib ', 'the zanubrutinib  ', 'zanubrutinib   ', '   ', '   results.', '  results. #lymsm', ' results. #lymsm .', 'Here for the  #ASH22', 'for the  #ASH22 late-breaking', 'the  #ASH22 late-breaking abstracts!', ' #ASH22 late-breaking abstracts! Looking', '#ASH22 late-breaking abstracts! Looking forward', 'late-breaking abstracts! Looking forward to', 'abstracts! Looking forward to the', 'Looking forward to the zanubrutinib', 'forward to the zanubrutinib ', 'to the zanubrutinib  ', 'the zanubrutinib   ', 'zanubrutinib    ', '    results.', '   results. #lymsm', '  results. #lymsm .', 'Here for the  #ASH22 late-breaking', 'for the  #ASH22 late-breaking abstracts!', 'the  #ASH22 late-breaking abstracts! Looking', ' #ASH22 late-breaking abstracts! Looking forward', '#ASH22 late-breaking abstracts! Looking forward to', 'late-breaking abstracts! Looking forward to the', 'abstracts! Looking forward to the zanubrutinib', 'Looking forward to the zanubrutinib ', 'forward to the zanubrutinib  ', 'to the zanubrutinib   ', 'the zanubrutinib    ', 'zanubrutinib     results.', '    results. #lymsm', '   results. #lymsm .', 'Here for the  #ASH22 late-breaking abstracts!', 'for the  #ASH22 late-breaking abstracts! Looking', 'the  #ASH22 late-breaking abstracts! Looking forward', ' #ASH22 late-breaking abstracts! Looking forward to', '#ASH22 late-breaking abstracts! Looking forward to the', 'late-breaking abstracts! Looking forward to the zanubrutinib', 'abstracts! Looking forward to the zanubrutinib ', 'Looking forward to the zanubrutinib  ', 'forward to the zanubrutinib   ', 'to the zanubrutinib    ', 'the zanubrutinib     results.', 'zanubrutinib     results. #lymsm', '    results. #lymsm .', 'Here for the  #ASH22 late-breaking abstracts! Looking', 'for the  #ASH22 late-breaking abstracts! Looking forward', 'the  #ASH22 late-breaking abstracts! Looking forward to', ' #ASH22 late-breaking abstracts! Looking forward to the', '#ASH22 late-breaking abstracts! Looking forward to the zanubrutinib', 'late-breaking abstracts! Looking forward to the zanubrutinib ', 'abstracts! Looking forward to the zanubrutinib  ', 'Looking forward to the zanubrutinib   ', 'forward to the zanubrutinib    ', 'to the zanubrutinib     results.', 'the zanubrutinib     results. #lymsm', 'zanubrutinib     results. #lymsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '112', 'tokens': ['here', 'is', 'the', 'table', 'from', 'the', 'abstract', '-', 'sorry', 'for', 'formatting,', 'submission', 'system', 'was', 'very', 'unforgiving!', '#asco22', '#', 'enzamet', '.'], 'text_length': 20, 'triples': {'#|sorry for formatting, submission system was very unforgiving!': ([17, 17], [8, 15], 'negative')}, 'sentence': 'here is the table from the abstract - sorry for formatting, submission system was very unforgiving! #asco22 # enzamet .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(17, 17)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(8, 15)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['here', 'is', 'the', 'table', 'from', 'the', 'abstract', '-', 'sorry', 'for', 'formatting,', 'submission', 'system', 'was', 'very', 'unforgiving!', '#asco22', '#', 'enzamet', '.', 'here is', 'is the', 'the table', 'table from', 'from the', 'the abstract', 'abstract -', '- sorry', 'sorry for', 'for formatting,', 'formatting, submission', 'submission system', 'system was', 'was very', 'very unforgiving!', 'unforgiving! #asco22', '#asco22 #', '# enzamet', 'enzamet .', 'here is the', 'is the table', 'the table from', 'table from the', 'from the abstract', 'the abstract -', 'abstract - sorry', '- sorry for', 'sorry for formatting,', 'for formatting, submission', 'formatting, submission system', 'submission system was', 'system was very', 'was very unforgiving!', 'very unforgiving! #asco22', 'unforgiving! #asco22 #', '#asco22 # enzamet', '# enzamet .', 'here is the table', 'is the table from', 'the table from the', 'table from the abstract', 'from the abstract -', 'the abstract - sorry', 'abstract - sorry for', '- sorry for formatting,', 'sorry for formatting, submission', 'for formatting, submission system', 'formatting, submission system was', 'submission system was very', 'system was very unforgiving!', 'was very unforgiving! #asco22', 'very unforgiving! #asco22 #', 'unforgiving! #asco22 # enzamet', '#asco22 # enzamet .', 'here is the table from', 'is the table from the', 'the table from the abstract', 'table from the abstract -', 'from the abstract - sorry', 'the abstract - sorry for', 'abstract - sorry for formatting,', '- sorry for formatting, submission', 'sorry for formatting, submission system', 'for formatting, submission system was', 'formatting, submission system was very', 'submission system was very unforgiving!', 'system was very unforgiving! #asco22', 'was very unforgiving! #asco22 #', 'very unforgiving! #asco22 # enzamet', 'unforgiving! #asco22 # enzamet .', 'here is the table from the', 'is the table from the abstract', 'the table from the abstract -', 'table from the abstract - sorry', 'from the abstract - sorry for', 'the abstract - sorry for formatting,', 'abstract - sorry for formatting, submission', '- sorry for formatting, submission system', 'sorry for formatting, submission system was', 'for formatting, submission system was very', 'formatting, submission system was very unforgiving!', 'submission system was very unforgiving! #asco22', 'system was very unforgiving! #asco22 #', 'was very unforgiving! #asco22 # enzamet', 'very unforgiving! #asco22 # enzamet .', 'here is the table from the abstract', 'is the table from the abstract -', 'the table from the abstract - sorry', 'table from the abstract - sorry for', 'from the abstract - sorry for formatting,', 'the abstract - sorry for formatting, submission', 'abstract - sorry for formatting, submission system', '- sorry for formatting, submission system was', 'sorry for formatting, submission system was very', 'for formatting, submission system was very unforgiving!', 'formatting, submission system was very unforgiving! #asco22', 'submission system was very unforgiving! #asco22 #', 'system was very unforgiving! #asco22 # enzamet', 'was very unforgiving! #asco22 # enzamet .', 'here is the table from the abstract -', 'is the table from the abstract - sorry', 'the table from the abstract - sorry for', 'table from the abstract - sorry for formatting,', 'from the abstract - sorry for formatting, submission', 'the abstract - sorry for formatting, submission system', 'abstract - sorry for formatting, submission system was', '- sorry for formatting, submission system was very', 'sorry for formatting, submission system was very unforgiving!', 'for formatting, submission system was very unforgiving! #asco22', 'formatting, submission system was very unforgiving! #asco22 #', 'submission system was very unforgiving! #asco22 # enzamet', 'system was very unforgiving! #asco22 # enzamet .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '113', 'tokens': ['impressive', 'data', 'on', 'neoadjuvant', '#immunotherapy', 'in', 'resectable', '#melsm', '#melanoma', 'generated', 'in', 's1801', 'being', 'presented', 'at', '#esmo22', '2nd', 'presidential', 'symposium', '#esmo22', '.'], 'text_length': 21, 'triples': {'s1801|impressive': ([11, 11], [0, 0], 'positive')}, 'sentence': 'impressive data on neoadjuvant #immunotherapy in resectable #melsm #melanoma generated in s1801 being presented at #esmo22 2nd presidential symposium #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(11, 11)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['impressive', 'data', 'on', 'neoadjuvant', '#immunotherapy', 'in', 'resectable', '#melsm', '#melanoma', 'generated', 'in', 's1801', 'being', 'presented', 'at', '#esmo22', '2nd', 'presidential', 'symposium', '#esmo22', '.', 'impressive data', 'data on', 'on neoadjuvant', 'neoadjuvant #immunotherapy', '#immunotherapy in', 'in resectable', 'resectable #melsm', '#melsm #melanoma', '#melanoma generated', 'generated in', 'in s1801', 's1801 being', 'being presented', 'presented at', 'at #esmo22', '#esmo22 2nd', '2nd presidential', 'presidential symposium', 'symposium #esmo22', '#esmo22 .', 'impressive data on', 'data on neoadjuvant', 'on neoadjuvant #immunotherapy', 'neoadjuvant #immunotherapy in', '#immunotherapy in resectable', 'in resectable #melsm', 'resectable #melsm #melanoma', '#melsm #melanoma generated', '#melanoma generated in', 'generated in s1801', 'in s1801 being', 's1801 being presented', 'being presented at', 'presented at #esmo22', 'at #esmo22 2nd', '#esmo22 2nd presidential', '2nd presidential symposium', 'presidential symposium #esmo22', 'symposium #esmo22 .', 'impressive data on neoadjuvant', 'data on neoadjuvant #immunotherapy', 'on neoadjuvant #immunotherapy in', 'neoadjuvant #immunotherapy in resectable', '#immunotherapy in resectable #melsm', 'in resectable #melsm #melanoma', 'resectable #melsm #melanoma generated', '#melsm #melanoma generated in', '#melanoma generated in s1801', 'generated in s1801 being', 'in s1801 being presented', 's1801 being presented at', 'being presented at #esmo22', 'presented at #esmo22 2nd', 'at #esmo22 2nd presidential', '#esmo22 2nd presidential symposium', '2nd presidential symposium #esmo22', 'presidential symposium #esmo22 .', 'impressive data on neoadjuvant #immunotherapy', 'data on neoadjuvant #immunotherapy in', 'on neoadjuvant #immunotherapy in resectable', 'neoadjuvant #immunotherapy in resectable #melsm', '#immunotherapy in resectable #melsm #melanoma', 'in resectable #melsm #melanoma generated', 'resectable #melsm #melanoma generated in', '#melsm #melanoma generated in s1801', '#melanoma generated in s1801 being', 'generated in s1801 being presented', 'in s1801 being presented at', 's1801 being presented at #esmo22', 'being presented at #esmo22 2nd', 'presented at #esmo22 2nd presidential', 'at #esmo22 2nd presidential symposium', '#esmo22 2nd presidential symposium #esmo22', '2nd presidential symposium #esmo22 .', 'impressive data on neoadjuvant #immunotherapy in', 'data on neoadjuvant #immunotherapy in resectable', 'on neoadjuvant #immunotherapy in resectable #melsm', 'neoadjuvant #immunotherapy in resectable #melsm #melanoma', '#immunotherapy in resectable #melsm #melanoma generated', 'in resectable #melsm #melanoma generated in', 'resectable #melsm #melanoma generated in s1801', '#melsm #melanoma generated in s1801 being', '#melanoma generated in s1801 being presented', 'generated in s1801 being presented at', 'in s1801 being presented at #esmo22', 's1801 being presented at #esmo22 2nd', 'being presented at #esmo22 2nd presidential', 'presented at #esmo22 2nd presidential symposium', 'at #esmo22 2nd presidential symposium #esmo22', '#esmo22 2nd presidential symposium #esmo22 .', 'impressive data on neoadjuvant #immunotherapy in resectable', 'data on neoadjuvant #immunotherapy in resectable #melsm', 'on neoadjuvant #immunotherapy in resectable #melsm #melanoma', 'neoadjuvant #immunotherapy in resectable #melsm #melanoma generated', '#immunotherapy in resectable #melsm #melanoma generated in', 'in resectable #melsm #melanoma generated in s1801', 'resectable #melsm #melanoma generated in s1801 being', '#melsm #melanoma generated in s1801 being presented', '#melanoma generated in s1801 being presented at', 'generated in s1801 being presented at #esmo22', 'in s1801 being presented at #esmo22 2nd', 's1801 being presented at #esmo22 2nd presidential', 'being presented at #esmo22 2nd presidential symposium', 'presented at #esmo22 2nd presidential symposium #esmo22', 'at #esmo22 2nd presidential symposium #esmo22 .', 'impressive data on neoadjuvant #immunotherapy in resectable #melsm', 'data on neoadjuvant #immunotherapy in resectable #melsm #melanoma', 'on neoadjuvant #immunotherapy in resectable #melsm #melanoma generated', 'neoadjuvant #immunotherapy in resectable #melsm #melanoma generated in', '#immunotherapy in resectable #melsm #melanoma generated in s1801', 'in resectable #melsm #melanoma generated in s1801 being', 'resectable #melsm #melanoma generated in s1801 being presented', '#melsm #melanoma generated in s1801 being presented at', '#melanoma generated in s1801 being presented at #esmo22', 'generated in s1801 being presented at #esmo22 2nd', 'in s1801 being presented at #esmo22 2nd presidential', 's1801 being presented at #esmo22 2nd presidential symposium', 'being presented at #esmo22 2nd presidential symposium #esmo22', 'presented at #esmo22 2nd presidential symposium #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '114', 'tokens': ['vision', 'trial:', 'exploratory', 'post-hoc', 'analysis.', 'lu-psma', 'benefit', 'is', 'independent', 'of', 'prior', 'or', 'concomitant', 'treatments', 'but', 'os', 'seems', 'prolonged', 'if', '1', 'vs', '&gt;1', 'previous', 'taxane', 'and', 'concurrent', 'arpi', 'as', 'part', 'of', 'soc', '#asco22', '#prostatecancer', '.'], 'text_length': 34, 'triples': {'vision|exploratory post-hoc analysis. lu-psma benefit': ([0, 0], [2, 6], 'neutral')}, 'sentence': 'vision trial: exploratory post-hoc analysis. lu-psma benefit is independent of prior or concomitant treatments but os seems prolonged if 1 vs &gt;1 previous taxane and concurrent arpi as part of soc #asco22 #prostatecancer .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 6)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['vision', 'trial:', 'exploratory', 'post-hoc', 'analysis.', 'lu-psma', 'benefit', 'is', 'independent', 'of', 'prior', 'or', 'concomitant', 'treatments', 'but', 'os', 'seems', 'prolonged', 'if', '1', 'vs', '&gt;1', 'previous', 'taxane', 'and', 'concurrent', 'arpi', 'as', 'part', 'of', 'soc', '#asco22', '#prostatecancer', '.', 'vision trial:', 'trial: exploratory', 'exploratory post-hoc', 'post-hoc analysis.', 'analysis. lu-psma', 'lu-psma benefit', 'benefit is', 'is independent', 'independent of', 'of prior', 'prior or', 'or concomitant', 'concomitant treatments', 'treatments but', 'but os', 'os seems', 'seems prolonged', 'prolonged if', 'if 1', '1 vs', 'vs &gt;1', '&gt;1 previous', 'previous taxane', 'taxane and', 'and concurrent', 'concurrent arpi', 'arpi as', 'as part', 'part of', 'of soc', 'soc #asco22', '#asco22 #prostatecancer', '#prostatecancer .', 'vision trial: exploratory', 'trial: exploratory post-hoc', 'exploratory post-hoc analysis.', 'post-hoc analysis. lu-psma', 'analysis. lu-psma benefit', 'lu-psma benefit is', 'benefit is independent', 'is independent of', 'independent of prior', 'of prior or', 'prior or concomitant', 'or concomitant treatments', 'concomitant treatments but', 'treatments but os', 'but os seems', 'os seems prolonged', 'seems prolonged if', 'prolonged if 1', 'if 1 vs', '1 vs &gt;1', 'vs &gt;1 previous', '&gt;1 previous taxane', 'previous taxane and', 'taxane and concurrent', 'and concurrent arpi', 'concurrent arpi as', 'arpi as part', 'as part of', 'part of soc', 'of soc #asco22', 'soc #asco22 #prostatecancer', '#asco22 #prostatecancer .', 'vision trial: exploratory post-hoc', 'trial: exploratory post-hoc analysis.', 'exploratory post-hoc analysis. lu-psma', 'post-hoc analysis. lu-psma benefit', 'analysis. lu-psma benefit is', 'lu-psma benefit is independent', 'benefit is independent of', 'is independent of prior', 'independent of prior or', 'of prior or concomitant', 'prior or concomitant treatments', 'or concomitant treatments but', 'concomitant treatments but os', 'treatments but os seems', 'but os seems prolonged', 'os seems prolonged if', 'seems prolonged if 1', 'prolonged if 1 vs', 'if 1 vs &gt;1', '1 vs &gt;1 previous', 'vs &gt;1 previous taxane', '&gt;1 previous taxane and', 'previous taxane and concurrent', 'taxane and concurrent arpi', 'and concurrent arpi as', 'concurrent arpi as part', 'arpi as part of', 'as part of soc', 'part of soc #asco22', 'of soc #asco22 #prostatecancer', 'soc #asco22 #prostatecancer .', 'vision trial: exploratory post-hoc analysis.', 'trial: exploratory post-hoc analysis. lu-psma', 'exploratory post-hoc analysis. lu-psma benefit', 'post-hoc analysis. lu-psma benefit is', 'analysis. lu-psma benefit is independent', 'lu-psma benefit is independent of', 'benefit is independent of prior', 'is independent of prior or', 'independent of prior or concomitant', 'of prior or concomitant treatments', 'prior or concomitant treatments but', 'or concomitant treatments but os', 'concomitant treatments but os seems', 'treatments but os seems prolonged', 'but os seems prolonged if', 'os seems prolonged if 1', 'seems prolonged if 1 vs', 'prolonged if 1 vs &gt;1', 'if 1 vs &gt;1 previous', '1 vs &gt;1 previous taxane', 'vs &gt;1 previous taxane and', '&gt;1 previous taxane and concurrent', 'previous taxane and concurrent arpi', 'taxane and concurrent arpi as', 'and concurrent arpi as part', 'concurrent arpi as part of', 'arpi as part of soc', 'as part of soc #asco22', 'part of soc #asco22 #prostatecancer', 'of soc #asco22 #prostatecancer .', 'vision trial: exploratory post-hoc analysis. lu-psma', 'trial: exploratory post-hoc analysis. lu-psma benefit', 'exploratory post-hoc analysis. lu-psma benefit is', 'post-hoc analysis. lu-psma benefit is independent', 'analysis. lu-psma benefit is independent of', 'lu-psma benefit is independent of prior', 'benefit is independent of prior or', 'is independent of prior or concomitant', 'independent of prior or concomitant treatments', 'of prior or concomitant treatments but', 'prior or concomitant treatments but os', 'or concomitant treatments but os seems', 'concomitant treatments but os seems prolonged', 'treatments but os seems prolonged if', 'but os seems prolonged if 1', 'os seems prolonged if 1 vs', 'seems prolonged if 1 vs &gt;1', 'prolonged if 1 vs &gt;1 previous', 'if 1 vs &gt;1 previous taxane', '1 vs &gt;1 previous taxane and', 'vs &gt;1 previous taxane and concurrent', '&gt;1 previous taxane and concurrent arpi', 'previous taxane and concurrent arpi as', 'taxane and concurrent arpi as part', 'and concurrent arpi as part of', 'concurrent arpi as part of soc', 'arpi as part of soc #asco22', 'as part of soc #asco22 #prostatecancer', 'part of soc #asco22 #prostatecancer .', 'vision trial: exploratory post-hoc analysis. lu-psma benefit', 'trial: exploratory post-hoc analysis. lu-psma benefit is', 'exploratory post-hoc analysis. lu-psma benefit is independent', 'post-hoc analysis. lu-psma benefit is independent of', 'analysis. lu-psma benefit is independent of prior', 'lu-psma benefit is independent of prior or', 'benefit is independent of prior or concomitant', 'is independent of prior or concomitant treatments', 'independent of prior or concomitant treatments but', 'of prior or concomitant treatments but os', 'prior or concomitant treatments but os seems', 'or concomitant treatments but os seems prolonged', 'concomitant treatments but os seems prolonged if', 'treatments but os seems prolonged if 1', 'but os seems prolonged if 1 vs', 'os seems prolonged if 1 vs &gt;1', 'seems prolonged if 1 vs &gt;1 previous', 'prolonged if 1 vs &gt;1 previous taxane', 'if 1 vs &gt;1 previous taxane and', '1 vs &gt;1 previous taxane and concurrent', 'vs &gt;1 previous taxane and concurrent arpi', '&gt;1 previous taxane and concurrent arpi as', 'previous taxane and concurrent arpi as part', 'taxane and concurrent arpi as part of', 'and concurrent arpi as part of soc', 'concurrent arpi as part of soc #asco22', 'arpi as part of soc #asco22 #prostatecancer', 'as part of soc #asco22 #prostatecancer .', 'vision trial: exploratory post-hoc analysis. lu-psma benefit is', 'trial: exploratory post-hoc analysis. lu-psma benefit is independent', 'exploratory post-hoc analysis. lu-psma benefit is independent of', 'post-hoc analysis. lu-psma benefit is independent of prior', 'analysis. lu-psma benefit is independent of prior or', 'lu-psma benefit is independent of prior or concomitant', 'benefit is independent of prior or concomitant treatments', 'is independent of prior or concomitant treatments but', 'independent of prior or concomitant treatments but os', 'of prior or concomitant treatments but os seems', 'prior or concomitant treatments but os seems prolonged', 'or concomitant treatments but os seems prolonged if', 'concomitant treatments but os seems prolonged if 1', 'treatments but os seems prolonged if 1 vs', 'but os seems prolonged if 1 vs &gt;1', 'os seems prolonged if 1 vs &gt;1 previous', 'seems prolonged if 1 vs &gt;1 previous taxane', 'prolonged if 1 vs &gt;1 previous taxane and', 'if 1 vs &gt;1 previous taxane and concurrent', '1 vs &gt;1 previous taxane and concurrent arpi', 'vs &gt;1 previous taxane and concurrent arpi as', '&gt;1 previous taxane and concurrent arpi as part', 'previous taxane and concurrent arpi as part of', 'taxane and concurrent arpi as part of soc', 'and concurrent arpi as part of soc #asco22', 'concurrent arpi as part of soc #asco22 #prostatecancer', 'arpi as part of soc #asco22 #prostatecancer .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '115', 'tokens': ['"another', 'important', 'stampede', 'contribution', 'at', '#esmo2022', 'shows', 'that', 'transcriptomic', 'signatures', 'for', '#prostatecancer:', '1.', 'are', 'prognostic', 'of', 'survival', '2.', 'but', 'not', 'predictive', 'of', 'aboraterone', 'effect', '3.', 'may', 'differ', 'in', 'significance', 'between', 'm0', '&amp;', 'm1', 'pts', '.'], 'text_length': 35, 'triples': {'stampede|important': ([2, 2], [1, 1], 'positive')}, 'sentence': '"another important stampede contribution at #esmo2022 shows that transcriptomic signatures for #prostatecancer: 1. are prognostic of survival 2. but not predictive of aboraterone effect 3. may differ in significance between m0 &amp; m1 pts .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['"another', 'important', 'stampede', 'contribution', 'at', '#esmo2022', 'shows', 'that', 'transcriptomic', 'signatures', 'for', '#prostatecancer:', '1.', 'are', 'prognostic', 'of', 'survival', '2.', 'but', 'not', 'predictive', 'of', 'aboraterone', 'effect', '3.', 'may', 'differ', 'in', 'significance', 'between', 'm0', '&amp;', 'm1', 'pts', '.', '"another important', 'important stampede', 'stampede contribution', 'contribution at', 'at #esmo2022', '#esmo2022 shows', 'shows that', 'that transcriptomic', 'transcriptomic signatures', 'signatures for', 'for #prostatecancer:', '#prostatecancer: 1.', '1. are', 'are prognostic', 'prognostic of', 'of survival', 'survival 2.', '2. but', 'but not', 'not predictive', 'predictive of', 'of aboraterone', 'aboraterone effect', 'effect 3.', '3. may', 'may differ', 'differ in', 'in significance', 'significance between', 'between m0', 'm0 &amp;', '&amp; m1', 'm1 pts', 'pts .', '"another important stampede', 'important stampede contribution', 'stampede contribution at', 'contribution at #esmo2022', 'at #esmo2022 shows', '#esmo2022 shows that', 'shows that transcriptomic', 'that transcriptomic signatures', 'transcriptomic signatures for', 'signatures for #prostatecancer:', 'for #prostatecancer: 1.', '#prostatecancer: 1. are', '1. are prognostic', 'are prognostic of', 'prognostic of survival', 'of survival 2.', 'survival 2. but', '2. but not', 'but not predictive', 'not predictive of', 'predictive of aboraterone', 'of aboraterone effect', 'aboraterone effect 3.', 'effect 3. may', '3. may differ', 'may differ in', 'differ in significance', 'in significance between', 'significance between m0', 'between m0 &amp;', 'm0 &amp; m1', '&amp; m1 pts', 'm1 pts .', '"another important stampede contribution', 'important stampede contribution at', 'stampede contribution at #esmo2022', 'contribution at #esmo2022 shows', 'at #esmo2022 shows that', '#esmo2022 shows that transcriptomic', 'shows that transcriptomic signatures', 'that transcriptomic signatures for', 'transcriptomic signatures for #prostatecancer:', 'signatures for #prostatecancer: 1.', 'for #prostatecancer: 1. are', '#prostatecancer: 1. are prognostic', '1. are prognostic of', 'are prognostic of survival', 'prognostic of survival 2.', 'of survival 2. but', 'survival 2. but not', '2. but not predictive', 'but not predictive of', 'not predictive of aboraterone', 'predictive of aboraterone effect', 'of aboraterone effect 3.', 'aboraterone effect 3. may', 'effect 3. may differ', '3. may differ in', 'may differ in significance', 'differ in significance between', 'in significance between m0', 'significance between m0 &amp;', 'between m0 &amp; m1', 'm0 &amp; m1 pts', '&amp; m1 pts .', '"another important stampede contribution at', 'important stampede contribution at #esmo2022', 'stampede contribution at #esmo2022 shows', 'contribution at #esmo2022 shows that', 'at #esmo2022 shows that transcriptomic', '#esmo2022 shows that transcriptomic signatures', 'shows that transcriptomic signatures for', 'that transcriptomic signatures for #prostatecancer:', 'transcriptomic signatures for #prostatecancer: 1.', 'signatures for #prostatecancer: 1. are', 'for #prostatecancer: 1. are prognostic', '#prostatecancer: 1. are prognostic of', '1. are prognostic of survival', 'are prognostic of survival 2.', 'prognostic of survival 2. but', 'of survival 2. but not', 'survival 2. but not predictive', '2. but not predictive of', 'but not predictive of aboraterone', 'not predictive of aboraterone effect', 'predictive of aboraterone effect 3.', 'of aboraterone effect 3. may', 'aboraterone effect 3. may differ', 'effect 3. may differ in', '3. may differ in significance', 'may differ in significance between', 'differ in significance between m0', 'in significance between m0 &amp;', 'significance between m0 &amp; m1', 'between m0 &amp; m1 pts', 'm0 &amp; m1 pts .', '"another important stampede contribution at #esmo2022', 'important stampede contribution at #esmo2022 shows', 'stampede contribution at #esmo2022 shows that', 'contribution at #esmo2022 shows that transcriptomic', 'at #esmo2022 shows that transcriptomic signatures', '#esmo2022 shows that transcriptomic signatures for', 'shows that transcriptomic signatures for #prostatecancer:', 'that transcriptomic signatures for #prostatecancer: 1.', 'transcriptomic signatures for #prostatecancer: 1. are', 'signatures for #prostatecancer: 1. are prognostic', 'for #prostatecancer: 1. are prognostic of', '#prostatecancer: 1. are prognostic of survival', '1. are prognostic of survival 2.', 'are prognostic of survival 2. but', 'prognostic of survival 2. but not', 'of survival 2. but not predictive', 'survival 2. but not predictive of', '2. but not predictive of aboraterone', 'but not predictive of aboraterone effect', 'not predictive of aboraterone effect 3.', 'predictive of aboraterone effect 3. may', 'of aboraterone effect 3. may differ', 'aboraterone effect 3. may differ in', 'effect 3. may differ in significance', '3. may differ in significance between', 'may differ in significance between m0', 'differ in significance between m0 &amp;', 'in significance between m0 &amp; m1', 'significance between m0 &amp; m1 pts', 'between m0 &amp; m1 pts .', '"another important stampede contribution at #esmo2022 shows', 'important stampede contribution at #esmo2022 shows that', 'stampede contribution at #esmo2022 shows that transcriptomic', 'contribution at #esmo2022 shows that transcriptomic signatures', 'at #esmo2022 shows that transcriptomic signatures for', '#esmo2022 shows that transcriptomic signatures for #prostatecancer:', 'shows that transcriptomic signatures for #prostatecancer: 1.', 'that transcriptomic signatures for #prostatecancer: 1. are', 'transcriptomic signatures for #prostatecancer: 1. are prognostic', 'signatures for #prostatecancer: 1. are prognostic of', 'for #prostatecancer: 1. are prognostic of survival', '#prostatecancer: 1. are prognostic of survival 2.', '1. are prognostic of survival 2. but', 'are prognostic of survival 2. but not', 'prognostic of survival 2. but not predictive', 'of survival 2. but not predictive of', 'survival 2. but not predictive of aboraterone', '2. but not predictive of aboraterone effect', 'but not predictive of aboraterone effect 3.', 'not predictive of aboraterone effect 3. may', 'predictive of aboraterone effect 3. may differ', 'of aboraterone effect 3. may differ in', 'aboraterone effect 3. may differ in significance', 'effect 3. may differ in significance between', '3. may differ in significance between m0', 'may differ in significance between m0 &amp;', 'differ in significance between m0 &amp; m1', 'in significance between m0 &amp; m1 pts', 'significance between m0 &amp; m1 pts .', '"another important stampede contribution at #esmo2022 shows that', 'important stampede contribution at #esmo2022 shows that transcriptomic', 'stampede contribution at #esmo2022 shows that transcriptomic signatures', 'contribution at #esmo2022 shows that transcriptomic signatures for', 'at #esmo2022 shows that transcriptomic signatures for #prostatecancer:', '#esmo2022 shows that transcriptomic signatures for #prostatecancer: 1.', 'shows that transcriptomic signatures for #prostatecancer: 1. are', 'that transcriptomic signatures for #prostatecancer: 1. are prognostic', 'transcriptomic signatures for #prostatecancer: 1. are prognostic of', 'signatures for #prostatecancer: 1. are prognostic of survival', 'for #prostatecancer: 1. are prognostic of survival 2.', '#prostatecancer: 1. are prognostic of survival 2. but', '1. are prognostic of survival 2. but not', 'are prognostic of survival 2. but not predictive', 'prognostic of survival 2. but not predictive of', 'of survival 2. but not predictive of aboraterone', 'survival 2. but not predictive of aboraterone effect', '2. but not predictive of aboraterone effect 3.', 'but not predictive of aboraterone effect 3. may', 'not predictive of aboraterone effect 3. may differ', 'predictive of aboraterone effect 3. may differ in', 'of aboraterone effect 3. may differ in significance', 'aboraterone effect 3. may differ in significance between', 'effect 3. may differ in significance between m0', '3. may differ in significance between m0 &amp;', 'may differ in significance between m0 &amp; m1', 'differ in significance between m0 &amp; m1 pts', 'in significance between m0 &amp; m1 pts .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '116', 'tokens': ['dr.', 'armstrong', 'reviews', '#imaging', 'findings', '&amp;', 'responses', 'in', '#lupsma', '#', 'vision', 'trial', '#asco22.', 'higher', '#psma', '#suv', 'led', 'to', 'better', 'outcomes', 'among', 'others', 'data.', 'so', 'what', 'can', 'we', 'do', 'to', '#psma', 'expression', '&amp;', 'will', 'that', 'improve', 'responses?', '.'], 'text_length': 37, 'triples': {'#|reviews #imaging findings &amp; responses in #lupsma # vision trial #asco22. higher #psma #suv led to better outcomes among others data. so what can we do to #psma expression &amp; will that improve': ([9, 9], [2, 34], 'neutral')}, 'sentence': 'dr. armstrong reviews #imaging findings &amp; responses in #lupsma # vision trial #asco22. higher #psma #suv led to better outcomes among others data. so what can we do to #psma expression &amp; will that improve responses? .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(9, 9)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 34)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8)], 'span tokens': ['dr.', 'armstrong', 'reviews', '#imaging', 'findings', '&amp;', 'responses', 'in', '#lupsma', '#', 'vision', 'trial', '#asco22.', 'higher', '#psma', '#suv', 'led', 'to', 'better', 'outcomes', 'among', 'others', 'data.', 'so', 'what', 'can', 'we', 'do', 'to', '#psma', 'expression', '&amp;', 'will', 'that', 'improve', 'responses?', '.', 'dr. armstrong', 'armstrong reviews', 'reviews #imaging', '#imaging findings', 'findings &amp;', '&amp; responses', 'responses in', 'in #lupsma', '#lupsma #', '# vision', 'vision trial', 'trial #asco22.', '#asco22. higher', 'higher #psma', '#psma #suv', '#suv led', 'led to', 'to better', 'better outcomes', 'outcomes among', 'among others', 'others data.', 'data. so', 'so what', 'what can', 'can we', 'we do', 'do to', 'to #psma', '#psma expression', 'expression &amp;', '&amp; will', 'will that', 'that improve', 'improve responses?', 'responses? .', 'dr. armstrong reviews', 'armstrong reviews #imaging', 'reviews #imaging findings', '#imaging findings &amp;', 'findings &amp; responses', '&amp; responses in', 'responses in #lupsma', 'in #lupsma #', '#lupsma # vision', '# vision trial', 'vision trial #asco22.', 'trial #asco22. higher', '#asco22. higher #psma', 'higher #psma #suv', '#psma #suv led', '#suv led to', 'led to better', 'to better outcomes', 'better outcomes among', 'outcomes among others', 'among others data.', 'others data. so', 'data. so what', 'so what can', 'what can we', 'can we do', 'we do to', 'do to #psma', 'to #psma expression', '#psma expression &amp;', 'expression &amp; will', '&amp; will that', 'will that improve', 'that improve responses?', 'improve responses? .', 'dr. armstrong reviews #imaging', 'armstrong reviews #imaging findings', 'reviews #imaging findings &amp;', '#imaging findings &amp; responses', 'findings &amp; responses in', '&amp; responses in #lupsma', 'responses in #lupsma #', 'in #lupsma # vision', '#lupsma # vision trial', '# vision trial #asco22.', 'vision trial #asco22. higher', 'trial #asco22. higher #psma', '#asco22. higher #psma #suv', 'higher #psma #suv led', '#psma #suv led to', '#suv led to better', 'led to better outcomes', 'to better outcomes among', 'better outcomes among others', 'outcomes among others data.', 'among others data. so', 'others data. so what', 'data. so what can', 'so what can we', 'what can we do', 'can we do to', 'we do to #psma', 'do to #psma expression', 'to #psma expression &amp;', '#psma expression &amp; will', 'expression &amp; will that', '&amp; will that improve', 'will that improve responses?', 'that improve responses? .', 'dr. armstrong reviews #imaging findings', 'armstrong reviews #imaging findings &amp;', 'reviews #imaging findings &amp; responses', '#imaging findings &amp; responses in', 'findings &amp; responses in #lupsma', '&amp; responses in #lupsma #', 'responses in #lupsma # vision', 'in #lupsma # vision trial', '#lupsma # vision trial #asco22.', '# vision trial #asco22. higher', 'vision trial #asco22. higher #psma', 'trial #asco22. higher #psma #suv', '#asco22. higher #psma #suv led', 'higher #psma #suv led to', '#psma #suv led to better', '#suv led to better outcomes', 'led to better outcomes among', 'to better outcomes among others', 'better outcomes among others data.', 'outcomes among others data. so', 'among others data. so what', 'others data. so what can', 'data. so what can we', 'so what can we do', 'what can we do to', 'can we do to #psma', 'we do to #psma expression', 'do to #psma expression &amp;', 'to #psma expression &amp; will', '#psma expression &amp; will that', 'expression &amp; will that improve', '&amp; will that improve responses?', 'will that improve responses? .', 'dr. armstrong reviews #imaging findings &amp;', 'armstrong reviews #imaging findings &amp; responses', 'reviews #imaging findings &amp; responses in', '#imaging findings &amp; responses in #lupsma', 'findings &amp; responses in #lupsma #', '&amp; responses in #lupsma # vision', 'responses in #lupsma # vision trial', 'in #lupsma # vision trial #asco22.', '#lupsma # vision trial #asco22. higher', '# vision trial #asco22. higher #psma', 'vision trial #asco22. higher #psma #suv', 'trial #asco22. higher #psma #suv led', '#asco22. higher #psma #suv led to', 'higher #psma #suv led to better', '#psma #suv led to better outcomes', '#suv led to better outcomes among', 'led to better outcomes among others', 'to better outcomes among others data.', 'better outcomes among others data. so', 'outcomes among others data. so what', 'among others data. so what can', 'others data. so what can we', 'data. so what can we do', 'so what can we do to', 'what can we do to #psma', 'can we do to #psma expression', 'we do to #psma expression &amp;', 'do to #psma expression &amp; will', 'to #psma expression &amp; will that', '#psma expression &amp; will that improve', 'expression &amp; will that improve responses?', '&amp; will that improve responses? .', 'dr. armstrong reviews #imaging findings &amp; responses', 'armstrong reviews #imaging findings &amp; responses in', 'reviews #imaging findings &amp; responses in #lupsma', '#imaging findings &amp; responses in #lupsma #', 'findings &amp; responses in #lupsma # vision', '&amp; responses in #lupsma # vision trial', 'responses in #lupsma # vision trial #asco22.', 'in #lupsma # vision trial #asco22. higher', '#lupsma # vision trial #asco22. higher #psma', '# vision trial #asco22. higher #psma #suv', 'vision trial #asco22. higher #psma #suv led', 'trial #asco22. higher #psma #suv led to', '#asco22. higher #psma #suv led to better', 'higher #psma #suv led to better outcomes', '#psma #suv led to better outcomes among', '#suv led to better outcomes among others', 'led to better outcomes among others data.', 'to better outcomes among others data. so', 'better outcomes among others data. so what', 'outcomes among others data. so what can', 'among others data. so what can we', 'others data. so what can we do', 'data. so what can we do to', 'so what can we do to #psma', 'what can we do to #psma expression', 'can we do to #psma expression &amp;', 'we do to #psma expression &amp; will', 'do to #psma expression &amp; will that', 'to #psma expression &amp; will that improve', '#psma expression &amp; will that improve responses?', 'expression &amp; will that improve responses? .', 'dr. armstrong reviews #imaging findings &amp; responses in', 'armstrong reviews #imaging findings &amp; responses in #lupsma', 'reviews #imaging findings &amp; responses in #lupsma #', '#imaging findings &amp; responses in #lupsma # vision', 'findings &amp; responses in #lupsma # vision trial', '&amp; responses in #lupsma # vision trial #asco22.', 'responses in #lupsma # vision trial #asco22. higher', 'in #lupsma # vision trial #asco22. higher #psma', '#lupsma # vision trial #asco22. higher #psma #suv', '# vision trial #asco22. higher #psma #suv led', 'vision trial #asco22. higher #psma #suv led to', 'trial #asco22. higher #psma #suv led to better', '#asco22. higher #psma #suv led to better outcomes', 'higher #psma #suv led to better outcomes among', '#psma #suv led to better outcomes among others', '#suv led to better outcomes among others data.', 'led to better outcomes among others data. so', 'to better outcomes among others data. so what', 'better outcomes among others data. so what can', 'outcomes among others data. so what can we', 'among others data. so what can we do', 'others data. so what can we do to', 'data. so what can we do to #psma', 'so what can we do to #psma expression', 'what can we do to #psma expression &amp;', 'can we do to #psma expression &amp; will', 'we do to #psma expression &amp; will that', 'do to #psma expression &amp; will that improve', 'to #psma expression &amp; will that improve responses?', '#psma expression &amp; will that improve responses? .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '117', 'tokens': ['"', 'presidential', 'symposium', 'codebreak-200', 'study:', 'met', 'its', 'primary', 'endpoint', 'with', 'sotorasib', 'demonstrating', 'superior', 'pfs', 'over', 'docetaxel', '(hr', '0.66,', 'p', '=', '0.002);', '12-month', 'pfs', 'rate', 'was', '24.8%', 'for', 'sotorasib', 'and', '10.1%', 'for', 'docetaxel', '#esmo22', '.'], 'text_length': 34, 'triples': {'symposium|sotorasib demonstrating': ([2, 2], [10, 11], 'positive')}, 'sentence': '" presidential symposium codebreak-200 study: met its primary endpoint with sotorasib demonstrating superior pfs over docetaxel (hr 0.66, p = 0.002); 12-month pfs rate was 24.8% for sotorasib and 10.1% for docetaxel #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['"', 'presidential', 'symposium', 'codebreak-200', 'study:', 'met', 'its', 'primary', 'endpoint', 'with', 'sotorasib', 'demonstrating', 'superior', 'pfs', 'over', 'docetaxel', '(hr', '0.66,', 'p', '=', '0.002);', '12-month', 'pfs', 'rate', 'was', '24.8%', 'for', 'sotorasib', 'and', '10.1%', 'for', 'docetaxel', '#esmo22', '.', '" presidential', 'presidential symposium', 'symposium codebreak-200', 'codebreak-200 study:', 'study: met', 'met its', 'its primary', 'primary endpoint', 'endpoint with', 'with sotorasib', 'sotorasib demonstrating', 'demonstrating superior', 'superior pfs', 'pfs over', 'over docetaxel', 'docetaxel (hr', '(hr 0.66,', '0.66, p', 'p =', '= 0.002);', '0.002); 12-month', '12-month pfs', 'pfs rate', 'rate was', 'was 24.8%', '24.8% for', 'for sotorasib', 'sotorasib and', 'and 10.1%', '10.1% for', 'for docetaxel', 'docetaxel #esmo22', '#esmo22 .', '" presidential symposium', 'presidential symposium codebreak-200', 'symposium codebreak-200 study:', 'codebreak-200 study: met', 'study: met its', 'met its primary', 'its primary endpoint', 'primary endpoint with', 'endpoint with sotorasib', 'with sotorasib demonstrating', 'sotorasib demonstrating superior', 'demonstrating superior pfs', 'superior pfs over', 'pfs over docetaxel', 'over docetaxel (hr', 'docetaxel (hr 0.66,', '(hr 0.66, p', '0.66, p =', 'p = 0.002);', '= 0.002); 12-month', '0.002); 12-month pfs', '12-month pfs rate', 'pfs rate was', 'rate was 24.8%', 'was 24.8% for', '24.8% for sotorasib', 'for sotorasib and', 'sotorasib and 10.1%', 'and 10.1% for', '10.1% for docetaxel', 'for docetaxel #esmo22', 'docetaxel #esmo22 .', '" presidential symposium codebreak-200', 'presidential symposium codebreak-200 study:', 'symposium codebreak-200 study: met', 'codebreak-200 study: met its', 'study: met its primary', 'met its primary endpoint', 'its primary endpoint with', 'primary endpoint with sotorasib', 'endpoint with sotorasib demonstrating', 'with sotorasib demonstrating superior', 'sotorasib demonstrating superior pfs', 'demonstrating superior pfs over', 'superior pfs over docetaxel', 'pfs over docetaxel (hr', 'over docetaxel (hr 0.66,', 'docetaxel (hr 0.66, p', '(hr 0.66, p =', '0.66, p = 0.002);', 'p = 0.002); 12-month', '= 0.002); 12-month pfs', '0.002); 12-month pfs rate', '12-month pfs rate was', 'pfs rate was 24.8%', 'rate was 24.8% for', 'was 24.8% for sotorasib', '24.8% for sotorasib and', 'for sotorasib and 10.1%', 'sotorasib and 10.1% for', 'and 10.1% for docetaxel', '10.1% for docetaxel #esmo22', 'for docetaxel #esmo22 .', '" presidential symposium codebreak-200 study:', 'presidential symposium codebreak-200 study: met', 'symposium codebreak-200 study: met its', 'codebreak-200 study: met its primary', 'study: met its primary endpoint', 'met its primary endpoint with', 'its primary endpoint with sotorasib', 'primary endpoint with sotorasib demonstrating', 'endpoint with sotorasib demonstrating superior', 'with sotorasib demonstrating superior pfs', 'sotorasib demonstrating superior pfs over', 'demonstrating superior pfs over docetaxel', 'superior pfs over docetaxel (hr', 'pfs over docetaxel (hr 0.66,', 'over docetaxel (hr 0.66, p', 'docetaxel (hr 0.66, p =', '(hr 0.66, p = 0.002);', '0.66, p = 0.002); 12-month', 'p = 0.002); 12-month pfs', '= 0.002); 12-month pfs rate', '0.002); 12-month pfs rate was', '12-month pfs rate was 24.8%', 'pfs rate was 24.8% for', 'rate was 24.8% for sotorasib', 'was 24.8% for sotorasib and', '24.8% for sotorasib and 10.1%', 'for sotorasib and 10.1% for', 'sotorasib and 10.1% for docetaxel', 'and 10.1% for docetaxel #esmo22', '10.1% for docetaxel #esmo22 .', '" presidential symposium codebreak-200 study: met', 'presidential symposium codebreak-200 study: met its', 'symposium codebreak-200 study: met its primary', 'codebreak-200 study: met its primary endpoint', 'study: met its primary endpoint with', 'met its primary endpoint with sotorasib', 'its primary endpoint with sotorasib demonstrating', 'primary endpoint with sotorasib demonstrating superior', 'endpoint with sotorasib demonstrating superior pfs', 'with sotorasib demonstrating superior pfs over', 'sotorasib demonstrating superior pfs over docetaxel', 'demonstrating superior pfs over docetaxel (hr', 'superior pfs over docetaxel (hr 0.66,', 'pfs over docetaxel (hr 0.66, p', 'over docetaxel (hr 0.66, p =', 'docetaxel (hr 0.66, p = 0.002);', '(hr 0.66, p = 0.002); 12-month', '0.66, p = 0.002); 12-month pfs', 'p = 0.002); 12-month pfs rate', '= 0.002); 12-month pfs rate was', '0.002); 12-month pfs rate was 24.8%', '12-month pfs rate was 24.8% for', 'pfs rate was 24.8% for sotorasib', 'rate was 24.8% for sotorasib and', 'was 24.8% for sotorasib and 10.1%', '24.8% for sotorasib and 10.1% for', 'for sotorasib and 10.1% for docetaxel', 'sotorasib and 10.1% for docetaxel #esmo22', 'and 10.1% for docetaxel #esmo22 .', '" presidential symposium codebreak-200 study: met its', 'presidential symposium codebreak-200 study: met its primary', 'symposium codebreak-200 study: met its primary endpoint', 'codebreak-200 study: met its primary endpoint with', 'study: met its primary endpoint with sotorasib', 'met its primary endpoint with sotorasib demonstrating', 'its primary endpoint with sotorasib demonstrating superior', 'primary endpoint with sotorasib demonstrating superior pfs', 'endpoint with sotorasib demonstrating superior pfs over', 'with sotorasib demonstrating superior pfs over docetaxel', 'sotorasib demonstrating superior pfs over docetaxel (hr', 'demonstrating superior pfs over docetaxel (hr 0.66,', 'superior pfs over docetaxel (hr 0.66, p', 'pfs over docetaxel (hr 0.66, p =', 'over docetaxel (hr 0.66, p = 0.002);', 'docetaxel (hr 0.66, p = 0.002); 12-month', '(hr 0.66, p = 0.002); 12-month pfs', '0.66, p = 0.002); 12-month pfs rate', 'p = 0.002); 12-month pfs rate was', '= 0.002); 12-month pfs rate was 24.8%', '0.002); 12-month pfs rate was 24.8% for', '12-month pfs rate was 24.8% for sotorasib', 'pfs rate was 24.8% for sotorasib and', 'rate was 24.8% for sotorasib and 10.1%', 'was 24.8% for sotorasib and 10.1% for', '24.8% for sotorasib and 10.1% for docetaxel', 'for sotorasib and 10.1% for docetaxel #esmo22', 'sotorasib and 10.1% for docetaxel #esmo22 .', '" presidential symposium codebreak-200 study: met its primary', 'presidential symposium codebreak-200 study: met its primary endpoint', 'symposium codebreak-200 study: met its primary endpoint with', 'codebreak-200 study: met its primary endpoint with sotorasib', 'study: met its primary endpoint with sotorasib demonstrating', 'met its primary endpoint with sotorasib demonstrating superior', 'its primary endpoint with sotorasib demonstrating superior pfs', 'primary endpoint with sotorasib demonstrating superior pfs over', 'endpoint with sotorasib demonstrating superior pfs over docetaxel', 'with sotorasib demonstrating superior pfs over docetaxel (hr', 'sotorasib demonstrating superior pfs over docetaxel (hr 0.66,', 'demonstrating superior pfs over docetaxel (hr 0.66, p', 'superior pfs over docetaxel (hr 0.66, p =', 'pfs over docetaxel (hr 0.66, p = 0.002);', 'over docetaxel (hr 0.66, p = 0.002); 12-month', 'docetaxel (hr 0.66, p = 0.002); 12-month pfs', '(hr 0.66, p = 0.002); 12-month pfs rate', '0.66, p = 0.002); 12-month pfs rate was', 'p = 0.002); 12-month pfs rate was 24.8%', '= 0.002); 12-month pfs rate was 24.8% for', '0.002); 12-month pfs rate was 24.8% for sotorasib', '12-month pfs rate was 24.8% for sotorasib and', 'pfs rate was 24.8% for sotorasib and 10.1%', 'rate was 24.8% for sotorasib and 10.1% for', 'was 24.8% for sotorasib and 10.1% for docetaxel', '24.8% for sotorasib and 10.1% for docetaxel #esmo22', 'for sotorasib and 10.1% for docetaxel #esmo22 .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '118', 'tokens': ['immotion010', 'negative', 'trial', 'independently', 'of', 'pd-l1', 'results', '#esmo22', '#rccc2022', '.'], 'text_length': 10, 'triples': {'immotion010|negative trial': ([0, 0], [1, 2], 'negative')}, 'sentence': 'immotion010 negative trial independently of pd-l1 results #esmo22 #rccc2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 2)], 'related_span_array': array([[1, 0, 0, ..., 1, 0, 0],
       [0, 1, 0, ..., 1, 1, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8)], 'span tokens': ['immotion010', 'negative', 'trial', 'independently', 'of', 'pd-l1', 'results', '#esmo22', '#rccc2022', '.', 'immotion010 negative', 'negative trial', 'trial independently', 'independently of', 'of pd-l1', 'pd-l1 results', 'results #esmo22', '#esmo22 #rccc2022', '#rccc2022 .', 'immotion010 negative trial', 'negative trial independently', 'trial independently of', 'independently of pd-l1', 'of pd-l1 results', 'pd-l1 results #esmo22', 'results #esmo22 #rccc2022', '#esmo22 #rccc2022 .', 'immotion010 negative trial independently', 'negative trial independently of', 'trial independently of pd-l1', 'independently of pd-l1 results', 'of pd-l1 results #esmo22', 'pd-l1 results #esmo22 #rccc2022', 'results #esmo22 #rccc2022 .', 'immotion010 negative trial independently of', 'negative trial independently of pd-l1', 'trial independently of pd-l1 results', 'independently of pd-l1 results #esmo22', 'of pd-l1 results #esmo22 #rccc2022', 'pd-l1 results #esmo22 #rccc2022 .', 'immotion010 negative trial independently of pd-l1', 'negative trial independently of pd-l1 results', 'trial independently of pd-l1 results #esmo22', 'independently of pd-l1 results #esmo22 #rccc2022', 'of pd-l1 results #esmo22 #rccc2022 .', 'immotion010 negative trial independently of pd-l1 results', 'negative trial independently of pd-l1 results #esmo22', 'trial independently of pd-l1 results #esmo22 #rccc2022', 'independently of pd-l1 results #esmo22 #rccc2022 .', 'immotion010 negative trial independently of pd-l1 results #esmo22', 'negative trial independently of pd-l1 results #esmo22 #rccc2022', 'trial independently of pd-l1 results #esmo22 #rccc2022 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '119', 'tokens': ['samur', 'et', 'al.,', 'karmma', '-single', 'cell', 'sequencing', 'to', 'evaluate', 'bcma', 'car-t', 'cell', 'responders', 'vs', 'non', 'responders', '-resistance', 'from', 'different', 'factors', 'e/', 'changes', 'in', 'tumor', 'and', 'immune', 'cells', 'w/', 'rx', '#myeloma', '#ash22', '#imfash22', '#mmsm', '.'], 'text_length': 34, 'triples': {'karmma|evaluate': ([3, 3], [8, 8], 'neutral')}, 'sentence': 'samur et al., karmma -single cell sequencing to evaluate bcma car-t cell responders vs non responders -resistance from different factors e/ changes in tumor and immune cells w/ rx #myeloma #ash22 #imfash22 #mmsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(8, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['samur', 'et', 'al.,', 'karmma', '-single', 'cell', 'sequencing', 'to', 'evaluate', 'bcma', 'car-t', 'cell', 'responders', 'vs', 'non', 'responders', '-resistance', 'from', 'different', 'factors', 'e/', 'changes', 'in', 'tumor', 'and', 'immune', 'cells', 'w/', 'rx', '#myeloma', '#ash22', '#imfash22', '#mmsm', '.', 'samur et', 'et al.,', 'al., karmma', 'karmma -single', '-single cell', 'cell sequencing', 'sequencing to', 'to evaluate', 'evaluate bcma', 'bcma car-t', 'car-t cell', 'cell responders', 'responders vs', 'vs non', 'non responders', 'responders -resistance', '-resistance from', 'from different', 'different factors', 'factors e/', 'e/ changes', 'changes in', 'in tumor', 'tumor and', 'and immune', 'immune cells', 'cells w/', 'w/ rx', 'rx #myeloma', '#myeloma #ash22', '#ash22 #imfash22', '#imfash22 #mmsm', '#mmsm .', 'samur et al.,', 'et al., karmma', 'al., karmma -single', 'karmma -single cell', '-single cell sequencing', 'cell sequencing to', 'sequencing to evaluate', 'to evaluate bcma', 'evaluate bcma car-t', 'bcma car-t cell', 'car-t cell responders', 'cell responders vs', 'responders vs non', 'vs non responders', 'non responders -resistance', 'responders -resistance from', '-resistance from different', 'from different factors', 'different factors e/', 'factors e/ changes', 'e/ changes in', 'changes in tumor', 'in tumor and', 'tumor and immune', 'and immune cells', 'immune cells w/', 'cells w/ rx', 'w/ rx #myeloma', 'rx #myeloma #ash22', '#myeloma #ash22 #imfash22', '#ash22 #imfash22 #mmsm', '#imfash22 #mmsm .', 'samur et al., karmma', 'et al., karmma -single', 'al., karmma -single cell', 'karmma -single cell sequencing', '-single cell sequencing to', 'cell sequencing to evaluate', 'sequencing to evaluate bcma', 'to evaluate bcma car-t', 'evaluate bcma car-t cell', 'bcma car-t cell responders', 'car-t cell responders vs', 'cell responders vs non', 'responders vs non responders', 'vs non responders -resistance', 'non responders -resistance from', 'responders -resistance from different', '-resistance from different factors', 'from different factors e/', 'different factors e/ changes', 'factors e/ changes in', 'e/ changes in tumor', 'changes in tumor and', 'in tumor and immune', 'tumor and immune cells', 'and immune cells w/', 'immune cells w/ rx', 'cells w/ rx #myeloma', 'w/ rx #myeloma #ash22', 'rx #myeloma #ash22 #imfash22', '#myeloma #ash22 #imfash22 #mmsm', '#ash22 #imfash22 #mmsm .', 'samur et al., karmma -single', 'et al., karmma -single cell', 'al., karmma -single cell sequencing', 'karmma -single cell sequencing to', '-single cell sequencing to evaluate', 'cell sequencing to evaluate bcma', 'sequencing to evaluate bcma car-t', 'to evaluate bcma car-t cell', 'evaluate bcma car-t cell responders', 'bcma car-t cell responders vs', 'car-t cell responders vs non', 'cell responders vs non responders', 'responders vs non responders -resistance', 'vs non responders -resistance from', 'non responders -resistance from different', 'responders -resistance from different factors', '-resistance from different factors e/', 'from different factors e/ changes', 'different factors e/ changes in', 'factors e/ changes in tumor', 'e/ changes in tumor and', 'changes in tumor and immune', 'in tumor and immune cells', 'tumor and immune cells w/', 'and immune cells w/ rx', 'immune cells w/ rx #myeloma', 'cells w/ rx #myeloma #ash22', 'w/ rx #myeloma #ash22 #imfash22', 'rx #myeloma #ash22 #imfash22 #mmsm', '#myeloma #ash22 #imfash22 #mmsm .', 'samur et al., karmma -single cell', 'et al., karmma -single cell sequencing', 'al., karmma -single cell sequencing to', 'karmma -single cell sequencing to evaluate', '-single cell sequencing to evaluate bcma', 'cell sequencing to evaluate bcma car-t', 'sequencing to evaluate bcma car-t cell', 'to evaluate bcma car-t cell responders', 'evaluate bcma car-t cell responders vs', 'bcma car-t cell responders vs non', 'car-t cell responders vs non responders', 'cell responders vs non responders -resistance', 'responders vs non responders -resistance from', 'vs non responders -resistance from different', 'non responders -resistance from different factors', 'responders -resistance from different factors e/', '-resistance from different factors e/ changes', 'from different factors e/ changes in', 'different factors e/ changes in tumor', 'factors e/ changes in tumor and', 'e/ changes in tumor and immune', 'changes in tumor and immune cells', 'in tumor and immune cells w/', 'tumor and immune cells w/ rx', 'and immune cells w/ rx #myeloma', 'immune cells w/ rx #myeloma #ash22', 'cells w/ rx #myeloma #ash22 #imfash22', 'w/ rx #myeloma #ash22 #imfash22 #mmsm', 'rx #myeloma #ash22 #imfash22 #mmsm .', 'samur et al., karmma -single cell sequencing', 'et al., karmma -single cell sequencing to', 'al., karmma -single cell sequencing to evaluate', 'karmma -single cell sequencing to evaluate bcma', '-single cell sequencing to evaluate bcma car-t', 'cell sequencing to evaluate bcma car-t cell', 'sequencing to evaluate bcma car-t cell responders', 'to evaluate bcma car-t cell responders vs', 'evaluate bcma car-t cell responders vs non', 'bcma car-t cell responders vs non responders', 'car-t cell responders vs non responders -resistance', 'cell responders vs non responders -resistance from', 'responders vs non responders -resistance from different', 'vs non responders -resistance from different factors', 'non responders -resistance from different factors e/', 'responders -resistance from different factors e/ changes', '-resistance from different factors e/ changes in', 'from different factors e/ changes in tumor', 'different factors e/ changes in tumor and', 'factors e/ changes in tumor and immune', 'e/ changes in tumor and immune cells', 'changes in tumor and immune cells w/', 'in tumor and immune cells w/ rx', 'tumor and immune cells w/ rx #myeloma', 'and immune cells w/ rx #myeloma #ash22', 'immune cells w/ rx #myeloma #ash22 #imfash22', 'cells w/ rx #myeloma #ash22 #imfash22 #mmsm', 'w/ rx #myeloma #ash22 #imfash22 #mmsm .', 'samur et al., karmma -single cell sequencing to', 'et al., karmma -single cell sequencing to evaluate', 'al., karmma -single cell sequencing to evaluate bcma', 'karmma -single cell sequencing to evaluate bcma car-t', '-single cell sequencing to evaluate bcma car-t cell', 'cell sequencing to evaluate bcma car-t cell responders', 'sequencing to evaluate bcma car-t cell responders vs', 'to evaluate bcma car-t cell responders vs non', 'evaluate bcma car-t cell responders vs non responders', 'bcma car-t cell responders vs non responders -resistance', 'car-t cell responders vs non responders -resistance from', 'cell responders vs non responders -resistance from different', 'responders vs non responders -resistance from different factors', 'vs non responders -resistance from different factors e/', 'non responders -resistance from different factors e/ changes', 'responders -resistance from different factors e/ changes in', '-resistance from different factors e/ changes in tumor', 'from different factors e/ changes in tumor and', 'different factors e/ changes in tumor and immune', 'factors e/ changes in tumor and immune cells', 'e/ changes in tumor and immune cells w/', 'changes in tumor and immune cells w/ rx', 'in tumor and immune cells w/ rx #myeloma', 'tumor and immune cells w/ rx #myeloma #ash22', 'and immune cells w/ rx #myeloma #ash22 #imfash22', 'immune cells w/ rx #myeloma #ash22 #imfash22 #mmsm', 'cells w/ rx #myeloma #ash22 #imfash22 #mmsm .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '120', 'tokens': ['dr.', 'patel', 'presents', 'at', '#ash22', 'on', 'karmma', '(early', 'relapse', 'post', 'auto', 'treated', 'with', 'bcma', 'car', 't).', 'median', 'pfs', '11', 'months.', 'deeper', 'responses', 'result', 'in', 'longer', 'disease', 'control.', '.'], 'text_length': 28, 'triples': {'karmma|presents': ([6, 6], [2, 2], 'neutral')}, 'sentence': 'dr. patel presents at #ash22 on karmma (early relapse post auto treated with bcma car t). median pfs 11 months. deeper responses result in longer disease control. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['dr.', 'patel', 'presents', 'at', '#ash22', 'on', 'karmma', '(early', 'relapse', 'post', 'auto', 'treated', 'with', 'bcma', 'car', 't).', 'median', 'pfs', '11', 'months.', 'deeper', 'responses', 'result', 'in', 'longer', 'disease', 'control.', '.', 'dr. patel', 'patel presents', 'presents at', 'at #ash22', '#ash22 on', 'on karmma', 'karmma (early', '(early relapse', 'relapse post', 'post auto', 'auto treated', 'treated with', 'with bcma', 'bcma car', 'car t).', 't). median', 'median pfs', 'pfs 11', '11 months.', 'months. deeper', 'deeper responses', 'responses result', 'result in', 'in longer', 'longer disease', 'disease control.', 'control. .', 'dr. patel presents', 'patel presents at', 'presents at #ash22', 'at #ash22 on', '#ash22 on karmma', 'on karmma (early', 'karmma (early relapse', '(early relapse post', 'relapse post auto', 'post auto treated', 'auto treated with', 'treated with bcma', 'with bcma car', 'bcma car t).', 'car t). median', 't). median pfs', 'median pfs 11', 'pfs 11 months.', '11 months. deeper', 'months. deeper responses', 'deeper responses result', 'responses result in', 'result in longer', 'in longer disease', 'longer disease control.', 'disease control. .', 'dr. patel presents at', 'patel presents at #ash22', 'presents at #ash22 on', 'at #ash22 on karmma', '#ash22 on karmma (early', 'on karmma (early relapse', 'karmma (early relapse post', '(early relapse post auto', 'relapse post auto treated', 'post auto treated with', 'auto treated with bcma', 'treated with bcma car', 'with bcma car t).', 'bcma car t). median', 'car t). median pfs', 't). median pfs 11', 'median pfs 11 months.', 'pfs 11 months. deeper', '11 months. deeper responses', 'months. deeper responses result', 'deeper responses result in', 'responses result in longer', 'result in longer disease', 'in longer disease control.', 'longer disease control. .', 'dr. patel presents at #ash22', 'patel presents at #ash22 on', 'presents at #ash22 on karmma', 'at #ash22 on karmma (early', '#ash22 on karmma (early relapse', 'on karmma (early relapse post', 'karmma (early relapse post auto', '(early relapse post auto treated', 'relapse post auto treated with', 'post auto treated with bcma', 'auto treated with bcma car', 'treated with bcma car t).', 'with bcma car t). median', 'bcma car t). median pfs', 'car t). median pfs 11', 't). median pfs 11 months.', 'median pfs 11 months. deeper', 'pfs 11 months. deeper responses', '11 months. deeper responses result', 'months. deeper responses result in', 'deeper responses result in longer', 'responses result in longer disease', 'result in longer disease control.', 'in longer disease control. .', 'dr. patel presents at #ash22 on', 'patel presents at #ash22 on karmma', 'presents at #ash22 on karmma (early', 'at #ash22 on karmma (early relapse', '#ash22 on karmma (early relapse post', 'on karmma (early relapse post auto', 'karmma (early relapse post auto treated', '(early relapse post auto treated with', 'relapse post auto treated with bcma', 'post auto treated with bcma car', 'auto treated with bcma car t).', 'treated with bcma car t). median', 'with bcma car t). median pfs', 'bcma car t). median pfs 11', 'car t). median pfs 11 months.', 't). median pfs 11 months. deeper', 'median pfs 11 months. deeper responses', 'pfs 11 months. deeper responses result', '11 months. deeper responses result in', 'months. deeper responses result in longer', 'deeper responses result in longer disease', 'responses result in longer disease control.', 'result in longer disease control. .', 'dr. patel presents at #ash22 on karmma', 'patel presents at #ash22 on karmma (early', 'presents at #ash22 on karmma (early relapse', 'at #ash22 on karmma (early relapse post', '#ash22 on karmma (early relapse post auto', 'on karmma (early relapse post auto treated', 'karmma (early relapse post auto treated with', '(early relapse post auto treated with bcma', 'relapse post auto treated with bcma car', 'post auto treated with bcma car t).', 'auto treated with bcma car t). median', 'treated with bcma car t). median pfs', 'with bcma car t). median pfs 11', 'bcma car t). median pfs 11 months.', 'car t). median pfs 11 months. deeper', 't). median pfs 11 months. deeper responses', 'median pfs 11 months. deeper responses result', 'pfs 11 months. deeper responses result in', '11 months. deeper responses result in longer', 'months. deeper responses result in longer disease', 'deeper responses result in longer disease control.', 'responses result in longer disease control. .', 'dr. patel presents at #ash22 on karmma (early', 'patel presents at #ash22 on karmma (early relapse', 'presents at #ash22 on karmma (early relapse post', 'at #ash22 on karmma (early relapse post auto', '#ash22 on karmma (early relapse post auto treated', 'on karmma (early relapse post auto treated with', 'karmma (early relapse post auto treated with bcma', '(early relapse post auto treated with bcma car', 'relapse post auto treated with bcma car t).', 'post auto treated with bcma car t). median', 'auto treated with bcma car t). median pfs', 'treated with bcma car t). median pfs 11', 'with bcma car t). median pfs 11 months.', 'bcma car t). median pfs 11 months. deeper', 'car t). median pfs 11 months. deeper responses', 't). median pfs 11 months. deeper responses result', 'median pfs 11 months. deeper responses result in', 'pfs 11 months. deeper responses result in longer', '11 months. deeper responses result in longer disease', 'months. deeper responses result in longer disease control.', 'deeper responses result in longer disease control. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '121', 'tokens': ['dr.', 'vaishampayan', 'presents', 'an', 'update', 'of', 'the', '#lupsma', '#', 'vision', 'trial', 'data', 'based', 'on', 'prior', '&amp;', 'concurrent', 'treatments', '#asco22', '#prostatecancer', 'anticipate', 'further', 'data', 'of', '#lupsma+anti-androgen', 'in', '#mcrpc', '.'], 'text_length': 28, 'triples': {'#|presents an update of the #lupsma # vision trial data based on prior &amp; concurrent treatments #asco22 #prostatecancer anticipate': ([8, 8], [2, 20], 'neutral')}, 'sentence': 'dr. vaishampayan presents an update of the #lupsma # vision trial data based on prior &amp; concurrent treatments #asco22 #prostatecancer anticipate further data of #lupsma+anti-androgen in #mcrpc .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['dr.', 'vaishampayan', 'presents', 'an', 'update', 'of', 'the', '#lupsma', '#', 'vision', 'trial', 'data', 'based', 'on', 'prior', '&amp;', 'concurrent', 'treatments', '#asco22', '#prostatecancer', 'anticipate', 'further', 'data', 'of', '#lupsma+anti-androgen', 'in', '#mcrpc', '.', 'dr. vaishampayan', 'vaishampayan presents', 'presents an', 'an update', 'update of', 'of the', 'the #lupsma', '#lupsma #', '# vision', 'vision trial', 'trial data', 'data based', 'based on', 'on prior', 'prior &amp;', '&amp; concurrent', 'concurrent treatments', 'treatments #asco22', '#asco22 #prostatecancer', '#prostatecancer anticipate', 'anticipate further', 'further data', 'data of', 'of #lupsma+anti-androgen', '#lupsma+anti-androgen in', 'in #mcrpc', '#mcrpc .', 'dr. vaishampayan presents', 'vaishampayan presents an', 'presents an update', 'an update of', 'update of the', 'of the #lupsma', 'the #lupsma #', '#lupsma # vision', '# vision trial', 'vision trial data', 'trial data based', 'data based on', 'based on prior', 'on prior &amp;', 'prior &amp; concurrent', '&amp; concurrent treatments', 'concurrent treatments #asco22', 'treatments #asco22 #prostatecancer', '#asco22 #prostatecancer anticipate', '#prostatecancer anticipate further', 'anticipate further data', 'further data of', 'data of #lupsma+anti-androgen', 'of #lupsma+anti-androgen in', '#lupsma+anti-androgen in #mcrpc', 'in #mcrpc .', 'dr. vaishampayan presents an', 'vaishampayan presents an update', 'presents an update of', 'an update of the', 'update of the #lupsma', 'of the #lupsma #', 'the #lupsma # vision', '#lupsma # vision trial', '# vision trial data', 'vision trial data based', 'trial data based on', 'data based on prior', 'based on prior &amp;', 'on prior &amp; concurrent', 'prior &amp; concurrent treatments', '&amp; concurrent treatments #asco22', 'concurrent treatments #asco22 #prostatecancer', 'treatments #asco22 #prostatecancer anticipate', '#asco22 #prostatecancer anticipate further', '#prostatecancer anticipate further data', 'anticipate further data of', 'further data of #lupsma+anti-androgen', 'data of #lupsma+anti-androgen in', 'of #lupsma+anti-androgen in #mcrpc', '#lupsma+anti-androgen in #mcrpc .', 'dr. vaishampayan presents an update', 'vaishampayan presents an update of', 'presents an update of the', 'an update of the #lupsma', 'update of the #lupsma #', 'of the #lupsma # vision', 'the #lupsma # vision trial', '#lupsma # vision trial data', '# vision trial data based', 'vision trial data based on', 'trial data based on prior', 'data based on prior &amp;', 'based on prior &amp; concurrent', 'on prior &amp; concurrent treatments', 'prior &amp; concurrent treatments #asco22', '&amp; concurrent treatments #asco22 #prostatecancer', 'concurrent treatments #asco22 #prostatecancer anticipate', 'treatments #asco22 #prostatecancer anticipate further', '#asco22 #prostatecancer anticipate further data', '#prostatecancer anticipate further data of', 'anticipate further data of #lupsma+anti-androgen', 'further data of #lupsma+anti-androgen in', 'data of #lupsma+anti-androgen in #mcrpc', 'of #lupsma+anti-androgen in #mcrpc .', 'dr. vaishampayan presents an update of', 'vaishampayan presents an update of the', 'presents an update of the #lupsma', 'an update of the #lupsma #', 'update of the #lupsma # vision', 'of the #lupsma # vision trial', 'the #lupsma # vision trial data', '#lupsma # vision trial data based', '# vision trial data based on', 'vision trial data based on prior', 'trial data based on prior &amp;', 'data based on prior &amp; concurrent', 'based on prior &amp; concurrent treatments', 'on prior &amp; concurrent treatments #asco22', 'prior &amp; concurrent treatments #asco22 #prostatecancer', '&amp; concurrent treatments #asco22 #prostatecancer anticipate', 'concurrent treatments #asco22 #prostatecancer anticipate further', 'treatments #asco22 #prostatecancer anticipate further data', '#asco22 #prostatecancer anticipate further data of', '#prostatecancer anticipate further data of #lupsma+anti-androgen', 'anticipate further data of #lupsma+anti-androgen in', 'further data of #lupsma+anti-androgen in #mcrpc', 'data of #lupsma+anti-androgen in #mcrpc .', 'dr. vaishampayan presents an update of the', 'vaishampayan presents an update of the #lupsma', 'presents an update of the #lupsma #', 'an update of the #lupsma # vision', 'update of the #lupsma # vision trial', 'of the #lupsma # vision trial data', 'the #lupsma # vision trial data based', '#lupsma # vision trial data based on', '# vision trial data based on prior', 'vision trial data based on prior &amp;', 'trial data based on prior &amp; concurrent', 'data based on prior &amp; concurrent treatments', 'based on prior &amp; concurrent treatments #asco22', 'on prior &amp; concurrent treatments #asco22 #prostatecancer', 'prior &amp; concurrent treatments #asco22 #prostatecancer anticipate', '&amp; concurrent treatments #asco22 #prostatecancer anticipate further', 'concurrent treatments #asco22 #prostatecancer anticipate further data', 'treatments #asco22 #prostatecancer anticipate further data of', '#asco22 #prostatecancer anticipate further data of #lupsma+anti-androgen', '#prostatecancer anticipate further data of #lupsma+anti-androgen in', 'anticipate further data of #lupsma+anti-androgen in #mcrpc', 'further data of #lupsma+anti-androgen in #mcrpc .', 'dr. vaishampayan presents an update of the #lupsma', 'vaishampayan presents an update of the #lupsma #', 'presents an update of the #lupsma # vision', 'an update of the #lupsma # vision trial', 'update of the #lupsma # vision trial data', 'of the #lupsma # vision trial data based', 'the #lupsma # vision trial data based on', '#lupsma # vision trial data based on prior', '# vision trial data based on prior &amp;', 'vision trial data based on prior &amp; concurrent', 'trial data based on prior &amp; concurrent treatments', 'data based on prior &amp; concurrent treatments #asco22', 'based on prior &amp; concurrent treatments #asco22 #prostatecancer', 'on prior &amp; concurrent treatments #asco22 #prostatecancer anticipate', 'prior &amp; concurrent treatments #asco22 #prostatecancer anticipate further', '&amp; concurrent treatments #asco22 #prostatecancer anticipate further data', 'concurrent treatments #asco22 #prostatecancer anticipate further data of', 'treatments #asco22 #prostatecancer anticipate further data of #lupsma+anti-androgen', '#asco22 #prostatecancer anticipate further data of #lupsma+anti-androgen in', '#prostatecancer anticipate further data of #lupsma+anti-androgen in #mcrpc', 'anticipate further data of #lupsma+anti-androgen in #mcrpc .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '122', 'tokens': ['presenting', 'results', 'of', 'codebreak-200', 'phase', '3', 'in', '#esmo22', 'presidential', 'symposium.met', 'primary', 'endpoint', 'improved', 'pfs', 'hr', '0.66', '#lcsm', '.'], 'text_length': 18, 'triples': {'codebreak-200|presenting results of codebreak-200 phase 3 in #esmo22 presidential symposium.met primary endpoint improved': ([3, 3], [0, 12], 'positive')}, 'sentence': 'presenting results of codebreak-200 phase 3 in #esmo22 presidential symposium.met primary endpoint improved pfs hr 0.66 #lcsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8)], 'span tokens': ['presenting', 'results', 'of', 'codebreak-200', 'phase', '3', 'in', '#esmo22', 'presidential', 'symposium.met', 'primary', 'endpoint', 'improved', 'pfs', 'hr', '0.66', '#lcsm', '.', 'presenting results', 'results of', 'of codebreak-200', 'codebreak-200 phase', 'phase 3', '3 in', 'in #esmo22', '#esmo22 presidential', 'presidential symposium.met', 'symposium.met primary', 'primary endpoint', 'endpoint improved', 'improved pfs', 'pfs hr', 'hr 0.66', '0.66 #lcsm', '#lcsm .', 'presenting results of', 'results of codebreak-200', 'of codebreak-200 phase', 'codebreak-200 phase 3', 'phase 3 in', '3 in #esmo22', 'in #esmo22 presidential', '#esmo22 presidential symposium.met', 'presidential symposium.met primary', 'symposium.met primary endpoint', 'primary endpoint improved', 'endpoint improved pfs', 'improved pfs hr', 'pfs hr 0.66', 'hr 0.66 #lcsm', '0.66 #lcsm .', 'presenting results of codebreak-200', 'results of codebreak-200 phase', 'of codebreak-200 phase 3', 'codebreak-200 phase 3 in', 'phase 3 in #esmo22', '3 in #esmo22 presidential', 'in #esmo22 presidential symposium.met', '#esmo22 presidential symposium.met primary', 'presidential symposium.met primary endpoint', 'symposium.met primary endpoint improved', 'primary endpoint improved pfs', 'endpoint improved pfs hr', 'improved pfs hr 0.66', 'pfs hr 0.66 #lcsm', 'hr 0.66 #lcsm .', 'presenting results of codebreak-200 phase', 'results of codebreak-200 phase 3', 'of codebreak-200 phase 3 in', 'codebreak-200 phase 3 in #esmo22', 'phase 3 in #esmo22 presidential', '3 in #esmo22 presidential symposium.met', 'in #esmo22 presidential symposium.met primary', '#esmo22 presidential symposium.met primary endpoint', 'presidential symposium.met primary endpoint improved', 'symposium.met primary endpoint improved pfs', 'primary endpoint improved pfs hr', 'endpoint improved pfs hr 0.66', 'improved pfs hr 0.66 #lcsm', 'pfs hr 0.66 #lcsm .', 'presenting results of codebreak-200 phase 3', 'results of codebreak-200 phase 3 in', 'of codebreak-200 phase 3 in #esmo22', 'codebreak-200 phase 3 in #esmo22 presidential', 'phase 3 in #esmo22 presidential symposium.met', '3 in #esmo22 presidential symposium.met primary', 'in #esmo22 presidential symposium.met primary endpoint', '#esmo22 presidential symposium.met primary endpoint improved', 'presidential symposium.met primary endpoint improved pfs', 'symposium.met primary endpoint improved pfs hr', 'primary endpoint improved pfs hr 0.66', 'endpoint improved pfs hr 0.66 #lcsm', 'improved pfs hr 0.66 #lcsm .', 'presenting results of codebreak-200 phase 3 in', 'results of codebreak-200 phase 3 in #esmo22', 'of codebreak-200 phase 3 in #esmo22 presidential', 'codebreak-200 phase 3 in #esmo22 presidential symposium.met', 'phase 3 in #esmo22 presidential symposium.met primary', '3 in #esmo22 presidential symposium.met primary endpoint', 'in #esmo22 presidential symposium.met primary endpoint improved', '#esmo22 presidential symposium.met primary endpoint improved pfs', 'presidential symposium.met primary endpoint improved pfs hr', 'symposium.met primary endpoint improved pfs hr 0.66', 'primary endpoint improved pfs hr 0.66 #lcsm', 'endpoint improved pfs hr 0.66 #lcsm .', 'presenting results of codebreak-200 phase 3 in #esmo22', 'results of codebreak-200 phase 3 in #esmo22 presidential', 'of codebreak-200 phase 3 in #esmo22 presidential symposium.met', 'codebreak-200 phase 3 in #esmo22 presidential symposium.met primary', 'phase 3 in #esmo22 presidential symposium.met primary endpoint', '3 in #esmo22 presidential symposium.met primary endpoint improved', 'in #esmo22 presidential symposium.met primary endpoint improved pfs', '#esmo22 presidential symposium.met primary endpoint improved pfs hr', 'presidential symposium.met primary endpoint improved pfs hr 0.66', 'symposium.met primary endpoint improved pfs hr 0.66 #lcsm', 'primary endpoint improved pfs hr 0.66 #lcsm .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '123', 'tokens': ['#asco22', 'christopher', 'ryan', 'presenting', 'the', 'results', 'of', 'the', 'everest', 'study', 'of', 'adjuvant', 'everolimus', 'in', 'patients', 'with', '#rcc', 'important', 'data', 'that', 'helps', 'to', 'increase', 'our', 'knowledge', 'of', 'adj.', 'treatment', 'in', '#kidneycancer', '.'], 'text_length': 31, 'triples': {'everest|important data that helps to increase': ([8, 8], [17, 22], 'neutral'), 'everolimus|important data that helps to increase': ([12, 12], [17, 22], 'neutral')}, 'sentence': '#asco22 christopher ryan presenting the results of the everest study of adjuvant everolimus in patients with #rcc important data that helps to increase our knowledge of adj. treatment in #kidneycancer .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(8, 8), (12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['#asco22', 'christopher', 'ryan', 'presenting', 'the', 'results', 'of', 'the', 'everest', 'study', 'of', 'adjuvant', 'everolimus', 'in', 'patients', 'with', '#rcc', 'important', 'data', 'that', 'helps', 'to', 'increase', 'our', 'knowledge', 'of', 'adj.', 'treatment', 'in', '#kidneycancer', '.', '#asco22 christopher', 'christopher ryan', 'ryan presenting', 'presenting the', 'the results', 'results of', 'of the', 'the everest', 'everest study', 'study of', 'of adjuvant', 'adjuvant everolimus', 'everolimus in', 'in patients', 'patients with', 'with #rcc', '#rcc important', 'important data', 'data that', 'that helps', 'helps to', 'to increase', 'increase our', 'our knowledge', 'knowledge of', 'of adj.', 'adj. treatment', 'treatment in', 'in #kidneycancer', '#kidneycancer .', '#asco22 christopher ryan', 'christopher ryan presenting', 'ryan presenting the', 'presenting the results', 'the results of', 'results of the', 'of the everest', 'the everest study', 'everest study of', 'study of adjuvant', 'of adjuvant everolimus', 'adjuvant everolimus in', 'everolimus in patients', 'in patients with', 'patients with #rcc', 'with #rcc important', '#rcc important data', 'important data that', 'data that helps', 'that helps to', 'helps to increase', 'to increase our', 'increase our knowledge', 'our knowledge of', 'knowledge of adj.', 'of adj. treatment', 'adj. treatment in', 'treatment in #kidneycancer', 'in #kidneycancer .', '#asco22 christopher ryan presenting', 'christopher ryan presenting the', 'ryan presenting the results', 'presenting the results of', 'the results of the', 'results of the everest', 'of the everest study', 'the everest study of', 'everest study of adjuvant', 'study of adjuvant everolimus', 'of adjuvant everolimus in', 'adjuvant everolimus in patients', 'everolimus in patients with', 'in patients with #rcc', 'patients with #rcc important', 'with #rcc important data', '#rcc important data that', 'important data that helps', 'data that helps to', 'that helps to increase', 'helps to increase our', 'to increase our knowledge', 'increase our knowledge of', 'our knowledge of adj.', 'knowledge of adj. treatment', 'of adj. treatment in', 'adj. treatment in #kidneycancer', 'treatment in #kidneycancer .', '#asco22 christopher ryan presenting the', 'christopher ryan presenting the results', 'ryan presenting the results of', 'presenting the results of the', 'the results of the everest', 'results of the everest study', 'of the everest study of', 'the everest study of adjuvant', 'everest study of adjuvant everolimus', 'study of adjuvant everolimus in', 'of adjuvant everolimus in patients', 'adjuvant everolimus in patients with', 'everolimus in patients with #rcc', 'in patients with #rcc important', 'patients with #rcc important data', 'with #rcc important data that', '#rcc important data that helps', 'important data that helps to', 'data that helps to increase', 'that helps to increase our', 'helps to increase our knowledge', 'to increase our knowledge of', 'increase our knowledge of adj.', 'our knowledge of adj. treatment', 'knowledge of adj. treatment in', 'of adj. treatment in #kidneycancer', 'adj. treatment in #kidneycancer .', '#asco22 christopher ryan presenting the results', 'christopher ryan presenting the results of', 'ryan presenting the results of the', 'presenting the results of the everest', 'the results of the everest study', 'results of the everest study of', 'of the everest study of adjuvant', 'the everest study of adjuvant everolimus', 'everest study of adjuvant everolimus in', 'study of adjuvant everolimus in patients', 'of adjuvant everolimus in patients with', 'adjuvant everolimus in patients with #rcc', 'everolimus in patients with #rcc important', 'in patients with #rcc important data', 'patients with #rcc important data that', 'with #rcc important data that helps', '#rcc important data that helps to', 'important data that helps to increase', 'data that helps to increase our', 'that helps to increase our knowledge', 'helps to increase our knowledge of', 'to increase our knowledge of adj.', 'increase our knowledge of adj. treatment', 'our knowledge of adj. treatment in', 'knowledge of adj. treatment in #kidneycancer', 'of adj. treatment in #kidneycancer .', '#asco22 christopher ryan presenting the results of', 'christopher ryan presenting the results of the', 'ryan presenting the results of the everest', 'presenting the results of the everest study', 'the results of the everest study of', 'results of the everest study of adjuvant', 'of the everest study of adjuvant everolimus', 'the everest study of adjuvant everolimus in', 'everest study of adjuvant everolimus in patients', 'study of adjuvant everolimus in patients with', 'of adjuvant everolimus in patients with #rcc', 'adjuvant everolimus in patients with #rcc important', 'everolimus in patients with #rcc important data', 'in patients with #rcc important data that', 'patients with #rcc important data that helps', 'with #rcc important data that helps to', '#rcc important data that helps to increase', 'important data that helps to increase our', 'data that helps to increase our knowledge', 'that helps to increase our knowledge of', 'helps to increase our knowledge of adj.', 'to increase our knowledge of adj. treatment', 'increase our knowledge of adj. treatment in', 'our knowledge of adj. treatment in #kidneycancer', 'knowledge of adj. treatment in #kidneycancer .', '#asco22 christopher ryan presenting the results of the', 'christopher ryan presenting the results of the everest', 'ryan presenting the results of the everest study', 'presenting the results of the everest study of', 'the results of the everest study of adjuvant', 'results of the everest study of adjuvant everolimus', 'of the everest study of adjuvant everolimus in', 'the everest study of adjuvant everolimus in patients', 'everest study of adjuvant everolimus in patients with', 'study of adjuvant everolimus in patients with #rcc', 'of adjuvant everolimus in patients with #rcc important', 'adjuvant everolimus in patients with #rcc important data', 'everolimus in patients with #rcc important data that', 'in patients with #rcc important data that helps', 'patients with #rcc important data that helps to', 'with #rcc important data that helps to increase', '#rcc important data that helps to increase our', 'important data that helps to increase our knowledge', 'data that helps to increase our knowledge of', 'that helps to increase our knowledge of adj.', 'helps to increase our knowledge of adj. treatment', 'to increase our knowledge of adj. treatment in', 'increase our knowledge of adj. treatment in #kidneycancer', 'our knowledge of adj. treatment in #kidneycancer .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '124', 'tokens': ['the', 'feels', 'are', 'real', '-', 'we', 'did', 'this', 'w/', 'the', 'support', 'of', 'amazing', 'ops', 'and', 'stats', 'team', '(*lauding*', 'the', 'spectacular', 'megan', 'othus)', 'and', 'commitment', 'fr', 'concept', 'to', 'completion', 'of', 'and', '#esmo22', 's1801', '#neoadjuvant', 'from', 'here', 'fwd', '.'], 'text_length': 37, 'triples': {'s1801|real - we did this w/ the support of amazing ops and stats team (*lauding* the spectacular': ([31, 31], [3, 19], 'positive')}, 'sentence': 'the feels are real - we did this w/ the support of amazing ops and stats team (*lauding* the spectacular megan othus) and commitment fr concept to completion of and #esmo22 s1801 #neoadjuvant from here fwd .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(31, 31)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 19)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8)], 'span tokens': ['the', 'feels', 'are', 'real', '-', 'we', 'did', 'this', 'w/', 'the', 'support', 'of', 'amazing', 'ops', 'and', 'stats', 'team', '(*lauding*', 'the', 'spectacular', 'megan', 'othus)', 'and', 'commitment', 'fr', 'concept', 'to', 'completion', 'of', 'and', '#esmo22', 's1801', '#neoadjuvant', 'from', 'here', 'fwd', '.', 'the feels', 'feels are', 'are real', 'real -', '- we', 'we did', 'did this', 'this w/', 'w/ the', 'the support', 'support of', 'of amazing', 'amazing ops', 'ops and', 'and stats', 'stats team', 'team (*lauding*', '(*lauding* the', 'the spectacular', 'spectacular megan', 'megan othus)', 'othus) and', 'and commitment', 'commitment fr', 'fr concept', 'concept to', 'to completion', 'completion of', 'of and', 'and #esmo22', '#esmo22 s1801', 's1801 #neoadjuvant', '#neoadjuvant from', 'from here', 'here fwd', 'fwd .', 'the feels are', 'feels are real', 'are real -', 'real - we', '- we did', 'we did this', 'did this w/', 'this w/ the', 'w/ the support', 'the support of', 'support of amazing', 'of amazing ops', 'amazing ops and', 'ops and stats', 'and stats team', 'stats team (*lauding*', 'team (*lauding* the', '(*lauding* the spectacular', 'the spectacular megan', 'spectacular megan othus)', 'megan othus) and', 'othus) and commitment', 'and commitment fr', 'commitment fr concept', 'fr concept to', 'concept to completion', 'to completion of', 'completion of and', 'of and #esmo22', 'and #esmo22 s1801', '#esmo22 s1801 #neoadjuvant', 's1801 #neoadjuvant from', '#neoadjuvant from here', 'from here fwd', 'here fwd .', 'the feels are real', 'feels are real -', 'are real - we', 'real - we did', '- we did this', 'we did this w/', 'did this w/ the', 'this w/ the support', 'w/ the support of', 'the support of amazing', 'support of amazing ops', 'of amazing ops and', 'amazing ops and stats', 'ops and stats team', 'and stats team (*lauding*', 'stats team (*lauding* the', 'team (*lauding* the spectacular', '(*lauding* the spectacular megan', 'the spectacular megan othus)', 'spectacular megan othus) and', 'megan othus) and commitment', 'othus) and commitment fr', 'and commitment fr concept', 'commitment fr concept to', 'fr concept to completion', 'concept to completion of', 'to completion of and', 'completion of and #esmo22', 'of and #esmo22 s1801', 'and #esmo22 s1801 #neoadjuvant', '#esmo22 s1801 #neoadjuvant from', 's1801 #neoadjuvant from here', '#neoadjuvant from here fwd', 'from here fwd .', 'the feels are real -', 'feels are real - we', 'are real - we did', 'real - we did this', '- we did this w/', 'we did this w/ the', 'did this w/ the support', 'this w/ the support of', 'w/ the support of amazing', 'the support of amazing ops', 'support of amazing ops and', 'of amazing ops and stats', 'amazing ops and stats team', 'ops and stats team (*lauding*', 'and stats team (*lauding* the', 'stats team (*lauding* the spectacular', 'team (*lauding* the spectacular megan', '(*lauding* the spectacular megan othus)', 'the spectacular megan othus) and', 'spectacular megan othus) and commitment', 'megan othus) and commitment fr', 'othus) and commitment fr concept', 'and commitment fr concept to', 'commitment fr concept to completion', 'fr concept to completion of', 'concept to completion of and', 'to completion of and #esmo22', 'completion of and #esmo22 s1801', 'of and #esmo22 s1801 #neoadjuvant', 'and #esmo22 s1801 #neoadjuvant from', '#esmo22 s1801 #neoadjuvant from here', 's1801 #neoadjuvant from here fwd', '#neoadjuvant from here fwd .', 'the feels are real - we', 'feels are real - we did', 'are real - we did this', 'real - we did this w/', '- we did this w/ the', 'we did this w/ the support', 'did this w/ the support of', 'this w/ the support of amazing', 'w/ the support of amazing ops', 'the support of amazing ops and', 'support of amazing ops and stats', 'of amazing ops and stats team', 'amazing ops and stats team (*lauding*', 'ops and stats team (*lauding* the', 'and stats team (*lauding* the spectacular', 'stats team (*lauding* the spectacular megan', 'team (*lauding* the spectacular megan othus)', '(*lauding* the spectacular megan othus) and', 'the spectacular megan othus) and commitment', 'spectacular megan othus) and commitment fr', 'megan othus) and commitment fr concept', 'othus) and commitment fr concept to', 'and commitment fr concept to completion', 'commitment fr concept to completion of', 'fr concept to completion of and', 'concept to completion of and #esmo22', 'to completion of and #esmo22 s1801', 'completion of and #esmo22 s1801 #neoadjuvant', 'of and #esmo22 s1801 #neoadjuvant from', 'and #esmo22 s1801 #neoadjuvant from here', '#esmo22 s1801 #neoadjuvant from here fwd', 's1801 #neoadjuvant from here fwd .', 'the feels are real - we did', 'feels are real - we did this', 'are real - we did this w/', 'real - we did this w/ the', '- we did this w/ the support', 'we did this w/ the support of', 'did this w/ the support of amazing', 'this w/ the support of amazing ops', 'w/ the support of amazing ops and', 'the support of amazing ops and stats', 'support of amazing ops and stats team', 'of amazing ops and stats team (*lauding*', 'amazing ops and stats team (*lauding* the', 'ops and stats team (*lauding* the spectacular', 'and stats team (*lauding* the spectacular megan', 'stats team (*lauding* the spectacular megan othus)', 'team (*lauding* the spectacular megan othus) and', '(*lauding* the spectacular megan othus) and commitment', 'the spectacular megan othus) and commitment fr', 'spectacular megan othus) and commitment fr concept', 'megan othus) and commitment fr concept to', 'othus) and commitment fr concept to completion', 'and commitment fr concept to completion of', 'commitment fr concept to completion of and', 'fr concept to completion of and #esmo22', 'concept to completion of and #esmo22 s1801', 'to completion of and #esmo22 s1801 #neoadjuvant', 'completion of and #esmo22 s1801 #neoadjuvant from', 'of and #esmo22 s1801 #neoadjuvant from here', 'and #esmo22 s1801 #neoadjuvant from here fwd', '#esmo22 s1801 #neoadjuvant from here fwd .', 'the feels are real - we did this', 'feels are real - we did this w/', 'are real - we did this w/ the', 'real - we did this w/ the support', '- we did this w/ the support of', 'we did this w/ the support of amazing', 'did this w/ the support of amazing ops', 'this w/ the support of amazing ops and', 'w/ the support of amazing ops and stats', 'the support of amazing ops and stats team', 'support of amazing ops and stats team (*lauding*', 'of amazing ops and stats team (*lauding* the', 'amazing ops and stats team (*lauding* the spectacular', 'ops and stats team (*lauding* the spectacular megan', 'and stats team (*lauding* the spectacular megan othus)', 'stats team (*lauding* the spectacular megan othus) and', 'team (*lauding* the spectacular megan othus) and commitment', '(*lauding* the spectacular megan othus) and commitment fr', 'the spectacular megan othus) and commitment fr concept', 'spectacular megan othus) and commitment fr concept to', 'megan othus) and commitment fr concept to completion', 'othus) and commitment fr concept to completion of', 'and commitment fr concept to completion of and', 'commitment fr concept to completion of and #esmo22', 'fr concept to completion of and #esmo22 s1801', 'concept to completion of and #esmo22 s1801 #neoadjuvant', 'to completion of and #esmo22 s1801 #neoadjuvant from', 'completion of and #esmo22 s1801 #neoadjuvant from here', 'of and #esmo22 s1801 #neoadjuvant from here fwd', 'and #esmo22 s1801 #neoadjuvant from here fwd .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '125', 'tokens': ['excellent', 'propel', 'updates', 'from', 'dr.', 'fred', 'saad', 'showing', 'ongoing', 'rpfs', 'benefit', 'from', '1l', 'mcrpc', 'treatment', 'w/', 'abiraterone+olaparib', '.', 'look', 'forward', 'to', 'ongoing', 'os', 'updates', 'and', 'biomarker', 'data', '#esmo22', '#prostatecancer', '.'], 'text_length': 30, 'triples': {'propel|ongoing rpfs benefit from 1l mcrpc treatment w/ abiraterone+olaparib . look forward to': ([1, 1], [8, 20], 'positive'), 'abiraterone+olaparib|ongoing rpfs benefit from 1l mcrpc treatment w/ abiraterone+olaparib . look forward to': ([16, 16], [8, 20], 'positive')}, 'sentence': 'excellent propel updates from dr. fred saad showing ongoing rpfs benefit from 1l mcrpc treatment w/ abiraterone+olaparib . look forward to ongoing os updates and biomarker data #esmo22 #prostatecancer .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(1, 1), (16, 16)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(8, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8)], 'span tokens': ['excellent', 'propel', 'updates', 'from', 'dr.', 'fred', 'saad', 'showing', 'ongoing', 'rpfs', 'benefit', 'from', '1l', 'mcrpc', 'treatment', 'w/', 'abiraterone+olaparib', '.', 'look', 'forward', 'to', 'ongoing', 'os', 'updates', 'and', 'biomarker', 'data', '#esmo22', '#prostatecancer', '.', 'excellent propel', 'propel updates', 'updates from', 'from dr.', 'dr. fred', 'fred saad', 'saad showing', 'showing ongoing', 'ongoing rpfs', 'rpfs benefit', 'benefit from', 'from 1l', '1l mcrpc', 'mcrpc treatment', 'treatment w/', 'w/ abiraterone+olaparib', 'abiraterone+olaparib .', '. look', 'look forward', 'forward to', 'to ongoing', 'ongoing os', 'os updates', 'updates and', 'and biomarker', 'biomarker data', 'data #esmo22', '#esmo22 #prostatecancer', '#prostatecancer .', 'excellent propel updates', 'propel updates from', 'updates from dr.', 'from dr. fred', 'dr. fred saad', 'fred saad showing', 'saad showing ongoing', 'showing ongoing rpfs', 'ongoing rpfs benefit', 'rpfs benefit from', 'benefit from 1l', 'from 1l mcrpc', '1l mcrpc treatment', 'mcrpc treatment w/', 'treatment w/ abiraterone+olaparib', 'w/ abiraterone+olaparib .', 'abiraterone+olaparib . look', '. look forward', 'look forward to', 'forward to ongoing', 'to ongoing os', 'ongoing os updates', 'os updates and', 'updates and biomarker', 'and biomarker data', 'biomarker data #esmo22', 'data #esmo22 #prostatecancer', '#esmo22 #prostatecancer .', 'excellent propel updates from', 'propel updates from dr.', 'updates from dr. fred', 'from dr. fred saad', 'dr. fred saad showing', 'fred saad showing ongoing', 'saad showing ongoing rpfs', 'showing ongoing rpfs benefit', 'ongoing rpfs benefit from', 'rpfs benefit from 1l', 'benefit from 1l mcrpc', 'from 1l mcrpc treatment', '1l mcrpc treatment w/', 'mcrpc treatment w/ abiraterone+olaparib', 'treatment w/ abiraterone+olaparib .', 'w/ abiraterone+olaparib . look', 'abiraterone+olaparib . look forward', '. look forward to', 'look forward to ongoing', 'forward to ongoing os', 'to ongoing os updates', 'ongoing os updates and', 'os updates and biomarker', 'updates and biomarker data', 'and biomarker data #esmo22', 'biomarker data #esmo22 #prostatecancer', 'data #esmo22 #prostatecancer .', 'excellent propel updates from dr.', 'propel updates from dr. fred', 'updates from dr. fred saad', 'from dr. fred saad showing', 'dr. fred saad showing ongoing', 'fred saad showing ongoing rpfs', 'saad showing ongoing rpfs benefit', 'showing ongoing rpfs benefit from', 'ongoing rpfs benefit from 1l', 'rpfs benefit from 1l mcrpc', 'benefit from 1l mcrpc treatment', 'from 1l mcrpc treatment w/', '1l mcrpc treatment w/ abiraterone+olaparib', 'mcrpc treatment w/ abiraterone+olaparib .', 'treatment w/ abiraterone+olaparib . look', 'w/ abiraterone+olaparib . look forward', 'abiraterone+olaparib . look forward to', '. look forward to ongoing', 'look forward to ongoing os', 'forward to ongoing os updates', 'to ongoing os updates and', 'ongoing os updates and biomarker', 'os updates and biomarker data', 'updates and biomarker data #esmo22', 'and biomarker data #esmo22 #prostatecancer', 'biomarker data #esmo22 #prostatecancer .', 'excellent propel updates from dr. fred', 'propel updates from dr. fred saad', 'updates from dr. fred saad showing', 'from dr. fred saad showing ongoing', 'dr. fred saad showing ongoing rpfs', 'fred saad showing ongoing rpfs benefit', 'saad showing ongoing rpfs benefit from', 'showing ongoing rpfs benefit from 1l', 'ongoing rpfs benefit from 1l mcrpc', 'rpfs benefit from 1l mcrpc treatment', 'benefit from 1l mcrpc treatment w/', 'from 1l mcrpc treatment w/ abiraterone+olaparib', '1l mcrpc treatment w/ abiraterone+olaparib .', 'mcrpc treatment w/ abiraterone+olaparib . look', 'treatment w/ abiraterone+olaparib . look forward', 'w/ abiraterone+olaparib . look forward to', 'abiraterone+olaparib . look forward to ongoing', '. look forward to ongoing os', 'look forward to ongoing os updates', 'forward to ongoing os updates and', 'to ongoing os updates and biomarker', 'ongoing os updates and biomarker data', 'os updates and biomarker data #esmo22', 'updates and biomarker data #esmo22 #prostatecancer', 'and biomarker data #esmo22 #prostatecancer .', 'excellent propel updates from dr. fred saad', 'propel updates from dr. fred saad showing', 'updates from dr. fred saad showing ongoing', 'from dr. fred saad showing ongoing rpfs', 'dr. fred saad showing ongoing rpfs benefit', 'fred saad showing ongoing rpfs benefit from', 'saad showing ongoing rpfs benefit from 1l', 'showing ongoing rpfs benefit from 1l mcrpc', 'ongoing rpfs benefit from 1l mcrpc treatment', 'rpfs benefit from 1l mcrpc treatment w/', 'benefit from 1l mcrpc treatment w/ abiraterone+olaparib', 'from 1l mcrpc treatment w/ abiraterone+olaparib .', '1l mcrpc treatment w/ abiraterone+olaparib . look', 'mcrpc treatment w/ abiraterone+olaparib . look forward', 'treatment w/ abiraterone+olaparib . look forward to', 'w/ abiraterone+olaparib . look forward to ongoing', 'abiraterone+olaparib . look forward to ongoing os', '. look forward to ongoing os updates', 'look forward to ongoing os updates and', 'forward to ongoing os updates and biomarker', 'to ongoing os updates and biomarker data', 'ongoing os updates and biomarker data #esmo22', 'os updates and biomarker data #esmo22 #prostatecancer', 'updates and biomarker data #esmo22 #prostatecancer .', 'excellent propel updates from dr. fred saad showing', 'propel updates from dr. fred saad showing ongoing', 'updates from dr. fred saad showing ongoing rpfs', 'from dr. fred saad showing ongoing rpfs benefit', 'dr. fred saad showing ongoing rpfs benefit from', 'fred saad showing ongoing rpfs benefit from 1l', 'saad showing ongoing rpfs benefit from 1l mcrpc', 'showing ongoing rpfs benefit from 1l mcrpc treatment', 'ongoing rpfs benefit from 1l mcrpc treatment w/', 'rpfs benefit from 1l mcrpc treatment w/ abiraterone+olaparib', 'benefit from 1l mcrpc treatment w/ abiraterone+olaparib .', 'from 1l mcrpc treatment w/ abiraterone+olaparib . look', '1l mcrpc treatment w/ abiraterone+olaparib . look forward', 'mcrpc treatment w/ abiraterone+olaparib . look forward to', 'treatment w/ abiraterone+olaparib . look forward to ongoing', 'w/ abiraterone+olaparib . look forward to ongoing os', 'abiraterone+olaparib . look forward to ongoing os updates', '. look forward to ongoing os updates and', 'look forward to ongoing os updates and biomarker', 'forward to ongoing os updates and biomarker data', 'to ongoing os updates and biomarker data #esmo22', 'ongoing os updates and biomarker data #esmo22 #prostatecancer', 'os updates and biomarker data #esmo22 #prostatecancer .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '126', 'tokens': ['#ASH22', 'LBA', 'ALPINE', 'study', '', 'zanubrutinib', 'superior', 'to', 'ibrutinib', 'in', '#CLL', '@OncLive', 'include', 'tp53', 'mutated', 'pts.', '#leusm', 'https://t.co/7CsqCYT9Rz', '.'], 'text_length': 19, 'triples': {'ALPINE|superior': ([2, 2], [5, 5], 'positive'), 'ibrutinib|superior to': ([7, 7], [5, 6], 'negative'), 'zanubrutinib|superior': ([4, 4], [5, 5], 'positive')}, 'sentence': '#ASH22 LBA ALPINE study  zanubrutinib superior to ibrutinib in #CLL @OncLive include tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(2, 2), (7, 7), (4, 4)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(5, 5), (5, 6)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['#ASH22', 'LBA', 'ALPINE', 'study', '', 'zanubrutinib', 'superior', 'to', 'ibrutinib', 'in', '#CLL', '@OncLive', 'include', 'tp53', 'mutated', 'pts.', '#leusm', 'https://t.co/7CsqCYT9Rz', '.', '#ASH22 LBA', 'LBA ALPINE', 'ALPINE study', 'study ', ' zanubrutinib', 'zanubrutinib superior', 'superior to', 'to ibrutinib', 'ibrutinib in', 'in #CLL', '#CLL @OncLive', '@OncLive include', 'include tp53', 'tp53 mutated', 'mutated pts.', 'pts. #leusm', '#leusm https://t.co/7CsqCYT9Rz', 'https://t.co/7CsqCYT9Rz .', '#ASH22 LBA ALPINE', 'LBA ALPINE study', 'ALPINE study ', 'study  zanubrutinib', ' zanubrutinib superior', 'zanubrutinib superior to', 'superior to ibrutinib', 'to ibrutinib in', 'ibrutinib in #CLL', 'in #CLL @OncLive', '#CLL @OncLive include', '@OncLive include tp53', 'include tp53 mutated', 'tp53 mutated pts.', 'mutated pts. #leusm', 'pts. #leusm https://t.co/7CsqCYT9Rz', '#leusm https://t.co/7CsqCYT9Rz .', '#ASH22 LBA ALPINE study', 'LBA ALPINE study ', 'ALPINE study  zanubrutinib', 'study  zanubrutinib superior', ' zanubrutinib superior to', 'zanubrutinib superior to ibrutinib', 'superior to ibrutinib in', 'to ibrutinib in #CLL', 'ibrutinib in #CLL @OncLive', 'in #CLL @OncLive include', '#CLL @OncLive include tp53', '@OncLive include tp53 mutated', 'include tp53 mutated pts.', 'tp53 mutated pts. #leusm', 'mutated pts. #leusm https://t.co/7CsqCYT9Rz', 'pts. #leusm https://t.co/7CsqCYT9Rz .', '#ASH22 LBA ALPINE study ', 'LBA ALPINE study  zanubrutinib', 'ALPINE study  zanubrutinib superior', 'study  zanubrutinib superior to', ' zanubrutinib superior to ibrutinib', 'zanubrutinib superior to ibrutinib in', 'superior to ibrutinib in #CLL', 'to ibrutinib in #CLL @OncLive', 'ibrutinib in #CLL @OncLive include', 'in #CLL @OncLive include tp53', '#CLL @OncLive include tp53 mutated', '@OncLive include tp53 mutated pts.', 'include tp53 mutated pts. #leusm', 'tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz', 'mutated pts. #leusm https://t.co/7CsqCYT9Rz .', '#ASH22 LBA ALPINE study  zanubrutinib', 'LBA ALPINE study  zanubrutinib superior', 'ALPINE study  zanubrutinib superior to', 'study  zanubrutinib superior to ibrutinib', ' zanubrutinib superior to ibrutinib in', 'zanubrutinib superior to ibrutinib in #CLL', 'superior to ibrutinib in #CLL @OncLive', 'to ibrutinib in #CLL @OncLive include', 'ibrutinib in #CLL @OncLive include tp53', 'in #CLL @OncLive include tp53 mutated', '#CLL @OncLive include tp53 mutated pts.', '@OncLive include tp53 mutated pts. #leusm', 'include tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz', 'tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz .', '#ASH22 LBA ALPINE study  zanubrutinib superior', 'LBA ALPINE study  zanubrutinib superior to', 'ALPINE study  zanubrutinib superior to ibrutinib', 'study  zanubrutinib superior to ibrutinib in', ' zanubrutinib superior to ibrutinib in #CLL', 'zanubrutinib superior to ibrutinib in #CLL @OncLive', 'superior to ibrutinib in #CLL @OncLive include', 'to ibrutinib in #CLL @OncLive include tp53', 'ibrutinib in #CLL @OncLive include tp53 mutated', 'in #CLL @OncLive include tp53 mutated pts.', '#CLL @OncLive include tp53 mutated pts. #leusm', '@OncLive include tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz', 'include tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz .', '#ASH22 LBA ALPINE study  zanubrutinib superior to', 'LBA ALPINE study  zanubrutinib superior to ibrutinib', 'ALPINE study  zanubrutinib superior to ibrutinib in', 'study  zanubrutinib superior to ibrutinib in #CLL', ' zanubrutinib superior to ibrutinib in #CLL @OncLive', 'zanubrutinib superior to ibrutinib in #CLL @OncLive include', 'superior to ibrutinib in #CLL @OncLive include tp53', 'to ibrutinib in #CLL @OncLive include tp53 mutated', 'ibrutinib in #CLL @OncLive include tp53 mutated pts.', 'in #CLL @OncLive include tp53 mutated pts. #leusm', '#CLL @OncLive include tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz', '@OncLive include tp53 mutated pts. #leusm https://t.co/7CsqCYT9Rz .'], 'spans_aspect_label': [0, 0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '127', 'tokens': ['watching', 'on', 'demand', 'great', 'data', 'from', 'on', 'the', 'karmma', 'trial', 'and', 'the', 'importance', 'of', 'mrd', 'testing', '#ash22', '#mmsm', '#cart', 'congrats!', '.'], 'text_length': 21, 'triples': {'karmma|demand great data': ([8, 8], [2, 4], 'neutral')}, 'sentence': 'watching on demand great data from on the karmma trial and the importance of mrd testing #ash22 #mmsm #cart congrats! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['watching', 'on', 'demand', 'great', 'data', 'from', 'on', 'the', 'karmma', 'trial', 'and', 'the', 'importance', 'of', 'mrd', 'testing', '#ash22', '#mmsm', '#cart', 'congrats!', '.', 'watching on', 'on demand', 'demand great', 'great data', 'data from', 'from on', 'on the', 'the karmma', 'karmma trial', 'trial and', 'and the', 'the importance', 'importance of', 'of mrd', 'mrd testing', 'testing #ash22', '#ash22 #mmsm', '#mmsm #cart', '#cart congrats!', 'congrats! .', 'watching on demand', 'on demand great', 'demand great data', 'great data from', 'data from on', 'from on the', 'on the karmma', 'the karmma trial', 'karmma trial and', 'trial and the', 'and the importance', 'the importance of', 'importance of mrd', 'of mrd testing', 'mrd testing #ash22', 'testing #ash22 #mmsm', '#ash22 #mmsm #cart', '#mmsm #cart congrats!', '#cart congrats! .', 'watching on demand great', 'on demand great data', 'demand great data from', 'great data from on', 'data from on the', 'from on the karmma', 'on the karmma trial', 'the karmma trial and', 'karmma trial and the', 'trial and the importance', 'and the importance of', 'the importance of mrd', 'importance of mrd testing', 'of mrd testing #ash22', 'mrd testing #ash22 #mmsm', 'testing #ash22 #mmsm #cart', '#ash22 #mmsm #cart congrats!', '#mmsm #cart congrats! .', 'watching on demand great data', 'on demand great data from', 'demand great data from on', 'great data from on the', 'data from on the karmma', 'from on the karmma trial', 'on the karmma trial and', 'the karmma trial and the', 'karmma trial and the importance', 'trial and the importance of', 'and the importance of mrd', 'the importance of mrd testing', 'importance of mrd testing #ash22', 'of mrd testing #ash22 #mmsm', 'mrd testing #ash22 #mmsm #cart', 'testing #ash22 #mmsm #cart congrats!', '#ash22 #mmsm #cart congrats! .', 'watching on demand great data from', 'on demand great data from on', 'demand great data from on the', 'great data from on the karmma', 'data from on the karmma trial', 'from on the karmma trial and', 'on the karmma trial and the', 'the karmma trial and the importance', 'karmma trial and the importance of', 'trial and the importance of mrd', 'and the importance of mrd testing', 'the importance of mrd testing #ash22', 'importance of mrd testing #ash22 #mmsm', 'of mrd testing #ash22 #mmsm #cart', 'mrd testing #ash22 #mmsm #cart congrats!', 'testing #ash22 #mmsm #cart congrats! .', 'watching on demand great data from on', 'on demand great data from on the', 'demand great data from on the karmma', 'great data from on the karmma trial', 'data from on the karmma trial and', 'from on the karmma trial and the', 'on the karmma trial and the importance', 'the karmma trial and the importance of', 'karmma trial and the importance of mrd', 'trial and the importance of mrd testing', 'and the importance of mrd testing #ash22', 'the importance of mrd testing #ash22 #mmsm', 'importance of mrd testing #ash22 #mmsm #cart', 'of mrd testing #ash22 #mmsm #cart congrats!', 'mrd testing #ash22 #mmsm #cart congrats! .', 'watching on demand great data from on the', 'on demand great data from on the karmma', 'demand great data from on the karmma trial', 'great data from on the karmma trial and', 'data from on the karmma trial and the', 'from on the karmma trial and the importance', 'on the karmma trial and the importance of', 'the karmma trial and the importance of mrd', 'karmma trial and the importance of mrd testing', 'trial and the importance of mrd testing #ash22', 'and the importance of mrd testing #ash22 #mmsm', 'the importance of mrd testing #ash22 #mmsm #cart', 'importance of mrd testing #ash22 #mmsm #cart congrats!', 'of mrd testing #ash22 #mmsm #cart congrats! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '128', 'tokens': ['gu', 'abstract', '#asco2022', 'moderated', 'by', 'dr.', 'eric', 'singer', 'and', 'dr.', 'buphati.', 'dr.', 'ryan', 'presenting', 'everest', 'results.', '.'], 'text_length': 17, 'triples': {'everest|presenting': ([14, 14], [13, 13], 'neutral')}, 'sentence': 'gu abstract #asco2022 moderated by dr. eric singer and dr. buphati. dr. ryan presenting everest results. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(14, 14)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(13, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8)], 'span tokens': ['gu', 'abstract', '#asco2022', 'moderated', 'by', 'dr.', 'eric', 'singer', 'and', 'dr.', 'buphati.', 'dr.', 'ryan', 'presenting', 'everest', 'results.', '.', 'gu abstract', 'abstract #asco2022', '#asco2022 moderated', 'moderated by', 'by dr.', 'dr. eric', 'eric singer', 'singer and', 'and dr.', 'dr. buphati.', 'buphati. dr.', 'dr. ryan', 'ryan presenting', 'presenting everest', 'everest results.', 'results. .', 'gu abstract #asco2022', 'abstract #asco2022 moderated', '#asco2022 moderated by', 'moderated by dr.', 'by dr. eric', 'dr. eric singer', 'eric singer and', 'singer and dr.', 'and dr. buphati.', 'dr. buphati. dr.', 'buphati. dr. ryan', 'dr. ryan presenting', 'ryan presenting everest', 'presenting everest results.', 'everest results. .', 'gu abstract #asco2022 moderated', 'abstract #asco2022 moderated by', '#asco2022 moderated by dr.', 'moderated by dr. eric', 'by dr. eric singer', 'dr. eric singer and', 'eric singer and dr.', 'singer and dr. buphati.', 'and dr. buphati. dr.', 'dr. buphati. dr. ryan', 'buphati. dr. ryan presenting', 'dr. ryan presenting everest', 'ryan presenting everest results.', 'presenting everest results. .', 'gu abstract #asco2022 moderated by', 'abstract #asco2022 moderated by dr.', '#asco2022 moderated by dr. eric', 'moderated by dr. eric singer', 'by dr. eric singer and', 'dr. eric singer and dr.', 'eric singer and dr. buphati.', 'singer and dr. buphati. dr.', 'and dr. buphati. dr. ryan', 'dr. buphati. dr. ryan presenting', 'buphati. dr. ryan presenting everest', 'dr. ryan presenting everest results.', 'ryan presenting everest results. .', 'gu abstract #asco2022 moderated by dr.', 'abstract #asco2022 moderated by dr. eric', '#asco2022 moderated by dr. eric singer', 'moderated by dr. eric singer and', 'by dr. eric singer and dr.', 'dr. eric singer and dr. buphati.', 'eric singer and dr. buphati. dr.', 'singer and dr. buphati. dr. ryan', 'and dr. buphati. dr. ryan presenting', 'dr. buphati. dr. ryan presenting everest', 'buphati. dr. ryan presenting everest results.', 'dr. ryan presenting everest results. .', 'gu abstract #asco2022 moderated by dr. eric', 'abstract #asco2022 moderated by dr. eric singer', '#asco2022 moderated by dr. eric singer and', 'moderated by dr. eric singer and dr.', 'by dr. eric singer and dr. buphati.', 'dr. eric singer and dr. buphati. dr.', 'eric singer and dr. buphati. dr. ryan', 'singer and dr. buphati. dr. ryan presenting', 'and dr. buphati. dr. ryan presenting everest', 'dr. buphati. dr. ryan presenting everest results.', 'buphati. dr. ryan presenting everest results. .', 'gu abstract #asco2022 moderated by dr. eric singer', 'abstract #asco2022 moderated by dr. eric singer and', '#asco2022 moderated by dr. eric singer and dr.', 'moderated by dr. eric singer and dr. buphati.', 'by dr. eric singer and dr. buphati. dr.', 'dr. eric singer and dr. buphati. dr. ryan', 'eric singer and dr. buphati. dr. ryan presenting', 'singer and dr. buphati. dr. ryan presenting everest', 'and dr. buphati. dr. ryan presenting everest results.', 'dr. buphati. dr. ryan presenting everest results. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '129', 'tokens': ['#asco22', 'really', 'interesting', 'result', 'in', 'the', 'highest', 'group', 'actually', 'with', 'a', 'hr', 'or', 'almost', '0.8.', 'i', 'think', 'of', 'everolimus', 'as', 'a', 'well', 'tolerated', 'drug', 'when', 'mouth', 'ulcerations', 'are', 'prevented', '/', 'managed.', 'also,', 'generic', 'now..', 'cheap', 'and', 'no', 'permanent', 'organ', 'damage', 'as', 'with', 'io.', 'enthusiasm', 'to', 'revisit?', '.'], 'text_length': 47, 'triples': {'everolimus|really interesting result in the highest group actually with a hr or almost 0.8. i think of everolimus as a well tolerated': ([18, 18], [1, 22], 'positive')}, 'sentence': '#asco22 really interesting result in the highest group actually with a hr or almost 0.8. i think of everolimus as a well tolerated drug when mouth ulcerations are prevented / managed. also, generic now.. cheap and no permanent organ damage as with io. enthusiasm to revisit? .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8)], 'span tokens': ['#asco22', 'really', 'interesting', 'result', 'in', 'the', 'highest', 'group', 'actually', 'with', 'a', 'hr', 'or', 'almost', '0.8.', 'i', 'think', 'of', 'everolimus', 'as', 'a', 'well', 'tolerated', 'drug', 'when', 'mouth', 'ulcerations', 'are', 'prevented', '/', 'managed.', 'also,', 'generic', 'now..', 'cheap', 'and', 'no', 'permanent', 'organ', 'damage', 'as', 'with', 'io.', 'enthusiasm', 'to', 'revisit?', '.', '#asco22 really', 'really interesting', 'interesting result', 'result in', 'in the', 'the highest', 'highest group', 'group actually', 'actually with', 'with a', 'a hr', 'hr or', 'or almost', 'almost 0.8.', '0.8. i', 'i think', 'think of', 'of everolimus', 'everolimus as', 'as a', 'a well', 'well tolerated', 'tolerated drug', 'drug when', 'when mouth', 'mouth ulcerations', 'ulcerations are', 'are prevented', 'prevented /', '/ managed.', 'managed. also,', 'also, generic', 'generic now..', 'now.. cheap', 'cheap and', 'and no', 'no permanent', 'permanent organ', 'organ damage', 'damage as', 'as with', 'with io.', 'io. enthusiasm', 'enthusiasm to', 'to revisit?', 'revisit? .', '#asco22 really interesting', 'really interesting result', 'interesting result in', 'result in the', 'in the highest', 'the highest group', 'highest group actually', 'group actually with', 'actually with a', 'with a hr', 'a hr or', 'hr or almost', 'or almost 0.8.', 'almost 0.8. i', '0.8. i think', 'i think of', 'think of everolimus', 'of everolimus as', 'everolimus as a', 'as a well', 'a well tolerated', 'well tolerated drug', 'tolerated drug when', 'drug when mouth', 'when mouth ulcerations', 'mouth ulcerations are', 'ulcerations are prevented', 'are prevented /', 'prevented / managed.', '/ managed. also,', 'managed. also, generic', 'also, generic now..', 'generic now.. cheap', 'now.. cheap and', 'cheap and no', 'and no permanent', 'no permanent organ', 'permanent organ damage', 'organ damage as', 'damage as with', 'as with io.', 'with io. enthusiasm', 'io. enthusiasm to', 'enthusiasm to revisit?', 'to revisit? .', '#asco22 really interesting result', 'really interesting result in', 'interesting result in the', 'result in the highest', 'in the highest group', 'the highest group actually', 'highest group actually with', 'group actually with a', 'actually with a hr', 'with a hr or', 'a hr or almost', 'hr or almost 0.8.', 'or almost 0.8. i', 'almost 0.8. i think', '0.8. i think of', 'i think of everolimus', 'think of everolimus as', 'of everolimus as a', 'everolimus as a well', 'as a well tolerated', 'a well tolerated drug', 'well tolerated drug when', 'tolerated drug when mouth', 'drug when mouth ulcerations', 'when mouth ulcerations are', 'mouth ulcerations are prevented', 'ulcerations are prevented /', 'are prevented / managed.', 'prevented / managed. also,', '/ managed. also, generic', 'managed. also, generic now..', 'also, generic now.. cheap', 'generic now.. cheap and', 'now.. cheap and no', 'cheap and no permanent', 'and no permanent organ', 'no permanent organ damage', 'permanent organ damage as', 'organ damage as with', 'damage as with io.', 'as with io. enthusiasm', 'with io. enthusiasm to', 'io. enthusiasm to revisit?', 'enthusiasm to revisit? .', '#asco22 really interesting result in', 'really interesting result in the', 'interesting result in the highest', 'result in the highest group', 'in the highest group actually', 'the highest group actually with', 'highest group actually with a', 'group actually with a hr', 'actually with a hr or', 'with a hr or almost', 'a hr or almost 0.8.', 'hr or almost 0.8. i', 'or almost 0.8. i think', 'almost 0.8. i think of', '0.8. i think of everolimus', 'i think of everolimus as', 'think of everolimus as a', 'of everolimus as a well', 'everolimus as a well tolerated', 'as a well tolerated drug', 'a well tolerated drug when', 'well tolerated drug when mouth', 'tolerated drug when mouth ulcerations', 'drug when mouth ulcerations are', 'when mouth ulcerations are prevented', 'mouth ulcerations are prevented /', 'ulcerations are prevented / managed.', 'are prevented / managed. also,', 'prevented / managed. also, generic', '/ managed. also, generic now..', 'managed. also, generic now.. cheap', 'also, generic now.. cheap and', 'generic now.. cheap and no', 'now.. cheap and no permanent', 'cheap and no permanent organ', 'and no permanent organ damage', 'no permanent organ damage as', 'permanent organ damage as with', 'organ damage as with io.', 'damage as with io. enthusiasm', 'as with io. enthusiasm to', 'with io. enthusiasm to revisit?', 'io. enthusiasm to revisit? .', '#asco22 really interesting result in the', 'really interesting result in the highest', 'interesting result in the highest group', 'result in the highest group actually', 'in the highest group actually with', 'the highest group actually with a', 'highest group actually with a hr', 'group actually with a hr or', 'actually with a hr or almost', 'with a hr or almost 0.8.', 'a hr or almost 0.8. i', 'hr or almost 0.8. i think', 'or almost 0.8. i think of', 'almost 0.8. i think of everolimus', '0.8. i think of everolimus as', 'i think of everolimus as a', 'think of everolimus as a well', 'of everolimus as a well tolerated', 'everolimus as a well tolerated drug', 'as a well tolerated drug when', 'a well tolerated drug when mouth', 'well tolerated drug when mouth ulcerations', 'tolerated drug when mouth ulcerations are', 'drug when mouth ulcerations are prevented', 'when mouth ulcerations are prevented /', 'mouth ulcerations are prevented / managed.', 'ulcerations are prevented / managed. also,', 'are prevented / managed. also, generic', 'prevented / managed. also, generic now..', '/ managed. also, generic now.. cheap', 'managed. also, generic now.. cheap and', 'also, generic now.. cheap and no', 'generic now.. cheap and no permanent', 'now.. cheap and no permanent organ', 'cheap and no permanent organ damage', 'and no permanent organ damage as', 'no permanent organ damage as with', 'permanent organ damage as with io.', 'organ damage as with io. enthusiasm', 'damage as with io. enthusiasm to', 'as with io. enthusiasm to revisit?', 'with io. enthusiasm to revisit? .', '#asco22 really interesting result in the highest', 'really interesting result in the highest group', 'interesting result in the highest group actually', 'result in the highest group actually with', 'in the highest group actually with a', 'the highest group actually with a hr', 'highest group actually with a hr or', 'group actually with a hr or almost', 'actually with a hr or almost 0.8.', 'with a hr or almost 0.8. i', 'a hr or almost 0.8. i think', 'hr or almost 0.8. i think of', 'or almost 0.8. i think of everolimus', 'almost 0.8. i think of everolimus as', '0.8. i think of everolimus as a', 'i think of everolimus as a well', 'think of everolimus as a well tolerated', 'of everolimus as a well tolerated drug', 'everolimus as a well tolerated drug when', 'as a well tolerated drug when mouth', 'a well tolerated drug when mouth ulcerations', 'well tolerated drug when mouth ulcerations are', 'tolerated drug when mouth ulcerations are prevented', 'drug when mouth ulcerations are prevented /', 'when mouth ulcerations are prevented / managed.', 'mouth ulcerations are prevented / managed. also,', 'ulcerations are prevented / managed. also, generic', 'are prevented / managed. also, generic now..', 'prevented / managed. also, generic now.. cheap', '/ managed. also, generic now.. cheap and', 'managed. also, generic now.. cheap and no', 'also, generic now.. cheap and no permanent', 'generic now.. cheap and no permanent organ', 'now.. cheap and no permanent organ damage', 'cheap and no permanent organ damage as', 'and no permanent organ damage as with', 'no permanent organ damage as with io.', 'permanent organ damage as with io. enthusiasm', 'organ damage as with io. enthusiasm to', 'damage as with io. enthusiasm to revisit?', 'as with io. enthusiasm to revisit? .', '#asco22 really interesting result in the highest group', 'really interesting result in the highest group actually', 'interesting result in the highest group actually with', 'result in the highest group actually with a', 'in the highest group actually with a hr', 'the highest group actually with a hr or', 'highest group actually with a hr or almost', 'group actually with a hr or almost 0.8.', 'actually with a hr or almost 0.8. i', 'with a hr or almost 0.8. i think', 'a hr or almost 0.8. i think of', 'hr or almost 0.8. i think of everolimus', 'or almost 0.8. i think of everolimus as', 'almost 0.8. i think of everolimus as a', '0.8. i think of everolimus as a well', 'i think of everolimus as a well tolerated', 'think of everolimus as a well tolerated drug', 'of everolimus as a well tolerated drug when', 'everolimus as a well tolerated drug when mouth', 'as a well tolerated drug when mouth ulcerations', 'a well tolerated drug when mouth ulcerations are', 'well tolerated drug when mouth ulcerations are prevented', 'tolerated drug when mouth ulcerations are prevented /', 'drug when mouth ulcerations are prevented / managed.', 'when mouth ulcerations are prevented / managed. also,', 'mouth ulcerations are prevented / managed. also, generic', 'ulcerations are prevented / managed. also, generic now..', 'are prevented / managed. also, generic now.. cheap', 'prevented / managed. also, generic now.. cheap and', '/ managed. also, generic now.. cheap and no', 'managed. also, generic now.. cheap and no permanent', 'also, generic now.. cheap and no permanent organ', 'generic now.. cheap and no permanent organ damage', 'now.. cheap and no permanent organ damage as', 'cheap and no permanent organ damage as with', 'and no permanent organ damage as with io.', 'no permanent organ damage as with io. enthusiasm', 'permanent organ damage as with io. enthusiasm to', 'organ damage as with io. enthusiasm to revisit?', 'damage as with io. enthusiasm to revisit? .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '130', 'tokens': ['excellent', 'presentation', 'on', 'subgroup', 'analysis', 'by', 'prior', 'and', 'concurrent', 'therapy', 'from', 'vision', '.', 'consistent', 'benefit', 'independent', 'of', 'prior', 'or', 'concurrent', 'therapy.', '.'], 'text_length': 22, 'triples': {'vision|excellent presentation on subgroup analysis by prior and concurrent therapy from vision . consistent benefit': ([11, 11], [0, 14], 'positive')}, 'sentence': 'excellent presentation on subgroup analysis by prior and concurrent therapy from vision . consistent benefit independent of prior or concurrent therapy. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(11, 11)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 14)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['excellent', 'presentation', 'on', 'subgroup', 'analysis', 'by', 'prior', 'and', 'concurrent', 'therapy', 'from', 'vision', '.', 'consistent', 'benefit', 'independent', 'of', 'prior', 'or', 'concurrent', 'therapy.', '.', 'excellent presentation', 'presentation on', 'on subgroup', 'subgroup analysis', 'analysis by', 'by prior', 'prior and', 'and concurrent', 'concurrent therapy', 'therapy from', 'from vision', 'vision .', '. consistent', 'consistent benefit', 'benefit independent', 'independent of', 'of prior', 'prior or', 'or concurrent', 'concurrent therapy.', 'therapy. .', 'excellent presentation on', 'presentation on subgroup', 'on subgroup analysis', 'subgroup analysis by', 'analysis by prior', 'by prior and', 'prior and concurrent', 'and concurrent therapy', 'concurrent therapy from', 'therapy from vision', 'from vision .', 'vision . consistent', '. consistent benefit', 'consistent benefit independent', 'benefit independent of', 'independent of prior', 'of prior or', 'prior or concurrent', 'or concurrent therapy.', 'concurrent therapy. .', 'excellent presentation on subgroup', 'presentation on subgroup analysis', 'on subgroup analysis by', 'subgroup analysis by prior', 'analysis by prior and', 'by prior and concurrent', 'prior and concurrent therapy', 'and concurrent therapy from', 'concurrent therapy from vision', 'therapy from vision .', 'from vision . consistent', 'vision . consistent benefit', '. consistent benefit independent', 'consistent benefit independent of', 'benefit independent of prior', 'independent of prior or', 'of prior or concurrent', 'prior or concurrent therapy.', 'or concurrent therapy. .', 'excellent presentation on subgroup analysis', 'presentation on subgroup analysis by', 'on subgroup analysis by prior', 'subgroup analysis by prior and', 'analysis by prior and concurrent', 'by prior and concurrent therapy', 'prior and concurrent therapy from', 'and concurrent therapy from vision', 'concurrent therapy from vision .', 'therapy from vision . consistent', 'from vision . consistent benefit', 'vision . consistent benefit independent', '. consistent benefit independent of', 'consistent benefit independent of prior', 'benefit independent of prior or', 'independent of prior or concurrent', 'of prior or concurrent therapy.', 'prior or concurrent therapy. .', 'excellent presentation on subgroup analysis by', 'presentation on subgroup analysis by prior', 'on subgroup analysis by prior and', 'subgroup analysis by prior and concurrent', 'analysis by prior and concurrent therapy', 'by prior and concurrent therapy from', 'prior and concurrent therapy from vision', 'and concurrent therapy from vision .', 'concurrent therapy from vision . consistent', 'therapy from vision . consistent benefit', 'from vision . consistent benefit independent', 'vision . consistent benefit independent of', '. consistent benefit independent of prior', 'consistent benefit independent of prior or', 'benefit independent of prior or concurrent', 'independent of prior or concurrent therapy.', 'of prior or concurrent therapy. .', 'excellent presentation on subgroup analysis by prior', 'presentation on subgroup analysis by prior and', 'on subgroup analysis by prior and concurrent', 'subgroup analysis by prior and concurrent therapy', 'analysis by prior and concurrent therapy from', 'by prior and concurrent therapy from vision', 'prior and concurrent therapy from vision .', 'and concurrent therapy from vision . consistent', 'concurrent therapy from vision . consistent benefit', 'therapy from vision . consistent benefit independent', 'from vision . consistent benefit independent of', 'vision . consistent benefit independent of prior', '. consistent benefit independent of prior or', 'consistent benefit independent of prior or concurrent', 'benefit independent of prior or concurrent therapy.', 'independent of prior or concurrent therapy. .', 'excellent presentation on subgroup analysis by prior and', 'presentation on subgroup analysis by prior and concurrent', 'on subgroup analysis by prior and concurrent therapy', 'subgroup analysis by prior and concurrent therapy from', 'analysis by prior and concurrent therapy from vision', 'by prior and concurrent therapy from vision .', 'prior and concurrent therapy from vision . consistent', 'and concurrent therapy from vision . consistent benefit', 'concurrent therapy from vision . consistent benefit independent', 'therapy from vision . consistent benefit independent of', 'from vision . consistent benefit independent of prior', 'vision . consistent benefit independent of prior or', '. consistent benefit independent of prior or concurrent', 'consistent benefit independent of prior or concurrent therapy.', 'benefit independent of prior or concurrent therapy. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '131', 'tokens': ['updates', 'of', 'cm-9er', 'cabozantinib', '/nivolumab', '', '1st', 'line', 'rcc', 'presented', 'at', 'today', 's', 'oral', 'gu', 'session', '&amp;', 'we', 'await', 'results', 'of', '#pdigree', 'which', 'may', 'continue', 'to', 'change', 'the', 'rcc', 'tx', 'landscape:', 'ipi/nivolumab', '', 'followed', 'by', 'cabozantinib', 'vs', 'nivolumab', '', 'vs', 'cabozantinib', '/', 'nivolumab', '', 'based', 'on', 'response', '#asco22', '.'], 'text_length': 49, 'triples': {'cabozantinib /nivolumab 1st line rcc presented at today s oral gu session &amp; we await results of #pdigree which may continue to change the rcc tx landscape: ipi/nivolumab followed by cabozantinib vs nivolumab vs cabozantinib|await results': ([3, 37], [17, 18], 'neutral'), 'cm-9er|await results': ([2, 2], [17, 18], 'neutral'), '/nivolumab 1st line rcc presented at today s oral gu session &amp; we await results of #pdigree which may continue to change the rcc tx landscape: ipi/nivolumab followed by cabozantinib vs nivolumab vs cabozantinib /|await results': ([4, 38], [17, 18], 'neutral')}, 'sentence': 'updates of cm-9er cabozantinib /nivolumab  1st line rcc presented at today s oral gu session &amp; we await results of #pdigree which may continue to change the rcc tx landscape: ipi/nivolumab  followed by cabozantinib vs nivolumab  vs cabozantinib / nivolumab  based on response #asco22 .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(3, 37), (2, 2), (4, 38)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(17, 18)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8)], 'span tokens': ['updates', 'of', 'cm-9er', 'cabozantinib', '/nivolumab', '', '1st', 'line', 'rcc', 'presented', 'at', 'today', 's', 'oral', 'gu', 'session', '&amp;', 'we', 'await', 'results', 'of', '#pdigree', 'which', 'may', 'continue', 'to', 'change', 'the', 'rcc', 'tx', 'landscape:', 'ipi/nivolumab', '', 'followed', 'by', 'cabozantinib', 'vs', 'nivolumab', '', 'vs', 'cabozantinib', '/', 'nivolumab', '', 'based', 'on', 'response', '#asco22', '.', 'updates of', 'of cm-9er', 'cm-9er cabozantinib', 'cabozantinib /nivolumab', '/nivolumab ', ' 1st', '1st line', 'line rcc', 'rcc presented', 'presented at', 'at today', 'today s', 's oral', 'oral gu', 'gu session', 'session &amp;', '&amp; we', 'we await', 'await results', 'results of', 'of #pdigree', '#pdigree which', 'which may', 'may continue', 'continue to', 'to change', 'change the', 'the rcc', 'rcc tx', 'tx landscape:', 'landscape: ipi/nivolumab', 'ipi/nivolumab ', ' followed', 'followed by', 'by cabozantinib', 'cabozantinib vs', 'vs nivolumab', 'nivolumab ', ' vs', 'vs cabozantinib', 'cabozantinib /', '/ nivolumab', 'nivolumab ', ' based', 'based on', 'on response', 'response #asco22', '#asco22 .', 'updates of cm-9er', 'of cm-9er cabozantinib', 'cm-9er cabozantinib /nivolumab', 'cabozantinib /nivolumab ', '/nivolumab  1st', ' 1st line', '1st line rcc', 'line rcc presented', 'rcc presented at', 'presented at today', 'at today s', 'today s oral', 's oral gu', 'oral gu session', 'gu session &amp;', 'session &amp; we', '&amp; we await', 'we await results', 'await results of', 'results of #pdigree', 'of #pdigree which', '#pdigree which may', 'which may continue', 'may continue to', 'continue to change', 'to change the', 'change the rcc', 'the rcc tx', 'rcc tx landscape:', 'tx landscape: ipi/nivolumab', 'landscape: ipi/nivolumab ', 'ipi/nivolumab  followed', ' followed by', 'followed by cabozantinib', 'by cabozantinib vs', 'cabozantinib vs nivolumab', 'vs nivolumab ', 'nivolumab  vs', ' vs cabozantinib', 'vs cabozantinib /', 'cabozantinib / nivolumab', '/ nivolumab ', 'nivolumab  based', ' based on', 'based on response', 'on response #asco22', 'response #asco22 .', 'updates of cm-9er cabozantinib', 'of cm-9er cabozantinib /nivolumab', 'cm-9er cabozantinib /nivolumab ', 'cabozantinib /nivolumab  1st', '/nivolumab  1st line', ' 1st line rcc', '1st line rcc presented', 'line rcc presented at', 'rcc presented at today', 'presented at today s', 'at today s oral', 'today s oral gu', 's oral gu session', 'oral gu session &amp;', 'gu session &amp; we', 'session &amp; we await', '&amp; we await results', 'we await results of', 'await results of #pdigree', 'results of #pdigree which', 'of #pdigree which may', '#pdigree which may continue', 'which may continue to', 'may continue to change', 'continue to change the', 'to change the rcc', 'change the rcc tx', 'the rcc tx landscape:', 'rcc tx landscape: ipi/nivolumab', 'tx landscape: ipi/nivolumab ', 'landscape: ipi/nivolumab  followed', 'ipi/nivolumab  followed by', ' followed by cabozantinib', 'followed by cabozantinib vs', 'by cabozantinib vs nivolumab', 'cabozantinib vs nivolumab ', 'vs nivolumab  vs', 'nivolumab  vs cabozantinib', ' vs cabozantinib /', 'vs cabozantinib / nivolumab', 'cabozantinib / nivolumab ', '/ nivolumab  based', 'nivolumab  based on', ' based on response', 'based on response #asco22', 'on response #asco22 .', 'updates of cm-9er cabozantinib /nivolumab', 'of cm-9er cabozantinib /nivolumab ', 'cm-9er cabozantinib /nivolumab  1st', 'cabozantinib /nivolumab  1st line', '/nivolumab  1st line rcc', ' 1st line rcc presented', '1st line rcc presented at', 'line rcc presented at today', 'rcc presented at today s', 'presented at today s oral', 'at today s oral gu', 'today s oral gu session', 's oral gu session &amp;', 'oral gu session &amp; we', 'gu session &amp; we await', 'session &amp; we await results', '&amp; we await results of', 'we await results of #pdigree', 'await results of #pdigree which', 'results of #pdigree which may', 'of #pdigree which may continue', '#pdigree which may continue to', 'which may continue to change', 'may continue to change the', 'continue to change the rcc', 'to change the rcc tx', 'change the rcc tx landscape:', 'the rcc tx landscape: ipi/nivolumab', 'rcc tx landscape: ipi/nivolumab ', 'tx landscape: ipi/nivolumab  followed', 'landscape: ipi/nivolumab  followed by', 'ipi/nivolumab  followed by cabozantinib', ' followed by cabozantinib vs', 'followed by cabozantinib vs nivolumab', 'by cabozantinib vs nivolumab ', 'cabozantinib vs nivolumab  vs', 'vs nivolumab  vs cabozantinib', 'nivolumab  vs cabozantinib /', ' vs cabozantinib / nivolumab', 'vs cabozantinib / nivolumab ', 'cabozantinib / nivolumab  based', '/ nivolumab  based on', 'nivolumab  based on response', ' based on response #asco22', 'based on response #asco22 .', 'updates of cm-9er cabozantinib /nivolumab ', 'of cm-9er cabozantinib /nivolumab  1st', 'cm-9er cabozantinib /nivolumab  1st line', 'cabozantinib /nivolumab  1st line rcc', '/nivolumab  1st line rcc presented', ' 1st line rcc presented at', '1st line rcc presented at today', 'line rcc presented at today s', 'rcc presented at today s oral', 'presented at today s oral gu', 'at today s oral gu session', 'today s oral gu session &amp;', 's oral gu session &amp; we', 'oral gu session &amp; we await', 'gu session &amp; we await results', 'session &amp; we await results of', '&amp; we await results of #pdigree', 'we await results of #pdigree which', 'await results of #pdigree which may', 'results of #pdigree which may continue', 'of #pdigree which may continue to', '#pdigree which may continue to change', 'which may continue to change the', 'may continue to change the rcc', 'continue to change the rcc tx', 'to change the rcc tx landscape:', 'change the rcc tx landscape: ipi/nivolumab', 'the rcc tx landscape: ipi/nivolumab ', 'rcc tx landscape: ipi/nivolumab  followed', 'tx landscape: ipi/nivolumab  followed by', 'landscape: ipi/nivolumab  followed by cabozantinib', 'ipi/nivolumab  followed by cabozantinib vs', ' followed by cabozantinib vs nivolumab', 'followed by cabozantinib vs nivolumab ', 'by cabozantinib vs nivolumab  vs', 'cabozantinib vs nivolumab  vs cabozantinib', 'vs nivolumab  vs cabozantinib /', 'nivolumab  vs cabozantinib / nivolumab', ' vs cabozantinib / nivolumab ', 'vs cabozantinib / nivolumab  based', 'cabozantinib / nivolumab  based on', '/ nivolumab  based on response', 'nivolumab  based on response #asco22', ' based on response #asco22 .', 'updates of cm-9er cabozantinib /nivolumab  1st', 'of cm-9er cabozantinib /nivolumab  1st line', 'cm-9er cabozantinib /nivolumab  1st line rcc', 'cabozantinib /nivolumab  1st line rcc presented', '/nivolumab  1st line rcc presented at', ' 1st line rcc presented at today', '1st line rcc presented at today s', 'line rcc presented at today s oral', 'rcc presented at today s oral gu', 'presented at today s oral gu session', 'at today s oral gu session &amp;', 'today s oral gu session &amp; we', 's oral gu session &amp; we await', 'oral gu session &amp; we await results', 'gu session &amp; we await results of', 'session &amp; we await results of #pdigree', '&amp; we await results of #pdigree which', 'we await results of #pdigree which may', 'await results of #pdigree which may continue', 'results of #pdigree which may continue to', 'of #pdigree which may continue to change', '#pdigree which may continue to change the', 'which may continue to change the rcc', 'may continue to change the rcc tx', 'continue to change the rcc tx landscape:', 'to change the rcc tx landscape: ipi/nivolumab', 'change the rcc tx landscape: ipi/nivolumab ', 'the rcc tx landscape: ipi/nivolumab  followed', 'rcc tx landscape: ipi/nivolumab  followed by', 'tx landscape: ipi/nivolumab  followed by cabozantinib', 'landscape: ipi/nivolumab  followed by cabozantinib vs', 'ipi/nivolumab  followed by cabozantinib vs nivolumab', ' followed by cabozantinib vs nivolumab ', 'followed by cabozantinib vs nivolumab  vs', 'by cabozantinib vs nivolumab  vs cabozantinib', 'cabozantinib vs nivolumab  vs cabozantinib /', 'vs nivolumab  vs cabozantinib / nivolumab', 'nivolumab  vs cabozantinib / nivolumab ', ' vs cabozantinib / nivolumab  based', 'vs cabozantinib / nivolumab  based on', 'cabozantinib / nivolumab  based on response', '/ nivolumab  based on response #asco22', 'nivolumab  based on response #asco22 .', 'updates of cm-9er cabozantinib /nivolumab  1st line', 'of cm-9er cabozantinib /nivolumab  1st line rcc', 'cm-9er cabozantinib /nivolumab  1st line rcc presented', 'cabozantinib /nivolumab  1st line rcc presented at', '/nivolumab  1st line rcc presented at today', ' 1st line rcc presented at today s', '1st line rcc presented at today s oral', 'line rcc presented at today s oral gu', 'rcc presented at today s oral gu session', 'presented at today s oral gu session &amp;', 'at today s oral gu session &amp; we', 'today s oral gu session &amp; we await', 's oral gu session &amp; we await results', 'oral gu session &amp; we await results of', 'gu session &amp; we await results of #pdigree', 'session &amp; we await results of #pdigree which', '&amp; we await results of #pdigree which may', 'we await results of #pdigree which may continue', 'await results of #pdigree which may continue to', 'results of #pdigree which may continue to change', 'of #pdigree which may continue to change the', '#pdigree which may continue to change the rcc', 'which may continue to change the rcc tx', 'may continue to change the rcc tx landscape:', 'continue to change the rcc tx landscape: ipi/nivolumab', 'to change the rcc tx landscape: ipi/nivolumab ', 'change the rcc tx landscape: ipi/nivolumab  followed', 'the rcc tx landscape: ipi/nivolumab  followed by', 'rcc tx landscape: ipi/nivolumab  followed by cabozantinib', 'tx landscape: ipi/nivolumab  followed by cabozantinib vs', 'landscape: ipi/nivolumab  followed by cabozantinib vs nivolumab', 'ipi/nivolumab  followed by cabozantinib vs nivolumab ', ' followed by cabozantinib vs nivolumab  vs', 'followed by cabozantinib vs nivolumab  vs cabozantinib', 'by cabozantinib vs nivolumab  vs cabozantinib /', 'cabozantinib vs nivolumab  vs cabozantinib / nivolumab', 'vs nivolumab  vs cabozantinib / nivolumab ', 'nivolumab  vs cabozantinib / nivolumab  based', ' vs cabozantinib / nivolumab  based on', 'vs cabozantinib / nivolumab  based on response', 'cabozantinib / nivolumab  based on response #asco22', '/ nivolumab  based on response #asco22 .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '132', 'tokens': ['enzamet', 'updates', '#asco2022', 'always', 'thoughtful', '!', 'well', 'done', 'anzup', 'australia', '!', 'combo', 'doce/enzo+break', 'the', 'curse', 'of', 'de', 'novo', 'high', 'volume', 'pca?', '.'], 'text_length': 22, 'triples': {'enzamet|updates #asco2022 always thoughtful ! well': ([0, 0], [1, 6], 'positive')}, 'sentence': 'enzamet updates #asco2022 always thoughtful ! well done anzup australia ! combo doce/enzo+break the curse of de novo high volume pca? .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 6)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['enzamet', 'updates', '#asco2022', 'always', 'thoughtful', '!', 'well', 'done', 'anzup', 'australia', '!', 'combo', 'doce/enzo+break', 'the', 'curse', 'of', 'de', 'novo', 'high', 'volume', 'pca?', '.', 'enzamet updates', 'updates #asco2022', '#asco2022 always', 'always thoughtful', 'thoughtful !', '! well', 'well done', 'done anzup', 'anzup australia', 'australia !', '! combo', 'combo doce/enzo+break', 'doce/enzo+break the', 'the curse', 'curse of', 'of de', 'de novo', 'novo high', 'high volume', 'volume pca?', 'pca? .', 'enzamet updates #asco2022', 'updates #asco2022 always', '#asco2022 always thoughtful', 'always thoughtful !', 'thoughtful ! well', '! well done', 'well done anzup', 'done anzup australia', 'anzup australia !', 'australia ! combo', '! combo doce/enzo+break', 'combo doce/enzo+break the', 'doce/enzo+break the curse', 'the curse of', 'curse of de', 'of de novo', 'de novo high', 'novo high volume', 'high volume pca?', 'volume pca? .', 'enzamet updates #asco2022 always', 'updates #asco2022 always thoughtful', '#asco2022 always thoughtful !', 'always thoughtful ! well', 'thoughtful ! well done', '! well done anzup', 'well done anzup australia', 'done anzup australia !', 'anzup australia ! combo', 'australia ! combo doce/enzo+break', '! combo doce/enzo+break the', 'combo doce/enzo+break the curse', 'doce/enzo+break the curse of', 'the curse of de', 'curse of de novo', 'of de novo high', 'de novo high volume', 'novo high volume pca?', 'high volume pca? .', 'enzamet updates #asco2022 always thoughtful', 'updates #asco2022 always thoughtful !', '#asco2022 always thoughtful ! well', 'always thoughtful ! well done', 'thoughtful ! well done anzup', '! well done anzup australia', 'well done anzup australia !', 'done anzup australia ! combo', 'anzup australia ! combo doce/enzo+break', 'australia ! combo doce/enzo+break the', '! combo doce/enzo+break the curse', 'combo doce/enzo+break the curse of', 'doce/enzo+break the curse of de', 'the curse of de novo', 'curse of de novo high', 'of de novo high volume', 'de novo high volume pca?', 'novo high volume pca? .', 'enzamet updates #asco2022 always thoughtful !', 'updates #asco2022 always thoughtful ! well', '#asco2022 always thoughtful ! well done', 'always thoughtful ! well done anzup', 'thoughtful ! well done anzup australia', '! well done anzup australia !', 'well done anzup australia ! combo', 'done anzup australia ! combo doce/enzo+break', 'anzup australia ! combo doce/enzo+break the', 'australia ! combo doce/enzo+break the curse', '! combo doce/enzo+break the curse of', 'combo doce/enzo+break the curse of de', 'doce/enzo+break the curse of de novo', 'the curse of de novo high', 'curse of de novo high volume', 'of de novo high volume pca?', 'de novo high volume pca? .', 'enzamet updates #asco2022 always thoughtful ! well', 'updates #asco2022 always thoughtful ! well done', '#asco2022 always thoughtful ! well done anzup', 'always thoughtful ! well done anzup australia', 'thoughtful ! well done anzup australia !', '! well done anzup australia ! combo', 'well done anzup australia ! combo doce/enzo+break', 'done anzup australia ! combo doce/enzo+break the', 'anzup australia ! combo doce/enzo+break the curse', 'australia ! combo doce/enzo+break the curse of', '! combo doce/enzo+break the curse of de', 'combo doce/enzo+break the curse of de novo', 'doce/enzo+break the curse of de novo high', 'the curse of de novo high volume', 'curse of de novo high volume pca?', 'of de novo high volume pca? .', 'enzamet updates #asco2022 always thoughtful ! well done', 'updates #asco2022 always thoughtful ! well done anzup', '#asco2022 always thoughtful ! well done anzup australia', 'always thoughtful ! well done anzup australia !', 'thoughtful ! well done anzup australia ! combo', '! well done anzup australia ! combo doce/enzo+break', 'well done anzup australia ! combo doce/enzo+break the', 'done anzup australia ! combo doce/enzo+break the curse', 'anzup australia ! combo doce/enzo+break the curse of', 'australia ! combo doce/enzo+break the curse of de', '! combo doce/enzo+break the curse of de novo', 'combo doce/enzo+break the curse of de novo high', 'doce/enzo+break the curse of de novo high volume', 'the curse of de novo high volume pca?', 'curse of de novo high volume pca? .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '133', 'tokens': ['transcriptome', 'signatures', 'in', 'the', 'stampede', 'aap', 'trial', 'decipher', 'gc:', 'prognostic', 'in', 'advanced', 'pca:', 'per', '0.1', 'increment,', 'm1', 'os', '(hr', '1.18,', '95%', 'ci', '1.09', '-', '1.26,),', 'm0', 'mfs', '(hr', '1.20,', '95%', 'ci', '1.09', '-', '1.31)', 'prognostic', 'across', 'all', 'endpoints', 'in', 'm0', 'and', 'm1', 'cohorts', '#esmo22', '.'], 'text_length': 45, 'triples': {'stampede|prognostic in advanced pca: per 0.1 increment, m1 os (hr 1.18, 95% ci 1.09 - 1.26,), m0 mfs (hr 1.20, 95% ci 1.09 - 1.31) prognostic': ([4, 4], [9, 34], 'neutral')}, 'sentence': 'transcriptome signatures in the stampede aap trial decipher gc: prognostic in advanced pca: per 0.1 increment, m1 os (hr 1.18, 95% ci 1.09 - 1.26,), m0 mfs (hr 1.20, 95% ci 1.09 - 1.31) prognostic across all endpoints in m0 and m1 cohorts #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 34)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8)], 'span tokens': ['transcriptome', 'signatures', 'in', 'the', 'stampede', 'aap', 'trial', 'decipher', 'gc:', 'prognostic', 'in', 'advanced', 'pca:', 'per', '0.1', 'increment,', 'm1', 'os', '(hr', '1.18,', '95%', 'ci', '1.09', '-', '1.26,),', 'm0', 'mfs', '(hr', '1.20,', '95%', 'ci', '1.09', '-', '1.31)', 'prognostic', 'across', 'all', 'endpoints', 'in', 'm0', 'and', 'm1', 'cohorts', '#esmo22', '.', 'transcriptome signatures', 'signatures in', 'in the', 'the stampede', 'stampede aap', 'aap trial', 'trial decipher', 'decipher gc:', 'gc: prognostic', 'prognostic in', 'in advanced', 'advanced pca:', 'pca: per', 'per 0.1', '0.1 increment,', 'increment, m1', 'm1 os', 'os (hr', '(hr 1.18,', '1.18, 95%', '95% ci', 'ci 1.09', '1.09 -', '- 1.26,),', '1.26,), m0', 'm0 mfs', 'mfs (hr', '(hr 1.20,', '1.20, 95%', '95% ci', 'ci 1.09', '1.09 -', '- 1.31)', '1.31) prognostic', 'prognostic across', 'across all', 'all endpoints', 'endpoints in', 'in m0', 'm0 and', 'and m1', 'm1 cohorts', 'cohorts #esmo22', '#esmo22 .', 'transcriptome signatures in', 'signatures in the', 'in the stampede', 'the stampede aap', 'stampede aap trial', 'aap trial decipher', 'trial decipher gc:', 'decipher gc: prognostic', 'gc: prognostic in', 'prognostic in advanced', 'in advanced pca:', 'advanced pca: per', 'pca: per 0.1', 'per 0.1 increment,', '0.1 increment, m1', 'increment, m1 os', 'm1 os (hr', 'os (hr 1.18,', '(hr 1.18, 95%', '1.18, 95% ci', '95% ci 1.09', 'ci 1.09 -', '1.09 - 1.26,),', '- 1.26,), m0', '1.26,), m0 mfs', 'm0 mfs (hr', 'mfs (hr 1.20,', '(hr 1.20, 95%', '1.20, 95% ci', '95% ci 1.09', 'ci 1.09 -', '1.09 - 1.31)', '- 1.31) prognostic', '1.31) prognostic across', 'prognostic across all', 'across all endpoints', 'all endpoints in', 'endpoints in m0', 'in m0 and', 'm0 and m1', 'and m1 cohorts', 'm1 cohorts #esmo22', 'cohorts #esmo22 .', 'transcriptome signatures in the', 'signatures in the stampede', 'in the stampede aap', 'the stampede aap trial', 'stampede aap trial decipher', 'aap trial decipher gc:', 'trial decipher gc: prognostic', 'decipher gc: prognostic in', 'gc: prognostic in advanced', 'prognostic in advanced pca:', 'in advanced pca: per', 'advanced pca: per 0.1', 'pca: per 0.1 increment,', 'per 0.1 increment, m1', '0.1 increment, m1 os', 'increment, m1 os (hr', 'm1 os (hr 1.18,', 'os (hr 1.18, 95%', '(hr 1.18, 95% ci', '1.18, 95% ci 1.09', '95% ci 1.09 -', 'ci 1.09 - 1.26,),', '1.09 - 1.26,), m0', '- 1.26,), m0 mfs', '1.26,), m0 mfs (hr', 'm0 mfs (hr 1.20,', 'mfs (hr 1.20, 95%', '(hr 1.20, 95% ci', '1.20, 95% ci 1.09', '95% ci 1.09 -', 'ci 1.09 - 1.31)', '1.09 - 1.31) prognostic', '- 1.31) prognostic across', '1.31) prognostic across all', 'prognostic across all endpoints', 'across all endpoints in', 'all endpoints in m0', 'endpoints in m0 and', 'in m0 and m1', 'm0 and m1 cohorts', 'and m1 cohorts #esmo22', 'm1 cohorts #esmo22 .', 'transcriptome signatures in the stampede', 'signatures in the stampede aap', 'in the stampede aap trial', 'the stampede aap trial decipher', 'stampede aap trial decipher gc:', 'aap trial decipher gc: prognostic', 'trial decipher gc: prognostic in', 'decipher gc: prognostic in advanced', 'gc: prognostic in advanced pca:', 'prognostic in advanced pca: per', 'in advanced pca: per 0.1', 'advanced pca: per 0.1 increment,', 'pca: per 0.1 increment, m1', 'per 0.1 increment, m1 os', '0.1 increment, m1 os (hr', 'increment, m1 os (hr 1.18,', 'm1 os (hr 1.18, 95%', 'os (hr 1.18, 95% ci', '(hr 1.18, 95% ci 1.09', '1.18, 95% ci 1.09 -', '95% ci 1.09 - 1.26,),', 'ci 1.09 - 1.26,), m0', '1.09 - 1.26,), m0 mfs', '- 1.26,), m0 mfs (hr', '1.26,), m0 mfs (hr 1.20,', 'm0 mfs (hr 1.20, 95%', 'mfs (hr 1.20, 95% ci', '(hr 1.20, 95% ci 1.09', '1.20, 95% ci 1.09 -', '95% ci 1.09 - 1.31)', 'ci 1.09 - 1.31) prognostic', '1.09 - 1.31) prognostic across', '- 1.31) prognostic across all', '1.31) prognostic across all endpoints', 'prognostic across all endpoints in', 'across all endpoints in m0', 'all endpoints in m0 and', 'endpoints in m0 and m1', 'in m0 and m1 cohorts', 'm0 and m1 cohorts #esmo22', 'and m1 cohorts #esmo22 .', 'transcriptome signatures in the stampede aap', 'signatures in the stampede aap trial', 'in the stampede aap trial decipher', 'the stampede aap trial decipher gc:', 'stampede aap trial decipher gc: prognostic', 'aap trial decipher gc: prognostic in', 'trial decipher gc: prognostic in advanced', 'decipher gc: prognostic in advanced pca:', 'gc: prognostic in advanced pca: per', 'prognostic in advanced pca: per 0.1', 'in advanced pca: per 0.1 increment,', 'advanced pca: per 0.1 increment, m1', 'pca: per 0.1 increment, m1 os', 'per 0.1 increment, m1 os (hr', '0.1 increment, m1 os (hr 1.18,', 'increment, m1 os (hr 1.18, 95%', 'm1 os (hr 1.18, 95% ci', 'os (hr 1.18, 95% ci 1.09', '(hr 1.18, 95% ci 1.09 -', '1.18, 95% ci 1.09 - 1.26,),', '95% ci 1.09 - 1.26,), m0', 'ci 1.09 - 1.26,), m0 mfs', '1.09 - 1.26,), m0 mfs (hr', '- 1.26,), m0 mfs (hr 1.20,', '1.26,), m0 mfs (hr 1.20, 95%', 'm0 mfs (hr 1.20, 95% ci', 'mfs (hr 1.20, 95% ci 1.09', '(hr 1.20, 95% ci 1.09 -', '1.20, 95% ci 1.09 - 1.31)', '95% ci 1.09 - 1.31) prognostic', 'ci 1.09 - 1.31) prognostic across', '1.09 - 1.31) prognostic across all', '- 1.31) prognostic across all endpoints', '1.31) prognostic across all endpoints in', 'prognostic across all endpoints in m0', 'across all endpoints in m0 and', 'all endpoints in m0 and m1', 'endpoints in m0 and m1 cohorts', 'in m0 and m1 cohorts #esmo22', 'm0 and m1 cohorts #esmo22 .', 'transcriptome signatures in the stampede aap trial', 'signatures in the stampede aap trial decipher', 'in the stampede aap trial decipher gc:', 'the stampede aap trial decipher gc: prognostic', 'stampede aap trial decipher gc: prognostic in', 'aap trial decipher gc: prognostic in advanced', 'trial decipher gc: prognostic in advanced pca:', 'decipher gc: prognostic in advanced pca: per', 'gc: prognostic in advanced pca: per 0.1', 'prognostic in advanced pca: per 0.1 increment,', 'in advanced pca: per 0.1 increment, m1', 'advanced pca: per 0.1 increment, m1 os', 'pca: per 0.1 increment, m1 os (hr', 'per 0.1 increment, m1 os (hr 1.18,', '0.1 increment, m1 os (hr 1.18, 95%', 'increment, m1 os (hr 1.18, 95% ci', 'm1 os (hr 1.18, 95% ci 1.09', 'os (hr 1.18, 95% ci 1.09 -', '(hr 1.18, 95% ci 1.09 - 1.26,),', '1.18, 95% ci 1.09 - 1.26,), m0', '95% ci 1.09 - 1.26,), m0 mfs', 'ci 1.09 - 1.26,), m0 mfs (hr', '1.09 - 1.26,), m0 mfs (hr 1.20,', '- 1.26,), m0 mfs (hr 1.20, 95%', '1.26,), m0 mfs (hr 1.20, 95% ci', 'm0 mfs (hr 1.20, 95% ci 1.09', 'mfs (hr 1.20, 95% ci 1.09 -', '(hr 1.20, 95% ci 1.09 - 1.31)', '1.20, 95% ci 1.09 - 1.31) prognostic', '95% ci 1.09 - 1.31) prognostic across', 'ci 1.09 - 1.31) prognostic across all', '1.09 - 1.31) prognostic across all endpoints', '- 1.31) prognostic across all endpoints in', '1.31) prognostic across all endpoints in m0', 'prognostic across all endpoints in m0 and', 'across all endpoints in m0 and m1', 'all endpoints in m0 and m1 cohorts', 'endpoints in m0 and m1 cohorts #esmo22', 'in m0 and m1 cohorts #esmo22 .', 'transcriptome signatures in the stampede aap trial decipher', 'signatures in the stampede aap trial decipher gc:', 'in the stampede aap trial decipher gc: prognostic', 'the stampede aap trial decipher gc: prognostic in', 'stampede aap trial decipher gc: prognostic in advanced', 'aap trial decipher gc: prognostic in advanced pca:', 'trial decipher gc: prognostic in advanced pca: per', 'decipher gc: prognostic in advanced pca: per 0.1', 'gc: prognostic in advanced pca: per 0.1 increment,', 'prognostic in advanced pca: per 0.1 increment, m1', 'in advanced pca: per 0.1 increment, m1 os', 'advanced pca: per 0.1 increment, m1 os (hr', 'pca: per 0.1 increment, m1 os (hr 1.18,', 'per 0.1 increment, m1 os (hr 1.18, 95%', '0.1 increment, m1 os (hr 1.18, 95% ci', 'increment, m1 os (hr 1.18, 95% ci 1.09', 'm1 os (hr 1.18, 95% ci 1.09 -', 'os (hr 1.18, 95% ci 1.09 - 1.26,),', '(hr 1.18, 95% ci 1.09 - 1.26,), m0', '1.18, 95% ci 1.09 - 1.26,), m0 mfs', '95% ci 1.09 - 1.26,), m0 mfs (hr', 'ci 1.09 - 1.26,), m0 mfs (hr 1.20,', '1.09 - 1.26,), m0 mfs (hr 1.20, 95%', '- 1.26,), m0 mfs (hr 1.20, 95% ci', '1.26,), m0 mfs (hr 1.20, 95% ci 1.09', 'm0 mfs (hr 1.20, 95% ci 1.09 -', 'mfs (hr 1.20, 95% ci 1.09 - 1.31)', '(hr 1.20, 95% ci 1.09 - 1.31) prognostic', '1.20, 95% ci 1.09 - 1.31) prognostic across', '95% ci 1.09 - 1.31) prognostic across all', 'ci 1.09 - 1.31) prognostic across all endpoints', '1.09 - 1.31) prognostic across all endpoints in', '- 1.31) prognostic across all endpoints in m0', '1.31) prognostic across all endpoints in m0 and', 'prognostic across all endpoints in m0 and m1', 'across all endpoints in m0 and m1 cohorts', 'all endpoints in m0 and m1 cohorts #esmo22', 'endpoints in m0 and m1 cohorts #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '134', 'tokens': ['updated', 'results', 'of', 'the', 'propel', 'showed', 'that', 'improved', 'os', 'trending', 'is', 'continuing', 'in', 'the', 'aap+', 'olaparib', 'arm.', '#esmo2022', '.'], 'text_length': 19, 'triples': {'propel|improved os trending': ([4, 4], [7, 9], 'positive')}, 'sentence': 'updated results of the propel showed that improved os trending is continuing in the aap+ olaparib arm. #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['updated', 'results', 'of', 'the', 'propel', 'showed', 'that', 'improved', 'os', 'trending', 'is', 'continuing', 'in', 'the', 'aap+', 'olaparib', 'arm.', '#esmo2022', '.', 'updated results', 'results of', 'of the', 'the propel', 'propel showed', 'showed that', 'that improved', 'improved os', 'os trending', 'trending is', 'is continuing', 'continuing in', 'in the', 'the aap+', 'aap+ olaparib', 'olaparib arm.', 'arm. #esmo2022', '#esmo2022 .', 'updated results of', 'results of the', 'of the propel', 'the propel showed', 'propel showed that', 'showed that improved', 'that improved os', 'improved os trending', 'os trending is', 'trending is continuing', 'is continuing in', 'continuing in the', 'in the aap+', 'the aap+ olaparib', 'aap+ olaparib arm.', 'olaparib arm. #esmo2022', 'arm. #esmo2022 .', 'updated results of the', 'results of the propel', 'of the propel showed', 'the propel showed that', 'propel showed that improved', 'showed that improved os', 'that improved os trending', 'improved os trending is', 'os trending is continuing', 'trending is continuing in', 'is continuing in the', 'continuing in the aap+', 'in the aap+ olaparib', 'the aap+ olaparib arm.', 'aap+ olaparib arm. #esmo2022', 'olaparib arm. #esmo2022 .', 'updated results of the propel', 'results of the propel showed', 'of the propel showed that', 'the propel showed that improved', 'propel showed that improved os', 'showed that improved os trending', 'that improved os trending is', 'improved os trending is continuing', 'os trending is continuing in', 'trending is continuing in the', 'is continuing in the aap+', 'continuing in the aap+ olaparib', 'in the aap+ olaparib arm.', 'the aap+ olaparib arm. #esmo2022', 'aap+ olaparib arm. #esmo2022 .', 'updated results of the propel showed', 'results of the propel showed that', 'of the propel showed that improved', 'the propel showed that improved os', 'propel showed that improved os trending', 'showed that improved os trending is', 'that improved os trending is continuing', 'improved os trending is continuing in', 'os trending is continuing in the', 'trending is continuing in the aap+', 'is continuing in the aap+ olaparib', 'continuing in the aap+ olaparib arm.', 'in the aap+ olaparib arm. #esmo2022', 'the aap+ olaparib arm. #esmo2022 .', 'updated results of the propel showed that', 'results of the propel showed that improved', 'of the propel showed that improved os', 'the propel showed that improved os trending', 'propel showed that improved os trending is', 'showed that improved os trending is continuing', 'that improved os trending is continuing in', 'improved os trending is continuing in the', 'os trending is continuing in the aap+', 'trending is continuing in the aap+ olaparib', 'is continuing in the aap+ olaparib arm.', 'continuing in the aap+ olaparib arm. #esmo2022', 'in the aap+ olaparib arm. #esmo2022 .', 'updated results of the propel showed that improved', 'results of the propel showed that improved os', 'of the propel showed that improved os trending', 'the propel showed that improved os trending is', 'propel showed that improved os trending is continuing', 'showed that improved os trending is continuing in', 'that improved os trending is continuing in the', 'improved os trending is continuing in the aap+', 'os trending is continuing in the aap+ olaparib', 'trending is continuing in the aap+ olaparib arm.', 'is continuing in the aap+ olaparib arm. #esmo2022', 'continuing in the aap+ olaparib arm. #esmo2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '135', 'tokens': ['subgroup', 'analysis', 'of', '#', 'vision', 'study', 'shows', 'improved', 'rpfs', 'and', 'os', 'with', '177lu-psma-617', 'in', 'men', 'with', 'mcrpc', 'regardless', 'of', 'prior', 'or', 'concomitant', 'treatment,', 'presented', 'by', 'nitin', 'vaishampayan,', 'md', '#asco22', '#prostatecancer', '.'], 'text_length': 31, 'triples': {'#|study shows improved rpfs and': ([3, 3], [5, 9], 'positive'), 'with|study shows improved rpfs and': ([11, 11], [5, 9], 'positive')}, 'sentence': 'subgroup analysis of # vision study shows improved rpfs and os with 177lu-psma-617 in men with mcrpc regardless of prior or concomitant treatment, presented by nitin vaishampayan, md #asco22 #prostatecancer .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(3, 3), (11, 11)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['subgroup', 'analysis', 'of', '#', 'vision', 'study', 'shows', 'improved', 'rpfs', 'and', 'os', 'with', '177lu-psma-617', 'in', 'men', 'with', 'mcrpc', 'regardless', 'of', 'prior', 'or', 'concomitant', 'treatment,', 'presented', 'by', 'nitin', 'vaishampayan,', 'md', '#asco22', '#prostatecancer', '.', 'subgroup analysis', 'analysis of', 'of #', '# vision', 'vision study', 'study shows', 'shows improved', 'improved rpfs', 'rpfs and', 'and os', 'os with', 'with 177lu-psma-617', '177lu-psma-617 in', 'in men', 'men with', 'with mcrpc', 'mcrpc regardless', 'regardless of', 'of prior', 'prior or', 'or concomitant', 'concomitant treatment,', 'treatment, presented', 'presented by', 'by nitin', 'nitin vaishampayan,', 'vaishampayan, md', 'md #asco22', '#asco22 #prostatecancer', '#prostatecancer .', 'subgroup analysis of', 'analysis of #', 'of # vision', '# vision study', 'vision study shows', 'study shows improved', 'shows improved rpfs', 'improved rpfs and', 'rpfs and os', 'and os with', 'os with 177lu-psma-617', 'with 177lu-psma-617 in', '177lu-psma-617 in men', 'in men with', 'men with mcrpc', 'with mcrpc regardless', 'mcrpc regardless of', 'regardless of prior', 'of prior or', 'prior or concomitant', 'or concomitant treatment,', 'concomitant treatment, presented', 'treatment, presented by', 'presented by nitin', 'by nitin vaishampayan,', 'nitin vaishampayan, md', 'vaishampayan, md #asco22', 'md #asco22 #prostatecancer', '#asco22 #prostatecancer .', 'subgroup analysis of #', 'analysis of # vision', 'of # vision study', '# vision study shows', 'vision study shows improved', 'study shows improved rpfs', 'shows improved rpfs and', 'improved rpfs and os', 'rpfs and os with', 'and os with 177lu-psma-617', 'os with 177lu-psma-617 in', 'with 177lu-psma-617 in men', '177lu-psma-617 in men with', 'in men with mcrpc', 'men with mcrpc regardless', 'with mcrpc regardless of', 'mcrpc regardless of prior', 'regardless of prior or', 'of prior or concomitant', 'prior or concomitant treatment,', 'or concomitant treatment, presented', 'concomitant treatment, presented by', 'treatment, presented by nitin', 'presented by nitin vaishampayan,', 'by nitin vaishampayan, md', 'nitin vaishampayan, md #asco22', 'vaishampayan, md #asco22 #prostatecancer', 'md #asco22 #prostatecancer .', 'subgroup analysis of # vision', 'analysis of # vision study', 'of # vision study shows', '# vision study shows improved', 'vision study shows improved rpfs', 'study shows improved rpfs and', 'shows improved rpfs and os', 'improved rpfs and os with', 'rpfs and os with 177lu-psma-617', 'and os with 177lu-psma-617 in', 'os with 177lu-psma-617 in men', 'with 177lu-psma-617 in men with', '177lu-psma-617 in men with mcrpc', 'in men with mcrpc regardless', 'men with mcrpc regardless of', 'with mcrpc regardless of prior', 'mcrpc regardless of prior or', 'regardless of prior or concomitant', 'of prior or concomitant treatment,', 'prior or concomitant treatment, presented', 'or concomitant treatment, presented by', 'concomitant treatment, presented by nitin', 'treatment, presented by nitin vaishampayan,', 'presented by nitin vaishampayan, md', 'by nitin vaishampayan, md #asco22', 'nitin vaishampayan, md #asco22 #prostatecancer', 'vaishampayan, md #asco22 #prostatecancer .', 'subgroup analysis of # vision study', 'analysis of # vision study shows', 'of # vision study shows improved', '# vision study shows improved rpfs', 'vision study shows improved rpfs and', 'study shows improved rpfs and os', 'shows improved rpfs and os with', 'improved rpfs and os with 177lu-psma-617', 'rpfs and os with 177lu-psma-617 in', 'and os with 177lu-psma-617 in men', 'os with 177lu-psma-617 in men with', 'with 177lu-psma-617 in men with mcrpc', '177lu-psma-617 in men with mcrpc regardless', 'in men with mcrpc regardless of', 'men with mcrpc regardless of prior', 'with mcrpc regardless of prior or', 'mcrpc regardless of prior or concomitant', 'regardless of prior or concomitant treatment,', 'of prior or concomitant treatment, presented', 'prior or concomitant treatment, presented by', 'or concomitant treatment, presented by nitin', 'concomitant treatment, presented by nitin vaishampayan,', 'treatment, presented by nitin vaishampayan, md', 'presented by nitin vaishampayan, md #asco22', 'by nitin vaishampayan, md #asco22 #prostatecancer', 'nitin vaishampayan, md #asco22 #prostatecancer .', 'subgroup analysis of # vision study shows', 'analysis of # vision study shows improved', 'of # vision study shows improved rpfs', '# vision study shows improved rpfs and', 'vision study shows improved rpfs and os', 'study shows improved rpfs and os with', 'shows improved rpfs and os with 177lu-psma-617', 'improved rpfs and os with 177lu-psma-617 in', 'rpfs and os with 177lu-psma-617 in men', 'and os with 177lu-psma-617 in men with', 'os with 177lu-psma-617 in men with mcrpc', 'with 177lu-psma-617 in men with mcrpc regardless', '177lu-psma-617 in men with mcrpc regardless of', 'in men with mcrpc regardless of prior', 'men with mcrpc regardless of prior or', 'with mcrpc regardless of prior or concomitant', 'mcrpc regardless of prior or concomitant treatment,', 'regardless of prior or concomitant treatment, presented', 'of prior or concomitant treatment, presented by', 'prior or concomitant treatment, presented by nitin', 'or concomitant treatment, presented by nitin vaishampayan,', 'concomitant treatment, presented by nitin vaishampayan, md', 'treatment, presented by nitin vaishampayan, md #asco22', 'presented by nitin vaishampayan, md #asco22 #prostatecancer', 'by nitin vaishampayan, md #asco22 #prostatecancer .', 'subgroup analysis of # vision study shows improved', 'analysis of # vision study shows improved rpfs', 'of # vision study shows improved rpfs and', '# vision study shows improved rpfs and os', 'vision study shows improved rpfs and os with', 'study shows improved rpfs and os with 177lu-psma-617', 'shows improved rpfs and os with 177lu-psma-617 in', 'improved rpfs and os with 177lu-psma-617 in men', 'rpfs and os with 177lu-psma-617 in men with', 'and os with 177lu-psma-617 in men with mcrpc', 'os with 177lu-psma-617 in men with mcrpc regardless', 'with 177lu-psma-617 in men with mcrpc regardless of', '177lu-psma-617 in men with mcrpc regardless of prior', 'in men with mcrpc regardless of prior or', 'men with mcrpc regardless of prior or concomitant', 'with mcrpc regardless of prior or concomitant treatment,', 'mcrpc regardless of prior or concomitant treatment, presented', 'regardless of prior or concomitant treatment, presented by', 'of prior or concomitant treatment, presented by nitin', 'prior or concomitant treatment, presented by nitin vaishampayan,', 'or concomitant treatment, presented by nitin vaishampayan, md', 'concomitant treatment, presented by nitin vaishampayan, md #asco22', 'treatment, presented by nitin vaishampayan, md #asco22 #prostatecancer', 'presented by nitin vaishampayan, md #asco22 #prostatecancer .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '136', 'tokens': ['stampede', 'is', 'the', 'best', 'example', 'of', 'how', 'the', 'cooperative', 'efforts', 'of', 'many', 'professionals,', 'hospitals,', 'health', 'authorities,', 'the', 'pharmaceutical', 'industry', 'and', 'patients', 'with', '#prostatecancer', 'contribute', 'to', 'innovation', 'and', 'improvement', 'in', 'the', 'fight', 'against', 'cancer!', 'congratulations!!!', '#esmo2022', '.'], 'text_length': 36, 'triples': {'stampede|best example of how the cooperative efforts of many professionals, hospitals, health authorities, the pharmaceutical industry and patients with #prostatecancer contribute': ([0, 0], [3, 23], 'positive')}, 'sentence': 'stampede is the best example of how the cooperative efforts of many professionals, hospitals, health authorities, the pharmaceutical industry and patients with #prostatecancer contribute to innovation and improvement in the fight against cancer! congratulations!!! #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 23)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['stampede', 'is', 'the', 'best', 'example', 'of', 'how', 'the', 'cooperative', 'efforts', 'of', 'many', 'professionals,', 'hospitals,', 'health', 'authorities,', 'the', 'pharmaceutical', 'industry', 'and', 'patients', 'with', '#prostatecancer', 'contribute', 'to', 'innovation', 'and', 'improvement', 'in', 'the', 'fight', 'against', 'cancer!', 'congratulations!!!', '#esmo2022', '.', 'stampede is', 'is the', 'the best', 'best example', 'example of', 'of how', 'how the', 'the cooperative', 'cooperative efforts', 'efforts of', 'of many', 'many professionals,', 'professionals, hospitals,', 'hospitals, health', 'health authorities,', 'authorities, the', 'the pharmaceutical', 'pharmaceutical industry', 'industry and', 'and patients', 'patients with', 'with #prostatecancer', '#prostatecancer contribute', 'contribute to', 'to innovation', 'innovation and', 'and improvement', 'improvement in', 'in the', 'the fight', 'fight against', 'against cancer!', 'cancer! congratulations!!!', 'congratulations!!! #esmo2022', '#esmo2022 .', 'stampede is the', 'is the best', 'the best example', 'best example of', 'example of how', 'of how the', 'how the cooperative', 'the cooperative efforts', 'cooperative efforts of', 'efforts of many', 'of many professionals,', 'many professionals, hospitals,', 'professionals, hospitals, health', 'hospitals, health authorities,', 'health authorities, the', 'authorities, the pharmaceutical', 'the pharmaceutical industry', 'pharmaceutical industry and', 'industry and patients', 'and patients with', 'patients with #prostatecancer', 'with #prostatecancer contribute', '#prostatecancer contribute to', 'contribute to innovation', 'to innovation and', 'innovation and improvement', 'and improvement in', 'improvement in the', 'in the fight', 'the fight against', 'fight against cancer!', 'against cancer! congratulations!!!', 'cancer! congratulations!!! #esmo2022', 'congratulations!!! #esmo2022 .', 'stampede is the best', 'is the best example', 'the best example of', 'best example of how', 'example of how the', 'of how the cooperative', 'how the cooperative efforts', 'the cooperative efforts of', 'cooperative efforts of many', 'efforts of many professionals,', 'of many professionals, hospitals,', 'many professionals, hospitals, health', 'professionals, hospitals, health authorities,', 'hospitals, health authorities, the', 'health authorities, the pharmaceutical', 'authorities, the pharmaceutical industry', 'the pharmaceutical industry and', 'pharmaceutical industry and patients', 'industry and patients with', 'and patients with #prostatecancer', 'patients with #prostatecancer contribute', 'with #prostatecancer contribute to', '#prostatecancer contribute to innovation', 'contribute to innovation and', 'to innovation and improvement', 'innovation and improvement in', 'and improvement in the', 'improvement in the fight', 'in the fight against', 'the fight against cancer!', 'fight against cancer! congratulations!!!', 'against cancer! congratulations!!! #esmo2022', 'cancer! congratulations!!! #esmo2022 .', 'stampede is the best example', 'is the best example of', 'the best example of how', 'best example of how the', 'example of how the cooperative', 'of how the cooperative efforts', 'how the cooperative efforts of', 'the cooperative efforts of many', 'cooperative efforts of many professionals,', 'efforts of many professionals, hospitals,', 'of many professionals, hospitals, health', 'many professionals, hospitals, health authorities,', 'professionals, hospitals, health authorities, the', 'hospitals, health authorities, the pharmaceutical', 'health authorities, the pharmaceutical industry', 'authorities, the pharmaceutical industry and', 'the pharmaceutical industry and patients', 'pharmaceutical industry and patients with', 'industry and patients with #prostatecancer', 'and patients with #prostatecancer contribute', 'patients with #prostatecancer contribute to', 'with #prostatecancer contribute to innovation', '#prostatecancer contribute to innovation and', 'contribute to innovation and improvement', 'to innovation and improvement in', 'innovation and improvement in the', 'and improvement in the fight', 'improvement in the fight against', 'in the fight against cancer!', 'the fight against cancer! congratulations!!!', 'fight against cancer! congratulations!!! #esmo2022', 'against cancer! congratulations!!! #esmo2022 .', 'stampede is the best example of', 'is the best example of how', 'the best example of how the', 'best example of how the cooperative', 'example of how the cooperative efforts', 'of how the cooperative efforts of', 'how the cooperative efforts of many', 'the cooperative efforts of many professionals,', 'cooperative efforts of many professionals, hospitals,', 'efforts of many professionals, hospitals, health', 'of many professionals, hospitals, health authorities,', 'many professionals, hospitals, health authorities, the', 'professionals, hospitals, health authorities, the pharmaceutical', 'hospitals, health authorities, the pharmaceutical industry', 'health authorities, the pharmaceutical industry and', 'authorities, the pharmaceutical industry and patients', 'the pharmaceutical industry and patients with', 'pharmaceutical industry and patients with #prostatecancer', 'industry and patients with #prostatecancer contribute', 'and patients with #prostatecancer contribute to', 'patients with #prostatecancer contribute to innovation', 'with #prostatecancer contribute to innovation and', '#prostatecancer contribute to innovation and improvement', 'contribute to innovation and improvement in', 'to innovation and improvement in the', 'innovation and improvement in the fight', 'and improvement in the fight against', 'improvement in the fight against cancer!', 'in the fight against cancer! congratulations!!!', 'the fight against cancer! congratulations!!! #esmo2022', 'fight against cancer! congratulations!!! #esmo2022 .', 'stampede is the best example of how', 'is the best example of how the', 'the best example of how the cooperative', 'best example of how the cooperative efforts', 'example of how the cooperative efforts of', 'of how the cooperative efforts of many', 'how the cooperative efforts of many professionals,', 'the cooperative efforts of many professionals, hospitals,', 'cooperative efforts of many professionals, hospitals, health', 'efforts of many professionals, hospitals, health authorities,', 'of many professionals, hospitals, health authorities, the', 'many professionals, hospitals, health authorities, the pharmaceutical', 'professionals, hospitals, health authorities, the pharmaceutical industry', 'hospitals, health authorities, the pharmaceutical industry and', 'health authorities, the pharmaceutical industry and patients', 'authorities, the pharmaceutical industry and patients with', 'the pharmaceutical industry and patients with #prostatecancer', 'pharmaceutical industry and patients with #prostatecancer contribute', 'industry and patients with #prostatecancer contribute to', 'and patients with #prostatecancer contribute to innovation', 'patients with #prostatecancer contribute to innovation and', 'with #prostatecancer contribute to innovation and improvement', '#prostatecancer contribute to innovation and improvement in', 'contribute to innovation and improvement in the', 'to innovation and improvement in the fight', 'innovation and improvement in the fight against', 'and improvement in the fight against cancer!', 'improvement in the fight against cancer! congratulations!!!', 'in the fight against cancer! congratulations!!! #esmo2022', 'the fight against cancer! congratulations!!! #esmo2022 .', 'stampede is the best example of how the', 'is the best example of how the cooperative', 'the best example of how the cooperative efforts', 'best example of how the cooperative efforts of', 'example of how the cooperative efforts of many', 'of how the cooperative efforts of many professionals,', 'how the cooperative efforts of many professionals, hospitals,', 'the cooperative efforts of many professionals, hospitals, health', 'cooperative efforts of many professionals, hospitals, health authorities,', 'efforts of many professionals, hospitals, health authorities, the', 'of many professionals, hospitals, health authorities, the pharmaceutical', 'many professionals, hospitals, health authorities, the pharmaceutical industry', 'professionals, hospitals, health authorities, the pharmaceutical industry and', 'hospitals, health authorities, the pharmaceutical industry and patients', 'health authorities, the pharmaceutical industry and patients with', 'authorities, the pharmaceutical industry and patients with #prostatecancer', 'the pharmaceutical industry and patients with #prostatecancer contribute', 'pharmaceutical industry and patients with #prostatecancer contribute to', 'industry and patients with #prostatecancer contribute to innovation', 'and patients with #prostatecancer contribute to innovation and', 'patients with #prostatecancer contribute to innovation and improvement', 'with #prostatecancer contribute to innovation and improvement in', '#prostatecancer contribute to innovation and improvement in the', 'contribute to innovation and improvement in the fight', 'to innovation and improvement in the fight against', 'innovation and improvement in the fight against cancer!', 'and improvement in the fight against cancer! congratulations!!!', 'improvement in the fight against cancer! congratulations!!! #esmo2022', 'in the fight against cancer! congratulations!!! #esmo2022 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '137', 'tokens': ['#esmo22', 'abs#', '1357o:', 'updated', 'results', 'from', 'the', 'phase', '3', 'propel', 'trial', 'in', 'mcrpc', '#prostatecancer', 'showed', 'rpfs', 'benefit', 'of', 'using', 'abiraterone+olaparib', 'vs', 'abiraterone', 'biomarker', 'subgroup', 'analysis.', 'significant', 'pfs', 'benefit,', 'os', 'trending', 'favorably', '.'], 'text_length': 32, 'triples': {'propel|showed rpfs benefit of using abiraterone+olaparib vs abiraterone biomarker subgroup analysis. significant pfs benefit,': ([9, 9], [14, 27], 'positive'), 'abiraterone+olaparib|benefit of using abiraterone+olaparib vs abiraterone biomarker subgroup analysis. significant pfs benefit,': ([19, 19], [16, 27], 'positive')}, 'sentence': '#esmo22 abs# 1357o: updated results from the phase 3 propel trial in mcrpc #prostatecancer showed rpfs benefit of using abiraterone+olaparib vs abiraterone biomarker subgroup analysis. significant pfs benefit, os trending favorably .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(9, 9), (19, 19)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(14, 27), (16, 27)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['#esmo22', 'abs#', '1357o:', 'updated', 'results', 'from', 'the', 'phase', '3', 'propel', 'trial', 'in', 'mcrpc', '#prostatecancer', 'showed', 'rpfs', 'benefit', 'of', 'using', 'abiraterone+olaparib', 'vs', 'abiraterone', 'biomarker', 'subgroup', 'analysis.', 'significant', 'pfs', 'benefit,', 'os', 'trending', 'favorably', '.', '#esmo22 abs#', 'abs# 1357o:', '1357o: updated', 'updated results', 'results from', 'from the', 'the phase', 'phase 3', '3 propel', 'propel trial', 'trial in', 'in mcrpc', 'mcrpc #prostatecancer', '#prostatecancer showed', 'showed rpfs', 'rpfs benefit', 'benefit of', 'of using', 'using abiraterone+olaparib', 'abiraterone+olaparib vs', 'vs abiraterone', 'abiraterone biomarker', 'biomarker subgroup', 'subgroup analysis.', 'analysis. significant', 'significant pfs', 'pfs benefit,', 'benefit, os', 'os trending', 'trending favorably', 'favorably .', '#esmo22 abs# 1357o:', 'abs# 1357o: updated', '1357o: updated results', 'updated results from', 'results from the', 'from the phase', 'the phase 3', 'phase 3 propel', '3 propel trial', 'propel trial in', 'trial in mcrpc', 'in mcrpc #prostatecancer', 'mcrpc #prostatecancer showed', '#prostatecancer showed rpfs', 'showed rpfs benefit', 'rpfs benefit of', 'benefit of using', 'of using abiraterone+olaparib', 'using abiraterone+olaparib vs', 'abiraterone+olaparib vs abiraterone', 'vs abiraterone biomarker', 'abiraterone biomarker subgroup', 'biomarker subgroup analysis.', 'subgroup analysis. significant', 'analysis. significant pfs', 'significant pfs benefit,', 'pfs benefit, os', 'benefit, os trending', 'os trending favorably', 'trending favorably .', '#esmo22 abs# 1357o: updated', 'abs# 1357o: updated results', '1357o: updated results from', 'updated results from the', 'results from the phase', 'from the phase 3', 'the phase 3 propel', 'phase 3 propel trial', '3 propel trial in', 'propel trial in mcrpc', 'trial in mcrpc #prostatecancer', 'in mcrpc #prostatecancer showed', 'mcrpc #prostatecancer showed rpfs', '#prostatecancer showed rpfs benefit', 'showed rpfs benefit of', 'rpfs benefit of using', 'benefit of using abiraterone+olaparib', 'of using abiraterone+olaparib vs', 'using abiraterone+olaparib vs abiraterone', 'abiraterone+olaparib vs abiraterone biomarker', 'vs abiraterone biomarker subgroup', 'abiraterone biomarker subgroup analysis.', 'biomarker subgroup analysis. significant', 'subgroup analysis. significant pfs', 'analysis. significant pfs benefit,', 'significant pfs benefit, os', 'pfs benefit, os trending', 'benefit, os trending favorably', 'os trending favorably .', '#esmo22 abs# 1357o: updated results', 'abs# 1357o: updated results from', '1357o: updated results from the', 'updated results from the phase', 'results from the phase 3', 'from the phase 3 propel', 'the phase 3 propel trial', 'phase 3 propel trial in', '3 propel trial in mcrpc', 'propel trial in mcrpc #prostatecancer', 'trial in mcrpc #prostatecancer showed', 'in mcrpc #prostatecancer showed rpfs', 'mcrpc #prostatecancer showed rpfs benefit', '#prostatecancer showed rpfs benefit of', 'showed rpfs benefit of using', 'rpfs benefit of using abiraterone+olaparib', 'benefit of using abiraterone+olaparib vs', 'of using abiraterone+olaparib vs abiraterone', 'using abiraterone+olaparib vs abiraterone biomarker', 'abiraterone+olaparib vs abiraterone biomarker subgroup', 'vs abiraterone biomarker subgroup analysis.', 'abiraterone biomarker subgroup analysis. significant', 'biomarker subgroup analysis. significant pfs', 'subgroup analysis. significant pfs benefit,', 'analysis. significant pfs benefit, os', 'significant pfs benefit, os trending', 'pfs benefit, os trending favorably', 'benefit, os trending favorably .', '#esmo22 abs# 1357o: updated results from', 'abs# 1357o: updated results from the', '1357o: updated results from the phase', 'updated results from the phase 3', 'results from the phase 3 propel', 'from the phase 3 propel trial', 'the phase 3 propel trial in', 'phase 3 propel trial in mcrpc', '3 propel trial in mcrpc #prostatecancer', 'propel trial in mcrpc #prostatecancer showed', 'trial in mcrpc #prostatecancer showed rpfs', 'in mcrpc #prostatecancer showed rpfs benefit', 'mcrpc #prostatecancer showed rpfs benefit of', '#prostatecancer showed rpfs benefit of using', 'showed rpfs benefit of using abiraterone+olaparib', 'rpfs benefit of using abiraterone+olaparib vs', 'benefit of using abiraterone+olaparib vs abiraterone', 'of using abiraterone+olaparib vs abiraterone biomarker', 'using abiraterone+olaparib vs abiraterone biomarker subgroup', 'abiraterone+olaparib vs abiraterone biomarker subgroup analysis.', 'vs abiraterone biomarker subgroup analysis. significant', 'abiraterone biomarker subgroup analysis. significant pfs', 'biomarker subgroup analysis. significant pfs benefit,', 'subgroup analysis. significant pfs benefit, os', 'analysis. significant pfs benefit, os trending', 'significant pfs benefit, os trending favorably', 'pfs benefit, os trending favorably .', '#esmo22 abs# 1357o: updated results from the', 'abs# 1357o: updated results from the phase', '1357o: updated results from the phase 3', 'updated results from the phase 3 propel', 'results from the phase 3 propel trial', 'from the phase 3 propel trial in', 'the phase 3 propel trial in mcrpc', 'phase 3 propel trial in mcrpc #prostatecancer', '3 propel trial in mcrpc #prostatecancer showed', 'propel trial in mcrpc #prostatecancer showed rpfs', 'trial in mcrpc #prostatecancer showed rpfs benefit', 'in mcrpc #prostatecancer showed rpfs benefit of', 'mcrpc #prostatecancer showed rpfs benefit of using', '#prostatecancer showed rpfs benefit of using abiraterone+olaparib', 'showed rpfs benefit of using abiraterone+olaparib vs', 'rpfs benefit of using abiraterone+olaparib vs abiraterone', 'benefit of using abiraterone+olaparib vs abiraterone biomarker', 'of using abiraterone+olaparib vs abiraterone biomarker subgroup', 'using abiraterone+olaparib vs abiraterone biomarker subgroup analysis.', 'abiraterone+olaparib vs abiraterone biomarker subgroup analysis. significant', 'vs abiraterone biomarker subgroup analysis. significant pfs', 'abiraterone biomarker subgroup analysis. significant pfs benefit,', 'biomarker subgroup analysis. significant pfs benefit, os', 'subgroup analysis. significant pfs benefit, os trending', 'analysis. significant pfs benefit, os trending favorably', 'significant pfs benefit, os trending favorably .', '#esmo22 abs# 1357o: updated results from the phase', 'abs# 1357o: updated results from the phase 3', '1357o: updated results from the phase 3 propel', 'updated results from the phase 3 propel trial', 'results from the phase 3 propel trial in', 'from the phase 3 propel trial in mcrpc', 'the phase 3 propel trial in mcrpc #prostatecancer', 'phase 3 propel trial in mcrpc #prostatecancer showed', '3 propel trial in mcrpc #prostatecancer showed rpfs', 'propel trial in mcrpc #prostatecancer showed rpfs benefit', 'trial in mcrpc #prostatecancer showed rpfs benefit of', 'in mcrpc #prostatecancer showed rpfs benefit of using', 'mcrpc #prostatecancer showed rpfs benefit of using abiraterone+olaparib', '#prostatecancer showed rpfs benefit of using abiraterone+olaparib vs', 'showed rpfs benefit of using abiraterone+olaparib vs abiraterone', 'rpfs benefit of using abiraterone+olaparib vs abiraterone biomarker', 'benefit of using abiraterone+olaparib vs abiraterone biomarker subgroup', 'of using abiraterone+olaparib vs abiraterone biomarker subgroup analysis.', 'using abiraterone+olaparib vs abiraterone biomarker subgroup analysis. significant', 'abiraterone+olaparib vs abiraterone biomarker subgroup analysis. significant pfs', 'vs abiraterone biomarker subgroup analysis. significant pfs benefit,', 'abiraterone biomarker subgroup analysis. significant pfs benefit, os', 'biomarker subgroup analysis. significant pfs benefit, os trending', 'subgroup analysis. significant pfs benefit, os trending favorably', 'analysis. significant pfs benefit, os trending favorably .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '138', 'tokens': ['dr.', 'chria', 'ryan', 'reports', 'on', 'everest', 'ph3', 'trial.', '1', 'year', 'of', 'adjuvant', 'everolimus', 'for', 'intermediate', 'to', 'high', 'risk', 'rcc', '#kcsm', 'everolimus', 'improved', 'rfs', 'in', 'in', 'the', 'very', 'high', 'risk', 'but', 'missed', 'the', 'statistical', 'significance', 'threshold', 'for', 'the', 'overall', 'population.', 'no', 'improvement', 'in', 'os', '#asco22', '.'], 'text_length': 45, 'triples': {'everest|improved rfs in in the very high risk but missed the statistical significance threshold for the overall population. no improvement': ([5, 5], [21, 40], 'negative'), 'everolimus for intermediate to high risk rcc #kcsm everolimus|improved rfs in in the very high risk but missed the statistical significance threshold for the overall population. no improvement': ([12, 20], [21, 40], 'negative')}, 'sentence': 'dr. chria ryan reports on everest ph3 trial. 1 year of adjuvant everolimus for intermediate to high risk rcc #kcsm everolimus improved rfs in in the very high risk but missed the statistical significance threshold for the overall population. no improvement in os #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 5), (12, 20)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(21, 40)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8)], 'span tokens': ['dr.', 'chria', 'ryan', 'reports', 'on', 'everest', 'ph3', 'trial.', '1', 'year', 'of', 'adjuvant', 'everolimus', 'for', 'intermediate', 'to', 'high', 'risk', 'rcc', '#kcsm', 'everolimus', 'improved', 'rfs', 'in', 'in', 'the', 'very', 'high', 'risk', 'but', 'missed', 'the', 'statistical', 'significance', 'threshold', 'for', 'the', 'overall', 'population.', 'no', 'improvement', 'in', 'os', '#asco22', '.', 'dr. chria', 'chria ryan', 'ryan reports', 'reports on', 'on everest', 'everest ph3', 'ph3 trial.', 'trial. 1', '1 year', 'year of', 'of adjuvant', 'adjuvant everolimus', 'everolimus for', 'for intermediate', 'intermediate to', 'to high', 'high risk', 'risk rcc', 'rcc #kcsm', '#kcsm everolimus', 'everolimus improved', 'improved rfs', 'rfs in', 'in in', 'in the', 'the very', 'very high', 'high risk', 'risk but', 'but missed', 'missed the', 'the statistical', 'statistical significance', 'significance threshold', 'threshold for', 'for the', 'the overall', 'overall population.', 'population. no', 'no improvement', 'improvement in', 'in os', 'os #asco22', '#asco22 .', 'dr. chria ryan', 'chria ryan reports', 'ryan reports on', 'reports on everest', 'on everest ph3', 'everest ph3 trial.', 'ph3 trial. 1', 'trial. 1 year', '1 year of', 'year of adjuvant', 'of adjuvant everolimus', 'adjuvant everolimus for', 'everolimus for intermediate', 'for intermediate to', 'intermediate to high', 'to high risk', 'high risk rcc', 'risk rcc #kcsm', 'rcc #kcsm everolimus', '#kcsm everolimus improved', 'everolimus improved rfs', 'improved rfs in', 'rfs in in', 'in in the', 'in the very', 'the very high', 'very high risk', 'high risk but', 'risk but missed', 'but missed the', 'missed the statistical', 'the statistical significance', 'statistical significance threshold', 'significance threshold for', 'threshold for the', 'for the overall', 'the overall population.', 'overall population. no', 'population. no improvement', 'no improvement in', 'improvement in os', 'in os #asco22', 'os #asco22 .', 'dr. chria ryan reports', 'chria ryan reports on', 'ryan reports on everest', 'reports on everest ph3', 'on everest ph3 trial.', 'everest ph3 trial. 1', 'ph3 trial. 1 year', 'trial. 1 year of', '1 year of adjuvant', 'year of adjuvant everolimus', 'of adjuvant everolimus for', 'adjuvant everolimus for intermediate', 'everolimus for intermediate to', 'for intermediate to high', 'intermediate to high risk', 'to high risk rcc', 'high risk rcc #kcsm', 'risk rcc #kcsm everolimus', 'rcc #kcsm everolimus improved', '#kcsm everolimus improved rfs', 'everolimus improved rfs in', 'improved rfs in in', 'rfs in in the', 'in in the very', 'in the very high', 'the very high risk', 'very high risk but', 'high risk but missed', 'risk but missed the', 'but missed the statistical', 'missed the statistical significance', 'the statistical significance threshold', 'statistical significance threshold for', 'significance threshold for the', 'threshold for the overall', 'for the overall population.', 'the overall population. no', 'overall population. no improvement', 'population. no improvement in', 'no improvement in os', 'improvement in os #asco22', 'in os #asco22 .', 'dr. chria ryan reports on', 'chria ryan reports on everest', 'ryan reports on everest ph3', 'reports on everest ph3 trial.', 'on everest ph3 trial. 1', 'everest ph3 trial. 1 year', 'ph3 trial. 1 year of', 'trial. 1 year of adjuvant', '1 year of adjuvant everolimus', 'year of adjuvant everolimus for', 'of adjuvant everolimus for intermediate', 'adjuvant everolimus for intermediate to', 'everolimus for intermediate to high', 'for intermediate to high risk', 'intermediate to high risk rcc', 'to high risk rcc #kcsm', 'high risk rcc #kcsm everolimus', 'risk rcc #kcsm everolimus improved', 'rcc #kcsm everolimus improved rfs', '#kcsm everolimus improved rfs in', 'everolimus improved rfs in in', 'improved rfs in in the', 'rfs in in the very', 'in in the very high', 'in the very high risk', 'the very high risk but', 'very high risk but missed', 'high risk but missed the', 'risk but missed the statistical', 'but missed the statistical significance', 'missed the statistical significance threshold', 'the statistical significance threshold for', 'statistical significance threshold for the', 'significance threshold for the overall', 'threshold for the overall population.', 'for the overall population. no', 'the overall population. no improvement', 'overall population. no improvement in', 'population. no improvement in os', 'no improvement in os #asco22', 'improvement in os #asco22 .', 'dr. chria ryan reports on everest', 'chria ryan reports on everest ph3', 'ryan reports on everest ph3 trial.', 'reports on everest ph3 trial. 1', 'on everest ph3 trial. 1 year', 'everest ph3 trial. 1 year of', 'ph3 trial. 1 year of adjuvant', 'trial. 1 year of adjuvant everolimus', '1 year of adjuvant everolimus for', 'year of adjuvant everolimus for intermediate', 'of adjuvant everolimus for intermediate to', 'adjuvant everolimus for intermediate to high', 'everolimus for intermediate to high risk', 'for intermediate to high risk rcc', 'intermediate to high risk rcc #kcsm', 'to high risk rcc #kcsm everolimus', 'high risk rcc #kcsm everolimus improved', 'risk rcc #kcsm everolimus improved rfs', 'rcc #kcsm everolimus improved rfs in', '#kcsm everolimus improved rfs in in', 'everolimus improved rfs in in the', 'improved rfs in in the very', 'rfs in in the very high', 'in in the very high risk', 'in the very high risk but', 'the very high risk but missed', 'very high risk but missed the', 'high risk but missed the statistical', 'risk but missed the statistical significance', 'but missed the statistical significance threshold', 'missed the statistical significance threshold for', 'the statistical significance threshold for the', 'statistical significance threshold for the overall', 'significance threshold for the overall population.', 'threshold for the overall population. no', 'for the overall population. no improvement', 'the overall population. no improvement in', 'overall population. no improvement in os', 'population. no improvement in os #asco22', 'no improvement in os #asco22 .', 'dr. chria ryan reports on everest ph3', 'chria ryan reports on everest ph3 trial.', 'ryan reports on everest ph3 trial. 1', 'reports on everest ph3 trial. 1 year', 'on everest ph3 trial. 1 year of', 'everest ph3 trial. 1 year of adjuvant', 'ph3 trial. 1 year of adjuvant everolimus', 'trial. 1 year of adjuvant everolimus for', '1 year of adjuvant everolimus for intermediate', 'year of adjuvant everolimus for intermediate to', 'of adjuvant everolimus for intermediate to high', 'adjuvant everolimus for intermediate to high risk', 'everolimus for intermediate to high risk rcc', 'for intermediate to high risk rcc #kcsm', 'intermediate to high risk rcc #kcsm everolimus', 'to high risk rcc #kcsm everolimus improved', 'high risk rcc #kcsm everolimus improved rfs', 'risk rcc #kcsm everolimus improved rfs in', 'rcc #kcsm everolimus improved rfs in in', '#kcsm everolimus improved rfs in in the', 'everolimus improved rfs in in the very', 'improved rfs in in the very high', 'rfs in in the very high risk', 'in in the very high risk but', 'in the very high risk but missed', 'the very high risk but missed the', 'very high risk but missed the statistical', 'high risk but missed the statistical significance', 'risk but missed the statistical significance threshold', 'but missed the statistical significance threshold for', 'missed the statistical significance threshold for the', 'the statistical significance threshold for the overall', 'statistical significance threshold for the overall population.', 'significance threshold for the overall population. no', 'threshold for the overall population. no improvement', 'for the overall population. no improvement in', 'the overall population. no improvement in os', 'overall population. no improvement in os #asco22', 'population. no improvement in os #asco22 .', 'dr. chria ryan reports on everest ph3 trial.', 'chria ryan reports on everest ph3 trial. 1', 'ryan reports on everest ph3 trial. 1 year', 'reports on everest ph3 trial. 1 year of', 'on everest ph3 trial. 1 year of adjuvant', 'everest ph3 trial. 1 year of adjuvant everolimus', 'ph3 trial. 1 year of adjuvant everolimus for', 'trial. 1 year of adjuvant everolimus for intermediate', '1 year of adjuvant everolimus for intermediate to', 'year of adjuvant everolimus for intermediate to high', 'of adjuvant everolimus for intermediate to high risk', 'adjuvant everolimus for intermediate to high risk rcc', 'everolimus for intermediate to high risk rcc #kcsm', 'for intermediate to high risk rcc #kcsm everolimus', 'intermediate to high risk rcc #kcsm everolimus improved', 'to high risk rcc #kcsm everolimus improved rfs', 'high risk rcc #kcsm everolimus improved rfs in', 'risk rcc #kcsm everolimus improved rfs in in', 'rcc #kcsm everolimus improved rfs in in the', '#kcsm everolimus improved rfs in in the very', 'everolimus improved rfs in in the very high', 'improved rfs in in the very high risk', 'rfs in in the very high risk but', 'in in the very high risk but missed', 'in the very high risk but missed the', 'the very high risk but missed the statistical', 'very high risk but missed the statistical significance', 'high risk but missed the statistical significance threshold', 'risk but missed the statistical significance threshold for', 'but missed the statistical significance threshold for the', 'missed the statistical significance threshold for the overall', 'the statistical significance threshold for the overall population.', 'statistical significance threshold for the overall population. no', 'significance threshold for the overall population. no improvement', 'threshold for the overall population. no improvement in', 'for the overall population. no improvement in os', 'the overall population. no improvement in os #asco22', 'overall population. no improvement in os #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '139', 'tokens': ['great', 'data', 'from', 'stampede', 'showing', 'no', 'benefits', 'to', 'adding', 'enza', 'to', 'abi', 'in', 'mhspc:', 'more', 'toxicity,', 'no', 'more', 'efficacy.', '#esmo2022', '.'], 'text_length': 21, 'triples': {'stampede|no benefits to adding enza to abi in mhspc: more toxicity, no more efficacy.': ([3, 3], [5, 18], 'negative')}, 'sentence': 'great data from stampede showing no benefits to adding enza to abi in mhspc: more toxicity, no more efficacy. #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 18)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['great', 'data', 'from', 'stampede', 'showing', 'no', 'benefits', 'to', 'adding', 'enza', 'to', 'abi', 'in', 'mhspc:', 'more', 'toxicity,', 'no', 'more', 'efficacy.', '#esmo2022', '.', 'great data', 'data from', 'from stampede', 'stampede showing', 'showing no', 'no benefits', 'benefits to', 'to adding', 'adding enza', 'enza to', 'to abi', 'abi in', 'in mhspc:', 'mhspc: more', 'more toxicity,', 'toxicity, no', 'no more', 'more efficacy.', 'efficacy. #esmo2022', '#esmo2022 .', 'great data from', 'data from stampede', 'from stampede showing', 'stampede showing no', 'showing no benefits', 'no benefits to', 'benefits to adding', 'to adding enza', 'adding enza to', 'enza to abi', 'to abi in', 'abi in mhspc:', 'in mhspc: more', 'mhspc: more toxicity,', 'more toxicity, no', 'toxicity, no more', 'no more efficacy.', 'more efficacy. #esmo2022', 'efficacy. #esmo2022 .', 'great data from stampede', 'data from stampede showing', 'from stampede showing no', 'stampede showing no benefits', 'showing no benefits to', 'no benefits to adding', 'benefits to adding enza', 'to adding enza to', 'adding enza to abi', 'enza to abi in', 'to abi in mhspc:', 'abi in mhspc: more', 'in mhspc: more toxicity,', 'mhspc: more toxicity, no', 'more toxicity, no more', 'toxicity, no more efficacy.', 'no more efficacy. #esmo2022', 'more efficacy. #esmo2022 .', 'great data from stampede showing', 'data from stampede showing no', 'from stampede showing no benefits', 'stampede showing no benefits to', 'showing no benefits to adding', 'no benefits to adding enza', 'benefits to adding enza to', 'to adding enza to abi', 'adding enza to abi in', 'enza to abi in mhspc:', 'to abi in mhspc: more', 'abi in mhspc: more toxicity,', 'in mhspc: more toxicity, no', 'mhspc: more toxicity, no more', 'more toxicity, no more efficacy.', 'toxicity, no more efficacy. #esmo2022', 'no more efficacy. #esmo2022 .', 'great data from stampede showing no', 'data from stampede showing no benefits', 'from stampede showing no benefits to', 'stampede showing no benefits to adding', 'showing no benefits to adding enza', 'no benefits to adding enza to', 'benefits to adding enza to abi', 'to adding enza to abi in', 'adding enza to abi in mhspc:', 'enza to abi in mhspc: more', 'to abi in mhspc: more toxicity,', 'abi in mhspc: more toxicity, no', 'in mhspc: more toxicity, no more', 'mhspc: more toxicity, no more efficacy.', 'more toxicity, no more efficacy. #esmo2022', 'toxicity, no more efficacy. #esmo2022 .', 'great data from stampede showing no benefits', 'data from stampede showing no benefits to', 'from stampede showing no benefits to adding', 'stampede showing no benefits to adding enza', 'showing no benefits to adding enza to', 'no benefits to adding enza to abi', 'benefits to adding enza to abi in', 'to adding enza to abi in mhspc:', 'adding enza to abi in mhspc: more', 'enza to abi in mhspc: more toxicity,', 'to abi in mhspc: more toxicity, no', 'abi in mhspc: more toxicity, no more', 'in mhspc: more toxicity, no more efficacy.', 'mhspc: more toxicity, no more efficacy. #esmo2022', 'more toxicity, no more efficacy. #esmo2022 .', 'great data from stampede showing no benefits to', 'data from stampede showing no benefits to adding', 'from stampede showing no benefits to adding enza', 'stampede showing no benefits to adding enza to', 'showing no benefits to adding enza to abi', 'no benefits to adding enza to abi in', 'benefits to adding enza to abi in mhspc:', 'to adding enza to abi in mhspc: more', 'adding enza to abi in mhspc: more toxicity,', 'enza to abi in mhspc: more toxicity, no', 'to abi in mhspc: more toxicity, no more', 'abi in mhspc: more toxicity, no more efficacy.', 'in mhspc: more toxicity, no more efficacy. #esmo2022', 'mhspc: more toxicity, no more efficacy. #esmo2022 .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '140', 'tokens': ['#esmo22', '#lba8', 'ph3', 'cosmic-313', 'of', 'triplet', 'cabozantinib+nivolumab+ipilimumab', 'improved', 'pfs', '(hr=0.73,', 'p=0.013)', 'compared', 'to', 'ipinivo', 'in', 'untreated', 'mrcc', 'at', '1l,', 'os', 'pending.', '.'], 'text_length': 22, 'triples': {'cosmic-313|improved': ([3, 3], [7, 7], 'positive'), 'ipinivo|improved pfs (hr=0.73, p=0.013) compared to': ([13, 13], [7, 12], 'negative'), 'cabozantinib+nivolumab+ipilimumab|improved': ([6, 6], [7, 7], 'positive')}, 'sentence': '#esmo22 #lba8 ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared to ipinivo in untreated mrcc at 1l, os pending. .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(3, 3), (13, 13), (6, 6)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(7, 7), (7, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['#esmo22', '#lba8', 'ph3', 'cosmic-313', 'of', 'triplet', 'cabozantinib+nivolumab+ipilimumab', 'improved', 'pfs', '(hr=0.73,', 'p=0.013)', 'compared', 'to', 'ipinivo', 'in', 'untreated', 'mrcc', 'at', '1l,', 'os', 'pending.', '.', '#esmo22 #lba8', '#lba8 ph3', 'ph3 cosmic-313', 'cosmic-313 of', 'of triplet', 'triplet cabozantinib+nivolumab+ipilimumab', 'cabozantinib+nivolumab+ipilimumab improved', 'improved pfs', 'pfs (hr=0.73,', '(hr=0.73, p=0.013)', 'p=0.013) compared', 'compared to', 'to ipinivo', 'ipinivo in', 'in untreated', 'untreated mrcc', 'mrcc at', 'at 1l,', '1l, os', 'os pending.', 'pending. .', '#esmo22 #lba8 ph3', '#lba8 ph3 cosmic-313', 'ph3 cosmic-313 of', 'cosmic-313 of triplet', 'of triplet cabozantinib+nivolumab+ipilimumab', 'triplet cabozantinib+nivolumab+ipilimumab improved', 'cabozantinib+nivolumab+ipilimumab improved pfs', 'improved pfs (hr=0.73,', 'pfs (hr=0.73, p=0.013)', '(hr=0.73, p=0.013) compared', 'p=0.013) compared to', 'compared to ipinivo', 'to ipinivo in', 'ipinivo in untreated', 'in untreated mrcc', 'untreated mrcc at', 'mrcc at 1l,', 'at 1l, os', '1l, os pending.', 'os pending. .', '#esmo22 #lba8 ph3 cosmic-313', '#lba8 ph3 cosmic-313 of', 'ph3 cosmic-313 of triplet', 'cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab', 'of triplet cabozantinib+nivolumab+ipilimumab improved', 'triplet cabozantinib+nivolumab+ipilimumab improved pfs', 'cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73,', 'improved pfs (hr=0.73, p=0.013)', 'pfs (hr=0.73, p=0.013) compared', '(hr=0.73, p=0.013) compared to', 'p=0.013) compared to ipinivo', 'compared to ipinivo in', 'to ipinivo in untreated', 'ipinivo in untreated mrcc', 'in untreated mrcc at', 'untreated mrcc at 1l,', 'mrcc at 1l, os', 'at 1l, os pending.', '1l, os pending. .', '#esmo22 #lba8 ph3 cosmic-313 of', '#lba8 ph3 cosmic-313 of triplet', 'ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab', 'cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved', 'of triplet cabozantinib+nivolumab+ipilimumab improved pfs', 'triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73,', 'cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013)', 'improved pfs (hr=0.73, p=0.013) compared', 'pfs (hr=0.73, p=0.013) compared to', '(hr=0.73, p=0.013) compared to ipinivo', 'p=0.013) compared to ipinivo in', 'compared to ipinivo in untreated', 'to ipinivo in untreated mrcc', 'ipinivo in untreated mrcc at', 'in untreated mrcc at 1l,', 'untreated mrcc at 1l, os', 'mrcc at 1l, os pending.', 'at 1l, os pending. .', '#esmo22 #lba8 ph3 cosmic-313 of triplet', '#lba8 ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab', 'ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved', 'cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs', 'of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73,', 'triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013)', 'cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared', 'improved pfs (hr=0.73, p=0.013) compared to', 'pfs (hr=0.73, p=0.013) compared to ipinivo', '(hr=0.73, p=0.013) compared to ipinivo in', 'p=0.013) compared to ipinivo in untreated', 'compared to ipinivo in untreated mrcc', 'to ipinivo in untreated mrcc at', 'ipinivo in untreated mrcc at 1l,', 'in untreated mrcc at 1l, os', 'untreated mrcc at 1l, os pending.', 'mrcc at 1l, os pending. .', '#esmo22 #lba8 ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab', '#lba8 ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved', 'ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs', 'cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73,', 'of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013)', 'triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared', 'cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared to', 'improved pfs (hr=0.73, p=0.013) compared to ipinivo', 'pfs (hr=0.73, p=0.013) compared to ipinivo in', '(hr=0.73, p=0.013) compared to ipinivo in untreated', 'p=0.013) compared to ipinivo in untreated mrcc', 'compared to ipinivo in untreated mrcc at', 'to ipinivo in untreated mrcc at 1l,', 'ipinivo in untreated mrcc at 1l, os', 'in untreated mrcc at 1l, os pending.', 'untreated mrcc at 1l, os pending. .', '#esmo22 #lba8 ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved', '#lba8 ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs', 'ph3 cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73,', 'cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013)', 'of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared', 'triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared to', 'cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared to ipinivo', 'improved pfs (hr=0.73, p=0.013) compared to ipinivo in', 'pfs (hr=0.73, p=0.013) compared to ipinivo in untreated', '(hr=0.73, p=0.013) compared to ipinivo in untreated mrcc', 'p=0.013) compared to ipinivo in untreated mrcc at', 'compared to ipinivo in untreated mrcc at 1l,', 'to ipinivo in untreated mrcc at 1l, os', 'ipinivo in untreated mrcc at 1l, os pending.', 'in untreated mrcc at 1l, os pending. .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '141', 'tokens': ['data', 'from', 'galaxy', 'study', '#gi22', 'seems', 'to', 'be', 'inferior', 'to', 'sushine', 'study.', 'ctdna', 'to', 'predict', 'adjuvant', 'therapy', 'benefit', 'in', 'stage', 'ii-iv', 'colon', 'cancer?', 'circulate', 'and', 'cobra', 'eagerly', 'awaited!', '.'], 'text_length': 29, 'triples': {'galaxy|inferior': ([2, 2], [8, 8], 'negative'), 'sushine|to be inferior to sushine study. ctdna to': ([10, 10], [6, 13], 'positive'), 'circulate|benefit': ([23, 23], [17, 17], 'neutral'), 'cobra|eagerly awaited!': ([25, 25], [26, 27], 'neutral')}, 'sentence': 'data from galaxy study #gi22 seems to be inferior to sushine study. ctdna to predict adjuvant therapy benefit in stage ii-iv colon cancer? circulate and cobra eagerly awaited! .', 'aspect_num': 4, 'spans_aspect2opinion_label': [(2, 2), (10, 10), (23, 23), (25, 25)], 'reverse_opinion_num': 4, 'reverse_opinion2aspect_label': [(8, 8), (6, 13), (17, 17), (26, 27)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8)], 'span tokens': ['data', 'from', 'galaxy', 'study', '#gi22', 'seems', 'to', 'be', 'inferior', 'to', 'sushine', 'study.', 'ctdna', 'to', 'predict', 'adjuvant', 'therapy', 'benefit', 'in', 'stage', 'ii-iv', 'colon', 'cancer?', 'circulate', 'and', 'cobra', 'eagerly', 'awaited!', '.', 'data from', 'from galaxy', 'galaxy study', 'study #gi22', '#gi22 seems', 'seems to', 'to be', 'be inferior', 'inferior to', 'to sushine', 'sushine study.', 'study. ctdna', 'ctdna to', 'to predict', 'predict adjuvant', 'adjuvant therapy', 'therapy benefit', 'benefit in', 'in stage', 'stage ii-iv', 'ii-iv colon', 'colon cancer?', 'cancer? circulate', 'circulate and', 'and cobra', 'cobra eagerly', 'eagerly awaited!', 'awaited! .', 'data from galaxy', 'from galaxy study', 'galaxy study #gi22', 'study #gi22 seems', '#gi22 seems to', 'seems to be', 'to be inferior', 'be inferior to', 'inferior to sushine', 'to sushine study.', 'sushine study. ctdna', 'study. ctdna to', 'ctdna to predict', 'to predict adjuvant', 'predict adjuvant therapy', 'adjuvant therapy benefit', 'therapy benefit in', 'benefit in stage', 'in stage ii-iv', 'stage ii-iv colon', 'ii-iv colon cancer?', 'colon cancer? circulate', 'cancer? circulate and', 'circulate and cobra', 'and cobra eagerly', 'cobra eagerly awaited!', 'eagerly awaited! .', 'data from galaxy study', 'from galaxy study #gi22', 'galaxy study #gi22 seems', 'study #gi22 seems to', '#gi22 seems to be', 'seems to be inferior', 'to be inferior to', 'be inferior to sushine', 'inferior to sushine study.', 'to sushine study. ctdna', 'sushine study. ctdna to', 'study. ctdna to predict', 'ctdna to predict adjuvant', 'to predict adjuvant therapy', 'predict adjuvant therapy benefit', 'adjuvant therapy benefit in', 'therapy benefit in stage', 'benefit in stage ii-iv', 'in stage ii-iv colon', 'stage ii-iv colon cancer?', 'ii-iv colon cancer? circulate', 'colon cancer? circulate and', 'cancer? circulate and cobra', 'circulate and cobra eagerly', 'and cobra eagerly awaited!', 'cobra eagerly awaited! .', 'data from galaxy study #gi22', 'from galaxy study #gi22 seems', 'galaxy study #gi22 seems to', 'study #gi22 seems to be', '#gi22 seems to be inferior', 'seems to be inferior to', 'to be inferior to sushine', 'be inferior to sushine study.', 'inferior to sushine study. ctdna', 'to sushine study. ctdna to', 'sushine study. ctdna to predict', 'study. ctdna to predict adjuvant', 'ctdna to predict adjuvant therapy', 'to predict adjuvant therapy benefit', 'predict adjuvant therapy benefit in', 'adjuvant therapy benefit in stage', 'therapy benefit in stage ii-iv', 'benefit in stage ii-iv colon', 'in stage ii-iv colon cancer?', 'stage ii-iv colon cancer? circulate', 'ii-iv colon cancer? circulate and', 'colon cancer? circulate and cobra', 'cancer? circulate and cobra eagerly', 'circulate and cobra eagerly awaited!', 'and cobra eagerly awaited! .', 'data from galaxy study #gi22 seems', 'from galaxy study #gi22 seems to', 'galaxy study #gi22 seems to be', 'study #gi22 seems to be inferior', '#gi22 seems to be inferior to', 'seems to be inferior to sushine', 'to be inferior to sushine study.', 'be inferior to sushine study. ctdna', 'inferior to sushine study. ctdna to', 'to sushine study. ctdna to predict', 'sushine study. ctdna to predict adjuvant', 'study. ctdna to predict adjuvant therapy', 'ctdna to predict adjuvant therapy benefit', 'to predict adjuvant therapy benefit in', 'predict adjuvant therapy benefit in stage', 'adjuvant therapy benefit in stage ii-iv', 'therapy benefit in stage ii-iv colon', 'benefit in stage ii-iv colon cancer?', 'in stage ii-iv colon cancer? circulate', 'stage ii-iv colon cancer? circulate and', 'ii-iv colon cancer? circulate and cobra', 'colon cancer? circulate and cobra eagerly', 'cancer? circulate and cobra eagerly awaited!', 'circulate and cobra eagerly awaited! .', 'data from galaxy study #gi22 seems to', 'from galaxy study #gi22 seems to be', 'galaxy study #gi22 seems to be inferior', 'study #gi22 seems to be inferior to', '#gi22 seems to be inferior to sushine', 'seems to be inferior to sushine study.', 'to be inferior to sushine study. ctdna', 'be inferior to sushine study. ctdna to', 'inferior to sushine study. ctdna to predict', 'to sushine study. ctdna to predict adjuvant', 'sushine study. ctdna to predict adjuvant therapy', 'study. ctdna to predict adjuvant therapy benefit', 'ctdna to predict adjuvant therapy benefit in', 'to predict adjuvant therapy benefit in stage', 'predict adjuvant therapy benefit in stage ii-iv', 'adjuvant therapy benefit in stage ii-iv colon', 'therapy benefit in stage ii-iv colon cancer?', 'benefit in stage ii-iv colon cancer? circulate', 'in stage ii-iv colon cancer? circulate and', 'stage ii-iv colon cancer? circulate and cobra', 'ii-iv colon cancer? circulate and cobra eagerly', 'colon cancer? circulate and cobra eagerly awaited!', 'cancer? circulate and cobra eagerly awaited! .', 'data from galaxy study #gi22 seems to be', 'from galaxy study #gi22 seems to be inferior', 'galaxy study #gi22 seems to be inferior to', 'study #gi22 seems to be inferior to sushine', '#gi22 seems to be inferior to sushine study.', 'seems to be inferior to sushine study. ctdna', 'to be inferior to sushine study. ctdna to', 'be inferior to sushine study. ctdna to predict', 'inferior to sushine study. ctdna to predict adjuvant', 'to sushine study. ctdna to predict adjuvant therapy', 'sushine study. ctdna to predict adjuvant therapy benefit', 'study. ctdna to predict adjuvant therapy benefit in', 'ctdna to predict adjuvant therapy benefit in stage', 'to predict adjuvant therapy benefit in stage ii-iv', 'predict adjuvant therapy benefit in stage ii-iv colon', 'adjuvant therapy benefit in stage ii-iv colon cancer?', 'therapy benefit in stage ii-iv colon cancer? circulate', 'benefit in stage ii-iv colon cancer? circulate and', 'in stage ii-iv colon cancer? circulate and cobra', 'stage ii-iv colon cancer? circulate and cobra eagerly', 'ii-iv colon cancer? circulate and cobra eagerly awaited!', 'colon cancer? circulate and cobra eagerly awaited! .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '142', 'tokens': ['#esmo22', 'exciting', 'data', 'by', 's1801', '-', 'neoadjuvant', '&gt;', 'adjuvant', 'pembro', 'in', 'resectable', 'stage', '3-4', 'melanoma,', 'and', 'few', 'aes', '.'], 'text_length': 19, 'triples': {'s1801|exciting': ([4, 4], [1, 1], 'positive')}, 'sentence': '#esmo22 exciting data by s1801 - neoadjuvant &gt; adjuvant pembro in resectable stage 3-4 melanoma, and few aes .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8)], 'span tokens': ['#esmo22', 'exciting', 'data', 'by', 's1801', '-', 'neoadjuvant', '&gt;', 'adjuvant', 'pembro', 'in', 'resectable', 'stage', '3-4', 'melanoma,', 'and', 'few', 'aes', '.', '#esmo22 exciting', 'exciting data', 'data by', 'by s1801', 's1801 -', '- neoadjuvant', 'neoadjuvant &gt;', '&gt; adjuvant', 'adjuvant pembro', 'pembro in', 'in resectable', 'resectable stage', 'stage 3-4', '3-4 melanoma,', 'melanoma, and', 'and few', 'few aes', 'aes .', '#esmo22 exciting data', 'exciting data by', 'data by s1801', 'by s1801 -', 's1801 - neoadjuvant', '- neoadjuvant &gt;', 'neoadjuvant &gt; adjuvant', '&gt; adjuvant pembro', 'adjuvant pembro in', 'pembro in resectable', 'in resectable stage', 'resectable stage 3-4', 'stage 3-4 melanoma,', '3-4 melanoma, and', 'melanoma, and few', 'and few aes', 'few aes .', '#esmo22 exciting data by', 'exciting data by s1801', 'data by s1801 -', 'by s1801 - neoadjuvant', 's1801 - neoadjuvant &gt;', '- neoadjuvant &gt; adjuvant', 'neoadjuvant &gt; adjuvant pembro', '&gt; adjuvant pembro in', 'adjuvant pembro in resectable', 'pembro in resectable stage', 'in resectable stage 3-4', 'resectable stage 3-4 melanoma,', 'stage 3-4 melanoma, and', '3-4 melanoma, and few', 'melanoma, and few aes', 'and few aes .', '#esmo22 exciting data by s1801', 'exciting data by s1801 -', 'data by s1801 - neoadjuvant', 'by s1801 - neoadjuvant &gt;', 's1801 - neoadjuvant &gt; adjuvant', '- neoadjuvant &gt; adjuvant pembro', 'neoadjuvant &gt; adjuvant pembro in', '&gt; adjuvant pembro in resectable', 'adjuvant pembro in resectable stage', 'pembro in resectable stage 3-4', 'in resectable stage 3-4 melanoma,', 'resectable stage 3-4 melanoma, and', 'stage 3-4 melanoma, and few', '3-4 melanoma, and few aes', 'melanoma, and few aes .', '#esmo22 exciting data by s1801 -', 'exciting data by s1801 - neoadjuvant', 'data by s1801 - neoadjuvant &gt;', 'by s1801 - neoadjuvant &gt; adjuvant', 's1801 - neoadjuvant &gt; adjuvant pembro', '- neoadjuvant &gt; adjuvant pembro in', 'neoadjuvant &gt; adjuvant pembro in resectable', '&gt; adjuvant pembro in resectable stage', 'adjuvant pembro in resectable stage 3-4', 'pembro in resectable stage 3-4 melanoma,', 'in resectable stage 3-4 melanoma, and', 'resectable stage 3-4 melanoma, and few', 'stage 3-4 melanoma, and few aes', '3-4 melanoma, and few aes .', '#esmo22 exciting data by s1801 - neoadjuvant', 'exciting data by s1801 - neoadjuvant &gt;', 'data by s1801 - neoadjuvant &gt; adjuvant', 'by s1801 - neoadjuvant &gt; adjuvant pembro', 's1801 - neoadjuvant &gt; adjuvant pembro in', '- neoadjuvant &gt; adjuvant pembro in resectable', 'neoadjuvant &gt; adjuvant pembro in resectable stage', '&gt; adjuvant pembro in resectable stage 3-4', 'adjuvant pembro in resectable stage 3-4 melanoma,', 'pembro in resectable stage 3-4 melanoma, and', 'in resectable stage 3-4 melanoma, and few', 'resectable stage 3-4 melanoma, and few aes', 'stage 3-4 melanoma, and few aes .', '#esmo22 exciting data by s1801 - neoadjuvant &gt;', 'exciting data by s1801 - neoadjuvant &gt; adjuvant', 'data by s1801 - neoadjuvant &gt; adjuvant pembro', 'by s1801 - neoadjuvant &gt; adjuvant pembro in', 's1801 - neoadjuvant &gt; adjuvant pembro in resectable', '- neoadjuvant &gt; adjuvant pembro in resectable stage', 'neoadjuvant &gt; adjuvant pembro in resectable stage 3-4', '&gt; adjuvant pembro in resectable stage 3-4 melanoma,', 'adjuvant pembro in resectable stage 3-4 melanoma, and', 'pembro in resectable stage 3-4 melanoma, and few', 'in resectable stage 3-4 melanoma, and few aes', 'resectable stage 3-4 melanoma, and few aes .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '143', 'tokens': ['adds', 'fuel', 'to', 'the', 'triplet', 'vs', 'doublet', 'discussion', 'in', 'mhspc', 'with', 'his', 'enzamet', 'update.', '#asco2022', '#prostatecancer', '.'], 'text_length': 17, 'triples': {'enzamet|discussion in mhspc with his enzamet update.': ([12, 12], [7, 13], 'neutral')}, 'sentence': 'adds fuel to the triplet vs doublet discussion in mhspc with his enzamet update. #asco2022 #prostatecancer .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8)], 'span tokens': ['adds', 'fuel', 'to', 'the', 'triplet', 'vs', 'doublet', 'discussion', 'in', 'mhspc', 'with', 'his', 'enzamet', 'update.', '#asco2022', '#prostatecancer', '.', 'adds fuel', 'fuel to', 'to the', 'the triplet', 'triplet vs', 'vs doublet', 'doublet discussion', 'discussion in', 'in mhspc', 'mhspc with', 'with his', 'his enzamet', 'enzamet update.', 'update. #asco2022', '#asco2022 #prostatecancer', '#prostatecancer .', 'adds fuel to', 'fuel to the', 'to the triplet', 'the triplet vs', 'triplet vs doublet', 'vs doublet discussion', 'doublet discussion in', 'discussion in mhspc', 'in mhspc with', 'mhspc with his', 'with his enzamet', 'his enzamet update.', 'enzamet update. #asco2022', 'update. #asco2022 #prostatecancer', '#asco2022 #prostatecancer .', 'adds fuel to the', 'fuel to the triplet', 'to the triplet vs', 'the triplet vs doublet', 'triplet vs doublet discussion', 'vs doublet discussion in', 'doublet discussion in mhspc', 'discussion in mhspc with', 'in mhspc with his', 'mhspc with his enzamet', 'with his enzamet update.', 'his enzamet update. #asco2022', 'enzamet update. #asco2022 #prostatecancer', 'update. #asco2022 #prostatecancer .', 'adds fuel to the triplet', 'fuel to the triplet vs', 'to the triplet vs doublet', 'the triplet vs doublet discussion', 'triplet vs doublet discussion in', 'vs doublet discussion in mhspc', 'doublet discussion in mhspc with', 'discussion in mhspc with his', 'in mhspc with his enzamet', 'mhspc with his enzamet update.', 'with his enzamet update. #asco2022', 'his enzamet update. #asco2022 #prostatecancer', 'enzamet update. #asco2022 #prostatecancer .', 'adds fuel to the triplet vs', 'fuel to the triplet vs doublet', 'to the triplet vs doublet discussion', 'the triplet vs doublet discussion in', 'triplet vs doublet discussion in mhspc', 'vs doublet discussion in mhspc with', 'doublet discussion in mhspc with his', 'discussion in mhspc with his enzamet', 'in mhspc with his enzamet update.', 'mhspc with his enzamet update. #asco2022', 'with his enzamet update. #asco2022 #prostatecancer', 'his enzamet update. #asco2022 #prostatecancer .', 'adds fuel to the triplet vs doublet', 'fuel to the triplet vs doublet discussion', 'to the triplet vs doublet discussion in', 'the triplet vs doublet discussion in mhspc', 'triplet vs doublet discussion in mhspc with', 'vs doublet discussion in mhspc with his', 'doublet discussion in mhspc with his enzamet', 'discussion in mhspc with his enzamet update.', 'in mhspc with his enzamet update. #asco2022', 'mhspc with his enzamet update. #asco2022 #prostatecancer', 'with his enzamet update. #asco2022 #prostatecancer .', 'adds fuel to the triplet vs doublet discussion', 'fuel to the triplet vs doublet discussion in', 'to the triplet vs doublet discussion in mhspc', 'the triplet vs doublet discussion in mhspc with', 'triplet vs doublet discussion in mhspc with his', 'vs doublet discussion in mhspc with his enzamet', 'doublet discussion in mhspc with his enzamet update.', 'discussion in mhspc with his enzamet update. #asco2022', 'in mhspc with his enzamet update. #asco2022 #prostatecancer', 'mhspc with his enzamet update. #asco2022 #prostatecancer .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '144', 'tokens': ['lba', '-', 'updated', 'os', 'in', 'enzamet', 'med', 'f/u:', '68', 'm', 'mos:', 'enzalutamide', 'nr', '(95%', 'ci', 'nr', 'nr)', 'v', 'control', '73.2', 'm', '(95%', 'ci', '64.7', 'nr)', 'early', 'doc', 'planned:', 'yes', '(hr', '0.82,', 'ci', '0.63-1.06),', 'no', '(hr', '0.60,', 'ci', '0.47-0.78)', 'vol', 'of', 'dx:', 'low', '(hr', '0.54,', 'ci', '0.39-0.74),', 'high', '(hr', '0.79,', 'ci', '0.63-0.98)', '#asco22', '.'], 'text_length': 53, 'triples': {'enzamet|updated': ([5, 5], [2, 2], 'neutral'), 'enzalutamide|updated': ([11, 11], [2, 2], 'neutral')}, 'sentence': 'lba - updated os in enzamet med f/u: 68 m mos: enzalutamide nr (95% ci nr nr) v control 73.2 m (95% ci 64.7 nr) early doc planned: yes (hr 0.82, ci 0.63-1.06), no (hr 0.60, ci 0.47-0.78) vol of dx: low (hr 0.54, ci 0.39-0.74), high (hr 0.79, ci 0.63-0.98) #asco22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 5), (11, 11)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (52, 52, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (51, 52, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (50, 52, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (49, 52, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (48, 52, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (47, 52, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (46, 52, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8), (45, 52, 8)], 'span tokens': ['lba', '-', 'updated', 'os', 'in', 'enzamet', 'med', 'f/u:', '68', 'm', 'mos:', 'enzalutamide', 'nr', '(95%', 'ci', 'nr', 'nr)', 'v', 'control', '73.2', 'm', '(95%', 'ci', '64.7', 'nr)', 'early', 'doc', 'planned:', 'yes', '(hr', '0.82,', 'ci', '0.63-1.06),', 'no', '(hr', '0.60,', 'ci', '0.47-0.78)', 'vol', 'of', 'dx:', 'low', '(hr', '0.54,', 'ci', '0.39-0.74),', 'high', '(hr', '0.79,', 'ci', '0.63-0.98)', '#asco22', '.', 'lba -', '- updated', 'updated os', 'os in', 'in enzamet', 'enzamet med', 'med f/u:', 'f/u: 68', '68 m', 'm mos:', 'mos: enzalutamide', 'enzalutamide nr', 'nr (95%', '(95% ci', 'ci nr', 'nr nr)', 'nr) v', 'v control', 'control 73.2', '73.2 m', 'm (95%', '(95% ci', 'ci 64.7', '64.7 nr)', 'nr) early', 'early doc', 'doc planned:', 'planned: yes', 'yes (hr', '(hr 0.82,', '0.82, ci', 'ci 0.63-1.06),', '0.63-1.06), no', 'no (hr', '(hr 0.60,', '0.60, ci', 'ci 0.47-0.78)', '0.47-0.78) vol', 'vol of', 'of dx:', 'dx: low', 'low (hr', '(hr 0.54,', '0.54, ci', 'ci 0.39-0.74),', '0.39-0.74), high', 'high (hr', '(hr 0.79,', '0.79, ci', 'ci 0.63-0.98)', '0.63-0.98) #asco22', '#asco22 .', 'lba - updated', '- updated os', 'updated os in', 'os in enzamet', 'in enzamet med', 'enzamet med f/u:', 'med f/u: 68', 'f/u: 68 m', '68 m mos:', 'm mos: enzalutamide', 'mos: enzalutamide nr', 'enzalutamide nr (95%', 'nr (95% ci', '(95% ci nr', 'ci nr nr)', 'nr nr) v', 'nr) v control', 'v control 73.2', 'control 73.2 m', '73.2 m (95%', 'm (95% ci', '(95% ci 64.7', 'ci 64.7 nr)', '64.7 nr) early', 'nr) early doc', 'early doc planned:', 'doc planned: yes', 'planned: yes (hr', 'yes (hr 0.82,', '(hr 0.82, ci', '0.82, ci 0.63-1.06),', 'ci 0.63-1.06), no', '0.63-1.06), no (hr', 'no (hr 0.60,', '(hr 0.60, ci', '0.60, ci 0.47-0.78)', 'ci 0.47-0.78) vol', '0.47-0.78) vol of', 'vol of dx:', 'of dx: low', 'dx: low (hr', 'low (hr 0.54,', '(hr 0.54, ci', '0.54, ci 0.39-0.74),', 'ci 0.39-0.74), high', '0.39-0.74), high (hr', 'high (hr 0.79,', '(hr 0.79, ci', '0.79, ci 0.63-0.98)', 'ci 0.63-0.98) #asco22', '0.63-0.98) #asco22 .', 'lba - updated os', '- updated os in', 'updated os in enzamet', 'os in enzamet med', 'in enzamet med f/u:', 'enzamet med f/u: 68', 'med f/u: 68 m', 'f/u: 68 m mos:', '68 m mos: enzalutamide', 'm mos: enzalutamide nr', 'mos: enzalutamide nr (95%', 'enzalutamide nr (95% ci', 'nr (95% ci nr', '(95% ci nr nr)', 'ci nr nr) v', 'nr nr) v control', 'nr) v control 73.2', 'v control 73.2 m', 'control 73.2 m (95%', '73.2 m (95% ci', 'm (95% ci 64.7', '(95% ci 64.7 nr)', 'ci 64.7 nr) early', '64.7 nr) early doc', 'nr) early doc planned:', 'early doc planned: yes', 'doc planned: yes (hr', 'planned: yes (hr 0.82,', 'yes (hr 0.82, ci', '(hr 0.82, ci 0.63-1.06),', '0.82, ci 0.63-1.06), no', 'ci 0.63-1.06), no (hr', '0.63-1.06), no (hr 0.60,', 'no (hr 0.60, ci', '(hr 0.60, ci 0.47-0.78)', '0.60, ci 0.47-0.78) vol', 'ci 0.47-0.78) vol of', '0.47-0.78) vol of dx:', 'vol of dx: low', 'of dx: low (hr', 'dx: low (hr 0.54,', 'low (hr 0.54, ci', '(hr 0.54, ci 0.39-0.74),', '0.54, ci 0.39-0.74), high', 'ci 0.39-0.74), high (hr', '0.39-0.74), high (hr 0.79,', 'high (hr 0.79, ci', '(hr 0.79, ci 0.63-0.98)', '0.79, ci 0.63-0.98) #asco22', 'ci 0.63-0.98) #asco22 .', 'lba - updated os in', '- updated os in enzamet', 'updated os in enzamet med', 'os in enzamet med f/u:', 'in enzamet med f/u: 68', 'enzamet med f/u: 68 m', 'med f/u: 68 m mos:', 'f/u: 68 m mos: enzalutamide', '68 m mos: enzalutamide nr', 'm mos: enzalutamide nr (95%', 'mos: enzalutamide nr (95% ci', 'enzalutamide nr (95% ci nr', 'nr (95% ci nr nr)', '(95% ci nr nr) v', 'ci nr nr) v control', 'nr nr) v control 73.2', 'nr) v control 73.2 m', 'v control 73.2 m (95%', 'control 73.2 m (95% ci', '73.2 m (95% ci 64.7', 'm (95% ci 64.7 nr)', '(95% ci 64.7 nr) early', 'ci 64.7 nr) early doc', '64.7 nr) early doc planned:', 'nr) early doc planned: yes', 'early doc planned: yes (hr', 'doc planned: yes (hr 0.82,', 'planned: yes (hr 0.82, ci', 'yes (hr 0.82, ci 0.63-1.06),', '(hr 0.82, ci 0.63-1.06), no', '0.82, ci 0.63-1.06), no (hr', 'ci 0.63-1.06), no (hr 0.60,', '0.63-1.06), no (hr 0.60, ci', 'no (hr 0.60, ci 0.47-0.78)', '(hr 0.60, ci 0.47-0.78) vol', '0.60, ci 0.47-0.78) vol of', 'ci 0.47-0.78) vol of dx:', '0.47-0.78) vol of dx: low', 'vol of dx: low (hr', 'of dx: low (hr 0.54,', 'dx: low (hr 0.54, ci', 'low (hr 0.54, ci 0.39-0.74),', '(hr 0.54, ci 0.39-0.74), high', '0.54, ci 0.39-0.74), high (hr', 'ci 0.39-0.74), high (hr 0.79,', '0.39-0.74), high (hr 0.79, ci', 'high (hr 0.79, ci 0.63-0.98)', '(hr 0.79, ci 0.63-0.98) #asco22', '0.79, ci 0.63-0.98) #asco22 .', 'lba - updated os in enzamet', '- updated os in enzamet med', 'updated os in enzamet med f/u:', 'os in enzamet med f/u: 68', 'in enzamet med f/u: 68 m', 'enzamet med f/u: 68 m mos:', 'med f/u: 68 m mos: enzalutamide', 'f/u: 68 m mos: enzalutamide nr', '68 m mos: enzalutamide nr (95%', 'm mos: enzalutamide nr (95% ci', 'mos: enzalutamide nr (95% ci nr', 'enzalutamide nr (95% ci nr nr)', 'nr (95% ci nr nr) v', '(95% ci nr nr) v control', 'ci nr nr) v control 73.2', 'nr nr) v control 73.2 m', 'nr) v control 73.2 m (95%', 'v control 73.2 m (95% ci', 'control 73.2 m (95% ci 64.7', '73.2 m (95% ci 64.7 nr)', 'm (95% ci 64.7 nr) early', '(95% ci 64.7 nr) early doc', 'ci 64.7 nr) early doc planned:', '64.7 nr) early doc planned: yes', 'nr) early doc planned: yes (hr', 'early doc planned: yes (hr 0.82,', 'doc planned: yes (hr 0.82, ci', 'planned: yes (hr 0.82, ci 0.63-1.06),', 'yes (hr 0.82, ci 0.63-1.06), no', '(hr 0.82, ci 0.63-1.06), no (hr', '0.82, ci 0.63-1.06), no (hr 0.60,', 'ci 0.63-1.06), no (hr 0.60, ci', '0.63-1.06), no (hr 0.60, ci 0.47-0.78)', 'no (hr 0.60, ci 0.47-0.78) vol', '(hr 0.60, ci 0.47-0.78) vol of', '0.60, ci 0.47-0.78) vol of dx:', 'ci 0.47-0.78) vol of dx: low', '0.47-0.78) vol of dx: low (hr', 'vol of dx: low (hr 0.54,', 'of dx: low (hr 0.54, ci', 'dx: low (hr 0.54, ci 0.39-0.74),', 'low (hr 0.54, ci 0.39-0.74), high', '(hr 0.54, ci 0.39-0.74), high (hr', '0.54, ci 0.39-0.74), high (hr 0.79,', 'ci 0.39-0.74), high (hr 0.79, ci', '0.39-0.74), high (hr 0.79, ci 0.63-0.98)', 'high (hr 0.79, ci 0.63-0.98) #asco22', '(hr 0.79, ci 0.63-0.98) #asco22 .', 'lba - updated os in enzamet med', '- updated os in enzamet med f/u:', 'updated os in enzamet med f/u: 68', 'os in enzamet med f/u: 68 m', 'in enzamet med f/u: 68 m mos:', 'enzamet med f/u: 68 m mos: enzalutamide', 'med f/u: 68 m mos: enzalutamide nr', 'f/u: 68 m mos: enzalutamide nr (95%', '68 m mos: enzalutamide nr (95% ci', 'm mos: enzalutamide nr (95% ci nr', 'mos: enzalutamide nr (95% ci nr nr)', 'enzalutamide nr (95% ci nr nr) v', 'nr (95% ci nr nr) v control', '(95% ci nr nr) v control 73.2', 'ci nr nr) v control 73.2 m', 'nr nr) v control 73.2 m (95%', 'nr) v control 73.2 m (95% ci', 'v control 73.2 m (95% ci 64.7', 'control 73.2 m (95% ci 64.7 nr)', '73.2 m (95% ci 64.7 nr) early', 'm (95% ci 64.7 nr) early doc', '(95% ci 64.7 nr) early doc planned:', 'ci 64.7 nr) early doc planned: yes', '64.7 nr) early doc planned: yes (hr', 'nr) early doc planned: yes (hr 0.82,', 'early doc planned: yes (hr 0.82, ci', 'doc planned: yes (hr 0.82, ci 0.63-1.06),', 'planned: yes (hr 0.82, ci 0.63-1.06), no', 'yes (hr 0.82, ci 0.63-1.06), no (hr', '(hr 0.82, ci 0.63-1.06), no (hr 0.60,', '0.82, ci 0.63-1.06), no (hr 0.60, ci', 'ci 0.63-1.06), no (hr 0.60, ci 0.47-0.78)', '0.63-1.06), no (hr 0.60, ci 0.47-0.78) vol', 'no (hr 0.60, ci 0.47-0.78) vol of', '(hr 0.60, ci 0.47-0.78) vol of dx:', '0.60, ci 0.47-0.78) vol of dx: low', 'ci 0.47-0.78) vol of dx: low (hr', '0.47-0.78) vol of dx: low (hr 0.54,', 'vol of dx: low (hr 0.54, ci', 'of dx: low (hr 0.54, ci 0.39-0.74),', 'dx: low (hr 0.54, ci 0.39-0.74), high', 'low (hr 0.54, ci 0.39-0.74), high (hr', '(hr 0.54, ci 0.39-0.74), high (hr 0.79,', '0.54, ci 0.39-0.74), high (hr 0.79, ci', 'ci 0.39-0.74), high (hr 0.79, ci 0.63-0.98)', '0.39-0.74), high (hr 0.79, ci 0.63-0.98) #asco22', 'high (hr 0.79, ci 0.63-0.98) #asco22 .', 'lba - updated os in enzamet med f/u:', '- updated os in enzamet med f/u: 68', 'updated os in enzamet med f/u: 68 m', 'os in enzamet med f/u: 68 m mos:', 'in enzamet med f/u: 68 m mos: enzalutamide', 'enzamet med f/u: 68 m mos: enzalutamide nr', 'med f/u: 68 m mos: enzalutamide nr (95%', 'f/u: 68 m mos: enzalutamide nr (95% ci', '68 m mos: enzalutamide nr (95% ci nr', 'm mos: enzalutamide nr (95% ci nr nr)', 'mos: enzalutamide nr (95% ci nr nr) v', 'enzalutamide nr (95% ci nr nr) v control', 'nr (95% ci nr nr) v control 73.2', '(95% ci nr nr) v control 73.2 m', 'ci nr nr) v control 73.2 m (95%', 'nr nr) v control 73.2 m (95% ci', 'nr) v control 73.2 m (95% ci 64.7', 'v control 73.2 m (95% ci 64.7 nr)', 'control 73.2 m (95% ci 64.7 nr) early', '73.2 m (95% ci 64.7 nr) early doc', 'm (95% ci 64.7 nr) early doc planned:', '(95% ci 64.7 nr) early doc planned: yes', 'ci 64.7 nr) early doc planned: yes (hr', '64.7 nr) early doc planned: yes (hr 0.82,', 'nr) early doc planned: yes (hr 0.82, ci', 'early doc planned: yes (hr 0.82, ci 0.63-1.06),', 'doc planned: yes (hr 0.82, ci 0.63-1.06), no', 'planned: yes (hr 0.82, ci 0.63-1.06), no (hr', 'yes (hr 0.82, ci 0.63-1.06), no (hr 0.60,', '(hr 0.82, ci 0.63-1.06), no (hr 0.60, ci', '0.82, ci 0.63-1.06), no (hr 0.60, ci 0.47-0.78)', 'ci 0.63-1.06), no (hr 0.60, ci 0.47-0.78) vol', '0.63-1.06), no (hr 0.60, ci 0.47-0.78) vol of', 'no (hr 0.60, ci 0.47-0.78) vol of dx:', '(hr 0.60, ci 0.47-0.78) vol of dx: low', '0.60, ci 0.47-0.78) vol of dx: low (hr', 'ci 0.47-0.78) vol of dx: low (hr 0.54,', '0.47-0.78) vol of dx: low (hr 0.54, ci', 'vol of dx: low (hr 0.54, ci 0.39-0.74),', 'of dx: low (hr 0.54, ci 0.39-0.74), high', 'dx: low (hr 0.54, ci 0.39-0.74), high (hr', 'low (hr 0.54, ci 0.39-0.74), high (hr 0.79,', '(hr 0.54, ci 0.39-0.74), high (hr 0.79, ci', '0.54, ci 0.39-0.74), high (hr 0.79, ci 0.63-0.98)', 'ci 0.39-0.74), high (hr 0.79, ci 0.63-0.98) #asco22', '0.39-0.74), high (hr 0.79, ci 0.63-0.98) #asco22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '145', 'tokens': ['congratulations', 'to', 'on', 'the', 'amazing', 'results', 'of', 'the', 'niche-2', 'study', 'and', 'the', 'great', 'presentation', 'during', 'the', '2nd', 'presidential', 'symposium', 'during', '#esmo22.', '.'], 'text_length': 22, 'triples': {'niche-2|amazing results of the niche-2 study and the great': ([8, 8], [4, 12], 'positive')}, 'sentence': 'congratulations to on the amazing results of the niche-2 study and the great presentation during the 2nd presidential symposium during #esmo22. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8)], 'span tokens': ['congratulations', 'to', 'on', 'the', 'amazing', 'results', 'of', 'the', 'niche-2', 'study', 'and', 'the', 'great', 'presentation', 'during', 'the', '2nd', 'presidential', 'symposium', 'during', '#esmo22.', '.', 'congratulations to', 'to on', 'on the', 'the amazing', 'amazing results', 'results of', 'of the', 'the niche-2', 'niche-2 study', 'study and', 'and the', 'the great', 'great presentation', 'presentation during', 'during the', 'the 2nd', '2nd presidential', 'presidential symposium', 'symposium during', 'during #esmo22.', '#esmo22. .', 'congratulations to on', 'to on the', 'on the amazing', 'the amazing results', 'amazing results of', 'results of the', 'of the niche-2', 'the niche-2 study', 'niche-2 study and', 'study and the', 'and the great', 'the great presentation', 'great presentation during', 'presentation during the', 'during the 2nd', 'the 2nd presidential', '2nd presidential symposium', 'presidential symposium during', 'symposium during #esmo22.', 'during #esmo22. .', 'congratulations to on the', 'to on the amazing', 'on the amazing results', 'the amazing results of', 'amazing results of the', 'results of the niche-2', 'of the niche-2 study', 'the niche-2 study and', 'niche-2 study and the', 'study and the great', 'and the great presentation', 'the great presentation during', 'great presentation during the', 'presentation during the 2nd', 'during the 2nd presidential', 'the 2nd presidential symposium', '2nd presidential symposium during', 'presidential symposium during #esmo22.', 'symposium during #esmo22. .', 'congratulations to on the amazing', 'to on the amazing results', 'on the amazing results of', 'the amazing results of the', 'amazing results of the niche-2', 'results of the niche-2 study', 'of the niche-2 study and', 'the niche-2 study and the', 'niche-2 study and the great', 'study and the great presentation', 'and the great presentation during', 'the great presentation during the', 'great presentation during the 2nd', 'presentation during the 2nd presidential', 'during the 2nd presidential symposium', 'the 2nd presidential symposium during', '2nd presidential symposium during #esmo22.', 'presidential symposium during #esmo22. .', 'congratulations to on the amazing results', 'to on the amazing results of', 'on the amazing results of the', 'the amazing results of the niche-2', 'amazing results of the niche-2 study', 'results of the niche-2 study and', 'of the niche-2 study and the', 'the niche-2 study and the great', 'niche-2 study and the great presentation', 'study and the great presentation during', 'and the great presentation during the', 'the great presentation during the 2nd', 'great presentation during the 2nd presidential', 'presentation during the 2nd presidential symposium', 'during the 2nd presidential symposium during', 'the 2nd presidential symposium during #esmo22.', '2nd presidential symposium during #esmo22. .', 'congratulations to on the amazing results of', 'to on the amazing results of the', 'on the amazing results of the niche-2', 'the amazing results of the niche-2 study', 'amazing results of the niche-2 study and', 'results of the niche-2 study and the', 'of the niche-2 study and the great', 'the niche-2 study and the great presentation', 'niche-2 study and the great presentation during', 'study and the great presentation during the', 'and the great presentation during the 2nd', 'the great presentation during the 2nd presidential', 'great presentation during the 2nd presidential symposium', 'presentation during the 2nd presidential symposium during', 'during the 2nd presidential symposium during #esmo22.', 'the 2nd presidential symposium during #esmo22. .', 'congratulations to on the amazing results of the', 'to on the amazing results of the niche-2', 'on the amazing results of the niche-2 study', 'the amazing results of the niche-2 study and', 'amazing results of the niche-2 study and the', 'results of the niche-2 study and the great', 'of the niche-2 study and the great presentation', 'the niche-2 study and the great presentation during', 'niche-2 study and the great presentation during the', 'study and the great presentation during the 2nd', 'and the great presentation during the 2nd presidential', 'the great presentation during the 2nd presidential symposium', 'great presentation during the 2nd presidential symposium during', 'presentation during the 2nd presidential symposium during #esmo22.', 'during the 2nd presidential symposium during #esmo22. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '146', 'tokens': ['"impressive', 'results', 'from', 'niche-2', 'presented', 'by', '95%', 'complete', 'pathological', 'response', 'the', '#waterfall', 'plot', 'was', 'a', 'surprise!!', 'well', 'done', 'and', 'congrats', 'on', 'the', 'impressive', 'findings', 'and', 'on', 'catching', 'all', 'the', 'attention', 'during', '#esmo22', '.'], 'text_length': 33, 'triples': {'niche-2|"impressive results from niche-2 presented by 95% complete pathological response the #waterfall plot was a surprise!! well done and congrats on the impressive': ([3, 3], [0, 22], 'positive')}, 'sentence': '"impressive results from niche-2 presented by 95% complete pathological response the #waterfall plot was a surprise!! well done and congrats on the impressive findings and on catching all the attention during #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['"impressive', 'results', 'from', 'niche-2', 'presented', 'by', '95%', 'complete', 'pathological', 'response', 'the', '#waterfall', 'plot', 'was', 'a', 'surprise!!', 'well', 'done', 'and', 'congrats', 'on', 'the', 'impressive', 'findings', 'and', 'on', 'catching', 'all', 'the', 'attention', 'during', '#esmo22', '.', '"impressive results', 'results from', 'from niche-2', 'niche-2 presented', 'presented by', 'by 95%', '95% complete', 'complete pathological', 'pathological response', 'response the', 'the #waterfall', '#waterfall plot', 'plot was', 'was a', 'a surprise!!', 'surprise!! well', 'well done', 'done and', 'and congrats', 'congrats on', 'on the', 'the impressive', 'impressive findings', 'findings and', 'and on', 'on catching', 'catching all', 'all the', 'the attention', 'attention during', 'during #esmo22', '#esmo22 .', '"impressive results from', 'results from niche-2', 'from niche-2 presented', 'niche-2 presented by', 'presented by 95%', 'by 95% complete', '95% complete pathological', 'complete pathological response', 'pathological response the', 'response the #waterfall', 'the #waterfall plot', '#waterfall plot was', 'plot was a', 'was a surprise!!', 'a surprise!! well', 'surprise!! well done', 'well done and', 'done and congrats', 'and congrats on', 'congrats on the', 'on the impressive', 'the impressive findings', 'impressive findings and', 'findings and on', 'and on catching', 'on catching all', 'catching all the', 'all the attention', 'the attention during', 'attention during #esmo22', 'during #esmo22 .', '"impressive results from niche-2', 'results from niche-2 presented', 'from niche-2 presented by', 'niche-2 presented by 95%', 'presented by 95% complete', 'by 95% complete pathological', '95% complete pathological response', 'complete pathological response the', 'pathological response the #waterfall', 'response the #waterfall plot', 'the #waterfall plot was', '#waterfall plot was a', 'plot was a surprise!!', 'was a surprise!! well', 'a surprise!! well done', 'surprise!! well done and', 'well done and congrats', 'done and congrats on', 'and congrats on the', 'congrats on the impressive', 'on the impressive findings', 'the impressive findings and', 'impressive findings and on', 'findings and on catching', 'and on catching all', 'on catching all the', 'catching all the attention', 'all the attention during', 'the attention during #esmo22', 'attention during #esmo22 .', '"impressive results from niche-2 presented', 'results from niche-2 presented by', 'from niche-2 presented by 95%', 'niche-2 presented by 95% complete', 'presented by 95% complete pathological', 'by 95% complete pathological response', '95% complete pathological response the', 'complete pathological response the #waterfall', 'pathological response the #waterfall plot', 'response the #waterfall plot was', 'the #waterfall plot was a', '#waterfall plot was a surprise!!', 'plot was a surprise!! well', 'was a surprise!! well done', 'a surprise!! well done and', 'surprise!! well done and congrats', 'well done and congrats on', 'done and congrats on the', 'and congrats on the impressive', 'congrats on the impressive findings', 'on the impressive findings and', 'the impressive findings and on', 'impressive findings and on catching', 'findings and on catching all', 'and on catching all the', 'on catching all the attention', 'catching all the attention during', 'all the attention during #esmo22', 'the attention during #esmo22 .', '"impressive results from niche-2 presented by', 'results from niche-2 presented by 95%', 'from niche-2 presented by 95% complete', 'niche-2 presented by 95% complete pathological', 'presented by 95% complete pathological response', 'by 95% complete pathological response the', '95% complete pathological response the #waterfall', 'complete pathological response the #waterfall plot', 'pathological response the #waterfall plot was', 'response the #waterfall plot was a', 'the #waterfall plot was a surprise!!', '#waterfall plot was a surprise!! well', 'plot was a surprise!! well done', 'was a surprise!! well done and', 'a surprise!! well done and congrats', 'surprise!! well done and congrats on', 'well done and congrats on the', 'done and congrats on the impressive', 'and congrats on the impressive findings', 'congrats on the impressive findings and', 'on the impressive findings and on', 'the impressive findings and on catching', 'impressive findings and on catching all', 'findings and on catching all the', 'and on catching all the attention', 'on catching all the attention during', 'catching all the attention during #esmo22', 'all the attention during #esmo22 .', '"impressive results from niche-2 presented by 95%', 'results from niche-2 presented by 95% complete', 'from niche-2 presented by 95% complete pathological', 'niche-2 presented by 95% complete pathological response', 'presented by 95% complete pathological response the', 'by 95% complete pathological response the #waterfall', '95% complete pathological response the #waterfall plot', 'complete pathological response the #waterfall plot was', 'pathological response the #waterfall plot was a', 'response the #waterfall plot was a surprise!!', 'the #waterfall plot was a surprise!! well', '#waterfall plot was a surprise!! well done', 'plot was a surprise!! well done and', 'was a surprise!! well done and congrats', 'a surprise!! well done and congrats on', 'surprise!! well done and congrats on the', 'well done and congrats on the impressive', 'done and congrats on the impressive findings', 'and congrats on the impressive findings and', 'congrats on the impressive findings and on', 'on the impressive findings and on catching', 'the impressive findings and on catching all', 'impressive findings and on catching all the', 'findings and on catching all the attention', 'and on catching all the attention during', 'on catching all the attention during #esmo22', 'catching all the attention during #esmo22 .', '"impressive results from niche-2 presented by 95% complete', 'results from niche-2 presented by 95% complete pathological', 'from niche-2 presented by 95% complete pathological response', 'niche-2 presented by 95% complete pathological response the', 'presented by 95% complete pathological response the #waterfall', 'by 95% complete pathological response the #waterfall plot', '95% complete pathological response the #waterfall plot was', 'complete pathological response the #waterfall plot was a', 'pathological response the #waterfall plot was a surprise!!', 'response the #waterfall plot was a surprise!! well', 'the #waterfall plot was a surprise!! well done', '#waterfall plot was a surprise!! well done and', 'plot was a surprise!! well done and congrats', 'was a surprise!! well done and congrats on', 'a surprise!! well done and congrats on the', 'surprise!! well done and congrats on the impressive', 'well done and congrats on the impressive findings', 'done and congrats on the impressive findings and', 'and congrats on the impressive findings and on', 'congrats on the impressive findings and on catching', 'on the impressive findings and on catching all', 'the impressive findings and on catching all the', 'impressive findings and on catching all the attention', 'findings and on catching all the attention during', 'and on catching all the attention during #esmo22', 'on catching all the attention during #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '147', 'tokens': ['promising', 'transcriptomic', 'signatures', 'in', '#', 'stampede', '#esmo22', '.'], 'text_length': 8, 'triples': {'#|promising': ([4, 4], [0, 0], 'positive')}, 'sentence': 'promising transcriptomic signatures in # stampede #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 0)], 'related_span_array': array([[1, 0, 0, ..., 1, 0, 1],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [1, 1, 1, ..., 1, 1, 1],
       [0, 1, 1, ..., 1, 1, 1],
       [1, 1, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (0, 6, 7), (1, 7, 7), (0, 7, 8)], 'span tokens': ['promising', 'transcriptomic', 'signatures', 'in', '#', 'stampede', '#esmo22', '.', 'promising transcriptomic', 'transcriptomic signatures', 'signatures in', 'in #', '# stampede', 'stampede #esmo22', '#esmo22 .', 'promising transcriptomic signatures', 'transcriptomic signatures in', 'signatures in #', 'in # stampede', '# stampede #esmo22', 'stampede #esmo22 .', 'promising transcriptomic signatures in', 'transcriptomic signatures in #', 'signatures in # stampede', 'in # stampede #esmo22', '# stampede #esmo22 .', 'promising transcriptomic signatures in #', 'transcriptomic signatures in # stampede', 'signatures in # stampede #esmo22', 'in # stampede #esmo22 .', 'promising transcriptomic signatures in # stampede', 'transcriptomic signatures in # stampede #esmo22', 'signatures in # stampede #esmo22 .', 'promising transcriptomic signatures in # stampede #esmo22', 'transcriptomic signatures in # stampede #esmo22 .', 'promising transcriptomic signatures in # stampede #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '148', 'tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'More', 'discontinuations', 'on', 'ibrutinib', 'vs', 'zanubrutinib.', 'Median', 'age', '67-68.', 'Median', 'prior', 'line', 'of', 'therapy', '1.', '2yr', 'PFS', '79.5%', 'w', 'ZAN', 'vs', '67.3%', 'w', 'IBR.', 'ZAN', 'favored', 'in', 'all', 'subset', 'analyses.', '.'], 'text_length': 35, 'triples': {'ibrutinib|More discontinuations': ([7, 7], [4, 5], 'negative'), 'zanubrutinib.|favored': ([9, 9], [29, 29], 'positive')}, 'sentence': '#ASH22 #leusm #lymsm Brown: More discontinuations on ibrutinib vs zanubrutinib. Median age 67-68. Median prior line of therapy 1. 2yr PFS 79.5% w ZAN vs 67.3% w IBR. ZAN favored in all subset analyses. .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(7, 7), (9, 9)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(4, 5), (29, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'More', 'discontinuations', 'on', 'ibrutinib', 'vs', 'zanubrutinib.', 'Median', 'age', '67-68.', 'Median', 'prior', 'line', 'of', 'therapy', '1.', '2yr', 'PFS', '79.5%', 'w', 'ZAN', 'vs', '67.3%', 'w', 'IBR.', 'ZAN', 'favored', 'in', 'all', 'subset', 'analyses.', '.', '#ASH22 #leusm', '#leusm #lymsm', '#lymsm Brown:', 'Brown: More', 'More discontinuations', 'discontinuations on', 'on ibrutinib', 'ibrutinib vs', 'vs zanubrutinib.', 'zanubrutinib. Median', 'Median age', 'age 67-68.', '67-68. Median', 'Median prior', 'prior line', 'line of', 'of therapy', 'therapy 1.', '1. 2yr', '2yr PFS', 'PFS 79.5%', '79.5% w', 'w ZAN', 'ZAN vs', 'vs 67.3%', '67.3% w', 'w IBR.', 'IBR. ZAN', 'ZAN favored', 'favored in', 'in all', 'all subset', 'subset analyses.', 'analyses. .', '#ASH22 #leusm #lymsm', '#leusm #lymsm Brown:', '#lymsm Brown: More', 'Brown: More discontinuations', 'More discontinuations on', 'discontinuations on ibrutinib', 'on ibrutinib vs', 'ibrutinib vs zanubrutinib.', 'vs zanubrutinib. Median', 'zanubrutinib. Median age', 'Median age 67-68.', 'age 67-68. Median', '67-68. Median prior', 'Median prior line', 'prior line of', 'line of therapy', 'of therapy 1.', 'therapy 1. 2yr', '1. 2yr PFS', '2yr PFS 79.5%', 'PFS 79.5% w', '79.5% w ZAN', 'w ZAN vs', 'ZAN vs 67.3%', 'vs 67.3% w', '67.3% w IBR.', 'w IBR. ZAN', 'IBR. ZAN favored', 'ZAN favored in', 'favored in all', 'in all subset', 'all subset analyses.', 'subset analyses. .', '#ASH22 #leusm #lymsm Brown:', '#leusm #lymsm Brown: More', '#lymsm Brown: More discontinuations', 'Brown: More discontinuations on', 'More discontinuations on ibrutinib', 'discontinuations on ibrutinib vs', 'on ibrutinib vs zanubrutinib.', 'ibrutinib vs zanubrutinib. Median', 'vs zanubrutinib. Median age', 'zanubrutinib. Median age 67-68.', 'Median age 67-68. Median', 'age 67-68. Median prior', '67-68. Median prior line', 'Median prior line of', 'prior line of therapy', 'line of therapy 1.', 'of therapy 1. 2yr', 'therapy 1. 2yr PFS', '1. 2yr PFS 79.5%', '2yr PFS 79.5% w', 'PFS 79.5% w ZAN', '79.5% w ZAN vs', 'w ZAN vs 67.3%', 'ZAN vs 67.3% w', 'vs 67.3% w IBR.', '67.3% w IBR. ZAN', 'w IBR. ZAN favored', 'IBR. ZAN favored in', 'ZAN favored in all', 'favored in all subset', 'in all subset analyses.', 'all subset analyses. .', '#ASH22 #leusm #lymsm Brown: More', '#leusm #lymsm Brown: More discontinuations', '#lymsm Brown: More discontinuations on', 'Brown: More discontinuations on ibrutinib', 'More discontinuations on ibrutinib vs', 'discontinuations on ibrutinib vs zanubrutinib.', 'on ibrutinib vs zanubrutinib. Median', 'ibrutinib vs zanubrutinib. Median age', 'vs zanubrutinib. Median age 67-68.', 'zanubrutinib. Median age 67-68. Median', 'Median age 67-68. Median prior', 'age 67-68. Median prior line', '67-68. Median prior line of', 'Median prior line of therapy', 'prior line of therapy 1.', 'line of therapy 1. 2yr', 'of therapy 1. 2yr PFS', 'therapy 1. 2yr PFS 79.5%', '1. 2yr PFS 79.5% w', '2yr PFS 79.5% w ZAN', 'PFS 79.5% w ZAN vs', '79.5% w ZAN vs 67.3%', 'w ZAN vs 67.3% w', 'ZAN vs 67.3% w IBR.', 'vs 67.3% w IBR. ZAN', '67.3% w IBR. ZAN favored', 'w IBR. ZAN favored in', 'IBR. ZAN favored in all', 'ZAN favored in all subset', 'favored in all subset analyses.', 'in all subset analyses. .', '#ASH22 #leusm #lymsm Brown: More discontinuations', '#leusm #lymsm Brown: More discontinuations on', '#lymsm Brown: More discontinuations on ibrutinib', 'Brown: More discontinuations on ibrutinib vs', 'More discontinuations on ibrutinib vs zanubrutinib.', 'discontinuations on ibrutinib vs zanubrutinib. Median', 'on ibrutinib vs zanubrutinib. Median age', 'ibrutinib vs zanubrutinib. Median age 67-68.', 'vs zanubrutinib. Median age 67-68. Median', 'zanubrutinib. Median age 67-68. Median prior', 'Median age 67-68. Median prior line', 'age 67-68. Median prior line of', '67-68. Median prior line of therapy', 'Median prior line of therapy 1.', 'prior line of therapy 1. 2yr', 'line of therapy 1. 2yr PFS', 'of therapy 1. 2yr PFS 79.5%', 'therapy 1. 2yr PFS 79.5% w', '1. 2yr PFS 79.5% w ZAN', '2yr PFS 79.5% w ZAN vs', 'PFS 79.5% w ZAN vs 67.3%', '79.5% w ZAN vs 67.3% w', 'w ZAN vs 67.3% w IBR.', 'ZAN vs 67.3% w IBR. ZAN', 'vs 67.3% w IBR. ZAN favored', '67.3% w IBR. ZAN favored in', 'w IBR. ZAN favored in all', 'IBR. ZAN favored in all subset', 'ZAN favored in all subset analyses.', 'favored in all subset analyses. .', '#ASH22 #leusm #lymsm Brown: More discontinuations on', '#leusm #lymsm Brown: More discontinuations on ibrutinib', '#lymsm Brown: More discontinuations on ibrutinib vs', 'Brown: More discontinuations on ibrutinib vs zanubrutinib.', 'More discontinuations on ibrutinib vs zanubrutinib. Median', 'discontinuations on ibrutinib vs zanubrutinib. Median age', 'on ibrutinib vs zanubrutinib. Median age 67-68.', 'ibrutinib vs zanubrutinib. Median age 67-68. Median', 'vs zanubrutinib. Median age 67-68. Median prior', 'zanubrutinib. Median age 67-68. Median prior line', 'Median age 67-68. Median prior line of', 'age 67-68. Median prior line of therapy', '67-68. Median prior line of therapy 1.', 'Median prior line of therapy 1. 2yr', 'prior line of therapy 1. 2yr PFS', 'line of therapy 1. 2yr PFS 79.5%', 'of therapy 1. 2yr PFS 79.5% w', 'therapy 1. 2yr PFS 79.5% w ZAN', '1. 2yr PFS 79.5% w ZAN vs', '2yr PFS 79.5% w ZAN vs 67.3%', 'PFS 79.5% w ZAN vs 67.3% w', '79.5% w ZAN vs 67.3% w IBR.', 'w ZAN vs 67.3% w IBR. ZAN', 'ZAN vs 67.3% w IBR. ZAN favored', 'vs 67.3% w IBR. ZAN favored in', '67.3% w IBR. ZAN favored in all', 'w IBR. ZAN favored in all subset', 'IBR. ZAN favored in all subset analyses.', 'ZAN favored in all subset analyses. .', '#ASH22 #leusm #lymsm Brown: More discontinuations on ibrutinib', '#leusm #lymsm Brown: More discontinuations on ibrutinib vs', '#lymsm Brown: More discontinuations on ibrutinib vs zanubrutinib.', 'Brown: More discontinuations on ibrutinib vs zanubrutinib. Median', 'More discontinuations on ibrutinib vs zanubrutinib. Median age', 'discontinuations on ibrutinib vs zanubrutinib. Median age 67-68.', 'on ibrutinib vs zanubrutinib. Median age 67-68. Median', 'ibrutinib vs zanubrutinib. Median age 67-68. Median prior', 'vs zanubrutinib. Median age 67-68. Median prior line', 'zanubrutinib. Median age 67-68. Median prior line of', 'Median age 67-68. Median prior line of therapy', 'age 67-68. Median prior line of therapy 1.', '67-68. Median prior line of therapy 1. 2yr', 'Median prior line of therapy 1. 2yr PFS', 'prior line of therapy 1. 2yr PFS 79.5%', 'line of therapy 1. 2yr PFS 79.5% w', 'of therapy 1. 2yr PFS 79.5% w ZAN', 'therapy 1. 2yr PFS 79.5% w ZAN vs', '1. 2yr PFS 79.5% w ZAN vs 67.3%', '2yr PFS 79.5% w ZAN vs 67.3% w', 'PFS 79.5% w ZAN vs 67.3% w IBR.', '79.5% w ZAN vs 67.3% w IBR. ZAN', 'w ZAN vs 67.3% w IBR. ZAN favored', 'ZAN vs 67.3% w IBR. ZAN favored in', 'vs 67.3% w IBR. ZAN favored in all', '67.3% w IBR. ZAN favored in all subset', 'w IBR. ZAN favored in all subset analyses.', 'IBR. ZAN favored in all subset analyses. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '149', 'tokens': ['key', 'take', 'homes', 'from', 'stampede', '#esmo2022', 'more', 'is', 'not', 'always', 'better', 'for', 'ar', 'axis', 'targeting', 'gc', 'is', 'interestingly', 'prognostic', 'even', 'in', 'hr', 'pca', 'predictive', 'biomarkers', 'remain', 'elusive', '-', 'curious', 'to', 'see', 'lum', 'a', 'vs', 'lum', 'b', 'vs', 'basal', 'for', 'aap', 'effects', 'well', 'done', 'again', 'to', 'the', 'team!', '.'], 'text_length': 48, 'triples': {'stampede|not always better': ([4, 4], [8, 10], 'neutral')}, 'sentence': 'key take homes from stampede #esmo2022 more is not always better for ar axis targeting gc is interestingly prognostic even in hr pca predictive biomarkers remain elusive - curious to see lum a vs lum b vs basal for aap effects well done again to the team! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(8, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8)], 'span tokens': ['key', 'take', 'homes', 'from', 'stampede', '#esmo2022', 'more', 'is', 'not', 'always', 'better', 'for', 'ar', 'axis', 'targeting', 'gc', 'is', 'interestingly', 'prognostic', 'even', 'in', 'hr', 'pca', 'predictive', 'biomarkers', 'remain', 'elusive', '-', 'curious', 'to', 'see', 'lum', 'a', 'vs', 'lum', 'b', 'vs', 'basal', 'for', 'aap', 'effects', 'well', 'done', 'again', 'to', 'the', 'team!', '.', 'key take', 'take homes', 'homes from', 'from stampede', 'stampede #esmo2022', '#esmo2022 more', 'more is', 'is not', 'not always', 'always better', 'better for', 'for ar', 'ar axis', 'axis targeting', 'targeting gc', 'gc is', 'is interestingly', 'interestingly prognostic', 'prognostic even', 'even in', 'in hr', 'hr pca', 'pca predictive', 'predictive biomarkers', 'biomarkers remain', 'remain elusive', 'elusive -', '- curious', 'curious to', 'to see', 'see lum', 'lum a', 'a vs', 'vs lum', 'lum b', 'b vs', 'vs basal', 'basal for', 'for aap', 'aap effects', 'effects well', 'well done', 'done again', 'again to', 'to the', 'the team!', 'team! .', 'key take homes', 'take homes from', 'homes from stampede', 'from stampede #esmo2022', 'stampede #esmo2022 more', '#esmo2022 more is', 'more is not', 'is not always', 'not always better', 'always better for', 'better for ar', 'for ar axis', 'ar axis targeting', 'axis targeting gc', 'targeting gc is', 'gc is interestingly', 'is interestingly prognostic', 'interestingly prognostic even', 'prognostic even in', 'even in hr', 'in hr pca', 'hr pca predictive', 'pca predictive biomarkers', 'predictive biomarkers remain', 'biomarkers remain elusive', 'remain elusive -', 'elusive - curious', '- curious to', 'curious to see', 'to see lum', 'see lum a', 'lum a vs', 'a vs lum', 'vs lum b', 'lum b vs', 'b vs basal', 'vs basal for', 'basal for aap', 'for aap effects', 'aap effects well', 'effects well done', 'well done again', 'done again to', 'again to the', 'to the team!', 'the team! .', 'key take homes from', 'take homes from stampede', 'homes from stampede #esmo2022', 'from stampede #esmo2022 more', 'stampede #esmo2022 more is', '#esmo2022 more is not', 'more is not always', 'is not always better', 'not always better for', 'always better for ar', 'better for ar axis', 'for ar axis targeting', 'ar axis targeting gc', 'axis targeting gc is', 'targeting gc is interestingly', 'gc is interestingly prognostic', 'is interestingly prognostic even', 'interestingly prognostic even in', 'prognostic even in hr', 'even in hr pca', 'in hr pca predictive', 'hr pca predictive biomarkers', 'pca predictive biomarkers remain', 'predictive biomarkers remain elusive', 'biomarkers remain elusive -', 'remain elusive - curious', 'elusive - curious to', '- curious to see', 'curious to see lum', 'to see lum a', 'see lum a vs', 'lum a vs lum', 'a vs lum b', 'vs lum b vs', 'lum b vs basal', 'b vs basal for', 'vs basal for aap', 'basal for aap effects', 'for aap effects well', 'aap effects well done', 'effects well done again', 'well done again to', 'done again to the', 'again to the team!', 'to the team! .', 'key take homes from stampede', 'take homes from stampede #esmo2022', 'homes from stampede #esmo2022 more', 'from stampede #esmo2022 more is', 'stampede #esmo2022 more is not', '#esmo2022 more is not always', 'more is not always better', 'is not always better for', 'not always better for ar', 'always better for ar axis', 'better for ar axis targeting', 'for ar axis targeting gc', 'ar axis targeting gc is', 'axis targeting gc is interestingly', 'targeting gc is interestingly prognostic', 'gc is interestingly prognostic even', 'is interestingly prognostic even in', 'interestingly prognostic even in hr', 'prognostic even in hr pca', 'even in hr pca predictive', 'in hr pca predictive biomarkers', 'hr pca predictive biomarkers remain', 'pca predictive biomarkers remain elusive', 'predictive biomarkers remain elusive -', 'biomarkers remain elusive - curious', 'remain elusive - curious to', 'elusive - curious to see', '- curious to see lum', 'curious to see lum a', 'to see lum a vs', 'see lum a vs lum', 'lum a vs lum b', 'a vs lum b vs', 'vs lum b vs basal', 'lum b vs basal for', 'b vs basal for aap', 'vs basal for aap effects', 'basal for aap effects well', 'for aap effects well done', 'aap effects well done again', 'effects well done again to', 'well done again to the', 'done again to the team!', 'again to the team! .', 'key take homes from stampede #esmo2022', 'take homes from stampede #esmo2022 more', 'homes from stampede #esmo2022 more is', 'from stampede #esmo2022 more is not', 'stampede #esmo2022 more is not always', '#esmo2022 more is not always better', 'more is not always better for', 'is not always better for ar', 'not always better for ar axis', 'always better for ar axis targeting', 'better for ar axis targeting gc', 'for ar axis targeting gc is', 'ar axis targeting gc is interestingly', 'axis targeting gc is interestingly prognostic', 'targeting gc is interestingly prognostic even', 'gc is interestingly prognostic even in', 'is interestingly prognostic even in hr', 'interestingly prognostic even in hr pca', 'prognostic even in hr pca predictive', 'even in hr pca predictive biomarkers', 'in hr pca predictive biomarkers remain', 'hr pca predictive biomarkers remain elusive', 'pca predictive biomarkers remain elusive -', 'predictive biomarkers remain elusive - curious', 'biomarkers remain elusive - curious to', 'remain elusive - curious to see', 'elusive - curious to see lum', '- curious to see lum a', 'curious to see lum a vs', 'to see lum a vs lum', 'see lum a vs lum b', 'lum a vs lum b vs', 'a vs lum b vs basal', 'vs lum b vs basal for', 'lum b vs basal for aap', 'b vs basal for aap effects', 'vs basal for aap effects well', 'basal for aap effects well done', 'for aap effects well done again', 'aap effects well done again to', 'effects well done again to the', 'well done again to the team!', 'done again to the team! .', 'key take homes from stampede #esmo2022 more', 'take homes from stampede #esmo2022 more is', 'homes from stampede #esmo2022 more is not', 'from stampede #esmo2022 more is not always', 'stampede #esmo2022 more is not always better', '#esmo2022 more is not always better for', 'more is not always better for ar', 'is not always better for ar axis', 'not always better for ar axis targeting', 'always better for ar axis targeting gc', 'better for ar axis targeting gc is', 'for ar axis targeting gc is interestingly', 'ar axis targeting gc is interestingly prognostic', 'axis targeting gc is interestingly prognostic even', 'targeting gc is interestingly prognostic even in', 'gc is interestingly prognostic even in hr', 'is interestingly prognostic even in hr pca', 'interestingly prognostic even in hr pca predictive', 'prognostic even in hr pca predictive biomarkers', 'even in hr pca predictive biomarkers remain', 'in hr pca predictive biomarkers remain elusive', 'hr pca predictive biomarkers remain elusive -', 'pca predictive biomarkers remain elusive - curious', 'predictive biomarkers remain elusive - curious to', 'biomarkers remain elusive - curious to see', 'remain elusive - curious to see lum', 'elusive - curious to see lum a', '- curious to see lum a vs', 'curious to see lum a vs lum', 'to see lum a vs lum b', 'see lum a vs lum b vs', 'lum a vs lum b vs basal', 'a vs lum b vs basal for', 'vs lum b vs basal for aap', 'lum b vs basal for aap effects', 'b vs basal for aap effects well', 'vs basal for aap effects well done', 'basal for aap effects well done again', 'for aap effects well done again to', 'aap effects well done again to the', 'effects well done again to the team!', 'well done again to the team! .', 'key take homes from stampede #esmo2022 more is', 'take homes from stampede #esmo2022 more is not', 'homes from stampede #esmo2022 more is not always', 'from stampede #esmo2022 more is not always better', 'stampede #esmo2022 more is not always better for', '#esmo2022 more is not always better for ar', 'more is not always better for ar axis', 'is not always better for ar axis targeting', 'not always better for ar axis targeting gc', 'always better for ar axis targeting gc is', 'better for ar axis targeting gc is interestingly', 'for ar axis targeting gc is interestingly prognostic', 'ar axis targeting gc is interestingly prognostic even', 'axis targeting gc is interestingly prognostic even in', 'targeting gc is interestingly prognostic even in hr', 'gc is interestingly prognostic even in hr pca', 'is interestingly prognostic even in hr pca predictive', 'interestingly prognostic even in hr pca predictive biomarkers', 'prognostic even in hr pca predictive biomarkers remain', 'even in hr pca predictive biomarkers remain elusive', 'in hr pca predictive biomarkers remain elusive -', 'hr pca predictive biomarkers remain elusive - curious', 'pca predictive biomarkers remain elusive - curious to', 'predictive biomarkers remain elusive - curious to see', 'biomarkers remain elusive - curious to see lum', 'remain elusive - curious to see lum a', 'elusive - curious to see lum a vs', '- curious to see lum a vs lum', 'curious to see lum a vs lum b', 'to see lum a vs lum b vs', 'see lum a vs lum b vs basal', 'lum a vs lum b vs basal for', 'a vs lum b vs basal for aap', 'vs lum b vs basal for aap effects', 'lum b vs basal for aap effects well', 'b vs basal for aap effects well done', 'vs basal for aap effects well done again', 'basal for aap effects well done again to', 'for aap effects well done again to the', 'aap effects well done again to the team!', 'effects well done again to the team! .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}]]
<models.data_BIO_loader.DataTterator object at 0x7f93402d2070>
dev dataset: [[{'id': '0', 'tokens': ['$amgn', 'lumakras', 'disappoints', 'a', 'second', 'time:', 'os', 'curves', 'favour', 'docetaxel,', 'two', 'discontinuations', 'owing', 'to', 'drug-induced', 'liver', 'injury.', 'my', 'take', 'on', 'codebreak-200,', 'being', 'presented', 'at', '#esmo22', 'presidential', 'session', 'now', '-&gt;', '$mrtx.', '.'], 'text_length': 31, 'triples': {'lumakras|disappoints': ([1, 1], [2, 2], 'negative'), 'docetaxel,|os curves favour': ([9, 9], [6, 8], 'positive')}, 'sentence': '$amgn lumakras disappoints a second time: os curves favour docetaxel, two discontinuations owing to drug-induced liver injury. my take on codebreak-200, being presented at #esmo22 presidential session now -&gt; $mrtx. .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(1, 1), (9, 9)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(2, 2), (6, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['$amgn', 'lumakras', 'disappoints', 'a', 'second', 'time:', 'os', 'curves', 'favour', 'docetaxel,', 'two', 'discontinuations', 'owing', 'to', 'drug-induced', 'liver', 'injury.', 'my', 'take', 'on', 'codebreak-200,', 'being', 'presented', 'at', '#esmo22', 'presidential', 'session', 'now', '-&gt;', '$mrtx.', '.', '$amgn lumakras', 'lumakras disappoints', 'disappoints a', 'a second', 'second time:', 'time: os', 'os curves', 'curves favour', 'favour docetaxel,', 'docetaxel, two', 'two discontinuations', 'discontinuations owing', 'owing to', 'to drug-induced', 'drug-induced liver', 'liver injury.', 'injury. my', 'my take', 'take on', 'on codebreak-200,', 'codebreak-200, being', 'being presented', 'presented at', 'at #esmo22', '#esmo22 presidential', 'presidential session', 'session now', 'now -&gt;', '-&gt; $mrtx.', '$mrtx. .', '$amgn lumakras disappoints', 'lumakras disappoints a', 'disappoints a second', 'a second time:', 'second time: os', 'time: os curves', 'os curves favour', 'curves favour docetaxel,', 'favour docetaxel, two', 'docetaxel, two discontinuations', 'two discontinuations owing', 'discontinuations owing to', 'owing to drug-induced', 'to drug-induced liver', 'drug-induced liver injury.', 'liver injury. my', 'injury. my take', 'my take on', 'take on codebreak-200,', 'on codebreak-200, being', 'codebreak-200, being presented', 'being presented at', 'presented at #esmo22', 'at #esmo22 presidential', '#esmo22 presidential session', 'presidential session now', 'session now -&gt;', 'now -&gt; $mrtx.', '-&gt; $mrtx. .', '$amgn lumakras disappoints a', 'lumakras disappoints a second', 'disappoints a second time:', 'a second time: os', 'second time: os curves', 'time: os curves favour', 'os curves favour docetaxel,', 'curves favour docetaxel, two', 'favour docetaxel, two discontinuations', 'docetaxel, two discontinuations owing', 'two discontinuations owing to', 'discontinuations owing to drug-induced', 'owing to drug-induced liver', 'to drug-induced liver injury.', 'drug-induced liver injury. my', 'liver injury. my take', 'injury. my take on', 'my take on codebreak-200,', 'take on codebreak-200, being', 'on codebreak-200, being presented', 'codebreak-200, being presented at', 'being presented at #esmo22', 'presented at #esmo22 presidential', 'at #esmo22 presidential session', '#esmo22 presidential session now', 'presidential session now -&gt;', 'session now -&gt; $mrtx.', 'now -&gt; $mrtx. .', '$amgn lumakras disappoints a second', 'lumakras disappoints a second time:', 'disappoints a second time: os', 'a second time: os curves', 'second time: os curves favour', 'time: os curves favour docetaxel,', 'os curves favour docetaxel, two', 'curves favour docetaxel, two discontinuations', 'favour docetaxel, two discontinuations owing', 'docetaxel, two discontinuations owing to', 'two discontinuations owing to drug-induced', 'discontinuations owing to drug-induced liver', 'owing to drug-induced liver injury.', 'to drug-induced liver injury. my', 'drug-induced liver injury. my take', 'liver injury. my take on', 'injury. my take on codebreak-200,', 'my take on codebreak-200, being', 'take on codebreak-200, being presented', 'on codebreak-200, being presented at', 'codebreak-200, being presented at #esmo22', 'being presented at #esmo22 presidential', 'presented at #esmo22 presidential session', 'at #esmo22 presidential session now', '#esmo22 presidential session now -&gt;', 'presidential session now -&gt; $mrtx.', 'session now -&gt; $mrtx. .', '$amgn lumakras disappoints a second time:', 'lumakras disappoints a second time: os', 'disappoints a second time: os curves', 'a second time: os curves favour', 'second time: os curves favour docetaxel,', 'time: os curves favour docetaxel, two', 'os curves favour docetaxel, two discontinuations', 'curves favour docetaxel, two discontinuations owing', 'favour docetaxel, two discontinuations owing to', 'docetaxel, two discontinuations owing to drug-induced', 'two discontinuations owing to drug-induced liver', 'discontinuations owing to drug-induced liver injury.', 'owing to drug-induced liver injury. my', 'to drug-induced liver injury. my take', 'drug-induced liver injury. my take on', 'liver injury. my take on codebreak-200,', 'injury. my take on codebreak-200, being', 'my take on codebreak-200, being presented', 'take on codebreak-200, being presented at', 'on codebreak-200, being presented at #esmo22', 'codebreak-200, being presented at #esmo22 presidential', 'being presented at #esmo22 presidential session', 'presented at #esmo22 presidential session now', 'at #esmo22 presidential session now -&gt;', '#esmo22 presidential session now -&gt; $mrtx.', 'presidential session now -&gt; $mrtx. .', '$amgn lumakras disappoints a second time: os', 'lumakras disappoints a second time: os curves', 'disappoints a second time: os curves favour', 'a second time: os curves favour docetaxel,', 'second time: os curves favour docetaxel, two', 'time: os curves favour docetaxel, two discontinuations', 'os curves favour docetaxel, two discontinuations owing', 'curves favour docetaxel, two discontinuations owing to', 'favour docetaxel, two discontinuations owing to drug-induced', 'docetaxel, two discontinuations owing to drug-induced liver', 'two discontinuations owing to drug-induced liver injury.', 'discontinuations owing to drug-induced liver injury. my', 'owing to drug-induced liver injury. my take', 'to drug-induced liver injury. my take on', 'drug-induced liver injury. my take on codebreak-200,', 'liver injury. my take on codebreak-200, being', 'injury. my take on codebreak-200, being presented', 'my take on codebreak-200, being presented at', 'take on codebreak-200, being presented at #esmo22', 'on codebreak-200, being presented at #esmo22 presidential', 'codebreak-200, being presented at #esmo22 presidential session', 'being presented at #esmo22 presidential session now', 'presented at #esmo22 presidential session now -&gt;', 'at #esmo22 presidential session now -&gt; $mrtx.', '#esmo22 presidential session now -&gt; $mrtx. .', '$amgn lumakras disappoints a second time: os curves', 'lumakras disappoints a second time: os curves favour', 'disappoints a second time: os curves favour docetaxel,', 'a second time: os curves favour docetaxel, two', 'second time: os curves favour docetaxel, two discontinuations', 'time: os curves favour docetaxel, two discontinuations owing', 'os curves favour docetaxel, two discontinuations owing to', 'curves favour docetaxel, two discontinuations owing to drug-induced', 'favour docetaxel, two discontinuations owing to drug-induced liver', 'docetaxel, two discontinuations owing to drug-induced liver injury.', 'two discontinuations owing to drug-induced liver injury. my', 'discontinuations owing to drug-induced liver injury. my take', 'owing to drug-induced liver injury. my take on', 'to drug-induced liver injury. my take on codebreak-200,', 'drug-induced liver injury. my take on codebreak-200, being', 'liver injury. my take on codebreak-200, being presented', 'injury. my take on codebreak-200, being presented at', 'my take on codebreak-200, being presented at #esmo22', 'take on codebreak-200, being presented at #esmo22 presidential', 'on codebreak-200, being presented at #esmo22 presidential session', 'codebreak-200, being presented at #esmo22 presidential session now', 'being presented at #esmo22 presidential session now -&gt;', 'presented at #esmo22 presidential session now -&gt; $mrtx.', 'at #esmo22 presidential session now -&gt; $mrtx. .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '1', 'tokens': ['are', 'cytokines', 'still', 'worth', 'exploring', 'in', 'mrcc?', 'hard', 'to', 'know', 'given', 'disappointing', 'bempeg', 'results', 'reported', 'at', '#esmo22.', 'some', 'anti-tumor', 'activity', 'of', 'combo', 'with', 'nivo', 'but', 'not', 'enough.', 'pfs', 'not', 'reported', '(?).', 'podcast', 'with', 'nizar', 'coming', 'soon..', '', '.'], 'text_length': 38, 'triples': {'bempeg|hard to know given disappointing': ([12, 12], [7, 11], 'negative')}, 'sentence': 'are cytokines still worth exploring in mrcc? hard to know given disappointing bempeg results reported at #esmo22. some anti-tumor activity of combo with nivo but not enough. pfs not reported (?). podcast with nizar coming soon..  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8)], 'span tokens': ['are', 'cytokines', 'still', 'worth', 'exploring', 'in', 'mrcc?', 'hard', 'to', 'know', 'given', 'disappointing', 'bempeg', 'results', 'reported', 'at', '#esmo22.', 'some', 'anti-tumor', 'activity', 'of', 'combo', 'with', 'nivo', 'but', 'not', 'enough.', 'pfs', 'not', 'reported', '(?).', 'podcast', 'with', 'nizar', 'coming', 'soon..', '', '.', 'are cytokines', 'cytokines still', 'still worth', 'worth exploring', 'exploring in', 'in mrcc?', 'mrcc? hard', 'hard to', 'to know', 'know given', 'given disappointing', 'disappointing bempeg', 'bempeg results', 'results reported', 'reported at', 'at #esmo22.', '#esmo22. some', 'some anti-tumor', 'anti-tumor activity', 'activity of', 'of combo', 'combo with', 'with nivo', 'nivo but', 'but not', 'not enough.', 'enough. pfs', 'pfs not', 'not reported', 'reported (?).', '(?). podcast', 'podcast with', 'with nizar', 'nizar coming', 'coming soon..', 'soon.. ', ' .', 'are cytokines still', 'cytokines still worth', 'still worth exploring', 'worth exploring in', 'exploring in mrcc?', 'in mrcc? hard', 'mrcc? hard to', 'hard to know', 'to know given', 'know given disappointing', 'given disappointing bempeg', 'disappointing bempeg results', 'bempeg results reported', 'results reported at', 'reported at #esmo22.', 'at #esmo22. some', '#esmo22. some anti-tumor', 'some anti-tumor activity', 'anti-tumor activity of', 'activity of combo', 'of combo with', 'combo with nivo', 'with nivo but', 'nivo but not', 'but not enough.', 'not enough. pfs', 'enough. pfs not', 'pfs not reported', 'not reported (?).', 'reported (?). podcast', '(?). podcast with', 'podcast with nizar', 'with nizar coming', 'nizar coming soon..', 'coming soon.. ', 'soon..  .', 'are cytokines still worth', 'cytokines still worth exploring', 'still worth exploring in', 'worth exploring in mrcc?', 'exploring in mrcc? hard', 'in mrcc? hard to', 'mrcc? hard to know', 'hard to know given', 'to know given disappointing', 'know given disappointing bempeg', 'given disappointing bempeg results', 'disappointing bempeg results reported', 'bempeg results reported at', 'results reported at #esmo22.', 'reported at #esmo22. some', 'at #esmo22. some anti-tumor', '#esmo22. some anti-tumor activity', 'some anti-tumor activity of', 'anti-tumor activity of combo', 'activity of combo with', 'of combo with nivo', 'combo with nivo but', 'with nivo but not', 'nivo but not enough.', 'but not enough. pfs', 'not enough. pfs not', 'enough. pfs not reported', 'pfs not reported (?).', 'not reported (?). podcast', 'reported (?). podcast with', '(?). podcast with nizar', 'podcast with nizar coming', 'with nizar coming soon..', 'nizar coming soon.. ', 'coming soon..  .', 'are cytokines still worth exploring', 'cytokines still worth exploring in', 'still worth exploring in mrcc?', 'worth exploring in mrcc? hard', 'exploring in mrcc? hard to', 'in mrcc? hard to know', 'mrcc? hard to know given', 'hard to know given disappointing', 'to know given disappointing bempeg', 'know given disappointing bempeg results', 'given disappointing bempeg results reported', 'disappointing bempeg results reported at', 'bempeg results reported at #esmo22.', 'results reported at #esmo22. some', 'reported at #esmo22. some anti-tumor', 'at #esmo22. some anti-tumor activity', '#esmo22. some anti-tumor activity of', 'some anti-tumor activity of combo', 'anti-tumor activity of combo with', 'activity of combo with nivo', 'of combo with nivo but', 'combo with nivo but not', 'with nivo but not enough.', 'nivo but not enough. pfs', 'but not enough. pfs not', 'not enough. pfs not reported', 'enough. pfs not reported (?).', 'pfs not reported (?). podcast', 'not reported (?). podcast with', 'reported (?). podcast with nizar', '(?). podcast with nizar coming', 'podcast with nizar coming soon..', 'with nizar coming soon.. ', 'nizar coming soon..  .', 'are cytokines still worth exploring in', 'cytokines still worth exploring in mrcc?', 'still worth exploring in mrcc? hard', 'worth exploring in mrcc? hard to', 'exploring in mrcc? hard to know', 'in mrcc? hard to know given', 'mrcc? hard to know given disappointing', 'hard to know given disappointing bempeg', 'to know given disappointing bempeg results', 'know given disappointing bempeg results reported', 'given disappointing bempeg results reported at', 'disappointing bempeg results reported at #esmo22.', 'bempeg results reported at #esmo22. some', 'results reported at #esmo22. some anti-tumor', 'reported at #esmo22. some anti-tumor activity', 'at #esmo22. some anti-tumor activity of', '#esmo22. some anti-tumor activity of combo', 'some anti-tumor activity of combo with', 'anti-tumor activity of combo with nivo', 'activity of combo with nivo but', 'of combo with nivo but not', 'combo with nivo but not enough.', 'with nivo but not enough. pfs', 'nivo but not enough. pfs not', 'but not enough. pfs not reported', 'not enough. pfs not reported (?).', 'enough. pfs not reported (?). podcast', 'pfs not reported (?). podcast with', 'not reported (?). podcast with nizar', 'reported (?). podcast with nizar coming', '(?). podcast with nizar coming soon..', 'podcast with nizar coming soon.. ', 'with nizar coming soon..  .', 'are cytokines still worth exploring in mrcc?', 'cytokines still worth exploring in mrcc? hard', 'still worth exploring in mrcc? hard to', 'worth exploring in mrcc? hard to know', 'exploring in mrcc? hard to know given', 'in mrcc? hard to know given disappointing', 'mrcc? hard to know given disappointing bempeg', 'hard to know given disappointing bempeg results', 'to know given disappointing bempeg results reported', 'know given disappointing bempeg results reported at', 'given disappointing bempeg results reported at #esmo22.', 'disappointing bempeg results reported at #esmo22. some', 'bempeg results reported at #esmo22. some anti-tumor', 'results reported at #esmo22. some anti-tumor activity', 'reported at #esmo22. some anti-tumor activity of', 'at #esmo22. some anti-tumor activity of combo', '#esmo22. some anti-tumor activity of combo with', 'some anti-tumor activity of combo with nivo', 'anti-tumor activity of combo with nivo but', 'activity of combo with nivo but not', 'of combo with nivo but not enough.', 'combo with nivo but not enough. pfs', 'with nivo but not enough. pfs not', 'nivo but not enough. pfs not reported', 'but not enough. pfs not reported (?).', 'not enough. pfs not reported (?). podcast', 'enough. pfs not reported (?). podcast with', 'pfs not reported (?). podcast with nizar', 'not reported (?). podcast with nizar coming', 'reported (?). podcast with nizar coming soon..', '(?). podcast with nizar coming soon.. ', 'podcast with nizar coming soon..  .', 'are cytokines still worth exploring in mrcc? hard', 'cytokines still worth exploring in mrcc? hard to', 'still worth exploring in mrcc? hard to know', 'worth exploring in mrcc? hard to know given', 'exploring in mrcc? hard to know given disappointing', 'in mrcc? hard to know given disappointing bempeg', 'mrcc? hard to know given disappointing bempeg results', 'hard to know given disappointing bempeg results reported', 'to know given disappointing bempeg results reported at', 'know given disappointing bempeg results reported at #esmo22.', 'given disappointing bempeg results reported at #esmo22. some', 'disappointing bempeg results reported at #esmo22. some anti-tumor', 'bempeg results reported at #esmo22. some anti-tumor activity', 'results reported at #esmo22. some anti-tumor activity of', 'reported at #esmo22. some anti-tumor activity of combo', 'at #esmo22. some anti-tumor activity of combo with', '#esmo22. some anti-tumor activity of combo with nivo', 'some anti-tumor activity of combo with nivo but', 'anti-tumor activity of combo with nivo but not', 'activity of combo with nivo but not enough.', 'of combo with nivo but not enough. pfs', 'combo with nivo but not enough. pfs not', 'with nivo but not enough. pfs not reported', 'nivo but not enough. pfs not reported (?).', 'but not enough. pfs not reported (?). podcast', 'not enough. pfs not reported (?). podcast with', 'enough. pfs not reported (?). podcast with nizar', 'pfs not reported (?). podcast with nizar coming', 'not reported (?). podcast with nizar coming soon..', 'reported (?). podcast with nizar coming soon.. ', '(?). podcast with nizar coming soon..  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '2', 'tokens': ['more', 'parp', 'news', '-', 'worse', 'survival', 'with', 'rucaparib', 'in', 'trial', 'of', 'recurrent,', 'brca+', 'ovarian', 'cancer', '#gyncsm', '.'], 'text_length': 17, 'triples': {'rucaparib|worse survival': ([7, 7], [4, 5], 'negative')}, 'sentence': 'more parp news - worse survival with rucaparib in trial of recurrent, brca+ ovarian cancer #gyncsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 5)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8)], 'span tokens': ['more', 'parp', 'news', '-', 'worse', 'survival', 'with', 'rucaparib', 'in', 'trial', 'of', 'recurrent,', 'brca+', 'ovarian', 'cancer', '#gyncsm', '.', 'more parp', 'parp news', 'news -', '- worse', 'worse survival', 'survival with', 'with rucaparib', 'rucaparib in', 'in trial', 'trial of', 'of recurrent,', 'recurrent, brca+', 'brca+ ovarian', 'ovarian cancer', 'cancer #gyncsm', '#gyncsm .', 'more parp news', 'parp news -', 'news - worse', '- worse survival', 'worse survival with', 'survival with rucaparib', 'with rucaparib in', 'rucaparib in trial', 'in trial of', 'trial of recurrent,', 'of recurrent, brca+', 'recurrent, brca+ ovarian', 'brca+ ovarian cancer', 'ovarian cancer #gyncsm', 'cancer #gyncsm .', 'more parp news -', 'parp news - worse', 'news - worse survival', '- worse survival with', 'worse survival with rucaparib', 'survival with rucaparib in', 'with rucaparib in trial', 'rucaparib in trial of', 'in trial of recurrent,', 'trial of recurrent, brca+', 'of recurrent, brca+ ovarian', 'recurrent, brca+ ovarian cancer', 'brca+ ovarian cancer #gyncsm', 'ovarian cancer #gyncsm .', 'more parp news - worse', 'parp news - worse survival', 'news - worse survival with', '- worse survival with rucaparib', 'worse survival with rucaparib in', 'survival with rucaparib in trial', 'with rucaparib in trial of', 'rucaparib in trial of recurrent,', 'in trial of recurrent, brca+', 'trial of recurrent, brca+ ovarian', 'of recurrent, brca+ ovarian cancer', 'recurrent, brca+ ovarian cancer #gyncsm', 'brca+ ovarian cancer #gyncsm .', 'more parp news - worse survival', 'parp news - worse survival with', 'news - worse survival with rucaparib', '- worse survival with rucaparib in', 'worse survival with rucaparib in trial', 'survival with rucaparib in trial of', 'with rucaparib in trial of recurrent,', 'rucaparib in trial of recurrent, brca+', 'in trial of recurrent, brca+ ovarian', 'trial of recurrent, brca+ ovarian cancer', 'of recurrent, brca+ ovarian cancer #gyncsm', 'recurrent, brca+ ovarian cancer #gyncsm .', 'more parp news - worse survival with', 'parp news - worse survival with rucaparib', 'news - worse survival with rucaparib in', '- worse survival with rucaparib in trial', 'worse survival with rucaparib in trial of', 'survival with rucaparib in trial of recurrent,', 'with rucaparib in trial of recurrent, brca+', 'rucaparib in trial of recurrent, brca+ ovarian', 'in trial of recurrent, brca+ ovarian cancer', 'trial of recurrent, brca+ ovarian cancer #gyncsm', 'of recurrent, brca+ ovarian cancer #gyncsm .', 'more parp news - worse survival with rucaparib', 'parp news - worse survival with rucaparib in', 'news - worse survival with rucaparib in trial', '- worse survival with rucaparib in trial of', 'worse survival with rucaparib in trial of recurrent,', 'survival with rucaparib in trial of recurrent, brca+', 'with rucaparib in trial of recurrent, brca+ ovarian', 'rucaparib in trial of recurrent, brca+ ovarian cancer', 'in trial of recurrent, brca+ ovarian cancer #gyncsm', 'trial of recurrent, brca+ ovarian cancer #gyncsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '3', 'tokens': ['Improved', 'overall', 'survival', 'with', 'immunotherapy', 'compared', 'with', 'sorafenib', 'in', '#liver', '#cancer', 'at', '#GI22', 'Potential', 'for', 'a', 'new', 'standard', 'of', 'care.', '.'], 'text_length': 21, 'triples': {'sorafenib|Improved overall survival with immunotherapy compared with': ([7, 7], [0, 6], 'negative')}, 'sentence': 'Improved overall survival with immunotherapy compared with sorafenib in #liver #cancer at #GI22 Potential for a new standard of care. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 6)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['Improved', 'overall', 'survival', 'with', 'immunotherapy', 'compared', 'with', 'sorafenib', 'in', '#liver', '#cancer', 'at', '#GI22', 'Potential', 'for', 'a', 'new', 'standard', 'of', 'care.', '.', 'Improved overall', 'overall survival', 'survival with', 'with immunotherapy', 'immunotherapy compared', 'compared with', 'with sorafenib', 'sorafenib in', 'in #liver', '#liver #cancer', '#cancer at', 'at #GI22', '#GI22 Potential', 'Potential for', 'for a', 'a new', 'new standard', 'standard of', 'of care.', 'care. .', 'Improved overall survival', 'overall survival with', 'survival with immunotherapy', 'with immunotherapy compared', 'immunotherapy compared with', 'compared with sorafenib', 'with sorafenib in', 'sorafenib in #liver', 'in #liver #cancer', '#liver #cancer at', '#cancer at #GI22', 'at #GI22 Potential', '#GI22 Potential for', 'Potential for a', 'for a new', 'a new standard', 'new standard of', 'standard of care.', 'of care. .', 'Improved overall survival with', 'overall survival with immunotherapy', 'survival with immunotherapy compared', 'with immunotherapy compared with', 'immunotherapy compared with sorafenib', 'compared with sorafenib in', 'with sorafenib in #liver', 'sorafenib in #liver #cancer', 'in #liver #cancer at', '#liver #cancer at #GI22', '#cancer at #GI22 Potential', 'at #GI22 Potential for', '#GI22 Potential for a', 'Potential for a new', 'for a new standard', 'a new standard of', 'new standard of care.', 'standard of care. .', 'Improved overall survival with immunotherapy', 'overall survival with immunotherapy compared', 'survival with immunotherapy compared with', 'with immunotherapy compared with sorafenib', 'immunotherapy compared with sorafenib in', 'compared with sorafenib in #liver', 'with sorafenib in #liver #cancer', 'sorafenib in #liver #cancer at', 'in #liver #cancer at #GI22', '#liver #cancer at #GI22 Potential', '#cancer at #GI22 Potential for', 'at #GI22 Potential for a', '#GI22 Potential for a new', 'Potential for a new standard', 'for a new standard of', 'a new standard of care.', 'new standard of care. .', 'Improved overall survival with immunotherapy compared', 'overall survival with immunotherapy compared with', 'survival with immunotherapy compared with sorafenib', 'with immunotherapy compared with sorafenib in', 'immunotherapy compared with sorafenib in #liver', 'compared with sorafenib in #liver #cancer', 'with sorafenib in #liver #cancer at', 'sorafenib in #liver #cancer at #GI22', 'in #liver #cancer at #GI22 Potential', '#liver #cancer at #GI22 Potential for', '#cancer at #GI22 Potential for a', 'at #GI22 Potential for a new', '#GI22 Potential for a new standard', 'Potential for a new standard of', 'for a new standard of care.', 'a new standard of care. .', 'Improved overall survival with immunotherapy compared with', 'overall survival with immunotherapy compared with sorafenib', 'survival with immunotherapy compared with sorafenib in', 'with immunotherapy compared with sorafenib in #liver', 'immunotherapy compared with sorafenib in #liver #cancer', 'compared with sorafenib in #liver #cancer at', 'with sorafenib in #liver #cancer at #GI22', 'sorafenib in #liver #cancer at #GI22 Potential', 'in #liver #cancer at #GI22 Potential for', '#liver #cancer at #GI22 Potential for a', '#cancer at #GI22 Potential for a new', 'at #GI22 Potential for a new standard', '#GI22 Potential for a new standard of', 'Potential for a new standard of care.', 'for a new standard of care. .', 'Improved overall survival with immunotherapy compared with sorafenib', 'overall survival with immunotherapy compared with sorafenib in', 'survival with immunotherapy compared with sorafenib in #liver', 'with immunotherapy compared with sorafenib in #liver #cancer', 'immunotherapy compared with sorafenib in #liver #cancer at', 'compared with sorafenib in #liver #cancer at #GI22', 'with sorafenib in #liver #cancer at #GI22 Potential', 'sorafenib in #liver #cancer at #GI22 Potential for', 'in #liver #cancer at #GI22 Potential for a', '#liver #cancer at #GI22 Potential for a new', '#cancer at #GI22 Potential for a new standard', 'at #GI22 Potential for a new standard of', '#GI22 Potential for a new standard of care.', 'Potential for a new standard of care. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '4', 'tokens': ['Pembrolizumab', 'plus', 'chemotherapy', 'did', 'not', 'induce', 'clinically', 'meaningful', 'survival', 'benefit,', 'compared', 'with', 'nivolumab', 'alone', 'in', '', '#stomca', '#GI22', '#GICSM', '', '.'], 'text_length': 21, 'triples': {'nivolumab|not induce clinically meaningful survival benefit,': ([12, 12], [4, 9], 'positive'), 'Pembrolizumab|not induce clinically meaningful survival benefit, compared with': ([0, 0], [4, 11], 'negative')}, 'sentence': 'Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with nivolumab alone in  #stomca #GI22 #GICSM  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(12, 12), (0, 0)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(4, 9), (4, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['Pembrolizumab', 'plus', 'chemotherapy', 'did', 'not', 'induce', 'clinically', 'meaningful', 'survival', 'benefit,', 'compared', 'with', 'nivolumab', 'alone', 'in', '', '#stomca', '#GI22', '#GICSM', '', '.', 'Pembrolizumab plus', 'plus chemotherapy', 'chemotherapy did', 'did not', 'not induce', 'induce clinically', 'clinically meaningful', 'meaningful survival', 'survival benefit,', 'benefit, compared', 'compared with', 'with nivolumab', 'nivolumab alone', 'alone in', 'in ', ' #stomca', '#stomca #GI22', '#GI22 #GICSM', '#GICSM ', ' .', 'Pembrolizumab plus chemotherapy', 'plus chemotherapy did', 'chemotherapy did not', 'did not induce', 'not induce clinically', 'induce clinically meaningful', 'clinically meaningful survival', 'meaningful survival benefit,', 'survival benefit, compared', 'benefit, compared with', 'compared with nivolumab', 'with nivolumab alone', 'nivolumab alone in', 'alone in ', 'in  #stomca', ' #stomca #GI22', '#stomca #GI22 #GICSM', '#GI22 #GICSM ', '#GICSM  .', 'Pembrolizumab plus chemotherapy did', 'plus chemotherapy did not', 'chemotherapy did not induce', 'did not induce clinically', 'not induce clinically meaningful', 'induce clinically meaningful survival', 'clinically meaningful survival benefit,', 'meaningful survival benefit, compared', 'survival benefit, compared with', 'benefit, compared with nivolumab', 'compared with nivolumab alone', 'with nivolumab alone in', 'nivolumab alone in ', 'alone in  #stomca', 'in  #stomca #GI22', ' #stomca #GI22 #GICSM', '#stomca #GI22 #GICSM ', '#GI22 #GICSM  .', 'Pembrolizumab plus chemotherapy did not', 'plus chemotherapy did not induce', 'chemotherapy did not induce clinically', 'did not induce clinically meaningful', 'not induce clinically meaningful survival', 'induce clinically meaningful survival benefit,', 'clinically meaningful survival benefit, compared', 'meaningful survival benefit, compared with', 'survival benefit, compared with nivolumab', 'benefit, compared with nivolumab alone', 'compared with nivolumab alone in', 'with nivolumab alone in ', 'nivolumab alone in  #stomca', 'alone in  #stomca #GI22', 'in  #stomca #GI22 #GICSM', ' #stomca #GI22 #GICSM ', '#stomca #GI22 #GICSM  .', 'Pembrolizumab plus chemotherapy did not induce', 'plus chemotherapy did not induce clinically', 'chemotherapy did not induce clinically meaningful', 'did not induce clinically meaningful survival', 'not induce clinically meaningful survival benefit,', 'induce clinically meaningful survival benefit, compared', 'clinically meaningful survival benefit, compared with', 'meaningful survival benefit, compared with nivolumab', 'survival benefit, compared with nivolumab alone', 'benefit, compared with nivolumab alone in', 'compared with nivolumab alone in ', 'with nivolumab alone in  #stomca', 'nivolumab alone in  #stomca #GI22', 'alone in  #stomca #GI22 #GICSM', 'in  #stomca #GI22 #GICSM ', ' #stomca #GI22 #GICSM  .', 'Pembrolizumab plus chemotherapy did not induce clinically', 'plus chemotherapy did not induce clinically meaningful', 'chemotherapy did not induce clinically meaningful survival', 'did not induce clinically meaningful survival benefit,', 'not induce clinically meaningful survival benefit, compared', 'induce clinically meaningful survival benefit, compared with', 'clinically meaningful survival benefit, compared with nivolumab', 'meaningful survival benefit, compared with nivolumab alone', 'survival benefit, compared with nivolumab alone in', 'benefit, compared with nivolumab alone in ', 'compared with nivolumab alone in  #stomca', 'with nivolumab alone in  #stomca #GI22', 'nivolumab alone in  #stomca #GI22 #GICSM', 'alone in  #stomca #GI22 #GICSM ', 'in  #stomca #GI22 #GICSM  .', 'Pembrolizumab plus chemotherapy did not induce clinically meaningful', 'plus chemotherapy did not induce clinically meaningful survival', 'chemotherapy did not induce clinically meaningful survival benefit,', 'did not induce clinically meaningful survival benefit, compared', 'not induce clinically meaningful survival benefit, compared with', 'induce clinically meaningful survival benefit, compared with nivolumab', 'clinically meaningful survival benefit, compared with nivolumab alone', 'meaningful survival benefit, compared with nivolumab alone in', 'survival benefit, compared with nivolumab alone in ', 'benefit, compared with nivolumab alone in  #stomca', 'compared with nivolumab alone in  #stomca #GI22', 'with nivolumab alone in  #stomca #GI22 #GICSM', 'nivolumab alone in  #stomca #GI22 #GICSM ', 'alone in  #stomca #GI22 #GICSM  .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '5', 'tokens': ['the', 'immune', 'checkpoint', 'inhibitor', 'atezolizumab', '(tecentriq)', 'improved', 'overall', 'survival', 'compared', 'with', 'chemotherapy', 'in', 'patients', 'with', 'advanced', '#nsclc', 'who', 'were', 'ineligible', 'for', 'platinum', 'doublet', 'chemotherapy.', '#esmo22', '#lungcancer', '', '.'], 'text_length': 28, 'triples': {'atezolizumab|improved overall survival': ([4, 4], [6, 8], 'positive')}, 'sentence': 'the immune checkpoint inhibitor atezolizumab (tecentriq) improved overall survival compared with chemotherapy in patients with advanced #nsclc who were ineligible for platinum doublet chemotherapy. #esmo22 #lungcancer  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['the', 'immune', 'checkpoint', 'inhibitor', 'atezolizumab', '(tecentriq)', 'improved', 'overall', 'survival', 'compared', 'with', 'chemotherapy', 'in', 'patients', 'with', 'advanced', '#nsclc', 'who', 'were', 'ineligible', 'for', 'platinum', 'doublet', 'chemotherapy.', '#esmo22', '#lungcancer', '', '.', 'the immune', 'immune checkpoint', 'checkpoint inhibitor', 'inhibitor atezolizumab', 'atezolizumab (tecentriq)', '(tecentriq) improved', 'improved overall', 'overall survival', 'survival compared', 'compared with', 'with chemotherapy', 'chemotherapy in', 'in patients', 'patients with', 'with advanced', 'advanced #nsclc', '#nsclc who', 'who were', 'were ineligible', 'ineligible for', 'for platinum', 'platinum doublet', 'doublet chemotherapy.', 'chemotherapy. #esmo22', '#esmo22 #lungcancer', '#lungcancer ', ' .', 'the immune checkpoint', 'immune checkpoint inhibitor', 'checkpoint inhibitor atezolizumab', 'inhibitor atezolizumab (tecentriq)', 'atezolizumab (tecentriq) improved', '(tecentriq) improved overall', 'improved overall survival', 'overall survival compared', 'survival compared with', 'compared with chemotherapy', 'with chemotherapy in', 'chemotherapy in patients', 'in patients with', 'patients with advanced', 'with advanced #nsclc', 'advanced #nsclc who', '#nsclc who were', 'who were ineligible', 'were ineligible for', 'ineligible for platinum', 'for platinum doublet', 'platinum doublet chemotherapy.', 'doublet chemotherapy. #esmo22', 'chemotherapy. #esmo22 #lungcancer', '#esmo22 #lungcancer ', '#lungcancer  .', 'the immune checkpoint inhibitor', 'immune checkpoint inhibitor atezolizumab', 'checkpoint inhibitor atezolizumab (tecentriq)', 'inhibitor atezolizumab (tecentriq) improved', 'atezolizumab (tecentriq) improved overall', '(tecentriq) improved overall survival', 'improved overall survival compared', 'overall survival compared with', 'survival compared with chemotherapy', 'compared with chemotherapy in', 'with chemotherapy in patients', 'chemotherapy in patients with', 'in patients with advanced', 'patients with advanced #nsclc', 'with advanced #nsclc who', 'advanced #nsclc who were', '#nsclc who were ineligible', 'who were ineligible for', 'were ineligible for platinum', 'ineligible for platinum doublet', 'for platinum doublet chemotherapy.', 'platinum doublet chemotherapy. #esmo22', 'doublet chemotherapy. #esmo22 #lungcancer', 'chemotherapy. #esmo22 #lungcancer ', '#esmo22 #lungcancer  .', 'the immune checkpoint inhibitor atezolizumab', 'immune checkpoint inhibitor atezolizumab (tecentriq)', 'checkpoint inhibitor atezolizumab (tecentriq) improved', 'inhibitor atezolizumab (tecentriq) improved overall', 'atezolizumab (tecentriq) improved overall survival', '(tecentriq) improved overall survival compared', 'improved overall survival compared with', 'overall survival compared with chemotherapy', 'survival compared with chemotherapy in', 'compared with chemotherapy in patients', 'with chemotherapy in patients with', 'chemotherapy in patients with advanced', 'in patients with advanced #nsclc', 'patients with advanced #nsclc who', 'with advanced #nsclc who were', 'advanced #nsclc who were ineligible', '#nsclc who were ineligible for', 'who were ineligible for platinum', 'were ineligible for platinum doublet', 'ineligible for platinum doublet chemotherapy.', 'for platinum doublet chemotherapy. #esmo22', 'platinum doublet chemotherapy. #esmo22 #lungcancer', 'doublet chemotherapy. #esmo22 #lungcancer ', 'chemotherapy. #esmo22 #lungcancer  .', 'the immune checkpoint inhibitor atezolizumab (tecentriq)', 'immune checkpoint inhibitor atezolizumab (tecentriq) improved', 'checkpoint inhibitor atezolizumab (tecentriq) improved overall', 'inhibitor atezolizumab (tecentriq) improved overall survival', 'atezolizumab (tecentriq) improved overall survival compared', '(tecentriq) improved overall survival compared with', 'improved overall survival compared with chemotherapy', 'overall survival compared with chemotherapy in', 'survival compared with chemotherapy in patients', 'compared with chemotherapy in patients with', 'with chemotherapy in patients with advanced', 'chemotherapy in patients with advanced #nsclc', 'in patients with advanced #nsclc who', 'patients with advanced #nsclc who were', 'with advanced #nsclc who were ineligible', 'advanced #nsclc who were ineligible for', '#nsclc who were ineligible for platinum', 'who were ineligible for platinum doublet', 'were ineligible for platinum doublet chemotherapy.', 'ineligible for platinum doublet chemotherapy. #esmo22', 'for platinum doublet chemotherapy. #esmo22 #lungcancer', 'platinum doublet chemotherapy. #esmo22 #lungcancer ', 'doublet chemotherapy. #esmo22 #lungcancer  .', 'the immune checkpoint inhibitor atezolizumab (tecentriq) improved', 'immune checkpoint inhibitor atezolizumab (tecentriq) improved overall', 'checkpoint inhibitor atezolizumab (tecentriq) improved overall survival', 'inhibitor atezolizumab (tecentriq) improved overall survival compared', 'atezolizumab (tecentriq) improved overall survival compared with', '(tecentriq) improved overall survival compared with chemotherapy', 'improved overall survival compared with chemotherapy in', 'overall survival compared with chemotherapy in patients', 'survival compared with chemotherapy in patients with', 'compared with chemotherapy in patients with advanced', 'with chemotherapy in patients with advanced #nsclc', 'chemotherapy in patients with advanced #nsclc who', 'in patients with advanced #nsclc who were', 'patients with advanced #nsclc who were ineligible', 'with advanced #nsclc who were ineligible for', 'advanced #nsclc who were ineligible for platinum', '#nsclc who were ineligible for platinum doublet', 'who were ineligible for platinum doublet chemotherapy.', 'were ineligible for platinum doublet chemotherapy. #esmo22', 'ineligible for platinum doublet chemotherapy. #esmo22 #lungcancer', 'for platinum doublet chemotherapy. #esmo22 #lungcancer ', 'platinum doublet chemotherapy. #esmo22 #lungcancer  .', 'the immune checkpoint inhibitor atezolizumab (tecentriq) improved overall', 'immune checkpoint inhibitor atezolizumab (tecentriq) improved overall survival', 'checkpoint inhibitor atezolizumab (tecentriq) improved overall survival compared', 'inhibitor atezolizumab (tecentriq) improved overall survival compared with', 'atezolizumab (tecentriq) improved overall survival compared with chemotherapy', '(tecentriq) improved overall survival compared with chemotherapy in', 'improved overall survival compared with chemotherapy in patients', 'overall survival compared with chemotherapy in patients with', 'survival compared with chemotherapy in patients with advanced', 'compared with chemotherapy in patients with advanced #nsclc', 'with chemotherapy in patients with advanced #nsclc who', 'chemotherapy in patients with advanced #nsclc who were', 'in patients with advanced #nsclc who were ineligible', 'patients with advanced #nsclc who were ineligible for', 'with advanced #nsclc who were ineligible for platinum', 'advanced #nsclc who were ineligible for platinum doublet', '#nsclc who were ineligible for platinum doublet chemotherapy.', 'who were ineligible for platinum doublet chemotherapy. #esmo22', 'were ineligible for platinum doublet chemotherapy. #esmo22 #lungcancer', 'ineligible for platinum doublet chemotherapy. #esmo22 #lungcancer ', 'for platinum doublet chemotherapy. #esmo22 #lungcancer  .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '6', 'tokens': ['rubraca', 'improved', 'progression-free', 'survival', 'in', 'patients', 'with', 'relapsed', 'ovarian', 'cancer', 'that', 'harbors', 'a', 'deleterious', 'brca1/2', 'mutation', 'compared', 'to', 'chemotherapy,', 'according', 'to', 'findings', 'from', 'the', 'phase', '3', 'ariel4', 'clinical', 'trial.', '#esmo22', '#ovariancancerawarenessmonth', '', '.'], 'text_length': 33, 'triples': {'ariel4|improved progression-free': ([26, 26], [1, 2], 'positive'), 'rubraca|improved progression-free': ([0, 0], [1, 2], 'positive')}, 'sentence': 'rubraca improved progression-free survival in patients with relapsed ovarian cancer that harbors a deleterious brca1/2 mutation compared to chemotherapy, according to findings from the phase 3 ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(26, 26), (0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 2)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['rubraca', 'improved', 'progression-free', 'survival', 'in', 'patients', 'with', 'relapsed', 'ovarian', 'cancer', 'that', 'harbors', 'a', 'deleterious', 'brca1/2', 'mutation', 'compared', 'to', 'chemotherapy,', 'according', 'to', 'findings', 'from', 'the', 'phase', '3', 'ariel4', 'clinical', 'trial.', '#esmo22', '#ovariancancerawarenessmonth', '', '.', 'rubraca improved', 'improved progression-free', 'progression-free survival', 'survival in', 'in patients', 'patients with', 'with relapsed', 'relapsed ovarian', 'ovarian cancer', 'cancer that', 'that harbors', 'harbors a', 'a deleterious', 'deleterious brca1/2', 'brca1/2 mutation', 'mutation compared', 'compared to', 'to chemotherapy,', 'chemotherapy, according', 'according to', 'to findings', 'findings from', 'from the', 'the phase', 'phase 3', '3 ariel4', 'ariel4 clinical', 'clinical trial.', 'trial. #esmo22', '#esmo22 #ovariancancerawarenessmonth', '#ovariancancerawarenessmonth ', ' .', 'rubraca improved progression-free', 'improved progression-free survival', 'progression-free survival in', 'survival in patients', 'in patients with', 'patients with relapsed', 'with relapsed ovarian', 'relapsed ovarian cancer', 'ovarian cancer that', 'cancer that harbors', 'that harbors a', 'harbors a deleterious', 'a deleterious brca1/2', 'deleterious brca1/2 mutation', 'brca1/2 mutation compared', 'mutation compared to', 'compared to chemotherapy,', 'to chemotherapy, according', 'chemotherapy, according to', 'according to findings', 'to findings from', 'findings from the', 'from the phase', 'the phase 3', 'phase 3 ariel4', '3 ariel4 clinical', 'ariel4 clinical trial.', 'clinical trial. #esmo22', 'trial. #esmo22 #ovariancancerawarenessmonth', '#esmo22 #ovariancancerawarenessmonth ', '#ovariancancerawarenessmonth  .', 'rubraca improved progression-free survival', 'improved progression-free survival in', 'progression-free survival in patients', 'survival in patients with', 'in patients with relapsed', 'patients with relapsed ovarian', 'with relapsed ovarian cancer', 'relapsed ovarian cancer that', 'ovarian cancer that harbors', 'cancer that harbors a', 'that harbors a deleterious', 'harbors a deleterious brca1/2', 'a deleterious brca1/2 mutation', 'deleterious brca1/2 mutation compared', 'brca1/2 mutation compared to', 'mutation compared to chemotherapy,', 'compared to chemotherapy, according', 'to chemotherapy, according to', 'chemotherapy, according to findings', 'according to findings from', 'to findings from the', 'findings from the phase', 'from the phase 3', 'the phase 3 ariel4', 'phase 3 ariel4 clinical', '3 ariel4 clinical trial.', 'ariel4 clinical trial. #esmo22', 'clinical trial. #esmo22 #ovariancancerawarenessmonth', 'trial. #esmo22 #ovariancancerawarenessmonth ', '#esmo22 #ovariancancerawarenessmonth  .', 'rubraca improved progression-free survival in', 'improved progression-free survival in patients', 'progression-free survival in patients with', 'survival in patients with relapsed', 'in patients with relapsed ovarian', 'patients with relapsed ovarian cancer', 'with relapsed ovarian cancer that', 'relapsed ovarian cancer that harbors', 'ovarian cancer that harbors a', 'cancer that harbors a deleterious', 'that harbors a deleterious brca1/2', 'harbors a deleterious brca1/2 mutation', 'a deleterious brca1/2 mutation compared', 'deleterious brca1/2 mutation compared to', 'brca1/2 mutation compared to chemotherapy,', 'mutation compared to chemotherapy, according', 'compared to chemotherapy, according to', 'to chemotherapy, according to findings', 'chemotherapy, according to findings from', 'according to findings from the', 'to findings from the phase', 'findings from the phase 3', 'from the phase 3 ariel4', 'the phase 3 ariel4 clinical', 'phase 3 ariel4 clinical trial.', '3 ariel4 clinical trial. #esmo22', 'ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth', 'clinical trial. #esmo22 #ovariancancerawarenessmonth ', 'trial. #esmo22 #ovariancancerawarenessmonth  .', 'rubraca improved progression-free survival in patients', 'improved progression-free survival in patients with', 'progression-free survival in patients with relapsed', 'survival in patients with relapsed ovarian', 'in patients with relapsed ovarian cancer', 'patients with relapsed ovarian cancer that', 'with relapsed ovarian cancer that harbors', 'relapsed ovarian cancer that harbors a', 'ovarian cancer that harbors a deleterious', 'cancer that harbors a deleterious brca1/2', 'that harbors a deleterious brca1/2 mutation', 'harbors a deleterious brca1/2 mutation compared', 'a deleterious brca1/2 mutation compared to', 'deleterious brca1/2 mutation compared to chemotherapy,', 'brca1/2 mutation compared to chemotherapy, according', 'mutation compared to chemotherapy, according to', 'compared to chemotherapy, according to findings', 'to chemotherapy, according to findings from', 'chemotherapy, according to findings from the', 'according to findings from the phase', 'to findings from the phase 3', 'findings from the phase 3 ariel4', 'from the phase 3 ariel4 clinical', 'the phase 3 ariel4 clinical trial.', 'phase 3 ariel4 clinical trial. #esmo22', '3 ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth', 'ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth ', 'clinical trial. #esmo22 #ovariancancerawarenessmonth  .', 'rubraca improved progression-free survival in patients with', 'improved progression-free survival in patients with relapsed', 'progression-free survival in patients with relapsed ovarian', 'survival in patients with relapsed ovarian cancer', 'in patients with relapsed ovarian cancer that', 'patients with relapsed ovarian cancer that harbors', 'with relapsed ovarian cancer that harbors a', 'relapsed ovarian cancer that harbors a deleterious', 'ovarian cancer that harbors a deleterious brca1/2', 'cancer that harbors a deleterious brca1/2 mutation', 'that harbors a deleterious brca1/2 mutation compared', 'harbors a deleterious brca1/2 mutation compared to', 'a deleterious brca1/2 mutation compared to chemotherapy,', 'deleterious brca1/2 mutation compared to chemotherapy, according', 'brca1/2 mutation compared to chemotherapy, according to', 'mutation compared to chemotherapy, according to findings', 'compared to chemotherapy, according to findings from', 'to chemotherapy, according to findings from the', 'chemotherapy, according to findings from the phase', 'according to findings from the phase 3', 'to findings from the phase 3 ariel4', 'findings from the phase 3 ariel4 clinical', 'from the phase 3 ariel4 clinical trial.', 'the phase 3 ariel4 clinical trial. #esmo22', 'phase 3 ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth', '3 ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth ', 'ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth  .', 'rubraca improved progression-free survival in patients with relapsed', 'improved progression-free survival in patients with relapsed ovarian', 'progression-free survival in patients with relapsed ovarian cancer', 'survival in patients with relapsed ovarian cancer that', 'in patients with relapsed ovarian cancer that harbors', 'patients with relapsed ovarian cancer that harbors a', 'with relapsed ovarian cancer that harbors a deleterious', 'relapsed ovarian cancer that harbors a deleterious brca1/2', 'ovarian cancer that harbors a deleterious brca1/2 mutation', 'cancer that harbors a deleterious brca1/2 mutation compared', 'that harbors a deleterious brca1/2 mutation compared to', 'harbors a deleterious brca1/2 mutation compared to chemotherapy,', 'a deleterious brca1/2 mutation compared to chemotherapy, according', 'deleterious brca1/2 mutation compared to chemotherapy, according to', 'brca1/2 mutation compared to chemotherapy, according to findings', 'mutation compared to chemotherapy, according to findings from', 'compared to chemotherapy, according to findings from the', 'to chemotherapy, according to findings from the phase', 'chemotherapy, according to findings from the phase 3', 'according to findings from the phase 3 ariel4', 'to findings from the phase 3 ariel4 clinical', 'findings from the phase 3 ariel4 clinical trial.', 'from the phase 3 ariel4 clinical trial. #esmo22', 'the phase 3 ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth', 'phase 3 ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth ', '3 ariel4 clinical trial. #esmo22 #ovariancancerawarenessmonth  .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '7', 'tokens': ['P3', 'KEYLYNK-010', 'study', 'did', 'not', 'show', 'a', 'statistically', 'significant', 'improvement', 'in', 'rPFS', 'or', 'OS', 'with', 'pembrolizumab', 'plus', 'olaparib', 'vs', 'the', 'active', 'comparator', 'NHA', 'for', 'participants', 'with', 'molecularly', 'unselected,', 'previously', 'treated', 'mCRPC', '@myESMO', '#ESMO22', '@OncoAlert', '@APCCC_Lugano', '@neerajaiims', '@ASCO', 'https://t.co/5ZK0jvuGOr', '.'], 'text_length': 39, 'triples': {'KEYLYNK-010|not show a statistically significant improvement': ([1, 1], [4, 9], 'negative')}, 'sentence': 'P3 KEYLYNK-010 study did not show a statistically significant improvement in rPFS or OS with pembrolizumab plus olaparib vs the active comparator NHA for participants with molecularly unselected, previously treated mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8)], 'span tokens': ['P3', 'KEYLYNK-010', 'study', 'did', 'not', 'show', 'a', 'statistically', 'significant', 'improvement', 'in', 'rPFS', 'or', 'OS', 'with', 'pembrolizumab', 'plus', 'olaparib', 'vs', 'the', 'active', 'comparator', 'NHA', 'for', 'participants', 'with', 'molecularly', 'unselected,', 'previously', 'treated', 'mCRPC', '@myESMO', '#ESMO22', '@OncoAlert', '@APCCC_Lugano', '@neerajaiims', '@ASCO', 'https://t.co/5ZK0jvuGOr', '.', 'P3 KEYLYNK-010', 'KEYLYNK-010 study', 'study did', 'did not', 'not show', 'show a', 'a statistically', 'statistically significant', 'significant improvement', 'improvement in', 'in rPFS', 'rPFS or', 'or OS', 'OS with', 'with pembrolizumab', 'pembrolizumab plus', 'plus olaparib', 'olaparib vs', 'vs the', 'the active', 'active comparator', 'comparator NHA', 'NHA for', 'for participants', 'participants with', 'with molecularly', 'molecularly unselected,', 'unselected, previously', 'previously treated', 'treated mCRPC', 'mCRPC @myESMO', '@myESMO #ESMO22', '#ESMO22 @OncoAlert', '@OncoAlert @APCCC_Lugano', '@APCCC_Lugano @neerajaiims', '@neerajaiims @ASCO', '@ASCO https://t.co/5ZK0jvuGOr', 'https://t.co/5ZK0jvuGOr .', 'P3 KEYLYNK-010 study', 'KEYLYNK-010 study did', 'study did not', 'did not show', 'not show a', 'show a statistically', 'a statistically significant', 'statistically significant improvement', 'significant improvement in', 'improvement in rPFS', 'in rPFS or', 'rPFS or OS', 'or OS with', 'OS with pembrolizumab', 'with pembrolizumab plus', 'pembrolizumab plus olaparib', 'plus olaparib vs', 'olaparib vs the', 'vs the active', 'the active comparator', 'active comparator NHA', 'comparator NHA for', 'NHA for participants', 'for participants with', 'participants with molecularly', 'with molecularly unselected,', 'molecularly unselected, previously', 'unselected, previously treated', 'previously treated mCRPC', 'treated mCRPC @myESMO', 'mCRPC @myESMO #ESMO22', '@myESMO #ESMO22 @OncoAlert', '#ESMO22 @OncoAlert @APCCC_Lugano', '@OncoAlert @APCCC_Lugano @neerajaiims', '@APCCC_Lugano @neerajaiims @ASCO', '@neerajaiims @ASCO https://t.co/5ZK0jvuGOr', '@ASCO https://t.co/5ZK0jvuGOr .', 'P3 KEYLYNK-010 study did', 'KEYLYNK-010 study did not', 'study did not show', 'did not show a', 'not show a statistically', 'show a statistically significant', 'a statistically significant improvement', 'statistically significant improvement in', 'significant improvement in rPFS', 'improvement in rPFS or', 'in rPFS or OS', 'rPFS or OS with', 'or OS with pembrolizumab', 'OS with pembrolizumab plus', 'with pembrolizumab plus olaparib', 'pembrolizumab plus olaparib vs', 'plus olaparib vs the', 'olaparib vs the active', 'vs the active comparator', 'the active comparator NHA', 'active comparator NHA for', 'comparator NHA for participants', 'NHA for participants with', 'for participants with molecularly', 'participants with molecularly unselected,', 'with molecularly unselected, previously', 'molecularly unselected, previously treated', 'unselected, previously treated mCRPC', 'previously treated mCRPC @myESMO', 'treated mCRPC @myESMO #ESMO22', 'mCRPC @myESMO #ESMO22 @OncoAlert', '@myESMO #ESMO22 @OncoAlert @APCCC_Lugano', '#ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims', '@OncoAlert @APCCC_Lugano @neerajaiims @ASCO', '@APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr', '@neerajaiims @ASCO https://t.co/5ZK0jvuGOr .', 'P3 KEYLYNK-010 study did not', 'KEYLYNK-010 study did not show', 'study did not show a', 'did not show a statistically', 'not show a statistically significant', 'show a statistically significant improvement', 'a statistically significant improvement in', 'statistically significant improvement in rPFS', 'significant improvement in rPFS or', 'improvement in rPFS or OS', 'in rPFS or OS with', 'rPFS or OS with pembrolizumab', 'or OS with pembrolizumab plus', 'OS with pembrolizumab plus olaparib', 'with pembrolizumab plus olaparib vs', 'pembrolizumab plus olaparib vs the', 'plus olaparib vs the active', 'olaparib vs the active comparator', 'vs the active comparator NHA', 'the active comparator NHA for', 'active comparator NHA for participants', 'comparator NHA for participants with', 'NHA for participants with molecularly', 'for participants with molecularly unselected,', 'participants with molecularly unselected, previously', 'with molecularly unselected, previously treated', 'molecularly unselected, previously treated mCRPC', 'unselected, previously treated mCRPC @myESMO', 'previously treated mCRPC @myESMO #ESMO22', 'treated mCRPC @myESMO #ESMO22 @OncoAlert', 'mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano', '@myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims', '#ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO', '@OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr', '@APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr .', 'P3 KEYLYNK-010 study did not show', 'KEYLYNK-010 study did not show a', 'study did not show a statistically', 'did not show a statistically significant', 'not show a statistically significant improvement', 'show a statistically significant improvement in', 'a statistically significant improvement in rPFS', 'statistically significant improvement in rPFS or', 'significant improvement in rPFS or OS', 'improvement in rPFS or OS with', 'in rPFS or OS with pembrolizumab', 'rPFS or OS with pembrolizumab plus', 'or OS with pembrolizumab plus olaparib', 'OS with pembrolizumab plus olaparib vs', 'with pembrolizumab plus olaparib vs the', 'pembrolizumab plus olaparib vs the active', 'plus olaparib vs the active comparator', 'olaparib vs the active comparator NHA', 'vs the active comparator NHA for', 'the active comparator NHA for participants', 'active comparator NHA for participants with', 'comparator NHA for participants with molecularly', 'NHA for participants with molecularly unselected,', 'for participants with molecularly unselected, previously', 'participants with molecularly unselected, previously treated', 'with molecularly unselected, previously treated mCRPC', 'molecularly unselected, previously treated mCRPC @myESMO', 'unselected, previously treated mCRPC @myESMO #ESMO22', 'previously treated mCRPC @myESMO #ESMO22 @OncoAlert', 'treated mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano', 'mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims', '@myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO', '#ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr', '@OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr .', 'P3 KEYLYNK-010 study did not show a', 'KEYLYNK-010 study did not show a statistically', 'study did not show a statistically significant', 'did not show a statistically significant improvement', 'not show a statistically significant improvement in', 'show a statistically significant improvement in rPFS', 'a statistically significant improvement in rPFS or', 'statistically significant improvement in rPFS or OS', 'significant improvement in rPFS or OS with', 'improvement in rPFS or OS with pembrolizumab', 'in rPFS or OS with pembrolizumab plus', 'rPFS or OS with pembrolizumab plus olaparib', 'or OS with pembrolizumab plus olaparib vs', 'OS with pembrolizumab plus olaparib vs the', 'with pembrolizumab plus olaparib vs the active', 'pembrolizumab plus olaparib vs the active comparator', 'plus olaparib vs the active comparator NHA', 'olaparib vs the active comparator NHA for', 'vs the active comparator NHA for participants', 'the active comparator NHA for participants with', 'active comparator NHA for participants with molecularly', 'comparator NHA for participants with molecularly unselected,', 'NHA for participants with molecularly unselected, previously', 'for participants with molecularly unselected, previously treated', 'participants with molecularly unselected, previously treated mCRPC', 'with molecularly unselected, previously treated mCRPC @myESMO', 'molecularly unselected, previously treated mCRPC @myESMO #ESMO22', 'unselected, previously treated mCRPC @myESMO #ESMO22 @OncoAlert', 'previously treated mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano', 'treated mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims', 'mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO', '@myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr', '#ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr .', 'P3 KEYLYNK-010 study did not show a statistically', 'KEYLYNK-010 study did not show a statistically significant', 'study did not show a statistically significant improvement', 'did not show a statistically significant improvement in', 'not show a statistically significant improvement in rPFS', 'show a statistically significant improvement in rPFS or', 'a statistically significant improvement in rPFS or OS', 'statistically significant improvement in rPFS or OS with', 'significant improvement in rPFS or OS with pembrolizumab', 'improvement in rPFS or OS with pembrolizumab plus', 'in rPFS or OS with pembrolizumab plus olaparib', 'rPFS or OS with pembrolizumab plus olaparib vs', 'or OS with pembrolizumab plus olaparib vs the', 'OS with pembrolizumab plus olaparib vs the active', 'with pembrolizumab plus olaparib vs the active comparator', 'pembrolizumab plus olaparib vs the active comparator NHA', 'plus olaparib vs the active comparator NHA for', 'olaparib vs the active comparator NHA for participants', 'vs the active comparator NHA for participants with', 'the active comparator NHA for participants with molecularly', 'active comparator NHA for participants with molecularly unselected,', 'comparator NHA for participants with molecularly unselected, previously', 'NHA for participants with molecularly unselected, previously treated', 'for participants with molecularly unselected, previously treated mCRPC', 'participants with molecularly unselected, previously treated mCRPC @myESMO', 'with molecularly unselected, previously treated mCRPC @myESMO #ESMO22', 'molecularly unselected, previously treated mCRPC @myESMO #ESMO22 @OncoAlert', 'unselected, previously treated mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano', 'previously treated mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims', 'treated mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO', 'mCRPC @myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr', '@myESMO #ESMO22 @OncoAlert @APCCC_Lugano @neerajaiims @ASCO https://t.co/5ZK0jvuGOr .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '8', 'tokens': ['CABASTY:', 'Cabazitaxel', 'q2w', 'or', 'q3w', 'in', 'mCRPC', 'patients', 'aged', '&gt;', '65y', '(wouldn’t', 'dare', 'to', 'say', '“older”).', 'worst', 'toxicity', 'and', 'not', 'at', 'all', 'good', 'efficacy.', '#ESMO22', 'https://t.co/t8o6X8PV41', '.'], 'text_length': 27, 'triples': {'CABASTY:|worst toxicity and not at all good': ([0, 0], [16, 22], 'negative'), 'Cabazitaxel|worst toxicity and not at all good': ([1, 1], [16, 22], 'negative')}, 'sentence': 'CABASTY: Cabazitaxel q2w or q3w in mCRPC patients aged &gt; 65y (wouldn’t dare to say “older”). worst toxicity and not at all good efficacy. #ESMO22 https://t.co/t8o6X8PV41 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(16, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8)], 'span tokens': ['CABASTY:', 'Cabazitaxel', 'q2w', 'or', 'q3w', 'in', 'mCRPC', 'patients', 'aged', '&gt;', '65y', '(wouldn’t', 'dare', 'to', 'say', '“older”).', 'worst', 'toxicity', 'and', 'not', 'at', 'all', 'good', 'efficacy.', '#ESMO22', 'https://t.co/t8o6X8PV41', '.', 'CABASTY: Cabazitaxel', 'Cabazitaxel q2w', 'q2w or', 'or q3w', 'q3w in', 'in mCRPC', 'mCRPC patients', 'patients aged', 'aged &gt;', '&gt; 65y', '65y (wouldn’t', '(wouldn’t dare', 'dare to', 'to say', 'say “older”).', '“older”). worst', 'worst toxicity', 'toxicity and', 'and not', 'not at', 'at all', 'all good', 'good efficacy.', 'efficacy. #ESMO22', '#ESMO22 https://t.co/t8o6X8PV41', 'https://t.co/t8o6X8PV41 .', 'CABASTY: Cabazitaxel q2w', 'Cabazitaxel q2w or', 'q2w or q3w', 'or q3w in', 'q3w in mCRPC', 'in mCRPC patients', 'mCRPC patients aged', 'patients aged &gt;', 'aged &gt; 65y', '&gt; 65y (wouldn’t', '65y (wouldn’t dare', '(wouldn’t dare to', 'dare to say', 'to say “older”).', 'say “older”). worst', '“older”). worst toxicity', 'worst toxicity and', 'toxicity and not', 'and not at', 'not at all', 'at all good', 'all good efficacy.', 'good efficacy. #ESMO22', 'efficacy. #ESMO22 https://t.co/t8o6X8PV41', '#ESMO22 https://t.co/t8o6X8PV41 .', 'CABASTY: Cabazitaxel q2w or', 'Cabazitaxel q2w or q3w', 'q2w or q3w in', 'or q3w in mCRPC', 'q3w in mCRPC patients', 'in mCRPC patients aged', 'mCRPC patients aged &gt;', 'patients aged &gt; 65y', 'aged &gt; 65y (wouldn’t', '&gt; 65y (wouldn’t dare', '65y (wouldn’t dare to', '(wouldn’t dare to say', 'dare to say “older”).', 'to say “older”). worst', 'say “older”). worst toxicity', '“older”). worst toxicity and', 'worst toxicity and not', 'toxicity and not at', 'and not at all', 'not at all good', 'at all good efficacy.', 'all good efficacy. #ESMO22', 'good efficacy. #ESMO22 https://t.co/t8o6X8PV41', 'efficacy. #ESMO22 https://t.co/t8o6X8PV41 .', 'CABASTY: Cabazitaxel q2w or q3w', 'Cabazitaxel q2w or q3w in', 'q2w or q3w in mCRPC', 'or q3w in mCRPC patients', 'q3w in mCRPC patients aged', 'in mCRPC patients aged &gt;', 'mCRPC patients aged &gt; 65y', 'patients aged &gt; 65y (wouldn’t', 'aged &gt; 65y (wouldn’t dare', '&gt; 65y (wouldn’t dare to', '65y (wouldn’t dare to say', '(wouldn’t dare to say “older”).', 'dare to say “older”). worst', 'to say “older”). worst toxicity', 'say “older”). worst toxicity and', '“older”). worst toxicity and not', 'worst toxicity and not at', 'toxicity and not at all', 'and not at all good', 'not at all good efficacy.', 'at all good efficacy. #ESMO22', 'all good efficacy. #ESMO22 https://t.co/t8o6X8PV41', 'good efficacy. #ESMO22 https://t.co/t8o6X8PV41 .', 'CABASTY: Cabazitaxel q2w or q3w in', 'Cabazitaxel q2w or q3w in mCRPC', 'q2w or q3w in mCRPC patients', 'or q3w in mCRPC patients aged', 'q3w in mCRPC patients aged &gt;', 'in mCRPC patients aged &gt; 65y', 'mCRPC patients aged &gt; 65y (wouldn’t', 'patients aged &gt; 65y (wouldn’t dare', 'aged &gt; 65y (wouldn’t dare to', '&gt; 65y (wouldn’t dare to say', '65y (wouldn’t dare to say “older”).', '(wouldn’t dare to say “older”). worst', 'dare to say “older”). worst toxicity', 'to say “older”). worst toxicity and', 'say “older”). worst toxicity and not', '“older”). worst toxicity and not at', 'worst toxicity and not at all', 'toxicity and not at all good', 'and not at all good efficacy.', 'not at all good efficacy. #ESMO22', 'at all good efficacy. #ESMO22 https://t.co/t8o6X8PV41', 'all good efficacy. #ESMO22 https://t.co/t8o6X8PV41 .', 'CABASTY: Cabazitaxel q2w or q3w in mCRPC', 'Cabazitaxel q2w or q3w in mCRPC patients', 'q2w or q3w in mCRPC patients aged', 'or q3w in mCRPC patients aged &gt;', 'q3w in mCRPC patients aged &gt; 65y', 'in mCRPC patients aged &gt; 65y (wouldn’t', 'mCRPC patients aged &gt; 65y (wouldn’t dare', 'patients aged &gt; 65y (wouldn’t dare to', 'aged &gt; 65y (wouldn’t dare to say', '&gt; 65y (wouldn’t dare to say “older”).', '65y (wouldn’t dare to say “older”). worst', '(wouldn’t dare to say “older”). worst toxicity', 'dare to say “older”). worst toxicity and', 'to say “older”). worst toxicity and not', 'say “older”). worst toxicity and not at', '“older”). worst toxicity and not at all', 'worst toxicity and not at all good', 'toxicity and not at all good efficacy.', 'and not at all good efficacy. #ESMO22', 'not at all good efficacy. #ESMO22 https://t.co/t8o6X8PV41', 'at all good efficacy. #ESMO22 https://t.co/t8o6X8PV41 .', 'CABASTY: Cabazitaxel q2w or q3w in mCRPC patients', 'Cabazitaxel q2w or q3w in mCRPC patients aged', 'q2w or q3w in mCRPC patients aged &gt;', 'or q3w in mCRPC patients aged &gt; 65y', 'q3w in mCRPC patients aged &gt; 65y (wouldn’t', 'in mCRPC patients aged &gt; 65y (wouldn’t dare', 'mCRPC patients aged &gt; 65y (wouldn’t dare to', 'patients aged &gt; 65y (wouldn’t dare to say', 'aged &gt; 65y (wouldn’t dare to say “older”).', '&gt; 65y (wouldn’t dare to say “older”). worst', '65y (wouldn’t dare to say “older”). worst toxicity', '(wouldn’t dare to say “older”). worst toxicity and', 'dare to say “older”). worst toxicity and not', 'to say “older”). worst toxicity and not at', 'say “older”). worst toxicity and not at all', '“older”). worst toxicity and not at all good', 'worst toxicity and not at all good efficacy.', 'toxicity and not at all good efficacy. #ESMO22', 'and not at all good efficacy. #ESMO22 https://t.co/t8o6X8PV41', 'not at all good efficacy. #ESMO22 https://t.co/t8o6X8PV41 .'], 'spans_aspect_label': [1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '9', 'tokens': ['presented', 'today', 'at', '#esmo22,', 'new', '1l', 'treatment', 'option', 'in', 'unresectable', 'hepatocellular', 'carcinoma', '(uhcc)!', 'a', 'phase', 'iii', 'trial', 'found', 'camrelizumab+rivoceranib', '(c+r)', 'significantly', 'prolonged', 'pfs', 'and', 'os', 'and', 'improved', 'orr', 'compared', 'to', 'sorafenib', '(s)', 'alone.', 'share', 'your', 'thoughts', 'in', 'the', 'comments!', '', '.'], 'text_length': 41, 'triples': {'sorafenib|significantly prolonged pfs and os and improved orr compared to': ([30, 30], [20, 29], 'negative'), 'camrelizumab+rivoceranib|significantly prolonged pfs and os and improved': ([18, 18], [20, 26], 'positive')}, 'sentence': 'presented today at #esmo22, new 1l treatment option in unresectable hepatocellular carcinoma (uhcc)! a phase iii trial found camrelizumab+rivoceranib (c+r) significantly prolonged pfs and os and improved orr compared to sorafenib (s) alone. share your thoughts in the comments!  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(30, 30), (18, 18)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(20, 29), (20, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8)], 'span tokens': ['presented', 'today', 'at', '#esmo22,', 'new', '1l', 'treatment', 'option', 'in', 'unresectable', 'hepatocellular', 'carcinoma', '(uhcc)!', 'a', 'phase', 'iii', 'trial', 'found', 'camrelizumab+rivoceranib', '(c+r)', 'significantly', 'prolonged', 'pfs', 'and', 'os', 'and', 'improved', 'orr', 'compared', 'to', 'sorafenib', '(s)', 'alone.', 'share', 'your', 'thoughts', 'in', 'the', 'comments!', '', '.', 'presented today', 'today at', 'at #esmo22,', '#esmo22, new', 'new 1l', '1l treatment', 'treatment option', 'option in', 'in unresectable', 'unresectable hepatocellular', 'hepatocellular carcinoma', 'carcinoma (uhcc)!', '(uhcc)! a', 'a phase', 'phase iii', 'iii trial', 'trial found', 'found camrelizumab+rivoceranib', 'camrelizumab+rivoceranib (c+r)', '(c+r) significantly', 'significantly prolonged', 'prolonged pfs', 'pfs and', 'and os', 'os and', 'and improved', 'improved orr', 'orr compared', 'compared to', 'to sorafenib', 'sorafenib (s)', '(s) alone.', 'alone. share', 'share your', 'your thoughts', 'thoughts in', 'in the', 'the comments!', 'comments! ', ' .', 'presented today at', 'today at #esmo22,', 'at #esmo22, new', '#esmo22, new 1l', 'new 1l treatment', '1l treatment option', 'treatment option in', 'option in unresectable', 'in unresectable hepatocellular', 'unresectable hepatocellular carcinoma', 'hepatocellular carcinoma (uhcc)!', 'carcinoma (uhcc)! a', '(uhcc)! a phase', 'a phase iii', 'phase iii trial', 'iii trial found', 'trial found camrelizumab+rivoceranib', 'found camrelizumab+rivoceranib (c+r)', 'camrelizumab+rivoceranib (c+r) significantly', '(c+r) significantly prolonged', 'significantly prolonged pfs', 'prolonged pfs and', 'pfs and os', 'and os and', 'os and improved', 'and improved orr', 'improved orr compared', 'orr compared to', 'compared to sorafenib', 'to sorafenib (s)', 'sorafenib (s) alone.', '(s) alone. share', 'alone. share your', 'share your thoughts', 'your thoughts in', 'thoughts in the', 'in the comments!', 'the comments! ', 'comments!  .', 'presented today at #esmo22,', 'today at #esmo22, new', 'at #esmo22, new 1l', '#esmo22, new 1l treatment', 'new 1l treatment option', '1l treatment option in', 'treatment option in unresectable', 'option in unresectable hepatocellular', 'in unresectable hepatocellular carcinoma', 'unresectable hepatocellular carcinoma (uhcc)!', 'hepatocellular carcinoma (uhcc)! a', 'carcinoma (uhcc)! a phase', '(uhcc)! a phase iii', 'a phase iii trial', 'phase iii trial found', 'iii trial found camrelizumab+rivoceranib', 'trial found camrelizumab+rivoceranib (c+r)', 'found camrelizumab+rivoceranib (c+r) significantly', 'camrelizumab+rivoceranib (c+r) significantly prolonged', '(c+r) significantly prolonged pfs', 'significantly prolonged pfs and', 'prolonged pfs and os', 'pfs and os and', 'and os and improved', 'os and improved orr', 'and improved orr compared', 'improved orr compared to', 'orr compared to sorafenib', 'compared to sorafenib (s)', 'to sorafenib (s) alone.', 'sorafenib (s) alone. share', '(s) alone. share your', 'alone. share your thoughts', 'share your thoughts in', 'your thoughts in the', 'thoughts in the comments!', 'in the comments! ', 'the comments!  .', 'presented today at #esmo22, new', 'today at #esmo22, new 1l', 'at #esmo22, new 1l treatment', '#esmo22, new 1l treatment option', 'new 1l treatment option in', '1l treatment option in unresectable', 'treatment option in unresectable hepatocellular', 'option in unresectable hepatocellular carcinoma', 'in unresectable hepatocellular carcinoma (uhcc)!', 'unresectable hepatocellular carcinoma (uhcc)! a', 'hepatocellular carcinoma (uhcc)! a phase', 'carcinoma (uhcc)! a phase iii', '(uhcc)! a phase iii trial', 'a phase iii trial found', 'phase iii trial found camrelizumab+rivoceranib', 'iii trial found camrelizumab+rivoceranib (c+r)', 'trial found camrelizumab+rivoceranib (c+r) significantly', 'found camrelizumab+rivoceranib (c+r) significantly prolonged', 'camrelizumab+rivoceranib (c+r) significantly prolonged pfs', '(c+r) significantly prolonged pfs and', 'significantly prolonged pfs and os', 'prolonged pfs and os and', 'pfs and os and improved', 'and os and improved orr', 'os and improved orr compared', 'and improved orr compared to', 'improved orr compared to sorafenib', 'orr compared to sorafenib (s)', 'compared to sorafenib (s) alone.', 'to sorafenib (s) alone. share', 'sorafenib (s) alone. share your', '(s) alone. share your thoughts', 'alone. share your thoughts in', 'share your thoughts in the', 'your thoughts in the comments!', 'thoughts in the comments! ', 'in the comments!  .', 'presented today at #esmo22, new 1l', 'today at #esmo22, new 1l treatment', 'at #esmo22, new 1l treatment option', '#esmo22, new 1l treatment option in', 'new 1l treatment option in unresectable', '1l treatment option in unresectable hepatocellular', 'treatment option in unresectable hepatocellular carcinoma', 'option in unresectable hepatocellular carcinoma (uhcc)!', 'in unresectable hepatocellular carcinoma (uhcc)! a', 'unresectable hepatocellular carcinoma (uhcc)! a phase', 'hepatocellular carcinoma (uhcc)! a phase iii', 'carcinoma (uhcc)! a phase iii trial', '(uhcc)! a phase iii trial found', 'a phase iii trial found camrelizumab+rivoceranib', 'phase iii trial found camrelizumab+rivoceranib (c+r)', 'iii trial found camrelizumab+rivoceranib (c+r) significantly', 'trial found camrelizumab+rivoceranib (c+r) significantly prolonged', 'found camrelizumab+rivoceranib (c+r) significantly prolonged pfs', 'camrelizumab+rivoceranib (c+r) significantly prolonged pfs and', '(c+r) significantly prolonged pfs and os', 'significantly prolonged pfs and os and', 'prolonged pfs and os and improved', 'pfs and os and improved orr', 'and os and improved orr compared', 'os and improved orr compared to', 'and improved orr compared to sorafenib', 'improved orr compared to sorafenib (s)', 'orr compared to sorafenib (s) alone.', 'compared to sorafenib (s) alone. share', 'to sorafenib (s) alone. share your', 'sorafenib (s) alone. share your thoughts', '(s) alone. share your thoughts in', 'alone. share your thoughts in the', 'share your thoughts in the comments!', 'your thoughts in the comments! ', 'thoughts in the comments!  .', 'presented today at #esmo22, new 1l treatment', 'today at #esmo22, new 1l treatment option', 'at #esmo22, new 1l treatment option in', '#esmo22, new 1l treatment option in unresectable', 'new 1l treatment option in unresectable hepatocellular', '1l treatment option in unresectable hepatocellular carcinoma', 'treatment option in unresectable hepatocellular carcinoma (uhcc)!', 'option in unresectable hepatocellular carcinoma (uhcc)! a', 'in unresectable hepatocellular carcinoma (uhcc)! a phase', 'unresectable hepatocellular carcinoma (uhcc)! a phase iii', 'hepatocellular carcinoma (uhcc)! a phase iii trial', 'carcinoma (uhcc)! a phase iii trial found', '(uhcc)! a phase iii trial found camrelizumab+rivoceranib', 'a phase iii trial found camrelizumab+rivoceranib (c+r)', 'phase iii trial found camrelizumab+rivoceranib (c+r) significantly', 'iii trial found camrelizumab+rivoceranib (c+r) significantly prolonged', 'trial found camrelizumab+rivoceranib (c+r) significantly prolonged pfs', 'found camrelizumab+rivoceranib (c+r) significantly prolonged pfs and', 'camrelizumab+rivoceranib (c+r) significantly prolonged pfs and os', '(c+r) significantly prolonged pfs and os and', 'significantly prolonged pfs and os and improved', 'prolonged pfs and os and improved orr', 'pfs and os and improved orr compared', 'and os and improved orr compared to', 'os and improved orr compared to sorafenib', 'and improved orr compared to sorafenib (s)', 'improved orr compared to sorafenib (s) alone.', 'orr compared to sorafenib (s) alone. share', 'compared to sorafenib (s) alone. share your', 'to sorafenib (s) alone. share your thoughts', 'sorafenib (s) alone. share your thoughts in', '(s) alone. share your thoughts in the', 'alone. share your thoughts in the comments!', 'share your thoughts in the comments! ', 'your thoughts in the comments!  .', 'presented today at #esmo22, new 1l treatment option', 'today at #esmo22, new 1l treatment option in', 'at #esmo22, new 1l treatment option in unresectable', '#esmo22, new 1l treatment option in unresectable hepatocellular', 'new 1l treatment option in unresectable hepatocellular carcinoma', '1l treatment option in unresectable hepatocellular carcinoma (uhcc)!', 'treatment option in unresectable hepatocellular carcinoma (uhcc)! a', 'option in unresectable hepatocellular carcinoma (uhcc)! a phase', 'in unresectable hepatocellular carcinoma (uhcc)! a phase iii', 'unresectable hepatocellular carcinoma (uhcc)! a phase iii trial', 'hepatocellular carcinoma (uhcc)! a phase iii trial found', 'carcinoma (uhcc)! a phase iii trial found camrelizumab+rivoceranib', '(uhcc)! a phase iii trial found camrelizumab+rivoceranib (c+r)', 'a phase iii trial found camrelizumab+rivoceranib (c+r) significantly', 'phase iii trial found camrelizumab+rivoceranib (c+r) significantly prolonged', 'iii trial found camrelizumab+rivoceranib (c+r) significantly prolonged pfs', 'trial found camrelizumab+rivoceranib (c+r) significantly prolonged pfs and', 'found camrelizumab+rivoceranib (c+r) significantly prolonged pfs and os', 'camrelizumab+rivoceranib (c+r) significantly prolonged pfs and os and', '(c+r) significantly prolonged pfs and os and improved', 'significantly prolonged pfs and os and improved orr', 'prolonged pfs and os and improved orr compared', 'pfs and os and improved orr compared to', 'and os and improved orr compared to sorafenib', 'os and improved orr compared to sorafenib (s)', 'and improved orr compared to sorafenib (s) alone.', 'improved orr compared to sorafenib (s) alone. share', 'orr compared to sorafenib (s) alone. share your', 'compared to sorafenib (s) alone. share your thoughts', 'to sorafenib (s) alone. share your thoughts in', 'sorafenib (s) alone. share your thoughts in the', '(s) alone. share your thoughts in the comments!', 'alone. share your thoughts in the comments! ', 'share your thoughts in the comments!  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '10', 'tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial,', 'authors', 'noted', 'no', 'os', 'benefit', 'compared', 'to', 'zuma', 'trial', 'in', 'patients', 'with', 'metastatic', 'hormone-sensitive', '#prostate', 'cancer.', '.'], 'text_length': 24, 'triples': {'stampede|no os benefit': ([5, 5], [9, 11], 'negative'), 'zuma|no os benefit compared to': ([14, 14], [9, 13], 'positive')}, 'sentence': '#esmo22 abs# lba62: in the stampede trial, authors noted no os benefit compared to zuma trial in patients with metastatic hormone-sensitive #prostate cancer. .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 5), (14, 14)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(9, 11), (9, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8)], 'span tokens': ['#esmo22', 'abs#', 'lba62:', 'in', 'the', 'stampede', 'trial,', 'authors', 'noted', 'no', 'os', 'benefit', 'compared', 'to', 'zuma', 'trial', 'in', 'patients', 'with', 'metastatic', 'hormone-sensitive', '#prostate', 'cancer.', '.', '#esmo22 abs#', 'abs# lba62:', 'lba62: in', 'in the', 'the stampede', 'stampede trial,', 'trial, authors', 'authors noted', 'noted no', 'no os', 'os benefit', 'benefit compared', 'compared to', 'to zuma', 'zuma trial', 'trial in', 'in patients', 'patients with', 'with metastatic', 'metastatic hormone-sensitive', 'hormone-sensitive #prostate', '#prostate cancer.', 'cancer. .', '#esmo22 abs# lba62:', 'abs# lba62: in', 'lba62: in the', 'in the stampede', 'the stampede trial,', 'stampede trial, authors', 'trial, authors noted', 'authors noted no', 'noted no os', 'no os benefit', 'os benefit compared', 'benefit compared to', 'compared to zuma', 'to zuma trial', 'zuma trial in', 'trial in patients', 'in patients with', 'patients with metastatic', 'with metastatic hormone-sensitive', 'metastatic hormone-sensitive #prostate', 'hormone-sensitive #prostate cancer.', '#prostate cancer. .', '#esmo22 abs# lba62: in', 'abs# lba62: in the', 'lba62: in the stampede', 'in the stampede trial,', 'the stampede trial, authors', 'stampede trial, authors noted', 'trial, authors noted no', 'authors noted no os', 'noted no os benefit', 'no os benefit compared', 'os benefit compared to', 'benefit compared to zuma', 'compared to zuma trial', 'to zuma trial in', 'zuma trial in patients', 'trial in patients with', 'in patients with metastatic', 'patients with metastatic hormone-sensitive', 'with metastatic hormone-sensitive #prostate', 'metastatic hormone-sensitive #prostate cancer.', 'hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the', 'abs# lba62: in the stampede', 'lba62: in the stampede trial,', 'in the stampede trial, authors', 'the stampede trial, authors noted', 'stampede trial, authors noted no', 'trial, authors noted no os', 'authors noted no os benefit', 'noted no os benefit compared', 'no os benefit compared to', 'os benefit compared to zuma', 'benefit compared to zuma trial', 'compared to zuma trial in', 'to zuma trial in patients', 'zuma trial in patients with', 'trial in patients with metastatic', 'in patients with metastatic hormone-sensitive', 'patients with metastatic hormone-sensitive #prostate', 'with metastatic hormone-sensitive #prostate cancer.', 'metastatic hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the stampede', 'abs# lba62: in the stampede trial,', 'lba62: in the stampede trial, authors', 'in the stampede trial, authors noted', 'the stampede trial, authors noted no', 'stampede trial, authors noted no os', 'trial, authors noted no os benefit', 'authors noted no os benefit compared', 'noted no os benefit compared to', 'no os benefit compared to zuma', 'os benefit compared to zuma trial', 'benefit compared to zuma trial in', 'compared to zuma trial in patients', 'to zuma trial in patients with', 'zuma trial in patients with metastatic', 'trial in patients with metastatic hormone-sensitive', 'in patients with metastatic hormone-sensitive #prostate', 'patients with metastatic hormone-sensitive #prostate cancer.', 'with metastatic hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the stampede trial,', 'abs# lba62: in the stampede trial, authors', 'lba62: in the stampede trial, authors noted', 'in the stampede trial, authors noted no', 'the stampede trial, authors noted no os', 'stampede trial, authors noted no os benefit', 'trial, authors noted no os benefit compared', 'authors noted no os benefit compared to', 'noted no os benefit compared to zuma', 'no os benefit compared to zuma trial', 'os benefit compared to zuma trial in', 'benefit compared to zuma trial in patients', 'compared to zuma trial in patients with', 'to zuma trial in patients with metastatic', 'zuma trial in patients with metastatic hormone-sensitive', 'trial in patients with metastatic hormone-sensitive #prostate', 'in patients with metastatic hormone-sensitive #prostate cancer.', 'patients with metastatic hormone-sensitive #prostate cancer. .', '#esmo22 abs# lba62: in the stampede trial, authors', 'abs# lba62: in the stampede trial, authors noted', 'lba62: in the stampede trial, authors noted no', 'in the stampede trial, authors noted no os', 'the stampede trial, authors noted no os benefit', 'stampede trial, authors noted no os benefit compared', 'trial, authors noted no os benefit compared to', 'authors noted no os benefit compared to zuma', 'noted no os benefit compared to zuma trial', 'no os benefit compared to zuma trial in', 'os benefit compared to zuma trial in patients', 'benefit compared to zuma trial in patients with', 'compared to zuma trial in patients with metastatic', 'to zuma trial in patients with metastatic hormone-sensitive', 'zuma trial in patients with metastatic hormone-sensitive #prostate', 'trial in patients with metastatic hormone-sensitive #prostate cancer.', 'in patients with metastatic hormone-sensitive #prostate cancer. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '11', 'tokens': ['lag3', 'was', 'discovered', '!', 'anti-lag3', 'will', 'impact', 'nsclc', 'survival', 'as', 'in', 'melanoma?', 'no', 'clear', 'signal', 'so', 'far:', 'in', '2x30', 'patients', 'with', 'resectable', 'nsclc,', 'relatlimab+nivolumab', 'did', 'not', 'increase', 'pathological', 'response', 'compared', 'to', 'nivolumab', 'alone.', 'similar', '12mo', 'dfs.', '#esmo22po', '.'], 'text_length': 38, 'triples': {'nsclc,|did not increase pathological': ([22, 22], [24, 27], 'negative'), 'nsclc, relatlimab+nivolumab did not increase pathological response compared to|did not increase pathological response compared': ([22, 30], [24, 29], 'positive')}, 'sentence': 'lag3 was discovered ! anti-lag3 will impact nsclc survival as in melanoma? no clear signal so far: in 2x30 patients with resectable nsclc, relatlimab+nivolumab did not increase pathological response compared to nivolumab alone. similar 12mo dfs. #esmo22po .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(22, 22), (22, 30)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(24, 27), (24, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8)], 'span tokens': ['lag3', 'was', 'discovered', '!', 'anti-lag3', 'will', 'impact', 'nsclc', 'survival', 'as', 'in', 'melanoma?', 'no', 'clear', 'signal', 'so', 'far:', 'in', '2x30', 'patients', 'with', 'resectable', 'nsclc,', 'relatlimab+nivolumab', 'did', 'not', 'increase', 'pathological', 'response', 'compared', 'to', 'nivolumab', 'alone.', 'similar', '12mo', 'dfs.', '#esmo22po', '.', 'lag3 was', 'was discovered', 'discovered !', '! anti-lag3', 'anti-lag3 will', 'will impact', 'impact nsclc', 'nsclc survival', 'survival as', 'as in', 'in melanoma?', 'melanoma? no', 'no clear', 'clear signal', 'signal so', 'so far:', 'far: in', 'in 2x30', '2x30 patients', 'patients with', 'with resectable', 'resectable nsclc,', 'nsclc, relatlimab+nivolumab', 'relatlimab+nivolumab did', 'did not', 'not increase', 'increase pathological', 'pathological response', 'response compared', 'compared to', 'to nivolumab', 'nivolumab alone.', 'alone. similar', 'similar 12mo', '12mo dfs.', 'dfs. #esmo22po', '#esmo22po .', 'lag3 was discovered', 'was discovered !', 'discovered ! anti-lag3', '! anti-lag3 will', 'anti-lag3 will impact', 'will impact nsclc', 'impact nsclc survival', 'nsclc survival as', 'survival as in', 'as in melanoma?', 'in melanoma? no', 'melanoma? no clear', 'no clear signal', 'clear signal so', 'signal so far:', 'so far: in', 'far: in 2x30', 'in 2x30 patients', '2x30 patients with', 'patients with resectable', 'with resectable nsclc,', 'resectable nsclc, relatlimab+nivolumab', 'nsclc, relatlimab+nivolumab did', 'relatlimab+nivolumab did not', 'did not increase', 'not increase pathological', 'increase pathological response', 'pathological response compared', 'response compared to', 'compared to nivolumab', 'to nivolumab alone.', 'nivolumab alone. similar', 'alone. similar 12mo', 'similar 12mo dfs.', '12mo dfs. #esmo22po', 'dfs. #esmo22po .', 'lag3 was discovered !', 'was discovered ! anti-lag3', 'discovered ! anti-lag3 will', '! anti-lag3 will impact', 'anti-lag3 will impact nsclc', 'will impact nsclc survival', 'impact nsclc survival as', 'nsclc survival as in', 'survival as in melanoma?', 'as in melanoma? no', 'in melanoma? no clear', 'melanoma? no clear signal', 'no clear signal so', 'clear signal so far:', 'signal so far: in', 'so far: in 2x30', 'far: in 2x30 patients', 'in 2x30 patients with', '2x30 patients with resectable', 'patients with resectable nsclc,', 'with resectable nsclc, relatlimab+nivolumab', 'resectable nsclc, relatlimab+nivolumab did', 'nsclc, relatlimab+nivolumab did not', 'relatlimab+nivolumab did not increase', 'did not increase pathological', 'not increase pathological response', 'increase pathological response compared', 'pathological response compared to', 'response compared to nivolumab', 'compared to nivolumab alone.', 'to nivolumab alone. similar', 'nivolumab alone. similar 12mo', 'alone. similar 12mo dfs.', 'similar 12mo dfs. #esmo22po', '12mo dfs. #esmo22po .', 'lag3 was discovered ! anti-lag3', 'was discovered ! anti-lag3 will', 'discovered ! anti-lag3 will impact', '! anti-lag3 will impact nsclc', 'anti-lag3 will impact nsclc survival', 'will impact nsclc survival as', 'impact nsclc survival as in', 'nsclc survival as in melanoma?', 'survival as in melanoma? no', 'as in melanoma? no clear', 'in melanoma? no clear signal', 'melanoma? no clear signal so', 'no clear signal so far:', 'clear signal so far: in', 'signal so far: in 2x30', 'so far: in 2x30 patients', 'far: in 2x30 patients with', 'in 2x30 patients with resectable', '2x30 patients with resectable nsclc,', 'patients with resectable nsclc, relatlimab+nivolumab', 'with resectable nsclc, relatlimab+nivolumab did', 'resectable nsclc, relatlimab+nivolumab did not', 'nsclc, relatlimab+nivolumab did not increase', 'relatlimab+nivolumab did not increase pathological', 'did not increase pathological response', 'not increase pathological response compared', 'increase pathological response compared to', 'pathological response compared to nivolumab', 'response compared to nivolumab alone.', 'compared to nivolumab alone. similar', 'to nivolumab alone. similar 12mo', 'nivolumab alone. similar 12mo dfs.', 'alone. similar 12mo dfs. #esmo22po', 'similar 12mo dfs. #esmo22po .', 'lag3 was discovered ! anti-lag3 will', 'was discovered ! anti-lag3 will impact', 'discovered ! anti-lag3 will impact nsclc', '! anti-lag3 will impact nsclc survival', 'anti-lag3 will impact nsclc survival as', 'will impact nsclc survival as in', 'impact nsclc survival as in melanoma?', 'nsclc survival as in melanoma? no', 'survival as in melanoma? no clear', 'as in melanoma? no clear signal', 'in melanoma? no clear signal so', 'melanoma? no clear signal so far:', 'no clear signal so far: in', 'clear signal so far: in 2x30', 'signal so far: in 2x30 patients', 'so far: in 2x30 patients with', 'far: in 2x30 patients with resectable', 'in 2x30 patients with resectable nsclc,', '2x30 patients with resectable nsclc, relatlimab+nivolumab', 'patients with resectable nsclc, relatlimab+nivolumab did', 'with resectable nsclc, relatlimab+nivolumab did not', 'resectable nsclc, relatlimab+nivolumab did not increase', 'nsclc, relatlimab+nivolumab did not increase pathological', 'relatlimab+nivolumab did not increase pathological response', 'did not increase pathological response compared', 'not increase pathological response compared to', 'increase pathological response compared to nivolumab', 'pathological response compared to nivolumab alone.', 'response compared to nivolumab alone. similar', 'compared to nivolumab alone. similar 12mo', 'to nivolumab alone. similar 12mo dfs.', 'nivolumab alone. similar 12mo dfs. #esmo22po', 'alone. similar 12mo dfs. #esmo22po .', 'lag3 was discovered ! anti-lag3 will impact', 'was discovered ! anti-lag3 will impact nsclc', 'discovered ! anti-lag3 will impact nsclc survival', '! anti-lag3 will impact nsclc survival as', 'anti-lag3 will impact nsclc survival as in', 'will impact nsclc survival as in melanoma?', 'impact nsclc survival as in melanoma? no', 'nsclc survival as in melanoma? no clear', 'survival as in melanoma? no clear signal', 'as in melanoma? no clear signal so', 'in melanoma? no clear signal so far:', 'melanoma? no clear signal so far: in', 'no clear signal so far: in 2x30', 'clear signal so far: in 2x30 patients', 'signal so far: in 2x30 patients with', 'so far: in 2x30 patients with resectable', 'far: in 2x30 patients with resectable nsclc,', 'in 2x30 patients with resectable nsclc, relatlimab+nivolumab', '2x30 patients with resectable nsclc, relatlimab+nivolumab did', 'patients with resectable nsclc, relatlimab+nivolumab did not', 'with resectable nsclc, relatlimab+nivolumab did not increase', 'resectable nsclc, relatlimab+nivolumab did not increase pathological', 'nsclc, relatlimab+nivolumab did not increase pathological response', 'relatlimab+nivolumab did not increase pathological response compared', 'did not increase pathological response compared to', 'not increase pathological response compared to nivolumab', 'increase pathological response compared to nivolumab alone.', 'pathological response compared to nivolumab alone. similar', 'response compared to nivolumab alone. similar 12mo', 'compared to nivolumab alone. similar 12mo dfs.', 'to nivolumab alone. similar 12mo dfs. #esmo22po', 'nivolumab alone. similar 12mo dfs. #esmo22po .', 'lag3 was discovered ! anti-lag3 will impact nsclc', 'was discovered ! anti-lag3 will impact nsclc survival', 'discovered ! anti-lag3 will impact nsclc survival as', '! anti-lag3 will impact nsclc survival as in', 'anti-lag3 will impact nsclc survival as in melanoma?', 'will impact nsclc survival as in melanoma? no', 'impact nsclc survival as in melanoma? no clear', 'nsclc survival as in melanoma? no clear signal', 'survival as in melanoma? no clear signal so', 'as in melanoma? no clear signal so far:', 'in melanoma? no clear signal so far: in', 'melanoma? no clear signal so far: in 2x30', 'no clear signal so far: in 2x30 patients', 'clear signal so far: in 2x30 patients with', 'signal so far: in 2x30 patients with resectable', 'so far: in 2x30 patients with resectable nsclc,', 'far: in 2x30 patients with resectable nsclc, relatlimab+nivolumab', 'in 2x30 patients with resectable nsclc, relatlimab+nivolumab did', '2x30 patients with resectable nsclc, relatlimab+nivolumab did not', 'patients with resectable nsclc, relatlimab+nivolumab did not increase', 'with resectable nsclc, relatlimab+nivolumab did not increase pathological', 'resectable nsclc, relatlimab+nivolumab did not increase pathological response', 'nsclc, relatlimab+nivolumab did not increase pathological response compared', 'relatlimab+nivolumab did not increase pathological response compared to', 'did not increase pathological response compared to nivolumab', 'not increase pathological response compared to nivolumab alone.', 'increase pathological response compared to nivolumab alone. similar', 'pathological response compared to nivolumab alone. similar 12mo', 'response compared to nivolumab alone. similar 12mo dfs.', 'compared to nivolumab alone. similar 12mo dfs. #esmo22po', 'to nivolumab alone. similar 12mo dfs. #esmo22po .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '12', 'tokens': ['platform-b', 'study:', 'patients', 'with', 'early', 'molecular', 'response', 'have', 'better', 'response', '(77.5%', 'vs.', '25%,', 'p=0.008)', 'and', 'longer', 'pfs', '(hr=0.18,', 'p&lt;0.001)', 'compared', 'to', 'transform', 'trial.', '#ttdupdates', '#crc', '(3/3)', '', '.'], 'text_length': 28, 'triples': {'platform-b|response have better response (77.5% vs. 25%, p=0.008) and longer pfs': ([0, 0], [6, 16], 'positive'), 'transform|response have better response (77.5% vs. 25%, p=0.008) and longer pfs (hr=0.18, p&lt;0.001) compared to': ([21, 21], [6, 20], 'negative')}, 'sentence': 'platform-b study: patients with early molecular response have better response (77.5% vs. 25%, p=0.008) and longer pfs (hr=0.18, p&lt;0.001) compared to transform trial. #ttdupdates #crc (3/3)  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (21, 21)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(6, 16), (6, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8)], 'span tokens': ['platform-b', 'study:', 'patients', 'with', 'early', 'molecular', 'response', 'have', 'better', 'response', '(77.5%', 'vs.', '25%,', 'p=0.008)', 'and', 'longer', 'pfs', '(hr=0.18,', 'p&lt;0.001)', 'compared', 'to', 'transform', 'trial.', '#ttdupdates', '#crc', '(3/3)', '', '.', 'platform-b study:', 'study: patients', 'patients with', 'with early', 'early molecular', 'molecular response', 'response have', 'have better', 'better response', 'response (77.5%', '(77.5% vs.', 'vs. 25%,', '25%, p=0.008)', 'p=0.008) and', 'and longer', 'longer pfs', 'pfs (hr=0.18,', '(hr=0.18, p&lt;0.001)', 'p&lt;0.001) compared', 'compared to', 'to transform', 'transform trial.', 'trial. #ttdupdates', '#ttdupdates #crc', '#crc (3/3)', '(3/3) ', ' .', 'platform-b study: patients', 'study: patients with', 'patients with early', 'with early molecular', 'early molecular response', 'molecular response have', 'response have better', 'have better response', 'better response (77.5%', 'response (77.5% vs.', '(77.5% vs. 25%,', 'vs. 25%, p=0.008)', '25%, p=0.008) and', 'p=0.008) and longer', 'and longer pfs', 'longer pfs (hr=0.18,', 'pfs (hr=0.18, p&lt;0.001)', '(hr=0.18, p&lt;0.001) compared', 'p&lt;0.001) compared to', 'compared to transform', 'to transform trial.', 'transform trial. #ttdupdates', 'trial. #ttdupdates #crc', '#ttdupdates #crc (3/3)', '#crc (3/3) ', '(3/3)  .', 'platform-b study: patients with', 'study: patients with early', 'patients with early molecular', 'with early molecular response', 'early molecular response have', 'molecular response have better', 'response have better response', 'have better response (77.5%', 'better response (77.5% vs.', 'response (77.5% vs. 25%,', '(77.5% vs. 25%, p=0.008)', 'vs. 25%, p=0.008) and', '25%, p=0.008) and longer', 'p=0.008) and longer pfs', 'and longer pfs (hr=0.18,', 'longer pfs (hr=0.18, p&lt;0.001)', 'pfs (hr=0.18, p&lt;0.001) compared', '(hr=0.18, p&lt;0.001) compared to', 'p&lt;0.001) compared to transform', 'compared to transform trial.', 'to transform trial. #ttdupdates', 'transform trial. #ttdupdates #crc', 'trial. #ttdupdates #crc (3/3)', '#ttdupdates #crc (3/3) ', '#crc (3/3)  .', 'platform-b study: patients with early', 'study: patients with early molecular', 'patients with early molecular response', 'with early molecular response have', 'early molecular response have better', 'molecular response have better response', 'response have better response (77.5%', 'have better response (77.5% vs.', 'better response (77.5% vs. 25%,', 'response (77.5% vs. 25%, p=0.008)', '(77.5% vs. 25%, p=0.008) and', 'vs. 25%, p=0.008) and longer', '25%, p=0.008) and longer pfs', 'p=0.008) and longer pfs (hr=0.18,', 'and longer pfs (hr=0.18, p&lt;0.001)', 'longer pfs (hr=0.18, p&lt;0.001) compared', 'pfs (hr=0.18, p&lt;0.001) compared to', '(hr=0.18, p&lt;0.001) compared to transform', 'p&lt;0.001) compared to transform trial.', 'compared to transform trial. #ttdupdates', 'to transform trial. #ttdupdates #crc', 'transform trial. #ttdupdates #crc (3/3)', 'trial. #ttdupdates #crc (3/3) ', '#ttdupdates #crc (3/3)  .', 'platform-b study: patients with early molecular', 'study: patients with early molecular response', 'patients with early molecular response have', 'with early molecular response have better', 'early molecular response have better response', 'molecular response have better response (77.5%', 'response have better response (77.5% vs.', 'have better response (77.5% vs. 25%,', 'better response (77.5% vs. 25%, p=0.008)', 'response (77.5% vs. 25%, p=0.008) and', '(77.5% vs. 25%, p=0.008) and longer', 'vs. 25%, p=0.008) and longer pfs', '25%, p=0.008) and longer pfs (hr=0.18,', 'p=0.008) and longer pfs (hr=0.18, p&lt;0.001)', 'and longer pfs (hr=0.18, p&lt;0.001) compared', 'longer pfs (hr=0.18, p&lt;0.001) compared to', 'pfs (hr=0.18, p&lt;0.001) compared to transform', '(hr=0.18, p&lt;0.001) compared to transform trial.', 'p&lt;0.001) compared to transform trial. #ttdupdates', 'compared to transform trial. #ttdupdates #crc', 'to transform trial. #ttdupdates #crc (3/3)', 'transform trial. #ttdupdates #crc (3/3) ', 'trial. #ttdupdates #crc (3/3)  .', 'platform-b study: patients with early molecular response', 'study: patients with early molecular response have', 'patients with early molecular response have better', 'with early molecular response have better response', 'early molecular response have better response (77.5%', 'molecular response have better response (77.5% vs.', 'response have better response (77.5% vs. 25%,', 'have better response (77.5% vs. 25%, p=0.008)', 'better response (77.5% vs. 25%, p=0.008) and', 'response (77.5% vs. 25%, p=0.008) and longer', '(77.5% vs. 25%, p=0.008) and longer pfs', 'vs. 25%, p=0.008) and longer pfs (hr=0.18,', '25%, p=0.008) and longer pfs (hr=0.18, p&lt;0.001)', 'p=0.008) and longer pfs (hr=0.18, p&lt;0.001) compared', 'and longer pfs (hr=0.18, p&lt;0.001) compared to', 'longer pfs (hr=0.18, p&lt;0.001) compared to transform', 'pfs (hr=0.18, p&lt;0.001) compared to transform trial.', '(hr=0.18, p&lt;0.001) compared to transform trial. #ttdupdates', 'p&lt;0.001) compared to transform trial. #ttdupdates #crc', 'compared to transform trial. #ttdupdates #crc (3/3)', 'to transform trial. #ttdupdates #crc (3/3) ', 'transform trial. #ttdupdates #crc (3/3)  .', 'platform-b study: patients with early molecular response have', 'study: patients with early molecular response have better', 'patients with early molecular response have better response', 'with early molecular response have better response (77.5%', 'early molecular response have better response (77.5% vs.', 'molecular response have better response (77.5% vs. 25%,', 'response have better response (77.5% vs. 25%, p=0.008)', 'have better response (77.5% vs. 25%, p=0.008) and', 'better response (77.5% vs. 25%, p=0.008) and longer', 'response (77.5% vs. 25%, p=0.008) and longer pfs', '(77.5% vs. 25%, p=0.008) and longer pfs (hr=0.18,', 'vs. 25%, p=0.008) and longer pfs (hr=0.18, p&lt;0.001)', '25%, p=0.008) and longer pfs (hr=0.18, p&lt;0.001) compared', 'p=0.008) and longer pfs (hr=0.18, p&lt;0.001) compared to', 'and longer pfs (hr=0.18, p&lt;0.001) compared to transform', 'longer pfs (hr=0.18, p&lt;0.001) compared to transform trial.', 'pfs (hr=0.18, p&lt;0.001) compared to transform trial. #ttdupdates', '(hr=0.18, p&lt;0.001) compared to transform trial. #ttdupdates #crc', 'p&lt;0.001) compared to transform trial. #ttdupdates #crc (3/3)', 'compared to transform trial. #ttdupdates #crc (3/3) ', 'to transform trial. #ttdupdates #crc (3/3)  .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '13', 'tokens': ['Brown', 'shows', 'superiority', 'in', 'PFS', 'and', 'safety', 'for', 'Zanubrutinib', 'over', 'ibrutinib', 'in', 'R/R', 'BTKi', 'naive', 'CLL.', 'Benefit', 'in', 'TP53', 'mutated', 'disease,', 'less', 'AF', 'and', 'serious', 'cardiac', 'events.', '#CLLsm', '#ASH22', 'late', 'breaking', 'session', '.'], 'text_length': 33, 'triples': {'ibrutinib|shows superiority in PFS and safety for Zanubrutinib over': ([10, 10], [1, 9], 'negative'), 'Zanubrutinib|shows superiority in PFS and safety': ([8, 8], [1, 6], 'positive')}, 'sentence': 'Brown shows superiority in PFS and safety for Zanubrutinib over ibrutinib in R/R BTKi naive CLL. Benefit in TP53 mutated disease, less AF and serious cardiac events. #CLLsm #ASH22 late breaking session .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(10, 10), (8, 8)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(1, 9), (1, 6)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['Brown', 'shows', 'superiority', 'in', 'PFS', 'and', 'safety', 'for', 'Zanubrutinib', 'over', 'ibrutinib', 'in', 'R/R', 'BTKi', 'naive', 'CLL.', 'Benefit', 'in', 'TP53', 'mutated', 'disease,', 'less', 'AF', 'and', 'serious', 'cardiac', 'events.', '#CLLsm', '#ASH22', 'late', 'breaking', 'session', '.', 'Brown shows', 'shows superiority', 'superiority in', 'in PFS', 'PFS and', 'and safety', 'safety for', 'for Zanubrutinib', 'Zanubrutinib over', 'over ibrutinib', 'ibrutinib in', 'in R/R', 'R/R BTKi', 'BTKi naive', 'naive CLL.', 'CLL. Benefit', 'Benefit in', 'in TP53', 'TP53 mutated', 'mutated disease,', 'disease, less', 'less AF', 'AF and', 'and serious', 'serious cardiac', 'cardiac events.', 'events. #CLLsm', '#CLLsm #ASH22', '#ASH22 late', 'late breaking', 'breaking session', 'session .', 'Brown shows superiority', 'shows superiority in', 'superiority in PFS', 'in PFS and', 'PFS and safety', 'and safety for', 'safety for Zanubrutinib', 'for Zanubrutinib over', 'Zanubrutinib over ibrutinib', 'over ibrutinib in', 'ibrutinib in R/R', 'in R/R BTKi', 'R/R BTKi naive', 'BTKi naive CLL.', 'naive CLL. Benefit', 'CLL. Benefit in', 'Benefit in TP53', 'in TP53 mutated', 'TP53 mutated disease,', 'mutated disease, less', 'disease, less AF', 'less AF and', 'AF and serious', 'and serious cardiac', 'serious cardiac events.', 'cardiac events. #CLLsm', 'events. #CLLsm #ASH22', '#CLLsm #ASH22 late', '#ASH22 late breaking', 'late breaking session', 'breaking session .', 'Brown shows superiority in', 'shows superiority in PFS', 'superiority in PFS and', 'in PFS and safety', 'PFS and safety for', 'and safety for Zanubrutinib', 'safety for Zanubrutinib over', 'for Zanubrutinib over ibrutinib', 'Zanubrutinib over ibrutinib in', 'over ibrutinib in R/R', 'ibrutinib in R/R BTKi', 'in R/R BTKi naive', 'R/R BTKi naive CLL.', 'BTKi naive CLL. Benefit', 'naive CLL. Benefit in', 'CLL. Benefit in TP53', 'Benefit in TP53 mutated', 'in TP53 mutated disease,', 'TP53 mutated disease, less', 'mutated disease, less AF', 'disease, less AF and', 'less AF and serious', 'AF and serious cardiac', 'and serious cardiac events.', 'serious cardiac events. #CLLsm', 'cardiac events. #CLLsm #ASH22', 'events. #CLLsm #ASH22 late', '#CLLsm #ASH22 late breaking', '#ASH22 late breaking session', 'late breaking session .', 'Brown shows superiority in PFS', 'shows superiority in PFS and', 'superiority in PFS and safety', 'in PFS and safety for', 'PFS and safety for Zanubrutinib', 'and safety for Zanubrutinib over', 'safety for Zanubrutinib over ibrutinib', 'for Zanubrutinib over ibrutinib in', 'Zanubrutinib over ibrutinib in R/R', 'over ibrutinib in R/R BTKi', 'ibrutinib in R/R BTKi naive', 'in R/R BTKi naive CLL.', 'R/R BTKi naive CLL. Benefit', 'BTKi naive CLL. Benefit in', 'naive CLL. Benefit in TP53', 'CLL. Benefit in TP53 mutated', 'Benefit in TP53 mutated disease,', 'in TP53 mutated disease, less', 'TP53 mutated disease, less AF', 'mutated disease, less AF and', 'disease, less AF and serious', 'less AF and serious cardiac', 'AF and serious cardiac events.', 'and serious cardiac events. #CLLsm', 'serious cardiac events. #CLLsm #ASH22', 'cardiac events. #CLLsm #ASH22 late', 'events. #CLLsm #ASH22 late breaking', '#CLLsm #ASH22 late breaking session', '#ASH22 late breaking session .', 'Brown shows superiority in PFS and', 'shows superiority in PFS and safety', 'superiority in PFS and safety for', 'in PFS and safety for Zanubrutinib', 'PFS and safety for Zanubrutinib over', 'and safety for Zanubrutinib over ibrutinib', 'safety for Zanubrutinib over ibrutinib in', 'for Zanubrutinib over ibrutinib in R/R', 'Zanubrutinib over ibrutinib in R/R BTKi', 'over ibrutinib in R/R BTKi naive', 'ibrutinib in R/R BTKi naive CLL.', 'in R/R BTKi naive CLL. Benefit', 'R/R BTKi naive CLL. Benefit in', 'BTKi naive CLL. Benefit in TP53', 'naive CLL. Benefit in TP53 mutated', 'CLL. Benefit in TP53 mutated disease,', 'Benefit in TP53 mutated disease, less', 'in TP53 mutated disease, less AF', 'TP53 mutated disease, less AF and', 'mutated disease, less AF and serious', 'disease, less AF and serious cardiac', 'less AF and serious cardiac events.', 'AF and serious cardiac events. #CLLsm', 'and serious cardiac events. #CLLsm #ASH22', 'serious cardiac events. #CLLsm #ASH22 late', 'cardiac events. #CLLsm #ASH22 late breaking', 'events. #CLLsm #ASH22 late breaking session', '#CLLsm #ASH22 late breaking session .', 'Brown shows superiority in PFS and safety', 'shows superiority in PFS and safety for', 'superiority in PFS and safety for Zanubrutinib', 'in PFS and safety for Zanubrutinib over', 'PFS and safety for Zanubrutinib over ibrutinib', 'and safety for Zanubrutinib over ibrutinib in', 'safety for Zanubrutinib over ibrutinib in R/R', 'for Zanubrutinib over ibrutinib in R/R BTKi', 'Zanubrutinib over ibrutinib in R/R BTKi naive', 'over ibrutinib in R/R BTKi naive CLL.', 'ibrutinib in R/R BTKi naive CLL. Benefit', 'in R/R BTKi naive CLL. Benefit in', 'R/R BTKi naive CLL. Benefit in TP53', 'BTKi naive CLL. Benefit in TP53 mutated', 'naive CLL. Benefit in TP53 mutated disease,', 'CLL. Benefit in TP53 mutated disease, less', 'Benefit in TP53 mutated disease, less AF', 'in TP53 mutated disease, less AF and', 'TP53 mutated disease, less AF and serious', 'mutated disease, less AF and serious cardiac', 'disease, less AF and serious cardiac events.', 'less AF and serious cardiac events. #CLLsm', 'AF and serious cardiac events. #CLLsm #ASH22', 'and serious cardiac events. #CLLsm #ASH22 late', 'serious cardiac events. #CLLsm #ASH22 late breaking', 'cardiac events. #CLLsm #ASH22 late breaking session', 'events. #CLLsm #ASH22 late breaking session .', 'Brown shows superiority in PFS and safety for', 'shows superiority in PFS and safety for Zanubrutinib', 'superiority in PFS and safety for Zanubrutinib over', 'in PFS and safety for Zanubrutinib over ibrutinib', 'PFS and safety for Zanubrutinib over ibrutinib in', 'and safety for Zanubrutinib over ibrutinib in R/R', 'safety for Zanubrutinib over ibrutinib in R/R BTKi', 'for Zanubrutinib over ibrutinib in R/R BTKi naive', 'Zanubrutinib over ibrutinib in R/R BTKi naive CLL.', 'over ibrutinib in R/R BTKi naive CLL. Benefit', 'ibrutinib in R/R BTKi naive CLL. Benefit in', 'in R/R BTKi naive CLL. Benefit in TP53', 'R/R BTKi naive CLL. Benefit in TP53 mutated', 'BTKi naive CLL. Benefit in TP53 mutated disease,', 'naive CLL. Benefit in TP53 mutated disease, less', 'CLL. Benefit in TP53 mutated disease, less AF', 'Benefit in TP53 mutated disease, less AF and', 'in TP53 mutated disease, less AF and serious', 'TP53 mutated disease, less AF and serious cardiac', 'mutated disease, less AF and serious cardiac events.', 'disease, less AF and serious cardiac events. #CLLsm', 'less AF and serious cardiac events. #CLLsm #ASH22', 'AF and serious cardiac events. #CLLsm #ASH22 late', 'and serious cardiac events. #CLLsm #ASH22 late breaking', 'serious cardiac events. #CLLsm #ASH22 late breaking session', 'cardiac events. #CLLsm #ASH22 late breaking session .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '14', 'tokens': ['#ASH22', '#LBA', 'Dr', 'Jennifer', 'Brown', '&amp;', '', '#Zanubrutinib', 'or', '#Ibrutinib', 'in', 'Relapsed', 'or', 'Refractory', 'Chronic', 'Lymphocytic', 'Leukemia', '.'], 'text_length': 18, 'triples': {'#Ibrutinib|Relapsed or Refractory': ([8, 8], [10, 12], 'neutral'), '#Zanubrutinib|Relapsed or Refractory': ([6, 6], [10, 12], 'neutral')}, 'sentence': '#ASH22 #LBA Dr Jennifer Brown &amp;  #Zanubrutinib or #Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(8, 8), (6, 6)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8)], 'span tokens': ['#ASH22', '#LBA', 'Dr', 'Jennifer', 'Brown', '&amp;', '', '#Zanubrutinib', 'or', '#Ibrutinib', 'in', 'Relapsed', 'or', 'Refractory', 'Chronic', 'Lymphocytic', 'Leukemia', '.', '#ASH22 #LBA', '#LBA Dr', 'Dr Jennifer', 'Jennifer Brown', 'Brown &amp;', '&amp; ', ' #Zanubrutinib', '#Zanubrutinib or', 'or #Ibrutinib', '#Ibrutinib in', 'in Relapsed', 'Relapsed or', 'or Refractory', 'Refractory Chronic', 'Chronic Lymphocytic', 'Lymphocytic Leukemia', 'Leukemia .', '#ASH22 #LBA Dr', '#LBA Dr Jennifer', 'Dr Jennifer Brown', 'Jennifer Brown &amp;', 'Brown &amp; ', '&amp;  #Zanubrutinib', ' #Zanubrutinib or', '#Zanubrutinib or #Ibrutinib', 'or #Ibrutinib in', '#Ibrutinib in Relapsed', 'in Relapsed or', 'Relapsed or Refractory', 'or Refractory Chronic', 'Refractory Chronic Lymphocytic', 'Chronic Lymphocytic Leukemia', 'Lymphocytic Leukemia .', '#ASH22 #LBA Dr Jennifer', '#LBA Dr Jennifer Brown', 'Dr Jennifer Brown &amp;', 'Jennifer Brown &amp; ', 'Brown &amp;  #Zanubrutinib', '&amp;  #Zanubrutinib or', ' #Zanubrutinib or #Ibrutinib', '#Zanubrutinib or #Ibrutinib in', 'or #Ibrutinib in Relapsed', '#Ibrutinib in Relapsed or', 'in Relapsed or Refractory', 'Relapsed or Refractory Chronic', 'or Refractory Chronic Lymphocytic', 'Refractory Chronic Lymphocytic Leukemia', 'Chronic Lymphocytic Leukemia .', '#ASH22 #LBA Dr Jennifer Brown', '#LBA Dr Jennifer Brown &amp;', 'Dr Jennifer Brown &amp; ', 'Jennifer Brown &amp;  #Zanubrutinib', 'Brown &amp;  #Zanubrutinib or', '&amp;  #Zanubrutinib or #Ibrutinib', ' #Zanubrutinib or #Ibrutinib in', '#Zanubrutinib or #Ibrutinib in Relapsed', 'or #Ibrutinib in Relapsed or', '#Ibrutinib in Relapsed or Refractory', 'in Relapsed or Refractory Chronic', 'Relapsed or Refractory Chronic Lymphocytic', 'or Refractory Chronic Lymphocytic Leukemia', 'Refractory Chronic Lymphocytic Leukemia .', '#ASH22 #LBA Dr Jennifer Brown &amp;', '#LBA Dr Jennifer Brown &amp; ', 'Dr Jennifer Brown &amp;  #Zanubrutinib', 'Jennifer Brown &amp;  #Zanubrutinib or', 'Brown &amp;  #Zanubrutinib or #Ibrutinib', '&amp;  #Zanubrutinib or #Ibrutinib in', ' #Zanubrutinib or #Ibrutinib in Relapsed', '#Zanubrutinib or #Ibrutinib in Relapsed or', 'or #Ibrutinib in Relapsed or Refractory', '#Ibrutinib in Relapsed or Refractory Chronic', 'in Relapsed or Refractory Chronic Lymphocytic', 'Relapsed or Refractory Chronic Lymphocytic Leukemia', 'or Refractory Chronic Lymphocytic Leukemia .', '#ASH22 #LBA Dr Jennifer Brown &amp; ', '#LBA Dr Jennifer Brown &amp;  #Zanubrutinib', 'Dr Jennifer Brown &amp;  #Zanubrutinib or', 'Jennifer Brown &amp;  #Zanubrutinib or #Ibrutinib', 'Brown &amp;  #Zanubrutinib or #Ibrutinib in', '&amp;  #Zanubrutinib or #Ibrutinib in Relapsed', ' #Zanubrutinib or #Ibrutinib in Relapsed or', '#Zanubrutinib or #Ibrutinib in Relapsed or Refractory', 'or #Ibrutinib in Relapsed or Refractory Chronic', '#Ibrutinib in Relapsed or Refractory Chronic Lymphocytic', 'in Relapsed or Refractory Chronic Lymphocytic Leukemia', 'Relapsed or Refractory Chronic Lymphocytic Leukemia .', '#ASH22 #LBA Dr Jennifer Brown &amp;  #Zanubrutinib', '#LBA Dr Jennifer Brown &amp;  #Zanubrutinib or', 'Dr Jennifer Brown &amp;  #Zanubrutinib or #Ibrutinib', 'Jennifer Brown &amp;  #Zanubrutinib or #Ibrutinib in', 'Brown &amp;  #Zanubrutinib or #Ibrutinib in Relapsed', '&amp;  #Zanubrutinib or #Ibrutinib in Relapsed or', ' #Zanubrutinib or #Ibrutinib in Relapsed or Refractory', '#Zanubrutinib or #Ibrutinib in Relapsed or Refractory Chronic', 'or #Ibrutinib in Relapsed or Refractory Chronic Lymphocytic', '#Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia', 'in Relapsed or Refractory Chronic Lymphocytic Leukemia .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 3, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '15', 'tokens': ['A', '2nd-generation', 'drug,', 'zanubrutinib,', 'is', 'about', 'to', 'unseat', 'ibrutinib', 'as', 'the', 'king', 'on', 'the', 'block', 'for', 'chronic', 'lymphocytic', 'leukemia', 'treatment,', 'said', 'Catherine', 'Diefenbach,', 'from', '.', '"This', 'is', 'sort', 'of', 'the', 'end', 'of', 'ibrutinib."', '', '.'], 'text_length': 35, 'triples': {'ibrutinib as the king on the block for chronic lymphocytic leukemia treatment, said Catherine Diefenbach, from . "This is sort of the end of|unseat ibrutinib as the king on the block for chronic lymphocytic leukemia treatment, said Catherine Diefenbach, from . "This is sort of the end': ([8, 31], [7, 30], 'negative'), 'zanubrutinib,|unseat': ([3, 3], [7, 7], 'positive')}, 'sentence': 'A 2nd-generation drug, zanubrutinib, is about to unseat ibrutinib as the king on the block for chronic lymphocytic leukemia treatment, said Catherine Diefenbach, from . "This is sort of the end of ibrutinib."  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(8, 31), (3, 3)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(7, 30), (7, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['A', '2nd-generation', 'drug,', 'zanubrutinib,', 'is', 'about', 'to', 'unseat', 'ibrutinib', 'as', 'the', 'king', 'on', 'the', 'block', 'for', 'chronic', 'lymphocytic', 'leukemia', 'treatment,', 'said', 'Catherine', 'Diefenbach,', 'from', '.', '"This', 'is', 'sort', 'of', 'the', 'end', 'of', 'ibrutinib."', '', '.', 'A 2nd-generation', '2nd-generation drug,', 'drug, zanubrutinib,', 'zanubrutinib, is', 'is about', 'about to', 'to unseat', 'unseat ibrutinib', 'ibrutinib as', 'as the', 'the king', 'king on', 'on the', 'the block', 'block for', 'for chronic', 'chronic lymphocytic', 'lymphocytic leukemia', 'leukemia treatment,', 'treatment, said', 'said Catherine', 'Catherine Diefenbach,', 'Diefenbach, from', 'from .', '. "This', '"This is', 'is sort', 'sort of', 'of the', 'the end', 'end of', 'of ibrutinib."', 'ibrutinib." ', ' .', 'A 2nd-generation drug,', '2nd-generation drug, zanubrutinib,', 'drug, zanubrutinib, is', 'zanubrutinib, is about', 'is about to', 'about to unseat', 'to unseat ibrutinib', 'unseat ibrutinib as', 'ibrutinib as the', 'as the king', 'the king on', 'king on the', 'on the block', 'the block for', 'block for chronic', 'for chronic lymphocytic', 'chronic lymphocytic leukemia', 'lymphocytic leukemia treatment,', 'leukemia treatment, said', 'treatment, said Catherine', 'said Catherine Diefenbach,', 'Catherine Diefenbach, from', 'Diefenbach, from .', 'from . "This', '. "This is', '"This is sort', 'is sort of', 'sort of the', 'of the end', 'the end of', 'end of ibrutinib."', 'of ibrutinib." ', 'ibrutinib."  .', 'A 2nd-generation drug, zanubrutinib,', '2nd-generation drug, zanubrutinib, is', 'drug, zanubrutinib, is about', 'zanubrutinib, is about to', 'is about to unseat', 'about to unseat ibrutinib', 'to unseat ibrutinib as', 'unseat ibrutinib as the', 'ibrutinib as the king', 'as the king on', 'the king on the', 'king on the block', 'on the block for', 'the block for chronic', 'block for chronic lymphocytic', 'for chronic lymphocytic leukemia', 'chronic lymphocytic leukemia treatment,', 'lymphocytic leukemia treatment, said', 'leukemia treatment, said Catherine', 'treatment, said Catherine Diefenbach,', 'said Catherine Diefenbach, from', 'Catherine Diefenbach, from .', 'Diefenbach, from . "This', 'from . "This is', '. "This is sort', '"This is sort of', 'is sort of the', 'sort of the end', 'of the end of', 'the end of ibrutinib."', 'end of ibrutinib." ', 'of ibrutinib."  .', 'A 2nd-generation drug, zanubrutinib, is', '2nd-generation drug, zanubrutinib, is about', 'drug, zanubrutinib, is about to', 'zanubrutinib, is about to unseat', 'is about to unseat ibrutinib', 'about to unseat ibrutinib as', 'to unseat ibrutinib as the', 'unseat ibrutinib as the king', 'ibrutinib as the king on', 'as the king on the', 'the king on the block', 'king on the block for', 'on the block for chronic', 'the block for chronic lymphocytic', 'block for chronic lymphocytic leukemia', 'for chronic lymphocytic leukemia treatment,', 'chronic lymphocytic leukemia treatment, said', 'lymphocytic leukemia treatment, said Catherine', 'leukemia treatment, said Catherine Diefenbach,', 'treatment, said Catherine Diefenbach, from', 'said Catherine Diefenbach, from .', 'Catherine Diefenbach, from . "This', 'Diefenbach, from . "This is', 'from . "This is sort', '. "This is sort of', '"This is sort of the', 'is sort of the end', 'sort of the end of', 'of the end of ibrutinib."', 'the end of ibrutinib." ', 'end of ibrutinib."  .', 'A 2nd-generation drug, zanubrutinib, is about', '2nd-generation drug, zanubrutinib, is about to', 'drug, zanubrutinib, is about to unseat', 'zanubrutinib, is about to unseat ibrutinib', 'is about to unseat ibrutinib as', 'about to unseat ibrutinib as the', 'to unseat ibrutinib as the king', 'unseat ibrutinib as the king on', 'ibrutinib as the king on the', 'as the king on the block', 'the king on the block for', 'king on the block for chronic', 'on the block for chronic lymphocytic', 'the block for chronic lymphocytic leukemia', 'block for chronic lymphocytic leukemia treatment,', 'for chronic lymphocytic leukemia treatment, said', 'chronic lymphocytic leukemia treatment, said Catherine', 'lymphocytic leukemia treatment, said Catherine Diefenbach,', 'leukemia treatment, said Catherine Diefenbach, from', 'treatment, said Catherine Diefenbach, from .', 'said Catherine Diefenbach, from . "This', 'Catherine Diefenbach, from . "This is', 'Diefenbach, from . "This is sort', 'from . "This is sort of', '. "This is sort of the', '"This is sort of the end', 'is sort of the end of', 'sort of the end of ibrutinib."', 'of the end of ibrutinib." ', 'the end of ibrutinib."  .', 'A 2nd-generation drug, zanubrutinib, is about to', '2nd-generation drug, zanubrutinib, is about to unseat', 'drug, zanubrutinib, is about to unseat ibrutinib', 'zanubrutinib, is about to unseat ibrutinib as', 'is about to unseat ibrutinib as the', 'about to unseat ibrutinib as the king', 'to unseat ibrutinib as the king on', 'unseat ibrutinib as the king on the', 'ibrutinib as the king on the block', 'as the king on the block for', 'the king on the block for chronic', 'king on the block for chronic lymphocytic', 'on the block for chronic lymphocytic leukemia', 'the block for chronic lymphocytic leukemia treatment,', 'block for chronic lymphocytic leukemia treatment, said', 'for chronic lymphocytic leukemia treatment, said Catherine', 'chronic lymphocytic leukemia treatment, said Catherine Diefenbach,', 'lymphocytic leukemia treatment, said Catherine Diefenbach, from', 'leukemia treatment, said Catherine Diefenbach, from .', 'treatment, said Catherine Diefenbach, from . "This', 'said Catherine Diefenbach, from . "This is', 'Catherine Diefenbach, from . "This is sort', 'Diefenbach, from . "This is sort of', 'from . "This is sort of the', '. "This is sort of the end', '"This is sort of the end of', 'is sort of the end of ibrutinib."', 'sort of the end of ibrutinib." ', 'of the end of ibrutinib."  .', 'A 2nd-generation drug, zanubrutinib, is about to unseat', '2nd-generation drug, zanubrutinib, is about to unseat ibrutinib', 'drug, zanubrutinib, is about to unseat ibrutinib as', 'zanubrutinib, is about to unseat ibrutinib as the', 'is about to unseat ibrutinib as the king', 'about to unseat ibrutinib as the king on', 'to unseat ibrutinib as the king on the', 'unseat ibrutinib as the king on the block', 'ibrutinib as the king on the block for', 'as the king on the block for chronic', 'the king on the block for chronic lymphocytic', 'king on the block for chronic lymphocytic leukemia', 'on the block for chronic lymphocytic leukemia treatment,', 'the block for chronic lymphocytic leukemia treatment, said', 'block for chronic lymphocytic leukemia treatment, said Catherine', 'for chronic lymphocytic leukemia treatment, said Catherine Diefenbach,', 'chronic lymphocytic leukemia treatment, said Catherine Diefenbach, from', 'lymphocytic leukemia treatment, said Catherine Diefenbach, from .', 'leukemia treatment, said Catherine Diefenbach, from . "This', 'treatment, said Catherine Diefenbach, from . "This is', 'said Catherine Diefenbach, from . "This is sort', 'Catherine Diefenbach, from . "This is sort of', 'Diefenbach, from . "This is sort of the', 'from . "This is sort of the end', '. "This is sort of the end of', '"This is sort of the end of ibrutinib."', 'is sort of the end of ibrutinib." ', 'sort of the end of ibrutinib."  .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '16', 'tokens': ['Because', 'of', 'the', 'original', 'design,', '(non-inferiority', 'powered', 'to', 'response', 'rates)', 'and', 'attrition', 'on', 'Ibrutinib', 'arm,', 'I', 'think', 'what', 'convinces', 'me', 'the', 'most', 'is', 'the', 'safety', 'profile.', '.'], 'text_length': 27, 'triples': {'Ibrutinib|convinces me the most is the safety': ([13, 13], [18, 24], 'neutral')}, 'sentence': 'Because of the original design, (non-inferiority powered to response rates) and attrition on Ibrutinib arm, I think what convinces me the most is the safety profile. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(13, 13)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(18, 24)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8)], 'span tokens': ['Because', 'of', 'the', 'original', 'design,', '(non-inferiority', 'powered', 'to', 'response', 'rates)', 'and', 'attrition', 'on', 'Ibrutinib', 'arm,', 'I', 'think', 'what', 'convinces', 'me', 'the', 'most', 'is', 'the', 'safety', 'profile.', '.', 'Because of', 'of the', 'the original', 'original design,', 'design, (non-inferiority', '(non-inferiority powered', 'powered to', 'to response', 'response rates)', 'rates) and', 'and attrition', 'attrition on', 'on Ibrutinib', 'Ibrutinib arm,', 'arm, I', 'I think', 'think what', 'what convinces', 'convinces me', 'me the', 'the most', 'most is', 'is the', 'the safety', 'safety profile.', 'profile. .', 'Because of the', 'of the original', 'the original design,', 'original design, (non-inferiority', 'design, (non-inferiority powered', '(non-inferiority powered to', 'powered to response', 'to response rates)', 'response rates) and', 'rates) and attrition', 'and attrition on', 'attrition on Ibrutinib', 'on Ibrutinib arm,', 'Ibrutinib arm, I', 'arm, I think', 'I think what', 'think what convinces', 'what convinces me', 'convinces me the', 'me the most', 'the most is', 'most is the', 'is the safety', 'the safety profile.', 'safety profile. .', 'Because of the original', 'of the original design,', 'the original design, (non-inferiority', 'original design, (non-inferiority powered', 'design, (non-inferiority powered to', '(non-inferiority powered to response', 'powered to response rates)', 'to response rates) and', 'response rates) and attrition', 'rates) and attrition on', 'and attrition on Ibrutinib', 'attrition on Ibrutinib arm,', 'on Ibrutinib arm, I', 'Ibrutinib arm, I think', 'arm, I think what', 'I think what convinces', 'think what convinces me', 'what convinces me the', 'convinces me the most', 'me the most is', 'the most is the', 'most is the safety', 'is the safety profile.', 'the safety profile. .', 'Because of the original design,', 'of the original design, (non-inferiority', 'the original design, (non-inferiority powered', 'original design, (non-inferiority powered to', 'design, (non-inferiority powered to response', '(non-inferiority powered to response rates)', 'powered to response rates) and', 'to response rates) and attrition', 'response rates) and attrition on', 'rates) and attrition on Ibrutinib', 'and attrition on Ibrutinib arm,', 'attrition on Ibrutinib arm, I', 'on Ibrutinib arm, I think', 'Ibrutinib arm, I think what', 'arm, I think what convinces', 'I think what convinces me', 'think what convinces me the', 'what convinces me the most', 'convinces me the most is', 'me the most is the', 'the most is the safety', 'most is the safety profile.', 'is the safety profile. .', 'Because of the original design, (non-inferiority', 'of the original design, (non-inferiority powered', 'the original design, (non-inferiority powered to', 'original design, (non-inferiority powered to response', 'design, (non-inferiority powered to response rates)', '(non-inferiority powered to response rates) and', 'powered to response rates) and attrition', 'to response rates) and attrition on', 'response rates) and attrition on Ibrutinib', 'rates) and attrition on Ibrutinib arm,', 'and attrition on Ibrutinib arm, I', 'attrition on Ibrutinib arm, I think', 'on Ibrutinib arm, I think what', 'Ibrutinib arm, I think what convinces', 'arm, I think what convinces me', 'I think what convinces me the', 'think what convinces me the most', 'what convinces me the most is', 'convinces me the most is the', 'me the most is the safety', 'the most is the safety profile.', 'most is the safety profile. .', 'Because of the original design, (non-inferiority powered', 'of the original design, (non-inferiority powered to', 'the original design, (non-inferiority powered to response', 'original design, (non-inferiority powered to response rates)', 'design, (non-inferiority powered to response rates) and', '(non-inferiority powered to response rates) and attrition', 'powered to response rates) and attrition on', 'to response rates) and attrition on Ibrutinib', 'response rates) and attrition on Ibrutinib arm,', 'rates) and attrition on Ibrutinib arm, I', 'and attrition on Ibrutinib arm, I think', 'attrition on Ibrutinib arm, I think what', 'on Ibrutinib arm, I think what convinces', 'Ibrutinib arm, I think what convinces me', 'arm, I think what convinces me the', 'I think what convinces me the most', 'think what convinces me the most is', 'what convinces me the most is the', 'convinces me the most is the safety', 'me the most is the safety profile.', 'the most is the safety profile. .', 'Because of the original design, (non-inferiority powered to', 'of the original design, (non-inferiority powered to response', 'the original design, (non-inferiority powered to response rates)', 'original design, (non-inferiority powered to response rates) and', 'design, (non-inferiority powered to response rates) and attrition', '(non-inferiority powered to response rates) and attrition on', 'powered to response rates) and attrition on Ibrutinib', 'to response rates) and attrition on Ibrutinib arm,', 'response rates) and attrition on Ibrutinib arm, I', 'rates) and attrition on Ibrutinib arm, I think', 'and attrition on Ibrutinib arm, I think what', 'attrition on Ibrutinib arm, I think what convinces', 'on Ibrutinib arm, I think what convinces me', 'Ibrutinib arm, I think what convinces me the', 'arm, I think what convinces me the most', 'I think what convinces me the most is', 'think what convinces me the most is the', 'what convinces me the most is the safety', 'convinces me the most is the safety profile.', 'me the most is the safety profile. .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '17', 'tokens': ['Would', 'love', 'to', 'know:', '-', 'specific', 'reasons', 'for', 'ibrutinib', 'd/c', 'in', 'those', 'due', 'to', 'pt/dr', 'choice', '-', 'median', 'time', 'to', 'd/c', 'of', 'ibrutinib', 'vs', 'zanubrutinib', '', '', '', '', 'pts', 'for', 'reasons', 'other', 'than', 'PD', '-', 'availability/use', 'of', '2nd', 'gen', 'BTKi', '(ie', 'acala)', 'post', 'IBR', 'd/c', 'PFS', 'splits', 'v', 'early', 'for', 'low', 'risk', '(med', '1', 'prior', 'line)', 'R/R', '#CLL', 'cohort', '#ASH22', 'https://t.co/NdLwQW1uyC', '.'], 'text_length': 63, 'triples': {'zanubrutinib|love': ([24, 24], [1, 1], 'neutral'), 'ibrutinib d/c in those due to pt/dr choice - median time to d/c of ibrutinib|know:': ([8, 22], [3, 3], 'neutral')}, 'sentence': 'Would love to know: - specific reasons for ibrutinib d/c in those due to pt/dr choice - median time to d/c of ibrutinib vs zanubrutinib     pts for reasons other than PD - availability/use of 2nd gen BTKi (ie acala) post IBR d/c PFS splits v early for low risk (med 1 prior line) R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(24, 24), (8, 22)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(1, 1), (3, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (52, 52, 1), (53, 53, 1), (54, 54, 1), (55, 55, 1), (56, 56, 1), (57, 57, 1), (58, 58, 1), (59, 59, 1), (60, 60, 1), (61, 61, 1), (62, 62, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (51, 52, 2), (52, 53, 2), (53, 54, 2), (54, 55, 2), (55, 56, 2), (56, 57, 2), (57, 58, 2), (58, 59, 2), (59, 60, 2), (60, 61, 2), (61, 62, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (50, 52, 3), (51, 53, 3), (52, 54, 3), (53, 55, 3), (54, 56, 3), (55, 57, 3), (56, 58, 3), (57, 59, 3), (58, 60, 3), (59, 61, 3), (60, 62, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (49, 52, 4), (50, 53, 4), (51, 54, 4), (52, 55, 4), (53, 56, 4), (54, 57, 4), (55, 58, 4), (56, 59, 4), (57, 60, 4), (58, 61, 4), (59, 62, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (48, 52, 5), (49, 53, 5), (50, 54, 5), (51, 55, 5), (52, 56, 5), (53, 57, 5), (54, 58, 5), (55, 59, 5), (56, 60, 5), (57, 61, 5), (58, 62, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (47, 52, 6), (48, 53, 6), (49, 54, 6), (50, 55, 6), (51, 56, 6), (52, 57, 6), (53, 58, 6), (54, 59, 6), (55, 60, 6), (56, 61, 6), (57, 62, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (46, 52, 7), (47, 53, 7), (48, 54, 7), (49, 55, 7), (50, 56, 7), (51, 57, 7), (52, 58, 7), (53, 59, 7), (54, 60, 7), (55, 61, 7), (56, 62, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8), (45, 52, 8), (46, 53, 8), (47, 54, 8), (48, 55, 8), (49, 56, 8), (50, 57, 8), (51, 58, 8), (52, 59, 8), (53, 60, 8), (54, 61, 8), (55, 62, 8)], 'span tokens': ['Would', 'love', 'to', 'know:', '-', 'specific', 'reasons', 'for', 'ibrutinib', 'd/c', 'in', 'those', 'due', 'to', 'pt/dr', 'choice', '-', 'median', 'time', 'to', 'd/c', 'of', 'ibrutinib', 'vs', 'zanubrutinib', '', '', '', '', 'pts', 'for', 'reasons', 'other', 'than', 'PD', '-', 'availability/use', 'of', '2nd', 'gen', 'BTKi', '(ie', 'acala)', 'post', 'IBR', 'd/c', 'PFS', 'splits', 'v', 'early', 'for', 'low', 'risk', '(med', '1', 'prior', 'line)', 'R/R', '#CLL', 'cohort', '#ASH22', 'https://t.co/NdLwQW1uyC', '.', 'Would love', 'love to', 'to know:', 'know: -', '- specific', 'specific reasons', 'reasons for', 'for ibrutinib', 'ibrutinib d/c', 'd/c in', 'in those', 'those due', 'due to', 'to pt/dr', 'pt/dr choice', 'choice -', '- median', 'median time', 'time to', 'to d/c', 'd/c of', 'of ibrutinib', 'ibrutinib vs', 'vs zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' pts', 'pts for', 'for reasons', 'reasons other', 'other than', 'than PD', 'PD -', '- availability/use', 'availability/use of', 'of 2nd', '2nd gen', 'gen BTKi', 'BTKi (ie', '(ie acala)', 'acala) post', 'post IBR', 'IBR d/c', 'd/c PFS', 'PFS splits', 'splits v', 'v early', 'early for', 'for low', 'low risk', 'risk (med', '(med 1', '1 prior', 'prior line)', 'line) R/R', 'R/R #CLL', '#CLL cohort', 'cohort #ASH22', '#ASH22 https://t.co/NdLwQW1uyC', 'https://t.co/NdLwQW1uyC .', 'Would love to', 'love to know:', 'to know: -', 'know: - specific', '- specific reasons', 'specific reasons for', 'reasons for ibrutinib', 'for ibrutinib d/c', 'ibrutinib d/c in', 'd/c in those', 'in those due', 'those due to', 'due to pt/dr', 'to pt/dr choice', 'pt/dr choice -', 'choice - median', '- median time', 'median time to', 'time to d/c', 'to d/c of', 'd/c of ibrutinib', 'of ibrutinib vs', 'ibrutinib vs zanubrutinib', 'vs zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  pts', ' pts for', 'pts for reasons', 'for reasons other', 'reasons other than', 'other than PD', 'than PD -', 'PD - availability/use', '- availability/use of', 'availability/use of 2nd', 'of 2nd gen', '2nd gen BTKi', 'gen BTKi (ie', 'BTKi (ie acala)', '(ie acala) post', 'acala) post IBR', 'post IBR d/c', 'IBR d/c PFS', 'd/c PFS splits', 'PFS splits v', 'splits v early', 'v early for', 'early for low', 'for low risk', 'low risk (med', 'risk (med 1', '(med 1 prior', '1 prior line)', 'prior line) R/R', 'line) R/R #CLL', 'R/R #CLL cohort', '#CLL cohort #ASH22', 'cohort #ASH22 https://t.co/NdLwQW1uyC', '#ASH22 https://t.co/NdLwQW1uyC .', 'Would love to know:', 'love to know: -', 'to know: - specific', 'know: - specific reasons', '- specific reasons for', 'specific reasons for ibrutinib', 'reasons for ibrutinib d/c', 'for ibrutinib d/c in', 'ibrutinib d/c in those', 'd/c in those due', 'in those due to', 'those due to pt/dr', 'due to pt/dr choice', 'to pt/dr choice -', 'pt/dr choice - median', 'choice - median time', '- median time to', 'median time to d/c', 'time to d/c of', 'to d/c of ibrutinib', 'd/c of ibrutinib vs', 'of ibrutinib vs zanubrutinib', 'ibrutinib vs zanubrutinib ', 'vs zanubrutinib  ', 'zanubrutinib   ', '   ', '   pts', '  pts for', ' pts for reasons', 'pts for reasons other', 'for reasons other than', 'reasons other than PD', 'other than PD -', 'than PD - availability/use', 'PD - availability/use of', '- availability/use of 2nd', 'availability/use of 2nd gen', 'of 2nd gen BTKi', '2nd gen BTKi (ie', 'gen BTKi (ie acala)', 'BTKi (ie acala) post', '(ie acala) post IBR', 'acala) post IBR d/c', 'post IBR d/c PFS', 'IBR d/c PFS splits', 'd/c PFS splits v', 'PFS splits v early', 'splits v early for', 'v early for low', 'early for low risk', 'for low risk (med', 'low risk (med 1', 'risk (med 1 prior', '(med 1 prior line)', '1 prior line) R/R', 'prior line) R/R #CLL', 'line) R/R #CLL cohort', 'R/R #CLL cohort #ASH22', '#CLL cohort #ASH22 https://t.co/NdLwQW1uyC', 'cohort #ASH22 https://t.co/NdLwQW1uyC .', 'Would love to know: -', 'love to know: - specific', 'to know: - specific reasons', 'know: - specific reasons for', '- specific reasons for ibrutinib', 'specific reasons for ibrutinib d/c', 'reasons for ibrutinib d/c in', 'for ibrutinib d/c in those', 'ibrutinib d/c in those due', 'd/c in those due to', 'in those due to pt/dr', 'those due to pt/dr choice', 'due to pt/dr choice -', 'to pt/dr choice - median', 'pt/dr choice - median time', 'choice - median time to', '- median time to d/c', 'median time to d/c of', 'time to d/c of ibrutinib', 'to d/c of ibrutinib vs', 'd/c of ibrutinib vs zanubrutinib', 'of ibrutinib vs zanubrutinib ', 'ibrutinib vs zanubrutinib  ', 'vs zanubrutinib   ', 'zanubrutinib    ', '    pts', '   pts for', '  pts for reasons', ' pts for reasons other', 'pts for reasons other than', 'for reasons other than PD', 'reasons other than PD -', 'other than PD - availability/use', 'than PD - availability/use of', 'PD - availability/use of 2nd', '- availability/use of 2nd gen', 'availability/use of 2nd gen BTKi', 'of 2nd gen BTKi (ie', '2nd gen BTKi (ie acala)', 'gen BTKi (ie acala) post', 'BTKi (ie acala) post IBR', '(ie acala) post IBR d/c', 'acala) post IBR d/c PFS', 'post IBR d/c PFS splits', 'IBR d/c PFS splits v', 'd/c PFS splits v early', 'PFS splits v early for', 'splits v early for low', 'v early for low risk', 'early for low risk (med', 'for low risk (med 1', 'low risk (med 1 prior', 'risk (med 1 prior line)', '(med 1 prior line) R/R', '1 prior line) R/R #CLL', 'prior line) R/R #CLL cohort', 'line) R/R #CLL cohort #ASH22', 'R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC', '#CLL cohort #ASH22 https://t.co/NdLwQW1uyC .', 'Would love to know: - specific', 'love to know: - specific reasons', 'to know: - specific reasons for', 'know: - specific reasons for ibrutinib', '- specific reasons for ibrutinib d/c', 'specific reasons for ibrutinib d/c in', 'reasons for ibrutinib d/c in those', 'for ibrutinib d/c in those due', 'ibrutinib d/c in those due to', 'd/c in those due to pt/dr', 'in those due to pt/dr choice', 'those due to pt/dr choice -', 'due to pt/dr choice - median', 'to pt/dr choice - median time', 'pt/dr choice - median time to', 'choice - median time to d/c', '- median time to d/c of', 'median time to d/c of ibrutinib', 'time to d/c of ibrutinib vs', 'to d/c of ibrutinib vs zanubrutinib', 'd/c of ibrutinib vs zanubrutinib ', 'of ibrutinib vs zanubrutinib  ', 'ibrutinib vs zanubrutinib   ', 'vs zanubrutinib    ', 'zanubrutinib     pts', '    pts for', '   pts for reasons', '  pts for reasons other', ' pts for reasons other than', 'pts for reasons other than PD', 'for reasons other than PD -', 'reasons other than PD - availability/use', 'other than PD - availability/use of', 'than PD - availability/use of 2nd', 'PD - availability/use of 2nd gen', '- availability/use of 2nd gen BTKi', 'availability/use of 2nd gen BTKi (ie', 'of 2nd gen BTKi (ie acala)', '2nd gen BTKi (ie acala) post', 'gen BTKi (ie acala) post IBR', 'BTKi (ie acala) post IBR d/c', '(ie acala) post IBR d/c PFS', 'acala) post IBR d/c PFS splits', 'post IBR d/c PFS splits v', 'IBR d/c PFS splits v early', 'd/c PFS splits v early for', 'PFS splits v early for low', 'splits v early for low risk', 'v early for low risk (med', 'early for low risk (med 1', 'for low risk (med 1 prior', 'low risk (med 1 prior line)', 'risk (med 1 prior line) R/R', '(med 1 prior line) R/R #CLL', '1 prior line) R/R #CLL cohort', 'prior line) R/R #CLL cohort #ASH22', 'line) R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC', 'R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC .', 'Would love to know: - specific reasons', 'love to know: - specific reasons for', 'to know: - specific reasons for ibrutinib', 'know: - specific reasons for ibrutinib d/c', '- specific reasons for ibrutinib d/c in', 'specific reasons for ibrutinib d/c in those', 'reasons for ibrutinib d/c in those due', 'for ibrutinib d/c in those due to', 'ibrutinib d/c in those due to pt/dr', 'd/c in those due to pt/dr choice', 'in those due to pt/dr choice -', 'those due to pt/dr choice - median', 'due to pt/dr choice - median time', 'to pt/dr choice - median time to', 'pt/dr choice - median time to d/c', 'choice - median time to d/c of', '- median time to d/c of ibrutinib', 'median time to d/c of ibrutinib vs', 'time to d/c of ibrutinib vs zanubrutinib', 'to d/c of ibrutinib vs zanubrutinib ', 'd/c of ibrutinib vs zanubrutinib  ', 'of ibrutinib vs zanubrutinib   ', 'ibrutinib vs zanubrutinib    ', 'vs zanubrutinib     pts', 'zanubrutinib     pts for', '    pts for reasons', '   pts for reasons other', '  pts for reasons other than', ' pts for reasons other than PD', 'pts for reasons other than PD -', 'for reasons other than PD - availability/use', 'reasons other than PD - availability/use of', 'other than PD - availability/use of 2nd', 'than PD - availability/use of 2nd gen', 'PD - availability/use of 2nd gen BTKi', '- availability/use of 2nd gen BTKi (ie', 'availability/use of 2nd gen BTKi (ie acala)', 'of 2nd gen BTKi (ie acala) post', '2nd gen BTKi (ie acala) post IBR', 'gen BTKi (ie acala) post IBR d/c', 'BTKi (ie acala) post IBR d/c PFS', '(ie acala) post IBR d/c PFS splits', 'acala) post IBR d/c PFS splits v', 'post IBR d/c PFS splits v early', 'IBR d/c PFS splits v early for', 'd/c PFS splits v early for low', 'PFS splits v early for low risk', 'splits v early for low risk (med', 'v early for low risk (med 1', 'early for low risk (med 1 prior', 'for low risk (med 1 prior line)', 'low risk (med 1 prior line) R/R', 'risk (med 1 prior line) R/R #CLL', '(med 1 prior line) R/R #CLL cohort', '1 prior line) R/R #CLL cohort #ASH22', 'prior line) R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC', 'line) R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC .', 'Would love to know: - specific reasons for', 'love to know: - specific reasons for ibrutinib', 'to know: - specific reasons for ibrutinib d/c', 'know: - specific reasons for ibrutinib d/c in', '- specific reasons for ibrutinib d/c in those', 'specific reasons for ibrutinib d/c in those due', 'reasons for ibrutinib d/c in those due to', 'for ibrutinib d/c in those due to pt/dr', 'ibrutinib d/c in those due to pt/dr choice', 'd/c in those due to pt/dr choice -', 'in those due to pt/dr choice - median', 'those due to pt/dr choice - median time', 'due to pt/dr choice - median time to', 'to pt/dr choice - median time to d/c', 'pt/dr choice - median time to d/c of', 'choice - median time to d/c of ibrutinib', '- median time to d/c of ibrutinib vs', 'median time to d/c of ibrutinib vs zanubrutinib', 'time to d/c of ibrutinib vs zanubrutinib ', 'to d/c of ibrutinib vs zanubrutinib  ', 'd/c of ibrutinib vs zanubrutinib   ', 'of ibrutinib vs zanubrutinib    ', 'ibrutinib vs zanubrutinib     pts', 'vs zanubrutinib     pts for', 'zanubrutinib     pts for reasons', '    pts for reasons other', '   pts for reasons other than', '  pts for reasons other than PD', ' pts for reasons other than PD -', 'pts for reasons other than PD - availability/use', 'for reasons other than PD - availability/use of', 'reasons other than PD - availability/use of 2nd', 'other than PD - availability/use of 2nd gen', 'than PD - availability/use of 2nd gen BTKi', 'PD - availability/use of 2nd gen BTKi (ie', '- availability/use of 2nd gen BTKi (ie acala)', 'availability/use of 2nd gen BTKi (ie acala) post', 'of 2nd gen BTKi (ie acala) post IBR', '2nd gen BTKi (ie acala) post IBR d/c', 'gen BTKi (ie acala) post IBR d/c PFS', 'BTKi (ie acala) post IBR d/c PFS splits', '(ie acala) post IBR d/c PFS splits v', 'acala) post IBR d/c PFS splits v early', 'post IBR d/c PFS splits v early for', 'IBR d/c PFS splits v early for low', 'd/c PFS splits v early for low risk', 'PFS splits v early for low risk (med', 'splits v early for low risk (med 1', 'v early for low risk (med 1 prior', 'early for low risk (med 1 prior line)', 'for low risk (med 1 prior line) R/R', 'low risk (med 1 prior line) R/R #CLL', 'risk (med 1 prior line) R/R #CLL cohort', '(med 1 prior line) R/R #CLL cohort #ASH22', '1 prior line) R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC', 'prior line) R/R #CLL cohort #ASH22 https://t.co/NdLwQW1uyC .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '18', 'tokens': ['In', 'patients', 'with', 'relapsed', 'or', 'refractory', '#CLL', 'or', '#SLL,', 'progression-free', 'survival', 'was', 'longer', 'among', 'patients', 'who', 'received', '#zanubrutinib', 'than', 'among', 'those', 'who', 'received', '#ibrutinib,', 'and', 'zanubrutinib', 'was', 'associated', 'with', 'fewer', 'cardiac', 'adverse', 'events.', '#ASH22', '', '.'], 'text_length': 36, 'triples': {'#zanubrutinib than among those who received #ibrutinib, and zanubrutinib|progression-free survival was longer among patients who received #zanubrutinib than among those who received #ibrutinib, and zanubrutinib was associated with fewer cardiac adverse events.': ([17, 25], [9, 32], 'positive')}, 'sentence': 'In patients with relapsed or refractory #CLL or #SLL, progression-free survival was longer among patients who received #zanubrutinib than among those who received #ibrutinib, and zanubrutinib was associated with fewer cardiac adverse events. #ASH22  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(17, 25)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 32)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['In', 'patients', 'with', 'relapsed', 'or', 'refractory', '#CLL', 'or', '#SLL,', 'progression-free', 'survival', 'was', 'longer', 'among', 'patients', 'who', 'received', '#zanubrutinib', 'than', 'among', 'those', 'who', 'received', '#ibrutinib,', 'and', 'zanubrutinib', 'was', 'associated', 'with', 'fewer', 'cardiac', 'adverse', 'events.', '#ASH22', '', '.', 'In patients', 'patients with', 'with relapsed', 'relapsed or', 'or refractory', 'refractory #CLL', '#CLL or', 'or #SLL,', '#SLL, progression-free', 'progression-free survival', 'survival was', 'was longer', 'longer among', 'among patients', 'patients who', 'who received', 'received #zanubrutinib', '#zanubrutinib than', 'than among', 'among those', 'those who', 'who received', 'received #ibrutinib,', '#ibrutinib, and', 'and zanubrutinib', 'zanubrutinib was', 'was associated', 'associated with', 'with fewer', 'fewer cardiac', 'cardiac adverse', 'adverse events.', 'events. #ASH22', '#ASH22 ', ' .', 'In patients with', 'patients with relapsed', 'with relapsed or', 'relapsed or refractory', 'or refractory #CLL', 'refractory #CLL or', '#CLL or #SLL,', 'or #SLL, progression-free', '#SLL, progression-free survival', 'progression-free survival was', 'survival was longer', 'was longer among', 'longer among patients', 'among patients who', 'patients who received', 'who received #zanubrutinib', 'received #zanubrutinib than', '#zanubrutinib than among', 'than among those', 'among those who', 'those who received', 'who received #ibrutinib,', 'received #ibrutinib, and', '#ibrutinib, and zanubrutinib', 'and zanubrutinib was', 'zanubrutinib was associated', 'was associated with', 'associated with fewer', 'with fewer cardiac', 'fewer cardiac adverse', 'cardiac adverse events.', 'adverse events. #ASH22', 'events. #ASH22 ', '#ASH22  .', 'In patients with relapsed', 'patients with relapsed or', 'with relapsed or refractory', 'relapsed or refractory #CLL', 'or refractory #CLL or', 'refractory #CLL or #SLL,', '#CLL or #SLL, progression-free', 'or #SLL, progression-free survival', '#SLL, progression-free survival was', 'progression-free survival was longer', 'survival was longer among', 'was longer among patients', 'longer among patients who', 'among patients who received', 'patients who received #zanubrutinib', 'who received #zanubrutinib than', 'received #zanubrutinib than among', '#zanubrutinib than among those', 'than among those who', 'among those who received', 'those who received #ibrutinib,', 'who received #ibrutinib, and', 'received #ibrutinib, and zanubrutinib', '#ibrutinib, and zanubrutinib was', 'and zanubrutinib was associated', 'zanubrutinib was associated with', 'was associated with fewer', 'associated with fewer cardiac', 'with fewer cardiac adverse', 'fewer cardiac adverse events.', 'cardiac adverse events. #ASH22', 'adverse events. #ASH22 ', 'events. #ASH22  .', 'In patients with relapsed or', 'patients with relapsed or refractory', 'with relapsed or refractory #CLL', 'relapsed or refractory #CLL or', 'or refractory #CLL or #SLL,', 'refractory #CLL or #SLL, progression-free', '#CLL or #SLL, progression-free survival', 'or #SLL, progression-free survival was', '#SLL, progression-free survival was longer', 'progression-free survival was longer among', 'survival was longer among patients', 'was longer among patients who', 'longer among patients who received', 'among patients who received #zanubrutinib', 'patients who received #zanubrutinib than', 'who received #zanubrutinib than among', 'received #zanubrutinib than among those', '#zanubrutinib than among those who', 'than among those who received', 'among those who received #ibrutinib,', 'those who received #ibrutinib, and', 'who received #ibrutinib, and zanubrutinib', 'received #ibrutinib, and zanubrutinib was', '#ibrutinib, and zanubrutinib was associated', 'and zanubrutinib was associated with', 'zanubrutinib was associated with fewer', 'was associated with fewer cardiac', 'associated with fewer cardiac adverse', 'with fewer cardiac adverse events.', 'fewer cardiac adverse events. #ASH22', 'cardiac adverse events. #ASH22 ', 'adverse events. #ASH22  .', 'In patients with relapsed or refractory', 'patients with relapsed or refractory #CLL', 'with relapsed or refractory #CLL or', 'relapsed or refractory #CLL or #SLL,', 'or refractory #CLL or #SLL, progression-free', 'refractory #CLL or #SLL, progression-free survival', '#CLL or #SLL, progression-free survival was', 'or #SLL, progression-free survival was longer', '#SLL, progression-free survival was longer among', 'progression-free survival was longer among patients', 'survival was longer among patients who', 'was longer among patients who received', 'longer among patients who received #zanubrutinib', 'among patients who received #zanubrutinib than', 'patients who received #zanubrutinib than among', 'who received #zanubrutinib than among those', 'received #zanubrutinib than among those who', '#zanubrutinib than among those who received', 'than among those who received #ibrutinib,', 'among those who received #ibrutinib, and', 'those who received #ibrutinib, and zanubrutinib', 'who received #ibrutinib, and zanubrutinib was', 'received #ibrutinib, and zanubrutinib was associated', '#ibrutinib, and zanubrutinib was associated with', 'and zanubrutinib was associated with fewer', 'zanubrutinib was associated with fewer cardiac', 'was associated with fewer cardiac adverse', 'associated with fewer cardiac adverse events.', 'with fewer cardiac adverse events. #ASH22', 'fewer cardiac adverse events. #ASH22 ', 'cardiac adverse events. #ASH22  .', 'In patients with relapsed or refractory #CLL', 'patients with relapsed or refractory #CLL or', 'with relapsed or refractory #CLL or #SLL,', 'relapsed or refractory #CLL or #SLL, progression-free', 'or refractory #CLL or #SLL, progression-free survival', 'refractory #CLL or #SLL, progression-free survival was', '#CLL or #SLL, progression-free survival was longer', 'or #SLL, progression-free survival was longer among', '#SLL, progression-free survival was longer among patients', 'progression-free survival was longer among patients who', 'survival was longer among patients who received', 'was longer among patients who received #zanubrutinib', 'longer among patients who received #zanubrutinib than', 'among patients who received #zanubrutinib than among', 'patients who received #zanubrutinib than among those', 'who received #zanubrutinib than among those who', 'received #zanubrutinib than among those who received', '#zanubrutinib than among those who received #ibrutinib,', 'than among those who received #ibrutinib, and', 'among those who received #ibrutinib, and zanubrutinib', 'those who received #ibrutinib, and zanubrutinib was', 'who received #ibrutinib, and zanubrutinib was associated', 'received #ibrutinib, and zanubrutinib was associated with', '#ibrutinib, and zanubrutinib was associated with fewer', 'and zanubrutinib was associated with fewer cardiac', 'zanubrutinib was associated with fewer cardiac adverse', 'was associated with fewer cardiac adverse events.', 'associated with fewer cardiac adverse events. #ASH22', 'with fewer cardiac adverse events. #ASH22 ', 'fewer cardiac adverse events. #ASH22  .', 'In patients with relapsed or refractory #CLL or', 'patients with relapsed or refractory #CLL or #SLL,', 'with relapsed or refractory #CLL or #SLL, progression-free', 'relapsed or refractory #CLL or #SLL, progression-free survival', 'or refractory #CLL or #SLL, progression-free survival was', 'refractory #CLL or #SLL, progression-free survival was longer', '#CLL or #SLL, progression-free survival was longer among', 'or #SLL, progression-free survival was longer among patients', '#SLL, progression-free survival was longer among patients who', 'progression-free survival was longer among patients who received', 'survival was longer among patients who received #zanubrutinib', 'was longer among patients who received #zanubrutinib than', 'longer among patients who received #zanubrutinib than among', 'among patients who received #zanubrutinib than among those', 'patients who received #zanubrutinib than among those who', 'who received #zanubrutinib than among those who received', 'received #zanubrutinib than among those who received #ibrutinib,', '#zanubrutinib than among those who received #ibrutinib, and', 'than among those who received #ibrutinib, and zanubrutinib', 'among those who received #ibrutinib, and zanubrutinib was', 'those who received #ibrutinib, and zanubrutinib was associated', 'who received #ibrutinib, and zanubrutinib was associated with', 'received #ibrutinib, and zanubrutinib was associated with fewer', '#ibrutinib, and zanubrutinib was associated with fewer cardiac', 'and zanubrutinib was associated with fewer cardiac adverse', 'zanubrutinib was associated with fewer cardiac adverse events.', 'was associated with fewer cardiac adverse events. #ASH22', 'associated with fewer cardiac adverse events. #ASH22 ', 'with fewer cardiac adverse events. #ASH22  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '20', 'tokens': ['Final', 'results', 'of', 'the', 'ALPINE', 'trial', '#ASH22', 'Zanubrutinib', 'demonstrates', 'superior', 'PFS', 'and', 'ORR', '(no', 'OS', 'difference)', 'over', 'ibrutinib', 'in', 'pts', 'with', 'r/r', 'CLL/SLL', '💥', 'PFS', 'benefit', 'seen', 'across', 'all', 'major', 'subgroups,', 'including', 'the', 'del(17p)/TP53mut💥', 'With', 'less', 'Aes', '.'], 'text_length': 38, 'triples': {'ALPINE|demonstrates superior': ([4, 4], [8, 9], 'positive'), 'ibrutinib|demonstrates superior PFS and ORR (no OS difference) over': ([17, 17], [8, 16], 'negative'), 'Zanubrutinib|demonstrates superior': ([7, 7], [8, 9], 'positive')}, 'sentence': 'Final results of the ALPINE trial #ASH22 Zanubrutinib demonstrates superior PFS and ORR (no OS difference) over ibrutinib in pts with r/r CLL/SLL 💥 PFS benefit seen across all major subgroups, including the del(17p)/TP53mut💥 With less Aes .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(4, 4), (17, 17), (7, 7)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(8, 9), (8, 16)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8)], 'span tokens': ['Final', 'results', 'of', 'the', 'ALPINE', 'trial', '#ASH22', 'Zanubrutinib', 'demonstrates', 'superior', 'PFS', 'and', 'ORR', '(no', 'OS', 'difference)', 'over', 'ibrutinib', 'in', 'pts', 'with', 'r/r', 'CLL/SLL', '💥', 'PFS', 'benefit', 'seen', 'across', 'all', 'major', 'subgroups,', 'including', 'the', 'del(17p)/TP53mut💥', 'With', 'less', 'Aes', '.', 'Final results', 'results of', 'of the', 'the ALPINE', 'ALPINE trial', 'trial #ASH22', '#ASH22 Zanubrutinib', 'Zanubrutinib demonstrates', 'demonstrates superior', 'superior PFS', 'PFS and', 'and ORR', 'ORR (no', '(no OS', 'OS difference)', 'difference) over', 'over ibrutinib', 'ibrutinib in', 'in pts', 'pts with', 'with r/r', 'r/r CLL/SLL', 'CLL/SLL 💥', '💥 PFS', 'PFS benefit', 'benefit seen', 'seen across', 'across all', 'all major', 'major subgroups,', 'subgroups, including', 'including the', 'the del(17p)/TP53mut💥', 'del(17p)/TP53mut💥 With', 'With less', 'less Aes', 'Aes .', 'Final results of', 'results of the', 'of the ALPINE', 'the ALPINE trial', 'ALPINE trial #ASH22', 'trial #ASH22 Zanubrutinib', '#ASH22 Zanubrutinib demonstrates', 'Zanubrutinib demonstrates superior', 'demonstrates superior PFS', 'superior PFS and', 'PFS and ORR', 'and ORR (no', 'ORR (no OS', '(no OS difference)', 'OS difference) over', 'difference) over ibrutinib', 'over ibrutinib in', 'ibrutinib in pts', 'in pts with', 'pts with r/r', 'with r/r CLL/SLL', 'r/r CLL/SLL 💥', 'CLL/SLL 💥 PFS', '💥 PFS benefit', 'PFS benefit seen', 'benefit seen across', 'seen across all', 'across all major', 'all major subgroups,', 'major subgroups, including', 'subgroups, including the', 'including the del(17p)/TP53mut💥', 'the del(17p)/TP53mut💥 With', 'del(17p)/TP53mut💥 With less', 'With less Aes', 'less Aes .', 'Final results of the', 'results of the ALPINE', 'of the ALPINE trial', 'the ALPINE trial #ASH22', 'ALPINE trial #ASH22 Zanubrutinib', 'trial #ASH22 Zanubrutinib demonstrates', '#ASH22 Zanubrutinib demonstrates superior', 'Zanubrutinib demonstrates superior PFS', 'demonstrates superior PFS and', 'superior PFS and ORR', 'PFS and ORR (no', 'and ORR (no OS', 'ORR (no OS difference)', '(no OS difference) over', 'OS difference) over ibrutinib', 'difference) over ibrutinib in', 'over ibrutinib in pts', 'ibrutinib in pts with', 'in pts with r/r', 'pts with r/r CLL/SLL', 'with r/r CLL/SLL 💥', 'r/r CLL/SLL 💥 PFS', 'CLL/SLL 💥 PFS benefit', '💥 PFS benefit seen', 'PFS benefit seen across', 'benefit seen across all', 'seen across all major', 'across all major subgroups,', 'all major subgroups, including', 'major subgroups, including the', 'subgroups, including the del(17p)/TP53mut💥', 'including the del(17p)/TP53mut💥 With', 'the del(17p)/TP53mut💥 With less', 'del(17p)/TP53mut💥 With less Aes', 'With less Aes .', 'Final results of the ALPINE', 'results of the ALPINE trial', 'of the ALPINE trial #ASH22', 'the ALPINE trial #ASH22 Zanubrutinib', 'ALPINE trial #ASH22 Zanubrutinib demonstrates', 'trial #ASH22 Zanubrutinib demonstrates superior', '#ASH22 Zanubrutinib demonstrates superior PFS', 'Zanubrutinib demonstrates superior PFS and', 'demonstrates superior PFS and ORR', 'superior PFS and ORR (no', 'PFS and ORR (no OS', 'and ORR (no OS difference)', 'ORR (no OS difference) over', '(no OS difference) over ibrutinib', 'OS difference) over ibrutinib in', 'difference) over ibrutinib in pts', 'over ibrutinib in pts with', 'ibrutinib in pts with r/r', 'in pts with r/r CLL/SLL', 'pts with r/r CLL/SLL 💥', 'with r/r CLL/SLL 💥 PFS', 'r/r CLL/SLL 💥 PFS benefit', 'CLL/SLL 💥 PFS benefit seen', '💥 PFS benefit seen across', 'PFS benefit seen across all', 'benefit seen across all major', 'seen across all major subgroups,', 'across all major subgroups, including', 'all major subgroups, including the', 'major subgroups, including the del(17p)/TP53mut💥', 'subgroups, including the del(17p)/TP53mut💥 With', 'including the del(17p)/TP53mut💥 With less', 'the del(17p)/TP53mut💥 With less Aes', 'del(17p)/TP53mut💥 With less Aes .', 'Final results of the ALPINE trial', 'results of the ALPINE trial #ASH22', 'of the ALPINE trial #ASH22 Zanubrutinib', 'the ALPINE trial #ASH22 Zanubrutinib demonstrates', 'ALPINE trial #ASH22 Zanubrutinib demonstrates superior', 'trial #ASH22 Zanubrutinib demonstrates superior PFS', '#ASH22 Zanubrutinib demonstrates superior PFS and', 'Zanubrutinib demonstrates superior PFS and ORR', 'demonstrates superior PFS and ORR (no', 'superior PFS and ORR (no OS', 'PFS and ORR (no OS difference)', 'and ORR (no OS difference) over', 'ORR (no OS difference) over ibrutinib', '(no OS difference) over ibrutinib in', 'OS difference) over ibrutinib in pts', 'difference) over ibrutinib in pts with', 'over ibrutinib in pts with r/r', 'ibrutinib in pts with r/r CLL/SLL', 'in pts with r/r CLL/SLL 💥', 'pts with r/r CLL/SLL 💥 PFS', 'with r/r CLL/SLL 💥 PFS benefit', 'r/r CLL/SLL 💥 PFS benefit seen', 'CLL/SLL 💥 PFS benefit seen across', '💥 PFS benefit seen across all', 'PFS benefit seen across all major', 'benefit seen across all major subgroups,', 'seen across all major subgroups, including', 'across all major subgroups, including the', 'all major subgroups, including the del(17p)/TP53mut💥', 'major subgroups, including the del(17p)/TP53mut💥 With', 'subgroups, including the del(17p)/TP53mut💥 With less', 'including the del(17p)/TP53mut💥 With less Aes', 'the del(17p)/TP53mut💥 With less Aes .', 'Final results of the ALPINE trial #ASH22', 'results of the ALPINE trial #ASH22 Zanubrutinib', 'of the ALPINE trial #ASH22 Zanubrutinib demonstrates', 'the ALPINE trial #ASH22 Zanubrutinib demonstrates superior', 'ALPINE trial #ASH22 Zanubrutinib demonstrates superior PFS', 'trial #ASH22 Zanubrutinib demonstrates superior PFS and', '#ASH22 Zanubrutinib demonstrates superior PFS and ORR', 'Zanubrutinib demonstrates superior PFS and ORR (no', 'demonstrates superior PFS and ORR (no OS', 'superior PFS and ORR (no OS difference)', 'PFS and ORR (no OS difference) over', 'and ORR (no OS difference) over ibrutinib', 'ORR (no OS difference) over ibrutinib in', '(no OS difference) over ibrutinib in pts', 'OS difference) over ibrutinib in pts with', 'difference) over ibrutinib in pts with r/r', 'over ibrutinib in pts with r/r CLL/SLL', 'ibrutinib in pts with r/r CLL/SLL 💥', 'in pts with r/r CLL/SLL 💥 PFS', 'pts with r/r CLL/SLL 💥 PFS benefit', 'with r/r CLL/SLL 💥 PFS benefit seen', 'r/r CLL/SLL 💥 PFS benefit seen across', 'CLL/SLL 💥 PFS benefit seen across all', '💥 PFS benefit seen across all major', 'PFS benefit seen across all major subgroups,', 'benefit seen across all major subgroups, including', 'seen across all major subgroups, including the', 'across all major subgroups, including the del(17p)/TP53mut💥', 'all major subgroups, including the del(17p)/TP53mut💥 With', 'major subgroups, including the del(17p)/TP53mut💥 With less', 'subgroups, including the del(17p)/TP53mut💥 With less Aes', 'including the del(17p)/TP53mut💥 With less Aes .', 'Final results of the ALPINE trial #ASH22 Zanubrutinib', 'results of the ALPINE trial #ASH22 Zanubrutinib demonstrates', 'of the ALPINE trial #ASH22 Zanubrutinib demonstrates superior', 'the ALPINE trial #ASH22 Zanubrutinib demonstrates superior PFS', 'ALPINE trial #ASH22 Zanubrutinib demonstrates superior PFS and', 'trial #ASH22 Zanubrutinib demonstrates superior PFS and ORR', '#ASH22 Zanubrutinib demonstrates superior PFS and ORR (no', 'Zanubrutinib demonstrates superior PFS and ORR (no OS', 'demonstrates superior PFS and ORR (no OS difference)', 'superior PFS and ORR (no OS difference) over', 'PFS and ORR (no OS difference) over ibrutinib', 'and ORR (no OS difference) over ibrutinib in', 'ORR (no OS difference) over ibrutinib in pts', '(no OS difference) over ibrutinib in pts with', 'OS difference) over ibrutinib in pts with r/r', 'difference) over ibrutinib in pts with r/r CLL/SLL', 'over ibrutinib in pts with r/r CLL/SLL 💥', 'ibrutinib in pts with r/r CLL/SLL 💥 PFS', 'in pts with r/r CLL/SLL 💥 PFS benefit', 'pts with r/r CLL/SLL 💥 PFS benefit seen', 'with r/r CLL/SLL 💥 PFS benefit seen across', 'r/r CLL/SLL 💥 PFS benefit seen across all', 'CLL/SLL 💥 PFS benefit seen across all major', '💥 PFS benefit seen across all major subgroups,', 'PFS benefit seen across all major subgroups, including', 'benefit seen across all major subgroups, including the', 'seen across all major subgroups, including the del(17p)/TP53mut💥', 'across all major subgroups, including the del(17p)/TP53mut💥 With', 'all major subgroups, including the del(17p)/TP53mut💥 With less', 'major subgroups, including the del(17p)/TP53mut💥 With less Aes', 'subgroups, including the del(17p)/TP53mut💥 With less Aes .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '21', 'tokens': ['ALPINE', 'final', 'analysis:', 'zanubrutinib', 'shows', 'superior', 'efficiency', 'over', 'ibrutinib', 'in', 'r/r', '#CLL', 'both', 'in', 'all', 'pts', 'and', 'in', 'pre-planned', 'analysis', 'on', 'del17p/mTP53.', '#ash22', '', '.'], 'text_length': 25, 'triples': {'ALPINE|shows superior efficiency': ([0, 0], [4, 6], 'positive'), 'ibrutinib|shows superior efficiency over': ([8, 8], [4, 7], 'negative'), 'zanubrutinib|shows superior efficiency': ([3, 3], [4, 6], 'positive')}, 'sentence': 'ALPINE final analysis: zanubrutinib shows superior efficiency over ibrutinib in r/r #CLL both in all pts and in pre-planned analysis on del17p/mTP53. #ash22  .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(0, 0), (8, 8), (3, 3)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(4, 6), (4, 7)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8)], 'span tokens': ['ALPINE', 'final', 'analysis:', 'zanubrutinib', 'shows', 'superior', 'efficiency', 'over', 'ibrutinib', 'in', 'r/r', '#CLL', 'both', 'in', 'all', 'pts', 'and', 'in', 'pre-planned', 'analysis', 'on', 'del17p/mTP53.', '#ash22', '', '.', 'ALPINE final', 'final analysis:', 'analysis: zanubrutinib', 'zanubrutinib shows', 'shows superior', 'superior efficiency', 'efficiency over', 'over ibrutinib', 'ibrutinib in', 'in r/r', 'r/r #CLL', '#CLL both', 'both in', 'in all', 'all pts', 'pts and', 'and in', 'in pre-planned', 'pre-planned analysis', 'analysis on', 'on del17p/mTP53.', 'del17p/mTP53. #ash22', '#ash22 ', ' .', 'ALPINE final analysis:', 'final analysis: zanubrutinib', 'analysis: zanubrutinib shows', 'zanubrutinib shows superior', 'shows superior efficiency', 'superior efficiency over', 'efficiency over ibrutinib', 'over ibrutinib in', 'ibrutinib in r/r', 'in r/r #CLL', 'r/r #CLL both', '#CLL both in', 'both in all', 'in all pts', 'all pts and', 'pts and in', 'and in pre-planned', 'in pre-planned analysis', 'pre-planned analysis on', 'analysis on del17p/mTP53.', 'on del17p/mTP53. #ash22', 'del17p/mTP53. #ash22 ', '#ash22  .', 'ALPINE final analysis: zanubrutinib', 'final analysis: zanubrutinib shows', 'analysis: zanubrutinib shows superior', 'zanubrutinib shows superior efficiency', 'shows superior efficiency over', 'superior efficiency over ibrutinib', 'efficiency over ibrutinib in', 'over ibrutinib in r/r', 'ibrutinib in r/r #CLL', 'in r/r #CLL both', 'r/r #CLL both in', '#CLL both in all', 'both in all pts', 'in all pts and', 'all pts and in', 'pts and in pre-planned', 'and in pre-planned analysis', 'in pre-planned analysis on', 'pre-planned analysis on del17p/mTP53.', 'analysis on del17p/mTP53. #ash22', 'on del17p/mTP53. #ash22 ', 'del17p/mTP53. #ash22  .', 'ALPINE final analysis: zanubrutinib shows', 'final analysis: zanubrutinib shows superior', 'analysis: zanubrutinib shows superior efficiency', 'zanubrutinib shows superior efficiency over', 'shows superior efficiency over ibrutinib', 'superior efficiency over ibrutinib in', 'efficiency over ibrutinib in r/r', 'over ibrutinib in r/r #CLL', 'ibrutinib in r/r #CLL both', 'in r/r #CLL both in', 'r/r #CLL both in all', '#CLL both in all pts', 'both in all pts and', 'in all pts and in', 'all pts and in pre-planned', 'pts and in pre-planned analysis', 'and in pre-planned analysis on', 'in pre-planned analysis on del17p/mTP53.', 'pre-planned analysis on del17p/mTP53. #ash22', 'analysis on del17p/mTP53. #ash22 ', 'on del17p/mTP53. #ash22  .', 'ALPINE final analysis: zanubrutinib shows superior', 'final analysis: zanubrutinib shows superior efficiency', 'analysis: zanubrutinib shows superior efficiency over', 'zanubrutinib shows superior efficiency over ibrutinib', 'shows superior efficiency over ibrutinib in', 'superior efficiency over ibrutinib in r/r', 'efficiency over ibrutinib in r/r #CLL', 'over ibrutinib in r/r #CLL both', 'ibrutinib in r/r #CLL both in', 'in r/r #CLL both in all', 'r/r #CLL both in all pts', '#CLL both in all pts and', 'both in all pts and in', 'in all pts and in pre-planned', 'all pts and in pre-planned analysis', 'pts and in pre-planned analysis on', 'and in pre-planned analysis on del17p/mTP53.', 'in pre-planned analysis on del17p/mTP53. #ash22', 'pre-planned analysis on del17p/mTP53. #ash22 ', 'analysis on del17p/mTP53. #ash22  .', 'ALPINE final analysis: zanubrutinib shows superior efficiency', 'final analysis: zanubrutinib shows superior efficiency over', 'analysis: zanubrutinib shows superior efficiency over ibrutinib', 'zanubrutinib shows superior efficiency over ibrutinib in', 'shows superior efficiency over ibrutinib in r/r', 'superior efficiency over ibrutinib in r/r #CLL', 'efficiency over ibrutinib in r/r #CLL both', 'over ibrutinib in r/r #CLL both in', 'ibrutinib in r/r #CLL both in all', 'in r/r #CLL both in all pts', 'r/r #CLL both in all pts and', '#CLL both in all pts and in', 'both in all pts and in pre-planned', 'in all pts and in pre-planned analysis', 'all pts and in pre-planned analysis on', 'pts and in pre-planned analysis on del17p/mTP53.', 'and in pre-planned analysis on del17p/mTP53. #ash22', 'in pre-planned analysis on del17p/mTP53. #ash22 ', 'pre-planned analysis on del17p/mTP53. #ash22  .', 'ALPINE final analysis: zanubrutinib shows superior efficiency over', 'final analysis: zanubrutinib shows superior efficiency over ibrutinib', 'analysis: zanubrutinib shows superior efficiency over ibrutinib in', 'zanubrutinib shows superior efficiency over ibrutinib in r/r', 'shows superior efficiency over ibrutinib in r/r #CLL', 'superior efficiency over ibrutinib in r/r #CLL both', 'efficiency over ibrutinib in r/r #CLL both in', 'over ibrutinib in r/r #CLL both in all', 'ibrutinib in r/r #CLL both in all pts', 'in r/r #CLL both in all pts and', 'r/r #CLL both in all pts and in', '#CLL both in all pts and in pre-planned', 'both in all pts and in pre-planned analysis', 'in all pts and in pre-planned analysis on', 'all pts and in pre-planned analysis on del17p/mTP53.', 'pts and in pre-planned analysis on del17p/mTP53. #ash22', 'and in pre-planned analysis on del17p/mTP53. #ash22 ', 'in pre-planned analysis on del17p/mTP53. #ash22  .'], 'spans_aspect_label': [1, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '22', 'tokens': ['Brown', 'ALPINE', 'RCT', '#ASH22', 'zanubrutinib', '', '', '', '', 'v', 'ibrutinib', 'in', 'RR', '#CLL', 'N=652', 'ORR', '86%', 'v', '76%', '2yPFS', '80%', 'v', '63%.', 'OS', 'equiv,', 'prob', 'always', 'will', 'be', 'Cardiac', 'tox', 'lower', 'with', 'ZANU,', 'no', 'cardiac', 'death', 'v', '6', 'in', 'IBR', '(2%)!', 'One', 'caveat:', 'dead', 'kinase', 'muts', 'common', 'after', 'ZANU,', '?compromise', 'later', 'PIRTO?', 'See:', '.'], 'text_length': 55, 'triples': {'ALPINE|Cardiac tox lower with ZANU, no cardiac death': ([1, 1], [25, 32], 'positive'), 'zanubrutinib|Cardiac tox lower with ZANU, no cardiac death': ([4, 4], [25, 32], 'positive')}, 'sentence': 'Brown ALPINE RCT #ASH22 zanubrutinib     v ibrutinib in RR #CLL N=652 ORR 86% v 76% 2yPFS 80% v 63%. OS equiv, prob always will be Cardiac tox lower with ZANU, no cardiac death v 6 in IBR (2%)! One caveat: dead kinase muts common after ZANU, ?compromise later PIRTO? See: .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(1, 1), (4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(25, 32)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (46, 46, 1), (47, 47, 1), (48, 48, 1), (49, 49, 1), (50, 50, 1), (51, 51, 1), (52, 52, 1), (53, 53, 1), (54, 54, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (45, 46, 2), (46, 47, 2), (47, 48, 2), (48, 49, 2), (49, 50, 2), (50, 51, 2), (51, 52, 2), (52, 53, 2), (53, 54, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (44, 46, 3), (45, 47, 3), (46, 48, 3), (47, 49, 3), (48, 50, 3), (49, 51, 3), (50, 52, 3), (51, 53, 3), (52, 54, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (43, 46, 4), (44, 47, 4), (45, 48, 4), (46, 49, 4), (47, 50, 4), (48, 51, 4), (49, 52, 4), (50, 53, 4), (51, 54, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (42, 46, 5), (43, 47, 5), (44, 48, 5), (45, 49, 5), (46, 50, 5), (47, 51, 5), (48, 52, 5), (49, 53, 5), (50, 54, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (41, 46, 6), (42, 47, 6), (43, 48, 6), (44, 49, 6), (45, 50, 6), (46, 51, 6), (47, 52, 6), (48, 53, 6), (49, 54, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (40, 46, 7), (41, 47, 7), (42, 48, 7), (43, 49, 7), (44, 50, 7), (45, 51, 7), (46, 52, 7), (47, 53, 7), (48, 54, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8), (39, 46, 8), (40, 47, 8), (41, 48, 8), (42, 49, 8), (43, 50, 8), (44, 51, 8), (45, 52, 8), (46, 53, 8), (47, 54, 8)], 'span tokens': ['Brown', 'ALPINE', 'RCT', '#ASH22', 'zanubrutinib', '', '', '', '', 'v', 'ibrutinib', 'in', 'RR', '#CLL', 'N=652', 'ORR', '86%', 'v', '76%', '2yPFS', '80%', 'v', '63%.', 'OS', 'equiv,', 'prob', 'always', 'will', 'be', 'Cardiac', 'tox', 'lower', 'with', 'ZANU,', 'no', 'cardiac', 'death', 'v', '6', 'in', 'IBR', '(2%)!', 'One', 'caveat:', 'dead', 'kinase', 'muts', 'common', 'after', 'ZANU,', '?compromise', 'later', 'PIRTO?', 'See:', '.', 'Brown ALPINE', 'ALPINE RCT', 'RCT #ASH22', '#ASH22 zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' v', 'v ibrutinib', 'ibrutinib in', 'in RR', 'RR #CLL', '#CLL N=652', 'N=652 ORR', 'ORR 86%', '86% v', 'v 76%', '76% 2yPFS', '2yPFS 80%', '80% v', 'v 63%.', '63%. OS', 'OS equiv,', 'equiv, prob', 'prob always', 'always will', 'will be', 'be Cardiac', 'Cardiac tox', 'tox lower', 'lower with', 'with ZANU,', 'ZANU, no', 'no cardiac', 'cardiac death', 'death v', 'v 6', '6 in', 'in IBR', 'IBR (2%)!', '(2%)! One', 'One caveat:', 'caveat: dead', 'dead kinase', 'kinase muts', 'muts common', 'common after', 'after ZANU,', 'ZANU, ?compromise', '?compromise later', 'later PIRTO?', 'PIRTO? See:', 'See: .', 'Brown ALPINE RCT', 'ALPINE RCT #ASH22', 'RCT #ASH22 zanubrutinib', '#ASH22 zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  v', ' v ibrutinib', 'v ibrutinib in', 'ibrutinib in RR', 'in RR #CLL', 'RR #CLL N=652', '#CLL N=652 ORR', 'N=652 ORR 86%', 'ORR 86% v', '86% v 76%', 'v 76% 2yPFS', '76% 2yPFS 80%', '2yPFS 80% v', '80% v 63%.', 'v 63%. OS', '63%. OS equiv,', 'OS equiv, prob', 'equiv, prob always', 'prob always will', 'always will be', 'will be Cardiac', 'be Cardiac tox', 'Cardiac tox lower', 'tox lower with', 'lower with ZANU,', 'with ZANU, no', 'ZANU, no cardiac', 'no cardiac death', 'cardiac death v', 'death v 6', 'v 6 in', '6 in IBR', 'in IBR (2%)!', 'IBR (2%)! One', '(2%)! One caveat:', 'One caveat: dead', 'caveat: dead kinase', 'dead kinase muts', 'kinase muts common', 'muts common after', 'common after ZANU,', 'after ZANU, ?compromise', 'ZANU, ?compromise later', '?compromise later PIRTO?', 'later PIRTO? See:', 'PIRTO? See: .', 'Brown ALPINE RCT #ASH22', 'ALPINE RCT #ASH22 zanubrutinib', 'RCT #ASH22 zanubrutinib ', '#ASH22 zanubrutinib  ', 'zanubrutinib   ', '   ', '   v', '  v ibrutinib', ' v ibrutinib in', 'v ibrutinib in RR', 'ibrutinib in RR #CLL', 'in RR #CLL N=652', 'RR #CLL N=652 ORR', '#CLL N=652 ORR 86%', 'N=652 ORR 86% v', 'ORR 86% v 76%', '86% v 76% 2yPFS', 'v 76% 2yPFS 80%', '76% 2yPFS 80% v', '2yPFS 80% v 63%.', '80% v 63%. OS', 'v 63%. OS equiv,', '63%. OS equiv, prob', 'OS equiv, prob always', 'equiv, prob always will', 'prob always will be', 'always will be Cardiac', 'will be Cardiac tox', 'be Cardiac tox lower', 'Cardiac tox lower with', 'tox lower with ZANU,', 'lower with ZANU, no', 'with ZANU, no cardiac', 'ZANU, no cardiac death', 'no cardiac death v', 'cardiac death v 6', 'death v 6 in', 'v 6 in IBR', '6 in IBR (2%)!', 'in IBR (2%)! One', 'IBR (2%)! One caveat:', '(2%)! One caveat: dead', 'One caveat: dead kinase', 'caveat: dead kinase muts', 'dead kinase muts common', 'kinase muts common after', 'muts common after ZANU,', 'common after ZANU, ?compromise', 'after ZANU, ?compromise later', 'ZANU, ?compromise later PIRTO?', '?compromise later PIRTO? See:', 'later PIRTO? See: .', 'Brown ALPINE RCT #ASH22 zanubrutinib', 'ALPINE RCT #ASH22 zanubrutinib ', 'RCT #ASH22 zanubrutinib  ', '#ASH22 zanubrutinib   ', 'zanubrutinib    ', '    v', '   v ibrutinib', '  v ibrutinib in', ' v ibrutinib in RR', 'v ibrutinib in RR #CLL', 'ibrutinib in RR #CLL N=652', 'in RR #CLL N=652 ORR', 'RR #CLL N=652 ORR 86%', '#CLL N=652 ORR 86% v', 'N=652 ORR 86% v 76%', 'ORR 86% v 76% 2yPFS', '86% v 76% 2yPFS 80%', 'v 76% 2yPFS 80% v', '76% 2yPFS 80% v 63%.', '2yPFS 80% v 63%. OS', '80% v 63%. OS equiv,', 'v 63%. OS equiv, prob', '63%. OS equiv, prob always', 'OS equiv, prob always will', 'equiv, prob always will be', 'prob always will be Cardiac', 'always will be Cardiac tox', 'will be Cardiac tox lower', 'be Cardiac tox lower with', 'Cardiac tox lower with ZANU,', 'tox lower with ZANU, no', 'lower with ZANU, no cardiac', 'with ZANU, no cardiac death', 'ZANU, no cardiac death v', 'no cardiac death v 6', 'cardiac death v 6 in', 'death v 6 in IBR', 'v 6 in IBR (2%)!', '6 in IBR (2%)! One', 'in IBR (2%)! One caveat:', 'IBR (2%)! One caveat: dead', '(2%)! One caveat: dead kinase', 'One caveat: dead kinase muts', 'caveat: dead kinase muts common', 'dead kinase muts common after', 'kinase muts common after ZANU,', 'muts common after ZANU, ?compromise', 'common after ZANU, ?compromise later', 'after ZANU, ?compromise later PIRTO?', 'ZANU, ?compromise later PIRTO? See:', '?compromise later PIRTO? See: .', 'Brown ALPINE RCT #ASH22 zanubrutinib ', 'ALPINE RCT #ASH22 zanubrutinib  ', 'RCT #ASH22 zanubrutinib   ', '#ASH22 zanubrutinib    ', 'zanubrutinib     v', '    v ibrutinib', '   v ibrutinib in', '  v ibrutinib in RR', ' v ibrutinib in RR #CLL', 'v ibrutinib in RR #CLL N=652', 'ibrutinib in RR #CLL N=652 ORR', 'in RR #CLL N=652 ORR 86%', 'RR #CLL N=652 ORR 86% v', '#CLL N=652 ORR 86% v 76%', 'N=652 ORR 86% v 76% 2yPFS', 'ORR 86% v 76% 2yPFS 80%', '86% v 76% 2yPFS 80% v', 'v 76% 2yPFS 80% v 63%.', '76% 2yPFS 80% v 63%. OS', '2yPFS 80% v 63%. OS equiv,', '80% v 63%. OS equiv, prob', 'v 63%. OS equiv, prob always', '63%. OS equiv, prob always will', 'OS equiv, prob always will be', 'equiv, prob always will be Cardiac', 'prob always will be Cardiac tox', 'always will be Cardiac tox lower', 'will be Cardiac tox lower with', 'be Cardiac tox lower with ZANU,', 'Cardiac tox lower with ZANU, no', 'tox lower with ZANU, no cardiac', 'lower with ZANU, no cardiac death', 'with ZANU, no cardiac death v', 'ZANU, no cardiac death v 6', 'no cardiac death v 6 in', 'cardiac death v 6 in IBR', 'death v 6 in IBR (2%)!', 'v 6 in IBR (2%)! One', '6 in IBR (2%)! One caveat:', 'in IBR (2%)! One caveat: dead', 'IBR (2%)! One caveat: dead kinase', '(2%)! One caveat: dead kinase muts', 'One caveat: dead kinase muts common', 'caveat: dead kinase muts common after', 'dead kinase muts common after ZANU,', 'kinase muts common after ZANU, ?compromise', 'muts common after ZANU, ?compromise later', 'common after ZANU, ?compromise later PIRTO?', 'after ZANU, ?compromise later PIRTO? See:', 'ZANU, ?compromise later PIRTO? See: .', 'Brown ALPINE RCT #ASH22 zanubrutinib  ', 'ALPINE RCT #ASH22 zanubrutinib   ', 'RCT #ASH22 zanubrutinib    ', '#ASH22 zanubrutinib     v', 'zanubrutinib     v ibrutinib', '    v ibrutinib in', '   v ibrutinib in RR', '  v ibrutinib in RR #CLL', ' v ibrutinib in RR #CLL N=652', 'v ibrutinib in RR #CLL N=652 ORR', 'ibrutinib in RR #CLL N=652 ORR 86%', 'in RR #CLL N=652 ORR 86% v', 'RR #CLL N=652 ORR 86% v 76%', '#CLL N=652 ORR 86% v 76% 2yPFS', 'N=652 ORR 86% v 76% 2yPFS 80%', 'ORR 86% v 76% 2yPFS 80% v', '86% v 76% 2yPFS 80% v 63%.', 'v 76% 2yPFS 80% v 63%. OS', '76% 2yPFS 80% v 63%. OS equiv,', '2yPFS 80% v 63%. OS equiv, prob', '80% v 63%. OS equiv, prob always', 'v 63%. OS equiv, prob always will', '63%. OS equiv, prob always will be', 'OS equiv, prob always will be Cardiac', 'equiv, prob always will be Cardiac tox', 'prob always will be Cardiac tox lower', 'always will be Cardiac tox lower with', 'will be Cardiac tox lower with ZANU,', 'be Cardiac tox lower with ZANU, no', 'Cardiac tox lower with ZANU, no cardiac', 'tox lower with ZANU, no cardiac death', 'lower with ZANU, no cardiac death v', 'with ZANU, no cardiac death v 6', 'ZANU, no cardiac death v 6 in', 'no cardiac death v 6 in IBR', 'cardiac death v 6 in IBR (2%)!', 'death v 6 in IBR (2%)! One', 'v 6 in IBR (2%)! One caveat:', '6 in IBR (2%)! One caveat: dead', 'in IBR (2%)! One caveat: dead kinase', 'IBR (2%)! One caveat: dead kinase muts', '(2%)! One caveat: dead kinase muts common', 'One caveat: dead kinase muts common after', 'caveat: dead kinase muts common after ZANU,', 'dead kinase muts common after ZANU, ?compromise', 'kinase muts common after ZANU, ?compromise later', 'muts common after ZANU, ?compromise later PIRTO?', 'common after ZANU, ?compromise later PIRTO? See:', 'after ZANU, ?compromise later PIRTO? See: .', 'Brown ALPINE RCT #ASH22 zanubrutinib   ', 'ALPINE RCT #ASH22 zanubrutinib    ', 'RCT #ASH22 zanubrutinib     v', '#ASH22 zanubrutinib     v ibrutinib', 'zanubrutinib     v ibrutinib in', '    v ibrutinib in RR', '   v ibrutinib in RR #CLL', '  v ibrutinib in RR #CLL N=652', ' v ibrutinib in RR #CLL N=652 ORR', 'v ibrutinib in RR #CLL N=652 ORR 86%', 'ibrutinib in RR #CLL N=652 ORR 86% v', 'in RR #CLL N=652 ORR 86% v 76%', 'RR #CLL N=652 ORR 86% v 76% 2yPFS', '#CLL N=652 ORR 86% v 76% 2yPFS 80%', 'N=652 ORR 86% v 76% 2yPFS 80% v', 'ORR 86% v 76% 2yPFS 80% v 63%.', '86% v 76% 2yPFS 80% v 63%. OS', 'v 76% 2yPFS 80% v 63%. OS equiv,', '76% 2yPFS 80% v 63%. OS equiv, prob', '2yPFS 80% v 63%. OS equiv, prob always', '80% v 63%. OS equiv, prob always will', 'v 63%. OS equiv, prob always will be', '63%. OS equiv, prob always will be Cardiac', 'OS equiv, prob always will be Cardiac tox', 'equiv, prob always will be Cardiac tox lower', 'prob always will be Cardiac tox lower with', 'always will be Cardiac tox lower with ZANU,', 'will be Cardiac tox lower with ZANU, no', 'be Cardiac tox lower with ZANU, no cardiac', 'Cardiac tox lower with ZANU, no cardiac death', 'tox lower with ZANU, no cardiac death v', 'lower with ZANU, no cardiac death v 6', 'with ZANU, no cardiac death v 6 in', 'ZANU, no cardiac death v 6 in IBR', 'no cardiac death v 6 in IBR (2%)!', 'cardiac death v 6 in IBR (2%)! One', 'death v 6 in IBR (2%)! One caveat:', 'v 6 in IBR (2%)! One caveat: dead', '6 in IBR (2%)! One caveat: dead kinase', 'in IBR (2%)! One caveat: dead kinase muts', 'IBR (2%)! One caveat: dead kinase muts common', '(2%)! One caveat: dead kinase muts common after', 'One caveat: dead kinase muts common after ZANU,', 'caveat: dead kinase muts common after ZANU, ?compromise', 'dead kinase muts common after ZANU, ?compromise later', 'kinase muts common after ZANU, ?compromise later PIRTO?', 'muts common after ZANU, ?compromise later PIRTO? See:', 'common after ZANU, ?compromise later PIRTO? See: .'], 'spans_aspect_label': [0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '23', 'tokens': ['PROs', 'were', 'collected', 'in', 'the', 'ALPINE', 'RCT', 'of', 'zanubrutinib', '', '', '', '', 'vs', 'ibrutinib', 'just', 'reported', '#ASH22', '(EQ-5D-5L', 'and', 'EORTC', 'QLQ-C30', 'per', 'their', 'protocol),', 'but', 'nothing', 'was', 'yet', 'reported', 'in', 'the', '@NEJM', 'paper.', '', '.'], 'text_length': 36, 'triples': {'ALPINE|PROs were collected': ([5, 5], [0, 2], 'positive'), 'zanubrutinib|PROs were collected': ([8, 8], [0, 2], 'positive'), 'ibrutinib|reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30 per their protocol), but nothing was yet reported': ([10, 10], [12, 25], 'neutral')}, 'sentence': 'PROs were collected in the ALPINE RCT of zanubrutinib     vs ibrutinib just reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30 per their protocol), but nothing was yet reported in the @NEJM paper.  .', 'aspect_num': 3, 'spans_aspect2opinion_label': [(5, 5), (8, 8), (10, 10)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(0, 2), (12, 25)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8)], 'span tokens': ['PROs', 'were', 'collected', 'in', 'the', 'ALPINE', 'RCT', 'of', 'zanubrutinib', '', '', '', '', 'vs', 'ibrutinib', 'just', 'reported', '#ASH22', '(EQ-5D-5L', 'and', 'EORTC', 'QLQ-C30', 'per', 'their', 'protocol),', 'but', 'nothing', 'was', 'yet', 'reported', 'in', 'the', '@NEJM', 'paper.', '', '.', 'PROs were', 'were collected', 'collected in', 'in the', 'the ALPINE', 'ALPINE RCT', 'RCT of', 'of zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' vs', 'vs ibrutinib', 'ibrutinib just', 'just reported', 'reported #ASH22', '#ASH22 (EQ-5D-5L', '(EQ-5D-5L and', 'and EORTC', 'EORTC QLQ-C30', 'QLQ-C30 per', 'per their', 'their protocol),', 'protocol), but', 'but nothing', 'nothing was', 'was yet', 'yet reported', 'reported in', 'in the', 'the @NEJM', '@NEJM paper.', 'paper. ', ' .', 'PROs were collected', 'were collected in', 'collected in the', 'in the ALPINE', 'the ALPINE RCT', 'ALPINE RCT of', 'RCT of zanubrutinib', 'of zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  vs', ' vs ibrutinib', 'vs ibrutinib just', 'ibrutinib just reported', 'just reported #ASH22', 'reported #ASH22 (EQ-5D-5L', '#ASH22 (EQ-5D-5L and', '(EQ-5D-5L and EORTC', 'and EORTC QLQ-C30', 'EORTC QLQ-C30 per', 'QLQ-C30 per their', 'per their protocol),', 'their protocol), but', 'protocol), but nothing', 'but nothing was', 'nothing was yet', 'was yet reported', 'yet reported in', 'reported in the', 'in the @NEJM', 'the @NEJM paper.', '@NEJM paper. ', 'paper.  .', 'PROs were collected in', 'were collected in the', 'collected in the ALPINE', 'in the ALPINE RCT', 'the ALPINE RCT of', 'ALPINE RCT of zanubrutinib', 'RCT of zanubrutinib ', 'of zanubrutinib  ', 'zanubrutinib   ', '   ', '   vs', '  vs ibrutinib', ' vs ibrutinib just', 'vs ibrutinib just reported', 'ibrutinib just reported #ASH22', 'just reported #ASH22 (EQ-5D-5L', 'reported #ASH22 (EQ-5D-5L and', '#ASH22 (EQ-5D-5L and EORTC', '(EQ-5D-5L and EORTC QLQ-C30', 'and EORTC QLQ-C30 per', 'EORTC QLQ-C30 per their', 'QLQ-C30 per their protocol),', 'per their protocol), but', 'their protocol), but nothing', 'protocol), but nothing was', 'but nothing was yet', 'nothing was yet reported', 'was yet reported in', 'yet reported in the', 'reported in the @NEJM', 'in the @NEJM paper.', 'the @NEJM paper. ', '@NEJM paper.  .', 'PROs were collected in the', 'were collected in the ALPINE', 'collected in the ALPINE RCT', 'in the ALPINE RCT of', 'the ALPINE RCT of zanubrutinib', 'ALPINE RCT of zanubrutinib ', 'RCT of zanubrutinib  ', 'of zanubrutinib   ', 'zanubrutinib    ', '    vs', '   vs ibrutinib', '  vs ibrutinib just', ' vs ibrutinib just reported', 'vs ibrutinib just reported #ASH22', 'ibrutinib just reported #ASH22 (EQ-5D-5L', 'just reported #ASH22 (EQ-5D-5L and', 'reported #ASH22 (EQ-5D-5L and EORTC', '#ASH22 (EQ-5D-5L and EORTC QLQ-C30', '(EQ-5D-5L and EORTC QLQ-C30 per', 'and EORTC QLQ-C30 per their', 'EORTC QLQ-C30 per their protocol),', 'QLQ-C30 per their protocol), but', 'per their protocol), but nothing', 'their protocol), but nothing was', 'protocol), but nothing was yet', 'but nothing was yet reported', 'nothing was yet reported in', 'was yet reported in the', 'yet reported in the @NEJM', 'reported in the @NEJM paper.', 'in the @NEJM paper. ', 'the @NEJM paper.  .', 'PROs were collected in the ALPINE', 'were collected in the ALPINE RCT', 'collected in the ALPINE RCT of', 'in the ALPINE RCT of zanubrutinib', 'the ALPINE RCT of zanubrutinib ', 'ALPINE RCT of zanubrutinib  ', 'RCT of zanubrutinib   ', 'of zanubrutinib    ', 'zanubrutinib     vs', '    vs ibrutinib', '   vs ibrutinib just', '  vs ibrutinib just reported', ' vs ibrutinib just reported #ASH22', 'vs ibrutinib just reported #ASH22 (EQ-5D-5L', 'ibrutinib just reported #ASH22 (EQ-5D-5L and', 'just reported #ASH22 (EQ-5D-5L and EORTC', 'reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30', '#ASH22 (EQ-5D-5L and EORTC QLQ-C30 per', '(EQ-5D-5L and EORTC QLQ-C30 per their', 'and EORTC QLQ-C30 per their protocol),', 'EORTC QLQ-C30 per their protocol), but', 'QLQ-C30 per their protocol), but nothing', 'per their protocol), but nothing was', 'their protocol), but nothing was yet', 'protocol), but nothing was yet reported', 'but nothing was yet reported in', 'nothing was yet reported in the', 'was yet reported in the @NEJM', 'yet reported in the @NEJM paper.', 'reported in the @NEJM paper. ', 'in the @NEJM paper.  .', 'PROs were collected in the ALPINE RCT', 'were collected in the ALPINE RCT of', 'collected in the ALPINE RCT of zanubrutinib', 'in the ALPINE RCT of zanubrutinib ', 'the ALPINE RCT of zanubrutinib  ', 'ALPINE RCT of zanubrutinib   ', 'RCT of zanubrutinib    ', 'of zanubrutinib     vs', 'zanubrutinib     vs ibrutinib', '    vs ibrutinib just', '   vs ibrutinib just reported', '  vs ibrutinib just reported #ASH22', ' vs ibrutinib just reported #ASH22 (EQ-5D-5L', 'vs ibrutinib just reported #ASH22 (EQ-5D-5L and', 'ibrutinib just reported #ASH22 (EQ-5D-5L and EORTC', 'just reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30', 'reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30 per', '#ASH22 (EQ-5D-5L and EORTC QLQ-C30 per their', '(EQ-5D-5L and EORTC QLQ-C30 per their protocol),', 'and EORTC QLQ-C30 per their protocol), but', 'EORTC QLQ-C30 per their protocol), but nothing', 'QLQ-C30 per their protocol), but nothing was', 'per their protocol), but nothing was yet', 'their protocol), but nothing was yet reported', 'protocol), but nothing was yet reported in', 'but nothing was yet reported in the', 'nothing was yet reported in the @NEJM', 'was yet reported in the @NEJM paper.', 'yet reported in the @NEJM paper. ', 'reported in the @NEJM paper.  .', 'PROs were collected in the ALPINE RCT of', 'were collected in the ALPINE RCT of zanubrutinib', 'collected in the ALPINE RCT of zanubrutinib ', 'in the ALPINE RCT of zanubrutinib  ', 'the ALPINE RCT of zanubrutinib   ', 'ALPINE RCT of zanubrutinib    ', 'RCT of zanubrutinib     vs', 'of zanubrutinib     vs ibrutinib', 'zanubrutinib     vs ibrutinib just', '    vs ibrutinib just reported', '   vs ibrutinib just reported #ASH22', '  vs ibrutinib just reported #ASH22 (EQ-5D-5L', ' vs ibrutinib just reported #ASH22 (EQ-5D-5L and', 'vs ibrutinib just reported #ASH22 (EQ-5D-5L and EORTC', 'ibrutinib just reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30', 'just reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30 per', 'reported #ASH22 (EQ-5D-5L and EORTC QLQ-C30 per their', '#ASH22 (EQ-5D-5L and EORTC QLQ-C30 per their protocol),', '(EQ-5D-5L and EORTC QLQ-C30 per their protocol), but', 'and EORTC QLQ-C30 per their protocol), but nothing', 'EORTC QLQ-C30 per their protocol), but nothing was', 'QLQ-C30 per their protocol), but nothing was yet', 'per their protocol), but nothing was yet reported', 'their protocol), but nothing was yet reported in', 'protocol), but nothing was yet reported in the', 'but nothing was yet reported in the @NEJM', 'nothing was yet reported in the @NEJM paper.', 'was yet reported in the @NEJM paper. ', 'yet reported in the @NEJM paper.  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '24', 'tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'ALPINE', 'is', 'the', 'first', 'ph3', 'RCT', 'comparing', 'two', 'BTKi', 'head', 'to', 'head', 'in', 'RR', 'CLL/SLL.', '.'], 'text_length': 20, 'triples': {'ALPINE|first ph3 RCT comparing': ([4, 4], [7, 10], 'neutral')}, 'sentence': '#ASH22 #leusm #lymsm Brown: ALPINE is the first ph3 RCT comparing two BTKi head to head in RR CLL/SLL. .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(4, 4)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['#ASH22', '#leusm', '#lymsm', 'Brown:', 'ALPINE', 'is', 'the', 'first', 'ph3', 'RCT', 'comparing', 'two', 'BTKi', 'head', 'to', 'head', 'in', 'RR', 'CLL/SLL.', '.', '#ASH22 #leusm', '#leusm #lymsm', '#lymsm Brown:', 'Brown: ALPINE', 'ALPINE is', 'is the', 'the first', 'first ph3', 'ph3 RCT', 'RCT comparing', 'comparing two', 'two BTKi', 'BTKi head', 'head to', 'to head', 'head in', 'in RR', 'RR CLL/SLL.', 'CLL/SLL. .', '#ASH22 #leusm #lymsm', '#leusm #lymsm Brown:', '#lymsm Brown: ALPINE', 'Brown: ALPINE is', 'ALPINE is the', 'is the first', 'the first ph3', 'first ph3 RCT', 'ph3 RCT comparing', 'RCT comparing two', 'comparing two BTKi', 'two BTKi head', 'BTKi head to', 'head to head', 'to head in', 'head in RR', 'in RR CLL/SLL.', 'RR CLL/SLL. .', '#ASH22 #leusm #lymsm Brown:', '#leusm #lymsm Brown: ALPINE', '#lymsm Brown: ALPINE is', 'Brown: ALPINE is the', 'ALPINE is the first', 'is the first ph3', 'the first ph3 RCT', 'first ph3 RCT comparing', 'ph3 RCT comparing two', 'RCT comparing two BTKi', 'comparing two BTKi head', 'two BTKi head to', 'BTKi head to head', 'head to head in', 'to head in RR', 'head in RR CLL/SLL.', 'in RR CLL/SLL. .', '#ASH22 #leusm #lymsm Brown: ALPINE', '#leusm #lymsm Brown: ALPINE is', '#lymsm Brown: ALPINE is the', 'Brown: ALPINE is the first', 'ALPINE is the first ph3', 'is the first ph3 RCT', 'the first ph3 RCT comparing', 'first ph3 RCT comparing two', 'ph3 RCT comparing two BTKi', 'RCT comparing two BTKi head', 'comparing two BTKi head to', 'two BTKi head to head', 'BTKi head to head in', 'head to head in RR', 'to head in RR CLL/SLL.', 'head in RR CLL/SLL. .', '#ASH22 #leusm #lymsm Brown: ALPINE is', '#leusm #lymsm Brown: ALPINE is the', '#lymsm Brown: ALPINE is the first', 'Brown: ALPINE is the first ph3', 'ALPINE is the first ph3 RCT', 'is the first ph3 RCT comparing', 'the first ph3 RCT comparing two', 'first ph3 RCT comparing two BTKi', 'ph3 RCT comparing two BTKi head', 'RCT comparing two BTKi head to', 'comparing two BTKi head to head', 'two BTKi head to head in', 'BTKi head to head in RR', 'head to head in RR CLL/SLL.', 'to head in RR CLL/SLL. .', '#ASH22 #leusm #lymsm Brown: ALPINE is the', '#leusm #lymsm Brown: ALPINE is the first', '#lymsm Brown: ALPINE is the first ph3', 'Brown: ALPINE is the first ph3 RCT', 'ALPINE is the first ph3 RCT comparing', 'is the first ph3 RCT comparing two', 'the first ph3 RCT comparing two BTKi', 'first ph3 RCT comparing two BTKi head', 'ph3 RCT comparing two BTKi head to', 'RCT comparing two BTKi head to head', 'comparing two BTKi head to head in', 'two BTKi head to head in RR', 'BTKi head to head in RR CLL/SLL.', 'head to head in RR CLL/SLL. .', '#ASH22 #leusm #lymsm Brown: ALPINE is the first', '#leusm #lymsm Brown: ALPINE is the first ph3', '#lymsm Brown: ALPINE is the first ph3 RCT', 'Brown: ALPINE is the first ph3 RCT comparing', 'ALPINE is the first ph3 RCT comparing two', 'is the first ph3 RCT comparing two BTKi', 'the first ph3 RCT comparing two BTKi head', 'first ph3 RCT comparing two BTKi head to', 'ph3 RCT comparing two BTKi head to head', 'RCT comparing two BTKi head to head in', 'comparing two BTKi head to head in RR', 'two BTKi head to head in RR CLL/SLL.', 'BTKi head to head in RR CLL/SLL. .'], 'spans_aspect_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '25', 'tokens': ['Great', 'to', 'hear', 'results', 'of', 'ground', 'breaking', 'research', 'on', 'the', 'day', 'of', 'manuscript', 'publication', '!', 'Dr', 'Jennifer', 'Brown', '@DanaFarber', 'shares', 'results', 'of', 'the', 'ALPINE', 'randomized', 'phase', '3', 'study', '@ASH_hematology', '#ASH22', '', '.'], 'text_length': 32, 'triples': {'the|Great to hear results of ground breaking research on the day of manuscript publication ! Dr Jennifer Brown @DanaFarber shares': ([22, 22], [0, 19], 'positive')}, 'sentence': 'Great to hear results of ground breaking research on the day of manuscript publication ! Dr Jennifer Brown @DanaFarber shares results of the ALPINE randomized phase 3 study @ASH_hematology #ASH22  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(22, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(0, 19)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['Great', 'to', 'hear', 'results', 'of', 'ground', 'breaking', 'research', 'on', 'the', 'day', 'of', 'manuscript', 'publication', '!', 'Dr', 'Jennifer', 'Brown', '@DanaFarber', 'shares', 'results', 'of', 'the', 'ALPINE', 'randomized', 'phase', '3', 'study', '@ASH_hematology', '#ASH22', '', '.', 'Great to', 'to hear', 'hear results', 'results of', 'of ground', 'ground breaking', 'breaking research', 'research on', 'on the', 'the day', 'day of', 'of manuscript', 'manuscript publication', 'publication !', '! Dr', 'Dr Jennifer', 'Jennifer Brown', 'Brown @DanaFarber', '@DanaFarber shares', 'shares results', 'results of', 'of the', 'the ALPINE', 'ALPINE randomized', 'randomized phase', 'phase 3', '3 study', 'study @ASH_hematology', '@ASH_hematology #ASH22', '#ASH22 ', ' .', 'Great to hear', 'to hear results', 'hear results of', 'results of ground', 'of ground breaking', 'ground breaking research', 'breaking research on', 'research on the', 'on the day', 'the day of', 'day of manuscript', 'of manuscript publication', 'manuscript publication !', 'publication ! Dr', '! Dr Jennifer', 'Dr Jennifer Brown', 'Jennifer Brown @DanaFarber', 'Brown @DanaFarber shares', '@DanaFarber shares results', 'shares results of', 'results of the', 'of the ALPINE', 'the ALPINE randomized', 'ALPINE randomized phase', 'randomized phase 3', 'phase 3 study', '3 study @ASH_hematology', 'study @ASH_hematology #ASH22', '@ASH_hematology #ASH22 ', '#ASH22  .', 'Great to hear results', 'to hear results of', 'hear results of ground', 'results of ground breaking', 'of ground breaking research', 'ground breaking research on', 'breaking research on the', 'research on the day', 'on the day of', 'the day of manuscript', 'day of manuscript publication', 'of manuscript publication !', 'manuscript publication ! Dr', 'publication ! Dr Jennifer', '! Dr Jennifer Brown', 'Dr Jennifer Brown @DanaFarber', 'Jennifer Brown @DanaFarber shares', 'Brown @DanaFarber shares results', '@DanaFarber shares results of', 'shares results of the', 'results of the ALPINE', 'of the ALPINE randomized', 'the ALPINE randomized phase', 'ALPINE randomized phase 3', 'randomized phase 3 study', 'phase 3 study @ASH_hematology', '3 study @ASH_hematology #ASH22', 'study @ASH_hematology #ASH22 ', '@ASH_hematology #ASH22  .', 'Great to hear results of', 'to hear results of ground', 'hear results of ground breaking', 'results of ground breaking research', 'of ground breaking research on', 'ground breaking research on the', 'breaking research on the day', 'research on the day of', 'on the day of manuscript', 'the day of manuscript publication', 'day of manuscript publication !', 'of manuscript publication ! Dr', 'manuscript publication ! Dr Jennifer', 'publication ! Dr Jennifer Brown', '! Dr Jennifer Brown @DanaFarber', 'Dr Jennifer Brown @DanaFarber shares', 'Jennifer Brown @DanaFarber shares results', 'Brown @DanaFarber shares results of', '@DanaFarber shares results of the', 'shares results of the ALPINE', 'results of the ALPINE randomized', 'of the ALPINE randomized phase', 'the ALPINE randomized phase 3', 'ALPINE randomized phase 3 study', 'randomized phase 3 study @ASH_hematology', 'phase 3 study @ASH_hematology #ASH22', '3 study @ASH_hematology #ASH22 ', 'study @ASH_hematology #ASH22  .', 'Great to hear results of ground', 'to hear results of ground breaking', 'hear results of ground breaking research', 'results of ground breaking research on', 'of ground breaking research on the', 'ground breaking research on the day', 'breaking research on the day of', 'research on the day of manuscript', 'on the day of manuscript publication', 'the day of manuscript publication !', 'day of manuscript publication ! Dr', 'of manuscript publication ! Dr Jennifer', 'manuscript publication ! Dr Jennifer Brown', 'publication ! Dr Jennifer Brown @DanaFarber', '! Dr Jennifer Brown @DanaFarber shares', 'Dr Jennifer Brown @DanaFarber shares results', 'Jennifer Brown @DanaFarber shares results of', 'Brown @DanaFarber shares results of the', '@DanaFarber shares results of the ALPINE', 'shares results of the ALPINE randomized', 'results of the ALPINE randomized phase', 'of the ALPINE randomized phase 3', 'the ALPINE randomized phase 3 study', 'ALPINE randomized phase 3 study @ASH_hematology', 'randomized phase 3 study @ASH_hematology #ASH22', 'phase 3 study @ASH_hematology #ASH22 ', '3 study @ASH_hematology #ASH22  .', 'Great to hear results of ground breaking', 'to hear results of ground breaking research', 'hear results of ground breaking research on', 'results of ground breaking research on the', 'of ground breaking research on the day', 'ground breaking research on the day of', 'breaking research on the day of manuscript', 'research on the day of manuscript publication', 'on the day of manuscript publication !', 'the day of manuscript publication ! Dr', 'day of manuscript publication ! Dr Jennifer', 'of manuscript publication ! Dr Jennifer Brown', 'manuscript publication ! Dr Jennifer Brown @DanaFarber', 'publication ! Dr Jennifer Brown @DanaFarber shares', '! Dr Jennifer Brown @DanaFarber shares results', 'Dr Jennifer Brown @DanaFarber shares results of', 'Jennifer Brown @DanaFarber shares results of the', 'Brown @DanaFarber shares results of the ALPINE', '@DanaFarber shares results of the ALPINE randomized', 'shares results of the ALPINE randomized phase', 'results of the ALPINE randomized phase 3', 'of the ALPINE randomized phase 3 study', 'the ALPINE randomized phase 3 study @ASH_hematology', 'ALPINE randomized phase 3 study @ASH_hematology #ASH22', 'randomized phase 3 study @ASH_hematology #ASH22 ', 'phase 3 study @ASH_hematology #ASH22  .', 'Great to hear results of ground breaking research', 'to hear results of ground breaking research on', 'hear results of ground breaking research on the', 'results of ground breaking research on the day', 'of ground breaking research on the day of', 'ground breaking research on the day of manuscript', 'breaking research on the day of manuscript publication', 'research on the day of manuscript publication !', 'on the day of manuscript publication ! Dr', 'the day of manuscript publication ! Dr Jennifer', 'day of manuscript publication ! Dr Jennifer Brown', 'of manuscript publication ! Dr Jennifer Brown @DanaFarber', 'manuscript publication ! Dr Jennifer Brown @DanaFarber shares', 'publication ! Dr Jennifer Brown @DanaFarber shares results', '! Dr Jennifer Brown @DanaFarber shares results of', 'Dr Jennifer Brown @DanaFarber shares results of the', 'Jennifer Brown @DanaFarber shares results of the ALPINE', 'Brown @DanaFarber shares results of the ALPINE randomized', '@DanaFarber shares results of the ALPINE randomized phase', 'shares results of the ALPINE randomized phase 3', 'results of the ALPINE randomized phase 3 study', 'of the ALPINE randomized phase 3 study @ASH_hematology', 'the ALPINE randomized phase 3 study @ASH_hematology #ASH22', 'ALPINE randomized phase 3 study @ASH_hematology #ASH22 ', 'randomized phase 3 study @ASH_hematology #ASH22  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '26', 'tokens': ['swog', 's1801:', 'neoadjuvant', 'and', 'adjuvant', 'pembrolizumab', 'for', 'patients', 'with', 'stage', 'iiib', 'to', 'iv', 'melanoma', 'had', 'dissapointing', 'results', '#melsm', '#skcsm', '#immunotherapy', '#oncology', '#esmo22', '.'], 'text_length': 23, 'triples': {'s1801:|dissapointing results': ([1, 1], [15, 16], 'negative')}, 'sentence': 'swog s1801: neoadjuvant and adjuvant pembrolizumab for patients with stage iiib to iv melanoma had dissapointing results #melsm #skcsm #immunotherapy #oncology #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(15, 16)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8)], 'span tokens': ['swog', 's1801:', 'neoadjuvant', 'and', 'adjuvant', 'pembrolizumab', 'for', 'patients', 'with', 'stage', 'iiib', 'to', 'iv', 'melanoma', 'had', 'dissapointing', 'results', '#melsm', '#skcsm', '#immunotherapy', '#oncology', '#esmo22', '.', 'swog s1801:', 's1801: neoadjuvant', 'neoadjuvant and', 'and adjuvant', 'adjuvant pembrolizumab', 'pembrolizumab for', 'for patients', 'patients with', 'with stage', 'stage iiib', 'iiib to', 'to iv', 'iv melanoma', 'melanoma had', 'had dissapointing', 'dissapointing results', 'results #melsm', '#melsm #skcsm', '#skcsm #immunotherapy', '#immunotherapy #oncology', '#oncology #esmo22', '#esmo22 .', 'swog s1801: neoadjuvant', 's1801: neoadjuvant and', 'neoadjuvant and adjuvant', 'and adjuvant pembrolizumab', 'adjuvant pembrolizumab for', 'pembrolizumab for patients', 'for patients with', 'patients with stage', 'with stage iiib', 'stage iiib to', 'iiib to iv', 'to iv melanoma', 'iv melanoma had', 'melanoma had dissapointing', 'had dissapointing results', 'dissapointing results #melsm', 'results #melsm #skcsm', '#melsm #skcsm #immunotherapy', '#skcsm #immunotherapy #oncology', '#immunotherapy #oncology #esmo22', '#oncology #esmo22 .', 'swog s1801: neoadjuvant and', 's1801: neoadjuvant and adjuvant', 'neoadjuvant and adjuvant pembrolizumab', 'and adjuvant pembrolizumab for', 'adjuvant pembrolizumab for patients', 'pembrolizumab for patients with', 'for patients with stage', 'patients with stage iiib', 'with stage iiib to', 'stage iiib to iv', 'iiib to iv melanoma', 'to iv melanoma had', 'iv melanoma had dissapointing', 'melanoma had dissapointing results', 'had dissapointing results #melsm', 'dissapointing results #melsm #skcsm', 'results #melsm #skcsm #immunotherapy', '#melsm #skcsm #immunotherapy #oncology', '#skcsm #immunotherapy #oncology #esmo22', '#immunotherapy #oncology #esmo22 .', 'swog s1801: neoadjuvant and adjuvant', 's1801: neoadjuvant and adjuvant pembrolizumab', 'neoadjuvant and adjuvant pembrolizumab for', 'and adjuvant pembrolizumab for patients', 'adjuvant pembrolizumab for patients with', 'pembrolizumab for patients with stage', 'for patients with stage iiib', 'patients with stage iiib to', 'with stage iiib to iv', 'stage iiib to iv melanoma', 'iiib to iv melanoma had', 'to iv melanoma had dissapointing', 'iv melanoma had dissapointing results', 'melanoma had dissapointing results #melsm', 'had dissapointing results #melsm #skcsm', 'dissapointing results #melsm #skcsm #immunotherapy', 'results #melsm #skcsm #immunotherapy #oncology', '#melsm #skcsm #immunotherapy #oncology #esmo22', '#skcsm #immunotherapy #oncology #esmo22 .', 'swog s1801: neoadjuvant and adjuvant pembrolizumab', 's1801: neoadjuvant and adjuvant pembrolizumab for', 'neoadjuvant and adjuvant pembrolizumab for patients', 'and adjuvant pembrolizumab for patients with', 'adjuvant pembrolizumab for patients with stage', 'pembrolizumab for patients with stage iiib', 'for patients with stage iiib to', 'patients with stage iiib to iv', 'with stage iiib to iv melanoma', 'stage iiib to iv melanoma had', 'iiib to iv melanoma had dissapointing', 'to iv melanoma had dissapointing results', 'iv melanoma had dissapointing results #melsm', 'melanoma had dissapointing results #melsm #skcsm', 'had dissapointing results #melsm #skcsm #immunotherapy', 'dissapointing results #melsm #skcsm #immunotherapy #oncology', 'results #melsm #skcsm #immunotherapy #oncology #esmo22', '#melsm #skcsm #immunotherapy #oncology #esmo22 .', 'swog s1801: neoadjuvant and adjuvant pembrolizumab for', 's1801: neoadjuvant and adjuvant pembrolizumab for patients', 'neoadjuvant and adjuvant pembrolizumab for patients with', 'and adjuvant pembrolizumab for patients with stage', 'adjuvant pembrolizumab for patients with stage iiib', 'pembrolizumab for patients with stage iiib to', 'for patients with stage iiib to iv', 'patients with stage iiib to iv melanoma', 'with stage iiib to iv melanoma had', 'stage iiib to iv melanoma had dissapointing', 'iiib to iv melanoma had dissapointing results', 'to iv melanoma had dissapointing results #melsm', 'iv melanoma had dissapointing results #melsm #skcsm', 'melanoma had dissapointing results #melsm #skcsm #immunotherapy', 'had dissapointing results #melsm #skcsm #immunotherapy #oncology', 'dissapointing results #melsm #skcsm #immunotherapy #oncology #esmo22', 'results #melsm #skcsm #immunotherapy #oncology #esmo22 .', 'swog s1801: neoadjuvant and adjuvant pembrolizumab for patients', 's1801: neoadjuvant and adjuvant pembrolizumab for patients with', 'neoadjuvant and adjuvant pembrolizumab for patients with stage', 'and adjuvant pembrolizumab for patients with stage iiib', 'adjuvant pembrolizumab for patients with stage iiib to', 'pembrolizumab for patients with stage iiib to iv', 'for patients with stage iiib to iv melanoma', 'patients with stage iiib to iv melanoma had', 'with stage iiib to iv melanoma had dissapointing', 'stage iiib to iv melanoma had dissapointing results', 'iiib to iv melanoma had dissapointing results #melsm', 'to iv melanoma had dissapointing results #melsm #skcsm', 'iv melanoma had dissapointing results #melsm #skcsm #immunotherapy', 'melanoma had dissapointing results #melsm #skcsm #immunotherapy #oncology', 'had dissapointing results #melsm #skcsm #immunotherapy #oncology #esmo22', 'dissapointing results #melsm #skcsm #immunotherapy #oncology #esmo22 .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '27', 'tokens': ['#pearls/#keynote-091', 'interim', 'analysis:', '#pembrolizumab', 'significantly', 'improved', 'disease-free', 'survival', 'compared', 'with', 'durvalumab', 'in', 'completely', 'resected,', 'pd-l1-unselected,', 'stage', 'ib', 'iiia', '#nsclc', '#dataviz', '#visualabstract', '#esmo22', '#esmo2022', '#lungcancer', '', '.'], 'text_length': 26, 'triples': {'#pembrolizumab|significantly improved disease-free survival': ([3, 3], [4, 7], 'positive'), 'durvalumab|significantly improved disease-free survival compared with': ([10, 10], [4, 9], 'negative')}, 'sentence': '#pearls/#keynote-091 interim analysis: #pembrolizumab significantly improved disease-free survival compared with durvalumab in completely resected, pd-l1-unselected, stage ib iiia #nsclc #dataviz #visualabstract #esmo22 #esmo2022 #lungcancer  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(3, 3), (10, 10)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(4, 7), (4, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['#pearls/#keynote-091', 'interim', 'analysis:', '#pembrolizumab', 'significantly', 'improved', 'disease-free', 'survival', 'compared', 'with', 'durvalumab', 'in', 'completely', 'resected,', 'pd-l1-unselected,', 'stage', 'ib', 'iiia', '#nsclc', '#dataviz', '#visualabstract', '#esmo22', '#esmo2022', '#lungcancer', '', '.', '#pearls/#keynote-091 interim', 'interim analysis:', 'analysis: #pembrolizumab', '#pembrolizumab significantly', 'significantly improved', 'improved disease-free', 'disease-free survival', 'survival compared', 'compared with', 'with durvalumab', 'durvalumab in', 'in completely', 'completely resected,', 'resected, pd-l1-unselected,', 'pd-l1-unselected, stage', 'stage ib', 'ib iiia', 'iiia #nsclc', '#nsclc #dataviz', '#dataviz #visualabstract', '#visualabstract #esmo22', '#esmo22 #esmo2022', '#esmo2022 #lungcancer', '#lungcancer ', ' .', '#pearls/#keynote-091 interim analysis:', 'interim analysis: #pembrolizumab', 'analysis: #pembrolizumab significantly', '#pembrolizumab significantly improved', 'significantly improved disease-free', 'improved disease-free survival', 'disease-free survival compared', 'survival compared with', 'compared with durvalumab', 'with durvalumab in', 'durvalumab in completely', 'in completely resected,', 'completely resected, pd-l1-unselected,', 'resected, pd-l1-unselected, stage', 'pd-l1-unselected, stage ib', 'stage ib iiia', 'ib iiia #nsclc', 'iiia #nsclc #dataviz', '#nsclc #dataviz #visualabstract', '#dataviz #visualabstract #esmo22', '#visualabstract #esmo22 #esmo2022', '#esmo22 #esmo2022 #lungcancer', '#esmo2022 #lungcancer ', '#lungcancer  .', '#pearls/#keynote-091 interim analysis: #pembrolizumab', 'interim analysis: #pembrolizumab significantly', 'analysis: #pembrolizumab significantly improved', '#pembrolizumab significantly improved disease-free', 'significantly improved disease-free survival', 'improved disease-free survival compared', 'disease-free survival compared with', 'survival compared with durvalumab', 'compared with durvalumab in', 'with durvalumab in completely', 'durvalumab in completely resected,', 'in completely resected, pd-l1-unselected,', 'completely resected, pd-l1-unselected, stage', 'resected, pd-l1-unselected, stage ib', 'pd-l1-unselected, stage ib iiia', 'stage ib iiia #nsclc', 'ib iiia #nsclc #dataviz', 'iiia #nsclc #dataviz #visualabstract', '#nsclc #dataviz #visualabstract #esmo22', '#dataviz #visualabstract #esmo22 #esmo2022', '#visualabstract #esmo22 #esmo2022 #lungcancer', '#esmo22 #esmo2022 #lungcancer ', '#esmo2022 #lungcancer  .', '#pearls/#keynote-091 interim analysis: #pembrolizumab significantly', 'interim analysis: #pembrolizumab significantly improved', 'analysis: #pembrolizumab significantly improved disease-free', '#pembrolizumab significantly improved disease-free survival', 'significantly improved disease-free survival compared', 'improved disease-free survival compared with', 'disease-free survival compared with durvalumab', 'survival compared with durvalumab in', 'compared with durvalumab in completely', 'with durvalumab in completely resected,', 'durvalumab in completely resected, pd-l1-unselected,', 'in completely resected, pd-l1-unselected, stage', 'completely resected, pd-l1-unselected, stage ib', 'resected, pd-l1-unselected, stage ib iiia', 'pd-l1-unselected, stage ib iiia #nsclc', 'stage ib iiia #nsclc #dataviz', 'ib iiia #nsclc #dataviz #visualabstract', 'iiia #nsclc #dataviz #visualabstract #esmo22', '#nsclc #dataviz #visualabstract #esmo22 #esmo2022', '#dataviz #visualabstract #esmo22 #esmo2022 #lungcancer', '#visualabstract #esmo22 #esmo2022 #lungcancer ', '#esmo22 #esmo2022 #lungcancer  .', '#pearls/#keynote-091 interim analysis: #pembrolizumab significantly improved', 'interim analysis: #pembrolizumab significantly improved disease-free', 'analysis: #pembrolizumab significantly improved disease-free survival', '#pembrolizumab significantly improved disease-free survival compared', 'significantly improved disease-free survival compared with', 'improved disease-free survival compared with durvalumab', 'disease-free survival compared with durvalumab in', 'survival compared with durvalumab in completely', 'compared with durvalumab in completely resected,', 'with durvalumab in completely resected, pd-l1-unselected,', 'durvalumab in completely resected, pd-l1-unselected, stage', 'in completely resected, pd-l1-unselected, stage ib', 'completely resected, pd-l1-unselected, stage ib iiia', 'resected, pd-l1-unselected, stage ib iiia #nsclc', 'pd-l1-unselected, stage ib iiia #nsclc #dataviz', 'stage ib iiia #nsclc #dataviz #visualabstract', 'ib iiia #nsclc #dataviz #visualabstract #esmo22', 'iiia #nsclc #dataviz #visualabstract #esmo22 #esmo2022', '#nsclc #dataviz #visualabstract #esmo22 #esmo2022 #lungcancer', '#dataviz #visualabstract #esmo22 #esmo2022 #lungcancer ', '#visualabstract #esmo22 #esmo2022 #lungcancer  .', '#pearls/#keynote-091 interim analysis: #pembrolizumab significantly improved disease-free', 'interim analysis: #pembrolizumab significantly improved disease-free survival', 'analysis: #pembrolizumab significantly improved disease-free survival compared', '#pembrolizumab significantly improved disease-free survival compared with', 'significantly improved disease-free survival compared with durvalumab', 'improved disease-free survival compared with durvalumab in', 'disease-free survival compared with durvalumab in completely', 'survival compared with durvalumab in completely resected,', 'compared with durvalumab in completely resected, pd-l1-unselected,', 'with durvalumab in completely resected, pd-l1-unselected, stage', 'durvalumab in completely resected, pd-l1-unselected, stage ib', 'in completely resected, pd-l1-unselected, stage ib iiia', 'completely resected, pd-l1-unselected, stage ib iiia #nsclc', 'resected, pd-l1-unselected, stage ib iiia #nsclc #dataviz', 'pd-l1-unselected, stage ib iiia #nsclc #dataviz #visualabstract', 'stage ib iiia #nsclc #dataviz #visualabstract #esmo22', 'ib iiia #nsclc #dataviz #visualabstract #esmo22 #esmo2022', 'iiia #nsclc #dataviz #visualabstract #esmo22 #esmo2022 #lungcancer', '#nsclc #dataviz #visualabstract #esmo22 #esmo2022 #lungcancer ', '#dataviz #visualabstract #esmo22 #esmo2022 #lungcancer  .', '#pearls/#keynote-091 interim analysis: #pembrolizumab significantly improved disease-free survival', 'interim analysis: #pembrolizumab significantly improved disease-free survival compared', 'analysis: #pembrolizumab significantly improved disease-free survival compared with', '#pembrolizumab significantly improved disease-free survival compared with durvalumab', 'significantly improved disease-free survival compared with durvalumab in', 'improved disease-free survival compared with durvalumab in completely', 'disease-free survival compared with durvalumab in completely resected,', 'survival compared with durvalumab in completely resected, pd-l1-unselected,', 'compared with durvalumab in completely resected, pd-l1-unselected, stage', 'with durvalumab in completely resected, pd-l1-unselected, stage ib', 'durvalumab in completely resected, pd-l1-unselected, stage ib iiia', 'in completely resected, pd-l1-unselected, stage ib iiia #nsclc', 'completely resected, pd-l1-unselected, stage ib iiia #nsclc #dataviz', 'resected, pd-l1-unselected, stage ib iiia #nsclc #dataviz #visualabstract', 'pd-l1-unselected, stage ib iiia #nsclc #dataviz #visualabstract #esmo22', 'stage ib iiia #nsclc #dataviz #visualabstract #esmo22 #esmo2022', 'ib iiia #nsclc #dataviz #visualabstract #esmo22 #esmo2022 #lungcancer', 'iiia #nsclc #dataviz #visualabstract #esmo22 #esmo2022 #lungcancer ', '#nsclc #dataviz #visualabstract #esmo22 #esmo2022 #lungcancer  .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '28', 'tokens': ['Depressed', 'to', 'see', 'no', 'major', 'advancements', 'in', '1l', 'hcc/btc', 'treatment', 'in', 'galaxy', 'study.', 'today', 'is', 'an', 'incredible', 'day', 'for', '#livercancer', 'with', 'two', 'positive', 'p3', 'presentations:', '1l', '#topaz', '(btc)', 'and', '1l', '#himalaya', '(hcc)', 'at', '#gi22!', '.'], 'text_length': 35, 'triples': {'galaxy|no major advancements': ([11, 11], [3, 5], 'negative')}, 'sentence': 'Depressed to see no major advancements in 1l hcc/btc treatment in galaxy study. today is an incredible day for #livercancer with two positive p3 presentations: 1l #topaz (btc) and 1l #himalaya (hcc) at #gi22! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(11, 11)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 5)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['Depressed', 'to', 'see', 'no', 'major', 'advancements', 'in', '1l', 'hcc/btc', 'treatment', 'in', 'galaxy', 'study.', 'today', 'is', 'an', 'incredible', 'day', 'for', '#livercancer', 'with', 'two', 'positive', 'p3', 'presentations:', '1l', '#topaz', '(btc)', 'and', '1l', '#himalaya', '(hcc)', 'at', '#gi22!', '.', 'Depressed to', 'to see', 'see no', 'no major', 'major advancements', 'advancements in', 'in 1l', '1l hcc/btc', 'hcc/btc treatment', 'treatment in', 'in galaxy', 'galaxy study.', 'study. today', 'today is', 'is an', 'an incredible', 'incredible day', 'day for', 'for #livercancer', '#livercancer with', 'with two', 'two positive', 'positive p3', 'p3 presentations:', 'presentations: 1l', '1l #topaz', '#topaz (btc)', '(btc) and', 'and 1l', '1l #himalaya', '#himalaya (hcc)', '(hcc) at', 'at #gi22!', '#gi22! .', 'Depressed to see', 'to see no', 'see no major', 'no major advancements', 'major advancements in', 'advancements in 1l', 'in 1l hcc/btc', '1l hcc/btc treatment', 'hcc/btc treatment in', 'treatment in galaxy', 'in galaxy study.', 'galaxy study. today', 'study. today is', 'today is an', 'is an incredible', 'an incredible day', 'incredible day for', 'day for #livercancer', 'for #livercancer with', '#livercancer with two', 'with two positive', 'two positive p3', 'positive p3 presentations:', 'p3 presentations: 1l', 'presentations: 1l #topaz', '1l #topaz (btc)', '#topaz (btc) and', '(btc) and 1l', 'and 1l #himalaya', '1l #himalaya (hcc)', '#himalaya (hcc) at', '(hcc) at #gi22!', 'at #gi22! .', 'Depressed to see no', 'to see no major', 'see no major advancements', 'no major advancements in', 'major advancements in 1l', 'advancements in 1l hcc/btc', 'in 1l hcc/btc treatment', '1l hcc/btc treatment in', 'hcc/btc treatment in galaxy', 'treatment in galaxy study.', 'in galaxy study. today', 'galaxy study. today is', 'study. today is an', 'today is an incredible', 'is an incredible day', 'an incredible day for', 'incredible day for #livercancer', 'day for #livercancer with', 'for #livercancer with two', '#livercancer with two positive', 'with two positive p3', 'two positive p3 presentations:', 'positive p3 presentations: 1l', 'p3 presentations: 1l #topaz', 'presentations: 1l #topaz (btc)', '1l #topaz (btc) and', '#topaz (btc) and 1l', '(btc) and 1l #himalaya', 'and 1l #himalaya (hcc)', '1l #himalaya (hcc) at', '#himalaya (hcc) at #gi22!', '(hcc) at #gi22! .', 'Depressed to see no major', 'to see no major advancements', 'see no major advancements in', 'no major advancements in 1l', 'major advancements in 1l hcc/btc', 'advancements in 1l hcc/btc treatment', 'in 1l hcc/btc treatment in', '1l hcc/btc treatment in galaxy', 'hcc/btc treatment in galaxy study.', 'treatment in galaxy study. today', 'in galaxy study. today is', 'galaxy study. today is an', 'study. today is an incredible', 'today is an incredible day', 'is an incredible day for', 'an incredible day for #livercancer', 'incredible day for #livercancer with', 'day for #livercancer with two', 'for #livercancer with two positive', '#livercancer with two positive p3', 'with two positive p3 presentations:', 'two positive p3 presentations: 1l', 'positive p3 presentations: 1l #topaz', 'p3 presentations: 1l #topaz (btc)', 'presentations: 1l #topaz (btc) and', '1l #topaz (btc) and 1l', '#topaz (btc) and 1l #himalaya', '(btc) and 1l #himalaya (hcc)', 'and 1l #himalaya (hcc) at', '1l #himalaya (hcc) at #gi22!', '#himalaya (hcc) at #gi22! .', 'Depressed to see no major advancements', 'to see no major advancements in', 'see no major advancements in 1l', 'no major advancements in 1l hcc/btc', 'major advancements in 1l hcc/btc treatment', 'advancements in 1l hcc/btc treatment in', 'in 1l hcc/btc treatment in galaxy', '1l hcc/btc treatment in galaxy study.', 'hcc/btc treatment in galaxy study. today', 'treatment in galaxy study. today is', 'in galaxy study. today is an', 'galaxy study. today is an incredible', 'study. today is an incredible day', 'today is an incredible day for', 'is an incredible day for #livercancer', 'an incredible day for #livercancer with', 'incredible day for #livercancer with two', 'day for #livercancer with two positive', 'for #livercancer with two positive p3', '#livercancer with two positive p3 presentations:', 'with two positive p3 presentations: 1l', 'two positive p3 presentations: 1l #topaz', 'positive p3 presentations: 1l #topaz (btc)', 'p3 presentations: 1l #topaz (btc) and', 'presentations: 1l #topaz (btc) and 1l', '1l #topaz (btc) and 1l #himalaya', '#topaz (btc) and 1l #himalaya (hcc)', '(btc) and 1l #himalaya (hcc) at', 'and 1l #himalaya (hcc) at #gi22!', '1l #himalaya (hcc) at #gi22! .', 'Depressed to see no major advancements in', 'to see no major advancements in 1l', 'see no major advancements in 1l hcc/btc', 'no major advancements in 1l hcc/btc treatment', 'major advancements in 1l hcc/btc treatment in', 'advancements in 1l hcc/btc treatment in galaxy', 'in 1l hcc/btc treatment in galaxy study.', '1l hcc/btc treatment in galaxy study. today', 'hcc/btc treatment in galaxy study. today is', 'treatment in galaxy study. today is an', 'in galaxy study. today is an incredible', 'galaxy study. today is an incredible day', 'study. today is an incredible day for', 'today is an incredible day for #livercancer', 'is an incredible day for #livercancer with', 'an incredible day for #livercancer with two', 'incredible day for #livercancer with two positive', 'day for #livercancer with two positive p3', 'for #livercancer with two positive p3 presentations:', '#livercancer with two positive p3 presentations: 1l', 'with two positive p3 presentations: 1l #topaz', 'two positive p3 presentations: 1l #topaz (btc)', 'positive p3 presentations: 1l #topaz (btc) and', 'p3 presentations: 1l #topaz (btc) and 1l', 'presentations: 1l #topaz (btc) and 1l #himalaya', '1l #topaz (btc) and 1l #himalaya (hcc)', '#topaz (btc) and 1l #himalaya (hcc) at', '(btc) and 1l #himalaya (hcc) at #gi22!', 'and 1l #himalaya (hcc) at #gi22! .', 'Depressed to see no major advancements in 1l', 'to see no major advancements in 1l hcc/btc', 'see no major advancements in 1l hcc/btc treatment', 'no major advancements in 1l hcc/btc treatment in', 'major advancements in 1l hcc/btc treatment in galaxy', 'advancements in 1l hcc/btc treatment in galaxy study.', 'in 1l hcc/btc treatment in galaxy study. today', '1l hcc/btc treatment in galaxy study. today is', 'hcc/btc treatment in galaxy study. today is an', 'treatment in galaxy study. today is an incredible', 'in galaxy study. today is an incredible day', 'galaxy study. today is an incredible day for', 'study. today is an incredible day for #livercancer', 'today is an incredible day for #livercancer with', 'is an incredible day for #livercancer with two', 'an incredible day for #livercancer with two positive', 'incredible day for #livercancer with two positive p3', 'day for #livercancer with two positive p3 presentations:', 'for #livercancer with two positive p3 presentations: 1l', '#livercancer with two positive p3 presentations: 1l #topaz', 'with two positive p3 presentations: 1l #topaz (btc)', 'two positive p3 presentations: 1l #topaz (btc) and', 'positive p3 presentations: 1l #topaz (btc) and 1l', 'p3 presentations: 1l #topaz (btc) and 1l #himalaya', 'presentations: 1l #topaz (btc) and 1l #himalaya (hcc)', '1l #topaz (btc) and 1l #himalaya (hcc) at', '#topaz (btc) and 1l #himalaya (hcc) at #gi22!', '(btc) and 1l #himalaya (hcc) at #gi22! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '29', 'tokens': ['esmo', '2022:', 'pembrolizumab+durvalumab', 'tx', 'not', 'effective', 'for', 'locally', 'advanced', 'head,', 'neck', 'cancer', '#oncology', '.'], 'text_length': 14, 'triples': {'pembrolizumab+durvalumab|not effective for locally advanced': ([2, 2], [4, 8], 'negative')}, 'sentence': 'esmo 2022: pembrolizumab+durvalumab tx not effective for locally advanced head, neck cancer #oncology .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(2, 2)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8)], 'span tokens': ['esmo', '2022:', 'pembrolizumab+durvalumab', 'tx', 'not', 'effective', 'for', 'locally', 'advanced', 'head,', 'neck', 'cancer', '#oncology', '.', 'esmo 2022:', '2022: pembrolizumab+durvalumab', 'pembrolizumab+durvalumab tx', 'tx not', 'not effective', 'effective for', 'for locally', 'locally advanced', 'advanced head,', 'head, neck', 'neck cancer', 'cancer #oncology', '#oncology .', 'esmo 2022: pembrolizumab+durvalumab', '2022: pembrolizumab+durvalumab tx', 'pembrolizumab+durvalumab tx not', 'tx not effective', 'not effective for', 'effective for locally', 'for locally advanced', 'locally advanced head,', 'advanced head, neck', 'head, neck cancer', 'neck cancer #oncology', 'cancer #oncology .', 'esmo 2022: pembrolizumab+durvalumab tx', '2022: pembrolizumab+durvalumab tx not', 'pembrolizumab+durvalumab tx not effective', 'tx not effective for', 'not effective for locally', 'effective for locally advanced', 'for locally advanced head,', 'locally advanced head, neck', 'advanced head, neck cancer', 'head, neck cancer #oncology', 'neck cancer #oncology .', 'esmo 2022: pembrolizumab+durvalumab tx not', '2022: pembrolizumab+durvalumab tx not effective', 'pembrolizumab+durvalumab tx not effective for', 'tx not effective for locally', 'not effective for locally advanced', 'effective for locally advanced head,', 'for locally advanced head, neck', 'locally advanced head, neck cancer', 'advanced head, neck cancer #oncology', 'head, neck cancer #oncology .', 'esmo 2022: pembrolizumab+durvalumab tx not effective', '2022: pembrolizumab+durvalumab tx not effective for', 'pembrolizumab+durvalumab tx not effective for locally', 'tx not effective for locally advanced', 'not effective for locally advanced head,', 'effective for locally advanced head, neck', 'for locally advanced head, neck cancer', 'locally advanced head, neck cancer #oncology', 'advanced head, neck cancer #oncology .', 'esmo 2022: pembrolizumab+durvalumab tx not effective for', '2022: pembrolizumab+durvalumab tx not effective for locally', 'pembrolizumab+durvalumab tx not effective for locally advanced', 'tx not effective for locally advanced head,', 'not effective for locally advanced head, neck', 'effective for locally advanced head, neck cancer', 'for locally advanced head, neck cancer #oncology', 'locally advanced head, neck cancer #oncology .', 'esmo 2022: pembrolizumab+durvalumab tx not effective for locally', '2022: pembrolizumab+durvalumab tx not effective for locally advanced', 'pembrolizumab+durvalumab tx not effective for locally advanced head,', 'tx not effective for locally advanced head, neck', 'not effective for locally advanced head, neck cancer', 'effective for locally advanced head, neck cancer #oncology', 'for locally advanced head, neck cancer #oncology .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '30', 'tokens': ['the', 'combination', 'of', 'oleclumab+imfinzi', 'and', 'chemo', 'did', 'not', 'improve', 'clinical', 'outcomes', 'for', 'patients', 'with', 'advanced', 'triple-negative', 'breast', 'cancer,', 'according', 'to', 'synergy', 'clinical', 'trial', 'data', 'as', 'presented', 'by', 'from', 'at', '#esmo2022.', '#bcsm', '.'], 'text_length': 32, 'triples': {'oleclumab+imfinzi|not improve': ([3, 3], [7, 8], 'negative'), 'synergy|not improve': ([20, 20], [7, 8], 'negative')}, 'sentence': 'the combination of oleclumab+imfinzi and chemo did not improve clinical outcomes for patients with advanced triple-negative breast cancer, according to synergy clinical trial data as presented by from at #esmo2022. #bcsm .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(3, 3), (20, 20)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 8)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8)], 'span tokens': ['the', 'combination', 'of', 'oleclumab+imfinzi', 'and', 'chemo', 'did', 'not', 'improve', 'clinical', 'outcomes', 'for', 'patients', 'with', 'advanced', 'triple-negative', 'breast', 'cancer,', 'according', 'to', 'synergy', 'clinical', 'trial', 'data', 'as', 'presented', 'by', 'from', 'at', '#esmo2022.', '#bcsm', '.', 'the combination', 'combination of', 'of oleclumab+imfinzi', 'oleclumab+imfinzi and', 'and chemo', 'chemo did', 'did not', 'not improve', 'improve clinical', 'clinical outcomes', 'outcomes for', 'for patients', 'patients with', 'with advanced', 'advanced triple-negative', 'triple-negative breast', 'breast cancer,', 'cancer, according', 'according to', 'to synergy', 'synergy clinical', 'clinical trial', 'trial data', 'data as', 'as presented', 'presented by', 'by from', 'from at', 'at #esmo2022.', '#esmo2022. #bcsm', '#bcsm .', 'the combination of', 'combination of oleclumab+imfinzi', 'of oleclumab+imfinzi and', 'oleclumab+imfinzi and chemo', 'and chemo did', 'chemo did not', 'did not improve', 'not improve clinical', 'improve clinical outcomes', 'clinical outcomes for', 'outcomes for patients', 'for patients with', 'patients with advanced', 'with advanced triple-negative', 'advanced triple-negative breast', 'triple-negative breast cancer,', 'breast cancer, according', 'cancer, according to', 'according to synergy', 'to synergy clinical', 'synergy clinical trial', 'clinical trial data', 'trial data as', 'data as presented', 'as presented by', 'presented by from', 'by from at', 'from at #esmo2022.', 'at #esmo2022. #bcsm', '#esmo2022. #bcsm .', 'the combination of oleclumab+imfinzi', 'combination of oleclumab+imfinzi and', 'of oleclumab+imfinzi and chemo', 'oleclumab+imfinzi and chemo did', 'and chemo did not', 'chemo did not improve', 'did not improve clinical', 'not improve clinical outcomes', 'improve clinical outcomes for', 'clinical outcomes for patients', 'outcomes for patients with', 'for patients with advanced', 'patients with advanced triple-negative', 'with advanced triple-negative breast', 'advanced triple-negative breast cancer,', 'triple-negative breast cancer, according', 'breast cancer, according to', 'cancer, according to synergy', 'according to synergy clinical', 'to synergy clinical trial', 'synergy clinical trial data', 'clinical trial data as', 'trial data as presented', 'data as presented by', 'as presented by from', 'presented by from at', 'by from at #esmo2022.', 'from at #esmo2022. #bcsm', 'at #esmo2022. #bcsm .', 'the combination of oleclumab+imfinzi and', 'combination of oleclumab+imfinzi and chemo', 'of oleclumab+imfinzi and chemo did', 'oleclumab+imfinzi and chemo did not', 'and chemo did not improve', 'chemo did not improve clinical', 'did not improve clinical outcomes', 'not improve clinical outcomes for', 'improve clinical outcomes for patients', 'clinical outcomes for patients with', 'outcomes for patients with advanced', 'for patients with advanced triple-negative', 'patients with advanced triple-negative breast', 'with advanced triple-negative breast cancer,', 'advanced triple-negative breast cancer, according', 'triple-negative breast cancer, according to', 'breast cancer, according to synergy', 'cancer, according to synergy clinical', 'according to synergy clinical trial', 'to synergy clinical trial data', 'synergy clinical trial data as', 'clinical trial data as presented', 'trial data as presented by', 'data as presented by from', 'as presented by from at', 'presented by from at #esmo2022.', 'by from at #esmo2022. #bcsm', 'from at #esmo2022. #bcsm .', 'the combination of oleclumab+imfinzi and chemo', 'combination of oleclumab+imfinzi and chemo did', 'of oleclumab+imfinzi and chemo did not', 'oleclumab+imfinzi and chemo did not improve', 'and chemo did not improve clinical', 'chemo did not improve clinical outcomes', 'did not improve clinical outcomes for', 'not improve clinical outcomes for patients', 'improve clinical outcomes for patients with', 'clinical outcomes for patients with advanced', 'outcomes for patients with advanced triple-negative', 'for patients with advanced triple-negative breast', 'patients with advanced triple-negative breast cancer,', 'with advanced triple-negative breast cancer, according', 'advanced triple-negative breast cancer, according to', 'triple-negative breast cancer, according to synergy', 'breast cancer, according to synergy clinical', 'cancer, according to synergy clinical trial', 'according to synergy clinical trial data', 'to synergy clinical trial data as', 'synergy clinical trial data as presented', 'clinical trial data as presented by', 'trial data as presented by from', 'data as presented by from at', 'as presented by from at #esmo2022.', 'presented by from at #esmo2022. #bcsm', 'by from at #esmo2022. #bcsm .', 'the combination of oleclumab+imfinzi and chemo did', 'combination of oleclumab+imfinzi and chemo did not', 'of oleclumab+imfinzi and chemo did not improve', 'oleclumab+imfinzi and chemo did not improve clinical', 'and chemo did not improve clinical outcomes', 'chemo did not improve clinical outcomes for', 'did not improve clinical outcomes for patients', 'not improve clinical outcomes for patients with', 'improve clinical outcomes for patients with advanced', 'clinical outcomes for patients with advanced triple-negative', 'outcomes for patients with advanced triple-negative breast', 'for patients with advanced triple-negative breast cancer,', 'patients with advanced triple-negative breast cancer, according', 'with advanced triple-negative breast cancer, according to', 'advanced triple-negative breast cancer, according to synergy', 'triple-negative breast cancer, according to synergy clinical', 'breast cancer, according to synergy clinical trial', 'cancer, according to synergy clinical trial data', 'according to synergy clinical trial data as', 'to synergy clinical trial data as presented', 'synergy clinical trial data as presented by', 'clinical trial data as presented by from', 'trial data as presented by from at', 'data as presented by from at #esmo2022.', 'as presented by from at #esmo2022. #bcsm', 'presented by from at #esmo2022. #bcsm .', 'the combination of oleclumab+imfinzi and chemo did not', 'combination of oleclumab+imfinzi and chemo did not improve', 'of oleclumab+imfinzi and chemo did not improve clinical', 'oleclumab+imfinzi and chemo did not improve clinical outcomes', 'and chemo did not improve clinical outcomes for', 'chemo did not improve clinical outcomes for patients', 'did not improve clinical outcomes for patients with', 'not improve clinical outcomes for patients with advanced', 'improve clinical outcomes for patients with advanced triple-negative', 'clinical outcomes for patients with advanced triple-negative breast', 'outcomes for patients with advanced triple-negative breast cancer,', 'for patients with advanced triple-negative breast cancer, according', 'patients with advanced triple-negative breast cancer, according to', 'with advanced triple-negative breast cancer, according to synergy', 'advanced triple-negative breast cancer, according to synergy clinical', 'triple-negative breast cancer, according to synergy clinical trial', 'breast cancer, according to synergy clinical trial data', 'cancer, according to synergy clinical trial data as', 'according to synergy clinical trial data as presented', 'to synergy clinical trial data as presented by', 'synergy clinical trial data as presented by from', 'clinical trial data as presented by from at', 'trial data as presented by from at #esmo2022.', 'data as presented by from at #esmo2022. #bcsm', 'as presented by from at #esmo2022. #bcsm .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '31', 'tokens': ['galaxy', 'trial', 'part', 'of', 'circulate', 'japan', 'platform', 'ct', 'dna', 'brings', 'up', 'the', 'topic:', '?', 'omit', 'adj.', 'rx', 'in', 'stage', '2/3', 'resected', 'colon', 'ca', '#bespoke', '#gi22', '#natera', 'not', 'there', 'yet', '', '.'], 'text_length': 31, 'triples': {'galaxy|brings up the topic:': ([0, 0], [9, 12], 'neutral')}, 'sentence': 'galaxy trial part of circulate japan platform ct dna brings up the topic: ? omit adj. rx in stage 2/3 resected colon ca #bespoke #gi22 #natera not there yet  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8)], 'span tokens': ['galaxy', 'trial', 'part', 'of', 'circulate', 'japan', 'platform', 'ct', 'dna', 'brings', 'up', 'the', 'topic:', '?', 'omit', 'adj.', 'rx', 'in', 'stage', '2/3', 'resected', 'colon', 'ca', '#bespoke', '#gi22', '#natera', 'not', 'there', 'yet', '', '.', 'galaxy trial', 'trial part', 'part of', 'of circulate', 'circulate japan', 'japan platform', 'platform ct', 'ct dna', 'dna brings', 'brings up', 'up the', 'the topic:', 'topic: ?', '? omit', 'omit adj.', 'adj. rx', 'rx in', 'in stage', 'stage 2/3', '2/3 resected', 'resected colon', 'colon ca', 'ca #bespoke', '#bespoke #gi22', '#gi22 #natera', '#natera not', 'not there', 'there yet', 'yet ', ' .', 'galaxy trial part', 'trial part of', 'part of circulate', 'of circulate japan', 'circulate japan platform', 'japan platform ct', 'platform ct dna', 'ct dna brings', 'dna brings up', 'brings up the', 'up the topic:', 'the topic: ?', 'topic: ? omit', '? omit adj.', 'omit adj. rx', 'adj. rx in', 'rx in stage', 'in stage 2/3', 'stage 2/3 resected', '2/3 resected colon', 'resected colon ca', 'colon ca #bespoke', 'ca #bespoke #gi22', '#bespoke #gi22 #natera', '#gi22 #natera not', '#natera not there', 'not there yet', 'there yet ', 'yet  .', 'galaxy trial part of', 'trial part of circulate', 'part of circulate japan', 'of circulate japan platform', 'circulate japan platform ct', 'japan platform ct dna', 'platform ct dna brings', 'ct dna brings up', 'dna brings up the', 'brings up the topic:', 'up the topic: ?', 'the topic: ? omit', 'topic: ? omit adj.', '? omit adj. rx', 'omit adj. rx in', 'adj. rx in stage', 'rx in stage 2/3', 'in stage 2/3 resected', 'stage 2/3 resected colon', '2/3 resected colon ca', 'resected colon ca #bespoke', 'colon ca #bespoke #gi22', 'ca #bespoke #gi22 #natera', '#bespoke #gi22 #natera not', '#gi22 #natera not there', '#natera not there yet', 'not there yet ', 'there yet  .', 'galaxy trial part of circulate', 'trial part of circulate japan', 'part of circulate japan platform', 'of circulate japan platform ct', 'circulate japan platform ct dna', 'japan platform ct dna brings', 'platform ct dna brings up', 'ct dna brings up the', 'dna brings up the topic:', 'brings up the topic: ?', 'up the topic: ? omit', 'the topic: ? omit adj.', 'topic: ? omit adj. rx', '? omit adj. rx in', 'omit adj. rx in stage', 'adj. rx in stage 2/3', 'rx in stage 2/3 resected', 'in stage 2/3 resected colon', 'stage 2/3 resected colon ca', '2/3 resected colon ca #bespoke', 'resected colon ca #bespoke #gi22', 'colon ca #bespoke #gi22 #natera', 'ca #bespoke #gi22 #natera not', '#bespoke #gi22 #natera not there', '#gi22 #natera not there yet', '#natera not there yet ', 'not there yet  .', 'galaxy trial part of circulate japan', 'trial part of circulate japan platform', 'part of circulate japan platform ct', 'of circulate japan platform ct dna', 'circulate japan platform ct dna brings', 'japan platform ct dna brings up', 'platform ct dna brings up the', 'ct dna brings up the topic:', 'dna brings up the topic: ?', 'brings up the topic: ? omit', 'up the topic: ? omit adj.', 'the topic: ? omit adj. rx', 'topic: ? omit adj. rx in', '? omit adj. rx in stage', 'omit adj. rx in stage 2/3', 'adj. rx in stage 2/3 resected', 'rx in stage 2/3 resected colon', 'in stage 2/3 resected colon ca', 'stage 2/3 resected colon ca #bespoke', '2/3 resected colon ca #bespoke #gi22', 'resected colon ca #bespoke #gi22 #natera', 'colon ca #bespoke #gi22 #natera not', 'ca #bespoke #gi22 #natera not there', '#bespoke #gi22 #natera not there yet', '#gi22 #natera not there yet ', '#natera not there yet  .', 'galaxy trial part of circulate japan platform', 'trial part of circulate japan platform ct', 'part of circulate japan platform ct dna', 'of circulate japan platform ct dna brings', 'circulate japan platform ct dna brings up', 'japan platform ct dna brings up the', 'platform ct dna brings up the topic:', 'ct dna brings up the topic: ?', 'dna brings up the topic: ? omit', 'brings up the topic: ? omit adj.', 'up the topic: ? omit adj. rx', 'the topic: ? omit adj. rx in', 'topic: ? omit adj. rx in stage', '? omit adj. rx in stage 2/3', 'omit adj. rx in stage 2/3 resected', 'adj. rx in stage 2/3 resected colon', 'rx in stage 2/3 resected colon ca', 'in stage 2/3 resected colon ca #bespoke', 'stage 2/3 resected colon ca #bespoke #gi22', '2/3 resected colon ca #bespoke #gi22 #natera', 'resected colon ca #bespoke #gi22 #natera not', 'colon ca #bespoke #gi22 #natera not there', 'ca #bespoke #gi22 #natera not there yet', '#bespoke #gi22 #natera not there yet ', '#gi22 #natera not there yet  .', 'galaxy trial part of circulate japan platform ct', 'trial part of circulate japan platform ct dna', 'part of circulate japan platform ct dna brings', 'of circulate japan platform ct dna brings up', 'circulate japan platform ct dna brings up the', 'japan platform ct dna brings up the topic:', 'platform ct dna brings up the topic: ?', 'ct dna brings up the topic: ? omit', 'dna brings up the topic: ? omit adj.', 'brings up the topic: ? omit adj. rx', 'up the topic: ? omit adj. rx in', 'the topic: ? omit adj. rx in stage', 'topic: ? omit adj. rx in stage 2/3', '? omit adj. rx in stage 2/3 resected', 'omit adj. rx in stage 2/3 resected colon', 'adj. rx in stage 2/3 resected colon ca', 'rx in stage 2/3 resected colon ca #bespoke', 'in stage 2/3 resected colon ca #bespoke #gi22', 'stage 2/3 resected colon ca #bespoke #gi22 #natera', '2/3 resected colon ca #bespoke #gi22 #natera not', 'resected colon ca #bespoke #gi22 #natera not there', 'colon ca #bespoke #gi22 #natera not there yet', 'ca #bespoke #gi22 #natera not there yet ', '#bespoke #gi22 #natera not there yet  .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '32', 'tokens': ['"krystal-1', 'update', 'from', '#gi22', 'ph', '2,', 'single', 'arm,', 'showing', 'very', 'promising', 'results', 'of', '#adagrasib', 'in', 'kras-g12c', 'mut', 'gi', 'cancer:', '#pancreaticcancer:', 'orr', '50%', '&amp;', 'dcr', '100%.', 'others', 'gi:', 'orr', '35%', '(50%', 'in', 'btc)', '&amp;', 'dcr', '100%.', 'we', 'still', "don't", 'know', 'the', 'impact', 'on', 'os', '', '.'], 'text_length': 45, 'triples': {'"krystal-1|very promising': ([0, 0], [9, 10], 'positive'), '#adagrasib|very promising': ([13, 13], [9, 10], 'positive')}, 'sentence': '"krystal-1 update from #gi22 ph 2, single arm, showing very promising results of #adagrasib in kras-g12c mut gi cancer: #pancreaticcancer: orr 50% &amp; dcr 100%. others gi: orr 35% (50% in btc) &amp; dcr 100%. we still don\'t know the impact on os  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (13, 13)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8)], 'span tokens': ['"krystal-1', 'update', 'from', '#gi22', 'ph', '2,', 'single', 'arm,', 'showing', 'very', 'promising', 'results', 'of', '#adagrasib', 'in', 'kras-g12c', 'mut', 'gi', 'cancer:', '#pancreaticcancer:', 'orr', '50%', '&amp;', 'dcr', '100%.', 'others', 'gi:', 'orr', '35%', '(50%', 'in', 'btc)', '&amp;', 'dcr', '100%.', 'we', 'still', "don't", 'know', 'the', 'impact', 'on', 'os', '', '.', '"krystal-1 update', 'update from', 'from #gi22', '#gi22 ph', 'ph 2,', '2, single', 'single arm,', 'arm, showing', 'showing very', 'very promising', 'promising results', 'results of', 'of #adagrasib', '#adagrasib in', 'in kras-g12c', 'kras-g12c mut', 'mut gi', 'gi cancer:', 'cancer: #pancreaticcancer:', '#pancreaticcancer: orr', 'orr 50%', '50% &amp;', '&amp; dcr', 'dcr 100%.', '100%. others', 'others gi:', 'gi: orr', 'orr 35%', '35% (50%', '(50% in', 'in btc)', 'btc) &amp;', '&amp; dcr', 'dcr 100%.', '100%. we', 'we still', "still don't", "don't know", 'know the', 'the impact', 'impact on', 'on os', 'os ', ' .', '"krystal-1 update from', 'update from #gi22', 'from #gi22 ph', '#gi22 ph 2,', 'ph 2, single', '2, single arm,', 'single arm, showing', 'arm, showing very', 'showing very promising', 'very promising results', 'promising results of', 'results of #adagrasib', 'of #adagrasib in', '#adagrasib in kras-g12c', 'in kras-g12c mut', 'kras-g12c mut gi', 'mut gi cancer:', 'gi cancer: #pancreaticcancer:', 'cancer: #pancreaticcancer: orr', '#pancreaticcancer: orr 50%', 'orr 50% &amp;', '50% &amp; dcr', '&amp; dcr 100%.', 'dcr 100%. others', '100%. others gi:', 'others gi: orr', 'gi: orr 35%', 'orr 35% (50%', '35% (50% in', '(50% in btc)', 'in btc) &amp;', 'btc) &amp; dcr', '&amp; dcr 100%.', 'dcr 100%. we', '100%. we still', "we still don't", "still don't know", "don't know the", 'know the impact', 'the impact on', 'impact on os', 'on os ', 'os  .', '"krystal-1 update from #gi22', 'update from #gi22 ph', 'from #gi22 ph 2,', '#gi22 ph 2, single', 'ph 2, single arm,', '2, single arm, showing', 'single arm, showing very', 'arm, showing very promising', 'showing very promising results', 'very promising results of', 'promising results of #adagrasib', 'results of #adagrasib in', 'of #adagrasib in kras-g12c', '#adagrasib in kras-g12c mut', 'in kras-g12c mut gi', 'kras-g12c mut gi cancer:', 'mut gi cancer: #pancreaticcancer:', 'gi cancer: #pancreaticcancer: orr', 'cancer: #pancreaticcancer: orr 50%', '#pancreaticcancer: orr 50% &amp;', 'orr 50% &amp; dcr', '50% &amp; dcr 100%.', '&amp; dcr 100%. others', 'dcr 100%. others gi:', '100%. others gi: orr', 'others gi: orr 35%', 'gi: orr 35% (50%', 'orr 35% (50% in', '35% (50% in btc)', '(50% in btc) &amp;', 'in btc) &amp; dcr', 'btc) &amp; dcr 100%.', '&amp; dcr 100%. we', 'dcr 100%. we still', "100%. we still don't", "we still don't know", "still don't know the", "don't know the impact", 'know the impact on', 'the impact on os', 'impact on os ', 'on os  .', '"krystal-1 update from #gi22 ph', 'update from #gi22 ph 2,', 'from #gi22 ph 2, single', '#gi22 ph 2, single arm,', 'ph 2, single arm, showing', '2, single arm, showing very', 'single arm, showing very promising', 'arm, showing very promising results', 'showing very promising results of', 'very promising results of #adagrasib', 'promising results of #adagrasib in', 'results of #adagrasib in kras-g12c', 'of #adagrasib in kras-g12c mut', '#adagrasib in kras-g12c mut gi', 'in kras-g12c mut gi cancer:', 'kras-g12c mut gi cancer: #pancreaticcancer:', 'mut gi cancer: #pancreaticcancer: orr', 'gi cancer: #pancreaticcancer: orr 50%', 'cancer: #pancreaticcancer: orr 50% &amp;', '#pancreaticcancer: orr 50% &amp; dcr', 'orr 50% &amp; dcr 100%.', '50% &amp; dcr 100%. others', '&amp; dcr 100%. others gi:', 'dcr 100%. others gi: orr', '100%. others gi: orr 35%', 'others gi: orr 35% (50%', 'gi: orr 35% (50% in', 'orr 35% (50% in btc)', '35% (50% in btc) &amp;', '(50% in btc) &amp; dcr', 'in btc) &amp; dcr 100%.', 'btc) &amp; dcr 100%. we', '&amp; dcr 100%. we still', "dcr 100%. we still don't", "100%. we still don't know", "we still don't know the", "still don't know the impact", "don't know the impact on", 'know the impact on os', 'the impact on os ', 'impact on os  .', '"krystal-1 update from #gi22 ph 2,', 'update from #gi22 ph 2, single', 'from #gi22 ph 2, single arm,', '#gi22 ph 2, single arm, showing', 'ph 2, single arm, showing very', '2, single arm, showing very promising', 'single arm, showing very promising results', 'arm, showing very promising results of', 'showing very promising results of #adagrasib', 'very promising results of #adagrasib in', 'promising results of #adagrasib in kras-g12c', 'results of #adagrasib in kras-g12c mut', 'of #adagrasib in kras-g12c mut gi', '#adagrasib in kras-g12c mut gi cancer:', 'in kras-g12c mut gi cancer: #pancreaticcancer:', 'kras-g12c mut gi cancer: #pancreaticcancer: orr', 'mut gi cancer: #pancreaticcancer: orr 50%', 'gi cancer: #pancreaticcancer: orr 50% &amp;', 'cancer: #pancreaticcancer: orr 50% &amp; dcr', '#pancreaticcancer: orr 50% &amp; dcr 100%.', 'orr 50% &amp; dcr 100%. others', '50% &amp; dcr 100%. others gi:', '&amp; dcr 100%. others gi: orr', 'dcr 100%. others gi: orr 35%', '100%. others gi: orr 35% (50%', 'others gi: orr 35% (50% in', 'gi: orr 35% (50% in btc)', 'orr 35% (50% in btc) &amp;', '35% (50% in btc) &amp; dcr', '(50% in btc) &amp; dcr 100%.', 'in btc) &amp; dcr 100%. we', 'btc) &amp; dcr 100%. we still', "&amp; dcr 100%. we still don't", "dcr 100%. we still don't know", "100%. we still don't know the", "we still don't know the impact", "still don't know the impact on", "don't know the impact on os", 'know the impact on os ', 'the impact on os  .', '"krystal-1 update from #gi22 ph 2, single', 'update from #gi22 ph 2, single arm,', 'from #gi22 ph 2, single arm, showing', '#gi22 ph 2, single arm, showing very', 'ph 2, single arm, showing very promising', '2, single arm, showing very promising results', 'single arm, showing very promising results of', 'arm, showing very promising results of #adagrasib', 'showing very promising results of #adagrasib in', 'very promising results of #adagrasib in kras-g12c', 'promising results of #adagrasib in kras-g12c mut', 'results of #adagrasib in kras-g12c mut gi', 'of #adagrasib in kras-g12c mut gi cancer:', '#adagrasib in kras-g12c mut gi cancer: #pancreaticcancer:', 'in kras-g12c mut gi cancer: #pancreaticcancer: orr', 'kras-g12c mut gi cancer: #pancreaticcancer: orr 50%', 'mut gi cancer: #pancreaticcancer: orr 50% &amp;', 'gi cancer: #pancreaticcancer: orr 50% &amp; dcr', 'cancer: #pancreaticcancer: orr 50% &amp; dcr 100%.', '#pancreaticcancer: orr 50% &amp; dcr 100%. others', 'orr 50% &amp; dcr 100%. others gi:', '50% &amp; dcr 100%. others gi: orr', '&amp; dcr 100%. others gi: orr 35%', 'dcr 100%. others gi: orr 35% (50%', '100%. others gi: orr 35% (50% in', 'others gi: orr 35% (50% in btc)', 'gi: orr 35% (50% in btc) &amp;', 'orr 35% (50% in btc) &amp; dcr', '35% (50% in btc) &amp; dcr 100%.', '(50% in btc) &amp; dcr 100%. we', 'in btc) &amp; dcr 100%. we still', "btc) &amp; dcr 100%. we still don't", "&amp; dcr 100%. we still don't know", "dcr 100%. we still don't know the", "100%. we still don't know the impact", "we still don't know the impact on", "still don't know the impact on os", "don't know the impact on os ", 'know the impact on os  .', '"krystal-1 update from #gi22 ph 2, single arm,', 'update from #gi22 ph 2, single arm, showing', 'from #gi22 ph 2, single arm, showing very', '#gi22 ph 2, single arm, showing very promising', 'ph 2, single arm, showing very promising results', '2, single arm, showing very promising results of', 'single arm, showing very promising results of #adagrasib', 'arm, showing very promising results of #adagrasib in', 'showing very promising results of #adagrasib in kras-g12c', 'very promising results of #adagrasib in kras-g12c mut', 'promising results of #adagrasib in kras-g12c mut gi', 'results of #adagrasib in kras-g12c mut gi cancer:', 'of #adagrasib in kras-g12c mut gi cancer: #pancreaticcancer:', '#adagrasib in kras-g12c mut gi cancer: #pancreaticcancer: orr', 'in kras-g12c mut gi cancer: #pancreaticcancer: orr 50%', 'kras-g12c mut gi cancer: #pancreaticcancer: orr 50% &amp;', 'mut gi cancer: #pancreaticcancer: orr 50% &amp; dcr', 'gi cancer: #pancreaticcancer: orr 50% &amp; dcr 100%.', 'cancer: #pancreaticcancer: orr 50% &amp; dcr 100%. others', '#pancreaticcancer: orr 50% &amp; dcr 100%. others gi:', 'orr 50% &amp; dcr 100%. others gi: orr', '50% &amp; dcr 100%. others gi: orr 35%', '&amp; dcr 100%. others gi: orr 35% (50%', 'dcr 100%. others gi: orr 35% (50% in', '100%. others gi: orr 35% (50% in btc)', 'others gi: orr 35% (50% in btc) &amp;', 'gi: orr 35% (50% in btc) &amp; dcr', 'orr 35% (50% in btc) &amp; dcr 100%.', '35% (50% in btc) &amp; dcr 100%. we', '(50% in btc) &amp; dcr 100%. we still', "in btc) &amp; dcr 100%. we still don't", "btc) &amp; dcr 100%. we still don't know", "&amp; dcr 100%. we still don't know the", "dcr 100%. we still don't know the impact", "100%. we still don't know the impact on", "we still don't know the impact on os", "still don't know the impact on os ", "don't know the impact on os  ."], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}], [{'id': '33', 'tokens': ['re:', 'himalaya', '-', 'it', 'is', 'increasingly', 'clear', 'that', 'io', 'has', 'a', 'role', 'in', '1l', 'treatment', 'of', 'hcc.', 'do', 'combinations', 'provide', 'a', 'meaningful', 'improvement', 'on', 'io', 'single', 'agents?', 'is', 'it', 'worth', 'the', 'toxicity?', '#gi22', '.'], 'text_length': 34, 'triples': {'himalaya|increasingly clear': ([1, 1], [5, 6], 'neutral')}, 'sentence': 're: himalaya - it is increasingly clear that io has a role in 1l treatment of hcc. do combinations provide a meaningful improvement on io single agents? is it worth the toxicity? #gi22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 6)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8)], 'span tokens': ['re:', 'himalaya', '-', 'it', 'is', 'increasingly', 'clear', 'that', 'io', 'has', 'a', 'role', 'in', '1l', 'treatment', 'of', 'hcc.', 'do', 'combinations', 'provide', 'a', 'meaningful', 'improvement', 'on', 'io', 'single', 'agents?', 'is', 'it', 'worth', 'the', 'toxicity?', '#gi22', '.', 're: himalaya', 'himalaya -', '- it', 'it is', 'is increasingly', 'increasingly clear', 'clear that', 'that io', 'io has', 'has a', 'a role', 'role in', 'in 1l', '1l treatment', 'treatment of', 'of hcc.', 'hcc. do', 'do combinations', 'combinations provide', 'provide a', 'a meaningful', 'meaningful improvement', 'improvement on', 'on io', 'io single', 'single agents?', 'agents? is', 'is it', 'it worth', 'worth the', 'the toxicity?', 'toxicity? #gi22', '#gi22 .', 're: himalaya -', 'himalaya - it', '- it is', 'it is increasingly', 'is increasingly clear', 'increasingly clear that', 'clear that io', 'that io has', 'io has a', 'has a role', 'a role in', 'role in 1l', 'in 1l treatment', '1l treatment of', 'treatment of hcc.', 'of hcc. do', 'hcc. do combinations', 'do combinations provide', 'combinations provide a', 'provide a meaningful', 'a meaningful improvement', 'meaningful improvement on', 'improvement on io', 'on io single', 'io single agents?', 'single agents? is', 'agents? is it', 'is it worth', 'it worth the', 'worth the toxicity?', 'the toxicity? #gi22', 'toxicity? #gi22 .', 're: himalaya - it', 'himalaya - it is', '- it is increasingly', 'it is increasingly clear', 'is increasingly clear that', 'increasingly clear that io', 'clear that io has', 'that io has a', 'io has a role', 'has a role in', 'a role in 1l', 'role in 1l treatment', 'in 1l treatment of', '1l treatment of hcc.', 'treatment of hcc. do', 'of hcc. do combinations', 'hcc. do combinations provide', 'do combinations provide a', 'combinations provide a meaningful', 'provide a meaningful improvement', 'a meaningful improvement on', 'meaningful improvement on io', 'improvement on io single', 'on io single agents?', 'io single agents? is', 'single agents? is it', 'agents? is it worth', 'is it worth the', 'it worth the toxicity?', 'worth the toxicity? #gi22', 'the toxicity? #gi22 .', 're: himalaya - it is', 'himalaya - it is increasingly', '- it is increasingly clear', 'it is increasingly clear that', 'is increasingly clear that io', 'increasingly clear that io has', 'clear that io has a', 'that io has a role', 'io has a role in', 'has a role in 1l', 'a role in 1l treatment', 'role in 1l treatment of', 'in 1l treatment of hcc.', '1l treatment of hcc. do', 'treatment of hcc. do combinations', 'of hcc. do combinations provide', 'hcc. do combinations provide a', 'do combinations provide a meaningful', 'combinations provide a meaningful improvement', 'provide a meaningful improvement on', 'a meaningful improvement on io', 'meaningful improvement on io single', 'improvement on io single agents?', 'on io single agents? is', 'io single agents? is it', 'single agents? is it worth', 'agents? is it worth the', 'is it worth the toxicity?', 'it worth the toxicity? #gi22', 'worth the toxicity? #gi22 .', 're: himalaya - it is increasingly', 'himalaya - it is increasingly clear', '- it is increasingly clear that', 'it is increasingly clear that io', 'is increasingly clear that io has', 'increasingly clear that io has a', 'clear that io has a role', 'that io has a role in', 'io has a role in 1l', 'has a role in 1l treatment', 'a role in 1l treatment of', 'role in 1l treatment of hcc.', 'in 1l treatment of hcc. do', '1l treatment of hcc. do combinations', 'treatment of hcc. do combinations provide', 'of hcc. do combinations provide a', 'hcc. do combinations provide a meaningful', 'do combinations provide a meaningful improvement', 'combinations provide a meaningful improvement on', 'provide a meaningful improvement on io', 'a meaningful improvement on io single', 'meaningful improvement on io single agents?', 'improvement on io single agents? is', 'on io single agents? is it', 'io single agents? is it worth', 'single agents? is it worth the', 'agents? is it worth the toxicity?', 'is it worth the toxicity? #gi22', 'it worth the toxicity? #gi22 .', 're: himalaya - it is increasingly clear', 'himalaya - it is increasingly clear that', '- it is increasingly clear that io', 'it is increasingly clear that io has', 'is increasingly clear that io has a', 'increasingly clear that io has a role', 'clear that io has a role in', 'that io has a role in 1l', 'io has a role in 1l treatment', 'has a role in 1l treatment of', 'a role in 1l treatment of hcc.', 'role in 1l treatment of hcc. do', 'in 1l treatment of hcc. do combinations', '1l treatment of hcc. do combinations provide', 'treatment of hcc. do combinations provide a', 'of hcc. do combinations provide a meaningful', 'hcc. do combinations provide a meaningful improvement', 'do combinations provide a meaningful improvement on', 'combinations provide a meaningful improvement on io', 'provide a meaningful improvement on io single', 'a meaningful improvement on io single agents?', 'meaningful improvement on io single agents? is', 'improvement on io single agents? is it', 'on io single agents? is it worth', 'io single agents? is it worth the', 'single agents? is it worth the toxicity?', 'agents? is it worth the toxicity? #gi22', 'is it worth the toxicity? #gi22 .', 're: himalaya - it is increasingly clear that', 'himalaya - it is increasingly clear that io', '- it is increasingly clear that io has', 'it is increasingly clear that io has a', 'is increasingly clear that io has a role', 'increasingly clear that io has a role in', 'clear that io has a role in 1l', 'that io has a role in 1l treatment', 'io has a role in 1l treatment of', 'has a role in 1l treatment of hcc.', 'a role in 1l treatment of hcc. do', 'role in 1l treatment of hcc. do combinations', 'in 1l treatment of hcc. do combinations provide', '1l treatment of hcc. do combinations provide a', 'treatment of hcc. do combinations provide a meaningful', 'of hcc. do combinations provide a meaningful improvement', 'hcc. do combinations provide a meaningful improvement on', 'do combinations provide a meaningful improvement on io', 'combinations provide a meaningful improvement on io single', 'provide a meaningful improvement on io single agents?', 'a meaningful improvement on io single agents? is', 'meaningful improvement on io single agents? is it', 'improvement on io single agents? is it worth', 'on io single agents? is it worth the', 'io single agents? is it worth the toxicity?', 'single agents? is it worth the toxicity? #gi22', 'agents? is it worth the toxicity? #gi22 .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '34', 'tokens': ['#gi22', 'topaz-1', 'positive', 'results', 'testing', 'immunotherapy', 'and', 'chemotherapy', 'in', 'biliary', 'tract', 'cancer', '(btc)', '', '.'], 'text_length': 15, 'triples': {'topaz-1|positive results': ([1, 1], [2, 3], 'positive')}, 'sentence': '#gi22 topaz-1 positive results testing immunotherapy and chemotherapy in biliary tract cancer (btc)  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8)], 'span tokens': ['#gi22', 'topaz-1', 'positive', 'results', 'testing', 'immunotherapy', 'and', 'chemotherapy', 'in', 'biliary', 'tract', 'cancer', '(btc)', '', '.', '#gi22 topaz-1', 'topaz-1 positive', 'positive results', 'results testing', 'testing immunotherapy', 'immunotherapy and', 'and chemotherapy', 'chemotherapy in', 'in biliary', 'biliary tract', 'tract cancer', 'cancer (btc)', '(btc) ', ' .', '#gi22 topaz-1 positive', 'topaz-1 positive results', 'positive results testing', 'results testing immunotherapy', 'testing immunotherapy and', 'immunotherapy and chemotherapy', 'and chemotherapy in', 'chemotherapy in biliary', 'in biliary tract', 'biliary tract cancer', 'tract cancer (btc)', 'cancer (btc) ', '(btc)  .', '#gi22 topaz-1 positive results', 'topaz-1 positive results testing', 'positive results testing immunotherapy', 'results testing immunotherapy and', 'testing immunotherapy and chemotherapy', 'immunotherapy and chemotherapy in', 'and chemotherapy in biliary', 'chemotherapy in biliary tract', 'in biliary tract cancer', 'biliary tract cancer (btc)', 'tract cancer (btc) ', 'cancer (btc)  .', '#gi22 topaz-1 positive results testing', 'topaz-1 positive results testing immunotherapy', 'positive results testing immunotherapy and', 'results testing immunotherapy and chemotherapy', 'testing immunotherapy and chemotherapy in', 'immunotherapy and chemotherapy in biliary', 'and chemotherapy in biliary tract', 'chemotherapy in biliary tract cancer', 'in biliary tract cancer (btc)', 'biliary tract cancer (btc) ', 'tract cancer (btc)  .', '#gi22 topaz-1 positive results testing immunotherapy', 'topaz-1 positive results testing immunotherapy and', 'positive results testing immunotherapy and chemotherapy', 'results testing immunotherapy and chemotherapy in', 'testing immunotherapy and chemotherapy in biliary', 'immunotherapy and chemotherapy in biliary tract', 'and chemotherapy in biliary tract cancer', 'chemotherapy in biliary tract cancer (btc)', 'in biliary tract cancer (btc) ', 'biliary tract cancer (btc)  .', '#gi22 topaz-1 positive results testing immunotherapy and', 'topaz-1 positive results testing immunotherapy and chemotherapy', 'positive results testing immunotherapy and chemotherapy in', 'results testing immunotherapy and chemotherapy in biliary', 'testing immunotherapy and chemotherapy in biliary tract', 'immunotherapy and chemotherapy in biliary tract cancer', 'and chemotherapy in biliary tract cancer (btc)', 'chemotherapy in biliary tract cancer (btc) ', 'in biliary tract cancer (btc)  .', '#gi22 topaz-1 positive results testing immunotherapy and chemotherapy', 'topaz-1 positive results testing immunotherapy and chemotherapy in', 'positive results testing immunotherapy and chemotherapy in biliary', 'results testing immunotherapy and chemotherapy in biliary tract', 'testing immunotherapy and chemotherapy in biliary tract cancer', 'immunotherapy and chemotherapy in biliary tract cancer (btc)', 'and chemotherapy in biliary tract cancer (btc) ', 'chemotherapy in biliary tract cancer (btc)  .'], 'spans_aspect_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '35', 'tokens': ['in', 'advanced,', 'untreated', 'renal', 'cell', 'carcinoma', '(#rcc),', 'a', 'tki-immunotherapy', 'triplet', 'improved', 'pfs,', 'but', 'bempeg+nivolumab', 'numerically', 'worsened', 'objective', 'response', 'rate.', '#esmo22', '.'], 'text_length': 21, 'triples': {'bempeg+nivolumab|numerically worsened objective response rate.': ([13, 13], [14, 18], 'negative')}, 'sentence': 'in advanced, untreated renal cell carcinoma (#rcc), a tki-immunotherapy triplet improved pfs, but bempeg+nivolumab numerically worsened objective response rate. #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(13, 13)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(14, 18)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8)], 'span tokens': ['in', 'advanced,', 'untreated', 'renal', 'cell', 'carcinoma', '(#rcc),', 'a', 'tki-immunotherapy', 'triplet', 'improved', 'pfs,', 'but', 'bempeg+nivolumab', 'numerically', 'worsened', 'objective', 'response', 'rate.', '#esmo22', '.', 'in advanced,', 'advanced, untreated', 'untreated renal', 'renal cell', 'cell carcinoma', 'carcinoma (#rcc),', '(#rcc), a', 'a tki-immunotherapy', 'tki-immunotherapy triplet', 'triplet improved', 'improved pfs,', 'pfs, but', 'but bempeg+nivolumab', 'bempeg+nivolumab numerically', 'numerically worsened', 'worsened objective', 'objective response', 'response rate.', 'rate. #esmo22', '#esmo22 .', 'in advanced, untreated', 'advanced, untreated renal', 'untreated renal cell', 'renal cell carcinoma', 'cell carcinoma (#rcc),', 'carcinoma (#rcc), a', '(#rcc), a tki-immunotherapy', 'a tki-immunotherapy triplet', 'tki-immunotherapy triplet improved', 'triplet improved pfs,', 'improved pfs, but', 'pfs, but bempeg+nivolumab', 'but bempeg+nivolumab numerically', 'bempeg+nivolumab numerically worsened', 'numerically worsened objective', 'worsened objective response', 'objective response rate.', 'response rate. #esmo22', 'rate. #esmo22 .', 'in advanced, untreated renal', 'advanced, untreated renal cell', 'untreated renal cell carcinoma', 'renal cell carcinoma (#rcc),', 'cell carcinoma (#rcc), a', 'carcinoma (#rcc), a tki-immunotherapy', '(#rcc), a tki-immunotherapy triplet', 'a tki-immunotherapy triplet improved', 'tki-immunotherapy triplet improved pfs,', 'triplet improved pfs, but', 'improved pfs, but bempeg+nivolumab', 'pfs, but bempeg+nivolumab numerically', 'but bempeg+nivolumab numerically worsened', 'bempeg+nivolumab numerically worsened objective', 'numerically worsened objective response', 'worsened objective response rate.', 'objective response rate. #esmo22', 'response rate. #esmo22 .', 'in advanced, untreated renal cell', 'advanced, untreated renal cell carcinoma', 'untreated renal cell carcinoma (#rcc),', 'renal cell carcinoma (#rcc), a', 'cell carcinoma (#rcc), a tki-immunotherapy', 'carcinoma (#rcc), a tki-immunotherapy triplet', '(#rcc), a tki-immunotherapy triplet improved', 'a tki-immunotherapy triplet improved pfs,', 'tki-immunotherapy triplet improved pfs, but', 'triplet improved pfs, but bempeg+nivolumab', 'improved pfs, but bempeg+nivolumab numerically', 'pfs, but bempeg+nivolumab numerically worsened', 'but bempeg+nivolumab numerically worsened objective', 'bempeg+nivolumab numerically worsened objective response', 'numerically worsened objective response rate.', 'worsened objective response rate. #esmo22', 'objective response rate. #esmo22 .', 'in advanced, untreated renal cell carcinoma', 'advanced, untreated renal cell carcinoma (#rcc),', 'untreated renal cell carcinoma (#rcc), a', 'renal cell carcinoma (#rcc), a tki-immunotherapy', 'cell carcinoma (#rcc), a tki-immunotherapy triplet', 'carcinoma (#rcc), a tki-immunotherapy triplet improved', '(#rcc), a tki-immunotherapy triplet improved pfs,', 'a tki-immunotherapy triplet improved pfs, but', 'tki-immunotherapy triplet improved pfs, but bempeg+nivolumab', 'triplet improved pfs, but bempeg+nivolumab numerically', 'improved pfs, but bempeg+nivolumab numerically worsened', 'pfs, but bempeg+nivolumab numerically worsened objective', 'but bempeg+nivolumab numerically worsened objective response', 'bempeg+nivolumab numerically worsened objective response rate.', 'numerically worsened objective response rate. #esmo22', 'worsened objective response rate. #esmo22 .', 'in advanced, untreated renal cell carcinoma (#rcc),', 'advanced, untreated renal cell carcinoma (#rcc), a', 'untreated renal cell carcinoma (#rcc), a tki-immunotherapy', 'renal cell carcinoma (#rcc), a tki-immunotherapy triplet', 'cell carcinoma (#rcc), a tki-immunotherapy triplet improved', 'carcinoma (#rcc), a tki-immunotherapy triplet improved pfs,', '(#rcc), a tki-immunotherapy triplet improved pfs, but', 'a tki-immunotherapy triplet improved pfs, but bempeg+nivolumab', 'tki-immunotherapy triplet improved pfs, but bempeg+nivolumab numerically', 'triplet improved pfs, but bempeg+nivolumab numerically worsened', 'improved pfs, but bempeg+nivolumab numerically worsened objective', 'pfs, but bempeg+nivolumab numerically worsened objective response', 'but bempeg+nivolumab numerically worsened objective response rate.', 'bempeg+nivolumab numerically worsened objective response rate. #esmo22', 'numerically worsened objective response rate. #esmo22 .', 'in advanced, untreated renal cell carcinoma (#rcc), a', 'advanced, untreated renal cell carcinoma (#rcc), a tki-immunotherapy', 'untreated renal cell carcinoma (#rcc), a tki-immunotherapy triplet', 'renal cell carcinoma (#rcc), a tki-immunotherapy triplet improved', 'cell carcinoma (#rcc), a tki-immunotherapy triplet improved pfs,', 'carcinoma (#rcc), a tki-immunotherapy triplet improved pfs, but', '(#rcc), a tki-immunotherapy triplet improved pfs, but bempeg+nivolumab', 'a tki-immunotherapy triplet improved pfs, but bempeg+nivolumab numerically', 'tki-immunotherapy triplet improved pfs, but bempeg+nivolumab numerically worsened', 'triplet improved pfs, but bempeg+nivolumab numerically worsened objective', 'improved pfs, but bempeg+nivolumab numerically worsened objective response', 'pfs, but bempeg+nivolumab numerically worsened objective response rate.', 'but bempeg+nivolumab numerically worsened objective response rate. #esmo22', 'bempeg+nivolumab numerically worsened objective response rate. #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '36', 'tokens': ['expanded', 'and', 'longer-term', 'results', 'of', 'checkmate-649', '(nivo', 'plus', 'chemo,', 'advanced', 'esophageal)', 'and', 'keynote-590', '(pembro', 'plus', 'chemo,', 'adv', 'gc/gejc/eac)', 'trials', '#gi22', 'presentations', 'by', 'dr.', 'shitara', 'and', 'dr.', 'metges', '', '.'], 'text_length': 29, 'triples': {'checkmate-649|longer-term results': ([5, 5], [2, 3], 'neutral'), 'keynote-590|longer-term results': ([12, 12], [2, 3], 'neutral')}, 'sentence': 'expanded and longer-term results of checkmate-649 (nivo plus chemo, advanced esophageal) and keynote-590 (pembro plus chemo, adv gc/gejc/eac) trials #gi22 presentations by dr. shitara and dr. metges  .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(5, 5), (12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 1, 0, ..., 1, 1, 1],
       [0, 1, 0, ..., 1, 1, 1],
       [0, 1, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8)], 'span tokens': ['expanded', 'and', 'longer-term', 'results', 'of', 'checkmate-649', '(nivo', 'plus', 'chemo,', 'advanced', 'esophageal)', 'and', 'keynote-590', '(pembro', 'plus', 'chemo,', 'adv', 'gc/gejc/eac)', 'trials', '#gi22', 'presentations', 'by', 'dr.', 'shitara', 'and', 'dr.', 'metges', '', '.', 'expanded and', 'and longer-term', 'longer-term results', 'results of', 'of checkmate-649', 'checkmate-649 (nivo', '(nivo plus', 'plus chemo,', 'chemo, advanced', 'advanced esophageal)', 'esophageal) and', 'and keynote-590', 'keynote-590 (pembro', '(pembro plus', 'plus chemo,', 'chemo, adv', 'adv gc/gejc/eac)', 'gc/gejc/eac) trials', 'trials #gi22', '#gi22 presentations', 'presentations by', 'by dr.', 'dr. shitara', 'shitara and', 'and dr.', 'dr. metges', 'metges ', ' .', 'expanded and longer-term', 'and longer-term results', 'longer-term results of', 'results of checkmate-649', 'of checkmate-649 (nivo', 'checkmate-649 (nivo plus', '(nivo plus chemo,', 'plus chemo, advanced', 'chemo, advanced esophageal)', 'advanced esophageal) and', 'esophageal) and keynote-590', 'and keynote-590 (pembro', 'keynote-590 (pembro plus', '(pembro plus chemo,', 'plus chemo, adv', 'chemo, adv gc/gejc/eac)', 'adv gc/gejc/eac) trials', 'gc/gejc/eac) trials #gi22', 'trials #gi22 presentations', '#gi22 presentations by', 'presentations by dr.', 'by dr. shitara', 'dr. shitara and', 'shitara and dr.', 'and dr. metges', 'dr. metges ', 'metges  .', 'expanded and longer-term results', 'and longer-term results of', 'longer-term results of checkmate-649', 'results of checkmate-649 (nivo', 'of checkmate-649 (nivo plus', 'checkmate-649 (nivo plus chemo,', '(nivo plus chemo, advanced', 'plus chemo, advanced esophageal)', 'chemo, advanced esophageal) and', 'advanced esophageal) and keynote-590', 'esophageal) and keynote-590 (pembro', 'and keynote-590 (pembro plus', 'keynote-590 (pembro plus chemo,', '(pembro plus chemo, adv', 'plus chemo, adv gc/gejc/eac)', 'chemo, adv gc/gejc/eac) trials', 'adv gc/gejc/eac) trials #gi22', 'gc/gejc/eac) trials #gi22 presentations', 'trials #gi22 presentations by', '#gi22 presentations by dr.', 'presentations by dr. shitara', 'by dr. shitara and', 'dr. shitara and dr.', 'shitara and dr. metges', 'and dr. metges ', 'dr. metges  .', 'expanded and longer-term results of', 'and longer-term results of checkmate-649', 'longer-term results of checkmate-649 (nivo', 'results of checkmate-649 (nivo plus', 'of checkmate-649 (nivo plus chemo,', 'checkmate-649 (nivo plus chemo, advanced', '(nivo plus chemo, advanced esophageal)', 'plus chemo, advanced esophageal) and', 'chemo, advanced esophageal) and keynote-590', 'advanced esophageal) and keynote-590 (pembro', 'esophageal) and keynote-590 (pembro plus', 'and keynote-590 (pembro plus chemo,', 'keynote-590 (pembro plus chemo, adv', '(pembro plus chemo, adv gc/gejc/eac)', 'plus chemo, adv gc/gejc/eac) trials', 'chemo, adv gc/gejc/eac) trials #gi22', 'adv gc/gejc/eac) trials #gi22 presentations', 'gc/gejc/eac) trials #gi22 presentations by', 'trials #gi22 presentations by dr.', '#gi22 presentations by dr. shitara', 'presentations by dr. shitara and', 'by dr. shitara and dr.', 'dr. shitara and dr. metges', 'shitara and dr. metges ', 'and dr. metges  .', 'expanded and longer-term results of checkmate-649', 'and longer-term results of checkmate-649 (nivo', 'longer-term results of checkmate-649 (nivo plus', 'results of checkmate-649 (nivo plus chemo,', 'of checkmate-649 (nivo plus chemo, advanced', 'checkmate-649 (nivo plus chemo, advanced esophageal)', '(nivo plus chemo, advanced esophageal) and', 'plus chemo, advanced esophageal) and keynote-590', 'chemo, advanced esophageal) and keynote-590 (pembro', 'advanced esophageal) and keynote-590 (pembro plus', 'esophageal) and keynote-590 (pembro plus chemo,', 'and keynote-590 (pembro plus chemo, adv', 'keynote-590 (pembro plus chemo, adv gc/gejc/eac)', '(pembro plus chemo, adv gc/gejc/eac) trials', 'plus chemo, adv gc/gejc/eac) trials #gi22', 'chemo, adv gc/gejc/eac) trials #gi22 presentations', 'adv gc/gejc/eac) trials #gi22 presentations by', 'gc/gejc/eac) trials #gi22 presentations by dr.', 'trials #gi22 presentations by dr. shitara', '#gi22 presentations by dr. shitara and', 'presentations by dr. shitara and dr.', 'by dr. shitara and dr. metges', 'dr. shitara and dr. metges ', 'shitara and dr. metges  .', 'expanded and longer-term results of checkmate-649 (nivo', 'and longer-term results of checkmate-649 (nivo plus', 'longer-term results of checkmate-649 (nivo plus chemo,', 'results of checkmate-649 (nivo plus chemo, advanced', 'of checkmate-649 (nivo plus chemo, advanced esophageal)', 'checkmate-649 (nivo plus chemo, advanced esophageal) and', '(nivo plus chemo, advanced esophageal) and keynote-590', 'plus chemo, advanced esophageal) and keynote-590 (pembro', 'chemo, advanced esophageal) and keynote-590 (pembro plus', 'advanced esophageal) and keynote-590 (pembro plus chemo,', 'esophageal) and keynote-590 (pembro plus chemo, adv', 'and keynote-590 (pembro plus chemo, adv gc/gejc/eac)', 'keynote-590 (pembro plus chemo, adv gc/gejc/eac) trials', '(pembro plus chemo, adv gc/gejc/eac) trials #gi22', 'plus chemo, adv gc/gejc/eac) trials #gi22 presentations', 'chemo, adv gc/gejc/eac) trials #gi22 presentations by', 'adv gc/gejc/eac) trials #gi22 presentations by dr.', 'gc/gejc/eac) trials #gi22 presentations by dr. shitara', 'trials #gi22 presentations by dr. shitara and', '#gi22 presentations by dr. shitara and dr.', 'presentations by dr. shitara and dr. metges', 'by dr. shitara and dr. metges ', 'dr. shitara and dr. metges  .', 'expanded and longer-term results of checkmate-649 (nivo plus', 'and longer-term results of checkmate-649 (nivo plus chemo,', 'longer-term results of checkmate-649 (nivo plus chemo, advanced', 'results of checkmate-649 (nivo plus chemo, advanced esophageal)', 'of checkmate-649 (nivo plus chemo, advanced esophageal) and', 'checkmate-649 (nivo plus chemo, advanced esophageal) and keynote-590', '(nivo plus chemo, advanced esophageal) and keynote-590 (pembro', 'plus chemo, advanced esophageal) and keynote-590 (pembro plus', 'chemo, advanced esophageal) and keynote-590 (pembro plus chemo,', 'advanced esophageal) and keynote-590 (pembro plus chemo, adv', 'esophageal) and keynote-590 (pembro plus chemo, adv gc/gejc/eac)', 'and keynote-590 (pembro plus chemo, adv gc/gejc/eac) trials', 'keynote-590 (pembro plus chemo, adv gc/gejc/eac) trials #gi22', '(pembro plus chemo, adv gc/gejc/eac) trials #gi22 presentations', 'plus chemo, adv gc/gejc/eac) trials #gi22 presentations by', 'chemo, adv gc/gejc/eac) trials #gi22 presentations by dr.', 'adv gc/gejc/eac) trials #gi22 presentations by dr. shitara', 'gc/gejc/eac) trials #gi22 presentations by dr. shitara and', 'trials #gi22 presentations by dr. shitara and dr.', '#gi22 presentations by dr. shitara and dr. metges', 'presentations by dr. shitara and dr. metges ', 'by dr. shitara and dr. metges  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '37', 'tokens': ['will', 'escalation', 'of', 'therapy', 'impact', 'patients', 'with', 'mrd', 'as', 'detected', 'by', 'ctdna.', 'two', 'ongoing', 'studies', 'currently', 'evaluating.', 'cobra', 'study', 'and', 'circulate', 'study', 'evaluating.', '#gi22', '', '.'], 'text_length': 26, 'triples': {'study|ongoing studies currently evaluating. cobra study and circulate study evaluating.': ([18, 18], [13, 22], 'neutral')}, 'sentence': 'will escalation of therapy impact patients with mrd as detected by ctdna. two ongoing studies currently evaluating. cobra study and circulate study evaluating. #gi22  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(13, 22)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['will', 'escalation', 'of', 'therapy', 'impact', 'patients', 'with', 'mrd', 'as', 'detected', 'by', 'ctdna.', 'two', 'ongoing', 'studies', 'currently', 'evaluating.', 'cobra', 'study', 'and', 'circulate', 'study', 'evaluating.', '#gi22', '', '.', 'will escalation', 'escalation of', 'of therapy', 'therapy impact', 'impact patients', 'patients with', 'with mrd', 'mrd as', 'as detected', 'detected by', 'by ctdna.', 'ctdna. two', 'two ongoing', 'ongoing studies', 'studies currently', 'currently evaluating.', 'evaluating. cobra', 'cobra study', 'study and', 'and circulate', 'circulate study', 'study evaluating.', 'evaluating. #gi22', '#gi22 ', ' .', 'will escalation of', 'escalation of therapy', 'of therapy impact', 'therapy impact patients', 'impact patients with', 'patients with mrd', 'with mrd as', 'mrd as detected', 'as detected by', 'detected by ctdna.', 'by ctdna. two', 'ctdna. two ongoing', 'two ongoing studies', 'ongoing studies currently', 'studies currently evaluating.', 'currently evaluating. cobra', 'evaluating. cobra study', 'cobra study and', 'study and circulate', 'and circulate study', 'circulate study evaluating.', 'study evaluating. #gi22', 'evaluating. #gi22 ', '#gi22  .', 'will escalation of therapy', 'escalation of therapy impact', 'of therapy impact patients', 'therapy impact patients with', 'impact patients with mrd', 'patients with mrd as', 'with mrd as detected', 'mrd as detected by', 'as detected by ctdna.', 'detected by ctdna. two', 'by ctdna. two ongoing', 'ctdna. two ongoing studies', 'two ongoing studies currently', 'ongoing studies currently evaluating.', 'studies currently evaluating. cobra', 'currently evaluating. cobra study', 'evaluating. cobra study and', 'cobra study and circulate', 'study and circulate study', 'and circulate study evaluating.', 'circulate study evaluating. #gi22', 'study evaluating. #gi22 ', 'evaluating. #gi22  .', 'will escalation of therapy impact', 'escalation of therapy impact patients', 'of therapy impact patients with', 'therapy impact patients with mrd', 'impact patients with mrd as', 'patients with mrd as detected', 'with mrd as detected by', 'mrd as detected by ctdna.', 'as detected by ctdna. two', 'detected by ctdna. two ongoing', 'by ctdna. two ongoing studies', 'ctdna. two ongoing studies currently', 'two ongoing studies currently evaluating.', 'ongoing studies currently evaluating. cobra', 'studies currently evaluating. cobra study', 'currently evaluating. cobra study and', 'evaluating. cobra study and circulate', 'cobra study and circulate study', 'study and circulate study evaluating.', 'and circulate study evaluating. #gi22', 'circulate study evaluating. #gi22 ', 'study evaluating. #gi22  .', 'will escalation of therapy impact patients', 'escalation of therapy impact patients with', 'of therapy impact patients with mrd', 'therapy impact patients with mrd as', 'impact patients with mrd as detected', 'patients with mrd as detected by', 'with mrd as detected by ctdna.', 'mrd as detected by ctdna. two', 'as detected by ctdna. two ongoing', 'detected by ctdna. two ongoing studies', 'by ctdna. two ongoing studies currently', 'ctdna. two ongoing studies currently evaluating.', 'two ongoing studies currently evaluating. cobra', 'ongoing studies currently evaluating. cobra study', 'studies currently evaluating. cobra study and', 'currently evaluating. cobra study and circulate', 'evaluating. cobra study and circulate study', 'cobra study and circulate study evaluating.', 'study and circulate study evaluating. #gi22', 'and circulate study evaluating. #gi22 ', 'circulate study evaluating. #gi22  .', 'will escalation of therapy impact patients with', 'escalation of therapy impact patients with mrd', 'of therapy impact patients with mrd as', 'therapy impact patients with mrd as detected', 'impact patients with mrd as detected by', 'patients with mrd as detected by ctdna.', 'with mrd as detected by ctdna. two', 'mrd as detected by ctdna. two ongoing', 'as detected by ctdna. two ongoing studies', 'detected by ctdna. two ongoing studies currently', 'by ctdna. two ongoing studies currently evaluating.', 'ctdna. two ongoing studies currently evaluating. cobra', 'two ongoing studies currently evaluating. cobra study', 'ongoing studies currently evaluating. cobra study and', 'studies currently evaluating. cobra study and circulate', 'currently evaluating. cobra study and circulate study', 'evaluating. cobra study and circulate study evaluating.', 'cobra study and circulate study evaluating. #gi22', 'study and circulate study evaluating. #gi22 ', 'and circulate study evaluating. #gi22  .', 'will escalation of therapy impact patients with mrd', 'escalation of therapy impact patients with mrd as', 'of therapy impact patients with mrd as detected', 'therapy impact patients with mrd as detected by', 'impact patients with mrd as detected by ctdna.', 'patients with mrd as detected by ctdna. two', 'with mrd as detected by ctdna. two ongoing', 'mrd as detected by ctdna. two ongoing studies', 'as detected by ctdna. two ongoing studies currently', 'detected by ctdna. two ongoing studies currently evaluating.', 'by ctdna. two ongoing studies currently evaluating. cobra', 'ctdna. two ongoing studies currently evaluating. cobra study', 'two ongoing studies currently evaluating. cobra study and', 'ongoing studies currently evaluating. cobra study and circulate', 'studies currently evaluating. cobra study and circulate study', 'currently evaluating. cobra study and circulate study evaluating.', 'evaluating. cobra study and circulate study evaluating. #gi22', 'cobra study and circulate study evaluating. #gi22 ', 'study and circulate study evaluating. #gi22  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '38', 'tokens': ['pembrolizumab+lenvatinib', 'showed', 'no', 'statistical', 'significance', 'versus', 'lenvatinib', 'monotherapy', 'in', '#patients', 'with', '#livercancer.', '#esmo22', '#esmo2022', '#onctwitter', '#cancer', '#oncology', '#news', '#media', '#medtwitter', '#news', '#media', '#conferences', '#esmo', '#globalhealth', '.'], 'text_length': 26, 'triples': {'pembrolizumab+lenvatinib|no statistical significance': ([0, 0], [2, 4], 'negative'), 'pembrolizumab+lenvatinib showed no statistical significance versus lenvatinib|statistical significance': ([0, 6], [3, 4], 'positive')}, 'sentence': 'pembrolizumab+lenvatinib showed no statistical significance versus lenvatinib monotherapy in #patients with #livercancer. #esmo22 #esmo2022 #onctwitter #cancer #oncology #news #media #medtwitter #news #media #conferences #esmo #globalhealth .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (0, 6)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(2, 4), (3, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['pembrolizumab+lenvatinib', 'showed', 'no', 'statistical', 'significance', 'versus', 'lenvatinib', 'monotherapy', 'in', '#patients', 'with', '#livercancer.', '#esmo22', '#esmo2022', '#onctwitter', '#cancer', '#oncology', '#news', '#media', '#medtwitter', '#news', '#media', '#conferences', '#esmo', '#globalhealth', '.', 'pembrolizumab+lenvatinib showed', 'showed no', 'no statistical', 'statistical significance', 'significance versus', 'versus lenvatinib', 'lenvatinib monotherapy', 'monotherapy in', 'in #patients', '#patients with', 'with #livercancer.', '#livercancer. #esmo22', '#esmo22 #esmo2022', '#esmo2022 #onctwitter', '#onctwitter #cancer', '#cancer #oncology', '#oncology #news', '#news #media', '#media #medtwitter', '#medtwitter #news', '#news #media', '#media #conferences', '#conferences #esmo', '#esmo #globalhealth', '#globalhealth .', 'pembrolizumab+lenvatinib showed no', 'showed no statistical', 'no statistical significance', 'statistical significance versus', 'significance versus lenvatinib', 'versus lenvatinib monotherapy', 'lenvatinib monotherapy in', 'monotherapy in #patients', 'in #patients with', '#patients with #livercancer.', 'with #livercancer. #esmo22', '#livercancer. #esmo22 #esmo2022', '#esmo22 #esmo2022 #onctwitter', '#esmo2022 #onctwitter #cancer', '#onctwitter #cancer #oncology', '#cancer #oncology #news', '#oncology #news #media', '#news #media #medtwitter', '#media #medtwitter #news', '#medtwitter #news #media', '#news #media #conferences', '#media #conferences #esmo', '#conferences #esmo #globalhealth', '#esmo #globalhealth .', 'pembrolizumab+lenvatinib showed no statistical', 'showed no statistical significance', 'no statistical significance versus', 'statistical significance versus lenvatinib', 'significance versus lenvatinib monotherapy', 'versus lenvatinib monotherapy in', 'lenvatinib monotherapy in #patients', 'monotherapy in #patients with', 'in #patients with #livercancer.', '#patients with #livercancer. #esmo22', 'with #livercancer. #esmo22 #esmo2022', '#livercancer. #esmo22 #esmo2022 #onctwitter', '#esmo22 #esmo2022 #onctwitter #cancer', '#esmo2022 #onctwitter #cancer #oncology', '#onctwitter #cancer #oncology #news', '#cancer #oncology #news #media', '#oncology #news #media #medtwitter', '#news #media #medtwitter #news', '#media #medtwitter #news #media', '#medtwitter #news #media #conferences', '#news #media #conferences #esmo', '#media #conferences #esmo #globalhealth', '#conferences #esmo #globalhealth .', 'pembrolizumab+lenvatinib showed no statistical significance', 'showed no statistical significance versus', 'no statistical significance versus lenvatinib', 'statistical significance versus lenvatinib monotherapy', 'significance versus lenvatinib monotherapy in', 'versus lenvatinib monotherapy in #patients', 'lenvatinib monotherapy in #patients with', 'monotherapy in #patients with #livercancer.', 'in #patients with #livercancer. #esmo22', '#patients with #livercancer. #esmo22 #esmo2022', 'with #livercancer. #esmo22 #esmo2022 #onctwitter', '#livercancer. #esmo22 #esmo2022 #onctwitter #cancer', '#esmo22 #esmo2022 #onctwitter #cancer #oncology', '#esmo2022 #onctwitter #cancer #oncology #news', '#onctwitter #cancer #oncology #news #media', '#cancer #oncology #news #media #medtwitter', '#oncology #news #media #medtwitter #news', '#news #media #medtwitter #news #media', '#media #medtwitter #news #media #conferences', '#medtwitter #news #media #conferences #esmo', '#news #media #conferences #esmo #globalhealth', '#media #conferences #esmo #globalhealth .', 'pembrolizumab+lenvatinib showed no statistical significance versus', 'showed no statistical significance versus lenvatinib', 'no statistical significance versus lenvatinib monotherapy', 'statistical significance versus lenvatinib monotherapy in', 'significance versus lenvatinib monotherapy in #patients', 'versus lenvatinib monotherapy in #patients with', 'lenvatinib monotherapy in #patients with #livercancer.', 'monotherapy in #patients with #livercancer. #esmo22', 'in #patients with #livercancer. #esmo22 #esmo2022', '#patients with #livercancer. #esmo22 #esmo2022 #onctwitter', 'with #livercancer. #esmo22 #esmo2022 #onctwitter #cancer', '#livercancer. #esmo22 #esmo2022 #onctwitter #cancer #oncology', '#esmo22 #esmo2022 #onctwitter #cancer #oncology #news', '#esmo2022 #onctwitter #cancer #oncology #news #media', '#onctwitter #cancer #oncology #news #media #medtwitter', '#cancer #oncology #news #media #medtwitter #news', '#oncology #news #media #medtwitter #news #media', '#news #media #medtwitter #news #media #conferences', '#media #medtwitter #news #media #conferences #esmo', '#medtwitter #news #media #conferences #esmo #globalhealth', '#news #media #conferences #esmo #globalhealth .', 'pembrolizumab+lenvatinib showed no statistical significance versus lenvatinib', 'showed no statistical significance versus lenvatinib monotherapy', 'no statistical significance versus lenvatinib monotherapy in', 'statistical significance versus lenvatinib monotherapy in #patients', 'significance versus lenvatinib monotherapy in #patients with', 'versus lenvatinib monotherapy in #patients with #livercancer.', 'lenvatinib monotherapy in #patients with #livercancer. #esmo22', 'monotherapy in #patients with #livercancer. #esmo22 #esmo2022', 'in #patients with #livercancer. #esmo22 #esmo2022 #onctwitter', '#patients with #livercancer. #esmo22 #esmo2022 #onctwitter #cancer', 'with #livercancer. #esmo22 #esmo2022 #onctwitter #cancer #oncology', '#livercancer. #esmo22 #esmo2022 #onctwitter #cancer #oncology #news', '#esmo22 #esmo2022 #onctwitter #cancer #oncology #news #media', '#esmo2022 #onctwitter #cancer #oncology #news #media #medtwitter', '#onctwitter #cancer #oncology #news #media #medtwitter #news', '#cancer #oncology #news #media #medtwitter #news #media', '#oncology #news #media #medtwitter #news #media #conferences', '#news #media #medtwitter #news #media #conferences #esmo', '#media #medtwitter #news #media #conferences #esmo #globalhealth', '#medtwitter #news #media #conferences #esmo #globalhealth .', 'pembrolizumab+lenvatinib showed no statistical significance versus lenvatinib monotherapy', 'showed no statistical significance versus lenvatinib monotherapy in', 'no statistical significance versus lenvatinib monotherapy in #patients', 'statistical significance versus lenvatinib monotherapy in #patients with', 'significance versus lenvatinib monotherapy in #patients with #livercancer.', 'versus lenvatinib monotherapy in #patients with #livercancer. #esmo22', 'lenvatinib monotherapy in #patients with #livercancer. #esmo22 #esmo2022', 'monotherapy in #patients with #livercancer. #esmo22 #esmo2022 #onctwitter', 'in #patients with #livercancer. #esmo22 #esmo2022 #onctwitter #cancer', '#patients with #livercancer. #esmo22 #esmo2022 #onctwitter #cancer #oncology', 'with #livercancer. #esmo22 #esmo2022 #onctwitter #cancer #oncology #news', '#livercancer. #esmo22 #esmo2022 #onctwitter #cancer #oncology #news #media', '#esmo22 #esmo2022 #onctwitter #cancer #oncology #news #media #medtwitter', '#esmo2022 #onctwitter #cancer #oncology #news #media #medtwitter #news', '#onctwitter #cancer #oncology #news #media #medtwitter #news #media', '#cancer #oncology #news #media #medtwitter #news #media #conferences', '#oncology #news #media #medtwitter #news #media #conferences #esmo', '#news #media #medtwitter #news #media #conferences #esmo #globalhealth', '#media #medtwitter #news #media #conferences #esmo #globalhealth .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '39', 'tokens': ['CLAIRE:', 'Disappointing', 'phase', '3', 'interim', 'analysis', 'of', '', 'Sintilimab', 'in', '#pancreatic', '#cancer', 'failing', 'to', 'demonstrate', 'benefit', 'for', 'PFS', 'and', 'OS', 'for', 'first', '110', 'pts', 'but', 'improved', 'RR.', '#cancerresearch', '#clinicaltrials', '#immunotherapy', '@OncoAlert', '#GI22', '@ASCOPost', '#immunotherapy', '.'], 'text_length': 35, 'triples': {'CLAIRE:|Disappointing phase 3 interim analysis of Sintilimab in #pancreatic #cancer failing': ([0, 0], [1, 11], 'negative'), 'Sintilimab|Disappointing phase 3 interim analysis of Sintilimab in #pancreatic #cancer failing': ([7, 7], [1, 11], 'negative')}, 'sentence': 'CLAIRE: Disappointing phase 3 interim analysis of  Sintilimab in #pancreatic #cancer failing to demonstrate benefit for PFS and OS for first 110 pts but improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8)], 'span tokens': ['CLAIRE:', 'Disappointing', 'phase', '3', 'interim', 'analysis', 'of', '', 'Sintilimab', 'in', '#pancreatic', '#cancer', 'failing', 'to', 'demonstrate', 'benefit', 'for', 'PFS', 'and', 'OS', 'for', 'first', '110', 'pts', 'but', 'improved', 'RR.', '#cancerresearch', '#clinicaltrials', '#immunotherapy', '@OncoAlert', '#GI22', '@ASCOPost', '#immunotherapy', '.', 'CLAIRE: Disappointing', 'Disappointing phase', 'phase 3', '3 interim', 'interim analysis', 'analysis of', 'of ', ' Sintilimab', 'Sintilimab in', 'in #pancreatic', '#pancreatic #cancer', '#cancer failing', 'failing to', 'to demonstrate', 'demonstrate benefit', 'benefit for', 'for PFS', 'PFS and', 'and OS', 'OS for', 'for first', 'first 110', '110 pts', 'pts but', 'but improved', 'improved RR.', 'RR. #cancerresearch', '#cancerresearch #clinicaltrials', '#clinicaltrials #immunotherapy', '#immunotherapy @OncoAlert', '@OncoAlert #GI22', '#GI22 @ASCOPost', '@ASCOPost #immunotherapy', '#immunotherapy .', 'CLAIRE: Disappointing phase', 'Disappointing phase 3', 'phase 3 interim', '3 interim analysis', 'interim analysis of', 'analysis of ', 'of  Sintilimab', ' Sintilimab in', 'Sintilimab in #pancreatic', 'in #pancreatic #cancer', '#pancreatic #cancer failing', '#cancer failing to', 'failing to demonstrate', 'to demonstrate benefit', 'demonstrate benefit for', 'benefit for PFS', 'for PFS and', 'PFS and OS', 'and OS for', 'OS for first', 'for first 110', 'first 110 pts', '110 pts but', 'pts but improved', 'but improved RR.', 'improved RR. #cancerresearch', 'RR. #cancerresearch #clinicaltrials', '#cancerresearch #clinicaltrials #immunotherapy', '#clinicaltrials #immunotherapy @OncoAlert', '#immunotherapy @OncoAlert #GI22', '@OncoAlert #GI22 @ASCOPost', '#GI22 @ASCOPost #immunotherapy', '@ASCOPost #immunotherapy .', 'CLAIRE: Disappointing phase 3', 'Disappointing phase 3 interim', 'phase 3 interim analysis', '3 interim analysis of', 'interim analysis of ', 'analysis of  Sintilimab', 'of  Sintilimab in', ' Sintilimab in #pancreatic', 'Sintilimab in #pancreatic #cancer', 'in #pancreatic #cancer failing', '#pancreatic #cancer failing to', '#cancer failing to demonstrate', 'failing to demonstrate benefit', 'to demonstrate benefit for', 'demonstrate benefit for PFS', 'benefit for PFS and', 'for PFS and OS', 'PFS and OS for', 'and OS for first', 'OS for first 110', 'for first 110 pts', 'first 110 pts but', '110 pts but improved', 'pts but improved RR.', 'but improved RR. #cancerresearch', 'improved RR. #cancerresearch #clinicaltrials', 'RR. #cancerresearch #clinicaltrials #immunotherapy', '#cancerresearch #clinicaltrials #immunotherapy @OncoAlert', '#clinicaltrials #immunotherapy @OncoAlert #GI22', '#immunotherapy @OncoAlert #GI22 @ASCOPost', '@OncoAlert #GI22 @ASCOPost #immunotherapy', '#GI22 @ASCOPost #immunotherapy .', 'CLAIRE: Disappointing phase 3 interim', 'Disappointing phase 3 interim analysis', 'phase 3 interim analysis of', '3 interim analysis of ', 'interim analysis of  Sintilimab', 'analysis of  Sintilimab in', 'of  Sintilimab in #pancreatic', ' Sintilimab in #pancreatic #cancer', 'Sintilimab in #pancreatic #cancer failing', 'in #pancreatic #cancer failing to', '#pancreatic #cancer failing to demonstrate', '#cancer failing to demonstrate benefit', 'failing to demonstrate benefit for', 'to demonstrate benefit for PFS', 'demonstrate benefit for PFS and', 'benefit for PFS and OS', 'for PFS and OS for', 'PFS and OS for first', 'and OS for first 110', 'OS for first 110 pts', 'for first 110 pts but', 'first 110 pts but improved', '110 pts but improved RR.', 'pts but improved RR. #cancerresearch', 'but improved RR. #cancerresearch #clinicaltrials', 'improved RR. #cancerresearch #clinicaltrials #immunotherapy', 'RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert', '#cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22', '#clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost', '#immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy', '@OncoAlert #GI22 @ASCOPost #immunotherapy .', 'CLAIRE: Disappointing phase 3 interim analysis', 'Disappointing phase 3 interim analysis of', 'phase 3 interim analysis of ', '3 interim analysis of  Sintilimab', 'interim analysis of  Sintilimab in', 'analysis of  Sintilimab in #pancreatic', 'of  Sintilimab in #pancreatic #cancer', ' Sintilimab in #pancreatic #cancer failing', 'Sintilimab in #pancreatic #cancer failing to', 'in #pancreatic #cancer failing to demonstrate', '#pancreatic #cancer failing to demonstrate benefit', '#cancer failing to demonstrate benefit for', 'failing to demonstrate benefit for PFS', 'to demonstrate benefit for PFS and', 'demonstrate benefit for PFS and OS', 'benefit for PFS and OS for', 'for PFS and OS for first', 'PFS and OS for first 110', 'and OS for first 110 pts', 'OS for first 110 pts but', 'for first 110 pts but improved', 'first 110 pts but improved RR.', '110 pts but improved RR. #cancerresearch', 'pts but improved RR. #cancerresearch #clinicaltrials', 'but improved RR. #cancerresearch #clinicaltrials #immunotherapy', 'improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert', 'RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22', '#cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost', '#clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy', '#immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy .', 'CLAIRE: Disappointing phase 3 interim analysis of', 'Disappointing phase 3 interim analysis of ', 'phase 3 interim analysis of  Sintilimab', '3 interim analysis of  Sintilimab in', 'interim analysis of  Sintilimab in #pancreatic', 'analysis of  Sintilimab in #pancreatic #cancer', 'of  Sintilimab in #pancreatic #cancer failing', ' Sintilimab in #pancreatic #cancer failing to', 'Sintilimab in #pancreatic #cancer failing to demonstrate', 'in #pancreatic #cancer failing to demonstrate benefit', '#pancreatic #cancer failing to demonstrate benefit for', '#cancer failing to demonstrate benefit for PFS', 'failing to demonstrate benefit for PFS and', 'to demonstrate benefit for PFS and OS', 'demonstrate benefit for PFS and OS for', 'benefit for PFS and OS for first', 'for PFS and OS for first 110', 'PFS and OS for first 110 pts', 'and OS for first 110 pts but', 'OS for first 110 pts but improved', 'for first 110 pts but improved RR.', 'first 110 pts but improved RR. #cancerresearch', '110 pts but improved RR. #cancerresearch #clinicaltrials', 'pts but improved RR. #cancerresearch #clinicaltrials #immunotherapy', 'but improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert', 'improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22', 'RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost', '#cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy', '#clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy .', 'CLAIRE: Disappointing phase 3 interim analysis of ', 'Disappointing phase 3 interim analysis of  Sintilimab', 'phase 3 interim analysis of  Sintilimab in', '3 interim analysis of  Sintilimab in #pancreatic', 'interim analysis of  Sintilimab in #pancreatic #cancer', 'analysis of  Sintilimab in #pancreatic #cancer failing', 'of  Sintilimab in #pancreatic #cancer failing to', ' Sintilimab in #pancreatic #cancer failing to demonstrate', 'Sintilimab in #pancreatic #cancer failing to demonstrate benefit', 'in #pancreatic #cancer failing to demonstrate benefit for', '#pancreatic #cancer failing to demonstrate benefit for PFS', '#cancer failing to demonstrate benefit for PFS and', 'failing to demonstrate benefit for PFS and OS', 'to demonstrate benefit for PFS and OS for', 'demonstrate benefit for PFS and OS for first', 'benefit for PFS and OS for first 110', 'for PFS and OS for first 110 pts', 'PFS and OS for first 110 pts but', 'and OS for first 110 pts but improved', 'OS for first 110 pts but improved RR.', 'for first 110 pts but improved RR. #cancerresearch', 'first 110 pts but improved RR. #cancerresearch #clinicaltrials', '110 pts but improved RR. #cancerresearch #clinicaltrials #immunotherapy', 'pts but improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert', 'but improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22', 'improved RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost', 'RR. #cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy', '#cancerresearch #clinicaltrials #immunotherapy @OncoAlert #GI22 @ASCOPost #immunotherapy .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[2, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '40', 'tokens': ['cd20x3', 'bite:', 'in', 'those', 'in', 'cr,', 'durable', 'responses', 'and', 'virtually', 'no', 'relapses', 'after', '12', 'cycles', 'fixed-course', 'glofitamab', 'monotherapy!', '#lymphoma', '#lymsm', '#ash22', '', '.'], 'text_length': 23, 'triples': {'glofitamab|durable responses and virtually no relapses': ([16, 16], [6, 11], 'positive')}, 'sentence': 'cd20x3 bite: in those in cr, durable responses and virtually no relapses after 12 cycles fixed-course glofitamab monotherapy! #lymphoma #lymsm #ash22  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(16, 16)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8)], 'span tokens': ['cd20x3', 'bite:', 'in', 'those', 'in', 'cr,', 'durable', 'responses', 'and', 'virtually', 'no', 'relapses', 'after', '12', 'cycles', 'fixed-course', 'glofitamab', 'monotherapy!', '#lymphoma', '#lymsm', '#ash22', '', '.', 'cd20x3 bite:', 'bite: in', 'in those', 'those in', 'in cr,', 'cr, durable', 'durable responses', 'responses and', 'and virtually', 'virtually no', 'no relapses', 'relapses after', 'after 12', '12 cycles', 'cycles fixed-course', 'fixed-course glofitamab', 'glofitamab monotherapy!', 'monotherapy! #lymphoma', '#lymphoma #lymsm', '#lymsm #ash22', '#ash22 ', ' .', 'cd20x3 bite: in', 'bite: in those', 'in those in', 'those in cr,', 'in cr, durable', 'cr, durable responses', 'durable responses and', 'responses and virtually', 'and virtually no', 'virtually no relapses', 'no relapses after', 'relapses after 12', 'after 12 cycles', '12 cycles fixed-course', 'cycles fixed-course glofitamab', 'fixed-course glofitamab monotherapy!', 'glofitamab monotherapy! #lymphoma', 'monotherapy! #lymphoma #lymsm', '#lymphoma #lymsm #ash22', '#lymsm #ash22 ', '#ash22  .', 'cd20x3 bite: in those', 'bite: in those in', 'in those in cr,', 'those in cr, durable', 'in cr, durable responses', 'cr, durable responses and', 'durable responses and virtually', 'responses and virtually no', 'and virtually no relapses', 'virtually no relapses after', 'no relapses after 12', 'relapses after 12 cycles', 'after 12 cycles fixed-course', '12 cycles fixed-course glofitamab', 'cycles fixed-course glofitamab monotherapy!', 'fixed-course glofitamab monotherapy! #lymphoma', 'glofitamab monotherapy! #lymphoma #lymsm', 'monotherapy! #lymphoma #lymsm #ash22', '#lymphoma #lymsm #ash22 ', '#lymsm #ash22  .', 'cd20x3 bite: in those in', 'bite: in those in cr,', 'in those in cr, durable', 'those in cr, durable responses', 'in cr, durable responses and', 'cr, durable responses and virtually', 'durable responses and virtually no', 'responses and virtually no relapses', 'and virtually no relapses after', 'virtually no relapses after 12', 'no relapses after 12 cycles', 'relapses after 12 cycles fixed-course', 'after 12 cycles fixed-course glofitamab', '12 cycles fixed-course glofitamab monotherapy!', 'cycles fixed-course glofitamab monotherapy! #lymphoma', 'fixed-course glofitamab monotherapy! #lymphoma #lymsm', 'glofitamab monotherapy! #lymphoma #lymsm #ash22', 'monotherapy! #lymphoma #lymsm #ash22 ', '#lymphoma #lymsm #ash22  .', 'cd20x3 bite: in those in cr,', 'bite: in those in cr, durable', 'in those in cr, durable responses', 'those in cr, durable responses and', 'in cr, durable responses and virtually', 'cr, durable responses and virtually no', 'durable responses and virtually no relapses', 'responses and virtually no relapses after', 'and virtually no relapses after 12', 'virtually no relapses after 12 cycles', 'no relapses after 12 cycles fixed-course', 'relapses after 12 cycles fixed-course glofitamab', 'after 12 cycles fixed-course glofitamab monotherapy!', '12 cycles fixed-course glofitamab monotherapy! #lymphoma', 'cycles fixed-course glofitamab monotherapy! #lymphoma #lymsm', 'fixed-course glofitamab monotherapy! #lymphoma #lymsm #ash22', 'glofitamab monotherapy! #lymphoma #lymsm #ash22 ', 'monotherapy! #lymphoma #lymsm #ash22  .', 'cd20x3 bite: in those in cr, durable', 'bite: in those in cr, durable responses', 'in those in cr, durable responses and', 'those in cr, durable responses and virtually', 'in cr, durable responses and virtually no', 'cr, durable responses and virtually no relapses', 'durable responses and virtually no relapses after', 'responses and virtually no relapses after 12', 'and virtually no relapses after 12 cycles', 'virtually no relapses after 12 cycles fixed-course', 'no relapses after 12 cycles fixed-course glofitamab', 'relapses after 12 cycles fixed-course glofitamab monotherapy!', 'after 12 cycles fixed-course glofitamab monotherapy! #lymphoma', '12 cycles fixed-course glofitamab monotherapy! #lymphoma #lymsm', 'cycles fixed-course glofitamab monotherapy! #lymphoma #lymsm #ash22', 'fixed-course glofitamab monotherapy! #lymphoma #lymsm #ash22 ', 'glofitamab monotherapy! #lymphoma #lymsm #ash22  .', 'cd20x3 bite: in those in cr, durable responses', 'bite: in those in cr, durable responses and', 'in those in cr, durable responses and virtually', 'those in cr, durable responses and virtually no', 'in cr, durable responses and virtually no relapses', 'cr, durable responses and virtually no relapses after', 'durable responses and virtually no relapses after 12', 'responses and virtually no relapses after 12 cycles', 'and virtually no relapses after 12 cycles fixed-course', 'virtually no relapses after 12 cycles fixed-course glofitamab', 'no relapses after 12 cycles fixed-course glofitamab monotherapy!', 'relapses after 12 cycles fixed-course glofitamab monotherapy! #lymphoma', 'after 12 cycles fixed-course glofitamab monotherapy! #lymphoma #lymsm', '12 cycles fixed-course glofitamab monotherapy! #lymphoma #lymsm #ash22', 'cycles fixed-course glofitamab monotherapy! #lymphoma #lymsm #ash22 ', 'fixed-course glofitamab monotherapy! #lymphoma #lymsm #ash22  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '41', 'tokens': ['promising', 'results', 'in', 'r/r', 'dlbcl', 'setting', '1)', 'durable', 'response', 'in', 'patients', 'achieving', 'cr', 'after', 'glofitamab', 'treatment', '2)', 'epcoritamab', '+', 'r-dhax/c:', 'high', 'response', 'rate', 'and', 'excellent', 'pfs', '3)interesting', 'data', 'about', 'car-t', 'in', 'primary', '&amp;', 'secondary', 'cns', 'involvement', '#ash2022', '#lymsm', '.'], 'text_length': 39, 'triples': {'glofitamab|promising results in r/r dlbcl setting 1) durable response in patients achieving cr after glofitamab treatment 2) epcoritamab + r-dhax/c: high response': ([14, 14], [0, 21], 'positive'), 'epcoritamab|response in patients achieving cr after glofitamab treatment 2) epcoritamab + r-dhax/c: high response rate and excellent pfs': ([17, 17], [8, 25], 'positive')}, 'sentence': 'promising results in r/r dlbcl setting 1) durable response in patients achieving cr after glofitamab treatment 2) epcoritamab + r-dhax/c: high response rate and excellent pfs 3)interesting data about car-t in primary &amp; secondary cns involvement #ash2022 #lymsm .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(14, 14), (17, 17)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(0, 21), (8, 25)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 0],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8)], 'span tokens': ['promising', 'results', 'in', 'r/r', 'dlbcl', 'setting', '1)', 'durable', 'response', 'in', 'patients', 'achieving', 'cr', 'after', 'glofitamab', 'treatment', '2)', 'epcoritamab', '+', 'r-dhax/c:', 'high', 'response', 'rate', 'and', 'excellent', 'pfs', '3)interesting', 'data', 'about', 'car-t', 'in', 'primary', '&amp;', 'secondary', 'cns', 'involvement', '#ash2022', '#lymsm', '.', 'promising results', 'results in', 'in r/r', 'r/r dlbcl', 'dlbcl setting', 'setting 1)', '1) durable', 'durable response', 'response in', 'in patients', 'patients achieving', 'achieving cr', 'cr after', 'after glofitamab', 'glofitamab treatment', 'treatment 2)', '2) epcoritamab', 'epcoritamab +', '+ r-dhax/c:', 'r-dhax/c: high', 'high response', 'response rate', 'rate and', 'and excellent', 'excellent pfs', 'pfs 3)interesting', '3)interesting data', 'data about', 'about car-t', 'car-t in', 'in primary', 'primary &amp;', '&amp; secondary', 'secondary cns', 'cns involvement', 'involvement #ash2022', '#ash2022 #lymsm', '#lymsm .', 'promising results in', 'results in r/r', 'in r/r dlbcl', 'r/r dlbcl setting', 'dlbcl setting 1)', 'setting 1) durable', '1) durable response', 'durable response in', 'response in patients', 'in patients achieving', 'patients achieving cr', 'achieving cr after', 'cr after glofitamab', 'after glofitamab treatment', 'glofitamab treatment 2)', 'treatment 2) epcoritamab', '2) epcoritamab +', 'epcoritamab + r-dhax/c:', '+ r-dhax/c: high', 'r-dhax/c: high response', 'high response rate', 'response rate and', 'rate and excellent', 'and excellent pfs', 'excellent pfs 3)interesting', 'pfs 3)interesting data', '3)interesting data about', 'data about car-t', 'about car-t in', 'car-t in primary', 'in primary &amp;', 'primary &amp; secondary', '&amp; secondary cns', 'secondary cns involvement', 'cns involvement #ash2022', 'involvement #ash2022 #lymsm', '#ash2022 #lymsm .', 'promising results in r/r', 'results in r/r dlbcl', 'in r/r dlbcl setting', 'r/r dlbcl setting 1)', 'dlbcl setting 1) durable', 'setting 1) durable response', '1) durable response in', 'durable response in patients', 'response in patients achieving', 'in patients achieving cr', 'patients achieving cr after', 'achieving cr after glofitamab', 'cr after glofitamab treatment', 'after glofitamab treatment 2)', 'glofitamab treatment 2) epcoritamab', 'treatment 2) epcoritamab +', '2) epcoritamab + r-dhax/c:', 'epcoritamab + r-dhax/c: high', '+ r-dhax/c: high response', 'r-dhax/c: high response rate', 'high response rate and', 'response rate and excellent', 'rate and excellent pfs', 'and excellent pfs 3)interesting', 'excellent pfs 3)interesting data', 'pfs 3)interesting data about', '3)interesting data about car-t', 'data about car-t in', 'about car-t in primary', 'car-t in primary &amp;', 'in primary &amp; secondary', 'primary &amp; secondary cns', '&amp; secondary cns involvement', 'secondary cns involvement #ash2022', 'cns involvement #ash2022 #lymsm', 'involvement #ash2022 #lymsm .', 'promising results in r/r dlbcl', 'results in r/r dlbcl setting', 'in r/r dlbcl setting 1)', 'r/r dlbcl setting 1) durable', 'dlbcl setting 1) durable response', 'setting 1) durable response in', '1) durable response in patients', 'durable response in patients achieving', 'response in patients achieving cr', 'in patients achieving cr after', 'patients achieving cr after glofitamab', 'achieving cr after glofitamab treatment', 'cr after glofitamab treatment 2)', 'after glofitamab treatment 2) epcoritamab', 'glofitamab treatment 2) epcoritamab +', 'treatment 2) epcoritamab + r-dhax/c:', '2) epcoritamab + r-dhax/c: high', 'epcoritamab + r-dhax/c: high response', '+ r-dhax/c: high response rate', 'r-dhax/c: high response rate and', 'high response rate and excellent', 'response rate and excellent pfs', 'rate and excellent pfs 3)interesting', 'and excellent pfs 3)interesting data', 'excellent pfs 3)interesting data about', 'pfs 3)interesting data about car-t', '3)interesting data about car-t in', 'data about car-t in primary', 'about car-t in primary &amp;', 'car-t in primary &amp; secondary', 'in primary &amp; secondary cns', 'primary &amp; secondary cns involvement', '&amp; secondary cns involvement #ash2022', 'secondary cns involvement #ash2022 #lymsm', 'cns involvement #ash2022 #lymsm .', 'promising results in r/r dlbcl setting', 'results in r/r dlbcl setting 1)', 'in r/r dlbcl setting 1) durable', 'r/r dlbcl setting 1) durable response', 'dlbcl setting 1) durable response in', 'setting 1) durable response in patients', '1) durable response in patients achieving', 'durable response in patients achieving cr', 'response in patients achieving cr after', 'in patients achieving cr after glofitamab', 'patients achieving cr after glofitamab treatment', 'achieving cr after glofitamab treatment 2)', 'cr after glofitamab treatment 2) epcoritamab', 'after glofitamab treatment 2) epcoritamab +', 'glofitamab treatment 2) epcoritamab + r-dhax/c:', 'treatment 2) epcoritamab + r-dhax/c: high', '2) epcoritamab + r-dhax/c: high response', 'epcoritamab + r-dhax/c: high response rate', '+ r-dhax/c: high response rate and', 'r-dhax/c: high response rate and excellent', 'high response rate and excellent pfs', 'response rate and excellent pfs 3)interesting', 'rate and excellent pfs 3)interesting data', 'and excellent pfs 3)interesting data about', 'excellent pfs 3)interesting data about car-t', 'pfs 3)interesting data about car-t in', '3)interesting data about car-t in primary', 'data about car-t in primary &amp;', 'about car-t in primary &amp; secondary', 'car-t in primary &amp; secondary cns', 'in primary &amp; secondary cns involvement', 'primary &amp; secondary cns involvement #ash2022', '&amp; secondary cns involvement #ash2022 #lymsm', 'secondary cns involvement #ash2022 #lymsm .', 'promising results in r/r dlbcl setting 1)', 'results in r/r dlbcl setting 1) durable', 'in r/r dlbcl setting 1) durable response', 'r/r dlbcl setting 1) durable response in', 'dlbcl setting 1) durable response in patients', 'setting 1) durable response in patients achieving', '1) durable response in patients achieving cr', 'durable response in patients achieving cr after', 'response in patients achieving cr after glofitamab', 'in patients achieving cr after glofitamab treatment', 'patients achieving cr after glofitamab treatment 2)', 'achieving cr after glofitamab treatment 2) epcoritamab', 'cr after glofitamab treatment 2) epcoritamab +', 'after glofitamab treatment 2) epcoritamab + r-dhax/c:', 'glofitamab treatment 2) epcoritamab + r-dhax/c: high', 'treatment 2) epcoritamab + r-dhax/c: high response', '2) epcoritamab + r-dhax/c: high response rate', 'epcoritamab + r-dhax/c: high response rate and', '+ r-dhax/c: high response rate and excellent', 'r-dhax/c: high response rate and excellent pfs', 'high response rate and excellent pfs 3)interesting', 'response rate and excellent pfs 3)interesting data', 'rate and excellent pfs 3)interesting data about', 'and excellent pfs 3)interesting data about car-t', 'excellent pfs 3)interesting data about car-t in', 'pfs 3)interesting data about car-t in primary', '3)interesting data about car-t in primary &amp;', 'data about car-t in primary &amp; secondary', 'about car-t in primary &amp; secondary cns', 'car-t in primary &amp; secondary cns involvement', 'in primary &amp; secondary cns involvement #ash2022', 'primary &amp; secondary cns involvement #ash2022 #lymsm', '&amp; secondary cns involvement #ash2022 #lymsm .', 'promising results in r/r dlbcl setting 1) durable', 'results in r/r dlbcl setting 1) durable response', 'in r/r dlbcl setting 1) durable response in', 'r/r dlbcl setting 1) durable response in patients', 'dlbcl setting 1) durable response in patients achieving', 'setting 1) durable response in patients achieving cr', '1) durable response in patients achieving cr after', 'durable response in patients achieving cr after glofitamab', 'response in patients achieving cr after glofitamab treatment', 'in patients achieving cr after glofitamab treatment 2)', 'patients achieving cr after glofitamab treatment 2) epcoritamab', 'achieving cr after glofitamab treatment 2) epcoritamab +', 'cr after glofitamab treatment 2) epcoritamab + r-dhax/c:', 'after glofitamab treatment 2) epcoritamab + r-dhax/c: high', 'glofitamab treatment 2) epcoritamab + r-dhax/c: high response', 'treatment 2) epcoritamab + r-dhax/c: high response rate', '2) epcoritamab + r-dhax/c: high response rate and', 'epcoritamab + r-dhax/c: high response rate and excellent', '+ r-dhax/c: high response rate and excellent pfs', 'r-dhax/c: high response rate and excellent pfs 3)interesting', 'high response rate and excellent pfs 3)interesting data', 'response rate and excellent pfs 3)interesting data about', 'rate and excellent pfs 3)interesting data about car-t', 'and excellent pfs 3)interesting data about car-t in', 'excellent pfs 3)interesting data about car-t in primary', 'pfs 3)interesting data about car-t in primary &amp;', '3)interesting data about car-t in primary &amp; secondary', 'data about car-t in primary &amp; secondary cns', 'about car-t in primary &amp; secondary cns involvement', 'car-t in primary &amp; secondary cns involvement #ash2022', 'in primary &amp; secondary cns involvement #ash2022 #lymsm', 'primary &amp; secondary cns involvement #ash2022 #lymsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '42', 'tokens': ['the', 'pivotal', 'phase', 'data', 'on', '#glofitamab', 'are', 'now', 'online', 'in', '#nejm,', 'released', 'simultaneously', 'with', 'our', 'presentation', 'of', 'durability', 'of', 'crs', 'beyond', 'end', 'of', 'therapy', 'at', '#ash22', 'this', 'morning.', 'a', 'pleasure', 'and', 'a', 'privilege', 'to', 'be', 'part', 'of', 'this', 'journey', 'with', 'and', 'many', 'others', '#lymsm', '', '.'], 'text_length': 46, 'triples': {'#glofitamab|now online in #nejm, released': ([5, 5], [7, 11], 'positive')}, 'sentence': 'the pivotal phase data on #glofitamab are now online in #nejm, released simultaneously with our presentation of durability of crs beyond end of therapy at #ash22 this morning. a pleasure and a privilege to be part of this journey with and many others #lymsm  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(5, 5)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(7, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (43, 43, 1), (44, 44, 1), (45, 45, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (42, 43, 2), (43, 44, 2), (44, 45, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (41, 43, 3), (42, 44, 3), (43, 45, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (40, 43, 4), (41, 44, 4), (42, 45, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (39, 43, 5), (40, 44, 5), (41, 45, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (38, 43, 6), (39, 44, 6), (40, 45, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (37, 43, 7), (38, 44, 7), (39, 45, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8), (36, 43, 8), (37, 44, 8), (38, 45, 8)], 'span tokens': ['the', 'pivotal', 'phase', 'data', 'on', '#glofitamab', 'are', 'now', 'online', 'in', '#nejm,', 'released', 'simultaneously', 'with', 'our', 'presentation', 'of', 'durability', 'of', 'crs', 'beyond', 'end', 'of', 'therapy', 'at', '#ash22', 'this', 'morning.', 'a', 'pleasure', 'and', 'a', 'privilege', 'to', 'be', 'part', 'of', 'this', 'journey', 'with', 'and', 'many', 'others', '#lymsm', '', '.', 'the pivotal', 'pivotal phase', 'phase data', 'data on', 'on #glofitamab', '#glofitamab are', 'are now', 'now online', 'online in', 'in #nejm,', '#nejm, released', 'released simultaneously', 'simultaneously with', 'with our', 'our presentation', 'presentation of', 'of durability', 'durability of', 'of crs', 'crs beyond', 'beyond end', 'end of', 'of therapy', 'therapy at', 'at #ash22', '#ash22 this', 'this morning.', 'morning. a', 'a pleasure', 'pleasure and', 'and a', 'a privilege', 'privilege to', 'to be', 'be part', 'part of', 'of this', 'this journey', 'journey with', 'with and', 'and many', 'many others', 'others #lymsm', '#lymsm ', ' .', 'the pivotal phase', 'pivotal phase data', 'phase data on', 'data on #glofitamab', 'on #glofitamab are', '#glofitamab are now', 'are now online', 'now online in', 'online in #nejm,', 'in #nejm, released', '#nejm, released simultaneously', 'released simultaneously with', 'simultaneously with our', 'with our presentation', 'our presentation of', 'presentation of durability', 'of durability of', 'durability of crs', 'of crs beyond', 'crs beyond end', 'beyond end of', 'end of therapy', 'of therapy at', 'therapy at #ash22', 'at #ash22 this', '#ash22 this morning.', 'this morning. a', 'morning. a pleasure', 'a pleasure and', 'pleasure and a', 'and a privilege', 'a privilege to', 'privilege to be', 'to be part', 'be part of', 'part of this', 'of this journey', 'this journey with', 'journey with and', 'with and many', 'and many others', 'many others #lymsm', 'others #lymsm ', '#lymsm  .', 'the pivotal phase data', 'pivotal phase data on', 'phase data on #glofitamab', 'data on #glofitamab are', 'on #glofitamab are now', '#glofitamab are now online', 'are now online in', 'now online in #nejm,', 'online in #nejm, released', 'in #nejm, released simultaneously', '#nejm, released simultaneously with', 'released simultaneously with our', 'simultaneously with our presentation', 'with our presentation of', 'our presentation of durability', 'presentation of durability of', 'of durability of crs', 'durability of crs beyond', 'of crs beyond end', 'crs beyond end of', 'beyond end of therapy', 'end of therapy at', 'of therapy at #ash22', 'therapy at #ash22 this', 'at #ash22 this morning.', '#ash22 this morning. a', 'this morning. a pleasure', 'morning. a pleasure and', 'a pleasure and a', 'pleasure and a privilege', 'and a privilege to', 'a privilege to be', 'privilege to be part', 'to be part of', 'be part of this', 'part of this journey', 'of this journey with', 'this journey with and', 'journey with and many', 'with and many others', 'and many others #lymsm', 'many others #lymsm ', 'others #lymsm  .', 'the pivotal phase data on', 'pivotal phase data on #glofitamab', 'phase data on #glofitamab are', 'data on #glofitamab are now', 'on #glofitamab are now online', '#glofitamab are now online in', 'are now online in #nejm,', 'now online in #nejm, released', 'online in #nejm, released simultaneously', 'in #nejm, released simultaneously with', '#nejm, released simultaneously with our', 'released simultaneously with our presentation', 'simultaneously with our presentation of', 'with our presentation of durability', 'our presentation of durability of', 'presentation of durability of crs', 'of durability of crs beyond', 'durability of crs beyond end', 'of crs beyond end of', 'crs beyond end of therapy', 'beyond end of therapy at', 'end of therapy at #ash22', 'of therapy at #ash22 this', 'therapy at #ash22 this morning.', 'at #ash22 this morning. a', '#ash22 this morning. a pleasure', 'this morning. a pleasure and', 'morning. a pleasure and a', 'a pleasure and a privilege', 'pleasure and a privilege to', 'and a privilege to be', 'a privilege to be part', 'privilege to be part of', 'to be part of this', 'be part of this journey', 'part of this journey with', 'of this journey with and', 'this journey with and many', 'journey with and many others', 'with and many others #lymsm', 'and many others #lymsm ', 'many others #lymsm  .', 'the pivotal phase data on #glofitamab', 'pivotal phase data on #glofitamab are', 'phase data on #glofitamab are now', 'data on #glofitamab are now online', 'on #glofitamab are now online in', '#glofitamab are now online in #nejm,', 'are now online in #nejm, released', 'now online in #nejm, released simultaneously', 'online in #nejm, released simultaneously with', 'in #nejm, released simultaneously with our', '#nejm, released simultaneously with our presentation', 'released simultaneously with our presentation of', 'simultaneously with our presentation of durability', 'with our presentation of durability of', 'our presentation of durability of crs', 'presentation of durability of crs beyond', 'of durability of crs beyond end', 'durability of crs beyond end of', 'of crs beyond end of therapy', 'crs beyond end of therapy at', 'beyond end of therapy at #ash22', 'end of therapy at #ash22 this', 'of therapy at #ash22 this morning.', 'therapy at #ash22 this morning. a', 'at #ash22 this morning. a pleasure', '#ash22 this morning. a pleasure and', 'this morning. a pleasure and a', 'morning. a pleasure and a privilege', 'a pleasure and a privilege to', 'pleasure and a privilege to be', 'and a privilege to be part', 'a privilege to be part of', 'privilege to be part of this', 'to be part of this journey', 'be part of this journey with', 'part of this journey with and', 'of this journey with and many', 'this journey with and many others', 'journey with and many others #lymsm', 'with and many others #lymsm ', 'and many others #lymsm  .', 'the pivotal phase data on #glofitamab are', 'pivotal phase data on #glofitamab are now', 'phase data on #glofitamab are now online', 'data on #glofitamab are now online in', 'on #glofitamab are now online in #nejm,', '#glofitamab are now online in #nejm, released', 'are now online in #nejm, released simultaneously', 'now online in #nejm, released simultaneously with', 'online in #nejm, released simultaneously with our', 'in #nejm, released simultaneously with our presentation', '#nejm, released simultaneously with our presentation of', 'released simultaneously with our presentation of durability', 'simultaneously with our presentation of durability of', 'with our presentation of durability of crs', 'our presentation of durability of crs beyond', 'presentation of durability of crs beyond end', 'of durability of crs beyond end of', 'durability of crs beyond end of therapy', 'of crs beyond end of therapy at', 'crs beyond end of therapy at #ash22', 'beyond end of therapy at #ash22 this', 'end of therapy at #ash22 this morning.', 'of therapy at #ash22 this morning. a', 'therapy at #ash22 this morning. a pleasure', 'at #ash22 this morning. a pleasure and', '#ash22 this morning. a pleasure and a', 'this morning. a pleasure and a privilege', 'morning. a pleasure and a privilege to', 'a pleasure and a privilege to be', 'pleasure and a privilege to be part', 'and a privilege to be part of', 'a privilege to be part of this', 'privilege to be part of this journey', 'to be part of this journey with', 'be part of this journey with and', 'part of this journey with and many', 'of this journey with and many others', 'this journey with and many others #lymsm', 'journey with and many others #lymsm ', 'with and many others #lymsm  .', 'the pivotal phase data on #glofitamab are now', 'pivotal phase data on #glofitamab are now online', 'phase data on #glofitamab are now online in', 'data on #glofitamab are now online in #nejm,', 'on #glofitamab are now online in #nejm, released', '#glofitamab are now online in #nejm, released simultaneously', 'are now online in #nejm, released simultaneously with', 'now online in #nejm, released simultaneously with our', 'online in #nejm, released simultaneously with our presentation', 'in #nejm, released simultaneously with our presentation of', '#nejm, released simultaneously with our presentation of durability', 'released simultaneously with our presentation of durability of', 'simultaneously with our presentation of durability of crs', 'with our presentation of durability of crs beyond', 'our presentation of durability of crs beyond end', 'presentation of durability of crs beyond end of', 'of durability of crs beyond end of therapy', 'durability of crs beyond end of therapy at', 'of crs beyond end of therapy at #ash22', 'crs beyond end of therapy at #ash22 this', 'beyond end of therapy at #ash22 this morning.', 'end of therapy at #ash22 this morning. a', 'of therapy at #ash22 this morning. a pleasure', 'therapy at #ash22 this morning. a pleasure and', 'at #ash22 this morning. a pleasure and a', '#ash22 this morning. a pleasure and a privilege', 'this morning. a pleasure and a privilege to', 'morning. a pleasure and a privilege to be', 'a pleasure and a privilege to be part', 'pleasure and a privilege to be part of', 'and a privilege to be part of this', 'a privilege to be part of this journey', 'privilege to be part of this journey with', 'to be part of this journey with and', 'be part of this journey with and many', 'part of this journey with and many others', 'of this journey with and many others #lymsm', 'this journey with and many others #lymsm ', 'journey with and many others #lymsm  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '43', 'tokens': ['good', 'news', 'if', 'you', 'are', 'in', 'the', '39.4%', 'of', 'patients', 'w', 'dlbcl', 'achieving', 'cr', 'following', '12', 'cycles', 'of', 'glofitamab', '-', 'responses', 'are', 'promisingly', 'durable', 'so', 'far,', 'with', 'the', 'significant', 'benefit', 'of', 'fixed', 'duration', 'treatment', '#ash22', '#lymsm', '', '.'], 'text_length': 38, 'triples': {'glofitamab|promisingly durable so far, with the significant benefit': ([18, 18], [22, 29], 'positive')}, 'sentence': 'good news if you are in the 39.4% of patients w dlbcl achieving cr following 12 cycles of glofitamab - responses are promisingly durable so far, with the significant benefit of fixed duration treatment #ash22 #lymsm  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(18, 18)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(22, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8)], 'span tokens': ['good', 'news', 'if', 'you', 'are', 'in', 'the', '39.4%', 'of', 'patients', 'w', 'dlbcl', 'achieving', 'cr', 'following', '12', 'cycles', 'of', 'glofitamab', '-', 'responses', 'are', 'promisingly', 'durable', 'so', 'far,', 'with', 'the', 'significant', 'benefit', 'of', 'fixed', 'duration', 'treatment', '#ash22', '#lymsm', '', '.', 'good news', 'news if', 'if you', 'you are', 'are in', 'in the', 'the 39.4%', '39.4% of', 'of patients', 'patients w', 'w dlbcl', 'dlbcl achieving', 'achieving cr', 'cr following', 'following 12', '12 cycles', 'cycles of', 'of glofitamab', 'glofitamab -', '- responses', 'responses are', 'are promisingly', 'promisingly durable', 'durable so', 'so far,', 'far, with', 'with the', 'the significant', 'significant benefit', 'benefit of', 'of fixed', 'fixed duration', 'duration treatment', 'treatment #ash22', '#ash22 #lymsm', '#lymsm ', ' .', 'good news if', 'news if you', 'if you are', 'you are in', 'are in the', 'in the 39.4%', 'the 39.4% of', '39.4% of patients', 'of patients w', 'patients w dlbcl', 'w dlbcl achieving', 'dlbcl achieving cr', 'achieving cr following', 'cr following 12', 'following 12 cycles', '12 cycles of', 'cycles of glofitamab', 'of glofitamab -', 'glofitamab - responses', '- responses are', 'responses are promisingly', 'are promisingly durable', 'promisingly durable so', 'durable so far,', 'so far, with', 'far, with the', 'with the significant', 'the significant benefit', 'significant benefit of', 'benefit of fixed', 'of fixed duration', 'fixed duration treatment', 'duration treatment #ash22', 'treatment #ash22 #lymsm', '#ash22 #lymsm ', '#lymsm  .', 'good news if you', 'news if you are', 'if you are in', 'you are in the', 'are in the 39.4%', 'in the 39.4% of', 'the 39.4% of patients', '39.4% of patients w', 'of patients w dlbcl', 'patients w dlbcl achieving', 'w dlbcl achieving cr', 'dlbcl achieving cr following', 'achieving cr following 12', 'cr following 12 cycles', 'following 12 cycles of', '12 cycles of glofitamab', 'cycles of glofitamab -', 'of glofitamab - responses', 'glofitamab - responses are', '- responses are promisingly', 'responses are promisingly durable', 'are promisingly durable so', 'promisingly durable so far,', 'durable so far, with', 'so far, with the', 'far, with the significant', 'with the significant benefit', 'the significant benefit of', 'significant benefit of fixed', 'benefit of fixed duration', 'of fixed duration treatment', 'fixed duration treatment #ash22', 'duration treatment #ash22 #lymsm', 'treatment #ash22 #lymsm ', '#ash22 #lymsm  .', 'good news if you are', 'news if you are in', 'if you are in the', 'you are in the 39.4%', 'are in the 39.4% of', 'in the 39.4% of patients', 'the 39.4% of patients w', '39.4% of patients w dlbcl', 'of patients w dlbcl achieving', 'patients w dlbcl achieving cr', 'w dlbcl achieving cr following', 'dlbcl achieving cr following 12', 'achieving cr following 12 cycles', 'cr following 12 cycles of', 'following 12 cycles of glofitamab', '12 cycles of glofitamab -', 'cycles of glofitamab - responses', 'of glofitamab - responses are', 'glofitamab - responses are promisingly', '- responses are promisingly durable', 'responses are promisingly durable so', 'are promisingly durable so far,', 'promisingly durable so far, with', 'durable so far, with the', 'so far, with the significant', 'far, with the significant benefit', 'with the significant benefit of', 'the significant benefit of fixed', 'significant benefit of fixed duration', 'benefit of fixed duration treatment', 'of fixed duration treatment #ash22', 'fixed duration treatment #ash22 #lymsm', 'duration treatment #ash22 #lymsm ', 'treatment #ash22 #lymsm  .', 'good news if you are in', 'news if you are in the', 'if you are in the 39.4%', 'you are in the 39.4% of', 'are in the 39.4% of patients', 'in the 39.4% of patients w', 'the 39.4% of patients w dlbcl', '39.4% of patients w dlbcl achieving', 'of patients w dlbcl achieving cr', 'patients w dlbcl achieving cr following', 'w dlbcl achieving cr following 12', 'dlbcl achieving cr following 12 cycles', 'achieving cr following 12 cycles of', 'cr following 12 cycles of glofitamab', 'following 12 cycles of glofitamab -', '12 cycles of glofitamab - responses', 'cycles of glofitamab - responses are', 'of glofitamab - responses are promisingly', 'glofitamab - responses are promisingly durable', '- responses are promisingly durable so', 'responses are promisingly durable so far,', 'are promisingly durable so far, with', 'promisingly durable so far, with the', 'durable so far, with the significant', 'so far, with the significant benefit', 'far, with the significant benefit of', 'with the significant benefit of fixed', 'the significant benefit of fixed duration', 'significant benefit of fixed duration treatment', 'benefit of fixed duration treatment #ash22', 'of fixed duration treatment #ash22 #lymsm', 'fixed duration treatment #ash22 #lymsm ', 'duration treatment #ash22 #lymsm  .', 'good news if you are in the', 'news if you are in the 39.4%', 'if you are in the 39.4% of', 'you are in the 39.4% of patients', 'are in the 39.4% of patients w', 'in the 39.4% of patients w dlbcl', 'the 39.4% of patients w dlbcl achieving', '39.4% of patients w dlbcl achieving cr', 'of patients w dlbcl achieving cr following', 'patients w dlbcl achieving cr following 12', 'w dlbcl achieving cr following 12 cycles', 'dlbcl achieving cr following 12 cycles of', 'achieving cr following 12 cycles of glofitamab', 'cr following 12 cycles of glofitamab -', 'following 12 cycles of glofitamab - responses', '12 cycles of glofitamab - responses are', 'cycles of glofitamab - responses are promisingly', 'of glofitamab - responses are promisingly durable', 'glofitamab - responses are promisingly durable so', '- responses are promisingly durable so far,', 'responses are promisingly durable so far, with', 'are promisingly durable so far, with the', 'promisingly durable so far, with the significant', 'durable so far, with the significant benefit', 'so far, with the significant benefit of', 'far, with the significant benefit of fixed', 'with the significant benefit of fixed duration', 'the significant benefit of fixed duration treatment', 'significant benefit of fixed duration treatment #ash22', 'benefit of fixed duration treatment #ash22 #lymsm', 'of fixed duration treatment #ash22 #lymsm ', 'fixed duration treatment #ash22 #lymsm  .', 'good news if you are in the 39.4%', 'news if you are in the 39.4% of', 'if you are in the 39.4% of patients', 'you are in the 39.4% of patients w', 'are in the 39.4% of patients w dlbcl', 'in the 39.4% of patients w dlbcl achieving', 'the 39.4% of patients w dlbcl achieving cr', '39.4% of patients w dlbcl achieving cr following', 'of patients w dlbcl achieving cr following 12', 'patients w dlbcl achieving cr following 12 cycles', 'w dlbcl achieving cr following 12 cycles of', 'dlbcl achieving cr following 12 cycles of glofitamab', 'achieving cr following 12 cycles of glofitamab -', 'cr following 12 cycles of glofitamab - responses', 'following 12 cycles of glofitamab - responses are', '12 cycles of glofitamab - responses are promisingly', 'cycles of glofitamab - responses are promisingly durable', 'of glofitamab - responses are promisingly durable so', 'glofitamab - responses are promisingly durable so far,', '- responses are promisingly durable so far, with', 'responses are promisingly durable so far, with the', 'are promisingly durable so far, with the significant', 'promisingly durable so far, with the significant benefit', 'durable so far, with the significant benefit of', 'so far, with the significant benefit of fixed', 'far, with the significant benefit of fixed duration', 'with the significant benefit of fixed duration treatment', 'the significant benefit of fixed duration treatment #ash22', 'significant benefit of fixed duration treatment #ash22 #lymsm', 'benefit of fixed duration treatment #ash22 #lymsm ', 'of fixed duration treatment #ash22 #lymsm  .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}, {'id': '44', 'tokens': ['glofitamab', 'for', 'r/r', 'dlbcl', 'n=154', 'med', 'fu', 'of', '12.6mo', 'cr', '39%', 'in', 'total', 'population', 'cr', '35%', '(prior', 'cart)', 'median', 'time', 'to', 'a', 'cr', '42', 'days', '78%', 'ongoing', 'cr', 'at', '12mo', 'gr', '&gt;=3crs', '4%', 'gr', '&gt;=3', 'neurotox', '3%', '#ashkudos', 'to', '#ash22', '#lysm', '', '.'], 'text_length': 43, 'triples': {'glofitamab|ongoing': ([0, 0], [26, 26], 'neutral')}, 'sentence': 'glofitamab for r/r dlbcl n=154 med fu of 12.6mo cr 39% in total population cr 35% (prior cart) median time to a cr 42 days 78% ongoing cr at 12mo gr &gt;=3crs 4% gr &gt;=3 neurotox 3% #ashkudos to #ash22 #lysm  .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(26, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (41, 41, 1), (42, 42, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (40, 41, 2), (41, 42, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (39, 41, 3), (40, 42, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (38, 41, 4), (39, 42, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (37, 41, 5), (38, 42, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (36, 41, 6), (37, 42, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (35, 41, 7), (36, 42, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8), (34, 41, 8), (35, 42, 8)], 'span tokens': ['glofitamab', 'for', 'r/r', 'dlbcl', 'n=154', 'med', 'fu', 'of', '12.6mo', 'cr', '39%', 'in', 'total', 'population', 'cr', '35%', '(prior', 'cart)', 'median', 'time', 'to', 'a', 'cr', '42', 'days', '78%', 'ongoing', 'cr', 'at', '12mo', 'gr', '&gt;=3crs', '4%', 'gr', '&gt;=3', 'neurotox', '3%', '#ashkudos', 'to', '#ash22', '#lysm', '', '.', 'glofitamab for', 'for r/r', 'r/r dlbcl', 'dlbcl n=154', 'n=154 med', 'med fu', 'fu of', 'of 12.6mo', '12.6mo cr', 'cr 39%', '39% in', 'in total', 'total population', 'population cr', 'cr 35%', '35% (prior', '(prior cart)', 'cart) median', 'median time', 'time to', 'to a', 'a cr', 'cr 42', '42 days', 'days 78%', '78% ongoing', 'ongoing cr', 'cr at', 'at 12mo', '12mo gr', 'gr &gt;=3crs', '&gt;=3crs 4%', '4% gr', 'gr &gt;=3', '&gt;=3 neurotox', 'neurotox 3%', '3% #ashkudos', '#ashkudos to', 'to #ash22', '#ash22 #lysm', '#lysm ', ' .', 'glofitamab for r/r', 'for r/r dlbcl', 'r/r dlbcl n=154', 'dlbcl n=154 med', 'n=154 med fu', 'med fu of', 'fu of 12.6mo', 'of 12.6mo cr', '12.6mo cr 39%', 'cr 39% in', '39% in total', 'in total population', 'total population cr', 'population cr 35%', 'cr 35% (prior', '35% (prior cart)', '(prior cart) median', 'cart) median time', 'median time to', 'time to a', 'to a cr', 'a cr 42', 'cr 42 days', '42 days 78%', 'days 78% ongoing', '78% ongoing cr', 'ongoing cr at', 'cr at 12mo', 'at 12mo gr', '12mo gr &gt;=3crs', 'gr &gt;=3crs 4%', '&gt;=3crs 4% gr', '4% gr &gt;=3', 'gr &gt;=3 neurotox', '&gt;=3 neurotox 3%', 'neurotox 3% #ashkudos', '3% #ashkudos to', '#ashkudos to #ash22', 'to #ash22 #lysm', '#ash22 #lysm ', '#lysm  .', 'glofitamab for r/r dlbcl', 'for r/r dlbcl n=154', 'r/r dlbcl n=154 med', 'dlbcl n=154 med fu', 'n=154 med fu of', 'med fu of 12.6mo', 'fu of 12.6mo cr', 'of 12.6mo cr 39%', '12.6mo cr 39% in', 'cr 39% in total', '39% in total population', 'in total population cr', 'total population cr 35%', 'population cr 35% (prior', 'cr 35% (prior cart)', '35% (prior cart) median', '(prior cart) median time', 'cart) median time to', 'median time to a', 'time to a cr', 'to a cr 42', 'a cr 42 days', 'cr 42 days 78%', '42 days 78% ongoing', 'days 78% ongoing cr', '78% ongoing cr at', 'ongoing cr at 12mo', 'cr at 12mo gr', 'at 12mo gr &gt;=3crs', '12mo gr &gt;=3crs 4%', 'gr &gt;=3crs 4% gr', '&gt;=3crs 4% gr &gt;=3', '4% gr &gt;=3 neurotox', 'gr &gt;=3 neurotox 3%', '&gt;=3 neurotox 3% #ashkudos', 'neurotox 3% #ashkudos to', '3% #ashkudos to #ash22', '#ashkudos to #ash22 #lysm', 'to #ash22 #lysm ', '#ash22 #lysm  .', 'glofitamab for r/r dlbcl n=154', 'for r/r dlbcl n=154 med', 'r/r dlbcl n=154 med fu', 'dlbcl n=154 med fu of', 'n=154 med fu of 12.6mo', 'med fu of 12.6mo cr', 'fu of 12.6mo cr 39%', 'of 12.6mo cr 39% in', '12.6mo cr 39% in total', 'cr 39% in total population', '39% in total population cr', 'in total population cr 35%', 'total population cr 35% (prior', 'population cr 35% (prior cart)', 'cr 35% (prior cart) median', '35% (prior cart) median time', '(prior cart) median time to', 'cart) median time to a', 'median time to a cr', 'time to a cr 42', 'to a cr 42 days', 'a cr 42 days 78%', 'cr 42 days 78% ongoing', '42 days 78% ongoing cr', 'days 78% ongoing cr at', '78% ongoing cr at 12mo', 'ongoing cr at 12mo gr', 'cr at 12mo gr &gt;=3crs', 'at 12mo gr &gt;=3crs 4%', '12mo gr &gt;=3crs 4% gr', 'gr &gt;=3crs 4% gr &gt;=3', '&gt;=3crs 4% gr &gt;=3 neurotox', '4% gr &gt;=3 neurotox 3%', 'gr &gt;=3 neurotox 3% #ashkudos', '&gt;=3 neurotox 3% #ashkudos to', 'neurotox 3% #ashkudos to #ash22', '3% #ashkudos to #ash22 #lysm', '#ashkudos to #ash22 #lysm ', 'to #ash22 #lysm  .', 'glofitamab for r/r dlbcl n=154 med', 'for r/r dlbcl n=154 med fu', 'r/r dlbcl n=154 med fu of', 'dlbcl n=154 med fu of 12.6mo', 'n=154 med fu of 12.6mo cr', 'med fu of 12.6mo cr 39%', 'fu of 12.6mo cr 39% in', 'of 12.6mo cr 39% in total', '12.6mo cr 39% in total population', 'cr 39% in total population cr', '39% in total population cr 35%', 'in total population cr 35% (prior', 'total population cr 35% (prior cart)', 'population cr 35% (prior cart) median', 'cr 35% (prior cart) median time', '35% (prior cart) median time to', '(prior cart) median time to a', 'cart) median time to a cr', 'median time to a cr 42', 'time to a cr 42 days', 'to a cr 42 days 78%', 'a cr 42 days 78% ongoing', 'cr 42 days 78% ongoing cr', '42 days 78% ongoing cr at', 'days 78% ongoing cr at 12mo', '78% ongoing cr at 12mo gr', 'ongoing cr at 12mo gr &gt;=3crs', 'cr at 12mo gr &gt;=3crs 4%', 'at 12mo gr &gt;=3crs 4% gr', '12mo gr &gt;=3crs 4% gr &gt;=3', 'gr &gt;=3crs 4% gr &gt;=3 neurotox', '&gt;=3crs 4% gr &gt;=3 neurotox 3%', '4% gr &gt;=3 neurotox 3% #ashkudos', 'gr &gt;=3 neurotox 3% #ashkudos to', '&gt;=3 neurotox 3% #ashkudos to #ash22', 'neurotox 3% #ashkudos to #ash22 #lysm', '3% #ashkudos to #ash22 #lysm ', '#ashkudos to #ash22 #lysm  .', 'glofitamab for r/r dlbcl n=154 med fu', 'for r/r dlbcl n=154 med fu of', 'r/r dlbcl n=154 med fu of 12.6mo', 'dlbcl n=154 med fu of 12.6mo cr', 'n=154 med fu of 12.6mo cr 39%', 'med fu of 12.6mo cr 39% in', 'fu of 12.6mo cr 39% in total', 'of 12.6mo cr 39% in total population', '12.6mo cr 39% in total population cr', 'cr 39% in total population cr 35%', '39% in total population cr 35% (prior', 'in total population cr 35% (prior cart)', 'total population cr 35% (prior cart) median', 'population cr 35% (prior cart) median time', 'cr 35% (prior cart) median time to', '35% (prior cart) median time to a', '(prior cart) median time to a cr', 'cart) median time to a cr 42', 'median time to a cr 42 days', 'time to a cr 42 days 78%', 'to a cr 42 days 78% ongoing', 'a cr 42 days 78% ongoing cr', 'cr 42 days 78% ongoing cr at', '42 days 78% ongoing cr at 12mo', 'days 78% ongoing cr at 12mo gr', '78% ongoing cr at 12mo gr &gt;=3crs', 'ongoing cr at 12mo gr &gt;=3crs 4%', 'cr at 12mo gr &gt;=3crs 4% gr', 'at 12mo gr &gt;=3crs 4% gr &gt;=3', '12mo gr &gt;=3crs 4% gr &gt;=3 neurotox', 'gr &gt;=3crs 4% gr &gt;=3 neurotox 3%', '&gt;=3crs 4% gr &gt;=3 neurotox 3% #ashkudos', '4% gr &gt;=3 neurotox 3% #ashkudos to', 'gr &gt;=3 neurotox 3% #ashkudos to #ash22', '&gt;=3 neurotox 3% #ashkudos to #ash22 #lysm', 'neurotox 3% #ashkudos to #ash22 #lysm ', '3% #ashkudos to #ash22 #lysm  .', 'glofitamab for r/r dlbcl n=154 med fu of', 'for r/r dlbcl n=154 med fu of 12.6mo', 'r/r dlbcl n=154 med fu of 12.6mo cr', 'dlbcl n=154 med fu of 12.6mo cr 39%', 'n=154 med fu of 12.6mo cr 39% in', 'med fu of 12.6mo cr 39% in total', 'fu of 12.6mo cr 39% in total population', 'of 12.6mo cr 39% in total population cr', '12.6mo cr 39% in total population cr 35%', 'cr 39% in total population cr 35% (prior', '39% in total population cr 35% (prior cart)', 'in total population cr 35% (prior cart) median', 'total population cr 35% (prior cart) median time', 'population cr 35% (prior cart) median time to', 'cr 35% (prior cart) median time to a', '35% (prior cart) median time to a cr', '(prior cart) median time to a cr 42', 'cart) median time to a cr 42 days', 'median time to a cr 42 days 78%', 'time to a cr 42 days 78% ongoing', 'to a cr 42 days 78% ongoing cr', 'a cr 42 days 78% ongoing cr at', 'cr 42 days 78% ongoing cr at 12mo', '42 days 78% ongoing cr at 12mo gr', 'days 78% ongoing cr at 12mo gr &gt;=3crs', '78% ongoing cr at 12mo gr &gt;=3crs 4%', 'ongoing cr at 12mo gr &gt;=3crs 4% gr', 'cr at 12mo gr &gt;=3crs 4% gr &gt;=3', 'at 12mo gr &gt;=3crs 4% gr &gt;=3 neurotox', '12mo gr &gt;=3crs 4% gr &gt;=3 neurotox 3%', 'gr &gt;=3crs 4% gr &gt;=3 neurotox 3% #ashkudos', '&gt;=3crs 4% gr &gt;=3 neurotox 3% #ashkudos to', '4% gr &gt;=3 neurotox 3% #ashkudos to #ash22', 'gr &gt;=3 neurotox 3% #ashkudos to #ash22 #lysm', '&gt;=3 neurotox 3% #ashkudos to #ash22 #lysm ', 'neurotox 3% #ashkudos to #ash22 #lysm  .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}]]
训练集与验证集加载完成
Epoch:0
Sample in enumerate:{'id': '0', 'tokens': ['#asco22', 'dr', 'chris', 'ryan', 'presenting', 'results', 'of', 'everest', 'ph3', 'results', 'for', '#rcc', '.'], 'text_length': 13, 'triples': {'everest|presenting': ([7, 7], [4, 4], 'neutral')}, 'sentence': '#asco22 dr chris ryan presenting results of everest ph3 results for #rcc .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(7, 7)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(4, 4)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8)], 'span tokens': ['#asco22', 'dr', 'chris', 'ryan', 'presenting', 'results', 'of', 'everest', 'ph3', 'results', 'for', '#rcc', '.', '#asco22 dr', 'dr chris', 'chris ryan', 'ryan presenting', 'presenting results', 'results of', 'of everest', 'everest ph3', 'ph3 results', 'results for', 'for #rcc', '#rcc .', '#asco22 dr chris', 'dr chris ryan', 'chris ryan presenting', 'ryan presenting results', 'presenting results of', 'results of everest', 'of everest ph3', 'everest ph3 results', 'ph3 results for', 'results for #rcc', 'for #rcc .', '#asco22 dr chris ryan', 'dr chris ryan presenting', 'chris ryan presenting results', 'ryan presenting results of', 'presenting results of everest', 'results of everest ph3', 'of everest ph3 results', 'everest ph3 results for', 'ph3 results for #rcc', 'results for #rcc .', '#asco22 dr chris ryan presenting', 'dr chris ryan presenting results', 'chris ryan presenting results of', 'ryan presenting results of everest', 'presenting results of everest ph3', 'results of everest ph3 results', 'of everest ph3 results for', 'everest ph3 results for #rcc', 'ph3 results for #rcc .', '#asco22 dr chris ryan presenting results', 'dr chris ryan presenting results of', 'chris ryan presenting results of everest', 'ryan presenting results of everest ph3', 'presenting results of everest ph3 results', 'results of everest ph3 results for', 'of everest ph3 results for #rcc', 'everest ph3 results for #rcc .', '#asco22 dr chris ryan presenting results of', 'dr chris ryan presenting results of everest', 'chris ryan presenting results of everest ph3', 'ryan presenting results of everest ph3 results', 'presenting results of everest ph3 results for', 'results of everest ph3 results for #rcc', 'of everest ph3 results for #rcc .', '#asco22 dr chris ryan presenting results of everest', 'dr chris ryan presenting results of everest ph3', 'chris ryan presenting results of everest ph3 results', 'ryan presenting results of everest ph3 results for', 'presenting results of everest ph3 results for #rcc', 'results of everest ph3 results for #rcc .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '1', 'tokens': ['enzamet', 'trial:', 'more', 'evidence', 'for', 'triplets', 'in', 'high', 'volume', 'mhspc.', 'benefit', 'for', 'adding', 'docetaxel+enzalutamide', 'in', 'this', 'setting.', '#asco22', '#prostatecancer', '.'], 'text_length': 20, 'triples': {'enzamet|more evidence for triplets in high': ([0, 0], [2, 7], 'neutral'), 'docetaxel+enzalutamide|benefit': ([13, 13], [10, 10], 'neutral')}, 'sentence': 'enzamet trial: more evidence for triplets in high volume mhspc. benefit for adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(0, 0), (13, 13)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(2, 7), (10, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['enzamet', 'trial:', 'more', 'evidence', 'for', 'triplets', 'in', 'high', 'volume', 'mhspc.', 'benefit', 'for', 'adding', 'docetaxel+enzalutamide', 'in', 'this', 'setting.', '#asco22', '#prostatecancer', '.', 'enzamet trial:', 'trial: more', 'more evidence', 'evidence for', 'for triplets', 'triplets in', 'in high', 'high volume', 'volume mhspc.', 'mhspc. benefit', 'benefit for', 'for adding', 'adding docetaxel+enzalutamide', 'docetaxel+enzalutamide in', 'in this', 'this setting.', 'setting. #asco22', '#asco22 #prostatecancer', '#prostatecancer .', 'enzamet trial: more', 'trial: more evidence', 'more evidence for', 'evidence for triplets', 'for triplets in', 'triplets in high', 'in high volume', 'high volume mhspc.', 'volume mhspc. benefit', 'mhspc. benefit for', 'benefit for adding', 'for adding docetaxel+enzalutamide', 'adding docetaxel+enzalutamide in', 'docetaxel+enzalutamide in this', 'in this setting.', 'this setting. #asco22', 'setting. #asco22 #prostatecancer', '#asco22 #prostatecancer .', 'enzamet trial: more evidence', 'trial: more evidence for', 'more evidence for triplets', 'evidence for triplets in', 'for triplets in high', 'triplets in high volume', 'in high volume mhspc.', 'high volume mhspc. benefit', 'volume mhspc. benefit for', 'mhspc. benefit for adding', 'benefit for adding docetaxel+enzalutamide', 'for adding docetaxel+enzalutamide in', 'adding docetaxel+enzalutamide in this', 'docetaxel+enzalutamide in this setting.', 'in this setting. #asco22', 'this setting. #asco22 #prostatecancer', 'setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for', 'trial: more evidence for triplets', 'more evidence for triplets in', 'evidence for triplets in high', 'for triplets in high volume', 'triplets in high volume mhspc.', 'in high volume mhspc. benefit', 'high volume mhspc. benefit for', 'volume mhspc. benefit for adding', 'mhspc. benefit for adding docetaxel+enzalutamide', 'benefit for adding docetaxel+enzalutamide in', 'for adding docetaxel+enzalutamide in this', 'adding docetaxel+enzalutamide in this setting.', 'docetaxel+enzalutamide in this setting. #asco22', 'in this setting. #asco22 #prostatecancer', 'this setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for triplets', 'trial: more evidence for triplets in', 'more evidence for triplets in high', 'evidence for triplets in high volume', 'for triplets in high volume mhspc.', 'triplets in high volume mhspc. benefit', 'in high volume mhspc. benefit for', 'high volume mhspc. benefit for adding', 'volume mhspc. benefit for adding docetaxel+enzalutamide', 'mhspc. benefit for adding docetaxel+enzalutamide in', 'benefit for adding docetaxel+enzalutamide in this', 'for adding docetaxel+enzalutamide in this setting.', 'adding docetaxel+enzalutamide in this setting. #asco22', 'docetaxel+enzalutamide in this setting. #asco22 #prostatecancer', 'in this setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for triplets in', 'trial: more evidence for triplets in high', 'more evidence for triplets in high volume', 'evidence for triplets in high volume mhspc.', 'for triplets in high volume mhspc. benefit', 'triplets in high volume mhspc. benefit for', 'in high volume mhspc. benefit for adding', 'high volume mhspc. benefit for adding docetaxel+enzalutamide', 'volume mhspc. benefit for adding docetaxel+enzalutamide in', 'mhspc. benefit for adding docetaxel+enzalutamide in this', 'benefit for adding docetaxel+enzalutamide in this setting.', 'for adding docetaxel+enzalutamide in this setting. #asco22', 'adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer', 'docetaxel+enzalutamide in this setting. #asco22 #prostatecancer .', 'enzamet trial: more evidence for triplets in high', 'trial: more evidence for triplets in high volume', 'more evidence for triplets in high volume mhspc.', 'evidence for triplets in high volume mhspc. benefit', 'for triplets in high volume mhspc. benefit for', 'triplets in high volume mhspc. benefit for adding', 'in high volume mhspc. benefit for adding docetaxel+enzalutamide', 'high volume mhspc. benefit for adding docetaxel+enzalutamide in', 'volume mhspc. benefit for adding docetaxel+enzalutamide in this', 'mhspc. benefit for adding docetaxel+enzalutamide in this setting.', 'benefit for adding docetaxel+enzalutamide in this setting. #asco22', 'for adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer', 'adding docetaxel+enzalutamide in this setting. #asco22 #prostatecancer .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '2', 'tokens': ['excited,', 'nervous', '(have', 'you', 'seen', 'the', 'paris', 'hall?!)', 'but', 'most', 'of', 'all', 'proud', 'that', 'niche', 'was', 'selected', 'for', 'the', 'presidential', 'symposium', '!', '#esmo22', 'niche-2', 'is', 'a', 'great', 'example', 'of', 'multidisciplinary', 'effort', 'and', 'science.', 'see', 'you', 'there?!', '.'], 'text_length': 37, 'triples': {'#esmo22|a great': ([22, 22], [25, 26], 'positive')}, 'sentence': 'excited, nervous (have you seen the paris hall?!) but most of all proud that niche was selected for the presidential symposium ! #esmo22 niche-2 is a great example of multidisciplinary effort and science. see you there?! .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(22, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(25, 26)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8)], 'span tokens': ['excited,', 'nervous', '(have', 'you', 'seen', 'the', 'paris', 'hall?!)', 'but', 'most', 'of', 'all', 'proud', 'that', 'niche', 'was', 'selected', 'for', 'the', 'presidential', 'symposium', '!', '#esmo22', 'niche-2', 'is', 'a', 'great', 'example', 'of', 'multidisciplinary', 'effort', 'and', 'science.', 'see', 'you', 'there?!', '.', 'excited, nervous', 'nervous (have', '(have you', 'you seen', 'seen the', 'the paris', 'paris hall?!)', 'hall?!) but', 'but most', 'most of', 'of all', 'all proud', 'proud that', 'that niche', 'niche was', 'was selected', 'selected for', 'for the', 'the presidential', 'presidential symposium', 'symposium !', '! #esmo22', '#esmo22 niche-2', 'niche-2 is', 'is a', 'a great', 'great example', 'example of', 'of multidisciplinary', 'multidisciplinary effort', 'effort and', 'and science.', 'science. see', 'see you', 'you there?!', 'there?! .', 'excited, nervous (have', 'nervous (have you', '(have you seen', 'you seen the', 'seen the paris', 'the paris hall?!)', 'paris hall?!) but', 'hall?!) but most', 'but most of', 'most of all', 'of all proud', 'all proud that', 'proud that niche', 'that niche was', 'niche was selected', 'was selected for', 'selected for the', 'for the presidential', 'the presidential symposium', 'presidential symposium !', 'symposium ! #esmo22', '! #esmo22 niche-2', '#esmo22 niche-2 is', 'niche-2 is a', 'is a great', 'a great example', 'great example of', 'example of multidisciplinary', 'of multidisciplinary effort', 'multidisciplinary effort and', 'effort and science.', 'and science. see', 'science. see you', 'see you there?!', 'you there?! .', 'excited, nervous (have you', 'nervous (have you seen', '(have you seen the', 'you seen the paris', 'seen the paris hall?!)', 'the paris hall?!) but', 'paris hall?!) but most', 'hall?!) but most of', 'but most of all', 'most of all proud', 'of all proud that', 'all proud that niche', 'proud that niche was', 'that niche was selected', 'niche was selected for', 'was selected for the', 'selected for the presidential', 'for the presidential symposium', 'the presidential symposium !', 'presidential symposium ! #esmo22', 'symposium ! #esmo22 niche-2', '! #esmo22 niche-2 is', '#esmo22 niche-2 is a', 'niche-2 is a great', 'is a great example', 'a great example of', 'great example of multidisciplinary', 'example of multidisciplinary effort', 'of multidisciplinary effort and', 'multidisciplinary effort and science.', 'effort and science. see', 'and science. see you', 'science. see you there?!', 'see you there?! .', 'excited, nervous (have you seen', 'nervous (have you seen the', '(have you seen the paris', 'you seen the paris hall?!)', 'seen the paris hall?!) but', 'the paris hall?!) but most', 'paris hall?!) but most of', 'hall?!) but most of all', 'but most of all proud', 'most of all proud that', 'of all proud that niche', 'all proud that niche was', 'proud that niche was selected', 'that niche was selected for', 'niche was selected for the', 'was selected for the presidential', 'selected for the presidential symposium', 'for the presidential symposium !', 'the presidential symposium ! #esmo22', 'presidential symposium ! #esmo22 niche-2', 'symposium ! #esmo22 niche-2 is', '! #esmo22 niche-2 is a', '#esmo22 niche-2 is a great', 'niche-2 is a great example', 'is a great example of', 'a great example of multidisciplinary', 'great example of multidisciplinary effort', 'example of multidisciplinary effort and', 'of multidisciplinary effort and science.', 'multidisciplinary effort and science. see', 'effort and science. see you', 'and science. see you there?!', 'science. see you there?! .', 'excited, nervous (have you seen the', 'nervous (have you seen the paris', '(have you seen the paris hall?!)', 'you seen the paris hall?!) but', 'seen the paris hall?!) but most', 'the paris hall?!) but most of', 'paris hall?!) but most of all', 'hall?!) but most of all proud', 'but most of all proud that', 'most of all proud that niche', 'of all proud that niche was', 'all proud that niche was selected', 'proud that niche was selected for', 'that niche was selected for the', 'niche was selected for the presidential', 'was selected for the presidential symposium', 'selected for the presidential symposium !', 'for the presidential symposium ! #esmo22', 'the presidential symposium ! #esmo22 niche-2', 'presidential symposium ! #esmo22 niche-2 is', 'symposium ! #esmo22 niche-2 is a', '! #esmo22 niche-2 is a great', '#esmo22 niche-2 is a great example', 'niche-2 is a great example of', 'is a great example of multidisciplinary', 'a great example of multidisciplinary effort', 'great example of multidisciplinary effort and', 'example of multidisciplinary effort and science.', 'of multidisciplinary effort and science. see', 'multidisciplinary effort and science. see you', 'effort and science. see you there?!', 'and science. see you there?! .', 'excited, nervous (have you seen the paris', 'nervous (have you seen the paris hall?!)', '(have you seen the paris hall?!) but', 'you seen the paris hall?!) but most', 'seen the paris hall?!) but most of', 'the paris hall?!) but most of all', 'paris hall?!) but most of all proud', 'hall?!) but most of all proud that', 'but most of all proud that niche', 'most of all proud that niche was', 'of all proud that niche was selected', 'all proud that niche was selected for', 'proud that niche was selected for the', 'that niche was selected for the presidential', 'niche was selected for the presidential symposium', 'was selected for the presidential symposium !', 'selected for the presidential symposium ! #esmo22', 'for the presidential symposium ! #esmo22 niche-2', 'the presidential symposium ! #esmo22 niche-2 is', 'presidential symposium ! #esmo22 niche-2 is a', 'symposium ! #esmo22 niche-2 is a great', '! #esmo22 niche-2 is a great example', '#esmo22 niche-2 is a great example of', 'niche-2 is a great example of multidisciplinary', 'is a great example of multidisciplinary effort', 'a great example of multidisciplinary effort and', 'great example of multidisciplinary effort and science.', 'example of multidisciplinary effort and science. see', 'of multidisciplinary effort and science. see you', 'multidisciplinary effort and science. see you there?!', 'effort and science. see you there?! .', 'excited, nervous (have you seen the paris hall?!)', 'nervous (have you seen the paris hall?!) but', '(have you seen the paris hall?!) but most', 'you seen the paris hall?!) but most of', 'seen the paris hall?!) but most of all', 'the paris hall?!) but most of all proud', 'paris hall?!) but most of all proud that', 'hall?!) but most of all proud that niche', 'but most of all proud that niche was', 'most of all proud that niche was selected', 'of all proud that niche was selected for', 'all proud that niche was selected for the', 'proud that niche was selected for the presidential', 'that niche was selected for the presidential symposium', 'niche was selected for the presidential symposium !', 'was selected for the presidential symposium ! #esmo22', 'selected for the presidential symposium ! #esmo22 niche-2', 'for the presidential symposium ! #esmo22 niche-2 is', 'the presidential symposium ! #esmo22 niche-2 is a', 'presidential symposium ! #esmo22 niche-2 is a great', 'symposium ! #esmo22 niche-2 is a great example', '! #esmo22 niche-2 is a great example of', '#esmo22 niche-2 is a great example of multidisciplinary', 'niche-2 is a great example of multidisciplinary effort', 'is a great example of multidisciplinary effort and', 'a great example of multidisciplinary effort and science.', 'great example of multidisciplinary effort and science. see', 'example of multidisciplinary effort and science. see you', 'of multidisciplinary effort and science. see you there?!', 'multidisciplinary effort and science. see you there?! .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '3', 'tokens': ['some', 'hints', 're', 'which', 'patients', 'should', 'receive', 'triplet', 'therapy', 'in', 'mhspc', 'from', 'enzamet', 'but', 'trial', 'can', 't', 'definitely', 'answer', 'the', 'question', 'as', 'docetaxel', 'use', 'not', 'randomised', 'so', 'outcomes', 'also', 'influenced', 'by', 'prognostic', 'factors', 'in', 'this', 'group', '#asco2022', '.'], 'text_length': 38, 'triples': {'enzamet|not randomised so outcomes also influenced': ([12, 12], [24, 29], 'neutral')}, 'sentence': 'some hints re which patients should receive triplet therapy in mhspc from enzamet but trial can t definitely answer the question as docetaxel use not randomised so outcomes also influenced by prognostic factors in this group #asco2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 12)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(24, 29)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8)], 'span tokens': ['some', 'hints', 're', 'which', 'patients', 'should', 'receive', 'triplet', 'therapy', 'in', 'mhspc', 'from', 'enzamet', 'but', 'trial', 'can', 't', 'definitely', 'answer', 'the', 'question', 'as', 'docetaxel', 'use', 'not', 'randomised', 'so', 'outcomes', 'also', 'influenced', 'by', 'prognostic', 'factors', 'in', 'this', 'group', '#asco2022', '.', 'some hints', 'hints re', 're which', 'which patients', 'patients should', 'should receive', 'receive triplet', 'triplet therapy', 'therapy in', 'in mhspc', 'mhspc from', 'from enzamet', 'enzamet but', 'but trial', 'trial can', 'can t', 't definitely', 'definitely answer', 'answer the', 'the question', 'question as', 'as docetaxel', 'docetaxel use', 'use not', 'not randomised', 'randomised so', 'so outcomes', 'outcomes also', 'also influenced', 'influenced by', 'by prognostic', 'prognostic factors', 'factors in', 'in this', 'this group', 'group #asco2022', '#asco2022 .', 'some hints re', 'hints re which', 're which patients', 'which patients should', 'patients should receive', 'should receive triplet', 'receive triplet therapy', 'triplet therapy in', 'therapy in mhspc', 'in mhspc from', 'mhspc from enzamet', 'from enzamet but', 'enzamet but trial', 'but trial can', 'trial can t', 'can t definitely', 't definitely answer', 'definitely answer the', 'answer the question', 'the question as', 'question as docetaxel', 'as docetaxel use', 'docetaxel use not', 'use not randomised', 'not randomised so', 'randomised so outcomes', 'so outcomes also', 'outcomes also influenced', 'also influenced by', 'influenced by prognostic', 'by prognostic factors', 'prognostic factors in', 'factors in this', 'in this group', 'this group #asco2022', 'group #asco2022 .', 'some hints re which', 'hints re which patients', 're which patients should', 'which patients should receive', 'patients should receive triplet', 'should receive triplet therapy', 'receive triplet therapy in', 'triplet therapy in mhspc', 'therapy in mhspc from', 'in mhspc from enzamet', 'mhspc from enzamet but', 'from enzamet but trial', 'enzamet but trial can', 'but trial can t', 'trial can t definitely', 'can t definitely answer', 't definitely answer the', 'definitely answer the question', 'answer the question as', 'the question as docetaxel', 'question as docetaxel use', 'as docetaxel use not', 'docetaxel use not randomised', 'use not randomised so', 'not randomised so outcomes', 'randomised so outcomes also', 'so outcomes also influenced', 'outcomes also influenced by', 'also influenced by prognostic', 'influenced by prognostic factors', 'by prognostic factors in', 'prognostic factors in this', 'factors in this group', 'in this group #asco2022', 'this group #asco2022 .', 'some hints re which patients', 'hints re which patients should', 're which patients should receive', 'which patients should receive triplet', 'patients should receive triplet therapy', 'should receive triplet therapy in', 'receive triplet therapy in mhspc', 'triplet therapy in mhspc from', 'therapy in mhspc from enzamet', 'in mhspc from enzamet but', 'mhspc from enzamet but trial', 'from enzamet but trial can', 'enzamet but trial can t', 'but trial can t definitely', 'trial can t definitely answer', 'can t definitely answer the', 't definitely answer the question', 'definitely answer the question as', 'answer the question as docetaxel', 'the question as docetaxel use', 'question as docetaxel use not', 'as docetaxel use not randomised', 'docetaxel use not randomised so', 'use not randomised so outcomes', 'not randomised so outcomes also', 'randomised so outcomes also influenced', 'so outcomes also influenced by', 'outcomes also influenced by prognostic', 'also influenced by prognostic factors', 'influenced by prognostic factors in', 'by prognostic factors in this', 'prognostic factors in this group', 'factors in this group #asco2022', 'in this group #asco2022 .', 'some hints re which patients should', 'hints re which patients should receive', 're which patients should receive triplet', 'which patients should receive triplet therapy', 'patients should receive triplet therapy in', 'should receive triplet therapy in mhspc', 'receive triplet therapy in mhspc from', 'triplet therapy in mhspc from enzamet', 'therapy in mhspc from enzamet but', 'in mhspc from enzamet but trial', 'mhspc from enzamet but trial can', 'from enzamet but trial can t', 'enzamet but trial can t definitely', 'but trial can t definitely answer', 'trial can t definitely answer the', 'can t definitely answer the question', 't definitely answer the question as', 'definitely answer the question as docetaxel', 'answer the question as docetaxel use', 'the question as docetaxel use not', 'question as docetaxel use not randomised', 'as docetaxel use not randomised so', 'docetaxel use not randomised so outcomes', 'use not randomised so outcomes also', 'not randomised so outcomes also influenced', 'randomised so outcomes also influenced by', 'so outcomes also influenced by prognostic', 'outcomes also influenced by prognostic factors', 'also influenced by prognostic factors in', 'influenced by prognostic factors in this', 'by prognostic factors in this group', 'prognostic factors in this group #asco2022', 'factors in this group #asco2022 .', 'some hints re which patients should receive', 'hints re which patients should receive triplet', 're which patients should receive triplet therapy', 'which patients should receive triplet therapy in', 'patients should receive triplet therapy in mhspc', 'should receive triplet therapy in mhspc from', 'receive triplet therapy in mhspc from enzamet', 'triplet therapy in mhspc from enzamet but', 'therapy in mhspc from enzamet but trial', 'in mhspc from enzamet but trial can', 'mhspc from enzamet but trial can t', 'from enzamet but trial can t definitely', 'enzamet but trial can t definitely answer', 'but trial can t definitely answer the', 'trial can t definitely answer the question', 'can t definitely answer the question as', 't definitely answer the question as docetaxel', 'definitely answer the question as docetaxel use', 'answer the question as docetaxel use not', 'the question as docetaxel use not randomised', 'question as docetaxel use not randomised so', 'as docetaxel use not randomised so outcomes', 'docetaxel use not randomised so outcomes also', 'use not randomised so outcomes also influenced', 'not randomised so outcomes also influenced by', 'randomised so outcomes also influenced by prognostic', 'so outcomes also influenced by prognostic factors', 'outcomes also influenced by prognostic factors in', 'also influenced by prognostic factors in this', 'influenced by prognostic factors in this group', 'by prognostic factors in this group #asco2022', 'prognostic factors in this group #asco2022 .', 'some hints re which patients should receive triplet', 'hints re which patients should receive triplet therapy', 're which patients should receive triplet therapy in', 'which patients should receive triplet therapy in mhspc', 'patients should receive triplet therapy in mhspc from', 'should receive triplet therapy in mhspc from enzamet', 'receive triplet therapy in mhspc from enzamet but', 'triplet therapy in mhspc from enzamet but trial', 'therapy in mhspc from enzamet but trial can', 'in mhspc from enzamet but trial can t', 'mhspc from enzamet but trial can t definitely', 'from enzamet but trial can t definitely answer', 'enzamet but trial can t definitely answer the', 'but trial can t definitely answer the question', 'trial can t definitely answer the question as', 'can t definitely answer the question as docetaxel', 't definitely answer the question as docetaxel use', 'definitely answer the question as docetaxel use not', 'answer the question as docetaxel use not randomised', 'the question as docetaxel use not randomised so', 'question as docetaxel use not randomised so outcomes', 'as docetaxel use not randomised so outcomes also', 'docetaxel use not randomised so outcomes also influenced', 'use not randomised so outcomes also influenced by', 'not randomised so outcomes also influenced by prognostic', 'randomised so outcomes also influenced by prognostic factors', 'so outcomes also influenced by prognostic factors in', 'outcomes also influenced by prognostic factors in this', 'also influenced by prognostic factors in this group', 'influenced by prognostic factors in this group #asco2022', 'by prognostic factors in this group #asco2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '4', 'tokens': ['the', 'awaited', '#', 'propel', 'biomarker', 'analysis', 'by', 'esteemed', '#fredsaad', 'rpfs', 'of', 'abiraterone+olaparib', 'best', 'for', 'patients', 'w', 'brca1/2', 'alterations,', 'next', 'for', 'those', 'w', 'homologous', 'recombination', 'repair', 'defects,', 'finally', 'in', 'non-hrr', 'altered.', 'os', 'benefit', 'holds', 'in', 'intention', 'to', 'treat', 'group.', '#esmo22', '.'], 'text_length': 40, 'triples': {'#|abiraterone+olaparib best for patients w brca1/2 alterations, next for those w homologous recombination repair defects, finally in non-hrr altered. os benefit': ([2, 2], [11, 31], 'neutral'), 'of|abiraterone+olaparib best for patients w brca1/2 alterations, next for those w homologous recombination repair defects, finally in non-hrr altered. os benefit': ([10, 10], [11, 31], 'neutral')}, 'sentence': 'the awaited # propel biomarker analysis by esteemed #fredsaad rpfs of abiraterone+olaparib best for patients w brca1/2 alterations, next for those w homologous recombination repair defects, finally in non-hrr altered. os benefit holds in intention to treat group. #esmo22 .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(2, 2), (10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(11, 31)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8)], 'span tokens': ['the', 'awaited', '#', 'propel', 'biomarker', 'analysis', 'by', 'esteemed', '#fredsaad', 'rpfs', 'of', 'abiraterone+olaparib', 'best', 'for', 'patients', 'w', 'brca1/2', 'alterations,', 'next', 'for', 'those', 'w', 'homologous', 'recombination', 'repair', 'defects,', 'finally', 'in', 'non-hrr', 'altered.', 'os', 'benefit', 'holds', 'in', 'intention', 'to', 'treat', 'group.', '#esmo22', '.', 'the awaited', 'awaited #', '# propel', 'propel biomarker', 'biomarker analysis', 'analysis by', 'by esteemed', 'esteemed #fredsaad', '#fredsaad rpfs', 'rpfs of', 'of abiraterone+olaparib', 'abiraterone+olaparib best', 'best for', 'for patients', 'patients w', 'w brca1/2', 'brca1/2 alterations,', 'alterations, next', 'next for', 'for those', 'those w', 'w homologous', 'homologous recombination', 'recombination repair', 'repair defects,', 'defects, finally', 'finally in', 'in non-hrr', 'non-hrr altered.', 'altered. os', 'os benefit', 'benefit holds', 'holds in', 'in intention', 'intention to', 'to treat', 'treat group.', 'group. #esmo22', '#esmo22 .', 'the awaited #', 'awaited # propel', '# propel biomarker', 'propel biomarker analysis', 'biomarker analysis by', 'analysis by esteemed', 'by esteemed #fredsaad', 'esteemed #fredsaad rpfs', '#fredsaad rpfs of', 'rpfs of abiraterone+olaparib', 'of abiraterone+olaparib best', 'abiraterone+olaparib best for', 'best for patients', 'for patients w', 'patients w brca1/2', 'w brca1/2 alterations,', 'brca1/2 alterations, next', 'alterations, next for', 'next for those', 'for those w', 'those w homologous', 'w homologous recombination', 'homologous recombination repair', 'recombination repair defects,', 'repair defects, finally', 'defects, finally in', 'finally in non-hrr', 'in non-hrr altered.', 'non-hrr altered. os', 'altered. os benefit', 'os benefit holds', 'benefit holds in', 'holds in intention', 'in intention to', 'intention to treat', 'to treat group.', 'treat group. #esmo22', 'group. #esmo22 .', 'the awaited # propel', 'awaited # propel biomarker', '# propel biomarker analysis', 'propel biomarker analysis by', 'biomarker analysis by esteemed', 'analysis by esteemed #fredsaad', 'by esteemed #fredsaad rpfs', 'esteemed #fredsaad rpfs of', '#fredsaad rpfs of abiraterone+olaparib', 'rpfs of abiraterone+olaparib best', 'of abiraterone+olaparib best for', 'abiraterone+olaparib best for patients', 'best for patients w', 'for patients w brca1/2', 'patients w brca1/2 alterations,', 'w brca1/2 alterations, next', 'brca1/2 alterations, next for', 'alterations, next for those', 'next for those w', 'for those w homologous', 'those w homologous recombination', 'w homologous recombination repair', 'homologous recombination repair defects,', 'recombination repair defects, finally', 'repair defects, finally in', 'defects, finally in non-hrr', 'finally in non-hrr altered.', 'in non-hrr altered. os', 'non-hrr altered. os benefit', 'altered. os benefit holds', 'os benefit holds in', 'benefit holds in intention', 'holds in intention to', 'in intention to treat', 'intention to treat group.', 'to treat group. #esmo22', 'treat group. #esmo22 .', 'the awaited # propel biomarker', 'awaited # propel biomarker analysis', '# propel biomarker analysis by', 'propel biomarker analysis by esteemed', 'biomarker analysis by esteemed #fredsaad', 'analysis by esteemed #fredsaad rpfs', 'by esteemed #fredsaad rpfs of', 'esteemed #fredsaad rpfs of abiraterone+olaparib', '#fredsaad rpfs of abiraterone+olaparib best', 'rpfs of abiraterone+olaparib best for', 'of abiraterone+olaparib best for patients', 'abiraterone+olaparib best for patients w', 'best for patients w brca1/2', 'for patients w brca1/2 alterations,', 'patients w brca1/2 alterations, next', 'w brca1/2 alterations, next for', 'brca1/2 alterations, next for those', 'alterations, next for those w', 'next for those w homologous', 'for those w homologous recombination', 'those w homologous recombination repair', 'w homologous recombination repair defects,', 'homologous recombination repair defects, finally', 'recombination repair defects, finally in', 'repair defects, finally in non-hrr', 'defects, finally in non-hrr altered.', 'finally in non-hrr altered. os', 'in non-hrr altered. os benefit', 'non-hrr altered. os benefit holds', 'altered. os benefit holds in', 'os benefit holds in intention', 'benefit holds in intention to', 'holds in intention to treat', 'in intention to treat group.', 'intention to treat group. #esmo22', 'to treat group. #esmo22 .', 'the awaited # propel biomarker analysis', 'awaited # propel biomarker analysis by', '# propel biomarker analysis by esteemed', 'propel biomarker analysis by esteemed #fredsaad', 'biomarker analysis by esteemed #fredsaad rpfs', 'analysis by esteemed #fredsaad rpfs of', 'by esteemed #fredsaad rpfs of abiraterone+olaparib', 'esteemed #fredsaad rpfs of abiraterone+olaparib best', '#fredsaad rpfs of abiraterone+olaparib best for', 'rpfs of abiraterone+olaparib best for patients', 'of abiraterone+olaparib best for patients w', 'abiraterone+olaparib best for patients w brca1/2', 'best for patients w brca1/2 alterations,', 'for patients w brca1/2 alterations, next', 'patients w brca1/2 alterations, next for', 'w brca1/2 alterations, next for those', 'brca1/2 alterations, next for those w', 'alterations, next for those w homologous', 'next for those w homologous recombination', 'for those w homologous recombination repair', 'those w homologous recombination repair defects,', 'w homologous recombination repair defects, finally', 'homologous recombination repair defects, finally in', 'recombination repair defects, finally in non-hrr', 'repair defects, finally in non-hrr altered.', 'defects, finally in non-hrr altered. os', 'finally in non-hrr altered. os benefit', 'in non-hrr altered. os benefit holds', 'non-hrr altered. os benefit holds in', 'altered. os benefit holds in intention', 'os benefit holds in intention to', 'benefit holds in intention to treat', 'holds in intention to treat group.', 'in intention to treat group. #esmo22', 'intention to treat group. #esmo22 .', 'the awaited # propel biomarker analysis by', 'awaited # propel biomarker analysis by esteemed', '# propel biomarker analysis by esteemed #fredsaad', 'propel biomarker analysis by esteemed #fredsaad rpfs', 'biomarker analysis by esteemed #fredsaad rpfs of', 'analysis by esteemed #fredsaad rpfs of abiraterone+olaparib', 'by esteemed #fredsaad rpfs of abiraterone+olaparib best', 'esteemed #fredsaad rpfs of abiraterone+olaparib best for', '#fredsaad rpfs of abiraterone+olaparib best for patients', 'rpfs of abiraterone+olaparib best for patients w', 'of abiraterone+olaparib best for patients w brca1/2', 'abiraterone+olaparib best for patients w brca1/2 alterations,', 'best for patients w brca1/2 alterations, next', 'for patients w brca1/2 alterations, next for', 'patients w brca1/2 alterations, next for those', 'w brca1/2 alterations, next for those w', 'brca1/2 alterations, next for those w homologous', 'alterations, next for those w homologous recombination', 'next for those w homologous recombination repair', 'for those w homologous recombination repair defects,', 'those w homologous recombination repair defects, finally', 'w homologous recombination repair defects, finally in', 'homologous recombination repair defects, finally in non-hrr', 'recombination repair defects, finally in non-hrr altered.', 'repair defects, finally in non-hrr altered. os', 'defects, finally in non-hrr altered. os benefit', 'finally in non-hrr altered. os benefit holds', 'in non-hrr altered. os benefit holds in', 'non-hrr altered. os benefit holds in intention', 'altered. os benefit holds in intention to', 'os benefit holds in intention to treat', 'benefit holds in intention to treat group.', 'holds in intention to treat group. #esmo22', 'in intention to treat group. #esmo22 .', 'the awaited # propel biomarker analysis by esteemed', 'awaited # propel biomarker analysis by esteemed #fredsaad', '# propel biomarker analysis by esteemed #fredsaad rpfs', 'propel biomarker analysis by esteemed #fredsaad rpfs of', 'biomarker analysis by esteemed #fredsaad rpfs of abiraterone+olaparib', 'analysis by esteemed #fredsaad rpfs of abiraterone+olaparib best', 'by esteemed #fredsaad rpfs of abiraterone+olaparib best for', 'esteemed #fredsaad rpfs of abiraterone+olaparib best for patients', '#fredsaad rpfs of abiraterone+olaparib best for patients w', 'rpfs of abiraterone+olaparib best for patients w brca1/2', 'of abiraterone+olaparib best for patients w brca1/2 alterations,', 'abiraterone+olaparib best for patients w brca1/2 alterations, next', 'best for patients w brca1/2 alterations, next for', 'for patients w brca1/2 alterations, next for those', 'patients w brca1/2 alterations, next for those w', 'w brca1/2 alterations, next for those w homologous', 'brca1/2 alterations, next for those w homologous recombination', 'alterations, next for those w homologous recombination repair', 'next for those w homologous recombination repair defects,', 'for those w homologous recombination repair defects, finally', 'those w homologous recombination repair defects, finally in', 'w homologous recombination repair defects, finally in non-hrr', 'homologous recombination repair defects, finally in non-hrr altered.', 'recombination repair defects, finally in non-hrr altered. os', 'repair defects, finally in non-hrr altered. os benefit', 'defects, finally in non-hrr altered. os benefit holds', 'finally in non-hrr altered. os benefit holds in', 'in non-hrr altered. os benefit holds in intention', 'non-hrr altered. os benefit holds in intention to', 'altered. os benefit holds in intention to treat', 'os benefit holds in intention to treat group.', 'benefit holds in intention to treat group. #esmo22', 'holds in intention to treat group. #esmo22 .'], 'spans_aspect_label': [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '5', 'tokens': ['s1801', ':', 'neo-', 'vs.', 'adjuvant', 'pembrolizumab', 'for', 'stage', 'iii-iv', 'melanoma', 'by', '.', 'striking', 'efs', 'benefits', 'by', 'neoadjuvant!', 'simple', 'but', 'highly', 'important', 'clinical', 'question.', 'expect', 'that', 'it', 'is', 'not', 'limited', 'to', 'melanoma.', 'direct', 'comparison', 'is', 'needed', 'in', 'thoracic', 'oncology.', '#lcsm', '#esmo22', '.'], 'text_length': 41, 'triples': {'s1801|by': ([0, 0], [10, 10], 'positive')}, 'sentence': 's1801 : neo- vs. adjuvant pembrolizumab for stage iii-iv melanoma by . striking efs benefits by neoadjuvant! simple but highly important clinical question. expect that it is not limited to melanoma. direct comparison is needed in thoracic oncology. #lcsm #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(0, 0)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(10, 10)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (39, 39, 1), (40, 40, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (38, 39, 2), (39, 40, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (37, 39, 3), (38, 40, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (36, 39, 4), (37, 40, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (35, 39, 5), (36, 40, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (34, 39, 6), (35, 40, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (33, 39, 7), (34, 40, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8), (32, 39, 8), (33, 40, 8)], 'span tokens': ['s1801', ':', 'neo-', 'vs.', 'adjuvant', 'pembrolizumab', 'for', 'stage', 'iii-iv', 'melanoma', 'by', '.', 'striking', 'efs', 'benefits', 'by', 'neoadjuvant!', 'simple', 'but', 'highly', 'important', 'clinical', 'question.', 'expect', 'that', 'it', 'is', 'not', 'limited', 'to', 'melanoma.', 'direct', 'comparison', 'is', 'needed', 'in', 'thoracic', 'oncology.', '#lcsm', '#esmo22', '.', 's1801 :', ': neo-', 'neo- vs.', 'vs. adjuvant', 'adjuvant pembrolizumab', 'pembrolizumab for', 'for stage', 'stage iii-iv', 'iii-iv melanoma', 'melanoma by', 'by .', '. striking', 'striking efs', 'efs benefits', 'benefits by', 'by neoadjuvant!', 'neoadjuvant! simple', 'simple but', 'but highly', 'highly important', 'important clinical', 'clinical question.', 'question. expect', 'expect that', 'that it', 'it is', 'is not', 'not limited', 'limited to', 'to melanoma.', 'melanoma. direct', 'direct comparison', 'comparison is', 'is needed', 'needed in', 'in thoracic', 'thoracic oncology.', 'oncology. #lcsm', '#lcsm #esmo22', '#esmo22 .', 's1801 : neo-', ': neo- vs.', 'neo- vs. adjuvant', 'vs. adjuvant pembrolizumab', 'adjuvant pembrolizumab for', 'pembrolizumab for stage', 'for stage iii-iv', 'stage iii-iv melanoma', 'iii-iv melanoma by', 'melanoma by .', 'by . striking', '. striking efs', 'striking efs benefits', 'efs benefits by', 'benefits by neoadjuvant!', 'by neoadjuvant! simple', 'neoadjuvant! simple but', 'simple but highly', 'but highly important', 'highly important clinical', 'important clinical question.', 'clinical question. expect', 'question. expect that', 'expect that it', 'that it is', 'it is not', 'is not limited', 'not limited to', 'limited to melanoma.', 'to melanoma. direct', 'melanoma. direct comparison', 'direct comparison is', 'comparison is needed', 'is needed in', 'needed in thoracic', 'in thoracic oncology.', 'thoracic oncology. #lcsm', 'oncology. #lcsm #esmo22', '#lcsm #esmo22 .', 's1801 : neo- vs.', ': neo- vs. adjuvant', 'neo- vs. adjuvant pembrolizumab', 'vs. adjuvant pembrolizumab for', 'adjuvant pembrolizumab for stage', 'pembrolizumab for stage iii-iv', 'for stage iii-iv melanoma', 'stage iii-iv melanoma by', 'iii-iv melanoma by .', 'melanoma by . striking', 'by . striking efs', '. striking efs benefits', 'striking efs benefits by', 'efs benefits by neoadjuvant!', 'benefits by neoadjuvant! simple', 'by neoadjuvant! simple but', 'neoadjuvant! simple but highly', 'simple but highly important', 'but highly important clinical', 'highly important clinical question.', 'important clinical question. expect', 'clinical question. expect that', 'question. expect that it', 'expect that it is', 'that it is not', 'it is not limited', 'is not limited to', 'not limited to melanoma.', 'limited to melanoma. direct', 'to melanoma. direct comparison', 'melanoma. direct comparison is', 'direct comparison is needed', 'comparison is needed in', 'is needed in thoracic', 'needed in thoracic oncology.', 'in thoracic oncology. #lcsm', 'thoracic oncology. #lcsm #esmo22', 'oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant', ': neo- vs. adjuvant pembrolizumab', 'neo- vs. adjuvant pembrolizumab for', 'vs. adjuvant pembrolizumab for stage', 'adjuvant pembrolizumab for stage iii-iv', 'pembrolizumab for stage iii-iv melanoma', 'for stage iii-iv melanoma by', 'stage iii-iv melanoma by .', 'iii-iv melanoma by . striking', 'melanoma by . striking efs', 'by . striking efs benefits', '. striking efs benefits by', 'striking efs benefits by neoadjuvant!', 'efs benefits by neoadjuvant! simple', 'benefits by neoadjuvant! simple but', 'by neoadjuvant! simple but highly', 'neoadjuvant! simple but highly important', 'simple but highly important clinical', 'but highly important clinical question.', 'highly important clinical question. expect', 'important clinical question. expect that', 'clinical question. expect that it', 'question. expect that it is', 'expect that it is not', 'that it is not limited', 'it is not limited to', 'is not limited to melanoma.', 'not limited to melanoma. direct', 'limited to melanoma. direct comparison', 'to melanoma. direct comparison is', 'melanoma. direct comparison is needed', 'direct comparison is needed in', 'comparison is needed in thoracic', 'is needed in thoracic oncology.', 'needed in thoracic oncology. #lcsm', 'in thoracic oncology. #lcsm #esmo22', 'thoracic oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant pembrolizumab', ': neo- vs. adjuvant pembrolizumab for', 'neo- vs. adjuvant pembrolizumab for stage', 'vs. adjuvant pembrolizumab for stage iii-iv', 'adjuvant pembrolizumab for stage iii-iv melanoma', 'pembrolizumab for stage iii-iv melanoma by', 'for stage iii-iv melanoma by .', 'stage iii-iv melanoma by . striking', 'iii-iv melanoma by . striking efs', 'melanoma by . striking efs benefits', 'by . striking efs benefits by', '. striking efs benefits by neoadjuvant!', 'striking efs benefits by neoadjuvant! simple', 'efs benefits by neoadjuvant! simple but', 'benefits by neoadjuvant! simple but highly', 'by neoadjuvant! simple but highly important', 'neoadjuvant! simple but highly important clinical', 'simple but highly important clinical question.', 'but highly important clinical question. expect', 'highly important clinical question. expect that', 'important clinical question. expect that it', 'clinical question. expect that it is', 'question. expect that it is not', 'expect that it is not limited', 'that it is not limited to', 'it is not limited to melanoma.', 'is not limited to melanoma. direct', 'not limited to melanoma. direct comparison', 'limited to melanoma. direct comparison is', 'to melanoma. direct comparison is needed', 'melanoma. direct comparison is needed in', 'direct comparison is needed in thoracic', 'comparison is needed in thoracic oncology.', 'is needed in thoracic oncology. #lcsm', 'needed in thoracic oncology. #lcsm #esmo22', 'in thoracic oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant pembrolizumab for', ': neo- vs. adjuvant pembrolizumab for stage', 'neo- vs. adjuvant pembrolizumab for stage iii-iv', 'vs. adjuvant pembrolizumab for stage iii-iv melanoma', 'adjuvant pembrolizumab for stage iii-iv melanoma by', 'pembrolizumab for stage iii-iv melanoma by .', 'for stage iii-iv melanoma by . striking', 'stage iii-iv melanoma by . striking efs', 'iii-iv melanoma by . striking efs benefits', 'melanoma by . striking efs benefits by', 'by . striking efs benefits by neoadjuvant!', '. striking efs benefits by neoadjuvant! simple', 'striking efs benefits by neoadjuvant! simple but', 'efs benefits by neoadjuvant! simple but highly', 'benefits by neoadjuvant! simple but highly important', 'by neoadjuvant! simple but highly important clinical', 'neoadjuvant! simple but highly important clinical question.', 'simple but highly important clinical question. expect', 'but highly important clinical question. expect that', 'highly important clinical question. expect that it', 'important clinical question. expect that it is', 'clinical question. expect that it is not', 'question. expect that it is not limited', 'expect that it is not limited to', 'that it is not limited to melanoma.', 'it is not limited to melanoma. direct', 'is not limited to melanoma. direct comparison', 'not limited to melanoma. direct comparison is', 'limited to melanoma. direct comparison is needed', 'to melanoma. direct comparison is needed in', 'melanoma. direct comparison is needed in thoracic', 'direct comparison is needed in thoracic oncology.', 'comparison is needed in thoracic oncology. #lcsm', 'is needed in thoracic oncology. #lcsm #esmo22', 'needed in thoracic oncology. #lcsm #esmo22 .', 's1801 : neo- vs. adjuvant pembrolizumab for stage', ': neo- vs. adjuvant pembrolizumab for stage iii-iv', 'neo- vs. adjuvant pembrolizumab for stage iii-iv melanoma', 'vs. adjuvant pembrolizumab for stage iii-iv melanoma by', 'adjuvant pembrolizumab for stage iii-iv melanoma by .', 'pembrolizumab for stage iii-iv melanoma by . striking', 'for stage iii-iv melanoma by . striking efs', 'stage iii-iv melanoma by . striking efs benefits', 'iii-iv melanoma by . striking efs benefits by', 'melanoma by . striking efs benefits by neoadjuvant!', 'by . striking efs benefits by neoadjuvant! simple', '. striking efs benefits by neoadjuvant! simple but', 'striking efs benefits by neoadjuvant! simple but highly', 'efs benefits by neoadjuvant! simple but highly important', 'benefits by neoadjuvant! simple but highly important clinical', 'by neoadjuvant! simple but highly important clinical question.', 'neoadjuvant! simple but highly important clinical question. expect', 'simple but highly important clinical question. expect that', 'but highly important clinical question. expect that it', 'highly important clinical question. expect that it is', 'important clinical question. expect that it is not', 'clinical question. expect that it is not limited', 'question. expect that it is not limited to', 'expect that it is not limited to melanoma.', 'that it is not limited to melanoma. direct', 'it is not limited to melanoma. direct comparison', 'is not limited to melanoma. direct comparison is', 'not limited to melanoma. direct comparison is needed', 'limited to melanoma. direct comparison is needed in', 'to melanoma. direct comparison is needed in thoracic', 'melanoma. direct comparison is needed in thoracic oncology.', 'direct comparison is needed in thoracic oncology. #lcsm', 'comparison is needed in thoracic oncology. #lcsm #esmo22', 'is needed in thoracic oncology. #lcsm #esmo22 .'], 'spans_aspect_label': [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '6', 'tokens': ['#esmo22', 'never', 'thought', 'that', 'i', 'would', 'see', 'near', '80%', 'event-free', 'survival', 'in', 'melanoma', 'during', 'my', 'professional', 'lifetime.', 'neoadjuvant', 'io', 'wins', 'indeed!!!', 's1801', '.'], 'text_length': 23, 'triples': {'s1801|see near 80% event-free survival in melanoma during my professional lifetime. neoadjuvant io wins indeed!!!': ([21, 21], [6, 20], 'positive')}, 'sentence': '#esmo22 never thought that i would see near 80% event-free survival in melanoma during my professional lifetime. neoadjuvant io wins indeed!!! s1801 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(21, 21)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(6, 20)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8)], 'span tokens': ['#esmo22', 'never', 'thought', 'that', 'i', 'would', 'see', 'near', '80%', 'event-free', 'survival', 'in', 'melanoma', 'during', 'my', 'professional', 'lifetime.', 'neoadjuvant', 'io', 'wins', 'indeed!!!', 's1801', '.', '#esmo22 never', 'never thought', 'thought that', 'that i', 'i would', 'would see', 'see near', 'near 80%', '80% event-free', 'event-free survival', 'survival in', 'in melanoma', 'melanoma during', 'during my', 'my professional', 'professional lifetime.', 'lifetime. neoadjuvant', 'neoadjuvant io', 'io wins', 'wins indeed!!!', 'indeed!!! s1801', 's1801 .', '#esmo22 never thought', 'never thought that', 'thought that i', 'that i would', 'i would see', 'would see near', 'see near 80%', 'near 80% event-free', '80% event-free survival', 'event-free survival in', 'survival in melanoma', 'in melanoma during', 'melanoma during my', 'during my professional', 'my professional lifetime.', 'professional lifetime. neoadjuvant', 'lifetime. neoadjuvant io', 'neoadjuvant io wins', 'io wins indeed!!!', 'wins indeed!!! s1801', 'indeed!!! s1801 .', '#esmo22 never thought that', 'never thought that i', 'thought that i would', 'that i would see', 'i would see near', 'would see near 80%', 'see near 80% event-free', 'near 80% event-free survival', '80% event-free survival in', 'event-free survival in melanoma', 'survival in melanoma during', 'in melanoma during my', 'melanoma during my professional', 'during my professional lifetime.', 'my professional lifetime. neoadjuvant', 'professional lifetime. neoadjuvant io', 'lifetime. neoadjuvant io wins', 'neoadjuvant io wins indeed!!!', 'io wins indeed!!! s1801', 'wins indeed!!! s1801 .', '#esmo22 never thought that i', 'never thought that i would', 'thought that i would see', 'that i would see near', 'i would see near 80%', 'would see near 80% event-free', 'see near 80% event-free survival', 'near 80% event-free survival in', '80% event-free survival in melanoma', 'event-free survival in melanoma during', 'survival in melanoma during my', 'in melanoma during my professional', 'melanoma during my professional lifetime.', 'during my professional lifetime. neoadjuvant', 'my professional lifetime. neoadjuvant io', 'professional lifetime. neoadjuvant io wins', 'lifetime. neoadjuvant io wins indeed!!!', 'neoadjuvant io wins indeed!!! s1801', 'io wins indeed!!! s1801 .', '#esmo22 never thought that i would', 'never thought that i would see', 'thought that i would see near', 'that i would see near 80%', 'i would see near 80% event-free', 'would see near 80% event-free survival', 'see near 80% event-free survival in', 'near 80% event-free survival in melanoma', '80% event-free survival in melanoma during', 'event-free survival in melanoma during my', 'survival in melanoma during my professional', 'in melanoma during my professional lifetime.', 'melanoma during my professional lifetime. neoadjuvant', 'during my professional lifetime. neoadjuvant io', 'my professional lifetime. neoadjuvant io wins', 'professional lifetime. neoadjuvant io wins indeed!!!', 'lifetime. neoadjuvant io wins indeed!!! s1801', 'neoadjuvant io wins indeed!!! s1801 .', '#esmo22 never thought that i would see', 'never thought that i would see near', 'thought that i would see near 80%', 'that i would see near 80% event-free', 'i would see near 80% event-free survival', 'would see near 80% event-free survival in', 'see near 80% event-free survival in melanoma', 'near 80% event-free survival in melanoma during', '80% event-free survival in melanoma during my', 'event-free survival in melanoma during my professional', 'survival in melanoma during my professional lifetime.', 'in melanoma during my professional lifetime. neoadjuvant', 'melanoma during my professional lifetime. neoadjuvant io', 'during my professional lifetime. neoadjuvant io wins', 'my professional lifetime. neoadjuvant io wins indeed!!!', 'professional lifetime. neoadjuvant io wins indeed!!! s1801', 'lifetime. neoadjuvant io wins indeed!!! s1801 .', '#esmo22 never thought that i would see near', 'never thought that i would see near 80%', 'thought that i would see near 80% event-free', 'that i would see near 80% event-free survival', 'i would see near 80% event-free survival in', 'would see near 80% event-free survival in melanoma', 'see near 80% event-free survival in melanoma during', 'near 80% event-free survival in melanoma during my', '80% event-free survival in melanoma during my professional', 'event-free survival in melanoma during my professional lifetime.', 'survival in melanoma during my professional lifetime. neoadjuvant', 'in melanoma during my professional lifetime. neoadjuvant io', 'melanoma during my professional lifetime. neoadjuvant io wins', 'during my professional lifetime. neoadjuvant io wins indeed!!!', 'my professional lifetime. neoadjuvant io wins indeed!!! s1801', 'professional lifetime. neoadjuvant io wins indeed!!! s1801 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '7', 'tokens': ['And', 'the', 'battle', 'of', 'the', 'BTKi', 'giants', 'in', 'r/r', 'cll', 'goes', 'to...', 'zanubrutinib!', 'Pfs', 'benefit', 'also', 'in', 'del17p', 'or', 'tp53', 'aberrations.', 'zanubrutinib', '', '', '', '', 'had', 'a', 'more', 'favorable', 'cardiac', 'profile', 'in', 'addition.', '#ASH22', '@ASH_hematology', '.'], 'text_length': 37, 'triples': {'zanubrutinib! Pfs benefit also in del17p or tp53 aberrations. zanubrutinib|favorable': ([12, 21], [25, 25], 'neutral')}, 'sentence': 'And the battle of the BTKi giants in r/r cll goes to... zanubrutinib! Pfs benefit also in del17p or tp53 aberrations. zanubrutinib     had a more favorable cardiac profile in addition. #ASH22 @ASH_hematology .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(12, 21)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(25, 25)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8)], 'span tokens': ['And', 'the', 'battle', 'of', 'the', 'BTKi', 'giants', 'in', 'r/r', 'cll', 'goes', 'to...', 'zanubrutinib!', 'Pfs', 'benefit', 'also', 'in', 'del17p', 'or', 'tp53', 'aberrations.', 'zanubrutinib', '', '', '', '', 'had', 'a', 'more', 'favorable', 'cardiac', 'profile', 'in', 'addition.', '#ASH22', '@ASH_hematology', '.', 'And the', 'the battle', 'battle of', 'of the', 'the BTKi', 'BTKi giants', 'giants in', 'in r/r', 'r/r cll', 'cll goes', 'goes to...', 'to... zanubrutinib!', 'zanubrutinib! Pfs', 'Pfs benefit', 'benefit also', 'also in', 'in del17p', 'del17p or', 'or tp53', 'tp53 aberrations.', 'aberrations. zanubrutinib', 'zanubrutinib ', ' ', ' ', ' ', ' had', 'had a', 'a more', 'more favorable', 'favorable cardiac', 'cardiac profile', 'profile in', 'in addition.', 'addition. #ASH22', '#ASH22 @ASH_hematology', '@ASH_hematology .', 'And the battle', 'the battle of', 'battle of the', 'of the BTKi', 'the BTKi giants', 'BTKi giants in', 'giants in r/r', 'in r/r cll', 'r/r cll goes', 'cll goes to...', 'goes to... zanubrutinib!', 'to... zanubrutinib! Pfs', 'zanubrutinib! Pfs benefit', 'Pfs benefit also', 'benefit also in', 'also in del17p', 'in del17p or', 'del17p or tp53', 'or tp53 aberrations.', 'tp53 aberrations. zanubrutinib', 'aberrations. zanubrutinib ', 'zanubrutinib  ', '  ', '  ', '  had', ' had a', 'had a more', 'a more favorable', 'more favorable cardiac', 'favorable cardiac profile', 'cardiac profile in', 'profile in addition.', 'in addition. #ASH22', 'addition. #ASH22 @ASH_hematology', '#ASH22 @ASH_hematology .', 'And the battle of', 'the battle of the', 'battle of the BTKi', 'of the BTKi giants', 'the BTKi giants in', 'BTKi giants in r/r', 'giants in r/r cll', 'in r/r cll goes', 'r/r cll goes to...', 'cll goes to... zanubrutinib!', 'goes to... zanubrutinib! Pfs', 'to... zanubrutinib! Pfs benefit', 'zanubrutinib! Pfs benefit also', 'Pfs benefit also in', 'benefit also in del17p', 'also in del17p or', 'in del17p or tp53', 'del17p or tp53 aberrations.', 'or tp53 aberrations. zanubrutinib', 'tp53 aberrations. zanubrutinib ', 'aberrations. zanubrutinib  ', 'zanubrutinib   ', '   ', '   had', '  had a', ' had a more', 'had a more favorable', 'a more favorable cardiac', 'more favorable cardiac profile', 'favorable cardiac profile in', 'cardiac profile in addition.', 'profile in addition. #ASH22', 'in addition. #ASH22 @ASH_hematology', 'addition. #ASH22 @ASH_hematology .', 'And the battle of the', 'the battle of the BTKi', 'battle of the BTKi giants', 'of the BTKi giants in', 'the BTKi giants in r/r', 'BTKi giants in r/r cll', 'giants in r/r cll goes', 'in r/r cll goes to...', 'r/r cll goes to... zanubrutinib!', 'cll goes to... zanubrutinib! Pfs', 'goes to... zanubrutinib! Pfs benefit', 'to... zanubrutinib! Pfs benefit also', 'zanubrutinib! Pfs benefit also in', 'Pfs benefit also in del17p', 'benefit also in del17p or', 'also in del17p or tp53', 'in del17p or tp53 aberrations.', 'del17p or tp53 aberrations. zanubrutinib', 'or tp53 aberrations. zanubrutinib ', 'tp53 aberrations. zanubrutinib  ', 'aberrations. zanubrutinib   ', 'zanubrutinib    ', '    had', '   had a', '  had a more', ' had a more favorable', 'had a more favorable cardiac', 'a more favorable cardiac profile', 'more favorable cardiac profile in', 'favorable cardiac profile in addition.', 'cardiac profile in addition. #ASH22', 'profile in addition. #ASH22 @ASH_hematology', 'in addition. #ASH22 @ASH_hematology .', 'And the battle of the BTKi', 'the battle of the BTKi giants', 'battle of the BTKi giants in', 'of the BTKi giants in r/r', 'the BTKi giants in r/r cll', 'BTKi giants in r/r cll goes', 'giants in r/r cll goes to...', 'in r/r cll goes to... zanubrutinib!', 'r/r cll goes to... zanubrutinib! Pfs', 'cll goes to... zanubrutinib! Pfs benefit', 'goes to... zanubrutinib! Pfs benefit also', 'to... zanubrutinib! Pfs benefit also in', 'zanubrutinib! Pfs benefit also in del17p', 'Pfs benefit also in del17p or', 'benefit also in del17p or tp53', 'also in del17p or tp53 aberrations.', 'in del17p or tp53 aberrations. zanubrutinib', 'del17p or tp53 aberrations. zanubrutinib ', 'or tp53 aberrations. zanubrutinib  ', 'tp53 aberrations. zanubrutinib   ', 'aberrations. zanubrutinib    ', 'zanubrutinib     had', '    had a', '   had a more', '  had a more favorable', ' had a more favorable cardiac', 'had a more favorable cardiac profile', 'a more favorable cardiac profile in', 'more favorable cardiac profile in addition.', 'favorable cardiac profile in addition. #ASH22', 'cardiac profile in addition. #ASH22 @ASH_hematology', 'profile in addition. #ASH22 @ASH_hematology .', 'And the battle of the BTKi giants', 'the battle of the BTKi giants in', 'battle of the BTKi giants in r/r', 'of the BTKi giants in r/r cll', 'the BTKi giants in r/r cll goes', 'BTKi giants in r/r cll goes to...', 'giants in r/r cll goes to... zanubrutinib!', 'in r/r cll goes to... zanubrutinib! Pfs', 'r/r cll goes to... zanubrutinib! Pfs benefit', 'cll goes to... zanubrutinib! Pfs benefit also', 'goes to... zanubrutinib! Pfs benefit also in', 'to... zanubrutinib! Pfs benefit also in del17p', 'zanubrutinib! Pfs benefit also in del17p or', 'Pfs benefit also in del17p or tp53', 'benefit also in del17p or tp53 aberrations.', 'also in del17p or tp53 aberrations. zanubrutinib', 'in del17p or tp53 aberrations. zanubrutinib ', 'del17p or tp53 aberrations. zanubrutinib  ', 'or tp53 aberrations. zanubrutinib   ', 'tp53 aberrations. zanubrutinib    ', 'aberrations. zanubrutinib     had', 'zanubrutinib     had a', '    had a more', '   had a more favorable', '  had a more favorable cardiac', ' had a more favorable cardiac profile', 'had a more favorable cardiac profile in', 'a more favorable cardiac profile in addition.', 'more favorable cardiac profile in addition. #ASH22', 'favorable cardiac profile in addition. #ASH22 @ASH_hematology', 'cardiac profile in addition. #ASH22 @ASH_hematology .', 'And the battle of the BTKi giants in', 'the battle of the BTKi giants in r/r', 'battle of the BTKi giants in r/r cll', 'of the BTKi giants in r/r cll goes', 'the BTKi giants in r/r cll goes to...', 'BTKi giants in r/r cll goes to... zanubrutinib!', 'giants in r/r cll goes to... zanubrutinib! Pfs', 'in r/r cll goes to... zanubrutinib! Pfs benefit', 'r/r cll goes to... zanubrutinib! Pfs benefit also', 'cll goes to... zanubrutinib! Pfs benefit also in', 'goes to... zanubrutinib! Pfs benefit also in del17p', 'to... zanubrutinib! Pfs benefit also in del17p or', 'zanubrutinib! Pfs benefit also in del17p or tp53', 'Pfs benefit also in del17p or tp53 aberrations.', 'benefit also in del17p or tp53 aberrations. zanubrutinib', 'also in del17p or tp53 aberrations. zanubrutinib ', 'in del17p or tp53 aberrations. zanubrutinib  ', 'del17p or tp53 aberrations. zanubrutinib   ', 'or tp53 aberrations. zanubrutinib    ', 'tp53 aberrations. zanubrutinib     had', 'aberrations. zanubrutinib     had a', 'zanubrutinib     had a more', '    had a more favorable', '   had a more favorable cardiac', '  had a more favorable cardiac profile', ' had a more favorable cardiac profile in', 'had a more favorable cardiac profile in addition.', 'a more favorable cardiac profile in addition. #ASH22', 'more favorable cardiac profile in addition. #ASH22 @ASH_hematology', 'favorable cardiac profile in addition. #ASH22 @ASH_hematology .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '8', 'tokens': ['it', 'would', 'be', 'interesting', 'to', 'see', 'the', 'data', 'from', 'stampede', 'based', 'on', 'gc', 'score', 'and', 'psa', 'response.', 'should', 'gc', 'low', 'with', 'a', 'psa', '&lt;', '0.2', 'a', 'good', 'population', 'to', 'stop', 'therapy?', '#esmo2022', '.'], 'text_length': 33, 'triples': {'stampede|interesting': ([9, 9], [3, 3], 'neutral')}, 'sentence': 'it would be interesting to see the data from stampede based on gc score and psa response. should gc low with a psa &lt; 0.2 a good population to stop therapy? #esmo2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(9, 9)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 3)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['it', 'would', 'be', 'interesting', 'to', 'see', 'the', 'data', 'from', 'stampede', 'based', 'on', 'gc', 'score', 'and', 'psa', 'response.', 'should', 'gc', 'low', 'with', 'a', 'psa', '&lt;', '0.2', 'a', 'good', 'population', 'to', 'stop', 'therapy?', '#esmo2022', '.', 'it would', 'would be', 'be interesting', 'interesting to', 'to see', 'see the', 'the data', 'data from', 'from stampede', 'stampede based', 'based on', 'on gc', 'gc score', 'score and', 'and psa', 'psa response.', 'response. should', 'should gc', 'gc low', 'low with', 'with a', 'a psa', 'psa &lt;', '&lt; 0.2', '0.2 a', 'a good', 'good population', 'population to', 'to stop', 'stop therapy?', 'therapy? #esmo2022', '#esmo2022 .', 'it would be', 'would be interesting', 'be interesting to', 'interesting to see', 'to see the', 'see the data', 'the data from', 'data from stampede', 'from stampede based', 'stampede based on', 'based on gc', 'on gc score', 'gc score and', 'score and psa', 'and psa response.', 'psa response. should', 'response. should gc', 'should gc low', 'gc low with', 'low with a', 'with a psa', 'a psa &lt;', 'psa &lt; 0.2', '&lt; 0.2 a', '0.2 a good', 'a good population', 'good population to', 'population to stop', 'to stop therapy?', 'stop therapy? #esmo2022', 'therapy? #esmo2022 .', 'it would be interesting', 'would be interesting to', 'be interesting to see', 'interesting to see the', 'to see the data', 'see the data from', 'the data from stampede', 'data from stampede based', 'from stampede based on', 'stampede based on gc', 'based on gc score', 'on gc score and', 'gc score and psa', 'score and psa response.', 'and psa response. should', 'psa response. should gc', 'response. should gc low', 'should gc low with', 'gc low with a', 'low with a psa', 'with a psa &lt;', 'a psa &lt; 0.2', 'psa &lt; 0.2 a', '&lt; 0.2 a good', '0.2 a good population', 'a good population to', 'good population to stop', 'population to stop therapy?', 'to stop therapy? #esmo2022', 'stop therapy? #esmo2022 .', 'it would be interesting to', 'would be interesting to see', 'be interesting to see the', 'interesting to see the data', 'to see the data from', 'see the data from stampede', 'the data from stampede based', 'data from stampede based on', 'from stampede based on gc', 'stampede based on gc score', 'based on gc score and', 'on gc score and psa', 'gc score and psa response.', 'score and psa response. should', 'and psa response. should gc', 'psa response. should gc low', 'response. should gc low with', 'should gc low with a', 'gc low with a psa', 'low with a psa &lt;', 'with a psa &lt; 0.2', 'a psa &lt; 0.2 a', 'psa &lt; 0.2 a good', '&lt; 0.2 a good population', '0.2 a good population to', 'a good population to stop', 'good population to stop therapy?', 'population to stop therapy? #esmo2022', 'to stop therapy? #esmo2022 .', 'it would be interesting to see', 'would be interesting to see the', 'be interesting to see the data', 'interesting to see the data from', 'to see the data from stampede', 'see the data from stampede based', 'the data from stampede based on', 'data from stampede based on gc', 'from stampede based on gc score', 'stampede based on gc score and', 'based on gc score and psa', 'on gc score and psa response.', 'gc score and psa response. should', 'score and psa response. should gc', 'and psa response. should gc low', 'psa response. should gc low with', 'response. should gc low with a', 'should gc low with a psa', 'gc low with a psa &lt;', 'low with a psa &lt; 0.2', 'with a psa &lt; 0.2 a', 'a psa &lt; 0.2 a good', 'psa &lt; 0.2 a good population', '&lt; 0.2 a good population to', '0.2 a good population to stop', 'a good population to stop therapy?', 'good population to stop therapy? #esmo2022', 'population to stop therapy? #esmo2022 .', 'it would be interesting to see the', 'would be interesting to see the data', 'be interesting to see the data from', 'interesting to see the data from stampede', 'to see the data from stampede based', 'see the data from stampede based on', 'the data from stampede based on gc', 'data from stampede based on gc score', 'from stampede based on gc score and', 'stampede based on gc score and psa', 'based on gc score and psa response.', 'on gc score and psa response. should', 'gc score and psa response. should gc', 'score and psa response. should gc low', 'and psa response. should gc low with', 'psa response. should gc low with a', 'response. should gc low with a psa', 'should gc low with a psa &lt;', 'gc low with a psa &lt; 0.2', 'low with a psa &lt; 0.2 a', 'with a psa &lt; 0.2 a good', 'a psa &lt; 0.2 a good population', 'psa &lt; 0.2 a good population to', '&lt; 0.2 a good population to stop', '0.2 a good population to stop therapy?', 'a good population to stop therapy? #esmo2022', 'good population to stop therapy? #esmo2022 .', 'it would be interesting to see the data', 'would be interesting to see the data from', 'be interesting to see the data from stampede', 'interesting to see the data from stampede based', 'to see the data from stampede based on', 'see the data from stampede based on gc', 'the data from stampede based on gc score', 'data from stampede based on gc score and', 'from stampede based on gc score and psa', 'stampede based on gc score and psa response.', 'based on gc score and psa response. should', 'on gc score and psa response. should gc', 'gc score and psa response. should gc low', 'score and psa response. should gc low with', 'and psa response. should gc low with a', 'psa response. should gc low with a psa', 'response. should gc low with a psa &lt;', 'should gc low with a psa &lt; 0.2', 'gc low with a psa &lt; 0.2 a', 'low with a psa &lt; 0.2 a good', 'with a psa &lt; 0.2 a good population', 'a psa &lt; 0.2 a good population to', 'psa &lt; 0.2 a good population to stop', '&lt; 0.2 a good population to stop therapy?', '0.2 a good population to stop therapy? #esmo2022', 'a good population to stop therapy? #esmo2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '9', 'tokens': ['vogel,', 'new', 'york', 'first', 'questions', 'fired', 'from', 'the', 'microphone', 'on', 'vision', '/therap', 'so', 'good', 'to', 'be', 'back', 'at', '#asco2022', '.'], 'text_length': 20, 'triples': {'vision|first questions fired from the microphone on vision /therap so good': ([10, 10], [3, 13], 'neutral')}, 'sentence': 'vogel, new york first questions fired from the microphone on vision /therap so good to be back at #asco2022 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(10, 10)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(3, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8)], 'span tokens': ['vogel,', 'new', 'york', 'first', 'questions', 'fired', 'from', 'the', 'microphone', 'on', 'vision', '/therap', 'so', 'good', 'to', 'be', 'back', 'at', '#asco2022', '.', 'vogel, new', 'new york', 'york first', 'first questions', 'questions fired', 'fired from', 'from the', 'the microphone', 'microphone on', 'on vision', 'vision /therap', '/therap so', 'so good', 'good to', 'to be', 'be back', 'back at', 'at #asco2022', '#asco2022 .', 'vogel, new york', 'new york first', 'york first questions', 'first questions fired', 'questions fired from', 'fired from the', 'from the microphone', 'the microphone on', 'microphone on vision', 'on vision /therap', 'vision /therap so', '/therap so good', 'so good to', 'good to be', 'to be back', 'be back at', 'back at #asco2022', 'at #asco2022 .', 'vogel, new york first', 'new york first questions', 'york first questions fired', 'first questions fired from', 'questions fired from the', 'fired from the microphone', 'from the microphone on', 'the microphone on vision', 'microphone on vision /therap', 'on vision /therap so', 'vision /therap so good', '/therap so good to', 'so good to be', 'good to be back', 'to be back at', 'be back at #asco2022', 'back at #asco2022 .', 'vogel, new york first questions', 'new york first questions fired', 'york first questions fired from', 'first questions fired from the', 'questions fired from the microphone', 'fired from the microphone on', 'from the microphone on vision', 'the microphone on vision /therap', 'microphone on vision /therap so', 'on vision /therap so good', 'vision /therap so good to', '/therap so good to be', 'so good to be back', 'good to be back at', 'to be back at #asco2022', 'be back at #asco2022 .', 'vogel, new york first questions fired', 'new york first questions fired from', 'york first questions fired from the', 'first questions fired from the microphone', 'questions fired from the microphone on', 'fired from the microphone on vision', 'from the microphone on vision /therap', 'the microphone on vision /therap so', 'microphone on vision /therap so good', 'on vision /therap so good to', 'vision /therap so good to be', '/therap so good to be back', 'so good to be back at', 'good to be back at #asco2022', 'to be back at #asco2022 .', 'vogel, new york first questions fired from', 'new york first questions fired from the', 'york first questions fired from the microphone', 'first questions fired from the microphone on', 'questions fired from the microphone on vision', 'fired from the microphone on vision /therap', 'from the microphone on vision /therap so', 'the microphone on vision /therap so good', 'microphone on vision /therap so good to', 'on vision /therap so good to be', 'vision /therap so good to be back', '/therap so good to be back at', 'so good to be back at #asco2022', 'good to be back at #asco2022 .', 'vogel, new york first questions fired from the', 'new york first questions fired from the microphone', 'york first questions fired from the microphone on', 'first questions fired from the microphone on vision', 'questions fired from the microphone on vision /therap', 'fired from the microphone on vision /therap so', 'from the microphone on vision /therap so good', 'the microphone on vision /therap so good to', 'microphone on vision /therap so good to be', 'on vision /therap so good to be back', 'vision /therap so good to be back at', '/therap so good to be back at #asco2022', 'so good to be back at #asco2022 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '10', 'tokens': ['#asco22', '#', 'nivolumab', 'cabozantinib', 'associated', 'with', 'greater', 'proportion', 'of', 'deep', 'objective', 'responses', 'for', 'advanced', '#renalcellcarcinoma', '.'], 'text_length': 16, 'triples': {'nivolumab|with greater proportion of deep': ([2, 2], [5, 9], 'neutral'), '#|with greater proportion of deep': ([1, 1], [5, 9], 'neutral')}, 'sentence': '#asco22 # nivolumab cabozantinib associated with greater proportion of deep objective responses for advanced #renalcellcarcinoma .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(2, 2), (1, 1)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(5, 9)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8)], 'span tokens': ['#asco22', '#', 'nivolumab', 'cabozantinib', 'associated', 'with', 'greater', 'proportion', 'of', 'deep', 'objective', 'responses', 'for', 'advanced', '#renalcellcarcinoma', '.', '#asco22 #', '# nivolumab', 'nivolumab cabozantinib', 'cabozantinib associated', 'associated with', 'with greater', 'greater proportion', 'proportion of', 'of deep', 'deep objective', 'objective responses', 'responses for', 'for advanced', 'advanced #renalcellcarcinoma', '#renalcellcarcinoma .', '#asco22 # nivolumab', '# nivolumab cabozantinib', 'nivolumab cabozantinib associated', 'cabozantinib associated with', 'associated with greater', 'with greater proportion', 'greater proportion of', 'proportion of deep', 'of deep objective', 'deep objective responses', 'objective responses for', 'responses for advanced', 'for advanced #renalcellcarcinoma', 'advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib', '# nivolumab cabozantinib associated', 'nivolumab cabozantinib associated with', 'cabozantinib associated with greater', 'associated with greater proportion', 'with greater proportion of', 'greater proportion of deep', 'proportion of deep objective', 'of deep objective responses', 'deep objective responses for', 'objective responses for advanced', 'responses for advanced #renalcellcarcinoma', 'for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated', '# nivolumab cabozantinib associated with', 'nivolumab cabozantinib associated with greater', 'cabozantinib associated with greater proportion', 'associated with greater proportion of', 'with greater proportion of deep', 'greater proportion of deep objective', 'proportion of deep objective responses', 'of deep objective responses for', 'deep objective responses for advanced', 'objective responses for advanced #renalcellcarcinoma', 'responses for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated with', '# nivolumab cabozantinib associated with greater', 'nivolumab cabozantinib associated with greater proportion', 'cabozantinib associated with greater proportion of', 'associated with greater proportion of deep', 'with greater proportion of deep objective', 'greater proportion of deep objective responses', 'proportion of deep objective responses for', 'of deep objective responses for advanced', 'deep objective responses for advanced #renalcellcarcinoma', 'objective responses for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated with greater', '# nivolumab cabozantinib associated with greater proportion', 'nivolumab cabozantinib associated with greater proportion of', 'cabozantinib associated with greater proportion of deep', 'associated with greater proportion of deep objective', 'with greater proportion of deep objective responses', 'greater proportion of deep objective responses for', 'proportion of deep objective responses for advanced', 'of deep objective responses for advanced #renalcellcarcinoma', 'deep objective responses for advanced #renalcellcarcinoma .', '#asco22 # nivolumab cabozantinib associated with greater proportion', '# nivolumab cabozantinib associated with greater proportion of', 'nivolumab cabozantinib associated with greater proportion of deep', 'cabozantinib associated with greater proportion of deep objective', 'associated with greater proportion of deep objective responses', 'with greater proportion of deep objective responses for', 'greater proportion of deep objective responses for advanced', 'proportion of deep objective responses for advanced #renalcellcarcinoma', 'of deep objective responses for advanced #renalcellcarcinoma .'], 'spans_aspect_label': [0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '11', 'tokens': ['Zanubrutinib', 'superior', 'to', 'Ibrutinib', 'late', 'breaking', 'abstracts', '#ASH22', 'Congratulations', 'to', 'my', 'colleague', '.'], 'text_length': 13, 'triples': {'Ibrutinib|superior to Ibrutinib late breaking abstracts #ASH22 Congratulations to': ([3, 3], [1, 9], 'negative'), 'Zanubrutinib|superior': ([0, 0], [1, 1], 'positive')}, 'sentence': 'Zanubrutinib superior to Ibrutinib late breaking abstracts #ASH22 Congratulations to my colleague .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(3, 3), (0, 0)], 'reverse_opinion_num': 2, 'reverse_opinion2aspect_label': [(1, 9), (1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 1, 1, 1],
       ...,
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1],
       [0, 0, 1, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8)], 'span tokens': ['Zanubrutinib', 'superior', 'to', 'Ibrutinib', 'late', 'breaking', 'abstracts', '#ASH22', 'Congratulations', 'to', 'my', 'colleague', '.', 'Zanubrutinib superior', 'superior to', 'to Ibrutinib', 'Ibrutinib late', 'late breaking', 'breaking abstracts', 'abstracts #ASH22', '#ASH22 Congratulations', 'Congratulations to', 'to my', 'my colleague', 'colleague .', 'Zanubrutinib superior to', 'superior to Ibrutinib', 'to Ibrutinib late', 'Ibrutinib late breaking', 'late breaking abstracts', 'breaking abstracts #ASH22', 'abstracts #ASH22 Congratulations', '#ASH22 Congratulations to', 'Congratulations to my', 'to my colleague', 'my colleague .', 'Zanubrutinib superior to Ibrutinib', 'superior to Ibrutinib late', 'to Ibrutinib late breaking', 'Ibrutinib late breaking abstracts', 'late breaking abstracts #ASH22', 'breaking abstracts #ASH22 Congratulations', 'abstracts #ASH22 Congratulations to', '#ASH22 Congratulations to my', 'Congratulations to my colleague', 'to my colleague .', 'Zanubrutinib superior to Ibrutinib late', 'superior to Ibrutinib late breaking', 'to Ibrutinib late breaking abstracts', 'Ibrutinib late breaking abstracts #ASH22', 'late breaking abstracts #ASH22 Congratulations', 'breaking abstracts #ASH22 Congratulations to', 'abstracts #ASH22 Congratulations to my', '#ASH22 Congratulations to my colleague', 'Congratulations to my colleague .', 'Zanubrutinib superior to Ibrutinib late breaking', 'superior to Ibrutinib late breaking abstracts', 'to Ibrutinib late breaking abstracts #ASH22', 'Ibrutinib late breaking abstracts #ASH22 Congratulations', 'late breaking abstracts #ASH22 Congratulations to', 'breaking abstracts #ASH22 Congratulations to my', 'abstracts #ASH22 Congratulations to my colleague', '#ASH22 Congratulations to my colleague .', 'Zanubrutinib superior to Ibrutinib late breaking abstracts', 'superior to Ibrutinib late breaking abstracts #ASH22', 'to Ibrutinib late breaking abstracts #ASH22 Congratulations', 'Ibrutinib late breaking abstracts #ASH22 Congratulations to', 'late breaking abstracts #ASH22 Congratulations to my', 'breaking abstracts #ASH22 Congratulations to my colleague', 'abstracts #ASH22 Congratulations to my colleague .', 'Zanubrutinib superior to Ibrutinib late breaking abstracts #ASH22', 'superior to Ibrutinib late breaking abstracts #ASH22 Congratulations', 'to Ibrutinib late breaking abstracts #ASH22 Congratulations to', 'Ibrutinib late breaking abstracts #ASH22 Congratulations to my', 'late breaking abstracts #ASH22 Congratulations to my colleague', 'breaking abstracts #ASH22 Congratulations to my colleague .'], 'spans_aspect_label': [1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '12', 'tokens': ['updated', 'results', 'from', 'the', 'phase', '3', 'propel', 'trial', 'in', 'mcrpc', '#prostatecancer', 'showed', 'rpfs', 'benefit', 'of', 'using', 'abiraterone+olaparib', 'vs', 'abiraterone.', 'os', 'trending!', '#esmo22', 'pr.', 'fred', 'saad', '.'], 'text_length': 26, 'triples': {'propel|showed rpfs benefit': ([6, 6], [11, 13], 'positive'), 'abiraterone+olaparib|showed rpfs benefit': ([16, 16], [11, 13], 'positive')}, 'sentence': 'updated results from the phase 3 propel trial in mcrpc #prostatecancer showed rpfs benefit of using abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr. fred saad .', 'aspect_num': 2, 'spans_aspect2opinion_label': [(6, 6), (16, 16)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(11, 13)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8)], 'span tokens': ['updated', 'results', 'from', 'the', 'phase', '3', 'propel', 'trial', 'in', 'mcrpc', '#prostatecancer', 'showed', 'rpfs', 'benefit', 'of', 'using', 'abiraterone+olaparib', 'vs', 'abiraterone.', 'os', 'trending!', '#esmo22', 'pr.', 'fred', 'saad', '.', 'updated results', 'results from', 'from the', 'the phase', 'phase 3', '3 propel', 'propel trial', 'trial in', 'in mcrpc', 'mcrpc #prostatecancer', '#prostatecancer showed', 'showed rpfs', 'rpfs benefit', 'benefit of', 'of using', 'using abiraterone+olaparib', 'abiraterone+olaparib vs', 'vs abiraterone.', 'abiraterone. os', 'os trending!', 'trending! #esmo22', '#esmo22 pr.', 'pr. fred', 'fred saad', 'saad .', 'updated results from', 'results from the', 'from the phase', 'the phase 3', 'phase 3 propel', '3 propel trial', 'propel trial in', 'trial in mcrpc', 'in mcrpc #prostatecancer', 'mcrpc #prostatecancer showed', '#prostatecancer showed rpfs', 'showed rpfs benefit', 'rpfs benefit of', 'benefit of using', 'of using abiraterone+olaparib', 'using abiraterone+olaparib vs', 'abiraterone+olaparib vs abiraterone.', 'vs abiraterone. os', 'abiraterone. os trending!', 'os trending! #esmo22', 'trending! #esmo22 pr.', '#esmo22 pr. fred', 'pr. fred saad', 'fred saad .', 'updated results from the', 'results from the phase', 'from the phase 3', 'the phase 3 propel', 'phase 3 propel trial', '3 propel trial in', 'propel trial in mcrpc', 'trial in mcrpc #prostatecancer', 'in mcrpc #prostatecancer showed', 'mcrpc #prostatecancer showed rpfs', '#prostatecancer showed rpfs benefit', 'showed rpfs benefit of', 'rpfs benefit of using', 'benefit of using abiraterone+olaparib', 'of using abiraterone+olaparib vs', 'using abiraterone+olaparib vs abiraterone.', 'abiraterone+olaparib vs abiraterone. os', 'vs abiraterone. os trending!', 'abiraterone. os trending! #esmo22', 'os trending! #esmo22 pr.', 'trending! #esmo22 pr. fred', '#esmo22 pr. fred saad', 'pr. fred saad .', 'updated results from the phase', 'results from the phase 3', 'from the phase 3 propel', 'the phase 3 propel trial', 'phase 3 propel trial in', '3 propel trial in mcrpc', 'propel trial in mcrpc #prostatecancer', 'trial in mcrpc #prostatecancer showed', 'in mcrpc #prostatecancer showed rpfs', 'mcrpc #prostatecancer showed rpfs benefit', '#prostatecancer showed rpfs benefit of', 'showed rpfs benefit of using', 'rpfs benefit of using abiraterone+olaparib', 'benefit of using abiraterone+olaparib vs', 'of using abiraterone+olaparib vs abiraterone.', 'using abiraterone+olaparib vs abiraterone. os', 'abiraterone+olaparib vs abiraterone. os trending!', 'vs abiraterone. os trending! #esmo22', 'abiraterone. os trending! #esmo22 pr.', 'os trending! #esmo22 pr. fred', 'trending! #esmo22 pr. fred saad', '#esmo22 pr. fred saad .', 'updated results from the phase 3', 'results from the phase 3 propel', 'from the phase 3 propel trial', 'the phase 3 propel trial in', 'phase 3 propel trial in mcrpc', '3 propel trial in mcrpc #prostatecancer', 'propel trial in mcrpc #prostatecancer showed', 'trial in mcrpc #prostatecancer showed rpfs', 'in mcrpc #prostatecancer showed rpfs benefit', 'mcrpc #prostatecancer showed rpfs benefit of', '#prostatecancer showed rpfs benefit of using', 'showed rpfs benefit of using abiraterone+olaparib', 'rpfs benefit of using abiraterone+olaparib vs', 'benefit of using abiraterone+olaparib vs abiraterone.', 'of using abiraterone+olaparib vs abiraterone. os', 'using abiraterone+olaparib vs abiraterone. os trending!', 'abiraterone+olaparib vs abiraterone. os trending! #esmo22', 'vs abiraterone. os trending! #esmo22 pr.', 'abiraterone. os trending! #esmo22 pr. fred', 'os trending! #esmo22 pr. fred saad', 'trending! #esmo22 pr. fred saad .', 'updated results from the phase 3 propel', 'results from the phase 3 propel trial', 'from the phase 3 propel trial in', 'the phase 3 propel trial in mcrpc', 'phase 3 propel trial in mcrpc #prostatecancer', '3 propel trial in mcrpc #prostatecancer showed', 'propel trial in mcrpc #prostatecancer showed rpfs', 'trial in mcrpc #prostatecancer showed rpfs benefit', 'in mcrpc #prostatecancer showed rpfs benefit of', 'mcrpc #prostatecancer showed rpfs benefit of using', '#prostatecancer showed rpfs benefit of using abiraterone+olaparib', 'showed rpfs benefit of using abiraterone+olaparib vs', 'rpfs benefit of using abiraterone+olaparib vs abiraterone.', 'benefit of using abiraterone+olaparib vs abiraterone. os', 'of using abiraterone+olaparib vs abiraterone. os trending!', 'using abiraterone+olaparib vs abiraterone. os trending! #esmo22', 'abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr.', 'vs abiraterone. os trending! #esmo22 pr. fred', 'abiraterone. os trending! #esmo22 pr. fred saad', 'os trending! #esmo22 pr. fred saad .', 'updated results from the phase 3 propel trial', 'results from the phase 3 propel trial in', 'from the phase 3 propel trial in mcrpc', 'the phase 3 propel trial in mcrpc #prostatecancer', 'phase 3 propel trial in mcrpc #prostatecancer showed', '3 propel trial in mcrpc #prostatecancer showed rpfs', 'propel trial in mcrpc #prostatecancer showed rpfs benefit', 'trial in mcrpc #prostatecancer showed rpfs benefit of', 'in mcrpc #prostatecancer showed rpfs benefit of using', 'mcrpc #prostatecancer showed rpfs benefit of using abiraterone+olaparib', '#prostatecancer showed rpfs benefit of using abiraterone+olaparib vs', 'showed rpfs benefit of using abiraterone+olaparib vs abiraterone.', 'rpfs benefit of using abiraterone+olaparib vs abiraterone. os', 'benefit of using abiraterone+olaparib vs abiraterone. os trending!', 'of using abiraterone+olaparib vs abiraterone. os trending! #esmo22', 'using abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr.', 'abiraterone+olaparib vs abiraterone. os trending! #esmo22 pr. fred', 'vs abiraterone. os trending! #esmo22 pr. fred saad', 'abiraterone. os trending! #esmo22 pr. fred saad .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '13', 'tokens': ['with', 'a', 'great', 'presentation', 'on', 'concordance', 'of', 'ngs/ngf,', 'serological', 'response,', 'and', 'more', 'impressive', 'reapearance', 'of', 'normal', 'pc', 'as', 'poor', 'prognostic', 'factors', 'in', 'karmma', 'biomarker', 'for', 'loss', 'of', 'on-target,', 'off-tumor', 'effect?', '#ash22', '#mmsm', '.'], 'text_length': 33, 'triples': {'karmma|great presentation on concordance of ngs/ngf, serological response, and more impressive': ([22, 22], [2, 12], 'positive')}, 'sentence': 'with a great presentation on concordance of ngs/ngf, serological response, and more impressive reapearance of normal pc as poor prognostic factors in karmma biomarker for loss of on-target, off-tumor effect? #ash22 #mmsm .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(22, 22)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(2, 12)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8)], 'span tokens': ['with', 'a', 'great', 'presentation', 'on', 'concordance', 'of', 'ngs/ngf,', 'serological', 'response,', 'and', 'more', 'impressive', 'reapearance', 'of', 'normal', 'pc', 'as', 'poor', 'prognostic', 'factors', 'in', 'karmma', 'biomarker', 'for', 'loss', 'of', 'on-target,', 'off-tumor', 'effect?', '#ash22', '#mmsm', '.', 'with a', 'a great', 'great presentation', 'presentation on', 'on concordance', 'concordance of', 'of ngs/ngf,', 'ngs/ngf, serological', 'serological response,', 'response, and', 'and more', 'more impressive', 'impressive reapearance', 'reapearance of', 'of normal', 'normal pc', 'pc as', 'as poor', 'poor prognostic', 'prognostic factors', 'factors in', 'in karmma', 'karmma biomarker', 'biomarker for', 'for loss', 'loss of', 'of on-target,', 'on-target, off-tumor', 'off-tumor effect?', 'effect? #ash22', '#ash22 #mmsm', '#mmsm .', 'with a great', 'a great presentation', 'great presentation on', 'presentation on concordance', 'on concordance of', 'concordance of ngs/ngf,', 'of ngs/ngf, serological', 'ngs/ngf, serological response,', 'serological response, and', 'response, and more', 'and more impressive', 'more impressive reapearance', 'impressive reapearance of', 'reapearance of normal', 'of normal pc', 'normal pc as', 'pc as poor', 'as poor prognostic', 'poor prognostic factors', 'prognostic factors in', 'factors in karmma', 'in karmma biomarker', 'karmma biomarker for', 'biomarker for loss', 'for loss of', 'loss of on-target,', 'of on-target, off-tumor', 'on-target, off-tumor effect?', 'off-tumor effect? #ash22', 'effect? #ash22 #mmsm', '#ash22 #mmsm .', 'with a great presentation', 'a great presentation on', 'great presentation on concordance', 'presentation on concordance of', 'on concordance of ngs/ngf,', 'concordance of ngs/ngf, serological', 'of ngs/ngf, serological response,', 'ngs/ngf, serological response, and', 'serological response, and more', 'response, and more impressive', 'and more impressive reapearance', 'more impressive reapearance of', 'impressive reapearance of normal', 'reapearance of normal pc', 'of normal pc as', 'normal pc as poor', 'pc as poor prognostic', 'as poor prognostic factors', 'poor prognostic factors in', 'prognostic factors in karmma', 'factors in karmma biomarker', 'in karmma biomarker for', 'karmma biomarker for loss', 'biomarker for loss of', 'for loss of on-target,', 'loss of on-target, off-tumor', 'of on-target, off-tumor effect?', 'on-target, off-tumor effect? #ash22', 'off-tumor effect? #ash22 #mmsm', 'effect? #ash22 #mmsm .', 'with a great presentation on', 'a great presentation on concordance', 'great presentation on concordance of', 'presentation on concordance of ngs/ngf,', 'on concordance of ngs/ngf, serological', 'concordance of ngs/ngf, serological response,', 'of ngs/ngf, serological response, and', 'ngs/ngf, serological response, and more', 'serological response, and more impressive', 'response, and more impressive reapearance', 'and more impressive reapearance of', 'more impressive reapearance of normal', 'impressive reapearance of normal pc', 'reapearance of normal pc as', 'of normal pc as poor', 'normal pc as poor prognostic', 'pc as poor prognostic factors', 'as poor prognostic factors in', 'poor prognostic factors in karmma', 'prognostic factors in karmma biomarker', 'factors in karmma biomarker for', 'in karmma biomarker for loss', 'karmma biomarker for loss of', 'biomarker for loss of on-target,', 'for loss of on-target, off-tumor', 'loss of on-target, off-tumor effect?', 'of on-target, off-tumor effect? #ash22', 'on-target, off-tumor effect? #ash22 #mmsm', 'off-tumor effect? #ash22 #mmsm .', 'with a great presentation on concordance', 'a great presentation on concordance of', 'great presentation on concordance of ngs/ngf,', 'presentation on concordance of ngs/ngf, serological', 'on concordance of ngs/ngf, serological response,', 'concordance of ngs/ngf, serological response, and', 'of ngs/ngf, serological response, and more', 'ngs/ngf, serological response, and more impressive', 'serological response, and more impressive reapearance', 'response, and more impressive reapearance of', 'and more impressive reapearance of normal', 'more impressive reapearance of normal pc', 'impressive reapearance of normal pc as', 'reapearance of normal pc as poor', 'of normal pc as poor prognostic', 'normal pc as poor prognostic factors', 'pc as poor prognostic factors in', 'as poor prognostic factors in karmma', 'poor prognostic factors in karmma biomarker', 'prognostic factors in karmma biomarker for', 'factors in karmma biomarker for loss', 'in karmma biomarker for loss of', 'karmma biomarker for loss of on-target,', 'biomarker for loss of on-target, off-tumor', 'for loss of on-target, off-tumor effect?', 'loss of on-target, off-tumor effect? #ash22', 'of on-target, off-tumor effect? #ash22 #mmsm', 'on-target, off-tumor effect? #ash22 #mmsm .', 'with a great presentation on concordance of', 'a great presentation on concordance of ngs/ngf,', 'great presentation on concordance of ngs/ngf, serological', 'presentation on concordance of ngs/ngf, serological response,', 'on concordance of ngs/ngf, serological response, and', 'concordance of ngs/ngf, serological response, and more', 'of ngs/ngf, serological response, and more impressive', 'ngs/ngf, serological response, and more impressive reapearance', 'serological response, and more impressive reapearance of', 'response, and more impressive reapearance of normal', 'and more impressive reapearance of normal pc', 'more impressive reapearance of normal pc as', 'impressive reapearance of normal pc as poor', 'reapearance of normal pc as poor prognostic', 'of normal pc as poor prognostic factors', 'normal pc as poor prognostic factors in', 'pc as poor prognostic factors in karmma', 'as poor prognostic factors in karmma biomarker', 'poor prognostic factors in karmma biomarker for', 'prognostic factors in karmma biomarker for loss', 'factors in karmma biomarker for loss of', 'in karmma biomarker for loss of on-target,', 'karmma biomarker for loss of on-target, off-tumor', 'biomarker for loss of on-target, off-tumor effect?', 'for loss of on-target, off-tumor effect? #ash22', 'loss of on-target, off-tumor effect? #ash22 #mmsm', 'of on-target, off-tumor effect? #ash22 #mmsm .', 'with a great presentation on concordance of ngs/ngf,', 'a great presentation on concordance of ngs/ngf, serological', 'great presentation on concordance of ngs/ngf, serological response,', 'presentation on concordance of ngs/ngf, serological response, and', 'on concordance of ngs/ngf, serological response, and more', 'concordance of ngs/ngf, serological response, and more impressive', 'of ngs/ngf, serological response, and more impressive reapearance', 'ngs/ngf, serological response, and more impressive reapearance of', 'serological response, and more impressive reapearance of normal', 'response, and more impressive reapearance of normal pc', 'and more impressive reapearance of normal pc as', 'more impressive reapearance of normal pc as poor', 'impressive reapearance of normal pc as poor prognostic', 'reapearance of normal pc as poor prognostic factors', 'of normal pc as poor prognostic factors in', 'normal pc as poor prognostic factors in karmma', 'pc as poor prognostic factors in karmma biomarker', 'as poor prognostic factors in karmma biomarker for', 'poor prognostic factors in karmma biomarker for loss', 'prognostic factors in karmma biomarker for loss of', 'factors in karmma biomarker for loss of on-target,', 'in karmma biomarker for loss of on-target, off-tumor', 'karmma biomarker for loss of on-target, off-tumor effect?', 'biomarker for loss of on-target, off-tumor effect? #ash22', 'for loss of on-target, off-tumor effect? #ash22 #mmsm', 'loss of on-target, off-tumor effect? #ash22 #mmsm .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '14', 'tokens': ['nodal', 'burden', 'and', 'nodal', 'metastases', 'response', 'in', 'mhspc', '(', 'stampede', ').', 'should', 'we', 'take', 'these', 'data', 'into', 'account', 'in', 'everyday', 'practice?', '#esmo22', '.'], 'text_length': 23, 'triples': {'(|stampede ). should': ([8, 8], [9, 11], 'neutral')}, 'sentence': 'nodal burden and nodal metastases response in mhspc ( stampede ). should we take these data into account in everyday practice? #esmo22 .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(8, 8)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(9, 11)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8)], 'span tokens': ['nodal', 'burden', 'and', 'nodal', 'metastases', 'response', 'in', 'mhspc', '(', 'stampede', ').', 'should', 'we', 'take', 'these', 'data', 'into', 'account', 'in', 'everyday', 'practice?', '#esmo22', '.', 'nodal burden', 'burden and', 'and nodal', 'nodal metastases', 'metastases response', 'response in', 'in mhspc', 'mhspc (', '( stampede', 'stampede ).', '). should', 'should we', 'we take', 'take these', 'these data', 'data into', 'into account', 'account in', 'in everyday', 'everyday practice?', 'practice? #esmo22', '#esmo22 .', 'nodal burden and', 'burden and nodal', 'and nodal metastases', 'nodal metastases response', 'metastases response in', 'response in mhspc', 'in mhspc (', 'mhspc ( stampede', '( stampede ).', 'stampede ). should', '). should we', 'should we take', 'we take these', 'take these data', 'these data into', 'data into account', 'into account in', 'account in everyday', 'in everyday practice?', 'everyday practice? #esmo22', 'practice? #esmo22 .', 'nodal burden and nodal', 'burden and nodal metastases', 'and nodal metastases response', 'nodal metastases response in', 'metastases response in mhspc', 'response in mhspc (', 'in mhspc ( stampede', 'mhspc ( stampede ).', '( stampede ). should', 'stampede ). should we', '). should we take', 'should we take these', 'we take these data', 'take these data into', 'these data into account', 'data into account in', 'into account in everyday', 'account in everyday practice?', 'in everyday practice? #esmo22', 'everyday practice? #esmo22 .', 'nodal burden and nodal metastases', 'burden and nodal metastases response', 'and nodal metastases response in', 'nodal metastases response in mhspc', 'metastases response in mhspc (', 'response in mhspc ( stampede', 'in mhspc ( stampede ).', 'mhspc ( stampede ). should', '( stampede ). should we', 'stampede ). should we take', '). should we take these', 'should we take these data', 'we take these data into', 'take these data into account', 'these data into account in', 'data into account in everyday', 'into account in everyday practice?', 'account in everyday practice? #esmo22', 'in everyday practice? #esmo22 .', 'nodal burden and nodal metastases response', 'burden and nodal metastases response in', 'and nodal metastases response in mhspc', 'nodal metastases response in mhspc (', 'metastases response in mhspc ( stampede', 'response in mhspc ( stampede ).', 'in mhspc ( stampede ). should', 'mhspc ( stampede ). should we', '( stampede ). should we take', 'stampede ). should we take these', '). should we take these data', 'should we take these data into', 'we take these data into account', 'take these data into account in', 'these data into account in everyday', 'data into account in everyday practice?', 'into account in everyday practice? #esmo22', 'account in everyday practice? #esmo22 .', 'nodal burden and nodal metastases response in', 'burden and nodal metastases response in mhspc', 'and nodal metastases response in mhspc (', 'nodal metastases response in mhspc ( stampede', 'metastases response in mhspc ( stampede ).', 'response in mhspc ( stampede ). should', 'in mhspc ( stampede ). should we', 'mhspc ( stampede ). should we take', '( stampede ). should we take these', 'stampede ). should we take these data', '). should we take these data into', 'should we take these data into account', 'we take these data into account in', 'take these data into account in everyday', 'these data into account in everyday practice?', 'data into account in everyday practice? #esmo22', 'into account in everyday practice? #esmo22 .', 'nodal burden and nodal metastases response in mhspc', 'burden and nodal metastases response in mhspc (', 'and nodal metastases response in mhspc ( stampede', 'nodal metastases response in mhspc ( stampede ).', 'metastases response in mhspc ( stampede ). should', 'response in mhspc ( stampede ). should we', 'in mhspc ( stampede ). should we take', 'mhspc ( stampede ). should we take these', '( stampede ). should we take these data', 'stampede ). should we take these data into', '). should we take these data into account', 'should we take these data into account in', 'we take these data into account in everyday', 'take these data into account in everyday practice?', 'these data into account in everyday practice? #esmo22', 'data into account in everyday practice? #esmo22 .'], 'spans_aspect_label': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Sample in enumerate:{'id': '15', 'tokens': ['3', 'excellent', '#mhspc', 'stampede', 'talks', 'at', '#esmo22', 'today:', 'lba62', 'os', 'results', 'of', 'm1', 'socvsadt+aap', '&amp;', 'socvsadt+aap+enza', '1358o', 'transcriptomic', 'signatures', 'in', 'adt', 'aap', '1359mo', 'nodal', 'mets', 'as', 'a', 'marker', 'of', 'prognosis', 'and', 'differential', 'rx', 'response', 'w/', 'aap', 'vs', 'doce', '.'], 'text_length': 39, 'triples': {'stampede|excellent': ([3, 3], [1, 1], 'neutral')}, 'sentence': '3 excellent #mhspc stampede talks at #esmo22 today: lba62 os results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt aap 1359mo nodal mets as a marker of prognosis and differential rx response w/ aap vs doce .', 'aspect_num': 1, 'spans_aspect2opinion_label': [(3, 3)], 'reverse_opinion_num': 1, 'reverse_opinion2aspect_label': [(1, 1)], 'related_span_array': array([[1, 0, 0, ..., 0, 0, 0],
       [0, 1, 0, ..., 0, 0, 0],
       [0, 0, 1, ..., 0, 0, 0],
       ...,
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1],
       [0, 0, 0, ..., 1, 1, 1]]), 'spans': [(0, 0, 1), (1, 1, 1), (2, 2, 1), (3, 3, 1), (4, 4, 1), (5, 5, 1), (6, 6, 1), (7, 7, 1), (8, 8, 1), (9, 9, 1), (10, 10, 1), (11, 11, 1), (12, 12, 1), (13, 13, 1), (14, 14, 1), (15, 15, 1), (16, 16, 1), (17, 17, 1), (18, 18, 1), (19, 19, 1), (20, 20, 1), (21, 21, 1), (22, 22, 1), (23, 23, 1), (24, 24, 1), (25, 25, 1), (26, 26, 1), (27, 27, 1), (28, 28, 1), (29, 29, 1), (30, 30, 1), (31, 31, 1), (32, 32, 1), (33, 33, 1), (34, 34, 1), (35, 35, 1), (36, 36, 1), (37, 37, 1), (38, 38, 1), (0, 1, 2), (1, 2, 2), (2, 3, 2), (3, 4, 2), (4, 5, 2), (5, 6, 2), (6, 7, 2), (7, 8, 2), (8, 9, 2), (9, 10, 2), (10, 11, 2), (11, 12, 2), (12, 13, 2), (13, 14, 2), (14, 15, 2), (15, 16, 2), (16, 17, 2), (17, 18, 2), (18, 19, 2), (19, 20, 2), (20, 21, 2), (21, 22, 2), (22, 23, 2), (23, 24, 2), (24, 25, 2), (25, 26, 2), (26, 27, 2), (27, 28, 2), (28, 29, 2), (29, 30, 2), (30, 31, 2), (31, 32, 2), (32, 33, 2), (33, 34, 2), (34, 35, 2), (35, 36, 2), (36, 37, 2), (37, 38, 2), (0, 2, 3), (1, 3, 3), (2, 4, 3), (3, 5, 3), (4, 6, 3), (5, 7, 3), (6, 8, 3), (7, 9, 3), (8, 10, 3), (9, 11, 3), (10, 12, 3), (11, 13, 3), (12, 14, 3), (13, 15, 3), (14, 16, 3), (15, 17, 3), (16, 18, 3), (17, 19, 3), (18, 20, 3), (19, 21, 3), (20, 22, 3), (21, 23, 3), (22, 24, 3), (23, 25, 3), (24, 26, 3), (25, 27, 3), (26, 28, 3), (27, 29, 3), (28, 30, 3), (29, 31, 3), (30, 32, 3), (31, 33, 3), (32, 34, 3), (33, 35, 3), (34, 36, 3), (35, 37, 3), (36, 38, 3), (0, 3, 4), (1, 4, 4), (2, 5, 4), (3, 6, 4), (4, 7, 4), (5, 8, 4), (6, 9, 4), (7, 10, 4), (8, 11, 4), (9, 12, 4), (10, 13, 4), (11, 14, 4), (12, 15, 4), (13, 16, 4), (14, 17, 4), (15, 18, 4), (16, 19, 4), (17, 20, 4), (18, 21, 4), (19, 22, 4), (20, 23, 4), (21, 24, 4), (22, 25, 4), (23, 26, 4), (24, 27, 4), (25, 28, 4), (26, 29, 4), (27, 30, 4), (28, 31, 4), (29, 32, 4), (30, 33, 4), (31, 34, 4), (32, 35, 4), (33, 36, 4), (34, 37, 4), (35, 38, 4), (0, 4, 5), (1, 5, 5), (2, 6, 5), (3, 7, 5), (4, 8, 5), (5, 9, 5), (6, 10, 5), (7, 11, 5), (8, 12, 5), (9, 13, 5), (10, 14, 5), (11, 15, 5), (12, 16, 5), (13, 17, 5), (14, 18, 5), (15, 19, 5), (16, 20, 5), (17, 21, 5), (18, 22, 5), (19, 23, 5), (20, 24, 5), (21, 25, 5), (22, 26, 5), (23, 27, 5), (24, 28, 5), (25, 29, 5), (26, 30, 5), (27, 31, 5), (28, 32, 5), (29, 33, 5), (30, 34, 5), (31, 35, 5), (32, 36, 5), (33, 37, 5), (34, 38, 5), (0, 5, 6), (1, 6, 6), (2, 7, 6), (3, 8, 6), (4, 9, 6), (5, 10, 6), (6, 11, 6), (7, 12, 6), (8, 13, 6), (9, 14, 6), (10, 15, 6), (11, 16, 6), (12, 17, 6), (13, 18, 6), (14, 19, 6), (15, 20, 6), (16, 21, 6), (17, 22, 6), (18, 23, 6), (19, 24, 6), (20, 25, 6), (21, 26, 6), (22, 27, 6), (23, 28, 6), (24, 29, 6), (25, 30, 6), (26, 31, 6), (27, 32, 6), (28, 33, 6), (29, 34, 6), (30, 35, 6), (31, 36, 6), (32, 37, 6), (33, 38, 6), (0, 6, 7), (1, 7, 7), (2, 8, 7), (3, 9, 7), (4, 10, 7), (5, 11, 7), (6, 12, 7), (7, 13, 7), (8, 14, 7), (9, 15, 7), (10, 16, 7), (11, 17, 7), (12, 18, 7), (13, 19, 7), (14, 20, 7), (15, 21, 7), (16, 22, 7), (17, 23, 7), (18, 24, 7), (19, 25, 7), (20, 26, 7), (21, 27, 7), (22, 28, 7), (23, 29, 7), (24, 30, 7), (25, 31, 7), (26, 32, 7), (27, 33, 7), (28, 34, 7), (29, 35, 7), (30, 36, 7), (31, 37, 7), (32, 38, 7), (0, 7, 8), (1, 8, 8), (2, 9, 8), (3, 10, 8), (4, 11, 8), (5, 12, 8), (6, 13, 8), (7, 14, 8), (8, 15, 8), (9, 16, 8), (10, 17, 8), (11, 18, 8), (12, 19, 8), (13, 20, 8), (14, 21, 8), (15, 22, 8), (16, 23, 8), (17, 24, 8), (18, 25, 8), (19, 26, 8), (20, 27, 8), (21, 28, 8), (22, 29, 8), (23, 30, 8), (24, 31, 8), (25, 32, 8), (26, 33, 8), (27, 34, 8), (28, 35, 8), (29, 36, 8), (30, 37, 8), (31, 38, 8)], 'span tokens': ['3', 'excellent', '#mhspc', 'stampede', 'talks', 'at', '#esmo22', 'today:', 'lba62', 'os', 'results', 'of', 'm1', 'socvsadt+aap', '&amp;', 'socvsadt+aap+enza', '1358o', 'transcriptomic', 'signatures', 'in', 'adt', 'aap', '1359mo', 'nodal', 'mets', 'as', 'a', 'marker', 'of', 'prognosis', 'and', 'differential', 'rx', 'response', 'w/', 'aap', 'vs', 'doce', '.', '3 excellent', 'excellent #mhspc', '#mhspc stampede', 'stampede talks', 'talks at', 'at #esmo22', '#esmo22 today:', 'today: lba62', 'lba62 os', 'os results', 'results of', 'of m1', 'm1 socvsadt+aap', 'socvsadt+aap &amp;', '&amp; socvsadt+aap+enza', 'socvsadt+aap+enza 1358o', '1358o transcriptomic', 'transcriptomic signatures', 'signatures in', 'in adt', 'adt aap', 'aap 1359mo', '1359mo nodal', 'nodal mets', 'mets as', 'as a', 'a marker', 'marker of', 'of prognosis', 'prognosis and', 'and differential', 'differential rx', 'rx response', 'response w/', 'w/ aap', 'aap vs', 'vs doce', 'doce .', '3 excellent #mhspc', 'excellent #mhspc stampede', '#mhspc stampede talks', 'stampede talks at', 'talks at #esmo22', 'at #esmo22 today:', '#esmo22 today: lba62', 'today: lba62 os', 'lba62 os results', 'os results of', 'results of m1', 'of m1 socvsadt+aap', 'm1 socvsadt+aap &amp;', 'socvsadt+aap &amp; socvsadt+aap+enza', '&amp; socvsadt+aap+enza 1358o', 'socvsadt+aap+enza 1358o transcriptomic', '1358o transcriptomic signatures', 'transcriptomic signatures in', 'signatures in adt', 'in adt aap', 'adt aap 1359mo', 'aap 1359mo nodal', '1359mo nodal mets', 'nodal mets as', 'mets as a', 'as a marker', 'a marker of', 'marker of prognosis', 'of prognosis and', 'prognosis and differential', 'and differential rx', 'differential rx response', 'rx response w/', 'response w/ aap', 'w/ aap vs', 'aap vs doce', 'vs doce .', '3 excellent #mhspc stampede', 'excellent #mhspc stampede talks', '#mhspc stampede talks at', 'stampede talks at #esmo22', 'talks at #esmo22 today:', 'at #esmo22 today: lba62', '#esmo22 today: lba62 os', 'today: lba62 os results', 'lba62 os results of', 'os results of m1', 'results of m1 socvsadt+aap', 'of m1 socvsadt+aap &amp;', 'm1 socvsadt+aap &amp; socvsadt+aap+enza', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o', '&amp; socvsadt+aap+enza 1358o transcriptomic', 'socvsadt+aap+enza 1358o transcriptomic signatures', '1358o transcriptomic signatures in', 'transcriptomic signatures in adt', 'signatures in adt aap', 'in adt aap 1359mo', 'adt aap 1359mo nodal', 'aap 1359mo nodal mets', '1359mo nodal mets as', 'nodal mets as a', 'mets as a marker', 'as a marker of', 'a marker of prognosis', 'marker of prognosis and', 'of prognosis and differential', 'prognosis and differential rx', 'and differential rx response', 'differential rx response w/', 'rx response w/ aap', 'response w/ aap vs', 'w/ aap vs doce', 'aap vs doce .', '3 excellent #mhspc stampede talks', 'excellent #mhspc stampede talks at', '#mhspc stampede talks at #esmo22', 'stampede talks at #esmo22 today:', 'talks at #esmo22 today: lba62', 'at #esmo22 today: lba62 os', '#esmo22 today: lba62 os results', 'today: lba62 os results of', 'lba62 os results of m1', 'os results of m1 socvsadt+aap', 'results of m1 socvsadt+aap &amp;', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures', 'socvsadt+aap+enza 1358o transcriptomic signatures in', '1358o transcriptomic signatures in adt', 'transcriptomic signatures in adt aap', 'signatures in adt aap 1359mo', 'in adt aap 1359mo nodal', 'adt aap 1359mo nodal mets', 'aap 1359mo nodal mets as', '1359mo nodal mets as a', 'nodal mets as a marker', 'mets as a marker of', 'as a marker of prognosis', 'a marker of prognosis and', 'marker of prognosis and differential', 'of prognosis and differential rx', 'prognosis and differential rx response', 'and differential rx response w/', 'differential rx response w/ aap', 'rx response w/ aap vs', 'response w/ aap vs doce', 'w/ aap vs doce .', '3 excellent #mhspc stampede talks at', 'excellent #mhspc stampede talks at #esmo22', '#mhspc stampede talks at #esmo22 today:', 'stampede talks at #esmo22 today: lba62', 'talks at #esmo22 today: lba62 os', 'at #esmo22 today: lba62 os results', '#esmo22 today: lba62 os results of', 'today: lba62 os results of m1', 'lba62 os results of m1 socvsadt+aap', 'os results of m1 socvsadt+aap &amp;', 'results of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures in', 'socvsadt+aap+enza 1358o transcriptomic signatures in adt', '1358o transcriptomic signatures in adt aap', 'transcriptomic signatures in adt aap 1359mo', 'signatures in adt aap 1359mo nodal', 'in adt aap 1359mo nodal mets', 'adt aap 1359mo nodal mets as', 'aap 1359mo nodal mets as a', '1359mo nodal mets as a marker', 'nodal mets as a marker of', 'mets as a marker of prognosis', 'as a marker of prognosis and', 'a marker of prognosis and differential', 'marker of prognosis and differential rx', 'of prognosis and differential rx response', 'prognosis and differential rx response w/', 'and differential rx response w/ aap', 'differential rx response w/ aap vs', 'rx response w/ aap vs doce', 'response w/ aap vs doce .', '3 excellent #mhspc stampede talks at #esmo22', 'excellent #mhspc stampede talks at #esmo22 today:', '#mhspc stampede talks at #esmo22 today: lba62', 'stampede talks at #esmo22 today: lba62 os', 'talks at #esmo22 today: lba62 os results', 'at #esmo22 today: lba62 os results of', '#esmo22 today: lba62 os results of m1', 'today: lba62 os results of m1 socvsadt+aap', 'lba62 os results of m1 socvsadt+aap &amp;', 'os results of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt', 'socvsadt+aap+enza 1358o transcriptomic signatures in adt aap', '1358o transcriptomic signatures in adt aap 1359mo', 'transcriptomic signatures in adt aap 1359mo nodal', 'signatures in adt aap 1359mo nodal mets', 'in adt aap 1359mo nodal mets as', 'adt aap 1359mo nodal mets as a', 'aap 1359mo nodal mets as a marker', '1359mo nodal mets as a marker of', 'nodal mets as a marker of prognosis', 'mets as a marker of prognosis and', 'as a marker of prognosis and differential', 'a marker of prognosis and differential rx', 'marker of prognosis and differential rx response', 'of prognosis and differential rx response w/', 'prognosis and differential rx response w/ aap', 'and differential rx response w/ aap vs', 'differential rx response w/ aap vs doce', 'rx response w/ aap vs doce .', '3 excellent #mhspc stampede talks at #esmo22 today:', 'excellent #mhspc stampede talks at #esmo22 today: lba62', '#mhspc stampede talks at #esmo22 today: lba62 os', 'stampede talks at #esmo22 today: lba62 os results', 'talks at #esmo22 today: lba62 os results of', 'at #esmo22 today: lba62 os results of m1', '#esmo22 today: lba62 os results of m1 socvsadt+aap', 'today: lba62 os results of m1 socvsadt+aap &amp;', 'lba62 os results of m1 socvsadt+aap &amp; socvsadt+aap+enza', 'os results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o', 'results of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic', 'of m1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures', 'm1 socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in', 'socvsadt+aap &amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt', '&amp; socvsadt+aap+enza 1358o transcriptomic signatures in adt aap', 'socvsadt+aap+enza 1358o transcriptomic signatures in adt aap 1359mo', '1358o transcriptomic signatures in adt aap 1359mo nodal', 'transcriptomic signatures in adt aap 1359mo nodal mets', 'signatures in adt aap 1359mo nodal mets as', 'in adt aap 1359mo nodal mets as a', 'adt aap 1359mo nodal mets as a marker', 'aap 1359mo nodal mets as a marker of', '1359mo nodal mets as a marker of prognosis', 'nodal mets as a marker of prognosis and', 'mets as a marker of prognosis and differential', 'as a marker of prognosis and differential rx', 'a marker of prognosis and differential rx response', 'marker of prognosis and differential rx response w/', 'of prognosis and differential rx response w/ aap', 'prognosis and differential rx response w/ aap vs', 'and differential rx response w/ aap vs doce', 'differential rx response w/ aap vs doce .'], 'spans_aspect_label': [0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'spans_opinion_label': [[0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]], 'reverse_opinion_label': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'reverse_aspect_label': [[0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]]}
Issue related to batch number batch_num0 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num1 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([1, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num1 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([2, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num2 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([3, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num3 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([4, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num4 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([5, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num4 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([6, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num5 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([7, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num6 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([8, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num7 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num8 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([9, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num9 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([10, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num10 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([11, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num10 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([12, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num11 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([13, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num11 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([14, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num12 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([15, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num12 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([16, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num13 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([17, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num14 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([18, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num15 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([19, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num0 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num1 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([1, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num1 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([2, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num2 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([3, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num3 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([4, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num4 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num5 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([5, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num6 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num7 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([6, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([10, 1, 1024])
Issue related to batch number batch_num8 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([16, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num9 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num10 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([17, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num11 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num11 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([18, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num12 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([19, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num13 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
Issue related to batch number batch_num14 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([20, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
Issue related to batch number batch_num15 and spanstensor([[[1, 3, 1],
         [4, 4, 1],
         [5, 6, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 4, 1],
         [5, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 5, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        ...,

        [[1, 1, 1],
         [2, 2, 1],
         [3, 3, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 2, 1],
         [3, 3, 1],
         [4, 4, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]],

        [[1, 1, 1],
         [2, 2, 1],
         [3, 7, 1],
         ...,
         [0, 0, 0],
         [0, 0, 0],
         [0, 0, 0]]])
all_span_aspect_tensor:=> torch.Size([21, 1, 1024])	aspect_span_embedding_unspilt:=> torch.Size([1, 1, 1024])
mismatching tensors for matrix multiplication
